adherence rate parental anger and physical discipline/force, and family problems overall levels of parental anger and physical discipline/force autonomy-support low attrition rate efficacy of pcit structure moderate stability and parent-child correspondence autonomy|the overall levels of parental anger and physical discipline/force were lower in cbt than ft families, though each group showed a reduction on these items from the early to late treatment sessions. twenty-six maltreating families were randomly assigned to one of two conditions: the 16-hour weekly intervention group, or the 4-month wait list control group. the relative superiority of pcit was mediated by greater reduction in negative parent-child interactions, consistent with the pcit change model.|physically abusive parents (n=110 maltreating families child physical abuse physical abuse among abusive parents twenty-six maltreating families participants had multiple past child welfare reports, severe parent-to-child violence, low household income, and significant levels of depression, substance abuse, and antisocial behavior maltreating mothers and on the autonomy of their children (3-8 years physically abused, school-aged children and their parents/guardians who were randomly assigned to
mean migraine headache frequency functional restriction frequency of headache attacks, the frequency of use of drugs for the acute management of migraine, the patients' opinion of treatment and the hamilton anxiety and depression rating scales headache intensity valproic acid serum levels responder rate migraine headache frequency headache days nausea headache duration reductions with extended-release divalproex sodium migraine headache rate symptoms with migraine migraine attacks number of responders frequency of migraine attacks mean standard deviation (sd) of monthly migraine frequency duration, monthly frequency, and intensity of headache symptomatic medication per episode migraine attack frequencies 4-week migraine attack frequency side effects average peak severity or duration of individual migraine headaches tolerance and safety migraine headaches efficacy and safety initial migraine frequency frequency, severity and duration of the attacks migraine headache days reduction of headache severity various side effects number of days with migraine severity and duration of the migraine attacks nausea, dizziness and tremor in which incidence rates migraine headache migraine headache rates mean score of the 21-item hamilton rating scale for depression migraine frequency frequency of migraine attacks and the number of migraine headache days visual analog scale (vas), and headache duration mean sd of monthly headache frequency frequency, intensity, and duration of migraine headaches as well as midas score and symptomatic medications frequency, intensity, duration, associated symptoms with headaches, analgesics use, as well as drugs' side effects incidence of any specific treatment-emergent adverse event adverse events|the outcome of group 1 (low serum level) was significantly better than that of group 2 with respect to both parameters (p<.05). among those with migraine headaches, divalproex-treated patients reported significantly less functional restriction than placebo-treated patients and used significantly less symptomatic medication per episode. the severity and duration of the migraine attacks that did occur were not affected by sodium valproate when compared with placebo. a total of 64 patients with migraine headache, aged 14 to 57 years, were randomly allocated to the 2 treatment groups. the reduction of headache severity in the topiramate group was significantly more than that in the valproate group (p = .027). no significant difference was identified between divalproex and propranolol for the prophylaxis of migraine without aura. no significant differences were detected between treatment groups in either the overall incidence or in the incidence of any specific treatment-emergent adverse event; 8% of subjects treated with extended-release divalproex sodium and 9% of those treated with placebo discontinued for adverse events. the patients who were treated with flunarizine showed an increase in the mean score of the 21-item hamilton rating scale for depression, but the difference was not significant; morning dysthymia however, was significantly more often observed in the flunarizine patients, compared to the valproate patients. adverse events were similar in the dvpx and placebo treatment groups except for nausea, dizziness and tremor in which incidence rates were significantly higher in the dvpx 1500 mg group (nausea was also higher in 500 mg group) than in the placebo group. our results show that in 86.2% of the patients sodium valproate was effective in preventing migraine or reducing the frequency, severity and duration of the attacks.|migraine 43 patients with migraine without aura in a triple-blind 56 patients who completed the course of study one-hundred-and-seventy-six patients (44 placebo, 132 dvpx) were randomized; 171 provided efficacy data and 137 completed the study migraine prophylaxis migraine prevention patients with migraine subjects with more than two migraine headache attacks during a 4-week baseline october 2003 to september 2004 private practice of a general neurologist with a special interest in headache disorders twenty-nine patients 37 patients (30 women and 7 men) selected, 32 completed the study 64 patients with migraine headache, aged 14 to 57 years migraine without aura 52 patients received patients were previously untreated or had failed no more than two adequate trials of prophylactic therapy one hundred seven patients randomized to 34 patients completed the trial twenty-two migraine sufferers patients with two or more migraine attacks during the baseline patients with migraine headaches
response to treatment: at least 20% improvement from basal conditions on clinical, laboratory, or specific neurological testing variables response rate|of the 32 patients studied, 18/19 receiving cy and 7/13 receiving mp responded to treatment (p<0.03).|32 patients studied, 18/19 receiving cy and 7/13 receiving mp responded to treatment (p<0.03 two tertiary care centres of patients with sle according to the acr criteria, with incident (no more than 15 days) onset of severe np manifestations such as seizures, optic neuritis, peripheral or cranial neuropathy, coma, brainstem disease, or transverse myelitis systemic lupus erythematosus
average total cost of delivering care nurse job satisfaction patients' length of stay, functional status, subsequent move to more dependent living arrangement inpatient length of stay functional dependence (barthel index), discharge destination and length of hospital stay functional independence daily cost of care length of inpatient stay mortality, functional status, or living arrangements at any time initial length of stay discharge destination or dependence cost savings decision making and quality of care length of stay, mortality, readmission, complications, satisfaction, and cost length of hospital stay, discharge destination, functional dependence (barthel index) and direct healthcare costs quality of care scores quality of care, job satisfaction, length of patient stay length of stay, mortality, or complications mean total cost|inpatient length of stay was significantly longer in the nurse-led unit than in general medical wards (14.3 days longer (95% confidence interval 7.8 to 20.7)), but this difference became non-significant when transfers to community hospitals were included in the measure of initial length of stay (4.5 days longer (-3.6 to 12.5)). there were no differences between nurse job satisfaction between the study and comparison wards or in length of patient stay throughout the period of evaluation. patients undergoing usual care stayed in hospital for less time (mean difference 18 days, p<0.01) but the same number of patients were in hospital 90 days after recruitment (23% nliu, 24% usual care p0.05) due to re-admissions. few significant differences were found between the two groups in length of stay, mortality, or complications. length of inpatient stay was significantly increased for the treatment group (p=0.036; 95% confidence interval 1.1-20.7 days).|of patients referred to a nliu from acute wards, 80 were randomly assigned to 238 patients accepted for admission to nurse-led unit elderly people participants patients were identified as medically stable but in need of additional nursing intervention by referring medical staff prior to full nursing assessment of suitability 89 patients urban teaching hospital and surrounding area, including nine community hospitals 220 chronically critically ill patients 175 patients assessed to be medically stable but requiring further inpatient care, referred to the unit from acute wards chronically critically ill: special care unit versus intensive care unit
complete response clinical complete response survival or response cap median survival times anemia clinical complete response (cr) rate for ca pathologic response rate myelosuppression median time to progression overall survival and activity index overall median response rate larger proportion of 48-month survivors median progression free survival (pfs response rate to cmf overall toxicity overall response rate alopecia nadir blood counts survival rates clinical toxicities and abnormalities in laboratory findings complete pathological response rate superior progression-free survival side-effects and haematological toxicity complete and partial response rate time to progression and survival survival of crs clinical complete response rates and longer time to failure efficacy and toxicity progression free survival clinical response rates efficacy survival median response duration myelosuppression, especially thrombocytopenia better survival myelosuppression, particularly thrombocytopenia response rate toxicity deaths macroscopic disease left thrombocytopenia toxicity and treatment efficacy assessed by pathological response rate, progression-free survival, and survival median duration of response median survival durations response rate of ac, fu, and cy early nausea and vomiting and later hematologic toxicity nausea and emesis life-threatening toxicities, including hematologic toxicity clinical response rate efficacy and tolerance hearing loss nausea, vomiting and alopecia survival or progression-free survival response duration overall pathological response rate median survivals renal toxicity pathologic complete response rates complete remissions (crs overall response rates response rates toxicity neuromuscular toxicities lethal toxicities, including gastrointestinal hemorrhage (1 patient) and neutropenic sepsis overall survival complete and partial response rates likewise, time to treatment failure response to therapy, time to treatment failure, and overall survival response rate, time to progression, disease-free survival and overall survival partial response bone marrow disorders and death due to toxicity progressive disease (pd), nonresponse, or toxicity survival curves toxicity/refusal survival and time to treatment failure unacceptable toxicity cell differentiation and volume of postoperative disease hematologic and gastrointestinal toxicity progression-free interval median survival cap therapeutic index small survival incidence of side effects survival superiority severe hematological toxicity median survival 5-year relapse-free survival rates leucopenia clinical complete response rates optimal survival with minimal toxicity 5-year survival rates tinnitus toxicity and efficacy mortality partial response rates median duration of crs|there was a strong trend for better survival in stage iii (p less than .05) but not in stage iv patients treated with cisplatin alone. the incidence of side effects was significantly higher in the combination-treatment arm. no statistical difference in median survival was observed between single-drug treatment (12 months) and caf (14 months), despite the fact that responders lived significantly longer than nonresponders (17 vs 10 months). mortality attributed to cancer was slightly lower on arm t (p = 0.06), but this was offset by the greater toxicity of this regimen, and overall survival and activity index were similar on the two arms. the extent of initial surgery significantly affected the survival of patients receiving prednimustine but not of those receiving combination chemotherapy. no statistically significant difference was found between the two treatments in terms of median survival. patients with stage iv measurable disease had a greater response rate to cmf, 22/52 (42%) versus l-pam, 6/39 (15%). the complete and partial response rates were 45.6% in the cap arm and 45.4% in the ca arm, but the cap regimen is of special importance in patients with bulky disease. this response rate was not enhanced by the addition of fu or fu and ac and not substantially different than the response rate of ac, fu, and cy. no significant difference was observed between these two regimens in response rates, and no significant differences were noted between the two regimens in each of the clinical toxicities and abnormalities in laboratory findings. efficacy was similar, with no significant differences for the cisplatin and carboplatin arms in clinical response rate (57% v 59% in those with measurable disease), pathologic response rate (52% v 54% in those suitable for relaparotomy), time to progression (median, 56 v 58 weeks), or overall survival (median, 100 weeks v 110 weeks). failure to achieve a significant degree of leucopenia was associated with worse progression free survival (p less than 0.001). a univariate analysis of pretreatment prognostic factors indicated significantly better prognosis (p less than 0.02) for patients with no palpable tumor, platelet count less than 400,000/mm3, residual tumor less than 2 cm, resting pulse less than 91/min. no significant differences in response rate, time to progression, disease-free survival and overall survival were observed between the two treatment arms. survival did not differ between the two arms (median survivals of 17.5 months with initial melphalan therapy and 19.5 months with chad), probably because women treated initially with melphalan received salvage therapy with had). cisplatin was more nephrotoxic while carboplatin induced a higher degree of myelosuppression, especially thrombocytopenia; however, severe hematological toxicity was seldom observed. in 1982 a randomized trial was started to compare a cisplatin-containing polychemotherapy (cap: there was less thrombocytopenia on the cisplatin arm (p less than .001); however, there was less nausea and emesis (p less than or equal to .001 for courses 1 to 5), renal toxicity (p less than .001), anemia (p = .01), hearing loss (p less than .001), tinnitus (p = .01), neuromuscular toxicities (p = .001), and alopecia (p less than .001) on the carboplatin arm. combination-agent chemotherapy produced a larger proportion of 48-month survivors than single-agent therapy (p = 0.001); 70% of these survivors were clinically free of disease. none of the other parameters showed a statistically significant advantage for combination chemotherapy, but the combinations caused more hematologic and gastrointestinal toxicity. cell differentiation and volume of postoperative disease did not influence response. crossover due to toxicity was more frequent in the cisplatin than the carboplatin arm, occurring in 50% and 3.3% of patients, respectively. following treatment crossover, the relative risk of death associated with original allocation to cbdca receded from 1.79 to 0.97, indicating success of the salvage treatment using the cddp-based regimen. the response duration for patients with measurable disease (median 14.6 versus 8.8 months), progression-free interval for all patients (13.1 versus 7.7 months), and survival for patients with measurable disease (19.7 versus 15.7 months) showed a statistically significant advantage for cap; however, there was no difference in survival of patients with nonmeasurable disease.|ninety-six patients (24%) were living at 48 months, 89 of whom had second-look laparotomies 233 evaluable patients with measurable disease, there were 64 treated with stage iii-iv epithelial ovarian carcinoma ovarian cancer was conducted by a cooperative study group consisting of 22 institutions nationwide previously untreated patients with international federation of gynecology and obstetrics stage iii or iv carcinoma of the ovary following surgery patients with untreated advanced epithelial ovarian cancer advanced ovarian cancer (adovca between march 1985 and january 1987, 103 women with histologically proven stage iii-iv ovarian carcinoma 149 patients patients with advanced ovarian carcinoma after intensive staging 74 ovarian cancer patients 136 evaluable patients without measurable disease by progression-free interval and duration of survival patients with stage iii (suboptimal) and stage iv ovarian cancer women with advanced ovarian cancer patients with ovarian cancer 264 eligible patients with advanced ovarian cancer women with postoperative macroscopic residual ovarian cancer 97 patients receiving southwest oncology group of a phase iii randomized trial in stages iii and iv ovarian cancer one hundred seventy-three patients with advanced epithelial ovarian cancer, f.i.g.o. (international federation of gynecology and obstetrics) stage iii and iv were accrued in the trial patients with bulky disease advanced ovarian carcinoma 135 women with advanced ovarian carcinoma women with disseminated or recurrent advanced ovarian cancer with patients with ovarian carcinoma (figo stages iii and iv three hundred forty-two patients sixty-one patients with figo stage iii ovarian carcinoma and 30 patients with stage iv ovarian carcinoma 76 patients with advanced epithelial ovarian carcinoma ovarian carcinoma 44 patients undergoing advanced epithelial ovarian carcinoma between 1985 and 1989, 447 (417 eligible) patients were randomized advanced epithelial ovarian cancer 118 eligible patients initially treated with melphalan and 126 with chad women with bulky (suboptimal) stage iii and stage iv ovarian carcinoma, using advanced ovarian cancer one hundred fifty-three patients (41%) had measurable disease, 109 (29%) had evaluable disease, and 113 (30%) had nonmeasurable, nonevaluable disease patients with advanced or recurrent, stage iii and iv, ovarian epithelial carcinoma thirteen patients were excluded from response analyses because they were incorrectly randomized 18 long term survivors who had retrospective pathologic review, 8 had borderline tumors of the ovary figo stages iib, iii and iv ovarian adenocarcinoma four hundred twenty-nine patients were entered into four prospective randomized clinical studies between january 1, 1973, and july 1, 1979 sixty-four patients women with suboptimal (greater than or equal to 3 cm residual) stage iii, stage iv, and recurrent ovarian adenocarcinoma stage iib patients 440 evaluable cases, of which 227 had measurable disease patients who had clinical or radiologic evidence of response after five courses of chemotherapy underwent second-look surgery stage iii-iv ovarian carcinoma one hundred twenty of these latter patients were treated with fifteen patients were not included in the final analysis and the remaining 134 patients patients with large (greater than 2 cm) residual disease 413 patients with advanced ovarian carcinoma three hundred seventy-five patients have been analyzed (l-pam, 190; cmf, 185 advanced ovarian cancer patients patients with international federation of gynecology and obstetrics (figo) stage iii or iv carcinoma of the ovary receive treatment with stage iii (suboptimal) and stage iv ovarian cancer twenty-three patients were excluded because of protocol violation, leaving 156 patients evaluable for survival with an observation period of 3-6 yr patients who cannot be given 161 previously untreated patients with figo stage iii or iv epithelial ovarian cancer between 1974 and 1982, 273 patients with epithelial cancer of the ovary (international federation of gynaecology and obstetrics stages iii and iv 253 patients with advanced epithelial carcinoma of the ovary patients with advanced ovarian cancer untreated advanced epithelial ovarian cancer twenty patients were in stage iib, while the remaining 136 patients were classified as stages iii and iv four hundred and twenty-seven patients were in the study, 314 of whom are evaluable for progression-free interval (pfi), survival, and toxicity: 102 in regimen 73 patients were treated with patients had stage iii (82%), grade 3 (54%) tumors with bulky residual (greater than 2 cm in 59%), and good performance status (eastern cooperative oncology group [ecog] 0 or 1, 77 24 patients still receiving ovarian cancer from 1977 until 1980, 179 patients with newly diagnosed figo stages iib, iii or iv ovarian adenocarcinoma
number of withheld feeds gastric emptying, maturation of gastrointestinal motor patterns, and time to achieve full enteral feedings time taken to attain full enteral feedings of at least 130 ml/kg/d mean time to attain full enteral feedings gastric emptying and characteristics of antroduodenal motor contractions gastrointestinal function feeding outcome mean birth weight episodes of large residual gastric aspirates median gestational age, birth weight and postnatal age at start of feeds feed toleration, time taken to establish full enteral feeding, vomiting, prescription of glycerine suppositories and occurrence of necrotising enterocolitis time to full feeding gestational age at birth gastric emptying and feed tolerance symptoms of gastroesophageal reflux episodes of sepsis, necrotizing enterocolitis, and cholestasis gastroesophageal reflux time to establish full enteral feeds efficacy and safety total parenteral nutrition or to the time needed to regain birthweight length of time taken to establish full enteral feeding since enrollment full enteral feeding earlier times to full feeding cardiac dysrhythmia, pyloric stenosis, or septicaemia time taken to attain full enteral feedings feeding tolerance feed tolerance tolerated gastric emptying episodes of gastric residuals (p<0.05) and shorter duration of parenteral nutrition (pn necrotizing enterocolitis gastrointestinal dysmotility cholestatic jaundice time to achieve full feeds full enteral feeding|oral erythromycin is effective in facilitating enteral feeding in preterm very low birthweight infants with moderately severe gastrointestinal dysmotility. low-dose enteral erythromycin is associated with better tolerance of feeding and shorter duration of pn in infants >32 weeks gestation. times to full feeding were significantly shorter and the number of withheld feeds were significantly less in the em group than the control group; the respective medians (interquartile ranges) were 7 days (6 to 9 days) versus 13 days (9 to 15 days) low-dose erythromycin promoted gastric emptying and feed tolerance in premature infants at a lower gestational age than previously reported. low-dose erythromycin did not reduce the time taken to attain full enteral feedings in preterm infants with very low birth weight and feeding intolerance. there were no significant differences between the groups for any of the outcomes. time to achieve full feeds was not significantly different in the two groups. erythromycin, a motilin receptor agonist, triggers migrating motor complexes and accelerates gastric emptying in adults with feeding intolerance.|premature infants subjects were 27 preterm infants who were admitted to the neonatal intensive care unit and who did not achieve full enteral feeding volumes (150 ml/kg/day) within 8 days of the initiation of feedings preterm infants with very low birth weight and feeding intolerance preterm infants a tertiary referral centre of a university teaching hospital was conducted on 56 preterm infants (< 1500 g) consecutively admitted to the neonatal unit feeding-intolerant preterm infants 1500 g) with feeding intolerance moderately severe gastrointestinal dysmotility in preterm very low birthweight infants two groups of preterm infants (birth weight younger preterm infants preterm infants < 35 weeks gestation preterm infants with feeding intolerance preterm infants of < or = 32 wk gestation preterm neonates 60 premature infants suffering from feeding intolerance neonates < 32 weeks, ready for enteral feeds preterm infants with established feeding intolerance preterm very low birthweight infants with moderately severe gastrointestinal dysmotility premature infants with established feed intolerance 23 preterm infants, almost all of whom were < 32 weeks gestation seventy-three consecutive neonates ventilated infants < 31 weeks gestation thirty infants eligible infants adults with feeding intolerance premature infants at a lower gestational age than previously reported
overall incidence of death and major complications total operative time mean arterial pressure and in calculated systemic vascular resistance incidence of new myocardial infarction, stroke, and respiratory failure endotracheal intubation time overall postoperative complication rate surgical intensive care stay postoperative pain control cardiovascular failure adverse cardiac outcome total number or type of postoperative complications gastrin auc analgesic medication heart and respiratory rate perioperative ischaemia visual analog pain scores vo2, ci and mixed venous o2 saturation electrogastrographic activity and serum gastrin secretion analgesic efficacy and side effects surgical "risk pain relief complications svo2 hypotension plasma catecholamines postoperative ischaemia postoperative pain scores length of hospitalization morbidity or mortality postoperative hospital length of stay, direct medical costs, selected postoperative morbidities, and postoperative recovery milestones respiratory inductive plethysmographic data 72-hour fluid requirement values of cardiac index (ci) and qo2 perioperative myocardial ischaemia length of stay and direct medical costs egg activity and serum gastrin secretion postoperative outcomes major infectious complications respiratory rate, vital capacity, peak expiratory volume in the first second, pao2, paco2, arterial ph, heart rate, and systolic and diastolic blood pressure intraoperative ischaemia postoperative apneas, slow respiratory rates, desaturation, and s-t segment depression urinary cortisol excretion, a marker of the stress response frequency of electrical waves (tachygastria power ratio (postprandial/fasting total power times to intensive care unit discharge, ward admission, first bowel sounds, first flatus, tolerating clear liquids, tolerating regular diet, and independent ambulation postoperative morbidity systemic hemodynamic function and systemic oxygen supply-demand relationship stress response indices vo2 during recovery overall incidence of myocardial ischemia death, myocardial infarction, myocardial ischemia, reoperation, pneumonia, and renal failure postoperative analgesia neuroendocrine response haemodynamic stability lung volume gastric electrical activity and serum gastrin secretion early myocardial ischemia duration of intensive care unit and hospital stay hypertension and tachycardia plasma noradrenaline total duration of ischemia incidence of death and major complications intraoperative vasopressors intraoperative cardiovascular changes and postoperative complications cortisol, epinephrine, norepinephrine, total catecholamines, crp, and il-6 in the postoperative period serum cortisol, epinephrine norepinephrine, total catecholamines, interleukin (il)-1beta, il-6, tumor necrosis factor (tnf)-alpha, and c-reactive protein (crp shorter time to extubation o2 delivery (qo2) and consumption (vo2 postoperative myocardial ischemia hypotensive il-1beta and tnf-alpha crp, il-1beta, il-6, and tnf-alpha levels blood loss, volume replacement or in the number of patients requiring postoperative ventilation intraoperative decrease in svo2 operative outcome myocardial ischaemia perioperative outcome egg parameters or the serum gastrin integrated value (area under the curve [auc postoperative forced pulmonary volumes plasma vasopressin myocardial ischemia length of stay in intensive care duration of postoperative ventilation lowest value of svo2 after extubation serum gastrin secretion myocardial ischaemia or morbidity postoperative analgesia at rest and during coughing and movement postoperative pain, time of ambulation, and length of hospital stay postoperative pain relief cardiac index time of hospitalization risk of respiratory or cardiac complications stress response cardiac filling pressure and systemic vascular resistance incidence of most side effects oxygen supply-demand ratio (qo2/vo2 hospital costs plasma vasopressin and adrenaline death and major complications gastrin levels cardiovascular and hormonal responses intubation time and intensive care stay heart rate|in group i patients, svo2 decreased during surgery to less than 60% (n = 2) and less than 70% (n = 4). postoperative forced pulmonary volumes were higher in the morphine group (p less than 0.01). nurse-administered intravenous morphine and time to tracheal extubation were less in group epi, as were visual analog pain scores at rest and after movement from 20 to 48 h. complications and the duration of intensive care unit and hospital stay were comparable. epidural anesthesia and epidural analgesia improve the overall outcome and shorten the intubation time and intensive care stay in patients undergoing abdominal aortic operations. combined general and epidural anaesthesia and postoperative epidural analgesia do not reduce the incidence of myocardial ischaemia or morbidity compared with general anaesthesia and postoperative intravenous analgesia. when compared to control patients, patients who received eaa had a reduction in the overall postoperative complication rate (p = 0.002) and in the incidence of cardiovascular failure (p = 0.007) and major infectious complications (p = 0.007). postoperative analgesia with epidural sufentanil or morphine and bupivacaine after major abdominal surgery seemed to be better than the conventional method of im morphine treatment, despite optimal administration, i.e., fixed doses at fixed intervals with regular adjustments. we found no difference in outcome between epidural and control groups in subgroups at increased risk of respiratory or cardiac complications or undergoing aortic surgery, nor in a subgroup with failed epidural block (all p > 0.05). postoperative outcomes were similar among the four treatment groups with respect to death, myocardial infarction, myocardial ischemia, reoperation, pneumonia, and renal failure. in these patients undergoing elective aortic surgery, the use of postoperative tea did not result in a lower incidence of early myocardial ischemia compared with intravenous pca with morphine, despite better analgesia with tea. post-operative hypertension and tachycardia as well as the increase in plasma noradrenaline are prevented by epidural administration of bupivacaine-fentanyl. all patients showed a significant increase in cortisol, epinephrine, norepinephrine, total catecholamines, crp, and il-6 in the postoperative period (p < 0.05). before surgery, no significant difference was found for any of the egg parameters or the serum gastrin integrated value (area under the curve [auc]) between the two groups of patients. at comparable vo2, ci and mixed venous o2 saturation were always less in the tea group than in the nla group. there was no significant difference between groups in regard to blood loss, volume replacement or in the number of patients requiring postoperative ventilation.|thirty-four patients (all males: 28 with abdominal aorta aneurysm, 6 with obstructive aorto-iliac disease; mean age: 68+/-7 years abdominal aortic surgery patients undergoing abdominal aortic surgery patients receiving perioperative epidural analgesia and those receiving iv opioids, apart from the incidence of respiratory failure patients undergoing major abdominal surgery patients undergoing elective aortic surgery 20 patients anaesthetized either with forty patients classified as american society of anesthesiologists physical status 2 or 3 received patients undergoing aortic surgery under thoracic epidural anaesthesia patients subjected to general anesthesia (ga) vs 53 patients were admitted to the study, 28 received eaa, and 25 received major surgical stress 1,021 patients who required anesthesia for one of the intraabdominal aortic, gastric, biliary, or colon operations 90 patients undergoing major abdominal surgery one hundred and five patients undergoing abdominal aortic surgery fifty patients undergoing elective abdominal aortic surgery group pca; n = 21) or one hundred twenty-four patients patients undergoing surgery of the abdominal aorta, thoracic epidural anesthesia combined with a patients undergoing surgery of the abdominal aorta one hundred sixty-eight patients undergoing surgery of the abdominal aorta 39 patients undergoing uncomplicated abdominal aortic replacement fourteen patients a group of high-risk surgical patients after aortic surgery elective aortic surgery patients undergoing aortic surgery high-risk surgical patients versus patient-controlled analgesia following abdominal aortic surgery aortic surgery 9 patients patients undergoing major vascular surgery high-risk patients 915 high-risk patients undergoing major abdominal surgery 39 patients patients surviving to discharge patients undergoing abdominal aortic operations
amblyopic eye acuity 4-month visual acuity 1-year visual acuity outcome median spherical equivalent refractive error unilateral visual loss acuity corrected amblyopic logmar visual acuity and contrast sensitivity function single letter and linear acuity (near and distance) and contrast sensitivity bcva severe amblyopia visual acuity and contrast sensitivity visual acuity amblyopia mean change in visual acuity of the amblyopic eye visual acuity in the amblyopic eye visual acuity, contrast sensitivity and resolution of amblyopia amblyopic eye visual acuity median anisometropia mean time to the resolution of amblyopia mean time for patching binocular function average number of training sessions bcva, binocular function, and refractive errors resolution of amblyopia residual visual acuity deficit responder rates moderate to severe amblyopia unilateral acuity loss visual acuity outcome visual acuity of the amblyopic eye rapid visual acuity recovery mean dose rates contrast sensitivity and slight linear acuity improvement visual outcome mean visual acuities of the amblyopic eyes|experimental and controls results were indistinguishable. the mean change in visual acuity of the amblyopic eye was not significantly different (p=0.64) between the two groups ( the median spherical equivalent refractive error increased significantly during the study in the amblyopic eyes (p<0.05) and the fellow eyes (p<0.001). performing common near activities does not improve visual acuity outcome when treating anisometropic, strabismic, or combined amblyopia with 2 hours of daily patching. improvement in va of the amblyopic eye from baseline to 5 weeks averaged 1.1 lines in the patching group and 0.5 lines in the control group (p = 0.006), and improvement from baseline to best measured va at any visit averaged 2.2 lines in the patching group and 1.3 lines in the control group (p<0.001). visual acuity in the amblyopic eye improved a similar amount in both groups. amblyopia improved by two or more lines in 20 of 26 (76%) patients in the perceptual learning group and 26 of 27 (96%) patients in the patching group (p=0.0001). amblyopia improves with optical correction alone in about one fourth of patients aged 7 to 17 years, although most patients who are initially treated with optical correction alone will require additional treatment for amblyopia. children in the full and glasses treatment groups had incrementally better visual acuity at follow up than children who received no treatment, but the mean treatment effect between full and no treatment was equivalent to only one line on a snellen chart (0.11 log units; 95% confidence interval 0.050 to 0.171; p < 0.0001).|children aged 7 to 17 years eight uk eye departments ninety were eligible for occlusion but 10 dropped out in this phase, leaving 80 children who were randomised to a prescribed dose rate of six (n=40) or 12 (n=40) hours a day 189 children younger than 7 years with amblyopia in the range of 20/40 to 20/80 older children and adult patients with anisometropic amblyopia 177 children aged 3-5 years with mild to moderate unilateral impairment of acuity (6/9 to 6/36) detected by screening unilateral visual impairment detected at preschool vision screening children younger than 7 years eighty children (mean age, 4.4 years) with untreated anisometropic amblyopia and a median best-corrected visual acuity (bcva) in the amblyopic eye of 0.4 logarithm of the minimum angle of resolution (logmar children with severe amblyopia severe amblyopia in children amblyopia anisometropic amblyopia in children 507 patients with amblyopic eye visual acuity ranging from 20/40 to 20/400 were provided with one hundred eighty children 3 to 7 years old with best-corrected amblyopic-eye visual acuity (va) of 20/40 to 20/400 associated with strabismus, anisometropia, or both who had worn optimal refractive correction (if needed) for at least 16 weeks or for 2 consecutive visits without improvement moderate amblyopia in children one hundred seventy-five children younger than 7 years with amblyopia in the range of 20/100 to 20/400 adults and children by perceptual learning 425 children, aged 3 to <7 years, with amblyopia (20/40-20/400) that was caused by anisometropia, strabismus, or both, and that persisted after treatment with spectacles eyes with anisometropic amblyopia younger children children aged 3 to less than 7 years 64 children with moderate acuity loss research clinics in two london hospitals strabismic and anisometropic amblyopia in children 97 children with a confirmed diagnosis of amblyopia associated with strabismus, anisometropia, or both patients with anisometropic amblyopia moderate to severe amblyopia in children 3 to 7 years old
intensive care unit admissions, artificial ventilation, antibiotic treatment, description of side effects during procedures, and parental perception of comfort frequency of vomiting and transient respiratory destabilization average hospital stay respiratory rate wheezing bradycardia with or without desaturation heart rate time to recovery, defined as 8 hours without oxygen supplementation associated with minimal or no chest recession, and ingesting more than two-thirds of daily food requirements intensive care admission mean length of illness in hospital wheezing, respiratory rate, retractions, and general condition) and measured s(po(2)) and heart rate mean clinical score for respiratory disability wheezing score ventilatory support exhalation technique (iet) and assisted cough (ac retractions median time to recovery child's comfort|the treatment group showed a mean clinical score for respiratory disability at admission of 5.56 (+/- there was no clinically discernable benefit on the course of their illness. between the groups: at t30 the improvement was significantly better in the new-method-cpt group for overall wang score (p = .02), retractions (p = .05), respiratory rate (p = .001), and heart rate (p < .001). no evidence of differences between groups in intensive care admission (rr=0.7, 95% ci 0.3-1.8, p=0.62), ventilatory support (rr=2.5, 95% ci 0.5-13.0, p=0.29), and antibiotic treatment (rr=1.0, 95% ci 0.7-1.3, p=1.00) was observed.|acute bronchiolitis 496 infants hospitalized for first-episode acute bronchiolitis between october 2004 and january 2008 seven french pediatric departments acute bronchiolitis, 32 patients infants without a history of atopy forty four children with acute bronchiolitis infants with acute respiratory syncytial virus bronchiolitis 20 infants (mean age 4.2 months) into 2 groups: 8 patients received hospitalized infants with bronchiolitis previously healthy infants hospitalized for a first episode of acute bronchiolitis respiratory syncytial virus bronchiolitis in infants infants with respiratory syncytial virus bronchiolitis infants hospitalized with acute bronchiolitis
bronchoconstriction bronchodilator response overall bronchodilatory effects forced expiratory volume in 1 s and forced vital capacity exercise heart rate cardiovascular parameters airway resistance forced vital capacity and peak expiratory flow fev1 or forced vital capacity slopes of the salbutamol dose-response curves of specific airway conductance evening peak flow rate fev1 changes in fev1 resting minute ventilation monthly asthma attacks fev1 and the forced vital capacity (fvc respiratory function resting heart rate and fev1 dilevalol resting heart rate diastolic blood pressure resting or exercise pao2 or paco2 co2 production vital capacity (vc) and forced expiratory volume in one second (fev1 nonspecific bronchial reactivity ventilatory function bronchial obstruction largely dyspnea systolic and diastolic blood pressure (bp changes in forced one-second expiratory volume (fev1) and mid-maximal expiratory flow (mmef airways obstruction (fev1, specific airways resistance cardiac and pulmonary function hr, sbp, and dbp 2 h postmedication heart rate and fall in diastolic blood pressure heart rate (hr highest plasma levels fev1 and vital capacity (vc forced expiratory volume heart rate and systolic blood pressure beta-blocking activity plasma levels fef basal forced expiratory volume heart rate (hr), systolic blood pressure (sbp), and diastolic blood pressure (dbp 1 cardiovascular and airways response baseline forced expiratory volume in 1 second (fev1 fev1 and pefr specific airway conductance, finger tremor amplitude, heart rate, and blood pressure resting heart rate and forced expiratory volume in one sec (fev1 o2 consumption awr beta 1-selectivity pulmonary function effect of bronchodilator awr and increased pefr, fev1, and vc lung function parameters--vital capacity (vc), airway resistance (awr), peak expiratory flow rate (pefr), forced expiratory volume (fev1)--at baseline and at predetermined intervals following each medication and salbutamol challenge blood pressure peak expiratory flow rate (pefr density dependence of expiratory airflow fev1 and fvc 12-min walking distance cardioselectivity ventilation lung function, heart rate and blood pressure pre- and postexercise values of mef50 and mef25 maximal expiratory flow rates time to exhaustion on a cycle ergometer resting pulse rate ventilatory effects expiratory volume (fev1) and maximal midexpiratory flow rate pulmonary function, heart rate and blood pressure histamine bronchial provocation exercise tolerance mean reduction in resting pulse rate ventilatory effect degree of reactivity with each active drug bronchial tone clinical exam, spirometry, or ejection fraction ventilation, heart rate, and arterial blood gas tensions lung function median cumulative salbutamol concentrations hr and bp fev1 and in pefr heart rate and fev1 bronchoconstrictor response left or right ventricular ejection fraction hyperventilation and exercise tolerance heart rate, blood pressure, and derived indexes at peak plasma drug levels pefr, fev1, and vc ventilatory indices, hr or bp forced vital capacity (fvc) and maximal midexpiratory flow (mmef forced expiratory volume in 1 second and specific airway conductance specific airway conductance arterial o2 or co2 tension (pao2 and paco2, respectively maximal expiratory flow-volume (mefv) curves bronchial reactivity overall changes in fev1 improvement of airflow pulse rate, forced expiratory volume in one second (fev1) and specific airways conductance expiratory airflow parameters ventilatory indices mean plasma levels bronchomotor tone, skeletal muscle, and the circulatory system average monthly asthma attacks heart rate resting airways obstruction and reduction in bronchodilator response mefv curves|both beta-blockers, in all the doses given, caused a significant decrease in peak expiratory flow rate (pefr). atenolol caused significantly (p less than 0.05) less bronchospasm in terms of fewer asthmatic attacks, more asthma-free days, less frequent sensations of moderate to very severe, wheeziness and less effect on the evening peak flow rate. in contrast the 3 doses of atenolol caused significantly less (p less than 0.05 to 0.01) b2-blockade as evidenced by a smaller fall in fev1. both atenolol and metoprolol lowered resting heart rate and fev1 both beta-blockers reduced the basal forced expiratory volume in one second (fev1), and the effect tended to be more pronounced after propranolol. inhalation of terbutaline to a cumulative dose of 2.0 mg induced a stepwise improvement in expiratory airflow parameters for large and small airways function when breathing air. metoprolol reduced heart rate by 14% (p less than 0.001) and ventilation by 11% (p less than 0.01), but there was no significant difference in arterial o2 or co2 tension (pao2 and paco2, respectively). the median cumulative salbutamol concentrations causing a 35% increase in tremor were 732 and 706 micrograms for placebo, 812 and 1213 micrograms for metoprolol, and 797 and 1323 micrograms for atenolol.(abstract truncated at 250 words) responsiveness to beta-2 agonist therapy was retained with both agents (p less than 0.05). all active treatments produced only small nonsignificant reductions in pefr, fev1, and vc, compared with baseline, without any significant differences between the four groups. changes in one-second forced expiratory volume (fev1) and maximal midexpiratory flow rate (fef25-75) prior to albuterol or isoproterenol were positive after placebo and both doses of celiprolol. both dilevalol and metoprolol similarly and significantly (p less than or equal to 0.01) inhibited the isoproterenol (160 and 480 micrograms) response in fev1 as compared to placebo.(abstract truncated at 250 words) unlike propranolol and oxprenolol, which significantly reduced fev1 and inhibited the bronchodilator response to inhaled salbutamol, atenolol and celiprolol did not significantly affect respiratory function and did not antagonize salbutamol effects. both metoprolol and atenolol significantly reduced forced vital capacity and peak expiratory flow, with no difference between drugs. compared to placebo, metoprolol did not significantly affect fev1 or forced vital capacity. following salbutamol, labetalol was associated with a significantly greater improvement of airflow than either propranolol or metoprolol. bevantolol significantly decreased the forced expiratory volume in 1 second (fev1) and the peak expiratory flow rate (pefr) at rest, while there was no such change with placebo or atenolol. after administration of 200 mg in slow-release tablets the plasma levels were lower and the ventilatory effect was less marked. there was no significant difference between the effects of atenolol and xamoterol of fev1 and fvc. celiprolol 400 mg and 600 mg neither caused bronchoconstriction nor antagonized albuterol in this acute study. monthly asthma attacks increased by more than 100% in five patients on celiprolol and four on chlorthalidone. following each active drug, resting heart rate changed to a similar extent and to a greater degree than after placebo (p less than 0.01). in the remaining five patients, bronchoconstriction was greatest following propranolol (mean reduction in fev1 26.6%) and least following atenolol (mean reduction in fev1 6.5%). mean reduction in resting pulse rate was statisitcally greater after acebutolol compared with placebo but not after practolol compared with placebo. the effects of the three treatments on forced vital capacity (fvc) and maximal midexpiratory flow (mmef) were qualitatively similar to those observed in fev1.|hypertensive asthmatics eight asthmatic patients patients with obstructive lung disease emphysema patients with obstructive airways disease ten asthmatic patients, all males, aged 50-66 years were studied twelve patients with asthma patients with asthma and hypertension 12 patients with emphysema patients with bronchial asthma sixteen normotensive asthmatic patients 18 patients with reversible bronchial asthma [isoproterenol-induced increase in forced expiratory volume in 1 second (fev1) of greater than or equal to 15 airways obstruction in asthmatics 10 patients with emphysema after intravenous patients with reversible airways obstruction patients with chronic airflow obstruction using a double-blind trial asthmatics with mild to moderate hypertension 12 patients with reversible obstructive airway disease hypertensive asthmatic patients eight asthmatic patients in relation to the plasma level of the agent following its administration in ordinary and slow-release tablets 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm hg hypertensive patients with chronic obstructive lung disease 16 patients with reversible bronchial asthma [isoproterenol-induced increase in forced expiratory volume in 1 s (fev1) of greater than or equal to 15 6 patients with chronic reversible airways obstruction and no cardiac dysfunction asthmatic patients 14 hypertensive patients with asthma, involving ten asthmatic patients with mild to moderate essential hypertension 12 mild asthmatics chronic airway obstruction patients with asthma 8 asthmatic patients asthma chronic obstructive pulmonary disease patients with asthma who require beta blockade 66 patients patients with concomitant bronchial asthma 34 asthmatic patients healthy subjects asthmatics hypertensive patients with reversible bronchial obstruction 11 patients with asthma patients with co-existent hypertension and reversible airways obstruction 12 hypertensive asthmatic patients stable patients with chronic reactive airways disease
blood, physical, ecg, and audiometric examinations visual analogue scores for dyspnoea, fatigue, and general well-being nyha functional class blood pressure to hypertensive values serum creatinine levels echocardiographic-determined measurements of left ventricular systolic and diastolic function pulmonary oedema plasma magnesium perceived exertion during submaximal exercise right-sided, pulmonary arterial wedge pressure or cardiac outputs symptom-limited exercise tolerance bun pulmonary artery pressure on exercise pulmonary wedge pressure heart size and echocardiographically measured ventricular volume cardiac output pulmonary arterial pressure ventricular arrhythmias on 24-hour ambulatory electrocardiography diastolic pressure right-sided and pulmonary artery wedge pressures and systemic arterial pressures time taken to walk 100 m at a self-selected slow speed systolic blood pressure urinary sodium/potassium ratio exercise tolerance cardiac sympathetic activity, and increased ventricular arrhythmias 24-hour urinary potassium excretion hemodynamics plasma renin activity, plasma aldosterone 24-hour urinary sodium excretion occasional kaliuretic response cardiac norepinephrine uptake pulmonary oedema of breathlessness plasma urea ankle oedema blood pressure new york heart association functional class status plasma potassium levels heart failure heart rate myocardial norepinephrine uptake diuretic therapy mild hypokalemia reduced urinary magnesium excretion|however, there was no significant increase in serum creatinine levels. statistically significant clinical improvement occurred in both treatment groups. during follow up diuretic therapy was required in 50 patients in the withdrawal group and 13 in the control group (risk difference 36%; 95% confidence interval 22% to 50%). blood pressure rose slightly in the placebo group and plasma urea rose slightly in the diuretic group. although 10 patients remained stable on captopril alone, 4 patients deteriorated, with the development of pulmonary oedema of breathlessness. both drugs were well tolerated, and both caused a similar reduction in systolic blood pressure. at rest there were no significant differences in the right-sided, pulmonary arterial wedge pressure or cardiac outputs between the patients on amiloride (a) versus placebo (p). spironolactone also elevated plasma magnesium (p < 0.05), reduced urinary magnesium excretion (p < 0.05), and caused a reduction in ventricular arrhythmias on 24-hour ambulatory electrocardiography (p < 0.05). the higher dose of frusemide also had a more favourable effect on visual analogue scores for dyspnoea, fatigue, and general well-being. cardiac output decreased at rest, but not significantly, and on exercise not at all.|chronic congestive heart failure secondary to coronary artery disease moderate but deteriorating heart failure 15 patients with moderate congestive heart failure not completely controlled on moderate heart failure patients with mild heart failure and a history of overt pulmonary oedema patients taking digoxin for chronic heart failure thirteen patients completed the 3 months study: two dropped-out in the frusemide group old people receiving long-term patients with heart failure 42 patients with new york heart association ii to iii congestive heart failure sixteen patients in heart failure and sinus rhythm were, after a four-week treatment-free period 202 patients taking long-term diuretics without manifest heart failure or hypertension patients with symptomatic (nyha functional class 2) mild heart failure 14 patients who had previously been treated with diuretics patients with chronic congestive heart failure treated with chronic digoxin and diuretics 141 elderly patients in the long-stay wards of six hospitals were found to be taking maintenance diuretics, and for 33 of these the drugs were judged to be mandatory patients with mild to moderately severe congestive heart failure elderly eleven men with a history of congestive heart failure mild heart failure ten patients with moderate heart failure who still had symptoms despite 40 mg elderly patients symptomatic mild heart failure chronic heart failure
incidence of rds bpd incidence of bpd corresponding mortality rate efficacy and safety rds-related mortality rates excess mortality rates death at day 28 and 36 weeks postmenstrual age (pma), air leaks, neuroimaging abnormalities, and other complications related to either prematurity or rds major dosing complications air leaks, and causes of death mortality rate incidences of common complications of prematurity, including intraventricular hemorrhage (grades 3 and 4) and cystic periventricular leukomalacia alive without bpd morbidity and mortality rates incidence of being alive without bronchopulmonary dysplasia (bpd mortality rates, bronchopulmonary dysplasia (bpd) rates, and rates of other complications of prematurity rates of rds at 24 hours and the rates of death related to rds|lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of rds. the corresponding mortality rate through day 28 for the lucinactant group was lower than that for the poractant alfa group (11.8% [95% ci: 6.0-17.6%] vs 16.1% [95% ci: 9.7-22.6%]), as was the rate at 36 weeks pma (16% and 18.5%, respectively).|252 infants born between 24 and 28 weeks of completed gestation, with birth weights between 600 and 1250 g very preterm infants n = 509), lucinactant (n = 527), or beractant (n = 258) within 20 to 30 minutes after birth preterm infants at risk for rds premature infants treated with preterm infants very premature infants at high risk for respiratory distress syndrome 1294 very preterm infants, weighing 600 to 1250 g and of < or =32 weeks gestational age
muscle power, functional ability, locomotor score, contractures, and forced vital capacity muscular x-ray density flushing, dizziness, and leg edema muscle strength, contractures, functional ability, cardiopulmonary changes, and laboratory data muscular power, muscle state, muscular functional ability (vignos), serum myoglobin and serum creative phosphokinase number of calcium-positive muscular fibres satisfactory blood levels|compared with before therapy, the number of calcium-positive muscular fibres was remarkably reduced in the treated dmd patients, but not in the placebo group. at monthly intervals, muscle power, functional ability, locomotor score, contractures, and forced vital capacity were measured by a team not involved in clinical care. the study had a power greater than 0.99 to detect a slowing of the illness to 25% of its original rate of progression. no significant difference was detected between the two groups regarding muscular power, muscle state, muscular functional ability (vignos), serum myoglobin and serum creative phosphokinase.|46 untreated dmd patients of the same age and stage in our department one hundred and five patients duchenne dystrophy duchenne muscular dystrophy 26 patients of the study and 20 additional dmd patients who were treated with twenty-seven boys with duchenne muscular dystrophy (dmd 13 dmd patients aged from 3-10 years (mean, 7 years 17 patients in the
relieving pain low-back and suprapubic pain intensity of pain pain concept or relief pain relief kaplan-meier survival analysis and mantel-cox log rank analysis intensity and unpleasantness of pain back pain operative delivery unpleasantness duration of labor course of labor, uterine activity and fetal heart patterns vas score reduction labour agentry scale and the labor and delivery satisfaction index visual analog scale (vas), sensory level (pinprick), motor blockade (bromage score), cervical dilation, and duration of analgesia apgar score, assays of blood samples from the umbilical vein including blood lactate, plasma hypoxanthine and blood gas, and neurobehavioral assessment relief of pain quality or duration of labour analgesia degree of pain relief pain relief, amount of administered analgesics, obstetrical and neonatal outcome, and side effects intensity of low back pain and abdominal pain duration of the spinal portion of the cse analgesia pain component mean pain intensity intensity of low-back pain quality of analgesia suprapubic pain rate of vas score duration of analgesia operative delivery rate analgesic effects pain epidural labor analgesia change of pain pain (vas), sensory level (pinprick), motor blockade (bromage), cervical dilatation, and duration of analgesia, and at delivery on fetal and neonatal outcome number of requests for pethidine/promethazine labour pain minimal or moderate low-back pain visual analogue pain scale visual analogue scale (vas level of control and satisfaction with labor and delivery|the duration of analgesia produced by the initial dose of epidural bupivacaine did not differ between groups (tens turned off 82.3 +/- all newborn infants were in good condition and no significant differences between the two groups could be demonstrated. there was no significant difference between the placebo, unspecific tns and control groups as regarded the increase in pain during the test period. mean pain intensity at 15 and 60 minutes after randomization was significantly reduced in the isw group compared with the 2 other groups. in healthy labouring parturients, the application of a tens unit did not alter the quality or duration of labour analgesia provided by the spinal portion of cse analgesia. there was no difference in the intensity of pain recorded by each group. no significant differences occurred between groups in the number of requests for pethidine/promethazine. tens group experienced vas score reduction 3 significantly more common than the tens placebo group (31/50 [62%] vs 7/50 [14%], p<0.001). the results showed that this method, with or without nitrous oxide inhalation, decreased by 80% the number of epidural and general anaesthesias that would otherwise have been unavoidable. there was no difference between the two groups in the degree of pain relief. in order to test the effectiveness of anesthelec (transcutaneous cranial electrical stimulation with limoge currents) during labour and delivery, a randomized study was carried out in 120 primiparous women with extradural anaesthesia during active labor. although the outcome of labour for mother and infant were similar in the two groups, there was a higher operative delivery rate in women who also had epidural analgesia.|healthy labouring parturients tertiary-care academic medical center first stage of labor one hundred women were eligible for analysis 10-th 12; one group of 5 had unspecific pain relief in labour was evaluated by randomizing 280 patients in early labour into 2 groups 26 30 parturient women during the first stage of labour newborn infant randomly assigned healthy full-term parturients in active phase of first-stage labor to either seventy parturient women 20 cases for whom analgesia was necessary healthy laboring parturients in childbirth pain relief in labour 34 women suffering from low back pain during labor 50 deliveries carried out under anesthelec were compared with 50 deliveries carried out under epidural analgesia forty-six patients, during the first stage of labour, were treated with tens, and 48 with a placebo apparatus 40 asa physical status i and ii parturients in early, active spontaneous labor with a singleton, vertex term fetus, and requesting analgesia forty parturients in active spontaneous labour, with a singleton, vertex, term fetus, requesting analgesia pain relief during labor low back pain during labor 120 primiparous women with extradural anaesthesia during active labor 100 primigravidae and 50 women in their third labour
cbz concentration cbz dosage reductions plasma cbz concentration|cbz dosage reductions ranging from 14 to 50% were required by 63% of patients who received rem.|patients taking patients with refractory epilepsy refractory epilepsy
clinical activity index (cai) and endoscopic index (ei recurrence rates|recurrence rates evaluated on the basis of intention to treat showed significant difference between curcumin and placebo (p=.049).|patients with quiescent uc patients with ulcerative colitis (uc patients with quiescent ulcerative colitis (uc eighty-nine patients with quiescent uc ulcerative colitis
rate of recovery from mood episodes of bipolar i disorder mental health problems depressive and anxiety symptoms and family conflict psychosocial functioning, prophylaxis against recurrences of mood episodes, or compliance with pharmacotherapy|this study was designed to answer, in part, the following question: what is the relative efficacy of hospitalization with family intervention as compared with hospitalization without family intervention for patients with major psychiatric disorders who are in need of hospital treatment and for whom both treatments are judged clinically feasible? neither adjunctive family therapy nor adjunctive multifamily psychoeducational group therapy significantly improves the rate of recovery from mood episodes of bipolar i disorder, compared to treatment with pharmacotherapy alone. at post-treatment, 81% of the patients treated with abft no longer met criteria for mdd, in contrast with 47% of patients in the waitlist group. suicidal depressed adolescents had a higher dropout rate and were more likely to be depressed at the end of treatment, in large part due to the particularly poor response of suicidal patients to nst. the program led to parental ratings of increased warmth in their relationships with their children, increased satisfaction with their social support, and the maintenance of family discussion of grief-related issues.|ninety-two patients meeting criteria for a current bipolar i mood episode suicidal depressed adolescents the sample was 78% female and 69% african american; 69% were from low-income, inner-city communities older children 144 patients (80 with schizophrenic disorder and 64 with major affective disorder children who had experienced the death of a parent patients with major psychiatric disorders who are in need of hospital treatment and for whom both treatments are judged clinically feasible 32 adolescents meeting criteria for major depressive disorder (mdd 107 depressed adolescents who participated in a clinical trial, and received either depressed adolescents
plasma renin-activity incidence of postoperative hemodialysis serum creatinine values glomerular filtration, urinary output, and renal histopathology bleeding volume, homologous blood transfusion volume, furosemide dose, and corrected kcl volume serum creatinine and urea plasma anp levels systolic blood pressure hemodynamics, urine output, intensive care unit (icu) and hospital stay, bleeding volume, homologous blood transfusion volume, furosemide dose, corrected kcl volume, and postoperative respiratory, hepatic, and renal function overall rate of dialysis-free survival glomerular filtration rate or rbf anuria plasma anp, brain natriuretic peptide and cyclic guanosine monophosphate (cgmp) levels, hemodynamic variables and renal function rapid onset of diuresis systemic vascular resistance central venous pressure, systemic vascular resistance index, and pulmonary vascular resistance index duration of hemofiltration and frequency of hemodialysis urine output creatinine clearances (ccr acute renal failure incidence of mechanical renal replacement therapy dialysis-free survival rates postoperative lv remodeling natriuresis and systemic vasodilation serum creatinine levels total number of hemodialyses due to oligo-/anuria plasma cyclic guanosine monophosphate levels creatinine clearance acute renal failure (arf postoperative peak levels of creatine kinase-mb frequency of hemodialysis/hemofiltration morbidity and mortality rates delayed hypertension (ht) and renal dysfunction (rd probability of dialysis, and improves dialysis-free survival systolic blood pressures free-rate of cardiac events incidence of postoperative ventricular arrhythmia and the postoperative peak level of creatine kinase-mb dialysis diuresis renal function oliguria, dialysis-free survival preoperative median serum creatinine postoperative hypertension and renal dysfunction renal excretory function frequency of hemodialysis age, sex, etiology of arf, entry serum creatinines (scr baseline serum creatinine level lv function incidence of postoperative arrhythmias peak serum creatinine anp levels safety and efficacy of anp baseline serum creatinine, change in serum creatinine, or the incidence of rcin hemodynamics, levels of atrial and brain natriuretic peptides (bnp), angiotensin-ii and aldosterone, renin activity, and left ventricular (lv) function dialysis and mortality status and/or hyperkalemia hemodynamic status oliguria cumulative duration of hemofiltration incidence of rcin: placebo renal blood flow levels of anp, cyclic guanosine monophosphate, glomerular filtration rate, and respiratory index, and significantly lower levels of renin, angiotensin-ii, aldosterone, and pleural effusion ccr glomerular filtration rate and renal blood flow dialysis-free survival serum creatinine rate of dialysis-free survival stable diuresis glomerular filtration rate bun levels oliguria / anuria and required subsequent hemofiltration / hemodialysis renal blood flow (rbf) and radiocontrast-induced nephropathy (rcin rbf aldosterone level urine volume needed dialysis hemodynamics, urine volume, dosage of furosemide, respiratory index, pleural effusion, anp, cyclic guanosine monophosphate, renin activity (renin), angiotensin-ii, aldosterone, and glomerular filtration rate fractional sodium excretion dialysis-free survival at day 21 and creatinine clearance dialysis or death plasma cyclic guanosine monophosphate levels, urine output and fractional sodium excretion, and decreased preload, afterload and plasma brain natriuretic peptide levels hemodynamic status and renal function mean arterial blood pressure postoperative creatinine clearance serum creatinine concentration, and mortality mortality rates renal vasodilatory response incidence of rcin postoperative brain natriuretic peptide renin activity and lower levels of angiotensin-ii and aldosterone medications, and quantity of radiocontrast|anp levels rose significantly from baseline at 5, 15, 65 and 120 minutes in both groups (p less than 0.05). the urine output during cpb and from cpb weaning to return to icu was significantly better in the hanp group. the hanp group showed significantly higher levels of anp, cyclic guanosine monophosphate, glomerular filtration rate, and respiratory index, and significantly lower levels of renin, angiotensin-ii, aldosterone, and pleural effusion, as compared with the non-hanp group. the incidence of postoperative ventricular arrhythmia and the postoperative peak level of creatine kinase-mb were significantly lower in the hanp group. no hemodynamic side effects or adverse events due to urodilatin were observed. plasma cyclic guanosine monophosphate levels correlated with plasma anp levels (r = 0.95, p = 0.0001), correlated with fractional sodium excretion (r = 0.53, p = 0.02), and correlated inversely with systemic vascular resistance (r = -0.54, p = 0.02). patients with diabetes mellitus had a significantly greater incidence of rcin: placebo, 26% versus 9%; anaritide (0.01), 33% versus 13%; anaritide (0.05), 26% versus 21%; anaritide (0.1), 39% versus 8% (diabetic v nondiabetic, p < 0.002). the frequency of hemodialysis/hemofiltration during uro or placebo infusion was significantly reduced (p = 0.03) in the uro-treated patients in comparison with placebo. urodilatin induced a rapid onset of diuresis in contrast to placebo-treated patients, who remained oliguric. group h showed significantly smaller furosemide dosage in the initial 3 days (h vs. c; 9.2 +/- h-anp improved creatinine clearance in contrast to placebo (p =.040). the postoperative brain natriuretic peptide was significantly lower in the hanp group as compared with that in the non-hanp group until 1 year after the operation. the incidence of postoperative hemodialysis and the number of treatments did not differ between the groups either (urodilatin group 4, vs. placebo group 6 and 22 for both groups, respectively). postoperative creatinine clearance was higher in group h (p=0.03). the rate of dialysis-free survival was 47 percent in the placebo group and 43 percent in the anaritide group (p = 0.35). mortality rates of 17% for group i and 35% for group ii were not significantly different (p = 0.11). mean arterial blood pressure was stable during the urodilatin infusion period and was not different to that observed in placebo patients. the results indicate that ularitide does not reduce the incidence of mechanical renal replacement therapy compared with placebo-treated patients during the first 12 h of treatment (u0: 36 (20), u5: 35 (11), u20: 36 (9), u40: 28 (8), u80: 41 (12), (% (n) (p = 0.87)). although a trend was present, there was no statistically significant beneficial effect of anp in dialysis-free survival or reduction in dialysis in these subjects with oliguric acute renal failure.|patients with established intrinsic arf 12 critically ill patients after major abdominal surgery with acute renal failure in an intensive care unit (icu) received 20 ng/kg b.w./min urodilatin (ularitide, inn) or renal impairment by continuous infusion of human atrial natriuretic peptide after liver transplantation acute renal failure occurring immediately after liver transplantation and requiring hemodialysis acute coronary syndrome (acs fifty-three consenting patients meeting clinical and urine composition criteria for established intrinsic arf acute renal failure requiring renal replacement therapy acute renal failure following heart and liver transplantation acute kidney failure following liver transplantation patients with established acute renal failure and that urodilatin did not eliminate the need for apparatus-based renal replacement treatment five patients receiving i.v twenty consecutive patients with chronic renal failure (60% with diabetes patients suffering from oliguric acute renal failure critically ill patients in intensive care units (icu cardiothoracic intensive care units of two tertiary care centers patients undergoing thoracic aortic surgery eighteen patients undergoing mitral valve surgery twenty-nine patients ischemic acute renal failure patients after heart transplantation 378 patients without 24 patients following heart transplantation to investigate whether prophylactic i.v 504 patients with acute tubular necrosis (oliguric and nonoliguric), anp decreased the need for dialysis only in the oliguric patients one hundred and twenty-four patients patients undergoing emergent cabg for acs 504 critically ill patients with acute tubular necrosis patients with diabetes mellitus patients with diabetes mellitus and a baseline serum creatinine > or = 1.8 mg/dl, with the lowest-risk group, defined as patients without diabetes mellitus acute renal failure following cardiac surgery acute renal failure after liver transplantation patients with acute renal failure after major abdominal surgery renal impairment following liver transplantation 40 patients undergoing thoracic aortic surgery into two groups: the patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome 150 patients who underwent scheduled coronary artery bypass grafting to compare a group of patients receiving 0.02 microg x kg(-1 patients with stable chronic renal failure (serum creatinine greater than 1.8 mg/dl or serum creatinine between 1.5 and 1.8 mg/dl with estimated creatinine clearance of < or = 65 ml/min sixty-one patients with normal preoperative renal function suffering from postcardiac surgical heart failure requiring significant inotropic and vasoactive support chronic renal failure patients suffering from incipient acute renal failure following cardiac surgery clinical acute renal failure 222 patients with oliguric acute renal failure patients undergoing cardiopulmonary bypass patients with emerging arf following ltx acute renal failure requiring hemodialysis after liver transplantation 360, u80: 158 ml/12h (median), (p = 0.16 patients with acute renal insufficiency after major abdominal surgery and the necessity of apparatus-based renal replacement treatment cardiac surgery under cardiopulmonary bypass (cpb fifty patients undergoing elective aneurysmectomy for infrarenal-aaa between 1998 and 2001 (m:f = 43:7, mean age 70.5 +/- 7.7 years thoracic aortic surgery 176 patients randomized into 4 different ularitide doses groups (u5, u20, u40, and u80 ng/kg/min) and a liver transplantation forty patients undergoing coronary artery bypass grafting were investigated patients suffering from arf following heart and liver transplantation (htx, ltx laboratory animals with acute renal dysfunction subjects with oliguric acute renal failure cardiac surgery acute renal failure critically ill patients with acute tubular necrosis critically ill patients suffering from oliguric acute renal failure seventy consecutive recipients of primary liver transplants were included in the study following randomization, and 33 patients continuously received patients with preexisting chronic renal failure, with or without diabetes mellitus patients suffering from oliguric acute renal failure to avoid mechanical renal replacement therapy during the first 12 hours 247 patients who completed the study, 50% had diabetes mellitus thirty-seven patients who underwent live donor liver transplantation with model for end-stage liver disease scores greater than 15 were the subjects of the study optional inclusion criteria were oliguria/anuria ( < 0.5 ml/kg/h), refractory to conventional treatment including administration of furosemide and dopamine, increase of serum creatinine to a least 200% of preoperative values, and bun levels > or = 25 mmol/l 6 of the 12 patients in the urodilatin group and 6 of the 12 patients in the human subjects with chronic renal failure oliguric acute renal failure
relapse into an affective episode (mania and/or depression rapid remission of symptoms on the brmas serious haematological changes, nor abnormalities in clinical chemistry drowsiness antimanic response quality of life brief psychiatric rating scale (bprs), the bech-rafaelsen mania rating scale (brmas) (only manic patients) and globally on the clinical global impression (cgi manic symptoms without sedation extrapyramidal symptoms total score for all rating scales mania rating scale, brief psychiatric rating scale, physician global impression scale, and side effects scales weight gain extrapyramidal side effects side effects psychotic features, rates of remission severity of illness scores hypokinesia rates of remission (young-mania rating scale score of < or =12 and 21-item hamilton rating scale for depression score efficacy and safety extrapyramidal symptom rating scale total scores quality of life on several dimensions young mania rating scale survival analysis techniques manic and psychotic symptoms magnitude of or time to response young mania rating scale total scores young mania rating scale scores standard ratings of psychopathology and side effects extrapyramidal side-effects (eps brief psychiatric rating scale, the clinical global impression scale, and safety measures ymrs scores tolerated hp, and gastrointestinal symptoms rate of extrapyramidal symptoms mean young mania rating scale (ymrs) score reductions overall remission of bipolar mania serum valproate concentrations adverse events|weight gain was significantly greater in the olanzapine group compared with the haloperidol group (2.82 vs 0.02 kg, p<.001). there was no evidence for a significant difference between the two treatment groups in the magnitude of or time to response (5.0 +/- by 8 weeks both groups were improved from baseline without statistically reliable differences between them. groups b and c did not differ from each other, either in degree of improvement or in side effects. the assessments on the cgi showed that all 3 treatments caused a clear reduction of the severity of illness scores in all 3 diagnostic categories, with no differences between treatments. the patients in all three groups showed a similar improvement on the total score for all rating scales at day 28 (brief psychiatric rating scale; lithium 9.1, haloperidol 4.9, risperidone 6.5, f = 1.01, df = 2, p = 0.37; mania rating scale; lithium 15.7, haloperidol 10.2, risperidone 12.4, f = 1.07, df = 2, p = 0.35 significantly greater reductions in young mania rating scale scores at endpoint and over time were seen in the risperidone group and in the haloperidol group, compared with the placebo group. no serious haematological changes, nor abnormalities in clinical chemistry occurred in either group. further reductions in ymrs scores were seen in patients receiving risperidone or haloperidol during the subsequent 9 weeks. the rating scales are not sensitive enough to monitor manic psychopathology; this accounts for the lack of statistically significant differences among drug groups at treatment termination, despite the widely disparate discharge rates. side effects were infrequent and minor for both treatments, except for extrapyramidal side effects which were significantly more common with haloperidol.|acute psychosis mania acute psychotic mania 156 bipolar disorder patients with a current manic or mixed episode who received a bipolar mania sixty patients entered the study but only 33 remained for randomization after drug washout acutely disturbed, psychotic patients patients were stratified into 3 diagnostic categories: acute psychoses (48 patients), mania (22 patients), and exacerbation of chronic psychoses (73 patients patients taking these drugs, in patients with bipolar mania patients presenting with mania (dsm iii 20 hospitalized patients with a dsm-iii-r diagnosis of bipolar disorder who were being treated concomitantly with 438 patients, 154 were randomized to patients with acute bipolar mania received severely ill hospitalized manics forty-five inpatients with dsm-iv mania hospitalized manic patients 36 consecutive hospitalized patients with bipolar disorder, manic or mixed phase and with psychotic features 21 severely ill manic patients who all met rigorous criteria for bipolar illness and who required in hospital treatment acutely disturbed psychotic patients acute mania
risk of zoster influenza a/h3 neutralizing antibody levels neutralizing antibody levels stimulation index seroconversion rates zoster mean stimulation index antibody response vaccination response mean (+/-se) stimulation index (si protective antibody titres of > or = 4 to poliovirus type 1 (pv1), poliovirus type 2 (pv2) and poliovirus type 3 (pv3 induration, erythema, or local pain poliovirus antibody titres seroconversion and seroresponse rates respective rates clinical disease protective antibody titre antibody titers severity scores vzv reactivation seroresponse rates|disease severity associated with vzv reactivation was decreased dramatically in vaccinees given three doses; severity scores were 6.4 +/- in order to evaluate the impact of influenza-like illness and the effectiveness of influenza vaccination in children with oncohematological disease who have completed cancer therapy, 182 children with a diagnosis of oncohematological disease were divided into two subgroups on the basis of the length of time off therapy (<6 months or 6-24 months) and randomised 1:1 to receive influenza vaccination or not. zoster developed in 7 of 53 vaccinated patients (13 percent) and in 19 of 58 unvaccinated patients (33 percent) (p=0.01). children with all developed significant antibody titers to a/panama /2007/ 99 antigen 4 weeks after the second immunization. chronic gvhd neither influenced the patient's ability to retain poliovirus antibodies prior to vaccination nor impaired responses to vaccinations. the responses were not improved by two doses compared with one (influenza a virus serotypes h1/n1 18% vs. 22% and h3/n2 26% vs. 14%; influenza b 25% vs. 22%). for each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine.|24 patients vaccinated at 1, 2, and 3 months, mean si was 8.43 children with oncohematological disease who have completed cancer therapy, 182 children with a diagnosis of oncohematological disease 70 patients with haematological malignancies recipients of hematopoietic-cell transplants 65 children under 15 years old were studied, including 25 children with all undergoing chemotherapy, 30 with asthma in remission who were regularly followed at clinics, and 10 healthy children children with acute lymphoblastic leukemia (all 75 bmt patients randomized to receive oncohematological children who have been off therapy for less than 6 months bmt patients children with leukemia undergoing chemotherapy patients with haematological malignancies with one or two doses of patients with haematological malignancies 119 patients enrolled, 111 received a transplant forty-five adult hla-matched sibling bmt recipients children with all who received children with either all or asthma in taiwan oncohematological children who have completed cancer therapy 23 unvaccinated patients at 4 months and 8.56 varicella-zoster virus (vzv) causes herpes zoster after bone marrow transplantation (bmt adult patients with non-hodgkin b cell lymphoma bone marrow transplant recipients immunized with 27 patients randomized to receive 91 otherwise healthy children unvaccinated against influenza for non-hodgkin's or hodgkin's lymphoma to receive
mean pvl baseline cd(8 serious reaction liver enzymes and hematological parameters adverse reactions ability to take single-strength tmp-smz daily hypersensitivity reactions incidence of new allergic reactions mean cd(4) counts plasma viral load (pvl) and cd(4)/cd(8) counts liver enzymes|our study was undertaken to evaluate if desensitization treatment is more effective than rechallenge in preventing hypersensitivity reactions in hiv-positive patients with previous allergic reactions to tmp-smx; the secondary aim was to evaluate the frequency of reactions to tmp alone. seventy-five percent of the dose-escalation group and 57% of the direct-rechallenge group continued to receive daily single-strength tmp-smz for 6 months (p= .014). dose regimen is not a predictor of the development of new allergic reactions amongst patients challenged with sulfonamides after an initial allergic reaction.|patients with previous documented hypersensitivity to tmp-smx who required primary or secondary pcp prophylaxis were enrolled; subjects who had previously had serious adverse reactions to tmp-smx were excluded hiv-infected patients who had experienced previous treatment-limiting reactions aids patients with previous allergic reactions to sulfonamides and requiring prophylaxis against pneumocistis carinii, central nervous system toxoplasmosis and diarrhea caused by isospora belli patients with a previous, not serious, allergic reaction to tmp-smx seventy-three patients were enrolled; 14 subjects (19%) presented reactions on tmp alone during the pre-enrollment phase aids patients allergic to sulfonamides hiv-positive patients with previous allergic reactions to tmp-smx patients challenged with sulfonamides after an initial allergic reaction hiv-positive patients with previous hypersensitivity to tmp-smx human immunodeficiency virus-infected patients with previous adverse reaction to tmp-smz patients developing new reactions eighteen patients were enrolled in the study (15 men and 3 women), with ages ranging from 30 to 57 years (mean 39.9 59 subjects
normalized alanine aminotransferase hepatorenal syndrome normal transaminase levels partial or complete antiviral responses periportal necrosis posttreatment histologic scores lost hepatitis b virus dna normal serum aminotransferase levels rate of anti-hbe seroconversion biopsy score alanine aminotransferase values hepatitis b viral dna efficacy of interferon therapy galactose elimination capacity and aminopyrine breath test late seroconversion hbeag clearance and seroconversion to anti-hbe loss of hb surface antigen (hbsag chronic active hepatitis alanine aminotransferase normalization safety and effectiveness loss of hbeag with anti-hbe seroconversion response rates normal alanine aminotransferase (alt) activity active viral replication hbv-dna or degree of histological activity inflammation and disappearance of core antigen in liver tissue elevated transaminase levels severe cytolytic episode flu-like syndrome, granulocytopenia (1), depression (3) and thyroid dysfunction (2 response rate loss of hb virus dna and hbeag from serum spontaneous seroconversion rate loss of hepatitis b baseline transaminases levels and hbv-dna concentrations baseline clinical, biochemical, and histological features active cirrhosis baseline aspartate aminotransferase (ast) level anti-hbe seroconversion hepatitis b e antigen and hepatitis b viral dna loss of dna-polymerase activity hepatic decompensation e antigen (hbeag) and hepatitis b virus (hbv)-dna reversion to hbeag and hbv dna negativity chronic hepatitis b (hb) infection hbeag disappearance and hbeag to anti-hbe seroconversion persistent loss of hepatitis b virus dna hbeag disappearance and hbeag to anti-hbe seroconversion rates chronic persistent hepatitis clearance of serum hepatitis b virus-dna and hbeag (complete response transaminase levels inflammatory and fibrotic activity hbeag clearance complete response rate surface antigen (hbsag|transaminase levels were normal in 27/34 of the responders but in only 4/21 of the non-responders (p < 0.0001). only three patients (10.3%) cleared hepatitis b surface antigen and seroconverted to anti-hbs. prednisolone pre-treatment tended to be more effective in patients with higher transaminase levels and in patients with low levels of hbv dna. partial or complete antiviral responses were achieved in 17 (21.5%) of 79 treated patients and 3 (8.3%) of 36 controls (p = 0.14). those with a baseline serum hepatitis b virus-dna < or = 1000 pg/ml also showed a higher complete response rate when pretreated with prednisolone (59%) than when treated with interferon alone (29%, p = 0.084) or untreated (22%, p < 0.03). hepatitis b e antigen and hepatitis b viral dna disappeared from serum significantly more often in the patients given prednisone plus interferon (16 of 44 patients, or 36 percent) or 5 million units of interferon alone (15 of 41; 37 percent) than in the untreated controls (3 of 43; 7 percent; p less than 0.001); the difference between those given 1 million units of interferon (7 of 41; 17 percent) and the controls was not significant. after a posttreatment 2-year follow-up there were still no differences in the response rates of the two treatments; of the 21 pooled treated patients, 61% lost hbeag and dna and 67% normalized alanine aminotransferase (vs. 33 and 44% of controls, respectively; p = 0.32 and 0.40). interferon induced a sustained cessation of hbv replication as judged by loss of dna-polymerase activity in 26 (59%) patients, 20 (45%) patients seroconverted to anti-hbe. the majority (85 percent) had a baseline aspartate aminotransferase (ast) level < or = 100 iu/l. liver biopsies carried out in 20 patients showed that responders had a noticeable reduction in inflammation and disappearance of core antigen in liver tissue, changes not seen in non-responders. hbeag clearance was similar in both groups (44% after prednisolone/interferon and 53% after interferon alone). at 24 months of follow-up, persistent loss of hepatitis b virus dna occurred in none of the children in the control group, in one child receiving recombinant alpha 2b-interferon alone, who also seroconverted to anti-hbe and anti-hbs and in five children receiving interferon with steroid priming (p = 0.0571 compared with controls), with four seroconverting to anti-hbe and one also seroconverting to anti-hbs.|chronic hepatitis children with chronic hepatitis patients with cirrhosis and avoided in patients showing signs, or with a history, of decompensated cirrhosis chronic hepatitis b chronic active hepatitis b chinese hbsag carrier children patients with chronic hepatitis b to one of the following regimens children with chronic hepatitis b infection 31 children with hb e antigen (hbeag)-positive chronic hepatitis who randomly received either no treatment (n = 9) or 10 million units of thirty-five children with chronic hbv infection, hbv-dna and eag serum positivity, and hbcag in liver tissue 200 evaluable patients, 33 (16.5%) were females, and 50 (25%) were male homosexuals twenty-nine children with chronic hepatitis b (chb children with chronic hb infection carrier children, aged 2-17 years, positive for hepatitis b e antigen (hbeag) and hepatitis b virus dna on at least three occasions in 6 months n = 34 children with chronic hepatitis b chronic type b hepatitis in asians children with chb patients with chronic hepatitis b. patients chinese adults with chronic hepatitis b virus infection two hundred and thirteen patients with chronic hepatitis b 102 patients (51 chronic hepatitis b. 44 patients with documented chronic hepatitis type b (12 women and 32 men; mean age 37.5 years, range 23-59 years) and satisfying the entry criteria were subjects of the study chronic hepatitis b. the hepatitis interventional therapy group 22 patients with cirrhosis (14 thirty children patients oriental patients with chronic active hepatitis b, 120 male chinese patients 30 patients had chronic active hepatitis on liver biopsy, while 14 had chronic persistent hepatitis fifty-six patients with biopsy-proven, chronic active hepatitis b ninety chinese hepatitis b surface antigen (hbsag 95 hepatitis b virus (hbv)-dna/hepatitis b e antigen (hbeag)-positive children (median age, 9 years [range, 2-16 years]; 56 boys; 84 [89 percent] white), all having inflammatory changes on liver biopsy
r5 impedance at 5 hz (r5), resistance as a function of oscillation frequency (dr/df), reactance at 5 hz (x5), resonant frequency (f(0) ) and integral of reactance between 5 hz and resonant frequency (ax flutter valve residual volume (rv), functional residual capacity (frc) and total lung capacity (tlc) (p<0.05 radioaerosol clearance removal of pulmonary secretions 24-h sputum volume, forced expiratory volume in 1 s (fev(1)), forced vital capacity (fvc), forced expiratory flow at 25-75% of fvc (fef(25-75%)), maximum inspiratory pressure (mip), maximum expiratory pressure (mep), exercise capacity, sputum microbiology and st george's respiratory questionnaire (sgrq yield of sputum did exercise capacity respiratory mechanics and sputum production lung hyperinflation total lcq score leicester cough questionnaire (lcq sgrq total score sputum production sputum bacteriology, fev(1), fvc, fef(25-75%), mip or mep 24-h sputum volume total and peripheral airway resistance|use of both nebulised saline and nebulised terbutaline immediately before chest physiotherapy gave a significantly greater yield of sputum than did physiotherapy alone, and terbutaline also significantly increased radioaerosol clearance from the whole lung and from regions of interest. there was a higher sputum production during eltgol compared with control and flutter vrp1 (p<0.05). flutter valve increases sputum removal during treatment and diminishes total and peripheral airway resistance in hypersecretive patients with bronchiectasis. no significant differences were seen in sputum bacteriology, fev(1), fvc, fef(25-75%), mip or mep.|methods: patients with clinical and radiological diagnosis of bronchiectasis were included bronchiectatic patients eight patients with stable bronchiectasis hypersecretive patients with bronchiectasis 20 patients not practising regular chest physiotherapy non-cystic fibrosis bronchiectasis bronchiectasis patients patients with bronchiectasis 10 patients, two males and eight females (mean age: 55.918.1 years hypersecretive patients non-cystic fibrosis bronchiectasis compared with no regular chest physiotherapy
structured continence and medical histories number of wet episodes urodynamic analysis (including cystometrogram), provocative stress test, and behavioral assessment frequency of correct toileting cost of assessing and treating these acute conditions frequency of incontinence urinary incontinence change in incontinence dermatological, genitourinary, gastrointestinal, respiratory and cardiovascular systems; falls; pain; and psychiatric and nutritional disturbances endurance, strength, and urinary incontinence strength, mobility endurance, urinary and fecal incontinence mini-mental status exam functional outcomes timed measures of walking or wheeling a wheelchair (mobility), sit-to-stand exercises, independence in locomotion and toileting as assessed using the functional independence measure (fim), one-repetition maximum weight for several measures of upper and lower body strength, frequency of urine and stool incontinence, and appropriate toileting ratios older american research and service physical and instrumental activities of daily living scales, folstein mini mental state examination, clock drawing test, geriatric depression scale, performance-based toileting assessment, bladder diaries, and physical examination daytime incontinent episodes continence levels|three behavioral measures that can be easily collected by nursing staff significantly predicted continence levels during treatment (multiple r, 0.79) and change in incontinence during treatment (multiple r, 0.64). the intervention group had significantly better functional outcomes than the control group (strength, mobility endurance, urinary and fecal incontinence) and a reduction of 10% in the incidence of the acute conditions, which was not significant. a behavioral management system designed to reduce urinary incontinence was evaluated in two nursing homes with a pretest-posttest control group design with repeated measures. the number of wet episodes in the control group remained about the same throughout training and the 22-week follow-up period. there was a significant effect of the fit intervention on virtually all measures of endurance, strength, and urinary incontinence but not on the fim for locomotion or toileting. among all subjects completing the treatment protocol, there was a 22% reduction in daytime incontinent episodes compared with true baseline (immediately following the control phase for those crossing over from the control group).|nursing homes older patients residing in va nursing homes 15 subjects completed the pv protocol 126 incontinent nursing home patients were checked on an hourly basis, asked if they needed toileting assistance (prompted), and socially reinforced for appropriate toileting frail nursing home residents four nursing homes nursing home patients older patients in department of veterans affairs (va) nursing homes four va nursing homes nursing home residents adults aged 60 years and older with urinary incontinence and who met center for medicare and medicaid services criteria for being homebound were referred to the study by home care nurses from 2 large medicare-approved home health agencies in a large metropolitan county in southwestern pennsylvania one hundred thirty-three incontinent women in seven nursing homes nineteen cognitively impaired older adults veterans affairs nursing homes cognitively impaired homebound older adults nineteen subjects all 528 patients in the nursing homes were screened; 178 were eligible, and 107 were randomized to an two nursing homes with a pretest-posttest control group design with repeated measures one hundred ninety incontinent, long-stay nursing home residents 64 subjects completed the intervention phase of the trial geriatric incontinence in nursing homes
bacterial colonisation, wound size, wound asepsis score and pain unadjusted hazard ratio healing earlier satisfactory epithelialization eradication of bacterial infections mean healing time control of infection mean healing times time (days) taken for complete re-epithelialisation of the nail bed control of infection and quicker wound healing graft take rate wound dehiscence, six of them needed re-suturing under general anesthesia reparative activity with inflammatory changes complete wound healing without wound disruption or need for re-suturing positive wound cultures mild dehiscence healing times of shallow wounds and abrasions; side-effects; patient satisfaction with treatment; and amount of honey and intrasite gel used complete cure average duration of healing relief of pain time to healing, change in ulcer area, incidence of infection, costs per healed ulcer, adverse events and quality of life median reduction in wound size mean wound area covered in slough bacterial infections, (2) reduce period of antibiotic use and hospital stay, (3) accelerate wound healing, (4) prevent wound dehiscence and need for re-suturing and (5) result in minimal scar formation wound healing healing rates amniotic membrane mean percentage of blood volume skin grafting take rate admission point of time safety and effectiveness healing median rate of healing cosmetic and functional results venous ulcer healing itching epithelialization average cost itching and pain healing rates of wounds healing healthy granulation tissue median time to healing probability of healing residual scars size of postoperative scar infection pain healing outcomes histological evidence of reparative activity healing rate ulcer healing complete wound healing healing times mean hospital stay hazard ratio skin grafting proportion of ulcers healed reparative activity bacterial contamination and promoting wound healing incidence of healing, effective desloughing and a lower incidence of infection adverse events|of the wounds treated with honey, 100 per cent healed within 15 days as against 50 per cent in the wounds treated with boiled potato peel dressings (mean 10.4 vs. 16.2 days). in the case of abrasions there was also no significant difference (p = 0.83, 95% ci: -4.98; 6.19 days). in the glucantime alone treated group, 32 patients (71.1%) had complete cure whereas in the group treated with both glucantime & topical honey, 23 patients (51.1%) achieved complete cure. early tangential excision and skin grafting was clearly superior to expectant treatment using topical honey in patients with moderate burns in this randomised, prospective study performed at a general hospital in the indian subcontinent. partial avulsion wounds healed statistically significantly faster (p=0.01) with paraffin tulle gras (19.62 days, sd 9.31) than with the honey dressing (31.76 days, sd 18.8), but no significant difference (p=0.21) was found following total avulsion when comparing honey (45.28 days, sd 18.03.) with paraffin tulle gras dressings (52.03 days, sd 21.3). honey impregnated gauze dressed wounds showed healing earlier as compared to opsite (mean 10.8 versus 15.3 days). mean wound area covered in slough reduced to 29% and 43%, respectively (p = 0.065). at 12 weeks, 104 ulcers (55.6 per cent) in the honey-treated group and 90 (49.7 per cent) in the usual care group had healed (absolute increase 5.9 (95 per cent confidence interval (c.i.) honey appears to be more effective than sugar in reducing bacterial contamination and promoting wound healing, and slightly less painful than sugar during dressing changes and motion. residual scars were noted in 8 per cent of patients treated with honey-impregnated gauze and in 16.6 per cent of cases treated with amniotic membrane (p < 0.001). the mean healing time in the standard dressing group was 15.4 days (range 9-36 days) compared to 14.4 days (range 7-26 days) in the honey group (p < 0.005). histological evidence of reparative activity was seen in 80 per cent of wounds treated with the honey dressing by the 7th day with minimal inflammation. the healing rate at 12 weeks was equal to 46.2% in the honey group compared with 34.0% in the conventional group, and the difference in the healing rates (95% confidence interval, ci) at 12 weeks between the two groups was 12.2% (-13.6%, 37.9%). honey dressing improves wound healing, makes the wound sterile in lesser time, has a better outcome in terms of prevention of hypertrophic scarring and post-burn contractures, and decreases the need of debridement irrespective of time of admission, when compared to ssd dressing. of the wounds treated with honey 87 per cent healed within 15 days as against 10 per cent in the control group. after using honey, 22/26 patients (84.4%) showed complete wound healing without wound disruption or need for re-suturing and only 4 patients showed mild dehiscence.|patients with open or infected wounds wagner's grade-ii diabetic foot ulcers with 30 patients age between 31 to 65-years-old (mean of 52.1 years sixty-four patients were studied fifty patients having postoperative wound infections following caesarean sections or total abdominal hysterectomies with gram positive or gram negative bacterial infections partial thickness burns wagner grade-ii diabetic foot ulcers venous leg ulcers 50 patients treated with venous ulcers 2008 british journal of surgery society ltd 25 patients in the tangential excision (te) group had burns of 23 burns patients (n=78) of both sexes, with age group between 10 and 50 years and with first and second degree of burn of less than 50% of tbsa (total body surface area) were included in the study, over a period of 2 years (2006-08 caesarean sections and hysterectomies cutaneous leishmaniasis 50 burn patients 368 participants, 187 were randomized to honey and 181 to usual care 45 patients that had cutaneous leishmaniasis twenty-six patients (group a) were treated with 12 hourly application of crude honey and 24 patients (group b) were treated with 52 patients treated with burn patients a sample of 105 patients were involved in a single centre participants (n=100 wagner type ii diabetic foot ulcers 100 patients with confirmed cutaneous leishmaniasis forty patients were enrolled; 18 received 104 cases of superficial burn injury ten patients left out the study one hundred and eight patients with venous leg ulcers having goldmine workers patients with moderate burns
adenoma detection rate increased adenoma detection rate means of nbi colonoscopy miss or detection rates neoplasm miss rate neoplasm detection rates withdrawal time rates steadily demographics, indication for colonoscopy, and quality of preparation adenoma rates detection rates prolongation of extubation time colorectal neoplasm miss rate total number of adenomas flat adenoma detection rates general adenoma detection rate adenoma detection rate (ie, number of adenomas/total number of patients extubation time number of diminutive adenoma detection rates number of total and mean per-patient adenomas neoplasm detection rate prevalence of non-polypoid and the total number of adenomas|however, the pan-colonic nbi system significantly increased the total number of adenomas detected (p < 0.05) and the number of diminutive (<5 mm) adenomas detected (p < 0.05). the adenoma detection rates were 57.3% for patients examined by nbi and 58.3% for those examined by wl (p = .88). in 276 tandem colonoscopy patients, there was no significant difference of miss or detection rates between nbi or wl colonoscopy techniques. only hyperplastic polyps were found more frequently in the nbi group (p = .03). adenomas were detected more frequently in the nbi group (23%) than in the control group (17%) with a number of 17 colonoscopies needed to find one additional adenoma patient; however, the difference was not statistically significant (p = 0.129). nbi did not result in better detection of adenomas by an endoscopist with a known high detection rate using white light.|multicenter private practice setting involving 6 examiners with substantial lifetime experience (>10,000 colonoscopies), 1256 patients (men:women, 47%:53%; mean age, 64.4 y colorectal cancer (crc 434 patients aged 50 years or older with intact colons consecutive 50- to 69-year-old patients with positive immunologic fecal occult blood tests 130 patients (47%) had at least one neoplasm 276 tandem colonoscopy patients two hundred forty-three patients were randomized, 121 to neoplastic colonic polyps a total of 401 patients were included (mean age 59.4 years, 52.6% men eligible patients presenting for diagnostic colonoscopy elective colonoscopy adults
peak flow rate of failure with deterioration crp levels symptoms death in hospital and need for an additional course of antibiotics, both separately and in combination low pct levels changes in symptoms, peak expiratory flow, and sputum flora symptom scores (wheeze, dyspnoea, cough with and without mucus production, and awakening with dyspnoea), peak expiratory flow values (pef, expressed as % predicted), and sublingual temperature side effects peak flow and symptom scores resolution of symptoms gasometric and spirometric measures success rate shortness of breath, wheezing, or exacerbations of cough with or without sputum production need for additional courses of antibiotics pct levels death in hospital and need for additional antibiotics number of relapses clinical success rate duration of mechanical ventilation and hospital stay clinical cure at end of therapy visit (eot dyspnea, sputum production, and sputum purulence clinical and microbiologic response, serum c-reactive protein (crp) level (cutoffs 5 and 50 mg/l), and serum procalcitonin level (pct median time to the next exacerbation|the main effect parameter--the doctors' overall evaluation of the treatment--did not demonstrate any statistically significant difference between amoxicillin or placebo, 63% versus 64% of the patients. side effects were uncommon and did not differ between antibiotic and placebo. the median time to the next exacerbation was significantly longer in patients receiving antibiotic compared with placebo (233 d [interquartile range, 110-365] compared with 160 d [interquartile range, 66-365]; p < 0.05). symptoms improved in all three groups, improvements ranging from 0.54 to 0.75 points per day on a four point scale. the three groups were homogeneous at their admission and there were no statistical differences at their discharge. absolute risk reduction 17.5%, 95% ci 4.3-30.7, p=0.01). although crp levels were higher in the presence of bacteria (median, 33.0 mg/l [interquartile range, 9.75-88.25] vs 17 mg/l [interquartile range, 5.0-61.0] [p = .004]), pct levels were similar.|patients with exacerbations of copd who required mechanical ventilation 90 patients hospitalized due to an acute episode of copd patients with asthma or copd seen in general practice acute exacerbations of mild to moderate chronic obstructive pulmonary disease chronic obstructive pulmonary disease (copd patients with chronic bronchitis acute uncomplicated exacerbations of chronic bronchitis patients with moderate exacerbations of chronic obstructive pulmonary disease (copd acute exacerbations of chronic bronchitis in patients from general practice acute exacerbations of copd acute exacerbations of copd (aecopd acute episodes of chronic obstructive pulmonary disease (copd 243 exacerbations out of 205 patients from a patients with asthma or chronic obstructive pulmonary disease (copd copd exacerbation requiring mechanical ventilation group patients with chronic obstructive pulmonary disease in exacerbation moderate exacerbations of mild-to-moderate copd 93 patients with acute exacerbation of copd who required mechanical ventilation 195 patients enrolled 71 (36%) contacted their physician for symptoms of an exacerbation patients aged 40 years or older, smokers, or ex-smokers of 10 pack-years or more with spirometrically confirmed mild-to-moderate copd (fev(1) > 50% predicted and fev(1)/fvc ratio < 0.7) and diagnosed with an exacerbation were enrolled in the study ambulatory patients with mild to moderate asthma or copd when treated by their general practitioners 117 patients with amoxicillin/clavulanate (74.1%) and 91 with 173 patients, 362 exacerbations were treated, 180 with placebo and 182 with antibiotic chronic obstructive pulmonary disease chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation acute episodes of chronic obstructive pulmonary disease 310 subjects fulfilled all the criteria for efficacy analysis 131 general practitioners included 278 patients over a period of 30 months patients with chronic obstructive pulmonary disease in general practice patients with pneumonia, a temperature above 38.5 degrees c or heart rate over 100 were excluded for safety reasons
electromyographic recording of deep tendon reflexes spasticity, clonus, and hyperreflexia, and the complaints of muscle stiffness tiredness cybex flexion scores variables: spasticity, clonus, flexor spasms, gait and bladder function antispasmodic efficacy and safety pain relief painful spasms toxic effects on hepatologic, hematopoietic, or renal function efficacy and tolerability parameters good overall tolerability objective rating scale hepatic, renal, or hematological function resistance to passive stretch, clonus and hyperreflexia side-effects symptom, well-being and intoxication scores on a daily basis using visual analogue scales functionality and nursing care efficacy of baclofen antispastic effect and tolerability mild depressive effect on blood pressure safety, tolerability, and efficacy physical or psychological dependence clonus spasticity of the leg adductors side effects dry mouth and drowsiness muscle weakness alleviating flexor and extensors spasms moderate quadriceps spasticity muscle strength, bladder function and the activities of daily living sedation increase weakness adverse reactions total number and severity of side-effects elevated liver function test muscle strength observer rated severity and frequency of symptoms on numerical rating scales, administered standard measures of disability (barthel index), mood and cognition, and recorded adverse events muscular tonus joint and muscle pain muscle tone antispastic effect spasticity cybex ii isokinetic unit, timed gait, ashworth scale frequency of spasms, and clonus efficacy and tolerability levels of threonine somnolence and xerostomia motor weakness flexor spasms, pain and stiffness, resistance to passive joint movements, and tendon stretch reflexes focal spastic muscle contractions clinical spasticity and hyperreflexia tolerated functional status overall spastic state, spasms and clonus intractable neurogenic symptoms antispastic efficacy of tizanidine ease of nursing care antispastic efficacy muscle tone (ashworth scale) and type and frequency of muscle spasms (patient diaries efficacy and tolerance impaired bladder control, muscle spasms and spasticity hyperactive stretch reflexes and ankle clonus sedation, nausea and vomiting sleepiness, muscular weakness and dry mouth spasms and clonus (patient diaries range of joint movement subjective sensation of relief with reference to the symptoms of spasms adverse events adverse effects|we found that botulinum toxin produced a significant reduction in spasticity (p = 0.009) and a significant improvement in the ease of nursing care (p = 0.009). both drugs reduced the findings of spasticity, clonus, and hyperreflexia, and the complaints of muscle stiffness and cramping. tizanidine had a mild depressive effect on blood pressure. this double-blind cross-over study of 14 severely spastic inpatients with chronic multiple sclerosis reveals that once-daily doses of ketazolam, a new drug, are effective in reducing spasticity in a significant proportion of patients without significant side-effects. we found no toxic effects on hepatologic, hematopoietic, or renal function, acutely or for over 3 years of follow-up. both thc and plant-extract treatment worsened the participant's global impression. patient self-evaluation results also showed a significant reduction in clonus. while on baclofen, patients obtained a significant (p less than 0.001) reduction in spasticity compared to controls. in the fourteen subjects who completed the trial there was a statistically significant decrease in resistance to passive stretch, clonus and hyperreflexia without significant reduction of muscle strength. there was not statistically significant superiority of either diazepam or ketazolam, but both relieved symptoms significantly better than the placebo, as measured clinically and by electromyographic recording of deep tendon reflexes. tizanidine and baclofen improved the functional status of patients in 80% and 76% of cases, respectively, but there were no significant differences between the two drugs. overall, treatment with baclofen alone significantly improved moderate quadriceps spasticity as measured by cybex flexion scores. levels of threonine were elevated in serum and cerebrospinal fluid during treatment, but glycine levels did not change. as to the residual urinary volume, no relevant differences and alterations were determinated in the course of the treatment as well. a statistically significant benefit was noted in spastic muscle groups in the legs with concomitant significant reduction in hyperactive stretch reflexes and ankle clonus. both baclofen and tizanidine appear to be useful adjuncts in the treatment of spasticity in patients with multiple sclerosis. in contrast, muscle strength, bladder function and the activities of daily living were more improved on tizanidine than on baclofen. in the spasticity group, botulinum toxin a reduced the tone of all patients significantly, improved functionality and nursing care in eight of 12 patients, and alleviated painful spasms in five of five patients. tizanidine produced a significantly greater reduction than placebo in spasms and clonus (patient diaries) but no significant differences in ashworth scores. pain relief associated with both thc and cbd was significantly superior to placebo. the total number and severity of side-effects were equal in the two treatment groups.|14 severely spastic inpatients with chronic multiple sclerosis 47 patients of either sex at the age of 23 until 63 40 seriously handicapped patients with multiple sclerosis (ms 9 patients who were either chair-bound or bed-bound with chronic stable multiple sclerosis twenty-four patients with multiple sclerosis (18), spinal cord injury (4), brachial plexus damage (1), and limb amputation due to neurofibromatosis (1 106 patients with spasticity secondary to multiple sclerosis spasticity caused by multiple sclerosis multiple sclerosis patients attended as outpatients, but took the cme at home patients with multiple sclerosis (ms 50 patients for its effects in neurologic spasticity chronic spasticity of varying etiology 12 patients with spasticity and in eight patients with rigidity patients with multiple sclerosis patients with minimal to moderate spasticity spastic movement disorders of the lower extremities thirty-nine patients completed the study thirty men and women diagnosed with definite multiple sclerosis (ms three patients had transient hypotension and intoxication with rapid initial dosing of thc-containing cme 42 patients with spasticity due to stable multiple sclerosis sixty-six patients entered an eight week therapeutic trial and fifty-nine completed the trial 100 patients suffering from chronic spasticity due to multiple sclerosis twenty-one hospitalized patients with stable spasticity participated in the 6-week trial 26 ambulatory patients 16 patients with ms who presented with severe spasticity sixty-six patients entered the trial and forty-eight completed both treatment phases patients suffering from multiple sclerosis with spastic motor disturbances of the lower extremities seventeen patients, 13 males and 4 females, with moderate to severe spasticity caused by varying neurological disorders spastic patients chronic spasticity in multiple sclerosis ms patients spasticity due to multiple sclerosis
serious toxicity complete response peripheral neuropathy and hematologic and renal toxic effects gastrointestinal toxicity grade 3 to 4 (who distant metastasis rate myelosuppression median time to progression performance status (karnofsky), and weight loss survival time survival and 58 for response and toxicity survival analysis time to recurrence or overall survival progressive disease in arm b. median survival severe neurotoxicity overall response rate response and toxicity survival or delayed recurrence of disease long-term survival median number of chemotherapy cycles survival rates reversible renal toxicity grade 2 serious infections requiring hospitalization overall survival time rates of survival whole survival leukopenia of severe quality of life local tumor response toxic symptoms of varying severity severe weight loss 5-year survivals survival advantage survival response rate histology, performance status, extent of operation, and tumor and nodal status death objective response 2-year survival rate toxic death mean survival time to progressive disease excellent performance status, minimal weight loss, and visible disease on radiography improved survival 5-year survival rate overall response rates (complete response [cr] plus partial response [pr toxic effects incidence of death with metastases, metastasis-free survival (mfs) nor overall survival (s acute or late radiation pulmonary or oesophageal toxicity drug mortality response rates toxicity response rates or in survival overall survival, disease-free survival, and relapse pattern severe vomiting recurrence overall survival adjusted survival rate and disease-free survival rate survival and response rates survival benefit response rate and survival response rate and morbidity partial response local response unacceptable toxicity median survival times (5-year survival karnofsky performance status score five-year survival toxic reactions response rate, time to progressive disease and overall survival 5-year disease-free survival rate local control rate and survival acute toxicity median survival major clinical responses 5-year survival rates median survival time 3-year disease-free survivals disease-free and overall survival acute toxicity (dysphagia, myelosuppression 5-year survival|no statistically significant differences in survival time were found between the two treatment techniques. survival was significantly shorter in patients with histological involvement of the resected intrathoracic nodes (log-rank test p much less than 0.001). there were no differences in time to recurrence or overall survival (not stratified by histology) between the two groups, even when analyses were adjusted for prognostic variables. when compared by chemotherapy, immunotherapy, and performance status, no statistically significant difference was found in response rates or in survival. the 3-year disease-free survivals of the chemotherapy and control groups were 37% and 42%, respectively. high-dose radiotherapy preceded by high-dose chemotherapy was more toxic than radiotherapy alone and did not result in this study in any benefit in terms of response rate, time to progressive disease and overall survival. no drug mortality was noted, but toxic symptoms of varying severity were seen after 43.6% of the drug courses. the overall response rate to chemotherapy was 28%; there were no significant differences according to major prognostic criteria. the 2-year survival rate was 14% in group a and 21% in group b (p = .08). major clinical responses were observed in 31 of 56 (55%; 95% cl, 42% to 68%) patients treated with combination therapy and 37 of 58 (64%; although the patients receiving combination chemotherapy had a slightly longer median survival (20.43 weeks versus 13.57 weeks), it was not statistically significant (p = 0.09). toxicity on the chemotherapy arm was hematologic (world health organization [who] grade greater than 3) in 12% of ce'p and in 13% of mec' courses and gastroenteric (who grade greater than 3) in 24% of ce'p courses and in 8% of mec' courses. survival was directly related to initial performance status in both groups (p < .01) and was significantly (p < .01) longer for patients with squamous cell carcinoma than for those with nonsquamous cell carcinoma. the median survival was greater for those in group 1-13.8 versus 9.7 months (p = 0.0066 by log-rank test). no evidence of improved survival or delayed recurrence of disease was seen in treated patients as a whole or when examined by cell type and by postsurgical tnm category. thereafter the adjusted survival rate and disease-free survival rate for group a became significantly higher than for group b (p = 0.044 and p = 0.036, respectively). the 5-year survival rate was 67% in the chemotherapy group and was 56% in the control group (p = .050). neither the incidence of death with metastases, metastasis-free survival (mfs) nor overall survival (s) were significantly affected by treatment with the drug. eighty-one patients were evaluated and for the group as a whole survival was better in the undifferentiated group assigned to receive adjuvant chemotherapy but survival in the patients with squamous tumours was not significantly prolonged. median survival was 11.74 and 10.03 months, respectively, without statistically significant differences between the two groups of patients. induction chemotherapy produced a better response rate and a trend of improved survival (4 months) but a significant survival advantage was not achieved (p < 0.11), probably because of the small number of patients enrolled in the trial. the 5-year survivals were 3%, 3%, and 1%, respectively (p = 0.56). the treatment groups were comparable in terms of age, sex, performance status, histology, disease extent, and weight loss.|non-small-cell lung cancer limited squamous cell carcinoma of the lung patients had documented non-small-cell cancer of the lung with stage iii disease established by clinical or surgical staging patients with limited squamous cell carcinoma of the lung eligible patients with stage i disease were classified by known prognostic factors nonresectable non-small-cell lung cancer patients who underwent radical surgery for non-small-cell lung cancer (nsclc patients with unresectable non-small cell lung cancer after resection of carcinoma of the lung two hundred and one patients with stage iiib or iv nsclc locally advanced epidermoid bronchogenic carcinoma july 1985 to december 1987 patients with stage iii non-small-cell lung cancer 177 patients received advanced non-small-cell lung cancer 17 patients advanced non-small cell lung cancer (nsclc 353 patients patients with advanced non-small-cell carcinoma of the lung (nsclc patients for whom non-small cell lung cancer had been resected completely 61 eligible patients were comparable in terms of age, performance status, histology and treatment 233 patients were eligible 123 patients (62 treated and 61 controls) eligible for survival, 115 were fully evaluable for response (58 treated and 57 controls eighty-two patients with histologically confirmed lung cancer non-small-cell lung cancer patients with complete surgical resection of disease 66 consecutive patients with stage iii unresectable nsclc patients (n = 102) with stage iv non-small-cell lung cancer a total of 121 patients were enrolled in the study, of whom 7 (5.8%) were ineligible patients with advanced metastatic non-small cell lung cancer patients with non-small cell lung cancer squamous cell lung cancer, 50 patients with locoregional disease between february 1983 and january 1986, 23 centers across canada entered 251 patients on study national cancer institute of canada (ncic among them, 24 cases (7.2%) were excluded, because of incomplete resection (15), pathologically benign tumour (3), small cell lung cancer (2) and other factors (4 patients with locally advanced, unresectable non-small cell lung cancer patients with completely resected stage i non-small-cell lung cancer 319 patients with locally advanced, unresectable non-small cell lung cancer who had no evidence of extrathoracic metastases four hundred and seventeen patients were randomized into three groups; 132 patients received patients with nsclc at pathologic stage i who have undergone radical surgery benefit from adjuvant chemotherapy regionally advanced unresectable non-small-cell lung cancer (nsclc advanced non-small cell lung cancer completely resected stage iii non-small-cell lung cancer lung cancer (chubu, japan patients who had progression of disease after chest irradiation only were treated with two hundred nine patients with completely resected stage iii non-small-cell lung cancer patients with stage iv non-small-cell lung cancer 726 patients with carcinoma of the bronchus patients with locoregional squamous cell lung cancer locally unresectable non-small cell lung cancer patients with extensive non-small cell lung cancer patients with medically inoperable or unresectable stage iii non-small cell lung cancer treated with seventy eligible patients patients with resected stage i lung cancer eight hundred sixty-five patients with a microscopically curative resection for carcinoma of the lung eligible patients in chemotherapy (n = 90) and control groups (n = 91) were equally distributed after a successful curative resection of a carcinoma of the lung in men patients with medically inoperable or unresectable stage iii non-small cell lung cancer from april 1985 to september 1988, 128 patients with advanced non-small-cell lung cancer (nsclc nonresectable squamous cell and large-cell lung carcinoma locally advanced non-small-cell lung cancer one hundred ten patients with t1-3n0 all patients were ambulatory and had measurable or evaluable disease patients with advanced non-small-cell lung cancer patients with locally or regionally advanced non-small-cell lung cancer radiation patients with non-small cell lung cancer who have inoperable metastatic non-small cell lung cancer patients who developed progressive disease while receiving stage iii non-small-cell lung cancer 87 patients with inoperable, extensive non-small cell lung cancer (nsclc eligible patients in group 1 (n = 78) and group 2 (n = 77) were comparable in terms of age (median, 60 years), sex, performance status, histologic features, stage of disease, and completeness of radiation therapy locally advanced unresectable non-small-cell lung cancer metastatic non-small-cell lung cancer three hundred and thirty-three resected cases were registered 188 evaluable patients, 97 received chemotherapy and 91 were in the control arm patients had measurable or evaluable disease, with either distant metastases (82.5%) or bulky limited disease considered inoperable or unsuitable for radical radiotherapy patients with locally advanced non-small cell lung cancer treated with between june 1980 and december 1983, 111 patients with inoperable epidermoid bronchogenic carcinoma (limited disease three hundred and nine cases were eligible: 155 cases in group a (p-stage i 93, ii 19, iii 43) and 154 in group b 107 eligible patients, 15 (14%) had complete responses and 20 (19%) had partial responses thirty-five of 62 (56.4 269 patients entered in the study, 101 had recurrence and 127 have died patients with tnm stage iv non-small-cell lung cancer bronchogenic carcinoma eighteen centers participated in the three-arm schema (150 patients); centers choosing not to participate in a study with a no-chemotherapy arm followed a two-arm schema comparing vp with cap (101 additional patients
maternal tolerance scale remaining dry and time to dry, non-attendance and dropout rates maternal anger functional enuresis (fe|a wide variety of outcome measures showed improvement for the entire sample regardless of specific mode of delivery. two studies examined the effectiveness of the body-worn alarm in out-patient treatment of childhood nocturnal enuresis. no significant intervention effect was found for any of the outcome measures recorded during treatment, at discharge or six-months post discharge. functional enuresis (fe) was present in the majority of our patients (168/204). both procedures were equally effective, and in the total sample a better response to treatment was predicted by the child's report of being teased by siblings.|childhood enuresis nocturnal enuresis education 168 subjects, aged from 6 to 11 years twenty-three children, ranging in age from 4 to 14, received dry bed training without the additional use of a urine alarm childhood nocturnal enuresis 40 children, previously untreated by conditioning methods, treated with either the body-worn alarm or the traditional pad and bell alarm 74 enuretic children 270 children collected longitudinally fifteen school nurse-led community enuresis clinics in leicestershire, uk
sleep disorders body weight gain efficacy and safety slight drowsiness dyspnea bronchodilatation and normalizing pulmonary function total ige or igg4 oxatomide persistent coughing monitoring cough, dyspnea at rest, dyspnea following exercise, wheezing, sleep disorders levels of eosinophil cationic protein and total asthma symptom scores efficacy intensity of wheezing|the levels of eosinophil cationic protein and total asthma symptom scores were significantly reduced during treatment with oxatomide. in all parameters examined, oxatomide was significantly more active than placebo at the first examination (p < 0.05 and p < 0.01).|eight patients (7 males, 1 female), aged 22 months childhood asthma adults infantile bronchial asthma asthma in children young children sixty-four asthmatic children of both sexes, aged between 5 and 16 years paediatric clinic; sixteen children divided into two balanced groups took
improvement in eular criteria and secondary endpoints were patient and physician global evaluation, incidence of remission and biochemical and clinical adverse events diarrhea, nausea, and alopecia incidence of side reactions functional disability efficacy and safety profile disease activity parameters rate of achievement of 20% improvement in acr criteria (acr20 general effective rate and notable effective rate larsen scores and erosive joint counts mean time to initial response erosive joint counts improvement and remission measures of function and heath-related quality of life (mhaq scores, all scales and disability index of the haq, weighted top 5 score of the pet, 5 of 8 scales and physical component score of the sf-36, and work productivity safe and well tolerated gastrointestinal symptoms, weight loss, allergic reactions, skin rash, and reversible alopecia signs and symptoms of active ra, delayed disease progression haq scores rheumatoid arthritis serious adverse drug effects alopecia overall incidences of adverse events mean das28 adverse events diarrhea and nausea adverse events (aes disease activity deltahaq disability index asymptomatic transaminase elevations symptoms, signs and joint functions initial rate of enhancement (ire) and the maximal signal intensity (si) enhancement (me mhaq scores, haq disability index, weighted top 5 score of the pet, physical component score of the sf-36, and bodily pain scale discontinuation rates acr20 response rates ire improved haq scores safety and effectiveness reversible agranulocytosis elevated transaminases mean haq disability index (di efficacy and safety adverse events (aes) resulting in treatment withdrawal response rate function and health-related quality of life american college of rheumatology improvement response rates incidence of adverse events tender joint count functional ability adverse events or late toxicity rheumatoid arthritis activity tolerated slowing of disease progression haq di with lef4(-0.60 sf-36 scales and component scores overall rates of effectiveness esr, tender and swollen joint counts, the duration of morning stiffness, disease activity score-28 (das 28), visual analogue scale (vas) and health assessment questionnaire (haq incidence of aes rate of withdrawal due to adverse events mean change in total sharp radiologic damage scores acr 50% response rate pet score, sf-36 physical component score, and work productivity disease progression response rates toxicity severe gastrointestinal symptoms and hepatotoxicity acr20 responder rates mhaq scores, 5 of 8 scales and disability index of the haq patients' functional ability global assessments, acr20% response gastrointestinal symptoms, skin rash, alopecia, nervous system symptoms, decreased leukocyte count, and elevation of alanine aminotransferase (alt synovial inflammation symptoms, signs, and joint function tender joint count (tjc), swollen joint count (sjc) and health assessment questionnaire disability index (haq di transiently abnormal liver function das28 response diarrhoea radiographic progression diarrhoea, nausea, and alopecia gastrointestinal complaints, skin rash, and reversible alopecia remission physical function nausea incidence of infections upper respiratory tract infections, diarrhea, nausea and vomiting, rash, reversible alopecia, and transient liver enzyme elevations das28 response rate, and secondary efficacy outcomes disease activity assessed by das 28 comparable disease activity score 28 reduction rates ra activity safety and efficacy side effects larsen scores mean haq scores radiographic disease progression physical function and health-related quality of life sustained retardation of radiographic progression acr response rates opportunistic infections rates of remarkable improvement clinical signs and symptoms demri scans health assessment questionnaire (haq health assessment questionnaire (haq) disability index (haq di) and the physical component score of the medical outcomes survey 36-item short health assessment questionnaire disability index tender and swollen joint counts and investigator's and patient's overall assessments acr response and success rates health assessment questionnaire (haq), modified health assessment questionnaire (mhaq), problem elicitation technique (pet), medical outcomes study short form 36 (sf-36), and questions regarding work productivity serious treatment-related adverse events|disease activity assessed by das 28 decreased significantly in all groups: the results were comparable in groups treated with mtx and lef and significantly more prominent in the group treated with a tnf-alpha blocker. by the fourth to sixth month, the response was comparable on both groups (6/6 and 6/8 patients achieving acr 50 in the daily and weekly dose, respectively) and prevailed through the end of the study. significant improvements in function and health-related quality of life occurred in patients with ra during treatment with leflunomide or methotrexate. improvement in synovial inflammation as measured by ire was significantly better with leflunomide than with methotrexate over 4 months of therapy. adverse events (aes) resulting in treatment withdrawal were higher in the 10 mg (15.3%) than in the 20 mg treatment group (12.0%), as were serious adverse events (saes): 12.9 vs 10.0%. leflunomide, though effective, was associated with adverse events and has not been extensively studied in the indian population. changes in larsen scores and erosive joint counts with leflunomide and sulfasalazine at 6 months showed significantly less radiographic progression than placebo. lef was statistically significantly superior to mtx in improving physical function as measured by the haq di over 24 months of treatment. lef, mtx, and ssz treatment resulted in statistically significantly less radiographic progression compared with placebo at 6 and 12 months: for protocol us301, lef versus placebo p = both leflunomide and mtx could improve the symptoms, signs, and joint function, but there were no changes in x-ray observations of patients with rheumatoid arthritis. deltamean haq -0.65 v -0.36, p=0.0149; deltahaq disability index -0.89 v -0.60, p=0.059). diarrhea and nausea were less frequent during the open-label extension in patients who did not receive a lef loading dose. leflunomide and sulphasalazine were significantly superior to placebo the incidence of side reactions was lower in lef group (17.86%) than in mtx group (40.00%, p < 0.05). discontinuation rates were similar in both treatment groups (23.1% in the leflunomide group and 24.8% in the placebo group), as were the overall incidences of adverse events (89.2% vs. 89.5%, respectively). 1.16 for the lef-group) was significantly different neither in between the both treatment groups nor in comparison to the week 8 evaluation. comparable disease activity score 28 reduction rates were noted at trial termination for all 3 treatment arms: leflunomide and methotrexate treatment improved measures of physical function and health-related quality of life significantly more than placebo (p<.001 and p<.05, respectively). the safety profiles of both groups were comparable. leflunomide significantly improved patients' functional ability compared to placebo (p < or = 0.0001) and sulfasalazine (p < or = 0.01) at 6 months. the incidence of infections was similar between the treatment and placebo groups; no opportunistic infections were seen.|one hundred six patients with active ra refractory to at least one disease modifying antirheumatic drug (methotrexate obligatorily patients with active ra (n = 39 358 patients patients with active rheumatoid arthritis failing mtx monotherapy patients with refractory rheumatoid arthritis patients with active rheumatoid arthritis (ra rheumatoid arthritis patients treated with cohorts of patients with ra from the initial study who volunteered to continue treatment with leflunomide or sulfasalazine rheumatoid arthritis patients 6, 12, and 24 month patient cohorts 482 patients studied were predominantly women (mean age, 54 years; mean disease duration, 6.7 years) for whom a mean of 0.8 disease-modifying antirheumatic drugs had failed 106 inadequate responders entered the double blind phase; 56 received patients with active rheumatoid arthritis (ra) treated for 6 months 482 patients randomized in a 3:3:2 ratio thirty-four patients (17 treated with leflunomide and 17 with seventy-eight patients with active ra patients with rheumatoid arthritis patients with active rheumatoid arthritis nave patients with ra (mean time since diagnosis: 2.3 years patients with active ra patients with active ra ((das28) >3.2) who were enrolled in the first open label phase of the relief study received 358 patients with rheumatoid arthritis 999 patients severe rheumatoid arthritis (ra sixteen patients were included (18-72 years, disease duration 2-32 years patients with rheumatoid arthritis--longterm treatment with severe rheumatoid arthritis four hundred two patients rheumatoid arthritis (ra patients continuing into the second year of treatment with > or = 1 dose of study medication and > or = 1 followup visit after week 52, consisted of 235 patients (lef n = 98; placebo n = 36; mtx n = 101 active rheumatoid arthritis (ra patients with active rheumatoid arthritis who are receiving methotrexate therapy active rheumatoid arthritis patients with ra with an inadequate response to leflunomide monotherapy patients with persistently active rheumatoid arthritis 402 patients with active rheumatoid arthritis (ra patients with rheumatoid arthritis (ra) in china forty-seven university and private rheumatology practices in the united states and canada 81 patients with ra refractory rheumatoid arthritis patients rheumatoid arthritis 84 patients patients with persistent rheumatoid arthritis, as defined by american college of rheumatology (acr) criteria, despite receiving methotrexate for at least 6 months patients who complete 2 years of treatment patients refractory to conventional disease-modifying agents refractory rheumatoid arthritis patients inadequately responding to leflunomide 402 ra patients patients with rheumatoid arthritis (ra 20 centers in the united states and canada five hundred and sixty-six patients with active rheumatoid arthritis
overall survival of ecmo survival intracerebral hemorrhage|extracorporeal membrane oxygenation allows lung rest and improves survival compared to conventional ventilator therapy in newborn infants with severe respiratory failure. all three treatment groups (cmt and ecmo in phase i and ecmo, phase ii) were comparable in severity of illness and mechanical ventilator support.|neonatal respiratory failure 12 infants with birth weight greater than 2 kg met objective criteria for high mortality risk thirty-nine newborn infants with severe persistent pulmonary hypertension and respiratory failure who met criteria for 85% likelihood of dying neonates with persistent pulmonary hypertension of the newborn newborn infants with severe respiratory failure newborns with respiratory failure
bone pain body height occasional gastroenteric discomfort survival or in objective bone response rate side-effects vertebral index pain intensity, pain frequency, general well-being and who pain score urinary calcium urinary calcium, ohp and serum ictp levels urinary calcium, hydroxyproline (ohp) and serum cross-linked carboxyterminal telopeptide region of type i collagen (ictp) levels bone remineralization degree of hypercalcaemia and hypercalciuria, and decreases pain frequency of pathologic fractures, hypercalcemia, and bone pain hypercalcemia or hypercalciuria skeletal-related morbidity serum calcium concentration control of bone pain sclerosis or stabilisation of lytic metastases mean baseline pain daily visual analogue scales (vas) and analgesic diaries pain with dichloromethylene diphosphonate gastrointestinal toxicity myalgia adverse events efp pain palliation pain scores or analgesic requirements skeletal morbidity rate skeletal complications pain relief median duration of pain response daily oral morphine equivalent analgesic requirement pain intensity quality of life activity scores episodes of severe pain bone pain, episodes of hypercalcemia, or development of pathologic fractures urinary calcium/creatinine and hydroxyproline/creatinine ratios, and bone alkaline phosphatase concentrations deterioration of performance status pain and mobility clinical and laboratory parameters of toxicity efficacy skeletal complications, including pathologic fractures, the need for radiation to bone or bone surgery, spinal cord compression, and hypercalcemia (a serum calcium concentration incidence of bone-related complications (pathological fractures, tumor-induced hypercalcemia, need for radiotherapy), sclerotic response of lytic lesions, who performance status, and analgesic score nausea and vomiting progression of vertebral fractures gastrointestinal adverse events event-rates totally free of bone pain osteolysis of multiple myeloma skeletal morbidity and the radiologic course of metastatic bone disease bone pain and no deterioration in performance status and quality of life trabecular bone volume performance status and reduced consumption of analgesics percentage of patients feeling no pain skeletal events bone-derived isoenzyme alkaline phosphatase values event-free period (efp), radiologic course of disease, and survival bone resorption markers measured included urinary calcium (uca), hydroxyproline (hyp), and the collagen breakdown products: ntx, crosslaps and free dpd tolerated clinical (pain, karnofsky, survival), biological and radiological radiologic skeletal lesions healing of lytic lesions symptomatic response rate or analgesic requirement bone pain, use of analgesic drugs, performance status, and quality of life mean pain symptomatic improvement median time to the occurrence of the first skeletal complication bone resorption excretion of hydroxyproline average change in dmed intensity of pain severe adverse reactions or worsening of chemotherapy-induced toxicities vas scores for general pain, pain at rest, and pain total-body bone mineral density analgesic effect metastatic bone pain skeletal complications: pathologic fractures, spinal cord compression, irradiation of or surgery on bone, or hypercalcemia skeletal events (pathologic fracture, irradiation of or surgery on bone, and spinal cord compression), hypercalcemia (symptoms or a serum calcium concentration compliance symptomatic response bone pain, analgesic-drug use, performance status, and quality of life mean pain scores mean overall pain toxicity delayed progression of bone metastases fasting calcium excretion fasting urinary calcium excretion skeletal pain relief median survival or survival rates patient survival rate of bone resorption serum calcium and urinary calcium excretion time to progressive bone disease (evaluated by blind extramural review), and improvement in pain (according to a 6-point self-assessment scale analgesics requirement karnofsky performance status skeletal morbidity visual analogue scales (vas pain parameters, analgesic consumption and performance status skeletal complication visual analog pain scores and adverse events median time to radiotherapy proportion of patients with progression of osteolytic bone lesions iliac bone biopsy vertebral deformity deoxypyridinoline resorption markers safety and efficacy pain score, performance status, and changes in analgesic use osteoclast number time to the first skeletal complication subjective benefit event-rates of systemic treatment and radiotherapy pain score bone alkaline phosphatase levels visual analog pain score urinary hydroxyproline levels occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures histologic bone parameters height loss bone pain, use of analgesics, quality of life, performance status, bone tumor response, and biochemical parameters bone pain (visual analog score), analgesic use, and compliance with therapy analgesic efficacy analgesic use increased with disease progression thickening of the preexisting osteolytic lesions visual analogue scale assessments number and/or size of bone lesions palliative effects pain bone pain and mobility scores narcotic scores, urinary calcium/creatinine and hydroxyproline/creatinine ratios, serum osteocalcin and bone alkaline phosphatase concentrations, and bone lesion (radiologic) response daily consumption of analgesics karnofsky performance status, pain score (measured by a visual-analogue scale) and analgesic requirement pain scores urinary calcium levels median time to bone progression opioid requirements|reduction in bone pain was accompanied by decreases in urinary calcium/creatinine and hydroxyproline/creatinine ratios, and bone alkaline phosphatase concentrations. urinary calcium, ohp and serum ictp levels increased in group c and decreased in groups a and b, but only the decrease of urinary calcium levels of group b was significant (p = 0.003). unlike the controls, the patients who received cl2mdp presented a significant reduction in urinary calcium (p = 0.003) and in hydroxyproline (p = 0.05) on the 7th day. analgesic use increased with disease progression to a similar extent in both groups (59% increased use in the clodronate group v 64% of placebo group; difference not significant). bone resorption decreased significantly in patients with etidronate compared with those with placebo (p < 0.05). no significant differences were seen in median survival or survival rates between the groups. as regards mean worst pain a substantial numerical fall was registered for the treatment group, 21 mm, but the improvement was not significant compared to that of the placebo group. oral pamidronate produced either sclerosis or stabilisation of lytic metastases for at least 24 weeks in 5 of 24 and 3 of 23 patients at the 300 and 150 mg dose levels, respectively. the event-free period (efp), radiologic course of disease, and survival did not improve. there were no adverse effects other than transient diarrhea in some patients. ci2mdp treatment resulted in a marked reduction in bone pain, with no progression of radiologic skeletal lesions during the first year. although the repeated measures analysis showed a significant height loss, there was no difference between treatment arms (p = .98). no difference in clinical and laboratory parameters of toxicity was evident between the placebo and cl2mdp arms of the trial. bone-derived isoenzyme alkaline phosphatase values increased in all groups, with a significant difference between baseline and final values in the 1,600-mg and 3,200-mg groups (p < .01 and p = .03, respectively). serum calcium and urinary calcium excretion decreased significantly in both groups, but the changes were greater in the clodronate group. analgesics requirement increased in both groups, but significantly more in patients receiving placebo (p = 0.042), in whom increase in opioid requirements was particularly evident. in weeks 0-6, the daily consumption of analgesics was reduced in 3 patients in the 45-mg arm, in 4 patients in the 60-mg arm, and in 7 patients in the 90-mg arm. the skeletal morbidity rate was significantly reduced at 12, 18, and 24 cycles in patients treated with 90 mg of pamidronate (p = .028, .023, and .008, respectively). resorption markers did not decrease after placebo, but ntx and crosslaps both decreased by 70% after pamidronate (p = 0.001). the proportion of patients who had any skeletal events was significantly lower in the pamidronate group (24 percent) than in the placebo group (41 percent, p < 0.001), and the reduction was evident in both stratum 1 (p = 0.04) and stratum 2 (p = 0.004). however, in patients treated with pamidronate there were fewer episodes of severe pain (p=0.02) and a decreased reduction of body height of 1.5 cm (p= 0.02). the results do not support the superiority of combined intravenous and oral treatment with clodronate compared with oral administration only. no difference was seen in the symptomatic response rate or analgesic requirement between patients treated with sodium etidronate and placebo. patients in the 90-mg group had more pronounced bone remineralization as measured by total-body bone mineral density. marked improvement in bone pain was observed in 44% of patients receiving pamidronate compared to 30% in controls (p = 0.025). the average change in dmed was -6.4 (se = 2.9) following clodronate and was +24.6 (se = 14.9) following placebo (p = 0.03). there was significantly less increase in bone pain (p=0.046) and deterioration of performance status (p=0.027) in the pamidronate group than in the placebo group.|fifty patients with bone pain caused by bm ninety-four previously untreated patients with stage ii or iii multiple myeloma patients with breast cancer 392 treated patients bone metastases from breast cancer seventy patients were enrolled in this study, for a total of 265 infusions 64 patients who completed 12 weeks of therapy patients with advanced metastatic cancer forty-eight patients took nonsteroidal antinflammatory drugs, while 22 patients received patients with stage iii multiple myeloma eight patients had moderate to severe bone pain patients with advanced metastatic bone disease ambulatory female patients age 18 years or older with breast cancer metastatic to bone and a life expectancy of at least 3 months were eligible for the study three hundred seventy-two women with breast cancer who had at least one lytic bone lesion and who were receiving hormonal therapy protocol 19 aredia breast cancer study group 350 patients from 23 hospitals one hundred eighty-two patients who received metastatic bone disease sixty-one patients were treated as outpatients patients with stable disease and persistent bone pain patients with malignant osteolytic bone disease and pain patients with advanced osteolytic bone disease metastatic bone pain fifty-five patients with hormone refractory prostate cancer and painful bone metastases patients with breast cancer and lytic bone metastases protocol 18 aredia breast cancer study group women with breast carcinoma metastatic to the skeleton multiple myeloma palliation of pain arising from bone metastases (bm patients with breast carcinoma metastasizing to the skeleton patients with refractory bone pain due to metastatic bone disease patients with advanced multiple myeloma patients with prostate cancer bone metastases from tumors poorly responsive to chemotherapy sixty-six patients with poorly responsive tumors such as non-small cell lung cancer (nsclc), bladder cancer, gastrointestinal cancers, kidney cancer, melanoma and metastatic carcinoma of unknown origin entered the study patients with advanced malignant osteolytic bone disease and bone pain 12 evaluable patients treated with patients with metastatic bone disease, 60 patients with established osseous metastases and persistent bone pain patients with metastatic bone disease and pain 173 newly diagnosed multiple myeloma patients of women with advanced breast cancer and lytic bone lesions thirty-eight normocalcemic patients with bone metastases from breast carcinoma seventy patients eighty-four patients with tumor-induced osteolysis 24 patients with metastatic bone disease and pain patients with bone metastases from tumors poorly responsive to chemotherapy fifty-five patients with progressing bone metastases fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy patients with painful bone disease from prostatic cancer after failure of hormonal therapy women with stage iv breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion affected patients patients with metastatic breast cancer women with lytic bone metastases from breast cancer treated with hormone therapy fifty-seven patients all patients had hormone refractory metastatic prostatic cancer and bone pain requiring analgesics patients with breast cancer, prostate cancer and myeloma patients with newly diagnosed multiple myeloma who required chemotherapy, 300 patients fifty-two patients with painful bone metastases 47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer patients with stage iii multiple myeloma and at least one lytic lesion women with stage iv breast cancer who have osteolytic bone metastases patients with painful bone metastases breast cancer patients 66 patients enrolled, 9 were observed for one month or less; 7 were followed for two months; only 50 patients were followed for more than 2 months and could be adequately evaluated patients with bone metastases patients with painful osteolytic bone metastases 295 patients with lytic bone metastases from breast cancer cancer patients with painful osteolytic bone metastases who had failed initial treatment with hormones and/or chemotherapy 380 of 382 randomized patients, 185 receiving pamidronate and 195 receiving patients with metastic prostatic cancer patients with painful bone metastases from prostatic cancer patients with bone metastases from breast cancer finnish leukaemia group patients with osteolytic metastases from breast cancer ten women with skeletal metastases from breast carcinoma received
numeric rating scales morphine requirements pain relief serious side effects average pain scales pain scales|no serious side effects were observed in this study.|patients with terminal cancer pain terminal cancer pain patients
iop, medications, need for surgery, or visual function efficacy and safety intraocular pressure (iop), peripheral anterior synechiae, corneal endothelial cell count, and complications peripheral anterior synechiae iop|there was no significant difference in iop, medications, need for surgery, or visual function between groups at the 1-year visit.|in eyes with synechial primary angle-closure or primary angle-closure glaucoma 2010 elsevier inc primary angle-closure glaucoma seventy-seven eyes (77 patients) were randomized to the iridotomy group, and 81 eyes (81 patients eligible patients consecutive patients older than 40 years with synechial primary angle-closure or primary angle closure glaucoma were recruited eyes with synechial primary angle-closure or primary angle-closure glaucoma
health status psychosomatic discomfort scale arterial oxygen tension cost and effectiveness asthma-related emergency department visits knowledge of asthma shown quality of life scores of knowledge of drugs forced expiratory volume in one second (fev1 mortality or morbidity hospital admissions number of urgent care visits patients' perceptions of asthma severity and both medication severity rating self-management ability or asthma morbidity number of days lost through sickness scheduled visits number of days in hospital knowledge scores quality of life, knowledge and need for nursing number of days in hospital and emergency visits asthma morbidity asthma-related emergency visits severity of their asthma diurnal variation rating evening peak expiratory flow rate percentage mean duration of illness resources, productive output and in health status severe asthmatics|the self-assessments all showed that patients in the intervention group felt better than those in the control group. the knowledge test score of the experimental group was found to have decreased to the level of the control group. neither group showed any change in self-management ability or asthma morbidity that differed significantly from changes in the control group. the intervention group had significantly fewer asthma-related emergency visits (16 visits per 100 persons) than did the control group (39 per 100 persons); p = 0.0005 for the 12 months of follow-up. changes in the use of resources, productive output and in health status were measured for the patient education group and the control group. a statistically significant association was noted between patients' perceptions of asthma severity and both medication severity rating (p < .001) and diurnal variation rating (p = .003) and evening peak expiratory flow rate percentage (p = .019). one year after the end of the school, we could find no differences between the two groups (school versus controls) with regard to the number of urgent care visits (9 vs 9), scheduled visits (22 vs 21) and hospital admissions (2 vs 2). the asthmatic nurse educator was generally more effective in achieving short-term reduction of emergency department visits. knowledge about the use of drugs was significantly increased in the groups who received the material after three months and persisted after 12 months. there were significant improvements in knowledge scores after both types of education.|adults who have asthma people with asthma adult patients at an "asthma school 360 asthmatics attending the clinic between 1989 and 1994: 53, 45 and 2% of them were suffering from extrinsic, intrinsic and occupational asthma, respectively 274 patients were reassessed after one 1 year patients with asthma to decrease utilization of emergency services adults with asthma educating asthmatic patients in primary care up to november 1994, 430 adult asthmatics were recruited, classified and managed according to the recommendations of the international guidelines forty four patients were recruited, stratified according to the severity of their asthma and randomized into two groups: 22 patients attended the school, and 22 patients did not 339 patients by means of a questionnaire 177 patients with asthma in general practice 119 patients in the intervention group and the 122 in the control group, 185 (76%) were available for follow-up general practice two sites--an urban emergency room and a suburban emergency room adult asthma patients at a special "asthma school asthmatic patients 241 asthma patients between the ages of 18 and 70 years patients with asthma 62 patients adult asthmatics adult asthmatics and to reduce use of emergency department services for asthma attacks thirty-four patients were educated individually and 34 patients were educated in small groups 323 patients age 18 to 50 years who were members of the kaiser foundation health plan for > or = 1 year in a randomized control trial of an asthma education program
circulating eosinophilocytes, serum ige, orosomucoid, hla-antigens, and immunofluorescence of skin biopsies eczema pruritus, sleeplessness and antihistamine consumption disease activity serum total and milk-specific ige concentrations mean reduction in surface area affected by eczema percentage of surface area mean concentration of essential amino acids in plasma length standard deviation score severity score activity of atopic dermatitis atopic eczema eczema activity, number of areas affected, pruritus, sleeplessness, and antihistamine usage skin severity score weight-for-length values dermatitis severity energy intake gastrointestinal reactions scorad index|thirty seven breast fed infants with eczema were studied to see whether changes in their mothers' diets affected their skin condition. four patients reported of less pruritus, sleeplessness and antihistamine consumption (three vivasorb, one placebo) while 21 did not (13 vivasorb, eight placebo). there was no correlation between a positive prick test to egg and cows' milk antigen and response to the trial diet. the mean concentration of essential amino acids in plasma was lower in group after six weeks, there was a significant reduction in all three groups in the percentage of surface area involved (controls, median reduction (mr) = 4.9% (95% confidence interval 1.5%, 11.9%); whey hydrolysate group, mr = 17.8% (8.3%, 23.0%); casein hydrolysate group, mr = 5% (1.6%, 21.2%), and skin severity score (controls, mr = 15.9 (5.0, 22.5); whey hydrolysate group, mr = 21.8 (12.8, 30.2); casein hydrolysate group, mr = 13.5 (3.4, 38.0). in the aa group there was a significant increase in the length standard deviation score (p < 0.04), whilst there was no difference in the ehf group. this response rate to the diet was not statistically significant. the mean reduction in surface area affected by eczema was significantly greater (p = 0.02) in the group receiving dietary advice (from 19.6% to 10.9% area affected) than in the control group (from 21.9% to 18.9%).|fifty-five such children eighty five children (median age 2.3 years, range 0.3 to 13.3 years) with refractory atopic dermatitis affecting more than 12% of the body surface area nineteen mothers and babies took part in a double blind crossover trial of exclusion of egg and cows' milk, and 18 took part in open exclusion of 11 foods followed by double blind challenge to those mothers whose infants seemed to respond young children fifty-three patients with atopic eczema took part in a double blind controlled cross-over trial of an egg and cow's milk exclusion diet adult patients with atopic dermatitis twenty-five patients were evaluable, two of whom had their diet stopped after a few days due to exacerbation infants with cow's milk allergy/intolerance and atopic dermatitis infants with cow milk allergy thirty seven breast fed infants with eczema young children with atopic eczema and sensitivity to eggs infants with severe cow's milk allergy intolerance breast fed infants with eczema 20 out of 36 children (aged two to eight years) with atopic eczema 74 atopic children with cow milk allergy 73 infants (median age 5.7 months) with cow's milk allergy/intolerance and atopic dermatitis severe atopic dermatitis atopic eczema thirty five patients who received the diet and four controls had to be withdrawn because of non-compliance with the diet or intercurrent illness 33 adults with severe atopic dermatitis infants with cow's milk allergy/intolerance infants with an early onset of symptoms of cow's milk allergy/intolerance 22 infants with a mean age of 6 months (95% confidence interval, 4 to 7), who were fed an extensively hydrolyzed whey formula (group we), and 23 infants with a mean age of 17 (95% confidence interval, 4 to 7) months, who were given an amino acid-derived formula (group aa
moderate or severe pain (pain intensity rating pain intensity and qol scores morphine consumption, vas, ps, and self-assessed qol scores morphine consumption and the vas score pain relief pain intensity (0-10 numerical rating scale), qol, opioid consumption and related adverse effects, and survival time pain scores and delayed or prevented the subsequent onset of pain quality of life ps and qol scores quality of life (qol transient diarrhoea and hypotension standardized assessment of pain, mood, and disability due to pain frequency of opioid adverse effects mean pain scores side effects vas scores mean (sd) baseline pain visual analogue scale (vas) pain scores morphine consumption hospital mortality or complications, return to oral intake, or length of hospital stay survival pain, mood, and disability morphine consumption, visual analogue pain scale (vas), performance status (ps) determined by medical and nursing staffs, and answers to qol questionnaires ps score slightly self-assessed qol scores pain relief, qol, and survival immediate and long-term efficacy, mean analgesic consumption, mortality and morbidity existing pain pain relief, quality of life, and survival qol pain opioid consumption nausea and/or vomiting qol or survival gastric ulcer and one gluteal abscess pain relief and quality of life (qol mean analgesic consumption|mean pain scores were significantly lower in the alcohol group at 2-, 4-, and 6-month follow-up and at the final assessment (p < 0.05). morphine consumption was significantly lower in weeks 4-7 (inclusive) following the procedure in the cpb group and continued to be lower thereafter, though not significantly so. however, the differences in the improvement of quality of life (qol) between two groups were not statistically significant. the first week after randomization, pain intensity and qol scores were improved (pain intensity, p< or =.01 for both groups; qol, p<.001 for both groups), with a larger decrease in pain for the ncpb group (p =.005). drug-related adverse effects were constipation (five of 12 patients in group 1 versus 12 of 12 in group 2), nausea and/or vomiting (four of 12 patients in group 1 versus 12 of 12 in group 2) (p < 0.05), one gastric ulcer and one gluteal abscess in group 2.|pain due to pancreatic cancer 65 patients, whereas 72 patients received the 56 patients who were placed randomly in either a patients with pancreatic cancer pain patients with unresectable pancreatic cancer enrolled (october 1997 and january 2001) were 100 eligible patients with unresectable pancreatic cancer experiencing pain patients with histologically proven unresectable pancreatic cancer pancreatic cancer pain pain from pancreatic cancer patients with pancreatic cancer twenty-one patients with pancreatic cancer pain twenty-four patients were divided into two groups: 12 patients underwent intractable pancreatic cancer pain
septum wall motion abnormalities incidence and degree of cardiotoxicity, response rates to four cycles of chemotherapy, event-free and overall survival, and incidence and severity of noncardiac toxicities mean ef at control echocardiography response rates to chemotherapy, event-free and overall survival, and noncardiac toxicities severe incidence of congestive heart failure antitumor activity rates of fever, infection, or hemorrhage e velocities severe supraventricular arrhythmia noncardiac toxicity plasma lipid profile and relative mrna levels of key enzymes of oxidative metabolism (carnitine acyltransferases percentage left ventricular fractional shortening (%lvfs progressive disease occurrence and severity of anthracycline-induced cardiotoxicity lvef assessable endomyocardial biopsy tumor response rate left ventricular ejection fraction noncardiac toxicity or antitumor efficacy interventricular septum wall thickening time to progression and survival arrhythmic risk myocardial injury grade 1 cardiac toxicity toxicity prevention qt and qtc dispersion systolic and diastolic functions survival event-free or overall survival excellent survival incidence of transient grade 1 serum transaminase elevations frequency of adverse events plasma carnitine troponin t levels abnormal antimyosin uptake noninvasive testing and clinical chf resting left ventricular ejection fraction (lvef incidence of clinical congestive heart failure qtc dispersion cumulative probability of developing cardiotoxicity renal toxicity e velocities and e/a ratios lvfs toxicities qt interval dispersion toxicity serum cardiac troponin t grade 1 and 2 audiologic toxicity congestive heart failure (chf risk of developing short-term subclinical cardiotoxicity hazards ratio (hr) of pla to dzr qt dispersion response rate with dzr, but time to progression and survival antitumor response rates, time to progression, and survival subclinical cardiotoxicity overall survival rate of event-free survival value of radioimmunoscintigraphy (ris systolic and diastolic echocardiographic parameters mean ef hematologic toxicity cardiac function doxorubicin cardiotoxicity cardiac toxicity mode-m echocardiograms and 24-hour ambulatory ecgs elevations of troponin t minimum qt interval icrf-187 cardiac protection ototoxicity and nephrotoxicity renal, hearing and cardiac toxicity died noncardiac toxicity, objective response, progression-free survival, and overall survival pain on injection clinical activity and the noncardiac toxicity of epirubicin objective response rates elevated troponin t levels cardiotoxicity ejection fraction changes or congestive heart failure (chf left ventricular ejection fraction (ef) and systolic and diastolic diameters oxidative metabolism cardiac events relative mrna levels systolic and diastolic diameters control ef|left ventricular ejection fraction fell significantly in patients receiving placebo (radiotherapy: 67 +/- prenylamine (pnl), a calcium antagonistic drug, provided partial protection against adm-induced cardiotoxicity in mice and in the rabbit. five-year event-free-survival was 84%: 86% for the rer and 83% for the slow early responders (p = .85). the frequency of adverse events was similar between groups and there were no significant between-group differences in the number of dose modifications/interruptions. grade 1 and 2 audiologic toxicity was present in 100% of the experimental group against 85% of the controls (p = 0.501). carnitine treated patients showed a rise in plasma carnitine which led to an increase of relative mrna levels from cpt1a (liver isoform of carnitine palmitoyltransferase) and octn2 (carnitine transporter). toxicities on the dzr arms included lower granulocyte and platelet counts at nadir (p = .009 and p = .004, respectively) and more pain on injection (p = .001), with no difference in the rates of fever, infection, or hemorrhage. in either disease, antitumor response rates, time to progression, and survival did not significantly differ between the two arms. serial measurements of serum cardiac troponin t were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin. so far, no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens (tad/tad - tad/ham). icrf-187 cardiac protection was observed in patients with and without prior chest-wall radiation or other risk factors for developing doxorubicin cardiac toxicity. objective response rates were identical in the two groups, with no significant differences seen in event-free or overall survival. percentage left ventricular fractional shortening (%lvfs) decreased from baseline (40.36 +/- 4.3 ms, p<0.001), while the 10 patients not supplemented with dexrazoxane did not (qt dispersion: 69.3 +/- control ef was below 50% in 1 patient in the carvedilol group and in 5 in the control group. cardiotoxicity was recorded in 18 of 78 patients (23.1%) in the control arm and in six of 82 (7.3%) in the dexrazoxone arm.|patients with breast cancer thirty patients have been evaluated for pre- and posttreatment cardiological investigations pediatric osteosarcoma patients treated with one hundred sixty-two advanced breast cancer patients pediatric sarcoma patients non-hodgkin lymphoma patients patients with advanced breast cancer and soft tissue sarcomas (sts) treated with patients receiving ant children with acute lymphoblastic leukemia or non-hodgkin lymphoma, treated with anthracyclines (ant), were studied: group 67 since july 1986, 64 patients have been included 25 patients in carvedilol and control groups 216 eligible patients were younger than 22 years with intermediate- or high-risk hodgkin lymphoma 20 patients were scheduled to patients who had previously received adjuvant chemotherapy that contained anthracyclines were treated with 28 patients, mean age was 11.6 years, five had metastatic disease patients at high risk of cardiotoxicity due to prior anthracycline use children with acute lymphoblastic leukemia (all patients with advanced breast cancer and soft tissue sarcomas patients who might benefit between november 1988 and january 1991, 534 patients with advanced breast cancer 14 patients with chemotherapy and 10 patients with 150 women with advanced breast cancer massachusetts medical society for advanced breast cancer patients with non-hodgkin lymphoma 101 children with all to receive patients with osteosarcoma receiving thirty-eight patients one hundred sixty patients were evaluated women receiving children with acute lymphoblastic leukemia and non-hodgkin lymphoma advanced/metastatic breast cancer patients treated with patients with malignancies receiving high dose chemo- or radiotherapy patients with acute myeloid leukemia (aml) treated with double induction and consolidation chemotherapy (aml coop study 1986, [3 advanced breast cancer patients who are at risk of arrhythmic events treated children with acute lymphoblastic leukemia twenty-six patients in the induced cardiomyopathy twenty-six patients children and adolescents with intermediate- and high-risk hodgkin lymphoma group b (n = 13 164 female breast cancer patients patients with aggressive non-hodgkin lymphoma (nhl pediatric sarcoma patients treated with women with breast cancer twenty untreated patients, <or=60 years of age with newly-diagnosed aggressive nhl, eligible for a treatment with epirubicin-based chemotherapy were selected for the study group a (n = 13
initiation of alcohol, tobacco, drug use, and/or sexual activity found aa youth 30-day use of alcohol and marijuana and lower intentions to smoke, drink, and take illicit drugs adolescent smoking and drinking prevalence violent behavior heavy weekly drinking, weekly drinking and frequency of drinking sexual risks chances of initiating sex or substance use substance use and/or sexual activity positive 2-year outcomes drug use harm or delinquency self-efficacy girls' and mothers' substance use and mediator variables related to girls' substance use risk and protective factors rates of weekly alcohol consumption incidence of (heavy) weekly alcohol use and frequency of monthly drinking prevalence of smoking cigarettes and drinking alcohol rate of change in attitudes about drug use or frequency of delinquent or violent behavior alcohol initiation and frequency, and marijuana initiation and frequency (p's<.05|a significant repeated measures interaction (group  time) was found (f(4,344)=2.48, p=.04), with univariate tests showing less alcohol use frequency and problems (p's<.05) among adolescents exposed to parent materials. following program delivery and 1 year later, girls randomly assigned to the intervention arm improved more than girls in a control arm on variables associated with reduced risks for substance use, including communication with their mothers, knowledge of family rules about substance use, awareness of parental monitoring of their discretionary time, non-acceptance of peer substance use, problem-solving skills, and ability to refuse peer pressure to use substances. at follow-up, girls in the intervention reported fewer sexual risks (adjusted odds ratio [aor] = 0.39, confidence interval [ci] = 0.17-0.88) and less drinking (aor = 0.38, ci = 0.15-0.97, p < .05). intent-to-treat analyses indicated that fewer prevention than control adolescents initiated alcohol use; those who did evinced slower increases in use over time. at first follow-up, only the combined student-parent intervention showed substantial and statistically significant effects on heavy weekly drinking, weekly drinking and frequency of drinking. the findings suggest that the program significantly reduced the prevalence of smoking cigarettes and drinking alcohol among adolescents. odds ratios indicated the chances of initiating sex or substance use were reduced by almost 70% (or = 0.31) for aa teens in the sa condition compared to controls, and 75% (or = 0.25) for the aa teens in the pa compared to controls. a computer-delivered prevention program for adolescent girls and their mothers was effective in changing girls' risk and protective factors and girls' and mothers' substance use behavior.|adolescents and their parents 684 high school students african american 11-year-olds and their primary caregivers from 9 rural communities (n = 332 families 268 families with sixth-graders were recruited from new york city public schools 2937 students were eligible for analyses in this study heavy drinking in first- and second-year high school students european american (ea) and african american (aa) youth and their parents (n = 331 n aa = 163; n ea = 168 adolescent girls adolescents (pas parents adolescent girls and their mothers urban black and latino parents a total of 3490 first-year high school students (mean 12.68 years, sd=0.51) and their parents urban young adolescent girls group from 152 classes of 19 high schools in the netherlands rural african american adolescents girls' mothers september 2006 and february 2009 with participants from greater new york city, including southern connecticut and eastern new jersey 916 girls aged 12.76+/-1.0 years and their mothers adult family members with follow-up telephone calls by health educators
pain and function isokinetic quadriceps strength, quadriceps length, pain measured during four activities and maximum eccentric, posturally controlled, pain-free knee flexion angle during a step-down patellofemoral pain womac, visual analogue, and had scores visual analog scales for pain and the functional index questionnaire pain and function scores subjective visual analog scale and changes in isokinetic strength and electromyographic activity of the quadriceps muscle activity womac and had womac, visual analogue, and the anxiety score visual analogue pain score; the womac lower limb function score; the hospital anxiety and depression scale (had); and quadriceps strength symptoms quadriceps muscle isokinetic strength|all groups showed significant improvements in womac, visual analogue, and had scores; these improvements did not vary significantly between the four groups or between exercising/non-exercising and taped/non-taped patients at three and 12 months. results showed significant changes over time (p < 0.01) in two out of seven measures for the taping group, in five out of seven for the strengthening group and five out of seven for the stretching group and none in the control group. there were no significant differences between the placebo taping-and-exercise group and exercise-alone group at any time point. likewise, both groups demonstrated significant improvement in quadriceps muscle isokinetic strength (p < 0.05) and activity (p < 0.001), but no difference in improvement was noted between groups.|subjects with anterior knee pain 81 young adults with anterior knee pain individuals with patellofemoral pain syndrome anterior knee pain 1.2 years) participated in the study patellofemoral pain patellofemoral pain syndrome patellofemoral pain patients twenty-five patients with patellofemoral pain twenty-four men and 6 women aged 17 to 25 years (mean 41 subjects with 60 knees diagnosed with patellofemoral pain
horizontal and vertical stability of the b-point and the pogonion radiographic measurements postoperative changes of the proximal and distal segments lateral gonial deviation condyle position|one year later the condyle position demonstrated a tendency to approximate the preoperative position, especially with respect to the posterior part, but there was still a significant (p less than 0.01) difference when related to the original position. at 1 year after surgery, there was no significant difference between the 2 groups in the horizontal and vertical stability of the b-point and the pogonion.|thirty japanese adults with a diagnosis of prognathic mandible 53 patients with mandibular prognathism
protective ventilation involved end-expiratory pressures oxyhemoglobin saturation by pulse oximetry (spo2), fio2/peep, blood pressure, and heart rate tidal volumes rates of clinical barotrauma rate of barotrauma rates of refractory hypoxemia death with refractory hypoxemia positive end-expiratory pressure (peep) and recruitment maneuvers (rms lr manoeuvre end-expiratory lung volume systolic blood pressure lower q(va)/q(t lower venous admixture (q(va)/q(t barotrauma rates survival to hospital discharge gas exchange, hemodynamics, respiratory mechanics, and the end expiratory lung volume (eelv fio2/peep requirements survival tracheal aspirate mass rates of weaning from mechanical ventilation higher peep and mean airway pressures arterial carbon dioxide tension (pa(co2 barotrauma pao2/fio2 and qs pao2 eelv hospital mortality rates gas exchange and respiratory mechanics arterial oxygen tension (pa(o2 body weight and normal arterial carbon dioxide levels mean positive end-expiratory pressures negative pressure cppv(vrm target tidal volumes of 6 ml/kg of predicted body weight, plateau airway pressures not exceeding 30 cm h2o, and conventional levels of positive end-expiratory pressure mortality partial arterial oxygen tension (pao2) and end-expiratory lung volume arterial blood gases oxygenation and venous admixture|open endotracheal suctioning induced a significant 18% decrease in arterial oxygen tension (pa(o2)) (range, +13 to -71%) and an 8% increase in arterial carbon dioxide tension (pa(co2)) (range, -2 to +16%) that persisted 15 min after the end of the procedure. no significant differences in pao2/fio2 and qs/ changes in fio2/peep requirements were not significantly different at any time after rms vs. sham rms. as compared with conventional ventilation, the protective strategy was associated with improved survival at 28 days, a higher rate of weaning from mechanical ventilation, and a lower rate of barotrauma in patients with the acute respiratory distress syndrome. compared to cppv(lo), cppv(vrm) resulted in higher pao2 (117.9 +/- this "open-lung" strategy did appear to improve secondary end points related to hypoxemia and use of rescue therapies. without lr manoeuvre, pao2 was reduced (p = 0.05) until 7 min after ets.|patients ventilated with low tidal volumes and high levels of positive end-expiratory pressure (peep early adult respiratory distress syndrome acute respiratory distress syndrome acute lung injury and acute respiratory distress syndrome 30 consecutive patients ventilated with low tidal volumes and high levels of peep eight consecutive mechanically ventilated patients with acute lung injury or acute respiratory distress syndrome patients with acute lung injury patients with acute lung injury and acute respiratory distress syndrome ventilated with high positive end-expiratory pressure acute lung injury 18 patients with acute lung injury mechanically ventilated acute respiratory distress syndrome (ards) patients 15 peep responder ards patients undergoing thirty-four intensive care units at 19 hospitals patients with the acute respiratory distress syndrome acute respiratory distress syndrome (ards) patients, ventilated at relatively low positive end-expiratory pressure nine hundred eighty-three consecutive patients with acute lung injury and a ratio of arterial oxygen tension to inspired oxygen fraction not exceeding 250 patients with the acute respiratory distress syndrome, massive alveolar collapse and cyclic lung reopening and overdistention during mechanical ventilation may perpetuate alveolar injury august 2000 and march 2006 in 30 intensive care units in canada, australia, and saudi arabia patients: seventy-two patients with early ali/ards 15-bed general intensive care unit at a university hospital patients with early extrapulmonary adult respiratory distress syndrome patients with acute lung injury and acute respiratory distress syndrome (ali/ards) receiving ventilation with low tidal volumes and high levels of peep eighty-five percent of the 983 study patients met criteria for acute respiratory distress syndrome at enrollment patients with acute lung injury and acute respiratory distress syndrome critically ill patients with acute lung injury and acute respiratory distress syndrome 53 patients with early acute respiratory distress syndrome (including 28 described previously), all of whom were receiving
health status morning peak expiratory flow rate (pef); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations 2-h postdose fev(1 pretreatment fev1 biopsy cd8+ cells lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status morning pef (l/s), the daily symptom score, and the number of exacerbations frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration ic average daily morning pef cd68+ cells lung hyperinflation and exercise endurance postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire (sgrq respiratory function (such as fev(1), morning pef), and and symptom score predose fev(1 fev1 biopsy cd45+ and cd4+ cells and cells expressing genes for tumor necrosis factor-alpha and ifn-gamma and sputum total eosinophils dyspnea, quality of life, and symptoms of chronic bronchitis daily beta(2) short acting prn consumption postdose frc and increased inspiratory capacity (ic lung hyperinflation morning predose fev(1 severity of dyspnea fev(1 morning pef morning predose (ie, trough fev(1)) for fsc compared with sm and 2-h postdose fev(1 mean fev(1 lung function and health status tidal volume and minute ventilation daily symptoms score lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations postdose ic efficacy and safety exercise endurance time exercise time adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms symptom scores and use of reliever beta2-agonists exercise performance antiinflammatory effects predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations pretreatment forced expiratory volume in 1s (fev1 mean prebronchodilator forced expiratory volume daily symptoms prebronchodilator fev1 transition dyspnea index mean number of severe exacerbations prebronchodilator peak expiratory flow exacerbations 2-hour postdose fev(1 lung function tolerated morning lung function mean number of exacerbations/yr adverse effects prolonged time to first exacerbation severe exacerbations and fev1 (primary variables), peak expiratory flow (pef), copd symptoms, health-related quality of life (hrql), mild exacerbations, use of reliever beta2-agonist and safety variables|combination therapy improved pretreatment fev1 significantly more than did placebo (treatment difference 133 ml, 95% ci 105-161, p<0.0001), salmeterol (73 ml, 46-101, p<0.0001), or fluticasone alone (95 ml, 67-122, p<0.0001). postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire (sgrq) by 4.5 units after run-in. the incidence of adverse effects (except for an increase in oral candidiasis with fsc and fp) were similar among the treatment groups. the incidence of adverse effects (except for an increase in oral candidiasis with fsc and f) was similar among the treatment groups. morning pef improved significantly on day 1 versus placebo and budesonide; after 1 week, morning pef was improved versus placebo, budesonide and formoterol. morning pef (l/min) increased in subjects treated with sm&fp (anova p<0.001), while it remained unchanged in sm and p group (in both, anova p=ns). 0.05 l over placebo with associated improvements in tidal volume and minute ventilation (p < 0.05 vs placebo at week 8). the combination also significantly reduced biopsy cd45+ and cd4+ cells and cells expressing genes for tumor necrosis factor-alpha and ifn-gamma and sputum total eosinophils (all p < or = 0.03).|seven hundred twenty-three patients > or =40 years of age with copd and a mean baseline fev(1) of 42% predicted chronic obstructive pulmonary disease (copd patients with copd moderate-to-severe chronic obstructive pulmonary disease chronic obstructive lung disease copd patients already treated with 812 adults (mean age 64 yrs, mean forced expiratory volume in one second (fev1) 36% predicted normal 1465 patients with copd were recruited from outpatient departments in 25 countries copd 185 patients (mean baseline fev1 of 41% predicted) were enrolled seventy-six investigative sites in the united states eligible patients were > or = 40 years old with a diagnosis of copd, prealbuterol fev(1 691 patients with copd patients with moderate-to-severe chronic obstructive pulmonary disease (copd smokers with chronic obstructive pulmonary disease chronic obstructive pulmonary disease eighteen moderate copd patients symptomatic chronic obstructive pulmonary disease (copd 140 current and former smokers (mean age, 64 yr) with moderate to severe disease
therapeutic success mean age and mean duration of pregnancy symptoms of urinary tract infection cure rate difference bacteriologic cure rates bacteriologic cure on day 14 of treatment maternal and foetal toxicity side effects asymptomatic bacteriuria mean birth weight and mean gestational age at delivery bacteriological cure rates number of reinfections development of symptomatic urinary infections eradication rate cure rates efficacy and tolerability clinical and microbiological efficacy adverse effects significant bacteriuria number of persistences|treatment groups were comparable in terms of age, gravidity and socioeconomic status, and the outcome of pregnancy in the two groups did not differ significantly. the cure rate difference was -10.5% (95% confidence interval -16.1% to -4.9%). according to recent studies, long course antibiotherapy did not prove to be more effective than a single-dose one in the case of non-complicated bacteriuria. the efficacy of the two regimens was similar and the eradication rate was over 80% in both groups (p = 0.720) (relative risk [rr] 1.195, 95% confidence interval [ci]: 0.451-3.165). therapeutic success was achieved in 93.2% of the patients treated with fosfomycin trometamol vs 95% of those treated with cefuroxime axetyl. control urine cultures one week and 4-6 weeks after start of treatment revealed the same cure rates of approximately 50% in both groups. there were no detrimental effects on the outcome of the pregnancies. bacteriological cure rates at 1 and 4 weeks were in group a 77% and 74% and in group b 62% each respectively. there were no side-effects of treatment, and no detrimental effects on the outcome of pregnancy.|pregnant women 1,248 women, 778 women were successfully recruited, and 386 and 392 women antenatal clinics in thailand, the philippines, vietnam, and argentina pregnant women with asymptomatic bacteriuria twenty-one of 24 women were cured with a single dose asymptomatic bacteriuria in pregnancy twenty-seven of 30 women were cured with a single dose asymptomatic bacteriuria during pregnancy women with asymptomatic bacteriuria in pregnancy 1,248 of 24,430 eligible women had asymptomatic bacteriuria, making the overall prevalence of 5.1 41 patients 4,274 pregnant women 91 pregnant women with a mean gestational age of 25 weeks (14-38 ninety obstetric patients with significant bacteriuria sixty consecutive pregnant women with asymptomatic (covert) bacteriuria detected between 16 and 30 weeks gestation pregnant women with bacteriuria one hundred and nine patients asymptomatic (covert) bacteriuria of pregnancy forty-four pregnant women with covert (asymptomatic) bacteriuria proven by suprapubic bladder aspiration pregnant women seeking antenatal care between march 2004 and march 2007 who met the inclusion and exclusion criteria were invited to participate in the study
mean clinical-activity score fell renal function clinical improvement, discharge from the hospital, and remission severe attacks of ulcerative colitis serious drug-related toxicity|the mean clinical-activity score fell from 13 to 6 in the cyclosporine group, as compared with a decrease from 14 to 13 in the placebo group. at 12 months, 7 of 9 patients (78%) initially controlled with cyclosporine maintained their remission vs. 3 of 8 (37%) initially treated with methylprednisolone.|patients with severe ulcerative colitis since corticosteroids patients with severe corticosteroid-resistant ulcerative colitis thirty patients were included 32 patients with active ulcerative colitis refractory to corticosteroid therapy had a response to cyclosporine therapy patients with a severe attack of uc patients with steroid-refractory attacks of ulcerative colitis (uc 20 patients with severe ulcerative colitis severe ulcerative colitis refractory to steroid therapy patients with severe attacks of uc
free or fast walking gait kinematics loading response knee flexion stride characteristics, joint motion, and ground reaction forces oxygen consumption symmetry indexes of the knee range of motion, cadence, and walking speed free velocity initial peak of the vertical ground reaction force on the sound limb metabolic parameters energy expenditure and gait efficiency metabolic efficiency terminal stance dorsiflexion residual limb emg data subjective responses and gait patterns physiologic responses whole body gait kinematics and lower limb kinetics energy cost decline walking tests energy consumption knee flexion and prolonged heel only support self-selected walking velocity (sswv), and steps per day (daily activity walking under different speeds and different inclines prosthetic mobility comfortable walking speed and the nadir of metabolic rate and efficiency energy expenditure peak shank velocity, peak ankle plantarflexion and peak knee flexion compromised shank and knee stability rate of energy expenditure metabolic rate or efficiency free walking distal pressure measurements, pulse plethysmography, transcutaneous oxygen tension gait analysis and energy consumption mean free walking speed physiologic responses (energy expenditure, gait efficiency, exercise intensity, rating of perceived exertion [rpe foot and shank mobility shank velocity ankle mobility energy expenditure, gait efficiency, and relative exercise intensity walking abilities sach, single axis and multiple axis foot in the velocity, cadence, stride length and single limb stance energy cost, efficiency, and relative exercise intensity bioenergetic efficiency contralateral toe off times peak knee flexion rate of energy consumption gait performance peak foot and shank velocities cardiocirculatory effects oxygen uptake (vo2 foot and shank velocity as the thigh velocity knee flexion reflected delayed dorsiflexion and tibial advancement stride length walking velocity physiologic measurements, self-selected walking velocity, and physical activity|significant differences were found in energy consumption between the traumatic and vascular groups, and significant changes in walking under different speeds and different inclines. stride characteristics, joint motion, and ground reaction forces were recorded simultaneously during a self-selected free walking velocity in seven subjects wearing five different prosthetic feet (sach, flex-foot, carbon copy ii, seattle, quantum). during the level treadmill test, the traumatic amputee subjects showed a decrease of energy expenditure with the new prosthetic foot, more significant at sufficient speed (4 km/h): 17.00 +/- the dynamic flex foot allowed subjects to rely more heavily on the prosthetic foot for propulsion and stability during walking with minimal compensations at the remaining joints. a covariance analysis (anova) of these variables was made, which showed that the factors influencing tt amputee gait were, in order of importance, cadence and leg studied (sound or prosthetic), inter-individual variability and, finally, the prosthetic mechanism used. in early stance, peak foot and shank velocities were lower (p < 0.01) for both the sl and ff while only shank velocity was lower (p < 0.01) with the sa compared to na controls. no clear trend for preference for either type of foot was evident from the subjective survey; in general the patients showed a preference for the foot that they were accustomed to. compared with conventional hydraulic knee controls, the oxygen consumption of transfemoral amputees provided with an electronically controlled hydraulic knee joint is reduced. because no energy savings resulted for the der feet, the release of stored energy in the flexible feet may not occur at the proper time to assist in ambulation as a result of the natural frequency of oscillation. the sach foot consistently produced the greatest ground reaction forces on the sound limb; however, this was not statistically significant. in the subjects with amputations, the amputated limb had a weaker propulsion and the nonamputated limb had a stronger propulsion than controls. mean free walking speed was significantly slower for those with transtibial amputations regardless of the prosthetic foot worn (p < 0.05). the following statistically significant differences (improvements) between the re-flex vsp versus the ff and the sach foot were found. increased efficiency of pushoff in the seattle ankle/lite foot exists as evidenced by the decrease loading on the opposite limb during double support and a less shortened step length on the sound side compared to the sach foot. the main differences in the range of motion of the joints were in the frontal plane: the eversion-inversion movement of the ankle and the adduction-abduction movement of the hip. the flex-foot resulted in significantly different gait kinematics at the "ankle" compared to the other four feet, however, this foot did not produce an increased velocity nor an improved energy cost. overall, the traumatic amputees had a similar oxygen consumption per meter traveled compared to the dysvascular amputees; however, the rate of energy consumption was much higher in the traumatic group. compared with the c-walk and sach, the flex-foot showed no significant differences in energy expenditure and gait efficiency, but significantly lower percentage of age-predicted maximum heart rate and rpe values. however, no significant differences were found for the symmetry indexes of the knee range of motion, cadence, and walking speed.|subjects with vascular amputation nine individuals who had undergone unilateral below knee amputation normal and transtibial amputees dysvascular and traumatic below-knee amputees nine right-limb traumatic amputees individuals with a unilateral trans-tibial amputation ten male individuals with transtibial amputations five physically active men with unilateral transtibial amputations served as subjects (aged 31.6 16 male below-knee amputees, eight vascular and eight traumatic, while elderly patients with amputation with a slow walk persons with dysvascular below-knee amputations normal gait pattern of leg amputees traumatic unilateral transtibial amputees wearing two different prosthetic feet in the early rehabilitation stage below-knee amputee gait with dynamic elastic response prosthetic feet 19.9 years) and 12 patients with vascular below-knee amputations (mean age: 73 people with transtibial amputations with 3 different prostheses twelve patients with traumatic below-knee amputations (mean age: 50.0 eleven individuals with a unilateral trans-tibial amputation participated in two traumatic below-knee vascular amputations seventeen male subjects with below-knee amputation (nine traumatic and seven dysvascular eight men with unilateral transtibial amputation subjects on a walkway at a self-selected velocity; only the subjects with traumatic amputation 1341 gait trials at different cadences were analysed (383 with normal subjects and 958 with amputees, using the four prosthetic feet under study eight men who had unilateral traumatic below-knee amputation and on nine control subjects lower limb amputee gait nine amputees were included in the trial persons with transtibial amputations with various prostheses knee disarticulation amputees dysvascular below-knee amputees below-knee amputees wearing three different prosthetic feet trans-tibial (tt) amputees 10 traumatic below-knee amputees people with transtibial amputation adults with unilateral below-knee amputations
birth weight, treatment with antibiotics, and the starting time of breast-feeding duration of lactobacillus gg and placebo supplementation incidence and severity of necrotizing enterocolitis incidence of death or necrotizing enterocolitis feeding intolerance somatic growth, tolerance, rates of sepsis and necrotizing enterocolitis colonisation rates of administered bacteria bifidobacterial numbers incidence of fungal enteric colonization death or necrotizing enterocolitis (bell's stage faecal reservoir of potential pathogens gastrointestinal tolerance percentage of infants receiving >50% of their nutritional needs via enteral feeding on the 14th day of life incidence of death or nec gram-negative enteric organisms time to reach full enteral feeding supplementation median bifidobacteria counts death or nec (bell's stage 2 bacterial sepsis number of enterobacteriaceae present incidence of utis, nec and sepsis weight gain sb tolerance and weight gain, faecal flora analysis, intestinal d-xylose absorption and faecal lipid excretion median log of colony forming units per gram of faeces for escherichia coli and enterococci lactobacilli fecal excretion of calprotectin intestinal permeability head growth l/m ratio urinary tract infection, bacterial sepsis and necrotizing enterocolitis incidence and severity of nec gastrointestinal microbiota necrotizing enterocolitis (nec cell counts of bifidobacteria death or nec incidence of late-onset sepsis incidence of nec numbers of fungal isolates colonisation rates d-xylose and lipid absorption viable counts of enterobacteriaceae (log(10) values gastrointestinal bacterial colonization urinary tract infections (utis), bacterial sepsis and necrotizing enterocolitis (nec hospital stay bacterial and fungal sepsis acceptance and tolerance of the formula necrotizing enterocolitis intestinal microbiota median counts of stool bifidobacteria and lactulose/mannitol ratios number of bifidobacteria and staphylococci in the stools incidence of a first episode of late-onset sepsis cell counts of enterobacteria and clostridia deaths adverse effect, such as sepsis, flatulence, or diarrhea|bacterial sepsis was more frequent in the probiotics group (4.4%, n = 11) than in the placebo group (3.8%, n = 9), but the difference was not significant. in comparison between group a and b, bifidobacterium was detected significantly earlier in group a, and the number of enterobacteriaceae present in the infants at 2 weeks after birth was significantly lower in group a. after 7 days of supplementation median bifidobacteria counts were significantly higher in the study group than in the control group (p=0.0356) and they remained higher to the end of the study (p at day 30=0.075). orally administered l. casei subspecies rhamnosus significantly reduces the incidence and the intensity of enteric colonization by candida species among very low birth weight neonates. feeding intolerance was significantly lower in the probiotics group than in the control group (44.5% (n: 49) vs 63.1% (n: 70), respectively; our study showed that enteral administration of prophylactic probiotics in neonatal intensive care setup could significantly reduce morbidity due to necrotising enterocolitis in very low birth weight newborn. median log of colony forming units per gram of faeces for escherichia coli and enterococci was significantly lower in the sb group [e. coli: 2.67 (0.045) vs. 2.75 (0.058), p<0.001; b breve can colonise the immature bowel very effectively and is associated with fewer abnormal abdominal signs and better weight gain in vlbw infants, probably as a result of stabilisation of their intestinal flora and accelerated feeding schedules. the primary endpoint was not significantly different between the probiotic (57.8%) and placebo (57.1%) groups (p = 0.95). however, colonisation with lactobacillus gg did not reduce the faecal reservoir of potential pathogens and there was no evidence that colonisation had any positive clinical benefit for this particular group of infants. the incidence of nec (>or= stage 2) was also significantly lower in the study when compared with the control group (2 of 180 vs 10 of 187). the incidence of death or necrotizing enterocolitis (stage >or=2) was significantly lower in the study group (4 of 217 infants vs 20 of 217 infants). the incidence of nec was reduced in the study group (4% vs 16.4%; p=.03). there was no significant difference between the study groups in the number of resistant organisms or in the proportion of resistant organisms per gram-negative enteric isolates (4 of 40 vs. 0 of 28). for blf vs control and risk ratio, 0.27; 95% confidence interval, 0.12-0.60; p < .001 for blf plus lgg vs control). however, the probiotic supplementation increased the cell counts of bifidobacteria and reduced the cell counts of enterobacteria and clostridia.|preterm infants in a neonatal intensive care unit differs from that of term infants preterm infants and leads to increased head growth 221 infants were studied: 110 in the study group and 111 in the control group premature infants with lactobacillus gg premature infants newborn infants with a gestational age <33 weeks or birthweight <1,500 g 7 nicus in taiwan very low birth weight (vlbw) infants very low birth weight newborns preterm infants very low birth weight infants preterm infants born with a very low or extremely low birth weight neonates < or =1500 g birth weight very low birth weight neonates very low-birth weight infants vlbw infants vlbw infants who started to fed enterally and survived beyond the seventh day after birth were eligible for the trial 2011 macmillan publishers limited very-low-birth-weight preterm infants thirty premature infants were matched by birth weight and gestational age for 72 study and 73 control infants, respectively, birth weight (1152 twenty preterm infants with a gestational age of 33 weeks or less who were resident on a neonatal unit were studied from the initiation of milk feeds until discharge 69 preterm infants 87 healthy babies with gestational age 28-32 weeks were studied 80 preterm neonates with a very low birth weight was conducted in a large tertiary neonatal intensive care unit three hundred sixty-seven infants were enrolled: 180 in the study group and 187 in the control group 11 italian tertiary neonatal intensive care units 91 vlbw infants patients were 472 vlbw infants enrolled from october 1, 2007, through july 31, 2008, and assessed until discharge for development of sepsis 12 italian nicus preterm neonates intestinal flora of low birth weight infants very low birth weight infants who survived to start enteral feeding were eligible four hundred thirty-four infants were enrolled, 217 in the study group and 217 in the control group very low-birth-weight neonates human infants to preterm infants very low-birth weight (vlbw) infants low birth weight infants (average birth weight 1489 g preterm infants with a gestational age of <33 weeks or birth weight of <1500 g. vlbw infants who survived to start enteral feeding very low birth weight preterm infants necrotizing enterocolitis among very low birth weight infants (birth weight 41 stable preterm infants of 27 to 36 weeks gestation and 34 matched comparison infants consecutively admitted to the neonatal unit were studied gastrointestinal colonization by candida species in preterm, very low birth weight (i.e., < 1500-g) neonates during their stay in a neonatal intensive care unit premature infants with saccharomyces boulardii 278 g), gestational age (30 five hundred eighty-five patients were studied 66 vlbw infants (preliminary study premature infants in the neonatal intensive care unit
rop stage ii or graver retinopathy of prematurity gestational age, birth weight, apgar scores, the time of exposure to oxygen and in the incidence of pda or in the number of exchange transfusions and rbts|the two groups did not differ significantly in gestational age, birth weight, apgar scores, the time of exposure to oxygen and in the incidence of pda or in the number of exchange transfusions and rbts.|204 infants with birthweights between 751 and 2000 g and 26-35 weeks gestational age (100 treated and 104 control subjects
disease-free survival and/or overall survival progression-free survival rates 2-year overall survival rates died median disease-free survival dermatologic events cumulative probability of recurring progression-free survival or overall survival peritoneal relapses hazard ratio of progression progression-free survival (pfs pfs grade 2 or greater motor neurotoxicity and sensory neurotoxicity number of recurrences recurrence-free interval (rfi) and safety profile rfi side effects late intestinal radiation reactions median overall survival time survival median pfs thrombocytopenia pathologic remission, progression-free survival overall survival late radiation reactions death infection/fever incidence of grade 2 or worse peripheral neuropathy overall survival or disease-free survival partial response neutropenia probability of surviving 5 years|in the subgroup with microscopic residual carcinoma there were no significant differences in survival between the radiotherapy and the chemotherapy-treated patients. a consolidation treatment with six cycles of paclitaxel does not prolong progression-free survival or overall survival in patients in complete response after first-line paclitaxel/platinum-based regimens. peritoneal relapses were 25% for cisplatin treatment vs. 16.4 % for nihil. there was no statistically significant difference in pfs between the arms (p =.83; log-rank test): median pfs was 18.2 months in the topotecan arm and 28.4 in the control arm. the incidence of grade 2 or worse peripheral neuropathy (15.5% vs. 6%), infection/fever (19.9% vs. 8.7%), and dermatologic events (70.8% vs. 52.1%) was higher on the maintenance regimen (p<0.001).|patients with ovarian cancer patients affected by epithelial ovarian cancer patients with advanced epithelial ovarian cancer in complete response after six courses of two hundred patients were randomly assigned from march 1999 to july 2006 122 randomized patients in complete remission as judged by laparoscopy or laparotomy following first-line chemotherapy consisting of patients with advanced epithelial ovarian cancer who are in complete response after first-line paclitaxel/platinum-based chemotherapy 172 patients with epithelial ovarian carcinoma, figo stage iii, with complete surgical remission after primary cytoreductive surgery and induction chemotherapy two hundred seventy-three patients were randomly assigned (topotecan, n = 137; observation, n = 136), with a median age of 56 years 571 patients enrolled onto this study, of whom 29 were deemed ineligible due to inappropriate stage or pathology, leaving 542 patients patients with stages iib to iv disease in clinical or pathologic complete response after six courses of patients with early-stage ovarian carcinoma patients with completely resected high-risk early-stage ovarian cancer treated with patients with advanced ovarian cancer who respond to initial chemotherapy with advanced (figo stage iii) ovarian carcinoma in complete surgical remission after induction chemotherapy sixty patients in the patients with stage ia/b (grade 3 or clear cell), all ic or ii epithelial ovarian cancer epithelial ovarian cancer advanced ovarian cancer
action research arm test and the upper extremity section of the fugl-meyer assessment activities of daily living (barthel index fugl-meyer and ara scores caregiver ratings of quality of movement fugl-meyer assessment of motor recovery (fugl-meyer) and action research arm test (ara daily arm function peak force of the pinch grip and generalized feasibility and efficacy ara scores demographic variable or movement scale motor activity log and action research arm (ara) test peak force of the pinch grip using a force transducer and manipulation functions of the upper extremity (jebsen-test|at baseline (t0) there were no significant differences at mi and aft between the two groups. a wilcoxon test on the ara scores revealed significantly ( p =.004) greater changes in the mp group's scores. mental training resulted in an increase in the peak force of the pinch grip and generalized in a better functionality of the upper extremity (jebsen-test). however, subjects in the mcit+mental practice group exhibited significantly larger changes on both movement measures after intervention after intervention, fugl-meyer and ara scores of patients in the therapy only group remained virtually the same; therapy plus imagery group scores improved by 13.8 and 16.4 points, respectively, on the fugl-meyer and ara. subjects receiving mp showed significant reductions in affected arm impairment and significant increases in daily arm function (both at the p<0.0001 level).|five patients participated in a control intervention consisting of exposure to stroke information chronic stroke patients acute stroke stroke patients upper limb recovery after stroke thirty-six hemiparetic stroke patients (15 females and 21 males chronic stroke eleven patients who had a stroke more than 1 year before study entry (9 men; mean age, 62.3+/-5.1 range, 53-71 y thirty-two chronic stroke patients (mean=3.6 years) with moderate motor deficits patients with chronic stroke thirteen consecutively admitted patients between four weeks and one year post stroke exhibiting stable motor deficits in their affected upper limbs 17 patients after their first hemiparetic stroke ten patients with chronic stroke (7 males; mean age, 61.4+/-3.02 years; age range, 48 to 79 years; mean time since stroke, 28.5 months; range, 13 to 42 months) exhibiting stable, affected arm motor deficits
likelihood of haemoglobin testing perinatal outcomes, anxiety and maternal satisfaction anxiety scores fetal and maternal morbidity, health service use, psychosocial outcomes, and maternal and professional satisfaction levels of satisfaction cesarean delivery low birth weight labour referrals for severe hypertension or eclampsia treated urinary-tract infection pregnancy outcome, including antenatal referrals for other causes, labour referrals, obstetric interventions, low birthweight, and perinatal and maternal mortality and morbidity rates of low birthweight perinatal mortality preterm delivery, preeclampsia, cesarean delivery, low birth weight and patient's satisfaction with care median maternal age, parity and gestational age at booking patient satisfaction regarding the number of prenatal visits rates of hospital admission, diagnosis, and length of stay low birthweight (<2500 g), pre-eclampsia/eclampsia, severe postpartum anaemia satisfaction with quality of prenatal care urinary-tract infection postpartum anaemia rates of preterm delivery or low birthweight satisfaction with provider subscale number of prenatal visits number of antenatal day admissions and ultrasound scans proportion of women with five or less visits ultrasound scans number of antenatal visits, antepartum and intrapartum referrals, utilization of health centre for delivery and perinatal outcomes satisfaction with the prenatal care system subscale median number of visits pregnancy outcomes of infant and maternal morbidity and mortality, anxiety and satisfaction quality of care and an economic evaluation referrals for pregnancy-induced hypertension level of satisfaction preeclampsia proportion of antenatal referrals perinatal outcomes or anxiety adverse perinatal outcomes intrapartum transfers|the study vs. control group differed significantly (p < .0001) in patient satisfaction regarding the number of prenatal visits. women in the apcvs group reported significantly higher levels of satisfaction than women in the tpcvs group on both the satisfaction with provider subscale (f = 5.74, p = .02) and the satisfaction with the prenatal care system subscale (f = 2.01, p = .04). there was no difference in median maternal age, parity and gestational age at booking between women in the standard model and those in the new model. there were no other significant differences between the programmes in other major indices of pregnancy outcome, including antenatal referrals for other causes, labour referrals, obstetric interventions, low birthweight, and perinatal and maternal mortality and morbidity. there were no differences between the two groups in patients' satisfaction with quality of prenatal care. the groups had similar rates of low birthweight (new model 7.68% vs standard model 7.14%; stratified rate difference 0.96 pregnant women allocated to new style care had fewer day admissions (0.8 v 1.0; p=0.002) and ultrasound scans (1.6 v 1.7; p=0.003) and were less often suspected of carrying fetuses that were small for gestational age (odds ratio 0.73; 95% confidence interval 0.54 to 0.99).|antenatal care in harare, zimbabwe five hundred forty-nine low-risk pregnant women women booking for anc in the clinics were eligible women enrolled in clinics offering the new model were classified on the basis of history of obstetric and clinical conditions seven primary care clinics 15,994 women were recruited into the study at the time they booked antenatal care two antenatal care models in rural zimbabwe low risk women, together with maternal and professional satisfaction with care all women presenting for antenatal care at these clinics over an average of 18 months were enrolled low-risk patients in a rural area in zimbabwe low-risk women at a free-standing birthing center 13,517 women (new, n = 6897 and standard, n = 6620) in the study, and 78% (10,572) of their pregnancy records were retrieved clinics in argentina, cuba, saudi arabia, and thailand 81 women receiving prenatal care at a free-standing birthing center according to either an alternative prenatal care visit schedule (apcvs) (n = 43) or the traditional prenatal care visit schedule (tpcvs) (n = 38 97% of the women were followed up, 9,394 who had followed the new programme, and 6,138 from clinics with the standard one low-risk women 2764 pregnant women, judged to be at low risk of adverse perinatal outcomes women attending clinics assigned the new model (n=12568) had a median of five visits compared with eight within the standard model (n=11958 2794 women at low risk fulfilling the trial's inclusion criteria between june 1993 and july 1994 twenty-three rural health centres were stratified prior to random allocation to the new (n = 11) or standard (n = 12) model of care women receiving shared care and planning to deliver in one of three hospitals or at home
total dyskinesia score parkinsonian and dyskinesia scores motor response complications patient-kept diaries and unified parkinson's disease rating scale (updrs) interviews motor fluctuations and dyskinesias daily off-time levodopa dyskinesias motor fluctuations dyskinesia assessments on the unified parkinson's disease rating scale, part iv self-scoring dyskinesia diaries dyskinesia severity|we found a 24% reduction in the total dyskinesia score after amantadine administration (p = 0.004). in the 14 patients completing this trial, amantadine reduced dyskinesia severity by 60% (p = 0.001) compared to placebo, without altering the antiparkinsonian effect of levodopa. the magnitude of the l-dopa motor response to oral challenges was not different after amantadine or placebo treatment, and there was no significant reduction of daily off-time when patients received active treatment.|parkinson's disease primates and pd patients parkinson's disease (pd eighteen patients with advanced pd
hospital at home care and hospital care fatal complications oxford hip score functional status, lower extremity functioning, health-related quality of life, satisfaction with care, and use and cost of healthcare services quality of life with hospital at home care lower readmission rate sd) total cost earlier ambulation mean length of stay functional status, health-related quality of life, or lower extremity functioning function and quality of life sd) total length of stay satisfaction with access to care total length of stay and cost from orthopedic and rehabilitation hospital admissions, functional performance rand 36-item health survey i and the functional status index carer burden hospital stay on function, pain and quality of life (qol rapid attainment of short-term functional milestones mean hospital stay home healthcare costs|clinical pathway patients had a shorter mean length of stay (p = 0.011), earlier ambulation (p = 0.001), a lower readmission rate (p = 0.06) and closer matching of discharge destination. these data showed that high-risk individuals were able to tolerate early intensive rehabilitation, and this intervention yielded faster attainment of short-term functional milestones in fewer days using less total cost. a marginally significant gain in satisfaction with access to care (p =.059) was found in the intervention group at 6 months. the difference in oxford hip score between the groups was not statistically significant before the operation, but was better for the sg at 2 months (p = 0.03) and this difference remained more or less constant throughout the study. at follow up, there were no major differences in outcome between hospital at home care and hospital care for any of the patient groups except that those recovering from hip replacement reported a significantly greater improvement in quality of life with hospital at home care (difference in change from baseline value 0.50, 95% confidence interval 0.13 to 0.88).|total joint replacement (tjr) patients after surgery a hospital-affiliated home healthcare agency in a large midwestern city early inpatient rehabilitation after elective hip and knee arthroplasty 50 patients with 6 months of follow-up medicare-eligible individuals undergoing elective total hip or knee replacement surgery (n = 136 163 patients (56 men and 107 women; mean age, 66 years) undergoing primary hip or knee arthroplasty, and randomly allocated to the clinical pathway (92 patients) and the control group (71 patients total joint replacement 1994 to 1996 patients treated through a clinical pathway with those treated by an established standard of care at a single tertiary referral university hospital patients who completed the study and began inpatient rehabilitation on postoperative day 3 exhibited shorter mean carers of patients recovering from knee replacement preferred hospital at home care, while carers of patients recovering from a hysterectomy preferred hospital care patients with hysterectomy; disease specific measures-chronic respiratory disease questionnaire, barthel index for elderly medical patients patients who cannot function at home soon after surgery patients in all groups preferred hospital at home care except those with chronic obstructive airways disease hospital at home care with inpatient hospital care patients recovering from hip replacement (n=86), knee replacement (n=86), and hysterectomy (n=238); elderly medical patients (n=96); and patients with chronic obstructive airways disease (n=32 86 patients undergoing elective hip or knee arthroplasty and who met the following criteria for being high risk: 70 years of age or older and living alone, 70 years of age or older with 2 or more comorbid conditions, or any age with 3 or more comorbid conditions 50 patients from two hospitals 27 patients receiving 86 patients, 71 completed the study hip and knee arthroplasty
minimum regional cbf values clinical outcomes, clinically evident and transcranial doppler sonography-evident vasospasm, spect findings, complications, and costs cerebral vasospasm net fluid balance or on blood volume spect findings and neuropsychological function results cardiac filling pressures and fluid intake minimum regional cbf mean global cbf incidence of clinical vasospasm incidence of preoperative vasospasm cbf or blood volume cerebral blood flow (cbf pulmonary artery diastolic and central venous pressures cerebral blood flow regional cerebral blood flow symptomatic vasospasm cbf ((133)xenon clearance|the incidence of preoperative vasospasm in the treated group was 20%, as compared to 60% in the untreated group (p less than 0.01). hv therapy resulted in increased cardiac filling pressures and fluid intake but did not increase cbf or blood volume compared with nv therapy. no differences were observed between the two groups with respect to cerebral vasospasm (as observed clinically or on transcranial doppler recordings).|subarachnoid hemorrhage sixteen patients received after aneurysmal subarachnoid hemorrhage cases of subarachnoid hemorrhage 32 patients with subarachnoid hemorrhage thirty hypertensive patients with subarachnoid hemorrhage
atypical symptoms uku side effect rating scale number and severity of side effects productivity hamilton depression rating scale, sad version (sigh-sad), the clinical global impression of severity (cgi-s) and improvement (cgi-i) and the uku side effect rating scale seasonal affective disorder (sad, fall-winter depression remission rate response rate (sigh-sad social adaptation self evaluation scale (sass), the sheehan disability scale (sds), and assessments of days lost due to illness and days with reduction in productivity remission rate (sigh-sad <8 effectiveness and tolerability sigh-sad score, cgi-s and cgi side effects clinical response rates sass score remission rate (sigh-sad<8 clinical response overall response efficacy and safety negative social consequences of sad rate of clinical response response rate 24-item hamilton depression rating scale greater treatment-emergent adverse events (agitation, sleep disturbance, palpitations hdrs scores remission rates lower depression scores sigh-sad score sigh-sad score and cgi severity score rate of remission efficacy and tolerability time to response and to remission depression score 29-item modified hamilton depression rating scale, administered by experienced clinicians, and the self-rated beck depression inventory; adverse events and safety data tolerated hamilton depression rating scale (sad version; sigh-sad) and the clinical global impression (cgi sigh-sad, cgi severity, sass, and sds scores hamilton depression rating scale (sad version; sigh-sad), the clinical global impression (cgi) and the social adaptation self evaluation scale (sass|sigh-sad score was significantly lower in the reboxetine group at weeks 1, 2 and 4 but not at the end of the study. the response rate (sigh-sad<50% of baseline value) after treatment for 8 weeks was 95%, the rate of remission (sigh-sad < or =7) was 85%. the remission rate in the bright light group tended to be superior (bright light 50%, fluoxetine 25%; p = 0.10). duloxetine led to a significant improvement (p<0.001) of sigh-sad, cgi severity, sass, and sds scores. the fluoxetine group had lower depression scores at termination than the placebo group, but these differences did not achieve statistical significance. fluoxetine was associated with greater treatment-emergent adverse events (agitation, sleep disturbance, palpitations), but both treatments were generally well-tolerated with no differences in overall number of adverse effects.|twenty sad patients were included in an 8-week drug surveillance seasonal affective disorder (sad forty patients entered phase ii and 35 completed it (one drop-out in the 40 patients (20 in each treatment condition) suffering from seasonal affective disorder (sad) according to dsm-iii-r who had a total score on the hamilton depression scale of at least 16 26 sad patients sixty-eight outpatients who met the dsm-iii-r criteria for recurrent major depressive episodes, seasonal (winter) pattern 96 patients patients met dsm-iv criteria for major depressive disorder with a seasonal (winter) pattern and had scores > or = 23 on the four canadian centers over three winter seasons patients with winter seasonal affective disorder seasonal affective disorder (winter type seasonal affective disorder 20 sad patients
time-lapse before cbz reached its peak fluctuations in serum cbz and cbze stability in serum cbz and cbze concentrations mean carbamazepine levels mean fluctuation of serum cbz concentration (cmax-cmin/css fluctuations of total cbz and 10, 11-epoxide plasma level daily profiles at steady-state serum cbz concentration mean serum carbamazepine levels systemic toxicity (strs) and neurotoxicity (ntrs serum concentrations of unchanged cbz and its main metabolite, carbamazepine-10,11-epoxide (cbze bioavailability of cbz occurrence of dizziness peak serum cbz concentrations cbz levels and summation of cbz and cbz-e levels bioavailability side effects mean cbz daily dose mean cbz concentrations peak concentrations of cbz and cbze cognitive performance frequency of seizures serum carbamazepine concentrations mean total values of ntrs blood samples intermittent side effects number of epileptic seizures diurnal fluctuations mean serum cbz concentration tolerability and pharmacokinetics total score of strs occurrence of seizures mean total number of seizures seizure frequency occurrence of headache, dizziness and disturbances of vision, speech and coordination quality and severity of side effects serum concentration of cbz fluctuation in serum cbz concentrations|the mean serum cbz concentration in the morning samples was significantly (p less than 0.001) higher during sr treatment. a systematic tendency was found toward higher test performance in the cr condition. all the items of ntrs scored lower during sr therapy, and the difference was significant for the occurrence of headache, dizziness and disturbances of vision, speech and coordination. the fluctuation in serum cbz concentrations did not differ significantly between the 2 treatment periods, even though the interdose interval of neurotol slow was 4 h longer than that of tegretol. there was no significant difference in bioavailability between the 2 preparations. there was no difference in the frequency of seizures between treatment (p = 0.103). 3%; p less than 0.01) in serum cbz concentration were substantially less with cbz-cr and were similar to those calculated during a 6 or 8 hourly dosage interval with conventional cbz (fluctuation 33 +/- at this stage the difference in mean carbamazepine levels of two groups became insignificant (p < 0.05). fluctuations of total cbz and 10, 11-epoxide plasma level daily profiles at steady-state were significantly (p less than 0.001) lower during cr cbz treatment, leading to a significant (p less than 0.001) decrease in intermittent side effects (6 patients on cr cbz vs 26 on conventional cbz).|twenty-one epileptic patients 24 adult patients with epilepsy twenty patients could be evaluated epileptic patients eighteen adult epileptic patients under 38 patients on indian epileptic patients twenty consecutive untreated patients of partial seizures twenty-one adult patients with epilepsy who had side effects related to the use of cbz took part in the trial 24 adult epileptic patients receiving cbz treatment of whom 20 patients were evaluable newly treated patients of epilepsy but without complete seizure control (n = 22) or with intermittent side effects (n = 4), or with both (n = 22 48 epileptic patients (21 men, 27 women; mean age 34.2 years) on mean age of the 20 evaluable patients was 24.9 and the duration of epilepsy 19.2 and carbamazepine treatment 7.0 years mentally retarded patients with a slow-release carbamazepine preparation eligible patients patients with epilepsy
bmd measurement or osteoporosis medication, provider reminder plus patient education electronic data and linear regression bmd measurement and osteoporosis medication osteoporosis management|the effect of provider advice combined with patient education was not significantly different from provider advice alone (p=.88).|after a fracture female patients aged 50 to 89 who suffered a fracture in 1999 and had not received bone mineral density (bmd) measurement or medication for osteoporosis (n=311) and their primary care providers (n=159 patients aged 60 to 69 were 18% (95% confidence interval=3-34) more likely to receive bmd measurement or an osteoporosis medication than those aged 80 to 89
pain severity and knee function score womac physical function scores femorotibial angle number of days with nsaids intake symptoms of knee oa femorotibial angle and symptomatic relief walking distance and quality of life talar tilt angle compliance maximum distance walked aggregate severity score alignment, degree of oa, origin of oa, and age compliance and tolerance pain on getting up from a seated position disease-specific quality of life patient's assessment of activity vas pain score womac subscales walking distances assessment of disease activity, in womac pain, joint stiffness, and physical functioning subscales nsaids consumption western ontario and mcmaster university osteoarthritis index (womac) and the mcmaster-toronto arthritis patient preference disability questionnaire (mactar), and function pain visual analog scale (vas) score for subjective knee pain aggregate score disease activity (5 grade scale), womac index subscales and concomitant treatments symptomatic improvement|participants wearing the elastically strapped insole (n = 46) had significantly decreased femorotibial angle (p < 0.0001) and talar tilt angle (p = 0.005) and significantly improved vas pain score (p = 0.045) in comparison with baseline assessments. this study failed to demonstrate a relevant short-term symptomatic effect of laterally-wedged insoles in medial femoro-tibial oa. in contrast, significant symptomatic improvement was detected only in the aggregate score (p = 0.016) in the sock-type ankle support group, but not in any of the 10 specific categories. the reported walking distances at 3 months, 12 months and overall were significantly longer in the brace group (p=0.03, p=0.04 and p=0.02, respectively). at the six-month follow-up evaluation, there was a significant improvement in the disease-specific quality of life (p = 0.001) and in function (p< or =0.001) in both the neoprene-sleeve group and the unloader-brace group compared with the control group.|osteoarthritis of the knee medial knee osteoarthritis outpatients with painful medial femoro-tibial knee oa nine patients withdrew from the study osteoarthritis (oa) of the knee ninety female outpatients with oa of the knee patients with medial compartment osteoarthritis (oa) of the knee 156 recruited patients (41 males, 115 females, mean age 64.8 years patients with varus-deformity knee oa patients with unicompartmental oa patients who had varus gonarthrosis were screened for eligibility one hundred and nineteen patients were randomized medial femoro-tibial oa patients with knee oa with varus deformity patients who had osteoarthritis in association with a varus deformity of the knee (varus gonarthrosis patients with medial or lateral compartmental osteoarthritis (oa) and concurrent varus or valgus alignment, respectively unicompartmental oa of the knee forty patients (thirty-one men and nine women; mean age, 60.9 years); the neoprene-sleeve group, of thirty-eight patients (twenty-seven men and eleven women; mean age, 58.2 years); and the unloader-brace group, of forty-one patients (twenty-eight men and thirteen women; mean age, 59.5 years eighty-eight female outpatients with knee oa patients with medial compartment osteoarthritis of the knee patients with medial femoro-tibial knee osteoarthritis (oa patients were stratified according to age (less than fifty years or at least fifty years), deformity (the mechanical axis in less than 5 degrees of varus or in at least 5 degrees of varus), and the status of the anterior cruciate ligament (torn or intact patients: 117 patients with unicompartmental oa of the knee orthopedic department of a university medical centre and of one general hospital
mechanical ventilation effectiveness (rse control, adverse events while infections and arterial hypotension mortality tolerability measures proportion of patients with rse|while infections and arterial hypotension did not differ between groups, barbiturate use was associated with a significantly longer mechanical ventilation (p = 0.03).|24 patients recruited of the 150 needed; 14 subjects received adults with rse not due to cerebral anoxia, medications were titrated toward eeg burst-suppression for 36-48 h and then progressively weaned
pain reduction plasma clearances of pethidine, and the time to peak concentration median time for first passage of flatus incident pain convalescence and hospital stay late postoperative pain, fatigue and conservative attitudes and routines stress hormones pain relief postoperative analgesia minimum respiratory rates pruritus pulseoximetry, arterial blood gas analysis and rate of breathing postoperative venous thrombosis totpar vps beta-endorphine release total blood loss visual analogue pain scales, total morphine consumption, and stress hormones pain relief (visual analogue scale), attainment of physical therapy goals and cardiopulmonary complications supplemental analgesia total incidence of deep vein thrombosis nausea, vomiting, itching and urinary retention pain control hypotension surgical outcome and duration of rehabilitation degree of analgesia, the adverse effects postoperative pain and knee rehabilitation postoperative pain intensity side effects pain scores, supplemental analgesia, side effects, degree of maximal knee flexion, day of first walk, and duration of hospital stay postoperative complications pain score postoperative pain relief actual discharge time perioperative blood loss, frequency and quantity of transfusions low pain scores somnolence early postoperative knee mobilization levels respiratory depression area under the curve (auc) of pain score versus time nausea and vomiting hypercapnia exceeding 6.0 kpa hypoalgesia to pin prick pain and consumption of postoperative analgesics knee flexion postoperative knee rehabilitation durations of stay visual analog scales pain urinary retention analgesic requirements pain scores bradycardia total pain score (totpar early postoperative maximal amplitude of knee flexion incidence of calf vein thrombosis antithrombotic efficacy catabolic response postoperative convalescence parameters, such as ambulation, patient activity including need for nursing care, fatigue or hospital stay pain relief and faster knee rehabilitation visual analogue pain scales pain scores, pain reduction and additional analgesia requirement (i.v. paracetamol faster ambulation, and shorter hospital stay adverse effects postoperative pain perioperative blood loss visual analogue scale (vas visual analog scale scores nonfatal pulmonary embolism plasma concentrations of pethidine|somnolence was observed more often in pca patients (8% vs 2%; p 0.05), while no significant differences were noted among other side effects incidence. the early postoperative knee mobilization levels in both continuous epidural infusion and continuous femoral block groups were significantly closer to the target levels prescribed by the surgeon than in the patient-controlled morphine group. however, the achieved pain relief had no impact on postoperative convalescence parameters, such as ambulation, patient activity including need for nursing care, fatigue or hospital stay. nausea, vomiting, itching and urinary retention were the most frequent side effects without significant differences between the groups. minimum respiratory rates were lower in patients receiving epidural morphine (15.0 +/- 0.3) than in those receiving patient-controlled analgesia (16.5 +/- perioperative blood loss, frequency and quantity of transfusions were significantly higher in group d (p<0.0001). epidural analgesia with a combination of bupivacaine and fentanyl did not result in any measurable improvement in rehabilitation milestones or reduction in postoperative complications following bilateral total knee arthroplasty than with fentanyl infusions alone. the incidence of calf vein thrombosis was 12% compared with 45% after general anaesthesia (p = 0.05). there were no significant differences between groups in pain scores, pain reduction and additional analgesia requirement (i.v. paracetamol). patients in groups b and c reported significantly lower pain scores than those in group a. supplemental analgesia was comparable in the three groups. the terminal half-lives and plasma clearances of pethidine, and the time to peak concentration were not different between the groups. the median time for first passage of flatus was shorter in the eda group than in the ga/pca group (26 vs. 47 h). application of intraarticular morphine did not reduce the amount of analgesics required for postoperative analgesia as compared to intravenous analgesia alone.|patients with postoperative pain patients undergoing total hip arthroplasty after total knee arthroplasty, patients regularly suffer from severe pain pain after hip and knee arthroplasty 32 patients after hip and knee arthroplasty after major knee surgery forty-one patients undergoing total knee arthroplasty 56 adult scheduled for major knee surgery forty-two patients scheduled for total knee arthroplasty (n = 20) or hip arthroplasty (n = 22 patients with epidural placebo (premo total hip arthroplasty patients undergoing knee arthroplasty early convalescence after major orthopaedic surgery hip replacement forty-five patients scheduled for elective tka under general anesthesia 51 patients undergoing bilateral one-stage total knee arthroplasty patients undergoing knee- or hip arthroplasty treated with joint replacement surgery one-stage bilateral total knee arthroplasty 90 patients were enrolled total knee arthroplasty (tka twenty-one patients who had undergone total hip replacement forty-eight patients unilateral total knee arthroplasty orthopedic surgery 30 patients recovering from total hip or total knee arthroplasty total knee arthroplasty thirty-seven patients, scheduled for total knee arthroplasty sixty patients
serum antibodies efficacy and side effects anti-vi antibodies serious adverse reactions frequencies of rises of fourfold or greater and of maximal vi antibody levels seroconversion rate degree of fever typhoid fever immune responses attack rate of typhoid mild local reaction protective rate and index of vaccine serum vi antibody levels (ria antibody levels protective efficacy erythema and/or induration mild and moderate fever overall incidence of side-effects vaccine efficacy safety and immunogenicity clinical and serum antibody responses safety, immunogenicity, and efficacy frequencies of adverse reactions and mean vi antibody levels fever (oral temperature fever seen levels of serum igg vi antibodies rate of blood-culture-positive typhoid fever rates of typhoid fever|the vi-repa conjugate typhoid vaccine is safe and immunogenic and has more than 90 percent efficacy in children two to five years old. fever (oral temperature > or = 100 degrees f (37.8 degrees c)) occurred in < 2% of vaccinees. over 36 months of surveillance, the liquid formulation (76.9% vaccine efficacy) was significantly superior to the enteric-coated capsules (33.2% vaccine efficacy). most of the isolates were from school-aged children: 22 cases in the placebo group versus 6 in the vi group (pe = 72%; 95% ci = 32%, 82%). the results of the follow-up indicate that, in the dosage schedule used, the ty21a mutant strain, found previously to be stable and safe, is protective against typhoid fever for at least one year. the seroconversion rate was 69% for those who received vaccine versus 14% for those who received placebo (p < 0.005). rates of typhoid fever were 379/100,000 per year for subjects who received the liquid formulation of vaccine and 468/100,000 per year for subjects who received enteric coated capsules. three doses, given within one week, of ty21a attenuated salmonella typhi oral vaccine in an enteric-coated formulation provided 67% efficacy for at least 3 years in a randomised, placebo-controlled field trial involving 109,000 schoolchildren in santiago, chile. protective efficacy in relation to the unvaccinated group was 77.4% and 81.0% after 21 months, calculated immediately and 6 weeks after vaccination, respectively. the attack rate of typhoid was 16.2 per 1000 among the controls and 4.1 per 1000 among those immunized with vi (p less than 0.00001). a total number of 81,506 vaccinees were investigated on the efficacy of vi vaccine, using positive blood culture of salmonolla typhi as a diagnostic criterion. vaccine efficacy in the first two years after vaccination was 59% for two doses and 29% for one dose; no efficacy was found 3-5 years after vaccination.|11,384 children children two to five years old in 16 communes in dong thap province, vietnam 81,621 schoolchildren aged 5-19 years south-western china 771 children who received only one injection, there was 1 case of typhoid in the vaccine group and 8 cases in the placebo group a total of 32 388 children were included in the study 634 thai children 2 to 6 years of age adults and in children 5 to 14 years old and has elicited a booster response in children 2 to 4 years old 6907 participants, of whom 6438 were members of the target population (5 to 44 years of age); each was visited every two days 109,000 schoolchildren in santiago, chile young thai children 11,691 unvaccinated children; 173 cases 5525 children who were fully vaccinated with vi-repa and from 47 of the 5566 children 777 children and adults indonesia with ty21a vaccine two-to-five-year-old children guangxi zhuang autonomous region in south-western china, using 30 micrograms doses of locally produced vi a total of 131,271 people the study population was followed for 19 months, with passive surveillance conducted in the ministry of health and the regional health and anti-epidemic centre (haec alexandria, egypt, in 1978-79 20,543 subjects (age range 3-44 years 82,543 schoolchildren enrolled subjects were 3-50 years of age, although the majority (92%) were school-aged children, who have the highest rate of typhoid fever in this setting 11,091 children children two to five years old persons who are more than five years old healthy adults typhoid fever in nepal with the vi capsular polysaccharide of salmonella typhi
mean costs of antimicrobials per episode peak incidence antibiotic use, hospital admissions, and mortality rate of mrsa infection reduced length of stay, a potential cost savings icu length of stay occurrence of a secondary episode of vap length of stay nosocomial infection and mortality reducing door-to-antibiotic time incidence of nosocomial infections medication costs mean durations of hospital stay surgical site infection rate total antibiotic exposure 30-day mortality rates antibiotic treatment duration severity of illness using apache (acute physiology and chronic health evaluation) ii score adjusted relative risk of antibiotic exposure 30-day mortality preintervention incidence of regimens involving 12-hour intervals mean risk of infection-related mortality gentamicin and tobramycin resistance bloodstream infections incidence of c. difficile diarrhoea proportion of antibiotic courses sd) hospital stay mean risk of clostridium difficile-associated diarrhea total number of courses of therapy diarrhea resistance to gentamicin and tobramycin antibiotic use and vre prevalence mean numbers of defined daily doses of appropriate antibiotic therapy hospital mortality pharmacy's 1985 average cost per antibiotic day and its monthly expenditures partial or total cessation of antibiotic treatment vre infection rate rate of unnecessary use of the 2 target antibiotics prolonged prophylaxis antibiotic choice, duration, timing, antibiotic volume and costs duration of antibiotic treatment for vap serological evidence of viral infection proportion of patients receiving appropriate antibiotics within 4 h of admission to hospital resistance among p. aeruginosa nosocomial infections microbiologically documented infections (mdi incidence and prevalence of patients with multiresistant enterobacteriaceae postoperative infection rate or death cost of antimicrobials per inpatient day fell training of the whole health care team, emphasizing measures to reduce cross-colonization, and the importance of rational usage of antibiotics and (2) suppression of usage of third-generation cephalosporins rates of discontinuation and hospital discharge vre prevalence vre infection laboratory studies, imaging procedures, days of intubation, and days in an intensive or intermediate-care area reintroduction of gentamicin readmissions median duration of iv therapy serum calcitonin precursor concentrations quality of care 30-day mortality decreased mortality quality of surgical prophylaxis patients response and mortality length of stay, intensive care unit transfers, readmission rates, and in-hospital death rates cephalosporins mean overall mortality rate hospital admissions numbers of intravenous piggyback cefazolin, cephalothin, cefamandole, cefoxitin, carbenicillin, and ticarcillin doses length of hospital stay, costs related to future resistance and total antibiotic costs mortality, rehospitalization, and return to usual activities mean number of cases of c. difficile-associated diarrhea overall and timely administration of prophylaxis 30-day all-cause mortality, length of hospital stay, and readmission rate incidence of toxicity cost savings mean acuity of patient care concordance with national antibiotic guidelines mean lengths of hospitalization hospital length of stay or mortality turnaround time hospital admission, severity of pneumonia, and 30-day mortality incidence of colonization and infection rates of ventouse delivery actual cost of alert antibiotics number of courses of therapy or cost mean length of total hospital stay antibiotics in caesarean section and use of polyglycolic acid sutures mortality from staphylococcal bacteraemia real-time pcr results cervical cytology history annualized savings clindamycin susceptibility guideline compliance incidence density of tobramycin-resistant organisms aminoglycoside resistance cefx use parenteral broad-spectrum antibiotics time elapsed from randomization until a first modification of the initial intravenous antibiotic therapy amikacin resistance infection rate vancomycin use mortality rates and length of hospital stay antimicrobial therapy costs, antimicrobial resistance, and superinfections without adversely affecting the length of stay or mortality antibiotic expenditure duration of stay median patient charges for radiology, laboratory, pharmacy, and room were reduced by $4404/intervention, and median hospital costs nosocomial clostridium difficile-associated diarrhea total expenditures compliance with other recommendations, patient satisfaction and costs of the implementation strategy (secondary outcomes nosocomial mrsa infection rate proportion of ceftazidime-resistant organisms acquired late turnaround time of microbiological procedures antibiotic prescriptions on admission turnaround time of the microbiological cycle antibiotic cost savings number of antibiotic entities stocked medical complications antibiotic costs carriage of gre time to first dose of antibiotics, proportion receiving antibiotics within 8 h, timely switch to oral antibiotics, timely discharge, length of stay, or patient education outcomes number of doses prepared and quarterly purchase data response rates clinical, laboratory, and radiographic outcome diagnostic costs intraoperative redosing annual rate of fluoroquinolone use febrile neutropenic episodes median length of stay cefamandole, cefoxitin, and ticarcillin costs antibiotic expenditures mean durations of therapy rate of appropriate empirical antibiotic treatment antibiotic use number of infants treated with antibiotics and 2) the number of infants with infections missed at the initial evaluation appropriateness of cefotaxime prescribing clinical pulmonary infection score performance of a sputum (p<.01) and blood (p<.001) cultures, antibiotic administration within 4 hours of hospital admission number of days that unnecessary levofloxacin or ceftazidime antibiotics and analysis was by intention to treat iv antibiotic duration, and appropriateness of the iv route and switching total antibiotic prescribing costs length of hospital stay, adverse events, mortality (interventional trial) and antibiotic costs (both studies), including costs related to future antibiotic resistance cdad fell usage of cephalosporins, imipenem, clindamycin, and vancomycin and increased usage of beta-lactam/beta-lactamase-inhibitor antibiotics overall, mean monthly acquisition cost savings shorter length of stay crude mortality rates average length of stay acute exacerbation of chronic obstructive pulmonary disease vre infections diagnostic yields, feasibility, and costs of real-time polymerase chain reaction (pcr nosocomial mrsa infections lastly, patient costs for hospitalization mortality or genital tract infection monthly incidence of c. difficile infection clinical and laboratory outcome hospital admission iv antibiotic expenditure hospital antibiotic prescribing serum aminoglycoside concentration data antibiotic costs, length of stay, need to restart intravenous antibiotics, in-hospital mortality, and 30-day readmissions clinical outcomes gram-negative resistance to gentamicin rate of mrsa isolation pneumonia severity index, the hazard ratio of antibiotic discontinuation rate of nosocomial methicillin-resistant staphylococcus aureus infection mortality and length of icu stay rate of unjustified prescriptions c. difficile diarrhoea febrile neutropenia and nosocomial infections coagulase-negative staphylococcus and enterococcus infection rates prevalence of mrsa and crp level of compliance mean antibiotic costs mortality odds ratio (or labor costs overall ssi rates number of antibiotics clostridium difficile-associated diarrhoea (cdad intervention markedly improved door-to-antibiotic time mrsa isolation quality, efficiency, and patient understanding of care incidence of surgical site infections (ssi infection rates overall antibiotic use clinical, laboratory, and microbiology characteristics, and pneumonia severity index quality and efficiency of pneumonia care clinical and microbiological response, antibiotic-associated toxic effects, in-hospital mortality, and readmission rates infections time-specific mortality risk clostridium difficile-associated diarrhea and cost ticarcillin total use and cost quality of prophylaxis mean lengths of time to provision of susceptibility and identification test results vre rates per patient antibiotic charges glycopeptide usage antibiotic choice duration of intravenous antibiotic therapy annual cost savings minimal fever diagnostic tests icu vancomycin use and vre prevalence readmission rate antimicrobial use calculated cost savings time to modification of intravenous antibiotic therapy mortality, morbidity, and cost antimicrobial portion of the total pharmacy drug budget mortality rates rate of surgical-site infection mortality acquisition rate of gre serum procalcitonin concentrations acquisition rate falling cost of development, dissemination and implementation|a 2-year general hospital/drug utilization health record screen found no drug substitution effect, nor any change in postoperative infection rate or death among metronidazole recipients. icf can be used safely to curb irrational overuse of vancomycin and teicoplanin in a hospital with high methicillin resistant s. aureus infection rates. the rate of appropriate empirical antibiotic treatment was higher in intervention versus control wards [73% versus 64%, odds ratio (or): 1.48, 95% confidence interval (ci): 0.95-2.29, intention to treat, adjusted for location and clustering]. in the fourth phase, the analysis of bacterial resistance profile indicated a reduction of nosocomial infections due to multiresistant bacteria from 18 cases in 1995 to 2 cases per year until 1999. the majority of prescribers (87.2%) who responded to the questionnaire (56.5% response rate) felt that the 1989 policy made a positive contribution to antibiotic usage in the hospital. however, there was an increase in the number of patients with cultures positive for cefotaxime-resistant acinetobacter species (from 2.4 +/- there was a trend for improved clinical outcomes in patients who received cefotaxime within hospital guidelines (or = 1.73; p = .31). antimicrobial use decreased from 121 to 79 ddd (defined daily doses)/100 procedures and costs reduced by 25% per procedure. improved response rates were seen in the experimental (60%; 42/68) compared with the control group (48%; 36/68). the proportion of antibiotic courses that were assessed as satisfactory in terms of duration increased significantly after the first campaign in the hospitals where the intervention was mounted. use of vancomycin decreased after a pharmacy-enforced restriction program was implemented. statistically significant improvements in process measures were demonstrated in the intervention hospitals, including performance of a sputum (p<.01) and blood (p<.001) cultures, antibiotic administration within 4 hours of hospital admission (p<.001), and administration of the first dose of antibiotic in the emergency department (p<.001). clinical pharmacists were effective in reducing the use of cefamandole, cefoxitin, and ticarcillin in situations where cefazolin or carbenicillin could be substituted. an outbreak of c. difficile infection in the elderly care unit at gloucestershire royal nhs trust continued despite increased ward cleaning and strict implementation of infection control measures. the costs of these 3 restricted drugs increased very sharply (69%) in 1996 when there was loss of endorsement and capacity to perform auditing and feed back by infectious disease specialists. the rate of mrsa infection was positively correlated with levofloxacin use (p=.01) and azithromycin use (p=.08), whereas it was negatively correlated with summer season (p=.05). the duration of antibiotic treatment for vap was statistically shorter among patients in the discontinuation group compared to patients in the conventional antibiotic management group (6.0 +/- there were no significant changes in the number of courses of therapy or cost for the unrestricted antimicrobials. only 39% of ward 2 patients underwent minimal fever diagnostic tests compared to 82% in ward 1 (p < 0.001). an example is given in the estimation of the cost savings attributable to an improved antibiotic prescribing policy at the royal liverpool hospital. in the overnight test group, these values were 19.6 and 25.9 h, respectively (p < 0.0005). however, vre prevalence increased steadily from 17.4% to 29.6% during the 10-year period (p<.001). term and preterm infants who were <72 hours of age and had clinical signs or obstetric risk factors suggesting neonatal bacterial infection but stable enough to wait for results of diagnostic tests were enrolled into the study. annualized savings was $74,371, with 40% of the recommendations resulting in an improved antimicrobial therapy. patients had medical complications during the index hospitalization (p = 0.04), with no differences in other medical outcomes, including mortality, rehospitalization, and return to usual activities, between treatment arms. length of stay, intensive care unit transfers, readmission rates, and in-hospital death rates were similar in both groups (p> or =.10 for all). thirty-day mortality was 13.4% (1,037 of 7,719) among admitted patients and 6.3% (1,801 of 28,661) overall. concordance with national antibiotic guidelines rose from 25% of courses pre-intervention to 51% within 5 months post-intervention (p < 0.002). moreover, the antibiotic use control was operationally successful, most house-staff and attending physicians, not only antibiotic evaluating team, have accepted the program in a very positive way. concomitantly, there was a significant (p = .002) decrease in nosocomial infections caused by c. difficile and a significant (p = .02) decrease in nosocomial infections caused by resistant enterobacteriaceae. per patient antibiotic charges were nearly $400 less in the intervention group vs controls (p = .05). these improvements were associated with increases in overall and timely administration of prophylaxis (p<.001) in both hospitals by time series analysis, with adjustment for volume and case mix. the prevalence of mrsa and crp remained stable, while that of epesb fell significantly (p<0.001). compared with the control group, intervention physicians wrote 32 percent fewer orders (11.3 versus 16.7 orders per physician; p = 0.04) and had 28 percent fewer patients for whom they either initiated or renewed an order for vancomycin (7.4 versus 10.3 orders per physician; p = 0.02). the readmission rate was also lower. over a period of 54 months, both gentamicin and tobramycin resistance decreased significantly when amikacin was used (p less than 0.001), then increased with reintroduction of gentamicin (p less than 0.05), and decreased significantly with reintroduction of amikacin (p less than 0.001). postintervention, treatment with pa and oa according to the guidelines was not significantly different between the two groups of randomized snfs. the results suggest that a short questionnaire, easily adaptable to automatization, has the potential to foster reassessment of antibiotic therapy. average length of stay decreased from 8.6 days in 1992 to 7.6 days in 1993, with a charge reduction of $1830 per patient. median length of stay after randomization for control and intervention groups was 9.0 days and 5.7 days, respectively (3.3-day difference, p=0.0001). the intervention significantly reduced mean antibiotic costs per patient ($19.82 vs $35.84, p = 0.03), but related labor costs exceeded this benefit. rates of ventouse delivery increased significantly in intervention units but not in control units; there was no difference between the two types of units in uptake of other practices. more patients in group 2 received appropriate exclusively iv therapy (65% vs. 96%, p < 0.01). in the months following the formulary restrictions, no significant detrimental changes occurred in hospital length of stay or mortality. the predicted use of ceftriaxone exceeded by 65% an estimate based on prior use of cefotaxime. lasting improvements in clinical practices may be brought about by means that are noncoercive, inexpensive and well-accepted by medical staff. in this study, practice changes focused towards specific icus were associated with decreases in icu vancomycin use and vre prevalence. this computer-assisted system of antimicrobial monitoring was used effectively to assess both individual patient therapy and overall antimicrobial use in a teaching hospital. uncertainty about the cost effectiveness of such interventions is likely to be resolved only by a well-designed, cluster randomised trial. use of selected systemic antimicrobial agents at boston city hospital (bch) has been monitored by requiring that choice of those agents be justified to a member of the infectious diseases unit before the agent is dispensed for use in a patient. for 13 months, the monthly incidence of c. difficile infection averaged more than five times that for the previous 21 months. real-time pcr increased the diagnostic yield from 23 cases (21% of patients) to 47 cases (43% of patients), compared with conventional diagnostic tests. mortality and length of icu stay did not differ despite a shorter duration (p = 0.0001) and lower cost (p = 0.003) of antimicrobial therapy in the experimental as compared with the standard therapy arm. reduction in ceftazidime use and barrier precautions markedly reduced the incidence of colonization and infection. glycopeptide usage was not reduced during the period of the study. we conclude that a structured antibiotic order form, coupled with graphic and educational interventions can improve antibiotic use in a university hospital. procalcitonin guidance reduced total antibiotic exposure (relative risk, 0.52; 95% confidence interval, 0.48-0.55; p < 0.001), antibiotic prescriptions on admission (85 vs. 99%; p < 0.001), and antibiotic treatment duration (median, 5 vs. 12 d; p < 0.001) compared with patients treated according to guidelines. this combination of clinical and administrative strategies reduced expenditures for antimicrobial agents by more than $700,000 over two years without the use of clinical specialists or any apparent sacrifice in the quality of patient care. a web-based intervention was deployed as part of an existing order entry system at a university hospital on 5 february 2002. intraoperative redosing was significantly more frequent in the reminder group (93 of 137; 68%) than in the control group (55 of 136; 40%) (adjusted odds ratio, 3.31; 95% confidence interval, 1.97 to 5.56; p < .0001). for the rapid groups, the turnaround time was significantly shorter for oral reporting of final susceptibility results in all three study periods and for reporting on paper in the third study period. the intervention increased the use of guideline-recommended antimicrobial therapy from 78.1 to 83.4% (p = 0.003). in the procalcitonin group, the adjusted relative risk of antibiotic exposure was 0.49 (95% ci 0.44-0.55; p<0.0001) compared with the standard group. in the years since, the incidence has remained at this low level, and the antibiotic costs have decreased to a level lower than before intervention. at the end of the intervention, the rate of mrsa isolation was significantly lower at caen hospital than at the control hospitals (353 [32.3%] of 1093 s. aureus isolates were mrsa, compared with 2495 all of the restrictions resulted in a decrease in the number of dosage units dispensed; however, the required countersignature by the chief of staff and deletion from the formulary were the most effective in restricting drug use. vre infections decreased from 0.29/100 patients discharged prior to initiating the program to 0.13/100 patients discharged after the second intervention (p = 0.01). there was an 80% decrease in the use of cloxacillin, a 74% decrease of aminoglycosides and a 59% decrease of cephalosporins. hospital formulary restriction of clindamycin is an effective way to decrease the number of infections due to c. difficile. ceftazidime restriction resulted in a small but nonsignificant decrease in the proportion of ceftazidime-resistant organisms acquired late (beyond 72 hrs) in the patients' icu course (56.5% vs. 45.9%). when therapeutic interchange was employed, the percentage of orders for extended intervals rose to an average of 97% over a 32-week postimplementation period. no intervention benefit was observed for any secondary outcome. the proportion of gentamicin-resistant strains such as e. cloacae or staphylococci decreased and there was no increase in aminoglycoside-resistant strains, except in escherichia coli, in which resistance to amikacin rose from 0 to 3%. the alert antibiotic monitoring intervention was associated with significant decreases in total use and cost in the 2 years after the programme was implemented. microbiological results were available within an average of 8.8 h by the direct method versus an average of 48 h by the routine method. ad did not lead to statistically significant additional changes in already high levels +12.5% (95% ci:-3%; 28%) of compliance. the program resulted in a reduction in the antimicrobial portion of the total pharmacy drug budget from 41.6% to 28.2%. the decrease in the vre infection rate corresponded with a significant increase in the use of piperacillin/tazobactam and a reduction in third-generation and total cephalosporin use. the relative risk for colonisation with strains resistant to the empirical therapy per 1000 patient days at risk was 18 times higher for the amoxicillin-cefotaxime regimen compared with the penicillin-tobramycin regimen (95% ci 5.6-58.0). for groups a, b, and c, the proportions of days on which adequate treatment was received were 66.3%, 92.1%, and 91.2% (p<.001); the mean numbers of defined daily doses of appropriate antibiotic therapy were 16.4, 22.2, and 20.7 (p=.003); the mean durations of hospital stay were 19.8, 23.6, and 24.1 days (p=.761); and the mortality rates during the late period were 12.9%, 15.6%, and 11% (p=.670), respectively. immediately after implementation of the form, nonrecommended dosing schedules dropped to under 6% of patient-days for all three antibiotics. the incidence of nosocomial infection and mortality also were similar across teams.|87-bed veterans affairs teaching hospital with an extended-care facility 2869 patients receiving 7471 prescriptions for an antimicrobial for an infection covered by the guidelines between july 2001 and september 2003 inpatients in a teaching hospital/tertiary referral centre where 33% of s. aureus isolates (72% from icu patients) were methicillin resistant patients suspected of harbouring bacterial infections in three hospitals (israel, germany and italy october 1995 through december 1999 in 4 phases: a cross-sectional study, a longitudinal study with intervention measures, monthly cross-sectional studies, and determination of nosocomial infections caused by multiresistant bacteria (oxacillin-resistant staphylococcus aureus and gram-negative bacteria resistant to either aminoglycosides or third-generation cephalosporins patients hospitalised with community-acquired pneumonia (cap 243 patients admitted with suspected lower respiratory tract infections 11-year period (1982-1992) in a 370-bed district general hospital in northern ireland patients with pneumonia in very small hospitals patients with an episode of pneumonia acquired more than 3 days after admission to snf (n = 350 302 consecutive patients with suspected community-acquired pneumonia were included all hospitalised patients with a bacterial infection confirmed by culture infected, hospitalized patients in a tertiary-care, teaching, medical center patients with respiratory failure and sepsis from pneumonia hospital stay: two hundred and fifty-two and 234 patients respectively with a discharge diagnosis of infection were admitted before and after the antibiotic policy change 238 neonates (g1), admitted between 1 january and 31 july 1989, and treated with gentamicin, were compared with 398 (g2) admitted between 1 august 1989 and 31 july 1990 who received 25 of the 26 district general obstetric units in two former nhs regions 107 patients (mean age patients with pulmonary infiltrates in the icu patients hospitalized with pneumonia 141 of 175 tested patients (81 three hundred ninety-six physicians and 1,798 patients in a tertiary-care teaching hospital 16 demographically similar hospitals (control group 102 inpatients meeting eligibility criteria boston city hospital (bch a total of 1291 infants recipients two hundred twenty-six patients with bacteremia university-affiliated teaching hospital 226 preintervention episodes of pneumonia and 116 postintervention episodes elderly patients with pneumonia patients with clinical infections pediatric intensive care unit (icu newborn infants patients with pulmonary infiltrates in the intensive care unit patients with cpis 436 admissions, divided equally between the two regimens (218 in each dutch hospitals royal melbourne hospital, a tertiary hospital in melbourne, victoria hospitalised patients in the netherlands 323 patients who were prescribed 17 general medical, oncology, and cardiology services either received adult inpatients receiving 1 or more of 10 designated parenteral antibiotics for 3 or more days during a 3-month period patients > or = 66 years old with primary international classification of diseases, ninth revision, clinical modification codes 480.0-483.9, 485.0-486.9, 487.0, 507.0 or 518.81, and 038.x with secondary code pneumonia 65 years with community-acquired pneumonia from 1993 through 1997 in utah; nursing home patients were excluded severe sepsis or pneumonia in medical patients 4 large teaching hospitals in northwest france, catering to a total of 5,882,600 persons four academic health centers in the new york city metropolitan area a medical icu from a university-affiliated urban teaching hospital nursing home residents admitted with pneumonia medicare-insured hospital admissions for pneumonia were reviewed from 20 small hospitals in oklahoma (intervention group) at baseline and after feedback one hundred and twenty-six eligible patients hospitalized patients with infection patients admitted with suspected infection were prescribed intravenous (i.v these included 14 bacteremias and 17 pulmonary infections among 52 infected patients patients treated by physicians who did not participate in the guideline program 13 dutch hospitals inpatient prescriptions surveyed, revealed that only 31 (17%) conformed with centre for disease control (cdc) guidelines a 487-bed general hospital in new york city 50 intensive-care units (icus) at 20 u.s. hospitals reporting data on antimicrobial-resistant organisms and antimicrobial agent use 700-bed minneapolis veterans administration medical center 1062 infants were studied during a 1-year period of 2365 admissions, 757 (32%) had 806 treated episodes hospitalised adults with community-acquired febrile syndromes february 1995 at an acute care teaching hospital after guidelines for vancomycin use were established by a multidisciplinary group patients hospitalized with community-acquired pneumonia clinically suspected ventilator-associated pneumonia (vap very small hospitals ten skilled nursing facilities (snfs) from a single metropolitan area hospitalized patients with symptomatic diarrhea consecutive children admitted to the pediatric icu over a 19-mo period community-acquired pneumonia all consecutive adults hospitalized for pneumonia during a 5-month period before (n = 1,013) and after (n = 1,081) implementation of an inpatient quality improvement (qi) initiative patients with pulmonary infiltrates for whom monotherapy with a short course of antibiotics was appropriate university-affiliated veterans affairs medical center located in southwestern united states patients hospitalized on the surgical and medical wards of a university hospital and treated with an intravenous antibiotic for 3-4 days 1203 patients included in the cohort study (350 with mdi university hospital in the south-eastern united states hospitalized patients nasopharyngeal and oropharyngeal swab specimens from patients admitted for antibiotic treatment of lrti 1988-1996 at a 900-bed, tertiary-care, medical school hospital in bangkok 12 victorian public hospitals 2326 patients, 570 with mdi hospitalized patients who developed diarrhea submitted stool specimens for cytotoxin assay all adult inpatients all 26 hospital gynaecology units in scotland providing induced abortion care antimicrobial prescribing at university hospital groningen 28,661 cases of pneumonia, including 7,719 (27%) that resulted in hospital admission 252 consecutive inpatients receiving suboptimal intravenous antibiotics identified by the clinical pharmacist, 127 were prospectively randomized to intervention and 125 to a control group medical admissions to a general hospital academic health centers university-affiliated hospital term and preterm infants who were <72 hours of age and had clinical signs or obstetric risk factors suggesting neonatal bacterial infection but stable enough to wait for results of diagnostic tests were enrolled into the study between april 2002 and july 2003, 290 patients completed the clinical trial adults before and after removal of a restriction policy university hospital pediatric icu consecutive hospitalized patients 60; 25%), acute bronchitis (59; 24%), asthma (13; 5%), and other respiratory affections (24; 10 hospitalized patients receiving intravenous antimicrobials norwegian paediatric department in 1994 inpatient quinolone orders placed from 1 february 2001 to 31 january 2003 1985 in six hospitals (two metropolitan teaching hospitals, one suburban general hospital and three rural hospitals), and six matched hospitals acted as control hospitals patients undergoing cesarean sections who receive patients with bsis university-affiliated veterans affairs medical center 25 obstetric units hospitalised adults with community-acquired infection was assessed by studying 402 consecutive febrile adults who were admitted randomly to either of two internal medicine wards over a 4-month period and given our hospital and others in hong kong were retrieved and analysed as were samples of records of our inpatients with staphylococcal septicaemia (pre and during icf 283 intervention patients who were admitted by one of 116 physician groups 322 patients with bacteremia treated before and after the onset of the controls revealed that antibiotics were more appropriately used afterwards neurology and neurosurgery wards of a university hospital 273 evaluable patients in the first group and 300 in the second group 12.0 years, 55.2% were female, and 96.0% were white women undergoing cesarean section in colombia patients with pneumonia one hundred fifty-five patients were colonized or infected, representing more than 70 per 1000 average daily census one hundred sixteen isolates were processed by routine methods patients who were less critically ill 14 hospitals immunocompetent patients 4508 pregnancies patients with lower respiratory tract infection patients with methicillin-resistant staphylococcus aureus (from 21.9 patients with prior hospitalization within 10 days, patients with hiv infection or transplant recipients, and patients not treated by physicians closely affiliated with study hospitals 342 patients were evaluated; 33% of them were colonized by e cloacae, and a multiresistant strain was isolated in 10.8% (37/342) of the babies 14 united states hospitals with experience in the minneapolis veterans administration medical center acute care hospitals 1991;143 lower respiratory tract infections 160 patients were treated in ward 1 and 242 in ward 2 (median age 66 years; 49% male clinically suspected ventilator-associated pneumonia hospitals four hundred thirty-two isolates of 17,728 pneumonia patients admitted to the hospital was 72.3
24-month life-table pregnancy rate pain midluteal progesterone levels mean duration of the procedure operating time perioperative outcomes hormone levels average surgical time for minilaparotomy serum estradiol and progesterone and urinary pregnanediol and estradiol progesterone levels demographic characteristics, educational level and operator experience surgical complications serum estradiol and progesterone levels and urinary estradiol and pregnanediol levels obtained during the luteal phase before, 1 year and 2 years after sterilization peri-operative complications hormonal changes surgical difficulties and injuries and technical failures|surgical difficulties and injuries and technical failures occurred with comparable frequency in the two groups. serum estradiol and progesterone and urinary pregnanediol and estradiol were not significantly changed over the 2-year period, nor were there significant differences between the two groups. the results showed little differences among patients in the three groups for age, number of living children, contraceptive and abortion histories and pre-existing medical conditions. the spring-loaded clip and tubal ring techniques of laparoscopic female sterilization were compared for ease of performance, safety and effectiveness at the asociacin demogrfica salvadorea in san salvador, where they were randomly assigned to a total of 299 patients. thirty-two obstetric patients consented for sterilization were randomized to pomeroy technique or filshie clip placement. no significant difference between the two groups was found in respect to long-term sequelae. the hulka-clemens clip and the falope ring have similar incidences of method failure when employed by inexperienced operators.|200 postpartum women at tri-service general hospital, taipei, taiwan patients; 332 women were sterilized with the tubal ring and 331 were sterilized with the rocket clip postpartum and intraoperative cesarean tubal sterilization 300 voluntary acceptors at the university hospital in medan, indonesia 365 women undergoing thirty-two obstetric patients consented for sterilization equal numbers of women female sterilization 118 fertile women seeking tubal sterilization and 57 fertile controls with at least three normal cyclic menstrual periods before entry into the study 299 patients healthy volunteers in an academic research environment
gh-induced height-velocity increase renal function deterioration phosphate, alkaline phosphatase (alp), parathyroid hormone (pth), and fasting insulin concentrations height velocity sds (hvsds efficacy (height velocity (hv), change in height standard deviation score (delta hsds)), and safety (glomerular filtration rate (gfr), incidence of rejection, and calcium and glucose metabolism) of recombinant human growth hormone (rhgh height velocity sd score calculated creatinine clearance serum igf-i levels efficacy and safety of rhgh pretreatment elevation of igf-binding protein-1 glomerular filtration rate hvsds height velocity bone mass bone maturation incidence of rejection serum igfbp-2 levels fructosamine levels igf mean fasting and postprandial insulin values standardized height igfbp-3 levels elevated pretreatment igfbp-3 levels plasma igf-ii levels plasma insulin-like growth factor-i number of adverse events growth rates integrated insulin levels (auc deterioration of graft function igf-i. fructosamine, lipid, and parathyroid concentrations mean (se) hv and delta hsds body length, body weight, bone age, biochemical and hormonal analyses, renal function, bone mass, and adverse effects serum insulin-like growth factor binding protein (igfbp)-1 and -2 levels forearm bone mass and increased serum concentrations of total and free igf-i and igf-binding protein 3 (igfbp-3), whereas igf-ii, igfbp-1, igfbp-2, gh-binding protein, ghrelin, and leptin growth rate and standardized height glomerular filtration rate and effective renal plasma flow serum igfbp-1 levels serum als, igfbp-3, total igf, igf-i, igf-ii and free igf-i levels height sds prestudy height velocity and height-velocity increase igf-ii plasma concentrations gfr or the incidence of rejection severe growth retardation length gain overt insulin dependent diabetes mellitus phosphate, alp, pth, and insulin anthropometric measurements and circulating growth factors growth, bone maturation, renal graft function, plasma insulin-like growth factors, serum binding proteins gfr bone formation rates growth rate, standardized height, bone age, fasting and 2-hour postprandial glucose and insulin levels, biochemical values, and insulin-like growth factor rejection episodes accelerated bone maturation igf-i/igfbp-3 ratio serum levels of igf-i, igf-ii, free igf-i, igfbp-3 and acid labile subunit (als linear growth and maintains bone mass mean fasting and 2-hour postprandial glucose values delta sds (standardized height serum calcium, phosphorus, osteocalcin, and pth levels annual growth velocity increased and standard deviation scores for height bone maturation, renal failure progression, or metabolic control acute rejection episode anthropometric measurements and blood for serum calcium, phosphorus, parathyroid hormone (pth), osteocalcin, and insulin-like growth factor-i lipid and parathyroid concentrations pretreatment elevation of igf-binding protein-1 (igfbp-1) levels growth and glomerular filtration rate height growth rate mean delta height age minus the delta bone age adverse events|impressive height-velocity increase can be achieved with gh therapy in children with crf and growth retardation without changes in renal function. the gh-induced stimulation of growth was associated with no undesirable effects on bone maturation, renal failure progression, or metabolic control. there was a significant increase in plasma insulin-like growth factor-i mean fasting and postprandial insulin values were elevated at 12 months but not at 24 months in the rhgh-treated patients. there was no difference in adverse events between the two groups. at baseline, serum insulin-like growth factor binding protein (igfbp)-1 and -2 levels were, while igfbp-3 levels were not, higher than those of children with normal renal function. serum calcium, phosphorus, osteocalcin, and pth levels did not differ between the treated and control groups. the incidence of a > 25% reduction in glomerular filtration rate over 2 years was not significantly higher in gh-treated patients than in non-gh-treated controls (39% vs 32%, p = 0.97). gh therapy in our patients resulted in a significant increase in height velocity with no inappropriate bone age progression and few serious adverse effects, all without relation to the dose of rhgh. phosphate, alkaline phosphatase (alp), parathyroid hormone (pth), and fasting insulin concentrations rose during the first year of treatment, but not thereafter.|fifteen prepubertal and seven pubertal children: mean (sd) age, 13.0 (2.6) and 15.2 (2.4) years, respectively infants with crf and growth retardation children with chronic renal insufficiency (cri 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with crf and severe growth retardation in a placebo-controlled, double-blind, cross-over trial renal allograft recipients despite successful transplantation children with severe growth retardation secondary to cri stable pediatric renal allograft recipients well-nourished infants with growth retardation secondary to chronic renal failure children with chronic renal failure sixty-eight growth retarded pediatric renal allograft recipients 23 prepubertal children (18 boys and 5 girls; mean 44 prepubertal children with growth failure and chronic renal failure (gfr = 10 to 40 ml/min/1.73 m2 growth-retarded children with chronic renal failure children with crf and growth retardation without changes in renal function children with chronic renal failure (crf one hundred twenty-five prepubertal growth-retarded children with chronic renal failure sixteen children completed the study sixteen infants who had growth retardation, were aged 12+/-3 months, had crf (gfr<or=60 ml/min per 1.73 m2), and had adequate nutritional intake and good metabolic control were recruited from eight pediatric nephrology departments from spain and portugal children prepubertal and pubertal children with renal transplants growth-retarded adolescents after renal transplant children with growth failure associated with chronic renal failure 18 adolescents (mean age 15.6, range 11.3-19.5) with severe growth retardation after renal transplantation were treated with infants with chronic renal failure (crf) and persistent growth retardation despite adequate nutritional and metabolic management six prepubertal and three pubertal children were controls during the first year; all received rhgh in the second year children with crf during rhgh-treatment 2.5 years and histological findings of normal bone formation and adynamic bone on bone biopsies prepubertal and pubertal renal transplant recipients 30 children receiving prepubertal children with chronic renal failure 23 stable prepubertal pediatric kidney recipients, aged 10 29 growth-retarded children with chronic renal failure (crf) (aged 3.4-15.1 years), 23 completed the first year of therapy, and 16 completed the second year prepubertal patients with chronic renal insufficiency many patients who have undergone renal transplantation severely growth-retarded adolescents after renal transplantation 17 pediatric nephrology centers in the united states pediatric renal allograft recipients
transmission through breastfeeding, and mortality death and prolonged hiv-free survival hiv infection rates postnatal hiv transmission mortality rate higher mortality frequency of breast-feeding postnatal hiv-1 infection cumulative probability of hiv-1 infection 2-year mortality rates safety (occurrence of infant adverse events number of adverse events (primarily neutropenia estimated rate of breast milk transmission cumulative infant mortality hiv-free survival child mortality and hiv-1 transmission through breastfeeding erythrocyte sedimentation rate hiv infection or death of the child by 24 months time-to-mortality distributions efficacy and safety median duration of breast-feeding acquire infection risk of transmission rate of hiv-free survival infant hiv-1 infection and death rate of hiv-1-free survival cumulative 3-month mortality total risk of hiv-1 transmission hiv-1 infection maternal cd4-cell counts transmission of hiv-1 median duration of breastfeeding breastfeeding transmission mortality rates and hiv-1-free survival relation to transmission of hiv-1 through breastfeeding and early child mortality median duration of cumulative exclusive breastfeeding primary efficacy (hiv infection by age 7 months and hiv-free survival rates of hiv-1 infection child survival hiv-1 transmission risks and survival mortality hiv infection risk of hiv-1 transmission hiv-1-free survival cumulative mortality or hiv infection rates grade 3 or 4 serious adverse events estimated rate of hiv-1 infection|in the overall cohort, there was no significant difference between the groups in the rate of hiv-free survival among the children; 68.4% and 64.0% survived to 24 months without hiv infection in the intervention and control groups, respectively (p=0.13). cumulative infant mortality at 7 months was significantly higher for the formula-fed group than for the breastfed plus zidovudine group (9.3% vs 4.9%; p = .003), but this difference diminished beyond month 7 such that the time-to-mortality distributions through age 18 months were not significantly different (p = .21). 393 infants in the single-dose group and 346 in the extended-dose group experienced grade 3 or 4 serious adverse events during the study (p=0.54). the rate of hiv-1-free survival at 2 years was significantly lower in the breastfeeding arm than in the formula feeding arm (58.0% vs 70.0%, respectively; p = .02). breastfed infants who also received solids were significantly more likely to acquire infection than were exclusively breastfed children (hr 10.87, 1.51-78.00, p=0.018), as were infants who at 12 weeks received both breastmilk and formula milk (1.82, 0.98-3.36, p=0.057). infants receiving extended dual prophylaxis had a significant increase in the number of adverse events (primarily neutropenia) that were deemed to be possibly related to a study drug. vitamin a increased the risk of transmission (rr 1.38, 95% ci 1.09-1.76, p = 0.009).|children born to women with low maternal immunological or nutritional status mother-infant pairs 958 hiv-infected women and their infants in lusaka, zambia 3016 infants 1078 hiv-infected pregnant women from tanzania 2024 liveborn infants randomised in the study had at least one specimen tested before 6 months of age (1047 infants in the single-dose group and 977 infants in the extended-dose group 425 hiv-1-seropositive, antiretroviral-naive pregnant women enrolled, 401 mother-infant pairs women with hiv-1 infection who were breast-feeding infants 1179 infants hiv-infected women breastfeeding their infants were eligible for participation november 1992 to july 1998 in antenatal clinics in nairobi, kenya, with a median follow-up period of 24 months women who are infected with the human immunodeficiency virus (hiv) stop breast-feeding early children in zambia 393 infants 1132 of 1372 9-month-old infants in botswana between march 27, 2001, and october 29, 2003, 1200 hiv-positive pregnant women were randomized from 4 district hospitals infants who were hiv-1-negative on dna polymerase-chain-reaction assay at birth breastfed and formula-fed infants 1276 infants with complete feeding data breastfed infants through 6 weeks of age can decrease hiv transmission via breastfeeding 986 infants in the single-dose group and 901 in the extended-dose group 2722 hiv-infected and uninfected pregnant women attending antenatal clinics in kwazulu natal, south africa (seven rural, one semiurban, and one urban mothers and infants 2008 massachusetts medical society
prolongation of pregnancy genital microflora number of days from admission to delivery, gestational age at delivery, rates of preterm delivery, low birthweight, maternal infections and neonatal infections success of magnesium sulfate tocolysis respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, sepsis, and admission and duration of newborn intensive special care unit hospitalization maternal outcomes, including duration of randomization-to-delivery interval, frequency of preterm delivery (< 37 weeks), frequency of preterm premature rupture of membranes, clinical chorioamnionitis, endometritis, and number of subsequent admissions for preterm labor overall prevalence of microbial invasion of the amniotic cavity necrotising enterocolitis incidence of preterm birth neonatal death, respiratory distress syndrome, proven sepsis, and birthweight birth weight likelihood of a beta error upper genital tract infection rate of delivery duration of pregnancy interval to delivery, birth weight, and neonatal outcomes mean cervical dilatation neonatal hospitalization time episodes of recurrent labor requiring parenteral tocolysis maternal and neonatal infectious morbidity frequency of preterm birth neonatal morbidity suspected sepsis rate of cesarean section prolongation of gestation survival analysis safe and well tolerated prolongation of pregnancy, the rate of preterm birth, and neonatal morbidity infectious morbidity pregnancy outcome higher gestational age at delivery interval to delivery or duration of pregnancy perinatal mortality and morbidity postpartum infections frequency of contractions, cervical bishop's score, and white blood cell count on admission maternal outcomes, including duration of randomization-to-delivery interval, frequency of preterm delivery, and frequency of clinical chorioamnionitis and endometritis rate of admission to neonatal intensive care unit preterm premature rupture of membranes time to delivery tolerated rate of neonatal suspected sepsis delivery interval or rate of delivery efficacy, safety, and tolerance shorter interval to delivery, lower gestational age at delivery, lower mean birth weight composite of neonatal death, chronic lung disease, or major cerebral abnormality on ultrasonography before discharge from hospital neonatal outcomes interval to delivery|ceftizoxime had no effect on interval to delivery or duration of pregnancy in women treated for preterm labor. no significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups. compared with the placebo group, the adjunctive antibiotic group had a similar frequency of preterm birth (38 versus 44%), time to delivery (34 versus 34 days), birth weight (2847 versus 2855 g), and episodes of recurrent labor requiring parenteral tocolysis (0.43 versus 0.49). women with bacterial vaginosis more often delivered preterm (p = 0.03; relative risk, 1.4; 95% confidence interval, 1.04 to 2.0). adjuvant ampicillin and metronidazole in the management of women in preterm labour with intact membranes significantly prolonged the pregnancy and decreased neonatal morbidity. similarly, no significant difference in neonatal outcomes could be detected between the two groups including respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, sepsis, and admission and duration of newborn intensive special care unit hospitalization. in our population adjunctive ampicillin-sulbactam with indomethacin did not improve the success of magnesium sulfate tocolysis. antibiotic treatment had no significant effects on infectious morbidity. no significant difference between both groups was found in maternal outcomes, including duration of randomization-to-delivery interval, frequency of preterm delivery, and frequency of clinical chorioamnionitis and endometritis. none of the trial antibiotics was associated with a lower rate of the composite primary outcome than placebo (erythromycin 90 [5.6%], co-amoxiclav 76 [5.0%], both antibiotics 91 [5.9%], vs placebo 78 [5.0%]).|preterm labour spontaneous preterm labour preterm labor with intact membranes one hundred and twelve women with singleton pregnancies, with threatened idiopathic preterm labour and intact amniotic membranes at 26 to 34 weeks of gestation patients with preterm labor and intact membranes patients in preterm labor who were receiving intravenous women in preterm labor with intact membranes patients with idiopathic preterm labor hospitalized women with preterm labor at less than or equal to 34 weeks' gestation who were treated with tocolytics women in preterm labor < or =34 weeks gestation with intact membranes preterm labor patients with preterm labor between 24 and 35 weeks' gestation 6295 women in spontaneous preterm labour with intact membranes and without evidence of clinical infection those patients 545 patients with intact membranes and without chorioamnionitis who were receiving six obstetric departments in the copenhagen area preterm labor and intact membranes idiopathic preterm labour one hundred three patients at 24-34 weeks' gestation women in preterm labour with intact membranes two hundred seventy-seven women with singleton pregnancies and preterm labor with intact membranes (24 to 34 weeks pregnancies receiving tocolysis for preterm labor women with bacterial vaginosis 117 consecutive, eligible, consenting patients 2373 patients screened for participation in this study in six medical centers, 277 women were enrolled (n = 133 for antibiotics group vs n = 144 for placebo group maternal-fetal medicine units network of the national institute of child health and human development eighty-one women in active preterm labour with otherwise uncomplicated singleton pregnancies between 26 and 34 weeks gestation or an ultrasound fetal weight estimate of 800 g to 1500 g idiopathic preterm labor one hundred three woman-perinate pairs were analyzed treat preterm labor 196 patients with singleton pregnancies and preterm labor with intact membranes (22-36 weeks women with threatened idiopathic preterm labour
complete pain relief satisfactory pain relief|de quervain's disease of pregnancy and lactation is usually self-limited and responds well to nonsurgical treatment.|19 wrists of 18 patients with de quervain's disease who were either pregnant or breast-feeding de quervain's disease of pregnancy and lactation
lower drive for thinness and greater body satisfaction metabolic control media-related attitudes and behaviors including internalization of sociocultural ideals, self-efficacy to impact weight-related social norms, and print media habits body weight body-related knowledge and attitudes disturbed eating behaviour body size acceptance, puberty knowledge, and perceived weight status physical appearance to their self-esteem body mass index body dissatisfaction body image and eating attitudes and behaviors weight, eating attitudes test and eating disorders inventory self-esteem; social acceptance, physical appearance, and athletic ability eating disorder examination questionnaire (ede-q), the children's version of the eating attitudes test (eat), the rosenberg self-esteem scale (rses), and a knowledge questionnaire (kq body image, eating attitudes, and behaviors knowledge physical appearance disturbed eating attitudes and behavior frequency of purging by insulin omission or hemoglobin a1c levels symptom scales body satisfaction weight-losing behaviors eating disorder risk factors risk of bulimic attitudes weight concern self-report symptom check-list (scl-90-r dieting behaviors, body image attitudes, and media knowledge, attitudes, and habits dieting behaviors eating disturbance lasting changes in body image and dieting behaviors self-esteem measures students' anxiety or depression restraint and eating concern subscales of the eating disorder examination (ede) and on the drive for thinness and body dissatisfaction subscales of the eating disorder inventory|the pe group was associated with reductions in eating disturbance, but not with improved metabolic control. providing schoolgirls with the correct information about eating disorders did not encourage unhealthy attitudes to eating and weight regulation practices. the data analyses revealed an improvement on all three symptom scales for both groups between t2 and t3, but there were no significant differences between the ighr and cghr groups. we did observe a significant increase in knowledge among girls receiving the intervention and among high-risk students only, there was a small albeit statistically significant effect on body mass index. unlike a previous school-based eating disorder prevention program, in the experimental group both an increase in knowledge and a decrease in some attitudes were maintained at 12-month follow-up (eating concerns ede-q scores). it is feasible to use community youth settings, such as the girl scouts, to implement interventions to prevent disordered eating behaviors. at postintervention the media literacy group had lower mean scores on weight concern than the control group (p =0.007) but the self-esteem group did not. the program significantly improved the body satisfaction of the intervention students and significantly changed aspects of their self-esteem; social acceptance, physical appearance, and athletic ability became less important for the intervention students and more important for control students.|young male and female adolescents young women with type 1 diabetes mellitus disturbed eating behaviour two hundred twelve young women attending a pediatric diabetes clinic were screened for signs of eating disturbance from the original sample (t1, n = 1944), a subgroup of 314 students of both sexes, 14-19 years of age, was selected a total of 254 16-year-old schoolgirls were evaluated, of whom 154 participated in the program and a further 154 subjects formed the control group 116 students (63% females) with low self-esteem and higher anxiety, who were considered at risk for the development of eating disorders one hundred and six (61 females and 45 males) 11 to 12-year-old students were evaluated, 55 of whom participated in the program (experimental group nine hundred sixty-seven sixth and seventh-grade girls adolescent schoolgirls 226 girls (mean age = 10.6 years, standard deviation = 0.7) from 24 girl scout troops young adolescents preadolescent girls children and adolescents eighty-five subjects disordered eating among preadolescent girls young adolescent girls girl scout troop members young women with type 1 diabetes mellitus (dm) and disordered eating attitudes and behavior 14- to 19-year-old swiss students four classes of 86 grade 8 students (53 boys and 33 girls), mean age of 13 years young male and female adolescents following the program and after 12 months eating disorders all 470 eligible students (63% female) aged 11-14 years volunteered to participate of these women, 130 passed the screening and were invited to participate in the intervention phase of the study
pfc, kps, and vas knee functional capacity patellofemoral pain syndrome pain and functional status visual analogue pain score; the womac lower limb function score; the hospital anxiety and depression scale (had); and quadriceps strength vas and fiq differences contraction values of the vastus medialis and the vastus lateralis muscles muscular strength cincinnati rating system and traditional measures of leg strength and flexibility womac, visual analogue, and the anxiety score pfc and joint function improved, and pfp quadriceps muscle performance perceived functional status kujala patellofemoral score (kps), and pain, through a visual analog scale (vas physical activity, pain, and muscle function isokinetic strength on a cybex ii+ dynamometer peak torque visual analog scale (vas) and the functional index questionnaire (fiq), respectively vastus lateralis muscles womac and had functional performance closed kinetic chain testing and perceived functional status walking, stair activity, running, jumping/twisting, and overall activity level patellar pain, position, and function overall knee function patellofemoral pain (pfp) and abnormal patellofemoral congruence (pfc pain womac, visual analogue, and had scores pfp and pfc quadriceps strength and hamstring range of motion muscle characteristics, subjective symptoms, and functional performance pain and improvements in torque, vertical jumping ability, and physical activity level mean contraction values contraction values|statistical analysis showed that both groups had significant improvement in peak torque at all speeds, but only the closed kinetic chain group showed significant improvement in closed kinetic chain testing and perceived functional status. all groups showed significant improvements in womac, visual analogue, and had scores; these improvements did not vary significantly between the four groups or between exercising/non-exercising and taped/non-taped patients at three and 12 months. electromyographic biofeedback treatment did not result in further clinical improvement when compared with a conventional exercise program in patients with patellofemoral pain syndrome. no significant differences, however, were determined to exist between the static and isokinetic groups. one-way analysis of variance tests found no difference between pre- and posttest results for the control group but found significant changes in pfc, kps, and vas (all p < 0.001). the clinical improvement was better on patients of groups i and iii. a reduction in pain and improvements in torque, vertical jumping ability, and physical activity level were seen in both groups after treatment. both groups experienced a statistically significant decrease in pain and an increase in functional performance.|patients with patellofemoral pain syndrome and (2 patellofemoral pain syndrome patients with anterior knee pain patients with patellofemoral dysfunction young women patients with patellofemoral pain 81 young adults with anterior knee pain twenty-three patients participated in an 8-week training period patients with patellofemoral pain syndrome cases of patellar chondromalacia clinical patients with pfp and abnormal pfc chondromalacia patella sixty patients with patellofemoral pain syndrome forty female patients with patellofemoral pain syndrome, aged 15 to 28 years (mean = 20.2, sd = 3.2 twenty-nine subjects were screened by an orthopaedic physician and assigned to a control (n = 9), static (n = 11), or isokinetic (n = 9) exercise group subjects with anterior knee pain anterior knee pain patellofemoral pain subjects with chondromalacia patella copyright 2001 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation 100 subjects sixty patients subjects with a clinical diagnosis of chondromalacia patella
y-bocs, scl-90-r oc and gsi scales, and poms anxiety y-bocs, scl-90-r oc, scl-90-r gsi, poms, pss, and pil treatment efficacy, onset of symptom amelioration, or maintenance of therapeutic gains yale-brown obsessive compulsive scale (y-bocs), symptoms checklist-90-revised obsessive compulsive (scl-90-r oc) and global severity index (scl-90-r gsi) scales, profile of moods scale (poms), perceived stress scale (pss), and purpose in life (pil) test pss and pil test|there were no differences between treatments with respect to treatment efficacy, onset of symptom amelioration, or maintenance of therapeutic gains. within-group statistics (student's paired t-tests) showed that group 1 significantly improved on all six scales, but group 2 had no improvements.|children's hospital, san diego, calif patients with obsessive-compulsive disorder (ocd patients were selected according to diagnostic and statistical manual of mental disorders, third edition-revised (dsm-iii-r) criteria and recruited by advertisements and referral 11 adults and 1 adolescent, and group 2 included 10 adults chronic anxiety patients with obsessive-compulsive disorder
left quadriceps strength cost per quality-adjusted life year (qaly functional gains physical function knee range of motion (rom), thigh girth, subjective pain scale, and time for a 1-mile walk pain score on the western ontario and mcmaster universities oa index (womac disability in functional activities right quadriceps strength functional levels subjective pain levels womac physical function quality of life strength functional activity and quality of life aquatic exercise knee rom, thigh girth, and time for a 1-mile walk aquatic exercisers reported equal (qwb) or better (chdr, haq, pqol) health-related quality of life strength and function walk speed and self efficacy satisfaction arthritis-specific health assessment questionnaire (haq), center for epidemiologic studies-depression scale (ces-d), and perceived quality of life scale (pqol womac pain pain related to motion and pain on load costs/qaly gained discounted mean pain score outcome assessments (muscle strength dynamometry, six minute walk test, womac oa index, total drugs, sf-12 quality of life, adelaide activities profile, and the arthritis self-efficacy scale strength and physical function quality of life, cost-effectiveness and physical function measurements quality of well-being scale (qwb) and current health desirability rating (chdr high levels of co-morbidity pain compliance rates disability rating index (dri), global self-rating index (gsi), and visual analogue scale (vas lower limb oa|pain related to motion and pain on load was reduced up to 3 months after last the treatment in the hydrotherapy group and up to 6 months in the ea group. there were no significant differences between the aquatic exercise group and the land-based exercise group pertaining to knee rom, thigh girth, and time for a 1-mile walk. the hydrotherapy group increased left quadriceps strength only at follow up, and this was significantly different from the control group. aquatic exercise exceeded $50,000 per qaly gained using the community-weighted outcome but fell below this arbitrary budget constraint when using the participant-weighted measure. water exercise remained effective in the main study but overall effect size was small, on womac pain at 1 year, a reduction of about 10% in group|106 patients (93 women, 13 men) over the age of 60 years with confirmed hip older adults with lower limb oa osteoarthritis of the hip older patients recruited 249 adults from washington state aged 55 to 75 with a doctor-confirmed diagnosis of osteoarthritis to participate in aquatic classes lower limb osteoarthritis osteoarthritis (oa forty-six subjects between the ages of 45 and 70 years participated in 1 of 2 exercise groups persons with knee osteoarthritis 105 community living participants aged 50 years and over with clinical oa of the hip or knee persons with osteoarthritis older patients with hip and/or knee oa 312 patients (196 women, 116 men) took part in the main study, randomised into control (159) and water exercise (153) groups forty-five patients, aged 42-86 years, with radiographic changes consistent with osteoarthritis in the hip, pain related to motion, pain on load, and ache were chosen 153 patients randomised to treatment, 82 (53.5%) were estimated to have complied satisfactorily with their treatment at the 1-year point patients with osteoarthritis fifty-four control and 53 exercise patients had hospital inpatient episodes during the study period
average (median) time taken to complete voice therapy voice therapy (perceptual auditory rating of voice quality measurement laryngeal status voice care knowledge areas voice quality ratings of laryngeal features, buffalo voice profile, amplitude and pitch perturbation, voice profile questionnaire, hospital anxiety and depression scale, clinical interview schedule, sf-36. voice therapy improved voice quality perceptual evaluation of voice quality and a questionnaire on the occurrence of vocal symptoms psychological distress and lower quality of life voice-related quality of life (vrqol) and the voice symptom severity scale (voiss voice severity, electrolaryngograph, and shimmer measurements and on ratings provided by a patient questionnaire|results revealed a significant difference between the 3 treatment groups in the amount of change for the voice severity, electrolaryngograph, and shimmer measurements and on ratings provided by a patient questionnaire (p<0.05). the difference in voice care knowledge areas was also significant for the treatment group (p < 0.05). no differences between groups were noted in the laryngeal status. patients with dysphonia had appreciable psychological distress and lower quality of life than controls, but voice therapy had no significant impact on either of these variables. subjects in both treatment groups demonstrated statistically significant improvements after voice therapy (perceptual auditory rating of voice quality measurement p < 0.01; instrumental electroglottographic measurement p < 0.01; patient questionnaire measurement p < 0.01).|forty-five patients diagnosed as having nonorganic dysphonia students with mild voice disorders teacher students fifty dysphonic subjects 20 teacher students with mild voice disorders participants: 204 outpatients aged 17-87 with a primary symptom of persistent hoarseness for at least two months 20 teachers with self-reported voice problems teachers with self-reported voice problems outpatient clinic in a teaching hospital 45 patients with nonorganic dysphonia twenty subjects 20 students with similar voice disorders served as a
time to return to uninterrupted sleep resolution of pain chronic pain and quality-of-life outcomes loss of vesicles pain severity achieving statistical significance incidence of ulceration post-zoster pain total crusting chronic pain frequency or severity of post-herpetic neuralgia active ocular disease quality of life laboratory adverse events duration and severity of acute pain local neurological symptoms full crusting frequent formation of new lesions times to last new lesion formation lesion healing, resolution of pain, return to usual activity, and return to uninterrupted sleep medical events resolution of postherpetic neuralgia extent and duration of the rash famciclovir accelerated lesion healing proportion of patients with pain scores persistent pain pain safety risk ratios analgesic requirements each day, and adverse events and laboratory abnormalities total analgesic use intraocular complications prevalence of pain time to total crusting and healing duration of viral shedding median duration of postherpetic neuralgia time to return to usual daily activity rash healing period of viral shedding accelerated time to cessation of acute neuritis weekly prevalence of pain reduction pain|most importantly, famciclovir recipients had faster resolution of postherpetic neuralgia (approximately twofold faster) than placebo recipients; differences between the placebo group and both the 500-mg famciclovir group (hazard ratio, 1.7 [95% ci, 1.1 to 2.7]) and the 750-mg famciclovir group (hazard ratio, 1.9 [ci, 1.2 to 2.9]) were statistically significant (p = 0.02 and 0.01, respectively). the duration and severity of acute pain were less in acyclovir recipients, with differences in pain severity achieving statistical significance (p = 0.03) between days 3 and 10 and correlating with the treatment differences in new lesion formation. time to total crusting and healing was accelerated for patients receiving acyclovir plus prednisone compared with patients receiving two placebos; the risk ratios were 2.27 the proportion of patients with pain scores greater than 0 was significantly lower in the acyclovir group between 2 and 3 months. no significant hastening of rash healing was seen in those who started therapy later than 48 hours after the onset of rash. total analgesic use in the first 4 weeks was reduced by acyclovir, but during follow up there was no difference in the prevalence of analgesic use between groups.|36 centers in the united states, canada, and australia herpes zoster in general practice herpes zoster ophthalmicus 15 university hospitals or affilliated clinics 419 immunocompetent adults with uncomplicated herpes zoster herpes zoster 208 immunocompetent patients older than 50 years of age who had localized herpes zoster that developed less than 72 hours before study enrollment 364 elderly immunocompetent patients with herpes zoster who were entered within 72 hours of the onset of rash forty patients aged 16 years or over, presenting to their general practitioners within 3 days of rash onset, received acute disease and postherpetic neuralgia acute herpes zoster acute herpes zoster and postherpetic neuralgia 46 patients with acute herpes zoster ophthalmicus of less than 72 hours duration relatively healthy persons older than 50 years of age who have localized herpes zoster, combined
incidence of heterosexual transmission number of sexual partners or other risk behaviors seroconversion rate heterosexual transmission genetically-linked hiv-1 transmission seroconversion rates transmission rates seroconversion hiv seroprevalence six hiv-1 seroconversions unprotected sexual intercourse as a risk factor for hiv-1 infection highest hiv-1 transmission rate hiv heterosexual transmission hiv-1 transmission rates sexual activity hiv-1 incidence and sexual risk behaviors rate of hiv seroconversion and last recorded cd4 cell count level hiv-1 quality of life score incidence rate difference signs of disease progression (symptoms of acquired immunodeficiency syndrome, p24 antigen positivity, or cd4+ cell counts rate of transmission median viral loads risk of seroconversion incidence of seroconversion incidence rates of seroconversion plasma hiv-1 cd4 counts viral load cd4 cell count|men with signs of disease progression transmitted infection to their partners more frequently and were more frequently treated with zidovudine. couples reported more consistent condom use during art use, but there was no significant difference in the number of sexual partners or other risk behaviors. transmitters showed significantly higher median viral loads (p = 0.042) suggesting that heterosexual transmission of hiv is more a function of viral load than gender of index case. in 144 couples the index partner was taking combined antiretroviral treatment; they accounted for over 7000 unprotected acts of intercourse and 47 natural pregnancies but no hiv seroconversion (0 to 0.0005 per unprotected intercourse). not always using condoms (rr=8.42; 95% ci, 4.83-14.67), sexual activity  4 times per month (rr=5.24; 95% ci, 2.55-10.77), not switching anti-retroviral treatment regimen (rr=1.99; 95% ci, 0.85-4.65), and a quality of life score <12 on the psychological domain (rr=2.33; 95% ci, 1.21-4.48) were associated with increased risk of seroconversion. in participants not on art, the highest hiv-1 transmission rate (8.79 per 100 person-years) was from those with cd4 cell counts lower than 200 cells per microl.|436 monogamous seronegative female sexual partners of human immunodeficiency virus type 1-infected males was followed up for 740 person-years with regular structured interviews and laboratory tests hiv-1 discordant couples were retrospectively identified between 2004 and 2009 26 couples with a male index case 476 couples in which the index partner was not taking antiretroviral treatment, hiv seroprevalence at enrolment in non-index partners was 9.2% (n=44), whereas in 149 couples in which the index partner was taking combined antiretroviral therapy no partner was infected (p<0.001 enrolled heterosexual african adults who were seropositive for both hiv-1 and herpes simplex virus type 2, and their hiv-1 seronegative partners 93 heterosexual hiv serodiscordant couples with no prior antiretroviral use were identified in a large referral center from february 2000 to january 2006 in southern brazil hiv-1 discordant couples in rakai, uganda two hundred and fifty hiv-1 discordant couples were followed between 2004 and 2009 and 32 hiv-1-positive partners initiated art 3381 couples were eligible for analysis patients infected with hiv-1 on risk of transmission to their uninfected partners hiv clinic in madrid, spain serodiscordant couples in porto alegre, southern brazil stable heterosexual couples with one partner with hiv-1 infection (index partner 349 (10%) participants with hiv-1 initiated art during the study, at a median cd4 cell count of 198 (iqr 161-265) cells per microl between january 2006 and december 2008, initially seronegative spouses human immunodeficiency virus type-1 infected men with serodiscordant couples from henan province, china serodiscordant couples men infected with human immunodeficiency virus type clinic records retrospectively identified 56 cases of untreated index cases whereas 37 couples were identified prospectively study participants underwent annual screening for hiv-1 and were interviewed to evaluate risk behaviors former plasma donors in henan, china 144 couples the index partner
attacks|stilboestrol 5 mg daily was better than the placebo in preventing attacks.|11 patients with stuttering attacks of priapism and homozygous sickle-cell (ss) disease homozygous sickle-cell disease
pregnancy rate and the miscarriage rate pregnancy rate and pregnancy maintenance total pregnancy rates and time for success pregnancy rates|although the results were not statistically significant in the group of women with intramural and intramural-subserosal fibroids, this study confirms the important role of the position of the uterine fibroid in infertility as well as the importance of fibroids removal before the achievement of a pregnancy, to improve both the chances of fertilization and pregnancy maintenance. women in the study group had a better possibility of becoming pregnant after polypectomy, with a relative risk of 2.1 (95% confidence interval 1.5-2.9).|215 infertile women from the infertility unit of a university tertiary hospital with ultrasonographically diagnosed endometrial polyps (ep) undergoing iui patients undergoing intrauterine insemination 181 women affected by uterine fibroids who had been trying to conceive for at least 1 year without success
serum immunoglobulin g levels cumulative mortality from liver disease mean alkaline phosphatase values mean alanine aminotransferase values pruritus score severity of symptoms or physical findings disease activity serum levels of immunoglobulin (ig) m and igg, and colchicine reduced igg levels pruritus number of treatment failures (i.e. dead, orthotopic liver transplantation (olt), complications of cirrhosis, doubling of bilirubin, untreatable pruritus serum cholesterol levels, and udca also reduced high-density lipoprotein cholesterol levels liver function test histologic changes noted at liver biopsy mean pruritus score levels of serum albumin, serum bilirubin, alkaline phosphatase, cholesterol, and aminotransferases liver histology histological grading score improvement of liver enzymes related to cholestasis and cytolysis and of amelioration of pruritus liver function and immunoglobulin levels mean bilirubin and immunoglobulin m values histological scores alkaline phosphatase and alanine aminotransferase activities progression of esophageal varices variceal bleeding clinical events, laboratory test results, and liver histology mayo score values procollagen type iii aminoterminal peptide (piiinp), hyaluronic acid, and sulfobromophthalein (bsp) elimination kinetics alanine aminotransferase (alt) level total globulin levels symptoms, laboratory findings (serum bilirubin level, alkaline phosphatase and alanine transaminase [alt] activities, immunoglobulin [ig] m level), serum markers of fibrosis, or histological features, except lobular inflammation blood test results, symptoms, and/or liver histology serum activities of aminotransferases, alkaline phosphatase, and gamma-glutamyltransferase histologic progression number of markers of liver disease diarrhea ductular proliferation serum total bilirubin levels serum albumin and bilirubin levels albumin levels alp level elevated serum level of aminoterminal propeptide of type iii procollagen hepatic reasons mean serum levels of alkaline phosphatase, total bilirubin, gamma-glutamyltranspeptidase, alanine aminotransferase, aspartate aminotransferase, and igm serum alkaline phosphatase (alp) levels mean alkaline phosphatase and alanine aminotransferase values bilirubin values serum level of carboxyterminal propeptide of type i procollagen serum bilirubin levels bsp elimination kinetics survival estimate immunoglobulin g levels|differences in mean bilirubin and immunoglobulin m values, although lower in the colchicine group, did not reach statistical significance. methotrexate but not colchicine significantly improved liver histology (p = 0.005) and serum immunoglobulin g levels (p = 0.0002). in comparison with placebo, colchicine produced a beneficial effect on serum albumin and bilirubin levels at 3 months in patients who had abnormal liver function (bilirubin greater than 20 mumol/l) at entry: (albumin, p = 0.047; bilirubin, p = 0.022). no significant differences were observed in terms of improvement of liver enzymes related to cholestasis and cytolysis and of amelioration of pruritus. after 2 years of treatment, relative to udca, colchicine combined with udca did not significantly improve symptoms, laboratory findings (serum bilirubin level, alkaline phosphatase and alanine transaminase [alt] activities, immunoglobulin [ig] m level), serum markers of fibrosis, or histological features, except lobular inflammation. in group 1, there were significant decreases in mean serum levels of alkaline phosphatase, total bilirubin, gamma-glutamyltranspeptidase, alanine aminotransferase, aspartate aminotransferase, and igm, and these changes were more remarkable in those who responded poorly to ursodeoxycholic acid. however, there was no such improvement in the severity of symptoms or physical findings; moreover, there was no significant difference in the histologic changes noted at liver biopsy in the two treatment groups. both colchicine and udca reduced serum cholesterol levels, and udca also reduced high-density lipoprotein cholesterol levels.|primary biliary cirrhosis patients with symptomatic primary biliary cirrhosis 600 mg/day) for 30 months twenty-two patients with primary biliary cirrhosis treated with primary biliary cirrhosis (pbc fifty-seven patients with biopsy-proven primary biliary cirrhosis 60 patients with primary biliary cirrhosis patients with nonadvanced pbc thirty patients had early disease (stages 1 and 2), and 30 had advanced disease (stages 3 and 4 64 patients with primary biliary cirrhosis symptomatic primary biliary cirrhosis a total of 90 patients patients with cirrhosis underwent endoscopy every 12 months treated patients with primary biliary cirrhosis patients with histologically confirmed primary biliary cirrhosis patients with nonadvanced primary biliary cirrhosis (pbc fifteen patients with early disease and 15 with advanced disease received 15 patients with pre-cirrhotic stage patients with primary biliary cirrhosis patients with symptomatic primary biliary cirrhosis (pbc), defined by the presence of liver cirrhosis, pruritus or bilirubin exceeding 2 mg/ml seventy-four patients with pbc who had been treated previously with udca (at least 8 months) but still had abnormal liver test results, especially elevated alkaline phosphatase activity
episodes of bleeding rate of postoperative nausea and vomiting median of the vas incidence of vomiting or dreaming quality of recovery number of children rating severe pain hannallah objective pain scale demographics, tracheal extubation times, and pain scores time to awaken from anaesthesia or incidence of postoperative vomiting side-effects concentration ability perioperatively scores (open scale 1-9) for stridor, sedation, bleeding, nausea, pain, heart rate, the need for analgesics and registered psychotomimesis and well-being at home times to leave recovery secondary hemorrhage total incidence of nausea/vomiting pain control headache, arthralgias and maculopapular rash symptoms of disorientation, restlessness, inconsolable crying and thrashing resemble an acute psychosis median (range) episodes of vomiting postoperative complications postoperative analgesic requirement colon perforation duration of postoperative analgesia pain scores in recovery and pain scores postoperative pain and behaviour operating theatre blood loss, the frequency of bleeding on the ward, or the need for operative haemostasis salivation acta anaesthesiologica scandinavica rate of recovery mean vas score adverse effects and duration of pca postoperative analgesia and side-effects aseptic tissue necrosis mpca overall, cheops scores satisfactory sedation scores median time to first analgesia postoperative haemorrhage and vomiting visual-analogue 10-point scale and the 0-4 point verbal pain assessment scale pain scores and postoperative morphine requirements incidence of motor block, urinary retention, postoperative vomiting or postoperative sedation post-operative pain scores frequency of vomiting and the degree of nausea phenotype nor morphine concentration post-operative pain analgesic requirements incidence of airway irritation or emergence delirium severe delirium child behavior postoperative pain sedation score or frequency of use of postoperative analgesics plasma morphine concentration normal activity hourly visual analogue pain scores and morphine patient controlled analgesia (mpca) usage postoperative morphine titration maximum pain score and pain score nausea/vomiting, analgesics and parents' aspects plasma proteins and igg levels child behavior checklist (cbcl pain relief swallowing-evoked pain longest analgesia duration pain severity postoperative pain scores plasma beta-endorphin level degree of postoperative sedation movement pain scoring diclofenac, 4'-hydroxydiclofenac and 5'-hydroxydiclofenac concentrations serious adverse events sedation score postoperative analgesia made by analgin and promedol plasma diclofenac and beta-endorphin concentrations time to first solid intake postoperative nausea and vomiting (ponv rapid return to calm wakefulness hemodynamic changes severe agitation formation clearances of diclofenac to hydroxyl metabolites age, weight, type of operation or induction of anaesthesia, 4-h sedation and pain scores and further analgesic requirements scores for salivation effective pain relief respiratory depression postoperative pain and anxiety efficacy and safety nausea and vomiting postoperative bleeding postoperative pain, oral intake, vomiting, temperature and complications full aldrete scores renal biopsy bleeding and restlessness incidence of postoperative vomiting pain and restlessness validated wong and baker scale (faces need analgesia nausea, vomiting and pain sedation scores and the heart rates self-report visual analogue scale to record pain objective pain scale (ops median duration of analgesia esr, plasma urea and creatinine concentrations fatigue, fever, gastrointestinal disturbances, anorexia and weight loss renal function nausea/vomiting postoperative morbidity demographics, induction technique, duration of anaesthesia and time between premedication and induction of anaesthesia cheops pain scoring point verbal pain rating scale (vprs nurse pain assessments mean operative time nausea and vomiting and allowed safer and earlier hospital discharge plasma morphine concentrations nausea, vomiting, apnea, desaturation, reintubation within 24 h and constipation volumes of distribution of parent diclofenac and its hydroxyl metabolite total morphine consumption postoperative analgesia elimination clearance of hydroxyl metabolites leucocyte and differential counts, lymphocyte and their subset counts, lymphocyte proliferative responses, and in serum cortisol, c-reactive protein, plasma interleukin-6 and group ii phospholipase a2 concentrations vt and total plasma clearance nausea and vomiting scores ops scores and requirement for supplementary analgesics analgesic effect pain scores, emetic episodes and supplemental morphine requirements mean total morphine consumption tissue necrosis pain and postoperative morbidity severity of the postoperative pain blood loss rescue analgesic pre-surgical child behavior ratings and pain management pain intensity and morphine requirements agitation score pain score [verbal analogue scales (vas), 0-10] and sedation level at 5-min intervals and recorded the total morphine consumption of the first hour in the pacu abdominal pain and peritonism pain-free children duration of anaesthesia spontaneous and swallowing-evoked pain total paracetamol consumption degree of pain incidence of reactionary post-operative haemorrhage overall incidence of postoperative vomiting acceptable pain scores cbcl rating and experience of pain incidence of ponv morbidity and pain postoperative comfort bleeding postoperative nausea absorption half-life postoperatively, time to first eye opening, sedation score, pain score, time for further analgesia requests and incidence of nausea and vomiting total plasma clearance postoperative vomiting severe vomiting discomfort analgesic effects pain, less elevation of temperature, more oral intake, and started drinking hypertension, oedema or evidence of acute infection reduced enzyme activity phenotype and plasma morphine marked restlessness onset of eating at home pain and demeanour ischaemia and ulceration postoperative nausea and vomiting or psychomotor reactions low urine specific gravity formation clearance to 4'-hydroxydiclofenac, diclofenac volume of distribution, absorption half-time and lag time for the suppository oral fluid intake formation clearance to 4'-hydroxydiclofenac intra-operative bleeding otitis media pain scale postoperative analgesic efficacy mean postoperative hospital stay cumulative morphine consumption arousal urinalysis, complete blood count, erytrocyte sedimentation rate (esr), plasma creatinine, glomerular filtration rate (gfr), electrolytes, proteins, igg, c3, c4 antinuclear-antibodies (ana), antistreptolysin-o and antibodies to hantaviruses quality of oral intake relative bioavailability pain and appearance functional parameters analgesia [behavioral pain scale (bps) score of 3 modified aldrete score, a pain/discomfort scale vomiting rescue analgesia unpleasant psychotomimesis end-tidal volatile agent concentration mean (sd) morphine concentrations heart rate and blood pressure glycosuria, aminoaciduria and decreased tubular reaposrption of phosphate (trp stridor scores side effects pain score postoperative pain relief pain rating scale emergency department visit for pain and dehydration normal blood pressure, non-oliguric renal failure, proteinuria, hypostenuria and abnormal urinary sediment postoperative pain scores, analgesic requirements, sedation scores, signs of respiratory depression and nausea and vomiting, as well as antiemetic requirements analgesic requirements and modified objective pain score enlarged hyperechoic kidneys analgesic efficacy wong and baker pain scale muscle relaxation clearance severe arthralgia median pain scores pain recovery time visual pain scale (vas) (0-100), side-effects such as vomiting and postoperative haemorrhage pain scores efficiency of postoperative analgesia score for stridor pain score or the need for rescue analgesia pre-operative anxiety and pain incidence and frequency of vomiting worst pain c3 and c4 levels incidence of above average bleeding objective pain score immediate postoperative analgesia nausea and vomiting scores, sedation scores and pain scores ketamine efficacy relevant pain-relief medication|in common with the experience of others, it is possible to perform tonsillectomies safely on a same-day basis. children given a caudal block alone were more likely to need analgesia in the first 24 h postoperatively. the rectum is a suitable route for administration of diclofenac in children 2-8 year of age and was associated with a higher relative bioavailabilty than enteric-coated tablets and an earlier maximum concentration (50 vs. 108 min). there were no significant differences in sedation score or frequency of use of postoperative analgesics at any time of assessment among the three inhalation anesthetics. group 1 comprised 63 patients and group 2 included 26 patients with identical diseases (inguinal hernias, varicocele, phimosis). there were no statistically significant differences in age, weight, type of operation or induction of anaesthesia, 4-h sedation and pain scores and further analgesic requirements. in the remaining 20 hours, the longest analgesia duration was seen in group s, which did not differ from groups f and m, but was significantly longer than for groups b and d. rectal diclofenac has not promoted effective pain relief. kartagener's syndrome (kgs) is an autosomal recessive disorder characterized by the clinical triad of bronchiectasis, sinusitis and dextrocardia (situs inversus). the total incidence of nausea/vomiting was 28% and fentanyl caused nausea and vomiting in a significantly higher proportion of cases. there were no significant differences in incidence of airway irritation or emergence delirium between the two agents. all operations were completed successfully and there were no intraoperative or postoperative complications except for subcutaneous emphysema in one patient (case 4). after cessation of the opioid infusion, the sedation scores and the heart rates were always higher in the remifentanil group compared with the fentanyl group. the incidence of ponv was much higher, 72% (p = 0.0000), in the morphine group, where 56% of the children also had severe vomiting. this is the first case report on colon perforation occurring in an adolescent (16-year-old girl) after short-term diclofenac intake. the incidence of postoperative vomiting was lower in the fentanyl group (p < 0.03) in the first 4 h, but similar by 24 h. children who received morphine at any time in the first 24 h had more median (range) episodes of vomiting [2 (0-7)] than children receiving fentanyl only [l (0-3); p < 0.03]. children who received the rectal diclofenac-paracetamol combination experienced a lower pain scale and a decreased need for morphine compared with children receiving each drug alone. an earlier awakening was observed in group 1, which we attributed to a more valuable antinociceptive protection and to lower doses of ketamine (group 1--3.2 mg/kg; group 2--4.3 mg/kg). no other differences were found between the ketamine and diazepam/diclofenac groups before and after premedication until induction of anaesthesia. the use of the nonsteroidal anti-inflammatory drug, diclofenac, for postoperative analgesia is well established for many types of surgery. clonidine 4 micrograms.kg-1 caused a lower incidence and frequency of vomiting than did placebo and diazepam (incidence and frequency: 11% and 1.37% and 3, and 34% and 2 in clonidine 4 micrograms.kg-1, placebo, and diazepam, respectively; p < 0.05 for clonidine 4 micrograms.kg-1 vs placebo and diazepam). there was no statistical significant difference in any of these parameters between the two groups. the time to first solid intake was significantly earlier in the diclofenac sodium group (p < 0.0001). an increased rate of postoperative nausea and vomiting (45% vs. 15%, p < 0.05) was the only adverse effect observed. significantly more mpca was demanded (t = 2.02, p < 0.02) and morphine received (t = 2.02, p < 0.005) by adults than children following appendicectomy. the decrease of pain severity was statistically significant (p <0.05). pain scores in the tenoxicam without fentanyl group were significantly higher in recovery (p < 0.05) than the diclofenac group without fentanyl and both fentanyl groups. laparotomy demonstrated ischaemia and ulceration in the caecum, and histology revealed full thickness mucosal ulceration with a prominent vasculitic process. analgesia, as assessed by movement pain scoring, was significantly improved by the addition of diclofenac despite lower morphine consumption. no significant differences in postoperative pain were found between the groups at any time. more children required rescue analgesia after codeine at both 2 (p<0.05) and 4 h after administration (p<0.01). the median pain scores (2 at 15 min and 1 at 30 min postoperatively) were the same in both groups. pain scores in the diclofenac group were only significantly lower at 12 h on day 1-3 compared to pain scores in the acetaminophen group (p<0.05). the duration of anaesthesia was longer in the diclofenac group (9.6 min, sd 3.5) compared with control (7.2 min, sd 2.6) and nalbuphine (6.9 min, sd 3.0) groups respectively (p < 0.05). caudal bupivacaine provided more pain-free patients at first but later the incidence of pain was similar in the two treatment groups. there was no difference between the groups except in the recovery area when group 3 cried more and had a higher pain score than group 2. on re-auditing two years later, in a group of 100 children, post-operative pain was significantly improved. a comparative analysis of the efficiency of postoperative analgesia by the discussed drugs showed that diclofenac possesses a sufficient analgetic activity and is free of any side-effects inherent in narcotic analgetics. the only difference related to the analgesic method was shorter duration of post-operative leucocytosis and lower phytohaemagglutinin (pha)-induced lymphocyte proliferative responses in peripheral blood in the opioid group than in the nsaid or epidural groups. the subpubic penile block provided significantly better analgesia than the subcutaneous ring block of the penis. aseptic tissue necrosis occurred around the injection site. there were no significant differences between the treatment groups in operating theatre blood loss, the frequency of bleeding on the ward, or the need for operative haemostasis. these children with sdb scored significantly higher on cbcl than did normative groups, but no connection was observed between cbcl rating and experience of pain. in children 1-3 yr, sevoflurane provided more rapid early recovery but not discharge after anaesthesia of <30-min duration. rectal diclofenac 2 mg.kg(-1) i.v. the ketamine group showed significantly lower pain scores both at rest and on swallowing, with less total paracetamol consumption (p < 0.05) during the 24 h after surgery. preemptive diclofenac given rectally reduced pain intensity and morphine requirements of children anaesthetized with remifentanil for tonsillectomy. the pain recordings showed significantly less pain for the tt children from the second hour postoperatively onward, and the tt children were pain free and in school 3 days earlier than the te group. esr, plasma urea and creatinine concentrations were increased in all, plasma proteins and igg levels in the majority of patients. overall, cheops scores were low for both groups at all times and did not differ between the groups at any time. worst pain observed in the recovery room was lower in the diclofenac group both at rest and during swallowing. caudal analgesia abolished the stress-induced increase in plasma beta-endorphin level which was found in the children given diclofenac and in those who served as controls. subjects in group l required significantly more doses of postoperative analgesia than those in group c (p < 0.05). vt and total plasma clearance were higher than in adults but the elimination half-life was similar. ketamine (median 2) or bupivacaine (median 2.5) groups (p<0.05). there were no significant differences between the two drugs in respect of time to awaken from anaesthesia or incidence of postoperative vomiting. we find the analgesic efficacy of diclofenac suppository combined with local anesthetic infiltration at port sites comparable to caudal block. voltarol appears to be the better pre-emptive analgesic for dental extractions under general anaesthesia when compared with paracetamol and no analgesia. the authors noticed a marked increase in the incidence of reactionary post-operative haemorrhage after tonsillectomy during the course of 1992. there were no obvious differences between the groups in intra-operative bleeding (as estimated by the surgeon), or in measured blood loss.|severely agitated children children undergoing extractions of primary teeth under general anaesthesia pediatric patients dysplastic kidney with ectopic ureter mean (sd) age and weight of the patients were 4.5 (1.5) years and 20.5 (4.1) kg mechanically ventilated postoperative children children receiving an anaesthetic which included intraoperative administration of fentanyl 1 microg x kg(-1 ninety-six children twenty consecutive children (6 months to 9 years of age) requiring repair of the hard or soft palate were included 150 children aged 1-7 years 133, asa i or ii children, aged 5-12 years undergoing general anaesthesia for simple dental extractions one hundred children between 10 and 15 kg of body weight scheduled for day-case adenoidectomy 24 boys who had subpubic penile blocks and nine of the 16 boys who had subcutaneous ring blocks children undergoing strabismus surgery ambulatory orthopedic surgeries in children children with a cheops score > 7 received further 80 children, aged 5-13 yr, who received 21 patients 33 children forty-nine children were operated on with tt and 43 with te their ages ranged from 3 to 13 years, and all belonged to american society of anesthesiologists (asa) class all patients had non-oliguric acute renal failure (arf): gfr was 21.7 children undergoing minor lower abdominal surgery pediatric postoperative icu patients four girls (mean age 5.3 years 19 children (6-16 years) and 23 adults (17-30 years) were recruited eight patients subsequently developed anterior uveitis as part of tinu syndrome subjects were 70 children from each site who were aged between 3 and 12 years, and were undergoing routine extractions of primary teeth 50 children undergoing laparoscopy for diagnostic and therapeutic purposes pain relief following simple dental extractions in children patients (asa i, 2-12 years) undergoing elective ophthalmological surgery twenty-two postoperative orthopedic surgery patients preschool children experiences severe emergence agitation after anaesthesia children following extractions of primary teeth under general anaesthesia pediatric laparoscopy pain relief following tonsillectomy children undergoing inguinal hernia repair children aged 1-3 years after appendicectomy using a standardized tracheal general anaesthetic children than in adults children after small-scope surgical interventions mechanically ventilated postoperative pediatric patients 1003-1014), mild proteinuria (0.3-0.4 g/24 h paediatric outpatient surgery children who were scheduled for elective tonsillectomy or adenotonsillectomy at the royal aberdeen children hospital children after desflurane and isoflurane anaesthesia paediatric tonsillectomy outpatients children eighty unpremedicated children undergoing day-case adenoidectomy infants (n = 26) undergoing preschool children sixty children undergoing caudal block during general anaesthesia for hernia repair or orchidopexy between january 1999 and july 2000, 80 children aged 3-14 years, underwent 51 children, aged from 2 to 12 years and undergoing major surgery under balanced anaesthesia 44 children scheduled for adenoidectomy (with or without myringotomy 127 children scheduled for 50 children undergoing surgery under general anaesthesia after inguinal herniotomy postoperative pain following adenotonsillectomy in children 60 children, undergoing the extraction of carious deciduous teeth under day-case general anaesthesia children receiving pca morphine forty children children undergoing laparoscopy children undergone "minor" surgical interventions paediatric patients for outpatient bilateral myringotomy and tube insertion pain after adenotonsillectomy in children three patients had an ectopic dysplastic kidney with ectopic ureter, and one patient had hydronephrosis with megaureter due to distal ureteral atresia of the upper moiety in a duplicated dysplastic kidney one hundred and eight patients children following extraction of carious deciduous teeth under general anaesthesia 125 children 100 children aged between 6 and 14 years after tonsillectomy in children post-tonsillectomy pain in children 140 children (3-12 yr) undergoing strabismus surgery sixty-three asa 1 ora sa 2 children aged one year and above paediatric myringotomy outpatients adults and children young boy who underwent lobectomy under general anaesthesia using a single lumen tube children undergoing ophthalmological surgery patients undergoing appendicectomy patients having tonsillectomy under the care of the senior author (p.m.r.) in 1992 revealed that four of the 73 patients (5.5%) receiving diclofenac at induction of anaesthesia suffered reactionary haemorrhage requiring operative control, as compared with two of 293 (0.7%) receiving other analgesics parents, 50 asa class i-ii children, 4-16 years of age twenty-nine children scheduled for adenotonsillectomy for either recurrent tonsillitis or adenotonsillar hypertrophy in prince zeid ben al-hussein hospital and prince rashid ben al-hussein hospital fifty children 200 paediatric daycase patients by using questionnaires and telephone interviews anaesthetized 211 children (1-5 yr) with 48 children, 5 to 15 years of age, following tonsillectomy one hundred fifty children, between 5 and 15 years of age 11 children given enteric-coated 24 h(-1 between 1986 and 1997 we observed 21 patients, aged 7-16 years (mean, 12.8), with acute tubulointerstitial nephritis, including eight with tubulointerstitial nephritis and uveitis (tinu syndrome children after strabismus surgery ninety-two children (5-15 years) with sleep-disordered breathing (sdb) and with or without recurrent tonsillitis pain after tonsillectomy in children small children sixty children between 3 and 13 years of age one hundred and ninety-eight children, aged 3 to 12 years, who were scheduled for tonsillectomy 100 children, aged 2 to 12 years, allocated in 5 groups of 20 children each, who received, right after anesthesia, the following analgesics: group b, 0.25 forty-five boys having circumcision as day-case patients paediatric patients thirty-nine, asa grade 1 or 2, children undergoing inguinal or penoscrotal surgery following cleft palate surgery one tertiary care ent clinic and two secondary care clinics after paediatric tonsillectomy 7 patients suffered a postoperative haemorrhage, 4 out of the 7 needed a surgical revision and 2 out of 100 patients vomited children anaesthetized with remifentanil for tonsillectomy children following tonsillectomy 8-year-old child with kartagener's syndrome children undergoing adenotonsillectomy children were consecutively operated upon from may 1999 to january 2001 all children had previously been healthy children undergoing elective ophthalmological surgery short day-case anaesthesia in a specifically limited age group of children 1-3 yr children after inguinal herniotomy or orchidopexy forty-seven children and 10 children with identical diseases like groin hernia, varicocele and dropsy of testicular membranes children undergoing tonsillectomy after forty-three children for day case inguinal herniotomy under general anaesthesia children with both a history of obstructive problems and recurrent tonsillitis forty boys weighing less than 25 kg undergoing unilateral orchidopexy paediatric patients undergoing tonsillectomy remains problematic pain following minor surgery in children 60 children patients between 6 and 30 years of age who underwent an unscheduled appendicectomy were prospectively recruited children undergoing adenotonsillectomy or tonsillectomy children and adults two hundred and fifty children undergoing herniotomy or orchidopexy under general anaesthesia pediatric icu patients fifty-four infants and children assigned in groups according to age and expected length of operation children having day case circumcision urban population of children sixty-one children 74 pediatric patients under 12 years of age children who received an analgesic regimen combining an opioid and a nsaid 26 patients with identical diseases (inguinal hernias, varicocele, phimosis children undergoing tonsillectomy four out of 59 children strabismus surgery in children
complete remission|at the 6-month follow-up timepoint, tumour volume had decreased by >/=10% in a total of 7 patients with a 37.9% (95% ci 31.3-44.5%) mean volume reduction in this subgroup.|patients with a central giant cell granuloma central giant cell granuloma of the jaw patients with a tumour reduction 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years
peak inspiratory pressure of </=16 cm h(2)o, positive end expiratory pressure of </=5 h(2)o, intermittent mandatory ventilation rate apnea/bradycardia episodes extubation failure incidence of abdominal distension or feeding intolerance pulmonary function tests (pft blood gases lower incidence of failed extubation demographics, severity of initial illness and associated complications, time to extubation, ventilatory management before extubation, weight, age, or nutritional status at the time of extubation mean birth weight respiratory failure|the nsimv group had a lower incidence of failed extubation 4/27 compared with the continuous positive airway pressure group, 12/27. thirty-two (94%) of 34 infants were extubated successfully with the use of snippv versus 18 (60%) of 30 with the use of ncpap (p <.01). no statistically significant differences between groups with regard to demographics, severity of initial illness and associated complications, time to extubation, ventilatory management before extubation, weight, age, or nutritional status at the time of extubation were noted.|in a university-based level iii neonatal intensive care unit preterm infants being ventilated for respiratory distress syndrome (rds premature infants 55 infants who had pft, 80% (8 of 10) with dynamic lung compliance of >/=0.5 ml/kg/cm h(2)o and expiratory airway resistance of </=70 cm h(2)o/l/s were extubated successfully very low birth weight infants after extubation objective criteria for failure of extubation were as follows: a paco(2) >70; fio(2) >0.7; or severe recurrent apnea (>2 apneas requiring intermittent positive-pressure ventilation in 24 hours or >6 apneas >20 seconds per day after extubation of very low birth weight infants 41 vlbw infants were studied; 19 were in the npcpap group, and 22 were in the np-simv group infants who were </=34 weeks' gestational age and who were ventilated for rds infants with poor lung function (dynamic lung compliance: <0.5 ml/kg/cm h(2)o; expiratory airway resistance: >70 cm h(2)o/l/s), successful extubation was seen in 93% (27 of 29) in the snippv group and 60% (15 of 25) in the ncpap group infants of <1251-g birth weight who were due to be extubated before 6 weeks of age were eligible once they were receiving <35% oxygen and were on a ventilator rate of <18 breaths per minute (bpm
serum zinc and vitamin e, superoxide dismutase (sod), glutathione peroxidase (gpx), total antioxidant capacity (tac) and body mass index (bmi mean number of episodes of crisis growth and body composition circumference z scores knee height serum testosterone level number of hospitalizations and decreased number of vaso-occlusive pain crisis bmi bacteriologically positive infections interleukin-2 production antioxidant status serum vitamin e levels lymphocyte and granulocyte zinc acceleration of growth in height linear growth in beta-thalassemia serum testosterone, neutrophil zinc, and neutrophil alkaline phosphatase activity mean number of infective episodes and associated morbidity growth velocity (height incidence of infections and hospital admissions mean gpx activity mean sod activity and tac sitting height zinc deficiency affects adversely t-helper1 (th1) functions and cell mediated immunity and interleukin (il)-2 production mean height velocity of early-zinc supplemented children height-for-age and weight-for-age z scores body weight increased and serum lactic dehydrogenase activity mean duration of hospital stay anthropometric, high-precision knee-height, and plasma zinc measurements body composition sickle cell crisis height serum zinc levels serum testosterone levels|after 12 mo, the zinc group had significantly greater mean (+/- se) increases in height (0.66 +/- the mean height velocity of early-zinc supplemented children was significantly greater than that of normal children (p less than 0.01). an increase in serum testosterone, neutrophil zinc, and neutrophil alkaline phosphatase activity ws observed in the zinc-supplemented group in comparison with the group on placebo. mean gpx activity in group1, 2 and 3 decreased significantly (p<0.015, p<0.032 and p<0.029, respectively). prolonged zinc supplementation resulted in an increase in lymphocyte and granulocyte zinc (p = 0.0001), and an increase in interleukin-2 production (p = 0.0001), decreased incidence of documented bacteriologically positive infections (p = 0.0026), decreased number of hospitalizations and decreased number of vaso-occlusive pain crisis (p = 0.0001). there was a significant reduction of the mean number of infective episodes and associated morbidity in patients with sickle cell anaemia.|adult sickle-cell disease (scd) patients thirty-eight children completed the study forty-two prepubertal children (20 girls and 22 boys) aged 4-10 y with scd-ss children with scd patients with scd patients with sickle cell anaemia beta-thalassemic major patients adult male subjects with sickle cell anemia sickle cell anemia 32 patients with beta-thalassemia major adult male sickle cell anemia subjects adult male patients with sickle cell anemia prepubertal children with scd-ss children with sickle cell disease (scd sickle cell disease (scd patients who received delayed zinc retardation 120 beta thalassemic patients older than 18 years beta thalassemia major patients children with sickle cell disease 145 patients were recruited in the trial while 130 completed it 32 scd subjects
serum lipid profile body weight overall visual analog scale (vas absenteeism mean (+/-se) hba1c and fasting blood glucose levels general health vitality glycosylated hemoglobin health economic benefits and quality of life vas emotional health psychomotor speed and concentration cognitive functioning productive capacity cognitive function ginseng therapy elevated mood, improved psychophysical performance, and reduced fasting blood glucose (fbg) and body weight glycated hemoglobin, serum piiinp, and physical activity psychophysical tests and measurements of glucose balance, serum lipids, aminoterminalpropeptide (piiinp) concentration, and body weight depression sleep disorientation and detachment cognitive deficits glucose and hemoglobin a1c (hba1c) levels and symptom distress, qol, and health economic indicators by questionnaires and diaries quality-of-life treatment differences (sd units) for symptom distress general perceived health subscales of acuity|quality-of-life treatment differences (sd units) for symptom distress (+0.59; p<.001), general perceived health (+0.36; p= .004), cognitive functioning (+0.34; p=.005), and the overall visual analog scale (vas) (+0.24; p=.04) were significantly more favorable for active therapy. psychomotor speed and concentration improved only after inpatient treatment (p < 0.01; p < 0.05, respectively). ginseng therapy elevated mood, improved psychophysical performance, and reduced fasting blood glucose (fbg) and body weight.|patients with diabetes 569 male and female volunteers with type 2 dm 36 niddm patients patients with type 2 diabetes mellitus elderly niddm patients 20 elderly patients with non-insulin-dependent diabetes mellitus (niddm newly diagnosed non-insulin-dependent diabetes mellitus (niddm) patients non-insulin-dependent diabetic patients elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control type 2 diabetes mellitus (dm
improved glucose disposal beta-cell response metabolic control insulin sensitivity peak oxygen uptake (p<0.05) and exercise test duration (p<0.001) increased following training, whilst glycated hemoglobin (p<0.05) and fasting blood glucose muscle density glucose disposal by hyperinsulinemic-euglycemic clamp and computed tomography scans of abdominal at and mid-thigh skeletal muscle brs, hrv, and hemodynamics body weight abdominal fat distribution, glycemic control, and insulin sensitivity triglycerides glycosylated hemoglobin a1 fell fat mass (fm risk for coronary artery disease insulin sensitivity and hb a(1c) concentration time or frequency domain measures of hrv or in systemic hemodynamics glycosylated hemoglobin vo2max subcutaneous at, visceral at, and muscle density glycemic control and fitness muscular strength coronary risk factors abdominal fat and glucose metabolism physical fitness visceral abdominal fat glycemic control brs sensitivity visceral adipose tissue (vat percent body fat glycaemic control and lowers fasting insulin levels fasting glucose and insulin beta-cell responses cardiovascular risk factors: physical fitness, systolic blood pressure, plasma triglycerides, and glycemic control glycaemic control vo(2max glycosylated haemoglobin (hba 1c ), fasting glucose and insulin, glucose and insulin 120 minutes (2h) after a 75 g oral glucose load, body composition and muscular strength and endurance vo(2 max self-monitored glucose levels lipids, glucose, insulin, glycosylated hemoglobin and cardiovascular fitness 2 hour plasma glucose in oral glucose tolerance test change in self-monitored glucose levels and insulin area under the curve responses of plasma insulin and c-peptide to oral glucose cardiac index, systemic vascular resistance index, stroke index, and pulse wave velocity resting heart rate mean fall in fasting plasma glucose 2-h glucose and insulin glycemic control and body composition baroreflex sensitivity (brs) and heart rate variability (hrv fasting glucose, insulin, serum lipids and lipoproteins, or resting blood pressure body weight, total and hdl cholesterol, glucose, and insulin functional capacity, lean body mass, strength and glycemic control submaximal exercise heart rate and rate pressure product glucose infusion rates brs glucose metabolism baroreflex sensitivity vo2 peak muscular strength and endurance beta-cell function resting systolic blood pressure glycemic control, cardiorespiratory fitness, muscular strength and body composition insulin sensitivity and hb a(1c) levels lean body mass (lbm fasting serum glucose and insulin insulin resistance fasting glucose and hba 1c heart rate increased insulin response reduced abdominal subcutaneous and visceral at and increased muscle density plasma levels of triglycerides, fructosamine and glycohemoglobin exercise capacity and muscle strength and improving glucose control vo(2max), standard time and frequency domain measures of hrv during 24-h recording, and brs waist:hip ratio fat free mass (ffm ventilatory threshold muscle strength, and glycemic control|during the 3 mo of sedentary lifestyle, insulin and c-peptide responses to the clamp procedures were unchanged in both moderate and low secretors. concurrently, peak oxygen uptake (p<0.05) and exercise test duration (p<0.001) increased following training, whilst glycated hemoglobin (p<0.05) and fasting blood glucose (p<0.05) decreased. physical training significantly decreased abdominal fat evaluated by magnetic resonance imaging (umbilicus), with a greater loss of visceral adipose tissue (vat) (48%) in comparison with the loss of subcutaneous adipose tissue (18%), but did not significantly affect body weight. in the rt group fasting glucose and insulin decreased with training (p < 0.05) and decreases in hba 1c approached significance (p = 0.057). glucose infusion rates increased significantly (p < 0.05) in the ae+rt group. significant reductions from baseline values were observed in both the glucose (-213 mmol l-1 per 120 min, p < 0.05) and insulin (-6130 pmol l-1 per 120 min, p < 0.05) area under the curve following cwt relative to controls. body weight, total and hdl cholesterol, glucose, and insulin did not change in either group. significant improvements in vo(2max) (exercise group: +2.3 ml x kg(-1) in the exercise group glycosylated hemoglobin a1 fell from 9.6-8.6% (p less than 0.01) and the 2 hour plasma glucose in oral glucose tolerance test decreased from 19.7-16.5 mmol/l (p less than 0.01). at the end of the study the exercise group had a significant reduction in plasma levels of triglycerides, fructosamine and glycohemoglobin. high-intensity progressive resistance training, in combination with moderate weight loss, was effective in improving glycemic control in older patients with type 2 diabetes.|patients with type 2 diabetes twenty-seven untrained, sedentary subjects (mean age, 51) with niddm participated healthy young subjects forty patients aged 56.6 obese type 2 diabetics eighteen subjects type 2 diabetes twenty-one subjects completed the study (cwt, n = 11) (control, n = 10 obese type 2 diabetic men subjects with type 2 diabetes 2 years) with type 2 diabetes 28 obese postmenopausal women with type 2 diabetes type 2 diabetic patients subjects (50 men, mean age 53.3 patients with niddm patients with non-insulin-dependent diabetes 5.1 years) with type 2 diabetes type 2 diabetes subjects nine women and seven men, mean age 56 uncontrolled elderly patients with non-insulin-dependent diabetes mellitus patients with mild and moderate non-insulin-dependent diabetes sedentary, overweight men and women with type 2 diabetes, aged 60-80 years (n = 36 older patients with type 2 diabetes non-insulin-dependent diabetes were studied in 25 patients divided randomly into exercise (n = 13) and control (n = 12) groups type ii diabetes obese, type 2 diabetic men patients, stratified into "moderate" and "low" secretors according to individual c-peptide responses to an intravenous glucagon test postmenopausal women with type 2 diabetes 16 subjects (age 52 type 2 diabetes patients niddm patients twenty-four patients (ages 45 women with type 2 diabetes
patency rate minor bleeding and slight rise in temperature average size of the thrombi clot lysis short- and long-term efficacy mean change in venographic score symptoms of the postphlebitic syndrome major bleeding complications risk of bleeding venographic severity deep venous insufficiency clinical symptoms of post-thrombotic syndrome number of closed vein segments and the occurrence of postthrombotic syndrome level of serum glutamic oxaloacetic transaminase degree of thrombosis, evaluated phlebographically complete lysis clot lysis and deep venous reflux lysis rate pulmonary emboli blood transfusions efficacy and safety major bleeding and pulmonary emboli initial thrombi major bleeding segmental valve preservation signs or symptoms of venous insufficiency plasma fibrinogen concentration postthrombotic syndrome nonfatal intracranial hemorrhage rates of complete recanalization significant thrombolysis overt bleeding venous reflux deep vein thrombosis serious post-thrombotic changes number of closed vein segments peripheral edema no lysis|at follow-up examination after 12 months, there were serious post-thrombotic changes in 14 of 22 patients in the rt-pa group, in 9 of 22 patients in the urokinase group and in 15 of 22 patients in the group of patients who received no lysis treatment. we found no superiority in the regimen consisting of urokinase preceding heparin infusion, compared with that of heparin infusion alone. using the chi2-test for overall association, this difference was statistically highly significant (p = 0.002). bleeding complications classified as major were noted in 8/25 patients receiving the combined treatment. systemic thrombolytic treatment for acute dvt achieved a significantly better short- and long-term clinical outcome than conventional heparin/anticoagulation therapy but at the expense of a serious increase in major bleeding and pulmonary emboli. when diagnosis was delayed there was a very great risk of permanent damage to the valves. the 4-h infusion of rt-pa produced a 40 percent reduction and the 8-h infusion an 11 percent reduction in plasma fibrinogen concentration. vein recanalization without preservation of valves occurred in 18 patients: 8 (54%) of those on streptokinase, and 10 (83%) of those on heparin. at 7 to 10 days after initiation of treatment, the level of serum glutamic oxaloacetic transaminase nearly doubled among all patients, including those assigned to receive heparin alone. signs or symptoms of venous insufficiency were found in 37%, and foot volumetry showed deep venous insufficiency in 26% of the cases. in the short-term patients treated with catheter directed thrombolysis obtained better patency and competence than those treated with standard anticoagulation.|12 patients receiving thrombolysis (9 systemic, 3 local) suffered all patients with complete or partial valve preservation became asymptomatic patients with symptoms of deep vein thrombosis for less than 10 days deep venous thrombosis patients with deep vein thrombosis twenty-seven patients with deep vein thrombosis whose primary therapy thirty-six patients with symptomatic cvt, verified by venography acute proximal deep vein thrombosis in 83 patients only patients with extensive thromboses patients benefited from locoregional lysis treatment of recent deep leg vein thrombosis after 1 year proximal deep venous thrombosis patients with acute deep vein thrombosis with proximal extension of the thrombus beyond the calf veins 69 patients aged between 22 and 58 years, in whom recent lower leg vein and popliteal vein thromboses were diagnosed by phlebography patients with leg or pelvic deep venous thrombosis (dvt twenty-two patients who had an acute episode of thrombosis in the deep veins of the legs 35 eligible patients 250 patients averaging 40 years of age with acute dvt twenty patients with clinical signs of deep vein thrombosis of a duration not exceeding 72 hours, and with the condition confirmed phlebographically patients with iliofemoral dvt deep vein thrombosis venographically documented proximal deep venous thrombosis (dvt) of the leg deep vein thrombosis of the lower extremities and/or pelvis 42 medical patients with a history of deep vein thrombosis of less than five days
deep venous thromboses incidence of a venous thromboembolic event pulmonary embolism and venous thrombosis thromboembolic incidence postoperative thromboembolic complications frequency of deep-vein thrombosis safe; operative blood loss frequency of postoperative deep-vein thrombosis frequency of deep vein thrombosis, in blood loss or bleeding complications deep venous thrombosis postoperative haemorrhagic complications incidence of p. e postoperative swelling major hemorrhagic complication haemorrhagic complications and blood loss indices wound hematoma or infection rate dvt fatal pulmonary embolism pulmonary embolism and/or deep vein thrombosis protection against postoperative deep vein thrombosis doppler ultrasonography mean blood transfusions deep-vein thrombosis bleeding and transfusions efficacy or safety deep venous thrombosis (dvt pulmonary embolism bilateral thrombosis deep-vein thrombosis and swelling overall frequency of venous thrombosis deep vein thromboses frequency of thrombosis venous thromboembolism efficacy and safety overall incidence of dvt rate of venous thrombosis thromboembolic event overall frequency of thrombosis haemorrhagic complications bleeding or other complications thromboembolic disease incidence of wound complications distal and proximal thrombosis calf and thigh circumferences thromboembolic event incidence absence of propagation or tail formation incidence of pulmonary embolism incidence of thromboembolism antithrombotic efficacy frequency of major thrombosis deep vein thrombosis mortality thromboembolic events incidence of observed bleeding complications incidence of proximal deep-vein thrombosis bleeding complications or transfusion requirements thigh dvts venographycally proven deep vein thrombosis (dvt occurrence of dvts frequency of pulmonary perfusion defects incidence of dvt|low-dose heparin reduced the overall frequency of venous thrombosis and its extent as judged by the frequency of bilaterally abnormal scans, but this reduction did not achieve statistical significance. nineteen (59.4 per cent) of thirty-two placebo-treated arthroplasty patients showed evidence of a thromboembolic event in contrast with eight (22.9 per cent) of thirty-five heparin-treated patients (p less than 0.003). a and b proved to be equally safe but failed to provide any protection against deep-vein thrombosis, although b showed a tendency to reduce the incidence. there was no difference in the wound hematoma or infection rate. dhe does not seem to reduce the incidence of d.v.t. any further in this group of patients. mortality did not differ between the groups, nor did haemorrhagic complications. distal and proximal thrombosis occurred in 18.3% of patients in group a and in 10.4% in group b. no major hemorrhagic complication was observed, except for two hematomas in each group. the a-v impulse system appears to be a safe and effective method of reducing the incidence of proximal deep-vein thrombosis, and of postoperative swelling. five patients in the alfa lmwh group (20 per cent) developed venographycally proven deep vein thrombosis (dvt) versus seven (29 per cent) in the ufh group. there was significantly less d. v. t. in the heparinized group than in the control group (p < 0.01) and the incidence of p. e. was smaller in the heparinized group, 0 and 4 per cent respectively. significant improvement in protection against postoperative deep vein thrombosis, assessed by venography, was observed in the adjusted group undergoing hip replacement (p = 0.013) and overall in both groups (p = 0.017) compared with a conventional fixed dose subcutaneous regimen (calcium heparin 5000 units, 8-hourly). there were no differences in bleeding or other complications in the two groups. sequential treatment was not shown to be better or worse than treatment with enoxaparin, but the trends favoured sequential treatment rather than drug treatment alone. there were no statistically significant differences in the frequency of deep vein thrombosis, in blood loss or bleeding complications between the three prophylaxis groups. the heparin regime was safe; operative blood loss was not increased, nor was there an increased incidence of wound complications as compared to the placebo group. deep vein thrombosis was diagnosed in both groups with the 125i-fibrinogen test and pulmonary perfusion defects in the arthroplasty group with a combination of pulmonary x-ray and perfusion scintigraphy. postoperative haemorrhagic complications were seen in 6.1% in the group of standard-heparin and in 8% in the group of low-molecular-heparin. there was no statistically significant difference in the incidence of dvt between the control and lmwh groups, and the incidence of dvt in elderly chinese patients after hip replacement for a hip fracture is similar to that in other studies in caucasians. this showed that the 0-hypothesis could not be rejected, and that consequently no difference in the frequency of deep-vein thrombosis was detected. the incidence of a venous thromboembolic event in the control group was 11% and in the experimental group 4%. a deep-vein thrombosis developed in ten patients (19 per cent) in the control group and in only one patient (2 per cent) in the group that was treated with compression.|210 patients undergoing nailing of a fractured neck of the femur patients with hip fractures orthopaedic trauma patients 100 patients undergoing surgery for hip replacement or fractured neck of femur 82 patients in whom hip fracture surgery deep-vein thrombosis after hip fractures elderly chinese patients 33 patients have been treated with patients with proximal femur fractures one hundred and ten female patients, over the age of 60, with intertrochanteric or transcervical fractures patients with fractures of the proximal end of the femur proximal femoral fractures fifty-two hip-fracture patients one hundred and sixty-one patients were analyzed patients with a fractured neck of the femur one hundred and ninety-three patients post-operative venous thromboembolism after hip fractures after hemiarthroplasty for hip fracture hip fractures 103 elderly patients with a fracture of the neck of the femur 116 women and 34 men with a mean age of 73 years (38 to 92 304 orthopaedic trauma patients with hip and pelvic fractures 90 patients admitted because of hip fracture fulfilled the inclusion criteria and were analyzed for development of pulmonary embolism and deep vein thrombosis: 46 patients were included in the low molecular weight heparin (lmwh) group, and 44 in the conventional heparin group two hundred and thirteen patients surgically treated for fractures of the hip hip-fracture patients hip fracture elderly patients with hip fractures two hundred and thirty-eight patients with femoral neck fractures 130 patients endured the trial and the results were registered on a sequential diagram 150 patients with proximal femoral fractures patients undergoing operations on the hip for either replacement or fracture elderly surgically treated patients sixty-seven hip-arthroplasty and 50 patients with a fractured neck of the femur patients with transcervical and intertrochanteric femoral fractures deep vein thrombosis in hip surgery 197 patients were randomised patients with proximal femoral fractures patients undergoing hip fracture surgery patients with hip fracture (77) and patients undergoing elective hip arthroplasty (213 82 patients treated by hemiarthroplasty for subcapital fracture of the femoral neck elderly patients with a fracture of the neck of the femur patients undergoing post-traumatic hip surgery total hip arthroplasty and surgical repair of hip fractures hip fracture surgery patients with hip fracture after hip surgery thromboembolism after elective and post-traumatic hip surgery seventy-eight patients of average age 78 years suffering from an unilateral non-pathological hip fracture underwent forty-nine patients
physical examination, psa assay and compilation of ipss, iief-5 and eortc-qlq-c30/pr25 questionnaires longer lasting rate of urinary irritative disorders and better erective function functional outcomes quality of life aspects 5-year biochemical disease-free survival rates|with regards to oncological outcomes, similar 5-year biochemical disease-free survival rates were reported for rrp (91.0%) or bt (91.7%).|between may 1999 and october 2002, 200 patients (mean age 65.3 low-risk prostatic cancer (cap low-risk prostatic cancer 200 patients studied, 174 completed the 5-year follow-up assessment
annual incidence of erroneous extraction incidence of erroneous extraction annual incidence rates of erroneous extraction cognitive failure incidence of wrong-site tooth extraction|there was a significant difference in the incidence of erroneous extraction between the preintervention and intervention periods (p<.01).|outpatient department of a university hospital in taiwan
patency rate patency rates overall secondary patency rates secondary patency rates no perioperative (30 day) limb loss or death primary 3-year patency for dacron grafts secondary patency preoperative risk factors and operative and postoperative treatment mortality, primary assisted patency and secondary patency previous cerebro-vascular events primary patency rate ankle-brachial pressures or imaging in case of doubt secondary patency or limb salvage primary patency 3-year secondary patency history of myocardial infarction limb salvage rate distal gangrene cumulative 5-year patency rate bypass graft patency and limb salvage patency rates for dacron and ptfe ptfe patency rate primary patency rates for huv ptfe failure graft occlusions secondary patency rate for hbd prosthetic patency 5-year patency rate limb salvage cumulative 3-year patency rate 30-days mortality and complications (wound infections died with patent grafts cumulative primary patency rates median postoperative ankle-arm blood pressure index long-term graft performance hospital mortality number of patent crural vessels rest pain, ulceration, or gangrene cumulative patency rates primary "assisted" patency rate mortality rates incidence of major limb amputation primary patency rate, measured with kaplan-meier survival analysis major amputation number of patent crural arteries overall cumulative limb salvage major limb amputation|for umbilical vein the corresponding figures were 74% and 42% (p = 0.005, gehan test). miller cuffs had no effect on patency rates for femoral to above-knee popliteal bypasses at 5 years and did not improve limb salvage in either group. there was no statistically significant difference in primary "assisted" patency rate for the two grafts: 100%, 98%, and 94% for sv grafts, and 96%, 84%, and 84% for ptfe grafts (p =.09), after 1, 3, and 5 years, respectively. during prolonged follow-up (10 years), dacron femoro-popliteal bypass grafts have superior patency compared to those of eptfe grafts. at 6 years the primary patency rate was 38.7% in the ptfe group and 71.4% in the huv group (p < 0.001). during a follow-up period of 2 years, we found no statistically significant difference in primary and secondary patency between saphenous vein and polytetrafluoroethylene. there was no difference in long-term graft performance between huv and hbd for above knee infrainguinal bypass. significantly better patency rates were achieved with hbd than with ptfe at 3 years (p < .044), but the difference was no longer statistically significant at 5 years (p < .055). during this follow-up period of 2 years, we found no statistically significant difference in primary and secondary patency between saphenous vein and collagen impregnated woven polyester prosthesis. upon multivariate analysis below-knee anastomosis was the principal independent predictor of primary graft failure (risk ratio 1.7 [c.i. 1.05-2.8]), impaired secondary patency was associated with infragenicular bypass (risk ratio 3.3 [c.i. 1.8-6.3]) and distal gangrene (risk ratio [c.i. 1.01-3.8]p=0.048), major amputation was independently predicted by below-knee bypass, tissue necrosis, and poor run-off index. the two-year primary patency rates for dacron and ptfe were 70% and 57% (p=0.02), whereas the secondary patency rates were 76% and 65% (p=0.04), respectively.|patients with claudication who underwent bilateral above-knee femoropopliteal revascularization 235 (120 with a miller cuff, 115 without ninety-six extremities 129 patients between 1996 and 2001 209 patients (179 above-knee disease, 30 below-knee disease between 1992 and 1996, 228 ak femoro-popliteal bypass grafts two hundred and sixty-one bypass operations 13 centres in denmark (n=261), norway (n=113) & finland (n=53) between 1993 and 1998 85 patients (52 male, 33 female above-knee femoropopliteal bypass grafting age, gender, indication (claudication: 65%), run-off (2 or 3 vessels: 76%), diabetes (17%) and hypertension (31%) as well as cerebrovascular (9%) and cardiac (33%) risks were evenly distributed patients with claudication femoropopliteal bypass 427 patients femoro-popliteal bypass fifty-five patients twenty-three limbs had three patent tibial arteries, 46 limbs had two tibial arteries, 31 limbs had one patent artery, and five limbs had isolated popliteal segments patients were eligible for inclusion if presenting with disabling claudication, rest pain or tissue loss 203 patients randomised, 194 were included in the final analysis (103 dacron grafts and 91 ptfe grafts between january 1994 and december 1997, 51 patients (102 limbs) with bilateral disabling claudication due to superficial femoral artery occlusion underwent above-knee femoropopliteal bypass grafting, with sv in one limb and ptfe graft in the other limb fourteen (3%) patients were excluded, leaving 413 patients with 208 dacron and 205 ptfe grafts for analysis 136 patients (77 male, 59 female one hundred five patients (105 limbs) entered the trial
cell degeneration (p<0.001), necrosis (p<0.01) and the expression of nm23 (p<0.001 stomach tumor localization fas/fasl,pd-ecgf and pcna palliative or radical resection complete or partial response frequency of fas expression lymphatic spread number of tumour emboli type of resection (r0, r1, r2, or no resection apoptotic index (ai expression rate of fasl survival rate disease-free survival, relapse pattern ecf-related adverse effects overall survival, tumour response, toxic effects, patterns of failure, and quality of life pcna index (pi disease-free survival 5-year survival rate survival, response, and patterns of failure of trimodality therapy progression-free survival nor overall survival expression rates of fas and fasl positive lymph nodes r0 resection rate lymph node metastases numbers of deaths year survival rate rates of postoperative complications postoperative complications resectability and survival 3-year survival rates median survival rates complete resections with clear margins uicc stages progression-free or overall survival five-year survival invasion depth postoperative 5-year survival rate survival intensity of cd44 expression curative resection rate, disease-free survival, and os median survival since randomisation grade 3 to 4 toxicity overall survival expression rate of pd-ecgf median survival resectability rates curative resection rate gastric cancer survival benefit expressions of nm23 and cd44 progression-free and overall survival alive and free of disease tolerated disease-free and overall survival international union against cancer r0 resection rate progression-free survival postoperative morbidity 5-year survival patient mean age, gender, white blood cell count, haematoglobin (hb),thromboplastin, perioperative complication incidence, radical or palliation resection, invasion depth (t), lymphonode involvement (n),metastasis (m) and tnm staging os overall survival (os|the surgery-only group had more lymph node metastases than the neoadjuvant group (76.5% v 61.4%; p = .018). with a median follow-up of 83 months the median survival since randomisation is 18 months in the famtx group vs. 30 months in the surgery alone group (p=0.17). rates of postoperative complications were similar in the perioperative-chemotherapy group and the surgery group (46 percent and 45 percent, respectively), as were the numbers of deaths within 30 days after surgery. median survival, based on intention-to-treat, was 17 months for multimodal therapy vs. 12 months for surgery alone (p=0.002). the median survival rates for patients with r1, r2, or no resections were not significantly different. the expression rate of fasl in 5'-dfur group was significantly lower than that in the other two groups (chi2=6.708, p=0.035). perioperative chemotherapy significantly improved the curative resection rate (84% v 73%; p = .04). preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone. survival at 3 years was 16% in arm i and 30% in arm ii (p = .15). the pyrimidine nucleoside phosphorylase (pynpase) activity in gastric carcinoma tissue from group the postoperative 5-year survival rate was 40% in the fplc-treated group and 23% in the controls (p=0.17). three-year survival by type of resection was r0 42.4%, r1 was 18.0%, and r2 was 8.6%. patient and tumor characteristics were similar between groups.|patients with localized esophageal cancer 43 patients with potentially resectable esophageal carcinoma treated with an intensive regimen of preoperative chemoradiation with patients undergoing radical surgery for esophageal cancer esophageal cancer patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (aeg ii and iii patients with resectable adenocarcinoma of the lower esophagus, gej, or stomach, perioperative chemotherapy using patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either perioperative chemotherapy and surgery (250 patients) or surgery alone (253 patients fifty-six patients were enrolled between october 1997 and march 2000, when the trial was closed due to poor accrual patients with this disease six patients were excluded patients with nonmetastatic esophageal cancer four hundred seventy-five eligible patients were planned for enrollment advanced stage esophageal adenocarcinoma patients aged 75 years or less with advanced gastric cancer thirty patients patients with locally advanced gastric cancer benefit from one hundred patients with esophageal carcinoma thirty patients were treated with resectable cancer of the oesophagus patients with resectable oesophageal cancer 128 patients 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including aeg type ii and iii patients with operable gastric or lower esophageal adenocarcinomas resectable gastroesophageal adenocarcinoma fifty-nine patients were randomised; 29 patients sixty gastric cancer patients fifty-four patients received gastrectomy, including 12 palliative resections and 42 radical resections patients with minimal residual disease two hundred sixteen patients received preoperative chemotherapy, 227 underwent immediate surgery patients with potentially curable gastric cancer patients with proven adenocarcinoma of the stomach operable esophageal cancer resectable gastroesophageal cancer patients with carcinoma of the esophagus or gastroesophageal junction sixty patients with gastric cardia cancer patients with gastric cancer locally advanced cancer of the stomach and cardia 149 patients in the perioperative-chemotherapy group and 170 in the surgery group had died before surgery showed a median survival of 29 months in comparison with the 12-month median survival of 100 historical controls treated with surgery alone at the same institution oeo2 recruited 802 patients, 400 on cs and 402 on s 224 patients with resectable adenocarcinoma of the lower esophagus, gastroesophageal junction (gej), or stomach patients with locoregional esophageal carcinoma gastric cancer patients with potentially resectable esophageal carcinoma patients with incurable locally advanced or metastatic gastric adenocarcinoma patients with gastric cardia cancer esophageal cancer: calgb 9781 operable gastric cancer patients with squamous-cell tumours gastric carcinoma tissue from group patients with advanced gastric cancer advanced-stage disease
trichomonas vaginalis vaginal infection delivery delivery before 37 weeks of gestation birth weights and gestational age at delivery preterm delivery resulting from spontaneous preterm labor|the birth weights and gestational age at delivery were similar in all three groups. between randomization and follow-up, trichomoniasis resolved in 249 of 269 women for whom follow-up cultures were available in the metronidazole group (92.6 percent) and 92 of 260 women with follow-up cultures in the placebo group (35.4 percent).|screened pregnant women for trichomoniasis by culture of vaginal secretions pregnant women with asymptomatic trichomoniasis pregnant women 617 women with asymptomatic trichomoniasis who were 16 to 23 weeks pregnant pregnant women with asymptomatic trichomonas vaginalis infection 315 women in the metronidazole group and 289 women in the placebo group asymptomatic pregnant women
health status morning peak expiratory flow rate (pef); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations pretreatment fev1 2-h postdose fev(1 lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration incidence of pneumonia average daily morning pef incidence of individual non-fatal serious adverse events postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire (sgrq number of exacerbations resulting in hospitalization prolonged time to first exacerbation predose fev(1 fev1 dyspnea, quality of life, and symptoms of chronic bronchitis dyspnoea (measured using the breathlessness diary) and health-related quality-of-life (hr-qol) scores (based on the st george's respiratory questionnaire total score morning predose fev(1 severity of dyspnea lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations lung function and health status morning predose (ie, trough fev(1)) for fsc compared with sm and 2-h postdose fev(1 efficacy morning pef efficacy and safety dyspnoea scores and hr-qol adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms symptom scores and use of reliever beta2-agonists tolerated relative pretreatment forced expiratory volume in 1s (fev1 daily symptoms mean prebronchodilator forced expiratory volume pre-dose forced expiratory volume in 1 second (fev(1)) and 1-hour post-dose fev(1 transition dyspnea index efficacy and tolerability mean number of severe exacerbations prebronchodilator peak expiratory flow exacerbations 2-hour postdose fev(1 lung function tolerated morning lung function adverse effects efficacy for pulmonary function severe exacerbations and fev1 (primary variables), peak expiratory flow (pef), copd symptoms, health-related quality of life (hrql), mild exacerbations, use of reliever beta2-agonist and safety variables|combination therapy improved pretreatment fev1 significantly more than did placebo (treatment difference 133 ml, 95% ci 105-161, p<0.0001), salmeterol (73 ml, 46-101, p<0.0001), or fluticasone alone (95 ml, 67-122, p<0.0001). postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire (sgrq) by 4.5 units after run-in. the incidence of adverse effects (except for an increase in oral candidiasis with fsc and fp) were similar among the treatment groups. the incidence of adverse effects (except for an increase in oral candidiasis with fsc and f) was similar among the treatment groups. dyspnoea scores and hr-qol were significantly improved with both budesonide/formoterol pmdi dosage strengths versus both monocomponents and placebo. morning pef improved significantly on day 1 versus placebo and budesonide; after 1 week, morning pef was improved versus placebo, budesonide and formoterol.|patients with moderate-to-severe chronic obstructive pulmonary disease (copd patients with moderate to very severe chronic obstructive pulmonary disease patients with chronic obstructive pulmonary disease (copd) who have frequent exacerbations chronic obstructive pulmonary disease seven hundred twenty-three patients > or =40 years of age with copd and a mean baseline fev(1) of 42% predicted moderate-to-severe chronic obstructive pulmonary disease 812 adults (mean age 64 yrs, mean forced expiratory volume in one second (fev1) 36% predicted normal chronic obstructive pulmonary disease (copd 1465 patients with copd were recruited from outpatient departments in 25 countries 1704 patients aged > or =40 years with moderate to very severe copd conducted in 194 centres in the us, czech republic, the netherlands, poland and south africa seventy-six investigative sites in the united states patients with copd symptomatic chronic obstructive pulmonary disease (copd 691 patients with copd
geometric mean titer of antibodies incidence rates anti-hav seroconversion cumulative attack rate for hepatitis a symptomatic infection attack rates safety, tolerability, and immunogenicity attack rate detectable elisa anti-hav antibodies quantitative anti-hav response ria seropositivity in ihav vaccines|administration of a booster dose given 1 or 2 months after primary immunization did not significantly improve the quantitative anti-hav response at 6 months as compared to the effect of the primary dose.(abstract truncated at 250 words) the results of a strictly controlled experiment showed that prevention of hepatitis a by the injection of immunoglobulin with hepatitis a virus (hav) antibody titer 1:10000 was 3 times as effective as that achieved with immunoglobulin containing hav antibodies in titer 1:2500. several weeks after each vaccine dose, the geometric mean titer of antibodies was significantly lower in those who received vaccine with ig but higher than in those who received ig alone. in the second and third 4-month intervals after immunization, attack rates were higher (but not significantly so) among soldiers given 2 ml than among those given 5 ml. twelve months after immunization, the cumulative attack rate for hepatitis a was significantly different for the two groups (2.78/10,000 vs. 1.30/10,000; p < .05). symptomatic infection with hepatitis a virus was confirmed in 25 contacts receiving vaccine (4.4%) and in 17 contacts receiving immune globulin (3.3%) (relative risk, 1.35; 95% confidence interval, 0.70 to 2.67). a controlled trial with pre-exposure immune serum globulin was undertaken in israel defence forces (idf) recruits, an indigenous population living in a hyperendemic area for hepatitis a. the incidence rates were zero in group a, 1.31/1000 in group b (0.61/1000 among the immunized and 1.72/1000 among the non-immunized) and 2.49/1000 in group c over the 6-month follow-up. pre-exposure isg afforded excellent protection and even at the low rate of incidence was cost-effective.|israel defence forces (idf) recruits, an indigenous population living in a hyperendemic area for hepatitis a adults altogether 23 447 recruits viral hepatitis in army recruits 75 healthy volunteers (aged 18-50 years 15 volunteers who received 25 units ihav i.m. at 0 and 24 weeks healthy volunteers; 28 received indigenous population in whom approximately 70% have antibody to hav at age 18 of 4524 contacts who underwent randomization, 1414 (31%) were susceptible to hepatitis a virus and 1090 were eligible for the per-protocol analysis
diabetes care processes generic prescribing mammography duration of hospital stay final hba1c (a1c) with feedback + reminders influenza and pneumococcal immunisation rates mean number of tests per physician proportion of elderly survivors of ami cost of tests per patient ordered health care provider behavior number of requests rates of three screening behaviors (cholesterol, blood pressure, and cervical screening fractional prescribing rates for proton-pump inhibitors adjusted prescription rates patient care processes (lab work, nursing, dietary management, ventilator management, ventilator weaning mean systolic pressure asthma steps information-giving and communication skills malaria and diarrhoea pneumococcal vaccination rates blood pressure data hba1c testing rates mean overall physical examination rating rates of foot examination and eye examination time on dialysis systolic blood pressure cost-effectiveness ratio glycemic control overall intern-documented cholesterol management objective assessment of attacks mean proportion diagnostic performance guideline adherence and resource utilization composite ami and chf indicators based on 12 ami and 6 chf process-of-care indicators practice facsimile (fax) referrals task performance hemoglobin a1c and lipid monitoring, and the achievement of intermediate clinical outcomes (hemoglobin a1c <7.0%, ldl cholesterol <100 mg/dl, and blood pressure safety or quality of diabetes care mammography, breast exam, colorectal screening, and pap testing compliance rates overall cost antibiotic prescribing sma-6s risk factors (blood pressure, cholesterol, and smoking status); prescribing of hypotensive agents, lipid lowering drugs, and antiplatelet drugs; blood pressure, serum cholesterol level, and plasma cotinine levels number of consultations involving aids prevention and the number of talks about aids initiated by the gp, and some elements of the content were registered on a chart immunization level bone mineral density (bmd) testing and osteoporosis medication prescribing vaccination rates bmd testing or osteoporosis medication prescribing ldl cholesterol test ordering hospital mortality rates for chf inappropriate transfusions number of tests per patient ordered glycemic, lipid and blood pressure control mean percentage reduction blood cholesterol levels rbc transfusions quality of cervical smears quality percentage of records containing at least one periodontal diagnostic notation quality indicators angina pectoris qis measuring falls, behavioral symptoms, little or no activity, and pressure ulcers total length of stay and icu length of stay fell influenza and pneumococcal vaccination rates quality or safety of diabetes care and worsened a1c control mean number of encounters with an inappropriate antibiotic with respect to diagnosis, doses and/ or duration of therapy acute ischemic stroke care quality preventive cardiovascular care urinary tract infection acetylsalicylic acid rates of bmd testing and osteoporosis medication prescribing rates of practice specific ppv coverage number of radiograph requests test usage and cost savings influenza vaccination ldl quality of selective case finding and quality of diagnostic procedures frequency of consultations involving aids prevention physician performance quality of care ima intervention sites glycosylated hemoglobin (hba1c) measurements patient satisfaction scores prescribing preferences communication skills minimum data set (mds physician questionnaires transfusion appropriateness rate of adherence efficacy of qcs wa-mrsa rates rates of preventive services mean blood pressure percentage of smears lacking endocervical cells hemoglobin a1c, low density lipoprotein-cholesterol and systolic blood pressure performance of clinical breast examination rates of skin cancer prevention counseling special blood chemistry mean change in mai and number of medications a1c test ordering ami care glucose control, cholesterol level, and triglyceride level rationality pneumococcal immunization number of targeted tests requested by primary-care practices tonsillitis/streptococcal pharyngitis quantity of cholesterol testing serum cholesterol and triglycerides prescription rate influenza immunization blood pressure control sma-12s systolic blood pressure (sbp) and ldl cholesterol tetanus immunization guideline adherence prescribing behaviour internal qi proportion of long-acting benzodiazepine prescriptions rates of delivery of selected preventive services malaria, diarrhoea and pneumonia acute, in-hospital, or discharge care prescription rate recordings time in total compliance scores per cent of time clinical and histologic diagnosis, and excisions of skin lesions mean total number of inappropriate tests patient care processes, patient morbidity and mortality outcomes, and resource use physician compliance baseline performance fecal occult blood testing, pneumococcal vaccination overall antibiotic prescribing cervical cytology history initial blood pressure compliance rates physician documentation and knowledge of child sexual abuse cost-effectiveness intern documentation concerning a low-fat hospital diet, cholesterol history, screening blood cholesterol level assessment effectiveness and cost-effectiveness rates of bmd testing actual performance of audits improved ordering of mammography total preventive health, diabetes, hypertension, and total disease management cholesterol screening odds ratios (ors health care quality quality of osteoporosis care quality of rural icu care response to an asthma symptom questionnaire or the seattle angina questionnaire, and levels of patient satisfaction inappropriate prescribing according to the medication appropriateness index (mai proportions of patients dialyzed with prescribed blood flow kruskal-wallis test, mann whitney test, wilcoxon test and chi-square test hemoglobin a1c testing care quality mean scores per cep dimension mammography utilization facility-specific mean urea reduction ratio (urr clinical breast examination telephone referrals low-density lipoprotein (ldl) cholesterol level, blood pressure, annual hemoglobin a(1c) testing, annual ldl screening, annual eye exam, annual foot exam, and annual renal assessment delivery of individual emergency plans risky prescribing events technical quality of data compliance with other recommendations, patient satisfaction and costs of the implementation strategy (secondary outcomes ordering of laboratory and radiologic tests overall chlamydia testing (odds ratio (or) cost of unnecessary tests delayed feedback of physician performance adjusted mortality compliance low hemoglobin levels cbcs lumbar decompressions antibiotic prescription rate and 2) the fraction of prescriptions for narrow-spectrum antibiotics prescribing preference for thiazides mean center urr emergency visits lower costs for carotid endarterectomies total cholesterol risk of falls and fractures, motor vehicle accidents and cognitive impairment continuity and medical care median weighted rates of generic prescribing counseling rates accurate classification of hazardous or harmful alcohol drinkers request numbers blood pressure screening diabetes outcomes quality circles (qcs sbp mean total number of tests ordered by physicians prescribing of lipid lowering drugs mean charge for a prescription osteoporosis medication prescribing quality of cardiac care provision of preventive care meeting patient preferences, metabolic status, and complication rates clinical data and receipt of complete blood count (cbc), creatinine testing, and cytoprotective agents (process measures proportion of episodes with antibiotics quality assurance intervention, quality of performance upper abdominal complaints individual process-of-care indicators, a hospital report card impact survey, and all-cause ami and chf mortality nsaid-related safety practices mammography rates peritoneal dialysis requests for spinal examinations total prescribing charges genital tract infection medication appropriateness costs per practice time to next visit overall compliance provider behavior and lowered hba1c levels post-intervention chlamydia testing rates unscheduled emergency visits end-stage renal disease (esrd overall glycemic control duration of pain, prior history of low back pain, and number of visits beta-blockade g1 average treatment cost guideline-consistent behavior total tests eye examination proportion with peak flow missed immunization opportunity rates and appointment failure rates cumulative ppv claims coverage rate of antibiotic prescribing for all indications, for urti and prescribing of select antibiotics for tonsillitis/streptococcal pharyngitis clinical outcomes of mortality or nosocomial events prescribing rates sustained control of hypertension time spent in target inr range postintervention immunization levels ldl testing recording of peak flow reduced emergency visits diastolic pressure quality of management of oral anticoagulation risk factors mean 30-day ami mortality rates hypertension, peptic ulcer/dyspepsia and depression ldl cholesterol values compliance rates with evidence-based recommendations pertaining to discussion of body weight control, discussion of problems with medication, blood pressure measurement, foot examination, eye examination, initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose, and scheduling a follow-up appointment cotinine levels overall attitudes of dutch and norwegian doctors rates of giop management statin prescribing moderate rates of improvement rates of influenza immunization immunization rates median prescription cost cholesterol management charges, sma-6, or complete blood cell counts (cbcs referral and completion rates venous thromboembolism total charges hypertension lumbar spine attainment of american diabetes association goals antibiotic resistance number of patients with hemoglobin a(1c red blood cell (rbc) transfusions median prescribing rates asthma education and peak flow meter usage hemoglobin a(1c) level mean total number of requested tests per 6 months per physician length of in-hospital stay, physician visits after discharge, waiting times for invasive cardiac procedures, and readmissions for cardiac complications total number of encounters with antibiotics chlamydia screening physician's median antibiotic cost and proportion of episodes of care in which a prespecified first-line antibiotic was used first diabetic population proportion of oral corticosteroid use for exacerbation treatment overall cesarean section rate adequate surgical excision of skin lesions chf quality indicators glycated hemoglobin (hba1c) levels mortality rates behavior changes number of inappropriate prescriptions practice performance total number of requests per practice acute myocardial infarction (ami) care diagnoses of hypertension quality of documentation and physician knowledge performance scores change in fraction of asthmatics treated with inhaled steroids and incidence rate of treatment with inhaled steroids post-intervention 'out-of-control' episodes hospital ventilator days a1c values vaginal birth rates|physicians who received the feedback letters did not differ from those in the control group in terms of their proportion of prescriptions compliant with the criteria, either before the feedback or after it (p > 0.05). the intensive intervention had greater improvement in the increased proportions of patients dialyzed with prescribed blood flow (p = 0.02) and documented review of prescription (p = 0.01). medication appropriateness improved in the combined intervention group but not in the single intervention group. small reductions in inappropriate transfusions were found at the second audit, but the change was significant only for the hospitals receiving the letter-only intervention. hii quality managers perceived the chf project as significantly more successful compared with lii quality managers (63% versus 13%, p < .01). for all patients the length of follow up was significantly longer in test practices (test 199 days, control 167), and a smaller percentage dropped out of active treatment in test practices (test 37.5%, control 42.1%). prescribing feedback significantly reduced overall and second-line antibiotic prescribing, but academic detailing was not significantly more effective than postal bulletin in changing antibiotic prescribing practice. both interventions tended to have more impact at lower-volume cabg sites (for interaction: p =.04 for beta-blockade; p =.02 for ima grafting). most of the inappropriateness occurred in the ordering of microbiology (50%) and special blood chemistry (40%). multifaceted interventions involving audit and feedback combined with either academic detailing or seminars appear more effective in changing prescribing practices of antibiotics than audit and feedback alone. with the exception of mds qi 27 (little or no activity), no significant differences in resident assessment measures were detected between the groups of facilities. however, the between group difference in the adjusted combined assessment score, whilst non-significant at 6 months (early: 2.48 (se 0.43) vs. delayed 2.26 (se 0.33) practices where primary care teams received an educational outreach visit demonstrated a significantly greater improvement in uptake in high-risk groups for pneumococcal but not influenza vaccine. among 45 physicians completing all modules (343 patients), intervention physicians had numerically but not significantly higher rates of bmd testing (26% vs 16%, p =.04; rate difference, 10%; 95% ci, 1%-20%) and bisphosphonate prescribing (24% vs 17%, p =.09; rate difference, 7%; 95% ci, -1% to 16%) or met a combined end point of bmd testing or osteoporosis medication prescribing (54% vs 44%, p =.07; rate difference, 10%; 95% ci, -1% to 21%) compared with control physicians. the intervention had a statistically significant impact on prescribing of lipid lowering drugs [odds ratio 1.59; 95% confidence interval (ci) 1.00 to 2.53] and acetylsalicylic acid (odds ratio 2.54; 95% ci 1.21 to 5.31). repeated measures anova demonstrated a significant increase in all three study groups throughout the time in total compliance scores (from 56%-73%), as well as scores for immunizations (from 62%-79%) and other preventive care (from 54%-71%). the aggregated mean scores for all diseases, and for malaria and diarrhoea, improved significantly. results indicated that the outreach program significantly improved many patient care processes (lab work, nursing, dietary management, ventilator management, ventilator weaning). audit and feedback together with seminars and practice guidelines reduced inappropriate prescriptions by 43% (p < 0.001). interventions had no effect on ldl cholesterol values (p = 0.64), which improved in all groups over time. implementation of an education and feedback-supported acute low back pain care guideline for primary care clinicians was associated with an increase in guideline-consistent behavior. the groups did not differ in the change in proportion of patients who received a properly timed antimicrobial prophylaxis dose (-3.8 percentage points [95% ci, -13.9 to 6.2 percentage points]) after adjustment for region, hospital size, and surgery type. over a 2-year period, overall glycemic control improved in the intervention site but did not change in other primary care sites (final a1c 7.5 vs. 8.2%, p < 0.001). the proportion of patients at intervention hospitals who said that their surgeon did not discuss options decreased significantly (p < 0.001) from 33% to 17%, but a similar decrease was observed among control hospitals. had higher adherence to guideline recommendations for hemoglobin a1c testing (61.5% vs 48.1%, p = .01) and ldl testing (75.8% vs 64.1%, p = .02). a moderately intensive outreach intervention to increase rates of breast cancer screening through the development of office systems was modestly successful in increasing indicators of office systems and in documenting mention of mammography, but had little impact on actual performance of breast cancer screening. however, a significantly larger decrease in the percentage of smears lacking endocervical cells was found in the groups receiving monthly overviews of their results with peer comparison, when compared with the groups not receiving this type of feedback (odds ratio 0.75). the tools and data-generating capabilities designed and constructed in stage i of the project were integral components of all subsequent stages of the program. secular trends were significant with improvement in both experimental and control hospitals for acute (odds ratio = 2.7, p = 0.007) and in-hospital (odds ratio = 1.5, p < 0.0001) care but not discharge care. the proportion of patients who received influenza vaccine improved from 40% to 58% in the experimental group (p<.001) vs from 40% to 46% in the comparison group (p =.02). yet 59% of all quality managers perceived the amvt project as being successful to very successful, and more efi quality managers perceived success than did wfi managers (71% versus 40%). significant reductions in total charges (9.8%), total tests (15.1%), sma-12s (20.6%), sma-6s (12.5%), and cbcs (18.5%) were observed in the intervention group, as compared with the control group. g1 and g2 subgroup with internal qi improved significantly in all criteria, and in g1 average treatment cost decreased by 60% (p < 0.01). after 24 months the trial of labor and vaginal birth rates in the audit and feedback group were no different from those in the control group, but rates were 46% and 85% higher, respectively, among physicians educated by an opinion leader. prescribing in the patient education group and the patient education and feedback group increased at a significantly lower rate than in the control group. the interaction of the 2 interventions was significant (p=0.03); the largest impact was observed with the combination of physician and patient intervention (9.7 +/- tailored feedback to the physician with directed educational materials did not seem to improve most aspects of documentation and knowledge of child sexual abuse, although notable improvement was seen during the time period studied. we studied two methods to reduce the ordering of laboratory and radiologic tests by medical residents in their first postgraduate year. centralized mailings of guideline summaries, performance feedback reports, and chart reminders had no observable impact on quality of care in this setting. nevertheless, the last investigation shows a significant (p < 0.05) difference between the two groups in favour of the experimental group: 12 process indicators versus one for catheter management protocol and seven versus one for protocol on pressure lesions. the intervention resulted in statistically significant improvement for two of the seven outcome measures: foot examination (odds ratio 1.68; 95% confidence interval 1.19-2.39) and eye examination (1.52; 1.07-2.16). postintervention immunization levels were 71.4% (95% confidence limits [cls]: 63.2%, 78.7%) for patients from the intervention group and 68.5% (95% cls: 60.8%, 75.4%) for patients from the control group. in addition, adjusted mortality was similar in both groups, as were length of in-hospital stay, physician visits after discharge, waiting times for invasive cardiac procedures, and readmissions for cardiac complications. when we controlled for diagnosis, the manual plus feedback group had the most profound decrease (42%) in laboratory use, followed by the manual group. statistically significant and sustained decreases in wa-mrsa rates were identified in all three arms (p<0.001; p=0.015; p<0.001). there was a general decline in the prescription rate recordings, but there were no significant differences between the intervention groups and the control group. there was no significant difference over the study period in either combination prescribing of benzodiazepines or in prescriptions for long-term benzodiazepine therapy. at posttest, these proportions were 3.7% and 66.7%, respectively (p < .001). the addition of feedback had no impact on gp prescribing patterns. professional standards review organization claims data were used in defining, planning, implementing and evaluating an approach to an ambulatory medical care problem utilizing educational intervention. practices participating in the intervention showed increases in the percentage of records containing at least one periodontal diagnostic notation, and those practices employing hygienists showed an increase in the percentage of records with at least one preventive notation and one treatment item.(abstract truncated at 250 words) physicians randomized to telephone follow-up showed significantly higher rates of practice specific ppv coverage in 2000 than those receiving the routine mailing only, and 27% vs. 17% (p = 0.01) of high volume physicians and 34% vs. 22% (p = .052) of african american serving physicians achieved at least a 5% increase in their cumulative ppv claims coverage. a higher case-mix index and presence of a clinic champion were associated with higher rates of referral to a state-level quitline. the intervention group of doctors showed improved performance in providing clinical information on pathology requests and in adequate surgical excision of skin lesions. concordance between groups did not differ significantly. there was no evidence, however, that feedback caused hospitals to change their practices in regard to cesarean sections. there were no consistent differences between the interventions in stimulating improvements in performance as indicated by adherence to the recommendations for asthma or angina. both univariate and multivariate analyses demonstrated no effect of the intervention in increasing the proportion of patients who received reperfusion, aspirin, beta-blockers, or angiotensin-converting enzyme inhibitors. practices that received either or both the enhanced feedback and the reminder messages were significantly less likely than the control group to request the targeted tests in total (enhanced feedback odds ratio 0.87, 95% ci 0.81-0.94; reminder messages 0.89, 0.83-0.93). the proportion of requests that were non-rational decreased more in the intervention than in the control groups (p = 0.009). as a result of quality assurance intervention, quality of performance was significantly improved in two of the tasks (p less than 0.0001, with 6.7, and 9.8 percentage points improvement), and marginally improved in one task (p = 0.06, 5.7 percentage points improvement). this increase was seen in all study groups: control hospitals, 40% to 51% (p < .001); cme hospitals, 21% to 49% (p < .0001); and cme+qa hospitals, 27% to 55% (p < .0001). there were no significant differences between the intervention and control groups in meeting patient preferences, metabolic status, and complication rates. overall compliance with the preventive care protocols was low: 10-15% in physicians receiving neither feedback nor reminders, increasing to 15-30% in those receiving reminders. immunization rates in the two intervention groups were 30% higher than in the control group; the control group immunized 50% (2,405/4,772) of its target population, while the poster and poster/postcard groups immunized 66% (1,420/2,149) and 67% (2,427/3,604), respectively. printed educational materials alone may be as effective as audit and feedback and educational outreach in improving nurses' performance and outcomes of care for people with ui. during both a baseline and subsequent intervention period, interns documented significantly more cholesterol management for inpatients with coronary artery disease (cad) than without cad. passive receipt of results improved ordering of vaccination from 40% to 59% and ordering of mammography from 8% to 16%. in practices receiving the guidelines there was a 20% reduction in requests for spinal examinations compared with control practices (p < 0.05). there was no difference in prescribing change based on type of intervention (education versus feedback). the fractional prescribing rates for proton-pump inhibitors decreased from 61.0% to 52.6% in the intervention arm and increased from 68.1% to 76.0% in the control arm (not significant due to low power). the intervention did not increase thrombolysis in the elderly (from 0.73 at baseline), but nearly two thirds of eligible nonrecipients were older than 85 years, had severe comorbidities, or presented after at least 6 hours. the increase was greater in practices receiving feedback plus reminders for only two of the five criteria "told about dependency" increasing from 52 (11.1%) to 118 (25.8%) in the feedback only group, and from 27 (10.5%) to 184 (43.0%) in the feedback plus reminders group; odds ratio (or) 1.46 (95% confidence interval (95% ci) compared to physician-feedback alone, a dual intervention combining a patient letter with physician feedback produced modest improvements in glycemic, lipid and blood pressure control individually, but substantial improvement in a combined measure of these three outcomes together. delivery of individual emergency plans increased (p = 0.008), and unscheduled emergency visits decreased (p = 0.064). prescriber feedback and management guidelines were shown to influence antibiotic prescribing for urti and choice of antibiotic for tonsillitis/streptococcal pharyngitis. for all 3 clinical topics, the decrease in mean total number of tests ordered by physicians in the intervention arm was far more substantial (on average 51 fewer tests per physician per half-year) than the decrease in mean number of tests ordered by physicians in the feedback arm (p = .005). during phase 2, 6 months later, the physicians in all three groups were exposed to 4 months of concurrent reminders. the interventions significantly improved the quality of management of oral anticoagulation by belgian gps, mainly as a result of an education and support programme. the increase in generic prescribing by physicians in the experimental group was significantly greater than for control physicians (p = 0.01). at baseline, there was no significant difference between the patients with respect to osteoporosis medication use (intervention 32% versus control 34%) or bone densitometry use (intervention 9% versus control 5%). we undertook a study to assess the impact of comparative feedback vs general reminders on practice-based referrals to a tobacco cessation quit line and estimated costs for projected quit responses. however, testing rates increased significantly among women making preventive care visits (or, pap test visit = 1.23, 95% ci, 1.01-1.51, p = 0.04; or, physical exam visit = 1.22, 95% ci 1.06-1.42, p = 0.009, intervention vs. control clinics). seminars and feedback were no more effective in modifying practice than guidelines alone, which was thus the most cost-effective option. multilevel regression analysis showed that, after correction for baseline scores, patients' evaluations of continuity and medical care were less positive after the intervention in the intervention group (4.60 v 4.77, p < 0.05 and 4.68 v 4.71, p < 0.05, respectively). results; there were no changes in the numbers of tests per thousand requested in either of the study groups for any of the tests. physicians in arm a had a significant reduction in mean total number of inappropriate tests ordered for problems allocated to arm a, whereas the reduction in inappropriate test ordered physicians in arm b for problems allocated to arm b was not statistically significant. mean percent change in performance between intervention and control physicians for cbc monitoring was 16% versus 10%; for creatinine monitoring, 0% versus 17%; and use of cytoprotective agents, -3% versus -1%. for process of care measures, decreases were seen in all groups, with no significant differences in change scores. the intervention, which is simple and could easily be applied in other settings, produced improvements significant at the p = .001 level. however, intensification increased more in the feedback alone and feedback plus reminders groups than for reminders alone and control groups (p<.001). this revealed a significant rebound in overall cost by the feedback group for both carotid endarterectomies and lumbar surgery. intervention practices implemented more of the processes than control practices overall (p = .003), for adults (p = .05), and for children (p = .04). there were no differences in performance scores between residents receiving report cards and those who had not in immunizations, counseling, total preventive health, diabetes, hypertension, and total disease management. the mean proportions of acceptable treatments of urinary tract infection before intervention in the urinary tract infection group and asthma (control) group were 12% for both groups which increased by 13% in the urinary tract infection group relative to the control group. we tested the efficacy of an educational program conducted by professional standards review organizations in reducing the inappropriate use of x-ray pelvimetry. from 1993 to 1995, screening rates doubled overall (from 24% to 50%), with no significant differences between intervention and control group sites. there was a 3% increase in statin prescribing in cvd patients at 6 months post-intervention for both randomized groups, but there was no statistical difference between the groups (beta = 0.004; 95% ci = -0.01 to 0.02). public release of hospital-specific quality indicators did not significantly improve composite process-of-care indicators for ami or chf. the weighted t-test for a and f versus no a and f (p=0.62) and cal versus no cal (p=0.76) were not statistically significant. the numbers of untreated and uncontrolled patients in each group reduced (control = 32.3%; audit = 38.3%; risk = 32.6%). patients in intervention practices had greater improvements than those in control practices for diagnoses of hypertension (improvement difference, 15.7 percentage points [95% ci, 5.2 to 26.3 percentage points]) and blood pressure control in patients with hypertension (improvement difference, 8.0 percentage points [ci, 0.0 to 16.0 percentage points]). patient satisfaction scores improved significantly in the comprehensive intervention group (by 0.06 points on a 1 to 5 scale, p = 0.02) but not in the education only group (by 0.02 points, p = 0.42); however, the improvement was not significantly greater in the comprehensive intervention group (p = 0.20). prescribing rates in the intervention and control groups for the five main drug groups, total prescribing and potential substitute prescribing and ordering before and after the interventions. compliance increases were greatest for physicians who were older, nonwhite, with a second speciality, in solo practice, not members of the ama, not residency trained, and not board certified. setting up a register and recall system improved patient assessment at 18 months' follow up but was not consistently better than audit alone in improving treatment or risk factor levels. physician interventions that included practice-level feedback about monitoring of glycemic control successfully led to improved care of diabetic medicare beneficiaries. the visits by non-physician observers resulted in a higher score on extent of use of records and on assessment on outcome and year report. preference in the group receiving both module and portrait increased by +0.115 overall attitudes of dutch and norwegian doctors also improved significantly (effect sizes 1.06 and 0.87, respectively), as did both knowledge (effect size 1.06) and attitudes (effect size 1.49) concerning exacerbation treatment in slovakia. information-giving and communication skills improved significantly in subjects receiving training and feedback on their performance, with the greatest improvements occurring before feedback was given. no intervention benefit was observed for any secondary outcome. the percentage of children who were up to date for diphtheria, tetanus, and pertussis and haemophilus influenzae type b; polio; and measles-mumps-rubella immunization in the study's bonus group improved by 25.3 percentage points (p < .01). no significant differences were observed between the study groups on any measures. at 3-month follow-up, statistically significant differences were evident in the following outcome measures: accurate classification of benzodiazepine users (z = 2.8540, p < 0.05); accurate classification of non-benzodiazepine users (z = 2.7339, p < 0.05); accurate classification of hazardous or harmful alcohol drinkers (z = 2.3079, p < 0.02); blood pressure screening (z = 3.4136, p < 0.001); and cholesterol screening (z = 6.6313, p < 0.001). performance of the procedure necessary to diagnose hypercholesterolaemia even deteriorated. no statistically significant difference was observed in the frequency of consultations involving aids prevention between the intervention group (1.2% of consultations) and the control group (1.4%). the intervention reduced the mean charge for a prescription by 6.7% (p less than 0.025), but with a long latent period and minimal impact on resident knowledge of drug charges. group 1 stabilized at approximately 80% while group 2 continued to improve from 76.6% to 84.0% (p less than 0.001). a simple program of confidential feedback and educational materials blunted cost increases, increased the use of first-line antibiotics and was highly acceptable to ontario primary care physicians. compliance rates for 12 evidence-based indicators for the management of patients with hypertension, hypercholesterolaemia, angina pectoris, or heart failure. none of the two types of feedback on prescribing of asthma drugs had a statistically significant impact on gps' prescribing patterns.|patients with ami nursing homes 124 general practices in the netherlands 2001-2002, 23 primary care clinics at group health cooperative in washington state eligible women patients aged 50 years and over were done at baseline (n = 2,887) and follow-up (n = 2,874 44 internal medicine residents using an individualized 78-item report card based on outpatient record audits young women 44 physicians, 17 midlevel providers, and approximately 200 staff members; data from the electronic medical records of 87,291 patients medicaid managed care prescribers at 24 departments at eight provincial hospitals, matched into four pairs inpatients 28 gps in ringkjbing county, denmark physicians with delivery privileges at each study hospital participated in an ontario residents aged 65 years and over for drugs selected from a minimally restrictive formulary patients in rural hospitals 700 patients per year (1999-2002) in 131 practices accordance with the uk royal college of radiologists' guidelines on lumbar spine and knee radiographs patients with hypertension, hypercholesterolaemia, angina pectoris, or heart failure patients who had been taking a benzodiazepine anxiolytic or hypnotic drug for four weeks or longer thirty-two hospitals in 4 states medicare beneficiaries who present to the hospital with venous thromboembolic disease patients' evaluations of general practice care 47 rural and small community hospitals in texas that had previously received a web-based benchmarking and case-review tool surgical patients cholesterol with inpatients 15 short-stay hospitals in central massachusetts patient mean age was 60 years, 61% were women, and 37% were black 29 internal medicine interns eligible elderly patients, beta-blockers in all eligible patients) for acute myocardial infarction (ami), and (2) decrease use of a potentially harmful therapy (prophylactic lidocaine sixty-nine practices referring patients to st george's healthcare trust patients with end-stage renal disease physicians and lifestyle modification for patients eligible patients, a multidisciplinary team of intensive care unit specialists from an academic medical center delivered an educational program with content specific to the findings and capacity of the hospital general practitioners' prescribing in australia 194 primary care physicians from 27 local primary care practice groups in 5 health care regions (5 diagnostic centers twenty mostly rural counties in north carolina one hundred fifty-two patients were eligible for monitoring 16 primary care (8 medical, 8 pediatric) group practices was conducted thirty general practices in the trent region, uk 50 randomly selected children between 3 and 35 months of age were reviewed per physician patients with cvd or diabetes at 3 and 6 months post intervention and (ii) to evaluate the intervention from a gp's perspective forty general practitioners 183 doctors taking cervical smears patients aged 40 years and older general practices in two primary care groups in leicestershire, uk general practitioners (gps twenty health centers all 356 general practitioners in the county of aarhus, denmark municipal hospital primary care clinic in a large academic medical center major urban hospitals asthma health centers of khartoum state, sudan province of quebec, canada: one with physicians and another with pharmacists 417 patients with adult-type 2 diabetes from four primary care clinics patients with "moderate" hypertension 299 gps representing 181 practices with 455,843 listed patients in the county of funen, denmark participating hospital corporations were randomized to early (january 2004) or delayed (september 2005 sixty family physicians practices employing hygienists (n = 12) and not employing dental hygienists (n = 12 twenty-nine hospitals in five states acute asthma eighty-one general practices in leicestershire, lincolnshire, northamptonshire, north derbyshire, and nottinghamshire randomly selected private general dental practices in adelaide, south australia minnesota hospitals 20 community-based family or general internal medicine practices in 14 states in community-based primary care clinics january 1987 to may 1988, consisting of pre-intervention period (jan-may 1987 elderly patients 1906 patients aged 55-75 years with established coronary heart disease patients with newly detected hypertension test practices seventy-five wards in 24 hospitals in the uk pediatric resident continuity clinic in an urban hospital-based primary care clinic malaria, diarrhoea and pneumonia--a randomized controlled trial at provincial hospitals in lao pdr patients aged 65 years and over, and patients with coronary heart disease (chd), diabetes and a history of splenectomy general practice trainees in new south wales (n = 157 older patients patients with breast cancer one hundred fifty-three participating physicians clinical records of all 16-24-year-old patients over two, four-month periods in 1999 (pre-intervention) and 2000 (post-intervention african americans with diabetes (ipcaad) 8 patients with coronary heart disease patients suffering from ischemic heart disease diabetes resource nurse case management and physician profiling in a fee-for-service setting elderly patients exposed to polypharmacy in primary care all physicians who performed evaluations for sexual abuse during 1991 to 1992 22 practices in a fee-for-service metropolitan network with 92 primary care physicians caring for 1891 medicare patients 65 years with diabetes mellitus primary care practices of a mixed group- and network-model university-affiliated hmo eligible patients receiving each study drug patients with chd asthma patients nineteen general practitioners primary-care radiology referrals twenty-six midwives and nine obstetricians completed the study according to the protocol 59 general practices in grampian, scotland to participate twenty-six primary care physician groups, including 174 primary care physicians women who reported that surgeons did not discuss options prior to surgery for early stage breast cancer patients cared for by residents in the intervention group participants were 251 randomly selected primary care physicians from southern ontario who consented to participate (135 in the feedback group and 116 in the control group patients within primary care primary care physicians in a single southern state treating medicare beneficiaries with diabetes mellitus ten primary health centres were randomly selected from the centres in the murcia's region acute uncomplicated cystitis in adult women elderly (>65 years) patients exposed to polypharmacy fourteen physician groups with 120 primary care physician and associate practitioners from 2 group model hmo practices ambulatory clinic physicians and staff of 62 randomly selected family medicine and general internal medicine practices, primarily fee-for-service, half group practices and half solo practitioners patients with ami who were admitted to 76 acute care hospitals in quebec that treated at least 30 ami patients per year between april 1, 1999, and march 31, 2003 tonsillitis/streptococcal pharyngitis inpatients with cad general practices in the netherlands in 1993 and 1994 six radiology departments and 244 general practices that they served one hundred and thirty-three gps completed the project patients with "moderate" hypertension of a baseline diastolic pressure of greater than 104 mm quarterly chart audits of a defined sample (n = 11,716) of women patients 50 years of age or older of the 277 gps invited to participate; 41 (14.8%) volunteered cardiovascular care medicare inpatients with venous thrombosis participants were from general practices in copenhagen and the counties of funen and vejle, denmark december 1996, with follow-up through 1998 199 general practitioners in 32 groups physicians' ordering behavior and to learn whether doctors who actually performed audits behaved differently from physicians who passively received audit results patients taking long term benzodiazepine drugs medical records of up to 120 patients at each hospital (n=1117 patients admitted between 4 and 10 months after randomization thirty-seven community hospitals in minnesota frail elderly patients general practitioners patients 75 years or older 27 anesthesiology residents 20 experimental hospitals who influenced peers through small and large group discussions, informal consultations, and revisions of protocols and clinical pathways 345 internal medicine residents 30 345 patients aged 65-79 years hospitals were randomly assigned to receive rapid (immediate; n = 38 hospitals and 2533 patients) or delayed (14 months; n = 38 hospitals and 3142 patients general practitioners (gps) for patients with diabetes high-risk patients hypertension in general practice physicians who prescribed long-term glucocorticoid therapy to at least 3 patients nursing facilities (n = 113 101 physicians initially randomized, 85 remained eligible (38 internists, 36 family physicians, 11 rheumatologists) postintervention three hundred eight clinicians participated (171 family medicine, 88 internal medicine, 49 obstetrics-gynecology) from 87 primary care practices in michigan inpatients with coronary artery disease (cad) than without cad people with ui sixteen ambulatory care practices 3509 women 18 general practices in leicestershire general practitioners (gps) in the county of funen, denmark (292 gps representing 178 practices four hundred ninety-seven charts were retrospectively audited at baseline and 284 charts in follow-up 574 patients three hundred fifty-nine academic and nonacademic hospitals (treating 267 917 patients using cabg surgery) participating in the society of thoracic surgeons national cardiac database between january 2000 and july 2002 1410 consultations with type 2 diabetic patients at baseline and 1449 consultations after the intervention period thirty-two postgraduate level 2 and postgraduate level 3 pediatric residents patients (4,138) with type 2 diabetes who were seen in continuity clinics by 345 internal medicine residents women making preventive care visits thirty-two dutch gps in 20 general practices, 3950 patient records thirty group-model (at two academic and four nonacademic sites) and 33 network-model (all in full-time private practice patients with chd in a network-model managed-care setting seventy-eight categorical internal medicine residents caring for 483 diabetic patients participated volunteer gp practices (n = 98 five of the 10 physician participants internal medicine inpatients (n = 459 96 general practitioners one group of family doctors (n = 39) received resident continuity clinic during the 2003-2004 academic year for elderly patients patients with uncontrolled hypertension asthma in four european countries sixty-three dental practices across scotland thirteen practices with 45 physicians twenty-eight hospitals in minnesota upper respiratory infection six health care centres and three continuing medical education groups in stockholm anesthesia primary care all 26 hospital gynaecology units in scotland providing induced abortion care acute low back pain hypertension in primary care coronary heart disease in primary care 256 patients participated in the survey, of whom 185 (72.3%) responded to the follow-up 1 year later 58 general practitioners in 17 practices patients with diabetes mellitus of the 742 in the first samples, 543 (73.2%) were women, the mean (sd) age was 68.7 (14.9) years, and they had been taking a benzodiazepine for 10.1 (6.7) years all patients with ami admitted to study hospitals over 10 months before (1992-1993, n=2409) or after (1995-1996, n=2938) the intervention health professionals general practice academic general medicine clinic general practitioners (gps) in cardiovascular care medical residents 44 acute care hospitals, each of which randomly sampled approximately 100 selected surgical cases (cardiac, hip or knee replacement, and hysterectomy) at both the baseline and remeasurement phases medical residents of a large county hospital all patients aged 65 years and over who were seen in participating physicians' practices within the preceding two years primary care physicians authors' residents' clinic in 1985 persons with coronary heart disease (chd 194 community nurses in 157 family practices and 1078 patients with diagnosis of urinary incontinence (ui) for nurses compliance with evidence-linked review criteria for the assessment and management of ui and impact on psychologic and social well-being and symptoms of a total population of 125,846 registered with the 18 practices, 2409 (1.9%) had been taking a benzodiazepine for four weeks or longer private practice general practice in rural australia elderly patients in primary care community-acquired pneumonia and congestive heart failure of 21 rheumatologists fifty-two scottish general practices nineteen hospitals were randomized with a total of 1,211 acute ischemic stroke cases preintervention and 1,094 cases postintervention fifteen practices seventy community physicians and 2978 fee-for-service medicare patients with diabetes mellitus who were part of the ambulatory care quality improvement project in alabama asthma patients in the netherlands, norway, sweden, and slovakia 86 hospital corporations in ontario, canada, with patients admitted for acute myocardial infarction (ami) or congestive heart failure (chf 90 general practitioners (gps) in 68 practices; follow up after one year comprised 81 gps in 62 practices acute myocardial infarction women 50 years of age and older in a medicaid health maintenance organization (hmo volunteer general practitioner practices (n = 98 seventy-one physicians and 60 pharmacists participated in the study pediatric upper respiratory infections (uris a total of 43 778 radiological requests were made during the two years 1994-1996 fifty-four pharmacies primary care physicians participated in the study esrd patients sexually active women ages 14-25 asymptomatic women patients with cardiovascular disease (cvd) or diabetes patients receiving long-term glucocorticoid therapy older patients with hypertension 23 consenting practices medical residents in their first postgraduate year patients' evaluations of care to general practitioners pediatric out-patient department ramathibodi hospital a total of 1,800 patient encounters, 30 from each health center nurses with advanced training-diabetes resource nurses (drns)-can improve care for people with diabetes in capitated payment settings 18 hospitals nested within the cooperative cardiovascular project obstetricians' and midwives' explanations to patients of a routine prenatal screening test adults with asthma or for care of people with angina patients undergoing coronary artery bypass graft surgery ten major urban hospitals in sydney, new south wales, in 1998 and 1999 primary care physician groups in 5 regions in the netherlands with diagnostic centers recruited from may to september 1998 african americans with diabetes (ipcaad) 7 study subjects included 123 primary care physicians and 3,703 eligible adult diabetic patients with elevated a1c or ldl cholesterol 216 physicians and 124,092 episodes of care patients with angina in practices that had received criteria or criteria plus feedback reported better symptom control participating physicians had their antibiotic prescribing assessed for the period of july 1, 1996, to november 30, 1997, with an intervention in june 1997 diabetes care 47 hospitals thirteen groups of primary care physicians underwent the strategy for 3 clinical problems (arm a; cardiovascular topics, upper and lower abdominal complaints), while 13 other groups underwent the strategy for 3 other clinical problems (arm b; chronic obstructive pulmonary disease and asthma, general complaints, degenerative joint complaints 168 physicians agreed to be in the intervention group and 206 in the control group 41 primary care physicians who cared for 1,810 randomly selected patients aged 65 to 75 years old at kaiser permanente woodland hills, a group-model health maintenance organization in southern california primary care physicians in small, community practices primary care physicians managing pediatric respiratory infections in medicaid impacted and unerupted third molars in primary dental care 20 health centres randomly assigned to four different 20 general practices medicare inpatients with congestive heart failure 373 patients with ra taking oral glucocorticoids whose records were assessed patients with rheumatoid arthritis (ra) taking rural hospitals 1624 primary care physicians who wrote at least 10 prescriptions for the target drugs in a 2-month period and randomly assigned these physicians to the intervention group or the control group asthma care 4394 patients receiving a first-line antihypertensive 19 primary care clinics in oregon 20 rural iowa hospitals as the unit of analysis patients comprised ami medicare patients admitted before (n = 929, 1994 and 1995) and after intervention (n = 438, 1996 124 practices and 185 gps in the netherlands 76 physicians in 16 community hospitals evaluated audit and feedback and local opinion leader education as methods of encouraging compliance with a guideline for the management of women with a previous cesarean section suspicious skin lesions sixty-one practices one hundred forty-seven physicians were randomized to control (n = 75) and intervention (n = 72) groups, 122 (83%) remained at follow-up, and 87 of the 122 (71%) had done evaluations for child sexual abuse elderly patients exposed to polypharmacy hospitals long-term glucocorticoid users 85 primary-care practices (370 family practitioners) that request all laboratory tests from one regional centre new york primary care physicians with high volume (n = 732) or african-american serving (n = 329) practices 2440 full time recognised general practitioners practising in non-urban areas rural and small community texas hospitals 3158 patients in acute-care hospitals with multiple risk factors for venous thromboembolism eight primary care practices (32 physicians 200 family physicians in british columbia, canada patients with hypertension
mean time to defervescence serum creatinine level median gentamicin treatment durations eradication rates no relapse circulatory compromise and renal cortical scintigraphic defects urinary tract infection (acute pyelonephritis or cystitis reduction in inflammatory indices, and percentage with sterile urine recurrence of urinary infection health care expenditure percentage of patients with sequelae trough level drug-related clinical adverse events bacteremia rates of cures and recurrence history of recurrences prevalence of scarring peak serum levels urine culture safety and efficacy recurrence rate of first lower uti severity of the urinary tract infection (risk of renal scars symptomatic reinfections clinical efficacy radiological abnormality frequency of side effects nephro- or ototoxicity development of renal scarring mean trough concentrations bacteriologic eradication therapeutic effect and usefulness evaluated by physicians in charge therapeutic effectiveness rates successful eradication trough serum levels persistent infection, and 6 infection relapses satisfactory clinical response time-courses of improvement of clinical signs and symptoms clinical and bacteriological response rates efficacy and safety ototoxicity recurrence rate overall cure rate duration of hospitalization bacteriological efficacy (sterilization of the urine), and biological efficacy peak serum netilmicin concentrations white blood cell count and erythrocyte sedimentation rate rate of renal scarring rate of recurrent infection late dmsa rates of efficacy by severity, presence or absence of underlying and/or complication diseases, daily dose and causative microorganisms bacteriologic efficacy urinary tract infections mean costs got and 1 with increased gpt nephrotoxicity resolution of vomiting, fever, general appearance, abdominal tenderness, and hydration state (p>.05 rate of reinfection mean peak gentamicin concentrations total or partial persistence of renal abnormalities urine sterilization rate, degree of clinical improvement, or subsequent hospital admission rate renal scarring bacteriologic failures mean extent of scarring efficacy and tolerance gpt serious adverse effects blood cell count, and erythrocyte sedimentation rate (p>.05 suppression upon rectal upper urinary tract infection|(time to normalization of the indices of the acute inflammatory response) were identical for both groups regardless of the duration of iv antibiotic treatment (seven days for amoxycillin/clavulanate; 14 days for cefotaxime). in group b, the percentage of patients with sequelae was significantly higher (p<0.01) when the delay was more than 1 week. during follow up, 15 children had recurrence of urinary infection with no significant difference between the two treatment groups. eradication rates for causative microorganisms were 65.9% for the suppository and 62.5% for the oral form. rates of cures and recurrence in the compared groups were not statistically different (p greater than 0.05). cefepime and ceftazidime are equally safe and efficacious treatment for pyelonephritis in pediatric patients. seven treatment failures, 1 persistent infection, and 6 infection relapses were identified, all of which were in the 2-week treatment group. intention to treat analysis showed no significant differences between oral (n=244) and parenteral (n=258) treatment, both in the primary outcome (scarring scintigraphy at 12 months 27/197 (13.7%) v 36/203 (17.7%), difference in risk -4%, 95% confidence interval -11.1% to 3.1%) and secondary outcomes (time to defervescence 36.9 hours (sd 19.7) v 34.3 hours (sd 20), mean difference 2.6 (-0.9 to 6.0); white cell count 9.8x10(9)/l (sd 3.5) v 9.5x10(9)/l (sd 3.1), mean difference 0.3 (-0.3 to 0.9); percentage with sterile urine 185/186 v 203/204, risk difference -0.05% (-1.5% to 1.4%)). isepamicin was shown to be as effective and safe as amikacin in the treatment of children with pyelonephritis and might prove an advantageous alternative in areas with high incidence of resistance to other aminoglycosides. no differences in the overall treatment outcome could be observed between the treatment regimens used and, at the end of treatment, all pathogens were eradicated with neither relapse, nor persistence of the isolated pathogen, nor reinfection occurring. at the 48-hour follow-up visit, there were no differences between the 2 treatment groups in resolution of vomiting, fever, general appearance, abdominal tenderness, and hydration state (p>.05). the incidence of renal scarring was 66.6 per cent and 61.1 per cent in the study group and the control group respectively. no nephro- or ototoxicity was identified. single dose therapy had significantly less suppression upon rectal (p less than 0.001) and periurethral (p less than 0.02) flora. the overall cure rate was significantly better in the ceftriaxone group than the cefotaxime group in terms of recurrence and reinfections (p < 0.05). the recurrence rate of first lower uti after 10-day therapy was significantly lower than that after 42-day treatment. mean costs were at least twofold higher for children treated intravenously ($3577 vs $1473) compared with those treated orally. at 4 weeks posttreatment, no relapse was detected and the rate of reinfection was essentially identical in the two treatment groups.|sixty-nine children were enrolled, 34 in the im + po group and 35 in the po group 220 patients aged 3 months to 16 years with positive urine culture and acute renal lesions on initial dmsa scintigraphy children aged 1 month to 12 years acute pyelonephritis 80 patients with aln were enrolled children with urinary tract infections thirty-seven patients with a median age of 5 years with symptomatic lower or upper urinary tract infection, documented by a clean-catch midstream urine culture and sediment examination patients with positive ct findings acute lobar nephronia children with fever and urinary tract infection childhood upper urinary tract infections pediatric patients urinary tract infection with tissue penetration patients who were suspected of having an upper urinary tract infection underwent a systematic scheme of ultrasonographic and computed tomographic (ct) evaluation for aln diagnosis patients with complicated and uncomplicated upper uti two hundred ninety-nine pediatric patients (ages 1 month to 12 years) with pyelonephritis (300 episodes children older than one year gram-negative pyelonephritis in children children with a first episode of acute pyelonephritis 502 children aged 1 month to <7 years with clinical pyelonephritis febrile children aged 6 months to 12 years with a presumptive urinary tract infection based on history, physical examination, and urinalysis findings pediatric patients who had aln with a 3- vs 2-week intravenous plus oral antimicrobial-therapy regimen 28 paediatric units in north east italy 18 patients had no recurrences hospitalized children ages 1 month to 12 years with uti pyelonephritis 179 children enrolled (90 od, 89 td 278 children with confirmed acute pyelonephritis on scintigraphy at study entry urinary infections in children acute pyelonephritis often leaves children with permanent renal scarring young febrile children sixty-nine children with urinary tract infections children patients 12 years of age and older with uncomplicated and complicated urinary tract infections including pyelonephritis, but not in younger patients 37 children with acute pyelonephritis, whose ages ranged from 2 to 14 years 36 99mtc-dimercaptosuccinic acid (dmsa) scan proved pyelonephritis patients childhood pyelonephritis children with acute pyelonephritis 235 infants and children pediatric patients with aln pyelonephritis in children patients with upper urinary tract infections (utis 300 pediatric cases eighteen patients 306 children 1 to 24 months old with fever and urinary tract infection, in terms of short-term clinical outcomes (sterilization of the urine and defervescence) and long-term morbidity (incidence of reinfection and incidence and extent of renal scarring documented at 6 months by 99mtc-dimercaptosuccinic acid renal scans young, febrile children with urinary tract infection children with pyelonephritis urinary tract infections febrile children with urinary tract infections acute pyelonephritis in children pediatric patients younger than 12 years of age 92 children included in the study, 87 were followed for at least 6 months (43 in group a and 44 in group b) and were eligible for analysis acute lobar nephronia (aln groups were 7.5 (<5 years old), 6.0 (5 to 10 years old) and 4.5 (>10 years old tertiary care children's hospital emergency department children with severe urinary tract infections (uti 800 pediatric patients sixteen children were enrolled in the study; ten received subjects were in-patients with bacterial urinary tract infections, ranging in age 4 months to 11 years 4 months
intraventricular haemorrhage rate clinical characteristics ventilator rate of 6/minute severe apnea, or predefined clinical deterioration, and extubation success birth weight and duration of intubation overall, nasal cpap oxygen dependency stable condition, fraction of inspired oxygen (fio2) of < or = 35%, peak inspiratory pressure (pip oxygen requirement greater successfully extubated to ncpap apnoeas and respiratory acidosis requiring rescue nasal cpap total number of days of assisted ventilation or the duration of inpatient stay respiratory acidosis severe apnea and/or respiratory failure failures alveolar-arterial oxygen gradient fio2, pao2, and respiratory rates failure rate of extubation likelihood of extubation failure total number of days of ventilation rates of successful extubation mean respiratory rate extubation failure failure rates individual successful extubation rate of post-extubation overall success rate of early extubation failure rate paco2 values respiratory distress syndrome postextubation nasal continuous positive airway pressure oxygen requirements pulmonary status, fraction of inspired oxygen (fio2|there were also no differences in fio2, pao2, and respiratory rates before and after discontinuation of imv among the three groups. groups were comparable in birth weight and duration of intubation. overall, nasal cpap significantly reduced the need for increased respiratory support (relative risk, 0.57, 95% ci 0.43-0.73), but not for re-intubation (relative risk 0.89, 95% ci 0.68-1.17). there was no significant difference between groups with respect to total number of days of ventilation (headbox median, 4; range, 1-24; cpap median, 2; range, 1-20). there was no significant difference in the failure rate of extubation among infants randomised to receive nasal cpap or headbox oxygen in either the acute or chronic respiratory distress groups. there were no differences in baseline characteristics between the two groups. there was no significant difference between the groups in the total number of days of assisted ventilation or the duration of inpatient stay. there were no significant differences in clinical characteristics between the two groups. after stratification by birth weight, there were no significant differences in the rates of successful extubation among the treatment groups.|very low birthweight infants infants with acute rather than chronic respiratory distress 18 neonates recovering from respiratory distress syndrome 87 preterm infants (mean very low birth weight (vlbw) infants 58 neonates comparing nasal continuous positive airway pressure (ncpap) vs oxyhood following extubation of neonates weighing less than 1 kg preterm infants very low birth weight infants very low birth weight neonates fifteen nasal cpap infants and 25 headbox infants ninety-seven babies were entered into the study (48 cpap and 49 headbox oxygen neonatal intensive care unit of the royal women's hospital, melbourne, of infants with birthweights between 600 and 1250 g, ventilated via an endotracheal tube for more than 12 hours, requiring less than 50% oxygen, a ventilator rate < or = 20/minute, considered by the clinical management team to be ready for extubation infants at less than 32 weeks of gestation who had received 150 infants (median gestational age 30 weeks, range 24-34 weeks infants weighing 600 premature infants less than 28 days of age 23 neonates who failed oxyhood, 21 were then given a trial of 50 babies eligible infants included patients weighing 600 to 1500 gm at birth who required tracheal intubation within 48 hours of birth and who met specific predetermined criteria for extubation by day 14 of life 188 g; gestational age: 28.8 +/- 2.2 weeks) who were in the process of being weaned from intermittent mandatory ventilation (imv all infants weighed less than 1500 g, had a gestational age of less than 34 weeks, and had been weaning from mechanical ventilation within seven days of life the reintubation criteria included fio2 > or = 70% to maintain arterial oxygen tension (pao2) of > or = 50 mm hg (6.67 kpa) or pulse oximetry between 90-96% and ph of < 7.25, and arterial carbon dioxide tension (paco2) of > 60 mm hg (8.00 kpa) and severe or recurring apnoea acute and chronic respiratory distress sixty infants (median gestational age 29 weeks) with acute and 60 infants (median gestational age 25 weeks) with chronic respiratory distress
transcutaneous po2 transcutaneous oxygen tension (tcpo2) and heart rate odds ratios mean serum concentration bradycardia proportion of infants with recurrent hypoxaemic episodes mean proportion of infants with more than six hypoxaemic episodes death or disability gestational age, birth weight, delivery mode, sex distribution, and apgar scores neurodevelopmental benefits hypoxaemic episodes|our results suggest that prophylactic caffeine has little if any effect on the risk of developing hypoxaemic episodes and bradycardia in small preterm infants and the supposed 50% reduction which was considered clinically important at the start of the trial can be rejected with confidence. the size and direction of the caffeine effect on death or disability differed depending on ppv at randomization (p = .03).|fifty spontaneously breathing, preterm infants 48 h old, of 32 weeks' gestation or less premature infants copyright 2010 three subgroups of 2006 participants in the caffeine for apnea of prematurity (cap) trial
frequency of pregnancy-induced hypertension, preeclampsia and preterm birth systolic and diastolic blood pressure serum ionized calcium levels preterm birth diastolic and systolic blood pressure urinary excretion of calcium and creatinine preeclampsia, pregnancy-associated hypertension, or adverse perinatal outcomes low birth weight pregnancy induced hypertension hypertensive disorders eclampsia pregnancy-induced hypertension incidence of preeclampsia diagnosis of preeclampsia incidence of preterm delivery hypertensive disorders of pregnancy (gestational hypertension and preeclampsia duration of pregnancy compliance average daily calcium intake risk of hypertension and preeclampsia neonatal mortality rate reduction of pre-eclampsia risk of pregnancy-induced hypertension hypertensive disorders of pregnancy frequency of pregnancy-induced hypertension mean systolic and diastolic bp value rates of hypertensive disorders of pregnancy dietary calcium intake occurrence of pre-eclamsia blood pressure (bp incidence of gestational hypertension mean duration of calcium supplementation mean systolic and diastolic blood pressures numbers of preterm deliveries, small-for-gestational-age births, or fetal and neonatal deaths risk of preeclampsia incidence or severity of preeclampsia or delay its onset early preterm delivery rate of pregnancy induced hypertension low ratios of urinary calcium to urinary creatinine incidence of pregnancy induced hypertension hypertension initial blood pressure (bp systolic bp systolic/diastolic blood pressure preeclampsia and preterm delivery; secondary outcomes focused on severe morbidity and maternal and neonatal mortality rates risk of preterm birth risk of both gestational hypertension and preeclampsia blood pressure and urinary protein excretion urinary tract infection, and chlamydial infection spontaneous labor and preterm delivery blood pressure calcium intake and bp reduction severity, maternal morbidity, and neonatal mortality preeclampsia severe preeclamptic complications index incidence of pregnancy-induced hypertension prevalence of pregnancy-associated hypertension without preeclampsia risk of preeclampsia and preterm birth severe maternal morbidity and mortality index pre-eclampsia severe gestational hypertension|the calcium group had a lower incidence of preterm delivery (less than 37 weeks; 7.4% vs 21.1%; p = 0.007); spontaneous labor and preterm delivery (6.4% vs 17.9%; p = 0.01); and low birth weight (9.6% vs 21.1%; p = 0.03). the rate of pregnancy induced hypertension was lower in the calcium group than in the placebo group 8.24%; vs 29.03%; (rr = 0.28; 95% ci 0.14-0.59). calcium supplementation was associated with a significantly decreased risk of pregnancy-induced hypertension, with 4.1% developing pregnancy-induced hypertension in the treatment group versus 27.9% in the placebo group. the rates of hypertensive disorders of pregnancy were lower in the calcium group than in the placebo group (9.8 percent vs. 14.8 percent; odds ratio, 0.63; 95 percent confidence interval, 0.44 to 0.90). calcium did not reduce the numbers of preterm deliveries, small-for-gestational-age births, or fetal and neonatal deaths; nor did it increase urolithiasis during pregnancy. the incidence of pregnancy-induced hypertension was 11.1% in the placebo group and 4.0% in the calcium group, a nonsignificant difference. no major effect on pregnancy induced hypertension was seen (66% in placebo and 76% in calcium group developed hypertension) but the onset of hypertension was delayed 3 weeks in the calcium group. the neonatal mortality rate was lower (risk ratio, 0.70; 95% ci, 0.56-0.88) in the calcium group. calcium supplementation was associated with a significantly decreased risk of preeclampsia (risk reduction 12.35%; p < .001), with 3.2% (n = 4) developing preeclampsia in the treatment group versus 15.5% (n = 21) in the placebo group. treatment with calcium reduced the risk of preeclampsia (relative risk 0.44 [95% ci, 0.21-0.90], p = 0.02) and the risk of preterm birth (relative risk 0.44 [95% ci, 0.21-0.90], p = 0.02).|pregnant women with low calcium intake reduces preeclampsia and preterm delivery two hundred sixty teenaged pregnant girls attending the hospital gneco-obsttrico isidro ayora in quito, ecuador, were included 125 girls to receive 2000 mg of 1194 nulliparous women who were in the 20th week of gestation at the beginning of the study pregnant and nonpregnant women low calcium intake pregnant women nulliparous normotensive women from populations with dietary calcium < 600 mg/d iranian women at high risk of developing pre-eclampsia the inclusion criteria were positive rollover test, having at least one risk factor for pre-eclampsia, between 28 and 32 weeks of pregnancy, and blood pressure less than 140/90 (mm hg fifty-two healthy pregnant women nulliparous women for the prevention of pregnancy-induced hypertension, preeclampsia and preterm birth healthy nulliparous women 5 maternity hospitals in australia nulliparous women 201 healthy nulliparous women 8325 women who were assigned randomly ecuadorian pregnant teenagers hypertensive disorders of pregnancy iranian women at high risk of pre-eclampsia. thirty pregnant women at high risk of developing pre-eclampsia 4589 healthy nulliparous women who were 13 to 21 weeks pregnant to 106 young healthy nulliparous women, residing in quito, ecuador all participants were 17 years of age or less and clinically healthy pregnant teenagers during pregnancy 456 nulliparas with a singleton pregnancy pregnant women who receive women who were recruited before gestational week 20 received selection criteria were age less than 17.5 years, nulliparity, first prenatal visit before 20 weeks' gestation, and residency in quito (2800-m altitude
success rate|the effect of zbd is superior to that of progesterone in treating women of early threatened abortion with dark area surrounding pregnancy sac.|women of early threatened abortion with dark area surrounding pregnancy sac 105 patients with early threatened abortion, in whom vaginal bleeding was shown already treating women of early threatened abortion with dark area surrounding pregnancy sac
peak caffeine concentration bronchoconstriction serum caffeine levels exhaled nitric oxide (feno) measurements exercise-induced bronchoconstriction caffeine consumption increases or decreases feno forced expiratory flow peak theophylline level airway reactivity reduction in bronchoconstriction pulmonary function feno measurements baseline fev1 and prevented exercise-induced bronchoconstriction serum levels of caffeine and theophylline, forced expired volume and flow, specific airway conductance (gaw/vl), vital signs, and reported symptoms histamine responsiveness tolerated exhaled nitric oxide measurements average peak serum concentration feno serum caffeine concentrations bronchoconstrictor response gaw/vl|no significant changes in feno occurred after caffeine compared with the control. caffeine significantly improved baseline fev1 and prevented exercise-induced bronchoconstriction only at a dose of 7 mg/kg. there was also a significant difference for percent change in fef25-75 with peak occurring at 4 h. percent change in vmax25 was significantly different at 3.0 h only. these caffeine levels did not produce any appreciable attenuation of the bronchoconstrictor response to carbachol inhalations. caffeine (10 mg/kg) significantly reduced bronchoconstriction compared to placebo (p = 0.02). comparable peak increases in the forced expiratory volume in one second (fev1), the forced expiratory flow during the middle half of the forced vital capacity (fef25-75%), and gaw/vl occurred at 120 minutes following aminophylline and the highest dose of caffeine, indicating that caffeine is an effective bronchodilator but is only 40 percent as active as an equivalent molar dose of theophylline. the pc20 for histamine bronchoprovocation after caffeine ingestion was 2.65 (95% confidence limits 0.99, 7.10)|8 patients: 4 men and 4 women with previously documented airway reactivity asthma adults with asthma ten patients with bronchial asthma subjects with asthma adult asthmatics patients with asthma 20 patients with asthma (10 steroid-naive and 10 steroid-treated) received a eleven nonsmoking men, aged 18 to 42 years, with normal baseline spirometry and evidence of exercise-induced bronchospasm asthmatic subjects nine asthmatic adults who ingested decaffeinated coffee containing varying amounts of added caffeine (mean of 0.2,2.5,5.6, and 7.2 mg/kg of body weight) on different days 7 patients with asymptomatic asthma 10 subjects with mild asthma (prechallenge fev1 84% of predicted value asthmatic children
mean total scag score benton visual retention test, p = 0.002) and attention and concentration (letter cancellation test mini-mental state and the scag score efficacy and safety rezek score global improvement (cgi item 2 p300 latency delta and theta, increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum clinical global impression, 3 subtests of the weschsler adult intelligence scale and blessed a scale for activities of daily living, and all endpoints in 2-month intervals tolerance of nicergoline sandoz clinical assessment geriatric scale (scag) and mini-mental state examination (mmse) scores wais-r digit symbol subtest therapeutic efficacy and safety nine neuropsychological tests exploring memory, concentration, verbal and motor performances mmse scores (itt and vc memory function (avlt short term recall adverse events delayed recall of the auditory verbal learning test (avlt|eeg mapping demonstrated in nic-treated sdat and mid patients a significant decrease in delta and theta, increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum as compared with pretreatment, while opposite changes occurred in plac-treated sdat and mid patients. the safety of nicergoline, as judged by hemodynamic changes and drug-related adverse reactions, was quite satisfactory. nicergoline was well tolerated and a similar number of adverse events were observed in both the placebo and the nicergoline group. significant differences were observed for memory function (avlt short term recall, p = 0.026; avlt delayed recall, p = 0.013; and, benton visual retention test, p = 0.002) and attention and concentration (letter cancellation test, p = 0.043; and, wais-r digit symbol subtest, p = 0.006).|male and female patients, 55-85 years of age with a clinical diagnosis of mild to moderate multi-infarct dementia according to dsm-iii to evaluate the 315 patients suffering from mild to moderate dementia mild to moderate dementia 252 patients were screened, 136 patients entered the double-blind phase and were evaluated as intent-to-treat (itt) patients senile dementia of alzheimer type and multi-infarct dementia fifty-six were subdiagnosed as senile dementia of the alzheimer type (sdat), 56 as multiinfarct dementia (mid), based on computed tomography and hachinski scores (< or = 49 sdat, > or = 7 mid patients with multi-infarct dementia 72 non-demented and non-depressive elderly hypertensive patients with evidence of leukoaraiosis on cerebral computed tomography scan (rezek score: > 16 elderly hypertensive patients with leukoaraiosis 112 patients with mild to moderate dementia, diagnosed according to dsm iii-r criteria (mms 13-25), living in pensioners' homes, were included fifteen patients were excluded from the efficacy analyses of valid cases (vc) due to protocol violations or because they dropped out of the study prematurely
survival rates response survival curves 1-month mortality rates complications of cirrhosis and worsening of the performance status test 1-year survival rate median survival times probability of disease progression baseline performance status maintenance adverse drug reactions survival progression of hepatocellular carcinoma median survival survival outcome baseline performance status, and tumor stage tolerated cumulative survival complete remission risk of death tolerated and no marked side effects|this difference was not statistically significant nor was the difference in survival when compared by life-table analysis. complications of cirrhosis and worsening of the performance status test occurred less in the treated patients than in the controls, but not significantly so. the survival of patients treated with tamoxifen improved significantly compared to the controls (logrank-test, p = 0.04). the 1-year survival rate was similar in both groups (30% in group 1 vs 37.8% in group 2; p = 0.31). data were further analysed separately for advanced patients and for those eligible to potentially curative locoregional treatments: relative hazard of death for patients receiving tamoxifen was equal to 0.98 tamoxifen has no efficacy in the treatment of patients with advanced hcc and response to treatment was not affected by the expression of hormone receptors. tamoxifen had no antitumoral effect with no differences in the survival between groups (1- and 2-year actuarial rate: group a, 51% and 27%; and group b, 43% and 29%; p = 0.75), even when stratifying patients according to baseline status. three-month survival rates for the p, tmx60, and tmx120 groups were 44%, 41%, and 35%, respectively, with a statistically significant trend difference in survival across the 3 treatment regimens (p =.011).|patients with cirrhosis and advanced hepatocellular carcinoma patients with hepatocellular carcinoma (hcc 477 patients patients with advanced hcc one hundred twenty patients with this neoplasm who were not suitable for surgery, ethanol injection, or transarterial embolization were included in a patients with inoperable hcc patients with inoperable hcc with respect to survival and quality of life (qol patients with this neoplasm twenty-two patients were matched and coupled for sex, age, child hepatocellular carcinoma one hundred nineteen patients with advanced and otherwise untreatable hcc 496 patients were randomised by 30 institutions from january 1995 to january 1997 329 patients from 10 centers in 9 countries in the asia-pacific region enrolled patients with advanced hepatocellular carcinoma (hcc 59 patients, half of whom received 480 patients 120 patients hepatocellular carcinoma (hcc patients with any stage hcc were eligible, irrespective of locoregional treatment 66 patients advanced hepatocellular carcinoma with inoperable hepatocellular carcinoma thirty-six consecutive patients with advanced hepatocellular carcinoma and chronic liver disease patients with advanced hepatocellular carcinoma patients with cirrhosis and advanced inoperable hepatocellular carcinoma patients with advanced hepatocellular carcinoma, we included 80 patients with cirrhosis and advanced hepatocellular carcinoma patients with terminal diseases were excluded
nasogastric decompression time to first passage of flatus, the time to first passage of stool, the time elapsed postoperative stay, and postoperative complications such as anastomotic leakage, acute dilation of stomach, wound infection and dehiscense, fever, pulmonary infection and pharyngolaryngitis morbidity and delayed return of gastrointestinal function rate of abdominal distention, nausea, and vomiting length of the first passage of gas by anus and defecation gastrointestinal decompression first passage of stool injury severity score, morbidity, and lab values median and average days to the first passage of flatus morbidity and mortality and hospital stay risk of pulmonary complications feasibility, safety, and tolerance subjective complaints, eg, ear pain, painful swallowing, and nasal soreness overall failure rate postoperative complications reinsertion rate time until the first bowel movement postoperative abdominal distention and vomiting gas passage, defecation and bowel sounds (bss) auscultation, as well as the duration of postoperative hospitalization, nausea and vomiting, abdominal distension, pulmonary complications, wound complications, anastomosis leak, and the need for placing/replacing the ng tube aspiration pneumonia, gastric dilatation, or wound dehiscence major complications, eg, pneumonia, atelectasis, gastrointestinal bleeding, and wound breakdown or infection hindered deglutition and nasal soreness occurrence of nausea and vomiting rates of major postoperative complications fever nasogastric intubation hospital mortality feasibility, safety, and tolerance of early feeding duration of postoperative perfusion morbidity, mortality, and speed of recovery overall postoperative mortality vomiting or abdominal distention incidence of vomiting and nasogastric tube insertion presence of atelectasis, postoperative fever, wound infections and anastomotic leaks earlier bowel sounds, return of flatus, oral intake and first bowel movement volume of gastric juice adverse events pulmonary complications postoperative course, morbidity, and mortality febrile morbidity medical morbidity complications pain with and frequency of swallowing, and nose/throat discomfort overall failure occurrence of respiratory complications longer times to first passage of flatus and tolerance of a clear liquid diet nasogastric reintubation length of hospitalization overall surgical complications prolonged operating times, or difficult endotracheal intubation pain, abdominal distention, and vomiting emesis sore throat mechanisms of injury, injury severity score, operative findings, ngt removal times, morbidity, laboratory data, and reasons for failure intensive care unit stay nausea and vomiting postoperative fever postoperative nasogastric decompression incidence of pharyngolaryngitis postoperative complications such as anastomotic leakage nasogastric output mean time of gas passage, defecation, bs auscultation, and the duration of postoperative hospitalization tolerated duration of hospitalization, time to begin peroral fluid intake, occurrence of hiccups, vomiting, nausea, parotiditis, nasal septum necrosis, anastomotic leak and wound dehiscence gastrointestinal function, postoperative course, and complications overall incidence of complications pneumonias frequencies of postoperative complications premature removal of the tube mean length of hospitalization history of upper gastrointestinal bleeding and pyloric obstruction postoperative abdominal distention preoperative risk factors, aortic cross-clamp time, estimated blood loss, length of procedure, length of intensive care unit stay, numbers of days with nasogastric tube, number of days until clear liquid and regular diets commenced, and the length of hospital stay gastrointestinal tract pressure decompression average daily nasogastric output postoperative mortality or morbidity, especially fistula or intra-abdominal sepsis mean+/-sd time to passage of flatus clinical therapeutic outcome and incidence of complication wound complications abdominal distention shorter postoperative stay longer time until passage of flatus, bowel movement, and cessation of intravenous fluids time to tolerance of a regular diet and hospital stay severe discomfort abdominal distension, pyrosis, otalgia, dysphagia, odynophagia and atelectasis postoperative pain, or postoperative abdominal distention feasibility and safety risk of respiratory complications and the length of hospital stay duration of postoperative stay duration and severity of postoperative paralysis incidence rate of fever, pharyngolaryngitis and pulmonary infection postoperative loss of fluid acute dilation of stomach subsequent insertion of a nasogastric tube postoperative fever, nausea, vomiting, anastomotic leaks, or pulmonary or wound complications nausea, vomiting, time to first passage of flatus and stool, time elapsed before adequate tolerance of a regular diet, postoperative stay, and complications occurrence and duration of nausea and vomiting, postoperative peroral fluid intake and time for defecation incidence of postoperative complications earlier passage of flatus and feces and the lower incidence of postoperative gastrectasy time to passage of first flatus, time to taking liquid diet, length of operation, and postoperative hospital stay atelectasis incidence of incisional hernia nausea incidence of complications postoperative complications, mortality, and postoperative course length of hospital stay hematological indices and electrolytes length of hospital stay, duration of postoperative ileus, adequacy of intraoperative intestinal decompression, gastric dilatation, and operative complications pulmonary infection vomiting rate of reinsertion of nasogastric tube and morbidity postoperative length of hospital stay return of bowel function, return to a regular diet, and postoperative length of hospital stay incidence of mortality, complications (including vomiting) or time to return of intestinal motility tolerance of ngt withdrawal and postoperative complications incidence of abdominal distention or nausea and vomiting postoperative ileus nausea postoperatively incidence of anastomosis leak anastomotic disruption length of postoperative stay passage of flatus incidence of vomiting duration of ileus recurrent nausea and vomiting rates of nausea and vomiting subsequent nasogastric decompression pharyngolaryngitis time to pass flatus incidence of nasogastric tube insertion pneumonia abdominal distention, nausea, and vomiting start of oral intake occurrence of postoperative nausea, vomiting, abdominal distension, complications and day of clinical release hospital stay operative times rate of minor symptoms of nausea, vomiting, and abdominal distention incisional hernias incidence of vomiting or the duration of intubation rates of anastomotic leak nasopharyngeal or gastric bleeding, inability to cough effectively, respiratory infections, wound disruptions, reoperation, and wound infection rates|this study does not support a significant effect of early removal of ngts on nausea and vomiting in patients undergoing open repair of the infrarenal aorta. no significant differences were found between the two groups in the duration of hospitalization, time to begin peroral fluid intake, occurrence of hiccups, vomiting, nausea, parotiditis, nasal septum necrosis, anastomotic leak and wound dehiscence. injury severity score, morbidity, and lab values were not significantly different. early oral feeding in patients in arm a was associated with a significantly faster resolution of postoperative ileus (p < .01), with a more rapid return to a regular diet (p < .01), with an earlier first passage of stool (p < .01), and with a shorter postoperative stay (p < .05) than patients in arm b. rates of nausea and vomiting were similar in both arms. the return of bowel function, return to a regular diet, and postoperative length of hospital stay were similar in both groups. postoperative abdominal distention was more common in patients without nasogastric tubes, whereas pulmonary complications were more common in patients with nasogastric tubes. there were no significant differences in nasopharyngeal or gastric bleeding, inability to cough effectively, respiratory infections, wound disruptions, reoperation, and wound infection rates (5%) between the two groups. nasogastric tubes reduced the incidence of vomiting from 28 in the no-tube group to 10 in the tube group (p less than 0.05), but most had only one or two episodes. there were no significant differences in the presence of atelectasis, postoperative fever, wound infections and anastomotic leaks between the two groups. no difference in length of the first passage of gas by anus and defecation after operation was found between two groups. the nasogastric and orogastric groups were similar in age, case distribution, surgery length, and blood loss. the incidence of nasogastric tube insertion in the tubeless group was similar to the incidence of nasogastric tube reinsertion in the intubated group (p=0.747). the incidence of anastomosis leak was significantly higher in the ng-tube group (6 vs. 0; p=0.016). no significant difference could be seen in the tubed or no-tube group. no statistical difference was recorded concerning the occurrence of postoperative nausea, vomiting, abdominal distension, complications and day of clinical release. the postoperative complications such as anastomotic leakage (1.24% vs 2.58%), acute dilation of stomach (1.86% vs 0.06%) and wound complications (2.48% vs 1.94%) were similar in the groups, but fever (3.73% vs 9.68%, p<0.05), pulmonary infection (0.62% vs 4.52%, p<0.05) and pharyngolaryngitis (3.11% vs 23.23%, p<0.001) were much more in the control group than in the experimental group. the length of hospital stay was similar in both groups and three patients in each group required a nasogastric tube or reinsertion of one. there was no statistically significant difference in the incidence of mortality, complications (including vomiting) or time to return of intestinal motility between the two groups. pneumonia (13.0 versus 5.0 per cent; p = 0.047) and atelectasis (81 versus 67 per cent; p = 0.043) were significantly more common in the ngt group. the incidence of vomiting and nasogastric tube insertion (21.5%) was higher in patients in group i than in those in group ii. developed incisional hernias compared with 15 (6.6 percent) of 229 patients who were not decompressed (p = 0.085). the rates of anastomotic leak were similar in both groups (6.9% and 5.8% for the njt group and no-njt group, respectively; p = .71), as were the rates of major postoperative complications (25.9% and 21.5%, respectively; p = .42) and overall postoperative mortality (0.9% and 0.8%, respectively; p = .50). patients who were not intubated mobilised more quickly, and spent less time in hospital. there were no significant differences between the two groups in the incidence of postoperative complications. however, no significant differences were found between the two groups with respect to duration and severity of postoperative paralysis, as measured by occurrence and duration of nausea and vomiting, postoperative peroral fluid intake and time for defecation. postoperative fever was noted in 23 patients (58%) in group 1 and 14 (38%) in group 2 (p = 0.13); atelectasis was diagnosed in 38 per cent of patients in group 1 and 14 per cent in group 2 (p = 0.03). there were no significant differences between the two groups concerning the presence of postoperative fever, nausea, vomiting, anastomotic leaks, or pulmonary or wound complications. duration of postoperative perfusion (p = 0.02) and length of hospital stay (p = 0.03) were also significantly longer in the tube group.|malignant and premalignant lesions patients undergoing total gastrectomy for gastric cancer university hospital, korea after elective abdominal surgery elective colonic surgery gynecologic oncology patients 80 patients undergoing abdominal aortic surgery early nasogastric tube removal after infrarenal aortic surgery patients with bowel anastomosis patients with duodenal or esophageal injuries, those with airway intubations that were >24 hours, or those who had undergone same-hospitalization repeat celiotomy group i (n = 95 251 patients who received ng decompression, 8 (3.2 percent forty patients were assigned to group 1 (21 males, 19 females) and 37 to group 2 (22 males and 15 females uncomplicated, elective abdominal colorectal surgery seventy-seven consecutive patients 200 general surgeons 97 patients were and 100 were not allocated 177 patients qualified for the study elective total gastrectomy for gastric cancer patients undergoing elective abdominal colorectal surgery seven patients with gastric outlet obstruction who had not been intubated needed to be so 175 patients, 151 sustained penetrating injuries and 24 sustained blunt injuries patients with gastric cancer 119 patients with gastric adenocarcinoma eighteen patients in the patients with chronic bowel obstruction, peritonitis, gross fecal contamination or spillage, and previous abdominal or pelvic irradiation five hundred thirty-five patients 24 blunt injury patients n = 69) or not (n = 67 postoperative care of esophagectomy 136 patients with gastric cancer who underwent radical gastrectomy with d2 or more lymph node dissection three hundred and sixty-eight patients with excision and anastomosis of lower digestive tract elective colorectal surgery trauma patients who have undergone emergency celiotomy to removal based on clinical signs of return of bowel function 74 patients with gastric cancer including 11 with gastric outlet obstruction who underwent six patients were subsequently excluded from the study 200 patients postceliotomy trauma patients patients undergoing surgery of the infrarenal aorta all trauma patients who underwent an emergency celiotomy between november 1994 and august 1997 200 consecutive patients who underwent major abdominal procedures three hundred and sixteen patients submitted to operations associated with colorectostomy from january 2004 to september 2005 gynecologic oncology patients undergoing extensive intra-abdominal surgery elective gastrectomy one hundred thirty-eight consecutive patients undergoing elective colonic resections 52 patients with suture lines constructed in the gastrointestinal tract received no 200 patients who had elective hepatic resection, including 68 who had previously had colorectal surgery, 100 were randomized to 100 patients who had elective uncomplicated abdominal surgery: 50 subjects had the early removal of ngt and in 50 patients it was maintained until passage of flatus/feces after major oncologic gynecologic surgery patients with prior irradiation or substantial edema from bowel obstruction patients who had emergency surgery with peritonitis, extensive fibrous adhesions, enterotomies, previous pelvic irradiation, intra-abdominal infection, pancreatitis, chronic obstruction gynecologic oncology patients undergoing intra-abdominal surgery 110 gynecologic oncology patients undergoing extensive intra-abdominal surgery patients undergoing major surgery for gynecologic malignancies patients having major retroperitoneal or vascular procedures 40 randomized subjects, 20 patients were included in each group intestinal paralysis after elective colorectal operations routine postoperative ng decompression benefited such patients, 102 patients patients without undergoing gastrointestinal decompression patients with paralytic ileus patients with esophageal cancer group ii (n = 95 patients who have elective colorectal surgery patients undergoing open repair of the infrarenal aorta benefitted patients undergoing this type of surgery 84 patients undergoing elective partial or total gastrectomy forty-six patients underwent aortic operations patients undergoing surgery for colorectal carcinoma fifty-six patients undergoing elective colonic resection two hundred seventy-four patients received ng decompression (salem sump, argyle co., division of sherwood medical, st. louis, mo) and two hundred sixty-one did not 37 patients 76 patients who were randomized into two groups: those who received between october 2001 and may 2002, consecutive patients underwent scheduled infrarenal aortic operations two hundred thirty-seven patients undergoing total gastrectomy for gastric cancer patients' rehabilitation after colorectostomy patients undergoing surgery for gynecologic malignancies 190 patients who underwent an elective colon or rectal operation surgical department, taichung veterans general hospital, taiwan one hundred and nine patients after elective hepatic resection stomach after elective colorectal operations, 97 patients patients subjected to elective open colorectal surgery 151 patients in the penetrating injury group, 68 were randomized to the 24-hour pull (study) group and 83 were randomized to the clinical pull (control) group fifty-eight percent of patients in the selective ngd group who required intubation had had major vascular or retroperitoneal dissections
rate of symptomatic hemorrhage symptomatic intracranial hemorrhage mrs scores asymptomatic parenchymal hemorrhages higher rate of minimal residual disability bleeding complications asymptomatic hemorrhagic transformation major intracranial hemorrhage distribution of outcomes at 3 months after stroke using the modified rankin scale (mrs) based on an ordinal regression model of outcomes, adjusting for baseline severity of stroke, age, and interval from stroke asymptomatic hemorrhagic lesions|symptomatic intracranial hemorrhage within 5 days was diagnosed in 7 of 195 (3.6%) patients treated with abciximab and 2 of 199 (1%) patients given placebo (odds ratio [or], 3.7; p=0.09; 95% confidence interval [ci], 0.7 to 25.9). asymptomatic parenchymal hemorrhages were detected on post-study agent ct in 4 of 54 abciximab patients (7%) and in 1 of 20 placebo patients (5%).|seventy-four eligible and consenting patients presenting within 24 hours after ischemic stroke onset at 38 study sites 400 patients within 6 hours of onset of ischemic stroke 11 patients with asymptomatic hemorrhage had a baseline national institutes of health stroke scale score >14 patients with stroke patients underwent a scheduled follow-up acute ischemic stroke patients with acute ischemic stroke
mean scores number of "off" hours wearing off and symptom severity improvement of "on" and "off" time while awake (patient diary and updrs part iv item 39), investigators' global assessment, the sf-36 health survey, and changes in levodopa dosages safety data bradykinesia side effects (orthostatic hypotension, exogenous psychotic symptoms beneficial response quality of life and activities of daily living advanced pd dizziness, insomnia, nausea, and postural hypotension aggravated parkinsonism clinical efficacy and safety off-periods updrs (activities of daily living; adl levodopa state quality-of-life measures average hoehn and yahr stage of disease, and schwab and england activities of daily living index time increased (1.7 h) and 'off' time increased dyskinesias mean daily l-dopa dose responder rates parkinsonian disability and health-related quality of life (qol safe and well tolerated motor fluctuations and pd symptoms updrs total scores, subscores part ii, iii (activities of daily living and motor examination), and iv (complications of therapy clinical laboratory test results (blood chemistry, hematology, and urinalysis), vital signs, and electrocardiograms clinical global improvement (cgi) score and unified parkinson's disease rating scale (updrs) scores diarrhea home diaries ('on' and 'off' times), unified parkinson's disease rating scale (updrs) and changes in levodopa dosage, and safety by adverse-event inquiry, vital signs, electro cardiography (ecg) and laboratory tests dopamine antagonistic actions mean reduction in daily "off" time cgi scores number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the unified parkinson's disease rating scale-based measures of motor fluctuations and dyskinesias number of daily levodopa intakes bromocriptin dosage objective quality of the "on" state efficacy, safety, and tolerance updrs activities of daily living and motor scores unified parkinson disease rating scale (updrs), and recording of daily levodopa dose therapeutic effectiveness principal adverse events (mainly dyskinesia and nausea adverse events efficacy and safety of zydis selegiline disability safety and tolerability rasagiline treatment, including scores on an investigator-rated clinical global impression scale and the unified parkinson's disease rating scale (activities of daily living in the off state and motor performance in the "on" state safety and tolerability profile levodopa requirements retirement rate self-perception of disability progression unified parkinson's disease rating scale (updrs) part ii activities of daily living (adl) and the parkinson's disease questionnaire (pdq)-39 summary index updrs "overall dyskinesia score quality of life (sickness impact profile) scores mean updrs total score total unified parkinson's disease rating scale (updrs) score absolute on time (mean (sd duration of off periods as assessed by self-scoring diary cards total score of the unified parkinson's disease rating scale (updrs adverse events, vital signs, laboratory measurements, and ecg recordings dyskinesia change in hours and percent of daily "on" time and "on" time without troublesome dyskinesia, unified pd rating scale motor and activities of daily living subscales, beck depression inventory-ii, pdq-39 subscales of mobility, activities of daily living, emotional well-being, stigma and communication, and pd sleep scale rasagiline efficacy and safety cardiac or electrocardiographic abnormalities effective and well tolerated daily on-time without troublesome dyskinesia efficacy frequency of withdrawals because of adverse events mean daily sinemet dosage decreases stride length and angular excursion of the hip and knee joints efficacy and safety total "on" time total number of off hours safety evaluation of adverse events (aes), vital signs, ecg, and laboratory parameters adverse reactions mean hourly overall symptom control platelet mao-b inhibition mean updrs total scores dopaminergic and nondopaminergic adverse events proportion of daily on time efficacy and tolerability frequency of adverse events updrs motor scores gastrointestinal and cardiovascular tolerability adl scores tolerated percent "on" time mean daily levodopa dose daily off time employment rate mean daily levodopa dose requirement activities of daily living levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints motor function and overall efficacy unified parkinson disease rating scale safety, tolerability, and efficacy of rasagiline total scores of the updrs part ii, part iii, and parts ii and iii combined vital signs, ecg or laboratory results total score on the unified parkinson's disease rating scale (updrs side-effect lower absenteeism rate number of discontinuations mean daily off-time average number of dyskinesia-free reduction in hours of daily "off" time entacapone efficacy pdq-39 subscores, the sf-36 variables or the eq-5d utility score unified parkinson's disease rating scale (updrs motor function nausea, light-headedness, dyskinesias, and hallucinations, all of which abated after the sinemet dose motor examination levodopa requirements, improvement in patients' clinical status, duration of improvements, and tolerability of tolcapone wearing-off phenomena and frozen gait toxicity mean hourly self-assessment of gait mean reduction in l-dopa requirement global assessment of change, pdq-39 subscores, and the short-form (sf)-36 and the european quality of life adverse events, laboratory safety and vital signs five-dimension questionnaire (eq-5d updrs part iii (motor) scores total levodopa requirements daily levodopa dose time spent in "off" periods overall safety profile activities of daily living, motor function wearing off dyskinesia and nausea mean total daily levodopa dose subitems motivation/initiative and depression in a subpopulation with increased unified parkinson's disease rating scale i scores time adl, global function, motor performance and was well tolerated safety, tolerability efficacy, safety percent awake time spent "off mean daily off-time and improves symptoms of parkinson's disease occurrence of drug-related adverse events fatigue, dyskinesia, and vivid dreams severity of "off" periods, decreased disability and pd severity off" time absolute change in total hours "off" (assessed by home diaries nausea updrs scores safety, tolerance, and efficacy percentage of "on" time (relief of parkinsonism efficacy, safety, and tolerability total daily off-time (intention-to-treat population fluctuations total parkinson's score, scores of activities of daily living, motor function, number of "off" hours, hoehn and yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity nonserious dopaminergic adverse events dyskinesias total score of the webster and the nuds scales levodopa dosage dyskinesia, nausea, dizziness, somnolence, hallucinations, and orthostatic hypotension and aes led to study withdrawal updrs sum scores nausea, cramps, dyskinesia, and dystonia side effects updrs part ii dryness of mouth, urine discoloration and diarrhoea somnolence mean percentage of "asleep" time hepatic enzyme activity, ecg or haemodynamic parameters unified parkinson's disease rating scale motor and total scores both motor and non-motor pd symptoms mean adjusted total daily off time dopaminergic adverse events unified parkinson's disease rating scale (updrs) parts ii and iii hours "off united parkinson's disease rating scale motor subscale and "on/off" and dyskinesia assessments levodopa requirement unified parkinson's disease rating scale subscale ii activity and tolerability employment, medical absenteeism, and disability perception adverse effects efficacy, parkinsonian symptoms motor fluctuations|in this group of patients, adl scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). both rasagiline and entacapone reduced mean daily off-time (-1.18 h rasagiline and -1.2 h entacapone vs placebo -0.4 h; p=0.0001, p<0.0001, respectively) and increased daily on-time without troublesome dyskinesia (0.85 h vs placebo 0.03 h; p=0.0005 for both). adverse events occurred in 79 patients (69.9%) in placebo, 82 (72.6%) in 100 mg, and 98 (86.0%) in 200 mg. total score on the unified parkinson's disease rating scale (updrs) for the intent-to-treat population was significantly improved in the pramipexole-treated group compared with the placebo-treated group (16.9 +/- the cabergoline patients had significantly better activities of daily living (p = 0.032) and motor examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. no irreversible side effects were noted. in terms of change in absolute off time, rotigotine was non-inferior to pramipexole. ld + ent treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; p = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; p < 0.0001), improved self-perception of disability progression over 2 years (change score 1.0 vs. 4.5; p < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to ld monotherapy. the updrs part iii showed improvements of 34% for pramipexole (p = 0.0006) and 23.8% for bromocriptine (p = 0.01) versus 5.7% for placebo. ropinirole significantly reduced the duration of off periods as assessed by self-scoring diary cards. dryness of mouth, urine discoloration and diarrhoea were more frequent non-dopaminergic aes with entacapone than with placebo. mean hourly overall symptom control improved in 29 (58%) taking deprenyl (mean 0.34) and in 12 (26.1%) taking placebo (mean 0.15) (p less than 0.01 for each parameter). adverse effects related to the central nervous system were similar to those reported with other dopamine agonists, and the gastrointestinal and cardiovascular tolerability of the compound was satisfactory. following incremental dose titration, patients in the cabergoline group had a significant reduction in hours "off" per day from 5.0 (sd 2.1) to 3.0 (sd 2.5), but there was no change in this measure in the placebo group [4.0 (2.2) and 3.3 (2.3) respectively]. no apparent differences were detected in the occurrence of drug-related adverse events between the zydis selegiline group and placebo-treated groups. we found significant improvements in motor function and overall efficacy in the tolcapone groups (p < 0.01). long-term entacapone treatment effectively prolonged the beneficial response to levodopa in parkinsonian patients with the wearing-off phenomenon. there were no significant differences between treatments for any of the pdq-39 subscores, the sf-36 variables or the eq-5d utility score. the addition of bromocryptine in high doses (average daily dose 71 mg) induced a significant improvement in the total score of the webster and the nuds scales. in the total population, the updrs activities of daily living and motor scores were significantly improved (p < 0.05) by entacapone vs placebo. investigators' global measures of disease severity indicated that significantly more tolcapone-treated patients had reduced wearing off and symptom severity (p<.001 vs placebo). with 200 mg tolcapone tid, unified parkinson's disease rating scale motor and total scores were significantly reduced, and quality of life (sickness impact profile) scores were significantly improved. there was a mean reduction in daily "off" time of 2.1 hours in the ropinirole 24-hour group and 0.3 hours with placebo. compared with placebo, patients treated with 1.0 mg/d rasagiline had 0.94 hour less off time per day, and patients treated with 0.5 mg/d rasagiline had 0.49 hour less off time per day. tolcapone is a potent catechol-o-methyltransferase inhibitor that prolongs the plasma half-life of levodopa. pramipexole was also superior to placebo as measured by improvement in the modified hoehn and yahr scale and a reduction in the number of "off" hours for patients on concomitant levodopa therapy. the proportion of patients showing an improvement at the investigators' global assessment was significantly higher (p = 0.0006) in the entacapone-treated group of patients. entacapone is effective at increasing the duration of response to levodopa and at relieving parkinsonism in patients experiencing motor fluctuations and was well tolerated during the 24 weeks of treatment. this resulted in a significant decrease in the amount of levodopa side-effects while maintaining or improving the original parkinsonian clinical stage. the trial demonstrates that with deprenyl the levodopa dosage can be reduced considerably without prejudicing the therapeutic outcome. there was a significant improvement of the pramipexole group in updrs total scores, subscores part ii, iii (activities of daily living and motor examination), and iv (complications of therapy). at 6 months, patients randomized to pergolide had a statistically significant improvement in total parkinson's score, scores of activities of daily living, motor function, number of "off" hours, hoehn and yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. the mean daily l-dopa dose was reduced significantly with ropinirole treatment (242 mg versus 51 mg; p < 0.001) as was the percent awake time spent "off" (11.7% versus 5.1%; p = 0.039). adverse events were no different than those of patients taking placebo. gait analysis disclosed a significant improvement by levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints. differences between the treatment groups became significant at a daily dose of 0.75 mg of pramipexole dihydrochloride. the symptoms of parkinson's disease were favourably influenced, with rigor, tremor and also walking disturbances responding better than bradykinesia of the hands. both tolcapone groups had greater reductions in levodopa dosage than the placebo group at week 6 (not statistically different).|40 patients of both sexes with at least 3 years history of parkinson's disease who were undergoing stabilized levodopa therapy seventy eight patients of either sex with advanced parkinson's disease and treatment complications such as motor fluctuations japanese parkinson's disease (pd) patients with wearing-off motor fluctuations eligible participants advanced pd advanced parkinsonian patients with motor fluctuations 58 patients received chinese patients with parkinson's disease parkinsonians with motor fluctuations 162 patients with parkinson's disease (pd) treated with patients with pd one hundred fifty-one patients completed the study germany and austria (celomen study patients with parkinson's disease and motor fluctuations (largo levodopa-treated parkinson's disease patients patients with fluctuating parkinson disease 19 patients) or two hundred five patients parkinson disease patients (n = 472) with at least 21/2 hours of daily "off" (poor motor function) time, despite optimized treatment with other anti-pd medications parkinsonian patients stable parkinsonian patients advanced parkinson's disease (pd three hundred and seventy-six subjects with advanced parkinson's disease parkinson's disease parkinsonian patients with the wearing-off phenomenon fifteen parkinson disease clinics 97 patients 96 patients with marked symptom fluctuations at three centers to receive either patients who are manifesting various difficulties in levodopa therapy parkinsonian patients with the "wearing-off" phenomenon cases of parkinson's disease with both fluctuating and non-fluctuating response to treatment parkinson's disease (pd) patients who were experiencing motor fluctuations with levodopa full-time-employed patients with parkinson's disease (pd 23 patients with advanced parkinson's disease forty-six patients with parkinson's disease experiencing motor fluctuations and not optimally controlled on patients with parkinson's disease experiencing motor fluctuations 172 fluctuating and 128 non-fluctuating patients fluctuating parkinsonian patients thirty full-time-employed pd patients (disease onset before age 60 years) and on optimized monotherapy with ld exhibiting minor motor fluctuations or dyskinesias 202 parkinsonian patients who were experiencing the "wearing-off" phenomenon on levodopa therapy 57.4 y treated patients with advanced parkinson's disease and wearing-off type motor fluctuations parkinsonian patients with motor fluctuations 37 patients with severe fluctuations in response to treatment progressive stages of parkinson's disease (author's transl 393 subjects with pd levodopa-treated parkinsonian patients untreated and levodopa-treated chinese patients with early or advanced parkinson's disease parkinson's disease (pd) patients copyright 2004 movement disorder society subjects with parkinson's disease (pd) experiencing motor fluctuations study population represented 'typical' pd outpatients, including patients with varying disease severity and with various concomitant medications mean disease duration, 5.7 y; 32 patients had motor fluctuations patients with parkinson's disease 171 parkinsonian patients with wearing-off-type motor fluctuations 247 patients with "wearing off advanced parkinson's disease fluctuating parkinson's disease patients patients with early illness patients with pd with wearing-off motor fluctuations patients with parkinson's disease manifesting various problems 301 pd patients, the majority with motor fluctuations, received 204 patients levodopa-treated pd patients patients with parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations patients with parkinson disease (pd) and motor fluctuations advanced parkinson's disease (pd) patients patients with advanced parkinson's disease treated patients with suboptimally controlled parkinson's disease (pd patients with parkinson's disease (pd) experiencing motor fluctuations from 326 patients with idiopathic parkinson's disease (pd parkinsonian patients with moderate motor disability and motor fluctuations pd patients with motor fluctuations advanced pd patients with motor fluctuations under levodopa treatment patients with parkinson disease (pd) not optimally controlled with patients with moderately advanced parkinson's disease with treated "wearing-off" phenomenon forty patients with severe parkinson's disease (23 men, 17 women) who had been treated for six years with l-dopa-decarboxylase inhibitor, were part of a and experiencing wearing-off motor fluctuations treated patients with parkinson's disease and motor fluctuations 74 hospitals and academic centres in israel, argentina, and europe) trial, 687 outpatients patients experiencing wearing-off type fluctuations 262 patients who were subsequently enrolled into the open-label study featuring a maximum duration of up to 57 months treated patients with pd and motor fluctuations patients with moderately severe parkinson's disease two hundred fifteen referred outpatients with parkinson disease who showed predictable end-of-dose motor fluctuations that were not controlled by a stable levodopa-carbidopa (sinemet) regimen of at least 4 weeks' duration parkinson's disease patients with motor fluctuations 341 patients to receive parkinson's disease patients with suboptimal levodopa response 88 (13%) patients who were assigned treatment did not complete the study (23 rasagiline, 30 advanced parkinson disease patients with advanced pd with motor fluctuations treated patients with parkinson disease and motor fluctuations 69 patients with advanced parkinson's disease (33 received patients with early parkinson's disease (pd 40 patients with wearing-off phenomenon 70 patients with pd (mean age 354 patients with parkinson's disease (pd) and motor fluctuations under individually adjusted therapy with patients with fluctuating parkinson disease treated with 270 pd patients treated patients with parkinson's disease treated, fluctuating parkinsonian patients patients with fluctuating parkinson's disease over 6 months of treatment
liver enzymes, kidney function tests, hematologic parameters, blood glucose, insulin, and c-peptide assays hba1c, fasting glucose, lipids, blood pressure, and weight glycosylated haemoglobin (hba1c) and fasting blood sugar (fbs), alteration of lipid profile by serum cholesterol, ldl, vldl, hdl and triglycerides hdl safety and effectiveness mean change, with inolter, in serum cholesterol total cholesterol fasting blood sugar efficacy and safety fasting plasma glucose (fpg), lipids, body mass index (bmi), body composition, blood pressure, insulin sensitivity estimates using the minimal model, glucose and insulin responses to a meal challenge, quality of life, adverse events, or other safety indices serum triglyceride hba(1c glucose control hypoglycemic effect liver function tests, hematologic parameters, or the kidney function tests hba(1c) reductions fasting glucose low-density lipoprotein (ldl) cholesterol tolerated levels of fasting and postprandial blood glucose, cholesterol, triglycerides, glycated hemoglobin (hb a(1c)) and fasting insulin satisfactory and no adverse effects change in hba(1c|there were no significant treatment-related differences in the fasting plasma glucose (fpg), lipids, body mass index (bmi), body composition, blood pressure, insulin sensitivity estimates using the minimal model, glucose and insulin responses to a meal challenge, quality of life, adverse events, or other safety indices between treatment groups. using analysis of co-variance (ancova), we found no significant differences for clinical outcomes at 6 months between on-study patient groups, though trends favored the ayurvedic group. cogent db did not alter the liver function tests, hematologic parameters, or the kidney function tests. inolter appears to be an useful adjunctive therapy to exercise and diet control in newly diagnosed type 2 diabetes mellitus.|control patients attended standard diabetes education classes with primary care clinician follow-up two major peripheral clinics of kuala lumpur in the klang valley, malaysia patients with type 2-diabetes 36 subjects who completed the study were comparable between treatment groups type 2 diabetic patients inadequately treated with diet/lifestyle or stable doses of patients with type 2 diabetes for >/= 1 year were entered into 2 strata of hemoglobin a(1c) (hba(1c type 2 diabetes mellitus participants: we recruited 60 adult patients with baseline glycosylated hemoglobin (hba1c) values between 6.0 and 8.0 nineteen (19) subjects (10 and 9 from control and treatment groups, respectively) dropped out of the study leaving a total of 60 subjects (30 each for control and treatment groups) who completed the study 39 cogent db-treated cases and 40 age-matched controls newly diagnosed people with type 2 diabetes patients with type 2 diabetes nineteen subjects entered stratum 1 and 17 entered stratum 2 sixty newly diagnosed patients of type-2 diabetes newly diagnosed type 2 diabetics type 2 diabetes newly diagnosed type 2 diabetes mellitus
index and lactate dehydrogenase (ld) of the cystic fluids, blood and cerebrospinal fluids and the endocrine function adephagia obesity and cerebral infarction blood chemistry, liver, kidney and endocrine functions blood chemistry, liver, kidney, pituitary and endocrinal functions hyponatremia severe complications|at follow-up, the volumes of the cysts in groups a and b regressed from 92 to 0%, while the drug-free cysts enlarged.|a series of cystic craniopharyngiomas
fatality rate mean cost per fall overall injury rates incidence of occupational injuries injury rates rate of falls from height rate of fatal injury fatal falls cost savings fatal construction falls rate of decline in falls|training led to a 6% reduction in injury rates, which was not statistically significant. a statistically significant downward trend in fatal falls was evident in all construction and within several construction categories during the decade. the fatality rate from trench cave-in in union construction workers was approximately half that of nonunion workers, but we were unable to determine whether this was best explained by union status, employment of union workers at larger construction firms, or both. the drug-free workplace intervention was associated (p < .05) with a statistically significant decrease in injury rates for three industry groups: construction, manufacturing, and services. construction notifications showed building sites increased in number from the 200 sites/year before the earthquake to almost 1400 per year at maximum reconstruction activity. there was a significant reduction in mean paid lost days per event after the standard change and there was a significant reduction in mean cost per fall when adjusting for age and the temporal trend for costs among non-fall injuries.|workers at construction sites of the high-speed railway line between torino and novara 2,795 workers involved in a safety training program at the construction sites of the high-speed railway line torino-novara umbria during reconstruction after an earthquake two hundred and sixty-one companies that enrolled in the drug-free workplace program during the latter half of 1996 were compared with approximately 20,500 nonintervention companies
plasma orosomucoid levels mean crohn's disease activity index and quality-of-life scores disease activity serious adverse events use of prednisone and 5-amino-salicylates, mean score on the crohn's disease activity index and mean quality-of-life score, and the need for surgery median time to worsening of disease clinically important worsening of crohn's disease, defined as a 100-point increase in the crohn's disease activity index crohn's disease activity index full remission|the condition of more patients worsened with cyclosporine than with placebo (91 of 151, or 60.3 percent, vs. 80 of 154, or 51.9 percent; p = 0.10). at month 12, only 20% (95% cl, 12%-31%) vs. 20% (95% cl, 12%-31%) of the patients had maintained a continuous remission. during cyclosporine treatment, there was significant improvement in plasma orosomucoid levels (p = 0.0025) and the crohn's disease activity index (p = 0.00012).|patients with active chronic crohn's disease and resistance to or intolerance of corticosteroids adult patients whose disease had been active within the previous two years crohn's disease 71 patients with active chronic crohn's disease who were resistant to or intolerant of corticosteroids to treatment with chronic active crohn's disease 193 patients had scores of 150 or less, and 112 had scores greater than 150 active chronic crohn's disease patient cohort was stratified at entry into a stratum with low crohn's disease activity index (cdai) ( < 200) and high cdai ( > 200 one hundred eighty-two patients from 33 european centers were included
year survival rate of local and regional control gender, haemoglobin drop, tumour site, tumour and nodal stage g3+ skin, s.c. tissue, and mucosal late side effects (rtog scale median time to loco-regional and distant progression complete response (cr) rates acute morbidity and deaths complete remission rate and overall survival severe (grade 3 or higher) adverse effects radiotherapy died of recurrence or regional metastasis local/regional failure rate median progression-free survival 3-year disease-free survival survival rates locoregional recurrence rates phlebitis higher distant metastasis-free survival (dmfs activity and toxicity pathological macroscopic regression survival and postoperative quality of life median survival and doubles the probability of survival survival voice quality nausea and vomiting overall survival and locoregional control rates excellent survival toxic deaths severe complications actuarial 3-year locoregional control rates toxic effects and lethal reactions local and regional recurrences risk of death actuarial 3-year overall survival and progression free survival local efficacy toxicity and response disease free survival local control relapse-free survival rate overall crude survival local late mucosal and skin toxicities 5-year survival and late toxicity locoregional control and overall survival rates overall survival, progression free survival, or locoregional control corresponding median efs hematologic high-grade toxicity disease progression complete lymph node response response rates actuarial dfs patient survival 3-year locoregional control rate tumor-free survival locoregional control and distant disease-free survival cumulative incidence of local or regional relapses incidence of first failure in the neck nodes 2-year actuarial survival rate disease-free survival rate of locoregional control of disease lrpfs and dmfs efs events initial tumor clearance rates incidence of distant metastasis superior disease-free survival overall response stage iv, hemoglobin level acute toxicity rates of secondary localization and distant metastasis voicing and oral intake corresponding recurrence-free rates and five-year survival rates rates of neutropenia and febrile neutropenia overall median survival duration 3-year projected overall survival postoperative quality of life 2-year survival rates median overall survival grade 3 or worse toxicity local disease-free and disease-free intervals prognostic factors of short survival and locoregional failure survival at acceptable toxicity rate of block dissection of the neck overall survival, specific disease-free survival, and locoregional control rates rate of overall survival mucosal toxicity myelosuppression recurrence at death longer survival disease-free survival rates tumour response rates alopecia serious toxicities tolerance 3-year overall survival rate chemotherapy responses and toxicities, surgical complications, radiotherapy toxicities, patient compliance, survival time, and patterns of treatment failure survival of such patients response rate to induction chemotherapy for lymph node metastases quality of life (qol efficacy and toxicity hospitalized with mtx toxicity, none died of mtx toxicity median time to any treatment failure survival advantage incidence of distant metastases death rate of radiologic complete response (cr poor survival disease control and survival 2-year os rates occurrence of local toxic effects (i.e., mucositis and epidermatitis 5-year lrfs grade 3-4 neutropenia remission rate survival rate similar activity (complete response, progression-free and overall survival rates loco-regional failure or in disease-free or overall survival 5-year overall survival rate favourable response rate total clinical healing of the lesion incidence of local recurrences serious late morbidity overall duration of mucositis recurrences, new tumours, and deaths uncontrolled disease and local recurrence overall survival survival time differences clinically tumor free progression-free and overall survival mucosal and skin toxicity complete remission rate complete responses relapse while no relapses survival curves acute high grade toxicity severe mucositis overall tumor response rates safety and efficacy feasibility and efficacy survival data median survival time (mst long-term survival rates longer survival time event-free survival metastatic rate overall chemotherapy response late toxicity radical neck dissections of recidive metastases disease-free and overall survival adverse effects loco-regional tumour control, survival or morbidity cerebral vascular damage mean duration response remaining tumour cells overall qol loco-regional control rates of local and regional control and disease-free survival hematologic and non-hematologic toxic effects four-year progression-free survival overall survival rate incidence of either acute or late high-grade rt-induced toxicity 2-year disease-free survival mucositis and vomiting febrile neutropenia and grade 3 or 4 late mucous membrane toxicity distant metastases higher locoregional progression-free survival (lrpfs tolerated, with moderate hematologic and gastrointestinal toxicity locoregional failure-free rates survival improvement 1-year survival with local control (slc 10-year local-regional recurrence-free survival rates in stage iv disease locoregional control rate overall survival rates total treatment time response rates and locoregional control moderate myelosuppression and renal toxicity median disease-free survival 10-year local-regional recurrence-free survival rates overall survival and disease-free interval 1-year slc incidence of acute adverse effects 5-year disease-free actuarial survival rate year rate of local and regional control acute mucositis grade locoregional control occurrence of persistent g3 xerostomia late reactions and overall rates of secondary neoplasms tube feeding severe side effects, affecting mainly digestive tract, and bone marrow disease-free survival or survival rates of complete and partial responses cr + pr rates haematological side effects of mmc granulocytopenia, asthenia and stomatitis overall survival (os median overall survival and progression free survival duration of objectives remission rates of complete tumor resorption leukopenia 6-year survival rate oropharyngeal carcinoma only: disease-free survival overall survival improvement stage iv disease five-year recurrence-free rates and disease-free survival patient refusal or cumulative toxicity toxicities grade 3 and 4 toxicity rates hematological toxicity incidence of moderate to severe mucositis 10-year disease-free survival rates grade 3-4 acute mucositis acute morbidity estimated 2-year disease-free and overall survival rates confluent mucositis and dry skin desquamation significant long-term toxicity rate locoregional recurrence cardiac toxicity local disease control or actuarial survival rates acute mucositis, pneumonitis and dermatitis mucositis, moist desquamation, and erythema 3-and 5-year survival rates local control and survival fatal nephrotoxicity, only hematologic g3+ (grade 3 or higher) acute sequelae local tumour control and survival complete remissions (cr) and four partial remissions (pr acute skin effects and late mucosal and skin toxicities severe late morbidity objective response rate severe hematological toxicity regional lymph node and distant metastasis control actuarial overall survival rates grade 3 to 4 complications clinical cr rate median survival clinical regression rate (rr complete remission leukopenia, thrombopenia, vomiting and nephrotoxicity unresectable disease time to any treatment failure; secondary end points were locoregional failure, metastatic relapse, overall survival, and late toxicity complete response relapse-free survival median time to local recurrence (mtlr) and 5-year local recurrence-free survival (lrfs satisfactory efficacy and acceptable toxicity profile anemia response (cr + pr) rate postoperative complications median peak mtx dose rates of distant metastasis failure-free rate thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss rate of mutilating surgery haematological toxicity grade 3-4 overall 3-year primary locoregional tumour control, disease-specific and overall survival rates cause-specific survival rate overall response rate 4-year actuarial survival rate g3+ acute mucositis progression-free survival confluent mucositis complete response rate septic shock mucositis loco-regional tumour control late high grade toxicity peripheral neuropathy favorable outcomes (complete response [cr] plus any grade of toxicity and pr plus grade 0 to 3 toxicity rates of death from toxic effects l- and 2-year local-regional control (lrc) rates tumour regression 5-year kaplan-meier estimates of progression-free survival complete clinical and pathologic response rate response rate thrombocytopenia 5-year disease-free actuarial survival rates 2-year survival rate response and survival rates tolerated rate of freedom from recurrence local control and overall survival overall immediate effectiveness frequency of complete responses grade 3+ (world health organization) acute skin and mucosal reactions cr rate severe mucosal adverse effects leukopenia and neutropenia overall long-term survival overall response rates toxicity disease-free survival (dfs) and overall survival mucosal reaction year failure-free survival rates overall survival (from randomisation), and event-free survival (efs; recurrence, new tumour, or death 3-year survival hematologic toxicity median progression-free survival and overall survival failure-free survival, time to locoregional failure, or quality of life as measured by functional assessment of cancer therapy-head and neck overall survival and locoregional control of stage iii or iv oropharynx carcinoma serious late side effects proportion of patients without relapse morbidity survival and toxicity overall survival (os), disease-free survival (dfs), and specific survival (ss severe mucositis (who level 5 reactions mucosal tolerance survival and recurrence rate of progression-free survival tumor objective response rate 3-year overall survival and of 3-year loco-regional control progression-free and freedom from metastases rates 5-yr progression-free survival side effects grade 4 cardiac dysfunction overall incidence of distant metastases radiation toxicity hematologic adverse events rates of residual and recurrent disease cr rates locoregional control or survival 5-year survival rates median survival time incidence or severity of acute and late radiation side effects 5-yr overall survival incidence of late adverse effects acceptable toxicity profiles|five-year overall survival, specific disease-free survival, and locoregional control rates were 22% and 16% (log-rank p =.05), 27% and 15% (p =.01), and 48% and 25% (p =.002), in arm b and arm a, respectively. the 3, 5 and 10-year local-regional recurrence-free survival rates in stage iv disease were statistically better in arm ii (21.5%, 15.9% and 15.9%) than in arm treatment with tpf resulted in a reduction in the risk of death of 27% (p=0.02), with a median overall survival of 18.8 months, as compared with 14.5 months in the pf group. after a follow-up of 12-96 months overall survival was 58% in arm a and 45% in arm b (n.s.). mucosal tolerance was significantly worse in treatment arm b (p less than 0.00004). the rates of distant metastasis were 10% for chemotherapy group and 32% for control group (p=0.06). no significant difference in overall survival was found. among responders, the survival was found highly correlated with a good initial general status (p less than 0.01), and with the highest total doses of cisplatin (p less than 0.02).(abstract truncated at 250 words) no statistically significant differences in the 5-yr progression-free survival, in the median time to loco-regional and distant progression and in the 5-yr overall survival were observed. median progression-free survival and overall survival were, respectively, 19.7 and 33.3 months (arm a) and 30.4 and 39.6 months (arm b). there was a significantly better 1-year slc after rct (58%) compared with rt (44%, p = 0.05). there was better locoregional control in the tpf group than in the pf group (p=0.04), but the incidence of distant metastases in the two groups did not differ significantly (p=0.14). the response rate for the 12 rt & ct patients was four complete remissions (cr) and four partial remissions (pr); the 11 rt patients had one cr and three pr. patients from both groups with a complete response had a significantly longer survival time than those with a partial response (p less than 0.001). the occurrence of local toxic effects (i.e., mucositis and epidermatitis) was significantly greater in the rt-blm group (rt-blm, 72%, vs. rt, 21%). on the other hand, crp-rt gives a significantly higher incidence of stomatitis (p=0.0067) and a marginally worse thrombocytopenia (p=0.09). the difference in complete response rate between both treatment groups (24% in group a and 63% in group b) was statistically significant (p = 0.015). the rates of complete tumor resorption were: group a--27.3%, group b--19.2% and group c--16.7%. occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients). no survival improvement was observed. the overall survival rate was also significantly higher in the combined-therapy group than in the radiotherapy group (p=0.02 by the log-rank test; hazard ratio for death, 0.70; 95 percent confidence interval, 0.52 to 0.95), with five-year kaplan-meier estimates of overall survival of 53 percent and 40 percent, respectively. however, bleomycin had no significant effect on the 3-and 5-year survival rates, and it did not significantly reduce the incidence of local recurrences. the corresponding recurrence-free rates and five-year survival rates were 71.8% and 17%, and 65.5 and 23.5% respectively. the addition of tpz increased hematologic toxicity but did not improve outcomes in patients with resectable, stage iv hnscc using the protocol administered this small randomized study. there was no significant difference in the response rates at the end of treatment but disease free survival at three years was better in the ct/rt group (63.3% vs 20%). at 24 months, the proportion of patients without relapse was 42% for arm c vs. 23% for arm a and 20% for arm b. patients in arm a less frequently developed g3+ acute mucositis than their counterparts in arm b or c (14.7% vs. 40.3% vs. 44%). for c-hart, maximum acute reactions of mucositis, moist desquamation, and erythema were lower than with hart, whereas no differences in late reactions and overall rates of secondary neoplasms were observed. overall survival was significantly better (p = 0.03) in the neoadjuvant chemotherapy group than in the control group, with a median survival of 5.1 years versus 3.3 years in the no chemotherapy group. the overall 3-year primary locoregional tumour control, disease-specific and overall survival rates were 19, 36 and 30%, respectively. after surgery 62% of the patients randomized to chemotherapy-radiotherapy and 60% of the patients in the standard treatment group were clinically tumor free. it also offered higher progression-free survival (46% v 25% at 5 years; p =.0068), higher locoregional progression-free survival (lrpfs) (50% v 36% at 5 years; p =.041), and higher distant metastasis-free survival (dmfs) (86% v 57% at 5 years; p =.0013). the incidence of distant metastasis was significantly reduced (p less than 0.03) with chemotherapy. there was no significant difference in the overall survival rate, due to the radical neck dissections of recidive metastases. with a median follow-up of 41 months, the 3-year projected overall survival for patients enrolled in arm a is 23%, compared with 37% for arm b (p =.014) and 27% for arm c (p = not significant). loco-regional tumour control was 31% after cf, 32% after v-chart and 48% after v-chart+mmc, respectively (p<0.05). enteral nutrition through gastrostomy tube was more frequent in arm b before treatment and at 6 months (p < 0.01). the overall median survival duration was 33 months for i-fu and 25 months for placebo (p = .08). iv patients were significantly more fatigued (p <.006). there was superior disease-free survival for patients with n1 disease on the maintenance arm (70%) compared with the standard arm (42%) (p = .024). estimated 2-year disease-free and overall survival rates were 38.2% and 57.4% for arm 1, 48.6% and 69.4% for arm 2, and 51.3% and 66.6% for arm 3. at 4 years, overall survival rates were 56 and 46%; disease-free survival rates were 33 and 30% in the ct+lrt and the lrt groups, respectively. mucositis and vomiting predominated in the cddp-fu arm (p = .03, p < .001, respectively). locoregional control and distant disease-free survival were significantly improved with cisplatin (log-rank test, p = .039 and .011, respectively). there were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by functional assessment of cancer therapy-head and neck. we could not demonstrate a benefit with the addition of carboplatin to postoperative radiotherapy, possibly because of insufficient sample size. acute mucositis grade 3 or 4 was more frequent in arm b (38%) than in arm a (16%) (p < .001). rates of residual and recurrent disease, as well as distant metastases, were similar for the two groups. after adjustment for these factors, the chemotherapy did not seem to improve the effectiveness of the local treatment in terms of loco-regional control and survival. no difference could be detected in the survival of patients who received simultaneous versus sequential chemotherapy. three-year locoregional failure-free rates were 84% in the tpz/cis arm (95% ci, 71% to 92%) and 66% in the chemoboost arm (95% ci, 51% to 79%; p = .069). disease-free survival was significantly longer in the combined-therapy group than in the radiotherapy group (hazard ratio for disease or death, 0.78; 95 percent confidence interval, 0.61 to 0.99; p=0.04), but overall survival was not (hazard ratio for death, 0.84; 95 percent confidence interval, 0.65 to 1.09; p=0.19). patients in groups ii and iii had significantly higher overall response rates then those in group i (p = 0.011 and p = 0.0025, respectively) with no difference between groups ii and iii (p = 0.60). however, toxicity was more common in patients treated with the two modalities of combined treatment and there were no differences in overall survival rates (p = 0.706). tumour regression after chemotherapy either complete (cr) or partial (pr greater than 50%) was observed in 48% in the fm group and 41% in the poc group, and lymph-node regression (cr + pr) was respectively 15% and 23%. acute morbidity and deaths during intervention were higher in the study group (p = 0.007). the percentages were higher after radical surgery alone for locoregional recurrence (31% and 15.6%) and for death (28% and 18.6%). although there has not been any significant benefit in overall survival, the primary control rate is higher in patients who received methotrexate in addition to radiotherapy. this analysis at 12 months showed a disease free survival of 71% in the test arm vs. 45% in the control arm, which is statistically highly significant (p less than 0.01). at a median follow-up of 84 months, no significant differences have emerged in overall survival, 15 vs 37 months, or time to progression, 8.5 vs 14.5 months, for groups 1 and 2, respectively. concurrent non-platinum chemoradiotherapy reduces recurrences, new tumours, and deaths in patients who have not undergone previous surgery, even 10 years after starting treatment. this final analysis demonstrates no benefit in survival using preoperative chemotherapy for advanced stage, resectable head and neck squamous cell carcinoma. two-phase' treatment was applied to cancer of the tongue (table 3) and to cancer of the paranasal sinuses (table 4). there was no difference in toxicity between the two treatments with regard to leukopenia, thrombopenia, vomiting and nephrotoxicity. for inoperable patients, the combined treatment was significantly associated with an increase in complete remission rate (group a, 44%) as compared with radiotherapy alone (group b, 30%) (p = .037). there was no significant difference between the sites of recurrence at death or last follow-up (p = .38). analysis of preliminary results has shown that: 1) early and late side effects are similar in both groups; 2) after completion of treatment, the percentage of patients in complete remission was 71% (20/28) in the experimental group and 43% (12/28) in the control group; this difference was statistically significant among non responders to induction chemotherapy (1/15 versus 13/20, p = 0.001), but non significant among responders (11/13 versus 7/8) and 3) there were no differences between both randomized groups in term of 3-year overall survival and of 3-year loco-regional control. disease-free survival at 4 years was 38% on the rt arm compared to 46% on the ct/rt arm (p = n.s.). the median survival was 16.5 months in the combined-therapy group and 11.7 months in the radiotherapy group (p less than 0.05); the 3-year survival was 41 percent and 23 percent, respectively. actuarial 3-year locoregional control rates were 32% in the alt group and 27% in the pa-rt group. hyperthermia did not confer any benefit. the incidence of moderate to severe mucositis was significantly higher on arm a than arm b (p = 0.02). no significant difference in survival existed between the two groups. no significant differences were demonstrated in local disease control or actuarial survival rates at three and five years. a sequential analysis was used, and blm demonstrated a significantly greater local efficacy after the 32nd matched pair was assessed. in our experience the radio-chemotherapy combination, according to the described schedules, failed to improve both local control and overall survival; the comparison with the control group does not suggest that induction or intercalated chemotherapy can increase long-term survival even if initial complete and partial response rates are high. the relapse-free survival rate was higher in the combined-treatment group (61 percent vs. 41 percent, p=0.08).|consenting patients with an eastern cooperative oncology group (ecog) performance status < or = 2; with stage iii or iv schnc of the oral cavity, oropharynx, hypopharynx, or larynx; and who were recommended for locally advanced unresectable squamous cell carcinoma of the head and neck multicenter trial enrolling patients with a resectable, stage t2-t4 locally advanced (stages iii and iv) squamous cell carcinoma of the head and neck high-risk patients with resected head and neck cancer advanced squamous cell carcinoma of the oral cavity and the oropharynx (a 3-year follow-up a total of 558 patients were recruited in the trial from february 1996 to december 1999 patients with advanced head and neck cancer patients with high-risk head and neck cancer forty-six patients with squamous cell carcinoma of the head and neck region 122 patients who underwent randomization, 116 were included in the analysis patients with stage iv-m0 head and neck cancer 2 groups of patients with squamous cell carcinoma of the oropharynx (t2, t3, and t4; international union against cancer classification between january 1993 and june 1998, 192 previously untreated patients affected with stage iii and iv oropharyngeal carcinoma (excluding t1n1 and t2n1 it included 195 patients patients with unresectable locally advanced squamous cell cancer of the head and neck resectable stage iii and iv squamous head and neck carcinomas 358 patients underwent randomization, with 177 assigned to the tpf group and 181 to the pf group sixty-five patients with stage iii and iv squamous cell carcinomas of oral cavity, oropharynx, hypopharynx and larynx with no distant metastasis planocellular cancer of the head and neck region patients with locally advanced unresectable cancer of the head and neck inoperable head and neck cancer--preliminary report patients were stratified according to the primary site: floor of the mouth (fm) versus posterior oral cavity or oropharynx (poc) and institution patients who have not undergone previous surgery, even 10 years after starting treatment 47 patients were previously untreated and 32 patients had recurrent disease advanced cancers of the head and neck 95 patients were included advanced stage, resectable head and neck squamous cell carcinoma seventy-six patients were randomized, of whom 72 were eligible and analyzable (36 in each arm a total of 101 t3 and t4 buccal squamous cancers 29 patients on 163 evaluable patients patients with stage iii and iv (uicc from november 2000 to march 2003, eighty histopathologically proven cases of squamous cell head and neck carcinoma were included in this trial, 40 patients 53 patients are entered in the study: 27 in the cddp arm and 26 in the crp locally advanced head and neck carcinomas advanced head and neck cancers treated with thirty-eight patients patients who have undergone previous surgery for head and neck cancer locally advanced and/or node-positive nonmetastatic carcinomas of the head and neck patients with advanced head and neck cancer who were treated only with 60 patients with potentially resectable stage iii or iv squamous head and neck carcinomas between 1997 and 1999, 241 patients were entered onto study; 231 were analyzable unresectable head and neck cancer copyright 2001 american cancer society locally advanced squamous cell carcinoma (scc) of the head and neck advanced resectable head and neck cancer 33 patients in group 2, 29 were men patients with locoregionally advanced, unresectable disease thirty patients received a total of 226 patients patients with previously untreated stage iii or iv (excluding t1-2n1 and m1) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx patients with advanced squamous carcinoma of the head and neck 136 consecutive patients with previously untreated unfavorable stage ii or stage iii-iv (international union against cancer) scc of the oral cavity, pharynx, and larynx were enrolled from march 1983 to december 1989, 208 patients with locally advanced squamous cell carcinoma of the head and neck from march 1983 to june 1986, 100 patients with locally advanced squamous cell carcinoma of the head and neck 318 patients were enrolled in the study between 1986 and 1992 eight hundred sixty-one patients were accrued from 89 sites in 16 countries patients with primary (biopsy proven) scc of the oral cavity or the oropharynx with tumor nodes metastasis (tnm) stages t2-4, n0-3, m0 were included in the study advanced head and neck cancer locoregionally advanced carcinoma of the oropharynx eligible patients after undergoing surgery with curative intent, 167 patients copyright 1999 american cancer society patients who receive chemoradiation for head and neck cancer between january 1988 and december 1991, 159 patients with stage iii/iv (m0) squamous cell carcinoma of the head and neck 100 patients, consisted of two cycles of a combination of locally advanced inoperable head and neck squamous cell carcinoma stage iii or iv head and neck cancers eligible patients between the ages of 18 and 70 years who had stage iii or stage iv disease and no distant metastases to receive either two hundred and forty-one patients, with advanced squamous cell carcinoma of head and neck locally advanced-stage iii or iv (mo)-head and neck cancer patients who did not achieve a complete response at 50 grays underwent surgical treatment squamous-cell carcinoma of the head and neck compared 462 patients patients with a performance status of greater than 2 or a carbon monoxide diffusion capacity of less than 50% of the predicted value were assigned to the arm locally advanced squamous-cell carcinoma of the head and neck with concurrent 133 patients with advanced disease, 83 were included in the study--43 in the chemotherapy group and 40 in the control group patients with locally advanced squamous cell carcinoma of the head and neck (scc-hn), alternating patients with advanced disease a total of 442 analyzable patients 67 patients unresectable locally advanced cancer of the head and neck eligible patients had completely resected tumors of the oral cavity, oropharynx, hypopharynx, or larynx patients with oropharyngeal cancer 178 oropharyngeal and 62 hypopharyngeal carcinomas from 1987 to 1989, 42 patients with locally advanced squamous cell carcinoma of the head and neck (stages iii-iv, mo ninety-six patients with advanced squamous cell carcinoma of the head and neck one hundred thirty-one patients with operable sublingual or lingual squamous cell carcinoma in stages t2nxm0 to t4mxm0 patients with stage iii or iv squamous carcinoma of the oral cavity, oropharynx, or hypopharynx were eligible 106 patients with t1 plus t2 disease advanced head and neck carcinoma three hundred eighty-four stage iii (6%) and iv (94 stage iv head and neck squamous cell carcinoma advanced head-and-neck cancer from 1983 to 1986, 90 patients entered the trial resectable squamous cell carcinomas of the head and neck patients with primary resectable carcinomas of the oral cavity and tonsils and stage t2-t3 and n0-n2 disease prior to surgery patients with squamous-cell carcinoma of the head and neck who received november 1997 and march 2002 patients with a performance status of 0 to 2 and normal end-organ function patients with locally-advanced but operable squamous cell cancers of the head and neck region, a randomized clinical trial was conducted under the auspices of the head and neck intergroup (radiation therapy oncology group, southwest oncology group, eastern oncology group, cancer and leukemia group b, northern california oncology group, and southeast group patients with resectable disease head and neck cancers patients with advanced oral cavity cancer sixty-two patients with lymph node-positive, resectable, tnm stage iv hnscc intraoral and oropharyngeal cancer one hundred seventy-five patients 79 patients with squamous cell head and neck cancer one hundred thirty patients patients with advanced head and neck squamous cancer, the head and neck contracts program unresectable oro- and hypopharyngeal carcinomas 197 eligible patients were paired off successively on the basis of tumor sites and uicc stage 69 patients (group a oral cancer previously untreated patients with locally advanced head and neck cancer patients with resectable head and neck cancer between 1992 and 1999, 295 patients were entered on this trial unresectable pharyngeal carcinoma patients with resectable stage iv head and neck squamous cell carcinomas 34 patients, 30 of whom were men, with a median age of 57.5 years; 79% of this group had a karnofsky performance status of 90% to 100%; 70% had a squamous and 29% an undifferentiated histology advanced, unresectable epidermoid tumors of oropharynx patients with locoregionally advanced head and neck cancer 141 patients were treated by radical surgery alone, whereas 127 patients were treated by two hundred seven patients with inoperable stage iv disease-152 men and 55 women; mean age, 55 years-were included in this study group 97-03 between march 1991 and october 1993, 49 patients with inoperable head and neck carcinoma head and neck cancer patients and 34 patients on the control group were analysed advanced unresectable squamous cell carcinoma of the upper respiratory and digestive system advanced squamous cell carcinomas of the head and neck patients with advanced, unresectable squamous-cell carcinoma of the head and neck (h&n patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible between february 1986 and february 1991, 93 eligible patients with locally advanced unresectable cancer of the head and neck were stratified by who ps, t and n class and primary site between september 9, 1995, and april 28, 2000, 459 patients were enrolled advanced cancer of the head and neck patients with advanced, resectable oral cavity cancer forty-two of 62 employed patients returned to work one hundred fifty patients underwent ct+lrt; 150 patients had lrt alone patients with unresectable squamous cell head and neck cancer one hundred and fifty-seven previously untreated t3 and t4 and n0, n1 or n2 buccal squamous cell carcinomas patients with locally advanced squamous cell head and neck cancer (schnc advanced squamous cell carcinoma of the head and neck oral squamous cell carcinoma is the commonest male (29%) and the second commonest female (18%) malignancy in south india after undergoing total resection of all visible and palpable disease, 231 patients squamous cell head and neck cancer head and neck squamous cell carcinoma patients with stage ii disease of the pyriform sinus and stage ii and iv disease of the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, and paranasal sinuses were eligible all 966 patients were included in the analyses patients with advanced unresectable squamous-cell carcinoma of the head and neck, chemotherapy alternating with patients with locally advanced head and neck cancer, and who had not previously undergone surgery patients (pts from october 1990 to december 1997, 239 patients with squamous cell cancers originating in the head and neck region advanced cases of head and neck cancers 136 patients with previously untreated stage iii or iv squamous cell carcinoma of the head and neck patients with unresectable squamous-cell carcinoma of the head and neck 42 patients who were evaluated, 16 were randomized to arm a, 13 to arm b, and 13 to arm c advanced oropharyngeal squamous-cell carcinomas between february 1978 and january 1984, 222 eligible patients fifty-four previously untreated patients with locally advanced resectable squamous cell carcinoma of the head and neck (scchn stage iii or iv head and neck cancer locally advanced head and neck cancer squamous cell carcinoma (scc patients with macroscopically resected stage iii/iv scchn with high-risk pathologic features (> or =3 lymph nodes, extracapsular extension, perineural or angiolymphatic invasion, or involved margins patients with neck nodes high-risk squamous-cell carcinoma of the head and neck between january 1996 and november 1998 38 patients were treated with resectable oral cavity squamous cell cancer between jan 15, 1990, and june 20, 2000, 966 patients were recruited from 34 centres in the uk and two centres from malta and turkey from july 1994 to july 2000, 224 patients with squamous cell carcinomas of the head and neck (excluding nasopharynx and paranasal sinus head and neck carcinoma a total of 101 patients advanced (stage iii and iv) head and neck squamous cell carcinoma (i.e., surgery with postoperative radiotherapy in operable patients and radiotherapy alone in inoperable patients one hundred twenty-two previously untreated patients with stage iii/iv scc of the head and neck previously untreated squamous cell carcinoma of the head and neck head and neck carcinoma was initiated in 1973 by the european organization for research and treatment of cancer locally advanced squamous cell head and neck cancer head and neck cancer patients with local treatment failure were surgically salvaged from 1989 to 1993, 298 patients were enrolled and 270 patients were assessable 478 patients from seven centres patients with advanced stage resectable squamous cell carcinoma of the head and neck patients were categorized as having either "low-risk" or "high-risk" treatment volumes depending on whether the surgical margin was greater than or equal to 5 mm, there was extracapsular nodal extension, and/or there was carcinoma-in-situ at the surgical margins four-hundred sixty-one patients from denmark, norway and sweden with tumors in oral cavity, oropharynx, hypopharynx and larynx oropharyngeal carcinoma 158 eligible patients squamous cell carcinoma of the head and neck region eligible patients (n = 237 carcinoma of the oral cavity patients in the trial had biopsy-confirmed unresectable, previously untreated stage iii or iv, squamous-cell carcinoma of the oral cavity, pharynx, or larynx 240 patients: 113 patients with rct and 127 patients with rt, qualified for protocol and starting treatment advanced unresectable head-and-neck cancer patients with advanced stage iii and iv disease patients with stage iii-ivm0 scchn, eastern cooperative oncology group performance status of zero to one patients with a cardiac or vascular history between 1975 and 1978, 23 patients with stage iv, unresectable, squamous cell carcinoma of the head and neck oral cavity and oropharynx carcinoma advanced inoperable squamous cell carcinoma of the head and neck 109 patients with n2 disease patients with stage iii and iv unresectable head and neck squamous cell carcinoma between 1983 and 1986, the national institute for cancer research in genoa and affiliated institutions advanced-stage oropharynx carcinoma locally advanced, unresectable head and neck cancer patients had previously untreated, advanced nonmetastatic (stages iii and iv) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and paranasal sinuses patients with locally advanced h&n cancer 362 patients and resulted in premature study closure stage iv-m0 head and neck cancer thirty patients advanced stage iv unresectable head and neck cancer 241 advanced carcinomas of the upper respiratory and digestive tract from april 1987 to october 1992, 67 patients with inoperable squamous cell carcinoma of the head and neck region patients with the mentioned disease stages patients with inoperable head and neck carcinoma control advanced squamous cell carcinoma of the head and neck massachusetts medical society patients with locally advanced head and neck cancer from november 1992 through december 1995, a total of 164 patients patients with head and neck squamous cell carcinomas (hnscc 85 patients with untreated squamous cell carcinomas of the oral cavity patients with tumors of the head and neck twenty patients completed chemotherapy courses patients with locally advanced head and neck carcinomas 80 patients given advanced squamous-cell carcinoma of the head and neck with patients with oropharyngeal carcinomas patients with unresectable advanced head and neck cancer squamous-cell carcinoma of the head and neck 192 patients with oral cavity cancer three hundred patients were analyzed: 79 had tumors of the oral cavity, 106 oropharyngeal tumors, and 115 pharyngolaryngeal tumors locally advanced squamous cell carcinoma of the head and neck (scchn 179 patients, tumor beds and cervical lymph nodes were irradiated, and 20 patients underwent 135 patients of alveolobuccal carcinoma, clinically stage iii and iv, were entered on the protocol cancer patients patients with head and neck cancer patients with advanced, unresectable squamous-cell carcinoma of the head and neck 501 patients (all of whom had stage iii or iv disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation) to receive either locally advanced squamous cell carcinomas of the buccal mucosa previously untreated patients with unresectable stage iii/iv head and neck cancer patients with tumors of the oral cavity patients had stage iii (n=223) or stage iv (n=255) squamous cell carcinoma of the oral cavity (n=230), oropharynx (n=140), hypopharynx (n=65) or larynx (n=43 locally advanced squamous cell carcinoma of the head and neck advanced head and neck tumors from january 1981 through december 1983, 49 untreated patients with locally advanced head and neck cancers 324 patients, was conducted from january 1988 to july 1991 since head and neck cancer patients advanced head and neck cancer patients one hundred sixteen patients one hundred forty-three patients were evaluable for efficacy epidermoid carcinomas of the oropharynx stage iv carcinoma of the head and neck patients who had previously undergone radical surgery to remove their tumour between july 1995 and may 1999, 263 patients were randomized (median age 56 years; 96% stage iv tumors, 4% stage iii tumors cancer of the oral cavity and tonsils squamous cell carcinoma of the head and neck (scchn
serum gh basal gh|in response to l-dopa and arginine hydrochloride stimulation, serum gh rose to above 7 mg/ml in all patients.|16 children studied with x-linked hypophosphatemia patients with x-linked hypophosphatemia have short stature patients with x-linked hypophosphatemia children with x-linked hypophosphatemia
moderate and transient cd4 lymphopenia fibrosis index hcv-rna cd3, cd3 cd4, cd3 cd8, cd3 cd4 human leucocyte antigen normal transaminase levels plasma hiv rna levels clinical and biological events positive predictive value of evr reversible cd4 lymphopenia chronic hcv infection lymphopenia concerned mainly cd8 t-cells svr rate peak concentrations early virologic response deaths or opportunistic infections neutropenia and thrombocytopenia frequent blood lactate measurement and relative quantitation of mitochondrial dna (mtdna) content in peripheral blood mononuclear cells drug interactions, toxicity, tolerance and acceptance sustained virologic responses sustained virologic response safety and efficacy rate of sustained virologic response (an hcv rna level safety, tolerability, and efficacy pancreatitis or symptomatic hyperlactatemia virologic response side effects serious adverse event virologic efficacy and safety virologic response or histologic improvement svrs rates of sustained virologic response sustained virological response (svr: negative hcv-rna negative serum hcv-rna values efficacy and safety sustained virological response rate of drop-outs tolerability and feasibility premature interruptions sustained response rates evr sustained virologic response (svr), defined as an undetectable hcv rna level hla)-dr and cd3 cd8 hla-dr lymphocyte subsets response rate hyperlactataemia serum hcv rna level overall rate of sustained virologic response cd3 cd8 hla-dr t-cell percentages viral response svr serum hcv rna levels plasma hiv rna level overall svr early virological response serum hcv-rna histologic activity serum hcv rna intracellular peripheral blood mononuclear cells' stavudine-triphosphate (tp) concentrations cd4 lymphocyte counts and hiv-1 rna remained stable cd3 cd4 and cd3 cd8 t-cells counts hcv-rna levels sustained response cd4 counts median residual concentration of intracellular stavudine-tp predictive values of early virological response (evr hiv infection hcv rna cd4 cell count histologic responses adverse events sustained virological response (svr|among genotypes 1 or [corrected] 4, svrs were 28% versus 32% (p = 0.67) and 62% versus 71% (p = 0.6) in genotypes 2 or [corrected] 3 for peg 2b and peg 2a, respectively. coprescription of ribavirin and stavudine has no short-term impact on plasma hiv rna level in hiv-hcv-coinfected patients treated with stavudine as a part of their antiretroviral treatment; this coprescription can be safely used, although an in vivo interaction between ribavirin and stavudine is possible. peginterferon alpha-2b plus ribavirin was more effective than interferon alpha-2b plus ribavirin in hiv-coinfected patients. this difference between the treatments was found in patients with hcv genotype 1 or 4 infection (17% for peginterferon vs 6% for standard interferon, p = .006) but was not found in patients with hcv genotype 2, 3, or 5 (44% for peginterferon vs 43% for standard interferon, p = .88). neutropenia and thrombocytopenia were more common among patients treated with regimens that contained peginterferon alfa-2a, and anemia was more common among patients treated with regimens containing ribavirin. cd4 lymphocyte counts and hiv-1 rna remained stable. patients with hcv genotypes 2 or 3 had a 7-fold higher response rate than those with hcv genotypes 1 or 4. sustained virological response (svr) was achieved in 41.8% (37.3% in genotype 1, 54.6% in genotype 2/3, 20% in genotype 4). peg-inf + rbv was significantly more effective than inf + rbv for the treatment of chronic hepatitis c in hiv co-infected patients, mainly of genotype 1 or 4. in a per-protocol analysis, svr was reached by 54% of patients in arm a (genotype 2-3, 11/16; genotype 1-4, 4/12) and 22% in arm b (genotype 2-3, 3/15; genotype 1-4, 3/12). < 200 cells/ micro l. hiv infection at inclusion was responsible for higher cd3 cd8 hla-dr t-cell percentages in co-infected patients than in healthy and hcv mono-infected subjects. treatment with peginterferon and ribavirin was associated with a significantly higher rate of sustained virologic response (an hcv rna level of less than 60 iu per milliliter 24 weeks after completion of therapy) than was treatment with interferon and ribavirin (27 percent vs. 12 percent, p=0.03). however, while no deaths or opportunistic infections were observed, nearly 30% of subjects stopped treatment due to adverse events and 7 subjects experienced a serious adverse event. amantadine addition and interferon intensification do not improve the low efficacy of combination of interferon alfa plus ribavirin in hiv/hcv co-infected patients.|hiv/hcv-coinfected patients undergoing highly active antiretroviral therapy (haart 66 subjects hiv-coinfected patients human immunodeficiency virus patients one hundred and ten patients were included (mean age 38.7 years, mean weight 68 kg, 74% males, 74% on highly active antiretroviral therapy, mean cd4+ t-cell count 564 cells/mm3 co-infected persons 135 coinfected patients fifty-three had an hcv load patients without evr at week 12 patients who were also infected with hiv patients were enrolled from february 2000 to february 2002 and followed up for 72 weeks patients without evr 180 randomized subjects, 162 received at least 1 dose of study medication, constituting the modified intention-to-treat population 182 human immunodeficiency virus (hiv)-hepatitis c virus (hcv) patients nave for hcv therapy was performed chronic hepatitis c patients coinfected with hiv and hepatitis c virus hiv and hcv co-infected patients on stable antiretroviral combination therapy human immunodeficiency virus (hiv)-infected patients chronic hepatitis c in hiv-coinfected patients on haart patients with: detectable hcv-rna, alanine aminotransferase persons infected with the human immunodeficiency virus (hiv persons coinfected with hiv thirty patients (15 from arm a and 15 from arm b) dropped out of the trial prematurely due to side effects massachusetts medical society hiv-hcv coinfected patients 1,013 hiv-infected patients were consecutively evaluated chronic hepatitis c in hiv-coinfected patients one hundred twenty-one hepatitis c virus (hcv)-hiv-coinfected patients hiv-hcv-coinfected patients treated with weekly for 48 weeks, and 67 subjects hiv-positive patients one hundred six hiv-infected patients with chronic hepatitis c virus (hcv) infection 30 patients coinfected with human immunodeficiency virus (hiv) and hepatitis c virus (hcv hiv coinfected individuals on antiretroviral therapy chronic hepatitis c in hiv-infected patients 36 hcv-hiv co-infected patients with chronic hepatitis c, t-cd4 cell count > 250 cells/ micro l and a plasma viral load of < 10 000 hiv rna copies/ml. patients were given ifn for 48 weeks hiv-coinfected persons eighty co-infected patients fifty-five patients (28 from arm a and 27 from arm b) completed 48 weeks of therapy chronic hepatitis c in hiv-infected persons human immunodeficiency virus (hiv) infected patients seven patients enrolled because of side effects and/or failure of anti-hcv therapy hiv/hcv-coinfected patients with no early virological response hiv/hcv co-infected patients hiv/hepatitis c virus (hcv)-coinfected patients without early virological response (evr four hundred twelve hiv-hcv coinfected patients with detectable serum hcv-rna, abnormal liver histology, a cd4 cell count of at least 200 x 10(6)/l, and stable plasma hiv-rna subjects in both groups were similar with respect to age, gender, hcv genotype, and hiv disease status persons who are also infected with the human immunodeficiency virus (hiv hiv-infected patients 868 persons who were infected with both hiv and hcv and who had not previously been treated with
pain of childbirth pain using a visual analogue scale (vas) and a verbal descriptor scale (vds pain childbirth pain labour and delivery performance measures acute pain|also, women in the biofeedback group labored an average of 2 hr less and used 30% fewer medications. however, no difference between effectively trained electromyographic, ineffectively trained skin-conductance and control groups was found on labour and delivery performance measures.|facilitate childbirth in primiparae forty primigravidae
final visual outcome, symblepharon formation, corneal clarity and vascularisation with or without amniotic membrane transplantation rate of epithelial healing rate of healing of corneal epithelial defect, visual acuity, extent of corneal vascularisation, corneal clarity and formation of symblepharon|there was no overall difference in the final visual outcome, symblepharon formation, corneal clarity and vascularisation with or without amniotic membrane transplantation.|acute ocular burns 50 patients with grade ii-iii burns were graded as moderate burns, and 50 patients with grade iv burns were graded as severe burns patients with moderate grade burns patients with acute ocular burns 100 patients with grade ii to iv acute ocular burns (roper hall classification eyes with acute ocular burns
febrile morbidity and endometritis rates blood loss measured at cesarean delivery perioperative hemorrhage febrile morbidity incidence of postoperative infections with spontaneous placental removal frequency of febrile morbidity postdelivery infections blood loss during cesarean section and postoperative endometritis rate incidence of postpartum endometritis blood loss mean gestational age, frequency or duration of ruptured membranes, frequency or duration of labor, or mean number of vaginal examinations incidence of endometritis, wound infection, and the need for blood transfusion postoperative hemoglobin levels postoperative endometritis postpartum maternal infectious morbidity operative blood loss postcesarean infection, defined as postecsarean endometritis or wound cellulitis requiring drainage and antibiotic therapy rate of postoperative endometritis and amount of blood loss cesarean section intraoperative blood loss and mode of placental separation preoperative hemoglobin levels incidence of postoperative endometritis postoperative endometritis rate post-cesarean endometritis postoperative complications hemoglobin levels incidence of endometritis endometritis hematocrit values postoperative endometritis or blood loss mean maternal age, parity, gestational age, presence and duration of membrane rupture and number of vaginal examinations placenta extracted postoperative hemoglobin postcesarean endometritis and operative blood loss febrile morbidity, endometritis, maximums and durations of elevated temperatures, as well as other demographic, intrapartum, and postpartum variables postcesarean endometritis hematocrit risk of post-cesarean endometritis manual removal of the placenta and postcesarean endometritis change in hemoglobin, reflecting operative blood loss outcome measures (frequency of endometritis and quantitative decrease in hemoglobin postoperative hemoglobin and hematocrit values, and postcesarean endometritis postoperative infections incidence of postpartum infectious morbidity postcesarean febrile morbidity incidence of endometritis, wound infection, and need for blood transfusion incidence of postcesarean infections perioperative blood loss and postpartum maternal infectious morbidity operative time|uterine position did not significantly affect blood loss in the spontaneous group (1 and 2; p = 0.971) or the manual placental removal groups (3 and 4; p = 0.061). there were no statistically significant differences in measures of postcesarean febrile morbidity based on placental delivery method or intraoperative glove change. manual delivery of the placenta is not associated with a significantly greater risk of operative blood loss, decreased postoperative hemoglobin levels or increased incidence of endometritis compared with spontaneous placental separation. there were no statistically significant differences in mean gestational age, frequency or duration of ruptured membranes, frequency or duration of labor, or mean number of vaginal examinations between the two study groups. the decrease in postoperative hemoglobin (p < 0.05) and hematocrit (p < 0.001) was significantly greater in the manual removal groups (groups 1 and 3) than in the spontaneous expulsion groups (groups 2 and 4) at 48 hr postoperatively. operator glove change did not alter the incidence of endometritis (relative risk 1.0, 95% confidence interval 0.79-1.3). the incidence of postpartum endometritis was sevenfold greater in the manual than the spontaneous group (23% vs 3%, respectively; p < 0.05). no difference in postoperative complications was noted between the groups. we found no significant difference in either postoperative endometritis or blood loss regardless of the means used to effect delivery of the placenta. the incidence of postpartum infectious morbidity was also significantly greater in the manual group (rr 15.8, 95% ci 2.19-117.5).|patients undergoing emergency cesareans and those with possible placenta accreta or evidence of preexisting infection 760 women entered into the study, we included 643 who did not have intrapartum chorioamnionitis or cesarean hysterectomy one-hundred-fifty-one were randomized to the manual removal group and 149 to the spontaneous group consenting patients 200 women with normal pregnancies undergoing cesarean section patients who had cesarean delivery assigned either to spontaneous delivery of the placenta (group 1) or parturients undergoing cesarean delivery 100 women who were undergoing a cesarean section three hundred and two patients admitted for abdominal delivery 400 women with normal pregnancies undergoing cesarean delivery at king abdulaziz university hospital, jeddah, saudi arabia patients were excluded from participation if they had received intrapartum prophylactic antibiotics or had been determined to have chorioamnionitis patients were excluded if they had received intrapartum antibiotics, had chorioamnionitis, required an emergency cesarean hysterectomy, had rupture of membranes for more than 12 hr, had bleeding diathesis, and had abnormal placentation or prior postpartum hemorrhage 840 women who underwent cesarean section a total of 333 women were enrolled in the investigation, with 165 assigned to the manual removal group and 168 allocated to have spontaneous removal study criteria were met for 375 subjects: 177 in group 1 and 198 in group 2 62 gravid women with manual (n = 31) or spontaneous (n = 31) placental delivery at cesarean section women who required cesarean
peak flow postexercise calf blood flow and symptoms of claudication heart rate, blood pressure, calf blood flow and vascular resistance calf blood flow symptomatic limbs, reactive hyperemic flow claudication distance skin temperature walking distance blood pressure changes calf blood flow and vascular resistance heart rate, blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance maximal exercise heart rate objective and subjective measures of walking performance and foot temperature blood pressure vascular resistance mean arterial pressure symptoms of claudication heart rate limb circulation blood flow hyperaemic flow|in the less symptomatic limbs, reactive hyperemic flow was greater after pindolol than after the other drugs and did not differ from the level recorded after placebo. there was no evidence of adverse or beneficial effects of atenolol or nifedipine, when given singly, on peripheral vascular disease. the peak flow was reduced by 20% (p greater than 0.01) with metoprolol and by 15% with methyldopa below the initial level and by 17% and by 12% below the level recorded on placebo, respectively. calf blood flow was not affected by either drug compared with placebo at rest or at either workload.|49 patients (40 men) aged 39-70 with chronic stable intermittent claudication intermittent claudication patients with intermittent claudication patients with peripheral arterial disease 19 patients with mild-to-moderate peripheral vascular disease 14 hypertensive patients with intermittent claudication seven patients with hypertension and intermittent claudication patients with peripheral vascular disease
health care revisit and admission rates bronchial obstruction respiratory rate, rdi, and oxygen saturation clinical score, oxygen saturation or reduction in duration of hospitalization heart rate, respiratory rate, oxygen saturation, and clinical variables related to respiratory compromise with the use of a standardized respiratory distress index (rdi respiratory score length of hospitalisation clinical scores or oxygen saturations rate of improvement and the final score inspiratory respiratory system resistance mean duration of fever, cough, coryza, noisy breathing, time to achieve normal feeding and normal sleep; and frequency of hospitalization or adverse effects time to reach discharge criteria as defined by sao2, accessory muscle use, or wheezing wheeze and retraction score, respiratory and heart rates, and pulse oximetry bronchodilation, peak inspiratory pressure and inspiratory respiratory system resistance clinical score, oxygen saturation and heart rate oxygen saturation rates and clinical scores and duration of hospitalization need for hospital admission or home oxygen improvement in respirations improvement rates and duration of hospitalization clinical score accessory muscle score shorter hospitalization shortest hospital stay oxygen saturation oxygen saturation rates improvement in oxygen saturation (sao2) during hospitalization and survival analysis to assess the time required to reach preestablished discharge criteria on three measures: sao2, accessory muscle use, and wheezing condition of hospitalised mild bronchiolitis respiratory distress assessment instrument (rdai) score, respiratory rate, oxygen saturation, heart rate and the duration of hospitalization total scores rdi mild accessory muscle use, and respiratory distress assessment instrument (rdai) score remaining tidal volume (tef10, tef25, and tef50), and the wheeze score clinical scores changes in clinical scores and oxygen saturations respiratory rate, heart rate, oxygen saturation and presence of cyanosis, wheezing, retractions tidal breathing flow-volume loops severity score, number of nebulisations required tidal expiratory flow peak inspiratory pressure and respiratory system resistance sao2 clinical scores and oxygen saturation levels respiratory failure time to normal feeding, normal sleeping, quiet breathing, resolved cough, and coryza fraction of tidal volume exhaled at peak tidal expiratory flow (ptef) to total tidal volume (vptef/ve), and the fraction of exhaled time at ptef to total expiratory time (tptef/te rdai score, oxygen saturation in room air, rate respiratory and heart rate chest radiographs, leukocyte counts, blood culture specimens, and nasal aspirate for viral antigen detection mean los heart rate or respiratory rate respiratory rate and clinical score wheeze scores clinical score or hospital duration demographic characteristics, initial oxygenation, and clinical score time from admission until the infant had normal hydration, oxygenation, and minimal respiratory distress clinical score and length of hospital stay mean sao2 respiratory rate respiratory rate, pulse oximetry, and a clinical score based on the degree of wheezing and retractions peak inspiratory pressure wheezing, retractions and respiratory rate time for resolution of illness (roi), duration of fever, cough,coryza, noisy breathing, time to achieve normal feeding and normal sleep, and frequency of hospitalization and adverse effects arterial oxygen saturation (sao2 actual length of hospital stay vptef/ve and tptef/te respiratory and heart rates, clinical score, oxygen saturation (spo2), and the infant's state and rdi scores length of hospital stay lengths of hospitalization decrease in respirations time to resolution of illness respiratory distress ptef bronchodilation duration of hospitalization fall in sao2 median (se, 95% ci) duration of resolution of overall illness tidal expiratory flows respiratory syncytial virus (rsv) positivity and enrollment score respiratory and heart rates, clinical score, and oxygen saturation length of hospital stay (los desaturation ie, asleep, awake, or feeding heart rate symptomatology of acute viral bronchiolitis adverse effects|both groups showed significant improvement in oxygen saturation over time, but there was no significant difference in improvement between the two groups. group differences were not statistically significant in any of the secondary outcomes. average daily improvements, as reflected by changes in the clinical score and length of hospital stay, was essentially the same for infants treated with placebo, salbutamol alone, and dexamethasone alone. the outcome of patients at 120 min was found significantly better than the baseline values (p < 0.05). racemic epinephrine and albuterol at equivalent doses had no effect on the need for hospitalization or supplemental oxygen in bronchiolitis in the outpatient setting compared to nebulized saline placebo, though this study may have missed less dramatic clinical effects due to small sample size. similar statistically significant bronchodilation occurred after all three bronchodilators as indicated by a decrease in peak inspiratory pressure and respiratory system resistance, but these changes were small and probably clinically insignificant. nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups. all infants had significantly decreased scores, except those in the control group; the aminophylline group included a greater percentage of patients who did not abate their scores, and they stayed in the hospital for more days than those in the other groups. the median (95% confidence interval) time to resolution of illness (days) was similar: albuterol, 9.0 (8-13); placebo, 8.0 (7-9); p =.3) there was no significant difference between the groups in terms of severity score, number of nebulisations required in the nebulised groups and the outcome as measured by the length of hospitalisation. the heart rate rose slightly more in the albuterol group (increases 7.76 from baseline) versus the placebo group (decreases 6.79). we did not find any significant difference in the rate of improvement and the final score (p = 0.49) in the four groups. the fall in sao2 with salbutamol was seen whether infants received it as the first or second nebulisation. there were no significant changes in vptef/ve and tptef/te after albuterol or saline treatment. clinical scores and oxygen saturation levels improved more rapidly in the bronchodilator groups than in the placebo group up to 24 h, but these drugs did not have a sufficient effect to change the natural course of the disease. children who received saline solution as initial therapy had no significant differences from baseline in any of the assessment measures. in a double blind randomised trial, we found no evidence that nebulised ipratropium bromide was of clinical benefit in acute bronchiolitis. there were no statistically significant differences in any outcomes among the four treatments, except for oral albuterol, which produced an increase in heart rate (15 beats per minute, p = .005). there was no difference between the groups in oxygen saturation (p = 0.74); patients treated with salbutamol had a small increase in heart rate after two treatments (159 +/- after two treatments, there was a significant improvement in the wheeze scores (p less than 0.05) and total scores (p less than 0.05) of the albuterol group compared with the placebo group. the change in oxygen saturation of recipients of both agents was significantly better than that of recipients of salbutamol alone or ipratropium bromide alone. nebulized terbutaline therapy does not appear effective in treating moderately ill infants with the first acute bronchiolitis. oxygen saturation decreased in group i without reaching statistical significance. oral salbutamol is not superior to placebo in reducing the duration of symptoms in mild cases of acute bronchiolitis in children.|eighty-nine patients, aged from 23 days to 11 months patients, who were 2 months to 2 years of age and without underlying cardiac or pulmonary disease, received 35 patients less than 12 months of age with diagnosis of moderately severe bronchiolitis hospitalized infants with moderate bronchiolitis infants hospitalized with acute, moderate bronchiolitis 2005 young children with acute bronchiolitis, we enrolled 83 children (median age 6 months, range 1 to 21 months pediatric emergency department and outpatient clinic at university of maryland in baltimore tertiary pediatric intensive care unit in a university affiliated hospital in the northeastern united states infants less than 12-months-old infants under 1 year of age twenty infants younger than 1 year of age (mean age, 5.8 infants with bronchiolitis 129 infants (albuterol, n = 64; placebo, n = 65 mild bronchiolitis acute wheezing in infancy all children less than 2 years old with bronchiolitis patients with respiratory syncytial virus bronchiolitis in respiratory failure 74 children aged 36 months or younger with acute wheezing participated in a double-masked, randomized young children with acute bronchiolitis mild cases of acute bronchiolitis in children infants with bronchiolitis in egypt infants eighty-eight infants (median age 5.5 months) being treated for their first episode of wheezing sixty-nine infants with moderate-severe bronchiolitis hospitalized at their first episode of wheezing or crepitations in the chest patients with moderate-severe bronchiolitis 186 children (mean age 9.5 infants with mild-to-moderate acute viral bronchiolitis pediatric unit in a community teaching hospital infants with mild-to-moderate illness moderately ill infants with the first acute bronchiolitis twenty-two patients with respiratory syncytial virus bronchiolitis and in respiratory failure were enrolled wheezing infants in the emergency department mildly affected ambulatory infants with acute bronchiolitis thirty-two infants, aged 1 to 12 months, hospitalized with acute wheezing, were studied infants aged 0 to 24 months who presented to the emergency department with wheezing mildly affected infants with acute bronchiolitis wheezing infants 52 patients <24 months of age with a diagnosis of moderately severe, acute viral bronchiolitis eight blocks of four infants each, matched by age and clinical score bronchiolitis pediatric outpatient department of a tertiary care hospital infants hospitalized for acute viral bronchiolitis fifty-one (42%) had respiratory syncytial virus (rsv) isolated from their nasopharyngeal aspirates a total of 149 infants were randomized; 50 34 children from whom nasal specimens were obtained by swab for viral identification, 24 had positive test results (21 for respiratory syncytial virus, 1 for parainfluenza, 1 for paramyxovirus, and 1 for influenza a wheezing infants and young children children's hospital of tunis from december 2004 to april 2006 young infants admitted for acute wheezing (aw young children with bronchiolitis admitted to hospital with moderate illness seventy-nine infants less than one year of age one hundred and fifty-six infants aged between 7 weeks and 24 months who had had an episode of wheezing and other signs and symptoms of bronchiolitis young acutely wheezing children 41 infants with recurrent wheezing acutely wheezing infants and young children young children infants hospitalized with acute viral bronchiolitis infants with bronchiolitis due to respiratory syncytial virus 140 infants (of 310 approached) with a clinical diagnosis of acute bronchiolitis with respiratory rate <or= 70 breath/min, heart rate <or= 200 beats/min, hemoglobin oxygen saturation (spo2 infants with first-time wheezing 21 infants, admitted with bronchiolitis positive for respiratory syncytial virus, had continuous sao2 measurements made before and after acute bronchiolitis infants with recurrent wheezing n=70 patients aged 12 months or younger (n = 37) benefited from metaproterenol treatment (improvement in respiratory rate and rdi) but not to the same degree as children aged 24 months or older (n = 23 december 1995 to march 1996 sixty-five patients between ages 6 weeks and 24 months with a diagnosis of bronchiolitis, defined as first-time wheezing, upper respiratory symptoms and/or fever, and a respiratory distress assessment instrument score of at least 4 twenty-five infants n = 20 128 egyptian infants with first-time wheezing (mean age 5.9 months infants with mild bronchiolitis due to respiratory syncytial virus acute wheezing in infants young children in hospital with bronchiolitis 120 patients bronchiolitis in egypt bronchiolitis in infancy 40 infants between 6 weeks and 24 months of age who had a first episode of wheezing and other signs and symptoms of bronchiolitis infants younger and those older than 6 months of age hospitalized infants with bronchiolitis infants with respiratory syncytial virus bronchiolitis on mechanical ventilation infants hospitalized with bronchiolitis
pain reduction disability headache-related and demographic characteristics headache intensity standard headache diaries cervicogenic headache pain on neck movement, upper cervical joint tenderness, a craniocervical flexion muscle test, and a photographic measure of posture pain level headache reduction pain intensity mcgill-melzack pain questionnaire headaches side effects that included drowsiness, dry mouth and weight gain headache pain levels headache frequency and intensity, and the neck pain and effects headache intensity and duration, the northwick park neck pain index, medication intake, and patient satisfaction overall function (sickness impact profile), and mental well-being (mood adjective check list) and the intensity and frequency of headache mean number of analgesics emg activity headache mean pain index change in headache frequency neck soreness and stiffness frequency and intensity of cephalalgia safety and effectiveness subjective level of headache side effects headache pain myogenic headache migraine activity average pain reduction headache intensity per episode frequency, intensity (visual analogue score), duration, disability, associated symptoms, and use of medication for each migraine episode daily hours of headache, pain intensity per episode, and daily analgesic use, as recorded in diaries overall function pain or stiffness in the neck, and pain/paraesthesia pain index intensity of headache muscle tension tension headache number of headache hours per day mean daily headache average response symptoms of cervicogenic headache tension headache pain daily headache intensity, weekly headache frequency, over-the-counter medication usage and functional health status (sf-36 quantity of muscle tension (motor unit potential spikes per time unit morbidity of each episode intensity and frequency of headache lateral flexion migraine headache headache index scores pain measured rotation pain scores migraine frequency number of headaches pain/paraesthesia headache frequency episodic tension-type headache headache pain intensity headache index score headache activity|all showed decreased headache activity (50% good, 38% excellent). the average response of the treatment group (n = 83) showed statistically significant improvement in migraine frequency (p < .005), duration (p < .01), disability (p < .05), and medication use (p< .001) when compared with the control group (n = 40). the intensity and frequency of headache was significantly reduced in both the physiotherapy group and the acupuncture group. patients were randomly assigned to treatment groups and received either short term intervention (15 or less treatments) or long term intervention (greater than 15 treatments). two weeks after the last treatment the mean pain index was significantly reduced to 43% in the group treated with manual therapy compared with the pretreatment level. after a follow-up period of 28 weeks, there was still a significant reduction of emg activity in both groups. a wilcoxon signed rank test for differences indicated that 90% of the subjects exposed to tt experienced a sustained reduction in headache pain, p less than .0001. cranial electrotherapy stimulation is distinct from tens, and is safe and often effective in ameliorating the pain intensity of tension headaches. during the trial migraine attacks reduced significantly by 28%, and reduced a further 19% up to the follow-up period. the number of headaches per week decreased from 4.03 during the baseline period to 0.43 during the initial 2-week follow-up period and to 0.14 during the extended follow-up which averaged 8.1 months. the use of analgesics decreased by 36% in the manipulation group, but was unchanged in the soft-tissue group; this difference was statistically significant (p = .04, chi 2 for trend). based on intent-to-treat analysis, no significant differences between the manipulation and control groups were observed in any of the 3 outcome measures. the reduction in headache index scores during treatment compared with baseline was 49% for amitriptyline, 40% for spinal manipulation and 41% for the combined group; p = .66. change in patient-reported daily headache intensity, weekly headache frequency, over-the-counter medication usage and functional health status (sf-36). at the 12-month follow-up assessment, both manipulative therapy and specific exercise had significantly reduced headache frequency and intensity, and the neck pain and effects were maintained (p < 0.05 for all). pt alone is not effective in reducing headache, with only 14% of subjects reporting significant headache reduction (mean reduction of 15.6% in comparison with 41.3% in rtb). manipulation also produced a significant increase in measured rotation that was maintained for three weeks and an immediate improvement in lateral flexion that was not maintained.|218 patients with the diagnosis of migraine headache 1015 adult patients with primary diagnosis of vascular/migraine or muscle contraction headache participated in the study investigating symptom frequency and severity over a 36 month period after receiving treatment migraine patients who fail to improve with relaxation training/thermal biofeedback (rtb volunteer sample of 26 men and 49 women aged 20 to 59 years who met the diagnostic criteria for episodic tension-type headache as defined by the international headache society patients with frequent migraine headaches cervicogenic headache adults with episodic tension-type headache 23 patients with chronic migraine post-traumatic headache one hundred patients thirteen subjects from the actual exposure group elected not to receive additional exposure 22 subjects who had actual exposure received 2 additional weeks of actual exposure after their initial 1-month follow-up chronic tension-type headache 23 patients with post-traumatic headache sixty-two female patients with chronic tension headache chiropractic college outpatient clinic 200 participants who met the diagnostic criteria for cervicogenic headache outpatient facility of a national health service-funded chiropractic research institution in denmark sixty volunteer subjects with tension headaches 448 people responded to the recruitment advertisements; 298 were excluded during the screening process one hundred twenty-seven volunteers between the ages of 10 and 70 years were recruited through media advertising 52 patients in general practice tension-neck and headache patients vascular and muscle contraction headache 42 subjects (34 women and 8 men), who met the international headache society's criteria for migraine, participate in a double-blind, placebo-controlled study subjects were recruited from 450 headache sufferers who responded to newspaper advertisements 19 patients (83 migraine headache twenty-two tension-neck and headache patients fifty-three subjects suffering from frequent headaches who fulfilled the international headache society criteria for cervicogenic headache (excluding radiological criteria seven hundred and ninety-three patients returned sufficient data to be included in the analysis patients with tension headache treated with 150 patients who were enrolled in the study, 24 (16%) dropped out: 5 (6.6%) from the spinal manipulative therapy and 19 (27.1%) from the amitriptyline therapy group 9 subjects kept a 3-week log of headache activity episodic tension-type headache chronic tension-type headaches one hundred and fifty patients between the ages of 18 and 70 with a diagnosis of tension-type headaches of at least 3 months' duration at a frequency of at least once per wk headache patients
forced expiratory volume eno levels daily sputum production exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score spirometry, 24-h sputum volume, sputum leukocyte density, bacterial densities, and concentrations of interleukin (il)-1beta, il-8, tumor necrosis factor-alpha (tnf-alpha), and leukotriene b4 (ltb4 hrqol eno 24 hour sputum volume quality of life pulmonary function, number or severity of exacerbations, or microbiological profile of the sputum exhaled nitric oxide (eno) levels sputum production sputum purulence score sputum volume exacerbation frequency adverse reactions fev1, fvc, 24 h sputum volume or number of bronchiectatic segments episodes of exacerbation dyspnea sputum leukocyte density and il-1beta, il-8, and ltb4 symptoms, pulmonary function and sputum production morning peak expiratory flow rate symptom scores for cough|a small, significant, improvement in morning peak expiratory flow rate (p less than 0.03) and forced expiratory volume in 1 s (p less than 0.03) was seen but the absolute changes are unlikely to be of clinical importance. logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency </=2/year (p = 0.04), and sputum purulence score >5 (p = 0.03). inhaled fluticasone therapy, despite being an effective anti-inflammatory agent, has no significant effect on eno production, either at individual time points or over the entire 52-week profile, in bronchiectasis. there were no significant changes in spirometry (p > 0.05) or any reported adverse reactions in either group. the group administered fp 1000 microg daily showed significant improvement in dyspnea (1.03 [2.1]-1.24 [2.2] points; p = 0.01-0.04), sputum production (p = 0.001),|patients with bronchiectasis remain unknown sixty non-smoking patients (38 women; mean age 56.4 patients with bronchiectasis ninety-three patients (mean age: 68.5 [8.4 severe bronchiectasis 20 patients with bronchiectasis stable non-smoking bronchiectasis patients 35 and 38 patients in the patients with pseudomonas aeruginosa (pa) infection patients with steady-state bronchiectasis not due to cystic fibrosis, and its repercussions for patient health-related quality of life (hrqol bronchiectasis twenty-four patients (12 female; mean age 51 yr 12.7 years) were recruited patients with steady-state bronchiectasis
equally sharing decision responsibility patient knowledge and satisfaction decisional conflict score psa knowledge patient-reported level of control over the decision to be screened realistic personal expectations of the benefits and risks, decisional conflict, and perceived acceptability of the intervention questionnaire assessed knowledge, attitudes, perceived risk and intention to have a psa test rates of noncompliance and rehospitalization back surgery rates acceptability of information delivery (1-7), knowledge about statins and coronary risk (0-9), and decisional conflict about statin use complete screening (i.e., having a digital rectal exam (dre) and prostate specific antigen (psa) testing), and (2) complete or partial screening (i.e., having a psa test with or without dre patient decision process and the decision outcome rate of vaginal birth decisional conflict regarding colorectal cancer screening decisions knowledge and perceived risk uptake rates of treatment options, length of consultation with the surgeon, time point of treatment decision making, perceived involvement in decision making, neither decision related nor general patient satisfaction breast cancer prevention knowledge postvisit psychological or acceptability outcomes risk of stroke level of knowledge, decisional conflict score, women's preference for mode of birth, and recorded mode of birth risk of procedure-related miscarriage adherence and optimize glycemic control participants' knowledge, realistic expectations, and decisional conflict decisional conflict scale (dcs unadjusted mean knowledge scores perceived limitations and risks of brca1 testing state anxiety change in knowledge knowledge, satisfaction, and anxiety positive attitudes change in antithrombotic therapy hysterectomy rates prostate cancer knowledge about risk management options icc rate of uptake of trial of labor or elective repeat cesarean section satisfaction with decision making greater knowledge mean consultation duration knowledge, risk awareness, intervention satisfaction, decisional conflict, and among women aged at least 35 years, use of invasive diagnostic testing preferences for watchful waiting survival rates decision making and quality of life elevated self-image expectations knowledge score postdecisional regret or actual genetic testing decision match between the patient's preferred and actual roles during consultation with the physician 10-year chd risk surgery rates number of patients receiving therapy appropriate to their stroke risk decisional conflict scale and state-trait anxiety inventory anxiety scale quality of life knowledge levels perceived clarity of values, a sub-scale of the decisional conflict scale; congruence between personal values of benefits and risks (measured on 0-10 importance rating scale) and choices (accept, decline, unsure regarding preventive hormone therapy [hrt values clarity anxiety, general health status, prostatic symptoms, utility, or costs (excluding costs associated with the video disc equipment participants' knowledge, risk perception, intention to undergo genetic testing, decisional conflict, satisfaction with decision, anxiety, and satisfaction intent to begin or continue fecal occult blood testing (fobt), flexible sigmoidoscopy, or both anxiety, use of health service resources, general health status, or utility percentage of preference matches knowledge about hypertension comparable demographics, prior computer experience, medical literacy, and baseline knowledge of breast cancer and genetic testing, and both counseling and computer use median duration of nvaf undergone revascularization shared decision-making program scores total score on decisional conflict scale, and mode of delivery amniocentesis or chorionic villus sampling referral for coronary revascularization menorrhagia specific utility quality-of-life scale, knowledge about menorrhagia, and anxiety and process measures mean (sd) decisional conflict scores psa test choice, prostate cancer treatment preferences, knowledge and concern about prostate cancer, and decisional conflict decisional conflict scores crc mortality risk reduction anxiety mean scores for decisional conflict anxiety, knowledge, or decisional regret undergoing psa screening knowledge scores knowledge, decisional conflict, state anxiety, satisfaction, use of pnd, and pregnancy outcomes overall surgery rate mean knowledge scores screening frequency general knowledge increased and of women with realistic expectations knowledge or seu scores congruence between personal values and decisions about hrt knowledge, satisfaction with decision, decisional conflict or ht use state anxiety levels knowledge scores relative likelihood of reaching a management decision median consultation times realistic expectations about the benefits and risks of lung transplantation test scores of knowledge decisional conflict, knowledge, state anxiety, intentions regarding starting treatment, and actual treatment decision general health and angina scores decisional conflict and greater self-advocacy general health knowledge of nhps perception of absolute risk of breast cancer decision, decisional conflict scores, treatment choice and prostatectomy rate, american urological association symptom scale, costs, anxiety, utility, and general health status anxiety levels informed choice and decisional conflict, and the secondary outcomes, anxiety, depression, attitudes to the pregnancy/fetus and acceptability of the resource knowledge of coronary artery disease, satisfaction, self-reported physical and mental health functioning, and the proportion of patients who were referred for coronary revascularization knowledge about menorrhagia perceived clarity of values and overall congruence between values and choices decisional conflict post intervention hba(1c) levels test decision, subjective expected utilities, knowledge, informed decision-making, risk perception, decisional conflict, anxiety, perceived usefulness and directiveness of consultation information imda percentage of women making an informed choice about whether to continue or stop screening and the percentage of women participating in the screening higher knowledge and lower risk-perception scores physicians' decisional conflict scores total decisional conflict score prostate cancer screening complete or partial screening questionnaires assessing knowledge, anxiety, and satisfaction knowledge mental health functioning satisfaction participants' ratings of convenience, effort, or satisfaction final management decision, decisional conflict, decisional satisfaction, and receipt of risk reducing mastectomy frequency of screening, patient knowledge, decisional conflict, and time spent discussing screening colorectal cancer patient interest in undergoing psa screening measured on a 5-point likert scale satisfaction or anxiety realistic expectations good' level of knowledge decreased anxiety, increased knowledge, and enhanced satisfaction patient satisfaction lower decisional conflict fecal occult blood testing or flexible sigmoidoscopy diagnostic procedure knowledge, decisional conflict, satisfaction with health care provider, and self-efficacy screening interest active decision-making role physical functioning decisional conflict and knowledge about genetic testing knowledge questions correctly menorrhagia quality of life satisfaction with decision-making process scores mean state anxiety scores health status chd risk knowledge (kn) scores anxiety scores postoperative satisfaction lower levels of decisional conflict surgery rate decision quality decisional conflict scale planned screening tests overall beneficial effect satisfaction-with-decision scale symptom and functional outcomes number of surgical procedures used, improve knowledge, or influence satisfaction or anxiety levels of depression outcomes and satisfaction; surgery rates hemoglobin a(1c) (hba(1c)) levels general knowledge of the risks and benefits of hrt, personal expectations and values concerning these risks and benefits, and women's views on hrt mean level of anxiety and increased satisfaction realistic risk perceptions screening decisions overall decisional conflict decisional conflict and satisfaction factual knowledge, reduced anxiety proportion of patients choosing allogeneic blood initial decision for and the final uptake of the prenatal screening test patient knowledge (measured using 20 questions about knowledge deemed necessary for an informed treatment decision), treatment decision, patient-angiographer agreement on decision, and general health scores psa screening higher knowledge scores psychological distress realistic expectations about the risk of stroke and hemorrhage patient satisfaction with the decision-making process number of knowledge questions mean costs decisional conflict and mode of delivery mortality due to early-stage prostate cancer, psa screening performance, treatment-related complications, and disadvantages of screening national rates of caesarean section number of patients receiving appropriate care adherence or hba(1c) levels decisional self-efficacy, preparedness to participate in decision-making, and arthritis self-efficacy sdmi improved decision making facial appearance intrusive thoughts proportion of colorectal cancer screening plans carried out dcs|unadjusted mean knowledge scores were significantly higher in the computer group than the counselor group (p =.048), but they were equivalent when adjusted for demographic differences (p = 0.34). ei group men had a screening frequency two times greater than that of si group men, but the difference was not statistically significant: 8% vs. 4 % (or = 1.94) fo rcomplete screening, and 19% vs. 10% (or = 2.08) for complete or partial screening. there were no statistically significant differences between interventions in perceived clarity of values and overall congruence between values and choices. results show that the educational intervention reduced intention to obtain genetic testing among women at average risk and increased intention among high-risk women at 6 months. there was no difference between groups in the measures of satisfaction or anxiety (mann-whitney u-test; p>0.05). no differences were found between the groups for anxiety, general health status, prostatic symptoms, utility, or costs (excluding costs associated with the video disc equipment). those in the group intervention showed a significantly greater increase in knowledge than those in the individual counseling intervention. these data indicate that preliminary print education can be used to educate low-risk individuals about brca1/brca2 genetic testing. mean state anxiety scores were reduced by counseling but were within normal ranges for both groups at baseline and after either intervention, regardless of risk status. an innovative decision aid effectively involved patients with type 2 diabetes mellitus in decisions about their medications but did not improve adherence or hba(1c) levels. there were no between-groups differences in participants' ratings of convenience, effort, or satisfaction following exposure to the decision aid. patients who received the informational intervention were significantly less interested in undergoing psa screening than controls (mean difference in interest, 0.8 on 5-point scale, p < .001). decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn. there was no difference between the groups in decision outcomes: 52% of patients in the control group and 49% in the experimental group completed planned screening tests (p = 1.0). two weeks after the intervention, there was significantly less decisional conflict in the intervention group (adjusted difference = -16.6 hysterectomy rates were lower for women in the interview group (38%) (adjusted odds ratio [or], 0.60; 95% confidence interval [ci], 0.38-0.96) than in the control group (48%) and women who received the information alone (48%) (adjusted or, 0.52; 95% ci, 0.33-0.82). in the enhanced participation arm patients not eligible for radical prostatectomy chose orchidectomy less frequently and favoured nonsurgical endocrine treatment than in the treatment protocol arm. the percentage of preference matches did not differ between groups (ig 49%, cg 51%, p = 0.71). in pre-post testing, the decision aid also appeared to increase the proportion of patients with plans to intervene on their chd risk (absolute increase ranging from 21% to 47% for planned medication use and 5% to 16% for planned behavioral interventions). there were no significant differences between the videotape and 'usual care' groups with respect to satisfaction with the decision making process (mean score 73 vs. 77%; p = 0.37), satisfaction with the decision made (mean score 73 vs. 78%; p = 0.28), physical functioning (38 vs. 38%; p = 0.76), mental health functioning (49 vs. 49%; p = 0.94), or in referral for coronary revascularization (or 0.60; 95% ci 0.22-1.65; p = 0.33). a decision-aid for women facing choices about birth after cesarean section is effective in improving knowledge and reducing decisional conflict. patients at the low-literacy site were more engaged with the entertainment-based aid than patients at the high-literacy site. there was no difference in screening interest between the control group and the two information groups (p =.8). women assigned to the interactive prenatal testing decision tool had higher knowledge scores (79.5% compared with 64.9%, p<.001), were more likely to correctly estimate their risk of procedure-related miscarriage (64.9% compared with 48.1%, p=.002) and carrying a down syndrome-affected fetus (63.5% compared with 15.1%, p<.001), were more satisfied with the intervention (p<.001), and had less decision uncertainty (p<.001) than controls after viewing the intervention. fecal occult blood testing or flexible sigmoidoscopy was ordered for 47.2% of intervention participants and 26.4% of controls (difference, 20.8 percentage points [95% ci, 8.6 to 32.9 percentage points]). there were no differences between intervention and control groups in the univariate analyses. video/leaflet patients had lower decisional conflict than corresponding controls (30.3 versus 36.8, adjusted 95% ci = -7.4 to -0.6, p = 0.021), greater knowledge (75% versus 65%, adjusted 95% ci = 6% to 13%, p < 0.001) and no evidence of increased state anxiety (35.7 versus 36.1, adjusted 95% ci = -3.9 to 1.7, p = 0.46). despite the low overall vaccine acceptance rate, it is concluded that individualized decision analysis can influence the clinical decisions taken by knowledgeable and interested patients. men who received the brief pda had significantly higher knowledge scores (p<0.0001) and less positive attitudes (p<0.0001) regarding psa testing than men in the control group. a tailored prenatal testing decision aid plays an important role in improving women's knowledge of first and second trimester screening tests and assisting them to make decisions about screening and diagnostic tests that are consistent with their values. the overall surgery rate was 22% lower in the videodisk group (26% versus 33%, p = 0.08). colorectal web is more effective than a standard colorectal cancer web site at prompting previously unscreened individuals to choose a preferred colorectal cancer screening test and to be screened for colorectal cancer. the use of imda did not affect the women's overall uptake rate of the prenatal screening test for down syndrome. treatment decision within 3 months was made more often in the intervention group than in the control group (96% and 89% respectively, p = 0.02). at three months a lower proportion of women in the intervention group than in the control group were undecided about treatment (14% v 26%; -12%, -23% to -0.4%), and a higher proportion had decided against hormone replacement therapy (46% v 32%; 14%, 1% to 28%); these differences were no longer apparent by nine months. both groups experienced a statistically significant reduction on the dcs (-0.55 +/- 0.59, p < 0.0001 versus -0.52 +/- decisional conflict was significantly lower amongst men receiving the evidence-based booklet (p = 0.038). motives for treatment did not differ significantly between the video image and standard cp groups. compared with the pamphlet, patients whose clinicians delivered the decision aid during the office visit showed significant improvements in knowledge (difference of 1.6 of 9 questions, ci 0.3, 2.8) and nonsignificant trends toward finding the decision aid more acceptable (odds ratio 3.1, ci 0.9, 11.2) and having less decisional conflict (difference of 7 of 100 points, ci -4, 18) than when a researcher delivered the decision aid just before the office visit. women in the decision-aided group had higher knowledge and lower risk-perception scores about both methods, more positive attitudes about the medical method, lower decisional conflict, more stable evaluations of the decision information over time and higher perceived usefulness of information ratings. informed decision-making was higher, perceived risk more realistic and decisional conflict over time lower in the decision analysis group. they also tended to have a reduced mean level of anxiety and increased satisfaction with the treatment choice compared with the control group. at 2-week follow-up, subjects undergoing videotape intervention showed a 78% improvement in the number of knowledge questions answered correctly (p = .001), and knowledge increased about mortality due to early-stage prostate cancer, psa screening performance, treatment-related complications, and disadvantages of screening. there was no difference between groups with respect to the primary outcomes of knowledge, satisfaction with decision, decisional conflict or ht use. the rate of vaginal birth was higher for women in the decision analysis group compared with the usual care group (37% v 30%, adjusted odds ratio 1.42, 0.94 to 2.14), but the rates were similar in the information programme and usual care groups. the intervention had no effect on uptake rates of treatment options, length of consultation with the surgeon, time point of treatment decision making, perceived involvement in decision making, neither decision related nor general patient satisfaction. congruence between personal values and decisions about hrt increased significantly more in the experimental group (p < or = .003). there was no difference in anxiety, knowledge, or decisional regret across the 2 groups. the beneficial effect of the decision aid did not persist (p = 0.44 for differences between study arms after 12 months). over the entire study period, satisfaction with decision making was higher for patients in the decision board arm than for patients in the control arm (p =.032). in addition, the videotape was more effective than vis alone in increasing short-term knowledge, regardless of practice type, race/ethnicity, or educational level. longitudinal analyses revealed that the da was effective among carriers who were initially undecided about how to manage their breast cancer risk. the total decisional conflict score was significantly lower in the decision aid group 3 weeks postrandomization compared with the usual care group (11.6 vs. 20.4; p = 0.0007). this form of educational material is successful in increasing knowledge about risk management options and in reducing decisional conflict in the shorter term. compared to pamphlets, das appear to improve the agreement between women's and physicians' decisional conflict about hrt. knowledge, decisional conflict, satisfaction with health care provider, and self-efficacy improved following intervention and were maintained for 12 months for all groups. patients in the ab group were more knowledgeable and had more realistic expectations about the risk of stroke and hemorrhage (in the ab group, 53%-80% correctly estimated different risks; in the control group, 16%-28% gave correct estimates). participants assigned to view public web sites were less likely to review information (116 participants [76.8%] reviewed) than those assigned to experimental groups (399 [86.7%] reviewed; p = .004). the counseling approach, but not the educational approach, was superior to the control condition in producing significant increases in perceived limitations and risks of brca1 testing (p < .01) and decreases in perceived benefits (p < .05). a decision aid for individuals considering genetic testing for hnpcc is an effective intervention to reduce uncertainty and assist individuals to make an informed choice regarding genetic testing for hnpcc after genetic counseling. information-giving was the most frequent activity for both gps and patients, although gps did this at twice the rate compared to patients and at higher rates in consultations involving computerised decision aids. reported use of the video was higher for patients who had greater than a high school education (or 1.73), were married (or 2.20), and reported no prior abnormal prostate cancer screening test results (or 3.39). had significantly improved knowledge (50% of items correct, 95% ci 46-53%; vs 45% correct, 95% ci 42-48%) (p = 0.048) and lower levels of decisional conflict (mean 21.6, 95% ci 20.7-22.5; vs mean 24.3, 95% ci 23.4-25.2) (p < 0.001). more da recipients from all education levels were 'informed' (p = 0.02), particularly in lower education (50.0% da versus 17.8% g) and university-educated groups (79.4% da versus 32.1% g). patients exposed to a decision aid answered a greater percentage of knowledge questions correctly (54% control vs 69% web site, p <.001, and vs 69% brochure, p <.001) and were less likely to be screened (94% control vs 86% web site, p = .06, and vs 85% brochure, p = .04). the illustrated pamphlet decision-aid was effective in improving knowledge of prostate cancer screening tests: 95% of the experimental group were aware of the possibility of false-negative test results compared with 85% of the comparison group (p <.01). compared with the pamphlet group, the decision-aid group had statistically significant (p < 0.05) improvements in terms of realistic personal expectations of the benefits and risks, decisional conflict, and perceived acceptability of the intervention. women who received the da (the intervention group) were better informed than the control group (mean increase in knowledge score out of 10, 2.62 for the intervention group vs 0.68 for the control group; p < .001), and a significantly greater percentage made an informed choice (73.5% vs 48.8%; p < .001). in the long term, with respect to well-being, patients in the sdmi group had less intrusive thoughts (p =.05) and better general health (p =.01) and tended to be less depressed (p =.07). the mean consultation duration was not significantly different between groups (24 minutes for intervention group versus 21 minutes for control group, p = 0.42). sixty newly diagnosed men were randomly assigned to receive either a self-efficacy information intervention that consisted of a written information package with discussion, a list of questions they could ask their physician, and an audiotape of the medical consultation (n = 30), or a written information package alone (n = 30). the developed decision aid improved patient outcomes better than a control pamphlet when implemented during genetic counseling and given to the patient to take home. the computerized da improved realistic expectations by 52.7% over baseline versus 27.6% with the audio-booklet (p=0.015). decisional self-efficacy, preparedness to participate in decision-making, and arthritis self-efficacy were greater in participants randomized to the intervention arm compared to those receiving the information pamphlet ( there was no significant difference in satisfaction with decision-making process scores between the ihd sdp and usual practice groups. the method of education did not affect patient involvement although patients tended to learn more about breast cancer treatment after using the multimedia program than after reading the brochure. the da group rated themselves better prepared for decision making and showed significant improvements in knowledge (p = 0.001) and realistic risk perceptions (p = 0.001). patients who used the decision board were more likely to choose bct (94% vs 76%, p =.03).|87 patients were randomized patients were recruited from november 1999 to april 2002 one hundred and ten (74.3 knee pain 1,152 men aged 50 and older from four medical facilities in the united states patients' and general practitioners' perceptions of who made the decision, decisional conflict, treatment choice, menopausal symptoms, costs, anxiety, and general health status women's and physicians' decisional conflict about hormone replacement therapy 287 parents/guardians of 2- to 3-month-olds presenting for well-child care and due for the first set of immunizations including poliovirus vaccine women and their health care providers women with 1 previous cesarean section and medically eligible for trial of vaginal birth were recruited at 12 to 18 weeks' gestation; 115 older patients with atrial fibrillation one hundred and forty-eight women breast cancer 26 general practices in the united kingdom early stage breast cancer 214 female (aged 21-75) brca1/brca2 mutation carriers 497 men participated (75 control, 196 brochure, 226 web site nine hundred and ninety of the men who were eligible for the study returned completed questionnaires (response rate=54 atrial fibrillation patients contemplating breast reconstruction brca1/brca2 mutation carriers men aged 40-75 years selected from 11 general practices in england and wales patient decision aid for colorectal cancer screening patients with various diagnoses and on local surgery rates five pediatric offices (two university-based, two health maintenance organization staff models, and one private practice) and a local health department immunization clinic in the greater lansing, mi, area men aged 45 through 70 years with no history of prostate cancer or treatment for prostate disease (n = 160 colorectal cancer screening in urban, suburban, and rural communities in michigan with high colorectal cancer burden may 1997 to april 1998 university hospital and veterans affairs hospital childbirth menopausal women brca1/2 mutation carriers eligible patients had no personal or family history of colon cancer and had not had fecal occult blood testing in the past year or flexible sigmoidoscopy, colonoscopy, or barium enema in the past 5 years seventy-four patients, ranging in age from 15 to 50 and presenting with a moderate to severe dentofacial deformity requiring orthognathic surgery women at increased risk of ovarian cancer copyright 2001 american cancer society women with a family history of breast cancer college-educated patients younger than 65 years of age were more active participants in these consultations than were older, less educated patients we enrolled 75 adults for colon cancer screening women at low to moderate risk who have a family history of breast and/or ovarian cancer 174 eligible adults c) 2008 american cancer society individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk 248 eligible men recruited, 214 (86% response rate) returned post-test questionnaires 153 individuals respondents were recruited from one community urology clinic in winnipeg, manitoba outpatient clinics offering cancer genetic counseling at 6 us medical centers enrolled 211 women with personal or family histories of breast cancer 742 pregnant women with one previous lower segment caesarean section and delivery expected at >or=37 weeks women aged 70 years who had regularly participated in mammography screening were eligible to participate in the trial elderly patients female callers (n = 279) to the national cancer institute's (nci's) atlantic region cancer information service (cis), developed and evaluated a theory-based, educational intervention designed to increase callers' understanding of the following: (a) the kinds of information required to determine inherited risk primary care consultations women with breast cancer a total of 40 physicians and 184 women provided data men who received the brief pda breast cancer prevention eighty-nine participants had been screened for colorectal cancer by 24 weeks post-intervention 242 african-american men from three primary care practices who were 40-69 years of age and had no history of prostate cancer women consulting their general practitioner with menorrhagia compared with written information alone. of study twenty-one general practices in south-west england, uk ischaemic heart disease gynaecology outpatient clinics in 14 finnish hospitals 149 adult patients with cystic fibrosis with an fev(1 patients with low or high health literacy patients' discussions with their doctor and their plans for chd prevention patients with early breast cancer one hundred forty-nine women presenting with menorrhagia 133 women participated, 66 in the control group and 67 in the study group women with a strong suspicion of breast cancer 120 patients were randomized menopausal francophone women 45 to 69 years old 1657 consecutive adult patients 50 to 75 years of age were contacted older men adults aged 32 to 80 years with newly diagnosed hypertension men aged 50 to 70 years undergoing a health maintenance examination at a large family practice were enrolled ashkenazi jewish women sixty newly diagnosed men nineteen general practices in the north of england patients referred for coronary angiography compared with standard patient-physician decision making (usual care women who have experienced previous cesarean birth men with operable cancer from february 2003 to january 2004, psychiatric state hospital inpatients with a diagnosis of schizophrenia (icd-10; n = 107 33 general practices in the united kingdom two hundred and one women were recruited from the prenatal clinic of a university teaching hospital and randomised into the women's and physicians' decisional conflict about hormone replacement therapy (hrt in early 1983, all 1,280 faculty and resident physicians at one hospital who were eligible to be vaccinated against hepatitis b between october 1996 and february 1998, 894 women with uncomplicated menorrhagia were recruited from 6 hospitals in southwest england english speakers were excluded fourteen centers that participated in the stroke prevention in atrial fibrillation (spaf low-risk women men about prostate cancer screening 434 nvaf patients from 102 community-based primary care practices three hundred and fourteen people aged 50-74 years received a women aged 70 years, a population-based, randomized controlled trial was conducted in new south wales, australia dentistry 6 familial cancer centers 651 (39%) agreed to participate; 249 of the 651 participants (38%) were eligible men considering the prostate specific antigen test patients with newly diagnosed hypertension patients with atrial fibrillation who had participated in a major clinical trial male primary care patients from two clinical sites, one characterized as serving patients with low health literacy (n=149) and the second as serving patients with high health literacy (n=301 advanced maternal age patients two hundred and twenty-six men, aged 50 years or older, and scheduled to complete a physical examination at an hmo health appraisal clinic patients with advanced cystic fibrosis considering referral for lung transplantation patients with cystic fibrosis considering lung transplantation primary care patients with low health literacy men aged 40-70 years were recruited from the practices of 13 local general practitioners (gps) in sydney, australia patients with multiple sclerosis (isdims two hundred forty ambulatory patients with fifty-one peri-menopausal women 96 patients at average risk for colorectal cancer seen in an internal medicine practice in rochester, new york twenty surgeons participated in the study uk hospital's prenatal diagnosis clinic breast reconstruction patients conducted from may 2004 to august 2006 n = 196 women patients with lower health literacy general surgeons in the communities of central-west, and eastern ontario, canada adult patients patients with prostate cancer patients with schizophrenia 227 pregnant women was conducted within 3 prenatal clinics and 3 private obstetric practices in new south wales, australia primary care patients with nonvalvular atrial fibrillation prostate cancer screening three hundred and twenty-eight women participated sixty patients with stage i or ii breast cancer (1) were pretested on their knowledge about breast cancer treatment and optimism for the future, (2 early breast cancer elective surgery candidates (n = 393) included 171 patients with herniated disks, 110 with spinal stenosis, and 112 with other diagnoses men with benign prostatic hypertrophy 210 men who had a histologically confirmed diagnosis of prostate cancer in 1993-94 at four major hospitals in finland patients with nonvalvular atrial fibrillation (nvaf 208 eligible women with newly diagnosed clinical stage i or ii breast cancer seen by study surgeons, 201 agreed to be evaluated: 94 were assigned to the decision board and 107 to usual practice thirty participants enrolled (15 per group two-hundred and one women aged 50-69 years from ottawa, canada, who had never used hormone therapy university-based family practice center patients (n=111) with a strong suspicion of breast cancer elderly patients' colorectal cancer (crc) screening preferences 177 post-menopausal women receiving care in a veterans affairs medical center 257 men aged 50 to 80 years who were receiving primary care at a department of veterans affairs hospital in milwaukee, wisconsin men considering prostate cancer screening four maternity units in south west england, and scotland seventy-two self-referred women with a first-degree relative with breast cancer received outpatient education and counseling at the clinical center of the national institutes of health (nih breast cancer susceptibility pregnant women with a previous caesarean section 90 women, aged 45-64 years, facing a decision about using nhps for menopausal symptoms, received a quebec city region patients' discussions with their doctor and their plans for prevention convenience sample of adults with no previous history of cardiovascular disease a woman's decision aid regarding postmenopausal hormone therapy between october 1995 and march 2000, 176 women with lymph node-negative breast cancer who were candidates for adjuvant chemotherapy 41 patients received the decision aid, 34 received usual care a total of 145 women menorrhagia women considering genetic testing for breast/ovarian cancer risk given during genetic counseling postmenopausal women considering long-term preventive hormone therapy on benign prostatic hypertrophy in primary care two hundred and ninety-seven ms patients who were considering or reconsidering immunotherapy participated in a randomized community-based controlled trial in germany ashkenazi jewish women from the general population 217 patients referred for coronary angiography breast cancer patients who were candidates for breast reconstruction women of advanced maternal age (>/=35 years) and their partners north american breast cancer outpatients 131 women with a family history of breast and/or ovarian cancer or of hereditary nonpolyposis colorectal cancer american college of chest physicians (accp) recommendations women with heavy menstruation 98 diabetes patients and randomizing them to 1) receive either the women with previous caesarean section women in early pregnancy consulting a gp patients with cystic fibrosis considering referral for lung transplantation women considering genetic testing for breast and ovarian cancer risk 399 elderly patients visiting their primary care provider for routine office visits breast cancer surgery 70-year-old women 112 men with benign prostatic hypertrophy 117/132 women receiving a screen-positive maternal serum screening result participated (58 routine, 59 decision analysis newly diagnosed hypertensive patients 249 participants men considering the prostate specific antigen (psa) test study participants were age 50 years and older, with no previous colorectal cancer screening three community primary care practices in central north carolina a total of 363 (randomized trial) plus 206 (cohort study) patients with menorrhagia colorectal cancer screening newly diagnosed breast cancer inpatients a subgroup of women who were initially leaning toward mastectomy or were unsure had lower decisional conflict men older than 50 years (n = 611 205 women considering hormone replacement therapy men newly diagnosed with prostate cancer three hundred and fifty-two women and 225 partners completed patients with lymph node-negative breast cancer patients with knee pain patients with knee pain in an outpatient primary care clinic setting patients with ischemic heart disease women considering post-menopausal hormone replacement therapy parents/guardians of children starting the polio vaccination series four hundred ninety-six english- or spanish-speaking women at 20 or fewer weeks of gestation 59% were female, 73% white, and 23% african-american midlife women (n = 248 asymptomatic men aged 50 years and older 217 patients randomised, 212 (98%) were analysed at the primary follow-up (mean age = 59 years, 49% female many women who have participated in mammography screening are now approaching 70 years of age women calling the nci's cancer information service patients with type 2 diabetes mellitus community surgeons men with prostate cancer hereditary nonpolyposis colorectal cancer (hnpcc 421 men recruited from the community participants completed a baseline survey questionnaire may 2000 to september 2002 mother and baby associated with planned vaginal birth, elective caesarean section, and emergency caesarean section patients with nvaf 287 patients from the spaf iii aspirin cohort study, in which patients with atrial fibrillation and a relatively low risk of stroke received 325 mg/d of men 50 years or older with no prior psa testing and no history of prostate cancer presenting to 1 of 4 university-affiliated primary care practices were eligible for enrollment lymph node-negative breast cancer prostate cancer
degree of desaturation 6mwd or steps achieved while breathing supplemental oxygen quality of life 6mwd or steps 6mwd and steps exercise performance (step tests and 6 min walking distance [6mwd laboratory exercise performance quality of life indices|supplemental oxygen increased 6mwd and steps by small, statistically significant increments acutely at baseline and after 6 and 12 wk, without corresponding falls in borg score.|patients with chronic obstructive pulmonary disease and mild hypoxemia patients with severe copd 26 patients (24 males) had a mean age of 73
baseline cross-sectional changes and 1-year changes in insulin resistance, fasting serum levels of insulin, c-peptide, proinsulin, glucose, and lipids as well as weight, mean blood pressure, and plasminogen activator inhibitor 1 (pai-1) values insulin resistance and changes in bmi calculated insulin resistance and bmi baseline bmi and fasting glucose, the diet, exercise, and diet-plus-exercise interventions pai-1 insulin resistance change insulin resistance rate of development of diabetes incidence of diabetes intake of fish and reduced total fat intake mean blood pressure (mbp calculated insulin resistance total cholesterol cumulative incidence of diabetes|when analyzed by clinic, each of the active intervention groups differed significantly from the control clinics (p < 0.05). the 1-year diet intervention gave a significant decrease in the calculated insulin resistance from 4.6 to 4.2 and a positive correlation between the changes in insulin resistance and changes in bmi (r = 0.40).|people with impaired glucose tolerance individuals with impaired glucose tolerance (igt 110,660 men and women from 33 health care clinics in the city of da qing, china, were screened for igt and niddm 219 men and women with diastolic blood pressure of 86-99 mmhg, hdl cholesterol < 1.20 mmol/l, triglycerides
bprs and cgi scores efficacy and side effects sedation brief psychiatric rating scale (bprs) and the clinical global impression scale (cgi rapid remission of symptoms on the brmas tardive dyskinesia minimal side effects brief psychiatric rating scale and clinical global impression scale extrapyramidal side effects hypokinesia brief psychiatric rating scale (bprs), clinical global impression (cgi) and uku side effects scale reduction of aggression based on bprs rating acute psychosis with aggression bprs or cgi scores severity of illness scores brief psychiatric rating scale (bprs), the bech-rafaelsen mania rating scale (brmas) (only manic patients) and globally on the clinical global impression (cgi serum creatinine phosphokinase levels|there was however no difference between the zuclopenthixol acetate and haloperidol group scores on all days (p > 0.05). the two treatments were found to be equally efficacious on the brief psychiatric rating scale and clinical global impression scale. both zpta and hal were effective in the treatment of acute psychosis with aggression, but frequency of administration was lower in the zpta group the assessments on the cgi showed that all 3 treatments caused a clear reduction of the severity of illness scores in all 3 diagnostic categories, with no differences between treatments.|acutely disturbed schizophrenic patient 50 subjects entered the study of which 44 completed thirty-eight patients acutely disturbed schizophrenics 40 newly admitted schizophrenic patients with acute exacerbation psychotic patients with aggression admitted to songkla neuropsychiatric hospital acute psychosis schizophrenic patients with acute exacerbation acutely disturbed, psychotic patients acutely disturbed psychotic patients 70 patients with diagnosis of schizophrenia, mania and acute psychosis patients were stratified into 3 diagnostic categories: acute psychoses (48 patients), mania (22 patients), and exacerbation of chronic psychoses (73 patients suitable subjects diagnosed as having schizophreniform disorder or acute exacerbation of schizophrenia admitted to the psychiatric wards hospital kuala lumpur acute psychotic disturbance with aggression
tumor resistance and morbidity severe complication nor death incidence of persistent trophoblastic disease time interval from evacuation of the mole to diagnosis of persistent trophoblastic disease complication of the prophylactic chemotherapy complete remission with therapeutic chemotherapy occurrence of choriocarcinoma secondary trophoblastic disease persistent trophoblastic disease incidence of malignant sequelae toxicity metastatic trophoblastic disease stomatitis, nausea/vomiting, sore throat with oral ulcer and hair loss until complete remission|after molar evacuation, four patients from the treated group (10.3%) and ten patients from the untreated group (31.3%) developed persistent trophoblastic disease. the side effects of prophylactic chemotherapy were stomatitis, nausea/vomiting, sore throat with oral ulcer and hair loss. choriocarcinoma after the molar pregnancy developed in two patients (0.7%) of the prophylactic chemotherapy group and two (1.6%) of the control.|seventy-one patients with complete hydatidiform mole patients with high-risk chm 420 patients with molar pregnancy patients with complete hydatidiform mole king chulalongkorn memorial hospital high-risk complete hydatidiform mole (chm 293 patients with prophylactic chemotherapy and 23 (18.1%) of 127 patients without sixty cases of chm classified as high risk
objective tumoral response actuarial survival rates partial response abdominal pain recurrence rate, the time to tumor recurrence and the median survival apoptosis of hepatocellular carcinoma (hcc) cells recurrence of hepatocellular carcinoma (hcc risk of hepatocellular carcinoma (hcc) recurrence 2-year overall survival probability of tumor progression spitzer index level assessing the quality of life level of bcl-2 protein and ratio of bcl-2 to bax protein of hcc cells survival: alpha-fetoprotein tumor size, tumor number, pvtt location self-limited postembolization syndrome probability of complications overall recurrence intrahepatic recurrence rate liver failure survival nor the quality of life disease-free survival curve spontaneous 1-year survival rate actuarial survival survival time survival hcc recurrence and survival local recurrence disease-free survival rates and prognostic factors apoptosis of hepatocellular carcinoma cells overall survival and quality of life recurrence rate relative risk of death rate of portal-vein invasion overall survival death from liver failure apoptotic index(ai) and level of bax protein in hcc cells time to tumor recurrence median survival survival probabilities nausea and loss of appetite tumour response (assessed by arteriography, ultrasonography and serum alphafetoprotein pugh's grade, okuda stage, or performance status test (pst expressions of bcl-2 and bax protein estimated survival rates risk of death incidence of portal obstruction catheter obstruction liver decompensation pugh score disease-free survival rate survival benefits tumor size and serum alpha-fetoprotein concentration 4-year survival rates|the disease-free survival curve was significantly different among the three groups, as estimated by the kaplan-meier method (both p < 0.05). there was no significant difference in survival between the two groups, although there was a trend favoring the chemoembolization group (estimated relative risk of death in the control group, 1.4; 95 percent confidence interval, 0.9 to 2.2; p = 0.13). there were four cases of local recurrence in the pta-only group and none in the tae/pta group (p=0.043). chemoembolization resulted in a marked tumor response, and the actuarial survival was significantly better in the chemoembolization group (1 year, 57%; 2 years, 31%; 3 years, 26%) than in the control group (1 year, 32%; 2 years, 11%; 3 years, 3%; p =.002). eighty-two percent of the patients presented a self-limited postembolization syndrome, without treatment-related mortality. for group a, b and c, the 1 year recurrence rate was 83.3%, 87.0% and 87.5% (p = 0.926), respectively. survival probabilities at 1 year and 2 years were 75% and 50% for embolisation; 82% and 63% for chemoembolisation, and 63% and 27% for control (chemoembolisation vs control p=0.009). an objective tumoral response was more frequently observed in the lipiodol chemoembolization group than in the tamoxifen group (24 versus 5.5%, respectively, p=0.046). afp>400ng/ml (p=.004) and spitzer index (p=.013) as shown by multivariable analysis. the apoptotic index(ai) and level of bax protein in hcc cells were significantly higher in groups a, b, c and d than those in the non-tace group (p < 0.05). a complete tumour response (assessed by arteriography, ultrasonography and serum alphafetoprotein) was observed in four patients, and a partial response in three other patients from group 1. the 1-, 2-, 3-, and 4-year survival rates were 72.3%, 52.7%, 35.1%, and 35.1% respectively for the patients who underwent radical resection only, and were 97.9%, 85.5%, 69.5%, and 56.9% for the patients who also underwent tace 3-4 weeks after radical resection (p < 0.001).|patients with nonsurgical hcc from april 1990 to december 1993, 140 patients patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis patients with unresectable hepatocellular carcinoma treated with 42 patients with unresectable hepatocellular carcinoma 58 patients had died: 30 in the hcc patients unresectable hepatocellular carcinoma in cirrhotic patients (fdration francophone de cancrologie digestive 9402 hepatocellular carcinoma from jan 2000 to dec 2002, 57 patients with hcc patients with hepatocellular carcinoma from 1995 to 2002, 138 patients patients with unresectable hepatocellular carcinoma not suitable for curative treatment, of child 136 patients with hcc underwent liver resection 30 patients assigned to chemoembolization asian patients with unresectable hepatocellular carcinoma 903 patients were assessed, and 112 (12%) patients were finally included in the study 25 of 37 patients assigned embolisation, 21 of 40 assigned chemoembolisation, and 25 of 35 assigned conservative treatment died 112 patients with hcc 37 patients in the seventy-three patients with unresectable hepatocellular carcinoma, but without severe liver disease or portal vein occlusion patients with nonsurgical hepatocellular carcinoma (hcc eighty consecutive patients primary liver carcinoma after hepatectomy patients with unresectable hepatocellular carcinoma who did not have severe liver disease and who met additional entry criteria between march 1997 and april 2001, 42 hcc patients were enrolled who satisfied the following inclusion criteria: (1) uninodular hcc as determined by angiography under computed tomography, (2) arterial hypervascularity, and (3) no prior history of hcc treatment patients with unresectable hepatocellular carcinoma hepatocellular carcinoma with cirrhosis patients with hepatocellular carcinoma (hcc) complicated by portal vein tumor thrombosis (pvtt patients with advanced hepatocellular carcinoma one hundred and twenty three patients were eligible including 61 in the tamoxifen group and 62 in the tace group from march 1996 to october 1997, 80 out of 279 asian patients with newly diagnosed unresectable hepatocellular carcinoma fulfilled the entry criteria patients with hcc and cirrhosis unresectable hepatocellular carcinoma
change of the thi, ghsi and hearing efficacy and tolerability neuropsychiatric inventory (npi rate of adverse events skt total score verbal fluency test, the clock-drawing test, the npi, the hamilton rating scale for depression (hamd), and the gottfries-brne-steen scale (gbs tinnitus handicap inventory (thi), glasgow health status inventory (ghsi) and average of hearing threshold at 0.5, 1, 2, 4 khz efficacy|the main outcome measures were the tinnitus handicap inventory (thi), glasgow health status inventory (ghsi) and average of hearing threshold at 0.5, 1, 2, 4 khz. under egb 761 treatment the skt total score improved by -3.0+/-2.3 and -3.4+/-2.3 points in patients with ad and vad, respectively, whereas the patients on placebo deteriorated by +1.2+/-2.5 and +1.5+/-2.2 points, respectively (p<0.01 for both drug-placebo differences).|761 by type of dementia participants included 66 adult patients with tinnitus and six (including our study) randomized 214 patients were diagnosed with alzheimer's disease (probable ad or possible ad with cerebrovascular disease) and 181 with probable vascular dementia (vad patients with tinnitus three hundred ninety-five patients aged 50 years or above, with dementia with neuropsychiatric features
electromyogram (emg) patterns and stride parameters unified parkinson's disease rating scale (updrs velocity updrs scores (activities of daily living and motor sections stride length gait velocity mean updrs scores|a significant reduction of updrs scores (activities of daily living and motor sections) was present after the rehabilitation phase in both groups. patients who trained with ras significantly (p < 0.05) improved their gait velocity by 25%, stride length by 12%, and step cadence by 10% more than self-paced subjects who improved their velocity by 7% and no-training subjects whose velocity decreased by 7%.|parkinson's disease patients parkinson's disease (pd) patients (n = 15 parkinsonian patients twenty stable, nondemented patients with pd entered a 6-week rehabilitation program patients with idiopathic parkinson's disease (pd moderately disabled patients with pd
polyp size|we found that betamethasone nasal drops showed a statistically significant reduction in polyp size in comparison to placebo.|adults with cystic fibrosis nasal polyps in cystic fibrosis
complete optimal cytoreduction (coc residual disease prolonged survival residual disease after scr, treatment-free interval (tfi residual disease (median survival endometrioid histologic type median diagnosis-to-recurrence interval number of recurrence sites secondary cytoreduction performance status (ps) [eastern cooperative oncology group (ecog median survival and estimated 5-year survival number of radiographic recurrence sites (median survival prognosis of survival median patient age at recurrence recurrent ascites recurrence-free interval (rfi median survival time (mst lengthened survival complete cytoreduction completeness of cytoreduction survival median and estimated 5-year survival median postrecurrence survival longer survival age, tumor grade, histology, ca-125 level, ascites, and tumor size probability of complete cytoreduction overall survival median survival survival benefit international federation of gynecology and obstetrics (figo) stage at initial diagnosis largest size of recurrent tumor cytoreductive outcome and survival recurrent epithelial ovarian cancer 5-year survival median progression-free interval survival benefits 2-year survival rates|the 2-year survival rates were 22.3, 62.9, and 22.7%, respectively, for patients with rfi 7-12, 13-24, and >24 months. logistic stepwise regression revealed that recurrent ascites (p = 0.0072, relative risk = 20.36) and residual disease after the second operation (p = 0.0096, relative risk = 5.16) were important determinants of secondary surgical outcome. on multivariate analysis, disease-free interval (p = .004), the number of recurrence sites (p = .01), and residual disease (p <.001) were significant prognostic factors. residual disease after scr, treatment-free interval (tfi) and age were found to be prognostic factors for overall survival (os) in multivariate analysis. age, tumor grade, histology, ca-125 level, ascites, and tumor size were not associated significantly with survival. most of them pointed out there was no difference in survival between residual disease of 0.1-1 cm (r1) and >1 cm (r2). complete resection was associated with significantly longer survival compared with surgery leaving any postoperative residuals [median 45.2 vs. 19.7 months; hazard ratio (hr) 3.71; 95% confidence interval (ci) 2.27-6.05; p < .0001]. multivariable analysis revealed 3 factors to be significant: optimal cytoreduction during primary (p = .003, odds ratio [or]: 0.30; 95% ci: 0.14-0.66), secondary cytoreduction (p = .04, or: 0.47; 95% ci: 0.22-0.99), and the endometrioid histologic type (p = .005, or: 0.09; 95% ci: 0.02-0.48). survival was influenced by the dfi after primary treatment (6-12 months median, 25.0 months vs. 13-36 months median, 44.4 months vs. > 36 months median, 56.8 months; p = 0.005), the completeness of cytoreduction (visibly disease free median, 44.4 months vs. any residual disease median, 19.3 months; p = 0.007), the use of salvage chemotherapy before secondary surgery (chemotherapy given median, 24.9 months vs. chemotherapy not given median, 48.4 months; p = 0.005), and the largest size of recurrent tumor (< 10 cm median, 37.3 months vs. > 10 cm median, 35.6 months; p = 0.04).|patients who underwent secondary cytoreduction for recurrent, platinum-sensitive epithelial ovarian cancer one hundred six patients with a disease free interval (dfi) > 6 months after primary treatment underwent secondary cytoreductive surgery patients with 1 or 2 radiographic recurrence sites fifty-five patients met the study inclusion criteria twenty-five member institutions of the arbeitsgemeinschaft gynaekologische onkologie ovarian committee (ago oc) and ago-ovar boards collected data on their patients with cytoreductive surgery for relapsed invasive epithelial ovarian cancer performed in 2000-2003 patients who had recurrent epithelial ovarian carcinoma between 1986 and 1997, 60 patients who received 157 patients underwent secondary cytoreduction, and 153 of those patients were evaluable patients with recurrent epithelial ovarian carcinoma patients who might benefit from surgery in relapsed ovarian cancer patients who have documented gross disease preoperatively should be selected for a secondary debulking operation 64 patients patients with recurrent epithelial ovarian cancer selected recurrent epithelial ovarian cancer patients patients with recurrent, platinum-sensitive epithelial ovarian carcinoma exclusion criteria included secondary cytoreduction during second-look laparotomy, interval cytoreduction, and palliative surgery in patients with intestinal obstruction or progressive disease study inclusion criteria required a complete clinical response to primary therapy, >or=12 months between initial diagnosis and recurrence, and <or=5 recurrence sites on preoperative imaging studies ovarian cancer: hacettepe university experience epithelial ovarian cancer 217 had scr and 572 were treated with chemotherapy alone 789 patients treated at the norwegian radium hospital during 1985-2000 for their initial recurrence patients with residual disease of 0.1-1 cm after secondary cytoreduction patients who underwent secondary surgical cytoreduction for recurrent epithelial ovarian cancer between september 1997 and march 2005 were identified retrospectively from tumor registry databases between 2002 and 2006, 123 patients with recurrent epithelial ovarian cancer undergoing secondary cytoreduction were identified from tumor registry databases patients with ascites at disease recurrence, however, were not suitable for aggressive secondary surgery, and redebulking surgery for those with residual disease of >1.0 cm after primary operation should be considered prudently relapsed ovarian cancer recurrent ovarian cancer for recurrent epithelial ovarian cancer from 1987 to 2001 two hundred and sixty-seven patients were included 17 patients (81%) with rfi >24 months were heavily treated with chemotherapy before secondary surgery fifty-one (41.5 individuals with progression-free interval right patients for cytoreductive surgery in recurrent ovarian cancer recurrent epithelial ovarian cancer copyright 2000 american cancer society for stage iii and iv epithelial ovarian cancer experienced disease recurrence at least 6 months after completion of primary therapy, and secondary surgical cytoreduction was performed
death rate lethal pulmonary embolism number of deep-vein thromboses, pulmonary emboli and deaths mortality rate functional activity level of survivors haemorrhagic thromboembolic complications development of dvt frequency of dvt frequency of proximal thrombi fatal pulmonary embolism deep-vein thrombosis deep venous thrombosis (dvt cerebral bleeding neurologic deficits serious intracranial bleeding events symptomatic ich laboratory values (pt, ptt, alkaline phosphatase, got, gpt, cholesterol and triglycerides, fibrinogen, blood glucose, azotemia and creatinine deep-vein thrombosis rate absence of pulmonary embolism or drug-induced haemorrhage time interval (from stroke to admission) and lactic dehydrogenase (ldh) concentration tolerated and no side-effects degree of neurologic change; incidence of stroke progression deaths and pulmonary emboli asymptomatic ich (7 events), major systemic hemorrhage (no event), or 90-day mortality mean factor xa inhibitory activity levels at peak concentration tolerated symptomatic intracranial hemorrhage (ich mortality glasgow outcome scale score of i or ii and a modified barthel index major hemorrhagic complications deaths|a statistically significant reduction was observed in deep-vein thrombosis as assessed by isotope leg scanning. in the placebo group there were 4 deaths during the trial versus 9 in the kabi-2165-treated group (ns). the mesoglycan influenced only slightly the laboratory values (pt, ptt, alkaline phosphatase, got, gpt, cholesterol and triglycerides, fibrinogen, blood glucose, azotemia and creatinine) performed before the beginning of the treatment, as their changes after thirty days of therapy were in the normal range. the frequency of dvt was 15 of 42 patients or 36% (95% confidence interval 22 to 52%) in the lmw heparin group and 17 of 50 patients or 34% (21 to 49%) in the placebo group. there was no significant difference in the development of dvt by treatment group. no deep-vein thrombosis was detected by the labelled fibrinogen test in the treated group, as against 12 patients in the control group. no significant between-group differences occurred in asymptomatic ich (7 events), major systemic hemorrhage (no event), or 90-day mortality (13.4% overall). at 3 months, 482 (75.2%) of 641 persons assigned to treatment with org 10172 and 467 (73.7%) of 634 patients treated with placebo had favorable outcomes (p=.49); 49.5% and 47%, respectively, of patients in each group had very favorable outcomes at 3 months. low-dose calcium heparin given subcutaneously following acute stroke reduced the number of deep-vein thromboses, pulmonary emboli and deaths without increasing the number of haemorrhagic strokes in this study. no statistically significant difference between the two groups was found in degree of neurologic change; incidence of stroke progression after 7 days; or functional activity level of survivors at 7 days, 3 months and at 1 year after treatment.|57 patients with acute cerebral infarct was performed 171 patients with acute (< or =12 hours from onset) stroke and national institutes of health stroke scale (nihss) scores of 5 to 22 persons with stroke patients confined to bed due to hemiplegia consecutive to a recent cerebral infarction acute partial stable stroke patients who have had acute partial stroke patients with dvt on admission (prevalent, n = 61) were compared with the study patients (n = 360 three hundred and sixty patients, over a 3-year period thirty patients stroke patients 225 patients with acute partial stable thrombotic stroke 30 patients patients after acute strokes patients with lighter strokes ischemic stroke patients kabi 2165 2 x 2,500 anti patients with acute ischemic stroke (argis-1 103 patients with acute ischemic stroke stroke patients during rehabilitation all patients underwent thrombosis surveillance with unilateral venography of the paretic limb 28 patients between december 22, 1990, and december 6, 1997, 1281 persons with acute stroke were enrolled at 36 centers across the united states acute ischemic stroke patients with hemiplegia following cerebral infarction 15 patients compared with a control group of 15 untreated patients 42 of 52 patients randomized to patients undergoing rehabilitation patients during rehabilitation three hundred and five elderly patients patients with acute ischemic stroke elderly patients admitted to hospital after an acute stroke acute focal cerebral ischemia
inulin clearance and urinary beta(2)-microglobulin and n-acetyl-beta-d-glucosaminidase (nag) excretion mpo levels renal function impairment tubular damage markers myeloperoxidase (mpo) release perioperative renal function venous stasis renal function lactic acid levels inulin clearance low mean arterial pressure at anesthesia induction|lactate determinations did not contribute to the quantification of the systemic and regional tissue oxygenation during olt. complement system factors and granulocyte activation, represented by myeloperoxidase (mpo) release, were analyzed by eia. no significant differences were observed between groups 1 and 2 at any perioperative phase, except during the anhepatic phase, in which a more marked renal function impairment occurred in group 2 patients.|liver transplantation 77 patients receiving liver transplants for chronic liver disease human liver transplantation (olt 20 patients during and 1 day after liver transplantation (olt twenty patients
working smoke alarms socket safety injury prevention knowledge or behavior rates of fires and related injuries safety practices storage of medicines safety consultation and provision of free and fitted stair gates, fire guards, smoke alarms, cupboard locks, and window locks injury rate per 100 fires smoke alarm safety physician counseling and parent satisfaction, knowledge, beliefs, and behaviors discharge book improved the burn-care-related knowledge of caregivers fireplace safety safe practice in storage of sharp objects home safety modifications hot-water temperature, poison storage, and presence of smoke alarms, safety gates for stairs, and ipecac syrup injury visits incidence of fires and related injuries unintentional injuries functioning alarms overall occurrence of injuries medical attendance safety knowledge and behavior scores working alarms annualized fire-injury rates home hazards requiring major effort to correct safety knowledge and practices self reported safety practices, possession and use of safety equipment, knowledge and confidence in dealing with first aid, and perceptions of risk of injury and risk of hazards assessed by postal questionnaire number of safety practices hot water temperatures mean hazard score similar risk factors for injury, sociodemographic characteristics, safety practices, possession and use of safety equipment, knowledge and confidence in dealing with first aid, and perceptions of risk installed alarms child in the family had at least one injury that required medical attendance and rates of attendance in primary and secondary care and of hospital admission for injury over a two year period frequency of minor unintentional injuries parents' knowledge, beliefs, and home safety behaviors socket covers rate of burn injuries range of safety practices admissions to hospital and deaths demographic and fire safety data attendance rate presence and functional status of smoke alarms rates of fires and rates of fire related injury parental safety knowledge hot water temperature total costs of care for injuries operational smoke detectors feasibility, acceptability, and effectiveness parents' safety practices injury prevention counseling possession of safety equipment and safety practices probability of having a working detector window safety knowledge gains smoke alarms frequency and severity of medically attended injuries proportion of families|stepwise multiple-regression analysis found that the influence of the book was limited to families with children who sustained scald burns (p < 0.05). giving out free smoke alarms in a deprived, multiethnic, urban community did not reduce injuries related to fire, mostly because few alarms had been installed or were maintained. although only one couple in the experimental group did not have an operational smoke detector, enough of the couples in the control group had operational smoke detectors that results were not significant.(abstract truncated at 250 words) households that reported participatory exposure to the interventions had higher safety knowledge and behavior scores than those that received other community exposure or no exposure to intervention activities. before the intervention the rate of burn injuries per 100,000 population was 4.2 times higher in the target area than in the rest of oklahoma city. parents seen by physicians in the intervention group received significantly more injury prevention counseling for 5 of the 6 safety practices, and they were significantly more satisfied with the help their physicians provided on safety topics. only 65% of voucher households had functioning alarms at follow up, largely due to failure to redeem vouchers. among families without a working smoke detector at baseline, the intervention was associated with an increased probability of having a working detector at follow up (relative risk (rr) 3.3, 95% confidence interval (ci) 1.3 to 8.6). the educational phase of the study was completed by 129 families, 65 in the intervention group and 64 in the control group. no significant differences in safety practices were found between study groups. the intervention package was not effective in reducing the frequency of minor unintentional injuries in children at home, and larger trials are required to assess the effect on more severe injuries. inspection performed four to six weeks after the office visits showed that of 55 experimental group parents without detectors prior to the program, 26 purchased and 19 installed them correctly. a higher percentage of males (25.0%) than females (17.3%) reported making safety changes following the intervention. knowledge gains were demonstrable only as a result of the school program. after intervention, significantly more families in intervention group used fireguards (relative risk 1.89, 95% confidence interval 1.18 to 2.94), smoke alarms (1.14, 1.04 to 1.25), socket covers (1.27, 1.10 to 1.48), locks on cupboards for storing cleaning materials (1.38, 1.02 to 1.88), and door slam devices (3.60, 2.17 to 5.97). the total costs of care for injuries were significantly lower in the intervention group compared with the nonintervention group with a cost of $372 per injury prevented. the intervention resulted in significant improvements in safety practices for up to two years but did not reduce injuries that necessitated medical attendance. there was a distinct difference between control and intervention homes with respect to safety knowledge and home hazards requiring minimal to moderate effort to correct.|families of low income children attending preschool enrichment programs in washington state children ages 0-5 years in the intervention compared with control communities, associated with participatory exposure of about 55 percent of households with children ages 0-5 years 1,583 installation group households and 1,545 voucher group households target population included occupants of high-risk households without working smoke alarms who were approached as part of a door-to-door canvassing program poor urban african-american community high-risk households first- and second-year pediatric residents and their patient-parent dyads 58 couples children ages 0-5 years children attending preschool head start programs in two regions were eligible families with children under 5 years children at home a hospital-based pediatric resident continuity clinic that serves families living in low-income, inner-city neighborhoods childhood injuries thirty-one residents the median age was 2 years, with males comprising ~60% of participants forty electoral wards in two boroughs of inner london, united kingdom pediatric patients with burns burn injuries in oklahoma city from september 1987 through april 1990 98% (165/169) of families with children aged under 5 years registered with the practice parents of their patients were enrolled when the patient was 6 months or younger and observed until 12 to 18 months of age all children aged 3-12 months registered with participating practices 120 patients of well children urban minority communities primarily households including elderly people or children and households that are in housing rented from the borough council high risk households across the u.s. five states (arkansas, maine, maryland, massachusetts, and north carolina) participated 4,455 households were enrolled in the study [installation group: 2,206 (49.5%), voucher group: 2,249 (50.5 families with children aged under 5 years and living in deprived areas children between september 1980 and june 1982, we implemented five injury prevention projects concurrently in nine massachusetts cities and town; five sites, matched on selected demographic characteristics, were control communities parents of 171 children coming to the yale-new haven hospital primary care center for their 6-month checkup 90% of households receiving the direct installation intervention 47 general practices in nottingham children <8 years old, initially enrolled in an injury case-control study, were eligible to participate a total of 213 families (77.8% of those eligible) from intervention sites, and 149 families (71.9% of those eligible) from concurrent comparison sites, agreed to participate and completed the trial community-dwelling elderly persons multiethnic urban population urban african-american community families with infants from birth to age 6 months were enrolled in the study (n = 196); they were followed up until the child was aged 12 to 18 months pediatric residents twenty families from intervention and control groups caregivers, we studied children less than 17 years of age admitted with an acute thermal injury to the pediatric burn unit of a large, tertiary care hospital in winnipeg, canada over a 32 month period residential-fire injuries 129 families, 65 in the intervention group and 64 in the control group 5 hospitals in 4 canadian urban centers 3428 families with children under 5 pediatric burn units with the exception that north american indian (nai) families were disproportionately admitted, with 59 out of the 123 (48%) admissions from a geographic area that has less than 15% nais public health clients aged 65 years and older parents' safety practices a total of 10,100 smoke alarms were distributed to 9291 homes; 45 percent were functioning four years later 42 percent of households with children ages 0-5 years 34,945 homes in the target area (34 percent) did not have smoke alarms 36 general practices in nottingham
recurrent preterm uterine activity mean days to delivery, the number of repeat triage visits, the incidence of preterm labor pregnancy outcomes shortest length of triage stay frequency of preterm deliveries|there were no intergroup differences in the mean days to delivery, the number of repeat triage visits, the incidence of preterm labor at < 34 weeks, or the frequency of preterm deliveries at < 34 weeks and < 37 weeks.|women in these three groups were similar with respect to maternal age, race, parity, prior preterm births, gestational age at randomization, contraction frequency, and mean cervical dilatation women with preterm uterine contractions one hundred seventy-nine women women who had progressive cervical change at < 34 weeks were treated with eligible women had a singleton gestation between 20 and 34 weeks, intact membranes, more than three contractions in 30 minutes, and a cervical dilation < or = 1 cm and effacement < 80 consenting women seen in our hospital triage area with preterm uterine contractions
resting systolic blood pressure functional work capacity specific physiological, psychological and cognitive functions fatigue, sleep, disability, and mood sf-36 physical functioning subscale net blood lactate production rating of perceived exertion scores fatigue, functional capacity, and fitness work capacity (w.kg(-1 depression fatigue efficacy and acceptability satisfactory outcome in physical functioning physical work capacity, as well as in specific psychological and cognitive variables health perception functional work capacity and fatigue|intention to treat analysis showed 79 (69%) of patients in the intervention groups achieved a satisfactory outcome in physical functioning compared with two (6%) of controls, who received standardised medical care (p<0.0001). exercise significantly improved health perception (p = 0.012) and fatigue (p = 0.028) at 28 weeks. following the graded exercise intervention, scores were improved for resting systolic blood pressure (p = 0.018), work capacity (w.kg(-1)) 12 of 22 patients who crossed over to exercise after flexibility treatment rated themselves as better after completing exercise treatment 32 of 47 patients rated themselves as better three months after completing supervised exercise treatment 35 of 47 patients rated themselves as better one year after completing supervised exercise treatment.|61 patients aged between 16 and 74 years diagnosed with cfs people with chronic fatigue syndrome (cfs chronic fatigue clinic in a general hospital department of psychiatry 21 patients dropped out, mainly from the intervention groups patients with chronic fatigue syndrome patients with the chronic fatigue syndrome 148 consecutively referred patients fulfilling oxford criteria for chronic fatigue syndrome human performance laboratory at the university of western australia ninety-six (71%) of 136 patients completed the trial 66 patients with the chronic fatigue syndrome who had neither a psychiatric disorder nor appreciable sleep disturbance chronic fatigue syndrome
rate of bone turnover and bone loss bone turnover bmd and bone biochemical markers rate of bone loss distal forearm bone mineral density and bone metabolism lumbar spine bmd and bone metabolism low bone mineral density (bmd total hip|after 12 months, the treatment group (n=15) showed a reduced rate of bone loss compared with the control group (n=15) in the lumbar spine (mean difference 1.9% [ci -0.9% to 4.6%])|adults with cystic fibrosis patients were invited to participate if they had a bmd z score of -1 or less in the lumbar spine, proximal femur or distal forearm adult patients with cystic fibrosis these subjects
fasting glucose levels hdl-cholesterol levels weight and waist circumference tbbmc ldl cholesterol levels levels of hdl cholesterol, hdl2, hdl3, triglycerides, lipoprotein populations and apolipoproteins ai and aii total cholesterol level, high-density lipoprotein cholesterol level, blood pressure, and body mass index low-density lipoprotein cholesterol (ldl-c serum cholesterol level triglyceride levels triglycerides triglyceride daily creatinine excretion levels of lipids and lipoproteins spine density and total body density extremity/trunk ratio systolic blood pressure baseline biochemical values total body calcium incidence of diabetes serum lipids or lipoproteins alcohol consumption lowered lipoprotein(a bone mineralization defects time for homocysteine levels fasting plasma total homocysteine concentrations ratio of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lipid changes, measurement of serum total cholesterol (tc), triglycerides (tg), low density lipoprotein (ldl), high density lipoprotein (hdl), apolipoprotein a-1 (apo-a) and apolipoprotein b (apo-b muscle performance, improve balance or reduce falls cortical and trabecular bone exercise performance final values of fibrinogen, fvii, atiii, protein s and hcii body cell mass and body fat mass metacarpal cortex maximum oxygen uptake postmenopausal bone loss serum lipids and coagulation factors leg extensor power bone mineral density hip, work activity body composition bone density, endometrium, and lipids of continuous hormones total and low density lipoprotein cholesterol levels low-density-lipoprotein (ldl) cholesterol total serum cholesterol levels fibrinogen levels levels of follicle-stimulating hormone levels of lipids, lipoproteins, apolipoproteins, fibrinogen and glucose tolerance lipid profile percent of body fat vaginal cytology profile (maturation index serum lipoproteins pai-1 body weight endometrial hyperplasia muscle performance and balance waist girth levels of total serum cholesterol and ldl-cholesterol blood pressure and body mass index fibrinogen serum oestradiol and serum oestrone endometrium against hyperplasia spine density, total body calcium, or radial density total body fat mass or total lean body mass antithrombin iii activity (mean levels baseline blood pressures and body weights plasma fasting homocysteine concentrations efficacy and safety high-density lipoprotein-2 cholesterol (hdl2-c urinary creatinine/body weight ratio incidence of estrogen-related side effects glucose tolerance or on fibrinogen levels fibrinogen, factor vii (fvii), factor viii apolipoprotein a1 hip and spine bmd growth hormone secretion patterns change high-density lipoprotein cholesterol (hdl-c), triglycerides, or plasminogen activator inhibitor-1 (pai-1 serum lipids and lipoproteins serum triglycerides levels serum triglycerides and hdl-cholesterol levels changes of other lipid profiles low-density lipoprotein (ldl) cholesterol gh and igf rate of hyperplasia and proliferative status cardiovascular risk endometrial proliferation and hyperplasia overall health risks gh- and igf loss of femoral neck bmd serum estradiol concentrations plasma homocysteine bone turnover, including bone-specific alkaline phosphatase, and urinary hydroxyproline:creatinine ratios fasting plasma homocysteine concentrations hdl cholesterol level total cardiovascular disease (arterial and venous disease overall activity weight or girth changes lumbar bmd bone mineral density (bmd antithrombin iii (atiii), protein c, protein s, heparin cofactor ii (hcii) and plasminogen activator inhibitor ratio of fat in the trunk/extremities hdl-c and pai-1 physical activity level sway, leg extensor power and self-paced walking speed weight gain plasma homocysteine levels levels of serum triglycerides serum e2 levels estradiol/estrone ratio total cholesterol hand grip strength fasting glucose level total serum cholesterol and ldl-cholesterol levels breast pain muscle strength breakthrough bleeding high-density lipoprotein (hdl) cholesterol-ldl ratio hot flushes lipids and lipoproteins frequency of moderate-to-severe hot flushes balance, muscle performance and falls pai-1) levels urinary creatinine excretion rate high density lipoprotein (hdl) cholesterol levels cardiovascular risk factors fasting glucose level and incident diabetes total exercise time (time spent on the treadmill until exhaustion during testing total and ldl cholesterol levels bmd body weight and waist and hip girths vaginal bleedings bone loss plasma homocysteine concentration ldl cholesterol skin tolerability anthropometry, lipoprotein levels, antithrombin iii activity, and endometrial histology hdl cholesterol trunk fat mass elevated ldl cholesterol levels hdl2-c and lipoprotein(a serum cholesterol levels femoral neck bmd spine density high-density-lipoprotein (hdl) cholesterol nonfatal myocardial infarction and chd death radial density total mortality estimated hazard ratios (hrs stroke, pulmonary embolism (pe), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes abdominal fat after menopause lipid metabolism lumbar spine lipid measures coronary heart disease (chd) height loss levels of apolipoprotein b and lipoprotein(a body weight, blood pressure, lipoprotein levels, antithrombin iii activity, and the endometrium total body bone mineral content (tbbmc hispanic ethnicity lipid levels and coagulation parameters total serum cholesterol and ldl-cholesterol overall values for body weight and blood pressure initial levels of oestradiol biochemical markers of cardiovascular risk by decreasing ldl-c, fibrinogen, and lipoprotein(a cholesterol, triglycerides, and ldl cholesterol, and an increase in the hdl-ldl ratio rate of new vertebral fractures secretion of growth hormone (gh) and igf physical fitness levels glycemic effects high-density lipoprotein cholesterol/total cholesterol fraction|the loss of femoral neck bmd was lower in the hrt (-0.3%) and the hrt + vit d (0.9%) groups compared with the vit d (-2.4%) and the placebo groups (-3.7%). factors that were independently associated with smaller increases in girths were: for waist, greater overall activity (p = 0.005) and hispanic ethnicity (p = 0.02); and for hip, work activity (p = 0.003) and greater alcohol consumption (p = 0.03). the percent of body fat increased in each group from baseline measurements, with the greatest increase in the hormonal replacement group. after 15 months of hormone treatment mean plasma homocysteine concentration was lowered by 12.6% compared with baseline (p < .001; analysis of variance for repeated measures). patients who received combined therapy had significantly higher bmd in both the vertebrae and in the femora (p <0.05) in comparison with patients who were treated with hrt or etidronate alone after 4 years. the hypocholesterolemic effect was correlated to body mass index in a way that indicated the most pronounced decrease in lean women. after 1 year tbbmc/w was lower in every group: -2.14% (p < 0.001) in the control group; -0.14% (p = ns) in the hrt group (p < 0.05 vs. controls); -0.18% (p = ns) in the calcium group (p < 0.05 vs. controls); and -0.06% (p = ns) in the calcitonin group (p < 0.01 vs. controls; p < 0.05 vs. calcium and hrt). exercise alone was associated with significant decreases in total cholesterol (5.2%, p < .05), triglycerides (2%, p < .05), and low-density lipoprotein (ldl) cholesterol (10%, p < .01), and a significant increase in the high-density lipoprotein (hdl) cholesterol-ldl ratio (17.2%, p < .01). frequent fallers swayed significantly more often than the others, but there was no evidence that their muscle strength was poorer or that the group treated with hormone replacement therapy fell less frequently. however, there was no significant difference in changes of other lipid profiles between the two groups at 6 and 12 months (non-hrt: tc -2.7%, +0.7%, hdl +2.9%, +5.1%, ldl -5.2%, -4.1%, apo-a +0.5%, +0.9%, apo-b +3.8%, +1.3%: hrt: tc -1.4%, -2.8%, hdl +4.7%, +6.2%, ldl -1.5%, -4.9%, apo-a -0.9%, +1.6%, apo-b total serum cholesterol levels were significantly reduced by 4-10% (p less than 0.05-p less than 0.001) in a dose-related way in the hormone groups. total and ldl cholesterol levels were reduced by 14% (95% ci, 11-17%) and 19% (95% ci, 14-23%), respectively, in the hrt group vs. 3% (95% ci, 0-7%) and 5% (95% ci, 0-11%) in the diet group. patients who received combined therapy had significantly higher bone mineral density in both vertebrae (p < 0.05) and femora (p < 0.01), in comparison to patients who were treated with hrt, or ice, alone. raloxifene did not significantly change high-density lipoprotein cholesterol (hdl-c), triglycerides, or plasminogen activator inhibitor-1 (pai-1); whereas hrt increased hdl-c by 11% and triglycerides by 20%, and decreased pai-1 by 29% (for all, p < .001). the urinary creatinine excretion rate was significantly increased (p less than 0.001) in the group receiving high-dose hormones, and the urinary creatinine/body weight ratio was significantly increased (p less than 0.05) in all treated groups as compared with the placebo-group. the therapy reduced postmenopausal bone loss significantly (p less than .001), whereas it did not have a statistically significant influence on total body fat mass or total lean body mass. those women who did not receive any hormonal treatment and the postmenopausal women before hrt showed nearly identical gh- and igf total serum cholesterol and ldl-cholesterol were reduced by approximately 5% (p less than 0.01) and 8% (p less than 0.01), respectively, after 1 year of combined oestrogen-cpa therapy in comparison with both the initial values and the placebo group but serum triglycerides and hdl-cholesterol levels were unchanged in both groups. the incidence of diabetes was 6.2% in the hormone therapy group and 9.5% in the placebo group (relative hazard, 0.65 [95% ci, 0.48 to 0.89]; p = 0.006). the continuous treatment group had significantly lower final values of fibrinogen, fvii, atiii, protein s and hcii than the placebo group; the cyclic treatment reduced fibrinogen in comparison with placebo but the difference was not significant. with treatment, there were no differences in overall values for body weight and blood pressure (p > 0.4), and order of treatment had no significant influence (p > 0.3). corresponding hrs (nominal 95% cis) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. the premarin-treated group had an increase in spine density and total body density (p less than 0.05), but a decrease in radial density (p less than 0.05). total serum cholesterol and ldl-cholesterol levels were reduced by approximately 15% and 20% (p less than 0.001), respectively in the hormone group but were unchanged in the placebo group. daily treatment with na-ee2 was well tolerated and protected the endometrium from ee2-induced proliferation and hyperplasia. the reduction in hot flushes for both active treatment groups remained significantly different from placebo throughout the 12-week trial.|255 women in physiological menopause for 1-5 years 273 postmenopausal women seventy-two postmenopausal women (mean age 64.9+/-0.5 years) attending metabolic bone disease outpatient clinics with established osteoporosis asymptomatic or mildly symptomatic women aged 40 years or older who had undergone the onset of spontaneous menopause within the last 5 years and who had an intact uterus hypercholesterolaemia among postmenopausal women 105 apparently healthy women in the menopause transition (40-52 years), with menstrual function, who were experiencing minor menopausal symptoms, were selected from the general population by advertising postmenopausal women experiencing menopausal symptoms 118 women who were within 6 years of menopause was conducted post-menopausal women postmenopausal women all patients enrolled in this study including the control group (n=18) received group (mean age 48 postmenopausal women who were experiencing at least 60 moderate-to-severe hot flushes per week non-osteoporotic early postmenopausal women 875 women assessing the effects on cardiovascular risk factors of four hormone regimens 167 women who took the treatment for at least 6 cycles were evaluable healthy postmenopausal women postmenopausal women with established osteoporosis women with postmenopausal osteoporosis 44 healthy postmenopausal women every 3 months during 1 year of treatment with either study population was a subgroup of the kuopio osteoporosis risk factor and prevention study (ostpre) (n = 13100 a total of 104 naturally or surgically postmenopausal women outpatient clinic of a city hospital early postmenopausal women 23 healthy postmenopausal women 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 us clinical centers in 1993-1998 81 postmenopausal women aged 51.7 136 post-menopausal women treated for at least 1 yr with 2763 postmenopausal women with coronary heart disease who were followed for 4.1 years 26 patients each: the untreated control group (mean age 50 74 postmenopausal women 27 postmenopausal women postmenopausal women in a 2.5-year randomized twelve hundred sixty-five patients entered the study early post-menopausal women women in the menopause transition group (mean age 50 76 healthy postmenopausal women treated for 1 year with either middle-aged women one hundred one postmenopausal women 116 post-menopausal women (aged 45-70 years), all of whom had suffered a distal radial fracture during the previous 3 months 20 u.s. clinical centers 464 early postmenopausal women healthy postmenopausal us women sixty-two early postmenopausal women 390 healthy postmenopausal women recruited by advertisement lean women 76 postmenopausal women, aged 43-60 years, with ldl cholesterol levels > or = 4.2 mmol 1-1, treated with a lipid-lowering diet 734 women had diabetes, 218 women had impaired fasting glucose, and 1811 women were normoglycemic; the 2029 women without diabetes were followed for incident diabetes outpatients at 65 centers hyperlipidaemic postmenopausal women 93 postmenopausal women fifty-eight early postmenopausal women attending metabolic bone disease outpatient clinics 87 healthy post-menopausal women treated for 1 yr with three different doses of osteoporosis in natural and surgical postmenopausal women who had been found to have rapid bone loss in analytical studies
duration of air leaks mean duration of postoperative air leakage control of air leaks intraoperatively and the time to postoperative air leak cessation mean time to chest drain removal and mean time to hospital discharge mean numbers of intraoperative aal after application of sls control of air leaks leak-free air leakage volume morbidity mean percentage of patients free of aal mean time to last observable aal paal volume of chest tube drainage or los median duration of intercostal drainage and in-hospital stay incidence of postoperative leakages time to chest tube removal, time to hospital discharge, and safety outcomes percentage of patients free of air leakage throughout hospitalization airway-tolerance-pressure test incidence of dead pleural space duration of stay in hospital reduction of intra-operative air leakage postoperative leakage intraoperative air leaks mortality, morbidity, duration of chest tubes, or immune responses quality of aerostasis, the post-operative drainage, the persistance of residual collection or faulty reexpansion surgical morbidity and costs length of the postoperative hospital stay localized empyema and incomplete lung expansion postoperative air leaks intercostal chest drainage mean time to chest tube removal air leak duration, chest drainage time, and hospital stay length of hospitalization procedure costs persisting air leakage postoperative morbidity and mortality median length of hospitalization incidence of paal air leaks duration of air leaks, chest tube drainage, or hospitalization postoperative air leakage intensity safety and effectiveness fever, intraoperative and postoperative intubation times overall incidence of air leakage free of air leaks during hospitalization alveolar air leaks reduction of intra-operative air leak intensity postoperative hospitalisation time mean times to chest drain removal and to hospital discharge efficacy and safety chest tube drains intraoperative leaks air leakage healing of healthy bronchial and lung tissues postoperative quantification of air leakage on postoperative days 1 and 2 mean times to last observable air leak mean intraoperative post-treatment air leakage mean bleeding/exudate volumes air leakage volumes mean air leak duration shorter median duration of air leaks postoperative hospitalization duration of postoperative chest tube time, hospital stay, or cost overall incidence of air leaks hospital stay reduced time to chest tube removal and earlier discharge overall incidence of aal incidence of air leakage duration of air leak, intercostal drainage, and hospital stay postthoracotomy alveolar air leak mean duration of aal postoperative air leakage incidence and duration of aal, prolonged aal (paal), the volume of pleural drainage, the time to tube removal, and the postoperative length of stay (los), as well as any complications related to treatment|an additional reduction of the duration of post-operative air leakages by the treatment with fibrin glue could not be shown. statistically significant reductions were found in the experimental group in the overall incidence of aal (34% versus 68%, p = 0.001), mean duration of aal (1.1 versus 3.1 days, p = 0.005), mean time to chest tube removal (3.5 versus 5.0 days, p = 0.02), and the incidence of paal (2% versus 16%, p = 0.015). intraoperative air leaks were sealed in 77% of the sealant group compared with 16% in the control group (p < 0.001). this study demonstrates clear benefit from bioglue in the treatment of alveolar air leaks through reduction of air leak duration, chest drainage time, and hospital stay. application of the sealant resulted in control of air leaks in 92% of treated patients (p < or = 0.001). in the clinical study, 100% of intraoperative leaks were sealed versus 18% of control patients (p =.001). there were no complications related to the use of the patches, and a significantly lower incidence of dead pleural space was observed in the es group (5% vs 40%, p = .020). statistical analysis revealed no differences between the groups. we conclude that the routine use of a fixed quantity of fibrin glue is not effective in reducing the duration of air leaks, chest tube drainage, or hospitalization after uncomplicated pulmonary lobectomy. the reduction of intra-operative air leak intensity in the subgroup with grades 1-2 was significantly higher for the tc group (p=0.015). postoperative hospitalisation time was shorter in the vivostat group than in the control group but the difference was not significant (0.5 days, p=0.12). tachosil showed a trend towards reduced incidence of postoperative leakage when measured >48h or >7 days after surgery (30.7% vs 38.96% and 24% vs 32.46%, respectively). in treated patients, the mean numbers of intraoperative aal after application of sls were significantly smaller than in untreated patients (38.5 ml versus 59.9 ml, p = 0.0401). no significant statistical difference was observed concerning the quality of aerostasis, the post-operative drainage, the persistance of residual collection or faulty reexpansion after removal of the latter, and the necessity for repeated drainage.|14 patients, and 14 patients served as controls air leakage after standard lobectomy 100 patients thoracic operations patients with grade 0 leakage were excluded fifteen large white pigs underwent a left upper lobectomy 189 patients undergoing lobectomy were enrolled in a multi-centre 172 patients undergoing thoracotomy 50 patients 124 patients undergoing standard lobectomy 66 patients undergoing lobectomies, segmentectomies, or decortication were randomized either to serve as controls (n = 33) or to have partial pulmonary excision surgery patients undergoing lobectomy 161 patients with a median age of 67 years old (range 18-85 years old 20 patients in each of the 2 groups nine male and 5 female patients with a mean age of 63.8 years were in the fibrin glue experimental group, and 8 male and 6 female patients with a mean age of 59 years, in the control group after pulmonary lobectomy pulmonary resection the mean age was 59 28 consecutive patients between november 1988 and may 1989 lung surgery 173 patients undergoing lobectomy or segmentectomy 113 patients enrolled, 13 became ineligible because of intraoperative findings patients with grade 1 or 2 air leaks from december 2002 to january 2005, 52 patients were randomized, 29 (56%) of whom were men 26 consecutive patients 50 patients undergoing partial pulmonary excision after lung resection 114 patients undergoing pulmonary resections and pneumonectomies
2-h postdose fev(1 lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status incidence of pneumonia average daily morning pef total number of exacerbations annual rate of exacerbations requiring oral corticosteroids number of exacerbations resulting in hospitalization respiratory function (such as fev(1), morning pef), and and symptom score fev1 annual rate of moderate/severe exacerbations annual rate of moderate to severe exacerbations fev(1 tidal volume and minute ventilation exercise performance daily symptoms mean prebronchodilator forced expiratory volume moderate/severe exacerbations mean number of exacerbations/yr severe exacerbations and fev1 (primary variables), peak expiratory flow (pef), copd symptoms, health-related quality of life (hrql), mild exacerbations, use of reliever beta2-agonist and safety variables adverse events health-related quality of life, peak expiratory flow, and use of rescue medication incidence of individual non-fatal serious adverse events morbidity and mortality lung hyperinflation and exercise endurance predose fev(1 dyspnea, quality of life, and symptoms of chronic bronchitis mean time to first exacerbation postdose frc and increased inspiratory capacity (ic lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations rate of moderate to severe exacerbations morning pef efficacy morning predose (ie, trough fev(1)) for fsc compared with sm and 2-h postdose fev(1 mean fev(1 efficacy and safety exercise time symptom scores and use of reliever beta2-agonists tolerated relative predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations rate of copd exacerbations pre-dose forced expiratory volume in 1 second (fev(1)) and 1-hour post-dose fev(1 efficacy and tolerability tolerated pre-dose forced expiratory volume in 1 second (fev1) and 1-hour post-dose fev1. pretreatment fev1 frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration ic reporting of pneumonia daily beta(2) short acting prn consumption morning predose fev(1 severity of dyspnea controlling dyspnoea and improving health status (st george's respiratory questionnaire worsening symptoms of copd requiring antibiotics, oral corticosteroids and/or hospitalization daily symptoms score postdose ic exercise endurance time pulmonary function and reduced symptoms and exacerbations pretreatment forced expiratory volume in 1s (fev1 albuterol use, dyspnea scores, and nighttime awakenings and numerical benefits on quality of life copd exacerbations transition dyspnea index exacerbations lung function morning lung function efficacy for pulmonary function moderate and severe exacerbations health status morning peak expiratory flow rate (pef); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations rate of moderate/severe exacerbations morning pef (l/s), the daily symptom score, and the number of exacerbations annual rate of moderate/severe exacerbations requiring hospitalization postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire (sgrq lung hyperinflation dyspnoea (measured using the breathlessness diary) and health-related quality-of-life (hr-qol) scores (based on the st george's respiratory questionnaire total score lung function and health status annualized rate of moderate and severe exacerbations dyspnoea scores and hr-qol adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms pneumonia mean number of severe exacerbations risk of time to first exacerbation prebronchodilator peak expiratory flow 2-hour postdose fev(1 frequency of moderate/severe exacerbations adverse effects copd exacerbations and impact on patient outcomes prolonged time to first exacerbation|combination therapy improved pretreatment fev1 significantly more than did placebo (treatment difference 133 ml, 95% ci 105-161, p<0.0001), salmeterol (73 ml, 46-101, p<0.0001), or fluticasone alone (95 ml, 67-122, p<0.0001). postmedication fev1 improved by 0.21 l and health-related quality of life using the st george's respiratory questionnaire (sgrq) by 4.5 units after run-in. the incidence of adverse effects (except for an increase in oral candidiasis with fsc and fp) were similar among the treatment groups. the incidence of adverse effects (except for an increase in oral candidiasis with fsc and f) was similar among the treatment groups. dyspnoea scores and hr-qol were significantly improved with both budesonide/formoterol pmdi dosage strengths versus both monocomponents and placebo. the rate of copd exacerbations was lower in both budesonide/formoterol groups compared with formoterol and placebo (p <or= 0.004). clinical improvements observed during run-in treatment with fsc 250/50 were better maintained over 52 weeks with fsc 250/50 compared to sal. morning pef (l/min) increased in subjects treated with sm&fp (anova p<0.001), while it remained unchanged in sm and p group (in both, anova p=ns). morning pef improved significantly on day 1 versus placebo and budesonide; after 1 week, morning pef was improved versus placebo, budesonide and formoterol. 0.05 l over placebo with associated improvements in tidal volume and minute ventilation (p < 0.05 vs placebo at week 8). clinical improvements observed during run-in treatment with fluticasone propionate/salmeterol 250/50 were better maintained over 12 months with fluticasone propionate/salmeterol 250/50 than salmeterol. other endpoints, including health-related quality of life, peak expiratory flow, and use of rescue medication, were significantly improved in the combination therapy group.|patients with chronic obstructive pulmonary disease (copd) who have frequent exacerbations seven hundred twenty-three patients > or =40 years of age with copd and a mean baseline fev(1) of 42% predicted chronic obstructive pulmonary disease (copd 797 subjects with copd (mean fev(1) patients with copd moderate-to-severe chronic obstructive pulmonary disease copd patients already treated with severe chronic obstructive pulmonary disease patients with moderate to very severe chronic obstructive pulmonary disease 812 adults (mean age 64 yrs, mean forced expiratory volume in one second (fev1) 36% predicted normal 1465 patients with copd were recruited from outpatient departments in 25 countries copd 185 patients (mean baseline fev1 of 41% predicted) were enrolled 782 patients with copd (mean seventy-six investigative sites in the united states patients with chronic obstructive pulmonary disease eligible patients were > or = 40 years old with a diagnosis of copd, prealbuterol fev(1 patients with severe copd 691 patients with copd 964 patients aged >or =40 years with moderate to very severe copd conducted from 2005 to 2007 at 237 sites in the us, europe and mexico patients with moderate-to-severe chronic obstructive pulmonary disease (copd patients with severe copd and a history of repeated exacerbations chronic obstructive pulmonary disease 994 clinically stable patients patients with moderate to very severe copd eighteen moderate copd patients 1704 patients aged > or =40 years with moderate to very severe copd conducted in 194 centres in the us, czech republic, the netherlands, poland and south africa symptomatic chronic obstructive pulmonary disease (copd
morphologic remissions response of active crohn's disease to sulphasalazine median cdai decrease remission disease activity morning plasma cortisol value corresponding cdai change serious adverse reactions change in the crohn's disease activity index (cdai clinical remission, defined as a score of 150 or less on the crohn's disease activity index clinical activity (harvey-bradshaw index) or laboratory indicators of inflammation mean 17-week cdai scores intention-to-treat basis remission rates median auc of the cdai serum albumin, esr, body weight released to height, abdominal mass, temperature, stool consistency, bowel resection, and extraintestinal symptoms related to crohn's disease remission of cd (cdai < 150) and decrease of at least 60 points side effects mean activity index crohn's disease activity index 72 cdai points disease deterioration crohn's disease activity index (cdai clinical improvement efficacy and safety activity index clinical improvement in crohn's disease active cd response rates respective rates total numbers rates of remission numbers of patients with adverse events diarrhoea response of active symptomatic disease faecal granulocyte excretion achieving partial or complete remission small bowel and colon disease cdai cdai median score value severe adverse events entered remission or improved their symptoms remission rate or withdrawal rate for active disease small bowel disease|there was no difference in the remission rate or withdrawal rate for active disease in the two groups. compared with placebo, the 4-g/day dose of pentasa was associated with a statistically significant overall improvement in the cdai from baseline to the final visit (p = 0.04). the response of active crohn's disease to sulphasalazine was significantly better than to placebo. the crohn's disease activity index decreased in the first 6 weeks to a median of 65% (interquartile range, 57% to 86%) in patients receiving sulphasalazine and prednisone and to a median of 75% (interquartile range, 58% to 101%) in patients receiving sulphasalazine alone (p = 0.13). on an intention-to-treat basis remission rates after 8 weeks were 40.0% in the 5-asa group and 56.3% in the 6-mpred group (p = 0.5867). after 10 days of treatment faecal granulocyte excretion fell in all patients receiving 5-asa, while no consistent change was found in the placebo group. for patients with quiescent disease, none of the drugs was superior to placebo in prophylaxis against flare-up or recurrence. the numbers of patients with adverse events were similar in the two groups, but those assigned to budesonide had fewer severe adverse events. in the 5-asa group 40% of the patients improved, versus 30% of the placebo-treated group ('intent to treat' basis; p greater than 0.1). sulfasalazine alone was least effective in overall comparison of all patients (p less than 0.05) and in all strata. no serious adverse reactions occurred. patients with ileum-only disease showed a 93-point improvement on 4 g mesalamine, compared with a 2-point improvement in similar patients on placebo. patients taking mesalamine tablets experienced a decrease of cdai median score value of 113.5 (95% confidence interval [ci], 33-149) compared with 123 (95% ci, 77-155) in the mesalamine microgranular group and 154 (95% ci, 99-197) in the 6-methylprednisolone group (p = 0.07 [ns]). clinical improvement in crohn's disease was seen in 87% of patients of the 5-aminosalicylic acid group and in 80% of the salazosulfapyridine group. oral mesalamine was effective in achieving partial or complete remission in 60% of patients as compared with 22% of placebo-treated patients.|patients taking microgranular mesalamine (ns twenty-six patients had ileal disease; 43, ileocolonic; and 22, colonic from august 1977 to august 1979 all patients with established crohn's disease patients with active crohn disease thirty-five of 46 patients taking olsalazine and 24 of 45 patients taking sixty-seven patients were included, of whom 30 were treated with 1500 mg slow-release 5-asa/day (pentasa) for a scheduled period of 16 weeks 452 patients with crohn's disease mild to moderate active crohn's ileitis active crohn's ileocolitis crohn's disease (cd patients with quiescent disease mild and moderately active crohn's disease localized in the small bowel 38 patients for the treatment of mildly to moderately active crohn's colitis or ileocolitis patients with colonic involvement patients with mild to moderate attacks of crohn's disease one hundred sixty patients were previously untreated; 292 patients were previously treated mild to moderate crohn's disease two groups with 30 patients each with ulcerative colitis and with crohn's disease patients with active crohn's disease affecting the ileum, the ascending colon symptomatic crohn's colitis and ileocolitis active crohn's disease patients with active crohn's disease 569 patients in a ninety-four patients with crohn's ileitis (crohn's disease activity index [cdai], 180-350 mild and moderate active crohn's colitis active ulcerative colitis patients with active crohn disease and a van hees activity index of 140 or more one hundred ninety-two patients completed the 2-yr study period seventeen patients were secondarily excluded, and the remaining 50 patients (23 receiving 17 patients were in the patients with active crohn's disease affecting the ileum, the ascending colon, or both patients with activer cd who are intolerant to or refuse glucocorticoids 34 patients with active cd (cdai > 150) were included 310 patients ninety-one patients from four centres 38 patients completed the 17-week study twelve patients crohn's disease patients who responded initially to treatment of active disease adult patients treated with pentasa 4 g/day for active crohn's disease 182 patients with scores of 200 to 400 on the crohn's disease activity index (with higher scores indicating greater disease activity 71 patients who were randomly assigned, 60 completed treatment and were analyzed multicenter trial in one university hospital and nine general hospitals 40 patients with active crohn's disease patients who fail or are intolerant of patients taking mesalamine tablets and 22 of 28 (79
incidence of proven ifi cutoff od index for positivity false-positive tests positive and negative predictive values sensitivity, specificity, positive predictive value (ppv) and negative predictive value (npv) of gm detection in ct-based bal fluid incidence of invasive fungal infections radiologic signs aspergillus antigenemia overall sensitivity consecutive serum gm titres median index of the initial nasba sensitivity of the elisa galactomannan positivity fever and pulmonary infiltrates overall specificity of the elisa diagnosis of invasive aspergillosis (ia positive gm titres signs of ifi diagnostic levels of gm galactomannan antigenemia elisa major pulmonary signs concentration of galactomannan false-positive reactions sensitivity and specificity roc curve overall specificity kinetics of nasba values: failure of negative conversion radiologic examination or aspergillus isolation eia and latex agglutination test pcr and elisa survival sensitivity, specificity, and positive and negative predictive values for gm and bg patient survival during hospitalization, serum galactomannan levels positive predictive value elisa cutoff value likelihood ratio of a positive test minor pulmonary signs gm positive predictive and negative predictive values serum galactomannan (gm sensitivity of diagnosis diagnostic levels of both bg and gm invasive aspergillosis sensitivity and specificity for the elisa test serum enzyme-linked immunosorbent assay (elisa) test false-positive and false-negative results overall sensitivity, specificity, and positive and negative predictive values sensitivity and specificity rates gm antigenemia specific dna galactomannan antigenemia preceded post-mortem histological diagnosis of invasive aspergillosis abnormal ct signs sensitivity negative predictive value pcr and bdg tests serum elisa results overall positive and negative predictive values serologic positivity false single-positive rate detection of serum galactomannan (gm rate of false-positive results specificity positive results for aga (od index predictive positive and negative values occurrence of invasive fungal infection (ifis sensitivity and specificity of the gm eia sensitivity, specificity, ppv and npv of gm detection in ct-based bal fluid|antigen was detected on at least two sequential sera in 48 of 53 patients, with a sensitivity of 90.6%. the specificity was 99.6% (748 of 751 cases). eleven patients (11%) having a positive result (od index >1.5 ng/ml) in two consecutive platelia aspergillus tests were considered galactomannan-positive cases. aspergillus species were detected by pcr or elisa with bal fluid samples from five of seven patients who had radiological evidence of ipa. this statistical profile was better than that of other triggers, including unexplained fever, new pulmonary infiltrates, isolation of aspergillus species, and abnormalities seen on computed tomography. although the elisa test did not have any role in the anticipation of the diagnosis, it clarifies the diagnosis of ia in allo-hsct. the incidence of proven ifi was 1/31 (3.2%) in the allogeneic stem cell transplant (sct) (aspergillus spp), 0/26 in the autologous sct, and 1/60 (1.6%) in the induction therapy group (c. krusei). the gm eia is a useful diagnostic toolfor the diagnosis and monitoring of the course ofla in the presented institute. galactomannan antigenemia preceded post-mortem histological diagnosis of invasive aspergillosis in two patients by 17 and 81 days, respectively. fourteen patients showed positive results for aga (od index> a combination of the two tests improved the specificity (to 100%) and positive predictive value (to 100%) of each individual test without affecting the sensitivity and negative predictive values. the double sandwich elisa detecting aspergillus galactomannan (gm) was prospectively evaluated for the diagnosis of invasive aspergillosis (ia) in 50 haematological patients at risk for ia. sensitivity and specificity rates for the nested-pcr assay were up to 63.6% [95% confidence interval (ci): 30.8-89%) and 63.5% (95% ci: 53.4-72.7%) respectively, and 33.3% and 98.9% (95% ci: 7.5-70.1% and 94.2-99.9%) for gm respectively. for gm detection in serially sampled serum, the sensitivity was 47%, the specificity 93%, the ppv 73% and the npv 82%. in addition to serial screening for gm antigenemia and radiological surveillance, pcr-elisa may improve the rates of early diagnosis of ia and the management of patients with hematological malignancies. a quantifiable response to antifungal therapy in clinical samples and the rabbit model supports the development of this assay for early diagnosis and therapeutic monitoring. univariate and multivariate analyses revealed no significant association between detection of gm by eia and detection of abnormal pulmonary signs by ct. fifteen of them had positive gm titers (87 samples) and 12 had positive pcrs (20 samples). despite enhanced sensitivity, the pcr method failed to detect nucleic acid in a probable case of invasive candida infection that was detected by elisa. increasing the cutoff value to >or= 0.66 yielded a sensitivity of 30%, specificity of 95%, and positive and negative likelihood ratios of 5.5 and 0.74. in a receiver-operating characteristic (roc) analysis, the area under the roc curve was greatest for elisa, using two consecutive positive results (0.97; p = 0.036 for elisa versus pcr, p = 0.055 for elisa versus bdg). case-control analysis showed that treatment with piperacillin-tazobactam was the only risk factor significantly associated with receiving false-positive test results. sensitivity was 69% and specificity 96% if only positive results are considered; when 'undetermined' test results were combined with positive results, sensitivity attained 100% and specificity 92% suggesting that the cutoff value for positivity can be lowered from 1.5 to 1.0. twelve of 16 patients with confirmed or suspected ia were elisa positive on two or more occasions, compared with 10 of 15 who were la positive. this pcr method is very sensitive for the diagnosis of ia but is associated with a moderate rate of false positives; the gm assay exhibited poor sensitivity but high specificity. applying both cut-offs to a subgroup of 21 'possible' fungal infections further identified and upgraded six cases of ia. after bmt, the eia and latex agglutination test were positive in 19 and 4 patients respectively of 25 patients with confirmed aspergillosis and 14 and 7 of 15 patients with probable aspergillosis. it was lower in children compared with adults (p <.0001) and in allo-hsct patients compared with non-allo-hsct adults (p =.0002). reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis (ia) has been widely variable, ranging from 29% to 100% in earlier clinical studies. requiring 2 consecutive samples with an od index > or = 0.5 resulted in the highest test accuracy, with an improved positive predictive value. a close relationship was found between clinical course and the kinetics of gm indices in survivors. positive or undetermined results were detected one to 4 months before the diagnosis of ia in eight of the 11 patients (72.7%) with proven ifi. galactomannan antigenemia (index, >0.5) was detected with a sensitivity of 86%. we compared an aspergillus fumigatus-specific taqman real-time pcr assay for the diagnosis of invasive aspergillosis (ia) with the enzyme-linked immunosorbent assay platelia aspergillus method. in the two patients found positive with both methods, the elisa test became positive earlier than the la test or remained positive after the la test had become negative. sensitivity of the test was 55.6%, specificity was 93.9%, the positive predictive value was 71.4%, and the negative predictive value was 88.6%. screening for aspergillus antigen and dna has been introduced for the early diagnosis of invasive aspergillosis (ia) in adults, but data in children at risk are scarce. galactomannan elisa had fewer false-positive and false-negative results in pediatric patients than in adult patients.|neutropenic patients with hematological disorders 201 adult patients with hematological malignancies who were included in the study, 55 ia cases were diagnosed patients receiving treatment for hematological malignancies 17 patients a possible invasive aspergillosis 19 patients without ia (83 samples), one had 3 gm-false-positive samples 281 serum samples collected weekly during the period at risk for ia from 41 selected hematology patients lung transplant recipients 128 patients with hematologic diseases during periods of neutropenic fever after undergoing chemotherapy or hematopoietic stem cell transplantation 66 patients did not fulfill any criteria of ia, 2 patients were classified with possible ia, 5 patients were classified with probable ia, and 1 patient was classified with proven ia adult patients at risk for ia at 2 european health care centers from february 2002 to june 2004, 74 hemato-oncologic patients undergoing allogeneic stem cell transplantation neutropenic cancer patients and haematological stem cell transplant recipients bmt patients 347 children from the pediatric hematology service and 450 patients from the bone marrow transplantation unit at the hpital saint-louis in paris patients with proven invasive aspergillosis and 50% for patients with proven and probable invasive aspergillosis 986 serum samples from 67 patients 40 neutropenic adult patients at high risk for ia june 2002 to january 2004 in a consecutive series of adult neutropenic patients with hematological disorders who were at risk for developing ia patients with ia 12 patients (12%) were diagnosed of proven or probable invasive aspergillosis children at risk 14 children invasive aspergillosis adult hematology patients fifteen of them had positive gm titers (87 samples) and 12 had positive pcrs (20 samples 109 episodes with no ia, 32 episodes with possible ia, and 20 episodes with probable or proven ia were identified hematological patients with invasive aspergillosis invasive aspergillosis (ia patients with hematological disorders all patients with proven invasive aspergillosis liver transplant recipients (olt nine case patients and 33 control patients met the criteria required for being considered "valid" for antigenemia analysis from january 1999 to january 2001, all consecutive adult patients undergoing allo-hsct were prospectively studied with a 124 neutropenic episodes with a high pretest probability for ia 74 patients underwent an 9 had probable ia, 26 had possible ia, and 149 had no ia invasive aspergillosis (ia) in bone marrow transplant recipients bone marrow transplant recipients twenty-two patients had confirmed, probable, or suspected ia, according to clinical and mycologic data invasive candida infection and invasive aspergillosis seven patients were classified with possible ipa and two patients, proven ipa liver transplant recipients patients undergoing allogeneic stem cell transplantation 849 sera from 54 hematological patients with prolonged neutropenia, which were classified according to the risk for invasive aspergillosis adult and pediatric oncohematologic patients in total, 2026 serum samples from 104 bone marrow transplant recipients 46 patients with ia and 3005 serum samples obtained from 269 control patients two adult and pediatric hematology units patients with hematologic diseases bone marrow transplanted children 50 haematological patients at risk for ia of 160 patients, 17 patients (10.6%) presented with proven, probable or suspected ipa pediatric patients than in adult patients 107 patients (65 allogeneic hsct recipients, 30 autologous hsct recipients, and 66 induction and/or consolidation chemotherapy recipients hematological patients with a high and intermediate risk for invasive aspergillosis patients with hematological malignancies who had undergone hematopoetic stem cell transplantation (hsct) or had received patients with hematological malignancies experiencing chemotherapy-induced prolonged neutropenia (anc < 500/mm(3) for more than 7 days neutropenic febrile patients neutropenic adult patients children with high-risk for infection neutropenic patients with hematological disorders in the authors' institution, king chulalongkorn memorial hospital (kcmh), bangkok, thailand patients with proven invasive aspergillosis patients with severe thrombocytopenia neutropenic patients treated for hematological malignancies allogeneic stem cell transplant recipients 189 patients at risk of ia during a 1-year period at a tertiary referral center surveying patients who are at high risk for ia haemato-oncological patients with neutropenia in 2004, patients undergoing hsct 189 patients, 5 had proven ia hematological patients patients undergoing hsct adult neutropenic cancer patients and haematological stem cell transplant recipients four patient groups: those with fever of unknown origin (fuo) during neutropenia, suspected pulmonary infection (pi), or nonpulmonary aspergillosis (npa) and those undergoing surveillance (s) after hematopoietic stem-cell transplantation (hsct 760 samples obtained from 100 patients hematology patients for galactomannan (gm) antigenemia from february to september 2002, adult patients hospitalized in our hematology unit for receiving intensive chemotherapy and/or hematopoietic stem cell transplant 70 consecutive lung transplant recipients patients at risk of invasive aspergillosis (ia patients were classified for potential ia according to international consensus criteria, with five patients classified as positive (four proven, one probable) and 20 classified as negative (seven possible, 13 no evidence ia 14 patients had false-positive tests, including nine who had cystic fibrosis or chronic obstructive pulmonary disease diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation 165 patients from six centres 218 patients surveyed from june 2002 through june 2003, 42 (19.3%) had > or =1 serum sample positive for gm (optical density index, >1.5 neutropenic patients twelve of 16 patients with confirmed or suspected ia seventeen 1-108 month-old children were screened for aspergillus antigenaemia by a commercial assay before and after bone marrow transplantation (bmt pediatric patients with cancer and hematologic disorders haematological patients at risk of ia, and analysed their samples retrospectively for galactomannan (gm) antigen using the platelia test and for aspergillus dna using an in-house pcr-elisa assay 19 patients who were treated for hematological malignancies and who were suspected of having invasive pulmonary aspergillosis (ipa patients at high risk for ia from 2 north american centers forty-four positive (index>1.5) and 26 'undetermined' (1.5 > index recipients of allogeneic hematopoietic stem cell transplantation haematological patients at risk for invasive pulmonary aspergillosis 98 consecutive high-risk pediatric patients neutropenic patients and stem cell transplantation recipients 149 consecutive treatment episodes in 96 patients with hematological disorders who were at high risk for ia and diagnosed 9 proven ia cases, 2 probable ia cases, and 13 possible invasive fugal infections patients who failed to respond to the antifungal treatment 44 patients with 5 proven, 12 probable, and 33 possible or no ia 67 sera from seven patients who had died with confirmed ia, 268 sera from nine patients who had died with suspected ia, and 1691 sera from 88 patients with no clinical, radiological, or microbiological signs of ia neutropenic patients with haematological malignancies patients with hematological malignancies patients with proven or probable ia hsct patients with proven invasive fungal infection (ifi diagnosing invasive aspergillosis 14 patients with ia (2 patients with proven ia and 12 with probable ia cancer patients 121 sct patients who underwent liver transplant patients 3,327 sera from 807 patients patients undergoing hematopoietic stem cell transplantation (hsct a total of 3,294 serum samples were collected during 797 episodes (fuo, 261; pi, 297; npa, 28; and surveillance, 211), and 153 episodes of ia were diagnosed (31 definite, 67 probable, and 55 possible 25 patients with confirmed aspergillosis and 14 and 7 of 15 patients with probable aspergillosis patients with cystic fibrosis or chronic obstructive pulmonary disease in total, 239 treatment episodes were included of which there were 19 episodes of proven ia and 19 episodes of probable ia patients studied, 53 presented with confirmed ia (n = 27 patients) or probable ia (n = 26 patients
pain reduction crying time and pain relieving pain pipp score sampling duration and numbers of heel lances neonatal facial actions (neonatal facial activity coding system-upper face), sleep-wake state oxygen saturation and heart rate and neonatal infant pain scale pain relief relative crying time and recovery time: behavioural state mean duration of crying babies' pain on a visual analogue scale (vas pain reaction pain related behaviours evaluated with two acute pain rating scales: the douleur aigu nouveau-n scale (range 0 to 10) and the premature infant pain profile scale analgesic effect pain of heel pricks analgesic effect of skin crying and pain scores median crying time, duration of the first cry, percent change in heart rate, maximum heart rate and neonatal facial coding system scores clinical characteristics and time spent squeezing the heel heart rate and oxygen saturation changes and behavioural responses median recovery time pain and the pipp score and crying time douleur aigu nouveau-n scores duration of cry and douleur aigu du nouveau lowest neonatal facial score pain score and crying time with parents' assessment neonatal facial coding system score; cry duration; and autonomic variables obtained from spectral analysis of heart rate variability before, during, and after heel-lancing heart rates, oxygen saturation levels and length of crying lowest cry duration mean pain scores total duration of crying pain score heart rate, oxygen saturation changes and length of crying median heart rate increase, oxygen saturation decrease, and duration of first cry sucking frequency relative crying time and recovery time duration of breastfeeding crying times neonatal infant pain scale (nips crying time mild pain heart rate differences median crying times median values of crying time, recovery time and percentage change in heart rate medians for crying time and the pain scores crying time, duration of the first cry, percent change in heart rate or maximum heart rate multidimensional acute pain rating scale of the premature infant pain profile, heart rate increase, oxygen saturation decrease, crying behavior (duration of first cry, cry percentage in 2 minutes, and during blood sampling), duration of sampling, and the number of performed heel lances median premature infant pain profile scores behavioural responses to pain analgesic effects median pain scores n (dan) score response to pain heart rate despite pain reactivity and extreme crying pain response premature infant pain profile scale crying and grimacing pain lowest pain score heart rate and oxygen saturation highest pain manifestation pain scores neonatal facial activity coding system and sleep-wake state scores and heart rates changes nociceptive reaction heart rate mean heart rate pain and duration of crying analgesic effect of breast feeding duration of crying mean oxygen saturation levels parasympathetic tone physiological (heart rate and oxygen saturation) and behavioural parameters [duration of crying and modified neonatal facial coding scores (nfcs premature infant pain profile (pipp|at 2 and 4 minutes pain scores were lowest in the nns and rocking groups as compared to sucrose, distilled water, expressed breast milk and massage. no differences were determined between the groups for heart rate and oxygen saturation in the newborns during painful interventions (p > 005). crying and grimacing were reduced by 91% and 84%, respectively, from control infant levels during the blood collection. the pipp score was significantly lower in the infants receiving glucose, than in those not given glucose (p=0.004). relative crying time and recovery time were significantly less in the sweetener group but not in the glycine and the breast milk group. median crying times were 36, 52, and 62 s in the sucrose, placebo and human milk groups, respectively (p = 0.0009). compared with the control group, the experimental group had significantly lower, neonatal facial activity coding system and sleep-wake state scores and heart rates changes. there were significant reductions in both scores for the breast feeding and glucose plus pacifier groups compared with the other two groups (p<0.0001, two tailed mann-whitney u tests between groups). as has been previously reported, sucrose markedly reduced both crying and grimacing, and attenuated the rise in heart rate that normally accompanies blood collection (p < .002). the change in heart rate and oxygen saturation was significantly lower in the ebm group and returned to baseline values sooner than in the dw group. breast milk and 10% glucose did not have a similar effect. infants who breastfed or received an oral formula showed the lowest increase in heart rate (21 and 23 beats per minute, respectively, vs 36; p < .01), lowest neonatal facial score (2.3 and 2.9, respectively, vs 7.1; p < .001), lowest cry duration (5 and 13 seconds, respectively, vs 49; p < .001), and lowest decrease in parasympathetic tone (-2 and -2.4, respectively, vs 1.2; p < .02) compared with the other groups. statistically significant differences between the three groups were not found in terms of crying time, duration of the first cry, percent change in heart rate or maximum heart rate (p = 0.19, p = 0.08, p = 0.22 and p = 0.91, respectively). the mean pain scores were 4.60, 5.82, 3.91, 4.94, 5, and 4.05 in groups 1-6, respectively (p= 0.068). median premature infant pain profile scores were lower in the breastfeeding group (3.0) than in the sucrose-solution group (8.5), and the median group difference was -5.0. heart rate, oxygen saturation changes and length of crying were significantly reduced in groups 1 and 2 compared with group 3 (p<0.001). during procedure, the mean oxygen saturation levels of sucrose group were found significantly higher than the control group, but no difference was observed between sucrose and breast feeding groups.|newborns during a standard blood collection infants with fructose intolerance full-term newborns healthy newborns (n= 142 102 term infants requiring a venous blood sample for routine screening of phenylketonuria (n=26) and hyperbilirubinemia (n= 76) were included in the study a random sample of 30 full-term, breastfed infants 180 term newborn infants undergoing neonates sixty-two healthy term infants requiring a heel prick blood sample for screening tests newborn infants undergoing heel lance-a routine, painful, hospital procedure 107 neonates undergoing heel-lance healthy term neonates newborns given oral glucose 180 term newborn infants who were undergoing heel-lancing for routine neonatal screening of phenylketonuria and hypothyroidism newborns undergoing routine heel-lance newborns undergoing blood collection for newborn screening term neonates receiving heel lance pain control in newborns and (2 newborn humans healthy infants (n = 102 newborns who had blood sampling by heel stick 60 newborn infants at boston medical center, boston, ma newborns neonatal unit of a public hospital in northern italy on 101 term neonates undergoing 81 full-term neonates, up to 4 wk of postnatal age, who needed venepuncture for blood investigations healthy newborns term newborn infants 104 stable term neonates eighty healthy term infants, four days old, with normal birth weight healthy newborns hospitalised in the gynaecology clinics of trabzon delivery and children's diseases hospital between february 2007-january 2008 for congenital disorders during neonatal heel prick newborns, primarily in preterm infants 2010 blackwell publishing ltd infants had a mean (sd) birthweight of 3355 (270 healthy term newborns during heel prick blood sampling 120 newborns in turkey 60 full-term newborns: 31 in the experimental group and 29 in the control group newborns undergoing minor painful procedures newborn infants 120 full term newborns undergoing venipuncture randomly assigned to on of four groups healthy term newborns infants undergoing venipuncture term neonates 120 babies requiring heel-prick tests
severe trachoma|a clean face at two or more follow-up visits was protective for any trachoma (odds ratio 0.58 [0.47-0.72]) and severe trachoma (0.35 [0.21-0.59]).|six villages in kongwa, tanzania 1417 children aged 1-7 years in these villages children with clean faces than in those with ocular or nasal discharge or flies on the face
vaginal birth back and pelvic pain and headache rates of preterm births rate of vaginal birth women's self-assessed motivation to attempt vaginal birth dystocic deliveries and cesarean section supportive behaviors cesarean deliveries and stays in neonatal intensive care units measurable clinical, obstetrical, and neonatal advantages pregnancy outcomes probability of vaginal delivery rates of vaginal birth after cesarean section women's satisfaction, knowledge of risk conditions, and perceived mastery in their lives|results were statistically significant only for the factor of the mothers' satisfaction with their obstetric care and preparation for the maternal role, in favor of the treatment group. preparation is significantly related to reduction in dystocic deliveries and cesarean section ( p(2) = 0.044). pregnancy outcomes did not differ significantly between the groups; however, among patients in augmented care, rates of preterm births were lower and cesarean deliveries and stays in neonatal intensive care units occurred in smaller proportions. findings suggest significant gains in knowledge for the experimental group at t-2 versus t-1 with regard to 1) pregnancy and prenatal care, and 2) infant development and child care. rates of vaginal birth after cesarean section were similar in the verbal and document groups: verbal, 339 of 641 (53%); document, 310 of 634 (49%); relative risk 1.1, 95% confidence interval 1.0 to 1.2.|28 black 15-18-year-old adolescent males who volunteered to participate in the study health of the mother and the newborn multiple-risk, medicaid-eligible african american women 200 primigravid women younger than age 35 years with gestational age of 20 weeks women with previous cesarean section, a prenatal education and support program promoting vaginal birth after cesarean unwed prospective adolescent fathers high-risk african american women mother-infant pairs women during pregnancy as a national health policy in iran sixteen subjects participated in the program women enrolled were african american, were eligible for medicaid, had scored 10 or higher on a risk assessment scale, were 16 years or older, and had no major medical complications unwed expectant adolescent father women with a single previous cesarean
symptomatic relief by questionnaires and visual analog scales (vas), and for saliva production by sialometry parotid salivary flow saliva production and relieved symptoms of xerostomia speaking ability symptomatic relief safety and efficacy sweating, rhinitis, headache, nausea, and urinary frequency serious drug-related adverse experiences saliva production oral dryness oral comfort agents such as artificial saliva, hard candy, and water side effects production of saliva and other manifestations of xerostomia comfort of the mouth and tongue overall global assessments|pilocarpine improved saliva production and relieved symptoms of xerostomia after irradiation for cancer of the head and neck, with minor side effects that were predominantly limited to sweating. it is concluded that pilocarpine produces clinically significant benefits for the symptomatic treatment of postradiation xerostomia. overall the patients found that the pilocarpine mouthwash was more effective than the artificial saliva in relieving their symptoms (p = 0.04), and 47 per cent of the patients wanted to continue with this treatment after the study had finished.|207 patients who had each received > or = 4000 cgy of radiation to the head and neck patients with head and neck cancer twenty patients with radiation-induced xerostomia head and neck cancer patients one hundred sixty-two head and neck cancer patients who had received at least 40 gy of radiation (117 patients had received > 60 gy) with clinically significant xerostomia
composite event "death from all vascular causes, nonfatal stroke, nonfatal myocardial infarction, or nonfatal major bleeding complication mean achieved inr bleeding incidence major hemorrhage myocardial infarctions major bleeding complications number of patients with tia/rind death or recurrent ischemic stroke severe stenosis or occlusion of a large artery myocardial infarction or sudden death rate of death from vascular causes cerebral infarctions efficacy and safety cerebral infarction hr for ischaemic events cerebral hemorrhage gastrointestinal disorders composite of death from all vascular causes, non-fatal stroke, non-fatal myocardial infarction, or major bleeding complication, whichever occurred first rate of death from nonvascular causes recurrent ischemic stroke or death or in the rate of major hemorrhage death rates of major hemorrhage ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke severe hemorrhage recurrent cerebral ischemic events recurrent ischemic stroke incidences of tia and tia-ir adverse events frequency of or time to the primary end point or major hemorrhage|cerebral infarction was recorded in 4 patients in each of these treatment groups during a mean follow-up period of 20 months. compared to the natural history of untreated tia/rind both treatments were found to have a prophylactic effect against cerebral infarction. the bleeding incidence increased by a factor of 1.43 (95% ci, 0.96-2.13) for each 0.5 unit increase of the achieved inr. the hr for ischaemic events was 0.73 (0.52-1.01) and for major bleeding complications 2.56 (1.48-4.43). the primary end point occurred in 22.1 percent of the patients in the aspirin group and 21.8 percent of those in the warfarin group (hazard ratio, 1.04; 95 percent confidence interval, 0.73 to 1.48; p=0.83). in the intention-to-treat analysis, no significant differences were found between the treatment groups in any of the outcomes measured.|patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive patients with intracranial arterial stenosis patients with cerebral ischemia of presumed arterial (noncardiac patients with transient ischaemic attack or minor stroke of presumed arterial origin against cerebral infarction in a prospective multicenter study from 5 hospitals in southern sweden 156 patients with transient ischemic attacks (tia) or reversible ischemic neurological deficit (rind patients who have had an ischemic stroke 569 patients had undergone randomization, enrollment was stopped because of concerns about the safety of the patients who had been assigned to receive 241 patients with symptoms of carotid transient attacks of ischemia, some of whom recovered completely within 24 hours (tia) while the others had slight residual symptoms (tia-ir 135 patients after cerebral ischaemia of arterial origin (esprit patients referred to a neurologist in one of 58 collaborating centers because of a transient ischemic attack or minor ischemic stroke (rankin grade < or =3) were eligible patients with a prior noncardioembolic ischemic stroke symptomatic intracranial arterial stenosis 1,316 patients participated; their mean follow-up was 14 months
actual maternal behaviors favorable attitudes toward feeding and communication maternal behavior scores adolescents' mothering behaviors|the effects of videotape instruction and feedback (videotherapy) on mothering behaviors were evaluated in this longitudinal study. brief culturally sensitive videotapes may be effective strategies to promote parenting skills and to prevent social and health problems among adolescents. parent-infant interactions and contingent responsiveness during teaching and feeding, and infant cognitive development were assessed when infants completed the program.|31 adolescents and their healthy infants adolescent mothers and their infants experimental group subjects reviewed the videotaped 1-month teaching episode and received feedback from a specially trained professional nurse who emphasized positive aspects of maternal behavior adolescent mothers' interactions with their infants high schools, wic (women, infants, and children) clinics, and family support centers serving low-income families six african-american adolescent mothers who were filmed feeding their infants in their homes fifty-nine first-time, african-american adolescent mothers of infants first-time adolescent parents, aged 15 to 19 years african-american adolescent mothers adolescents receiving adolescent mothers and their infants through videotape adolescents
obesity and whole body insulin sensitivity short insulin tolerance test (itt total/saturated fat intake and increased polyunsaturated fat/fiber intake and exercise level consecutive fasting plasma glucose (fpg) values body weight measures of eating, exercise, and fitness; weight losses weight, coronary heart disease (chd) risk factors, and incidence of diabetes 3-year cumulative incidences of diabetes net loss metabolic syndrome total fat consumption type 2 diabetes as diagnosed using world health organization criteria incidence of diabetes weight loss risk of type 2 diabetes hypertriglyceridemia metabolic abnormalities multiple metabolic/inflammatory abnormalities weight, waist circumference, high-sensitivity c-reactive protein, and most of the metabolic syndrome components weight losses baseline bmi and fasting glucose, the diet, exercise, and diet-plus-exercise interventions rate of development of diabetes prevalence of central obesity behavior, weight, or physiological parameters risk of diabetes plasma glucose values and higher bmi values changes from baseline in: nutrient intake; physical activity; anthropometry, glucose tolerance and insulin sensitivity modest weight loss body mass progression to diabetes mean (+/-sd) amount of weight lost gradual deterioration of behavioral and physiological changes relative risk reduction risk of developing diabetes, and weight loss glucose tolerance cumulative 4-year incidence of diabetes cumulative incidence of diabetes|body weight decreased by 0.39 kg in the control group and by 2.18 kg in the intervention group (p < 0.001). the relative risk reduction was 28.5% with lsm (95% ci 20.5-37.3, p=0.018), 26.4% with met (95% ci 19.1-35.1, p=0.029) and 28.2% with lsm + met (95% ci 20.3-37.0, p=0.022), as compared with the control group. whole body insulin sensitivity, assessed by the short insulin tolerance test (itt), improved after 12 months in the intervention group (0.52, 95% ci 0.15-0.89%/min). the lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. when analyzed by clinic, each of the active intervention groups differed significantly from the control clinics (p < 0.05). during the trial, the risk of diabetes was reduced by 58 percent (p<0.001) in the intervention group. lifestyle intervention significantly reduced metabolic syndrome (odds ratio [or] = 0.28; 95% ci 0.18-0.44), with a 31% (21-41) absolute risk reduction, corresponding to 3.2 (2-5) patients needing to be treated to prevent 1 case after 12 months. at 6 months, the groups differed significantly on measures of eating, exercise, and fitness; weight losses in the diet and diet-plus-exercise groups were significantly greater than in the exercise and control conditions.|subjects with impaired glucose tolerance (igt 110,660 men and women from 33 health care clinics in the city of da qing, china, were screened for igt and niddm igt males native asian indians with igt who were younger, leaner and more insulin resistant than the above populations overweight individuals with a family history of diabetes individuals with impaired glucose tolerance (igt persons at high risk participants with igt (n=78), diagnosed on two consecutive oral glucose tolerance tests (ogtts asian indian subjects with impaired glucose tolerance (idpp-1 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to male subjects with igt recruited from health-screening examinees people with impaired glucose tolerance (igt 531 (421 men 110 women) subjects with igt (mean age 45.9+/-5.7 years, bmi 25.8+/-3.5 kg/m(2)) into four groups 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive overweight individuals with a parental history of diabetes participants (n = 154), who were 30-100% over ideal body weight, had one or both parents with diabetes, and were currently nondiabetic three hundred and thirty-five patients participated from a dysmetabolic population-based cohort of 375 adults aged 45-64 years in northwestern italy multiethnic american, finnish and chinese populations subjects with impaired glucose tolerance people with impaired glucose tolerance 522 middle-aged, overweight subjects (172 men and 350 women; mean age, 55 years; mean body-mass index [weight in kilograms divided by the square of the height in meters], 31) with impaired glucose tolerance to either the intervention group or the control group the mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups
hearing loss total effective rate vertigo, nausea and headache with spontaneous recovery recovery time rate of side effects pure-tone average and subjective symptoms mean hearing loss side effects|a significant benefit of naftidrofuryl on hearing loss was also found at frequencies between 0.5 and 3 khz. no significant differences were observed in the improvements of pure-tone average and subjective symptoms between the pge1 and the placebo groups. the total effective rate was 76.92% in the carbogen group and 50.00% in the control group.|eighty patients with idiopathic sudden deafness existing no longer than 10 days sudden deafness idiopathic sudden sensorineural hearing loss 57 consecutive patients with diagnoses of idiopathic sudden sensorineural hearing loss fifty-two patients with sudden deafness
pain reduction efficacy and safety demographic data lequesne functional discomfort index, global efficacy assessed by the patient and the investigator, time to improvement, and use of acetaminophen as rescue analgesic medication sensation and pain thresholds il-6 synovial fluid concentrations pain intensities rapid pain relief pain relief physical function tolerated and effective nausea alleviating pain mean pain intensity score pain and functional capability functional parameters antinociceptive action pain at rest colonic transit times orocaecal transit time adverse events adverse event electrical sensation and pain thresholds synovial fluid concentrations of sp and il-6 effective and safe final vas score; secondary measures included final pain relief rating scores, subject/investigator overall medication assessments, rate and time to discontinuation due to lack of efficacy, and selected quality-of-life/physical functioning scores plasma and synovial fluid concentrations of tramadol and its active metabolite (o-desmethyl-tramadol, m1 global tolerability minimum effective naproxen dose (mend serious adverse events pain relief and functional improvement in osteoarthritis huskisson visual analog scale for pain mean final vas scores for tramadol/apap plus cox-2 nsaid nausea, vomiting, and dizziness median pain intensity synovial fluid concentrations womac pain, stiffness and physical function subscales, the womac composite scale, dropouts due to insufficient therapeutic effect, patient and physician global assessment of therapy, and sleep average daily pain intensity and average daily pain relief scores synovial fluid concentrations of sp somnolence efficacy and safety efficacy of tramadol lp bowel functions and symptoms pain, stiffness, physical function, global status, and sleep womac physical function and the medical outcome study short form-36 role-physical measures intestinal function global efficacy arthritis pain intensity vas rates of response intensity of joint pain efficacy and tolerability mend pain osteoarthritis flare pain synovial fluid concentrations of interleukin (il)-6 and substance p (sp mean (+/- sd) pain visual analog score multidimensional 'western ontario and mcmaster universities osteoarthritis index' (womac) questionnaire (pain, stiffness and functional impairment arthritis pain intensity visual analogue scale (vas), western ontario and mcmaster universities arthritis scale (womac) pain, stiffness, physical function vas subscales, patient and physician global assessment of therapy, sleep, dropouts due to insufficient therapeutic effect, and adverse events average daily pain intensity and pain relief scores analgesic effectiveness pain scores adverse event-related withdrawals plasma and synovial fluid the concentrations of m1 mean final pain relief rating scores western ontario and mcmaster universities osteoarthritis index questionnaire antinociceptive effects constipation oa flare pain|treatment with tramadol er results in statistically significant and clinically important and sustained improvements in pain, stiffness, physical function, global status, and sleep in patients with chronic pain. both in plasma and synovial fluid the concentrations of m1 were markedly lower than those of tramadol, with a t/m1 ratio of 14.7+/-4.6 and 9.3+/-3.9, respectively. average daily pain intensity and pain relief scores were significantly improved with tramadol/acetaminophen compared with placebo on the primary assessment of efficacy from days 1 through 5 (both, p < 0.001) and on the assessment of efficacy from days pain intensities at rest and during movement decreased highly significantly with tramadol and dihydrocodeine from median pre-treatment verbal ratings of over 3 (0=none, 4=unbearable) to 1 and below from the second treatment day onwards (anova p<0.0001). more patients reported adverse events with tramadol than with diclofenac (20 vs 3%, p = 0.0056), but there was no difference in adverse event-related withdrawals (p = 0.69). pain was significantly reduced in the tramadol lp group compared with the placebo group on day 7 (p = 0.002) and day 14 (p = 0.010). mean final vas scores for tramadol/apap plus cox-2 nsaid were significantly lower than placebo plus cox-2 nsaid (41.5 vs 48.3; p = 0.025) and mean final pain relief rating scores were significantly higher (p = 0.002). there was a significant difference (p = 0.040) in the treatment effect between the naproxen responders and nonresponders, thus demonstrating a difference in the way responders and nonresponders react to a decrease in naproxen dosage after the addition of tramadol.|patients with at least moderate pain (> or =40 mm on a 100-mm visual analog scale) of oa of the knee after a 1-week medication washout were treated with thirty patients with pain controlled by nsaid's alone formed the comparator group chronic pain the mean age was 61 years, mean duration of oa 12.9 years, and the mean twenty patients were enrolled patients with naproxen-responsive osteoarthritis pain two hundred forty-six patients were patients with painful oa of the knee responding to subjects with osteoarthritis (oa) pain inadequately controlled by cox-2 nonsteroidal antiinflammatory drugs (nsaid individual patients with painful osteoarthritis (oa patients with knee oa mean (sd) age, 67.1 (7.1) and 66.4 (92) years, respectively; female sex, 72.1% and 73.1%; and mean body weight, 74.7 (13.6) and 74.6 (14.8) kg 60 osteoarthritis patients with strong pain despite nsaid's 54 patients completed both study periods three hundred eight patients patients achieving inadequate pain relief from traditional non-steroidal anti-inflammatory drugs (nsaids) or patients with knee osteoarthritis patients with chronic pain patients with osteoarthritis who have not responded to first-line treatment with patients had a mean (+/-sd) age of 60.1 controlled trial enrolled subjects with symptomatic oa for >/= 1 year who experienced at least moderate pain [visual analog scale (vas) score 197 patients (85 oa patients two hundred thirty patients (167 women, 63 men severe pain from osteoarthritis with slow-release 9.87 years, and were predominantly female (71.8%) and white (87.7 43.5%) were included in the intent-to-treat population (n = 153 60 patients with oa of the hip (19 patients) or knee (41 patients) without clinical joint inflammation patients with moderate to severe chronic pain of osteoarthritis (oa subjects receiving a cox-2 nonsteroidal antiinflammatory drug symptomatic osteoarthritis of the hip or knee patients with osteoarthritis of the hip or knee (european league against rheumatism criteria 236 patients randomized (mean age 61 years; 147 females), 90 were stratified as naproxen responders and 146 as naproxen nonresponders eligible patients with radiographically confirmed oa of the knee meeting the american college of rheumatology diagnostic criteria, defined by knee pain and presence of osteophytes, plus at least age >50 years, morning stiffness <30 minutes in duration, and/or crepitus, entered a 2-7 day washout period during which all analgesics were discontinued patients with oa patients with osteoarthritis of the hip or knee 307 subjects randomized, 306 taking
rates of sustained response and remission if natalizumab rate of clinical remission highest remission rate sustained response through week 36 elevated circulating lymphocyte levels quality of life safety and efficacy serious adverse events response rates highest response rate circulating b and t lymphocytes higher rates of sustained response rates of clinical remission and response quality of life and c-reactive protein levels crohn's disease activity index (cdai) score change in cdai remission rates health-related quality of life, and c-reactive protein levels rates of response rescue medication rates of adverse events changes in scores for the crohn's disease activity index disease remission (a cdai score of less than 150 response and remission rates cdai adverse events remission|the frequency of commonly reported adverse events did not differ significantly between groups. natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue. the quality of life improved in all natalizumab groups; c-reactive protein levels improved in groups receiving two infusions of natalizumab.|patients with mild to moderately active crohn's disease thirty patients with active crohn's disease (crohn's disease activity index [cdai] > or =151 and < or =450 crohn's disease 248 patients with moderate-to-severe crohn's disease 905 patients active crohn's disease patients with active crohn's disease massachusetts medical society 339 patients who had a response to natalizumab in the first trial crohn's disease patients
qol function scores nutritional status, morbidity, and quality of life nutritional intake and status food intake, body weight, response rate, survival, and quality of life overall qol serum igf-i levels quality-of-life index (ql-index total caloric and protein intake immune responses bmi body weight and bcm serum albumin levels intake of protein body weight development nutritional intake (diet history), status (ottery's subjective global assessment), and qol (european organisation for research and treatment of cancer quality of life questionnaire version 3.0 g3 nutritional outcome, morbidity, and quality of life (qol total lean mass anthropometry, grip strength, and qol acceptability and palatability of the hp blend formula, ease of use, and cost total body weight lean body mass determined by bioelectrical impedance analysis hand-grip strength total protein and total calorie intake weight overall mean protein intake weight loss ottery's subjective global assessment), and qol (determined by the european organization for the research and treatment of cancer quality of life questionnaire version 3.0 [eortc qlq-c30 daily energy intake incidence of disease remission fat-free mass function and symptom scales age, body cell mass (bcm), muscle function, gender distribution and qol regain of lean body mass involuntary weight loss mean daily energy intake serum osteoprotegerin (opg bone metabolism body cell mass tumor response rate body weight, but triceps skinfold measurement rates of anorexia, nausea, vomiting, and diarrhea tumor response rates non-protein nitrogen appearance rate (npna calorie and protein intake weight loss, serum albumin concentration, and presence of liver metastases body composition function, symptoms, and single-item scores weight loss and improved adl functions st george's respiratory questionnaire total score peritoneal transport rate and mama nutritional intake and gain in lean body mass (lbm short form-36 health change score subjective global assessment body composition (body cell mass serum albumin level total energy intake body cell mass and weight gain anthropometric parameters and improved subjective global assessment evaluation nutritional intake body weight for colorectal cancer, serum albumin, alkaline phosphatase, lactic dehydrogenase (ldh) levels, and percent targeted caloric intake (tci weight, skinfold thickness measurements, or quality of life energy intake increased in g1/g2 weight, anthropometry, and grip strength readmissions quality of life nutritional status, respiratory and skeletal muscle strength, respiratory function, perceived dyspnoea, activities of daily living (adl) and quality of life handgrip strength physical performance triceps skinfold thickness, dietary intake, fecal fat, and pain score quality of life (qol body composition and bone mineral density (bmd energy intake after rt survival advantage inspiratory muscle strength whole body protein metabolism crohn's disease activity index progressive loss of kidney function morbidity, and quality of life (qol mean total energy serum albumin, calorie and protein intake, and npna energy intake or percent ideal body weight lean mass and physical function fiber intake baseline food intake main outcome measures: (1) nutritional status parameters, bmi and serum albumin; (2) functional status on a 10-point karnofsky scale; (3) adverse metabolic effects, hyperphosphatemia at start and end of study; and (4) subjective scoring for appetite, and acceptability of and tolerance to supplement serum albumin biochemical markers of bone turnover body weight, nutritional status, and quality of life reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia mean intervention time cd4 counts and viral load body weight gain fat-free mass and grip strength physical performance such as muscle strength, balance, mobility and activities of daily living, as well as nutritional aspects such as energy intake, body weight and fat-free mass weight and arm muscle circumference equal weight loss energy intake triceps skinfold thickness (tsf) and midarm muscle area (mama qol bone resorption nutritional status, qol, and morbidity nutritional status (subjective global assessment), and energy and protein intake (3-day food record change of ventilatory parameters body composition, muscle function and quality of life (qol response rates, median time to progression, or overall duration of survival weight, skinfold thickness, fat-free mass, grip strength, quality of life, and cognitive function (buschke test katz activities of daily living (adl) index, mini mental status examination (mmse) and quality of life (qol serum osteocalcin refeeding and weight gain weight bmd at the spine, femoral neck and total hip body weight, biochemical indices caloric intake karnofsky performance status scale initial nutritional status energy intake and weight lymphocyte cd4 counts, on plasma tnfr 55, tnfr 75 and ilr 2 concentrations and on quality of life serum albumin level and functional scoring efficacy and cost-effectiveness rapid weight gain expiratory muscle strength body composition and dietary intake rt toxicity protein malnutrition assessed by midarm muscle circumference, creatinine-height index and serum albumin weight gain katz adl index energy and protein intake antibiotic prescriptions weight (b), [mean (sd) % change in bmd lumbar spine factors: 'malaise', 'psychological distress', 'therapy side-effects weight and qol skin fold thickness respiratory function or skeletal and respiratory muscle strength grip strength bmd at the lumbar spine and total hip changes in handgrip strength, general well-being score, perception of health and number of falls reactivity to skin test antigens serum ctx, a marker of bone resorption sa levels dry weight and bmi total daily protein and caloric intake, food-derived protein and caloric intake, and supplement-derived protein and caloric intake bone-specific alkaline phosphatase body composition (increased lean mass, decreased fat mass functional status oral intake, body weight, response rate, survival, and quality of life gain in fat mass nutritional behaviour and quality of life intake dietary intake (protein, energy, fiber nutritional behaviour o(2) saturation and a decrease in paco(2 frequency of patients with moderate or severe malnutrition peak flow dietary intake e.g. insulin-like growth factor body weight and somatic protein compartments energy intake and nutritional status food intake functional status, qol and rehospitalization fat mass maintain nutrient intake energy intake and gained weight severe loss fat free mass lower- extremity muscle strength medical research council dyspnoea score qol ratings body weight and tricipital skinfold subjective global assessment, body composition by bioelectrical impedance and anthropometry, muscle function with hand-grip strength and peak flow median time to progression and overall duration of survival patient outcomes maximum mean (sd nutritional status shorter time of survival goal for energy intake and gained weight reduced symptomatology mild hyperphosphatemia weight loss and protein malnutrition muscle function and quality of life number of falls leucine oxidation (protein catabolism nutritional repletion improvement/deterioration of qol protein intake enhanced gain of lbm absolute lymphocyte count whole body leucine kinetics and leucine oxidation rate dietary intake (24-h recalls), body weight, and qol (eortc-qlq c-30 weight maintenance adequate intake or nutritional status mean intake per kilogram of body weight complications, namely wound infection, chest infection, and antibiotic use response rate and overall survival metabolic rate|nutritional interventions using dietary counselling had no impact on the percent of planned chemotherapy dose administered, the degree of toxicity experienced by patients, or the frequency of treatment delays. out-patients lost more weight than in-patients did (p < 0.05). in the study group, oral administration of the egg albumin-based supplement significantly improved serum albumin, calorie and protein intake, and npna, and, compared to controls, this maneuver was associated with a trend to increased anthropometric parameters and improved subjective global assessment evaluation. despite adequate statistical power, no functional measures differed except that the number of falls was lower among treated subjects vs. controls (0% vs. 21%; p = 0.05). nutritional behaviour correlated with subjective well-being, low intake with complaints of tumour treatment side effects and weight loss with malaise. food supplements did not affect treatment response or complications, nor did they offer any survival advantage. although a weight gain of 7 kg (p = 0.003) was obtained the difference to the control group was statistically not significant (p = 0.08). nutritional intervention had no significant effect on lymphocyte cd4 counts, on plasma tnfr 55, tnfr 75 and ilr 2 concentrations and on quality of life. enteral nutrient supplementation was shown to bring about a significant improvement in serum albumin level even in a short-term study. at radiotherapy completion, energy intake increased in g1/g2 (p < or = .04), g1 more than g2 (p = .001), and decreased in g3 (p < .01). there were similar improvements in triceps skinfold thickness, dietary intake, fecal fat, and pain score during a period of 3 months in both groups. serum igf-i levels increased in the i-group (p<0.001), but were unchanged in the c-group (p=0.07 between the groups). individualized dietary counselling for 6 months was associated with a significant decrease in the crohn's disease activity index, an increased incidence of disease remission, a decreased need for prednisone and salazopyrin therapy, a reduction in the number of days spent in hospital, and a reduction in the amount of time lost from work due to crohn's disease, when compared with control patients who did not receive dietary counselling but who were seen regularly in follow-up under similar circumstances. the intention-to-treat analysis indicated significant improvements in lower- extremity muscle strength in both training groups compared with the nutrition group at 1st follow-up. the increase in body weight and tricipital skinfold was significant in group i. total body water and fat free-mass remained without changes. quality of life measured by the quality-of-life index (ql-index) increased significantly in both groups, but did not differ between groups. the nutrition intervention group had a higher mean total energy (p=0.029) and protein intake (p<0.001) compared with the standard practice group. inspiratory muscle strength was also improved (intervention = +11.4 cm h2o versus control +4.8 cm h2o) although this did not quite reach statistical significance. fat free mass increased from baseline to week 8 (p<0.05) with no difference between groups a and b (p=0.97). the results showed the benefit of dietetic treatment in experimental patients with head and neck or abdominopelvic cancer. refeeding and weight gain were associated with a significant increase in absolute lymphocyte count and with an increase in reactivity to skin test antigens after 21 days of refeeding. patients in the nutritional supplement group (n = 19) had a significantly greater increase in body weight (2.57 +/- age, body cell mass (bcm), muscle function, gender distribution and qol did not differ between ons patients (n=38) and dc patients (n=42) at baseline. after rt, qol function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05); at 3 months, patients in group 1 maintained or improved overall qol, whereas patients in groups 2 and 3 maintained or worsened overall qol. one month after discharge, the control patients had a nutritional intake (3-d diet record) comparable with the intake of the general population that did not increase further. it was concluded that preoperative supplementation to achieve weight gain before surgery is of no apparent value. there was no significant change in energy intake or percent ideal body weight in either group. group a increased their energy intake from a median of 8.7 to 10.1 mj (p < 0.01 compared with the control group after intervention) and gained a mean of 2.9 kg body weight (95% ci 1.2; 4.7, p = 0.005 compared with the control group), while group b increased from 7.4 to 10.8 mj (p = 0.005) and gained 2.3 kg (1.2; 3.3, p = 0.002). in general, nutrient intake in the experimental group remained similar to that before surgery, whereas intake in the control group decreased significantly, particularly at the one-week postoperative evaluation. during follow-up, patients in the experimental group were far more likely to maintain nutritional repletion or continue to improve (61%) than patients in the control group (14%). serum osteoprotegerin (opg) increased significantly in group 2 with a maximal increase (27%) observed at 6 ( p<0.01) and 9 months ( p<0.05). no difference was observed between the control and adjunctive groups in clinical status at the end of treatment or in long-term outcome. there was a numerical difference, not statistically significant (p = 0.3), indicating a shorter time of survival in patients in the gr + sc group. compared with the control group, the supplement group had larger increases in fat-free mass and grip strength, although the differences did not reach statistical significance. fewer patients in the treatment group (7/52) required antibiotic prescriptions compared with the control group (15/49). the intervention group consumed more energy (difference 194 kcal/day; p = 0.02) and protein (difference 11.8 g/day; p<0.001) than controls. the intervention was associated with greater increases in energy and protein intake in women than men (interaction p < 0.001 for both). the compliance to the prescribed diet was very high in both groups, and no carry over effect of the previous dietary intake was observed during the follow-up period. the group-by-time interaction approached significance on the karnofsky performance status scale. subjects ingesting nutritional supplements between meals significantly increased their total caloric and protein intake above that of controls and did not reduce their food-derived caloric or protein intake compared to controls.|patients with hcv-related liver cirrhosis cancer patients, assessed as nutritionally at risk 40 newly diagnosed patients with cancer beginning external beam radiation therapy 70 patients, 66 of whom were fully evaluated for each study end point after application of prospectively determined evaluability criteria our participants were underweight (n = 42) and normal-weight (control group, n = 29) candidates for lung transplantation 24 in-patients and 25 out-patients enrolled at the department of otolaryngology, national hospital 90 consecutive outpatients (m/f=52/38) with liver cirrhosis, 30 in child class a and 60 in class b. patients malnourished hemodialysis patients patients with malignant disease undergoing treatment free-living frail elderly ninety-seven patients with cancer, undergoing radiation treatment, were studied underweight candidates for lung transplantation fifty-four patients, 29 in the i-group (86+/-7 years, 66% females) and 25 in the c-group (85+/-7 years, 72% females) completed the study according to the protocol 111 colorectal cancer outpatients referred for radiotherapy, stratified by staging 10 years; male, 84 advanced chronic obstructive pulmonary disease 67 patients with colorectal or gastric cancer postoperative surgical patients chronic pancreatitis women than men malnourished patients infected with the human immunodeficiency virus (hiv malnutrition for hemodialysis (hd) patients predialysis patients with chronic kidney disease (ckd; stages 4 and 5 patients with cp patients with acute leukaemia fifty ambulatory patients with head and neck cancer treated by definitive radiation therapy at the fox chase cancer center 32 hd patients with mild ha outpatients with copd who are at risk of malnutrition underweight patients with copd that combines an initial inpatient investigation (controlled nutritional support) with a prolonged outpatient follow-up interval maintenance hemodialysis patients frail community- dwelling elderly people over the age of 75 sixty malnourished patients with cp were randomized to counseling group (n = 29; mean age, 32 ninety-three nsclc patients eighty malnourished patients with benign digestive disease hiv-infected patients cancer patients with solid tumors undergoing aggressive chemotherapy twenty-four orthognathic surgery patients 70 patients with the same diagnoses randomized to ten outpatient hemodialysis centers in southeast lower michigan patients with advanced cancer malnourished patients with non-neoplastic gastrointestinal disease elderly people hemodialysis (hd) unit of a tertiary referral care hospital in southern india nondiabetic adult mhd patients with no intercurrent illness, on regular thrice weekly mhd for at least 1 month before recruitment, with a body mass index (bmi) <20 and a serum albumin level of <4.0 g/dl. patients frail elderly living at home subjects (n = 50) over age 60 (mean 78 y) requiring community services and at elevated risk of undernutrition (excessive weight loss or body mass index < 24 kg/m2 frail elderly people patients with copd sixty consecutive radiation oncology outpatients (51 men and nine women; age 61.9+/-14 years [mean+/-standard deviation copyright 1999 harcourt publishers ltd malnourished patients with digestive disease cancer patients treated with patients with chronic pancreatitis (cp 14.0 [sd] years) with ckd seventy-five patients with head and neck cancer who were referred for consecutive undernourished patients with cp (body mass index [bmi] <18.5 kg/m(2)) at a tertiary care hospital patients with newly diagnosed gi cancer ninety-nine men completed at least 4 weeks of treatment, 49 in the supplement group and 50 in the control group malnourished hiv-infected patients patients who started antituberculous therapy within the previous 2 wk twelve months 14 of 30 patients with an average fev1 of 0.8 l thirteen patients were excluded because of poor prognoses and the ethical need for food supplements patients undergoing radiotherapy patients with cancer of the lung (small-cell), ovary, or breast undergoing cyclic chemotherapy patients with gastrointestinal (gi) cancer malnourished adolescents and adults with cystic fibrosis patients with crohn's disease malnourished surgical patients hiv-infected patients with recent weight loss patients with child a or b hcv-related liver cirrhosis colorectal cancer patients undergoing patients admitted for gastrointestinal surgery underweight patients 13 malnourished patients (3 males, mean age 18.1 years) with cystic fibrosis 81 evaluable patients with colorectal cancer severe ckd peritoneal dialysis patients hiv-infected subjects elderly community-dwelling women gi cancer patients by individual support (is), including nutritional measures experimental patients with head and neck or abdominopelvic cancer elderly women with low bmi maintenance hemodialysis (mhd) patients using a high patients (n=108, age 85+/-6 years) at risk of malnutrition according to the short form of the mini nutritional assessment patients with cancer outpatients receiving radiotherapy malnourished patients with chronic obstructive pulmonary disease one hundred ninety-two patients with previously untreated metastatic cancer (102 non-small-cell lung cancer [nsclc]; 90 colorectal cancer orthognathic surgery patient 59 outpatients with copd (6 months intervention and 6 months follow-up patients with head and neck cancer undergoing lung cancer patients malnourished gi patients ninety-six community-dwelling elderly people (58 women patients at risk of protein-energy malnutrition (pem) discharged from a geriatric service were evaluated head and neck cancer fourteen hd patients with moderate to severe ha patients on continuous ambulatory peritoneal dialysis orthognathic surgery patients 137 outpatients with crohn's disease hiv-infected men (n=118) who were less than 90% of usual weight for height or who had lost more than 10% of body weight 101 patients: 52 fifty-five subjects completed a four-month intervention period during which they were visited biweekly by a nurse (except control subjects nine patients with advanced chronic obstructive pulmonary disease (copd) and recent weight loss resulting in a state of mild malnutrition 29 patients with acute leukaemia cancer patients undergoing 49 patients patients with tuberculosis and wasting patients with newly diagnosed tuberculosis and wasting elderly underweight women with osteoporosis capd patients frail elderly 105 assessable patients, 57 were randomized to receive chronic obstructive pulmonary disease (copd patients with colorectal and gastric cancer chronic obstructive lung disease patients with digestive disease hiv-infected individuals with a body mass index < 21 kg m-2 or cd4-t cells < 500 micro l-1 in stable clinical condition ninety-three cancer patients about to undergo geriatric patients at risk of malnutrition 28 capd patients were allocated to a study (n = 13) or a control (n = 15) group patients were affected by cancer of the head and neck, breast cancer, and abdominopelvic cancer patients who had undergone gastrointestinal surgery cancer patients 10 years; male, 83%) and supplementation group (n = 31; mean age, 28 56 outpatients (men, 62%; mean age, 70.7 71 ambulant women aged > or =70 years with bmi < or =21 kg/m(2 )and osteoporosis at the hip was undertaken a group of hiv-infected patients ons patients (n=38) and dc patients (n=42) at baseline patients with human immunodeficiency virus infection predialysis patients with ckd, structured advanced colorectal and non-small-cell lung cancer stable copd discharged geriatric patients at risk of malnutrition frail elderly people over age 75
control of hypertension development of severe hypertension gestational age at delivery clinician compliance preterm birth serious perinatal complications systolic and diastolic bp levels mean dbp diastolic blood pressure (dbp preterm delivery and birth weight serious maternal complications serious perinatal and maternal complications severe hypertension neonatal intensive care unit (nicu) admission rate of antenatal hospitalization|tight control of blood pressure reduces the rate of antenatal hospitalization and does not adversely affect perinatal outcomes in women with mild essential or gestational hypertension. mean dbp was significantly lower with tight control:|seventeen obstetric centres in canada, australia, new zealand, and uk mild chronic essential or gestational non-proteinuric hypertension in pregnancy a total of 132 women were randomised to less tight (n = 66; seven had no study visit) or tight control (n= 66; one was lost to follow up; seven had no study visit women with mild essential or gestational hypertension exclusion: systolic blood pressure > or = 170 mmhg and proteinuria, contraindication, or major fetal anomaly inclusion: pregnant women, dbp 90-109 mmhg, pre-existing/gestational hypertension; live fetus(es); and 20-33(+6) weeks mild essential and gestational hypertension in pregnancy 2006-2007 in the university of ain shams, egypt eligible participants (n=125
undetectable plasma hiv-1 rna concentration patients' adherence and minimise toxicity detectable hiv-1 rna viral loads cd4 cell counts plasma hiv-1 rna concentration initial virion-clearance rate suppression of plasma hiv rna viral suppression virologic failure (loss of hiv suppression loss of viral suppression rates of viral clearance risk of virologic failure virologic failure|similar results were obtained when the one abstract was excluded (odds ratio, 5.48; 95% confidence interval, 2.82 - 10.65). the initial virion-clearance rate during induction therapy was higher in five patients on maintenance therapy with a sustained undetectable plasma hiv-1 rna concentration than in nine patients with recurrence of a detectable plasma hiv-1 rna concentration at week 36 (0.35 vs 0.19 per day, respectively; p=0.0008). the presence of zidovudine-resistance mutations in hiv rna at base line was strongly predictive of the loss of viral suppression in subjects treated with zidovudine and lamivudine.|patients infected with hiv-1 hiv-infected adults who had successfully completed three- or four-drug antiretroviral induction therapy and who had less than 200 copies of hiv rna per milliliter of plasma after 16, 20, and 24 weeks of induction therapy hiv infected patients with undetectable plasma hiv rna after triple-drug therapy 39 62 patients had been enrolled enrolled patients infected with hiv-1 with at least 200 cd4 cells/microl, at least 1000 hiv-1 rna copies/ml in plasma, and no previous exposure to antiretroviral drugs years 1982-1999 using the search terms human immunodeficiency virus, antiretroviral therapy, maintenance therapy hiv-infected subjects who had cd4 cell counts greater than 200 per cubic millimeter, who had been treated with hiv-1 infected individuals
ami volume health plan choices individual process-of-care indicators, a hospital report card impact survey, and all-cause ami and chf mortality mean 30-day ami mortality rates hospital mortality rates for chf cabg volume composite ami and chf indicators based on 12 ami and 6 chf process-of-care indicators quality of cardiac care hmo choices|we found that cahps information did not affect health plan choices by iowa medicaid beneficiaries, similar to previously reported findings for new jersey medicaid. the strongest effects were among white patients and those with hmo coverage in california, and among white or other patients and those with medicare in new york. health plan performance information can influence plan choices by medicaid beneficiaries, but will do so only if they actually read it. public release of hospital-specific quality indicators did not significantly improve composite process-of-care indicators for ami or chf.|86 hospital corporations in ontario, canada, with patients admitted for acute myocardial infarction (ami) or congestive heart failure (chf participating hospital corporations were randomized to early (january 2004) or delayed (september 2005 iowa medicaid beneficiaries new cases entering medicaid in selected counties during february through may 2000 new beneficiaries in iowa medicaid plan choices by new jersey medicaid beneficiaries study sample was a statewide sample of all new medicaid cases that chose medicaid health plans during april 1998 patients admitted to nonfederal hospitals designated as outliers in reports on coronary bypass surgery (cabg) mortality in new york, acute myocardial infarction (ami) mortality in california, and postdiskectomy complications in california
total drainage volume, hourly zero drainage, heart rate, or occurrence of arrhythmias drainage, incidence of cardiac tamponade, incidence of surgical reentry, hemodynamic values, and number of manipulation episodes volume of drainage|statistical analyses revealed no difference in any of the dependent variables when milking and stripping were used. four to 16 hours postoperatively, a significantly higher volume of drainage occurred in the subjects whose chest tubes had been stripped.|200 patients, 78 did not require any manipulation of the chest tubes in the first 8 hours after surgery two hundred adult patients immediately after myocardial revascularization patients after myocardial revascularization surgery patients undergoing myocardial revascularization 49 male subjects had their chest tubes milked every 2 hours, had them stripped every 2 hours, or served as controls (i.e., their tubes were neither milked nor stripped
pain severity of the headache relief of pdph measured as delta vas (initial vas - vas 10-cm visual analogue scale, severity of headache pdph headache mean headache intensity intensity of headache, quantitated using a visual analogue pain scale (vas mean pain score mean of headache intensity headache intensity severity of headache or requirement for epidural blood patch visual analog scale post-puncture headache postdural puncture headache|relief of pdph measured as delta vas (initial vas - vas at 4 h) was significantly better in the caffeine than in the placebo group (p = 0.014). ten patients with postdural puncture headache presenting for an epidural blood patch were given either saline or sumatriptan subcutaneously. when the headache was provoked by orthostatic strain, the six patients in the verum group showed significantly less pain ( there was no difference in the severity of headache or requirement for epidural blood patch. after 24 hours, mean headache intensity was 3.87 (+/- 1.63) in conventionally treated group versus 0.73 (+/- 0.74) in hydrocortisone group (p <0.001).|11 patients with typical headache following diagnostic lumbar puncture women who underwent cesarean section sixty patients with headache after spinal anesthesia were included after spinal anesthesia lumbar puncture patients who have exhausted conservative management of postdural puncture headache ten patients with postdural puncture headache presenting for an epidural blood patch patients undergoing this procedure forty postpartum patients with postdural puncture headache (pdph patients presenting for an epidural blood patch for the management of postdural puncture headache headache after spinal anesthesia in women who have undergone cesarean section patients with postdural puncture headache 18 parturients with postdural puncture headache following deliberate or accidental dural puncture postdural puncture headache
therapeutic concentrations infection rate average length of hospitalization and convalescence rate of postoperative infectious complications post-operative wound sepsis rate erythematous rash rate of post-operative infections hospital wound infections wound sepsis frequency of non-clostridial anaerobic infection majority of wound infections incidence of complications rate of postoperative infections incidence of anaerobic wound infection incidence or severity of wound infection or post-operative intra-abdominal sepsis wound infection rate incidence of wound infection overall rate of wound infection days of hospitalization safety and efficacy sepsis rates morbidity and prolongs hospital stay number of aerobic organisms occurrence of both anaerobic and aerobic bacteria infection rates incidence of postoperative wound infection toxicity wound-infection rate rate of infectious complications overall incidence of infection anaerobic infection overall infection rates postoperative wound infection wound infection anaesthetic complication incidence of infectious complications overall infection rate septic complications postoperative wound infections rate of wound infection postoperative infections duration of postoperative hospital stay late sepsis rate of postoperative wound infection wound infection, the hospital stay wound infections nonperforative appendicitis septic morbidity blood levels|no differences occurred in the incidence of wound infection in the two groups. the efficacy of a single 500 mg intravenous intra-operative dose of metronidazole in the prevention of postoperative wound infection, following appendicectomy for acute mural appendicitis, was studied in a prospective randomized placebo controlled trial. the rate of infectious complications in group i was 6.3% but only 2.1 and 2.3 in groups ii and iii, respectively. cefazolin significantly reduced the number of aerobic organisms isolated from wound infections, but did not significantly reduce the incidence of wound infection. sepsis rates were found to be 27% for the untreated group, 9% for the group receiving metronidazole only, 8% for the group receiving cotrimoxazole injection only and 2.7% for the group receiving both drugs. significant reduction in wound infection occurred in the study group compared with control subjects irrespective of the underlying pathologic lesion. there were no side-effects due to the drugs. anaerobic infection did not develop in any of the metronidazole-treated patients, but infections did develop in nine (19%) of the 46 controls. the use of prophylactic antibiotics did not yield better results than the use of placebos. the majority of wound infections were due to b. fragilis, either alone or in association with aerobic organisms, but infection due to e. coli and staphylococcus aureus also occurred. a significant reduction in the incidence of anaerobic wound infection was observed in the treated group (p less than 0.02). antibiotic prophylaxis lowered the post-operative wound sepsis rate, especially following clinically contaminated interventions, but this reduction did not reach statistical significance. in those receiving both drugs the infection rate was 3%, a highly significant difference from that in the other three groups. the study showed for each group a significant reduction of the incidence of wound infection in patients receiving prophylaxis. no toxic effects of the antibiotics were detected, no anaesthetic complication occurred, and resistant strains of bacteria normally sensitive to the antibiotics were not isolated from wounds. no significant difference was found in the incidence of complications between the treated and a control group, raising doubts as to whether this substance is of value when used intraperitoneally in peritonitis. there were 13 wound infections (as defined by the discharge of pus), 12 (out of 51) in the saline group and 1 (out of 49) in the metronidazole group. 17.5% of the patients in the control group developed a wound infection compared with 3.4% of those receiving metronidazole (p less than 0.001). the 3-day tinidazole treatment, as compared with the single-dose prophylaxis, did not further improve the outcome. ceftizoxime decreased the infection rate compared with pla (0 vs. 8; p less than .01). septic morbidity after appendectomy for nonperforating appendicitis is significantly reduced by systemic antibiotics, and brief administration of a single broad-spectrum agent (cefoxitin) is effective prophylaxis. one of 21 patients who received the placebo had a wound infection; none of the 21 patients given cefamandole had infection. wound sepsis occurred in 12.3% of metronidazole-treated patients compared with 24% in the povidone-iodine group and 23.5% in an untreated control group. post-appendicectomy sepsis still causes considerable morbidity and prolongs hospital stay. there was no significant difference in the incidence or severity of wound infection or post-operative intra-abdominal sepsis between the metronidazole-treated and placebo groups. in the non-perforated cases the infection rates were 3.4% in the metronidazole and 7.9% in the placebo group. the infection rate differed in both groups (antibiotic and placebo) only for perforated appendices significantly. the postoperative wound infection rate is insufficient to demonstrate the efficacy of metronidazole for prophylaxis in nonperforated acute appendicitis, although there appears to be a tendency of to assume its efficacy in this regard. blood levels of metronidazole taken at the end of operation showed a wide variation but there was no correlation with subsequent infection. the three groups of patients were similar in regard to age, sex, duration of operation and pathologic classification of the appendix. there were 16 wound infections, 15 (out of 50) in the placebo group, 1 (out of 54) in the metronidazole group. postoperative wound infections were detected in 11.6% of placebo-treated patients and in 1.4% of cephaloridine-treated patients (p less than .02).|this study included 127 patients patients who cannot take oral drugs 588 consecutive patients who were operated on on suspicion of appendicitis one hundred patients undergoing appendicectomy through a right iliac fossa incision children with appendicitis twenty-six patients were excluded for the following reasons: diagnosis other than acute appendicitis (16), perforation of the appendix (8), administration of other antibiotics (1), and refusal to enter study (1 175 patients studied at two hospitals, preoperative guidelines were used to exclude perforative appendicitis acute nonperforative appendicitis (npa 203 patients 95 patients who had undergone acute appendicectomy: 49 received sepsis after emergency appendicectomy patients receiving prophylaxis patients with perforated appendicitis 1735 patients undergoing 131 patients from 158 appendicectomies 400 cases emergency appendicectomy acute nonperforating appendicitis 102 patients with presumptive acute appendicitis 139 patients studied, 70 received perforated appendicitis wound infection following appendicectomy appendicectomy 82 patients showed a wound infection rate of 4.8%; 3 of 53 patients who did not receive antibiotics had a wound infection compared with 1 of 29 patients who received ninety-eight patients with suspected nonperforated acute appendicitis against wound infection after appendicectomy 544 children operated upon for uncomplicated appendicitis following appendicectomy from november 1978 to january 1980 acute mural appendicitis seventy-two patients, 47 men and 25 women, with a mean age of 27.5 years (range 15 to 60 years), underwent appendectomy and were studied wound infections in appendectomy bacteroides infections after appendicectomy patients undergoing appendicectomy two hundred and seventy-one patients were assessed two hundred and fifty patients 25 of 220 patients had to be excluded patients undergoing surgery for uncomplicated appendicitis acute nonperforated appendicitis emergency abdominal surgery anaerobic infections after emergency appendicectomy patients over the age of 12 undergoing emergency appendicectomy patients with peritonitis due to perforated appendicitis children undergoing appendicectomy thirty patients received patients with generalized peritonitis 223 consecutive suspected appendicitis patients gastrointestinal surgery uncomplicated childhood appendicitis 133 children, aged 16 months to 15 years (mean 6.7 years), with presumptive acute appendicitis 166 patients) or the 100 patients undergoing uncomplicated appendicitis during childhood appendectomy 283 patients was finally accepted into the study 496 patients one hundred patients with uncomplicated appendicitis septic complications after emergency appendectomy for nonperforated appendicitis 122 patients with npa 102 consecutive patients undergoing appendectomy through an incision in the right iliac fossa 400 cases of uncomplicated appendicitis operated upon by three senior surgeons patients were divided into three groups: patients with a normal appendix, patients with an acutely inflamed appendix, and patients with a gangrenous appendix 104 patients with a presumptive diagnosis of acute appendicitis elderly patients uncomplicated appendicitis in children
mean glucose levels average adherence insulin sensitivity dietary intake blood pressure, glycemic control, lipids and insulin sensitivity urine ketones adherence metabolic effects dietary intakes energy intake adequacy glycaemia fasting plasma glucose and glucose tolerance effectiveness, safety and tolerability pregnancy outcomes adverse pregnancy outcomes birth weight ketonemia prevalence of macrosomia diastolic blood pressure and no adverse effects on blood lipids prevalence of gestational diabetes mellitus (gdm glycemic control ketonuria fasting plasma insulin birth weight centile blood glucose glycaemic control postprandial glucose values mean birthweight pre-pregnancy bmi diastolic blood pressure self-perception fasting blood glucose fasting levels of beta-hydroxybutyrate effectiveness, tolerability and safety frequency of insulin therapy key obstetric and fetal outcomes glucose concentration blood pressure pregnancy outcomes, neonatal anthropometry, and maternal metabolic profile energy restriction optimal glycemic control blood pressure and glucose metabolism ambulatory blood pressure, blood lipids, glycemic control and insulin sensitivity estimated by an intravenous glucose tolerance test self-monitored-blood-glucose (smbg), maternal and infant weight obstetrical outcomes|a low-glycemic index diet is effective as a treatment for individuals with diabetes and has been shown to improve pregnancy outcomes when used from the first trimester. the h-mufa diet had no advantage to the h-cho diet in ameliorating the decline of insulin sensitivity in third term of pregnancy in gdm. energy restriction did not alter the frequency of insulin therapy (17.5% in the intervention group and 16.9% in the control group). finally, urine ketones increased significantly (p less than 0.02) in the calorie-restricted group, whereas they remained absent in the control group.(abstract truncated at 250 words) optimal glycemic control was observed in 50% of women; no association was found with adherence measured with any of the three methods studied. no changes in fasting blood glucose were noticed in the group that had followed a low carbohydrate diet, although a significant decrease in glucose concentration was observed after breakfast (102 +/- p = 0.969), prevalence of macrosomia (lgi 2.1% vs. hf 6.7%; p = 0.157), insulin treatment (lgi 53% vs. hf 65%; p = 0.251), or adverse pregnancy outcomes. diet gi on control (58, 95% ci: 56,60) was significantly higher than on low-gi (49, 95% ci: 47,51; p=0.001).|individuals with diabetes gestational diabetes mellitus (gdm n = 49 women with gdm women with gestational diabetes 30 caucasian women newly diagnosed with gdm, with a mean age of 28.7 women with gestational diabetes mellitus (gdm ninety-nine women (age 26-42 years; mean  sd prepregnancy bmi 24  5 kg/m) diagnosed with gdm at 20-32 weeks' gestation obese pregnant women with gestational diabetes 27 women with gestational diabetes mellitus in an outpatient clinic women with gestational diabetes or impaired glucose tolerance of pregnancy gestational diabetes mellitus women with gestational diabetes mellitus women who experience the highest glycaemia levels after breakfast women (n = 63 women with gestational hyperglycaemia obese women with gestational diabetes obese gestationally diabetic women mexican pregnant women with diabetes participants, recruited from the diabetes-in-pregnancy clinic of an inner-city teaching hospital serving a predominantly non-caucasian population pregnant women with diabetes gestational diabetes women analyzed in this study (n=69) had an age range of 22-42 years; 47.8% had type 2 diabetes (dm2) and 52.2% had gestational diabetes (gdm
clinical sites of infection, degree of neutropenia underlying malignancy, and organisms overall success rate infections and unexplained fever depth and duration of granulocytopenia as well the distribution of the infection categories and rate of bacteremia duration of fever, neutropenia, and hospitalization, mortality, and the need for additional antibiotics or antifungal drugs control of infection severe neutropenia median durations of neutropenia infectious mortality median duration for defervescence febrile neutropenia median duration of antibiotic therapy renal tubular damage durations of fever, neutropenia, and hospitalization global response clinical efficacy neutrophil counts of <100/microl. microbiologically documented infection febrile neutropenia episodes microbiological eradication of gram-negative response rate regarding gram-negative infections gram-positive complete response rates clinical response gram-positive bacteremia fever and neutropenia tolerated and produced response rates hodgkin's lymphoma (nhl granulocytopenic episode febrile neutropenia (fn initial clinical response rate tolerability occurrence of gram-negative bacteria nephrotoxicity overall response rate febrile infective episodes serum peak and trough concentrations of the antibiotics infection-related mortality skin rash and vomiting microbiological adverse effects efficacy, safety, and tolerance median neutrophil count duration of neutropenia adverse events leukemia or lymphoma allergic reactions superinfections and toxicity prolonged neutropenia rate of treatment modification satisfactory response, eradication of the infecting organism, development of superinfections, and occurrence of adverse events infection, and unexplained fever percentages of patients responding to therapy renal side effects haematological malignancies fifty febrile netropenic episodes mean total antibiotic drug cost initial clinical response rates of clinical cure or improvement and of elimination of causative pathogens morbidity and mortality total episode cost febrile episodes febrile events clinical and laboratory adverse effects 876 febrile, neutropenic episodes granulocytopenia cure rates for gram-negative bacteremias clinical response rates efficacy overall initial response efficacy and safety response rate six febrile episodes duration of fever, clinical symptoms, antibiotic therapy, and granulocytopenia infection-related death 69 febrile granulocytopenic episodes severe hypokalemia cure rates treatment failure efficacy and tolerability adverse experiences; drug-related adverse events overall treatment costs and duration of hospitalization tolerated urinary excretion of aap overall successful outcome mean neutrophil counts failure rate clinical cure or improvement average cost of antibiotics nausea or vomiting cost of change of antibiotics infection rate acute leukemia persistent bacteremia proportion of patients that became afebrile serum levels of creatinine, urea and beta 2-microglobulin and the urinary excretion of alanine aminopeptidase, n-acetyl-beta-d-glucosaminidase (beta-nag) and beta 2-microglobulin median duration of neutropenia and defervescence of fever leukopenia median time to fever defervescence median total duration of neutropenia lower potassium level fever of unknown origin duration of fever, hospitalization, and antimicrobial drug administration adverse events, duration of hospitalization, and cost between both groups overall treatment success cost effective overall response rates efficacy, safety and tolerance response rates toxicity febrile neutropenic episodes costs of the antimicrobial drugs, hospitalization, and total cost clinical efficacy and tolerability efficacy and costs success rate episodes of profound neutropenia withdrawals or deaths defervescence overall cure rate renal failure rates of superinfection infection superinfections of fungal origin reversible side effects rates for gram-negative rod bacteremia blood cultures urinary beta-nag gram-positive infections success or failure efficacy, safety, and cost of cefepime serum creatinine overall clinical rate of response to imipenem unexplained fever amikacin levels infection eradication success efficacy and cost effectiveness gram-negative nausea bacteremia persistent staphylococcus aureus bacteremia duration of fever excellent response adverse event success rates mean duration of neutropenia early death side effects nephrotoxicity nor hypokalemia alone superinfection incidence of side effects nausea/vomiting or seizure duration of hospitalization per episode antibiotic cost successful outcomes overall success costs of hospitalization, antimicrobial drugs, and supportive therapy gram positive cocci mortality partial response rates adverse effects incidence of gram-negative and gram-positive isolates occurrence of further infections|the overall cure rate for the ceftazidime group was 71% and for the gentamicin plus cefotaxime 47%. thirteen (29%) of the patients treated with ceftazidime failed to respond clinically to treatment, versus four (9%) of the patients treated with ceftazidime/tobramycin (p = 0.046). there were 18 cures in the cefepime group and 17 in the ceftriaxone plus amikacin group (p = 0.9). there was no difference between the two regimens for durations of fever, neutropenia, and hospitalization (p > .05 for all categories). adverse events were minimal, and three early deaths were observed at days 9, 16, and 16 among patients treated with a single antibiotic and three in the combination regimen group at days 14, 15, and 20. control of infection was achieved in 72% of patients treated with latamoxef and 55% treated with cephradine plus tobramycin. only minor reversible side effects were noted in both treatment arms. the occurrence of further infections assessed in patients for whom the allocated regimen was not modified did not differ between the two groups (12% in both groups). glycopeptide and antifungal drugs were added more frequently in the ceftazidime + amikacin group. the long term response to ceftazidime was 33/71 (46.5 per cent) and to cefotaxime + tobramycin 31/86 (36 per cent). superinfections and toxicity related to antibiotics were minimal in both groups. cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to p+g was noteworthy. treatment was successful without the need for modifications in 71% of the episodes in the t group and 81% in the c+a group (p=0.23). there was no difference in clinical response between the two therapeutic regimens as assessed 4 and 7 days after treatment began. the success rate with unmodified therapy was not significantly different between the meropenem group (72%) and the ceftazidime-plus-amikacin group (57%). the initial clinical response rate for both regimens was 60% (p > 0.05). no significant difference was found between piperacillin/ tazobactam and ceftazidime plus amikacin in terms of success rate (81% versus 83%), empirical addition of vancomycin (42% versus 38%), median time to fever defervescence (3.3 versus 2.9 days) or median duration of antibiotic therapy (7.2 versus 7.4 days). there was no statistically significant difference in the response to treatment at 72 hr or after necessary antimicrobial modifications. at day 3, patients with neutrophil counts of <500/ mu l receiving dual therapy had a better response than did those receiving monotherapy (45% vs. 27.6%; p=.024). seventy-two hours after the start of therapy, no significant between-group differences in treatment outcomes, including withdrawals or deaths, were seen. isolated bacteria were more sensitive to ceftazidime than to tobramycin with amoxycillin/ampicillin. single-agent therapy with imipenem is as effective as more conventional combination antibiotic therapy for the empirical treatment of febrile episodes in neutropenic patients with cancer. the proportion of patients that became afebrile in the first 24 hours was significantly higher in the cefepime group (41.7% vs 11.1%, respectively; p = 0.012). there were no significant differences in terms of efficacy between imipenem/cilastatin and amikacin plus piperacillin but a consistent trend towards higher rates of clinical cure or improvement and of elimination of causative pathogens was noted in the imipenem/cilastatin group. fewer adverse effects occurred in the piperacillin-treated group (42%) than in the combination-treated group (71%) (p = 0.0399 by fisher's exact test), although neither nephrotoxicity nor hypokalemia alone was significantly less frequent in patients receiving piperacillin. therapy with the combination resulted in a higher serum creatinine (p less than 0.001) and a lower potassium level (p less than 0.001) in comparison with monotherapy. a total of 733 patients were assessable for efficacy of the drug regimens, and an overall successful outcome was reported in 49% (179 of 364) of the patients who received monotherapy, compared with 53% (196 of 369) of patients who received combination therapy (p=.2). duration of fever was significantly shorter in the imi group (4 days vs 7 days, p < 0.04). monotherapy with pip/tazo was effective and safe for initial empirical treatment of febrile neutropenic episodes in children with al. clinical cure or improvement was noted in 10 of 12 culture verified infections in the tobramycin and cefuroxime group and 11 of 14 episodes in the ceftazidime-group. in group i, clinical response was observed in 10 of 19 febrile episodes (52.6%) treated with carbenicillin plus gentamicin and in 10 of 14 (71.4%) treated with latamoxef (p greater than 0.05). meropenem monotherapy was well tolerated and produced response rates similar to those obtained with ceftazidime/amikacin. gram-positive bacteremia responded poorly in the meropenem and ceftazidime/amikacin group (29% versus 25%), whereas all gram-negative bacteremias responded except for one in the meropenem group caused by pseudomonas aeruginosa. the solid tumor group had significantly less bacteremia (4/34 versus 17/56; p < 0.05) and treatment failure (3/34 versus 24/56; p < 0.001) than the nhl group. there was no significant difference in terms of success or failure between the two treatment groups. the initial clinical response rate to ceftriaxone/gentamicin was 62.5% and 84.6% to imipenem/cilastatin (p = 0.075). cefoperazone plus amikacin resulted in an 88% overall response rate and cured 14 of 15 patients with bacteremia. the difference in distribution proved to be statistically significant for gram-negative (p = 0.0001) as well as gram-positive (p = 0.025) bacteria, indicating that ciprofloxacin effectively prevented the occurrence of gram-negative bacteria and may have contributed to the relatively large number of gram-positive bacteria isolated. patients in the piperacillin plus gentamicin group experienced significantly more renal tubular damage whereas those who received imipenem suffered more nausea or vomiting. piperacillin-tazobactam monotherapy is significantly more effective and cost-efficient than ceftriaxone plus gentamicin as first-line therapy in febrile neutropenic patients with hematological malignancies. ceftazidime alone was as effective but safer than the combination of piperacillin and tobramycin for the empiric treatment of febrile, neutropenic patients, even those with profound and prolonged granulocytopenia. there was no statistically significant difference between the three treatment regimens with respect to efficacy, safety and tolerance (chi2 test, p>0.05), but while the third and fourth generation cephalosporins + aminoglycosides were comparable for cost, the monotherapy regimen was the most expensive. there was no difference with respect to the final response: 53% for the monotherapy group versus 48% for the combination group, and both regimens appeared to be equally safe. the two groups were equivalent with respect to clinical and laboratory parameters prior to antibiotic therapy and flucloxacillin was added to approximately 25% of the patients in each group on the clinical suspicion of gram positive infection. the response rate regarding gram-negative infections was 10 out of 14 (71%) in the ipm/cs group and seven out of 12 (58%) in the lmox+tob group. success without modification at the end of treatment was seen in 32.7% (c), 28.3% (c + g), 52.4% (c + t) and 65.2% (c + g + t).|15 patients with bacteremia granulocytopenic patients with cancer 733 patients febrile granulocytopenic cancer patients children with malignancy 157 patients with prolonged aplasia (pmn less than 500/mm3 during more than 21 days), hospitalized in a protected environment unit patients aged 2-16 years with hematological malignancies who had febrile neutropenia febrile neutropenia three-hundred and twelve episodes of fever in 234 neutropenic patients with haematological malignancies seventy-one patients with hematological malignancies (55%) or solid tumors (45%), neutropenia < 500/microliter, and fever > 38.5 degrees c seventy-two febrile episodes of 42 patients with a median age of 4.5 years (3.5 months to 19 years children with cancer and neutropenia febrile episodes in leukemia in adults a total of 165 patients were entered into the trial pediatric and adolescent patients with leukemia or lymphoma febrile neutropenic children with acute leukemia (al febrile neutropenic children twenty patients were included in each group febrile neutropenic patients with hematological malignancies evaluable patients with septicemia neutropenic cancer patients with fever 760 febrile, adult patients with cancer with chemotherapy-induced profound (<500 neutrophils/mm3) and prolonged (>10 days) neutropenia patients with leukemia ninety episodes of neutropenic fever in children (0.7-16.0; mean age 7.7 years) with solid tumors in a single center in our center between january 1998 and january 1999, 73 children with hematological malignancies [acute lymphoblastic leukemia (all), acute myeloid leukemia (aml)]; 9 children with solid tumors (rhabdomyosarcoma, neuroblastoma) had 87 febrile neutropenic episodes (related to chemotherapy febrile neutropenic children with malignancy in turkey febrile neutropenic patients receiving either febrile pediatric cancer patients with prolonged neutropenia 24 patients 129 febrile episodes in pediatric cancer patients with prolonged neutropenia from january 2001 to april 2002 patients with acute leukemia and febrile neutropenia granulocytopenic cancer patients febrile neutropenic patients febrile neutropenic cancer patients childhood hematological malignancies 50 evaluable neutropenic cancer patients admitted for fever 1,034 randomized patients, 958 were assessable in the intent-to-treat analysis for response to antibacterial therapy, including 483 in the meropenem group and 475 in the febrile neutropenic patients with lung cancer localized infections in febrile, granulocytopenic patients between july 1993 and september 1996, 107 consecutive febrile episodes in 83 neutropenic cancer patients with a median age of 41 years leukopenic, febrile patients with solid tumors pediatric cancer patients granulocytopenic patients with presumed bacteremia patients with lung cancer severe granulocytopenic patients neutropenic cancer patients febrile children (range 8 months to 18 years) with neutropenia secondary to cancer chemotherapeutic agents eighty three patients with neutropenia and cancer immunocompromised patients with ceftazidime or with febrile episodes in neutropenic patients children with febrile neutropenia patients who failed to respond to the initial antibiotic therapy were given patients who had received no cis-platinum fifty-two immunocompromised patients with suspected septicaemia acute leukemia patients 90 granulocytopenic febrile patients presenting with a localized infection children with cancer 212 consecutive febrile episodes in 130 neutropenic patients with hematological malignancies leukaemic patients with neutropenia immunocompromised neutropenic children undergoing chemotherapy for neoplastic disease pediatric patients with leukemia and lymphoma one hundred and two patients with neutropenia (less than 1 x 10(9)/l) secondary to primary hematological disorders or chemotherapy for hematological malignancies leukocytopenic febrile patients (less than 3,000 leukocytes per microliters; temperature greater than 38 degrees c) with lung cancer given induction therapy fever in the neutropenic patient without evidence of skin infections or anaerobic infections 87 patients, with a neutrophil count of less than 1000/mm3 at the start of the treatment one hundred fifty-three patients were evaluable for response 87 febrile neutropenic episodes that were evaluable for comparison, 46 patients received pta and 41 patients were treated with cancer chemotherapy-induced neutropenic fever severely neutropenic children 10 haematology departments of university hospitals on 174 leukaemic patients with prolonged bone marrow aplasia and presenting with a febrile episode seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study seventy-seven patients (37%) were non-evaluable due to effective antibiotic treatment before the trial, early institution of other antibiotics during the trial, verified non-bacterial infections, no neutropenia or other reasons seventy seven patients were available for analysis a total of 93 febrile episodes (46 meropenem, 47 143 aplastic episodes with fever in 91 haematological patients with granulocytopenia serious bacterial infections both adults and children children with acute leukemia fifty-four pediatric cancer patients with a total of 100 febrile neutropenic episodes treated at china medical college hospital fifty-one episodes eligible neutropenic patients with cancer febrile pediatric cancer patients with anticipated prolonged neutropenia patients with bacteriologically proven infections febrile neutropenic patients with hematological disorders group study group of turkey 120 febrile children with neoplastic diseases and granulocytopenia febrile neutropenic patients with hematologic disorders pediatric febrile cancer patients children with lymphoma and solid tumors children with acute lymphoblastic leukemia or acute myeloblastic leukemia of 30 evaluable episodes, 15 were treated with patients who developed fever with neutrophil counts <1,000/microl pediatric cancer patients at the high risk of severe infection febrile neutropenic patients with haematological malignancies sixty neutropenic patients with infection patients with severe neutropenia and leukemia who may benefit from dual therapy patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy febrile neutropenic (< 1000/mm3) patients with liquids and solid tumours granulocytopenic patients 210 neutropenic cancer patients patients who remained febrile granulocytopenic and nongranulocytopenic febrile patients patients with a high risk of complications neutropenic infection neutropenic patients 111 patients were enrolled and 99 patients acute leukemia in therapeutic aplasia children with al who had febrile neutropenic episodes cancer patients in chemotherapy who have fever and neutropenia febrile granulocytopenic patients neutropenic patients with malignancies febrile cancer patients with and without granulocytopenia 76 assessable febrile episodes (39 with meropenem and 37 with patients with solid tumors treated with patients with solid tumors treated with high dose chemotherapy (hdc) and peripheral blood stem cell support (pbscs) with febrile neutropenia neutropenic patients with cancer 106 adult patients diagnosed with presumed bacterial infection and an underlying malignancy with an absolute neutrophil count (anc) < 500/mm3 were enrolled in this open-label study c&t patients those patients with a long intravenous line-associated infection cancer patients hematopoietic proliferative diseases neutropenic patients with predominantly gram-positive infections patients with granulocytopenia neutropenic patients with underlying malignancy was conducted at two oncology centers neutropenic patients with infection persistently granulocytopenic cancer patients 696 patients (83% acute leukemia or bone marrow transplantation); 92 episodes were excluded from analysis because of protocol violation fifty two patients (26 female) aged 16 to 80 years old with 60 episodes of neutropenia were studied children with al immunocompromised children with malignancy febrile cancer patients patients without previous prophylactic antibiotics
global qol scores peak oxygen consumption changes in qol (cares short form) and depressive symptoms (ces-d qol, depression, exercise behavior, aerobic fitness; outcomes overall qol adherence depressive and state anxiety scores overall qol, psychosocial functioning, cardiovascular fitness, and body composition mental distress, as assessed by the hospital anxiety and depression scale, and hrqol, as assessed by the european organisation for research and treatment of cancer core quality of life questionnaire physical fitness test and qol measures (e.g. functional assessment of cancer therapy scales change in crf, as determined by astrand-rhyming indirect bicycle ergometer test (maximum oxygen uptake [vo(2max)]), between baseline (t0) and follow-up (t1 mental health dimension of quality of life fatigue, social physique anxiety, and physical fitness good adherence helplessness/hopelessness quality of life questionnaire peak oxygen consumption and overall qol physical, cognitive and emotional status and somatic complaints with the european organization for research and treatment of cancer quality of life questionnaire core module (eortc-qlq-30) questionnaire, and maximal physical performance back/leg muscle strength physical global score bodily pain fatigue score sleep quality fatigue self-perceptions of appearance, health, physical strength, sexuality, relationships, and social functioning body fat social functioning quality of life, fatigue, mood and inflammation lean mass cardiorespiratory fitness and health-related quality of life strength and health subscale exercise and dietary behavior, fatigue, health-related quality of life (qol), aerobic exercise tolerance, functional capacity, muscle strength, and anthropometery sleep physical functioning and quality of life (qol higher satisfaction upper extremity endurance time interaction for overall qol peak oxygen uptake (vo2peak), a dynamic strength endurance test (maximum number of repetitions for chest and leg press exercise body image and relationship scale quality of life benefits cardiovascular fitness inflammation (crp overall quality of life (qol waist-to-hip ratio sleep quality and quality of life of cancer patients fatigue and global health scores sleep quality and quality of life fatigue, sleep disturbances, depressive symptoms, biomarkers, and exercise fatigue and pain intrusion or avoidance, state anxiety, depression, or fatigue depressive and anxiety symptoms and self-esteem health-related quality of life (hrql) and self-esteem cardiopulmonary function and qol biomarkers, fatigue, sleep disturbances, and depressive symptoms fatigue (multidimensional fatigue symptom inventory-short form and functional assessment in chronic illness therapy-fatigue subscale quality of life anxiety, depression, body image, and quality of life physical performance physical activity strength and qol improvements quality of life (qol isometric muscle strength and aerobic capacity aerobic fitness fatigue, energy level, and emotional distress quality of life (qol) and physical performance and activity performance in leg press objective physical functioning neck dissection impairment, fatigue, and quality of life qol and the overall physical fitness decreased depression birs total score cardiopulmonary function and quality of life (qol median adherence individual body image anxiety 12-month birs total and subscale scores, upper and lower body strength, and general quality of life (qol functional assessment of cancer therapy-breast, social/family well-being, functional well-being, and breast cancer subscale scores functional assessment of cancer therapy-general and functional assessment of cancer therapy-fatigue functional assessment of cancer therapy-breast scale cancer qlq-c30 (eortc-c30) questionnaire physical fitness and quality of life outcomes cancer-related fatigue subjective sleep quality dietary behavior, fatigue, aerobic exercise tolerance, functional capacity, and waist-to-hip ratio physical quality of life depressive and anxiety symptoms qol longer sleep duration physiological and psychological function self-esteem faster sleep latency mood disturbance (t(122) quality of life, mood, and spiritual integration fatigue and improving energy level, quality of life (mental and physical), fitness (vo 2submax), and emotional distress exercise behavior quality of life (qol), fatigue, distressed mood, and spiritual well-being psychosocial adjustment and quality of life physical functioning and quality of life total minutes of pa, more minutes of moderate-intensity pa, and higher energy expenditure global health distressed mood fatigue and health-related quality of life strength and qol changes inflammatory marker serum c-reactive protein (crp general health risk of disease recurrence/progression tai chi chuan, health-related quality of life and self-esteem changes in qol (eg, functional assessment of cancer therapy physical global qol score global quality of life, physical well-being, and functionality patient-rated physical functioning assessed by the trial outcome index-anemia accelerometer physical activity counts psychological adjustment and sleep quality depression and state and trait anxiety overall mood and body esteem quality of life, physical functioning, positive and negative affect, depression, body composition, sleep dysfunction and self-reported physical activity qol. physical activity level dietary fiber intake vigor and a reduction in fatigue symptoms of side effects of cancer treatment and inflammation biomarker (crp measures of spiritual integration quality of life and physical performance and activity hrql physical performance measures muscle strength cardiorespiratory fitness (crf), mental distress, and health-related quality of life (hrqol) parameters decreased confusion joint stiffness depression psychological health outcomes psychosocial global score mild fatigue levels, sleep disturbance, and mild pain serotonin levels quality of life and symptoms sleep disturbance baseline birs scores fatigue, sleep disturbance, depression, and pain spiritual quantified physical performance and self-reported physical functioning aerobic capacity body mass index and percent body fat adherences psychosocial (i.e. global quality of life, emotional function, and diarrhea) variables decreased anxiety sleep scores global qol fatigue (p<0.001), depression (p<0.001), body mass index psqi qol and fatigue lower morning and 5 p.m. salivary cortisol and improved emotional well-being and fatigue scores cardiorespiratory fitness, strength endurance, task specific functional muscle capacity, body composition and quality of life (qol functional assessment of cancer therapy-colorectal maximum heart rate piper fatigue scale, general sleep disturbance scale, center for epidemiological studies-depression scale, and worst pain intensity scale upper extremity strength and endurance, range of motion, fatigue, and quality of life exercise and quality of life depression, (beck depression inventory), anxiety (speilberger state-trait anxiety inventory), and self-esteem (rosenberg self-esteem inventory reductions in distress lean body mass upper body strength qol. physical performance and activity level shoulder pain and disability and improved upper extremity muscular strength and endurance quality of life and social body image hrql and self-esteem self-perceived psychosocial function and diurnal salivary cortisol secretion shoulder pain and disability sleep actigraphy baseline quality of life self-esteem and depressive and anxiety symptoms lower-body flexibility sleep disturbance scores sleep medications maximal oxygen uptake (vo(2)max/kg fatigue (p=.005), aerobic exercise tolerance (p=.010), chair sit-to-stand performance (p=.003), and waist-to-hip ratio strength and qol variables chronic fatigue and quality of life mental health, depression, positive affect, and spirituality (peace/meaning vo(2max initial fighting spirit psychosocial wellbeing, individual body image, and physical fitness fatigue and diurnal salivary cortisol concentration change in qol happiness, depressive symptoms, anxiety, stress, self-esteem, and quality of life overall well-being and quality of life qol and depressive symptoms psychological distress fatigue (t(153) fatigue and physical performance anxiety, depression, body image, and health-related quality of life body image (physical condition and weight concerns subscales upper extremity strength quality of life over time mental distress or hrqol taiwanese version of the pittsburgh sleep quality index, the medical outcomes study short form-36, the taiwanese version ratings of the perceived exertion scale, and a walking exercise log body composition measurement, quantified walking activity and patient-reported outcomes (physical activity, fatigue and health-related quality of life patient-rated shoulder pain and disability eortc qlq-c30, facit-f, rbdi, and whq (for vasomotor symptoms) questionnaires pa and improved fitness and specific aspects of psychological well-being enhanced sleep quality ces-d scores peak cardiovascular fitness range of motion of the shoulder joint, and psychosocial adjustment and quality of life self-reported emotional, health-related quality of life, and symptom outcomes cortisol, serotonin, interleukin-6, and bilirubin biomarkers and fatigue, sleep disturbances, and depressive symptoms pittsburgh sleep quality index (psqi), the piper revised fatigue scale, and the center for epidemiological studies-depression scale psychosocial variables of emotional irritability, gastrointestinal symptoms, cognitive disorganization, mood disturbance, tension, depression, and confusion|the yoga group had lower morning and 5 p.m. salivary cortisol and improved emotional well-being and fatigue scores. the results revealed statistically significant increases in aerobic capacity (p < 0.001) and lower-body flexibility (p = 0.027), a significant decrease in body fat (p < 0.001), and a significant increase in quality of life (p < 0.001) and a measure of energy (p = 0.038) in the exercise group when compared with the control group. the pret program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage. no group differences were found in the changing scores over time. only the cam group showed increases in measures of spiritual integration (p=0.001) which were also significant between groups (p=0.003). data showed that the women in the exercise group improved significantly in body image (physical condition and weight concerns subscales) vs control group participants at post-treatment. this study indicates that mq can improve cancer patients' overall qol and mood status and reduce specific side-effects of treatment. aet significantly improved important patient-rated outcomes and objective physical functioning in lymphoma patients without interfering with medical treatments or response. adherence in the exercise group was good (75.8%) but contamination in the control group was problematic (51.6%). the yoga group demonstrated a significant within-group improvement in fatigue; no significant difference was noted for the control group. regression analyses indicated that the control group had a greater decrease in social well-being compared with the intervention group after controlling for baseline social well-being and covariates (p < .0001). in response to training, qol, vo2peak (mean 3.9 ml/kg/min; 95 % ci, 0.93, 6.90) performance in leg press (17.9 kg; 95 % ci, 12.8, 22.4) and sit-stand test (- 0.67 s; 95 % ci, - 0.52, - 1.2) improved (p < or = 0.05). there were also trends for group differences, in the hypothesized directions, for the psychosocial variables of emotional irritability, gastrointestinal symptoms, cognitive disorganization, mood disturbance, tension, depression, and confusion (all p's <0.10). a behavior change intervention for breast cancer survivors based on the social cognitive theory is feasible and results in potentially meaningful improvements in physical activity and selected health outcomes. patients in the ig improved significantly over time with regard to anxiety (p = 0.03, d = 0.45), depression (p = 0.05, d = 0.43), individual body image (p = 0.006, d = 0.44), and vo(2)max/kg (p < 0.001, d = 0.50), whereas no improvements were observed in the wg. we also found borderline significant interactions for physical well-being, satisfaction with life, and flexibility. the scores for global quality of life, physical well-being, and functionality increased from t1 to t2, but further improvement in the follow-up (t3) was only observed in the training group. fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01); however, there was no significant difference between changes in the scores of both groups (p=0.67). health-related quality of life (hrql) and self-esteem are often diminished among women diagnosed and treated for breast cancer. exercise group scores on the psqi decreased significantly over time (indicating improved sleep quality), although scores did not change significantly within the control group. the global qol was lower than in general population (69.4 vs 74.7, p<0.001). patients in the ty group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; p < 0.004). a differential impact of the intervention on the strength and health subscale was observed for older women (>50 years old) in the treatment group (p = 0.03). exercise was not associated with quality of life benefits in the full sample of either study; however exercise was associated with improved social functioning among post-treatment survivors who reported low social functioning at baseline (p<0.05). repeated measures analyses of variance revealed a significant group by time interaction for overall qol (p<0.001). baseline values for peak oxygen consumption (p =.254) and overall qol (p =.286) did not differ between groups. significant differences that favored aerobic exercise therapy relative to usual care were recorded for functional assessment of cancer therapy-breast, social/family well-being, functional well-being, and breast cancer subscale scores at 8-week follow-up. self-esteem did not change significantly. the mq intervention also reduced the symptoms of side effects of cancer treatment and inflammation biomarker (crp) compare to the control group. the results showed an increased range of motion of the shoulder joint, and psychosocial adjustment and quality of life were shown to be significantly higher in the intervention group than in the control group. significant intervention effects were observed at both posttreatment and follow-up on physical performance measures. significant differences favouring the intervention group were observed for fatigue at 12 weeks and 6 months follow-up (12 week: the lifestyle intervention elicited improvements in exercise behavior (p=.068), fatigue (p=.005), aerobic exercise tolerance (p=.010), chair sit-to-stand performance (p=.003), and waist-to-hip ratio (p=.002). results showed that participants in the intervention group showed greater improvement in fatigue, energy level, and emotional distress at 3-month follow-up, and physical quality of life at postintervention, compared with the participants in the control group. patients in the exercise group reported significant improvements in sleep quality (beta = -3.54, p < 0.01) and the mental health dimension of quality of life (beta = 10.48, p < 0.01). the psychosocial global score also improved significantly in the treatment group compared with the control group (standardized difference = 0.52, p = .02). the intervention successfully increased pa and improved fitness and specific aspects of psychological well-being among early-stage breast cancer patients. the fatigue score decreased by 17.0 points in the control group compared with only 5.8 points in the intervention group (p < .01). patients in the programme improved significantly more than the controls with respect to appraisal of having received sufficient information, physical training, physical strength and fighting spirit.|participants (n = 119 108 women who had been treated for breast cancer 12 to 36 months previously the majority of the sample had a diagnosis of ovarian (n=12) or endometrial cancer (n=11 women treated for breast cancer recently resected colorectal cancer survivors, most of whom were receiving adjuvant therapy edmonton, alberta, canada, between 2005 and 2008 that stratified 122 lymphoma patients by major disease type and current treatment status and randomly assigned them to usual care (uc; n = 62) or 12 weeks of thirty patients diagnosed with heterogeneous cancers head and neck cancer survivors early-stage breast cancer patients study population included two hundred and thirty-four women randomly assigned to breast cancer subjects who received exercise recommendations from their physicians exercised significantly more than subjects who received no recommendation women with early breast cancer in south korea fifty-three postmenopausal breast cancer survivors patients who had recently completed surgery and chemotherapy for colon cancer gynaecological cancer survivors during and post anti-cancer treatments women diagnosed and treated for breast cancer 63 breast cancer patients with cancer-related chronic fatigue eligible participants (per-screened with par-q/par-med-x recent breast cancer survivors sixteen subjects older women receiving hormonal treatment for their breast cancer breast cancer patients cancer-related fatigue in women during and after chemotherapy with or without radiation therapy eighty-seven french-speaking women who had completed their treatments for nonmetastatic breast cancer at a university hospital in quebec city, canada sixty-nine percent of intervention participants attended classes (mean number of classes attended by active class participants = 7.00 older women receiving hormonal treatment for breast cancer women with breast cancer gynaecological cancer survivors head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage forty-one sedentary women on estrogen receptor modulators or aromatase inhibitors for stage i, ii, or iiia breast cancer copyright 2004 american cancer society patients' physical performance and psychosocial well-being 234 breast cancer survivors (112 with lymphedema) who participated in the physical activity and lymphedema (pal) trial group (n = 8; age: 51  2011 american congress of rehabilitation medicine eighteen (n=18) colon cancer survivors (mean age=69y; range, 52-80y), dukes stage a to c. participants stage ii-iv breast cancer survivors (n = 18 hematopoietic stem-cell transplantation recipients older women (>50 years old managing fatigue with gynaecological cancer survivors multiethnic sample of breast cancer patients thirty three sedentary gynaecological cancer survivors (stage i-iii; 3 years post diagnosis), experiencing cancer-related fatigue (mild-severe) took part breast cancer survivors (n=58) within 2 years of completing adjuvant therapy breast cancer survivors soon after completing adjuvant therapy 86 survivors (4-36 months posttreatment diagnosed breast cancer survivors undergoing adjuvant therapy and (b) a similar trial among post-treatment survivors patients with lymphoma northern ireland regional cancer centre young and middle-aged cancer patients shortly after curative chemotherapy finnish female breast cancer patients shortly after adjuvant treatments the mean age of the sample was 48.9 years breast cancer survivors with or at risk for lymphedema early breast cancer patients in south korea twenty-four breast cancer survivors (mean time following surgery 41.8 months; ranging from 1 to 99 months) recruited via mail and cancer support groups colorectal cancer survivors cancer survivors sedentary breast cancer survivors receiving hormone therapy breast cancer patients with tumor-related chronic fatigue 2010 american academy of nurse practitioners older women with breast cancer receiving hormonal therapy patients with cancer young and middle-aged cancer patients shortly after chemotherapy seventy-two patients who underwent surgery for lung (n=27) or gastrointestinal tumours (n=42 one hundred and sixty-two patients with a range of cancers were recruited women receiving chemotherapy and/or radiation postmenopausal breast cancer survivors most participants (93%) were white with mean age of 53 fifty-five women with early breast cancer 537 disease-free breast cancer survivors aged 35-68 years forty-five participants completed the trial for newly diagnosed survivors and 67 completed the trial for post-treatment survivors one hundred twenty-eight patients (42% african american, 31% hispanic) recruited from an urban cancer center 98 patients 20 women (aged 55 years or older) with breast cancer receiving hormonal treatment eighteen survivors of breast or colon cancer (15 female and 3 male, 40-65 yr of age) served as subjects fifty-two head and neck cancer survivors breast cancer survivors patients rehabilitating from cancer treatment one hundred eleven patients age 18 to 50 years who had received chemotherapy for lymphomas or breast, gynecologic, or testicular cancer completed the trial patients recovering from colon cancer women with primary nonmetastatic breast cancer after a minimum 4-week period post chemotherapy and/or radiotherapy completion midwestern university town 2010 postmenopausal breast cancer survivors who had completed surgery, radiotherapy, and/or chemotherapy with or without current hormone therapy use cancer patients and post-treatment survivors 24 women who had been diagnosed with breast cancer within the previous 3 years breast cancer patients after adjuvant treatments women breast cancer survivors 21 women diagnosed with breast cancer, who had completed treatment within the last 30 months 181 women with breast cancer patients recovering from surgery for solid tumours lymphoma patients patients who had completed hsct up to 6 months earlier participants were 8.7 (sd=9.1) months post diagnosis, with a mean age of 53 (sd=10.3) years cancer patients twenty five percent of eligible women took part (33/134 participants were recruited from oncology outpatient clinics in two university-based medical centers cancer patients after surgery postsurgical head and neck cancer survivors eighty-six sedentary women (mean age, 53.14 years; standard deviation, 9.70 years) who had completed treatment for stage 0 to ii breast cancer early breast cancer patients breast cancer survivors (wtbs) study thirty-nine patients with lymphoma who were undergoing treatment or who had concluded treatment within the past 12 months participants (m age=51.18 (10.33); 92% female) included primarily breast cancer survivors, on average 55.95 (54.39) months post-diagnosis older women receiving cancer patients who are suffering from sleep disturbances n=44; mean age 55.8 years) enrolled in this study; 34% were actively undergoing cancer treatment fifty newly diagnosed breast cancer survivors fifty-two participants completed the trial
forced expiratory volume positive expiratory pressure total lung capacity postural drainage (pd expectoration and lung function symptoms and lung function quantity of sputum pep-induced lung function improvement per milliliter of sputum whole lung tbc fvc mean clearance of tracer from the right lung by postural drainage, pep and physical exercise radioactivity content symptom scores, sputum production, or simple lung function tests sputum production, symptom score or peak expiratory flow rate number of spontaneous coughs forced expiratory flow clinical status, pulmonary function, and compliance lung function parameters (peak expiratory flow, forced vital capacity (fvc), forced expiratory volume in one second, maximal midexpiratory flow, maximal expiratory flow at 25% of fvc, thoracic gas volume, total lung capacity, residual volume/total lung capacity, airway resistance and specific airway conductance) and changes in transcutaneous oxygen haemoglobin saturation arterial oxygen saturation, fev1 or forced vital capacity sputum clearance pulmonary function tests (pfts fev(1 ventilation distribution, gas mixing, lung volumes, expiratory airflow, percentage of arterial blood oxyhemoglobin saturation (spo(2)), and sputum volume airway resistance (raw), or specific airway conductance (sgaw acceptability and subjective efficacy lung function, sputum expectoration, and spo(2 skin oxygen tension, pso2 whole lung or regional tbc pulmonary function sputum production or change in lung function mucus transport mucus clearance clearance of lung radioactivity shwachman-kulczycki clinical score pulmonary function studies pso2 functional residual capacity and total lung capacity mean annual rate of decline in forced vital capacity regards growth, shwachman score, chrispin-norman score or pulmonary function tests number of hospitalizations and antibiotic use wet and dry weight of sputum wet and dry weights of sputum huang scores positive expiratory pressure breathing residual volume lung function slow vital capacity clinical status and pulmonary function (forced vital capacity [fvc], fev1, and fef25-75 forced expiratory volume in the first second of expiration (fev1), forced expiratory flow mean (sem) functional residual capacity lung volumes whole lung and regional tracheobronchial clearance (tbc lung function parameter increased hospitalizations|paired t-test statistical analysis from the pft data indicated no significant changes in forced expiratory volume in the first second of expiration (fev1), forced expiratory flow from 25 percent to 75 percent of the loop (fef25-75), airway resistance (raw), or specific airway conductance (sgaw) among the three therapies studied. no significant changes in any lung function parameter occurred after a single session or after 2 weeks of physiotherapy with either method. there was a significant decline in huang scores (p =.05), increased hospitalizations (18 vs 5; p =.03), and antibiotic use in the flutter group. the differences between treatment groups were statistically significant for the changes in fvc (p = 0.02) and fev(1) (p = 0.04). lung function improved significantly after pep, ad, and pep-ad, but pep-induced changes did not exceed those after ad. no difference was shown in symptom scores, sputum production, or simple lung function tests. residual volume decreased by 13% after no pep, by 20% after low pep, and by 30% after high pep. there was no significant difference in sputum production or change in lung function between each technique as assessed by the physiotherapist. at the end of the trial, no significant difference was found between the programmes as regards growth, shwachman score, chrispin-norman score or pulmonary function tests. lung volumes were higher during breathing with an expiratory pressure of 15 cm h2o than with 5 cm h2o; both returned to baseline values immediately after positive expiratory pressure breathing. the differences were not statistically significant. no significant differences between the three cpt regimens for both wet and dry weights were found when the number of coughs was taken into account.(abstract truncated at 250 words) there was no significant difference in whole lung or regional tbc between the pd + fet and pep + fet treatments. during treatment a a significantly greater quantity of sputum was produced than during treatments b and c (p less than 0.025 and p less than 0.001 respectively). in terms of sputum expectorated, treatments b and c were superior to treatment d and especially to treatment a (p less than 0.05).|patients with airway hyperreactivity 10 patients with cystic fibrosis older patients individuals with cystic fibrosis (cf ten patients with cystic fibrosis patients with moderate to severe cf lung disease children with cystic fibrosis cystic fibrosis 15 patients who qualified, six completed the study fourteen patients with cystic fibrosis forty children with cf patients with cystic fibrosis patients with cystic fibrosis (cf patients with cystic fibrosis (cf) hospitalized for an acute pulmonary exacerbation twenty-eight patients suffering from cystic fibrosis, with an age range of 8-21 years patients hospitalized for pulmonary exacerbations of cystic fibrosis cystic fibrosis patients of five to 17 years of age with mild to moderate disease pediatric cystic fibrosis patients 18 patients with cystic fibrosis eight patients with cystic fibrosis nine clinically stable cystic fibrosis (cf) patients 5 patients with cf (mean age=18 years, sd=4, range=13-22) after no-pep, low-pep (10-20 cm h(2)o), and high-pep (>20 cm h(2)o) breathing conditions forty patients, ages 6 to 17 years, with shwachman scores between 52 and 93, attending the cystic fibrosis clinic sixteen patients with cf, 8 males, 8 females, aged 15-27 years (mean, 20.3 +/- 4), met the inclusion criteria: 1) age over 14 years; 2) mild or moderate airway obstruction; 3) sputum volume > 30 ml/day; 4) being proficient in pd and pep cpt 14 patients with cystic fibrosis most adolescent and adult patients 22 patients with cf (mean age 12 yrs, range 7-17 yrs) performed children with cf
survival curves percentage of patients alive survival rate median survival times toxicity longer survival period median time to progression histologic type (astrocytoma with anaplastic foci, versus glioblastoma multiforme), initial performance status, time since first symptoms and presence or absence of seizure survival long-term (18-month) survival longer survival longer survival time median time median survival severe myelotoxicity transient myelosuppression reversible leukopenia and thrombocytopenia total survival median survival time time to progression severe or worse thrombocytopenia cure rate|both relapse-free (p = 0.05) and total survival (p = 0.03) were significantly improved only in patients who were treated with radiotherapy plus ccnu compared to patients receiving radiotherapy alone after surgery. significantly longer survival was experienced by patients receiving procarbazine or bcnu alone compared to those receiving only high-dose methylprednisolone. the median time from diagnosis to crossover (groups 1 and 2) or to progression (group 3) was 163, 99, and 220 days, and the mean time was 172, 108, and 231 days. the combination of carmustine plus radiotherapy produced a modest benefit in long-term (18-month) survival as compared with radiotherapy alone, although the difference between survival curves was not significiant at the 0.05 level. the combination of methyl-ccnu + dtic was more toxic than bcnu, producing severe or worse thrombocytopenia in 23% of the patients as compared to 6% on bcnu. the percentage of patients alive at 18 and 24 months was 34% and 21% in group 2 compared with 21% and 12% in group 1. no severe myelotoxicity occurred, but combined treatment with ccnu and dbd occasionally caused a transient myelosuppression. tumor histological malignancy and patients age were found to be the only important prognostic factors, irrespective of the treatment modality.|358 patients in whom the initial protocol specifications were met (the valid study group malignant glioma after surgery 626 patients entered this protocol forty-one consecutive patients with supratentorial primary brain tumors (38 grade iii and iv astrocytomas, one giant-cell astrocytoma, and two cases with insufficient tissue for diagnosis patients with poor prognosis patients who were younger than age 40 years had an 18-month survival of 64%, patients who were age 40-60 years had an 18-month survival of 20%, and patients who were older than age 60 had an 18-month survival of 8 467 patients with histologically proved malignant glioma malignant gliomas adults with newly diagnosed supratentorial malignant gliomas 527 patients (87% with glioblastoma multiforme) in whom the initial protocol specifications were met (the valid study group 84 evaluable patients patients with anaplastic astrocytoma from september, 1972 to december, 1976, 102 consecutive patients operated on for glioblastoma multiforme patients with malignant glioma patients receiving radiation therapy alone was 61 91 patients with supratentorial glioblastomas and malignant astrocytomas high-grade supratentorial astrocytomas adults with malignant gliomas surgery plus radiotherapy for glioblastoma multiforme we enrolled 269 patients, 255 of whom were eligible 198 adult patients with supratentorial gliomas brain gliomas malignant glioma 609 patients with histologically demonstrated, supratentorial malignant glioma
bone turnover and bone mineral density efficacy, safety, and user satisfaction bmd and bmc of lumbar spine and femur and on bone metabolism urine hydroxyproline and creatinine ratio (hop/cr bmd loss serum and urinary calcium, osteocalcin (bgp), urinary pyridinoline and deoxypyridinoline bone geometry and volumetric bone mineral density (vbmd urinary levels of pyd and d-pyd bone turnover and bone mineral density (bmd percentage of change from baseline bone mineral density at the lumbar spine intermenstrual bleeding and spinal bone density bone mineral density and bone metabolism total body percentage of change from baseline bone mineral density urinary pyridinoline and deoxypyridinoline protein c antigen baseline bmd, body mass index (bmi) and difference in bmi bone metabolism and bone mineral density bone mineral density 2-year treatment-failure cumulative pregnancy rate greater trochanter maximum bone mass adverse events endometrial hyperplasia pyridinoline and deoxypyridinoline levels lumbar bone mineral density values incidence of bleeding anomalies bone turnover duration of bleeding days baseline demographic or anthropometric characteristics, or in bmd of users of either model of implant shbg levels lumbar bone mineral density spinal bmd values serum and urinary calcium, osteocalcin and urinary pyridinoline (pyd) and deoxypyridinoline (d-pyd) levels alkaline phosphatase bone formation mean lumbar spine bmd biological estrogenic effect bone resorption total triglycerides, hdl and hdl(2) cholesterol, and idl lipoproteins areal bmd lumbar spine bmd femoral neck lumbar bmd bone mineral density (bmd bone mineral density (bmd) and bone mineral content (bmc areal bone density levels of sex hormone-binding globulin (shbg mean bmd loss mean ntx urine concentrations total cholesterol forearm bone density (bmdprox bone turnover and bone-sparing effect bone mineral density (bmd) changes and contraceptive efficacy serum lipid and bone density patterns bone mineral density (bmd) and metabolic bone parameters bmd areal bone mineral density (abmd) of the femoral neck and the lumbar spine total cross-sectional area bmd and bmc of lumbar serum and urinary calcium, osteocalcin, urinary pyridinoline, and deoxypyridinoline bone density haemostasis, lipids, carbohydrates, bone metabolism, and sex hormone-binding globulin (shbg periosteal bone formation low-density lipoprotein cholesterol recovery of bmd skeletal effects urinary levels of pyridinoline and deoxypyridinoline, in calcium levels and in bgp levels total and ldl cholesterol, and apolipoproteins urinary levels of pyd and d-pyd, in calcium levels and in osteocalcin levels safe and well-tolerated bone density and bone metabolism urinary levels of pyr and d-pyr serum calcium levels urinary pyd and d-pyd levels shbg lumbar spine vertebral abmd bone resorption (urinary levels of pyridinoline (pyr) and dexoxypyridinoline (d-pyr maintaining bmd serum osteocalcin (bgp), urinary pyridinoline (pyd) and deoxypyridinoline (d-pyd radial trabecular vbmd|levonorgestrel releasing contraceptive subdermal implants were not deleterious to the skeleton in women of child-bearing age. adverse events were similar in the two groups except that injection site reactions were more common in the dmpa-sc group. radial trabecular vbmd declined by 1.4+/-1.8% in the deso group, while it remained unchanged in the levo group. bmd was significantly lower at 18 months of use at the midshaft of the ulna in both groups of users. during the 12 months of the study a significant decrease of urinary levels of pyr and d-pyr was found in 2 groups of young post-adolescent women taking the pills with 20 and 30 microg of ee2 in comparison with control women (subjects of the same age group with normal menstrual cycle who did not use contraception). pyridinoline and deoxypyridinoline levels were lower in group a than in group b throughout the study, but not significantly. increases were significantly greater (p <0.05) for protein c antigen (+11.8% vs. +6.1%) and shbg (+791 vs. +565 nmol/l), and significantly smaller (p <0.05, ranks) for d-dimer (+19 vs. +37 g fe/l). forearm bone density (bmdprox) increased with 2.94% (p = 0.006) in women who were prescribed levonorgestrel, which was in contrast to stable values in those prescribed depot-medroxy-progesterone acetate; group difference at 6 months for bmdprox 3.4% (95% ci 1.3, 5.5; p = 0.025) and bmddist 4.1% (95% ci - 1.3, 9.6; p = 0.077). no significant difference was detected between groups a and b in urinary levels of pyridinoline and deoxypyridinoline, in calcium levels and in bgp levels. no significant differences in urinary pyd and d-pyd levels were observed between groups a and b during the entire period of treatment. no significant difference was detected between group a and group b in urinary levels of pyd and d-pyd, in calcium levels and in osteocalcin levels. the direction of the change (increase or decrease) in all investigated bone-related variables was similar in both treatment groups. observed changes in bmd among dmpa users differed from women who used either type of pill (p < .002). a slight decrease in total triglycerides, hdl and hdl(2) cholesterol, and idl lipoproteins was observed with mesigyna. differences of lesser statistical magnitude were seen at the femoral neck (between group differences at 2 yr: 2.7%, p = 0.24), ward's triangle (5.0%, p = 0.055), greater trochanter (3.6%, p = 0.056), total body (1.3%, p = 0.046), legs (1.3%, p = 0.065), and trunk (2.0%, p = 0.029). at the femoral neck, the percentage of change from baseline bone mineral density was 4.7% in the estradiol cypionate group versus -5.1% in the placebo group ( p <.001).|one hundred twenty-three adolescents who began receiving adolescent girls who received twenty-seven subjects completed at least 18 months in the study, and 26 the full 2 yr, with similar numbers dropping out from each group (mainly for personal reasons young women 38 premenopausal women (mean age 37) with a minimum 2 yr dmpa use who had a below average baseline lumbar spine bmd (t score < or = 0 long-term users of depot young fertile women for contraception group; 36 women served as controls young postadolescent women 22 premenopausal women, age 32.6 (range 20-45 years fifty-two women (18-24 years volunteers participating in the study nineteen healthy fertile women adolescent girls who receive nineteen women 225 women completed the first 2 years of this study (dmpa-sc, n=116; dmpa-im, n=109 one hundred and eleven women, 19-43 years of age women receiving dmpa-sc (n=266) or dmpa-im (n=268) for 2 years with an option to continue for a third year 147 healthy women (age 18-49 years young, fertile women 40 women desiring contraception women of child-bearing age 33 women; 63 women who chose oral contraception female acceptors for 1 year 155 women were analyzed premenopausal users 48 volunteers aged healthy fertile women treated with 30 mcg women 18-33 years of age with those not using hormonal contraception 61 normal women of child-bearing age fifty-nine women who did not use hormonal contraception served as controls premenopausal women 2010 elsevier inc young post-adolescent women twenty patients underwent no treatment and were used as healthy controls (group c, n=20 healthy fertile women treated with 49 pre-menopausal women between 38 and 50 years, to 99 women fitted with an iud (nova-t
overall actuarial survivals died 3-year actuarial disease-free and overall survivals local control partial suppression of distant metastasis actuarial disease-free survival 5-year disease-free and overall survival 5-year overall survival suffered recurrences 5-year disease-free survival disease-free survival cardiotoxicity presenting as pulmonary edema overall actuarial survival freedom from local recurrence and/or metastases and overall survival vaginal recurrence distant metastases survival advantage actuarial percentage survival figures 3-year actuarial disease-free survival overall survival advantage survival congestive heart failure local recurrence relapse-free survival rates overall survival overall survival rates local control, metastasis-free survival, disease-free survival, and survival recurrence rates in specific cell types (leiomyosarcoma, homologous mixed mesodermal sarcoma, or heterologous mixed mesodermal sarcoma survival benefit actuarial 3-year overall survival local recurrence of disease local recurrence rate progression-free interval or survival|relapse-free survival rates were higher for cyvadic, 56% versus 43% (p = .007), and local recurrence was significantly reduced in the cyvadic arm at 17% versus 31% (p = .004). survival was not significantly different between adriamycin or control. local control was achieved in 46 patients (81%); 3-year actuarial disease-free and overall survivals were 67% and 77%, respectively. the difference between the two groups is statistically significant (p less than .005, log rank test). recent improvement in the survival of patients with soft-tissue sarcomas is not necessarily a result of adjuvant chemotherapy or radiation therapy. the 5-year disease-free and overall survival for patients treated with the reduced doses of chemotherapy was 72% and 75%, respectively, and was not significantly different from the high-dose regimen. the recurrence rates in specific cell types (leiomyosarcoma, homologous mixed mesodermal sarcoma, or heterologous mixed mesodermal sarcoma) were not significantly different although the pattern of recurrence differed, with pulmonary metastases being more common in leiomyosarcoma and extrapulmonary recurrence being more common in mixed mesodermal sarcoma. while a nonsignificant difference in local control, metastasis-free survival, disease-free survival, and survival was observed for extremity lesions, the advantage may be outweighed by the risk of cardiotoxicity. with a median follow-up of 40 months, there was no significant difference between the four treatment groups in overall survival (group 1, 75%; group 2, 70%; group 3, 69%; group 4, 73%), disease-free survival (group 1, 62%; group 2, 56%; group 3, 62%; group 4, 64%), or local tumor control (group 1, 92%; group 2, 92%; group 3, 87%; group 4, 90%).|dermatofibrosarcoma, lymphomas, myeloma, kaposi's sarcoma, and embryonal rhabdomyosarcoma were excluded as were patients with significant second primary cancers and those who received either preoperative or postoperative radiation therapy patients with high-grade soft tissue sarcoma 75 patients receiving seventeen patients received forty-two patients with localized intermediate and high-grade sarcoma 32 patients, 17 males and 15 females, with an age range of 17 to 75 years (median, 44 years after aggressive local treatment of high-grade sarcomas of the head, neck, breast, and trunk (excluding retroperitoneal sarcomas patients receiving uterine sarcomas high-grade soft-tissue sarcomas of the extremities in adult patients forty-seven patients with stage i, ii, or iii soft tissue sarcoma 172 control patients patients with extremity soft-tissue sarcomas patients with localized soft tissue sarcoma between january 1977 and june 1988, 468 patients entered this randomized study and 317 were considered eligible all patients after local treatment 145 eligible patients receiving eighty-eight patients were entered into this trial which has a median follow-up of 4.4 years high-grade soft tissue sarcoma between june 1975 and april 1981, 61 of the 177 eligible patients whose nonosseous sarcomas of extremity or trunk origin had been completely excised primarily or after local recurrences agreed to participate in a randomized study of sarcomas patients with high-grade extremity sarcomas patients undergoing 59 patients who entered the study, 79.1% in the adults with soft tissue sarcomas of the head and neck, breast, and trunk high-grade soft-tissue sarcomas of the extremities 156 evaluable patients with stage i (limited to the corpus) or stage ii (limited to the corpus and cervix) uterine sarcomas from january 1981 to february 1986, a total of 240 patients with primary, malignancy-grade iii or iv soft tissue sarcoma were entered into an adjuvant chemotherapy multicenter trial conducted by the scandinavian sarcoma group (ssg since 1977, 31 patients adult patients with soft tissue sarcomas patients with high-grade soft-tissue sarcomas of the extremity complete excision of nonosseous sarcomas patients with soft-tissue sarcomas
myasthenic muscular scores variation of a myasthenic muscular score (mss dropout rate duration of improvement qmgs, and ivig tolerated myasthenic muscular score mss variation quantified mg clinical score (qmgs qmgs efficacy and tolerance quantitative mg score (qmg qmg score for disease severity quantitative myasthenia gravis (qmg) score for disease severity|one week after the treatments, the patients who received plasma exchange treatment showed a significant improvement in qmgs compared to baseline but although some improvement was seen after ivig at day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. in ivig-treated patients, a clinically meaningful improvement in qmg score for disease severity was observed at day 14 and persisted at day 28. ig was better than that of pe with a total of 14 side effects observed in 9 patients, 8 in the pe group and 1 in the i.v. the dropout rate was the same for both treatment arms and both treatments were well-tolerated. however, the difference between the 2 groups was not significant (effect size, 3.84 [95% confidence interval, -1.03 to 8.71];|myasthenia gravis myasthenia gravis exacerbation myasthenia gravis (mg patients with chronic moderate to severe myasthenia gravis patients suffering from moderate to severe myasthenia gravis (mg) in a stable phase 84 patients with moderate to severe mg defined as a quantitative myasthenia gravis score for disease severity (qmgs) of >10.5 and worsening weakness to ivig (gamunex, talecris biotherapeutics) 1 g/kg/day for 2 consecutive days or plex (caridian spectra) 1.0 plasma volume exchanges for 5 exchanges eighty-seven patients with mg exacerbation adult patients with moderate to severe mg within 2 weeks of treatment classification of evidence patients with myasthenia gravis (mg one hundred seventy-three patients aged 15 to 85 years with acute exacerbation of myasthenia gravis twelve patients with generalized moderate to severe mg on immunosuppressive treatment for at least 12 months were included patients with worsening weakness due to myasthenia gravis fifteen patients were enrolled (6 to ivig; 9 to patients with myasthenia gravis (mg) and worsening weakness patients with moderate to severe mg 549-552, 2002 patients with myasthenia gravis fifty-one patients with worsening weakness due to mg
esr, tenderness on palpation and subjective pain efficacy and safety bone density activity indexes (esr and clinical parameters serum ca value duration of morning stiffness, number of joints with pain, number of joints with swelling and lansbury's index bone density (gs max, gs min and sigma gs/d bmc side effects percentage of patients with slight improvement mineral metabolism parameters (serum calcium, phosphorus, alkaline phosphatase, 24-h urinary calcium, phosphate and 24-h hydroxyproline excretion) and radial bone mineral content (bmc serum alkaline phosphatase and 24-h hydroxyproline excretion bone atrophy ratio of okt-4/okt-8|furthermore, serum alkaline phosphatase and 24-h hydroxyproline excretion decreased significantly only in group a, and bmc decreased significantly in group b but rose slightly in group a. the indexes of bone density (gs max, gs min and sigma gs/d) demonstrated that 1 alpha-oh-d3 prevents reduction in bone density.|140 patients with ra admitted to 31 institutes, using a induced osteopenia patients who had been treated with them before participating in the study (for oral steroidal preparations, the dose was limited to 5 mg/day or less as patients with rheumatoid arthritis (ra twenty-four patients (9 m and 15 f, age range 51-82) with polymyalgia rheumatica receiving
liver function tests consciousness semiquantitative nitrogen balance index of portal-systemic encephalopathy survival and discharge safety and efficacy encephalopathy driving capacity acute hepatic encephalopathy plasma aaa/baa ratio coma score mental state adverse reactions neuropsychologic function renal failure psychomotor disturbances negative nitrogen balance renal and two respiratory failure, and one remained encephalopathic cerebral state and on nitrogen homeostasis psychomotor functions (line tracing, tapping, steadiness, auditory reaction time), attention (digit table), and practical intelligence (digit symbol, number connection test recovery rate|the group receiving the modified amino acid mixture demonstrated a statistically significant improvement in encephalopathy as compared to the neomycin group, while maintaining nitrogen equilibrium. twelve patients (70.6%) in group a and eight (47%) in group b regained consciousness in a mean time of 27.6 and 31.5 hours, respectively. no significant difference was noted based on clinical evolution, even though the plasma aaa/baa ratio was corrected using the modified aa solution. the negative nitrogen balance on entry reversed in the amino acid group, but not in the glucose group. two or more parameters of the index improved in 24 patients treated with amino acids (80%; confidence limits, 61-92%), and only in 12 receiving casein (35%; confidence limits, 20-54%; p less than 0.001). branched-chain amino acids but not placebo significantly improved psychomotor disturbances (p < 0.01) and driving capacity (p < 0.002). taking into account the crossover design, significant improvements attributable to branched chain amino acid treatment could be demonstrated in psychomotor functions (line tracing, tapping, steadiness, auditory reaction time), attention (digit table), and practical intelligence (digit symbol, number connection test).|chronic hepatic encephalopathy thirty patients in the f080 group and 29 in the control group completed the trial 40 patients with grade 3-4 hepatic encephalopathy patients with chronic liver failure patients with stable cirrhosis and latent encephalopathy seventy-five patients with acute hepatic decompensation superimposed on chronic alcoholic cirrhosis 70 patients 65 patients with cirrhosis cirrhotic patients with chronic encephalopathy cirrhotic patients patients with severe hepatic encephalopathy seventeen patients with impaired driving capacity patients with cirrhosis hepatic encephalopathy chronic hepatic encephalopathy in cirrhosis acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a 19 patients with grade 3-4 hepatic encephalopathy 22 inpatients with liver cirrhosis and obtained evidence of latent (subclinical) portosystemic encephalopathy using an extensive psychometric test program 70 cirrhotic patients sixty-five patients
tidal volume lung compliance tidal volume and pulmonary compliance airway resistance pulmonary function measurements pulmonary mechanics birth weight lung compliance and decreased airway resistance urinary sodium, potassium, and chloride losses excretion of urinary electrolytes pulmonary resistance hypokalemia, chloride deficiency, hypercalciuria, nephrocalcinosis, and rickets urine volume efficacy and safety pulmonary function six hour urine output urinary electrolyte losses tidal volume and compliance diuresis or renal side effects urine output static respiratory compliance total respiratory resistance|there was no significant change in the pulmonary function measurements before treatment and 1 or 2 hours after treatment with either placebo or furosemide. doses of 1 mg/kg significantly improved lung compliance (51% at 2 hours after nebulization), pulmonary resistance (28% at 1 hour), and tidal volume (43% at 1 hour), starting as early as 30 minutes after the dose; the effect lasted for at least 4 hours in many of the infants and was not associated with diuresis or renal side effects. neither 1 nor 2 mg/kg of body weight of nebulized furosemide had any effect on airway resistance. single dose nebulised frusemide improves pulmonary function in premature infants with evolving chronic lung disease without adverse effects on fluid and electrolyte balance. also, tidal volume increased significantly by 33.8% and 28.7% at 1 and 2 h, respectively (p = 0.004 and 0.009).|ventilated premature infants ventilated infants with severe bronchopulmonary dysplasia premature infants with evolving chronic lung disease median postnatal age of 23 (range 14-52) days in 19 premature infants at 24 to 30 weeks gestational age, who had been dependent on mechanical ventilation since birth infants with chronic lung disease without excessive diuresis eight preterm infants with bronchopulmonary dysplasia who were supported by mechanical ventilation gestational age (mean ventilated preterm infants ventilated infants with bpd ventilator-dependent infants with severe bpd premature infants with evolving chronic lung disease and (b infants with chronic lung disease patients with asthma 9 infants with bpd, each serving as his own control infants with severe bpd who are ventilator dependent at 21 days of age premature infants with chronic lung disease pulmonary mechanics was studied at a mean postnatal age of 24 days (range 14 to 50 days) in 13 premature infants, 24 to 28 weeks' gestational age, who had been dependent on mechanical ventilation since birth infants with bronchopulmonary dysplasia 0.1 kg; age at study was 47 infants with bronchopulmonary dysplasia (bpd
cognitive function deteriorated cognitive function global functioning cognition cognitive performance as assessed using the eleven-item cognitive subscale of the alzheimer's disease assessment scale (adas-cog/11 cognition, daily function, and behavior improving cognition, including executive function efficacy and safety safety and tolerability adcs-adl score adas alzheimer's disease assessment scale-cognitive subscale (adas-cog/11) and the alzheimer's disease cooperative study-activities of daily living inventory (adcs-adl) total score activities of daily living efficacy clinician's interview based on impression of change-plus caregiver input (cibic-plus), neuropsychiatric inventory, and exit-25 for assessment of executive functioning|patients treated with galantamine had a greater improvement in adas-cog/11 after 26 weeks compared with placebo (-1.8 vs -0.3; p < 0.001). patients with ad + cvd treated with galantamine experienced statistically and clinically significant improvement in cognition at month 6 (mean change in adas-cog/11 score -1.1; p < or = 0.05 vs. baseline) and maintained their cognitive function for the entire 12-month study (mean change in adas-cog/11 score +0.1).|patients with vascular dementia two hundred and thirty-eight (84 two hundred and eighty-five patients with ad + cvd patients with alzheimer's disease plus cerebrovascular disease patients with vascular dementia (vad patients with ad + cvd 788 patients with probable vad who also satisfied strict centrally read mri criteria patients with alzheimer's disease plus cerebrovascular disease (ad + cvd or mixed dementia vascular dementia
risk of bond failures debonding time for gic frequency of failed brackets bracket failures survival time distributions bracket survival survival time and cariostatic potential strength of adhesion bracket failure rates bracket survival time|bracket failures for the cut groove base type occurred in 50 per cent with gic and 23 per cent with the acrylic, meshed foil bases failed in 22 per cent gic and in 7 per cent with the acrylic, respectively. the survival time distributions for brackets bonded with each bonding agent were not significantly different (p = .74, paired prentice-wilcoxon test; p = .75, akritas test), with bracket failure rates of 17% and 20% recorded for compomer and resin adhesive, respectively.|four hundred twenty-six brackets were bonded (213 with compomer and 213 with resin adhesive forty-five consecutive patients who attended for fixed appliance therapy 60 patients, with a mean age of 13 years 7 months (range 10 years 8 months to 19 years 1 month) were consecutively selected
cognitive and functional performance change in global cognitive function as determined by the alzheimer's disease assessment scale-cognitive subscale (adas-cog) and the mini mental status examination (mmse secondary endpoint montgomery asberg depression rating scale (madrs emotional symptoms of apathy and irritability cognitive function and quality of life cognitive and neuropsychological tests tests of information and orientation and various aspects of memory mini-mental state examination alzheimer's disease assessment scale--cognition cognitive tests, activities of daily living scale, neuropsychological battery and scales to evaluate caregivers' depressive and anxiety symptoms alzheimer's disease assessment scale - cognition (adas-cog relevance of discourse, (b) performance of functional abilities, (c) emotional symptoms, (d) quality of life, and (e) overall global function behavioural and functional outcomes quality of life - alzheimer's disease scales cognitive-communication, neuropsychiatric, functional performance, and quality of life evaluations cognitive and behavioural measures ig(mci negative emotional symptoms mmse score specific cognitive and psychopathological ratings cognitive and non-cognitive functions discourse abilities, functional abilities, emotional symptoms, and overall global performance backward digit span scores apathy, irritability, and patient-reported quality of life scores of mmse, osgp and gds psychiatric symptoms mini-mental state examination (mmse) scores|at follow-up the intervention group had significantly improved relative to the control group on the mini-mental state examination (p=0.044), the alzheimer's disease assessment scale - cognition (adas-cog) (p=0.014) and quality of life - alzheimer's disease scales (p=0.028). the group that received reality orientation followed by reminiscence therapy showed improvement in cognitive and behavioural measures which was not found in the other two groups. results confirmed previous investigation, cognitive and combined stimulation improved patients' performance throughout the 1st year; however, all groups deteriorated gradually throughout the 2nd year of treatment. at the end of the 3 months of therapy significant differences emerged in the scores of mmse, osgp and gds obtained by the two groups. the combined treatment group showed a better positive treatment effect on cognitive and neuropsychological tests applied to patients and reduction of psychiatric symptoms was observed in their caregivers (nonsignificant). sixty long-stay patients who were demented or withdrawn or both were randomly allocated to reality orientation or diversional occupational therapy and were assessed blind on two scales. at the end of the study, we found significant improvements in the ig(mci) compared to the cg(mci) in the adas-cog (p = 0.02) and for the secondary endpoint montgomery asberg depression rating scale (madrs) (p < 0.01) a group x time interaction was found for the donepezil-plus-stimulation group in the emotional symptoms of apathy and irritability as compared with the donepezil-only group. r.o. residents improved more on tests of information and orientation and various aspects of memory than controls. similarly for the alzheimer's disease assessment scale--cognition (treatment group mean change +0.4, s.e.=0.8; control group -2.5, s.e.=0.8; p=0.01).|people with dementia thirteen patients with mild alzheimer's disease treated with elderly confused people patients with alzheimer's disease one hundred and fifteen people alzheimer's disease 156 patients treated with patients with alzheimer's disease (ad patients with mild alzheimer's disease and their relatives forty-three subjects with amci and mild ad amnestic mild cognitive impairment and mild alzheimer's disease alzheimer's disease patients treated with twenty-three institutionalized subjects, confused and disoriented as to time, space and persons 68 subjects with mild alzheimer's disease underwent clinical and cognitive evaluation 201 older people with dementia sixty long-stay patients who were demented or withdrawn or both patients with mild alzheimer's disease and can reduce caregivers' psychiatric symptoms elderly people in a large residential home thirty-nine patients only group; n = 28) in 54 patients with mild to moderate alzheimer's disease (ad; mini-mental status examination score of 12- 28) ranging in age from 54 to 91 years older people with dementia group; n = 26 alzheimer's disease patients six patients residential home for the elderly mentally infirm with a 'social therapy' control group, receiving the same amount of staff attention as the r.o. group, in addition to an untreated control group elderly patients in the community subjects with amnestic mild cognitive impairment (amci) and mild ad patients amci subjects
caries increment effectiveness against caries incidence of dental caries dental caries incidence approximal dental caries dental caries|it was verified a reduction of 33.97% in the incidence of dental caries (in the permanent dentition). both the dentifrice and mouthrinse reduced the incidence of dental caries, but their combined use at the same time had no greater effect than either used alone. there was no significant difference in effectiveness against caries between the use of the organic or inorganic fluoride products. fluoride rinsing did not give any additional effect compared with placebo-rinsing when a fluoride dentifrice was used for home care. no statistically significant difference in caries increment during the two experimental years was found between the groups.|751 14- and 15-year old children completed a 3-year, double-blind, caries preventive program all 252 13-14-yr-old children at an elementary school preschool children 376 three-year old children approximal dental caries 246 students of both sexes aged from 7 to 11 years registered in "escola de educao bsica da universidade federal de uberlndia" and living in the urbana area of uberlndia, state of minas gerais, were examined
pain reduction pain, health and functional disability level flexion and pain sick-leaves and visits to health centers disability lvva-sm and hvla-sm intensity of low back pain, disability, handicap, medication, and quality of life pain and activity scores recurrent pain and moderate to severe symptoms visual analog pain scales and roland-morris activity scales rates of full compliance patient confidence pain relief mean functional status leg pain back pain roland morris disability questionnaire pain and better function roland-morris disability questionnaire (rmdq) and numerical rating scale sick-leaves pain and disability index regarding pain [risk difference stabilizing and flexibility exercises, the use of modalities, and cardiovascular training back pain and disability oswestry disability questionnaire oswestry disability scores patient-rated low back pain, disability, and functional health status average in functional status physical functioning and mental health dropout rate back pain, greater satisfaction with back care levels of disability and perceived pain mean pain intensity pain- and disability-score changes function (oswestry scale score decrease 6-month disability outcomes adjusted mean roland morris disability change scores low back pain intensity and disability patient-specific function (psfs, 3-30) and global perceived effect (gpe, -5 to 5) at 8weeks mean disability questionnaire scores leg and low back pain vertebral manipulation effectiveness pain improvement back pain and physical functioning and greater satisfaction mean improvement in rmdq perceived disability spinal flexion visual analog scale, range of motion, maximum voluntary extension effort, straight leg raising and biering-sorensen fatigue test physical outcome measures (range of motion, fatigue, strength or pain low back-related disability assessed with the 24-item roland morris disability questionnaire best extension effort and fatigue time relief from pain oswestry back pain index, neck disability index, short-form-36, and visual analogue scales sf-36 health survey, a 10-cm visual analog scale for overall back pain, the roland-morris disability questionnaire, lost work or school days because of back pain, and satisfaction with back care perception of pain and disability visual analogue scale (vas) for perceived pain, the roland morris (rm) questionnaire for low back function, and the sf-36 for overall health status average and most severe low back pain intensity in the past week, assessed with 0 to 10 numerical rating scales, and low back-related disability, assessed with the 24-item roland-morris disability questionnaire pain leg and low back pain intensity and disability (roland-morris disability questionnaire pain, disability, and perceived recovery pain scores fd measure of dysfunction physical functioning pain, general health and functional disability levels pain (visual analogic scale score decrease disability index|the mean changes in low back pain intensity and disability of participants in the medical and chiropractic care-only groups were similar at each follow-up assessment (adjusted mean differences at 6 months for most severe pain, 0.27, 95% confidence interval, -0.32-0.86; average pain, 0.22, -0.25-0.69; and disability, 0.75, -0.29-1.79). comparisons of initial and extended follow-up questionnaires to assess absolute efficacy showed that only the application of spinal manipulation revealed broad-based long-term benefit: 5 of the 7 main outcome measures showed significant improvements compared with only 1 item in each of the acupuncture and the medication groups. reduction in mean pain intensity at week 8 was 1.8 points greater for the chiropractic group than for the pain-clinic group (p = 0.023). motor control exercise and spinal manipulative therapy produce slightly better short-term function and perceptions of effect than general exercise, but not better medium or long-term effects, in patients with chronic non-specific back pain. there were no significant differences between groups on the roland morris and sf-36 outcome measures. pain scores were reduced to a significant degree within four weeks of starting treatment only in the group manipulated in the first treatment period. at the 3-month follow-up significantly more improved individuals were evident in the st group regarding pain, general health and functional disability levels. both manual therapy and the spinal stabilization program are significantly effective in pain reduction in comparison to an active control. individual group comparisons after 5 and 11 wk of intervention on all three main outcome measures did not reveal any clear clinically important or statistically significant differences. none of the changes in physical outcome measures (range of motion, fatigue, strength or pain) were significantly different between any of the groups. manipulative therapy also gave larger improvements in physical functioning (difference 0.6; -0.1 to 1.3). patients receiving the true manipulations showed significant improvement in pain (visual analogic scale score decrease from 71.8+/-18.11 to 49.37+/-16.78; p<0.001) and function (oswestry scale score decrease from 15.59+/-6.03 to 12.25+/-5.69; p<0.001). for subacute low back pain, combined joint manipulation and myofascial therapy was as effective as joint manipulation or myofascial therapy alone. the subjects who received sham manipulation also reported greater improvements in back pain and physical functioning and greater satisfaction than the no-intervention control subjects. visits to health centers for back pain were reduced only in the physiotherapy group (p =.01, wilcoxon test). at 7-week and 12-week follow-ups, statistically significant differences between the groups were found in all outcomes favoring the index group. exercise improved mean disability questionnaire scores at three months by 1.4 (95% confidence interval 0.6 to 2.1) more than "best care." at the 3-month follow-up point, significant improvements had occurred in all groups in leg and low back pain and in the disability index, but with no significant differences between the groups. biomechanically distinct forms of sm did not lead to different outcomes in older lbp patients and both sm procedures were associated with small yet clinically important changes in functional status by the end of treatment for this relatively healthy older population.|older patients for low back pain (lbp subjects with chronic low back disorder back pain in primary care chronic mechanical spinal pain syndromes patients with chronic (>13 weeks) spinal pain syndromes subacute low back pain persistent back and neck complaints chronic nonspecific low back pain patients with chronic low back disorder older lbp patients 134 subjects with low back disorders sixty-four patients participated in the study sub-acute and chronic low-back pain thirty-two patients with chronic low back pain 1,469 eligible patients, 681 were enrolled; 95.7% were followed through 6 months patients with subacute low back pain subjects, 18 years of age and older, with a primary complaint of low back pain (>3 months) were recruited 40 patients who had received exclusively the randomly allocated treatment for the whole observation period since randomization patients with clbp (i.e., symptom duration of >12 weeks) referred to a regional pain clinic (outpatient hospital clinic working adults patients with sub-acute or chronic low-back pain (lbp 199 subjects who responded to recruitment procedures, 91 met the eligibility criteria medical patients patients with chronic spinal pain syndromes adults 55 years and older with subacute or chronic low back pain low back pain patients presenting to a large managed care facility from october 30, 1995, through november 9, 1998 206 patients met the specific admission criteria, and 200 patients randomly received one of four treatments for 3 weeks multidisciplinary spinal pain unit of townsville's general hospital between february 1999 and october 2001 115 patients originally randomized, 69 had exclusively been treated patients with chronic non-specific back pain patients with low back pain patients consulting with back pain sixty-four patients patients with long-term back pain chiropractic patients older adults 256 patients with non-specific back and neck complaints of at least six weeks' duration who had not received national health service (nhs) hospital outpatient clinic (pain clinic) in the united kingdom university-based clinic from 2000 through 2001 patients with persistent non-specific back and neck complaints randomization placed 12 patients in the pain clinic and 18 in the chiropractic group, of which 11 and 16, respectively, completed the trial one hundred fourteen ambulatory patients of working age with back pain for 7 weeks or more chronic low-back pain in a national health service outpatient clinic back and neck pain patients chronic low back pain 346 subjects forty-seven patients back and neck pain two hundred and forty adults with non-specific low back pain 3months patients with chronic back pain two hundred forty participants (105 women and 135 men) ages 63.1 patients suffering with chronic low-back pain (clbp) when managed in a hospital by either a regional pain clinic or a chiropractor patients with femoral or sciatic root pain prolonged back pain participants at least 55 years old with subacute or chronic nonradicular lbp 235 subjects met the inclusion/exclusion criteria and signed the informed consent 181 general practices in medical research council general practice research framework; 63 community settings around 14 centres across the united kingdom four hundred and nine patients with pain and disability in the back or neck lasting for at least 2 weeks, recruited at 2 large public companies in sweden in 2005 chronic low back disorder low back pain patients in managed care participants with acute to chronic first or recurrent low back pain, excluding those with "red flag" criteria chronic low back pain (clbp 174 patients aged 20-60 yr were admitted to the study 1334 patients consulting their general practices about low back pain
seizure-free dizziness (0/14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), mood instability|in the lev group, 13 patients (87%) were seizure-free.|postoperative control of glioma-related seizures glioma-related seizure control following craniotomy 29 patients
c-reactive protein; interleukin-6 before, during, and after surgery; intensity and duration of postoperative pain; and complications and recovery period intensity of pain intensity of postoperative pain and the length of convalescence mean blood loss operative and hospitalization times and postoperative course mean hospitalization demographic characteristics intensity of postoperative pain relative risk for intraperitoneal spillage surgical difficulty recurrence of ovarian teratomas postoperative pain and minor complications milder pain, faster hospital discharge frequency of inadvertent rupture of the ovarian masses surgical times, estimated blood loss, post-surgical pain, time in hospital, speed of recovery and complications hospitalization time endometriotic cysts and dermoid cysts operative morbidity, postoperative pain, analgesic requirement, and recovery period levels of the interleukin-6 and c-reactive protein operative time, intraoperative complications, ileus, length of stay and recovery time intraoperative rupture rate of the cyst operative times post-surgical pain operating time post-operative pain, duration of stay in hospital and duration of convalescence recurrence of mature ovarian teratomas operative morbidity size of ovarian masses, adnexal adhesion score, or frequency of bilateral disease postoperative pain and analgesic requirement, hospital stay, and recovery period postoperative stay|there were no differences in demographic characteristics between the two groups nor any difference in the size of ovarian masses, adnexal adhesion score, or frequency of bilateral disease. post-surgical pain was significantly less in laparoscopy patients (p<0.05). laparoscopically guided minilaparotomy, when compared with laparoscopy, is able to reduce intraperitoneal spillage in patients with presumably benign large adnexal masses, with minimal increase in patient short- and long-term discomfort. forty premenopausal non-pregnant women with a unilateral teratoma no larger than 10 cm were randomised to laparoscopy or laparotomy. the levels of the interleukin-6 and c-reactive protein differed significantly between the 2 operative procedures (p = .013) in favor of the laparoscopic approach. concerning postoperative outcomes, postoperative pain and minor complications were significantly less in patients undergoing laparoscopy (p=0.001 and 0.04). no complications were reported in either group. the intensity of postoperative pain was significantly lower (p < .05) in the operative laparoscopy group than in the laparotomy group.|127 patients affected by adnexal cysts forty premenopausal, nonpregnant women, 18-40 years of age and without acute pelvic symptoms, were scheduled to undergo surgical management of anechoic, unilateral, unilocular, persistent adnexal cysts from january 1993 through june 1994 at the department of obstetrics and gynecology of the university of cagliari, cagliari, italy sixty eligible patients affected by nonendometriotic adnexal cysts with diameter between 7 and 18 cm women with dermoid cysts patients with presumably benign large adnexal masses dermoid cysts at the gynecology department of siena university between 1 january 1992 and 31 december 1996 benign adnexal cysts 50) in a teaching hospital from july 1994 to september 1995 forty premenopausal non-pregnant women with a unilateral teratoma no larger than 10 cm benign ovarian masses patients who were analgesic-free on day 2, discharged from hospital within 3 days, and feeling fully recuperated on day 15 tertiary referral center from january 2005 to september 2006 hundred and twenty-seven patients thirty-eight women with benign ovarian dermoid cyst patients older than 60 years old patients over 60 years old large adnexal masses nonendometriotic benign adnexal cysts twenty patients with a benign ovarian tumour elderly patients ovarian dermoid cysts 102 patients requiring surgical management of ovarian masses
patient global assessment of response to therapy (pgart) at 6 hours, onset of analgesia, peak analgesic effect, and duration of analgesia pain relief and intensity pain intensity, pain relief, and global assessments analgesic efficacy and tolerability profile faster onset of analgesic effect overall analgesic effect was total pain relief over 6 hours (topar6 supplemental analgesia sooner perceptible pain relief, and patient evaluations of pain intensity, pain relief, and global assessments pain intensity and pain relief for 24 h using visual analogue scales (vas) and verbal rating scales (vrs gastrointestinal safety profile 24-h pain severity scores total pain relief over 8 h (topar8 longer median time to use of rescue medication median onset of analgesia duration of effect duration of analgesic effect duration of analgesia pain intensity, pain relief, and global evaluations topar12 scores severe pain time to rescue medication tolerability nausea, postextraction alveolitis, and vomiting number-needed-to-treat (nnt shorter time to onset of analgesia median times to use of rescue medication peak pain relief score median times to confirmed perceptible pain relief total pain relief median times to first rescue medication adverse events scores [topar8, topar12, spid8, spid12, and patient's global assessment gastrointestinal and nervous system adverse events global assessment, onset of analgesia, or aes adverse events and nausea median times to meaningful pain relief total pain relief (topar) score over 8 hours (topar8; primary end point), topar score over 12 hours (topar12), sum of pain intensity difference (spid) over 8 and 12 hours (spid8 and spid12), patient's global assessment of study drug at 8 hours, time to confirmed perceptible pain relief (ie, time to onset of analgesic effect), peak pain intensity difference (pid), peak pain relief, time to first dose of rescue medication (ie, duration of analgesic effect), and percentage of patients using rescue medication pain relief analgesic activity pain severity overall analgesic effect, onset of action, peak effect, and duration of effect frequency of patient-reported adverse events supplemental analgesia mean topar12 scores meaningful pain relief peak pain relief summed pain intensity difference pain on global evaluations time-weighted pain relief score scores of pain intensity, pain relief, and global assessment at prespecified time intervals efficacy total pain relief over 6 hours (topar6, the primary end point) and 4 hours (topar4), patient's global assessment of treatment at 6 hours (global6) and 24 hours (global24), summed pain intensity difference over 6 hours (spid6), onset of analgesic effect (time to perceptible/meaningful pain relief, using a 2-stopwatch method), peak pain relief (peakpr), peak pain intensity difference (peakpid), and duration of analgesic effect (time to use of rescue analgesia maximum pain relief adverse experiences of nausea greater topar8 scores nausea and vomiting onset of analgesia analgesic onset and peak pain intensity difference and pain relief scores peak pain relief scores efficacy and tolerability analgesic efficacy and adverse effects tolerated postsurgical pain longer duration of analgesic effect brief pain inventory severity orthostatic blood pressure total pain relief over 8 hours (topar8) and 24 hours (topar24) and patient global assessments analgesic effect peak pain relief and peak pid moderate postoperative pain time to rescue analgesia adverse events overall pain, osteoarthritis, and rheumatoid arthritis dizziness onset of analgesic effect median time to use of rescue medication analgesic efficacy and tolerability supplemental narcotic analgesia tolerated and adverse events overall analgesic efficacy dizziness and orthostatic blood pressure reduction maximum possible pain relief peak analgesic effect analgesic effects level of pain and pain relief total pain relief (totpar time-weighted sum of total pain relief peak effects time to confirmed perceptible pain relief quicker onset of analgesia topar6 overall efficacy (total pain relief and patient global assessment adverse-events (ae) profile interference domain tolerated; the overall incidence of adverse experiences duration of action time to rescue medication, time to pain relief, and mean pain intensity difference (mpid), as well as safety profile time to onset of effect nausea pain relief, and lower pain intensity total pain relief over 8 hours (topar8 vomiting rescue analgesia overall analgesic effect incidence of clinical and drug-related adverse events pain and inflammation onset of action mpid patient global assessment for rofecoxib mean time-specific pain intensity difference and pain relief scores onset of analgesia, pain intensity levels, and pain relief over 24 hours, time-weighted sum of total pain, sum of pain intensity difference, the percentage of patients requiring rescue medication and experiencing regimen failure, and patients' global evaluation median time to first rescue medication topar over 6 h; spid clinical adverse experiences (aes) and vital signs overall analgesic effects, onset of analgesia, and peak analgesic effects moderate pain onset of analgesia, peak pain relief, and duration of response adverse experiences analgesic efficacy analgesic effect and peak analgesic effect topar12 total pain relief, onset time, and duration of response total pain relief (topar), sum of pain intensity difference (spid), and patient global assessment of response to therapy (pgart pain ex vivo cox-isoform specific assays (serum thromboxane b2 [txb2 adverse experiences, physical findings, and laboratory measurements safety profile adverse effects topar4, patient global assessment, peak pain relief, and duration of analgesic effect time to meaningful pain relief|significantly more patients in the codeine/acetaminophen group than in the rofecoxib group experienced adverse events overall (p < 0.050) and nausea in particular (p < 0.001). paracetamol and rofecoxib combined improved the analgesic effect compared with rofecoxib alone for the first 1.5 h. rofecoxib alone and the combination of paracetamol and rofecoxib had a significantly better analgesic effect than paracetamol alone from 3 h onwards. rofecoxib 50 mg exhibited overall analgesic effects, onset of analgesia, and peak analgesic effects that were not significantly different from those of ibuprofen 400 mg, with a significantly longer duration of action (p < 0.05). all active treatments showed greater improvement than placebo (p < .001) rofecoxib provided superior analgesic efficacy compared with codeine/acetaminophen with fewer gastrointestinal and nervous system adverse events. time to onset of analgesic effect and peak analgesic effect were similar for rofecoxib 50 mg and celecoxib 400 mg. mg had similar analgesic efficacy as equimolar doses of naproxen, but noninferiority to rofecoxib was not demonstrated. rofecoxib patients used significantly less (p < 0.001) supplemental analgesia than placebo patients over days 2-3 (1.1 tablets/day vs. 2.1 tablets/day) and days 2-5 (0.9 tablets/day vs. 1.8 tablets/day). patients receiving valdecoxib experienced a significantly quicker onset of analgesia, significantly improved pain relief, and lower pain intensity compared with patients receiving rofecoxib and greater satisfaction with their study medication after a single dose. the results showed that compared with celecoxib, rofecoxib had superior analgesic effects on all measures of analgesic efficacy, including overall analgesic effect (topar8, 18.3 vs. 12.5; p<0.001), time to onset of effect (30 vs. 60 minutes; p = 0.003), peak pain relief (score, 2.8 vs 2.3; p<0.05), and duration of effect (>24 vs. 5.1 hours; p<0.001). patients treated with oxycodone/ acetaminophen had a shorter time to onset of analgesia than patients treated with rofecoxib (24 vs 35 min, p < 0.05). the analgesic effect of rofecoxib was significantly greater than that of oxycodone/acetaminophen at p < 0.001 for topar6, topar4, global6, global24, and spid6; at p < 0.010 for peakpr and peakpid; and at p < 0.001 for median time to use of rescue analgesia. onset of action was significantly faster with valdecoxib 40 mg (30 minutes) compared with rofecoxib 50 mg (45 minutes), as measured by pain intensity difference and pain relief scores (p <or= 0.05). rofecoxib and dexketoprofen trometamol are effective treatments for acute pain using a dental pain model and are well tolerated. patient global assessment at 8 hours was also significantly better for rofecoxib compared with enteric-coated diclofenac sodium and placebo. rofecoxib 50 mg was superior to placebo (p < .05) and similar to naproxen sodium for all single-dose measures of pain relief. there were no significant differences in total pain relief at 4 or 8 hours, patients' global assessment, onset of analgesia, or aes between active treatments in either study. patient global evaluation of lumiracoxib was comparable to rofecoxib and superior to celecoxib and placebo. although analgesic onset and peak were significantly better for h/a than for both rofecoxib (p < 0.01, p < 0.05, respectively) and placebo (p < 0.05, p < 0.001, respectively), rofecoxib patients used significantly less rescue analgesia (p < 0.001) over 24 h. rofecoxib also provided better brief pain inventory severity (p = 0.008) and interference domain (p = 0.045) scores at 24 h compared to placebo and had lower 24-h pain severity scores than h/a (p < 0.05). adverse effects were uncommon, though post-extraction alveolitis (dry socket) occurred more often with rofecoxib 50 mg than with placebo, nnh 24 (14 to 80).|patients experiencing moderate or severe pain after the surgical extraction of > or = 2 third molars, at least 1 of which was a mandibular impaction patients in both studies were female (approximately 54%) and white ( approximately 66%), with a mean age of approximately 22 years and a mean weight of approximately 75 kg n = 155 post-orthopedic surgery pain patients with moderate to severe pain after surgical extraction of >or= 2 third molars, including one mandibular impaction patients with moderate to severe pain after dental surgery patients undergoing oral surgery patients with moderate to severe postoperative pain in the third molar extraction model acute postoperative dental pain acute pain treating pain after dental surgery patients undergoing extraction of > or =2 third molars, with > or =1 mandibular impaction, who experienced moderate or severe pain after extraction 282 patients patients with moderate-to-severe post-operative dental pain adults and adolescents with postoperative pain after third molar extraction two hundred twelve patients (63% female, 37% male; 76% white, 24% other; mean [sd] age, 20.9 [4.4] years; age range, 16-41 years patients experiencing moderate or severe pain received acute postoperative dental pain after the removal of an impacted mandibular third molar (ie, wisdom tooth patients with pain after dental surgery post-operative dental pain enrolling patients experiencing moderate or severe pain after knee arthroscopy patients with postoperative dental pain 200 patients 51 patients postoperative dental pain 271 patients treating pain after arthroscopy of the knee patients experiencing moderate to severe pain after the surgical extraction of > or = 2 third molars 120 patients undergoing surgical removal of a single mandibular third molar at the edinburgh dental institute 58% (164/282) were women; the mean (sd) age was 27 (6.4) years, mean weight was 71 kg, and mean (sd) bmi was 24.2 (3) kg/m2 surgical dentistry two hundred eighteen patients enrolled post-bunionectomy pain 120 patients with moderate to severe pain after third molar surgery a total of 393 patients were enrolled; 182 received patients with moderate to severe pain associated with oral surgery patients with acute postoperative dental pain 252 patients with moderate-to-severe pain the day after first metatarsal bunionectomy 52% (126/242) were women; the mean (sd) age was 25.1 (4) years, mean weight was 69.0 kg, and the mean (sd) body mass index (bmi) was 23.7 (3) kg/m2 two hundred and seventy-two patients experiencing pain after the removal of > or =2 third molars patients experiencing moderate to severe postoperative pain after extraction of > or =2 third molars (including > or =1 mandibular impaction patients who experienced moderate or severe pain after surgical extraction of at least 2 third molars acute pain relief after third molar surgery acute pain following oral surgery 305 patients patients with moderate-to-severe postoperative pain ambulatory patients 482 patients (358 females, 124 males; mean age, 22.1 years) were enrolled acute postoperative pain patients with moderate to severe pain after oral surgery 242 patients acute pain after bunionectomy surgery acute dental pain patients (n = 390) experiencing moderate or severe pain postextraction of 2 or more third molars, with at least 1 mandibular impaction 102 patients with dental pain patients with post-arthroscopic pain acute postsurgical pain patients following oral surgery 151 patients (50.3% women; mean age, 18.3 years; 93.4% white) experiencing moderate-to-severe pain post-dental surgery pain
hearing loss health status number of hospital acquired infections body mass frequency of problem detection or intervention average weight cost-effectiveness frequency of dietician referral costs number of patients with pressure sores malnutrition/weight loss, visual impairment, hearing loss, cognitive impairment, urinary incontinence, depression, physical limitations, and reduced leg mobility nutritional status, hospital-acquired infections and pressure sores detection of, and intervention for conditions screened, and health status 6 months admittance and discharge and hospital-acquired infections and pressure sores were scored and costs related to nutrition, infections and length of hospital stay frequencies of dietician referral and documentation of weight|the number of hospital acquired infections was significantly lower in the intervention group (33/140 versus 58/158, p=0.01) but no significant difference in number of patients with pressure sores (23/140 versus 33/158) was found. a brief measure to screen for common conditions in older persons was associated with more frequent detection and follow-up assessment of hearing loss. the nurses in charge of the wards felt that introduction of the screening tool had raised awareness of nutrition-related care.|twenty-six community-based office practices of internists and family physicians in los angeles district general hospital older persons seen in office practice two hundred and sixty-one patients aged > or = 70 years and seeing these physicians for a new visit or a physical examination participated in the study two similar general medical wards in a united kingdom (uk) district general hospital, with the help of staff and patients (n = 175) admitted during two study periods, may 1999 and january 2000 older people geriatric inpatients to prevent malnutrition all non-terminally ill patients admitted for more than two days were included 298 older patients (>60 years older persons inpatient geriatric service of a university hospital (umc nijmegen) and a geriatric ward of a non-academic teaching hospital (rijnstate hospital, arnhem
incidence of tumor lysis syndrome area under the serial plasma uric acid concentration curves hyperphosphatemia antirasburicase antibodies tls or anuria initial uric acid level metabolic problems rate of renal and metabolic complications renal dialysis highest risk to develop a tls anuria efficacy, safety, and pharmacokinetic profile of rasburicase response rates metabolic problems that included hypocalcemia initial plasma uric acid levels plasma uric acid severe allergic reaction to urate-oxidase uric acid levels blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count metabolic complications tls incidence of sepsis acute renal failure incidence of tls and anuria|rasburicase is effective and well tolerated for the management of hyperuricemia in japanese pediatric patients at high risk of developing tls. initial uric acid level decreased significantly by 4 hours (from 343 micromol/l to 58 micromol/l, p<0.001), except for one steroid-resistant patient who required hemodialysis on day 14 after having introduced combined cytostatic treatment. in the other 27 cases, metabolic problems were successfully resolved using urate-oxidase in combination with alkaline hyperhydration. for pediatric patients with advanced stage lymphoma or high tumor burden leukemia, rasburicase is a safe and effective alternative to allopurinol during initial chemotherapy. patients with b-all had the highest risk to develop a tls (26.4%) followed by b-all/burkitt's lymphoma and a ldh > or =500 u/l (14.9%).|patients with b-cell lymphoma and leukemia, treated in the socit franaise d'oncologie pdiatrique lmb89 protocol children with advanced stage burkitt's lymphoma/leukemia children with non-hodgkin's lymphoma (nhl children with leukemia and non-hodgkin's lymphoma children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-hodgkin's lymphoma children with leukemia and lymphoma 410 patients with stage iii and iv b-cell nhl and l3 leukemia treated in france and prospectively registered in the lmb89 protocol patients aged <18 years at high risk for tls, with newly diagnosed hematologic malignancies pediatric patients with advanced stage lymphoma or high tumor burden leukemia japanese patients patients with hematologic malignancies pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome patients at high risk for tumor lysis who received rasburicase compared to from november 1997 all children with b-all or stage iii and iv b-nhl and ldh > or =500 u/l should receive patients with b-cell advanced-stage non-hodgkin's lymphoma (nhl) and l3 leukemia at initiation of chemotherapy including the use of urate-oxidase children with b-cell acute lymphoblastic leukemia (b-all) or stage iii/iv burkitt's lymphoma and a lactate dehydrogenase (ldh) level > or =500 u/l before and after the introduction of a protocol amendment to use urate oxidase for the prophylaxis of tls 12 patients receiving rasburicase with that of a historic cohort of 14 patients treated with 1791 children with nhl enrolled in the two subsequent multicenter studies nhl-bfm 90 and 95 were evaluated children with lymphoma or leukemia at high risk for tumor lysis japanese pediatric patients at high risk of developing tls pediatric patients with hematologic malignancies pediatric patients with leukemia or lymphoma at high risk for tumor lysis
apgar score, cord blood gas analysis, and neurobehavioural assessment gastric secretion intragastric ph less gastric ph less pain relief pain intensity score on sitting and sedation alkaline values of gastric ph nalbuphine consumption risk of acid aspiration ph values of gastric fluid effective means to control and neutralize gastric secretion gastric ph and aspirated gastric volumes gastric ph smaller volumes of aspirated gastric contents gastric content narrowest range of ph values of gastric contents mean gastric ph neutralize acidity mean ph gastric volume and ph intragastric ph and volume volume and ph of the gastric contents mean ph1 and ph2 values higher intragastric ph but larger intragastric volumes gastric contents pi ph median gastric fluid ph volume of the gastric content innate ph of gastric juice incidence and severity of nausea and vomiting gastric volume mean ph1 and mean ph2 values gastric volumes adverse effects risk of acid aspiration of gastric contents gastric aspirate ph and volume|the use of sodium citrate resulted in higher intragastric ph but larger intragastric volumes (p less than 0.05). at induction of anaesthesia, treatment was judged successful (ph > or = 2.5 and volume < 25 ml) in 87%, 73%, 100% and 81% of patients in groups 1-4 respectively. no adverse effects were observed in newborn infants whose mothers had received cimetidine and there was no significant difference in ph values of gastric fluid from the newborn in the two groups. mean ph in patients receiving omeprazole was significantly higher (p < 0.001) than in the control group. seven patients in the cimetidine group and four in the antacid group had gastric volumes in excess of 50 ml after induction of anaesthesia, while two patients in each group had gastric ph less than 2.5 after induction. sodium citrate 0.3 mol litre-1 mixture resulted in the narrowest range of ph values of gastric contents (mean (a) 5.4, (b) 5.9; range 3.9-7.7). at 10 min, none patient in group c had a gastric ph less than 2.5, in the opposite to 92% of patients in the control group t. the alkalinizing effect of the citrate lasted throughout the evaluation time. percentages of patients with ph1 less than or equal to 2.5 in groups 1, 2 and 3 were, respectively, 75, 13.8 and 1.6. six patients (19%) in the ranitidine group had aspirates of ph less than 3.5, a significant difference from the omeprazole group (p less than 0.05). pi ph in patients receiving ranitidine/citrate (mean 5.2, sd 0.8) was significantly higher than in patients receiving citrate alone (mean 4.9, sd 1.1). patients receiving omeprazole in single oral dose regimen retained a greater gastric volume (> or = 0.4 ml/kg) than those who received famotidine or ranitidine (p < 0.005). gastric ph was significantly higher in the short interval group than in either the control group or in patients receiving their sodium citrate more than 60 min in advance. nalbuphine consumption in the first 24 h after operation was reduced by 35% in the tramadol group. the gastric ph was found to be higher after omeprazole than after ranitidine immediately after intubation (5.89 +/- in the cimetidine treated group only one patient had a gastric ph below 2.5, while in the control group 11 patients had a ph below this limit.|mendelson's syndrome before elective caesarean section women undergoing emergency caesarean section patients undergoing elective caesarean section obstetric patients undergoing emergency caesarean section gastric contents during general anaesthesia for elective caesarean section elective obstetric anaesthesia patients undergoing elective caesarean section received eitherrr 282 patients in the study group and 259 in the control group women undergoing elective caesarean section one hundred and sixty patients undergoing elective cesarean section under spinal anesthesia one hundred and forty-seven patients undergoing elective or emergency caesarean section under general anaesthesia pregnant patients with the need for preventative measures against aspiration during the induction of anaesthesia obstetric anaesthesia obstetrics one hundred and sixty-two chinese women undergoing emergency caesarean section elective cesarean section elective caesarean section aspiration pneumonia in obstetrics 30 parturients provided for elective cesarean section 52 unpremedicated women undergoing elective caesarean section under general anaesthesia at emergency cesarean section mothers undergoing emergency cesarean section under general anesthesia 78 obstetric patients during elective (a), or emergency (b) surgery obstetric patients given before caesarean section under general anaesthesia thirty-two healthy term parturients undergoing elective cesarean section randomly received either elective cesarean section patients parturients prophylaxis against aspiration pneumonitis in emergency caesarean section 17 patients undergoing elective caesarean section sixty-five women scheduled to undergo elective caesarean section under general anaesthesia regional anesthesia for elective cesarean section patients with both ph < 3.5 and volume patients with gastric volume > 25 ml and ph 80 consecutive women undergoing emergency caesarean section i parturients undergoing elective caesarean section elective cesarean section under regional anesthesia
forced expiratory volume forced expiratory volume in one second (fev1) and forced vital capacity (fvc mucus clearance and lung function fvc and secondarily on fev(1), fef(25-75), the number of days on antibiotic therapy, the shwachman score, a nutritional index (weight/height(2)), the change in sputum bacterial flora, and nocturnal cough forced vital capacity (fvc), forced expiratory volume in 1 sec (fev(1)), and forced mid-expiratory flow (fef(25-75 fev1 time to reach peak fev1 total lung capacity (rv:tlc respiratory function 1-hour rates of mucus clearance forced vital capacity (fvc), the forced expiratory flow 24-hour rates of mucus clearance mucus clearance and improved lung function lung function frequency of infective exacerbations volume of airway surface liquid, restore mucus clearance, and improve lung function forced expiratory volume in one second, forced vital capacity, oxygen saturation, body weight, sputum volume, culture and rheology, serum urea, and electrolytes, white cell count and erythrocyte sedimentation rate bronchopulmonary exacerbations respiratory symptoms time to reach peak fvc|no significant changes occurred in forced expiratory volume in one second, forced vital capacity, oxygen saturation, body weight, sputum volume, culture and rheology, serum urea, and electrolytes, white cell count and erythrocyte sedimentation rate during either treatment period. both forced expiratory volume in one second (fev1) and forced vital capacity (fvc) showed improvements over the course of treatment, although there was no difference in respiratory function between the two groups at any of three time periods during the study. a comparison of the changes in lung function in the two groups showed no significant difference. the effects on fvc and secondarily on fev(1), fef(25-75), the number of days on antibiotic therapy, the shwachman score, a nutritional index (weight/height(2)), the change in sputum bacterial flora, and nocturnal cough were assessed.|sixty-four patients were chronically colonized with pseudomonas aeruginosa patients with cystic fibrosis cystic fibrosis patients more than 5-years-old (n = 137 cystic fibrosis with hypertonic saline respiratory exacerbations of cystic fibrosis patients chronically colonized with pseudomonas received cystic fibrosis patients 23 patients with cystic fibrosis 27 cystic fibrosis patients (mean age 12.8 years 24 patients with cystic fibrosis two hospitals in leeds, uk fourteen patients completed the study
abnormal epithelial changes rocket samples cytological detection of persistent cervical intraepithelial neoplasia red blood cells number of positive papanicolaou smears endocervical or metaplastic cells endocervical cell pickup rates dyskaryotic smears condyloma, dysplasia, and cancer; dysplasia and cancer; moderate dysplasia, severe dysplasia, and cancer cytologic abnormalities rate of cervical intraepithelial neoplasia (cin) diagnosis production of smears containing endocervical cells (ec detection rate of dyskaryosis risk of bleeding effectiveness in obtaining satisfactory papanicolaou smears cervical intraepithelial neoplasia cervex-brush adequacy of ectocervical smears concentration of endocervical cells endocervical cells serious adverse events percentage of smears containing endocervical cells yield of endocervical cells efficacy rate of adequate smears number of adequate smears cellular composition of cervical smears incidence of scanty or unsatisfactory smears success rate multispatula samples rate of any pathology detection rate of cervical condyloma acuminatum and squamous dysplasia presence of columnar cells or squamous metaplasia rates of condyloma and dysplasia detection rate epithelial abnormalities incidence of smears with endocervical cells contain immature metaplastic cells bloody papanicolaou smears incidence of smears containing cylindrical and/or metaplastic cells proportion of smears containing one or other type of indicator cell sensitivities of cervical cytology detection of grade iii cervical intraepithelial neoplasia (cin iii presence or absence of endocervical cells rate of pathology and abnormal cytology number of moderately and severely atypical epithelial changes endocervical cells, and rate of cervical neoplasia endocervical detection of cin cellular quality of the smears false negative rate detection of endocervical cells smear quality and endocervical cell recovery endocervical cell yield|there was an increased detection of endocervical cells in pregnant patients with both the cytobrush and modified ayers spatula (90.7%) and the cervex-brush (83.3%) methods, compared with the cotton swab and modified ayers spatula (70.8%) (p = .0001 and p = .0233, respectively). the efficiency of the spatula in obtaining dyskaryotic cells and improving the cellular quality of smears was compared with that of the ayre spatula in a controlled trial. five of the 15 cytologically positive cases had histologic verification; the cytologic findings were predictive of the histologic findings in all. among smears obtained with the spatula plus swab, the rate of any pathology was higher in smears that contained endocervical cells than in smears in which endocervical cells were absent (2.0 versus 0.6%; p = .009). there was no statistically significant difference between the cytobrush-ayre spatula and the cervex brush sampling methods were equally effective in obtaining endocervical cells in papanicolaou smears. at the first screening, a significantly higher number of epithelial abnormalities was found in smears with endocervical columnar cells than in smears without endocervical columnar cells. the cervex smears were superior in quality of spread, transformation zone sampling in all degrees of cervical patency and in detection of histologically proven epithelial abnormalities, with a false negative rate of 10.9% compared with 20% for the ayre. we concluded that the multispatula produces a better quality smear which results in a decreased false negative rate in comparison with the ayres spatula. within each subgroup the endocervical brush consistently produced a higher number of adequate smears than did the cotton swab: after cryosurgery, 86% vs. 82%, p = .7242; after laser ablation, 95% vs. 88%, p = .61; after conization, 76% vs. 47%, p = .0675. endocervical cells were found more often and in greater numbers with cytobrush, also in women over 50 years of age. selecting which cervices should be samples ectocervically and which need combined sampling does not significantly improve the yield over ectocervical sampling alone. however, cervical intraepithelial neoplasia was detected 2.3 times more frequently in smears with endocervical cells. the sampling methods had similar abilities to obtain a satisfactory smear (cytobrush/spatula 63%, cotton swab/spatula 57%; p = .23). there was no significant advantage noted in the smears taken by either spatula. the presence or absence of endocervical cells in a smear was not significantly associated with any variation in success rate (chi (2)1 = 0.959, p > 0.30). no significant difference was found in the proportion of smears containing one or other type of indicator cell or in the yield of abnormal smears. for pregnant patients smear quality was improved with both cytobrush-spatula and bayne pap brush versus cotton swab-spatula in a controlled trial a new modified nylon brush (profile brush) was compared for endocervical cell pickup with the combination of an ayre spatula and traditional cytobrush. no difference was found between the methods with regard to detection of dyskaryosis, although there were significant differences in the percentage of smears containing endocervical cells. the differences between the sample takers and the sampling methods were significant in both the detection of grade iii cervical intraepithelial neoplasia (cin iii) (p less than .01) and in the production of smears containing endocervical cells (ec+) (p less than .018). red blood cells were more often present in smears taken with the armovical spatula than with the ayre spatula. a lower quality of smear was reflected by a lower incidence of epithelial atypical changes found, both between sample takers and by a single sample taker over a period of time. a significantly higher number of moderately and severely atypical epithelial changes was found in smears with endocervical cells as compared with smears without endocervical cells. the results of three quality control measures for evaluating a cytopathology laboratory's performance in the diagnosis of cervical abnormalities are presented. the same incidence (3.6%) of dyskaryotic smears was found using the ayre spatula (74/2077) as the aylesbury spatula (72/2003). also, the number of samples classed as inadequate was significantly greater with cervex brush smears (4.0%) than with cytobrush-ayre spatula smears (0.3%; p = .0003). the adequacy of ectocervical smears, as measured by the presence of columnar cells or squamous metaplasia, differed significantly among the four techniques studied. the multispatula had a significantly higher percentage of smears containing endocervical cells than the ayre spatula. significantly fewer ayre's samples contained endocervical cells than aylesbury samples (47% vs 59%, difference 12%; 95% ci 3%-21%; p less than 0.001), rocket samples (47% vs 67%; difference 20%, 95% ci; 12%-32%; p less than 0.001) or multispatula samples (47% vs 76%; difference 29%, 95% ci 19-38%; p less than 0.001). the zelsmyr cytobrush cell collector is an effective instrument, yielding increased numbers of endocervical cells on papanicolaou smear. in swabbed postmenopausal women, use of a milex spatula had a significantly higher yield than the use of a wooden spatula and a cotton-tipped applicator (43 percent vs 27 percent, p less than .03). there were large differences between the rates of adequate smears from the various doctors when using the spatula-cotton swab method (range, 14% to 82%); these differences were far less when using the spatula-cytobrush method (range, 75% to 100%). correct methods of sampling are essential for obtaining adequate smears for cytological diagnosis of cervicovaginal abnormalities.|982 women of childbearing age more than 17,000 smears were taken from women aged 14-86 years by more than 200 smear takers from 74 centres women participating in a cervical cancer screening program, a group of women was selected whose smears theoretically should have contained endocervical columnar cells patients with abnormal cytology vaginal smears pregnant women participants were all nonpregnant patients referred to the colposcopy clinic for abnormal papanicolaou smears 158 women who previously had abnormal smears and had been referred to colposcopy clinics in the lewisham and north southwark health authority of london women's hospital colposcopy clinic 11,061 patients 856 patients who had received local therapy (co2 laser or cold coagulation) for cin ii or iii between 9 and 30 months earlier 203 patients with a history of cryosurgery, laser ablation or cone biopsy were randomized into two groups: 114 patients had cervical smears done with a cotton swab and 89 patients with an endocervical brush persistent cervical intraepithelial neoplasia (cin older woman and from those with iatrogenic scarring of the cervix 107 women patients after treatment for cervical dysplasia 1063 patients referred for colposcopy with a recent abnormal smear 533 women who were attending a colposcopy clinic either for investigation of cytological abnormality or for review after treatment of cin 236 patients women attending the department of genitourinary medicine during a 16 month period genitourinary medicine clinic 36,853 papanicolaou smears six hundred fifty-four papanicolaou smears 352 pregnant women undergoing initial obstetric evaluation cervical cytology 10 pregnant patients (40%) and 14 of 18 postmenopausal patients (78%) contained endocervical cells.(abstract truncated at 250 words papanicolaou smears cervical cytology laboratories 192 patients, ranging in age from 18 to 82 yr, were referred to the gynecologic/oncologic clinic for follow-up of an atypical papanicolaou smear or of a previously diagnosed and treated cervical, vulvar, or endometrial lesion los angeles county + university of southern california collected 346 smears over a 6-month period, 110 with the cervex brush, 125 with the cotton swab plus ayre spatula and 111 with the cytobrush plus ayre spatula 89 patients who underwent repeat smear and colposcopic examinations because of abnormal screening smears eligible patients had a cervix and were not pregnant 802 women at initial follow-up after laser treatment of cervical lesions, 421 smears prepared using the cervex brush were compared with 381 smears prepared using the combination of a doctors in denmark 192 patients, 149 were premenopausal (15 of whom were pregnant), 12 were perimenopausal, and 31 were postmenopausal 358 women were reported two thousand fifteen patients undergoing routine cervical smears at the university of tennessee obstetrics and gynecology clinics 856 patients 130 had histologically proven persistent cin one hundred ninety-six (59 percent) of 332 ectocervical smears obtained with a curved brush were adequate compared with 190 (59 percent) of 323 ectocervical smears obtained with a spatula remaining patients with normal colposcopy 130 402 papanicolaou smears 280 paired cervical smears
bp reduction successful treatment response (diastolic blood pressure bp safety and tolerability safety and tolerability profile bp lowering msdbp mean sitting diastolic bp (msdbp hypokalemia rates of adverse events and laboratory abnormalities plasma renin activity (pra pra mean sitting dbp and systolic bp (sbp bp reductions mean sitting dbp adverse event rates msdbp and mean sitting systolic blood pressure (mssbp efficacy and safety antihypertensive effect mean sitting systolic bp (maximum mssbp/msdbp reduction trough sbp control rates dbp and sbp incidence of adverse events mean sitting diastolic bp adverse events and number of patients discontinuing therapy tolerability trough mean sitting dbp and systolic blood pressure (sbp blood pressure change in msdbp mean sitting systolic/diastolic blood pressure mean sitting systolic blood pressure efficacy and tolerability tolerated mean sitting diastolic blood pressure bp reductions (mean sitting systolic bp/mean sitting diastolic bp antihypertensive efficacy and safety blood pressure (bp) reduction mean sitting diastolic bp (dbp antihypertensive efficacy, safety and tolerability|at end point, aliskiren 150 and 300 mg significantly reduced msdbp (both, p < 0.001) and mean sitting systolic this study found a positive linear dose-response relationship in bp reduction with aliskiren 75, 150, and 300 mg dosed once daily, but only aliskiren 150 and 300 mg provided statistically significant reductions from baseline compared with placebo. once-daily oral treatment with aliskiren 300 mg significantly (p < .0001) lowered mean sitting dbp and systolic bp (sbp) compared with placebo; aliskiren monotherapy demonstrated a safety and tolerability profile comparable to placebo. aliskiren monotherapy was superior to placebo (p < 0.001; overall dunnett's test) in reducing msdbp and mean sitting systolic blood pressure (mssbp). rates of adverse events and laboratory abnormalities were similar in all groups. aliskiren 300 and 600 mg lowered mean sitting dbp significantly more than irbesartan 150 mg (p<0.05). aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (p<0.0005 vs. placebo for each dose) and mean sitting systolic blood pressure (p<0.001 vs. placebo for each dose). adverse event rates were similar with aliskiren- (65.2%) and hydrochlorothiazide-based therapy (61.5%).|patients with essential hypertension patients with mild-to-moderate hypertension forty hundred and fifty-five japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmhg 1123 patients with mild-to-moderate hypertension underwent a 3 to 4 week single-blind 642 patients (mean [sd] age, 52.0 [10.73] years; 60.0% male; 80.8% white; mean body weight, 89.2 [18.4] kg [range, 50-160 kg]) were included in the study 2776 patients aged >or=18 years with mean sitting diastolic blood pressure (msdbp) 95-109 1797 patients with hypertension (mean sitting diastolic blood pressure 95-109 mm hg and 8-h daytime ambulatory diastolic blood pressure > or =90 mm hg 1124 patients (mean sitting diastolic blood pressure [bp] 95 to 109 mm hg hypertensive patients 652 patients patients aged > or =18 years with stage 1 or 2 essential hypertension entered a 3- to 4-week, single-blind, placebo run-in period patients with mild-to-moderate hypertension (mean sitting diastolic blood pressure [dbp] > or =95 and <110 mm hg japanese patients with hypertension eligible patients adult patients with stage 1 or 2 essential hypertension patients with hypertension
preterm birth rate preterm birth rates|there was no evidence to suggest that the secondary interventions provided added benefit over the primary intervention protocol of preterm birth prevention education and increased visits.|high-risk patients (n = 1774) in experimental clinics were offered a program of education and more frequent visits high-risk women control clinic patients (n = 880) received eight west los angeles prenatal county clinics
clinical cure rates inflammation score cure efficacy, safety, and ear-pain resolution eradication rates overall cure rates relief of severe pain tolerability and efficacy visual analogue scale and a six-step infection score pain relief clinical symptom score (consisting of the subscores redness, swelling, pain, and secretion) and of the visual analogue scale (vas) rating for pain duration of symptoms (days) according to patient diaries resolution of discharge severe symptom score pain severity pain parameters microbiologic eradication rates change of the css from visit 1 to the study termination, and the changes in the subscores and of a visual analog scale for pain safety and efficacy swelling, pain, and redness relief of pain equivalent cure rates effective and safe change of an aggregate clinical symptom score (css) (subscores: redness, swelling, pain and secretion cure rate according to general practitioner completed questionnaires and recurrence of symptoms between days 21 and 42 frequency and type of adverse events low systemic exposure, absence of ototoxicity success rates ear pain glacial acetic acid staphylococcus aureus and pseudomonas pyocyanea median time to end of pain overall clinical-microbiological response severe redness clinical response efficacy and safety resolution of discharge, swelling, pain, and redness and the incidence of adverse side effects audiometric measurements cure]); microbiologic eradication glacial acetic acid, dexamethasone and neomycin sulphate edema efficacy, safety, and pain relief severe pain clinical or microbiological and clinical cure reduction of swelling severe secretion infected mastoid cavities signs and symptoms of aoe, including ear inflammation, tenderness, edema and discharge efficacy and tolerability pain-relieving tablets redness, pain and secretion frequency of adverse events time to end of pain, symptom scores (otalgia and tenderness) and microbiological eradication pain rates of adverse events tolerated clinical symptom score swelling reduction in ear inflammation recurrence of symptoms efficacy and tolerance inflammation css overall clinical response relief of significant pain (moderate or severe pain|higher percentages of cip/dex-treated patients had relief of severe pain over time (p=.0013) and relief of significant pain (moderate or severe pain) over time (p=.0456), compared with nph-treated patients. there was also a significantly greater decrease in the clinical symptom score from visit 1 to visit 2 in the pn+dx group in patients who had at least a moderately severe symptom score with more than seven points at visit 1 (p = 0.01) and in patients suffering from their current episode of otitis externa for more than 2 days (p = 0.02). otitis externa is an inflammatory disorder of the skin of the outer ear canal frequently associated with bacterial or fungal infection. 7 days treatment with cip/dex otic suspension administered twice daily is clinically and microbiologically superior to n/p/h otic suspension administered 3 times daily in the treatment of mild to severe aoe, and is equally well tolerated. this difference became highly significant on days 4 to 7 (p <.01 each). s. aureus seemed to be most resistant to treatment, while p. pyocyanea was less of a therapeutic problem. response to therapy was higher for chc (95.71% vs 89.83%) but was statistically noninferior (lower confidence limit, -4.98) to nph + amx. in the steroid group there was a slightly larger though not significant reduction in css at visit 2 and visit 3 versus baseline. twenty-seven patients with an initial diagnosis of otitis externa, untreated for the previous 2 weeks, were treated with weekly aural suction toilet and a choice of three topical drops. although there was a statistically significant improvement of pain parameters in the tac group, we found no significant differences in clinical findings between the two groups. patients on glacial acetic acid had only 38% (12/32) resolution after 4 weeks (p < 0.0005). there were no statistically significant differences in clinical or microbiological and clinical cure or in the rates of adverse events between treatment groups. the overall clinical-microbiological response was cure in the microbiologically evaluable patients demonstrated by both clinical cure and microbiological eradication. ear drops containing corticosteroids are more effective than acetic acid ear drops in the treatment of acute otitis externa in primary care. at visit 2, the patients in the glycerin group showed a significantly greater resolution of discharge. success rates in the com subgroup were 95% for ciprofloxacillin and 96% for gentamicin (p = 0.082), and in the deo subgroup, 87% for ciprofloxacillin and 79% for gentamicin (p = 0.19).|simple chronic otitis media (com) and diffuse external otitis (deo patients with active otitis externa, 71% (15/21) resolved with pediatric patients with otitis externa acute otitis externa in primary care patients were > or =1 year of age, had aoe >2 days with at least mild symptoms, and gave informed consent parallel group, multi-center clinical trial in ear, nose, and throat (ent) specialist practices with a planned interim analysis for sample size adaptation 151 patients with a unilateral acute bacterial otitis externa otitis externa and infected mastoid cavities 39 patients presenting with otitis externa 213 adults with acute otitis externa 34 centers in 278 pediatric oe patients aged 6 months to 12 years 47 patients with com and 54 patients with deo acute otitis externa (aoe fifty patients suffering from acute otitis externa 314 adults (12 years and older) and 287 children (younger than 12 years external otitis adults and children outpatients, derby royal infirmary, derby, uk children with oe otitis externa in adults and children patients of either sex and older than 1 year, with a clinical diagnosis of mild, moderate, or severe aoe and intact tympanic membranes were recruited to participate twenty-three primary care and referral ambulatory care sites per trial patients with acute otitis externa severe acute otitis externa acute bacterial otitis externa patients with acute bacterial otitis externa (aoe twenty-seven patients with an initial diagnosis of otitis externa, untreated for the previous 2 weeks 247 adults and 227 children were considered clinically evaluable (ce), and those for 98 children and 98 adults were microbiologically evaluable (me 208 patients were clinically evaluable and those for 90 patients were microbiologically evaluable patients enrolled numbered 468 acute external otitis 55 patients with acute external otitis 206 patients were enrolled (chc, 106; nph + amx, 100 simple chronic otitis media and diffuse external otitis children and adults patients with acute otitis externa treated with acute otitis externa 79 general practices, netherlands 64 patients were studied patients with acute otitis externa (aoe pediatric and adult patients emergency and gp referrals with acute otitis externa (n = 53) and infected mastoid cavities (n = 56 otitis externa pain otitis externa 33 patients 338 patients aged 18-76 who had a previous episode of otitis externa within the last year
number of tender joints esr, crp, thermographic joint score or functional score inflammatory activity disease activity objective signs of improvement average level of pain subjective symptoms of rheumatoid arthritis vitality furthermore, levels of antibodies against gliadin and beta-lactoglobulin weight body mass index haq-score subjective relief of rheumatic symptoms reduced pain, stiffness, consumption of analgetics, several clinical variables, and serum concentration of orosomucoid assessments of duration of early morning stiffness (ems), pain on a 10 cm visual analog scale (vas), the ritchie articular index (rai), swollen joint score, the stanford health assessment questionnaire, global patient and physician assessment, body weight, erythrocyte sedimentation rate (esr), c-reactive protein (crp) and haemoglobin controls concerning symptoms, drug consumption, or clinical and biochemical variables esr, crp and haemoglobin disease activity (health assessment questionnaire, duration of morning stiffness, pain at rest and pain on movement grip strength vas and rai rheumatic disease activity immunoglobulin g (igg) antibody levels against gliadin and beta-lactoglobulin disease activity variables erythrocyte sedimentation rate (esr disease activity according to composite symptoms (paulus index) of arthritis food intolerance, reduced gastrointestinal permeability pain intensity, morning stiffness, haq-score, number of swollen joints, joint tenderness, erythrocyte sedimentation rate, and patient's global assessment of health ritchie score disease activity measures das28 thrombocyte count pain, stiffness, medication, and clinical and biochemical findings adverse effects (nausea, diarrhoea fibre intake a composite disease activity index (das28), a physical function index (health assessment questionnaire (haq)), a health survey of quality of life (short form-36 (sf-36)), and the daily consumption of non-steroidal anti-inflammatory drugs radiological destruction tolerated and the rate of drop-outs swollen joint score rheumatologic, laboratory, immunologic, radiologic, or nutritional findings physical function, and improved vitality clear remission|improvement averaged 29% for patients on placebo and 32% for patients on experimental diets. percentage of patients with global 20 or 50% response didn't differ between experimental and control group after the 24-week of diet treatment. a composite disease activity index (das28), a physical function index (health assessment questionnaire (haq)), a health survey of quality of life (short form-36 (sf-36)), and the daily consumption of non-steroidal anti-inflammatory drugs were used as primary efficacy variables. the immunoglobulin g (igg) antibody levels against gliadin and beta-lactoglobulin decreased in the responder subgroup in the vegan diet-treated patients, but not in the other analysed groups. in a blind, placebo-controlled study of dietary manipulation therapy in outpatients with rheumatoid arthritis there was significant objective improvement during periods of dietary therapy compared with periods of placebo treatment, particularly among "good responders". all clinical parameters improved in both groups (p<0.05) except the swollen joint score in the elemental diet group. the diet resulted in a transient but statistically significant improvement in the average level of pain (p = 0.02), in haq-score (p=0.03), and a significant reduction in body mass index (p=0.001). a significant improvement was found in the number of tender joints (p = 0.04) in the experimental group, whereas improvement was found in the erythrocyte sedimentation rate (esr) (p = 0.03) and in the thrombocyte count (p = 0.02) in the control group. the positive subjective effect experienced by the patients was not discernible in the more objective measures of disease activity (health assessment questionnaire, duration of morning stiffness, pain at rest and pain on movement). after the elemental diet there was a statistically significant improvement in the diet group in grip strength (p = 0.008) and ritchie score (p = 0.006) but not in esr, crp, thermographic joint score or functional score. the fasting patients showed reduced pain, stiffness, consumption of analgetics, several clinical variables, and serum concentration of orosomucoid.|patients with active rheumatoid arthritis (ra fifty ra patients thirty patients with active rheumatoid arthritis patients with rheumatoid arthritis patients with active rheumatoid arthritis outpatients with rheumatoid arthritis patients with active ra thirty patients were included and followed for six months patients with well controlled, although active ra of at least two years' duration, who were receiving stable pharmacological treatment, were invited to participate rheumatoid arthritis (ra rheumatoid arthritis with a peptide diet 16 patients with classical rheumatoid arthritis (ra sixty-six patients with active ra rheumatoid arthritis twenty-six patients completed the study; 11 were on an selected patients with rheumatic disease patients with longstanding, progressive, active ra patients with rheumatoid arthritis (ra unselected ra patients
radiographic evaluation and range of motion recovery of isometric grip strength sustained maximal voluntary isometric contraction distal radial fractures overall function, range of movement and activities of daily living mean jebsen taylor scores and sf 36 bodily pain scores upper extremity mfa domain scores, overall jebsen taylor scores, and pinch and grip strength tests function isometric grip strength colles' type distal radial fracture grip strength better length and palmar tilt restoration radiological signs of post-traumatic arthritis roentgenographic loss of position during fracture union angulation of the distal radius complication rate noncomplicated pin-tract infection upper extremity function radial shortening pain global function and pain upper extremity mfa scores, jebsen taylor scores, sf-36 bodily pain scores, and grip strength transient sensory disturbance excellent or good outcome and patient satisfaction|aged osteoporotic patients tolerated better residual deformities, and the clinical results had a relatively low correlation with the final anatomic alignment. this randomized prospective study demonstrated no advantage in using an external fixator to immobilize reduced distal radial fractures over closed reduction and plaster cast immobilization in patients less than 60 years of age. the fixator group had significantly less radial shortening (p<0.05). a significant difference was registered between women with plaster casts and women with external fixators six weeks after the fracture. the technique of bipolar fixation proved to be safe and suitable for use in a busy district general hospital, without the necessity of elaborate equipment. in the final functional assessment (sarmiento) the results were (1) plaster 43% good and excellent, 50% fair and 7% poor, (2) external fixator 80% good and excellent, 20% fair and poor results, (3) open reduction and internal fixation 63% good and excellent, 26% fair, 11% poor. patients treated with external fixation had a good anatomical result, but their function was no better than that of the control group. the functional result correlated with the anatomical result, which was significantly better in patients treated by external fixation. the external fixator was more effective at holding the manipulated position, and the roentgenographic loss of position during fracture union was minimal compared with that seen in patients treated in plaster. functional results at six weeks, three and six months and at one year, however, showed no difference between any of the four groups. by 2 years, mean jebsen taylor scores and sf 36 bodily pain scores for patients in both groups were similar to scores for normal age- and gender-matched population controls. after 1 year, the patients allocated to primary external fixation had a better radiographic and functional end result; according to lidstrm's grading, 19/22 were excellent or good after external fixation as compared with 12/19 after plaster-cast treatment.|redisplaced unstable fractures of the distal radius 46 patients young patients with comminuted displaced colles' fractures 90 adult cases of acute displaced intra-articular fractures of the lower end of the radius were classified according to frykman's and ao classifications after obtaining radiographs in antero-posterior and lateral planes patients under 45 years of age patients less than 60 years of age distal radial fractures 101 colles' fractures in patients over the age of 55 years 126 cases 70 patients between the ages of 20 and 45 years with comminuted intra-articular fractures of the distal radius of types iii to viii (graded according to frykman 120 patients with redisplaced fractures of the distal radius comparing four methods of treatment colles' fracture for treatment of a colles' type distal radial fracture displaced intra-articular fractures of distal radius unstable colles' fractures in elderly patients 50 severely displaced comminuted colles' fractures treated by either multicenter study at 3 university teaching hospitals severely displaced colles' fractures 47 severely displaced colles' fractures, 23 had external fixation and 24 had a dorsal plaster cast 113 skeletally mature patients with distal radius fractures with metaphyseal displacement, but without joint incongruity 126 consecutive patients with a fracture of the distal radius were followed aged osteoporotic patients 28 females and 5 males with displaced colles' fracture involving the distal radio-ulnar joint patients less than 45 years of age eighty-five patients were reviewed 7 years after prospective randomization to
adverse reactions|over a battery of cognitive tests, indomethacin patients improved 1.3% (+/-|alzheimer's disease
intensity of exercise-induced pain in working muscles skeletal muscle function heart rate and perceived exertion body mass index tolerance to everyday activities monitoring heart rate and perceived exertion during exercise exercise capacity heart rate, level of perceived exertion, and venous blood glucose levels electromyographic amplitude neurologic adverse effects phosphorus 31 magnetic resonance spectroscopy variables exercise tolerance bcaa meal tripled plasma bcaa levels, increased bcaa catabolism depletion of phosphocreatine muscle complaints with creatine level of perceived exertion fell calorific intake maximal oxidative work capacity mean peak free fatty acid levels and reduced exercise capacity exercise endurance of the forearm muscles plasma glutamine and alanine work capacity peak oxygen consumption or level of leg fatigue serum creatine and serum creatine kinase levels, phosphorus 31 magnetic resonance spectroscopy, and surface electromyograms median frequency in surface electromyograms during contraction mean plasma glucose level phosphocreatine depletion mean (+/-se) heart rate limitation of daily activities|supplemental sucrose increased the mean plasma glucose level by more than 36 mg per deciliter (2.0 mmol per liter) and resulted in a marked improvement in exercise tolerance in all patients. the bcaa meal tripled plasma bcaa levels, increased bcaa catabolism as indicated by greater exercise increases in plasma glutamine and alanine, but lowered mean peak free fatty acid levels and reduced exercise capacity in five of six patients. during the constant workload, heart rate and perceived exertion were consistently lower (p<0.0005) on the carbohydrate- versus protein-rich diet. force-time integrals (p =.03) and depletion of phosphocreatine (p =.04) increased significantly during ischemic exercise with creatine. there was no significant difference between pre-treatment exercise tests for peak oxygen consumption or level of leg fatigue. although an improved exercise endurance of the forearm muscles was demonstrated with both short-acting and depot-glucagon, this was not statistically significant when compared with placebo or no treatment. there were no significant changes in phosphorus 31 magnetic resonance spectroscopy variables. both sucrose treatments dramatically improved exercise tolerance, compared with the placebo.|12 patients with mcardle's disease drank 660 ml of a beverage that had been sweetened with artificial sweeteners (placebo) or with 75 g of sucrose after an overnight fast mcardle's disease patients with mcardle's disease patients with myophosphorylase deficiency (mcardle's disease nine patients with biochemically and genetically proven mcardle disease were treated seven patients with mcardle disease mcardle disease myophosphorylase deficiency (mcardle disease six fasting patients with mcardle's disease healthy subjects six patients with biochemically and genetically diagnosed mcardle disease a group of 5 patients with mcardle's disease massachusetts medical society patients with mcardle disease nineteen patients with mcardle disease patient with myophosphorylase deficiency
clinical asthma score over time, length of pediatric intensive care unit stay, and incidence of adverse events mean proportionate increase in fev ass relative tachycardia rate of recovery peak expiratory flow rates pulse rate of 8 beats per minute and 2 beats per minute longer duration of oxygen therapy synergistic bronchodilator effect blood gas pressures nausea clinical asthma score over time, length of pediatric intensive care unit stay, or incidence of adverse events asthma severity score (ass length of hospital stay length of stay in hospital median hospital cost of medication and theophylline blood levels adverse events oxygen tension|hydrocortisone was given after 2 hours, but did not appear to affect the rate of recovery. a similar improvement in ass to 2 hours was seen in the two groups (mean difference -0.08, 95% ci -0.97 to 0.80), there was a trend (p=0.07) towards a longer duration of oxygen therapy in the salbutamol group (17.8 hours (95% ci 8.5 to 37.5) v 7.0 hours (95% ci 3.4 to 14.2)), and a significantly (p=0.02) longer length of hospital stay in the salbutamol group (85.4 (95% ci 66.1 to 110.2) hours v 57.3 hours (95% ci 45.6 to 72.0)). differences in results did not reach conventional levels of significance and no serious side effects were noted. peak expiratory flow rates showed a significant improvement after 15 minutes treatment with aminophylline and the combined infusion, but this was not seen until 60 minutes with the salbutamol infusion. the median hospital cost of medication and theophylline blood levels was significantly lower in group 1 compared with groups 2 and 3 (280 us dollars vs. 3,908 us dollars vs. 4,045 us dollars, respectively, p < .0001).|critically ill children with status asthmaticus who are already receiving continuous nebulized albuterol and intravenous corticosteroids acute severe asthma pediatric intensive care unit of a tertiary-care children's medical center acute asthma forty critically ill children between the ages of 3 and 15 yrs with impending respiratory failure secondary to status asthmaticus critically ill asthmatic children critically ill children with status asthmaticus children with severe asthma forty four subjects were enrolled, with 18 randomly allocated to receive severe acute childhood asthma children aged 1-16 years with acute severe asthma twenty-one patients admitted to hospital with acute severe asthma severe, acute asthma in childhood 23 patients with acute exacerbations of asthma
lipid management total national health service cost satisfaction score quality of life (sf-36 blood pressure management lipid concentrations (serum total cholesterol total cholesterol concentration smoking cessation serum total cholesterol concentration, blood pressure, distance walked in 6 minutes, confirmed smoking cessation, and body mass index quality of life body mass index consultations for coronary heart disease, the recording of risk factors, and advice given blood pressure and high-density lipoprotein cholesterol physical activity limits: systolic blood pressure systolic blood pressure patient risk of cardiovascular death and satisfaction mean blood pressure cotinine levels blood pressure and total cholesterol concentration health outcome total cholesterol non-fatal cardiovascular event numbers on aspirin or lifestyle measures taking daily physical exercise risk factors (blood pressure, cholesterol, and smoking status); prescribing of hypotensive agents, lipid lowering drugs, and antiplatelet drugs; blood pressure, serum cholesterol level, and plasma cotinine levels blood pressure (diastolic pressure serum cholesterol concentrations aspirin management diastolic blood pressure cholesterol lowering drugs concentration of low density lipoprotein cholesterol appropriate treatment [derived from the national service framework (nsf)], health status (sf-36, eq-5d) and an economic evaluation number of patients admitted to hospital restriction of everyday activities, dietary habit, smoking habit, frequency of physical exercise; blood pressure, body mass index, and serum total cholesterol concentration low density lipoprotein cholesterol smoking habit, systolic or diastolic blood pressure, cholesterol concentration, or body mass index event rates and all-cause mortality coronary heart disease consultation rates, process of care measures dietary habits|blood pressure and high-density lipoprotein cholesterol were more frequently within recommended levels in the intervention group than in controls: odds ratio 1.63, 95% confidence interval 1.05-2.51, and odds ratio 2.61, 95% confidence interval 1.32-5.18, respectively. setting up a register and recall system improved patient assessment at 18 months' follow up but was not consistently better than audit alone in improving treatment or risk factor levels. the intervention group also reported eating a healthier diet than the control group and less restriction by angina in any everyday activity. there were no significant differences in patients' self reported changes to lifestyle or to the belief that it is possible to modify the risk of another coronary event. at the 18 month follow-up there were no significant differences between intervention and control groups in the numbers (proportions) of patients above the recommended limits: systolic blood pressure, intervention 98/360 (27.2%) v control, 133/405 (32.8%), odds ratio 1.51 (95% confidence interval 0.99 to 2.30; p=0.06); diastolic blood pressure, intervention 32/360 (8.9%) v control, 40/405 (9.9%), 1.40 (0.75 to 2.64; p=0.29); and total cholesterol concentration, intervention 52/342 (15.2%) v control, 64/391 (16.4%), 1.13 (0.63 to 2.03; p=0.65). low density lipoprotein cholesterol was reduced by 0.5 mmol/l (95% confidence interval 0.2 to 0.8 mmol/l) (9.3% (2.9% to 15.8%)) from baseline in patients in the intervention group and by 0.5 (0.1 to 0.9) mmol/l compared with controls (p<0.05). the computerised decision support system had no significant effect on consultation rates, process of care measures (including prescribing), or any patient reported outcomes for either condition. there were few differences in quality of life (sf-36) between the intervention and control groups at baseline or follow-up or with overall eq-5d score over time. there were significant improvements in aspirin management (odds ratio 3.22, 95% confidence interval 2.15 to 4.80), blood pressure management (5.32, 3.01 to 9.41), lipid management (3.19, 2.39 to 4.26), physical activity (1.67, 1.23 to 2.26) and diet (1.47, 1.10 to 1.96). there was no significant difference between the intervention and control groups in smoking (cotinine validated quit rate 19% v 20%), lipid concentrations (serum total cholesterol 5.80 v 5.93 mmol/l), blood pressure (diastolic pressure 84 v 85 mm hg), or fitness (distance walked in 6 minutes 443 v 433 m).|559 surviving patients at 1 year, 502 (90%) were followed up 688 patients aged less than 75 years and known to have had angina for at least six months; 342 randomised to receive education and 346 to no education 18 general practices in the greater belfast area patients with coronary heart disease patients and general practitioners on the quality of primary care after a coronary event (post 1173 patients (685 men and 488 women) under 80 years with working diagnoses of coronary heart disease, but without terminal illness or dementia and not housebound 255 consecutive patients with coronary artery disease setting: 52 general practices in east london, 44 of which had received facilitation of local guidelines for coronary heart disease guidelines were mailed to all general practitioners (n=54) and presented at a common lecture general practices in northern ireland and the republic of ireland, regions with different healthcare systems patients at high cardiovascular risk setting: 60 general practices in north east england coronary heart disease in primary care nine sites in england 983 patients aged 30-79 were included heart disease in general practice primary care patients with coronary artery disease patients with myocardial infarction and angina patients with angina 903 patients with established coronary heart disease registered with one of 48 practices 597 adult patients (422 with myocardial infarction and 175 with a new diagnosis of angina) who were recruited during hospital admission or attendance at a chest pain clinic between april 1995 and september 1996 patients who had had acute coronary events and to their general practitioners in a locality where guidelines for coronary heart disease patients with stable coronary disease general practitioners asthma and angina in adults in primary care patients with coronary artery disease patients who have survived an acute coronary event and to their general practitioners improve secondary prevention of coronary heart disease participants: 328 patients admitted to hospital for myocardial infarction or unstable angina 19 general practices in northeast scotland coronary patients in primary care 1493 patients (980 intervention and 513 control), 62 pharmacists and 164 gps general practitioners and practice nurses in the study practices and their patients aged 18 or over with angina or asthma 1906 patients aged 55-75 years with established coronary heart disease all 67 practices in southampton and south west hampshire, england
somatic symptoms of the bdi oxygen consumption health and wellbeing measures of both emotional (clinician and self-report) and physical (observed and self-report) functioning trait anxiety and a standard psychiatric interview adverse events vitality depressive symptoms ces-d total depressive score major depressive disorder (mdd) and a ham-d score strength measured by 1 repetition maximum for chest press ham-d, gaf and cgi score strength mood, body weight and oxygen consumption depressive status, physical and mental health and quality of life median compliance ham-d or bdi scores 17-item hamilton rating scale for depression (hrsd depression measures (beck depression inventory quality of life subscales of bodily pain hamilton rating scale for depression (hrsd depression measured by the cornell scale for depression in dementia, mood measured by the dementia mood assessment scale and the alzheimer's mood scale, and affect measured by the observed affect scale geriatric depression scale, clinical global impression and patient global impression weight loss depression according to hrsd reduction of depression scores percentage of days absent from work during the last 10 working days physiologic capacity, quality of life, morale, function and self-efficacy without adverse events inventory of depressive symptoms (clinician and self-report), hrsd scores at 24 weeks, cardiorespiratory fitness, self-efficacy, and quality of life mood and energy regulation in seasonal and non-seasonal depression hamilton depression rating scale (ham-d presence and severity of mdd using diagnostic and statistical manual of mental disorders, fourth edition criteria and hamilton rating scale for depression (ham-d) and beck depression inventory (bdi) scores social functioning depressive state symptoms of depression psychological subscale of the beck depression inventory (bdi resting heart rate mood nor metabolic parameters ham-d and bdi scores depression scores muscle strength gaf and cgi scores strength, morale, and quality of life severity of depression assessed with the bech-rafaelsen melancholy scale (brms) and the center for epidemiologic studies depression scale (ces-d depression remission rates ces-d rating scale, urinary cortisol and epinephrine levels, and cardiorespiratory factors at rest and during exercise endurance test depression, neuroendocrine stress hormones and physiological fitness lower depression scores mean change in ham-d(17) score cognitive abilities aerobic capacity aerobic capacity, life satisfaction, self-esteem, anxiety, and dysfunctional cognitions brms scores role emotional maximal oxygen uptake psychiatric scores depressive state, hormonal response to stress and physiological fitness sf-36 mental health scores and clinician-rated depression scores physical functioning peak oxygen uptake and lung capacity severe depressive symptoms lower ham-d scores hamilton rating scale of depression ham-d(17) score 17-item hamilton rating scale for depression (ham-d(17 fastest initial response|after the sessions of exercise the ces-d total depressive score showed a significant decrease, whereas no effect was observed after the period of usual daily activities (anova). after 16 weeks of treatment, the groups did not differ statistically on ham-d or bdi scores (p = .67); adjustment for baseline levels of depression yielded an essentially identical result. at 10 weeks a significantly higher proportion of the exercise group (55% v. 33%) experienced a greater than 30% decline in depression according to hrsd (or=2.51, p=0.05, 95% ci 1.00-6.38). exercise as a behavioural approach to treatment of depression in nursing home residents with severe ad evidenced a clear benefit to participants in this study. the results indicated that subjects in the aerobic exercise condition evidenced reliably greater improvements in aerobic capacity than did the subjects in either of the other conditions (p less than .002 in both cases) and that the subjects in the aerobic exercise condition evidenced reliably greater decreases in depression than did subjects in the placebo condition (p = .05) or subjects in the no-treatment condition (p = .001). secondary outcome measures were the inventory of depressive symptoms (clinician and self-report), hrsd scores at 24 weeks, cardiorespiratory fitness, self-efficacy, and quality of life. there were modest improvements in health and wellbeing over time, but many scores were lower than reported in non-depressed people. quality of life subscales of bodily pain (p = .001), vitality (p = .002), social functioning (p = .008), and role emotional (p = .02) were all significantly improved by exercise compared to controls. exercise and social contact both resulted in significant reductions in both the total and the psychological subscale of the beck depression inventory (bdi). at 4 months, the mean change in ham-d(17) score was -1.3 in the first trial, an aerobic exercise group had a superior outcome compared with a control group in terms of trait anxiety and a standard psychiatric interview. in the control group ham-d, gaf and cgi scores do not show any statistically significant differences between t0 and t8. all treatment groups had lower ham-d scores after treatment; scores for the active treatment groups were not significantly different from the placebo group (p = .23). winter depression responded equally well to exercising and light, while a significant therapeutic difference in favor of exercising was found in non-seasonal depression. after 10 days, reduction of depression scores in the exercise group was significantly larger than in the placebo group (brms: 36% v 18%; ces-d: 41% v 21%; p for both = 0.01); the proportion of patients with a clinical response (reduction in the brms scores by more than six points) was also larger for the exercise group (65% v 22%, p<0.01). there were trends for the superiority of the exercise and sertraline conditions over usual care in improving sf-36 mental health scores and clinician-rated depression scores.|controls: 20 patients undergoing only pharmacological therapy moderately depressed elderly older patients elderly people patients were referred from general practitioners or psychiatrists and were eligible if they fulfilled the international classification of diseases, tenth revision, criteria for unipolar depression and were aged between 18 and 55 years 202 adults (153 women; 49 men) diagnosed with major depression patients with mild to moderate depression forty-three depressed women depressed chronic stroke survivors major depressive disorders mild to moderate major depressive disorder (mdd) in adults ages 20 to 45 years nursing home residents with severe ad age-matched groups of female subjects with winter depression, non-seasonal depression or without depression patients with mdd patients (n = 165 thirty community-dwelling, moderately depressed elderly patients with major depression nursing home residents with ad forty-nine female volunteers (aged 18-20 years; mean 18.8 +/- 0.7 years) with mild-to-moderate depressive symptoms, as measured by the centre for epidemiologic studies depression (ces-d) scale major depressive disorder older people with poorly responsive depressive disorder or usual care; 32 participants completed the 16-week study participants were 37 older adults with minor depression who were randomized to depressed older adults with alzheimer's disease patients with unipolar depression conducted from january 2005 through july 2007 forty-five nursing home residents with moderate to severe ad older adults with poorly responsive depressive disorder one hundred fifty-six men and women with mdd (age, > or = 50 years adolescent females with depressive symptoms patients selected from the clinical activity registries of the psychiatric unit of the university of cagliari, italy older adults with minor depression eighty men and women who were diagnosed with a structured clinical interview for depression and who had mild (hrsd 12-16) to moderate (hrsd 17-25) mdd older adults depression eligible people (n = 45 adults with clinical depression 32 subjects aged 60-84, mean age 71.3 between october 2000 and november 2005 inclusion criteria: female, between 40 and 60 years, diagnosis of major depressive disorders (dsm-iv tr) resistant to the ongoing treatment depressed elders volunteers aged 60 and above with major or minor depression or dysthymia nursing home residents with alzheimer's disease (ad 38 inpatients with a major depression episode undergoing standard clinical antidepressant drug treatment participants diagnosed with mdd older patients with major depressive disorder (mdd chronic post stroke patients with depression older people depressive persons patients with major depressive disorders participants' median age was 69 years: 27 were male older persons older patients with major depression
morbidity and mortality (m&m) entries and anonymous adverse/near-miss events number of submissions inpatient deaths|in the first six months following hospitalwide implementation, the number of events captured increased more than fivefold; it continues to increase. only 25% of complications and 42% of inpatient deaths were reported. comparison of quarterly data pre- and post-web forms showed an 83.5% increase in number of submissions and a 79.5% reduction in event-to-submission time.|surgical patients a metropolitan tertiary care center from september 2005 to august 2007, 15,524 surgical patients were reported including 957 (6.2%) adverse events and 34 (0.2%) anonymous reports
endotracheal cuff pressures ett tolerance et discomfort before tracheal extubation, and sore throat, hoarseness and coughing incidence sore throat and cough arterial blood pressure and cardiac frequencies no laryngospasm, rupture of ett cuff, or depression of the swallowing reflex plasma concentrations haemodynamic changes systolic arterial pressure frequency of sore throat plasma lidocaine concentrations nausea, postoperative vomiting, dysphonia, and hoarseness frequency of postoperative cough and sore throat cuff pressure postoperative cough and sore throat cough and restlessness before tracheal extubation postoperative sore throat, hoarseness and dysphagia cough incidence number of side-effects incidence and severity of postoperative sore throat, hoarseness and dysphagia peak cuff pressure hoarseness, bucking, dysphonia, dysphagia, cough, restlessness, and postoperative nausea and vomiting pressure and volume changes of tracheal tube cuff pressure and volume of a tracheal tube cuff postoperative sore throat visual analog scale postoperative sore throat and cough incidence of sore throat, hoarseness, or tracheal irritability sore throat, hoarseness or dysphagia incidence or severity of sputum sore throat peak cuff pressures, the incidence of reaction ('bucking postoperative sore throat occurs occurrence of high cuff pressures arterial blood pressure and heart rate sputum incidence effectiveness and safety et cuff pressures et discomfort and postoperative sore throat incidence postoperative throat problems sore throat and dysphagia incidence or severity of postoperative sore throat, hoarseness or dysphagia verbal analogue scale, melzack's present pain intensity scale of the mcgill pain questionnaire incidence of sore throat sore throat, cough and hoarseness lower et discomfort and sore throat incidence sore throat and hoarseness adverse emergence phenomena plasma lidocaine levels nausea, vomiting, dysphonia and hoarseness tracheal complaints postoperative airway symptoms of sore throat, cough, and sputum incidence and severity of sore throat induced hypotension pressures in lido cuffs severity of sore throat disturbance of haemodynamic responses sore throat incidence incidence of side-effects post-operative side-effects hemodynamic effects, restlessness, dysphonia, and hoarseness postoperative airway symptoms postoperative sore throat, including endotracheal cuff design, endotracheal tube size, intubation technique, laryngoscopy blade, airway placement, suctioning technique, and anesthetic technique|the incidence of sore throat was decreased for group lb in comparison to group l during the 24 postextubation hours. no laryngospasm, rupture of ett cuff, or depression of the swallowing reflex were recorded. the incidence of sore throat was significantly different at the 24-hour evaluation (59% air vs. 32% lidocaine, p = 0.01). tracheal complaints were similar for the two groups, except for lower et discomfort and sore throat incidence after 24 hours and lower systolic arterial pressure at the time of extubation in the lido group (p < 0.05). in group l patients, the haemodynamic changes were less (p < 0.05), and the peak cuff pressure was lower (p < 0.01) than for group s. the frequency of sore throat was significantly different among the six groups at 1 hour and at 24 hours, with greater frequency in the g3, g2, and g6 groups. women were more prone to have side-effects, especially sore throat and hoarseness, than men (p less than 0.05). analysis using the kruskal-wallis test suggested that there was no statistical difference in postoperative sore throat among the 3 groups. the pressure and volume of a tracheal tube cuff increased with air, decreased with mixture of n2o + o2 and almost remained the same with saline and 4% lidocaine. after extubation, nausea, vomiting, dysphonia and hoarseness were greater for patients with air-filled cuffs compared with the lidocaine-filled cuffs. there were significant differences in the incidences (p < 0.01) and severity (p < 0.01) of sore throat and cough in groups c and l (groups l1 + l2). there were no significant differences between the two groups, which suggests that topical anaesthesia of the mucosa of the upper airway is ineffective as a means of ameliorating airway complaints in connection with tracheal intubation. however, there was no significant difference in the incidence or severity of postoperative sore throat, hoarseness or dysphagia between the lidocaine group and the placebo group throughout the study.|193 asa i-ii surgical patients 122 asa i-iii patients aged 15-87 years 204 asa physical status i and ii patients scheduled for cataract surgery with general anesthesia 114 patients during n2o-o2 anaesthesia and in 54 patients after the replacement of n2o with nitrogen adult patients scheduled for total thyroidectomy surgery were consecutively enrolled (n = 20 for each group 94 surgical patients n=20 patients in each group) that included a group who received an 20 patients were given intubated patients sore throat, hoarseness and cough in connection with tracheal intubation seventy asa class participants were all asa physical status i, ii, or iii, female, adult patients undergoing general endotracheal anesthesia for gynecological procedures university-affiliated hospital 80 patients (33 male & 47 female after total intravenous anaesthesia 80 patients undergoing elective operations 106 asa physical status i and ii patients
improvement of semen and pregnancy rate sperm concentration increased and sperm motility infertility such as anovulation or tubal blockage sperm parameters and pregnancy rate seminal volume, sperm motility and abnormal sperm morphology sperm density and total motile sperm count male fertility sperm parameters (sperm density, motility and morphology pregnancy rate semen parameters, regardless of pregnancy occurrence sperm concentration subclinical or recurrent varicoceles, normal semen parameters, and azoospermia spontaneous pregnancy pregnancy rates mean seminal improvement and pregnancy rate incidence of pregnancy 1 year after randomisation spontaneous pregnancy rate pregnancy seminal improvement and pregnancy rates semen analysis and hormonal parameters pregnancy rate (pr sperm density and motility progressive motility semen parameters cumulative pregnancy rates occurrence of adverse events|there were no significant differences between groups 1 and 2 regarding change in seminal volume, sperm motility and abnormal sperm morphology. all seminal parameters increased after both surgical and medical treatment, but only increases in sperm density and motility following varicocelectomy were statistically significant. after operation in all patients of both groups, there was significant improvement in semen parameters, regardless of pregnancy occurrence. there was no significant increase in pregnancy rate in the treated group, compared to the controls, the confidence interval being 20.8% to 15.7%. in between-arm analysis, all semen parameters improved significantly in the ta versus ca (p<0.0001). during an observation period of 53 months (range 36 to 74 months) we found no statiscally significant improvement in the semen crude variables, the morphology or the progressive motility in the series of men submitted to surgery. when entering the study, there were no significant differences in semen analysis and hormonal parameters between the two groups, nor between the subgroups undergoing treatment. in the group of patients without treatment, the pregnancy rate in the women was higher (22/41, or 53.7%) than in the group receiving treatment (13/38, or 34.2%).|42 infertile men with left subclinical varicocele 67 patients had been randomized 47 couples in the treatment group (23 ligations and 24 embolizations) and 48 in the non-treatment group concluded the study subclinical varicocele infertile patients with varicocele 1995 with the collaboration of 15 german andrological centres varicocele and male fertility fifty-one patients were submitted to ligation of the testicular veins and 45 individuals infertile men subjects fulfilling the admission criteria 145 participants (ca: n=72; ta: n=73), with a mean age plus or minus standard deviation of 29.35.7 in the ca and 28.45.7 in the ta (p=0.34 14 collaborating centres 85 patients with a subclinical varicocele diagnosed by scrotal thermography presented with infertility male infertility from an evidence-based perspective infertile men with abnormal semen analysis because of varicocele only infertile men with clinical varicocele married men 20-39 yr of age who had experience infertility 1 yr, had palpable varicoceles, and with at least one impaired semen parameter (sperm concentration <20 million/ml, progressive motility <50%, or normal morphology <30%) were eligible forty-one patients with varicocele had no therapy patients with subclinical varicocele 26 patients varicocele was treated surgically and 12 patients male partners with left-sided varicoceles of 96 infertile couples seventeen patients were excluded from the study in accordance with exclusion criteria ninety-six patients with varicocele
tolerated mean plasma concentrations of ltg adverse events, vital signs, and physical, neurologic, and laboratory examinations sleep latency|the analysis of all the sleep logs disclosed a significant treatment effect of melatonin on sleep latency (p = 0.019). mean plasma concentrations of ltg, were linearly related to dose, although there was substantial interindividual variation.|typical absence seizures in children children, adolescents and young adults with mental retardation with or without epilepsy twenty-five patients (16 males, nine females), aged from 3.6 to 26 years (mean 10.5 years), all affected with mental retardation mostly with epileptic seizures newly diagnosed typical absence seizures in children and adolescents (aged 3-15 years, n = 45 young epileptic patients young patients with mental disabilities and epileptic seizures children, adolescents and young adults with wake-sleep disorder and mental retardation, most of them on chronic anticonvulsant therapy for epileptic seizures
cerebral malaria complications, including pneumonia and gastrointestinal bleeding parasitemia coma or hyperparasitemia level of consciousness became normal neurologic sequelae|there were no significant differences between the placebo- and dexamethasone-treated groups in time until patients became afebrile (median, 51 vs. 19 h), the level of consciousness became normal (mean, 80 vs. 83 h), or parasitemia was cleared (mean, 2.1 vs. 3.4 d) or in the incidence of complications. there were eight deaths in the dexamethasone group and nine in the placebo group (no significant difference; p = 0.8); at post-mortem examination the brain showed features diagnostic of cerebral malaria in all but one patient who died.|28 comatose patients with cerebral malaria quinine-treated patients with cerebral malaria 28 children six to 14 years old 100 comatose patients 100 comatose patients with strictly defined cerebral malaria patients were 18 mo to 42 y of age (geometric mean, 10.2 y), and the 19 patients in each group were comparable on admission
gastrointestinal irritation rate snellen equivalent visual acuity mean changes in visual acuity (va net subjective improvement functional parameters macular function visual acuity mean eye macular pigment optical density va, cs, and visual function mean zinc serum level choroidal neovascular membrane (cnv cs score serum levels of copper, hemoglobin, and red blood cell count contrast sensitivity (cs) and national eye institute visual function questionnaire (nei vfq-25) scores contrast sensitivity visual acuity, contrast sensitivity, color discrimination, and retinal grating acuity, as well as serum levels of zinc and copper, red blood cell count, hemoglobin, and morphologic changes detected by grading of monochrome fundus photographs and fluorescein angiograms stabilization of va visual acuity, contrast sensitivity, and light flash recovery time nonexudative alterations (drusen size, drusen confluence, hyperpigmentation, and focal degeneration of the retinal pigment epithelium visual acuity outcome visual and retinal acuity, color vision, and contrast sensitivity macular light flash recovery time macular degeneration visual acuity and visual function visual loss final mean nei vfq-25 composite scores serous pigment epithelial detachment developed without angiographic evidence of cnv contrast sensitivity (cs vfo-14 questionnaires conceming subjective glare recovery|in groups 1 l and 2 l/a, mean eye macular pigment optical density increased approximately 0.09 log units from baseline, snellen equivalent visual acuity improved 5.4 letters for group 1 l and 3.5 letters for group 2 l/a, and contrast sensitivity improved. the effect of the treatment was not statistically different between the two groups, admittedly small in number, in terms of visual and retinal acuity, color vision, and contrast sensitivity. an improvement in cs (p=0.001) and final mean nei vfq-25 composite scores at 12 and 24 months higher in treated group compared to nontreated group were also shown (p<0.001). in the treatment group, the mean zinc serum level increased significantly (p < 0.0001) from 79 +/- zmc 25 mg twice daily was well tolerated and was associated with improved macular function in comparison to a placebo in persons with dry amd. although some eyes in the zinc-treated group lost vision, this group had significantly less visual loss than the placebo group after a follow-up of 12 to 24 months. this paper outlines the primary aims of the vitamin e, cataract and age-related macular degeneration (vecat) study, the methodology, and the recruitment rates. the difference between these values is not statistically significant (z=-0.903, p=0.376).|atrophic age-related macular degeneration people with age-related macular disease (armd 151 subjects with drusen or macular degeneration age-related maculopathy (arm) and atrophic age-related macular degeneration (amd) participants 145 patients urban midwestern veterans administration hospital from august 1999 to may 2001 age-related macular degeneration 112 white patients with age-related macular degeneration and exudative lesions (choroidal neovascularization, pigment epithelial detachment, or both) in one eye and a visual acuity of better than 20/40 and macular degeneration without any exudative lesion in the second eye was performed age-related macular disease patients who have an exudative form of the disease in one eye patients over the age of 65 years age-related macular degeneration (armd ninety patients with atrophic armd were referred by ophthalmologists at two chicago-area veterans medical facilities groups enrolled 40 participants, with best corrected visual acuity 20/25 to 20/70, macular drusen, and pigment changes n=10) or active (n=15) groups persons with dry amd 20 patients in an early stage of amd were included a population of healthy volunteers aged 55-80 years at enrolment patients with an exudative form of the disease in the first eye macular degeneration persons with dry age-related macular degeneration (amd 14 patients during the treatment period (nine in the treatment group, five in the placebo group cataract and age-related maculopathy older persons age-related macular degeneration (amd
surgical complications and adverse effects pulse rate baseline behavioral state loss of oxygen saturation data physiologic and behavioral parameters heart rate, cry, and methemoglobin level baseline cry duration, tissue oxygenation, and heart rate pain control pain, crying, agitation, and physiologic stress infant pain response penile edema blood methemoglobin concentrations behavioral distress and adrenocortical responses higher oxygen saturation dorsal penile nerve block (dpnb distress scores and heart rates elevation of heart rates heart rate, oxygen saturation, and crying time crying duration and type, vomiting, gagging, breath holding, and jitteriness redness and blistering of the foreskin neonatal stress indicators peak plasma concentrations systolic severe pain heart rate, respiratory rate, and crying during circumcision physiologic and subjective stress reactions pain response heart rate, rhythm, dysrhythmias, blood pressure, transcutaneous oxygen (tcpo2), rate pressure product, and behavioral state pain-related measurements heart rate and oxygen saturation changes transcutaneous oxygen levels, crying time, heart rate, and respiratory rate nips scores postoperative pain behavioral and physiologic indicators of neonatal pain physiologic variables (heart rate, blood pressure, oxygen saturation, and respiratory rate) and behavioral score 20 minutes respiratory rate and oxygen saturation levels demographic characteristics such as gestational age and birth weight pain relief preoperative and postoperative serum beta-endorphin and lidocaine concentrations heart rate and crying time crying and lower heart rates physiologic stress reduction oxygen saturation differences plasma for cortisol levels rate of improvement or recovery curve oxygen saturation untoward reactions facial-activity scores seconds of crying time observational pain intensity rating scale and the physiologic parameters of heart rate, respiratory rate, oxygen saturation levels, salivary cortisol levels, and length of cry distress percentage of the procedure time neonates spent crying facial activity neonatal stress postoperative cortisol levels newborn distress facial expressions systolic blood pressures (sbp efficacy and safety heart rate changes and total crying time respiratory rates pulse rate and oxygen saturation feeding behavior pre- and postcircumcision cortisol levels indices of perceived pain including crying time, behavioral state, oxygen saturation, and heart and respiratory rates pain distress (percentage of time crying and heart rate pain responses percentage of circumcision procedure time a neonate spent crying blood pressure heart rate, respiratory rate, and behavioral distress scoring diastolic heart rate, respiratory rate, and behavioral score pain of neonatal circumcision neonatal pain excursion from baseline heart rate, tissue oxygenation, and cry duration adrenal cortisol response to surgery agitation heart rate, respiratory rate, and crying time infant state, salivary cortisol levels, and respiratory rates pain and physiologic stress transcutaneous oxygen pressure levels uncomplicated pregnancies and vaginal deliveries heart-rate oxygen perfusion, blood pressure, respiratory rate, heart rate, and cardiac rhythm circumcision (choking and apnea heart rate and less crying neonatal circumcision pain behavioral observations mean gomco time, 209 seconds) and percentage of respiratory rate change postoperative comfort scores heart rate, respiratory rate, sao2, cortisol changes, and duration of crying diastolic blood pressures (dbp percentage of crying time and percentage of sao2 change heart rate better methemoglobin levels mild erythema heart rate, transcutaneous oxygen saturation, facial activity, and crying facial actions indicative of pain heart rates and oxygen saturations cortisol levels heart rate and oxygen saturation, and subjective determinations of behavioral state physiological and behavioral monitoring subjective observation, measurement of heart rate, and the percent of time spent crying small hematomas mean peak heart rates average oxygen saturation neonatal cortisol response behavioral characteristics and amount of crying mean systolic blood pressure behavioral distress respiratory rate sbp and dbp behavioral (facial activity and time spent crying) and physiologic (heart rate and blood pressure) responses plasma cortisol levels heart rate, transcutaneous oxygen saturation, and crying pain reduction serum beta-endorphin concentrations arousal effective level of anesthesia time spent crying crying pain of circumcision sensitivity to cues and social-emotional growth-fostering scales heart rate and blood pressure spent less time crying behaviors (clarity of cues and responsiveness safety and efficacy heart rate, respiratory rate, oxygen saturation levels, seconds of crying time, and overt generalized reaction stress reactions distress scores salivary cortisol changes cardiac rate, rhythm, blood pressure, and transcutaneous oxygen spectral crying parameters heart rate, smaller drops in oxygen saturation, and less crying mean increase in their occurrence heart rate and high-pitched cry pain ratings heart rate, oxygen saturation, systolic and diastolic blood pressure, and crying time heart rate during circumcision local or systemic complications adrenal response total number distress and cortisol response shortened crying time pain heart rate, respiratory rate, and oxygen saturation (sao2 neonatal circumcision pain with and without dorsal penile nerve block (dpnb duration of the crying and grimacing pain and stress plasma neonatal infant pain scale (nips) score; secondary: heart rate, respiratory rate heart rate mean heart rate methemoglobin level percentage change in heart rate from baseline, the percentage of oxygen saturation, and the score from the modified behavioral pain scale brazelton neonatal assessment scale (bnas pain responses; sucrose alone|mean heart rate was above normal limits during all steps of the circumcision for the control group and during some of the steps for the other two groups. sbp and dbp differed significantly between groups during two of the noninvasive steps; and tcpo2 differed significantly during six steps. physiologic and behavioral parameters indicated significantly (p < 0.05) decreased pain response in all treatment groups compared with that in the control group. (n = 20) experienced significantly less stress, as evidenced by smaller decreases in transcutaneous oxygen pressure levels, less time spent crying, and smaller increases in heart rate, than infants circumcised in an identical manner without anesthetic (n = 10). during tightening of the bell clamp, significantly less crying was seen in the 5% lidocaine-prilocaine group (13 +/- compared with placebo, emla significantly attenuated the pain response as shown by lower heart rate of an average of 25 beats per minute (f [1, 25] = 14.92; p < .001), higher oxygen saturation of 5%, particularly during the clamping and lysis phases (f [1, 25] = 19.83; p < .0001), 20% less facial activity (f [1, 25] = 12.01; p < .002), and 15% less crying during the clamping, gomco clamp application, and incision of the foreskin. the pacifier dipped in sucrose had a distress-reducing effect during both the post-dpnb injection and circumcision periods. the average oxygen saturation of the control groups decreased by 5.6% from baseline (p less than 0.001), and that of the lidocaine group decreased by 1.0%, which was not a significant change. newborns in the untreated placebo group exhibited homogeneous responses that consisted of sustained elevation of heart rate and high-pitched cry throughout the circumcision and following. for all operative intervals combined, anesthetized infants had a smaller decrease in oxygen saturation (p < .001) and a smaller increase in respiratory rate (p = .005) than did controls. oxygen saturation differences were statistically significant for the music group (p =.02) and approached significance for the emla group. there was a significantly greater increase in heart rate over the duration of the circumcision in the emla group than in the dpnb group (49 vs 9 beats per minute). there were no significant differences between groups except on physiologic and subjective stress reactions during circumcision. ancova revealed significant group differences in subscales of the ncafs there were no local or systemic complications. the dpnb group had significantly lower pain-related measurements (p &lt.05). infants receiving lidocaine in a dorsal penile nerve block (dpnb) remained more attentive to animate and inanimate stimuli following circumcision and demonstrated a greater ability to quiet themselves when disturbed. the adrenal cortisol response to surgery was not significantly reduced by the administration of lidocaine. comparisons of the vital signs precircumcision and postcircumcision showed no differences between the placebo and treatment groups, with the exception of mean systolic blood pressure, which significantly increased in the placebo-treated newborns (p < .05). crying was reduced further to 31% (p less than .05) by providing infants with a sucrose-flavored pacifier to suck. statistically significant differences were noted in heart rate, respiratory rate, and behavioral score when comparing the dpnb group with controls during and after circumcision. cortisol levels measured 30 minutes postoperatively were lower in the local-anesthesia group than in either the controls or the dorsal penile nerve block group (p less than .05). facial-activity scores were 12 to 49 percent lower during various steps of the procedure in the lidocaine-prilocaine group. respiratory rates were higher in the eutectic mixture group but did not reach statistical significance. feeding behavior deteriorated in breast- and bottle-fed neonates in both groups, and acetaminophen did not seem to influence this deterioration. to determine if buffered lidocaine provided a more effective nerve block in a short time than plain lidocaine for neonatal circumcision. infants who had dpnb with lidocaine cried 50 percent less during circumcision compared to combined controls (p less than 0.01). dorsal penile nerve block was found to be a safe and easy technique that was effective in reducing behavioral distress and modifying the adrenocortical stress response. sucrose gave significant (p < .001) the results showed a significant difference in the heart rate between the treated and untreated group, but the respiratory rate and oxygen saturation levels did not differ significantly. sucrose on a pacifier was far more analgesic than water on a pacifier for infants in the gomco group. five groups of 15 neonates were matched for weight, age, and apgar scores and randomly assigned to a control group, one lidocaine group and three chloroprocaine groups with 2-, 3- and 5-minute postinjection waiting periods. fifty-six percent of infants circumcised with the mogen clamp and dpnb did not cry at all during the procedure.|48 healthy, full-term infants eighty healthy, term, newborn male infants scheduled for routine neonatal circumcision fifteen infants had dpnb with 68 full-term male neonates pain relief during circumcision one hundred ninety-four newborn males palliation of pain associated with circumcision in low-birth-weight infants pain during circumcision 121 neonates undergoing unanesthetized circumcision forty healthy male newborns neonatal circumcision pain eleven male newborns equal numbers (n = 20 university teaching hospital, general care nursery antenatal units in 2 tertiary care hospitals in edmonton, alberta physicians who circumcise newborns fifty infants were enrolled in the study: 19 randomized to the dpnb group, 19 to the control group, and 12 to the emla group neonatal circumcision sixty-one neonates infants undergoing circumcisions with 1 analgesia in infant circumcision 30 healthy full-term infants (including tertiary referral, neonatal intensive care nursery in a university teaching hospital unanesthetized newborn males and a group having dorsal penile nerve block (dpnb uncircumcised control infants newborn infants was assessed during two standard painful hospital procedures: blood collection via heel lance and circumcision five groups of 15 neonates were matched for weight, age, and apgar scores infant rats one hundred nineteen full-term male, normal birth weight neonates, 12 hours old or older thirty newborns 23 neonates fifty-eight neonates an additional cohort of term newborns (n = 20 neonates undergoing the procedure with ring block and those receiving no anesthesia low-birth-weight neonates eighteen control infants received fifty neonates with weights of 1600 to 2500 neonates undergoing circumcision infant circumcision twenty-seven newborn, full-term male neonates, aged 1 to 3 days normal newborn nursery in a university teaching hospital regional anesthesia during newborn circumcision 71 patients who were recruited from the inpatient nursery of a military community hospital over a 5-month period thirty newborn males who met the selection criteria newborn circumcision g at the time of circumcision who were discharged from the hospital between may 1994 and june 1995 newborn infants twenty infants receiving penile nerve block for circumcision were compared with ten infants having circumcision without anesthesia newborn behavior and mother/infant interaction pain from circumcision in neonates level iii nursery at a midwestern hospital 80 male infants subjects were healthy male newborns whose parents had requested circumcision 44 healthy full-term neonates undergoing circumcision was conducted a consecutive sample of 52 healthy, full-term, male newborns, aged 1 to 3 days twenty-five infants who were otherwise eligible were excluded because of parental refusal of consent to participate fifty infants >/=341/2 weeks postmenstrual age and stable for discharge at time of circumcision; gestational age at birth 25 to 41 weeks; birth weight 600 to 4390 g; age at study 3 to 105 days a total of 68 and 59 neonates infants undergoing circumcision thirty infants
bone histology 1,25(oh)2d3 quickly corrected hypocalcaemia, reduced serum-alkaline-phosphatases and serum-immunoreactive-parathyroid-hormone serum ipth incidence of hypercalcemia (serum calcium concentration serum al levels bone alkaline phosphatase respective median ipth concentrations p-osteocalcin and bone alkaline phosphatase serum calcium and ionized calcium concentrations parathyroid hormone (pth) suppression picp renal bone disease serum a1 levels hypercalcemia symptomatic or had radiological evidence of bone disease bone mineral density (bmd) estimated by dual energy x-ray absorptiometry and plasma levels of biochemical markers of bone turnover [osteocalcin, bone alkaline phosphatase, propeptide of type-i collagen (picp) and telopeptide of type-i collagen] and parameters of calcium homeostasis preservation of ob hypercalcaemic episodes bone mineral density ipth level serum calcium and phosphorus levels hypercalcaemia or hyperphosphataemia plasma ipth, serum calcium and phosphorus, urinary calcium, bone-specific serum markers, and serum lalpha,25-dihydroxyvitamin d levels hypercalcaemia mean ipth decrease ipth concentration plasma levels of parathyroid hormone ipth without causing hypercalcemia calcium levels, phosphorus balance, and kidney function elevated resorption and osteoid indices mean serum alkaline phosphatase activity and intact parathyroid hormone concentration resorption indices terminal renal failure adverse-event rates and changes in gfr urinary calcium and phosphorus excretion or deterioration in kidney function serum phosphorus and alkaline phosphatase concentrations biochemical, radiographic, and histological indices of bone metabolism glomerular filtration rate (gfr renal function plasma levels of vitamin d metabolites bone disease baseline 1,84 ipth concentrations bone mineral content ipth serum ipth (allegro nichols), 1-25 vitamin d (irma-mab), total and ionized calcium (nova 8 pabish), serum phosphate, alkaline phosphatase and creatinine clearance pth levels femoral neck creatinine clearances mean plasma ipth level serum ipth, calcium, and phosphorus levels parathyroid hormone levels ipth level reductions s-calcium, s-phosphate, and urinary excretion of calcium serum pth, urinary camp excretion, and bone resorption indices mineralizing boundaries (m.bd median intact pth (ipth) level bmd plasma-phosphorus, plasma-alkaline-phosphatase, or in the degree of bone mineralisation rate of progression of renal failure initial serum 1,25(oh)2d levels mineralizing activity glomerular filtration rate mean serum calcium or phosphorus or urinary calcium levels or incidence of hypercalcemia, hyperphosphatemia, or hypercalciuria risk of hypercalcemia final s-creatinine or change in s-creatinine incidences of hypercalcemia, hyperphosphatemia, and elevated calcium-phosphorus product levels bone metabolism and bone density serum c- and n-telopeptide and bone-specific alkaline phosphatase levels intestinal absorption of calcium and in plasma-calcium parathyroid hormone (pth) levels ipth levels femoral neck and lumbar spine height z scores serum ca rose steadily and cr.cl gfr percentage fall in creatinine clearance histological indices of bone turnover urinary excretion rate of calcium|no significant changes were induced in plasma-phosphorus, plasma-alkaline-phosphatase, or in the degree of bone mineralisation as measured by the phosphorus/hydroxyproline ratio in bone. s-calcium, s-phosphate, and urinary excretion of calcium did not change significantly on either placebo or on calcitriol. serum pth, urinary camp excretion, and bone resorption indices decreased in the treatment group, indicating suppression of parathyroid hyperfunction. whereas in group a, serum ca rose steadily and cr.cl declined, in group b both parameters levelled off between t6 and t9. 1,25(oh)2d3 quickly corrected hypocalcaemia, reduced serum-alkaline-phosphatases and serum-immunoreactive-parathyroid-hormone, and more than doubled the urinary excretion rate of calcium. 1,25(oh)2d3 treatment was associated with a significant fall in serum phosphorus and alkaline phosphatase concentrations as well as with histological evidence of an amelioration of hyperparathyroid changes. histological indices of bone turnover significantly improved in patients given alfacalcidol and significantly deteriorated in controls: among patients with abnormal bone histology before treatment, bone disease resolved in 23 (42%) of those given alfacalcidol compared with two (4%) of the controls (p < 0.001). paricalcitol capsule was well tolerated and effectively decreased ipth levels with minimal or no impact on calcium levels, phosphorus balance, and kidney function in patients with stages 3 and 4 ckd. a significant difference in bmd between the treatment groups in favour of the alfacalcidol-treated patients was found in the spine (4.2%), the femoral neck (4.9%) and the total femur (3.0%) (p<0.05). daily oral intake of 0.5 micrograms of calcitriol prevents an increase of ipth without causing hypercalcemia, but only oral boluses (b and c) decreased ipth: from 270 +/- after 6 weeks, ipth level reductions with doxercalciferol treatment exceeded those with placebo at all subsequent intervals (p <0.001). calcitriol reduced the ipth concentration in 23/29 patients in the daily group and in 21/30 in the intermittent group. after 1 year of study, an increase in bone mineral density in the calcitriol group measured by dual-energy x-ray absorptiometry was seen for the femoral neck and lumbar spine when compared to the placebo group (p < 0.001 and p < 0.01, respectively). there was no significant difference between calcitriol and dihydrotachysterol in promoting linear growth or causing hypercalcemia in children with chronic renal insufficiency.|patients with pre-dialysis chronic renal failure (crf non-dialysed patients with c.r.f 121 to 323 patients with moderate renal failure and elevated of 1,84 ipth patients with moderate renal failure (prospective between 15 and 60 ml/min/1.73 m2 (0.25 and 1.00 ml/s/1.73 m2), an average of 2 consecutive intact parathyroid hormone (ipth) levels greater than 150 pg/ml (ng/l), 2 consecutive serum calcium levels between 8.0 and 10.0 mg/dl (2.00 and 2.50 mmol/l), and 2 consecutive serum phosphorus levels of 5.2 mg/dl or less (< or = 1.68 mmol/l predialysis renal insufficiency children with renal diseases investigators patients with mild to moderate chronic renal failure patients with renal secondary hyperparathyroidism children with chronic renal failure two hundred twenty patients participated (n = 107, paricalcitol; n = 113 45 patients with mild to moderate renal failure 176 patients aged 18-81 with mild to moderate chronic renal failure (creatinine clearance 15-50 ml/min) and with no clinical, biochemical, or radiographic evidence of bone disease control group of fifteen (15) patients (mean age 47 children with renal failure mild to moderate renal failure predialytic chronic renal failure thirteen patients in the predialysis phase of chronic renal failure (crf patients with predialysis chronic renal failure 89 patients given alfacalcidol and the 87 controls given 36 patients with a glomerular filtration rate (gfr) of 6-60 ml/min sixteen (16) patients (mean age 51 16 years; creatinine clearance 22.9 18 non-dialysed patients with chronic renal failure (c.r.f 30 patients with predialysis chronic renal failure patients with stages 3 and 4 ckd with shpt patients with mild to moderate renal failure patients with chronic kidney disease (ckd patients with high ob sixteen patients with chronic renal impairment (creatinine clearance 20 to 59 ml per min) received either chronic renal failure ninety-four patients completed a mean of 8.0 months of control observations patients with crf patients with a creatinine clearance below 35 ml/min and mild renal osteodystrophy were selected secondary hyperparathyroidism in stages 3 and 4 ckd 24 patients with chronic renal failure (glomerular filtration-rate (g.f.r.) 5-25 ml/min) participated in a double-blind 59 children (mean age 8.4+/-4.7 years) with chronic renal insufficiency (mean ccr 22.4+/-11.6 ml/min per 1.73 m2) and secondary hyperparathyroidism 24 non-dialyzed patients with chronic renal insufficiency (cri), matched pairwise as to age, sex, and creatinine clearance (cr.cl children aged 1 1/2 through 10 years, with a calculated glomerular filtration rate between 20 and 75 ml/min per 1.73 m2, and with elevated serum parathyroid hormone concentrations 132 patients had histological evidence of bone disease at start of study patients with chronic kidney disease (ckd) stage 5 patients with stages 3 and 4 ckd patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4 17 nephrology centres from belgium, france, the netherlands, and the united kingdom children with chronic renal insufficiency fifty-five adults with stage 3 or 4 ckd and an intact pth (ipth) level greater than 85 pg/ml (ng/l children with chronic renal failure prior to dialysis patients with predialytic renal failure moderate renal failure
maternal arterial po2 umbilical arterial and venous blood neonatal rso(2), ua ph, uv ph and ua base excess (be uv oxygen content umbilical artery (ua) and venous (uv) blood samples fetal oxygen stores oxygen saturation and blood o2 contents maternal arterial samples and fetal uv and ua samples pulmonary function, maternal oxygenation maternal and fetal oxygenation and lipid peroxidation fetal arterial blood gases maternal and fetal oxygenation and oxygen free radical activity maternal and umbilical plasma concentrations of lipid peroxides (8-isoprostane, mda, ohp mean maternal rso(2 cord vein-artery po2 differential maternal arterial blood demographic or hemodynamic variables, time from uterine incision to fetal extraction, neonatal birth weight, presence of umbilical cord abnormalities, type of resuscitation required by the neonate, or apgar score u-d interval, umbilical arterial (ua) and venous (uv) blood gases and oxygen content and apgar scores ua and uv blood samples cord vein po2 oxygen free radical activity maternal pao2 levels and umbilical vein (uv) and umbilical artery (ua)po2 levels maternal fio2 and umbilical arterial (ua) and venous (uv) po2, pco2, ph, and neonatal apgar score umbilical cord arterial blood apgar score uv po(2) or oxygen content blood gases and the products of lipid peroxidation (8-isoprostane, malondialdehyde (mda), hydroperoxide (ohp)) and purine metabolites ua po2 levels fetal gasometric parameters fetal partial oxygen pressure uv po2 levels free radical activity and lipid peroxidation maternal inspired fraction of oxygen maternal and neonatal regional cerebral oxygenation (rso(2 cord gas values po2 in venous blood oxygen saturation in maternal blood by pulse oximetry maternal pao2 levels maternal arterial, uv, and ua base excess values fetal oxygenation 1- or 5-minute apgar scores inspired fraction of oxygen, maternal partial oxygen pressure, and fetal partial oxygen pressure umbilical arterial or venous ph, partial pressure of oxygen and partial pressure of carbon dioxide mean values of the uv blood samples umbilical arterial and venous blood samples neonatal rso(2) and apgar scores maternal mean arterial pressure, heart rate and peripheral oxygen saturation uv or ua blood gases, oxygen content or apgar scores umbilical venous po2 cord artery po2 arterial blood gases uv po(2 oxygenation mean values of the ua blood samples ua and uv po2 oxygen content|there was a significant increase in ua and uv po2 when using a simple o2 mask (p < 0.001).(abstract oxygen saturation in maternal blood by pulse oximetry was higher after 10 minutes in the group of women who received supplemental oxygen through face masks. the apgar score (1 min) in group fm was lower than that of group ra (p = 0.046). the cord artery po2 of the oxygen group was also significantly higher (p less than 0.05) at 20 mm hg (sd 6) versus 15 mm hg (sd 6). the results showed that there were no significant differences in the umbilical arterial or venous ph, partial pressure of oxygen and partial pressure of carbon dioxide between any of the three groups. an increase in maternal inspired fraction of oxygen did not show any correlation with an increase of fetal partial oxygen pressure. maternal arterial, uv, and ua base excess values in the hyperoxic groups were significantly higher than in the normoxic groups. maternal and umbilical plasma concentrations of lipid peroxides (8-isoprostane, mda, ohp) were greater in the oxygen group than in the air group (p<0.05). there was no increase in the uv po(2) or oxygen content when 40% oxygen was administered compared with air.|full-term parturients who had received prenatal care during pregnancy forty-four healthy parturients 20 parturients undergoing spinal block 40 healthy patients undergoing elective cesarean sections under lumbar epidural anesthesia 204 women having elective caesarean section under spinal anaesthesia to breathe 21, 40 or 60% oxygen one hundred thirty women were enrolled thirty-two healthy pregnant women at term who were to undergo cesarean section following epidural anesthesia mother to fetus during cesarean section under epidural anesthesia 45 patients receiving cesarean section under epidural anesthesia newborn for elective cesarean deliveries under spinal anesthesia healthy parturients under spinal anesthesia elective caesarean section under spinal anaesthesia parturients undergoing caesarean section under regional anaesthesia parturients having caesarean section under spinal anaesthesia mothers undergoing elective caesarean section under spinal anaesthesia they were scheduled for delivery by cesarean section under spinal anesthesia sixty-nine women undergoing elective caesarean section ninety parturients
hypoglycemia after admission cerebral malaria lethality rate evolution of parasitemia quinine toxicity body temperature peak concentrations case-fatality rates insulin concentrations mean trough and peak plasma quinine levels all blood concentrations mean high and low quinine concentrations mild toxic effects clinical and parasitological response mean peak concentrations mean cost transient partial hearing loss hypoglycaemia cardiovascular side effects cardiovascular toxicity fever clearance time parasite clearance time time taken to clear parasites coma mean durations|all blood concentrations exceeded the 99% in vitro inhibitory concentration (ec99) of 0.89 mg/l or less of quinine for 60 isolates of plasmodium falciparum, which were taken from children with malaria during the same period. coma mean durations were similar in the two groups: transient partial hearing loss occurred significantly more in the study than control group (p < 0.05).|59 children with severe malaria severe falciparum malaria at kenyatta national hospital, kenya severe malaria in africa african children from july 1989 to february 1990, 17 non-pregnant patients with severe falciparum malaria, aged 14 years and above received an seventy-two children eight months to 15 years of age with cerebral malaria were included
mental status, headache, unprovoked fall, focal weakness, neglect, and dysphasia frontal and parietal localizations noniatrogenic traumatic extracranial internal carotid artery dissections visual aura neurologic outcome risk of suffering a disabling stroke severe ipsilateral headache and orbital pain new cerebral ischemic events, defined as ischemic stroke, tia, or retinal ischemia, 2) symptomatic intracranial hemorrhage, and 3) major extracranial bleeding carotid recanalization arterial recanalization bleeding complications hemorrhagic adverse events recanalization rate variables stroke and arterial occlusion ischemic optic neuropathy internal carotid artery dissection intracranial haemodynamics retinal ischemia in 8, and local symptoms and signs (headache, neck pain, horner syndrome, cranial nerve palsy result of distal thromboembolism brain infarction migraine resolution of the angiographic appearances subsequent stroke functional independence seizures transient ischemic attacks recurrence of a dissection overt cerebral ischemia manifest by paresis (three), sensory deficits risk of stroke, tia, or dissection recurrence disabling stroke good recovery and early reopening of the occluded ica efficacy and safety risk of stroke and recurrent dissection hemorrhagic complications overall mortality functional outcome massive stroke, embolic mechanism and lack of local recanalization neck pain complete recanalization of vertebral dissections cad recurrences clinical symptoms of sudden unilateral headache and facial pain extracranial bleeding complications retinal ischemia irregular expansion, double lumen and aneurysmal dilation headache, facial pain, a subjective bruit, oculo-sympathetic palsy and transient monocular blindness occipital and nuchal pain, with vertebral artery dissection modified rankin scale (mrs) and barthel index (bi initiation of heparin subjective bruit or painful ischemic events or dissection recurrences traumatic extracranial ccad fibromuscular dysplasia central retinal artery occlusion or ischemic ocular syndrome cerebral ischaemia tia without cad recurrence painful scad rates for death and stroke chronic arterial stenosis recanalization contralateral icad arterial hypertension recurrent ischemic stroke new ischemic events preceding traumata, vascular risk factors, presenting local and ischemic symptoms, and patient-outcome bilateral dissections initiation of anticoagulation recanalization rate of cad transient ischemic symptoms or arrested progression of established neurologic deficits ischemic and hemorrhagic complications, occurrence of seizure and rates of arterial recanalization recurrence (stroke and death) and clinical outcome at 6 months cervical perforating wound nor atheromatous predisposing lesion ischemic optic neuropathy (ion verified cad recurrence cerebral infarction stagnating blood flow velocities deficit), fair (moderate deficit needing some assistance), poor (requiring institutionalization), and dead brachiofacial hemiparesis ph pattern neurologic outcomes recurrent cad without stroke bilateral vad|the spontaneous course of such a dissection most often (80%) leads to an almost complete resolution of clinical and angiographic signs. dissections cause approximately three per cent of non-haemorrhagic stroke and are usually observed in young and middle-aged patients. seven (2.3%) patients died during the follow-up (mean 4.0 years, 1186 patient years). the follow-up investigations moreover demonstrated that intracranial haemodynamics may change from day to day in patients suffering from internal carotid artery dissection. frontal and parietal localizations were significantly associated with internal carotid artery dissection (p=0.013 and p=0.010, respectively), whereas occipital and nuchal pain, with vertebral artery dissection (p=0.047 and p<0.001, respectively). there were no deaths. ischemic optic neuropathy occurred after a mean of 5.3 days (range, 3-8 days) following the first symptom, which was headache in 1 patient, transient monocular blindness in 2, and hemispheric transient ischemic attack in 1. doppler ultrasound screening of young patients presenting with stroke, identified 10 patients with reduced common and internal carotid blood flow without any evidence of atheroma. one group of cervical carotid dissecting aneurysms is characterized by spontaneous onset, unilaterality, and the absence of pseudoaneurysm formation. four anticoagulated patients developed seizures, compared to 2 patients with antiplatelets (p > 0.05). bleeding complications from full anticoagulation were higher than with antiplatelet agents (p = 0.05). early heparin sodium therapy may help prevent intraluminal clotting without carrying an important risk of extending the dissection, but its clinical benefit remains unproven. after a mean follow-up of 31 months, four (0.9%) patients presented a recurrent ischemic stroke attributable to either not yet completely recovered initial cad (n = 2) or a recurrent cad (n = 2). all recovered without deficits. the internal carotid artery (ica) was the most frequently involved vessel (63%), followed by the vertebral artery (30%, and multivessel involvement in two patients (7%). during follow-up, ischemic events were rare (ischemic stroke, 0.3%; tia, 3.4%; retinal ischemia, 1%); their frequency did not significantly differ between patients treated with anticoagulants (5.9%) and those treated with aspirin (2.1%). none of the 21 patients had a subsequent stroke. cerebral ischaemia was present in 90% of cases and occurred within a month of the initial event in all cases but one and was the first symptom in 53% of cases. examples of suspected dissection of the intracranial internal carotid, middle cerebral, posterior cerebral and extracranial vertebral arteries are also presented. among the patients studied, 82% were caucasian, 53% were male and the average age was 41.7 years old. complete recanalization of vertebral dissections was associated with a favorable prognosis [or 3.2 (95% ci 1.1-8.8; p = 0.02)]. patients with cad presented more often with a partial horner's syndrome and had a higher prevalence of fibromuscular dysplasia than patients with vad. five patients with spontaneous dissection of the cervical internal carotid artery (cica) are reported. no mortalities were noted. angiographic findings can verify this diagnosis, showing various signs of eccentric, narrowing stenosis, false lumen, pseudoaneurysms, or complete occlusion. the overall mortality was 12%. most dissections were extracranial. patients with lateral medullary infarction returned to functional independence (p = 0.026), while patients with deep hemispheric infarction tended to have a disabling stroke (p = 0.068). doppler investigation was able to detect, with a rather satisfying reliability, anomalies in the carotid flow before angiography ; angiogram showed lesions nearly always facing first or second cervical vertebra and bilateral lesions in four instances. spontaneous dissection of the internal carotid artery is not well known in scandinavia.|patients with this injury 1200 consecutive patients with a first stroke had a spontaneous dissection with occlusion of the cervical internal carotid artery (ica 33 consecutive eicad patients initially treated either with anticoagulation (n = 25) or with antiplatelets (n = 8), a standardized interview was performed after 28 twenty-two adult trauma patients were diagnosed with bci, for an incidence of 0.45% in the 8-year study period 68 patients patients with spontaneous dissection of the cervical carotid artery ten patients were diagnosed after an abnormal neurologic examination, and eight others were diagnosed after having carotid canal fractures 126 patients with cervical artery dissections thirteen patients (57%) had no or minimal deficits upon discharge sixteen patients (80%) survived, the majority with normal neurologic function extracranial internal carotid artery dissections: noniatrogenic traumatic lesions patients with dissection of cervical arteries (dca mean age was 35.4 years; 4 patients died (3%) and 126 were followed for 3,906 person/years; 17 patients (13%) had a heralding ischemic cerebral event (6 strokes, 11 tias) about 8 days before the diagnosis of dca 301 finnish patients 298 consecutive patients with sicad (56% men; mean age 46 sixteen cases of spontaneous dissection of the cervical internal carotid artery (6 verified seven patients, with four major bleeding complications requiring cessation of heparin and blood transfusions anticoagulated patients was bi 92 between april 1976 and april 1986, cervicocephalic arterial dissections were diagnosed in 19 of 4531 patients undergoing cerebral arteriography for acute cerebrovascular symptoms sixty-six patients diagnosed with sdcva were studied at two tertiary hospitals at so paulo 126 patients primary headaches and painful spontaneous cervical artery dissection eight patients were not anticoagulated, five because of intracranial injuries, two who had surgical cca repairs, and one with an aortic injury patients with carotid and vertebral artery dissections (cad, vad), (2 17 cases reports of traumatic injury affecting the extracranial portion of internal carotid artery five patients with spontaneous dissection of the cervical internal carotid artery (cica patients with spontaneous dissection of the cervical carotid artery (sicad patients suffering from internal carotid artery dissection patients with sdcva nine patients with dissections of the cervical arteries six patients subsequently had an operation for residual occlusive disease or aneurysm 130 patients with angiographically-proven dca admitted to the neurology institute in mexico city (mexico), and analyzed clinical and neuroimaging data, treatment and outcome countries with multiethnic population patients with cad the records from 1976 to 1995 of 24 patients who had 28 thirteen patients had accompanying closed head injuries multiethnic population 54 consecutive patients consecutive patients with a first event of cad who were admitted in 24 departments of neurology within a period of at least 1 year patients with spontaneous carotid dissection young patients presenting with stroke, identified 10 patients with reduced common and internal carotid blood flow without any evidence of atheroma nine patients had visual symptoms or headache, 10 had transient focal neurologic symptoms (tia), and five had stroke twelve patients with either unilateral or bilateral carotid mural injury were anticoagulated eighteen patients received patients having an ischemic stroke or tias blunt vascular injuries to the head and neck (bhvi patients were retrospectively selected from a stroke data bank or from the local administrative data bank using the 10th revision of the international statistical classification of diseases patients who have icad often have prodromal symptoms before stroke seventeen patients who had 19 icad underwent a duplex scan at the time of presentation 68 patients aged 20 to 71 (mean 46 38 patients with acute stroke following occlusion due to cad (18 males, 20 females, median age 50.5 years, range 16-82 one patient presented only with a painful post-ganglionic horner syndrome, another patient with neck pain and post-ganglionic horner syndrome, another patient solely with protracted unilateral headaches, three with transient ischemic attacks (tia), and 21 with ischemic strokes women were younger than men twenty patients with blunt mechanism injuries to the internal carotid artery 4 patients with ion (2 anterior and 2 posterior) due to internal carotid artery dissection of a consecutive series of 110 patients with internal carotid artery dissection (3.6 130 consecutive cases traumatic injury affecting the extracranial portion of internal carotid artery (17 case reports) (author's transl four hundred fifty-nine patients (mean age 44.0 27 patients with extracranial ccad who were evaluated, treated and/or followed by our stroke service from september 1995 to august 2001 15 men (56%) and 12 women (44%) with mean ages of 38 and 43 years respectively young and middle-aged patients selected patients who have failed medical therapy six patients (five men and one woman) 31 to 62 years old middle-aged man who after strenuous physical exertion suffers a transient ischemic attack or progressing stroke patients with closed head injuries and carotid canal fractures 457 survivors, 25 (5.5%) could not be contacted in 2002 because they had moved 11 patients aged between 34 and 57 years with clinical and angiographic findings typical of carotid dissection thirteen patients received only medical therapy, and six had surgery 9.7 years) were included in the study young adults blunt vascular injuries of the head and neck 22 patients who presented with bci and assessed neurologic and survival outcomes on the basis of injury grade and treatment with anticoagulation or antiplatelet therapy patients with sdcva from a multiethnic population spontaneous carotid dissection with acute stroke patients with bhvi 301 consecutive finnish patients, diagnosed from 1994 to 2007 298 patients twenty-nine bhvi in 23 patients were reviewed from 1989 to 1997 patients studied, 82% were caucasian, 53% were male and the average age was 41.7 years old blunt carotid injury
median of the peak maximal diameter of the llrs size and duration of the large local reactions hrql size and duration of large local reactions health-related quality of life (hrql objective systemic reactions systemic reaction after a deliberate sting challenge accidental stings positive skin-test reaction vespid allergy quality of life questionnaire (vqlq), burden of treatment and expectation of outcome health-related quality of life generalized urticaria 18 systemic reactions systemic reaction vqlq score recurrences of systemic reactions|vit results in a clinically significant improvement of hrql in most patients with reactions limited to the skin following yellow jacket stings. sixteen of these 18 reactions were judged to be milder than the patient's reaction to the first sting, 2 were similar in severity, and none were more severe. objectively defined systemic reactions to sting challenges arose in 21 of 29 participants (72%) on placebo (8 reactions were associated with hypotension) and none of 23 on vit (p<0.0001). sting challenge in 41 patients with previous large local reactions and positive venom skin tests caused large local reactions 16 cm or larger in 34 patients, and 29 consented to treatment. placebo and whole-body extract gave similar results and were significantly less effective than venom immunotherapy (p less than 0.01). sublingual immunotherapy (slit) proved effective and safe in respiratory allergy, and thus its use in hymenoptera allergy can be hypothesized.|children with allergy to insect stings 20 patients matched for history and sensitivity, as judged by venom skin test, histamine release and ige antibody to venom 68 healthy volunteers (aged 20-63 years) who were allergic to m pilosula venom to placebo (33) and vit (35 14 patients with failure of treatment with whole-body extract and 41 patients with previous large local reactions and positive venom skin tests caused large local reactions 16 cm or larger in 34 patients, and 29 consented to treatment patients with llrs who were monosensitized to honeybee 55 patients eligible for the study, 29 consented to randomization: 15 to vit, 14 to epipen adult patients with dermal reactions following yellow jacket stings thirty patients (18 male patients; mean age, 44.5 years) were enrolled, and 26 completed the study, with 1 dropout in the active group and 3 dropouts in the placebo group otherwise healthy adults 242 children, 2 through 16 years of age, each of whom had had a systemic allergic reaction, affecting only the skin, to an insect sting patients with solely dermal reactions
disability effective rate motor-evoked potential (mep), lower-extremity fugl-meyer score, and gait performance stimulus intensity simple and choice reaction time and improved performance of the purdue pegboard test day 10 mauef score fugl-meyer scores arterial ischaemic stroke (ais aachen aphasia test total score excitability of the non-stroke hemisphere and increased excitability of the stroke hemisphere nhpt baseline repetitions cumulative rebalance of excitability pinch force depressive symptoms cortical excitability hyperexcitability of lh parieto-frontal circuits motor-evoked potential frequency excitability of the stroke hemisphere safety and efficacy rating scales grip strength and the melbourne assessment of upper extremity function (mauef motor control and walking ability clinical efficacy mean grip strength motor function frequency of motor-evoked potentials in biceps and triceps, muscle function (torque about elbow), and purposeful movement (action research arm test greater behavioral and neurophysiologic outcomes motor learning cognitive functioning poststroke recovery and mortality ham-d scores, response and remission rates grip strength excitability age, laterality indices, or mean aachen aphasia test scores wolf motor function test (wmft) and the motor activity log (mal)--amount of use, and on secondary outcome measures including the box and block test (bbt) and the mal neglect symptoms disability scales motor function improvement and corticospinal excitability change motor function and corticospinal excitability motor function recovery spatial asymmetry of gait standardized behavioral inattention test (bit neuropsychologic battery and electroencephalogram fugl-meyer score, barthel index, and central spinal cord motor conduction time (cmct motor function performance cognitive performance and electroencephalogram safety dexterity, force, interhemispheric inhibition, and corticospinal excitability motor disability reduction of ham-d scores and frontal gray and white matter volumes change in laterality indices as quantified by activation positron emission tomography corticospinal excitability bit scores mild adverse effects cortical excitability and walking performance activation shift toward the right hemisphere basal rating scales clinical disability|there were no significant changes in cognitive functioning between the active and the sham stimulation groups. the findings demonstrate treatment-related changes observed in the stimulation group when compared to the placebo control group at 2 months post-stimulation on naming performance as well as other aspects of expressive language and auditory comprehension. contralesional inhibitory rtms was safe and feasible for patients with paediatric subcortical ais, and seemed to improve hand function in patients with hemiparesis. in the real-rtms + realvmc group, motor-evoked potential frequency increased 14% for biceps and 20% for triceps, whereas in the placebo-rtms + placebovmc group, it decreased 12% for biceps and 6% for triceps. we also found that hyperexcitability of lh parieto-frontal circuits was reduced following treatment with real but not sham ctbs. outcomes, including motor-evoked potential (mep), lower-extremity fugl-meyer score, and gait performance, were measured before and after training. a significant 'rtms x time' interaction was obtained indicating that real and sham rtms had different effects on rating scales. patients showed a significant decrease in simple and choice reaction time and improved performance of the purdue pegboard test with their affected hand after rtms of the motor cortex in the intact hemisphere as compared with sham rtms. increasing evidence suggests that the contralesional motor cortex (m1) inhibits the ipsilesional m1 in stroke patients. at the 3-month time point, both of the real rtms groups had improved significantly more in different rating scales than the sham group; in addition, the 1 hz group performed better than the 3 hz group. the effective rate was 90.5% in the rehabilitation subgroup and 68.3% in the control group (p < 0.05). repetitive transcranial magnetic stimulation (rtms) or sham stimulation was given over the motor cortex daily for 10 days to two randomly assigned groups of 26 patients with acute ischemic stroke. these effects were not observed in the sham rtms group (affected and unaffected hand) and in the unaffected hand in the active rtms group. these improvement in the motor function lasted for one week after rtms and motor training (p < 0.001).conclusion: rtms improved the motor learning of the affected hand in patients after stroke; thus, it can apply as anew rehabilitation strategy for patients after stroke. treatment induced cumulative rebalance of excitability in the 2 hemispheres and a reduction of interhemispheric inhibition in the rtms(r) groups. positron emission tomography revealed an activation shift toward the right hemisphere in the control group (p=0.0165), which was absent in the intervention group. regardless of group assignment, participants demonstrated significant gains on the primary outcome measures: the wolf motor function test (wmft) and the motor activity log (mal)--amount of use, and on secondary outcome measures including the box and block test (bbt) and the mal--|patients with paediatric subcortical ais nineteen individuals, one or more years poststroke patients with cerebral infarction patients with aphasic stroke acute ischaemic stroke forty-eight patients with acute ischemic stroke patients within 12 months of a stroke subjects with poststroke aphasia in the subacute stage subacute ischemic stroke patients patients with poststroke depression (psd) who do not respond to antidepressants 2010 classification of evidence patients with refractory depression and stroke stroke patients thirty patients two hundred twenty and three patients with the initial attack of cerebral infarction stroke survivors undergoing 3) forty patients aged 56 approximately 75 poststroke depression individuals with chronic stroke children chronic stroke patients acute stroke twelve patients early after subcortical stroke (mean: 7 days) received aphasic stroke 36 patients with acute ischaemic stroke participated in the study acute ischemic stroke patients were paired for age and weakness ten patients with paediatric stroke were enrolled (median age 13.25 [iqr 10.08-16.78] years, mean time post-stroke 6.33 [sd 3.56] years): four with mild weakness, two with moderate weakness, and four with severe weakness chronic hemiparesis in subcortical paediatric stroke chronic stroke patients with refractory psd patients with chronic non-fluent aphasia post-stroke one hundred twenty and three patients were randomly further divided into rehabilitation subgroup (n = 63, aged 64.0 subacute stroke patients chronic stroke patients with mild motor impairment patients with chronic deficits more than 6 months poststroke 2) sixty patients were divided into three subgroups according to the age: 35 approximately 55 (n = 11), 56 approximately 75 (n = 20), and over 76 (n = 30 twenty patients with chronic subcortical stroke mean age 75 years, mean 27 days after middle cerebral artery infarct (24 subjects completed outcome measures 24 patients with average fugl-meyer lower limb scores of 17.88  5.27 and average walking speeds of 63.81  18.25 cm/s chronic stroke patients with mild motor disabilities 26 patients with acute ischemic stroke patients with hemiparesis acute stroke patients patients with chronic stroke patients were eligible for this parallel, randomised trial if they were in the sickkids children's stroke program and had subcortical ais more than 2 years previously, had transcallosal sparing, were more than 7 years of age, had hand motor impairment, had no seizures or dyskinesia, and were taking no drugs that alter cortical excitability fifteen patients with chronic stroke patients with hemispatial neglect due to a right hemispheric (rh) stroke
cognition (assessed with the mini-mental state examination [mmse]) and functional ability (assessed with the bristol activities of daily living scale [badls change in adas-cog scores withdrawal rates slow cognitive decline alzheimer disease progression alzheimer's disease fatal cerebral bleeds bleeds that led to admission to hospital adas-cog score worsening cognitive subscale of the ad assessment scale (adas-cog cibic+ scores behavioral decline cognitive progression of alzheimer's disease serious adverse events mini-mental state examination, the clinician's interview based impression of change with caregiver input, the noncognitive subscale of the adas, the neuropsychiatric inventory, and the interview for deterioration in daily life in dementia cognitive decline cog score, 1-step worsening on the global clinical dementia rating scale, 15-point decline on the adcs activities of daily living inventory, institutionalization, or death 1-year change in the cognitive subscale of the ad assessment scale rate of cognitive decline efficacy and safety alzheimer's disease assessment scale cognitive and noncognitive subsections, global deterioration scale, clinical global impression of change, mini-mental state examination, instrumental activities of daily living, physical self-maintenance scale, and a caregiver-rated global impression of change adverse reactions clinical dementia rating scale sum-of-boxes, the neuropsychiatric inventory, the quality of life-ad, and the time to attainment of significant end points (4-point decline from baseline adas time to formal domiciliary or institutional care, progress of disability, behavioural symptoms, caregiver wellbeing, and care time mean mmse score changes in mmse, cdr, basic and instrumental activities of daily living scales, and neuropsychiatric inventory (npi alzheimer disease assessment scale- cognitive (adas-cog) subscale score fatigue, dizziness, and hypertension mean badls score 1-year change in the alzheimer disease assessment scale-cognitive (adas-cog) subscale score tolerated alzheimer's disease progression total assessment scores of measures of cognition, clinical status, activities of daily living, affect, and behavior cognitive subscale of the ad assessment scale (adas-cog) and score on the clinician's interview based impression of change with caregiver input (cibic 1-year mean (sd) change in adas-cog scores alzheimer's disease assessment scale-cognitive behavior (adas-cog) composite score and the week 52 clinician's interview-based impression of change plus (cibic intention to treat|there were no obvious differences between the groups in any other outcome measurements. short-term therapy with nimesulide, compared with placebo, had no significant effect on total assessment scores of measures of cognition, clinical status, activities of daily living, affect, and behavior. no significant differences between treatments were found on the mean change from baseline error score for the adas-cog (rofecoxib = 4.84; placebo = 5.44; difference = -0.60) or mean score on the cibic+ (rofecoxib = 4.90; placebo = 4.87; difference = 0.03) over 12 months. over a battery of cognitive tests, indomethacin patients improved 1.3% (+/- there were no serious drug-related adverse events. at 52 weeks, change in adas-cog scores from baseline was similar for placebo and celecoxib 200 mg bid groups (5.00 and 4.39, respectively). fifty-one patients (77%) in the ibuprofen vs 46 (70%) in the placebo group completed the protocol (p>0.20). this difference (1.5 points; ci -4.5-7.5) was not statistically significant, and neither were any of the secondary outcome measures. fatigue, dizziness, and hypertension were more commonly reported in the active drug groups, and more serious adverse events were found in the active treatment group than in the placebo group. there was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only.|patients > or =50 years with established mild-to-moderate ad patients with ad 474 participants screened, 351 were enrolled alzheimer's disease (ad alzheimer's disease 41 patients with mild-moderate ad participants with mild-to-moderate ad (mini-mental state examination score of 13-26) were recruited from december 1999 to november 2000 using clinic populations, referrals from community physicians, and local advertising patients with alzheimer's disease (ad 51 patients with mild to moderate ad four hundred eighty-one patients (70%) completed assessments and remained on treatment at 12 months forty persons with probable ad, most of whom were taking cholinesterase inhibitors group, 19 out of 25 patients completed the study, and 19 out of 26 patients in the patients with mild to moderate ad may 2000 and september 2005 in two hospitals in the netherlands patients had a median age of 75 years; 156 patients had mild ad, 154 had moderate ad, and 18 had concomitant vascular dementia forty ambulatory treatment centers affiliated with the alzheimer's disease cooperative study consortium 310 community-resident patients who had ad and who had no potential indication or definite contraindication for seven ad outpatient treatment centers screened 530 patients, 132 of whom were enrolled participants with inflammatory diseases that might respond to the study medications were excluded participants who tolerated the drug well and perceived benefit were invited to continue open-label nimesulide treatment subjects with ad alzheimer's disease (ad2000 patients with established ad participants with mild-moderate ad (mini-mental state examination score >15, <26; clinical dementia rating= 0.5-1), 65 years or older, with reliable caregivers, were recruited between april 2003 and september 2004 elderly population with a complex chronic medical condition patients with mild-to-moderate ad 138 subjects 692 patients with mild or moderate ad aged 50 years or older
immediate recall condition cognitive function and quality of life health risks memory and mood: verbal memory changes error rates noopsyche, thymopsyche, personality and psychophysiological measures cognitive function or in health-related quality of life somatic complaints and trait anxiety aggressivity memory, visuospatial abilities and frontal lobe function state anxiety estradiol levels mood, cognition and quality of life wechsler adult intelligence scales, measuring both digit span and digit symbol cognitive speed and accuracy, attention, and memory mental state and quality of life wechsler adult intelligence scales verbal memory memory function cognitive effects income management scale of the profile of adaptation to life physical performance extraversion executive functioning health-related quality of life in physical and mental domains cognitive functioning frontal lobe functions cognition incidence rates hpa response to task-induced stress postural stability adverse reactions balance scores, performance measures visuospatial abilities negative affect, or depressive symptoms memory performance baseline modified mini-mental state examination scores estradiol levels and mood changes associative verbal memory verbal and visual memory specific cognitive functions change from baseline and rate of change from baseline for the following psychometric tests: verbal fluency test, weschler paired associate learning and 20 min delayed recall, trailmaking a and b tests, cancellation random letter and random form tests plasma estradiol levels performance, mood and personality central processing speed or postural stability overall quality of life cognitive performance measures cognitive performance and serum e2 levels time to rise from a chair, timed walking, balance, instrumental activities of daily living, physical activity scale of the elderly, folstein mini-mental state examination, and falls beck depression inventory verbal memory performance mental rotation task cognitive performance change in cognitive or 36-item short-form general health survey scores overall hr for probable dementia hazard ratio (hr) for probable dementia mood, cognitive function and quality of life serum estradiol (e2) and fsh levels mild cognitive impairment dementia or cognitive decline physical performance measures, functional ability, physical activity, falls, and cognitive function cognition or balance rising time estrogen plasma levels bone density physical activity scale of the elderly pupillary and skin conductance variables memory, frontal lobe functions (inhibition and planning) and visuospatial abilities (mental rotation global cognitive function, verbal and visuospatial memory, language, executive function, and semantic memory physical measures of mobility, ability to rise from a chair, self-reported activities of daily living, physical activity scores, or falls minnesota multiphasic personality inventory-168, the profile of adaptation to life, and the beck depression inventory psychological function cognitive test scores or on the 36-item short-form general health survey quality of life scores (as measured by the sf-36) and cognitive function (camcog, block design, memory for faces, california verbal learning test (cvlt) and verbal fluency (vf walking normal working memory cognition and health-related quality of life postural instability and falls plasma estrone and estradiol levels folstein mini-mental state examination immediate or delayed recall of visual material, delayed recall of paragraphs, or digit span scores dementia or mci incidence mean (sd) time cortisol plasma levels correct reproductions brain activation patterns instrumental activities of daily living incidence of dementia and mild cognitive impairment cognitive function, mood and quality of life mild cognitive impairment (mci beck depression inventory (bdi) scores figural memory actual performance of the verbal and nonverbal memory tasks|there was no consistent evidence that the effect of treatment on change in cognitive or 36-item short-form general health survey scores depended on the level of baseline endogenous estradiol. the freiburger personality inventory showed an improvement in aggressivity after regimen a* as compared with the preceding placebo as well as an improvement in striving after dominancy after both regimen a and regimen ev as compared with pre-treatment, but also after regimen a* as compared with regimen ev. cognitive performance was tested at baseline and after 2 weeks of estradiol or placebo treatment using verbal, semantic, and spatial memory tests as well as a mental rotation task and the stroop. over 3 years, except for balance scores, performance measures declined significantly (all p<.05). intention-to-treat analysis showed that the active and placebo groups did not differ in their response to treatment in any of the outcome measures (p>0.05). results indicate that those receiving estrogen had no significant improvement in postural stability at 2 and 8 months of treatment relative to those receiving placebo. body mass index, a gross estimate of circulating estrogen, was significantly positively related to change in attentional and psychomotor processes regardless of treatment group, and to a weaker extent, verbal memory, but only in the estrogen-treated group. before hormone supplementation, working memory, tested with the subject ordered pointing test (sop), was worse in older subjects than younger subjects, and there was no evidence of gender differences at either age. cee + mpa had a negative impact on verbal memory (p <or= 0.01) and a trend to a positive impact on figural memory (p = 0.012) over time compared with placebo, but other cognitive domains were not affected. the income management scale of the profile of adaptation to life improved (p less than .05) with estrogen, as did the beck depression inventory (p less than .05), but these results were not dose-related. ehr was found to increase the hpa response to task-induced stress, as indicated by an increase in cortisol plasma levels. treatment effects on mild cognitive impairment did not differ between groups (hr, 1.07; 95% ci, 0.74-1.55; 63 vs 59 cases per 10 000 person-years; p =.72). treatment with estrogen increased activation in the inferior parietal lobule during storage of verbal material and decreased activation in the inferior parietal lobule during storage of nonverbal material. on the most demanding test of working memory, the reaction times (p = .045) and error rates (p = .043) differed between treatments, yet this finding proved to be an effect of learning rather than treatment. no hormonal effects were apparent on the immediate or delayed recall of visual material, delayed recall of paragraphs, or digit span scores. at baseline, women in the hrt group reported a younger age of onset of menopause and a higher prevalence of hysterectomy, but otherwise did not differ from women in the placebo group. incidence rates for probable dementia in the estrogen-alone trial were statistically similar to those in the estrogen plus progestin trial (45 vs 22 per 10 000 person-years for cee plus mpa vs placebo, respectively; p =.11).|community-dwelling women aged 65 to 79 years, conducted from june 1995 to july 8, 2002 women over 75 years who do not have dementia or depression women aged 75 years and older 93 participants receiving cee were diagnosed with either probable dementia or mci vs 69 receiving enrolling participants from the women's health initiative (whi) estrogen plus progestin trial in may 1996 70 healthy postmenopausal women, aged 47-65 years, with previous hysterectomy 36 asymptomatic women, aged 45-60 nineteen women treated with healthy elderly women forty-six postmenopausal women aged 33 to 61 years (mean [sd] age, 50.8 [4.7] years 47 participants were diagnosed with probable dementia, of whom 28 were assigned to elderly female subjects who did not suffer any of the postmenopausal symptoms and had never taken estrogen hormone replacement (ehr) previously n = 4532), or to february 29, 2004 (estrogen-alone; n = 2947), in 39 of the 40 whi clinical centers 87 elderly female subjects (age > 69 postmenopausal women menopausal syndrome patients postmenopausal women aged 65 years or older 65 years of age or older one hundred and fifteen women community volunteers tested in a hospital setting healthy postmenopausal women women aged 70 years and older women older men and women older women 49 women (16, 17, 16 valid patients per arm) aged between 46 and 67 years (mean 58, 58, 56 years, respectively) with the diagnoses of insomnia (g 47.0) related to postmenopausal syndrome (n 95.1 fifty-two elderly postmenopausal women (age range 75-91 years) without known contraindications to hrt or evidence of dementia or depression were enrolled 61 women were diagnosed with probable dementia, 40 (66%) in the community-dwelling elderly women older men women receiving combined hormone therapy postmenopausal elderly women participants were women from 14 of 40 clinical centers of the women's health initiative (whi women with dementia 373 community-dwelling women aged 65 years and older to receive asymptomatic postmenopausal women elderly healthy females 4894 eligible participants of the whi study, 4532 (92.6%) postmenopausal women free of probable dementia, aged 65 years or older, and recruited from 39 of 40 whi clinical centers were enrolled in the whims sixty-two women completed the study nine clinical centers in the united states healthy older female population 1996 through 1998 19 women who required a hysterectomy and bilateral oophorectomy for benign disease elderly women women who had been menopausal for an average of 17 years 76 participants were diagnosed with mci in the cee group vs 58 in the women at increased risk of cognitive decline (aged 70 years and over postmenopausal women (n = 417), aged 60 to 80 years, with a normal bone density for age and an intact uterus elderly healthy female subjects surgically menopausal women postmenopausal women during working memory tasks 38 healthy elderly women postmenopausal women in specific brain regions postmenopausal women (1416) aged 65 yr and older, free of probable dementia, and enrolled in whi and the whi memory study (whims) trial of combination estrogen and progestin for a mean of 3 yr and followed for a mean of 1.35 yr, were studied women in a clinical setting who either needed or wished to have the estrogen replacement and are mostly in the perimenopausal age-band
contractile cardiac function reoperation for bleeding frequency of neurocognitive deficit deterioration renal function mortality or morbidity serum ck-mb mass fraction, troponin i, and interleukin (il)-6, il-8, and il-10 levels homologous blood consumption stenosis-free patency rate renal tubular and glomerular functions neurologic deficit inhospital outcomes, similar completeness of revascularization, and shorter lengths of stay postoperative hepatocellular injury neurocognitive deficit mortality and morbidity low svr index endothelial function shorter ventilatory support opcab ipf2alpha-iii excretion haemoglobin concentration rate of atrial fibrillation ophthalmic function postoperative morbidity and blood loss coagulation parameters endothelial apoptosis and circulating endothelial cells cpb time intensive care unit stay, duration of intubation, hospital stay and bleeding respiratory morbidity hemodynamic variables (including creatine kinase-mb and troponin levels), intubation time, postoperative bleeding, and blood transfusions levels of troponin i and activation of cytokines resolution visual acuity (va), and cerebral injury, by transcranial doppler ultrasound-detected emboli and s100 protein values release of inflammatory markers aspirin efficacy mean number of grafts interleukin-6, interleukin-8, c3a, and troponin i levels after surgery cd11b surface expression on neutrophils temperature, svr index, cardiac index, and blood pressure cabg and opcab in inflammatory markers early mortality and morbidity serum cytokine levels overall graft patency rate cerebral perfusion with opcab vitro bleeding time systemic inflammation s-100 protein levels myocardial function peripheral tissue metabolism and microvascular blood flow global myocardial function mean intraoperative s100 demographic makeup, parsonnet score, functional status and extent of coronary revascularization inflammatory response and myocardial injury urinary rbp intensive care unit stay overall fibrinolysis potential negative fluid balance oxygenation, shunt (%) and ventilation-perfusions mismatch, described as deltapo(2) (kpa peak and total s100 levels, and n-acetyl-glucosaminidase activity volume of homologous blood transfusion levels of tissue-plasminogen activator tnf-alpha and il-8 release or endothelial function graft patency, clinical and quality-of-life outcomes, and cost mdrd gfr and serum creatinine levels salvaged mediastinal blood available for autologous transfusion early mortality neutrophil counts inflammatory response white blood cell (wbc) and neutrophil count average blood glucose major adverse events and neuropsychological functioning right ventricular systolic and diastolic function cardiovascular event inferotemporal retinal arterial embolization and microinfarction interleukin-1, interleukin-6 and myocardial enzyme response overall rate of graft patency echocardiographic markers of right ventricular function glucose homeostasis saphenous graft patency per patient volume of intraoperative autologous blood transfusion, postoperative mediastinal blood loss and homologous blood transfusion requirements respiratory failure postoperative va quality-of-life protein c1 esterase inhibitor and von willebrand factor concentrations lymphocyte activation stroke nor transient ischemic attack average stay in the intensive care unit nonfatal myocardial infarctions 1-year angiographic patency transcardiac ph differences levels of tumor necrosis factor-alpha blood samples hemoglobin levels mammary artery patency bleeding hospital deaths health related quality of life cumulative release of myoglobin crp postoperative peak values of creatine kinase-mb mass systemic inflammatory response intraoperative blood loss and homologous blood transfusion serial measurements of insulin/glucagon ratio, amylase, and glucose protein carbonyls tnf-system and sil-2r abnormal regional function ratio of insulin-like growth factor-1 concentration preoperative characteristics and risk factors plasma levels of complement (c3a), cytokines (il-8, tnf-alpha), endothelin-1 and neopterin total amount of cardiac troponin i released health status homologous blood length of stay in icu strength of the relationship between vo(2) and do(2 et levels cabg roteg signs of hyperfibrinolysis diastolic function expression of cd97 and adhesion molecules (cd11, cd18 prevalence of postoperative hemodialysis inflammatory response reactions frequency of no need for transfusion opcab and sharp increases during cabg c-reactive protein and systemic levels of tnf-alpha, tnf specific receptors rp1 and rp2, interleukin-6 (il-6) and soluble il-2 receptors (sil-2r time to extubation blood glucose and lactate central venous blood samples overall, t lymphocytes coronary bypass graft patency interstitial concentrations of the glucose, glycerol, pyruvate and lactate inflammatory response and myocardial ischaemia microvascular damage occluded graft platelet activity small intestine function hospital deaths or major postoperative complications postoperative systemic arterial et levels median postoperative length of stay systemic inflammatory response syndrome and early catecholamine requirement glucose, lactate, pyruvate and glycerol as markers of basic metabolism and tissue perfusion mortality expression of adhesion molecules (cd11, cd18) of leukocytes expression of cd25, cd26, cd69, and dr on t (cd3+) and b (cd19+) lymphocytes on peripheral blood cardiac release of interleukin-6, tumor necrosis factor-alpha, and blood lactate likelihood of graft occlusion composite of death from any cause, a repeat revascularization procedure, or a nonfatal myocardial infarction forced expiratory volumes inflammatory response (interleukin (il)-6, interleukin-10, icam-1, p-selectin) and of myocardial injury (myoglobin, creatine kinase-mb (ck-mb), troponin i mean svr index intraoperative and postoperative data creatine kinase-mb (ck-mb) release, the amount of bleeding and intensive care unit (icu) stay (p<0.05 gsh levels troponin-t and creatine kinase isoenzyme mb (ck-mb) levels right ventricular function hemodynamic data (cardiac index, systemic vascular resistance, left- and right-ventricular stroke-work indices, inotropic and mechanical support needs) and enzyme levels (ck-mb and sgot), as well as mortality, perioperative infarction rate, homologous transfusion requirements, and the symptomatology in the first follow-ups leukocyte elastase, platelet beta-thromboglobulin, and complement c3a prior anesthesia values of lipid hydroperoxides mean number of grafts per patient opcab deterioration in scores glomerular and tubular injury retinal microvascular damage postoperative pulmonary shunt atrial fibrillation free hemoglobin levels white cell and neutrophil counts neurologic and clinical morbidity neurocognitive outcomes circulating markers of inflammation and organ injury, (2) operative results, and (3) outcome at 1-year follow-up static and dynamic lung compliance measurements lactate/pyruvate ratio and the lactate/glucose ratio, indicating the aerobic and anaerobic tissue metabolism status postoperative atrial fibrillation hospital mortality neurocognitive function p-selectin expression free water clearance values leukocyte activation platelet expression of p-selectin deterioration of deltapo(2 functional class and exercise capacity maximum myocardial lactate production mean cec-number time on the relation between vo(2) and do(2 monobasic (mb) fraction of the creatinine kinase 24 h after the operation pai-1 nitric oxide arterial partial pressure of oxygen lower release of cardiac troponin renal function and clinical outcomes myocardial energy metabolism and tissue injury during cabg quality of life collateralized chronic total occlusions of native coronary arteries il-6. il-1 creatinine clearance incidence of in-hospital death and outcomes (low cardiac output syndrome, prolonged mechanical and pharmacologic cardiac support, prolonged mechanical ventilation support, and postoperative length of stay in intensive care unit and hospital plasma levels of interleukin-6 and tumor necrosis factor-alpha rates of death, stroke, myocardial infarction, angina, and reintervention perioperative complications plasma level of proinflammatory cytokine tumor necrosis factor (tnf)-alpha mechanical ventilation support and length of intensive care unit and postoperative stay interleukins (il)-6, il-8, il-10, myeloperoxidase, elastase, and terminal complex of the complement (tcc neuropsychologic and quality-of-life outcomes oxygen consumption (vo(2)) and delivery (do(2 postoperative bleeding demographic, hemodynamic, and respiratory parameters coronary artery bypass graft patency graft-patency rates exercise capacity improvement and attenuation of symptoms cd97 expression of granulocytes (pmn) and monocytes (mc s100 levels release of il-6 mean temperature complete revascularization peak s100 levels gastric intramucosal ph (phi), gastric-arterial carbon dioxide partial pressure difference (co(2) gap), whole-body oxygen delivery (do(2)) and consumption (vo(2)) and whole-body oxygen extraction fraction renal dysfunction myocardial ischemic markers graft patency urinary excretion of microalbumin and retinol binding protein (rbp) indexed to creatinine (cr peripheral tissue (skeletal muscles) energy metabolism doppler high-intensity transient signals (hits splanchnic organ injury cd11a and cd18 expression of leukocytes systemic nox levels interleukin-6 (il-6) levels transient neurologic dysfunction serum cytokines and myocardial tissue markers cardiac troponin i concentration cabg and opcab in oxygen consumption (vo(2)), delivery (do(2)), or extraction (exo(2 length of icu stay activation of coagulation and fibrinolysis plasma tissue factor levels mean health-related quality of life composite of major adverse cardiac and cerebrovascular events (macce) including all-cause mortality, acute myocardial infarction, cardiac arrest with successful resuscitation, low cardiac output syndrome/cardiogenic shock, stroke and coronary reintervention platelet function mean on-pump and off-pump sf-36 scores fresh frozen plasma survival free of any cardiac-related event cardiac-related death pulmonary artery pressures, ventilation requirement, and hospital stay organ function and inflammatory response adhesion molecule expression blood transfusions overall tissue factor production gastric mucosal hypoxia major adverse cardiac-related events or death cabg and opcab hospital death evaluation of myocardial infarct size measured by the perioperative serum release of cardiac troponin energetic metabolism completeness of revascularization, graft patency at 1 year, neuropsychological outcomes, and the use of major resources peripheral endothelial function macce all-cause mortality myocardial metabolism and inflammation (glutathione (gsh), superoxide dismutase (sod) and myeloperoxidase (mp)) and plasma samples for indicators of oxidative stress (conjugated dienes (s-bdc), oxidative products of proteins (s-ox-prot) and low-density lipoprotein (ldl)-total peroxyl radical trapping antioxidant potential (s-trap number of arterial grafts urinary isoprostane ipf2alpha-iii levels, plasma levels of free malondialdehyde, and total antioxidant status neutrophil activation renal tubular function il-6 cpb inclusive of cardioplegic arrest, left ventricular ejection fraction <50%, emergency surgery, prolonged aortic cross clamp and cpb time, post-operative low cardiac output syndrome, post-operative inotropic requirement, new onset atrial fibrillation (af), excessive post-operative blood loss and redo thoracotomy cd11b expression soluble p-selectin levels in plasma major postoperative complications blood collection times safety and efficacy plasmatic creatinine, urinary creatinine, creatinine clearance, proteinuria or osmolality vo(2) and do(2 nuclear derangement oxygen metabolism variables alpha2-macroglobulin, protein c1 esterase inhibitor, fibronectin, and von willebrand factor concentrations neuron-specific enolase levels 30-day mortality, no stroke, and no acute renal failure postoperative mortality and morbidity incidence of low svr, and patterns of svr changes peak s-100 protein perioperative oxidative stress risk ratios hospital stay age, gender, new york heart association class, canadian cardiovascular society functional classification of angina grade and number of cabg total antioxidant status homologous transfusion mean cardiac index clinical morbidity and costs wbc and neutrophil counts mean number of bypass grafts elastase length of hospital stay and use of blood products postoperative tissue factor and p-selectin expression intramyocardial levels of glucose, pyruvate and urea operative mortality and morbidity 1-year graft patency, cost, and quality-of-life outcomes insulin-like growth factor binding protein-1 high-sensitivity c-reactive protein (hs-crp) and fibrinogen gastric mucosal oxygenation expression of lymphocyte activation markers postoperative impairment anginal status or quality of life pai-1 values dialysate concentrations of glucose and lactate inflammatory markers cerebral perfusion local blood flow overall early graft patency rate blood glucose postoperative s-100 serum levels roteg signs of fibrinolysis pancreatic function median value of hits area under the curve of troponin t levels inflammatory reaction and myocardial metabolism and -10, c-reactive protein (crp) and neutrophils tcc systemic release of il-8 permanence on the ventilator myocardial damage intensive care stay mean total hospitalization cost per patient at hospital discharge cr troponin i postoperative renal functions renal failure and lesions of the circumflex artery and its branches rate of the 1-year composite outcome release of creatinine kinase cognitive outcomes preoperative clinical characteristics pai-1 antigen levels liver function shorter hospital stay plasma il-6 levels interleukin 8 concentrations cabg performance severely stenosed carotid arteries major deterioration cumulative blood release of troponin-t cardiac troponin gastrointestinal complications expression of p-selectin early activation of cd69+ and late activation of cd25+ on t lymphocytes protein s100 levels svr index responses troponin i release complement c3a and elastase levels angiographic graft patency postoperative et levels insulin-like growth factor-1 standard deviation score maximum creatine kinase-mb levels rey auditory verbal learning test (total and recognition scores angina recurrence aerobic metabolic activity differential white cell counts health-related quality of life neutrophils blood loss fibrinogen and t-pa levels permeability and absorption arachidonic acid-induced platelet aggregation postoperative gas exchange il-8, tnf-alpha, and se-selectin platelet count plasma total antioxidant status interstitial lactate levels postoperative clinical outcome (icu stay, ventilation duration, length of hospital stay tnf-alpha and elastase levels serum insulin, insulin-like growth factor-1 and its binding protein proportion of patent grafts neuropsychological outcomes or use of major resources earliest extubation time peak systolic and early diastolic velocities inflammatory response and organ function appearance of graft patency, myocardial function, and clinical outcome inotropic isoprostanes and oxidative stress patency rate sod levels endothelial response occurrence of cardiovascular events (all-cause mortality, stroke, myocardial infarction, and coronary reintervention), anginal status, and quality of life troponin release peak creatine kinase mean (+/-sd clinical outcomes and neuropsychological functioning bilirubin level expression of systemic proinflammatory cytokines ptx3 levels serum levels of cardiac troponin i cd11b levels mortality or perioperative myocardial infarction cognitive decline thrombin formation amylase levels myeloperoxydase content death, myocardial infarction, further revascularization (surgery or angioplasty), or stroke elevated d-dimer levels postoperative hospital stay number of grafts per patient insulin-like growth factor-1 incidence of in-hospital death forced vital capacity (fvc) values pulmonary abnormalities cabg ipf2alpha-iii levels global systolic right ventricular function postoperative vo(2), do(2), and exo(2) levels oxygenation and release of inflammatory mediators higher incidence of atrial fibrillation urinary albumine excretion venous serum levels of s-100 protein postoperative neutrophil counts mean number of anastomoses graft patency, major adverse cardiac-related events, and health-related quality of life resternotomy for bleeding 5-year cognitive or cardiac outcomes rate without stenosis dialysate concentrations of ethanol postoperative blood loss shorter duration of mechanical ventilation levels of creatine kinase mass fluid balance, serum cr and blood urea risk of graft occlusion allogeneic blood transfusion saphenous graft patency postoperative increases in fibrinogen and hs-crp patency expression of adhesion molecules level of tnf-alpha interleukin-1 (il-1 systemic nitric oxide production, total nitrate/nitrite (nox thirty-day complications, neuropsychological functioning, and one-year clinical and functional outcomes patency of grafts, better clinical outcome, shorter hospital stay, and better neurocognitive function apoptotic and normal cells plasminogen activator inhibitor-1 systemic inflammatory response, postoperative morbidity, and hospital stay overall hemostasis potential and overall coagulation potential systolic and diastolic function inflammatory markers, troponin i, protein s100, and free hemoglobin cec numbers and proportions of apoptotic hec mda levels platelet function and increased thrombin formation blood pressure responses adverse renal outcome cec numbers and proportions of endothelial apoptosis cec and proportions of apoptotic hec plasma tumor necrosis factor-alpha (tnf-alpha) and interleukin-6 (il-6) levels release of troponin t revascularization cognitive deficits total operation time 205.10 graft-patency rate length of the operation aggregation functional class and positive treadmill exercise tests neutrophil elastase levels graft occlusion glutathione peroxidase levels il-10 early graft patency intramyocardial lactate/pyruvate ratio i concentrations neuropsychological outcomes or short-term use of major resources response of t lymphocytes and their activation markers, as well as b lymphocytes and their activation markers myocardial preservation cardiac-related late deaths blood loss and homologous blood transfusion requirements immediately postoperatively il-10 levels composite of death or complications (reoperation, new mechanical support, cardiac arrest, coma, stroke, or renal failure endothelial activation postoperative inflammatory response neurocognitive status cpb, ptx3 levels index admission mortality, stroke, low-output cardiac failure, return to the operating room for bleeding, and postoperative troponin release main morbidity and hospital moratlity renal complication or serum markers of kidney dysfunction oxygen metabolism oxidative stress and inflammation total amount of heart-type fatty acid-binding protein, cardiac troponin operation time vein graft patency pulmonary function worsening of renal function minor adverse events (wound infection post-operative gastrointestinal complications death, neurological injury, renal failure, respiratory failure, and operative myocardial infarction chest tube drainage intraoperative mediastinal blood loss raw graft patency rate inflammatory response, myocardial, neurologic, and renal injury pyruvate concentrations rate of the 30-day composite outcome blood requirements troponin t levels renal function postoperative morbidity postoperative red cell count, hemoglobin level and hct d-dimers release platelet activity and aspirin efficacy c-reactive protein levels myocardial metabolism graft patency, survival, and health-related quality of life cardiac outcomes and health-related quality of life hazard of death worse composite outcomes and poorer graft patency pre- and postoperatively prothrombin time and partial thromboplastin time fibrin d dimer and prothrombin fragment 1+2 concentrations cardiac outputs and clinical outcomes incidence of high svr mean static and dynamic lung compliance postoperatively renal functions mortality or renal complication cerebral microemboli inflammation activation oxidative stress fasting blood glucose hepatic metabolic function clinical outcomes and s-100 protein, neuron-specific enolase, and maximum creatine kinase-mb levels systemic release of interleukin (il)-6, -8 levels of the same markers and blood lactate s100 concentration quality-of-life assessments pyruvate and glycerol interstitial concentrations, lactate/pyruvate ratio and lactate/glucose ratio c3a and neopterin concentrations incidence of neurocognitive impairment nitrotyrosine global systolic function and tricuspid early/late (atrial) ratio as a marker of the global diastolic function number of circulating endothelial cells and apoptotic endothelial cell death serial blood samples, plasma malondialdehyde (mda) as index of lipid peroxidation, red blood cells glutathione peroxidase (gpx) and superoxide dismutase (sod postoperative stay neurocognitive impairment hospital mortality and morbidity serum cr and blood urea morbidity rate of active cd97-positive lymphocytes aspartate transaminase and alanine-amino transferase levels clinical, angiographic, neurocognitive, and quality of life outcomes postoperative cognitive testing creatinine levels arterial graft patency overall hemostasis potential, overall coagulation potential, and overall fibrinolysis potential heart-type fatty acid-binding protein levels myocardial infarction hec apoptosis regional function intramyocardial concentrations of glucose, urea and lactate il-6 expression stroke risk score tnf-alpha and il-8 time of mechanical ventilation release of interleukin-6 cardiac index alveolar-arterial oxygen gradient discharge in vitro bleeding times time of inotrope drugs support monoethylglycinexylidide/lidocaine ratios and by serial measurements of transaminases (aspartate transaminase and alanine-amino transferase), bilirubin, and alkaline phosphatase mean mechanical ventilation time major adverse cardiac-related events and health-related quality of life incidence of low cardiac output syndrome number of hits neurocognitive function assessed using a 19-test neurocognitive battery at baseline, discharge, and 6 months ck-mb mass release|values were less important in the opcab group and return to the baseline was faster than in the cpb group. maximum creatine kinase-mb levels were significantly (p=0.046) lower in the off-pump group than in the on-pump group (17.1+/-16.7 iu/l versus 21.5+/-10.6 iu/l). the length of stay in icu was significantly different: 33.8+/-16.2 hours for group patients undergoing opcab had more severely stenosed carotid arteries (p=0.075), higher incidence of slightly diseased ascending aorta (p=0.087) and higher northern new england cardiovascular study group cd11b levels were significantly higher in the cpb group at 60 minutes (p = .002). at 6 months after revascularization, 57% (343 of 611) of dysfunctional segments improved contraction by at least 1 grade. interstitial lactate levels were higher during off-pump surgery (p<0.05). troponin i was significantly lower in the opcab than in the ccab group, either at the end of ischemia, end of surgery, 6-hour and 24-hour postoperatively (4 +/- the maximum myocardial lactate production was significantly higher (p = 0.02) in the group operated with cpb (0.56 mmol/l) than without it (0.17 mmol/l). interleukin-6, interleukin-8, c3a, and troponin i levels after surgery were significantly higher in the cpb group compared with the off-pump and rvad groups. insulin-like growth factor-1 decreased more (p=0.01) and insulin-like growth factor binding protein-1 increased more (p<0.001) with cardiopulmonary bypass than without. cardiopulmonary bypass, inclusive of cardioplegic arrest, is the main independent predictor of post-operative gastrointestinal complications in patients undergoing coronary revascularisation. the off-pump group had significantly less increase in creatinine levels when compared with the on-pump group (p<.05). postoperative s-100 serum levels were: 3.76 (0.13 to 11.2) microg/l (conventional) versus 0.13 (0.04 to 1.01) microg/l (off-pump), p less than 0.0001. the mean static and dynamic lung compliance postoperatively was lower in the stabilization group, although not statistically significant (p = 0.06). global oxygen utilization measurements showed superior do(2) and vo(2) in the opcab group throughout the study. the total amount of cardiac troponin i released was higher in the arrested heart revascularization group than in the beating heart revascularization group (8.25 +/- cardiac outcomes and health-related quality of life at 30 days and 1 year were similar and patients incurred a lower cost. cec numbers and proportions of apoptotic hec were significantly elevated during and after surgery in both groups (p<0.01). a certain degree of roteg signs of fibrinolysis was noticed at time t2 in both groups and in group b these marks were quite widely, but not significantly expressed (p for intergroup differences for lysis on set time at 60 and 150 minutes were p = 0.190 and p = 0.122, respectively), borderline differences were found for maximum clot firmness (p = 0.082) with a lower mean value for group b (arithmetic means urinary isoprostane ipf2alpha-iii levels, plasma levels of free malondialdehyde, and total antioxidant status were measured before, during, and up to 24 hours after surgery. the proportions of neuropsychologic deficits and improvement in quality-of-life were comparable regardless of whether patients were randomized to receive off-pump coronary artery bypass graft surgery or conventional coronary artery graft surgery with cardiopulmonary bypass. there were no significant intergroup differences in any of the echocardiographic markers of right ventricular function. opcab was followed by an attenuated systemic release of il-8 ck-mb mass release was 323.5+/-221.2 microg/l (24 h postoperatively) in operated patients without cpb and 1030. there were no hospital deaths in off-pump patients, and 2 patients (5%) undergoing onpump cabg died early following surgery (p =.2). no significant difference in myeloperoxydase content was noted; however, elastase was significantly higher in the two ec (on-pump) groups. postoperative systemic arterial et levels were significantly increased by 200% in the cpb group and 50% in the opcab group. plasma tumor necrosis factor-alpha (tnf-alpha) and interleukin-6 (il-6) levels significantly increased with respect to baseline from protamine administration up to eight postoperative days, whereas high-sensitivity c-reactive protein (hs-crp) and fibrinogen increased after surgery up to eight postoperative days in both groups. in the group that underwent minimally invasive coronary artery bypass grafting, leukocyte elastase, platelet beta-thromboglobulin, and complement c3a were unchanged at the end of the procedure compared with their baseline concentrations, whereas these inflammatory markers were increased significantly in the group that underwent conventional coronary artery bypass grafting with cardiopulmonary bypass. compared with base line, opcab patients performed better on the rey auditory verbal learning test (total and recognition scores) at both 2 weeks and at 1 year (p < or = 0.05), whereas cabg performance was statistically unchanged for all cognitive measures. off-pump cabg is potentially associated with reduced intraoperative blood loss and homologous blood transfusion in comparison to on-pump cabg. i, and high-sensitivity c-reactive protein released was significantly higher in the on-pump group than in the off-pump group. statistically significant differences were found between the 2 groups concerning the incidence of low cardiac output syndrome (p = .001), time of inotrope drugs support (p = .001), time of mechanical ventilation (p = .006), reoperation for bleeding (p = .04), intensive care unit stay (p = .01), and in-hospital stay (p = .02). we did not find any statistical difference in hospital mortality and morbidity using on-pump or off-pump techniques for low-risk patients. the lactate/pyruvate ratio and the lactate/glucose ratio, indicating the aerobic and anaerobic tissue metabolism status, were lower in the off-pump group. thirty-day complications, neuropsychological functioning, and one-year clinical and functional outcomes were not statistically different between the two techniques. the postoperative tissue factor and p-selectin expression did not differ between the on-pump and off-pump coronary artery bypass grafting groups. patients who underwent off-pump coronary artery bypass surgery showed similar patency of grafts, better clinical outcome, shorter hospital stay, and better neurocognitive function than patients who underwent conventional coronary artery bypass grafting surgery using cardiopulmonary bypass. gsh levels from the biopsies were increased in the perfusion group early in the reperfusion time showing that myocardial tissue was well protected and recovered more rapidly after cross-clamping than after the occlusion of the coronary arteries. there was no mortality or perioperative myocardial infarction in either group. thrombin formation was more elevated in the on-pump group (p < .001), particularly during the operation; prothrombin fragment 1.2 discharge values were higher than the preoperative ones (p = .002). in low-risk patients undergoing cabg surgery, avoiding the use of cardiopulmonary bypass had no effect on 5-year cognitive or cardiac outcomes. all-cause mortality was significantly increased in the off-pump group (24% vs 15%; hr 1.66, 95% ci 1.02 to 2.73; p=0.04), but cardiac-related death was not significantly different (10% vs 7%; hr 1.30, 95% ci 0.64 to 2.66; p=0.47). there was no significant difference in the median postoperative length of stay between the two groups (seven days in each group). the response of t lymphocytes and their activation markers, as well as b lymphocytes and their activation markers, was similar after on- and off-pump surgery. preoperative characteristics were comparable between the two groups. clinical outcome and hospital stay were comparable in both groups. the wbc and neutrophil counts rose markedly in both groups following the operation and remained at this increased level during the observation period. compared to baseline levels the highest ptx3 value (p<0.000) was attained on the 1(st) postoperative day in both "on-pump" and "off-pump" patients. levels of creatine kinase mass were statistically higher in the miniaturized extracorporeal circulation group than in the off-pump coronary artery bypass grafting group, but only at the end of the operation (p < .0001). the platelet activity is higher in the early postoperative period in off-pump compared with on-pump coronary artery bypass grafting. the mean intraoperative s100 in the on-pump group was 1.6 times greater compared to that in the off-pump group (95% ci 0.88-2.8; p=0.01). forced vital capacity (fvc) values were significantly lower than the preoperative values in all three groups (p < 0.05). the rate of active cd97-positive lymphocytes showed a marked, gradual increase until postoperative day 3 and remained elevated up to day 7 after cpb. peak s100 levels were four times higher in group a than in group b (2.1 microg/l versus 0.5 microg/l; p < 001). there was no diference between the two groups of patients regarding incidence of main morbidity and hospital moratlity. a residual perfusion defect at myocardial nuclear scan was less frequent among patients in the mecc group (3 versus 9 cases, p=0.14; odds ratio 0.32, 95% confidence interval 0.07 to 1.32). troponin-t and creatine kinase isoenzyme mb (ck-mb) levels were significantly higher in cpb procedures (p<0.0056; multivariate general linear model). after 5-year follow-up, the primary composite end point was not different between groups (hazard ratio 0.71, 95% ci 0.41 to 1.22; p=0.21). saphenous graft patency was 59% (on pump) versus 49% (off pump; p=ns). graft occlusion was more likely at the distal than the proximal anastomosis (odds ratio, 1.11; 95% confidence interval, 1.02-1.20). aspartate transaminase and alanine-amino transferase levels were higher in the cabg-cpb group for the first postoperative day, but levels converged by day 3 (interaction of surgery type and time; p < 0.0001 and p = 0.04, respectively). the on-pump group showed a significantly greater deterioration in scores for two and three tests at 1 week and 10 weeks postoperatively, respectively, than the off-pump group. fibrinogen and t-pa levels increased postoperatively in both the groups when compared with baseline values. no significant differences between cabg and opcab were detected in postoperative vo(2), do(2), and exo(2) levels. the extent and pattern of svr index responses were similar in both groups (p = 0.840). at 1 year of follow-up, patients in the off-pump group had worse composite outcomes and poorer graft patency than did patients in the on-pump group. fibrin d dimer and prothrombin fragment 1+2 concentrations were lower during surgery in the off-pump group (p < 0.001). there were no differences in exercise capacity improvement and attenuation of symptoms between the groups. there were no significant differences between on-pump and off-pump patients in any of the eight subscales at both stages. early mortality was 2.3% in group 1 and 3.4% in group 2 (p = not significant). glutathione peroxidase levels were not changed according to blood collection times in both of cabg group or opcab group (p > 0.05). however, in multivariate analysis fibrosis was confounded by myocyte vacuolization (p = .002) and nuclear derangement (p = .016), representing independent atrial fibrillation predictors. the off-pump coronary artery bypass graft group had fewer patients with troponin release than the conventional coronary artery bypass graft group. coronary revascularization with cpb was associated with a significant expression increase in the tnf-system and sil-2r when compared to the opcab patients. plasma levels of complement (c3a), cytokines (il-8, tnf-alpha), endothelin-1 and neopterin were measured before and during surgery and 2 and 24 h after surgery. protein s100 levels were higher in the cabg-cpb than in the opcab group 1 hour after surgery (p<0.001). no mortality or renal complication were observed. significant increases from prior anesthesia values of lipid hydroperoxides (190% at 4 hours), protein carbonyls (250% at 0.5 hours) and nitrotyrosine (510% at 0.5 hours) were seen in the cpb group, but they were abolished or significantly reduced in the off-pump group.|two similar groups of 25 patients (off-pump and on-pump groups twenty-five patients patients unselected for coronary anatomy, ventricular function, or comorbidities between march 10, 2000, and august 20, 2001, at a us academic center 168 patients (27 women) requiring primary isolated coronary artery bypass grafting surgery twenty patients scheduled for thirty-two patients fifty-four patients undergoing primary cabg by the same surgeon fifty-two patients submitted for elective cabg patients who undergo minimally invasive coronary artery bypass grafting without cardiopulmonary bypass from august 2004 through october 2005, 116 consecutive patients with preoperative non-dialysis-dependent renal insufficiency (glomerular filtration rate measured using the modification of diet in renal disease equation [mdrd gfr] < or = 60 ml x min(-1) x 1.73 m(-2)) undergoing primary coronary artery bypass grafting 201 patients undergoing patients with chronic obstructive pulmonary disease (copd fifty patients scheduled for elective coronary artery bypass surgery 50 cases 21 patients (group 3 patients undergoing coronary artery bypass operation twenty patients were randomized patients with pulmonary disease forty patients were recruited (20 per group thirty patient candidates for coronary surgery netherlands, which enrolled 281 low-risk cabg patients between 1998 and 2000 ten patients (eight male, two female; aged 59.6+/-11.0 years (mean+/-sd)); group 2, median sternotomy and off-pump in ten patients (seven male, three female; aged 65.1+/-10.0 years); group 3, minithoracotomy with cpb in ten patients (seven male, three female, aged 61.2+/-10.4 years); group 4, minithoracotomy and off-pump in ten patients (nine male, one female, aged 62.9+/-9.8 years thirty-seven patients operated upon in our institution between april 1997 and april 1998 showed an obstructive and/or restrictive pulmonary disease coronary artery bypass grafting (cabg patients with advanced pulmonary disease critically ill patients patients undergoing coronary artery revascularization with cardiopulmonary bypass patients undergoing opcab versus those undergoing cabg with cardiopulmonary bypass (cpb sixty patients (30 cabg and 30 opcab patients undergoing patients with chronic obstructive pulmonary disease patients undergoing cardiopulmonary bypass one hundred twenty patients 150 patients, 114 men, mean age 64 (45-75 years)] with mild hypothermic (32c) cpb and cardioplegic arrest of the heart or (2) off-pump surgery [150 patients, 113 men, mean age 64 (38-66) years] on the beating heart recruited patients had at least 3 of the following criteria: age greater than 65 years, high blood pressure, diabetes, serum creatinine greater than 133 mol/l, left ventricular ejection fraction lower than 45%, chronic pulmonary diseas e, unstable angina, congestive heart failure, repeat cabg, anemia, and carotid atherosclerosis patients with preoperative non-dialysis dependent renal insufficiency 2203 patients scheduled for urgent or 6 years of age underwent 3.4 eighty patients 341 patients with three-vessel disease and a euroscore of 5 or greater twenty-six of 40 (65%) patients undergoing cabg without cpb underwent complete revascularization low-risk patients with one or two vessel disease between october 2001 and september 2002, 65 high-risk patients fifty low-risk coronary patients sixty patients cardiac surgical patients, operated on either with or without the use of cardiopulmonary bypass (cpb twenty patients undergoing primary isolated cabg patients with severe left ventricular dysfunction (fe fifty patients 37 patients averaging 70 thirty patients, candidates for coronary surgery 88.90 patients with copd patients who underwent patients who undergo off-pump (beating heart twenty-one patients were operated on without cbpb (group a), while 16 patients were operated using coronary artery bypass graft surgery 30 patients were enrolled and scheduled for coronary bypass surgery under cpb (20 patients, group a) and with off-pump (op) operation (10 patients, group b 60 patients undergoing patients undergoing cardiac surgery twenty-six low-risk patients seventy patients one hundred and five were male and ages ranged from 39 to 70 years old; mean 58.81 forty low-risk patients with normal preoperative cardiac and renal functions awaiting elective cabg between july, 2002, and september, 2004, 167 consecutive unselected patients referred for elective primary cabg patients with triple vessel disease 150 patients underwent coronary surgery with the use of mecc and 150 underwent opcabg seventy-one diabetic patients (36 and 35 patients in the cpb and opcab groups, respectively fifty coronary artery bypass patients 123 and 117 patients in the off-pump and on-pump groups, respectively acute kidney injury (aki patients undergoing off patients undergoing coronary artery bypass surgery 30 patients undergoing opcab (off-pump coronary artery bypass grafting), 12 patients undergoing cabg (on-pump coronary artery bypass grafting) and 18 healthy controls patients after on-pump and off-pump coronary artery bypass graft surgery, and compare the data with an age-matched and sex-matched standard population patients with known risk factors for mortality and morbidity low-risk patients undergoing coronary artery bypass grafting (cabg) with and without cpb 308 patients undergoing coronary artery bypass graft surgery patients undergoing cabg on patients undergoing first elective coronary artery bypass graft, with patients undergoing coronary artery bypass grafting procedures participants patients undergoing coronary revascularization by comparing them with patients receiving coronary artery bypass grafts using off-pump (opcab) techniques 22 patients (11 with and 11 without cpb high-risk patients 40 patients randomized to two groups patients with significant risk factors for cpb-related morbidity low-risk patients scheduled for elective coronary revascularization patients undergoing coronary artery bypass surgery on-pump or off-pump techniques patients undergoing coronary artery bypass grafting with or without cardiopulmonary bypass diabetic patients with non-dialysis dependent renal insufficiency patients undergoing coronary artery bypass grafting using either off-pump techniques (opcab group, n = 25) or patients who have undergone off-pump coronary artery bypass graft surgery thirty-five patients admitted for cabg patients undergoing coronary revascularisation patients referred to single-vessel coronary artery bypass grafting twenty-six patients were operated with, and 26 without cardiopulmonary bypass (cpb tertiary cardiothoracic centre in middlesex, england patients with non-dialysis dependent renal insufficiency patients with normal renal function forty patients after coronary artery bypass surgery university hospital of wales, cardiff sixty patients with multivessels coronary artery diseases were scheduled to undergo coronary artery bypass grafting from january 15, 2006 to june 30, 2007 in our institution patients who underwent cabg one hundred and sixty selected low-risk patients were enrolled; 80 patients were operated on three hundred patients population with multivessels coronary artery disease seventy patients undergoing elective coronary revascularization the mean age of the patients was 63 years, and 87 percent were men 167 versus 788 108 randomized patients undergoing coronary bypass operation: 67 patients (group a) were operated on with twenty-six patients elective low-risk patients with multivessel disease diabetic patients, between on-pump (cpb) and off-pump (opcab) coronary artery bypass graft (cabg patients while in the hospital and at 1-year follow-up n = 99 sixty patients with normal preoperative renal functions undergoing cabg diabetic patients undergoing coronary bypass surgery patients with st-segment elevation myocardial infarction group: 10 patients forty-four patients admitted for elective cabg unselected patients with angiographic follow-up multivessel disease with versus without cpb 30 patients 2-4 h after surgery 8 years of age underwent 3 patients undergoing coronary bypass patients who undergo minimally invasive coronary artery bypass grafting patients who underwent minimally invasive coronary artery bypass grafting had a shorter duration of operation (104 patients undergoing coronary artery bypass surgery using either cardiopulmonary bypass or off-pump techniques, and (2 1371 patients who underwent 4093 grafts between february 2002 and october 2007, 128 patients with st-segment elevation myocardial infarction who underwent myocardial revascularization within 48 hours from the onset of symptoms patients undergoing on low-risk patients undergoing either opcab or on-pump coronary artery bypass (oncab low-risk patients patients with lesions in the left descending artery, alone or associated with the right coronary artery low risk patients massachusetts medical society twenty patients from june 1995 to june 1996, 62 consecutive patients with isolated stenosis of the left anterior descending coronary artery 30 patients undergoing cabg (randomly assigned to two groups: 15 patients off twenty-eight patients averaging 70 176 patients undergoing total arterial myocardial revascularization and assigned them at random to one of two groups: group 1 was composed of 88 patients undergoing patients operated under cardiopulmonary bypass (cpb sixty-six patients undergoing coronary artery bypass graft surgery and a control group of 50 participants not undergoing cardiac surgery eighty selected low-risk patients were enrolled patients with three-vessel disease and a high-risk operative profile 200 patients were enrolled; 3 patients were withdrawn after randomization for mitral valve repair or replacement 400 consecutive nonselected cardiac surgery candidates into group a (on pump; n=192) and group b (off patients undergoing minimally invasive coronary artery bypass grafting main exclusion criteria were previous heart surgery, poor left ventricular function (ejection fraction <30%), or unstable preoperative condition fifty eight patients with severe obstructive pulmonary disease had elective isolated coronary surgery one hundred and fifty patients one hundred consecutive patients patients undergoing cabg total arterial myocardial revascularization 255 patients fifty-eight patients coronary artery surgery (coronary artery bypass grafting (cabg twenty patients (on-pump group 28 patients randomized to off-pump (n = 13) or on diabetic patients patients receiving coronary surgery with or without cpb two hundred twelve patients admitted for elective coronary artery bypass graft surgery sixty consecutive patients patients having on-pump bypass grafting patients undergoing coronary artery bypass grafting
systolic and diastolic blood pressure (captopril glycosylated hemoglobin and 12-hr urinary microalbuminuria plasma clearance of 51cr-labeled edta 24-hour uae, creatinine clearance (ccr), and the regression coefficient of the yearly plasma creatinine reciprocal (beta-1/cr mean bp (diastolic + 1/3 pulse pressure diabetic glomerulopathy dbp lowering blood pressure time to the onset of microalbuminuria 24-hour uae target blood pressure transition to microalbuminuria systolic blood pressure urinary albumin excretion rate mbp or gfr acr estimated glomerular filtration rate (egfr urinary albumin excretion (uae) measurements microalbuminuria and albumin excretion rate blood sugar and glycosylated hemoglobin albumin excretion rate (aer hemoglobin a1c values prevalence of microalbuminuria hazard ratio [hr blood-pressure control gfr decline serum lipids and diabetes control risk for renal events creatinine clearance or serum creatinine urinary albumin excretion rate (aer fasting and post-prandial plasma glucose, glycosylated haemoglobin and plasma lipids mesangial fractional volume duration of diabetes and hypertension, systolic and diastolic blood pressure at rest, degree of lvh, metabolic control, and albumin excretion rate (aer composite renal outcome of dialysis or doubling of serum creatinine, changes in estimated glomerular filtration rate (gfr), and changes in albuminuria glycemic control and blood pressure major renal outcomes adverse events serum creatinine level glycated haemoglobin metabolic parameters bp composite renal outcome mean low-density lipoprotein cholesterol albumin excretion rate total cholesterol, hdl cholesterol, and ldl cholesterol times to the onset of renal and cardiovascular events highest frequency of clinical events blood pressure (bp), creatinine clearance (ccr) and urinary albumin excretion (uae long-term antihypertensive efficacy, tolerability, and metabolic effects rate of change in albuminuria urinary albumin excretion, progression of retinopathy and neuropathy and the incidence of cardiovascular disease lower systolic bp levels urine albumine/creatinine ratio (acr), mean blood pressure (mbp) and index of glomerular filtration rate (gfr) based on s-creatinine creatinine clearance renal function and albuminuria mean blood pressure risk of major vascular events fraction of glomerular volume occupied by mesangium in kidney-biopsy specimens nonfatal cardiovascular events--81 mean entrance bp efficacy and safety higher rate of fatal cardiovascular events bp response annual rate of change in albuminuria efficacy and tolerability blood pressure office blood pressure microalbuminuria incidence or rate of change in albuminuria tolerated chronic cough glomerular filtration rate (gfr retinopathy progression renal function microalbuminuria to overt albuminuria blood pressure (systolic/diastolic new microalbuminuria (3 or 4 collections of urinary albumin excretion rate systolic and diastolic blood pressure systolic blood pressure (24-h systolic blood pressure) reduction incidence of stroke gfr decline per year composite of dialysis, doubling of serum creatinine, and death serum lipids risk for microalbuminuria values of gfr, aer, and systolic and diastolic bp geometric mean x:tolerance factor absolute risk reduction albumin excretion progression to incipient and overt diabetic nephropathy urinary albumin excretion (uae antihypertensive effects microalbuminuria hba1c, triglycerides, and bmi systolic blood pressure (sbp) and diastolic blood pressure (dbp plasma glucose, insulin or lipid concentrations serum lipids and glucose metabolism progression of diabetic retinopathy microalbuminuria and/or hypertension blood pressure, kidney biopsies and kidney function tests seated and 24-h ambulatory systolic blood pressure renal events normal glomerular filtration rate (gfr total cholesterol fasting plasma glucose and glycated hemoglobin (hba1c) levels, and both maintain constant aers antihypertensive effect number of events degree of albuminuria at 24 hours, creatinine clearance, blood pressure, and hemoglobin a1c values doubling of serum creatinine antihypertensive efficacy sbp progression of uae rate of death from cardiovascular causes high-density lipoprotein cholesterol renal disease secondary renal outcome, dialysis or doubling of serum creatinine particularly hba1c, bmi, triglycerides, and cholesterol plasma values biochemical measures rate of deterioration in renal function likely to revert to being normoalbuminuric serum lipid fractions estimated gfr 5-year cumulative incidence of microalbuminuria serum triglycerides hypoglycaemic events fbs and 2-hr pmbs ldl cholesterol kidney function mesangial matrix volume and mesangial volume renal outcomes clinical outcomes baseline uae retinopathy severity scale baseline systolic or diastolic bp response (sbp and/or dbp normalized, or dbp fall beneficial effect on triglycerides death, cardiovascular events, and/or renal events (need for renal replacement therapy or doubling of baseline plasma creatinine diabetic vascular complications albuminuria duration of diabetes left ventricular end-diastolic volume index nor the left ventricular ejection fraction side effects overnight albumin excretion rate cardiovascular events total serum cholesterol, hdl cholesterol, hba1c, fasting serum glucose, or plasma insulin complete renal-biopsy and retinopathy data aer urinary albumin excretion incidence of side effects time to the first onset of microalbuminuria gfr uae rate mean ccr mean bp glomerular filtration rate and effective renal plasma flow determined with inulin and para-aminohippuric acid clearances acute myocardial infarction, stroke, or hospitalized angina antiproteinuric effect of losartan diastolic blood pressure (bp mean fall in the systolic and diastolic blood pressure normoalbuminuria to microalbuminuria change in creatinine clearance risk of hypoglycaemic events resting blood pressure|on intention-to-treat analysis at 2 years, aer was 2.2 micrograms/min lower in the lisinopril than in the placebo group, a percentage difference of 18.8% (95% ci 2.0-32.7, p = 0.03), adjusted for baseline aer and centre, absolute difference 2.2 micrograms/min. office blood pressure was significantly lower in the candesartan group at follow-up than in the placebo group. 10 mg/24 h at 6 years (p = 0.001 for enalapril compared with placebo). fasting and post-prandial plasma glucose, glycosylated haemoglobin and plasma lipids appeared to be unaffected by either agent. during treatment, a significant increase in acr in the placebo group (p=0.007), wilcoxon matched paired test) was observed. slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients (3.6%) as compared with 91 of 2215 patients (4.1%) (p=0.37)--but a greater number had fatal cardiovascular events--15 patients (0.7%) as compared with 3 patients (0.1%) (p=0.01), a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], p=0.02). treatment with prazosin gits resulted in a favourable effect on serum triglycerides at the end of 8 weeks (p = 0.017) and 16 weeks (p = 0.011), and no detrimental effect or a marginal beneficial effect on total cholesterol, hdl cholesterol, and ldl cholesterol. at the end of follow-up, between the two groups there was no significant difference in total serum cholesterol, hdl cholesterol, hba1c, fasting serum glucose, or plasma insulin. microalbuminuria in diabetes is strongly predictive of nephropathy, end-stage renal disease, and premature cardiovascular morbidity and mortality. early blockade of the renin-angiotensin system in patients with type 1 diabetes did not slow nephropathy progression but slowed the progression of retinopathy. versus placebo (46 patients [1.55%]) (hazard ratio, 1.29 [95% ci, 0.87 to 1.89]; although no difference was demonstrated in creatinine clearance (p = 0.43), a lower percentage of patients in the intensive group progressed from normoalbuminuria to microalbuminuria (p = 0.012) and microalbuminuria to overt albuminuria (p = 0.028). in the whole group at baseline, the overnight albumin excretion rate correlated with hba1c (r = 0.50, p < 0.01) and the duration of diabetes (r = 0.39, p < 0.05), and sbp correlated with both the overnight (r = 0.42, p < 0.05) and the exercise-induced (r = 0.48, p < 0.05) albumin excretion rate. no significant changes were observed concerning other clinical and biochemical features between the two antihypertensive therapies and particularly hba1c, bmi, triglycerides, and cholesterol plasma values. treatment with enalapril was associated with a greater reduction in albuminuria than with nifedipine in the entire patient group, and especially in those with microalbuminuria. neither drug showed any negative side effects on fasting plasma glucose and glycated hemoglobin (hba1c) levels, and both maintain constant aers. the increase in urinary albumin excretion was less with telmisartan (p=0.004) or with combination therapy (p=0.001) than with ramipril. during a mean follow-up of 4.3 yr, active treatment reduced the risk for renal events by 21% (p < 0.0001), which was driven by reduced risks for developing microalbuminuria and macroalbuminuria (both p < 0.003). no difference was observed in change in creatinine clearance or serum creatinine from baseline between the two groups. reduction in systolic blood pressure (24-h systolic blood pressure) reduction was obtained in both treatment arms (mean reduction at final follow-up: dual blockade 6 mmhg vs. lisinopril 2 mmhg), but no significant difference was found between dual-blockade and lisinopril 40 mg once daily (p = 0.10). bp was significantly decreased in both groups at the end of the 1st and 6th month to a similar extent.|102 hypertensive, type 2 diabetic patients with varying degrees of albuminuria followed up for a mean duration of five years, we observed the importance of good metabolic and blood pressure control on the progression of albuminuria and renal function normotensive, normoalbuminuric patients with type 2 diabetes mellitus patients with type 1 diabetes 285 normotensive patients with type 1 diabetes and normoalbuminuria and who hypertensive patients with diabetes 20 physicians in mumbai, india type 1 diabetes patients people at high vascular risk (the ontarget study hypertensive mainly normotensive patients or patients with well-controlled hypertension who were at low overall vascular risk, which resulted in a low rate of microalbuminuria normotensive, normoalbuminuric patients with type 1 diabetes mellitus 26 iddm patients with normoalbuminuria patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage 23 microalbuminuric patients on hypertensive type 2 diabetic patients normotensive type 2 diabetic patients 75 patients enrolled in this study presented stable type 2 diabetes (not treated with insulin) and mild-to-moderate hypertension with a left ventricular mass > or = 75 g/m2 by two-dimensional echocardiography exclusion criteria included a history of coronary heart disease or stroke, serum creatinine > 1.5 mg/dl, albuminuria normotensive iddm patients normotensive patients with type 1 diabetes mellitus with normal serum creatinine and no microalbuminuria were treated with either 129 type 2 diabetic patients with a bp of <140/80 to 90 mm 793 patients discontinued therapy and 63 were lost to follow-up normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes males and females, aged 30 to 70 yrs, with hypertension of jnc v stage 1 or 2 at the end of a 2-week placebo run-in period, and diabetes mellitus with at least acceptable glycaemic control (fbs < or = 140 mg/dl, 2-hr pmbs < or = 200 mg/dl, and glycosylated hemoglobin < or = 9.5 156 patients in whom type 2 diabetes was diagnosed after 40 years of age who had a baseline mean blood pressure less than 107 mm hg and albuminuria (albumin excretion < or = 30 mg/24 h patients with type 2 diabetes 167 patients were recruited from 18 european centres, and were not on medication for hypertension 380 hypertensive diabetics hypertensive patients with diabetes mellitus patients with hypertension and niddm patients, 26 were normoalbuminuric and 18 microalbuminuric patients with diabetes thirty-three type 2 diabetic hypertensive patients diabetes glomerulopathy 784 patients permanently discontinued randomised therapy during the trial because of hypotensive symptoms (406 on combination therapy, 149 on mainly normotensive patients with type 1 or type 2 diabetes normotensive patients with type 2 diabetes young normoalbuminuric and normotensive patients with type 1 diabetes diabetic patients with microalbuminuria eight outpatient clinics coordinated by a department of medicine in a university hospital hypertensive niddm patients during antihypertensive therapy 12 patients receiving niddm patients attending the outpatient's clinic of the internal medicine departments of the university of padova and sassari, 44 participated in the present study normoalbuminuric normotensive iddm patients patients with hypertension and diabetes niddm patients with hypertension n = 13, age 36 adults with vascular disease normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria adults at high vascular risk hypertensive niddm patients inclusion criteria included a diagnosis of niddm and hypertension (systolic blood pressure of > 140 mmhg or diastolic blood pressure of > 90 mmhg normotensive type 2 diabetic subjects 5927 adults with known cardiovascular disease or diabetes with end-organ damage but without macroalbuminuria or heart failure who cannot tolerate angiotensin-converting enzyme inhibitors hypertensive diabetic patients with left ventricular hypertrophy (lvh 17 participants had dialysis hypertension and non-insulin-dependent diabetes patients with preexisting coronary heart disease hypertensive niddm patients with or without incipient nephropathy normotensive, normoalbuminuric patients with type 2 diabetes normoalbuminuric and microalbuminuric patients 3326 and 1905 patients with type 1 and type 2 diabetes, respectively 4447 patients with type 2 diabetes to receive 162 non-insulin-dependent diabetic hypertensive patients for a 24-week period people with insulin-dependent diabetes (iddm patients with type 2 diabetes and normoalbuminuria 530 men and women with iddm aged 20-59 years with normoalbuminuria or microalbuminuria type 2 diabetes hg without overt albuminuria 2009 massachusetts medical society 480 normotensive type 2 diabetic patients 13 patients aged 24 years at baseline diabetes twenty patients 309 secondary care centers normotensive normoalbuminuric iddm patients 11,140 patients who had type 2 diabetes and participated in the action in diabetes and vascular disease: preterax and diamicron-mr controlled evaluation (advance) study 25 620 participants 102 hypertensive, type 2 diabetic patients diabetic patients type 1 diabetes 75 type 1 and type 2 diabetic patients aged 35-74 years
bone density severe side effects incidence of vertebral fracture biochemical parameters cortical and cortical and trabecular bone mineral content risk of osteoporosis and fracture back pain axial bone loss bone mineral density (bmd bone loss at the femoral neck and distal radius bone preservation dxa lumbar spine density dual-energy x-ray absorptiometry (dxa) of the lumbar spine and hip, and spine radiographs to detect vertebral fractures bone mass generalised pruritus lost lumbar bone efficacy and safety spinal bone loss mean bmd lumbar bone loss spinal bone mass bone turnover assessed by biochemical markers, bone loss assessed by serial measurement of lumbar spine density, and rates of bone fractures bone remodeling (alkaline phosphatase and osteocalcin loss of bone in the lumbar spine percentage change in bone mineral density of the lumbar spine bmd bone loss s.d. bone mineral density of the lumbar spine|in the controls there were significant decrements of 1.4% and 3.5%, respectively, in cortical and cortical and trabecular bone mineral content, whereas in subjects on calcitonin there were increments of 2.6% and 2.7%, respectively. there were no significant differences between groups in bone loss over 12 months at the lumbar spine (l1-l4), although analysis of the upper segment (l1-l2) suggested some possible benefit of sct. the bone mass in the calcitonin group increased by 2.7% in the first year while in the group receiving calcium alone it decreased by 2.8%; this difference was significant. the incidence of vertebral fracture was 12.5% (calcitonin plus calcium: 11%, versus placebo plus calcium: 14%, ns), with four fractures in the first year and one fracture in the second year. there were no significant differences between groups with respect to age, underlying disease, initial bone density, or corticosteroid dose during the first year. parameters of bone remodeling (alkaline phosphatase and osteocalcin) decreased significantly in the calcitonin-treated group but not in the control group. nasal salmon calcitonin prevented loss of bone in the lumbar spine as measured by dual-energy x-ray absorptiometry.|sixty-two steroid-dependent asthmatics who had not received any form of treatment to prevent patients with active rheumatoid arthritis receiving low dose 44 steroid-dependent asthmatic patients patients on long term glucocorticoid therapy for asthma thirty-six patients with steroid-dependent, chronic obstructive lung disease and associated steroid osteoporosis 23 patients corticosteroid-treated patients with polymyalgia rheumatica patients with rheumatoid arthritis (ra) taking low dose glucocorticoids 20 patients who completed the 12-month follow-up period were analyzed and compared with 20 sex-matched patients from the control group 32 women with ra the setting was a tertiary care university-affiliated hospital and a total of 31 patients were enrolled one hundred three patients starting long-term corticosteroid therapy corticosteroid-dependent asthma corticoid-induced osteoporosis 48 patients with newly diagnosed polymyalgia rheumatica, temporal arteritis, and other vasculitides
hospital admission free of vomiting frequency of emesis during an 8-h-period after enrollment tolerance of oral fluids greater oral intake rank sum of episodes of diarrhea hospital admission rate, fluid intake, general well-being of the children, and potential adverse effects hospitalization rates rates of hospitalization change of weight frequency of vomiting vomiting rates of intravenous fluid administration and hospital admission mean length of stay in the emergency department proportion of patients experiencing no emesis proportion who vomited while receiving oral rehydration number of emetic episodes weight gain hospital admission rate oral fluid tolerance vomiting and diarrhea return visits to the emergency department efficacy and safety nausea and vomiting diarrheal episodes admission rate vomiting episodes tolerated oral hydration diarrhea median number of episodes of vomiting number of mean episodes of vomiting or repeat visits to health care number of diarrhea episodes admission rates antiemetic activity number of episodes of vomiting number of vomiting episodes, fluid intake, parents' assessment of well-being, number of diarrheal episodes, and admission rate to hospital tolerated number of episodes of emesis revisit rate intravenous hydration mean number of vomiting episodes|there were no differences in number of mean episodes of vomiting or repeat visits to health care at 24 and 72 hours in the ondansetron, dexamethasone, or ns groups. during 0-24 h, the number of emetic episodes experienced was significantly greater (p = 0.048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (p = 0.039) with ondansetron (58%) than placebo (17%). a lower proportion of patients receiving ondansetron compared with placebo required intravenous fluid therapy (p =.015). the mean number of vomiting episodes between randomization and follow-up visit was 0.64 in the dimenhydrinate group and 1.36 in the placebo group. eleven of 51 (21.6%; 95% confidence interval [ci] 11.3% to 35.3%) of subjects who received ondansetron required intravenous hydration and 30 of 55 (54.5%; 95% ci 40.6% to 68%) of placebo subjects required intravenous hydration (p <0.001) for a difference of 32.9% (95% ci 14.54% to 48.37%). although the mean length of stay in the emergency department was reduced by 12 percent in the ondansetron group, as compared with the placebo group (p=0.02), the rates of hospitalization (4 percent and 5 percent, respectively; p=1.00) and of return visits to the emergency department (19 percent and 22 percent, p=0.73) did not differ significantly between groups. as compared with the children who received placebo, children who received ondansetron were less likely to vomit both during the first 8-h follow-up in the emergency department [relative risk (rr): 0.33, 95% ci: 0.19-0.56, nnt: 2, 95% ci: 1.6-3.5], and during the next 24-h follow-up (rr: 0.15, 95% ci: 0.07-0.33, nnt: 2, 95% ci: 1.3-2.1).|children, aged 5 months to 8 years acute gastroenteritis children with gastroenteritis in countries such as canada and germany children with acute gastroenteritis children with vomiting from acute gastroenteritis children with acute gastritis or acute gastroenteritis and mild to moderate dehydration who fail initial oral rehydration therapy subjects with acute gastritis/acute gastroenteritis and mild to moderate dehydration subjects requiring iv hydration [corrected] in each group 215 children 6 months through 10 years of age who were treated in a pediatric emergency department for gastroenteritis and dehydration 243 children with presumed gastroenteritis and vomiting to rectal dimenhydrinate or three groups of 12 patients each, receiving either a single i.v discharged patients were evaluated at 24 and 72 hours for vomiting and repeat health care visits convenience sample of subjects 1 to 10 years old, with acute gastritis or acute gastroenteritis, who failed oral rehydration therapy in the emergency department (ed children aged 6 months to 12 years presenting with more than three episodes of vomiting in the past 24 hours, mild/moderate dehydration, and failed oral hydration were included patients with vomiting from gastroenteritis in a pediatric emergency department children tertiary care pediatric emergency department children presenting to the emergency department with refractory vomiting from viral gastritis who had failed attempts at oral hydration children with infectious gastroenteritis gastroenteritis in a pediatric emergency department children with mild dehydration children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy children between the ages of 6 months and 12 years who had vomited at least 5 times during the preceding 24 hours a total of 166 subjects were enrolled; data for analysis were available for 44 ns-treated patients, 46 ondansetron-treated patients, and 47 dexamethasone-treated patients children with dehydration secondary to vomiting from acute viral gastritis patients with other medical causes were excluded one hundred forty-five patients were enrolled, of whom 51% (n=74 children with gastroenteritis and dehydration we enrolled 106 subjects: 51 received children with gastroenteritis children with no or mild dehydration were included university-affiliated children's hospital ed a hundred and nine patients were enrolled; 54 received children suffering from acute gastroenteritis interferes with the oral rehydration process and equally frustrates parents and health care providers paediatric patients
fatal or nonfatal myocardial infarction total serum cholesterol cardiac mortality and morbidity lowering blood pressure plaque regression hypokalemia 4-year cbm(max) progression cardiovascular events and total mortality systolic blood pressure blood pressure, clinical safety total cholesterol: high-density lipoprotein cholesterol ratio fatal and non-fatal myocardial infarction carotid imt progression and number of plaques per patient sd systolic and diastolic blood pressure (sbp and dbp, respectively) of 149.7 diastolic blood pressure cardiovascular morbidity and mortality vascular events non-fatal myocardial infarction (including silent myocardial infarction) and fatal chd serum lipids and diabetes control cardiovascular disease-related death mean dbp cardiovascular disease mortality and morbidity outcomes fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death jnc vi blood pressure goals cardiovascular mortality clinic blood pressure reductions antihypertensive efficacies, tolerabilities and cardiovascular event rates deaths blood pressure goals adverse events fatal and nonfatal myocardial infarctions peripheral oedema incidence and progression of complications of diabetes nonmajor vascular events and procedures (eg, transient ischemic attack, dysrhythmia, aortic valve replacement, and femoral popliteal bypass graft adverse cardiovascular events morbidity and mortality cardiovascular disease-related events cardiovascular death, myocardial infarction, heart failure, or stroke cardiovascular mortality and morbidity major cardiovascular events risk of major vascular events serious adverse events serum creatinine levels, end-stage renal disease, and death from any cause blood pressure control blood pressure, blood glucose and lipid concentrations, and smoking behavior fatal or nonfatal stroke blood pressure urinary protein to creatinine ratio cardiovascular outcomes overall mean blood pressure systolic and diastolic blood pressure marked systolic blood pressure reduction composite of cardiovascular and cerebrovascular events rates of cardiovascular events cardiac disease blood pressure change, side effects and quality-of-life indices; incidence of electrocardiographic and echocardiographic abnormalities; and incidence of cardiovascular clinical events, including death composite of cardiovascular events composite cardiovascular event rate occurrence of cardiovascular events serum lipids and glucose metabolism blood pressure 168.9 rate of progression of mean maximum intimal-medial thickness (imt asthenia renal disease progression cardiovascular disease and total mortality incidence of vascular events congestive heart failure blood pressure of the sitting subject, heart rate, and a standard clinical safety profile (electrocardiogram, laboratory tests, adverse events, cardiovascular events, and deaths incidence of developing diabetes sbp occurrence of death (all cause), nonfatal myocardial infarction, or nonfatal stroke; other: cardiovascular death, angina, adverse experiences, hospitalizations, and blood pressure control at 24 months biochemical measures stroke, myocardial infarction, or cardiovascular disease-related death time to cardiovascular death, myocardial infarction, congestive heart failure, strokes, and coronary revascularization fatal and nonfatal myocardial infarction yearly imt progression rate mean sbp renal outcomes treatment blood pressures rate of change in gfr composite index of the clinical end points of reduction in gfr of more than 50% or 25 ml/min per 1.73 m(2), end-stage renal disease, or death rates of hyperuricemia (plasma urate cardiovascular morbidity or mortality fatal and non-fatal stroke plaque progression rate of progression of mean maximum imt major vascular events (eg, myocardial infarction, stroke, congestive heart failure, angina, and sudden death myocardial infarction triglyceride level overall cardiovascular or cerebrovascular complications mean gfr decline relative risk for stroke, major cardiovascular events, and mortality cardiovascular events total mortality total serum cholesterol, hdl cholesterol, hba1c, fasting serum glucose, or plasma insulin mean diastolic values 24-hour ambulatory systolic/diastolic blood pressure changes gfr systolic and diastolic blood pressures cardiac morbidity and mortality acute myocardial infarction, stroke, or hospitalized angina strokes nonstroke hemorrhage heart rate risk of clinical end points total cardiovascular events hyperuricemia and hypokalemia rate of myocardial infarction|treatments were similarly effective in males and females and in age groups between 60 and 69 years (n = 763), 70 and 79 years (n = 744) and > or = 80 years (n = 375). in this population of patients with diabetes and hypertension, we found a significantly higher incidence of fatal and nonfatal myocardial infarction among those assigned to therapy with the calcium-channel blocker nisoldipine than among those assigned to receive enalapril. similar antihypertensive efficacies, tolerabilities and cardiovascular event rates were observed with verapamil and with chlorthalidone. blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4.0/2.1 mm hg lower in amlodipine than valsartan group after 1 month; two-year blood pressure control was similar between groups. will lowering ldl cholesterol in moderately hypercholesterolemic older individuals reduce the incidence of cardiovascular disease and total mortality? the composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy. deaths were mainly non-vascular (nifedipine 176 vs co-amilozide 172; p=0.81). statistical calculations indicate that 6,600 patients, followed for four years will be needed (2p < 0.05, power 90%) to obtain significance if there is a 25% difference between the new and the established therapy. ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria. a significant (p<0.0001) effect of lacidipine was found compared with atenolol, with a treatment difference in 4-year cbm(max) progression of -0.0227 mm (intention-to-treat population) and -0.0281 mm (completers). six classes of drugs were studied: (1) acebutolol fatal and non-fatal stroke occurred in 159 patients in the diltiazem group and in 196 in the diuretic and beta-blocker group (6.4 vs 7.9 events per 1000 patient-years; 0.80 [0.65-0.99], p=0.04) and fatal and non-fatal myocardial infarction in 183 and 157 patients (7.4 vs 6.3 events per 1000 patient-years; 1.16 [0.94-1.44], p=0.17). there was no difference in the rate of progression of mean maximum imt between isradipine and hydrochlorothiazide over 3 years (p=.68). nonstroke hemorrhage was more common with participants in the coer-verapamil group (n = 118) compared with the atenolol or hydrochlorothiazide group (n = 79) (hr, 1.54 [95% ci, 1.16-2.04]; p =.003). at the end of follow-up, between the two groups there was no significant difference in total serum cholesterol, hdl cholesterol, hba1c, fasting serum glucose, or plasma insulin. the amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol-based regimen.|patients with mild hypertension 22 576 hypertensive cad patients aged 50 years or older, which was conducted september 1997 to february 2003 at 862 sites in 14 countries 1414 hypertensive patients [692 men and 722 women, aged 53.2 patients with heart failure, diabetes, or renal impairment african americans males and females and in age groups between 60 and 69 years (n = 763), 70 and 79 years (n = 744) and > or = 80 years (n = 375 high-risk patients with hypertension 19 257 patients with hypertension who were aged 40-79 years and had at least three other cardiovascular risk factors isolated systolic hypertension 380 hypertensive diabetics elderly patients with isolated systolic hypertension in a prospective study with an open design subgroup of patients in the abcd trial who had hypertension hypertensive patients at high cardiovascular risk patients with diabetes a total of 16 602 participants diagnosed as having hypertension and who had 1 or more additional risk factors for cardiovascular disease were enrolled between september 1996 and december 1998 and followed up until december 31, 2000 1882 males and females outpatients > or = 60 years patients were recruited if sitting systolic blood pressure was > or = 160 mmhg with a diastolic blood pressure equal or lower than 95 mmhg niddm patients with hypertension patients with hypertension and niddm moderately hypercholesterolemic older individuals 20,000 moderately hypercholesterolemic patients (a subset of the 40,000) with a patients receiving patients with type 2 diabetes and overt nephropathy old patients with hypertension (stop-hypertension 1) was conducted in men and women aged 70-84 years 209 centers in the americas, europe, israel, and australasia sd patients with type 2 diabetic nephropathy who received group (237 patients) and the enalapril group (233 patients) throughout five years of follow-up patients with non-insulin-dependent diabetes and hypertension less than 140 mm hg (systolic) and less than 90 mm hg (diastolic); and less than 130 mm hg (systolic) and less than 85 mm hg (diastolic) if diabetes or renal impairment was present 1715 adults with type 2 diabetic nephropathy and hypertension; serum creatinine levels of 89 micromol/l (1.0 mg/dl) to 266 micromol/l (3.0 mg/dl) in women and 106 micromol/l (1.2 mg/dl) to 266 micromol/l (3.0 mg/dl) in men; and urinary protein excretion rates of at least 900 mg/d nine medical center clinics inclusion criteria included a diagnosis of niddm and hypertension (systolic blood pressure of > 140 mmhg or diastolic blood pressure of > 90 mmhg coronary artery disease (cad hypertensive renal disease progression patients with hypertension and cad treated with a calcium antagonist strategy (cas) or a non-calcium antagonist strategy (ncas 2334 patients with hypertension hypertension patients started in september 1992 and so far more than 100 patients/week have been included hypertensive nephrosclerosis exclusion criteria included a history of coronary heart disease or stroke, serum creatinine > 1.5 mg/dl, albuminuria elderly hypertensives 40,000 high-risk hypertensive patients 8241 participants received 180 mg of patients with hypertensive renal disease and proteinuria old patients with hypertension 661 centers in 15 countries 470 patients in the trial who had hypertension (base-line diastolic blood pressure, > or = 90 mm hg enrolled 10,881 patients, aged 50-74 years, at health centres in norway and sweden, who had diastolic blood pressure of 100 mm hg or more patients in primary health care (300 centres patients with diabetes and hypertension allhat's main eligibility criteria are: 1) age 55 or older; 2) systolic or diastolic hypertension; and 3) one or more additional risk factors for heart attack (eg, evidence of atherosclerotic disease or type ii diabetes elderly patients with isolated systolic hypertension patients with coronary artery disease hypertensive patients at high cardiovascular risk treated with regimens based on 1094 african americans aged 18 to 70 years with hypertensive renal disease (glomerular filtration rate [gfr] of 20-65 ml/min per 1.73 m(2)) enrolled between february 1995 and september 1998 in september 2000 15?245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events patients with type 2 diabetes and overt nephropathy treated with hypertensive cad patients members of a large population of hypertensive patients hypertensive patients patients had at least one additional cardiovascular risk factor 883 patients with baseline mean 6321 patients aged 55-80 years with hypertension (blood pressure > or = 150/95 mm hg, or > or = 160 mm hg systolic the study was stopped prematurely after 5.5 years' median follow-up and accumulated in total 106 153 patient-years of observation patients with non-insulin-dependent diabetes mellitus and hypertension
number of arterial blood gas samples drawn rate of reintubation rate of successful weaning rates of reintubation, non-invasive ventilation post-extubation, tracheostomy, sedation, neuromuscular blockade and use of corticosteroids hospital cost savings icu length of stay synchronized intermittent mandatory ventilation rate and pressure support (ps) based on predetermined limits of patient respiratory rate (rr) and tidal volume (tv simplified acute physiologic score ii median duration of mechanical ventilation severe disease glasgow coma scale (gcs) score vap frequency average time on mechanical ventilation prior to weaning intubation time weaning time and incidence of ventilator-associated pneumonia rates of reinstituting mechanical ventilation total costs number of minutes per hour outside acceptable limits complications -- removal of the breathing tube by the patient, reintubation, tracheostomy, and mechanical ventilation shorter durations of mechanical ventilation tracheostomies simv rate and ps reduction median time of mechanical ventilation need for reintubation, length of hospital stay, hospital mortality rate, and hospital costs icu duration of mechanical ventilation pulse oximeter oxygen saturation duration of mechanical ventilation, length of intensive care unit stay, mortality, rate of tracheotomy (secondary end points hospital costs duration of mechanical ventilation from tracheal intubation until discontinuation of mechanical ventilation mv interval and hospital length of stay median time mortality and ventilator discontinuation failure rates incidence of vap vap incidence of ventilator-associated pneumonia (vap arterial blood gas samples, shorter weaning times, and less time spent outside acceptable rr and tv parameters median time to successful extubation hospital mortality rates hospital mortality number of days of intensive care and hospital care partial pressure of arterial oxygen/fraction of inspired oxygen ratio median interval successful extubation estimated probability of reaching "separation potential pao2/fio2 ratio overall complications included death discontinuation of mechanical ventilation|simplified acute physiologic score ii (adjusted odds ratio 1.042 per unit; 95% confidence interval 1.006-1.080; p = 0.022) and inclusion in the control group (adjusted odds ratio 2.393; 95% confidence interval 1.000-5.726; p = 0.05) were the only two independent predictive factors for the risk of extubation failure. intubation time was significantly lower in group i than group ii and "fast track recovery" group (p=0.05). the study groups showed comparable rates of reintubation, non-invasive ventilation post-extubation, tracheostomy, sedation, neuromuscular blockade and use of corticosteroids. there were no significant baseline differences in patient characteristics between groups. twelve patients in the surgical control group had vap, compared with 5 in the surgical vmp group (p = 0.061). the study suggests that use of the computer-directed weaning system results in fewer arterial blood gas samples, shorter weaning times, and less time spent outside acceptable rr and tv parameters. overall complications included death (36%), reintubation (16%), and pneumonia (9%). total costs for the intensive care unit were lower in the intervention group (median, $15,740, vs. $20,890 in the controls, p=0.03); hospital costs were lower, though not significantly so (median, $26,229 and $29,048, respectively; p=0.3). the hospital mortality rates for the two treatment groups were similar (protocol-directed 22.3% vs. physician-directed 23.6%; p = .779).|neurosurgical patients university medical center in medical and coronary intensive care units patients that underwent cardiac surgery and cardiopulmonary bypass patients with neurologic disorders forty-nine patients with low and medium higgins risk score, who underwent, between february and november 1999, elective surgery at our institution medical and surgical patients by respiratory care practitioners and nurses three hundred eighteen intubated patients who had been receiving mechanical ventilation for at least 12 hrs and were able to trigger the ventilator medical patients patients with complex medical problems from mechanical ventilation and appropriately respond to signs of respiratory failure more effectively than traditional physician-directed weaning methods forty (82 102 patients were equally divided between smartcare/ps and control one australian intensive care unit three hundred eighty-five patients receiving mechanical ventilation between june 1997 and may 1998 neurosurgical (nsy) patients 300 adult patients receiving adults receiving 100 patients over a 14-mo period patients with neurologic diseases mechanically ventilated medical patients nurses and respiratory therapists with traditional physician-directed weaning patients requiring mechanical ventilation (n = 357 medical and surgical intensive care units in two university-affiliated teaching hospitals mechanically ventilated neurosurgical and neurologic patients patients in the intervention (n = 49) and control (n = 51) groups had similar demographic characteristics, illness severity, and neurologic injuries cardiac surgery adult patients requiring 15 patients who had required prolonged mechanical ventilation and met predetermined weaning tests
time to confirmed progression in disability neutralizing antibodies to ifnbeta-1b neurological deterioration regional functional status scale sensitive disability measure and relapse rate time to confirmed progression of disability edss scores first time in a large-scale ms trial median msfc z-score change 11 ms quality of life inventory subscales time to sustained disability efficacy and safety expanded disability status scale (edss mean change in edss score from baseline, relapse-related measures, mri activity, and a standardized neuropsychological function test new or enlarging t2-hyperintense brain mri lesions and gadolinium-enhancing lesions ms functional composite (msfc), comprising quantitative tests of ambulation (timed 25-foot walk), arm function (nine-hole peg test [9hpt]), and cognition (paced auditory serial addition test [pasat time to becoming wheelchair-bound, relapse rate and severity, number of steroid treatments and hospital admissions time to progression by > or =1.0 edss point (0.5 point if edss score tolerated msfc progression, relapses, quality of life, and mri activity neutralizing antibodies clinical relapses, newly active mri lesions, and accumulated burden of disease on t2-weighted mri edss (hazard ratio (hr) annual relapse rate disability measures|new or enlarging t2-hyperintense brain mri lesions and gadolinium-enhancing lesions were reduced at months 12 and 24 (both p < 0.001). positive results were also obtained regarding time to becoming wheelchair-bound, relapse rate and severity, number of steroid treatments and hospital admissions, as well as on magnetic resonance imaging variables. annual relapse rate was 0.27 with placebo and 0.25 with ifn (rate ratio = 0.90; 95% ci 0.64 to 1.27; p = 0.55). there was no significant difference in time to confirmed progression of edss scores between placebo-treated patients and either of the ifnbeta-1b treatment groups.|358 patients with sp-ms patients with secondary progressive ms secondary progressive ms 371 patients with clinically definite spms patients who are in the secondary progressive phase of the disease (sp-ms secondary progressive multiple sclerosis outpatients with sp-ms having scores of 3.0-6.5 on the expanded disability status scale (edss) received either patients with sp-ms subjects with secondary progressive multiple sclerosis (spms 939 subjects from the united states and canada with spms and expanded disability status scale (edss) scores ranging from 3.0 to 6.5 patients had been in the study for at least 2 years patients in the relapsing-remitting phase of multiple sclerosis (ms 436 subjects with spms and expanded disability status scale (edss) score 3.5 to 6.5
hospital admissions or mortality cause hospitalizations and total hospital days cardiovascular-related emergency room visits 59 chf hospital admissions and 13 deaths length of time between hospital discharge and readmission or death, reduced total number of rehospitalizations, and decreased healthcare costs self-care and quality of life emergency department admission readmissions for any reason lower mortality total number of readmissions death or unplanned readmission (event-free survival) and rate of recurrent, all-cause readmission within 6 months of hospital discharge re-admission rates number of short hospitalizations mortality and morbidity risk of death or readmission death or hospital readmission hospital readmissions qol or health care consumption hospital-based costs number of hospital readmissions and hospital days and improved quality of life rate of rehospitalization for heart failure readmission and death rates self-care abilities median total public health care and personal care costs quality of life (qol) and secondary end points were hospitalisation and mortality events (readmission or death satisfaction scale deaths admissions cardiovascular hospitalizations readmitted with heart failure risk of readmission lower risk of re-admission 1-year cumulative incidence of readmission or death quality of life and death or hospital readmissions minnesota living with heart failure questionnaire scores self-care abilities (appraisal of self-care agency scale), self-care behavior (heart failure self-care behavior scale), 3 dimensions of quality of life (functional capabilities, symptoms, and psychosocial adjustment to illness), and overall well-being (cantril's ladder of life readmissions readmission or died quality of life cause hospital admission rates and total number of days in hospital at 6 months frequency of unplanned readmission plus out-of-hospital death greater uptake of beta-blocker therapy hospital admissions composite of the number of chf hospital admissions and deaths year survival rate heterogeneous changes in nyha functional class cost savings cost-effective hospitalization days cost/utility ratios self-care abilities, self-care behavior, and quality of life number of days in hospital readmitted because of hf or died qol or readmission rate physical dimension of quality of life hospitalizations target doses of angiotensin converting enzyme (ace) inhibitors cause death and heart failure hospital admissions handicap in independence heart failure rate of first rehospitalization for heart failure effectiveness and cost-effectiveness effectiveness and cost/utility ratio quality of life and reduced total hospital admissions and total bed days mortality, morbidity and self-care behaviour quality-of-life score spent fewer days in hospital for heart failure unplanned readmission 134 admissions overall quality of life quality of life improved and overall cost of care mean time to readmission nyha functional class survival and self-care behaviour appearance of hard events recurrent readmission and event-free survival hospital readmission costs required readmission to hospital time to death or rehospitalization because of hf and the number of days lost to death or hospitalization total number of emergency department visits, quality of life and total mortality cardiac death ace inhibitor adherence rate of unplanned re-admission incidence of readmission, mortality, and emergency department admission hard cardiac events total hospital readmissions mean total costs time to first rehospitalization or death, number of rehospitalizations, quality of life, functional status, costs, and satisfaction with care median number of re-admissions patient satisfaction chronic heart failure (chf) hospital readmissions and mortality unplanned readmissions and survival higher self-care scores unplanned readmissions cost/utility ratio rate of all-cause rehospitalization health care costs unplanned outpatient visits all-cause mortality hospitalisation and health care costs higher level of treatment compliance admissions for heart failure hospital readmissions, improved survival and quality of life died readmitted or died rate of unplanned readmissions and associated health-care costs, prolong event-free and total survival quality of life, which was self-assessed using the minnesota living with heart failure questionnaire length of hospital stay recurrent hospital stay six-minute walking distance total number of emergency department visits symptom frequency and symptom distress ace inhibitor use recurrent hospitalisation time to first event, time to first all-cause and hf readmission, and time to death year readmission or mortality and costs of care mortality and quality of life (minnesota living with heart failure questionnaire and eq-5d adverse clinical outcomes and costs 43 chf hospital admissions and 7 deaths mean days of hospital stay hospital days events (death or admission cost of care functional status, quality of life and beta-blocker prescription rate hospital re-admissions, days of hospital stay, treatment compliance, satisfaction with the care received, and quality of life (euroqol number of days lost to death or hospitalization management (rate of readmissions, therapeutic interventions), functional parameters (new york heart association [nyha] functional class, left ventricular diameters, and ejection fraction, deceleration time of early diastolic mitral flow, peak oxygen uptake, and mitral regurgitation) and hard outcomes (cardiac death and urgent cardiac transplantation time to first readmission or death hospital costs rate of readmission or death and hospital costs performance, effectiveness, and cost/utility ratio time to readmission, days in hospital, and health care costs cause readmissions and all-cause deaths c+hbi number of unplanned re-admissions, six-minute walking distance, london handicap scale and public health care and personal care costs eq-5d scores mortality moderate to severe hf|compared with usual care, patients in the intervention group had fewer readmissions for any reason (86 v 114, p=0.018), fewer admissions for heart failure (19 v 45, p<0.001) and spent fewer days in hospital for heart failure (mean 3.43 v 7.46 days, p=0.0051). to determine whether a telephone-mediated nurse care management program for heart failure reduced the rate of rehospitalization for heart failure and for all causes over a 1-year period. a nurse based management programme is more effective than follow up in primary care in optimising medication for elderly patients with heart failure. there were 43 chf hospital admissions and 7 deaths in the intervention group, as compared with 59 chf hospital admissions and 13 deaths in the nonintervention group (p = 0.09). patients allocated to usual-care management showed heterogeneous changes in nyha functional class (13% improved and 16% worsened p = ns); in contrast, the dh group showed significant changes in nyha functional class (23% improved and 11% worsened, p < 0.009). no differences were recorded in quality of life, but the intervention group had a higher score in the satisfaction scale at two months [9.0 (sd=1.3) versus 8.2 (sd=1.8) p=0.026]. dmp patients reported, compared to baseline, significant improvements in functional status, quality of life and beta-blocker prescription rate. there were 81 all-cause hospital readmissions in the intervention group and 82 in the control group (p = ns). the one year survival rate was 71.8% (n = 79) in the control group and 70.0% (n = 56) in the intervention group (ns). there was no significant difference between the intervention and control groups for the combined end-point of death or hospital readmission. compared with usual care, care at a multidisciplinary specialized congestive heart failure outpatient clinic reduced the number of hospital readmissions and hospital days and improved quality of life. community nurse-supported post-discharge programme was effective in preserving independence and was probably effective in reducing the number of unplanned re-admissions. intervention patients showed a trend toward reduced all-cause hospitalizations and total hospital days. c+hbi was associated with a non-significant, 45% reduction in the risk of death or readmission when adjusting for potential confounders (rr 0.55, 95% ci 0.28-1.08: p=0.08). the intervention was associated with a 39% decrease in the total number of readmissions (intervention group: 49 readmissions; control group: 80 readmissions, p = 0.06). there were fewer patients with events (death or admission) after 12 months in the intervention group compared to the control group (29 vs 40, p=0.03) and fewer deaths after 12 months (7 vs 20, p=0.005). ace inhibitor use increased from 58% on admission to 83% at discharge (p < .0001), and the daily dose (in enalapril equivalents) increased from 11.3 +/- this community pharmacist intervention did not lead to reductions in hospital admissions in contrast to those found in trials of specialist nurse led interventions in heart failure. this comprehensive hospital discharge and outpatient management program prolonged time to first event, reduced hospital readmissions, improved survival and quality of life of patients hospitalized for hf, while reducing cost of management. more intervention-group than usual-care patients remained event-free (38 vs 51; p=0.04). the 3 dimensions of quality of life improved after hospitalization in both groups, with no differences between intervention and control group as measured at each follow-up measurement. a comprehensive transitional care intervention for elders hospitalized with heart failure increased the length of time between hospital discharge and readmission or death, reduced total number of rehospitalizations, and decreased healthcare costs, thus demonstrating great promise for improving clinical and economic outcomes. there were slightly more hospitalizations in the 2 intervention groups (basic intervention group, p = .89; and intensive support group, p = .60). at 1-year follow-up, 62 of the 137 patients (45.3%) in the intervention group had been readmitted or died, compared with 75 of the 142 (52.8%) in the control group, (relative risk=0.86, p=.232).|consecutive older outpatients two hundred thirty-nine eligible patients were aged 65 and older and hospitalized with heart failure 106 patients patients with chronic heart failure heart failure outpatients at high risk of hospital readmission patients admitted for hf patients with advanced (new york heart association class iii-iv) heart failure 234 prospective patients discharged by a hf unit were randomized to two management strategies: 122 patients to usual community care and 112 patients to a older chronic heart failure patients 179 patients (mean age 73 years, 58% men, new york heart association classification iii and iv) admitted to a university hospital with symptoms of heart failure older adults hospitalized with heart failure patients hospitalised due to heart failure for 12 months after discharge chf patients with evidence of left ventricular systolic dysfunction admitted to two hospitals in northern england patients with dementia, terminal non-cardiac disease, or chronic obstructive pulmonary disease were excluded patients with heart failure discharged after hospitalisation reduces health care costs and the need for readmission 200 patients with high baseline use of approved hf pharmacotherapy patients with heart failure (hf) remain poor university hospital with a primary catchment area of 250,000 inhabitants two hundred patients hospitalized with chf at increased risk of hospital readmission patients with chronic illness patients with heart failure elderly patients with heart failure 293 patients diagnosed with heart failure were included (149 intervention, 144 control) after an emergency admission all patients were scheduled for three observational study visits at six month intervals chf patients 2786 patients screened, 462 met clinical criteria for heart failure and were randomly assigned (228 to intervention and 234 to usual care patients with heart failure at low risk patients with advanced heart failure 134 patients were included, with a mean age of 75 years and a low educational level in stage 1 (766 patients 6 years, 48% women acute medical admissions unit in a teaching hospital heart failure patients with heart failure (hf patients' care with primary care physicians chronic chf patients discharged home after acute hospital admission 230 eligible patients who had experienced an acute episode of congestive heart failure to standard care (n = 115) or follow-up at a multidisciplinary specialized heart failure outpatient clinic (n = 115 elderly patients benefit from disease management programmes (dmps the median age of the study patients was 63.5 years, and 39.5% were women patients with hf patients admitted to hospital with heart failure patients with initial low qol had a poor prognosis patients hospitalized with hf 165 patients admitted with heart failure due to left ventricular systolic dysfunction six philadelphia academic and community hospitals hospitalized high-risk patients with chf heart failure patients patients with heart failure (new york heart association class ii-iv) and left ventricular systolic dysfunction aged 60 years or more 208 participants, 58% were men, mean age was 75 years, and mean ejection fraction 34 patients with congestive heart failure (chf heart failure (hf) patients implemented in a home care unit a non-selected cohort of patients hospitalized for hf patients discharged from hospital following admission for heart failure patients with chronic congestive heart failure one hundred and ninety-seven patients admitted to auckland hospital with an episode of heart failure were enrolled in the study heart failure (hf 190 patients (aged 65-84 years, 52.3% men) hospitalised because of heart failure two hundred consecutive patients admitted to the internal medicine department with a diagnosis of hf heart failure (coach patients with hf including medical components older patients with chronic heart failure patients hospitalized for heart failure from may 1998 through october 2001 mean age of patients (control n=121; intervention n=118) enrolled was 76; 43% were male, and 36% were african american 1023 patients were enrolled after hospitalization because of hf chronic heart failure patients with chronic chf patients admitted with decompensated hf university hospital in maastricht, the netherlands 279 hf patients who were discharged from a tertiary-care hospital between february 2001 and june 2002 low-risk patients with heart failure elderly heart failure patients multidisciplinary congestive heart failure clinic 173 patients aged > or =70 years (mean age 77 patients with chf 105 hospitalized patients aged 60 years or over with chronic heart failure and history of hospital admission(s) in previous year 5 northern california hospitals in a large health maintenance organization chronic heart failure (chf) outpatients elders hospitalized with heart failure elderly patients discharged with heart failure from a university hospital hospitalized patients with heart failure
extrapyramidal symptom rating scale brief psychiatric rating scale (bprs) and abnormal involuntary movement scale positive symptom improvement (bprs-positive), olz-m, olz-h, and hal moderate eps and drowsiness negative symptoms body weight global evaluation, bprs, and target symptom ratings positive symptoms incidence of extra-pyramidal side effects number of symptom-free days dose positive symptom scores plasma aag levels positive and negative syndrome scale (panss) total, panss positive, panss negative, panss-derived brief psychiatric rating scale (bprs) core, clinical global impressions (cgi)-severity of illness, and mean cgi-improvement scores total scores on the positive and negative syndrome scale for schizophrenia quicker onset of antipsychotic activity relapse rate overall symptomatology improvement (brief psychiatric rating scale [bprs]-total), olz-m, olz-h, and hal somnolence, agitation, asthenia, and nervousness total panss, general psychopathology, and brief psychiatric rating scale subscales incidence of extrapyramidal symptoms mean plasma haloperidol levels efficacy, safety, and tolerability safety and efficacy tardive dyskinesia panss negative score plasma alpha-one acid glycoprotein and haloperidol concentrations variables (basic data, mmpi, amdp, ham-a, ham-d qtc interval bprs scores rate of hal, and akathisia acute dystonia antidyskinetic effect safety and tolerability evaluations included extrapyramidal symptoms (eps), weight gain, serum prolactin level, and qtc interval prolactin elevations blood samples to measure plasma alpha-one acid glycoprotein (aag), haloperidol and reduced haloperidol concentrations clinical improvement blood samples efficacy and safety signs of tardive dyskinesia serum prolactin levels total positive and negative syndrome scale (panss) score and positive subscale, superiority to placebo bprs total, bprs positive-symptom cluster, and cgi severity of illness item scores panss total, panss positive, panss-derived bprs core, and cgi-severity scores bprs scores and plasma aag levels efficacy, rapidity of therapeutic onset, and safety remission state number of days of remission assessment scales of extrapyramidal side effects brief psychiatric rating scale (bprs), clinical global impression (cgi), and modified scale for the assessment of negative symptoms (sans) summary scores eps or prolactin elevation negative symptoms [sans]-composite), olz-l and olz-h prolactin levels|aripiprazole, 15 mg, and haloperidol, 10 mg, significantly improved panss negative score compared with placebo. the most common treatment-emergent adverse events included somnolence, agitation, asthenia, and nervousness. at the end of the 3-year trial, both chlorpromazine and haloperidol significantly prolonged the remission state as compared to the other three drugs. risperidone did not differ from placebo on assessment scales of extrapyramidal side effects, but produced significantly less than did haloperidol. in group comparison, no antipsychotic action of trazodone in schizophrenic patients could be proved. risperidone (6 mg) was superior to haloperidol on the total panss, general psychopathology, and brief psychiatric rating scale subscales. the incidence of extra-pyramidal side effects (measured by the extrapyramidal symptom rating scale) was significantly higher in patients treated with 16 mg of risperidone or 20 mg of haloperidol than placebo. haloperidol was superior to placebo for reduction of target symptoms with optimal haloperidol dose of 0.5 to 3.5 mg/day (0.02-0.12 mg/kg/day). quetiapine was no different from placebo across the dose range studied regarding incidence of extrapyramidal symptoms or change in prolactin concentrations. propericiazine at 10 mg and 30 mg also increased the number of symptom-free days dose-dependently but at 60 mg, the number decreased. the overall results indicated that the 5 mg and 2 mg haloperidol doses were significantly superior to the 1 mg haloperidol and 25 mg chlorpromazine doses and to placebo. significant correlations between decreasing bprs scores and plasma aag levels were not found with only a strong trend at week 2 (r = 0.445, p = 0.073).|45 patients with major depressive disorder and 75 patients with acute schizophrenia schizophrenic patients 55 schizophrenics in remission these children, 9 boys and 3 girls, were ages 5.5 to 11.75 years upon study entry patients with severe dyskinesia thirty six schizophrenic patients 335 patients who met the dsm-iii-r criteria for schizophrenia 135 inpatients with a diagnosis of chronic schizophrenia patients with schizophrenia and schizoaffective disorder 50 acute psychotic patients requiring rapid control patients with depressive symptoms hospitalized schizophrenic children symptom-free schizophrenics controlled trial with acute exacerbation of chronic schizophrenia (dsm-iii-r 388 schizophrenic patients drawn from 20 sites in the united states schizophrenia subjects are diagnosed schizophrenic by dsm-iii-r criteria and admitted to the bellevue hospital children's inpatient psychiatric unit three hundred sixty-one patients from 26 north american centers remitted schizophrenic outpatients 20 subjects, 12 have completed the study 414 patients with a primary dsm-iv diagnosis of schizophrenia or schizoaffective disorder 36 schizophrenic patients in acute exacerbation conducted at 36 u.s. centers between july 1997 and june 1998, compared psychiatric patients chronic schizophrenic patients patients with acute exacerbation of schizophrenia schizophrenic children
progression of renal failure (1/serum creatinine v time) or change in serum potassium serum creatinine and reciprocal of serum creatinine packed cell volume (pcv survival rate 51cr red cell mass average systolic and diastolic blood pressure slope of l/serum creatinine with time cumulative renal survival rates energy levels and work capacity appetite, activity level, and sense of well-being quality of life anemia erythroid, megakaryocyte, and granulocyte-monocyte progenitor cells safety and efficacy gfr, mean arterial blood pressure, and daily protein intake exercise capacity rate of the decline in renal function slope of l/serum creatinine hematocrit rose deterioration of renal function renal function, cardiac output, plasma renin activity and aldosterone total hemoglobin (thb physical exercise capacity hematocrit; mean hematocrit hypertension chronic renal failure renal survival rate gfr hematocrit hematocrit increased with r-huepo hemoglobin concentration maximal oxygen consumption during exercise serum ferritin and percent transferrin saturation (plasma iron/total iron-binding capacity blood pressure clearances of inulin and p-aminohippurate, fractional excretions of albumin and immunoglobulin g, cardiac output, plasma renin activity and aldosterone concentration blood pressure and hematocrit tolerated erythrocyte mass glomerular filtration rate (gfr degree of control of dietary protein and blood pressure and the frequency of angiotensin-converting enzyme inhibitor administration residual renal function cardiac output, plasma renin activity and aldosterone renal function serial gfrs median hematocrit thb rate of the response|there were lesser responses in pcv at the two lower doses of r-huepo and no response in the placebo group. there was a significant correlation between the increase in thb and the increase in exercise capacity in the epo group (r = 0.81, p less than 0.005). there was a statistically significant increase in hematocrit for the r-huepo-treated group that was not associated with acceleration of deterioration in residual renal function. 22 weeks of r-huepo therapy, the slope of l/serum creatinine did not worsen in any patient.(abstract truncated at 250 words) six of seven treated patients had a significant decrease in serum ferritin and percent transferrin saturation (plasma iron/total iron-binding capacity). cr doubled in 26 patients (84%) in group i as compared with 22 (52%) in group ii and 21 (60%) in group iii. all the patients reported improvements in appetite, activity level, and sense of well-being. correction of anemia (hematocrit of 40% for males, 35% for females) occurred in 87% of those given 150 u/kg, 64% of those given 100 u/kg, 46% of those given 50 u/kg rhuepo and in 3% of the placebo group. subjects who received active r-huepo showed a dose-dependent rise in hematocrit; mean hematocrit increased 41% from 0.27 +/-|predialytic uremic patients predialysis patients without adverse effects on renal function over a 12-week period chronic renal insufficiency patients pre-dialysis patients fourteen nondialyzed patients with chronic renal insufficiency (serum creatinine 265 to 972 mumol/l [3.0 to 11.0 mg/dl]) and severe anemia (hematocrit less than 30 chronic renal failure predialysis patients fourteen adult subjects with renal insufficiency (mean serum creatinine, 473 mumol/l 89 to 466 17 patients with anemia and progressive renal failure who did not yet require dialysis (serum creatinine level, 353 to 972 mumol per liter [4.0 to 11.0 mg per deciliter forty patients renal anemia in dialysis patients predialysis chronic renal failure patients 83 anemic, predialysis (serum creatinine 3 to 8 mg/dl) patients patients with moderate renal failure patients with progressive renal failure without affecting renal function chronic renal failure patients predialysis renal patients nondiabetic patients 124 and 357 patients with nonsevere or moderate anemia 61 14 patients before therapy, developed during therapy in 2 of the normotensive patients, and worsened in 9 patients, who required additional antihypertensive medications 12 years; 6 men, 6 women) with a mean glomerular filtration rate (gfr) of 10 +/- 4 ml/min x 1.73 m2 anemia associated with chronic renal failure in predialysis patients 12 patients with chronic renal insufficiency (creatinine clearances of 0.17-0.51 ml/second [10-30 ml/minute]) and uremic anemia predialysis patients predialysis patients with recombinant human erythropoietin anemic patients at the predialysis stage with a serum creatinine (cr) concentration ranging from 2 to 4 (average 2.9) mg/dl and a hematocrit (ht) of less than 30 one hundred seventeen patients with anemia related to chronic renal failure not severe enough to require maintenance dialysis hypertensive patients 12 predialytic uremic patients (epo group: mean age 46
mortality of tetanus mortality|in the other age group of 13-30 years, there were 27 and 38 patients in the treatment and control groups respectively.|young chicks tetanus patients aged 1-30 years tetanus
eating attitudes, eating behavior, and general psychopathology binge eating and depression dietary preoccupation and hunger binge eating and purging rates eating behavior items 'restraint', 'weight concern' and 'shape concern target-eating behaviors eating disorder examination (ede bulimic symptomatology body weight recurrence of symptoms symptoms of depression and anxiety energy intake and lost a modest amount of weight tolerated and had only minor adverse effects|the addition of antidepressant treatment to the intensive group psychotherapy component did not significantly improve outcome over intensive group psychotherapy combined with placebo treatment in terms of eating behavior, but did result in more improvement in the symptoms of depression and anxiety. nutritional counselling is an effective means of treating bulimia nervosa, with improvement maintained up to 3 months follow-up. in self-ratings and expert ratings concerning attitudes towards eating, eating behavior, and general psychopathology, significant improvements over time were observed in both groups. the combination of pharmacotherapy and psychotherapy was superior to pharmacotherapy alone on specific parameters and there was no statistically significant advantage to the combination over psychotherapy alone. cognitive-behavioral therapy was superior to supportive psychotherapy in reducing behavioral symptoms of bulimia nervosa (binge eating and vomiting). at 16 weeks, both cognitive-behavioral therapy and the combined treatment were superior to medication given for 16 weeks in reducing binge eating and purging. by this time it was also apparent that at posttreatment and at 6 months follow-up no benefit was being realized from combining cognitive-behavior therapy with desipramine.|patients participated in an intensive inpatient behavioral psychotherapy program bulimia nervosa (binge eating and vomiting bulimia nervosa participants were 76 women who sought treatment at the eating disorders program of the toronto hospital and who met dsm-iii-r criteria for bulimia nervosa sixty-seven patients referred to specialist eating disorder services who fulfilled strict diagnostic criteria were treated with patients for whom intensive nutritional counselling or other structured psychological programs bulimic outpatients outpatients with bulimia nervosa 120 women with bulimia nervosa bulimic inpatients undergoing intensive psychotherapy seventy-one patients meeting dsm-iii-r criteria for bulimia nervosa, recruited from an eating disorders clinic or by advertisements 40 patients with bulimia nervosa according to dsm iii-r criteria
several instances (oppositional/aggressive symptoms, internalizing symptoms, teacher-rated social skills, parent-child relations, and reading achievement|for most adhd symptoms, children in the combined treatment and medication management groups showed significantly greater improvement than those given intensive behavioral treatment and community care. no evidence of the superiority of the combined conditions relative to medication alone was found.|adhd children 96 attention deficit hyperactivity disorder children 579 children with adhd combined type, aged 7 to 9.9 years children with adhd attention-deficit/hyperactivity disorder
mean scores relative onset of analgesic response, overall analgesic efficacy, duration of effect, and safety time to onset of relief and overall analgesic efficacy postsurgical dental pain intensity of pain, relief of pain, and side effects pain intensity and pain relief and summary measures median time to meaningful pain relief total and peak analgesia ratings of pain intensity and pain relief pain relief analgesic effect serious adverse effects pain intensity pain relief and pain intensity difference sum pain intensity difference, total relief of pain, and overall evaluation parameters small additive effects number of hours until remedication meaningful relief drug tolerability overall analgesic effect pain intensity, pain relief, and side effects patient self-rating of pain intensity, pain relief, time to meaningful pain relief, need for additional analgesic medication, and patient global evaluation analgesia peak pain intensity difference (visual analog scale), summed pain intensity differences, total pain relief, peak pain relief, time to reduction of pain postoperative dental pain serious adverse events rapid analgesia side effects analgesic efficacy and safety median times to onset of relief marginal numerical superiority analgesic efficacy and tolerability later time to taking escape analgesics efficacy and safety pain intensity differences, peak pain intensity differences, total relief, peak relief, and hours of 50% relief frequency of adverse effects adverse reactions pain intensity difference, pain relief, and global evaluation duration of analgesic effect overall pain scores analgesic efficacy sumpi, totpar and maximum par (maxpar number of patients requiring rescue medication overall pain scores (auc(0,360 min), maximum pain relief, pain relief at 1 h after dosage and the number of patients taking escape analgesics incidence of adverse events pain intensity and relief and stopwatch onset of meaningful relief mean response with zomepirac analgesic effects tolerability rapid onset to meaningful relief pain intensity (pi) and pain intensity difference (pid pain median time to onset of analgesia pain scores tolerated onset of meaningful relief faster relief and superior overall efficacy peak and overall analgesic effects overall pain relief pain relief (par severe postoperative pain adverse reaction pain relief, pain intensity difference, total pain relief (totpar), and summed pain intensity difference (spid relative analgesic efficacy and safety onsets of first perceptible relief and meaningful relief analgesic efficacy measures sum pi (sumpi), sum pid (spid), and total par (totpar|piroxicam-beta-cyclodextrin and paracetamol were more rapid than piroxicam in inducing analgesia. at 4 hours after administration, the pain relief was significantly better with tablet acetaminophen than with effervescent acetaminophen. the most important finding was the statistically significantly shorter period until the onset of the action of paracetamol as against acetyl salicylic acid. a positive dose-effect relationship was evident for both acetaminophen 500 mg. all four active treatments were statistically superior to placebo for sum pain intensity difference, total relief of pain, and overall evaluation parameters. at 1 h after dosage, pain scores were significantly less (p < 0.01) after both doses of ketoprofen when compared with placebo. ibuprofen liquigel 200 and 400 mg were also significantly more efficacious than acetaminophen 1000 mg on the summary measures totpar 6 and spid 6 (p < 0.01 and p < 0.001, respectively). (r)- ketoprofen possesses analgesic activity and an acceptable side-effect profile in the oral surgery pain model. ibuprofen lysine had a significantly (p < or = 0.05) faster onset of action with greater peak and overall analgesic effect than did effect than did acetaminophen. in addition, both ibuprofen and ketoprofen showed statistical superiority over acetaminophen at earlier time points on the time-effect curves for pain relief and pain intensity difference. time to remedication, a measure of duration of analgesic effect, was significantly longer (p < 0.001) with naproxen sodium (median, 9.9 hours) than with either acetaminophen (median, 3.1 hours) or placebo (median, 2.0 hours). analgesia was similar for ketorolac 10 and 20 mg and ibuprofen 400 mg; however, these treatments were superior to acetaminophen alone and the acetaminophen-codeine combination. both doses of flurbiprofen resulted in significant analgesia in comparison with placebo, acetaminophen, and acetaminophen plus codeine as measured by pain intensity difference, pain relief, and global evaluation. there were no significant differences between treatment groups with respect to the number of patients requiring rescue medication, however the time to dosing was significantly longer for those taking soluble aspirin when compared with placebo (hazard ratio 2.34, 95% ci 1.41 to 3.88, p<0.001). although efficacy was lower for the acetaminophen-phenyltoloxamine combination than for acetaminophen alone, for every variable, the contrast for interaction was not statistically significant. the combination was statistically superior to apap 1000 mg on sumpi, totpar and maximum par (maxpar). pain relief after the initial dose of diclofenac-k (2 x 12.5 mg) was superior to placebo (p < .01 for all efficacy outcomes) and comparable to paracetamol (2 x 500 mg). flurbiprofen was significantly superior to the acetaminophen codeine combination with respect to the number of hours until remedication. for many efficacy variables, all active treatments were significantly (p less than or equal to 0.05) more effective than placebo.|148 outpatients with pain after oral surgery patients experiencing moderate or severe pain after surgical removal of impacted third molars 240 patients with moderate-to-severe postoperative dental pain oral surgery pain subjects undergoing the surgical removal of impacted third molars patients with postoperative dental pain eighty-eight outpatients with postoperative pain after the surgical removal of impacted third molars postoperative dental pain pain resulting from extraction of impacted third molar teeth 182 patients entered the study with moderate pain from a third molar extraction and were evaluated for six hours 177 patients experiencing moderate to severe pain after surgical removal of their impacted third molars patients with moderate or severe pain within 8 hours of extraction of impacted third molars post-operative oral surgery pain patients with headache and musculoskeletal pain two-hundred six outpatients with postoperative pain after the surgical removal of impacted third molars two hundred ninety-eight patients with post-operative pain after the surgical removal of an impacted third molar one hundred and sixty-seven patients consented to take part in the study, but only 153 were medicated patients with post-operative pain after third molar surgery over a 6 h investigation period patients with postoperative pain after third molar surgery outpatients who experienced moderate to severe pain after surgical removal of inpacted third molars postoperative oral surgery pain ambulatory patients acute postoperative pain 242 patients with moderate or severe pain following dental surgery postsurgical dental outpatients as subjects 3470 patients with moderate to severe postoperative pain following the surgical removal of a wisdom tooth postoperative pain after third molar surgery 210 patients experiencing moderate or severe postoperative pain 239 patients with moderate or severe pain following third molar extractions one hundred and sixty-seven (104 female) patients who required the removal of their impacted third molars under general anaesthesia
forced expiratory volume sf-36 general health subscale dyspnea with adl pulmonary rehabilitation programme morbidity health care use unnecessary clinic visits average visit costs chronic obstructive pulmonary disease (copd self-efficacy scores hospitalisations risk factors of copd readmission readmissions and mortality number of hospitalizations; secondary outcomes included emergency visits and patient health status emergency department visits unscheduled physician visits pulmonary function tests and dyspnea index scores admissions for other health problems total mean costs of care, excluding home health care costs knowledge, behavior and status scales quality indicators (medication compliance, knowledge of disease, and ability for self-care); extent of use of services; degree of patient satisfaction body mass index hospitalisations and, secondly, exacerbations, general practitioner (gp) calls and related cost-effectiveness of tele-assistance (ta acute exacerbations self-reported endurance exercise time self-efficacy for managing dyspnea technical quality of vvs urgent gp calls serum theophylline levels scores for activities of daily living at study discharge hospitalisations, emergency room admissions, urgent gp calls or exacerbations hospital utilization patient self-efficacy average overall cost hospital admissions for exacerbation of copd impact subscale and total quality-of-life scores telehomecare: quality, perception, satisfaction hospitalisation rate quality indicators, patient satisfaction, or use physical functioning mortality numbers of visits to an accident and emergency department, hospitalizations, and unscheduled visits by physicians exercise behavior, exercise performance, copd exacerbations, and mediators, such as self-efficacy and social support clinical and functional status, quality of life, lifestyle, and self-management questionnaires, visual analog scales, and other psychosocial measures chronic respiratory questionnaire chinese self-efficacy scale evolution of dyspnea, lung function, quality of life scores, lifestyle factors, or medical treatment|only copd patients, as a separate group, had fewer hospitalisations, emergency room admissions, urgent gp calls or exacerbations. self-reported endurance exercise time (p = .001), physical functioning (p = .04), and self-efficacy for managing dyspnea (p = .02) also showed positive improvements over time in both groups with no significant differences with respect to program modality. after 12 months' follow-up, ic showed a lower hospitalisation rate (1.5+/-2.6 versus 2.1+/-3.1) and a higher percentage of patients without re-admissions (49 versus 31%) than uc without differences in mortality (19 versus 16%, respectively). results indicated a significantly lower (p less than 0.05) number of changes in concomitant drug therapy in the home tdm group compared with controls. results suggest that integrated home telemedicine services can support health professionals caring for patients with chronic disease, and improve their health. discharge to a higher level of care (hospital, nursing home) within 6 months of study participation was 42% for c subjects, 21% for v subjects, and 15% for m subjects. there were a total of 567 virtual and 1,057 actual visits conducted for the 53 subjects completing the study. emergency department visits were reduced by 41.0% (p =.02) and unscheduled physician visits by 58.9% (p =.003). studies of cardiac and diabetic patients have shown that telephone follow-up care is an effective approach to increasing self-efficacy. there were no differences in the evolution of dyspnea, lung function, quality of life scores, lifestyle factors, or medical treatment. although those receiving telehealth had worse ratings on the sf-36 general health subscale after the intervention, this measure was only significant when controlling for a number of key variables in the model. remote video technology in the home health care setting was shown to be effective, well received by patients, capable of maintaining quality of care, and to have the potential for cost savings.|chronic obstructive pulmonary disease (copd chronic patients suffering from chronic obstructive pulmonary disease (copd people with chronic obstructive pulmonary disease (copd 113 exacerbated copd patients (14% female, mean (sd) age 73(8) years, fev(1 chronic obstructive pulmonary disease patients chronic respiratory patients requiring oxygen or home mechanical ventilation experience frequent exacerbations and hospitalisations with related costs 7 hospitals from february 1998 to july 1999 subjects receiving cardiac and diabetic patients congestive heart failure, chronic obstructive pulmonary disease, and chronic wound-care patients receiving skilled home nursing care patients with chronic disease 240 patients (101 with chronic obstructive pulmonary disease (copd 39 participants who completed the study (female: 44%; age: 69.5 hospital admissions due to chronic obstructive pulmonary disease (copd) exacerbations outpatients with chronic obstructive pulmonary diseases (copd) or asthma who were receiving long-term theophylline therapy all patients had advanced copd with at least 1 hospitalization for exacerbation in the previous year chronic respiratory failure patients 60 participants (30 telephone follow-up, 30 control) with chronic obstructive pulmonary disease were recruited from an acute care hospital in hong kong newly referred patients diagnosed as having congestive heart failure, chronic obstructive pulmonary disease, cerebral vascular accident, cancer, diabetes, anxiety, or need for wound care were eligible for random assignment to intervention (n = 102) or control (n = 110) groups telemedicine experience for chronic care in copd quasi-experimental study conducted from may 1996 to october 1997 patients with chronic obstructive pulmonary disease patients with chronic obstructive pulmonary disease (copd) and/or congestive heart failure (chf people living with copd 567 virtual and 1,057 actual visits conducted for the 53 subjects completing the study 50 participants with moderate to severe copd who were current internet users to either the edsmp (n = 26) or telehomecare linking homebound patients with their home health-care nurses over the chronic obstructive pulmonary disease 155 exacerbated copd patients (17% females) were recruited after hospital discharge from centres in barcelona (spain) and leuven (belgium patients with moderate to severe disease patients diagnosed with copd and/or chf who were prescribed home health-care services copd patients
70-point reduction in crohn's disease activity index efficacy and safety overall clinical response rate|lenalidomide was generally well tolerated with only one serious adverse event, a deep vein thrombosis, being attributed to treatment.|89 subjects subjects with moderately severe active crohn's disease crohn's disease moderately severe active crohn's disease
salmeterol xinafoate fev1 and sgaw bronchodilator response efficacy and safety dyspnea tolerated fev1 airways obstruction lung function daytime symptom scores and morning peak expiratory flow area under the curve for fev(1 diary symptoms and quality of life specific airway conductance (sgaw symptoms area under the curve for forced expiratory volume in 1 s (fev(1 adverse effects quality of life|salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with copd, including those "unresponsive" to albuterol. compared with placebo, both doses of formoterol significantly improved symptoms (all p < or = 0.007) and quality of life (p < 0.01 for total scores) whereas ipratropium did not show significant effects (all p > or = 0.3). both salmeterol and ipratropium reduced dyspnea related to activities of daily living compared with placebo; this improvement was associated with reduced use of supplemental albuterol. there was added benefit from the combination therapy in terms of improvement in airways obstruction, but not for improvement in symptom control or need for rescue salbutamol.|four hundred and five patients with copd chronic obstructive pulmonary disease four hundred eleven symptomatic patients with copd chronic obstructive pulmonary disease (copd patients with stable chronic obstructive pulmonary disease 780 patients with copd patients with severe stable chronic obstructive pulmonary disease patients (n=144; age 64+/-7 yrs, forced expiratory volume in one second (fev1) 44+/-11% pred) participated in a three-centre double-blind double patients with chronic obstructive pulmonary disease patients with copd copd patients were stratified on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement
thyrotropin-receptor antibody (trab) positive level of antibodies to tsh receptors serum levels of ft4, t3, stsh and tsh receptor antibody (trab mean duration of treatment relapse rate median duration suffered relapse serum thyrotropin concentration level of antibodies to tsh receptors further normalized antithyroperoxidase (tpo) antibody and anti-tsh receptor stimulating antibody (tsab) levels and early iodine uptake regular cigarette smoking recurrence of graves' disease disease relapse remission rates or delays relapse serum free t4 and t3 and tsh concentrations relapse of hyperthyroidism total t3, tsh-receptor antibodies frequency of graves' disease complications and thyrotoxicosis recurrence serum tri-iodothyronine (t3) and thyroxine (t4) concentrations gastrointestinal side effects or leucopenia rate of normalization of serum thyroid function tests, changes in serum thyroid auto-antibody levels and the rate of side-effects serum thyrotropin concentrations percentage of recurrence equalled serum tsh level and tbii activity relapse of graves' disease course of endocrine eye signs thyroid echostructure serum total t4 and tri-iodothyronine (t3), free t4 and t3, tsh, tsh-receptor antibodies (tshr-ab), thyroid scintigraphy and echography relapse of overt hyperthyroidism serum basal thyrotrophin (tsh) level and tsh receptor antibody activity cigarette smoking production of antibodies to tsh receptors and the frequency of recurrence of hyperthyroidism antibodies to tsh receptors goitre size during treatment, and tsh levels and tbii values thyroid-stimulating antibody levels rapid goitre growth relapse of hyperthyroidism, initial thyroid size relapse and remission groups, regardless of treatment duration, for hla abdr, serum t3 and t4, and t3/t4 ratio remission rates frequency of relapse final outcome and recurrence rates recurrences of hyperthyroidism rate of normalization of serum thyroid function tests or in serum thyroid auto-antibody levels area of low-to-moderate iodine intake (prevalence of 24h urinary iodine excretion recurrence rate 20 times lower plasma trab levels rate of relapse serum tsh remission rate serum basal tsh levels and tbii activities levels of antibodies to tsh receptors median relapse-free interval overall relapse rate number of side-effects mean serum thyroxine concentration target tsh concentration percentage of recurrence tsh secretion recurrence risk complications of graves' disease recurrence goitre size, pertechnetate uptake and presence of detectable plasma tsh lasting remission goiter size, frequency of ophthalmopathy, tsh and trab levels relapse rates clinical parameters, thyroid hormones, or tsh binding inhibitory immunoglobulins (tbii) levels ophthalmic symptoms long-term remission rates thyroid antibodies, serum thyroglobulin and pertechnetate uptake 2-year post-treatment remission rates thyroid volume recurrence rates positive tshr-ab normalize elevated tsh serum concentrations dropout rate recurrence of hyperthyroidism trab levels and goiter weight early iodine uptake serum tsh level and thyrotrophin binding inhibitor immunoglobulin (tbii) activity normalized clinical characteristics or hormonal or antibody values recurrence rate high trab levels and goiter weight goiter size relapse normal serum thyrotropin concentration drug intolerance symptoms tshr-ab titers hyperthyroidism goiter size with recurrence relapse rates of graves' disease remission|in the patients who received placebo and methimazole, the mean serum thyroxine concentration decreased and the level of antibodies to tsh receptors did not change. no significant difference was observed between relapse and remission groups, regardless of treatment duration, for hla abdr, serum t3 and t4, and t3/t4 ratio determined before treatment. levothyroxine therapy did not influence tsh-receptor antibody, nor did it reduce goiter size. the percentage of recurrence equalled (62.8% vs 60.7%, p = ns) on prolongation of follow-up of up to 36 months. after the third year of follow-up, this difference was not significative (p = 0.06). serum levels of ft4, t3, stsh and tsh receptor antibody (trab) were measured before starting treatment and at regular intervals during treatment and follow-up after drug withdrawal. patients who relapsed had bigger goiters at baseline (p = 0.02) and at the end of treatment (p = 0.03). at the beginning of the follow-up period patients who were going to recur had significantly higher trab levels and goiter weight than patients who were not (p < 0.05). the corresponding relapse rates calculated on an 'intention to treat' basis were: 51.7 vs. 66.7%; 62.1 vs. 81.5%: 72.4 vs. 81.5% (ns). treatment duration greater than 18 months did not improve remission rate determined 2 years after treatment withdrawal or immunological variables or early iodine uptake measured at the time of discontinuation of treatment. there was no significant difference in 2-year post-treatment remission rates on an intention-to-treat basis between the two treatment groups (18.7% vs. 5.9%, p = ns). there was no difference in relapse rates between the treatment groups (p=0.217, log--rank test). the remission rate one year after cessation of treatment was 59% with the 6 month course and 65% with 12 months; this was not significantly different. patients who relapsed and patients who remained in remission did not differ with respect to: age, goitre size, ophthalmopathy, median iodine excretion, serum t4 or serum t3, crook's therapeutic index and thyroid uptake at the time of study entry. patients of group i and in 3 (8.3%) of group ii, the difference was statistically significant (p<0.01). by 2 years after stopping treatment, recurrence had occurred in 50% of the hd and 66% of the td group. in conclusion, we were unable to detect a preventive effect of exogenous tsh suppression on the recurrence of hyperthyroidism. there was no difference between the recurrence rates in the two groups, despite the fact that serum thyrotropin concentrations were undetectable in 73 percent of patients in the carbimazole-t4 group on at least 75 percent of their visits. when both the serum tsh level and tbii activity were normalized, the relapse rate of group 2 was not significantly different from that of group i for treatment periods of 6-12 months (25 vs 24.2%, p greater than 0.1), 12-18 months (33.3 vs 40%, p greater than 0.1), and 18-24 months (46.2 vs 50%, p greater than 0.1). there were no significant differences in relapse rates after stopping methimazole. l-t4 administration, both during and after atd treatment, did not improve the final outcome and recurrence rates were similar in placebo and l-t4-treated patients (30%). no significant difference (p>0.05, chi square) was seen in relapse of hyperthyroidism after a mean follow-up of 16 months (range: 12-31 months;|patients with successful outcome of 12 to 15 months antithyroid drug therapy were stratified for risk factors spanish patients 174 patients with hyperthyroid graves' disease were entered consecutively into this study, 11 of whom were subsequently excluded graves' hyperthyroidism treated with antithyroid drugs 28 patients treated only with antithyroid drugs, the remaining 36 subjects additionally receiving patients with graves' hyperthyroidism one hundred and sixty-three patients patients after a mean observation period of 4.3 111 patients (89 women and 22 men) who had graves' hyperthyroidism 39 patients showed early relapse within 4 weeks, 61 endogenous tsh suppression, 7 tsh elevation, and 14 had to be excluded thirty-seven patients with a first episode of graves' disease were enrolled 70 patients with graves' disease, the patients being assigned randomly to one or other regimen patients with contraindications to the radical graves' disease treatment and in prophylaxis of its complications graves' disease 108 patients with graves' disease (22 males, age: 49.8 64 patients (47 females and 17 males aged 20-43 years) for the first time diagnosed with graves' disease patients with graves' disease outpatient clinic with patients referred from primary care eighty-two consecutive patients (70 women and 12 men; mean age 36 years) with a first episode of graves' hyperthyroidism patients with graves' disease followed for a mean of 28 months after the withdrawal of antithyroid drug treatment patients who received carbimazole at decreasing doses for 18 months (n = 62) vs 42 months (n = 72 graves' disease graves' disease with high-dose sd, and 86 females, age: 41.7 135 newly diagnosed patients with hyperthyroidism due to graves' disease north american population, 199 patients were treated with methimazole until they were euthyroid gd patients who had not been treated for this disease previously 19 patients in the high- and 22 in the low-dose group completed 6 months with methimazole three hundred and thirteen patients with graves' disease fifty-six patients were included patients with hyperthyroid graves' disease (gd 218 patients with graves' disease 197 randomly and equally distributed patients patients with graves' hyperthyroidism who are treated with an antithyroid drug fifty-two untreated graves' hyperthyroid patients fifty patients with recent onset of hyperthyroidism 109 patients with hyperthyroidism due to graves' disease one hundred forty-nine patients have been followed for at least 6 months after stopping methimazole (mean 27 months patients with graves' hyperthyroidism treated with atd patients with hyperthyroidism due to graves' disease patients who stayed in remission and who had relapse 346 patients with graves' disease enrolled 225 were euthyroid 4 weeks after antithyroid drug withdrawal graves' hyperthyroid patients sixty patients with graves' disease (gd) hyperthyroidism sixty patients patients who relapsed and patients who remained in remission did not differ with respect to: age, goitre size, ophthalmopathy, median iodine excretion, serum t4 or serum t3, crook's therapeutic index and thyroid uptake at the time of study entry
bronchial hyper-responsiveness 6 poms-bi scores respiratory sinus arrhythmia (rsa for bti, data collection (symptoms, lung function reduction of anxiety and depression scores symptoms (obstruction, fatigue), better quality of life (activity, symptoms, emotions), decreased negative affectivity, and increased adherence relaxation psychophysiological questionnaire panic and asthma outcomes occurrence of severe asthma flares external chance scale respiratory impedance forced expiratory flow baseline characteristics (anxiety, depression, psychophysiological disorders), emotional reactions to asthma attacks (panic-fear, etc,) and cognitive variables (external control, psychological stigma, internal beliefs, external chance, etc.) involved in the perceived illness external control subscale relaxation during emg or rsa biofeedback total power scores bronchial hyper-reactivity oscillation resistance feasibility and efficacy asthma morbidity, and asthma-related behaviour and cognitions wlc, bti reduced wheezing, anxiety, and chance loc, and increased asthma knowledge, attitude, and self-efficacy morning peak-flow expiratory rate and asthma-related quality of life heart rate variability (hrv) biofeedback ctam, bti reduced wheezing and chance loc, increased internal loc respiratory function pulmonary function, asthma symptoms, quality of life, depression, anxiety, and power differ over time pulmonary function spirometry (fev1); 2) medication use; 3) asthma quality of life questionnaire; 4) beck depression inventory; 5) spielberger anxiety scales (a-state and a-trait peak expiratory flow rates forced vital capacity (fvc), forced expiratory volume in the first sec (fev1), forced expiratory flow asthma symptoms (wheezing, coughing, sleep, activity, attacks, peak flow) and self-report assessments of profiles of mood states (poms-bi) (anxiety, hostility, depression, uncertainty, fatigue, confusion); knowledge, attitude, and self-efficacy asthma questionnaire (kase-aq); health attribution test (hat) for locus of control (loc); and the revised asthma problem behavior checklist (rapbc measures of perceived stress number of visits of the general practitioner choices sub-scale mcmaster asthma quality of life questionnaire, asthma symptom checklist, negative emotionality scale, knowledge, attitude and self-efficacy asthma questionnaire, adherence scale, and peak flow measurements asthma knowledge, attitude, self-efficacy, internal loc, and peak flow feasibility and effectiveness cognitive variables (knowledge, attitude towards asthma, self-efficacy) and day and night peak flow ratings daily asthma symptoms and twice-daily peak expiratory flows lung function asthma symptoms poms-bi scores except anxiety, increased internal loc, and reduced problematic behaviors mesoexpiratory flow symptoms and asthma management pulmonary impedance|nevertheless, the treatment group's sympathomimetics use was significantly reduced by 1 year of treatment (p less than 0.05); the use of steroids decreased as well. only the asthma rehabilitation group reported lower scores on the psychophysiological questionnaire and on the external control subscale after 1 year. subjects did not report significantly more relaxation during emg or rsa biofeedback than during the control condition. listening to music produced greater decreases in peaks of tension than progressive relaxation, and it produced greater compliance with relaxation practice, but it did not produce any specific therapeutic effects on asthma. the treatment group showed significant improvement in measures of lung function compared with the placebo group, but analysis revealed no differences in measures of perceived stress. persons who reduced or discontinued their medications showed neither an increase in pulmonary function prior to medication discontinuation, nor a fall in these parameters following discontinuation. no significant changes were observed in the control group. compared with the two control groups, subjects in both of the two hrv biofeedback groups were prescribed less medication, with minimal differences between the two active treatments. compared to wlc, bti reduced wheezing, anxiety, and chance loc, and increased asthma knowledge, attitude, and self-efficacy. daily home recordings of symptoms improved by 41% (p less than 0.01), peak expiratory flow rates improved by 5.5% (p less than 0.01), and use of bronchodilators decreased by 26.2% (p less than 0.05). the results demonstrate that the cbt-ae program is capable of producing substantial and durable antipanic and antianxiety treatment effects and led to substantial but nonsustained improvement in morning peak-flow expiratory rate and asthma-related quality of life. compared with controls the programme group reported less symptoms (obstruction, fatigue), better quality of life (activity, symptoms, emotions), decreased negative affectivity, and increased adherence, immediately after finishing the programme and at 3 months follow-up.|31 patients who were interested in taking part asthmatic subjects who reported complaints and impairment, despite adequate medical treatment individuals with asthma mild-to-moderate asthma patients (n=23 adult asthma patients forty-eight women with a confirmed diagnosis of asthma and panic disorder ninety-four adult outpatient paid volunteers with asthma adults with asthma suffering from coexisting panic disorder 16 experimental participants also completed the 4-session imagery protocol asthma patients individuals with chronic illnesses such as asthma adults with asthma and coexisting panic disorder adults with asthma patients enrolled in an asthma rehabilitation group (arg) and in a control group (cg 90 asthma patients were registered for the treatment in the heidelberg medical clinic adults with asthma who practice mental imagery adult asthmatics who are moderately to highly susceptible to hypnosis a control group 17 patients and 10 patients undergoing treatment with low susceptibility to hypnosis had no change in either bronchial hyper-responsiveness or any of the symptoms recorded at home asthma among patients prestabilized on asthma medication young adults with asthma sixty-eight adults with symptomatic asthma seventy (70) adults (53 women, 17 men) with asthma homogeneous groups of asthmatic patients (n = 24 asthmatic patients asthmatic adults adults with asthma who do and do not practice mental imagery (mi one hundred six asthmatic subjects asthma forty consecutive asthmatics were randomly enrolled, all of whom were diagnosed, treated and followed-up according to the international guidelines patients with moderate asthma after treatment with a hypnotic technique the psychophysiology laboratory at the university of medicine and dentistry of new jersey-robert wood johnson medical school, and the private outpatient offices of participating asthma physicians 39 adults with mild to moderate asthma graded for low and high susceptibility to hypnosis chronic asthmatic patients with autogenic therapy panic disorder combined with asthma education (ae
baseline lung function histamine sensitivity (pc20 adverse reactions bronchial reactivity positive reactions random nasal eosinophils methacholine challenges and random circulating and sputum eosinophils|no improvement occurred during the modified diet in anyone with positive challenge-tests or in all, but one, of those with a history of asa idiosyncrasy; paradoxically, several of these subjects worsened during this period. there was no change in baseline lung function after tartrazine, but histamine sensitivity (pc20) increased significantly in four of the children. only 4 of 156 patients (all polish) had positive reactions in a double-blind test, as evidenced by a fall in fev1 greater than 25% from baseline and corresponding clinical symptoms. methacholine challenges and random circulating and sputum eosinophils did not differentiate patients with a negative challenge from those with a positive challenge.|one hundred and fifty-six german, italian and polish patients with confirmed aspirin-induced asthma induced asthma childhood asthma ten asthmatic children who gave a history of cough or wheeze after orange drinks patients who respond to challenge with these substances or have asa idiosyncrasy adult asthmatic patients chronic asthma 50 patients with a suspicious history studied in detail, 96% of those with asa idiosyncrasy had sinusitis and 71% had nasal polyps patients with chronic asthma
pain scale 1-10) need for analgesia, ambulation (evaluated by a four-point scale), complications and return to work postoperative pain, analgesia requirements, limitation of daily activities, and return to work did not differ between laparoscopic and open tension-free repair postoperative pain, narcotic use, and time to resumption of usual activities and employment lowest recurrence rates nerve injuries postoperative pain, duration of narcotic use, and time to resumption of usual activity and employment recurrence rates wound hematomas, seromas, and superficial wound infection number of recurrences re-recurrence rate hernia recurrence, nerve damage, testicular atrophy and patient satisfaction ambulation grades sick leave longer operation time actuarial recurrence rate duration of surgery, the technique of anesthesia, the perioperative complications, the duration of postoperative care postoperative complications, return to work, and recurrences rate cost-effective recurrence rates, symptoms (including patient satisfaction), and infections duration of operation, postoperative pain assessed by visual analogue scale (vas), complications within 30 days, duration of sick leave, and recurrence within one year recurrence rate postoperative pain and patient's comfort chronic groin pain actual 2-year recurrence rate hernia recurrence recurrence hernia recurrence rate complication rate direct hernia, repair for recurrent hernia, hernial sac diameter patient satisfaction operating time narcotic analgesics recurrence rate, technical difficulty, convalescence and chronic pain recurrence of hernia operative time; postoperative pain sliding hernias duration of operation, pain score, or incidence of postoperative complications actual (not actuarial) recurrence rates redoubtable and litigious sequelae of testicular atrophy and chronic ilioinguinal pain pain of a higher scale|the recurrence rate was no different for staff surgeons and trainees (5.9 versus 5.6 per cent, p not significant). both operations gave almost the same results in the perioperative period and nearly identical recurrence rate (4.44% in shouldice and 5.0% in bassini-kirschner group). nerve injuries were significantly more frequent after open shouldice and lichtenstein repairs. fewer recurrences (5.9%) were observed with the stainless steel wire shouldice repair than with polypropylene version (6.5%), but the difference was not significant. there was no difference between the herniorrhaphy methods with respect to postoperative pain, duration of narcotic use, and time to resumption of usual activity and employment. for repair of recurrent hernia, the superiority of the shouldice technique was not statistically significant: re-recurrence rate 7.6% versus 13.5% for the original bassini group b. repair of recurrent hernia was the only patient-related risk factor of equal significance as the method of repair. both types of hernia repair are comparable and effective, but long-term results favor the lichtenstein technique for reducing recurrences (to a p value of .10), ease of technical mastery, and application to the outpatient setting by use of a local anesthetic. there was no significant difference in the two groups with respect to postoperative complications, return to work, and recurrences rate (2-year follow-up). hernia recurrence rate was lichtenstein 8%, mcvay 10%, shouldice 5% ( p>0.1) at 6-9 years follow-up. for surgeons in training the lichtenstein open mesh technique is a better method of inguinal hernia repair than the shouldice technique. after a follow-up of 36-77 months seven recurrences were found in the shouldice group (95 per cent confidence interval (c.i.) after a mean follow-up of 30 (range 24-48) months there were seven recurrences in the shouldice group and four in the plication darn group (p > 0.05). the life-table method showed the following longterm (12-15 years) recurrence rates: group i, bassini-stetten 33% versus ring narrowing 34%; group ii, bassini-stetten 32% versus shouldice 15% (p = 0.033). the complication rate was high but similar for both techniques (18%). postoperative pain, analgesia requirements, limitation of daily activities, and return to work did not differ between laparoscopic and open tension-free repair but were significantly lower in both groups compared with shouldice's operation.|primary inguinal hernia repair 178 patients were available for evaluation (n = 89 in each group patient age was 58.3(1.5 young patients having a primary hernia inguinal hernia operated on by surgeons in training between 1986 and 1992, 265 men of mean age 51 (range 16-75) years with a primary inguinal hernia fifteen general surgeons operated on 322 patients 280 men with a primary hernia seven hundred fifty inguinal hernia repairs from july 1980 to may 1983, 102 indirect primary inguinal hernias with a firm posterior wall (group i) and 263 primary inguinal hernias with a weakened posterior wall (group ii) were included three hundred patients with primary inguinal hernia in a u.s. veterans administration hospital, 150 primary hernia repairs for primary inguinal hernia repair one hundred five adult patients 85 patients of 129 142 adult male and female patients for primary inguinal hernias by the shouldice or the bassini-kirschner surgical technique fourteen surgeons in training not familiar with shouldice repair received 200 men with primary inguinal hernias range 20-84) years for shouldice repair and 57.0(1.2) (range 18-85 years) for plication darn primary inguinal hernia repair by surgical trainees male adult fifty-nine hernia repairs young patients six hundred seventy-two men with inguinal hernias, aged 20 to 90 years, seen at the hernia center between january 1, 1990, and december 31, 1995 89 patients with 100 hernia repairs had died, and for 30 repairs the patients could not be located 50 cases (age group 18-40 years 1578 patients for inguinal hernia a private suburban hernia center 129 adult patients, mean age 54 (17-87) years underwent operation on primary inguinal hernias in their department a total of 717 repairs in 672 patients, including 45 bilateral repairs, have been monitored to date district hospital, sweden between 1983 and 1989, 1578 adult males with a total of 1706 nonrecurrent inguinal hernias 322 inguinal hernias
duration of infections number of episodes severe illness episodes duration of symptoms and cold episodes; cumulative symptom severity scores duration and severity of symptoms of urt infections colds sickness experience duration and severity of colds incidence of symptoms of upper-respiratory-tract (urt) infections throat cultures yielding beta-hemolytic streptococcus mean illness plasma ascorbic acid levels overall complicated illness rate total number of days of upper respiratory tract infection duration and severity of respiratory infections development of symptoms of urt infection total number of common colds incidence and severity of winter illness cold duration or severity reduction of colds personality trait of neuroticism side effects severity of uris daily observations of cold symptoms, and multiple biochemical, anthropometric, and psychological measurements upper respiratory or general constitutional symptoms duration or severity of the common cold respiratory symptoms rate of respiratory infections duration or severity of cold symptoms postrace symptoms of upper-respiratory-tract infection severe illness cold symptoms incidence or duration of colds rate, length, or severity of uris shorter duration of severe symptoms symptoms of urt infections mean illness duration whole-blood ascorbic acid levels shortest duration of nasal, systemic and overall symptoms incidence of uris severity duration of respiratory infections incidence or morbidity of the common cold and other respiratory illnesses|children receiving vitamin c had fewer throat cultures yielding beta-hemolytic streptococcus (six versus 13, p less than 0.10), but no difference in overall complicated illness rate (24 versus 25). analysis of these data showed that ascorbic acid had at best only a minor influence on the duration and severity of colds, and that the effects demonstrated might be explained equally well by a break in the double blind. no side effects of substantive changes in serum biochemistry could be attributed to the vitamin c dose. although differences were not significant, the placebo group had the shortest duration of nasal, systemic and overall symptoms, and the lowest mean severity score at 14 days, and the second lowest at 7 and 28 days. paired comparisons showed no significant overall treatment effect on cold symptoms, but the response was not uniform in all sub-groups. whole-blood ascorbic acid levels measured six weeks after initiation of the study were significantly higher in the vitamin c group. there were no consistent or significant differences in the sickness experience of the subjects receiving the sustained-release vitamin capsules compared to those receiving the vitamin tablets, but subjects in both vitamin groups experienced less severe illness than subjects in the placebo group, with approximately 25 per cent fewer days spent indoors because of the illness (p smaller than 0.05). among the men who had any colds at all, significantly fewer on active than on placebo treatment had two or more colds; however, this effect was not seen in women. no proven biochemical effects were obtained. vitamin c had no effect on the incidence of uris (rate ratio = 1.01; 95% confidence interval (ci) = 0.70-1.46). no apparent reduction was seen for the severity and duration of the common cold. compared with the placebo group, the active-treatment group had significantly fewer colds (37 vs 50, p<.05), fewer days challenged virally (85 vs 178), and a significantly shorter duration of severe symptoms (1.8 vs 3.1 days, p<.03). there is evidence of a small reduction by vitamin c in the mean number of chest colds, but no evidence of any effect on simple colds. sixty-eight percent of the runners in the placebo group reported the development of symptoms of urt infection after the race; this was significantly more (p < 0.01) than that reported by the vitamin c-supplemented group (33%). the group taking d-isoascrobic acid suffered 34% fewer colds than the other two groups; the results were also analyzed in relation to the sex and smoking habits of the volunteers. none of the groups receiving vitamin c showed a difference in sickness experience that was statistically significant from that of the placebo groups, but the results obtained were compatible with an effect of small magnitude from both the prophylactic and therapeutic regimens, and an effect of somewhat greater magnitude from the combination regimen.|868 children 448 subjects who completed an average of 15 weeks in the study of total of 635 episodes of illness were recroded 622 volunteers received either male and female swimmers between december 1972 and february 1973, 2349 volunteers participated 70 student volunteers took 439 eligible subjects, 144 and 161 one hundred sixty-eight volunteers altogether 1524 volunteers were recruited from a number of working groups in different parts of the country; 482 developed colds participants in annual screening programs for circulatory diseases conducted under the national health and welfare services law for the aged, and diagnosed as having atrophic gastritis 44 school-aged monozygotic twins 149 participants returned records for 184 cold episodes male swimmers ultramarathon runners with age-matched controls healthy adult volunteers 172 children in the age group 8-9 one hundred ninety volunteers completed the study 95 pairs of identical twins aged 14-64 who took part in a double-blind trial of children 39 competitive young swimmers (mean age 13.8  1.6 years) in jerusalem, israel 642 children of the same age 674 marine recruits during an eight-week period 688 adult women ultramarathon runners marine recruits healthy children with after participation in a competitive ultramarathon race (> 42 km navajo school children three hundred eleven employees of the national institutes of health volunteered to take 1 gm of adolescent swimmers 400 healthy volunteers were recruited from staff and students of the australian national university, canberra, act, between may 1998 and november 1999 people who are under heavy physical stress, including recreational and competitive swimmers competitive swimmers
pain reduction gastro-enteric side effects pain rating scores medication-related side-effects analgesic drug intake pain intensities pain or stiffness (vas, physical tests nrs and aberdeen lbp scale psychotropic drug intake intensity of pain pain relief scale (100 mm visual analogue scale: vas) and a lbp score recommended by the japanese orthopaedic association (joa score initial pain levels correlated with state-anxiety, depression, pain duration, and abnormal illness behavior measures tablet count analgesic effect estimates of pain (on a visual analogue scale) and disability by both physician and patient, physical measures of trunk strength and spine range of motion, as well as the patient's perceptions of the relative contribution of the education, exercise training, and the electrical stimulation mean vas value pain intensity low back pain analgetic drugs neck disability index, and (3) reductions on the visual analogue scale activity related to pain; mobility; verbal descriptors of pain and the patient's subjective assessment of his condition rdq score vas neck disability index, and (3) three visual analogue scales of local pain intensity mean global transition score spinal arom and isokinetic trunk concentric strength side effects mean spinal flexion pain score joa score pain intensity and in pain disability, and secondary in psychological distress and in spine flexion average pain score nhp new episodes of low back pain aberdeen lbp scale, lumbar spinal active range of movement (arom), and the isokinetic strength pain, disability, and functional improvement scores pain diaries to score pain intensity twice daily, analgesic intake, and quality of sleep daily, and activity level weekly spinal flexion change in rdq score vas and nhp pain disability relapse of low back pain and number of days on sickness leave psychological distress disability scale chronic low back pain neck pain mcgill pain questionnaire pain initial pain severity mpq scores pain or stiffness mcgill pain questionnaire (mpq) and visual analog scales (vas) for pain pain severity on visual analogue scale (vas); (2) pain subscale of nottingham health profile (nhp); (3) number of analgesic tablets consumed in previous week; (4) spinal flexion from c7 to s1 numerical rating scale (nrs scores of the (1) oswestry back pain disability index, (2 pain scores depression, neuroticism, and hypochondriasis scores visual analogue scale measure of average pain spinal manipulation modified roland disability questionnaire (rdq adverse effects return to work, quality of sleep, and analgesic intake individual patient's pain score|a statistical difference existed between the two groups at the 3-month follow up, with a better result in the deeply stimulated group. in all five measures of efficacy chosen for study the acupuncture group achieved better responses than the placebo group; four of the five inter-group differences were statistically significant. there were no significant differences between treatment groups with respect to their overall rehabilitation. results indicated that therapy without injected medication (63% improvement rate) was at least as effective as therapy with drug injection (42% improvement rate), at a p value of 0.09. massage was also superior to acupuncture on the disability scale (5.89 vs 8.25, respectively; p =.01). there were no differences in pain or stiffness (vas, physical tests) at inclusion, nor in the reduction of pain or stiffness over a six month evaluation. analysis of results using t tests showed that in both groups there were significant pre-post improvements for all scores, except for mpq scores in the placebo-tens group. acupuncture was superior to the control condition (physiotherapy) regarding pain intensity (p=0.000), pain disability (p=0.000), and psychological distress (p=0.020) at the end of treatment. during the first phase of treatment, patients receiving acupuncture had a greater but not significantly different reduction in pain rating scores compared with those receiving placebo (t = 0.52; p greater than 0.6). the short-term controls, the delayed treatment group, had no reduction whatsoever in their pain scores at the comparable followup period. significant improvements were shown on vas (p < 0.001), nhp (p < 0.001) and tablet count (p < 0.05) between baseline and completion in both groups, these improvements remaining significant comparing baseline with follow-up with a further non-significant improvement in vas and nhp in the acupuncture group. mean vas value during the 2-weeks experimental period of the ea group was significantly smaller than that of the tens group (65 mm vs 86 mm; 95% ci, 4.126 - 37.953). there was a significant improvement in return to work, quality of sleep, and analgesic intake in subjects treated with acupuncture. significantly better scores in the nrs and aberdeen lbp scale were found in the exercise plus ea group immediately after treatment and at 1-month follow-up. after 6 weeks, patients receiving treatment showed significant improvement (p < 0.05 to p < 0.001) on three of the four measures compared to the untreated controls. outcome was measured by the modified roland disability questionnaire (rdq) at weeks 0, 2, 6 and 9. neither of the other interventions showed any significant improvement on any of the outcome measures.|elderly patients with chronic back pain both chronic back pain older patients twenty subjects, who suffered from low back pain (lbp) without sciatica, were recruited, using leaflets in tsukuba city chronic lbp ten patients were put on the waiting list for treatment but served as the untreated control group chronic low back pain (lbp) in older patients a total of 52 patients chronic spinal pain syndromes fifty-five patients were enrolled, with eight drop-outs specialized spinal pain syndrome out-patient unit at townsville general hospital, queensland, australia acute lumbago managing chronic (>13 weeks duration) spinal pain syndromes chronic nociceptive low back pain 77 patients lumbar myofascial pain low back pain subjects and interventions pain service unit of the university of padova 60 consecutively included patients with acute low back pain, 30 patients forty patients chronic low-back pain acute low back pain in general practice 63 individuals with low-back strain seventy-seven patients (without contraindication to manipulation or medication) were recruited 131 consecutive out-patients of the department of orthopaedics, university goettingen, germany, (age=48.1 years, 58.5% female, duration of pain: 9.6 years) with non-radiating lbp for at least 6 months and a normal neurological examination chronic low back pain patients fifty consecutive patients (33 women, 17 men; mean age, 49.8 years) with chronic low back pain (mean pain duration, 9.5 years) and without rhizopathy or history of acupuncture treatment were included in the study tsukuba college of technology clinic in japan patients (n = 60) with chronic low back pain people with low back pain a tertiary-level pain clinic at a swedish university hospital chronic back pain in the elderly chronic low back pain n = 94), therapeutic massage (n = 78), or self-care educational materials (n = 90 262 patients aged 20 to 70 years who had persistent back pain to receive patients with chronic low-back pain (lbp low-back pain patients fulfilling clinical criteria for chronic low back pain of nociceptive origin patients with this diagnosis had nonradiating low-back pain, normal neurologic examination, absence of tension signs, and lumbosacral roentgenograms interpreted as being within normal limits twenty-four subjects patients with chronic spinal pain syndromes spinal manipulation fifty-four patients treated in a 3-week inpatient rehabilitation program 46 patients completed the trial and were followed up at 6 months 42 patients with lumbar myofascial pain sixty patients aged 60 or over with back pain for at least 6 months were recruited from general practitioner referrals patients with chronic nociceptive low back pain patients with chronic lumbar myofascial pain
flatus and first bowel movement minor complications morbidity, hospital stay, and costs incisional hernia and adhesion-related problems demographic data, recurrence rates, need for additional surgery related to primary procedure, and medication use sf-36 and giqli questionnaires postoperative quality of life (qol conversion rate incisional hernia repair median overall costs incidences of anorectal disease, anorectal surgery, endoscopic or radiologic recurrence, and medication use median length of the incision forced expiratory volume (one second) and forced vital capacity overall reoperation rates median length of stay median operating time relapse free after ileocolic resection amount of morphine equivalents major complications quality of life (qol), body image and cosmesis hospital stay body image and cosmesis scores operating time, morbidity, hospital stay, postoperative morphine requirement, pain, and costs clinical recurrences giqli score qol number of patients with postoperative morbidity reoperation, readmission and repeat resection rates for recurrent crohn's disease sf-36 and giqli questionnaire|oc patients requiring operation during follow-up were significantly more likely than lc to require multiple operations (p = .006). within a single institution, single surgical team, prospective, randomized trial, laparoscopic techniques offered a faster recovery of pulmonary function, fewer complications, and shorter length of stay compared with conventional surgery for selected patients undergoing ileocolic resection for crohn's disease. although qol measured by sf-36 and giqli questionnaires was not different for laparoscopic-assisted compared with the open ileocolic resection, morbidity, hospital stay, and costs were significantly lower. overall reoperation rates for recurrent crohn's disease, incisional hernia and adhesion-related problems were two of 29 versus six of 26 (risk difference 16 (-3 to 35) per cent).|crohn's disease for refractory crohn's disease patients previously enrolled selected patients undergoing ileocolic resection for crohn's disease primary crohn's disease 60 patients (25 males), median age 34.4 (range, 10-60.1) years, undergoing refractory ileocolic crohn's disease 31 patients assigned to laparoscopic and 29 to the conventional group, all had isolated crohn's disease of the terminal ileum plus or minus the cecum sixty patients who underwent ileocolic resection between 1999 and 2003 were followed prospectively sixty patients ileocolic crohn's disease (cd two laparoscopic patients
bilirubin measurements moderated hyperbilirubinemia and reduced phototherapy (pt) time median hours to case closure number of bilirubin determinations severe hyperbilirubinemia exchange transfusion or interruption of breast-feeding|a single dose of snmp entirely supplanted the need for pt in jaundiced term and near-term newborns and significantly reduced medical resource use to monitor hyperbilirubinemia. no adverse effects of snmp use were observed.|male term infants; study ii: infants of both sexes and gestational age [ga] 245-265 days healthy full-term breastfed infants with a pbc between >/=256.5 micromol/l and </=307.8 micromol/l controlling hyperbilirubinemia in term and near-term newborns full-term breastfed infants with plasma bilirubin concentrations (pbc) of >/=256.5 micromol/l and </=307.8 micromol/l
work-related anxiety pre- and post-treatment anxiety scores stress hormone levels burnout rates mental health mean scores on the nurse stress checklist (nsc) and the chinese general health questionnaire (cghq levels of stress mean change in physiologic parameters anxiety measures attitudes, communication skills and occupational stress nursing stress scale and communication skills job turnover perceived stress scale (pss) and rathus assertiveness schedule (ras inhibitory behaviours stress levels level of occupational stress sick leave visual analog scale (vas) and increased relaxation anxiety, stress, self-care and caring relationships educated guesses cost savings psychoendocrine stress nursing stress scale, attitudes with a semantic differential questionnaire, cs total mood disturbance (tmd emotional exhaustion and lack of personal accomplishment, two dimensions of burnout tmd scores knowledge and attitudes about serious mental illness anxiety multiple burnout and mood dimensions job satisfaction, burnout, and sick leave semantic differential questionnaire, occupational stress nurses' satisfaction levels facilitative behaviours (open questions chinese version of state-trait anxiety inventory and the chinese version of the general health questionnaire blood pressure scores on 2 of 3 subscales of the maslach burnout inventory knowledge and attitudes, and increase in burnout mental health status psychophysiologic health level importance of touch in nursing care, stress reduction, increased self-awareness, the need for self-care prolactin levels|t.s. were significantly more in control of the interview than c.s. (p = 0.02). emotion-oriented care is used in the care for cognitively impaired elderly persons and is mainly based on the validation approach. participants were assessed at the pretreatment session, the fourth posttreatment session, and at the 1-month follow-up session. results suggested that stress management training was effective in reducing work-related anxiety among inexperienced nurses but not among experienced nurses. positive training effects were found on cs used during the simulated interview: a significant increase in facilitative behaviours (open questions: treatment group participants reduced scores on 2 of 3 subscales of the maslach burnout inventory significantly more than wait-list controls; within-group comparisons for both groups pretreatment and posttreatment revealed similar findings. a cost-effective, 6-session rmm protocol reduces burnout and mood dimensions, as well as tmd, in long-term care workers. subjects were randomly assigned to one of two treatments: assertiveness training (at) or alternate treatment control (atc), which served as a control and contained updated knowledge of new computer technology for in patient settings. the mean scores on the nurse stress checklist (nsc) and the chinese general health questionnaire (cghq) differed significantly between the experimental and control group in posttest 2 at week 5. results showed that although the burnout level did not change as a result of primary nursing, psychiatric nurses and the practical nurses seemed able to work according to the principles of primary nursing. subjects who participated in a 6-week program designed to improve coping reported significant short-term decreases in emotional exhaustion and lack of personal accomplishment, two dimensions of burnout. while both groups demonstrated decreased anxiety after intervention, the experimental group consistently showed greater differences between pre- and post-treatment anxiety scores. there was a significant time x group interaction with increasing prolactin levels on the c-ward as compared to decreasing levels on the i-ward during the intervention. staff in the experimental group showed significant improvements in their knowledge and attitudes about serious mental illness and a significant decrease in burnout rates, whilst staff in the control group showed a small but nonsignificant improvement in knowledge and attitudes, and increase in burnout.|chinese nurses who are employed in large teaching hospitals in taiwan professional caregivers in homes for elderly persons 65 nurse managers in hong kong 24 nurses working 12-hour shifts two wards within a geriatric hospital sixteen homes for the aged chinese registered nurses employed in large teaching hospitals to reduce their work stress in taiwan, republic of china nurses nurse managers in hong kong stress and assertiveness experienced by nurses in taiwan, republic of china health care personnel nurses in taiwan, republic of china nurse managers three hundred professional caregivers were included in the study oncology nurses working in a burn treatment unit seventy-two oncology nurses 118 health-care providers 137 subjects were selected randomly from three first-ranked teaching hospitals long-term care workers chinese nurses working in modern hospitals in taiwan psychiatric nurses in long-stay settings 60 volunteer chinese-speaking nurses participated in the study a total of 115 oncology nurses cognitively impaired elderly persons twenty of the nurses volunteered to be included in a psi training course twenty-three subjects in the experimental group and 23 in the control group from each hospital participated in the study mental health nurses working in secure environments with patients suffering from serious mental illness professional nurses in taiwan 112 employees participated in a 161 psychiatric nurses was followed for 2.5 years
pain reduction pain perception and function, and lastly numbers of patients continuing to surgery hand pain bctq symptomatic score frequency of awakening at night hand function or median nerve latency functional status scale, and a symptom severity scale electrophysiologic signs, clinical signs, or significant symptoms carpal tunnel syndrome grip strength and pain pain/paresthesia score of subjective symptom ratings assessed by visual analogue scale; electroneurographic measures (for example, motor distal latency and sensory antidromic nerve conduction velocity pain severity and greater satisfaction pre- and postassessments of self-reported physical and mental distress, nerve conduction studies and vibrometry boston carpal tunnel questionnaire (bctq) score functional score manipulation of the soft tissues and bony joints of the upper extremities and spine numbness, tingling, burning, and pain phalen sign levine's self-administered questionnaire, and physiologic impairment mean mnmdl, mnsv, and gss electroneurographic variables (motor distal latency sensory distal latency symptoms and functional deficits mean score functional deficits symptoms, function, and impairment in carpal tunnel syndrome (cts grip strength pain and other symptoms of carpal tunnel syndrome (cts mean median nerve motor distal latency (mnmdl), median nerve sensory velocity (mnsv), and global symptom score (gss superior distal latency improvement global symptom scores sensory distal latency improvement median nerve sensory and motor distal latency sensory antidromic nerve conduction velocity standardized symptom questionnaire, rating five categories of symptoms (pain, numbness, paresthesia, weakness/clumsiness, and nocturnal awakening) on a scale from 0 (no symptoms) to 10 (severe global symptom score (gss occasional daytime wear phalen test time motor nerve conduction velocity and increased motor distal latency perceived comfort and function, nerve conduction and finger sensation overall overall neurophysiological classification patient satisfaction pain relief scale pain visual analogue scale symptom severity efficacy and tolerability active range of wrist movement (rom flexion and extension), upper limb tension test with a median nerve bias (ultt2a subjects' global impression of change questionnaire (sgicq), median distal motor latency, sensory conduction velocity and amplitude, and neurophysiological class of severity sleep disturbance, tinel sign, and median nerve motor and sensory conduction time clinical findings, pain severity, functional hand status, and comfort grip strength, pain intensity, sleep disturbance, phalen sign, and tinel sign, and in median nerve motor and sensory conduction time pain severity and hand function electrophysiological measurements beginning pain, pain at 15 minutes, pain at 30 minutes, or pain relief of symptoms lateral pinch strength value carpal bone mobilization and median nerve mobilization|no differences in outcome were found in electrophysiologic signs, clinical signs, or significant symptoms. the results indicate that the neutral angle provided superior symptom relief, and that the relief did not often improve between 2 weeks and 2 months of wear. the improvement in group 2 was slightly greater, but the difference between the groups was not significant, except for the lateral pinch strength value. we evaluated the effectiveness of low-dose, short-term oral prednisone in ameliorating the pain and other symptoms of carpal tunnel syndrome (cts) in a randomized, double-blind, placebo-controlled study of patients with mild to moderate cts. subjects assigned keyboard a experienced a decrease in hand pain between weeks 6 and 12 when compared with keyboard b subjects (p = 0.05) and demonstrated an improvement in the phalen test time (right hand, p = 0.006; left hand, p = 0.06). no significant reduction from baseline gss was seen at second, and fourth weeks in the placebo, nsaid-sr, and diuretic groups. only scores on a pain relief scale (p<0.01) demonstrated highly significant differences between the three groups when analyzed using kruskal-wallis test. improvement was significantly more pronounced in actively treated than in sham treated wrists for both subjective symptoms (p < 0.001, paired t test) and electroneurographic variables (motor distal latency p < 0.001, paired t test; sensory antidromic nerve conduction velocity p < 0.001, paired t test). although there was no statistically significant before-after difference in electrophysiologic studies, slightly decreased motor nerve conduction velocity and increased motor distal latency were noted in groups a and b, but not in group c. ultrasound therapy in cts was comparable to placebo ultrasound in providing symptomatic relief, and the probability of a negative effect on motor nerve conduction needs to be considered. subjects in the yoga groups had significant improvement in grip strength (increased from 162 to 187 mm hg; p = .009) and pain reduction (decreased from 5.0 to 2.9 mm; p = .02), but changes in grip strength and pain were not significant for control subjects. compared to placebo, kb3 and to a lesser extent kb1 groups demonstrated an improving trend in pain severity and hand function following 6 months of keyboard use. a more significant improvement in the mean mnmdl, mnsv, and gss was observed in the insulin group when compared with the placebo group. the use of a magnet for reducing pain attributed to carpal tunnel syndrome was no more effective than use of the placebo device. vitamin b6 seems to have no advantage over conservative therapy for carpal tunnel syndrome. the treated group showed a reduction in bctq symptomatic score (from 2.75 to 1.54 at 4 weeks; p < 0.001) and functional score (from 1.89 to 1.48; p < 0.001). there was significant improvement in perceived comfort and function, nerve conduction and finger sensation overall, but no significant differences between groups in the efficacy of either treatment. subjects receiving full-time wear instructions showed superior distal latency improvement, both motor (.35 vs -.07msec, p = .04) and sensory (.46 vs .|niddm patients with carpal tunnel syndrome eighty computer users with musculoskeletal disorders veterans administration medical center, outpatient clinic wearers of splints immobilized at 20 degrees extension and at neutral a geriatric center and an industrial site in 1994-1995 thirty-two patients with the disease computer users with upper extremity musculoskeletal disorders carpal tunnel syndrome patients with carpal tunnel syndrome (cts 45 patients with mild to moderate bilateral carpal tunnel syndrome patients with mild to moderate cts patients with non-insulin-dependent diabetes (niddm) mellitus who have mild-to-moderate carpal tunnel syndrome (ts mild to moderate carpal tunnel syndrome (cts university hospital pm&r department outpatient clinic and neurology department electromyography laboratory carpal tunnel syndrome (cts mild to moderate idiopathic carpal tunnel syndrome eighteen women with diagnosis of cts in 30 hands patients with clinical symptoms and signs of cts, confirmed by standard electrodiagnosis niddm patients with mild-to-moderate cts who opt for conservative treatment twenty-one patients (30 hands) were enrolled, and 17 patients (24 hands) completed the study patients with mild to moderate idiopathic carpal tunnel syndrome wrist pain attributed to carpal tunnel syndrome twenty computer users idiopathic carpal tunnel syndrome computer users with hand paresthesias outpatient clinic of a university department of physical medicine and rehabilitation in vienna 30 patients with pain attributed to carpal tunnel syndrome had either a 1000 gauss magnet or a placebo metal disk applied to the carpal tunnel area using a velcro wrap for a period of 45 minutes wolfe-harris center for clinical studies at northwestern college of chiropractic in bloomington, minnesota patients experiencing carpal tunnel syndrome carpal tunnel syndrome with nerve and tendon gliding exercises outpatients with untreated cts were consecutively recruited from our electrodiagnostics lab forty-two employed or retired individuals with carpal tunnel syndrome (median age, 52 years; range, 24-77 years ninety-one of 96 eligible subjects who reported symptoms that were confirmed by clinical exam and nerve conduction studies 28 patients with the diagnosis of carpal tunnel syndrome in 36 hands
forced expiratory volume hearing loss toxicity and practicability tobramycin concentration mean change in fev1 efficacy, tolerance, and pharmacokinetics pa density mean body weight hearing impairment leukocyte count and inflammation markers respiratory function and changes in renal function and hearing forced expiratory flow acute dizziness safety and efficacy creatinine mean% change in fev1 tobramycin concentrations forced vital capacity (fvc efficacy change in forced expiratory volume in 1s (fev1), over the 14 days of treatment, expressed as a percentage of the predicted normal value for age, sex, and height respiratory function efficacy and safety serum potassium and magnesium levels, equivalence plasma prealbumin bilateral impairment variables forced expiratory volume in one second and forced mid-expiratory flow % pred and serum creatinine levels leukocyte count, and the secondary end-points were clinical and lung function parameters, pseudomonas quantification in sputum, and inflammation markers (immunoglobulin g, c-reactive protein) in serum serum trough nephrotoxicity nephrotoxic cochlear and renal tolerance forced vital capacity renal function serum peak concentration of tobramycin forced mid expiratory flow rate weight/height change in serum creatinine|forced expiratory volume increased by approximately 5% of the predicted volume, forced vital capacity increased by 2% of predicted capacity, and forced mid expiratory flow rate increased by 7% (a) or 4% (b) of the predicted normal value, although these changes were not statistically significant. improvement was not significantly different between groups. for changes in forced vital capacity % predicted and serum potassium and magnesium levels, equivalence was demonstrated. the mean change in fev1 (% predicted) over 14 days was similar on the two regimens (10.4% [once daily] vs 10.0% [three-times daily]; adjusted mean difference 0.4% [95% ci -3.3 to 4.1]).|sixty adult patients with an acute respiratory exacerbation adult patients with cystic fibrosis children patients with cystic fibrosis patients 22 patients with cystic fibrosis, mean (sd) age 11 (3.4) years (range 5.6-19.3), with pulmonary pseudomonas exacerbations 219 patients (107 once daily, 112 three-times daily) completed the study per protocol clinically stable patients with cf pseudomonas exacerbations in cystic fibrosis patients with cystic fibrosis who have chronic pseudomonas aeruginosa infection 30 patients (20 female, mean age 11.2 years, mean age range 1.7-18.1 years cystic fibrosis patients pulmonary exacerbations of cystic fibrosis 244 patients from 21 cystic-fibrosis centres in the uk chronic pseudomonas aeruginosa (pa) infection in cystic fibrosis (cf pediatric cystic fibrosis patients
gait speed self-care independence barthel activity of daily living index (bi) scores, "poor global outcome", (defined as deterioration in bi score, or death) and the rivermead mobility index socialization and self-esteem time taken to walk 10 m level of depression, self-esteem, and socialization manual dexterity, depression, and anxiety rivermead mobility index scores mobility including gait speed, functional ambulation categories, the nottingham extended activities of daily living index, and individual items from the barthel activities of daily living index and the frenchay activities index functional independence measure (fim), brunnstrom stages of motor recovery, timed mobility tasks, and the jebson hand evaluation|at 3 months bi score in survivors had increased by 0.6 (sd 3.9) in the intervention group and decreased by 0.9 (2.2) in the control group; a difference of 1.5 (95% ci allowing for cluster design, -0.5 to 3.5). a 9% (95% confidence interval 0% to 18%) decrease in time taken to walk 10 m was associated with treatment and a 12% (2% to 19%) increase when patients were untreated. the treated group improved in terms of socialization and self-esteem as evidenced by a lower sickness impact profile, whereas the controls tended to get worse.|forty-nine stroke survivors, who were at least l yr (mean, 2.9 yr) poststroke residents with stroke-related disability living in care homes twelve homes (118 residents) were randomly allocated to either intervention (6 homes, 63 residents) or control (6 homes, 55 residents 94 patients entered the trial and 49 patients seen more than one year after stroke postacute stroke patients patients who had reduced mobility due to a stroke more than one year before entry; 60 were recruited from a community stroke register and 34 in other ways patients' homes in oxfordshire residents with stroke in uk care homes postacute stroke survivors
discontinuation-emergent adverse events ham-d-17 total score rate of discontinuation due to adverse events acute phase; efficacy and safety/tolerability outcomes tolerability assessments included discontinuation rates, adverse events (aes), vital signs, and laboratory tests efficacy, safety and tolerability measures 17-item hamilton depression rating scale systolic blood pressure duloxetine, escitalopram, and placebo rates of remission or response hypertension incidence clinical global impressions (cgi)-severity of illness scale score remission rates (madrs score discontinuation rates, adverse event rates, vital signs, and laboratory tests total madrs score mean madrs total score madrs mean baseline madrs total scores clinical global impressions-improvement (cgi-i) score, montgomery asberg depression rating scale (madrs) score, clinical global impressions-severity (cgi-s) score, and 6-item hamilton rating scale for depression, bech version (ham-d(6 tolerability mean change from baseline in the 17-item hamilton rating scale for depression (hamd(17)) total score deaths mean change on the hamd(17 adverse events safety and tolerability 17-item hamilton rating scale for depression (ham-d-17) total score ham-d(17 adverse events (teaes), vital signs, and weight number of early discontinuations and overall teae increased sweating hamd(17) subscales, hamilton rating scale for anxiety, clinical global impressions-severity, patient global impressions-improvement, somatic symptoms inventory and visual analog scales (vas) for pain morbidity and mortality discontinuation rates madrs, hama, cgi-s, and pgi-i scales nausea and palpitations estimated probabilities of response and remission laboratory values, vital signs, weight or electrocardiograms efficacy hamilton rating scale for depression, hamilton rating scale for anxiety, and clinical global impressions-severity of illness total scores and the proportion of patients with clinical global impressions-improvement scores efficacy and safety remission at endpoint [17-item hamilton depression rating scale 17-item hamilton depression rating scale improvement probabilities of meeting onset criteria occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes overall pain severity efficacy and tolerability onset of antidepressant efficacy tolerated estimated probability of remission major depressive disorder (mdd total score, hamd(17) subscales, the montgomery-asberg depression rating scale (madrs), the hamilton anxiety rating scale (hama), visual analog scales (vas) for pain, the clinical global impression of severity (cgi-s) and patient global impression of improvement (pgi-i) scales, the 28-item somatic symptom inventory (ssi), and the sheehan disability scale (sds tolerated and safe withdrawal rate due to adverse events change from baseline to week 6 in montgomery-asberg depression rating scale (madrs) total score teae reporting rates cgi-i, madrs, and ham-d(6 insomnia and asthenia 17-item hamilton rating scale for depression (hamd(17 overall withdrawal rates gbr assessment hamd17 total score and subscales, hama, cgi-s, and pgi-i. safety and tolerability were assessed via analysis of reasons for discontinuation, treatment-emergent adverse events (teaes), discontinuation-emergent adverse events, and changes in vital signs, weight, and laboratory analytes response rates depression adverse events, vital signs, ecgs, laboratory tests, and the arizona sexual experiences scale (asex safety nausea, dry mouth, vomiting, yawning, and irritability montgomery-asberg depression rating scale, cgi-severity of illness and cgi-improvement, and patient global impression of improvement cgi-i, madrs, cgi-s, and ham-d(6 response and remission rates vas back pain maier subscale primary efficacy measure (maier subscale nausea safety and efficacy treatment-emergent adverse events (teae), vital signs, weight, laboratory analyses and electrocardiograms dry mouth, sedation, and somnolence for quetiapine xr and nausea, headache, dizziness, and dry mouth for duloxetine safety measures mean 17-item hamilton depression rating scale total change insomnia ham-d(17) total score somnolence therapeutic efficacy and safety/tolerability madrs total score hamd(17) total score estimated probabilities of remission incidence of acute treatment-emergent sexual dysfunction visual analog scales for pain, clinical global impression of severity, patient's global impression of improvement, and quality of life in depression scale constipation|both duloxetine (80 and 120 mg/day) and paroxetine treatment groups had significantly greater improvement, compared with placebo, in madrs, hama, cgi-s, and pgi-i scales. at week 8, escitalopram treatment resulted in significantly greater improvement compared with duloxetine on the prospectively defined primary efficacy endpoint of mean change from baseline in madrs total score using the locf approach (least-squares mean difference [lsmd] -2.42; 95% ci -4.73, -0.11; p < 0.05). there were no significant differences between duloxetine 60 mg/day and venlafaxine 150 mg/day as measured by gbr assessment at the end of 6 weeks (-1.418 vs. -1.079, p = 0.217) or 12 weeks (-0.349 vs. -0.121, p = 0.440), nor were there significant differences between treatment groups on the majority of efficacy measures. duloxetine at 40 mg/d was also significantly superior to placebo by 2.43 points (95% ci 0.19, 4.66; p = 0.034), while paroxetine was not (1.51 points; 95% ci -0.55, 3.56; p = 0.150). no differences were found between duloxetine, escitalopram, and placebo rates of remission or response at 8 weeks. no significant differences were observed in any scale between the desvenlafaxine 50 mg/d and placebo groups. non-inferiority of duloxetine to paroxetine was demonstrated because the upper bound of the confidence interval for mean difference in hamd(17) change (0.71) was less than the non-inferiority margin. paroxetine was not significantly different from placebo (p=0.089) on mean change on the hamd(17). duloxetine was superior to placebo in change on the ham-d-17 (p = .009). remission rates (madrs score <or= 8) were significantly higher for quetiapine xr 300 mg/day and duloxetine versus placebo (p < .05), but not for quetiapine xr 150 mg/day. the difference in mean change from baseline in madrs total score favoured escitalopram at weeks 1, 2, 4, 8, 12 and 16 (p < 0.05).|or= 18 years) meeting dsm-iv criteria for mdd received 612 patients with diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv)-defined mdd participants were outpatients aged > or =18 years with diagnostic and statistical manual of mental disorders, fourth edition-defined mdd and a 17-item hamilton rating scale for depression (ham-d(17)) score > or =20 adult outpatients (age 278 outpatients of 382 patients screened with diagnostic and statistical manual of mental disorders (4th edition)-diagnosed major depressive disorder (montgomery-asberg depression rating scale [madrs] total score > or =26 patients (> or = 18 years) meeting dsm-iv criteria for major depressive disorder (mdd) received patients who had a >or= 30% reduction from baseline in hamd(17) total score during the acute phase major depressive disorder 1388 patients (mean [sd] age range, 38.8-45.7 [12.1-12.6] years; mean weight range, 73.1-87.0 [17.6-23.9] kg; female sex, 896 [64.6%]; white race, 1136 [81.8 patients age > or =18 meeting dsm-iv criteria for mdd patients with moderate to severe major depressive disorder 20 april 2005 to 10 march 2006 in independent psychiatric research facilities with principal investigators who were board certified in psychiatry china, korea, taiwan and brazil patients with non-psychotic mdd 925 patients who were screened, 287 did not meet entry criteria, and 638 patients enrolled in the study; the intent-to-treat (itt) population included 615 patients who were evaluated for efficacy (mean [sd] age range, 38.8-40.7 [12.1-13.2] years; mean weight range, 83.3-87.0 [22.8-23.9] kg; female sex, 398 [64.7%]; white race, 458 [74.5 173 patients (aged 18-65 years) with dsm-iv major depressive disorder 21 centers across the united states major depressive disorder (mdd patients with major depressive disorder patients who had a > or =30% reduction from baseline in the hamd(17) total score at the end of the acute phase
serum retinol concentrations mean number of diarrheal episodes mrdr ratios breast milk retinol levels maternal serum retinol incidence of diarrhea incidence of diarrhea and acute respiratory infection (ari breastmilk retinol concentration infant mortality infant gut mucosal damage morbidity and mortality mean mrdr ratio safety and efficacy h pylori infection milk retinol hazard ratios serum retinol infant serum retinol maternal and infant serum retinol concentrations, modified relative dose-response (mrdr) ratios and breast milk vitamin a concentrations subclinical vitamin a deficiency relative risk of vad antipolio antibody titer, antitetanus toxoid antibodies, and avidity of antibodies to tetanus maternal pneumococcal carriage maternal and infant plasma vitamin a, reduce infant helicobacter pylori infection and nasopharyngeal pneumococcal carriage, and improve infant gut epithelial integrity vad mean mean incidence of febrile illness gram fat, milk retinol mothers' serum retinol concentrations mean maternal serum retinol concentrations maternal serum and breastmilk retinol levels and infant morbidity and anthropometry maternal vitamin a concentration milk retinol concentrations serum retinol and incidence of illness serum retinol of infants and the breast milk retinol levels liver stores) and higher milk vitamin a concentrations serum retinol levels infant pneumococcal carriage prevalences of low vitamin a stores milk vitamin duration of respiratory tract infection and febrile illness levels of maternal and infant plasma vitamin a, h pylori infection, pneumococcal carriage, and gut epithelial integrity mean duration of respiratory tract infection serum retinol and infant stores vitamin a status infant retinol stores clinic attendances lower maternal mrdr ratios tolerated antibody titers low serum retinol concentration cord blood levels infant serum retional and the breast milk retinol level adverse events|we found no evidence that vitamin a supplementation affects infants' antibody responses to tetanus toxoid or oral polio vaccine delivered at epi contacts. irrespective of treatment group, over 50% of women produced milk with low vitamin a concentrations (</=1.05 micromol/l or </=0.28 micromol/g fat) throughout the study. postpartum vitamin a supplementation had a beneficial impact on the infant serum retional and the breast milk retinol level but no effect on infant growth. the milk retinol concentrations of the vitamin a group were higher than those of the placebo group by 0.48 to 1.18 mumol/l at 1-8 mo postpartum (p < 0.05). hazard ratios (95% ci) for 12 mo mortality among infants in the maternal-supplemented and infant-supplemented groups were 1.17 (0.87, 1.58) and 1.08 (0.80, 1.46), respectively. serum retinol and incidence of illness did not differ significantly between the 2 groups. no differences were found in the primary outcomes for high-dose versus who schedule: maternal vitamin a concentration at 2 months +0.02 micromol/l (95% ci -0.10 to 0.15); infant vitamin a at 5 months +0.01 micromol/l (-0.06 to 0.08); h pylori infection at 12 months -0.3% (-14.7 to 14.2); maternal pneumococcal carriage at 12 months -2.0% (-13.7 to 9.7); infant pneumococcal carriage at 12 months -4.1% (-15.8 to 7.6); infant gut mucosal damage at 12 months 5.2% (-8.7 to 19.2). infant serum retinol was not different between groups. infants of the supplemented mothers had reduced mean duration of respiratory tract infection of 3.1 (2.7, 3.5) days compared to 3.7 (3.3, 4.2) days (p < 0.03) and mean incidence of febrile illness 0.1 (0.1, 0.1) compared to control infants 0.3 (0.3, 0.3) days, (p < 0.002). prophylactic administration of mega doses of vitamin a to the mother soon after delivery and to the infant at six months do not have any beneficial impact on the incidence of diarrhea and ari in infancy.|rural gambia, 220 mother-infant pairs 153 indonesian mothers 1-3 wk postpartum gambian mothers and infants pregnant women 564 women breast-feeding indonesian mothers kenyan mother-infant pairs lactating bangladeshi women benefits mothers and infants pregnant women in their third trimester using maternal serum retinol levels as the indicator; and (ii children living in areas endemic for vitamin a deficiency 909 newly delivered mother-and-infant pairs young infants mother and infant on morbidity in infancy 109 apparently healthy primi and second gravida women registered at the antenatal clinic were included in the study and followed up for three months postpartum mothers and morbidity of their infants fifty low income women young infants (n = 1085 infants born to hiv-negative mothers in zimbabwe pregnant mothers in their third trimester (35-37 weeks) and tanzanian infants malnourished mothers 197 infants kenya lactating mothers infants aged 1-3 mo 780 newborn infants and their mothers to a randomized double-blind controlled trial in ifakara in southern tanzania 51 villages in two contiguous primary health centers in villupuram health unit district of tamil nadu, south india 53 mothers who received a single dose of 2 lakh units of mothers and infants infants of hiv-negative women with an apparently adequate vitamin a status infants' immune responses to tetanus and polio vaccines 14,110 mothers and their infants; 9208 of the mothers were hiv-negative at delivery, remained such during the postpartum year, and were retained in the current analysis
heart rate and lower vagal tone pain scores, crying, or time to return to baseline behavior crying time and pain pulse rate frontal eeg asymmetry scores frequency distribution of ct loss of oxygen saturation data time crying adverse events, clinical outcomes, or neurobiological risk status validated infant pain measure, the premature infant pain profile (pipp), which includes measures of facial expressions, heart rate, and oxygen saturation and takes behavioral state and gestational age into consideration salivary cortisol neonatal facial coding system (nfcs pain control overall crying time and heart rate behavioural and physiological pain scores procedural pain baseline pain scores overall mean pain score adverse effects, such as apnoea or oxygen desaturation elevation of heart rates median (interquartile) pain scores heart mean pain score newborn acute pain scale (dan) and with the neonatal facial coding system (nfcs medians for crying time and the pain scores premature infant pain profile (pipp) scores mean pipp scores pain response douleur aigu nouveau-n (dan) behavioral scale lowest mean premature infant pain profile scores pain or heart rate crying time and pain score mean crying time, recovery time, maximum heart rate, and percent change in heart rate heart rate and oxygen saturation changes newborn infant pain responses nips scores o(2) saturation relative right frontal eeg activation premature infant pain profile (pipp facial grimacing scores crying in response to heel stab efficacy (pain response as measured using the premature infant pain profile facial expression of pain premature infant pain profile scores neuro-biological risk score (nbrs vital signs pain relief crying and pain scores plasma for cortisol levels effectiveness and safety of sucrose oxygen saturation median recovery time crying duration distress responses severity of illness, postnatal age, or number of painful procedures distress pain response measurements lowest pain scores facial activity pain and discomfort heart rate, oxygen saturation (sao2), neonatal facial coding score and presence or absence of cry pain-induced crying physiological (heart rate) and behavioural (facial actions) responses average score on the scale of discomfort crying time and the level of behavioural state sucrose pain scores pain behaviors efficacy and safety hr, bp, and pain score pulse rate variability pain-related behaviour pain/distress pain-specific brain activity evoked by one time-locked heel lance, recorded with electroencephalography and identified by principal component analysis adverse events and lidocaine levels median crying times crying time, behavioural state, skin conductance and heart rate cry with catheterization sg neonates with facial actions signaling pain pain responses sg neonates crying skin conductance (number and amplitude of the waves) and heart rate magnitude or latency of the spinal nociceptive reflex withdrawal discomfort and crying mean (sd) dan pain scores premature infant pain profile (pipp) scoring system majority of time actively crying pain response and clinical outcomes (e.g., health status and neurodevelopmental status pipp scores neonatal pain duration of crying pipp score relieving pain mean pipp score sampling duration and numbers of heel lances vital signs (i.e., pulse rate, respiratory rate, and oxygen saturation), crying time, and time for the vital signs to return to baseline values efficacy and immediate and long-term adverse events analgesic effect pain of heel pricks behavioural and physiological pain responses quiet sleep negative electroencephalographic response pain vocalizations mean gestational age at birth, mean birth weight or corrected gestational age behavioral observations duration of cry and douleur aigu du nouveau facial expression score, incidence and duration of crying, heart rate and oxygen saturation changes immediate pain response mean pain scores premature infant pain profile (pipp), a validated behavioral acute pain scale total duration of crying physiologic or behavioral responses to the eye exam pain-specific brain and spinal cord activity ct and nips scores facial actions indicative of pain crying times duration of crying whilst the blood collection vagal tone nfcs score median values of crying time, recovery time and percentage change in heart rate neonatal facial coding score during nasogastric tube passage median premature infant pain profile scores median neonatal pain, agitation and sedation scale (n-pass) score analgesic effects response to pain mean crying times lowest pain score cerebral blood volume safety heart rate, thoracic movements, and transcutaneous blood gases mean sao2 baseline behavioural and physiological measures, observational pain scores (pipp), and spinal nociceptive reflex withdrawal activity scores of the scale of discomfort motor development and vigor, and alertness and orientation components of the neurobehavioral assessment of the preterm infant pain and duration of crying cortisol response neonates' facial activity (nfcs), behavioral state, and heart rate plasma cortisol levels pain and distress mean glucose levels pain reduction pain assessment maximum heart rate crying and the total procedure time crying and the autonomic effects venipuncture-induced pain effective and safe for relieving pain oxygen saturation and heart rate and neonatal infant pain scale pain reaction facial scores blood collection, incidence and duration of crying neonatal heel prick responses facial expression time spent crying behavioral (crying and facial activity) and physiological (heart rate, vagal tone) responses overall physiological stability crying neonatal acute physiology ct and subsequent nips scores procedural pain relief lower pipp scores (single sucrose pain scores average crying time distress scores duration of cry and by facial expression (pain score pain score procedural pain control behavioural and physiological pain response median heart rate increase, oxygen saturation decrease, and duration of first cry standard deviation of pulse rate and number of doses of sucrose duration of first cry, the percentage of time spent crying longer crying time mean (sd) plasma lidocaine level nociceptive brain activity motor development and vigor, and alertness and orientation at 36 weeks', lower motor development and vigor mean recovery time responses of neonates to pain and distress episodes of desaturations or bradycardia crying time neonatal infant pain scale (nips) score, on crying time (ct) and subsequent nips score crying time, duration of the first cry and tachycardia, time needed for return to baseline heart rate, and the average and 1- and 5-minute nfcs scores neurobiological risk status median premature infant pain profile score behavioural responses to pain multidimensional acute pain rating scale of the premature infant pain profile, heart rate increase, oxygen saturation decrease, crying behavior (duration of first cry, cry percentage in 2 minutes, and during blood sampling), duration of sampling, and the number of performed heel lances median pain scores nfcs scores physiological responses of heart rate and oxygen saturation heart rate and oxygen saturation incidence of spitting up pain duration of the crying and grimacing heart rate and duration of crying pain scores duration of cry, vagal tone, and salivary cortisol mean dan and nfcs scores heart rate facial actions hr, rr, o(2) saturation, bp, pain (premature infant pain profile) and percent of time spent crying during the eye exam electroencephalographic (eeg) activity, heart rate activity, and infants' facial behaviors n (dan) score local skin reactions pain scores, less crying|there was a significant main effect of intervention (p = 0.03) between the sucrose plus pacifier group, and the standard care group (p = 0.01), but there was no main effect of time (p = 0.72). at 2 and 4 minutes pain scores were lowest in the nns and rocking groups as compared to sucrose, distilled water, expressed breast milk and massage. infants who received water showed increased relative right frontal eeg activation from baseline to the post-heelstroke phase, a pattern that typifies negative affect. no differences were determined between the groups for heart rate and oxygen saturation in the newborns during painful interventions (p > 005). the increase from before to during heel prick in skin conductance (number and amplitude of the waves) and heart rate correlated with the crying time (p < 0.01). the mean pipp score was 8.8 for the sucrose group and 11.4 for the water group ( t = 2.87, p = .008 two-tailed). two-week-old infants who received either the sterile water or sucrose solution cried significantly less than infants who received no intervention (f=5.92,p<.005). there was a significant reduction in overall crying time and heart rate after three minutes in the babies given 50% sucrose as compared with controls. cerebral blood volume decreased in 5 of 14 infants after sucrose and in 6 of 14 infants after placebo (difference not significant). the participants in the control group had a trend of longer crying time, but this trend did not reach a level of statistical significance. grimacing was reduced to almost naught by procedures that essentially eliminated crying and markedly reduced heart rate during the blood harvesting procedure. no significant difference was recorded between the sucrose and sterile water groups in the magnitude or latency of the spinal nociceptive reflex withdrawal recorded from the biceps femoris of the stimulated leg. the pacifier dipped in sucrose had a distress-reducing effect during both the post-dpnb injection and circumcision periods. significant differences in pain response existed among treatment groups (f = 22.49, p <.001), with the lowest mean premature infant pain profile scores in the sucrose and nonnutritive sucking group. there were no group differences in the cortisol response to a painful stimulus or in pulse rate variability over time. the duration of crying in response to sampling did not differ in the two groups but was related to level of arousal at the time of stimulation. oral sucrose significantly reduced the score of the hl group (58 v 47, p<0.01) and also tended to reduce the score of the vp group (23 v 2, p<0.1). infants who received sucrose demonstrated a significantly lower neonatal facial coding score during nasogastric tube passage compared with the placebo group (median 1 (range 0-4) vs 3 (0-4), p = 0.004). the pacifier with sucrose (f = 24.09, p < .0001) and pacifier with sterile water (f = 9.00, p = .003) significantly reduced pain. the comparative analysis between groups of non-nutritive sucking sucrose and placebo showed no significant differences. physiological responses of heart rate and oxygen saturation were not attenuated by sucrose at any time point during or following the blood collection. median crying times were 36, 52, and 62 s in the sucrose, placebo and human milk groups, respectively (p = 0.0009). the groups that received sucrose alone or in combination with simulated rocking showed less facial actions indicative of pain than the rocking alone or control group. no significant differences were seen between groups in physiologic or behavioral responses to the eye exam. repeated measures analysis of variance (anova) revealed that the sugar-coated pacifier group demonstrated significantly lower vagal tone during heelstick than the oral sucrose solution and control groups. the mean pain scores were 4.60, 5.82, 3.91, 4.94, 5, and 4.05 in groups 1-6, respectively (p= 0.068). the synergistic effect of the combination of sucrose and non-nutritive sucking was clinically effective and safe in relieving the pain of simple procedures such as venipuncture or heel stick in preterm and term infants, but further research is needed on these interventions alone and in combination with other behavioral interventions in neonates. pain was assessed with the newborn acute pain scale (dan) and with the neonatal facial coding system (nfcs). in a double blind cross over study sucrose reduced the pain response of preterm infants exposed to heel prick blood samples only when it was administered into the mouth. differences between group medians for these comparisons were 3 (2 to 5), 3 (1 to 5), and 1 (0 to 2), respectively. there was a significant reduction in the duration of first cry, the percentage of time spent crying in the 5 minutes after heel prick, and the pain score in the sucrose treated group. for physiological measures, the interventions interacted with each other and preintervention levels to reduce heart rate and lower vagal tone more during the procedure in infants in whom heart rate and vagal tone were higher before intervention. nips scores before the heel prick correlated significantly and positively with ct and subsequent nips scores in both the sucrose and the placebo groups. for 3 of the 5 definitions of pain response, patients experienced significantly less pain at speculum insertion with sucrose than with placebo. although mean recovery time was shorter in the sucrose group (102 seconds), there was neither a significant difference between the groups (10% glucose, 121 seconds; 30% glucose, 109 seconds; control group, 132 seconds [p =.09]), nor was there a difference in maximum heart rate and percent change in heart rate at 1, 2, and 3 minutes after heel prick (p =.14, p =.05, p = there was no overall treatment effect when using an oral sucrose solution before bladder catheterization in infants younger than 90 days of age. neither water nor lactose were effective during or after blood collection. we found that pain scores during intramuscular injection did not differ significantly between the sucrose and placebo groups for newborns of diabetic or nondiabetic mothers (newborns of nondiabetic mothers: mean difference facial grimacing scores were lower in the sucrose group compared with those in the liposomal lidocaine group (mean difference: -27 [95% confidence interval (ci): -36 to -19; p < .001) and for the sucrose plus liposomal lidocaine group compared with those in the liposomal lidocaine group (mean difference: -23 infants randomised to pacifiers scored lower than those without pacifiers (p = 0.003). median premature infant pain profile scores were lower in the breastfeeding group (3.0) than in the sucrose-solution group (8.5), and the median group difference was -5.0. both sucrose groups had lower pipp scores (single sucrose pain scores, 6.8-8.2, p = 0.07; repeated sucrose pain scores, 5.3-6. 2, p < 0.01) than water (pain scores 7.9-9.1), and in the last block, the repeated dose had lower scores than the single dose (6.2 vs. 8. 2, p < 0.05). repeated use of sucrose analgesia in infants <31 weeks' pca may put infants at risk for poorer neurobehavioral development and physiologic outcomes. sucrose gave significant (p < .001) the combination of sucrose and emla cream revealed a higher analgesic effect than sucrose alone during venipuncture in these preterm infants. there was no difference in mean gestational age at birth, mean birth weight or corrected gestational age at first examination between both groups. insertion of a feeding tube in preterm infants leads to a measurable degree of pain and discomfort, according to the premature infant pain profile assessment tool. there were significant reductions in crying time, duration of the first cry and tachycardia, time needed for return to baseline heart rate, and the average and 1- and 5-minute nfcs scores in the hindmilk group when compared with the distilled water group. sucrose on a pacifier was far more analgesic than water on a pacifier for infants in the gomco group. there was a significant reduction in crying time and pain score 3 minutes after the painful stimulus in all groups compared with the controls. there were significantly fewer sg neonates crying during a (ass.2), p (ass.2 and ass.4), and d (ass.3). the time spent crying was reduced in the group treated with the sweetest solution (s24, n = 8, mean = 19.1 s).| 2011 by the american academy of pediatrics term newborns during heel stick 40 infants were included in the study sick hospitalized infants 34 newborns patients studied were 16 preterm infants; birth weight, 900-1900 g; gestational wk, 27-34; corrected postmenstrual age at time of investigation, 33-36 wk thirty-three preterm neonates university teaching hospital, general care nursery term newborns neonates born at < or = 30 weeks' gestation 150 term newborns undergoing eighty-three patients were enrolled; 40 newborns during and after blood collection for phenylketonuria evaluation neonatal unit of a public hospital in northern italy on 101 term neonates undergoing 113 infants whose heels were pricked for the guthrie test were included in the study newborns of diabetic mothers 104 stable term neonates healthy newborns hospitalised in the gynaecology clinics of trabzon delivery and children's diseases hospital between february 2007-january 2008 newborn infants undergoing painful procedures preterm infants (n = 85) between 25-34 weeks post-conceptual age (pca) and 2-10 days postnatal age (pna sixty infants 59 newborn infants at university college hospital (london, uk newborn infants preterms prior to heel prick ambulatory care clinic of a large tertiary care center 100 healthy, full term newborn infants being screened for inborn errors of metabolism 240 newborns (120 from diabetic mothers, 120 from nondiabetic mothers healthy term newborns 23 neonates with a gestational age below 33 weeks of gestation and older than 8 days of life a consecutive sample of 285 infants 150 term infants, in three randomised groups, from the maternity unit of our hospital for a period of three months healthy premature infants healthy newborns (n= 142 twenty-three infants were studied, with 12 receiving sucrose and 11 receiving neonates preterm infants older infants neonates younger than 31 weeks' postconceptional age preterm infants undergoing screening for retinopathy of prematurity 50 newborns term neonates receiving heel lance infants at risk of retinopathy of prematurity population of newborns when cuddled and comforted during heel prick for diagnosis of phenylketonuria infants undergoing screening for retinopathy of prematurity newborns who had blood sampling by heel stick a total of 128 infants were included very low birth weight (vlbw) neonates infants born <31 weeks of gestational age and recruited within 48 h of life healthy infants (n = 102 forty infants <32 weeks gestation or <1500 g birth weight, in two neonatal units infants infants during immunization injections preterm and acutely ill term neonates who are hospitalized in a neonatal intensive care unit preterm neonates in neonatal intensive care units newborns (>or= 36 weeks gestation) of diabetic mothers and nondiabetic mothers preterm neonates undergo numerous painful procedures in the neonatal intensive care unit (nicu many infants admitted to hospital undergo repeated invasive procedures during neonatal heel prick 60 healthy infants of gestational age 37-42 weeks and postnatal age 1-6 days 2010 blackwell publishing ltd full term infants infants with prior bladder catheterization, previous painful procedures that day, or neurological or genital abnormalities fourteen study infants were swaddled, held, and given 24% sucrose solution during the examination 190 neonates were stratified by gestational age preterm infants who cannot feed by themselves healthy term newborns during heel prick blood sampling 76 children (37 in the s group, 39 in the s+e group premature infants undergoing eye examination for rop 107 preterm neonates who were born at <31 weeks' postconceptional age (pca) entered this double-blind, randomized, controlled trial within 48 hours of birth at 3 level iii university-affiliated neonatal intensive care units in canada, and 103 completed the study human newborns infants undergoing bladder catheterization in an emergency department (ed) population 24 preterm infants with postmenstrual age 28 to 32 weeks' who were in stable condition very low birth weight neonates one hundred nineteen full-term male, normal birth weight neonates, 12 hours old or older infants younger than 90 days of age neonatal intermediate care unit in a level 3 perinatal center preterm neonates with no side effects thirty-three neonates were included, representing 265 injections fifteen infants of 32-34 weeks postmenstrual age for congenital disorders 84 newborns undergoing heelstick 32 infants about to undergo rop screening exams infants younger than 37 weeks' gestational age during 1 routine venipuncture for blood sampling newborns during heel prick newborns undergoing various medical procedures within 2 days of birth 12 healthy preterm infants with a median gestational age of 32 wk and a median postnatal age of 14 d 120 newborns in turkey preterm infants, a sample of 28 healthy neonates (15m, 13f; gestational age at procedure less than 37 weeks) who were having routine blood drawn by arm venipuncture was studied 40 infants undergoing primary eye examination for rop screening infants < or = 90 days of age and requiring bladder catheterization preterm newborns retinopathy of prematurity premature infants using intraoral sucrose healthy neonates term neonates 330 healthy term newborns premature infants during eye examinations for retinopathy of prematurity preterm and term neonates eighty healthy, term, newborn male infants scheduled for routine neonatal circumcision preterm neonates undergoing routine heelstick procedure in the neonatal intensive care unit (nicu 29 infants healthy, term, newborn humans undergoing the painful, routine, procedure of heel lance and blood collection 30 preterm infants eighty-five normally developing newborn infants were studied with a mean gestational age of 39.4 weeks on the 2nd or 3rd day of life healthy normal babies 36 preterm infants (mean 31 weeks gestational age, range 27 to 36 weeks 52 infants received either newborns undergoing painful medical procedures 122 vlbw neonates using the premature infant pain profile following four randomly ordered interventions during consecutive routine heel lance procedures newborns newborns of nondiabetic mothers 30 stable preterm infants who underwent initial rop screening examinations infants (n = 48) in the first week of life with a mean gestational age of 31 weeks received 20 stable preterm infants who required nasogastric tube insertion for feeding, randomised on 51 occasions infants (age range, 2 weeks to 18 months preterm neonates healthy newborns requiring blood test by a heel-prick procedure and compare different pain management methods sixty-six preterm infants infants younger than 90 days of age who require bladder catheterization in the pediatric emergency department preterm and acutely ill term neonates 100 healthy full-term infants institutions caring for sick babies
benefit of ethyl-epa progression of early huntington disease functional checklist of the uhdrs chorea peak oxygen uptake motor function unified huntington's disease rating scale (uhdrs rate of deterioration tms-4 total motor score 4 subscale (tms-4 tfc functional, neuromuscular, and cognitive status neurologic symptoms total functional capacity quantified neurological examination and a set of cognitive and motor tests behavioral severity and frequency muscle functional capacity total functional capacity (tfc) score neurologic and neuropsychiatric symptoms huntington's disease activities of daily living scale (adl-an index of functional status) and the quantified neurologic examination (qne maximal static torque neurologic and neuropsychologic symptoms cognitive functioning, bimanual coordination ability, and general motor function (total motor scale, uhdrs symptomatic improvement adverse events|total functional capacity was not favorably influenced by baclofen treatment. scores on the functional checklist of the uhdrs (p < 0.05), maximal static torque (p < 0.05), and peak oxygen uptake (p < 0.05) decreased from the start to the end of the study, independent of the treatment received. treatment with d-alpha-tocopherol had no effect on neurologic and neuropsychiatric symptoms in the treatment group overall. both the lamotrigine and the placebo group deteriorated significantly on the tfc, in the lamotrigine group by 1.89 and the placebo group by 2.11 points. there were no significant differences between groups on the primary outcome measures of the huntington's disease activities of daily living scale (adl-an index of functional status) and the quantified neurologic examination (qne). in the pp cohort, ethyl-epa proved better than placebo on the chi2 test on tms-4 (p < 0.05), but missed significance on ancova (p = 0.06).|patients with high vs low cag repeats early huntington's disease 135 patients with hd 73 patients with huntington's disease patients with early huntington's disease (hd huntington disease huntington disease (hd 41 patients with hd (stage i through iii 64 patients with motor signs of less than 5 years' duration who were randomly assigned to either sixty patients with early hd huntington's disease huntington's disease (hd fifty-five patients (28 on lamotrigine, 27 on ninety-one patients completed the study one hundred patients with clinically diagnosed huntington's disease (hd 121 patients completed 12 months, and 83 did so without protocol violations (pp cohort healthy subjects and patients with neuromuscular disease (5 g/day
regional lymph node invasion neutrophil recovery median time to progression and median overall survival time life-threatening or fatal toxicity partial remission tumor response to chemotherapy peripheral blood stem cells (pbscs median hospital stay total 5-year survival rate growth of metastatic nodules progressive disease patient died of infection rate of trm 2-year event free survival (efs) rate median time to wbc recovery median os haematological complications, no who grade iii-iv complications complete remission (cr) and three in partial remission (pr recurrences or deaths absolute neutrophil granulocyte count prolonged infection major nonhematologic toxic effects were mucositis, nutritional impairment, hypotension, and peripheral neuropathy progression-free survival reversible grade 4 myelosuppression died of progressive disease and one child died of therapy-associated complications symptoms of acute appendicitis median progression-free survival abdominal distention, vague abdominal pain, and vomiting early discontinuation of therapy due to toxicities rhabdomyoblastic differentiation hematopoietic recovery time food intolerance interval between hdct1 and hdct2 toxicity, six died of disease partial remission (pr) and stable disease mean di efficacy and toxicity 5-year survival and 5-year event-free survival estimates hemopoietic recovery delayed hematologic recovery 5-year progression-free survival (pfs) and overall survival (os karnofsky index > 80%, r (0) resection and first-line asct survival sustained complete remission (cr frequency of relapse delayed-type hypersensitivity responses toxic death haematological and gastrointestinal toxicities overall survival (os peripheral blood stem cells (pbsc complete response (cr complete remission (cr pbsc leukopenia hematologic recovery cr rate severe toxicity 2-year efs rate probability of disease-free survival antitumor effect multiple organ toxicity, including venoocclusive disease, refractory thrombocytopenia, and hypertension toxicity partial response and partial response hematopoietic toxicity median pfs overall survival recurrence hepatic veno-occlusive disease, no serious complications ttp and survival rates survival benefit local recurrence and metastasis rate toxicity of and event-free survival partial response platelet transfusion independence feasibility, safety and efficacy rate of relapse in site of distant organs desmoplastic round cell tumor (dsct maximum plasma concentration (cmax) and area under the curve (auc multiple lung metastases median time to progression (ttp) and overall survival severe mucositis and erythema with superficial peeling glomerular filtration rate disease-free survival mortality (trm median number of granulocyte-macrophage colony forming units in the reinfused pbsc peripheral leukocyte count time to disease progression side effects response durations median pbsc collection total 2-year survival rate median overall survival (os disease recurrence or progression objective tumor regression median survival partial remission (pr 5-year survival rates complete remission synovial sarcoma (ss mortality excessive renal and gastrointestinal toxicity hematologic recovery in hdct2 died of toxicity|five patients received local radiotherapy: three were not assessable for response, but in two patients, antitumor effect was evident. complications related to the treatment were limited to one patient who developed hepatic veno-occlusive disease, no serious complications were seen in the other patients. there were no recurrences or deaths beyond 10 months after diagnosis. two years after primary diagnosis, metastases were found in the lung, trunk, gluteus region, upper extremities and brain. desmoplastic small round cell tumor (dsrct) is a rare, highly aggressive malignancy with distinctive histologic and immunohistochemical features occurring in a young population with a male predominance. after high-dose chemotherapy, no complete response conversion was obtained and ews-wt1 fusion transcript detection was positive in the peripheral blood during follow-up in all patients. median progression-free survival was 19.1 months (range: 0-121) for all patients, and 48.8 months (range: 3-121) for 12 patients with ned. no treatment-related mortality occurred and grade 3 or 4 toxicity was clinically tolerable. metastatic seeding to the omentum was most common, followed by spread of disease to liver, distant lymph nodes, lung, and occasionally to scrotum or to ovary. the treatment was reasonably well tolerated and both patients are alive with no evidence of disease 52 months and 65 months after the primary diagnosis. no side effects were observed. neuroleptic malignant syndrome (nms) is a rare disorder characterized by hyperthermia, elevated creatine phosphokinase, extrapyramidal effects, autonomic instability, altered level of consciousness and leukocytosis associated with neuroleptic and other psychotropic medications. in these five cases a partial response was observed in two of the three who had measurable response parameters, but all of them died because of disease progression in a short period of time. to increase the dose intensity (di) of chemotherapy for pediatric patients with metastatic sarcomas, including the ewing sarcoma family of tumors (esft) and rhabdomyosarcoma (rms), the authors tested the feasibility of an intensive regimen supported by granulocyte-colony stimulating factor (g-csf) and peripheral blood stem cells (pbsc). we report a very rapid engraftment after reinfusion of bone marrow cells derived from 'g-csf-primed bone marrow' in a small child. median time to wbc recovery (greater than or equal to 1,000/microl) was 13 days post-abmt (range, nine to 22 days) and to a platelet count of greater than or equal to 50,000/microl, 22 days (range, 13 to 83 days). c-reactive protein in neutropenic pts as an indicator for infection after tecc chemotherapy was detectable after 36 of 39 chemotherapy courses leading to further supportive therapy (median 10.4 mg/dl, range 1.1-28.3 mg/dl; sd 6.67 mg/dl). the ovarian involvement was unilateral in the first patient and bilateral in the second with tumor size ranging from 9 to 11 cm. further dose escalation was precluded by the development of multiple organ toxicity, including venoocclusive disease, refractory thrombocytopenia, and hypertension. reversible grade 4 myelosuppression was the most common toxicity. however, ttp and survival rates remained poor. the progression-free survival was similar in three types of transplants (57% abmt, 43% pbsct vs. 50% abmt + pbsct). relapse-free intervals until the 1st, 2nd and 3rd relapses were 40, 19 and 22 months, respectively. at a median follow-up of 100.6 months after asct, 11 patients are alive, with nine in sustained complete remission (cr) and each one in partial remission (pr) and stable disease. the response continued to improve with immunotherapy. malignant rhabdoid tumor (mrt) is a rare and highly aggressive tumor that primarily occurs in very young children. the child remains in complete remission at 36 months after completion of treatment. she remains alive and recurrence-free 7 years following the diagnosis of her second intracranial malignancy. treatment was well tolerated and the patient remains in complete remission at 36+ months. cytogenetic study showed translocation (9;22)(q34;q11). in some patients pbsc failed to influence engraftment and the use of combined chemotherapy and growth factor priming for pbsc collection may give improved results. overall survival (os) was 63% (95% ci: 47-79%) at 1 year and 33% (95% ci: 16-50%) at 3 years. the uniform survival achieved in our series indicates potential benefit for the combination of dose-intensive multiagent chemotherapy, local irradiation, and aggressive surgical approach in this disease. high-dose chemotherapy with autologous stem cell support reduced the tumor burden and led to a symptom-free interval of 6 months. the diagnosis of an intra-abdominal malignancy, most commonly a dsrct, should be considered in the presence of an umbilical mass in a child. a response exceeding 50% was observed in 6/18 patients (response rate 33%). he was diagnosed with a large peri-rectal mass and bulky metastases to the peritoneum, omentum and liver. this experience confirms that dsrct may be considered a chemosensitive tumour, highly aggressive, with short-lasting response to chemotherapy. the ews-wt1 transcript was detected in six of seven tumors tested. reverse transcriptase-polymerase chain reaction revealed the syt/ssx2 fusion transcript of the synovial sarcoma t(x;18) chromosomal rearrangement. median os was 23.7 months (range 12-34) vs 10.8 months (range 0-39), respectively. eighteen of 49 patients survive event-free 22+ to 55+ months (median, 33+) after transplantation, including nine of 16 treated before recurrence and nine of 33 treated after recurrence. topotecan appears to be relatively unaffected by the most common multidrug resistance mechanisms, may potentiate cytotoxicity of alkylators, has good penetration into the central nervous system, is active against a variety of neoplasms, and has myelosuppression as its paramount toxicity. the total 5-year survival rate of patients with ewing's sarcoma is 65.6%, the total 2-year survival rate of patients with soft tissue sarcomas is 62.2%, and the total 2-year survival rate of children with osteosarcoma is 76%. the probability of disease-free survival at 2 years after hdct2 in the shg and dhg were 66.7 and 25.0%, respectively (p-value=0.031). the disease-free survival of children with malignant disorders has increased impressively over the last three decades due to better understanding of tumour biology and the resultant improvement in diagnosis and therapy. radical surgical excision, radiotherapy and peripheral blood stem cell transplantation does not seem to improve prognosis significantly. pharmacokinetic evaluation of melphalan in 20 patients revealed a dose-related increase in maximum plasma concentration (cmax) and area under the curve (auc). haematological and gastrointestinal toxicities were severe. it is characterized by chromosomal translocation t(x;18)(p11.2;q11.2), which results in the fusion of the gene syt on chromosome 18 with ssx genes on chromosome x. heterogeneity within ss fusion junctions is rare.|sixteen consecutive stem cell transplantations (sct three patients with dsct, and reviewed the clinical experience with this newly described tumor as reported in the literature five patients with children and adolescents with metastatic sarcomas children with advanced and relapsed solid tumours, such as brain tumour, alveolar rhabdomyosarcoma, ewing's sarcoma, or neuroblastoma adult patients with advanced desmoplastic small round-cell tumour responders included eight of nine evaluable patients with breast carcinoma, two of five with melanoma, two of two with sarcoma, and four of four with colon carcinoma a 22-year-old woman with a newly detected chondroid liposarcoma located in the iliac muscle was diagnosed as having bilateral pulmonary embolism thirty-eight patients with bone (n = 17) and soft tissue sarcomas (n = 21) were included five patients had renal primary tumors, and 9 patients had extrarenal tumors cns malignant rhabdoid tumors 49 patients with recurrent or poor-prognosis cns malignancies with high-dose chemotherapy regimens followed by cardiac metastases in malignant fibrous histiocytoma 2 young women 10 desmoplastic small round-cell tumour patients patients with high-risk solid tumors of childhood ten patients had pelvic osteosarcomas (os), 6 had malignant fibrous histiocytomas, 5 had metastatic os, and 16 had miscellaneous histologies young population with a male predominance patients with high-risk pediatric sarcomas patients with metastatic soft tissue sarcomas consecutive patients with mrt at childrens hospital los angeles over the 20 years from 1983 to 2003 children with malignant disorders two children with primary cns rhabdoid tumour children with mrt patients with metastatic sarcomas patients with recurrent soft tissue sarcoma (sts pediatric patients with high-risk sarcomas the median age was 21 years (range 6-38 years) with 78 male patients and 23 female patients enrolled 34 soft tissue sarcoma patients with advanced and/or metastatic disease patients with locally advanced or metastatic/recurrent soft tissue and ewing's sarcoma (ews 11 pediatric patients with dsrct at our institution twenty-six adults, ages 27 to 60, with refractory metastatic solid tumors ewing sarcoma family of tumors, 9 patients had rhabdomyosarcoma, and 4 patients had unresectable desmoplastic small round cell tumors 20 patients copyright 2004 american cancer society extracranial malignant rhabdoid tumors in childhood patients with metastatic or relapsed es and dsrct patients with a diagnosis of ewing's sarcoma (es) or desmoplastic small round cell tumor (dsrct patients with recurrent and high-risk pediatric brain tumors two young males with intra-abdominal dsrct at the age of 28, a 33-year-old male was diagnosed with malignant fibrous histiocytoma (mfh) with a primary lesion in the right maxillary sinus 9-year-old boy with a high-grade spindle cell sarcoma sarcoma patients certain patients with high-risk cns malignancies children and young adults nine (82%) patients had metastatic disease five children with diffuse idsrct, managed with aggressive chemotherapy, surgery, radiotherapy and peripheral blood stem cell transplantation three patients also had autologous bmt 35 consecutive adult patients with poor-risk es or rhabdomyosarcoma (n = 11) and sts (n = 24 children nine patients (pts) with soft tissue sarcoma refractory to conventional therapy (incomplete response or relapse) intensified transplanted 36 patients on two consecutive protocols with a variety of histological diagnoses 11 patients with neuroblastoma 11 patients aged 7-17 years patients with high-risk tumours pediatric malignant mesenchymal tumors children with advanced stage or chemoresistant solid tumours three patients with inoperable tumor on admission were submitted initially to 11 children aged between 2.8 and 17.2 years with brain tumours, soft tissue sarcomas, germ-cell tumours and neuroblastomas were analysed over a 2-year-period median age at diagnosis was 14 years (range 5-21 years nineteen patients had medulloblastomas, 12 had glial tumors thirty children younger patients with a good performance status in partial or complete remission male adolescents and young adults intracranial fibrosarcoma arising 5 years after chemotherapy alone for glioblastoma multiforme in a child eleven of 14 patients had stage iii or iv disease at diagnosis twenty-three children and adolescents with metastatic sarcomas patients who had received prior chemotherapy before hdct1 adult patients with high-risk or advanced ewing and soft tissue sarcoma three adolescent boys with dsct chronic myelocytic leukemia (cml patients with high-risk pediatric solid tumors copyright 2002 american cancer society between august 1994 and march 1998, we evaluated three consecutive patients with dsrct at children's hospital and regional medical center, seattle, washington children with malignant tumors of the musculoskeletal system such patients pediatric patients with metastatic sarcomas, including the ewing sarcoma family of tumors (esft) and rhabdomyosarcoma (rms pediatric patients with metastatic sarcomas patient with a primary mrt of the orbit who received a 14-year-old male presented with an umbilical mass, which was found to be a metastatic lesion of a desmoplastic small round cell tumor (dsrct) of the abdomen children with advanced solid tumors 2 cases of desmoplastic small round cell tumor (dsrct) involving the ovaries in young women patients with good renal function patients with high-risk or metastatic/recurrent sarcoma, with some patients achieving long-term pfs and os adult patients with osteosarcomas and variants with a poor prognosis recurrent soft tissue sarcoma 33-year-old woman nine patients with high grade metastatic sarcomas high-risk sarcomas patients with localized extra-abdominal disease a 26-year-old man presented with bulky abdominal-pelvic disease patients with localized disease and complete surgical resection high-grade metastatic sarcomas metastatic gastric leiomyosarcoma neuroleptic malignant syndrome (nms two patients with recurrent sts who were treated with tandem hdc supported by autologous peripheral blood stem cell transplantation (pbsct patients with metastatic soft tissue sarcoma chronic myelocytic leukemia after chemotherapy for malignant fibrous histiocytoma patients receiving autotransplants who developed nms synovial sarcoma of the neck in a child cohort included 1 female and 10 male patients eleven of 24 patients (median age, 14.9 years) had fourteen children were diagnosed with mrt over the 20-year study period patients who responded to the protocols were eligible for myeloablative consolidation with autologous stem cell support 2006 patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis patients with advanced sarcoma synovial sarcoma in an 11-year-old japanese girl relapsed 5 months after autologous stem cell transplantation during the last decade five patients, four males and one female (mean age 9.6 years), with diffuse idsrct were managed in our department prospective high-risk sarcoma (hirisa sarcoma patients treated with this therapy option children with solid tumours patients with high risk soft tissue sarcoma (sts 10-year-old boy with syt-ssx1 positive left parapharyngeal ss, resistant to front-line vaia chemotherapy, who obtained a good partial response by patients with mrt synovial sarcoma patients with malignant rhabdoid tumour charts of 5 patients (4 males, mean age of 11 years) treated between 2000 and 2007 were reviewed patients with advanced disease stage twenty-nine patients were treated with 31 courses of high-dose combination patients had surgery with the intent of removing all disease 10 patients with refractory bone and soft tissue sarcoma (2 patients with primitive neuroectodermal tumor, 4 patients with ewing's sarcoma, 3 patients with synovial sarcoma and one patient with osteosarcoma n = 17), stable disease (n = 3) and progressive disease (pd; n = 6 high-risk ewing's sarcoma and other pediatric solid tumors child with disseminated fibrosarcoma child diagnosed with glioblastoma multiforme during infancy and successfully treated with the 'eight-in-one' chemotherapy regimen, who developed an intracranial fibrosarcoma 5 years later 23 patients between 1986 and 1998, 18 patients, previously treated with conventional therapy for metastatic or refractory mmt, entered the study n = 8), ascites or pleural effusion (n = 7), and metastases to liver (n = 5), lungs (n = 4), distant lymph nodes (n = 3), spleen (n = 2), and skeleton (n = 2 19-year-old man with poor prognosis intra-abdominal desmoplastic small round cell tumor between december 1994 and january 2001, 37 patients (20 males and 17 females) with a median age of 38 years (range, 18-63 years) entered the study patients with locally advanced or metastatic sarcoma 2006 american cancer society thirteen patients were enrolled onto this study
basilar skull fractures meningitis rates of meningitis patient's glasgow coma scale score, sex, and age, as well as for an intradural location of air, air volume, presence of cerebrospinal fluid (csf) rhinorrhea or csf otorrhea, radiological sign of a skull base fracture, or intracranial hemorrhage frequency of asymptomatic bacteriuria frequency of extra-neurological infections and of asymptomatic pulmonary bacterial colonization incidence of meningitis overall rate of meningitis overall incidence of infectious complications|the results of this study do not substantiate the efficacy of ceftriaxone used in the prevention of meningitis in patients with traumatic pneumocephalus after mild head injury or in any specific subgroup of these patients. there was no significant difference between the ceftriaxone group and the ampicillin/sulphadiazine group. the efficacy of chemoprophylaxis in the treatment of basilar skull fractures was studied in 129 patients over a 2-year period; antibiotics were found ineffective in preventing central nervous system infections, and in some cases may have proved harmful. the frequency of extra-neurological infections and of asymptomatic pulmonary bacterial colonization was similar in both groups, but frequency of asymptomatic bacteriuria was higher in the placebo-treated patients.|meningitis after traumatic pneumocephalus group a = 46 patients) or 109 patients open and basilar fractures of the skull 109 patients with mild head injury and traumatic pneumocephalus 157 patients 52 patients was studied, 26 in each treatment group patients with rhinorrhea or otorrhea patients with injury to the head and face which had caused rhinorrhea or otorrhea patients with traumatic pneumocephalus after mild head injury or in any specific subgroup of these patients patients with acute traumatic pneumocephalus 129 patients over a 2-year period; antibiotics
survival rates infection rate severe infections incidence of post-operative bacterial infections white blood cell count biopsy-proven rejection aerobic gram-positive flora, anaerobes, and yeast graft loss length of stay gastrointestinal intolerance and noncompliance median peak white blood cell count mean number of postoperative infectious episodes infection rate at sbd key sites (abdomen, bloodstream, surgical wound, and lungs serious adverse events rates of infection infection, rejection, or survival total costs mean number of postoperative bacterial and fungal infections duration of antibiotic therapy biopsy-proven rejection and nosocomial pneumonias bacterial infection rates infection and rejection rates of infection, death, and charges for medical care overall rates of bacterial and/or yeast infections death portal and systemic endotoxemia, colonization and infection rates, severity of illness (organ system failures, acute physiology and chronic health evaluation ii score, therapeutic intervention scoring system score), antibiotic costs, and hospital survival rates stool colonization thirty-day infection rate, length of hospital stay, duration of antibiotic therapy, non-infectious complications and side effects of enteral nutrition tolerated charges for medical care incidence of infection sepsis episodes, sepsis-related deaths, and rejection pulmonary infections and enteric, aerobic, and gram-negative bacillary colonization postoperative infection microbiologically-documented infection, biopsy-proven rejection, number of treatments for rejection, length of stay in the intensive care unit and hospital, graft survival, death, and adverse events nosocomial pneumonias|biopsy-proven rejection and nosocomial pneumonias were more common in patients treated with g-csf compared with those taking the placebo. infections involving gram-negative aerobic bacteria and candida species were significantly less frequent in patients receiving sdd (p <.001 and p <.05). the incidence of post-operative bacterial infections was significantly reduced; being 48% with only fibers and 3% with lab and fibers. the financial costs of the selective decontamination regimen outweighed the advantages gained from an associated reduction in antibiotic usage. rates of infection (32.4 vs. 27.9%), death (5.4 vs. 4.7%), or charges for medical care (median $194,000 vs. $163,000) were not reduced in patients assigned to sbd. overall rates of bacterial and/or yeast infections were nearly equal among control patients (42%) and sbd patients (39%).|43 patients adult patients undergoing elective liver transplantation: 26 patients receiving sdd and 29 patients receiving a bacterial infections frequently occur early after liver transplantation 66 liver transplant recipients patients undergoing sdd thirty-two patients were randomized to standard treatment (control group) and 27 patients liver transplant recipients patients undergoing elective orthotopic liver transplantation critically ill patients fifty-nine adult patients were recruited into the study and underwent liver transplantation patients undergoing elective liver transplantation liver transplant patients eighty candidates for liver transplantation patients awaiting cadaver liver transplants 69 patients randomly assigned to receive liver transplantation patients undergoing liver transplantation adult patients with a united network organ sharing classification of 1 or 2 patients undergoing elective transplantation of the liver
multiple positive findings abnormal physical examination yield of explanatory x-ray findings tenderness low back pain (lbp radiological interval changes contusion or abrasion lumbar spine degeneration|the overall prevalence of fracture, possible infection, possible tumour was low in our study population: 4, 0.8 and 0.7%, respectively. a total of 108 patients had radiographs (48%), with a total of seven fractures (6% of radiographs). radiation exposure and medical cost of noncontributory studies may be substantially reduced by judicious consideration of the potential diagnostic yield of the examination and by careful selection of repeated or follow-up studies. despite the low prevalence of serious pathology, most patients (80.4%) had at least 1 red flag (median 2, interquartile range 1-3). four clinical findings were present in significantly different frequencies between the positive group and others: an abnormal physical examination (90% vs 61.5%, respectively) (p less than .0001), tenderness (72.5% vs 41.2%) (p less than .0005), multiple positive findings (42.5% vs 20.7%) (p less than .005), and contusion or abrasion (15% vs 2.7%) (p less than .0005). the yield of explanatory x-ray findings was over three times greater among patients with indications for radiography than among those without.|low back pain patients presenting to primary care settings with acute low back pain older patients patients older than 55 years of age 225 consecutive patients presenting in a 6-month period with acute back pain were studied 108 patients had radiographs (48%), with a total of seven fractures (6% of radiographs back pain presenting to accident and emergency departments patients presenting to a primary care provider with back pain, previously undiagnosed serious pathology is rare patients with fractures had a history of direct trauma primary care 1,095 lumbar radiological examinations in 871 patients patients referred with low back pain by general practitioners 621 walk-in patients with lbp patients' histories and physical examination findings were correlated with four groups of radiological findings: (1) radiologically normal, (2) incidental findings unrelated to patients' complaints, (3) diagnostic films compatible with symptoms, and (4) radiological findings of questionable clinical significance 1,172 consecutive patients receiving primary care for acute low back pain was recruited from primary care clinics in sydney, australia 552 consecutive emergency department patients for whom lumbar spine x-rays were ordered 2007 radiographic reports of patients referred with low back pain for lumbar spine radiography to a large radiology department was performed
m. avium complex infection cell count elevation in alkaline phosphatase, and hospitalization m. avium complex disease or bacterial pneumonia bacteremia episodes of non-mac bacterial infection median cd4+ cell count median prior nadir cd4+ cell count ranges of minimal inhibitory concentrations signs and symptoms associated with disseminated m. avium complex infection, adverse events, hospitalization, and survival cd4+ cell count frequency of more severe adverse events incidence of taste perversion safety and efficacy rate of progression of hiv disease nor the mortality rate hiv rna value episodes of confirmed m. avium complex disease survival differences efficacy and safety rna levels mac infection followed by death hemoglobin level overall survival frequency of disseminated m. avium complex infection bacterial pneumonia rectal disorders disseminated mac infection plasma hiv-1 delayed fatigue, fever, decline in the karnofsky performance score mac infection risk of mac disease rate of m. avium complex infection cd4 substantial morbidity and reduces survival mortality cd4 lymphocyte count adverse effects time to death or number of deaths m. avium complex bacteremia adverse events mac disease|reduction in cd4 lymphocyte count to < 50/mm3 is a significant predictor of the development of disseminated mac infection. during follow-up over a median period of 12 months, there were no episodes of confirmed m. avium complex disease in either group (95 percent confidence interval for the rate of disease in each group, 0 to 1.5 episodes per 100 person-years). the distribution of minimal inhibitory concentrations of rifabutin among the isolates of m. avium complex did not differ significantly between the treatment groups. for deaths due to all causes, there was no difference in time to death or number of deaths between the two groups. m. avium complex infection developed in 19 of the 333 patients (6 percent) assigned to clarithromycin and in 53 of the 334 (16 percent) assigned to placebo (adjusted hazard ratio, 0.31; 95 percent confidence interval, 0.18 to 0.53; p<0.001). combination therapy was not more effective than clarithromycin (rr, 0.79; 95% ci, 0.48-1.31; p=.36). plasma hiv-1|29 university-based clinical centers in the united states patients with aids patients with human immunodeficiency virus (hiv) disease patients with advanced human immunodeficiency virus (hiv) infection patients with hiv disease 643 hiv-1-infected patients with a previous cd4(+) cell count less than 0.05 x 10(9) cells/l and a sustained increase to greater than 0.10 patients with aids and a cd4 cell count of < 100/mm3 subjects were 110 patients with a first episode of pneumocystis carinii pneumonia 2-4 months before enrollment or cd4 lymphocyte counts < or = 100/mm3 patients with aids and cd4 counts < or = 200 per cubic millimeter patients with the acquired immunodeficiency syndrome (aids patients with aids in the united states and europe patients with advanced acquired immunodeficiency syndrome 1178 patients with aids who had < or =100 cd4 t cells/microl adults with hiv infection who experience increases in cd4 patients with advanced stages of the acquired immunodeficiency syndrome (aids patients with antiretroviral therapy patients with increased cd4 patients with advanced aids 19 patients assigned to receive seventeen patients died: 9 in the treatment group and 8 receiving no treatment 520 patients entered the study; the hiv-infected patients whose cd4+ cell counts had increased from less than 50 to more than 100 per cubic millimeter in response to antiretroviral therapy hiv-infected patients who have a response to antiretroviral therapy
peak flow lying and standing blood pressures peripheral blood flow peripheral arterial circulation calf blood flow safety and efficacy tolerated and the side-effects cardiovascular and gastrointestinal complaints, headaches, and sleep and sexual disorders blood pressures drug fever systolic, diastolic and mean arterial blood pressures lying diastolic pressure normotension [diastolic blood pressure (dbp blood pressure, arterial blood flow and peripheral resistance rate of normalization calf blood flow and vascular resistance lowering supine and standing systolic and diastolic blood pressure heart rate, blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance psychometric performance efficacy and adverse reactions antihypertensive efficacy blood pressure, impaired card-sorting time and digital symbol substitution score blood pressure vascular resistance arterial blood flow blood pressure and peripheral resistance adverse effects supine and standing blood pressure and heart rate blood pressure and in peripheral resistance mean supine blood pressure hyperaemic flow|there were no significant differences in blood pressures as measured with the patients lying down; however, with the patients standing the systolic, diastolic and mean arterial blood pressures were significantly lower (p < 0.05) after treatment with alpha-methyldopa or the combination product. methyldopa (250 mg tid) for 14 days significantly reduced blood pressure, impaired card-sorting time and digital symbol substitution score, and caused trends for impairment of other psychometric tests. the mean supine blood pressure was not significantly affected by placebo. no acute effect was observed on the placebo or on indapamide: the latter induced a decrease in blood pressure and in peripheral resistance along with an increase in arterial blood flow during long-term treatment after four weeks of therapy. thic combination had similar effects to those of the combination of methyldopa with the cardioselective agent practolol except that it reduced lying diastolic pressure further. the peak flow was reduced by 20% (p greater than 0.01) with metoprolol and by 15% with methyldopa below the initial level and by 17% and by 12% below the level recorded on placebo, respectively. the most common adverse reactions reported were cardiovascular and gastrointestinal complaints, headaches, and sleep and sexual disorders, mostly by patients taking methyldopa.|24 carefully selected patients with moderate hypertension (mean initial lying blood pressure 189/117 mm hg 16 patients with mild to moderate hypertension twenty-two white men and two white women with uncomplicated essential hypertension 368 men, aged 40 to 65 years, with mild-to-moderate essential hypertension intermittent claudication hypertension eighteen patients with hypertension twenty-four patients with arterial hypertension, without target organ damage 14 hypertensive patients with intermittent claudication moderate hypertension hypertensive patients with concomitant lesions
antipsychotic effect negative symptoms d2 occupancies positive psychotic symptoms striatal and extrastriatal occupancies clinical response, side effects, striatal ([11c]-raclopride-positron emission tomography (pet)), and extrastriatal ([11c]-flb 457-pet) d2 receptors|the antipsychotic effect was highly significant and clinically relevant under both risperidone and clozapine. striatal d2 occupancy predicted response in positive psychotic symptoms (r=0.62, p=0.01), but not for negative symptoms (r=0.2, p=0.5).|schizophrenic patients with acute symptoms 59 patients with paranoid hallucinatory psychoses fourteen patients with recent onset psychosis
opportunistic superinfections (aspergillus fumigatus and pneumocystis carinii incidence of cmv pneumonia incidence of cmv excretion graft loss serious cmv-associated disease cmv viremia or pneumonitis incidence of viremia moderately severe cmv infections cmv-related death cmv viremia reactivation infections attack rate of cmv pneumonitis rate of cmv disease cmv disease slightly later incidence of positive shell vial assays severity score actuarial patient or allograft survival renal transplantation severity of cmv infection severity or duration of fever, leukopenia, or hepatic enzyme elevations cytomegalovirus reactivation syndromes rates of viral isolation or seroconversion mild leukopenia cytomegalovirus-associated glomerulopathy serum creatinine levels viral infections incidence of cmv disease number of days febrile and days hospitalized secondary to cmv illness cmv infection transplant survival or patients survival rates number of positive cmv isolates from urine and saliva onset of cmv excretion occurrence of viral infections rejection treatment with okt3 or atg, severity of cmv disease, and graft loss symptomatic cmv infections efficacy, safety, and cost survival patient and allograft survival survival; episodes of rejection, bacteremia, or fungemia; use of immunosuppressive agents; and incidence of leukopenia or thrombocytopenia moderate hypogammaglobulinemia episode of viremia cytomegalovirus pneumonitis incidence of posttransplant cmv disease tolerated incidence of reactivation infections duration of cmv excretion cytomegalovirus disease severe disease fungal or parasitic superinfections severe hypogammaglobulinemia incidence, timing, or severity of symptomatic cmv infections average episodes of > or =grade 2 rejection symptomatic herpes-simplex infections incidence of rejection and graft loss death or graft loss toxicity acute rejection or bronchiolitis obliterans syndrome mild cmv disease incidence of invasive cmv infection cmv infection and disease site of cmv excretion incidence of cmv disease and visceral involvement severity of primary cmv infection cytomegalovirus viremia incidence of virologically confirmed cmv-associated syndromes cmv reactivation reversible leukopenia and thrombocytopenia graft survival major non-cmv (including no ebv) viral infections severity of the cmv infection marked leukopenia cytomegalovirus and herpes simplex virus infections disease onset minimal toxicity cmv reactivation infections 1-year survival clinical signs of cytomegalovirus infection incidence of cmv isolation, viremia, or disease cytomegalovirus excretion began earlier and viremia cmv disease incidence of primary cmv infection incidence of cmv transmission incidence of infection adverse effects acute rejection and bronchiolitis obliterans syndrome and the survival rate|incidence of primary cmv infection was equal in both groups (50%) and no influence on the severity of primary cmv infection was seen. serological and cellular immune responses developed in most vaccines but were lower in the transplant patients than in healthy volunteers and some of the seronegative patients failed to mount responses. the towne strain of attenuated cmv vaccine was compared with placebo in seronegative renal transplants who later received kidneys from seropositive donors. opportunistic superinfections (aspergillus fumigatus and pneumocystis carinii) occurred only in patients given placebo. the incidence of rejection and graft loss was not different between the two groups. the incidence of cmv disease was 31% in the acv group and 20% in the acv + cmv ig group (n.s.). acyclovir, with or without ivig, did not prevent primary cmv infection or disease in d+r- solid organ transplant recipients at our institution. a significant reduction in cmv infection was noted in the cytogam group compared with the placebo group (15.4% [2/13] vs 60% [6/10], p = .039). passive immunization completely prevented cmv-related death, although it did not reduce the incidence of cmv isolation, viremia, or disease. the incidence of virologically confirmed cmv-associated syndromes was reduced from 60 percent in controls to 21 percent in recipients of cmv immune globulin (p less than 0.01). no death or graft loss was due to viral infection. the incidence of cmv disease and visceral involvement was much higher in the cmv immunoglobulin group than in the ganciclovir group (40 versus 6%, respectively; p = 0.03). patients receiving polyimmune gammaglobulin along with n/r-ats had an incidence of infection of only 10%. there were no significant complications related to the intravenous immunoglobulin infusions. cytomegalovirus viremia was detected in 13 of 22 recipients without prophylaxis and in 16 of 22 recipients with cmv-igiv prophylaxis (p = 0.19). ten patients were excluded from further analysis because of graft loss due to surgical complications, side effects of rifna2c, and because of lack of compliance. cmv disease occurred in fewer patients (n = 28, 21.0%) in the acv group, while significantly more patients (n = 42, 31.6%) in the gcv + hig group developed group developed cmv disease slightly later (2.83 +/- 0.70 months) than those who received gcv/hig (2.15 +/- 0.21 months, p > 0.01). though the clinical manifestation of the disease is lowered by his in cyclosporin-treated patients, there is a higher infection incidence with increased severity in his-treated atg/imurek patients compared to the respective control. cytomegalovirus excretion began earlier and viremia was more frequent in placebo-treated than in interferon-treated patients. both prophylactic regimens significantly reduced the incidence of invasive cmv infection (p < .05) and were well tolerated. among those who developed cmv infections, prophylactic igg had no effect on the severity or duration of fever, leukopenia, or hepatic enzyme elevations. there were also significantly fewer symptomatic herpes-simplex infections in the treatment (n = 6) than in the control group (n = 25). there was no difference between groups in terms of survival; episodes of rejection, bacteremia, or fungemia; use of immunosuppressive agents; and incidence of leukopenia or thrombocytopenia.|cardiac transplant recipients with moderate hypogammaglobulinemia children receiving liver transplants high-risk renal transplant patients (d+/r-) by 31 cmv-seropositive heart transplant recipients who had received early immunoprophylaxis with okt3 monoclonal antibodies combined pancreas-kidney transplant recipients patients with moderate hypogammaglobulinemia renal-transplant recipients immunosuppressed patients after kidney transplantation kidney transplantation unselected cadaver renal transplant recipients moderately hypogammaglobulinemic patients renal-transplant recipients receiving high-risk recipients of solid organ transplants renal-transplant recipients at risk for primary cmv disease renal transplant patients renal transplant recipients who were considered at high risk for secondary cmv infection was performed 650-bed tertiary medical center hospital renal transplant recipients at risk for primary cytomegalovirus (cmv) disease older patients with older donors transplant patients with previous cmv exposure who will be receiving prolonged anti-t-cell therapy because of acute rejection or primary nonfunction cmv-seropositive lung transplant recipients 74 renal transplant recipients fifty-one consecutive cmv-seronegative patients who received renal allografts from seropositive donors between march 1990 and april 1992 cytomegalovirus (cmv) infection after cadaver renal transplantation, 28 patients seropositive renal-transplant recipients seronegative recipients of seropositive allograft donors treated for rejection kidney and kidney/pancreas transplant recipients kidney and kidney/pancreas transplantation, consenting recipients with serologic evidence of previous cmv disease cmv-seronegative recipients of a cmv-seropositive kidney donor cardiac transplant recipients with severe hypogammaglobulinemia seronegative renal transplants who later received kidneys from seropositive donors 28 cytomegalovirus (cmv)-seronegative heart and kidney recipients with cmv-seropositive donors who were extensively monitored for active cmv infection and cmv disease 300 heart transplant recipients renal transplantation 44 cmv-seropositive lung transplant recipients renal transplant recipients fifteen of 21 patients (71%) who received prophylaxis fulfilled criteria for cmv disease 311 patients were stratified according to allograft type, age, and presence or absence or diabetes mellitus recipients of kidney transplants fifty-nine cmv-seronegative patients who received kidneys from donors who had antibodies against cmv renal transplant recipients who are at high risk for developing cmv infection, both primary and secondary 39 kidney transplant recipients treated for rejection with rabbit antithymocyte globulin seronegative renal transplant recipients 42 patients before transplant surgery was performed 21 cmv-seronegative organ transplant recipients with seropositive donors (d+r and 27 recipients of ivig alone cytomegalovirus disease after renal transplants cytomegalovirus infection after solid organ transplantation cmv-seropositive heart transplant recipients treated with okt3 and cytomegalovirus infection after renal transplantation thirty-four patients were studied, 16 receiving the intravenous immunoglobulin infusions and 18 being untreated controls 28 patients, we show that, in cytomegalovirus (cmv)-seronegative renal transplant recipients (r-) receiving a cmv-seropositive graft (d+), high doses of acyclovir (acv, i.e. 3,200 mg/day) during the first 3 months after transplantation recipients at risk for primary cmv disease high-risk renal transplant patients at risk for secondary cmv infection would benefit from prophylactic intravenous immunoglobulin infusions 91 renal transplant candidates 50 renal graft recipients immunosuppressed with recipients of solid organ transplants kidney transplant recipients treated for rejection 266 patients (acv, n = 133; gcv+hig, n = 133
rates of full breast feeding opinions about content and acceptability of the videotape, and smoking behavior change during pregnancy 30-day abstinence rates mean birth-weight acceptability and efficacy diet, cigarette and alcohol consumption, maternal physical strain, lactation at 40 days postpartum, and utilization of health facilities cotinine validated rates smoking cessation reducing smoking birth weight cigarette consumption cost-to-benefit ratios self-reported cigarette consumption cessation rates stress scores estimated fetal weight, femur length and abdominal circumference intervention increased end-of-pregnancy cessation rates smoking behaviour prevalence abstinence mean birthweight rates of cessation or reduction scn levels quitting rates urine cotinine concentrations rate of failed biochemical validation urinary cotinine/creatinine ratio number of cigarettes smoked per day, confidence in ability to quit, exposure to passive smoke, and educational level smoking rates number of cigarettes smoked rates of smoking cessation long-term relapse rates patients quit smoking levels of smoking status assessment by clinic staff; (2) proportion of women identifying as having been smokers at their first visit who reported receiving cessation advice; (3) proportion of these women who had quit (self report and expired air carbon monoxide (co)); and (4) smoking prevalence frequency of smoking during pregnancy rate of negative birth outcomes psychosocial measures quit rates smoking cessation rate size at birth mean infant birthweight incidence of preterm delivery number of cigarettes smoked daily chance of quitting smoking self-report and saliva cotinine assessments of tobacco exposure quit rate smoking status and cigarette consumption degree of clustering at the midwife level cigarette smoking efficacy body length 7-day point-prevalence abstinence self-reported cessation rates during pregnancy smoking outcomes birthweight and length smoking cessation or smoking reduction mean value of cotinine in saliva late pregnancy distribution of risk factors and demographic, obstetric, and psychologic characteristics median self reported daily cigarette consumption behavior and utilization of health resources point prevalence and consecutive quit rates smoking cessation rates cotinine-validated cessation rates during pregnancy smoking abstinence birth weight and length of gestation rate of preterm delivery exhaled carbon monoxide levels rate of low birthweight smoking consumption rates of cigarette smoking efficacy and cost-effectiveness smoking behavior self-report, exhaled carbon monoxide, and urinary cotinine number who quit smoking self esteem point-prevalence abstinence validated abstinence rates self-reported smoking cessation knowledge of seven of the nine alarm signs 7-day abstinence stopped smoking or maintained smoking changes relapse prevention 7-day abstinence, continuous abstinence, and partner smoking at 6 weeks post-intervention (t1) and 6 weeks postpartum (t2 smoking status based on self-report combined with a urinary cotinine level of <115 ng/ml, and birth-weight rate of low birth weight cotinine-verified quit rates smoking status mean birth weight difference mean action, stage of readiness, and motivation to quit scores larger quit rates relapse rates birth weight and preterm delivery average number of days abstinent number of cigarettes they smoked fetal growth outcomes self-report and urinary cotinine/creatinine ratios adjusted odds ratio (or) for smoking cessation smoking cessation validated by cotinine measurement at the end of the second trimester of pregnancy smoking habit and 4% increased their consumption postpartum relapse to smoking lower trait anxiety mean birth weight birthweight weight related to smoking prevalent abstinence postnatal telephone questionnaire measured client satisfaction co level cotinine-validated 7-day tobacco abstinence rates quit smoking validated smoking cessation rates kidney infections smoking habits salivary thiocyanate level and reported smoking absolute quit rates urinary cotinine/creatinine ratios serum thiocyanate or end expiratory carbon monoxide cigarette abstinence rates infant birth weight relapse salivary cotinine levels perinatal outcome, health-related behavior, or utilization of health facilities quitting efficacy and effectiveness expired carbon monoxide|results of this trial indicate that health education methods tailored to the pregnant smoker are more effective in changing smoking behavior than the standard clinic information and advice to quit and/or the use of smoking cessation methods not tailored to the needs of the pregnant smoker. contingent vouchers increased 7-day point-prevalence abstinence at the end-of-pregnancy (37% vs. 9%) and 12-week postpartum (33% vs. 0%) assessments. there was a statistically significant difference in 30-day abstinence rates between si (26%) and uc (12%) conditions at the end of pregnancy among women who had not quit spontaneously with pregnancy (odds ratio [ tools have been developed to answer the question: 'can proactive opportunistic home-based motivational interviewing help pregnant smokers reduce their habit?'. in a randomised controlled trial intensive individual anti-smoking advice given in parallel with hospital antenatal care did not influence the outcome of pregnancy. after one year, the results showed quit rates of 9% in the treatment group and 0% in the control group. positive effects of the program on birth weight and length of gestation were present for the offspring of young adolescents (less than 17 years of age) and smokers. at the long-term follow-up, reported quitting rates were significantly greater among intervention group women cared for in the publicly supported clinic than among those receiving the usual care, 14.5% versus 2.5%, p < 0.01. nineteen percent of the experimental group reported 7-day abstinence compared to 7% of the control group at t1, and 21 and 12%, respectively, at t2. we conclude that a low-cost prenatal self-help intervention can significantly affect the public health problem of smoking during pregnancy and its associated risks for maternal and child health. biochemical confirmation of continuous abstinence through delivery revealed that 16% of the women in the experimental self-help program relapsed compared with 20% of usual care controls (ns). compared to controls, smokers exposed to the intervention were more likely to have quit (14.5 versus 7.7%) or take actions toward quitting and had higher mean action, stage of readiness, and motivation to quit scores. a significantly higher percentage of patients quit smoking in the experimental group (17.3%) than in the control group (8.8%). smoking cessation rates were low: the cotinine validated rates were 18.8% (113/600) in the intervention group and 20.7% (144/695) in the normal care group (difference 1.9%, 95% confidence intervals -3.5% to 7.3%). the midwife-assisted smoking cessation intervention seems to be an effective tool to help pregnant smokers make a decision to quit smoking. there were no significant differences between the groups on change on any outcome. the intervention and usual care groups differed in post-delivery point prevalence abstinence rates for recent ex-smokers (65% vs. 53%, p < 0.05, one-tailed), but not in other outcome measures. pregnant smokers attending a local health department wic clinic were randomly assigned to one of two self-help smoking cessation programs or usual care. the experimental group received a stage of change-based, personalized feedback letter and two telephone counseling calls using motivational interviewing (mi) strategies. this exploratory study examined the acceptability and efficacy of a videotape modeling smoking cessation as an adjunct to smoking cessation advice delivered during prenatal care. the tfsb group consistently achieved greater smoking cessation across all measures when compared to the subjects in the other two groups. self-reported cigarette consumption fell significantly (p < 0.001) in the intervention group, with 16.2% giving up and 33.3% significantly reducing their cigarette consumption. prevalent abstinence was significantly greater for the pre/post intervention group than for the other groups at 8 weeks (booklet group, 30%; prepartum group, 35%; pre/post group, 39%; p = .02 there was no difference in the rates of smoking cessation between the screened group and the control group. kruskal-wallis tests revealed significant differences at the second visit in the stage distributions by condition for subjects who were initially in precontemplation or in preparation. the intervention failed to alter smoking but the intervention women did report more use of community resources (p = 0.02) and were less likely to skip meals (p = 0.03). compared with usual care, peer counseling reduced smoking (-9.1 versus -4.5 cigarettes daily, p =.03), but did not affect absolute quit rates (24% versus 21%) at 36 weeks' gestation. those receiving high feedback were more likely to report that they had acted on health advice given at the first antenatal visit to reduce their smoking and drinking. neither a computerized telephone cessation program nor systematic provision of motivational counseling improved cessation rates over a tailored self-help booklet delivered within the context of brief advice from prenatal providers. smoking during pregnancy has been linked to health problems, including the risk of low birthweight, preterm labour, spontaneous abortion and perinatal death. there were no significant differences among the three groups for either the number who quit smoking or who reduced the number of cigarettes smoked. self-reported cessation rates during pregnancy were significantly higher in the intervention group (14%) than in the group receiving usual care (5.0%) (p < 0.0001) however, significantly greater proportions of intervention group women reported either not smoking or reducing their cigarette consumption by 50% or more at their second visit (43% vs 29%, p = 0.02), at their 36th-week visit (40% vs 25%, p < 0.01), and at 1 year postpartum (26% vs 14%, p = 0.02). in groups 2 and 3, abstinence proved to be of the same magnitude as in the control group. twenty percent of intervention subjects and 10% of controls reported cessation, which was verified by co level (p = .052). the smoking intervention programme led to a significant 66 g increase in mean birthweight (p = 0.03; 95% ci+9 to +123 g) and to a 30% reduction in the rate of low birthweight in pregnancies managed by the 70 physicians who secured the highest rate of obtaining repeat serum samples for cotinine measurements in their intervention group. long-term relapse rates were not significantly different: intervention group, 50.9%, usual care group, 50.0%.(abstract truncated at 250 words) mean birth weight difference was 186 g (95% ci 35, 336 g) higher in the nicotine than placebo group, and there was an insignificantly lower rate of low birth weight (under 2500 g) in the former group. only one of the two women 'abstinent at delivery' was still abstinent 3 months after birth, the last contact point of the study. 11% in the intervention group did not change their smoking habit and 4% increased their consumption compared to 36% and 22% respectively in the control group. women in the cbt+nrt arm were almost three times more likely than women in the cbt-only arm to have biochemically validated cessation at both pregnancy time points (after 7 weeks: 24% vs 8%, p=0.02; at 38 weeks gestation: 18% vs 7%, p=0.04), but not at 3 months postpartum (20% vs 14%, p=0.55). the intervention consisted of individual skills instruction and counseling by a peer health counselor on the use of a self-help cessation guide and routine clinic reinforcement. black e and c group patients had higher quit rates than white e and c group patients. at the eighth month of pregnancy, differences between the two groups in salivary thiocyanate level and reported smoking were statistically significant. this model for intervention was cost-effective and was associated with significantly lower smoking rates at end of pregnancy. it was found that the planned educational intervention was incompletely carried out and was given more effectively to primigravidae in whom subsequent reduction of smoking was more evident. the magnitude of this difference persisted through late pregnancy (11.8% vs. 4.3%; ns) and delivery (10.6% vs. 4.7%; ns). at the eighth month of pregnancy, self-reported quitting was higher for intervention clinics than control clinics in all three states. a randomized trial evaluated the impact of smoking cessation interventions on point prevalence and consecutive quit rates at an australian public prenatal clinic. an intervention of psychosocial support and health education during pregnancy failed to show any benefit on perinatal outcome, health-related behavior, or utilization of health facilities. fewer women in the intervention group reported smoking more (18 (5.1%) v 44 (10.7%); relative risk 0.48, 95% confidence interval 0.28 to 0.81). there was no difference in rates of full breast feeding between the control and intervention groups for women who planned to breast feed. midwives in these practices delivered three interventions: a (standard care), b (ttm based self help manuals), and c (ttm based self help manuals plus sessions with an interactive computer program giving individualised smoking cessation advice). the intervention increased end-of-pregnancy cessation rates among 201 light smokers (< 10 cigarettes/day at study enrollment) (intervention 19.1% versus control 8.4%; or 2.58, 95% ci 1.1-6.1; number needed to treat = 9.3) and among 193 smokers who attempted to quit in pregnancy before enrollment (intervention 18.1% versus control 6.8%; or 3.02, ci 1.15-7.94; number needed to treat = 8.8); 63% of the sample (n = 267) was in one of these subgroups. no significant effect on smoking cessation or smoking reduction was obtained (p > 0.05). babies born to women receiving the intervention were on average 84 g heavier than babies born to controls (p=0.04). serial ultrasound examinations indicated significantly greater growth in terms of estimated fetal weight, femur length and abdominal circumference in the contingent compared to the non-contingent conditions. it was concluded that the intervention had either a small or no influence on cigarette smoking.|addictions-provided at home by specially trained midwives helps pregnant smokers to quit 104 pregnant women smoking 10 cigarettes or more daily at the time of routine ultrasound screening around the 18th week of pregnancy 1527 women who smoked at the start of pregnancy pregnant women (n=105 all pregnant smokers in the usual care group (n = 320) received all participants were given pregnancy-specific cessation counselling, and the 20 women in the treatment arm were offered offspring of young adolescents (less than 17 years of age) and smokers pregnant women in nine hospital and community trusts 2700 singleton viable pregnancies pregnant smokers four provinces with 42 practices including 118 midwives 1120 pregnant women in the third month of pregnancy (249 recent ex-smokers and 871 current smokers 814 female smokers at four public health maternity clinics pregnancy in an academic clinic pregnant women at a wic clinic woman's psychosocial status during pregnancy pregnant women stop smoking of two interventions (pro-change for a healthy pregnancy by midwives to help pregnant smokers quit or cut down and 144 current smokers and 37 spontaneous quitters were included in the control group pregnant women from the maternity centers in ld, central poland subjects were 683 (baseline) and 1,064 (experimental) smokers with measurements of smoking outcomes at both times five community health centers 22 antenatal clinics in new south wales, australia of 100 study-eligible women who were still smoking upon entering prenatal care, 58 were recruited from university-based and community obstetric practices to participate in a smoking cessation study pregnant women to aid smoking cessation during a 10 day program 82 smokers entering prenatal care participated in the trial smokers in public health maternity clinics two hundred fifty prenatal patients who smoked were enrolled at their first visit one hundred and seventy-five pregnant women who were smoking early in their pregnancy, but had quit by first prenatal visit women who registered for prenatal care at participating practices clinics attached to two maternity hospitals in glasgow pregnant heavy smokers the population (n = 171) of spontaneous quitters was an ethnically diverse group of women enrolled in a large health maintenance organization pregnant women and midwives pregnant women practicable routinely by midwives pregnant smoker in public health maternity clinics to quit during pregnancy urban, prenatal clinic serving predominantly low-income, african-american women obstetricians' and nurse midwives' usual advice during prenatal care smoking cessation in pregnancy public hospital antenatal clinics pregnant smokers wanting to quit the habit 66 women in the control group and 65 women in the intervention group pregnant teens 647 pregnant smokers three pregnant smokers sixty-one midwives recruited a total of 297 women pregnant medicaid recipients women in public maternity clinics forty-six subjects completed the post-intervention assessment of smoking status pregnant women in an urban setting pregnant women quit smoking study sample were women recruited from an antenatal clinic and general practice surgeries who were less than 20 weeks gestation and either single or in a relationship where the partner was unemployed 40 'high-risk' pregnant smokers who expressed interest in stopping smoking pregnant and postpartum women women who would have been eligible to take part in the trial were actually recruited by 178 recruiting midwives, with lack of time being cited as the main barrier pregnant women stop smoking resistant pregnant smokers infant size at birth 139 physician offices and clinic sites in maine providing antenatal care women who reported smoking at their first antenatal visit and satisfied the inclusion criteria were asked to participate in the trial pregnant smokers at 2 managed care organizations women, infants and children (wic) clinics on smoking and relapse rates in pregnant and postpartum women children born to primiparous women who were either teenagers, unmarried, or of low socioeconomic status 2848 pregnant women who smoked 10 or more cigarettes daily, enrolled at between 15 and 20 weeks gestation, from a population base of approximately 18,000 pregnancies pregnant adolescents women who receive obstetric care through publicly funded prenatal clinics 390 english-speaking women 18 years of age or older who self-reported to be active smokers at their initial prenatal appointment women who had attempted cessation earlier in pregnancy dutch pregnant women and their partners the population (n = 242) consisted of a socioeconomically and ethnically diverse group of pregnant women enrolled in a large health maintenance organization (hmo) who reported they were smoking at the time of their first prenatal visit young adolescents who were visited by nurses gave birth to newborns who were an average of 395 g heavier, and women who smoked and were visited by nurses cigarette smoking by public prenatal patients 265 pregnant smokers 284 women smoking five or more cigarettes a day at booking spontaneous quitters twenty-six midwives pregnant women one hundred and forty nine current smokers and 56 spontaneous quitters 319 women subjects (n =601) were current smokers or had quit with pregnancy women who stop smoking early in pregnancy pregnant women in an urban prenatal clinic resident-staffed prenatal clinics at the university of north carolina one hundred forty-two pregnant, predominantly hispanic women 762/1684 pregnant women who were regular smokers at antenatal booking: 351 in intervention group and 411 in control group pregnant women comparing interventions based on the transtheoretical (stages of change) model to standard care pregnant smokers in medicaid maternity care resistant pregnant smokers (n = 269 5849 women pre-dissemination (2374 sd, 3475 id) and weighted sample of 5145 women post-dissemination (2302 sd, 2843 id clients were 100 consecutive self-reported smokers booking at clinics in glasgow from march to may 1997 391 smokers pregnant women who smoked ten or more cigarettes after the first trimester (n = 250 city pregnant women (n = 193) who completed one of three interventions: a 856 pregnant women pregnant women who attempt to stop smoking by highlighting three women who used nicotine patches 600 pregnant women who smoked 442 pregnant smokers referred by prenatal providers and a managed care plan pregnant women in an hmo pregnant women still smoking around 18th week of pregnancy was carried out during the period 1992-1993 women's and children's hospital, adelaide, a public tertiary teaching hospital in south australia, with almost 4000 births annually midwives with 60 women pregnancy pregnant women who smoked subjects were 105 low income, predominantly hispanic, pregnant patients in an urban prenatal clinic four cities of latin america on pregnant women at risk women who did not quit spontaneously women in public health clinics pregnant women and one-to-one interviews of nurses and doctors heavy smokers multiple practices in six states smokers who quit during pregnancy 33 prenatal, family planning, and pediatric services in 12 public health clinics data were collected from 2003 through 2005; analyses were conducted in 2006 and 2007 ethnically diverse sample of pregnant smokers low-income women four hundred patients smokers who have stopped before entering prenatal care--"spontaneous quitters at buskerud central hospital in norway, a county hospital with 2000 deliveries per year 170 subjects, multiple measures of smoking, and data collection before the intervention and six weeks later pregnant smokers in public health maternity clinics nine hundred thirty-five pregnant smokers pregnant women receiving prenatal care and services from the women, infants, and children (wic) program in public clinics women's hospital pregnant women with low-intensity interventions 918 pregnant smokers 100 general practices three hundred and nine pregnant women from three public health maternity clinics heavier smokers three hundred and forty-six women who reported smoking one or more cigarettes per day prior to the 20th week of gestation public antenatal clinics 393 evaluable women in the control group (received antenatal clinics in west midlands, uk general practices a total of 119 women 217 women into the study and followed them up at 20 weeks' gestation to ascertain smoking cessation and to measure process variables women who are smoking during pregnancy all women were interviewed initially and at 34 weeks gestation 349 low-income, pregnant women women who quit smoking during pregnancy pregnant smokers attending a local health department wic clinic public prenatal patients women who present with a history of smoking
neurodevelopmental outcomes verbal iq, performance iq, and achievement scores mullen scales of early learning, wechsler preschool and primary scale of intelligence-revised, wechsler intelligence scale for children, wide-range achievement test, and child behavioral checklist cognitive, attention, and achievement scores full-scale iq scores|subjects with moderate ch had higher full-scale iq scores than subjects with severe ch, regardless of the initial treatment dose.|31 subjects included the severe and moderate congenital hypothyroidism (ch congenital hypothyroidism
students' general and specific attitudes toward drugs, the capability to resist peer pressure, and estimated level of drug use by peers grade 10 smoking rates decisional balance against smoking and decreased temptations to smoke enhanced school commitment and class participation new "smokers changes in knowledge prevalence rate of smoking daily cigarette smoking rate of passive smoking smoking cessation smoking prevalence rates knowledge and prevalence estimates and significant interactions of classroom and tv programming on knowledge (negative), disapproval of parental smoking, and coping effort tobacco knowledge, attitudes, offers, use, and intentions smoking-related beliefs regular smoking smoking behaviour, health knowledge, beliefs, or values health knowledge and attitude toward smoking number of students who started smoking adolescents' smoking-related knowledge alcohol consumption 30-day smoking adolescent smoking extracurricular activities positive norms, and social pressure to smoke lifetime and 30-day use of cigarettes, alcohol, marijuana, and inhalants smoking behaviour self-reported past-month and past-year use of tobacco, alcohol, and marijuana uptake of smoking coronary heart disease risk factors measures of non-smoking intentions, attitudes, predictions, problem-solving abilities, and peer interactions rate of attempting smoking resistance to smoking, behavioral intentions to smoke, and cigarette use alcohol consumption, alcohol initiation behaviors, alcohol use risk and protective factors, drug use behaviors, and exercise habits, and at 12-months for alcohol use risk and protective factors, cigarette use, and cigarette initiation attitude scores rate of smoking diastolic blood pressure, plasma total and high-density lipoprotein (hdl) cholesterol, serum thiocyanate, ponderosity index, triceps skinfold thickness, and postexercise pulse recovery rate stop smoking grade 8 smoking rates prevalence rate sensation seeking, physical maturity, antisocial behavior and parental smoking smoking rates rates of substance use and antisocial behavior prevalence of weekly cigarette use past month use of cigarettes based on a self-reported questionnaire several cognitive, attitudinal, and personality variables substance initiation index (sii) measuring lifetime use of alcohol, cigarettes, and marijuana and by rates of each individual substance lowering marijuana use growth trajectories of smoking, drinking, and antisocial behavior students' resistance or decision-making skills; substance use intentions, expectancies, or normative beliefs; or lifetime and recent substance use smoking initiation rates questionnaires, and saliva samples to validate self-reported smoking behavior resistance skill training self-efficacy condition lower probabilities of tobacco use adolescent alcohol and cigarette use and other health behaviors prevalence rates of the uptake of smoking relative knowledge and personality variables new regular cigarette smoking rate of smoking onset friends who smoke, outcome expectations for smoking, and smoking progression odds of baseline nonsmokers initiating smoking high risk of regular smoking uptake mean 30-day smoking prevalence rates tobacco use sex distribution episodes of drunkenness odds ratio of being a smoker technical assistance (ta) variables (e.g., effective collaboration with ta, frequency of ta requests weekly smoking onset ponderosity and improved fitness, and increased hdl cholesterol cigarette smoking efficacy systolic and diastolic blood pressures, plasma total and high-density lipoprotein (hdl) cholesterol, serum thiocyanate, ponderosity index, triceps skinfold thickness, and postexercise pulse recovery rate illegal drugs excluding marijuana smoking intentions systolic and diastolic blood pressures, ponderosity index, triceps skinfold thickness, postexercise pulse recovery rate, serum total and high density lipoprotein (hdl) cholesterol, and serum thiocyanate response rate self-efficacy knowledge and attitudes related to tobacco use adolescents' smoking behaviour blood pressure reduction 1-year covariate-adjusted smoking rate drinking or antisocial behavior diastolic blood pressure and thiocyanate mean knowledge scores past 30-day use of alcohol risk factors: systolic and diastolic pressures, hdl cholesterol, ratio of total to hdl cholesterol, fitness (postexercise pulse recovery rate), and smoking alcohol, cigarettes, marijuana, cocaine, and other drugs, as well as on knowledge uptake smoking prevalence of smokeless tobacco cannabis initiation and prevalence knowledge of alcohol pressures, effects, and skills to resist marihuana and organic solvents risk of smoking initiation refusal/self-efficacy, smoking intentions, or behavior behavioral intentions, perceptions of harm, or perceived peer norms levels of smoking onset prevalence of daily smoking refusal skill quality weekly smoking and monthly smoking pre-test smoking [odds ratio (or) rates of tobacco, alcohol, and marijuana use multiple measures of initiation and current use of alcohol, tobacco, and marijuana rapid increases in smoking smoking behavior smoking prevalence and use of smokeless tobacco (st smoking prevalence behavioral determinants and smoking 30-day smoking prevalence self-reported use of cigarettes, bidis (small hand-rolled, often flavored, cigarettes), and chewing tobacco and future intentions to smoke or use chewing tobacco adolescents' lifetime and 30-day use of cigarettes, alcohol, marijuana, and inhalants adolescent alcohol, marijuana, and cigarette use total cholesterol girls' smoking rates negative effect smoking uptake control schools knowledge level, attitudes, and the development of refusal, decision-making, and problem-solving skills incidence of initiation of smoking health knowledge, beliefs, and values objectively assessed smoking (carbon monoxide breath measure proportion of smokers social pressure smoking experimentation overall refusal skill quality weekly cigarette smoking early adolescent substance use and antisocial behavior regular smoking rates initial and current drinking or for current and regular marijuana use relapse rates normative expectations and knowledge concerning substance use, interpersonal skills, and communication skills tried smoking and 30-day smoking prevalence total cholesterol/hdl cholesterol ratio and for thiocyanate smoking, drinking, drunkenness, inhalant use, and polydrug use relative rates of smoking initiation and regular smoking smokeless tobacco, alcohol, and marijuana school-level clustering effects, socio-economic status, gender and family smoking prevalence, initiation and cessation rates probability of baseline non-smokers' initiating smoking smoking intentions, smoking knowledge, perceived peer and adult smoking norms, drug refusal skills, and risk taking cigarette smoking or bidi smoking sfa effectiveness and the general thrust of school-based, life skills-based prevention programs new cigarette smoking outcome assessment batteries measured youths' reported use of smoked and smokeless tobacco, alcohol, and marijuana health knowledge and nonsmoking intentions diastolic pressure social and school work skills smoking systolic pressure communication, self-instruction, self-praise, cigarette refusals, and noncompliance to smoke negative attitude towards smoking, increased social self-efficacy levels likelihood of heavy cigarette use adoption effectiveness of project towards no drug abuse (tnd student smoking behavior and curriculum implementation quit smoking 30-day use of alcohol, marijuana, and illegal drugs excluding marijuana, and drinking to intoxication probability of baseline experimental smokers' escalating to regular smoker smoking progression adjusted prevalence odds ratio (por smoking knowledge dichotomous measures of substance use (cigarette, alcohol, marijuana, and hard drugs smokeless tobacco use rates proportion of non-smokers social variables (e.g., peer resistance skills delaying or preventing the onset of tobacco use self-efficacy and resistance skills smoking initiation intervention response students' smoking-related knowledge, attitudes and behaviour tobacco use and violence rate of first-time consumers of cigarettes cigarette smoking, marijuana use, and immoderate alcohol use|for alcohol use, no effect of intervention during childhood was found. results indicated significant (p < .05) intervention effects in growth trajectories for frequency of alcohol and marijuana use but not for use versus nonuse. the school-based adolescent harm minimization intervention appears to have been more effective than the abstinence-based social influences programme at reducing regular smoking. the program did have an effect on the refusal skills of participants and the validity of this effect was not jeopardized by differential attrition. after one year of intervention, the program was found to be acceptable to school administrators, teachers, parents, and children. a pilot project for the prevention of substance abuse in schools (pase) has been developed in 1988-90 in sixth and seventh grades (12-14 years-old) in 11 primary schools in the city of barcelona (spain). both the peer-led and teacher-led interventions had positive, though not significant, effects on student perception of locus of control. the "smoke-free class competition" did not prevent smoking among adolescents and does not appear to be an effective substitute to the complete ban of tobacco advertising, the abolition of vending machines and the creation of smoke-free environments in german schools. the intervention group had a higher intention not to smoke (=0.13, 95% confidence interval=0.01-0.24) and started to smoke less often than the control group (odds ratio=0.59, 95% confidence interval=0.35-0.99): smoking increased from 2.5% to 3.6% in the intervention group and from 3.2% to 6.5% in the control group. across all program schools, the two different curricula failed to significantly reduce dichotomous measures of substance use (cigarette, alcohol, marijuana, and hard drugs) at one-year follow-up. moreover, the prevention program is also capable of producing a significant impact on several hypothesized mediating variables. further, in both classes, more rapid increases in smoking were observed for the control group as compared to the intervention group (or=1.22, p<0.01 slow escalators; or=1.54, p=0.08 rapid/moderate escalators). intervention and control groups were comparable in terms of tobacco use, gender, ethnicity, behavioral, environmental, and psychosocial characteristics. relative reduction rates for alcohol initiation were 30.0% for the combined intervention and 4.1% for lst only. repeated measures analysis of variance resulted in significant treatment by occasion interactions on the use of alcohol, cigarettes, marijuana, cocaine, and other drugs, as well as on knowledge. although prevalence decreased in intervention schools and increased in control schools in year 2 the significant difference between the two groups at baseline was not overcome by the intervention and increases in prevalence were observed in both groups in years 3 and 4. results revealed a marked suppression in the onset of both experimental and regular smoking among those students exposed to the pressure resistance training with peer leader involvement. the program was successful in improving smoking knowledge, but not attitudes, in intervention versus control group (p < 0.001). project sport participants demonstrated significant positive effects at 3-months postintervention for alcohol consumption, alcohol initiation behaviors, alcohol use risk and protective factors, drug use behaviors, and exercise habits, and at 12-months for alcohol use risk and protective factors, cigarette use, and cigarette initiation (p's < 0.05). in general, such programmes have been shown to be less effective than one might expect, and much remains to be learned about the types of educational experiences that are effective in preventing adolescents from becoming habitual smokers. self-control skills subjects had better 15-month follow-up scores than subjects in the other two conditions on measures of communication, self-instruction, self-praise, cigarette refusals, and noncompliance to smoke. students in the school health intervention program had statistically significant positive effects regarding knowledge level, attitudes, and the development of refusal, decision-making, and problem-solving skills. community intervention components appeared to exert no added beneficial influence on youths' substance use, beyond the impact of skills intervention components alone. this adaptation of mi was not demonstrated to be effective in either intention-to-treat or sub-group analyses for any outcome. the prospective study indicated that none of the interventions was more effective in reducing adolescent tobacco use compared with a randomized control group. the most successful program was the si program with boosters which resulted in a significantly lower increase in smoking rates (5.6 and 9.7%, respectively) compared to the control group (12.6 and 14.9%, respectively) at both 12 and 18 months follow-up. inadequate implementation of the programme by some teachers may have been associated with adverse effects on the children's behaviour, attitudes and knowledge. social pressure associated with starting to smoke (friends, sibsters, parents smokers) measured before intervention had no demonstrable influence on efficacy. school-based drug prevention programs can prevent occasional and more serious drug use, help low- to high-risk adolescents, and be effective in diverse school environments. findings showed that students in the intervention group were significantly less likely than were students in the control group to exhibit increases in cigarette smoking or bidi smoking over the 2-year study period. students in the program condition experienced a greater reduction in weekly smoking and monthly smoking, at 6-and-12-month follow-ups. post-test analyses indicated that the social program delivered to seventh grade subjects was effective in delaying the onset of tobacco, alcohol, and marijuana use. the rate of attempting smoking decreased form 7.8% to 2.6% and the rate of passive smoking from 53.6% to 41.8%. there were main effects of normative education for summary measures of alcohol (p = 0.0011), marijuana (p = 0.0096), and cigarette smoking (p = 0.0311). there were no significant differences among grade 10 smoking rates for females, or for students of either gender with previous smoking experience in grade 8. however, the refusal skills training, which was carried out throughout the 3-year intervention period, produced significant differences in overall refusal skill quality only at the seventh grade. improvements to social competence reduced multiple drug use at 1- and 2-year follow-ups. hispanic boys who received the multicultural curriculum were less likely to initiate smoking than were those who received the standard curriculum; effects were insignificant among other groups. the 5th grade kir curriculum generally appeared no more effective than the control schools' programming in changing students' resistance or decision-making skills; substance use intentions, expectancies, or normative beliefs; or lifetime and recent substance use. community team functioning (e.g., production of quality team promotional materials) and technical assistance (ta) variables (e.g., effective collaboration with ta, frequency of ta requests) were associated with higher recruitment rates, even after controlling for community and school district contextual influences. the two experimental curricula both produced similar overall reductions in smoking prevalence that were not significantly different from each other or the control group. at posttest and a 6-month follow-up, american-indian subjects who received preventive intervention based on bicultural competence skills concepts improved more than did american-indian subjects in a no-intervention control condition on measures of substance-use knowledge, attitudes, and interactive skills, and on self-reported rates of tobacco, alcohol, and drug use. a school-based drug abuse prevention approach previously found to be effective among white youth significantly reduced smoking initiation and escalation among urban minority girls. subgroup analyses indicated that the negative effect occurred among nonusers at baseline, and mostly among white students of both genders. there were no differences in the effects of the two program conditions. relative to randomized matched controls, adolescents whose parents engaged in the family check-up exhibited less growth in alcohol, tobacco, and marijuana use and problem behavior during ages 11 through 17, along with decreased risk for substance use diagnoses and police records of arrests by age 18. no significant differences were observed between intervention and comparison schools with respect to cigarette, alcohol, or marijuana use during the 7th grade, approximately 1 year after completion of the program, or over the full 5-year measurement interval. no significant difference in prevalence of daily smoking was found between students in the control and experimental districts, either at grade 12 (difference [delta] = 0.2%, 95% confidence interval [ci] = preventing tobacco use in youths may be an easier task than helping adults break the habit of smoking and overcome its ill effects. both teacher-led and older peer-led interventions were successful in increasing behavioral capabilities for nutrition and blood pressure, measured one year after the interventions. the amount of program exposure was low in many classes, but program use displayed a dose-response relationship with reduced smoking prevalence. using hierarchical linear modeling, we found that students in the control schools reported significantly less use of illegal drugs excluding marijuana than those in the intervention group at the first posttest; however, this effect did not persist one year later. both smoked and smokeless tobacco use rates increased in all groups, and youths in the skills intervention group consistently showed the lowest rates relative to the other groups. the intention to treat odds ratio for smoking in the intervention group relative to control was 1.08 there were no consistent program effects on refusal/self-efficacy, smoking intentions, or behavior. short-term effectiveness of the program was found for the children's knowledge of physiology of the heart and smoking. smoking rates at posttest and at both follow-ups were lower in the skills-building group than in the other three groups. the analyses for nonsmokers, however, showed no significant effects, and the program did not affect self-reported alcohol or marijuana use. this evaluation suggests that the program has some utility in preventing the uptake of tobacco use among young males; however, its efficacy with females has been negligible. in the short-term, an intervention based on peer pressure decreases the proportion of adolescents with lower education who start smoking. first-time consumers of drugs like cannabis, marihuana and organic solvents were found less often in the intervention group among boys in high schools than in the control group (i: 14.9%; k: 23.6%; p < 0.05). plus significantly enhanced the effectiveness of the d.a.r.e. curriculum among boys and was more effective than the delayed program controls, underscoring the potential for multiyear, multicomponent prevention programs and demonstrating sex differences in response to intervention programs. mediational analyses showed that prevention effects on some drug use outcomes were mediated in part by risk-taking, behavioral intentions, and peer normative expectations regarding drug use. at the end of 3 years, students in the intervention school districts report less onset and prevalence of alcohol use than students in the reference districts. significant program effects were documented, most clearly for those having some experience with smoking before the program began and for those with smoking peer and family models. the mean knowledge scores from baseline to the 1- and 2-year follow-ups increased more in the intervention group than in the control group, whereas there was little change in attitude scores. among boys who were recent smokers at baseline, the prevention program significantly reduced risk of remaining recent smokers at follow-up (or=0.45 with 95% ci=0.23, 0.88). smoking initiation was reduced in both cohorts for boys assigned to the behavioral intervention. one year after the program was concluded, the proportion of non-smokers was higher among those who had participated in the program than among the controls. no significant effects emerged for at-risk boys or at-risk adolescents in schools where the basic alert curriculum (covering seventh and eighth grades only) was delivered. latent growth curve analyses demonstrated significant treatment group effects, including reducing increases in friends who smoke, outcome expectations for smoking, and smoking progression, but had non-significant effects on drinking or antisocial behavior. school intervention condition was not a factor in the prediction of experimentation. at baseline, students in the intervention condition were slightly to moderately more likely to report use for each of the 8 measures examined than were students in the control condition. blood pressure reduction was associated with decreased ponderosity and improved fitness, and increased hdl cholesterol was associated with decreased ponderosity. at follow-up the proportion of smokers had increased by 8.3 percentage points in group a (control) and by 1.9 percentage points in group b (most extensive intervention). after 2 years of treatment, smoking rates in the treatment group (vs the control group) were lower for 30-day, 7-day, and 24-hour smoking. intervention students were significantly less likely than controls to have been offered, received, experimented with, or have intentions to use tobacco. it is concluded that brief family skills-training interventions designed for general populations have the potential to reduce adolescent substance use and thus have important public health implications. the girls in the group also evidenced lower rates of substance use initiation, while the boys exhibited increased social and school work skills. results indicated that the prevention program was able to reduce new cigarette smoking by 50% at the end of the first year and by 55% at the end of the second year for the intensive format condition. differences between groups in self-efficacy and resistance skills were not significant. there were no significant differences in outcome as a function of training method and no significant differences in outcome between teacher-provided and nurse-provided interventions in high- and medium-risk schools. prevention effects were also found for normative expectations and knowledge concerning substance use, interpersonal skills, and communication skills. we conclude that this peer pressure resistance skill program was effective in preventing experimentation with tobacco among sixth graders in tijuana, mexico. at 24-month follow-up, youths who received health information and skills intervention had lower intentions to smoke and less cigarette use than youths who received health information alone and youths who received no intervention. to test whether a social network tailored substance abuse prevention program can reduce substance use among high-risk adolescents without creating deviancy training (iatrogenic effects). process evaluations revealed that the project's ambitions were high, but were limited by various constraints including time and delays in receiving funds. the classroom-centered (cc) intervention was designed to reduce the risk for tobacco smoking by enhancing teachers' behavior management skills in first grade and, thereby, reducing child attention problems and aggressive and shy behavior-known risk behaviors for later substance use. at the end of the study the number of smokers had increased two times greater in the control schools than in the intervention schools (boys: 20.5% points vs 9.4% points; girls: 44.3% points vs 21.0% points). results from a longitudinal evaluation of the program in 36 schools in illinois provide only limited support for dare's impact on student's drug use immediately following the intervention, and no support for either continued or emerging impact on drug use 1 or 2 years after receiving dare instruction. baseline binge drinkers in sfa schools were less likely to report recent binge drinking than students in control schools (p<.01); there were no treatment differences among baseline nonbinge drinkers. significant net changes in the favorable direction also were observed for total cholesterol/hdl cholesterol ratio and for thiocyanate. in girls, both the teacher-led and peer-led programmes maintained their effects over the two years of follow-up with adjusted differences in prevalence rates of the uptake of smoking relative to the control group of -6.6% (95% cl, -17.3%, 4.0%) and -8.1% (95% cl, -18.9%, 2.7%), respectively, after two years. the impact of yat is consistent with experimental and nonexperimental evaluations of media campaigns to influence young people not to smoke. twelve months after the pre-test (post-test 2), the in-school intervention was successful in preventing vocational school students from continuing to smoke, compared with students in the control condition [odds ratio (or) = 0.49; 95% confidence interval (ci) = 0.29-0.84]. knowledge about effects of smoking rose in all groups from a mean score of 5.4 in 1988 to 6.4 in 1989 and 6.5 in 1990. a total of 8549 children aged 9-10 were allocated to the intervention group and 8897 to the control group. the programme embraced the social influence approach and concentrated on enhancing self-efficacy and the acquisition of cigarette refusal skills. the two pedagogical methods that were used in the present study influenced the young people's attitudes towards tobacco use only to a small extent. support was found for the intervention's overall effectiveness, with statistically significant effects on gateway drug use as well as norms, attitudes, and resistance strategies but with little support for the cultural matching hypothesis. analyses failed to yield any positive effects for substance use or mediators for use in the adult or teen-assisted delivery of the curriculum. the smoking zine intervention provided cessation motivation for smokers most resistant to quitting at baseline and prevented nonsmoking adolescents from becoming heavy smokers at 6 months. the community programme had significant effects on the prevalence of weekly cigarette use at times 2 and 5 and the effect approached significance at time 4. there were no differences between the two control conditions and the self-efficacy condition. there were significantly fewer new "smokers" in the experimental school than in the control school at both the initial posttest (p less than .01) and the three-month followup (p less than .05) along with significantly greater changes on some of the knowledge and personality variables. there were two experimental conditions: one group participated in a school-based intervention and were prompted to participate in a multi-media intervention and the other group had access to the multi-media intervention; however, they were not prompted to participate. four different school-based tobacco use prevention curricula were developed to counteract the effects of three types of tobacco use acquisition variables typically addressed within a comprehensive social influences program: (1) peer approval for using tobacco (normative social influence), (2) incorrect social informational provided about tobacco use (information social influence) and (3) lack of knowledge or misperceptions about physical consequences resulting from tobacco use. the odds ratio of being a smoker in intervention compared with control schools was 0.75 (95% ci 0.55-1.01) immediately after the intervention (n=9349 students), 0.77 (0.59-0.99) at 1-year follow-up (n=9147), and 0.85 (0.72-1.01) at 2-year follow-up (n=8756). program effects were found for daily cigarette smoking (por=0.70; 0.52-0.94) and episodes of drunkenness in the past 30 days (por=0.72; 0.58-0.90 for at least one episode, por=0.69; 0.48-0.99 for three or more episodes), while effects on cannabis use in the past 30 days were of marginal statistical significance (por=0.77; 0.60-1.00).|multiple substance abuse among seventh grade students 902 seventh graders from seven junior high schools in suburban new york over 2 years hispanic boys who received the all seventh-grade students in 24 schools in the academic year 1999-2000 (n = 6237 at baseline, 67.3% were white, and there was 84.0% retention at final follow-up american-indian people students (n = 442 subgroups of adolescents south african youth middle school students of family australian secondary schools primary school education against smoking 416 students aged 16-19 years old recruited in 12 london further education colleges without regard to substance use status seven middle schools substance abuse among native american youth young people's attitudes toward tobacco use five thousand two hundred sixty-six students completed the baseline survey australia (n = 2,077) and the united states (n = 1,234) in schools containing grades 6 through 9 schools from 11 states were enrolled in 2 successive cohorts from 2004 to 2008 20 schools (10 intervention; 10 control) in south central louisiana childhood disruptive behavior problems on tobacco and alcohol initiation from age 10 to 13 years adolescents in urban wuhan, china 1,234 students were eligible for the screening in which the following target risk factors were measured adolescents in italy elementary schools young adolescents 2 cohorts of 6th- and 8th-grade students in 2004; 14,063 students took part in the study and completed a survey in 2004, 2005, or 2006 678 urban, predominately african-american, public school students were randomly assigned to one of three grade 1 classrooms at entrance to primary school (age 6 general population families of young adolescents 3173 students completed the questionnaire; 57% completed all questionnaires representative districts in minnesota and wisconsin a total of 604 participants, 335 9th and 269 11th grade students from a suburban high school in northeast florida participated in this study 5691 eighth graders (77% of those who completed the sixth-grade survey and 87% of those who completed the seventh-grade survey minority youth substance abuse with american-indian adolescents middle schools two successive cohorts of alternative high schools young people 17,320 students who completed a baseline survey patients born in 1989 and 1992 who were judged by the dental personnel as potentially at risk for dental diseases, a total of 301 individuals, were included young people in india australian children using consider middle school students participating in a drug abuse, prevention trial young people's attitudes towards tobacco use only to a small extent seventh grade students (n = 234) in a second junior high school served as a measurement-only control 7th and 8th grade students (n = 2343) in four junior high schools in southern china during 2004-06 healthy children (rhc students from 32 schools in delhi and chennai, india chronic disease in childhood girls than boys (mean age 15 years) smoked 389 high-risk junior high-school students involved in a prevention program during their seventh, eighth, and ninth-grade years students who received seven lessons on alcohol in grade six, and eight lessons on tobacco, alcohol, marijuana, and cocaine in grade seven taught by their regular classroom teachers (after a 6-hour training in the social pressures resistance skills curriculum adolescents whose parents engaged in the family check-up exhibited less growth in alcohol, tobacco, and marijuana use and problem behavior during ages 11 through 17, along with decreased risk for substance use diagnoses and police records of arrests by age 18 2311 children in 2 classroom-based preventive interventions or controls cigarette smoking behaviors among male and female students (n=1874 6th graders; 50.4% male, mean age 11.8 years at baseline) participating in the unplugged school-based randomized control trial for substance use prevention the 9th grade cohort (n = 4,763; mean age = 15.4 yrs; 51% female; 61% caucasian; 30-day smoking prevalence at baseline = 25%) was followed over four years for 30-day smoking prevalence with the school as the unit of analysis eligible subjects (n = 3,028) had participated in a randomized trial of an elementary school smoking prevention curriculum high-risk adolescents parents and older peers in school-based cardiovascular prevention programs 1,649 seventh-grade students 24 schools, with 3 conditions: d.a.r.e. only, d.a.r.e. plus, and delayed program control fifty-five south dakota middle schools thai high school students hispanic boys study participants were children enrolled in two consecutive 3rd grades in the 40 districts (n = 8388); they were followed to 2 years after high school secondary school students in the czech republic older peers children in six school districts in westchester county, new york 1,396 third- through fifth-grade native american students from 27 elementary schools in five states school-based drug prevention among at-risk adolescents 38 for girls 998 eighth graders from 10 suburban new york junior high schools in 2002, 121 schools in the netherlands adolescent cigarette smoking in guangzhou, china thirty-six rural schools 10 schools were randomly assigned to the intervention in 5th grade with follow-up boosters in 6th grade; 13 schools teenagers high schools in southern california (n=18 urban minority girls twenty-two matched schools 40 schools that began the study, 34 (17 per condition) completed it eighty-three school clusters (representing school districts) from six metropolitan areas mexican schoolchildren annual surveys of ninth graders were conducted from 1986-1990 24 school districts and adjacent communities in northeastern minnesota since 1991, the intervention targets the class of 1998 (sixth-grade students in 1991) and has been implemented for 3 school years (1991 to 1994 20 public schools in hawaii two school smoking education programmes under normal classroom conditions students who were substance-free or who used substances at baseline 8352 students recruited, 7444 (89.1%) were followed up at 12 months children in elementary school for secondary school 52 schools in the west midlands region children one hundred elementary schools were stratified by school risk score (high risk = high smoking rate among senior students eight pairs of small oregon communities (population 1700 to 13 500 19 urban schools high-risk adolescents without creating deviancy training (iatrogenic effects adolescent females and males childhood 6,527 subjects in 96 schools in california, louisiana, minnesota, and texas answered questions about behaviors and potential correlates of smoking as part of the catch health behavior questionnaire in spring 1994 schoolchildren aged 13-14 vocational school students high school-aged adolescents predominantly white middle-class adolescent populations 20 schools in hawaii with close to 4000 participating students were recruited girls from 29 new york city public schools who received the program (n = 1,278) were compared to smoking rates in a control group of girls (n = 931) who did not tobacco and alcohol use from age 10 to 13 years was available for 477 children (72% of original sample 1444 students in the intervention and 1118 students in the control group, all in the first grade, average age 13 years participants: 8352 students in year 9 (age 13-14 years) at those schools 4000 students were recruited to participate and schools seven european countries participated in the study; 170 schools (7079 pupils 12-14 years of age substance abuse in schools (pase a cohort of adolescents in 22 public secondary schools in the hunter region of new south wales, australia. pre-test surveys were completed by students in the first 2 years of secondary school, with a 2-year post-test survey for black african students students (n = 541, mean age 16.3 years) in 75 classes from 14 alternative high schools completed surveys before and approximately 1 year after curriculum delivery 667 6th graders and their families two projects taught under normal classroom conditions seventh grade students (n = 540) from one junior high school in southern california elementary schools in four states all first year pupils in the schools were included and were assessed on three occasions (4538 before teaching (1988), 3930 immediately after teaching (1989), 3786 at one year follow up (1990 participants randomly assigned within grade levels to receive either a dusseldorf high school students 1992-94 876 students served as control (c) group twenty schools students in 10 experimental schools completed the american-indian youth italian students all public schools in the united states that included grades 6 through 8 and enrolled at least 100 students in sixth grade were recruited 1956 7th grade students of high schools and secondary modern schools in three cities with 110,000 to 180,000 inhabitants were asked about cigarette, alcohol and drug consumption using questionnaires after 1 year, using school (22 middle/elementary schools, 15 high schools 13-year-old students in primary schools and high schools 1852 students who completed both surveys 1,281 5th and 6th graders enrolled in 12 randomly selected washington state elementary schools south african high school students new smokers within the adolescent population in a black community six elementary schools in tijuana, mexico, were included in this prospective study with the participation of 168 sixth-graders 48 southern california junior high schools during early adolescence middle school students students with classroom friends elementary school students in xuhui district, shanghai romanian adolescents students who used marijuana at baseline cigarette smoking among adolescents junior high schools in los angeles and orange counties, california 4441 students at 99 schools (195 classes culturally diverse high-school students ninety-eight children between the ages of 9 and 12 years participated in the study primary schools in milan by the italian league against cancer (milan division students participating in the unplugged school 1730 adolescents in three high schools and six middle schools adolescent smokers black students 16 schools high school students two primary school intervention strategies to prevent early onset tobacco smoking 1988-90 in sixth and seventh grades (12-14 years-old) in 11 primary schools in the city of barcelona (spain black students in the district of columbia, who were in grades 4-6 at baseline, was begun in 1983 southern california pupils in norwegian secondary schools dutch vocational school students elementary school students schools adolescents' substance 23 125 adolescents minority adolescents eighth, ninth and tenth graders (n = 281) from two schools in suburban new york participated 14 community-university partnership teams randomly assigned to an intervention condition in which teams attempted sustained implementation of ebfis with two cohorts of middle school families 165 schools smoking prevalence among youth 40 middle schools, with a prevalence of tobacco use at or above the oregon median 48 school "units" which were randomly assigned to one of four conditions in 1987 males and females students twenty-three elementary schools adolescents in an urban area of india native american youth thirty-six public schools from two south african provinces, kwazulu-natal and the western cape 1097 students in 6 program and 6 control alternative high schools adolescents with lower education thirty-five middle schools children who were in their seventh year at school american children fifty-two schools students' smoking behavior schoolchildren american-indian adolescents early adolescent girls second grade classrooms (children aged 7 years a total of 1160 students, 1098 of whom were nonsmokers and 62 smokers at baseline, were included students with lower education smoke students were surveyed before the onset of the intervention, as sixth graders, and after the completion of the 2-year intervention, as seventh graders classes of adolescents (aged 11-12 years a total of 65 high schools from 14 school districts across the united states thirty-three public schools hunter region of new south wales, australia, using a sample of over 6000 children 1,956 students smoking with middle school subjects a school-based cluster randomized trial was conducted in perth, western australia in 30 government high schools from 1999 to 2000 midwestern schools and communities trained drug abuse resistance education 39 schools in wales and england matched for size and catchment profile 8549 children aged 9-10 adolescents living in a tobacco-producing region thai high school students through life skills training predominantly minority junior high school girls 10 730 students aged 12-13 years in 59 schools in england and wales black schoolchildren 19,529 seventh graders were enrolled in the 5-year study 5883 unique participants thirty-four schools (n=7426 consented sixth graders, 71% of the eligible population adolescents in lower education 29 schools (5372 students heidelberg children's panel study (1998 and 2000), a longitudinal sample of 1704 pupils was examined: 948 in the intervention group and 756 in the control group multi-ethnic cohort of youth in hawaii 26 dutch schools that provided junior secondary education students (n = 4,466) attending 56 schools in new york state school students (n=2734) by project health educators and regular classroom teachers thirty schools in new delhi, india adolescents using marijuana and/or cigarettes prior to intervention adolescents adolescent substance abuse prevention study chinese adolescents adolescents conducted in two public middle schools 1,402 male and female students in grades 9 through 11 from 14 secondary schools in toronto, canada students ages 11-17 elementary schools prepare children for secondary school early adolescents 792 children of 12-13 years of age from the health district of rozzano (mi) were the study base in a sample of predominantly minority students (n = 3,621) in 29 new york city schools school-age children the remaining 17 schools forty washington school districts 1980 among children in 22 elementary schools in the bronx, new york sixteen predominantly minority, inner-city high schools 689 adolescents 170 thai students in grades 7-12 were randomly selected young non-smokers from taking up smoking nineteen schools that already participated in the in-school program young males 10-12 year old primary schoolchildren 1998 with 7th grade students in seven schools with seven matched control schools 566 pupils in grade 4 and grade 5 of two schools adolescents living in a high tobacco production area sample of adolescents 36 schools in illinois ninth-grade at-risk adolescents ten public schools, which comprised 959 1st- and 2nd-grade students (54% male students, 18% minority, 28% low socioeconomic status students who received at least 60% of the prevention program (n = 3,684 german pupils romanian junior high school students aged 13-14 years baseline binge drinkers in sfa schools urban middle-school students
quality of care work-related anxiety morale, quality of care, and reduced absenteeism perceived stress scale (pss) and rathus assertiveness schedule (ras attitude scale concerning work (alienation), a personality measure (hardiness), and one of each scale for work satisfaction and for sources of satisfaction and dissatisfaction emotional exhaustion and lack of personal accomplishment, two dimensions of burnout mean scores on the nurse stress checklist (nsc) and the chinese general health questionnaire (cghq psychophysiologic health level levels of stress burnout symptoms, relaxation, and life satisfaction absenteeism efficacy and effectiveness anxiety measures quality of working relationships|the "low-dose" experimental subjects were more like the control subjects, with the exception of absenteeism, for which they had higher rates. results suggested that stress management training was effective in reducing work-related anxiety among inexperienced nurses but not among experienced nurses. in comparison with 14 wait-list control participants, 16 participants in the mindfulness intervention experienced significant improvements in burnout symptoms, relaxation, and life satisfaction. subjects were randomly assigned to one of two treatments: assertiveness training (at) or alternate treatment control (atc), which served as a control and contained updated knowledge of new computer technology for in patient settings. the mean scores on the nurse stress checklist (nsc) and the chinese general health questionnaire (cghq) differed significantly between the experimental and control group in posttest 2 at week 5. subjects who participated in a 6-week program designed to improve coping reported significant short-term decreases in emotional exhaustion and lack of personal accomplishment, two dimensions of burnout.|stress and assertiveness experienced by nurses in taiwan, republic of china chinese nurses who are employed in large teaching hospitals in taiwan nurse managers from the seven experimental units were paired with outside nurse consultants from the mcmaster university school of nursing (hamilton, ontario, canada) in a cooperative form of retraining in problem-solving through process consultation thirteen consenting clinical inpatient units one such group-nurses and nurse aides nurses in taiwan, republic of china twenty-three subjects in the experimental group and 23 in the control group from each hospital participated in the study 118 health-care providers professional nurses in taiwan 137 subjects were selected randomly from three first-ranked teaching hospitals nurses and nurse aides chinese nurses working in modern hospitals in taiwan chinese registered nurses employed in large teaching hospitals to reduce their work stress in taiwan, republic of china nurses working in a burn treatment unit 60 volunteer chinese-speaking nurses participated in the study
recovery of foot-drop gains in knee and ankle joint angle measurements emg feedback and the restoration of motor control basmajian scale higher arm function scores physical scores for active movement, mobility and adl over time knee and ankle minimum flexion angles active range of motion and surface emg potentials mild emg, severe emg, mild control and severe control muscle strength velocity of gait, cycle time, and symmetry of stance phases timed ambulation ankle active range of motion adams scale orientation, memory, spatial performance, language and iq active movement, muscle tone, sensation, proprioception, mobility and activities of daily living (adl recovery of functional locomotion electromyographic activity|electromyography through auditory and visual display was found effective in improving electromyographic activity, but more limited in training effective function as measured by active range of motion. the results showed that there were statistically significant improvements in all variables in both groups, but the improvements in active range of motion and surface emg potentials were significantly greater in the emg biofeedback group at the end of the treatment. electromyographic biofeedback patients showed significantly increased scores on the adams scale (p < .05) and basmajian scale (p < .01). one patient in the experimental group who was given 12 additional training sessions showed further gains in knee and ankle joint angle measurements during walking. multiple function tests by a "blinded" special technician in another location revealed that overall both forms of therapy obtained worthwhile clinical and statistical improvement, which was maintained at nine-month recheck testing; but there was no statistically significant superiority of one therapy over the other under the very specific circumstances of the research design. the results indicated no significant differences between the two methods. both the experimental and the control groups benefited from their treatment, but emgbf was shown to have an additional effect, both in the experimental patients, and in the control patients when they switched over to the experimental treatment condition. patients with severe impairment were shown to benefit most from emg biofeedback electromyographic biofeedback was compared with simple exercise therapy as to its effectiveness in improving foot-drop in 22 stroke patients. combined therapy with bfb and fes resulted in improvements in both knee and ankle minimum flexion angles during swing phase that were statistically significant with p = 0.05 and p = 0.02, respectively. scores on the psychological tests were within normal limits, and there was no difference in performance between the emg and control groups.|chronic hemiplegic patients neuromuscular retraining in hemiplegia 29 patients included and randomly assigned to one or the other heavily systematized therapies, 18 were classified as having early-severe and 11 as late-mild conditions patients tested were aged and had stroke of long duration 27 patients patients with hemiplegia stroke patients hemiplegic upper limb patients who had impaired arm function and were between 2 and 8 weeks after stroke scunthorpe general hospital in north lincolnshire 12 patients twenty-one patients were included in the study 22 stroke patients patients with hemiparesis and foot-drop after cerebral ischemia 12 hemiparetic patients patients with severe impairment thirty-six hemiplegic patients undergoing rehabilitation after stroke patients with hemiplegia after stroke hemiplegic patients sixteen patients with ischemic stroke hemiparetic patients--one heavily behavioral and the other based on bobath therapeutic exercises stroke patients who were at least six months beyond the onset of their disability thirty-two subjects completed the study foot-drop after stroke stroke rehabilitation subjects were acute stroke patients who had been admitted on to the medical and elderly wards
reduced skilfulness of arm motor behaviour modified barthel index, hospital anxiety and depression scale, and nottingham health profile emg activation levels online error correction motor performance, daily function, functional use of the affected arm, and quality of life motor control and functional performance movement time functional gains changes in activation motor capabilities arat pinch section upper limb function proximal ul motor impairment slower movement, lower maximal movement velocity, feedback control dominant and discontinuous movements positive intralimb transfer reaction time fma fugl-meyer assessment (fma), functional independence measure (fim), motor activity log (mal), and stroke impact scale (sis motor performance, daily functions, and quality of life varying levels of weight on the nonparetic hand motor impairment scale functional task, (2) chronometric reaction times to initiate movements, and (3) sustained muscle contraction capability peak acceleration, velocity, and movement time impairments (motor function, grip strength, gross and fine manual dexterity and motor co-ordination), (2) arm disabilities in tasks related to daily activities, and (3) functional independence in activities of daily living (adl) and instrumental adl (iadl activation in precentral (p<.001) and postcentral gyri mss and measures of strength electromyogram (emg) activation levels total movement time active elbow range of motion motor impairment hemispheric activation movement time of the impaired limb and increased upper limb functional ability motor reaction time (peripheral component), and (4) faster total reaction time distal part score of the fma higher muscle activation levels muscle activity brain activation during elbow movement assessed by functional magnetic resonance imaging (fmri) and functional outcome assessed using arm function scores functional outcome motor control and motor function action research arm test (arat), rivermead motor assessment upper-limb scale, and nine-hole peg test (9hpt motor control performance upper arm function scale bilateral symmetrical activities nonparetic peak acceleration motor assessment scale (mas), motor status scale (mss), and muscle strength fmri response voluntary emg activation levels kinematic analyses assessing motor control strategies for unilateral and bimanual reaching and clinical measures involving the fugl-meyer assessment (fma) of motor-impairment severity and the functional independence measure (fim) and the motor activity log (mal) evaluating functional ability velocity temporal and spatial efficiency movement time, higher peak limb velocity time to complete components of the tasks; comparison between sides; deviation of the hands from a linear trajectory; coordination of the two sides as indicated by relative phase angle electromyographic (emg) activity peak acceleration (p<.001) and velocity chronic hemiparesis reasonable strength, inter-limb coordination|combined unilateral and bilateral training yielded functional gains that were similar to the gains from equivalent doses of unilateral-only robotic training, although the combined group had more hypertonia and less movement out of synergy at baseline. whether patients practised with the affected arm or simultaneously with both the affected and non-affected arm only marginally modified outcome, unilateral training being slightly more efficacious. this work was designed to study the effects of bilateral elbow flexion on the reaction and movement times of the impaired upper extremity of patients with hemiparesis. the bilateral group had significantly greater improvement on the upper arm function scale (a subscale of the mas-upper limb items). changes in activation were observed in the contralesional cerebrum and ipsilesional cerebellum (p = .009). an arm training programme based on repetition of unilateral and symmetrical bilateral practice did not reduce impairment and disabilities nor improve functional outcomes in the subacute phase after stroke more than the usual therapy. during the posttest, the coupled bilateral group displayed improved movement time, higher peak limb velocity, less variability in peak velocity, and less percentage of total movement time in the deceleration phase than during the pretest. small increases in muscle activity were demonstrated by both experimental and control subjects during most bilateral practices in both actions. individuals receiving bilateral training showed a reduction in movement time of the impaired limb and increased upper limb functional ability compared to individuals receiving unilateral training. baseline severity significantly influenced improvement in all upper-limb outcomes (p<.05), but this was irrespective of the treatment group. this robust analysis revealed higher emg activation levels for the coupled bilateral movement/stimulation group than the unilateral movement/stimulation group. enhanced performance was found for the distributed cit group in the mal, the subtest of locomotion in the fim, and certain domains of the sis (eg, adl/iadl). both groups performed unimanual tasks faster than bimanual and stroke participants were only slightly less synchronised when performing bimanual tasks. nonparetic peak acceleration was higher (p=.015), velocity was unchanged, and movement time increased (p=.005) in the bilateral compared with the unilateral task. the bat group showed a significantly greater improvement in the fma than the control group but not in the fim and mal. significant findings for the (1) number of blocks moved in a functional task, (2) chronometric reaction times to initiate movements, and (3) sustained muscle contraction capability all favored the coupled bilateral movement training and emg-triggered neuromuscular stimulation protocol group. the analyses revealed distinct cumulative treatment evidence later in training in comparison to the baseline motor capabilities: (1) higher number of blocks moved; (2) higher percentage of blocks moved by the impaired hand; (3) faster motor reaction time (peripheral component), and (4) faster total reaction time. patients with moderate upper extremity motor impairment performed more discontinuous movements and less active elbow range of motion during bilateral reaching tasks; however, those with mild upper extremity motor impairment performed smoother movements and demonstrated greater active elbow range of motion during bilateral reaching tasks.|chronic stroke survivors with moderate upper extremity impairment twelve chronic stroke patients stroke survivors patients with hemiparesis (n = 25) and a control group of age-matched healthy volunteers (n = 26 individuals receiving 60 patients 33 stroke patients (mean age = 53.85 years) 6 to 67 months after onset of a first stroke 14 almost completely recovered hemiparetic stroke patients and 14 healthy control subjects subjects with mild to moderate chronic hemiparesis motor stroke patients with good clinical recovery stroke subjects voluntarily initiated their impaired wrist and finger extensor muscles individuals with moderate upper limb hemiparesis subjects with acute and chronic problems with one and two bilateral practice phases patients with hemiparesis for unilateral and bilateral elbow flexion twenty-six volunteers completed one of three motor recovery protocols according to group assignments: (1 upper extremity hemiparesis in stroke twenty subjects chronic cerebrovascular accident individuals with partial paralysis patients with moderate upper extremity motor impairment subacute stroke subjects patients with hemiparetic stroke chronic stroke patients thirty-two subjects with chronic stroke (57+/-14y; on fugl-meyer assessment arm score, 37+/-14 twenty unilateral stroke patients were recruited people with chronic stroke early poststroke rehabilitation chronic stroke forty-one people who had had a stroke, in the subacute phase, receiving conventional arm occupational and physical therapy sixteen chronic stroke subjects subacute stroke patients arm during the subacute phase after stroke patients with chronic stroke. 21 patients (median [iqr], 50.3 [34.8-77.3] months after unilateral stroke people in the subacute phase after stroke patients who have chronic motor impairment following stroke patients with hemiparesis twenty-five cva subjects volunteered to participate in this motor recovery protocol study thirteen stroke survivors aged 55 - 77 years and 13 healthy, neurologically intact participants aged 57 - 86 years performed a unimanual and two bimanual tasks involving the relocation of single and paired objects
akathisia neuroleptic-induced akathisia|neither propranolol nor placebo treated patients showed a significant improvement in akathisia.|eleven schizophrenic patients
rate of opioid-positive urine samples abstinence reinforcement opiate-negative urine specimens (thrice weekly urinalysis rates of opioid-positive urine samples objective and subjective measures of efficacy (urine toxicology, retention, craving, and withdrawal symptoms retention, opioid use, and opioid craving illicit drug use, program retention and attendance, and global staff judgments prognostic factors duration of sustained abstinence cocaine-positive urine samples retention rate retention time percentage of opiate-negative urine specimens illicit opioid use relative efficacy percentage of urine samples negative for opioids median time overdose mortality lifetime sedative dependence rates of cocaine abstinence safety abstinence orientation scale illicit heroin reduced self-reported frequency of use and self-reported craving rates of abstinence from illicit opioids detoxification rates of cocaine-positive urine samples retention rates|rates of abstinence from illicit opioids were significantly higher for females, within the buprenorphine 4-mg group, females also had significantly better retention, lower rates of opioid-positive urine samples, and higher rates of abstinence from illicit opioids. the more 'humane' clinic policy later in the decade is likely to have increased retention and reduced illicit drug use also. the estimated median time in maintenance for subjects given a maximum dose of 120 mg was 1150 days while for 80 mg it was 660 days. for the entire 25 weeks, retention rates for buprenorphine (30%, p less than .01) and methadone, 60 mg/ patients assigned to high-dose methadone maintenance performed significantly better on measures of retention, opioid use, and opioid craving than either the low-dose methadone or the buprenorphine group at both 26-week and 52-week time points. compared to idu not in maintenance, the adjusted relative risk for overdose mortality among those receiving 5-50 mg, 55-70 mg, and 75+ mg were 0.35, 0.13, and 0.11, respectively (p < .05). in 370 opioid-dependent patients included consecutively in a low-threshold methadone maintenance program, the effect of different variables on the retention rate was assessed. only the 50-mg treatment group had a reduced rate of opioid-positive urine samples (56.4% versus 67.6% and 73.6% for the 20-mg and 0-mg groups, respectively; p < 0.05) and cocaine-positive urine samples (52.6% versus 62.4% and 67.1% for the 20- and 0-mg groups, respectively; p < 0.05). methadone reduction treatment processes were associated with poor outcomes, and many patients who were allocated to methadone reduction treatment did not receive reduction treatment as intended. patients taking > or = 60 mg/day and 30-59 mg/day were respectively 70 and 50% more likely to remain in treatment than those receiving a < 30 mg daily dose. through day 210 no significant difference was evident between dose groups in treatment retention (high-dose group mean retention, 159 days; moderate-dose group mean retention, 157 days). relative efficacy was evaluated by illicit drug use, program retention and attendance, and global staff judgments. contingent vouchers and a methadone dose increase each significantly increased the percentage of opiate-negative urine specimens during intervention. dropouts were more likely among patients who enrolled in the first (rh 6.2, 95% ci 2.3-16.7) and second (rh 1.9, 95% ci 0.6-5.6) years of the programme, compared with subsequent years (rh 1.0). dose was not related to the likelihood of a positive morphine test but was related to the likelihood of a positive cocaine test. the influence of program orientation on retention was greater the higher the maximum dose of methadone.|patients enrolled in a methadone-maintainence program who continued to use heroin, abstinence reinforcement and a patient retention in a newly established methadone maintenance treatment programme 40 to 50 mg (n = 97) or 80 to 100 mg (n = 95), with concurrent substance abuse counseling 370 opioid-dependent patients included consecutively in a low-threshold methadone maintenance program 111 patients contributed 164.4 person-years of follow-up opioid dependence 229 hiv-negative clients and also from the 40 clients known to be infected with hiv during the decade one hundred sixty-two volunteers seeking treatment for opioid dependence heroin users in italy two hundred twenty-five treatment-seeking opioid addicts (46 women, 179 men eighty male and 36 female patients patients who have a long history of drug use and who have a stable income were more likely to stay in methadone maintenance treatment patients' age, sex, family situation, employment status, length of heroin use, current route of drug consumption, previous treatments, current consumption of cocaine, alcohol and benzodiazepines, needle sharing, hiv serostatus and methadone dose heroin addicts june 1992 and ending in october 1995 430 street heroin addicts from 12 veterans administration hospitals maintained patients 142 patients receiving 498 dutch injecting drug users (idu) provided 1,969 person years of follow-up (1989-1995 all patients who initiated treatment between february 1991 and january 1995 two hundred and eighty patients recently enrolled in single-person, private methadone programs were interviewed and followed for 8 years 146 patients receiving 610 opioid users admitted to methadone maintenance and followed for 1 year 307 heroin addicts admitted into a high-dose, australian methadone maintenance programme in the early 1970s 229 hiv-negative clients who received methadone between january 1981 and june 1991 outpatient substance abuse treatment research clinic at the johns hopkins university bayview campus, baltimore, md participants (n = 247) were opioid-dependent patients with a high rate of cocaine use 1503 heroin users attending public treatment centres in 1995 was studied low-threshold maintenance programs one hundred ninety-two eligible clinic patients
side effects, timing of expulsion and duration of bleeding overall success rate methotrexate levels complete medical abortion by the first or by the second follow-up visits mean duration of uterine bleeding days of bleeding rate of complete abortion and the side-effects prolactin pregnancy rate continued pregnancy efficacy rate incomplete abortion rate rates of complete abortion frequency of complaints, bleeding patterns, and changes in hemoglobin, beta-human chorionic gonadotropin, estradiol, and progesterone vomiting and diarrhea cramping and nausea early medical abortion number of women who passed the fetus within 4 h of receiving the prostaglandin abortions pregnancy advanced success rate of complete abortion severe pain overall acceptability and route acceptability overall ongoing pregnancy rate diarrhea median amount fever complete abortion efficacy outcome rate of continued pregnancy mean gestational age of the successful abortions onset of crampy abdominal pain shivering incidence of complete abortion, hemoglobin levels, duration of vaginal bleeding, and incidence of side effects nausea, vomiting and diarrhoea nausea, vomiting or diarrhoea human chorionic gonadotropin-beta level efficacy, adverse effects and acceptability efficacy, safety, and acceptability risk of failure of complete abortion rate of continuing pregnancies efficacy and adverse effects complete abortion rates gynecological examination, the level of beta-hcg and ultrasonography gastrointestinal side effects beta-hcg level complete abortion without surgical intervention serious adverse events duration and amount of bleeding measured blood loss overall, complete abortion without surgical intervention efficacy effectiveness, side effects, and acceptability nausea and vomiting ongoing pregnancy pregnancy-related symptoms complete medical abortion rates suction aspiration unpleasant mouth taste uterine sensitivity vaginal bleeding followed by complete abortion nausea/vomiting and headache/dizziness side effects such as vomiting and fall in haemoglobin, as well as the need for emergency curettage and blood transfusion blood pressure rates for complete abortion, incomplete abortion and treatment failure tolerated fever and chills successful abortion (complete abortion without requiring a surgical procedure) and side effects nausea and/or vomiting surgical abortion bleeding duration maximum concentration of methotrexate and the area under the curve longer duration of induced bleeding satisfaction and acceptability shorter bleeding time and a lower volume of blood loss uterine contractility vaginal bleeding abortion rates relative risk of failure efficacy and side effects overall complete abortion rate median duration of vaginal bleeding troubled by diarrhoea clearance rates efficacy or side effects failure to complete abortion overall successful termination rate successful abortion, duration of vaginal bleeding, side effects, and change in beta-human chorionic gonadotropin (beta-hcg) level abortion success duration and amount of vaginal bleeding prolonged vaginal bleeding efficacy outcomes incomplete abortion percentage of women with continuing pregnancies frequency of side effects incidence of side-effects, such as vomiting, nausea, headache, diarrhea and lower abdominal pain tolerance and efficacy serious complication successful medical abortions satisfaction blood transfusions rate of complete abortion heavy bleeding, necessitating emergency curettage success rate mean duration (range) of vaginal bleeding nausea, diarrhea, and warmth or chills blood transfusion time elapsed between ru 486 intake and expulsion of the conceptus fever, chills and gastrointestinal side-effects (nausea, vomiting and diarrhoea pregnancy experience diarrhoea duration of bleeding incomplete abortions with symptoms requiring a surgical aspiration abortion status pregnancy outcome, time of onset and duration of vaginal bleeding, subjective complaints, and hormone changes diarrhoea success rate (complete abortion successful abortions incomplete abortions side effects and acceptability rate of continuing pregnancy methotrexate clearance rates nausea successful abortion without surgery fever or chills vomiting success rate determined by the number of women who aborted without surgery pain and subject acceptability total bleeding 11.2 safety and efficacy diastolic pressure successful abortion treatment failures likelihood of complete abortion lower abdominal pain success rates risk of failure to abort efficacy of medical termination of pregnancy blood samples for blood group, hemoglobin, beta-chorion-gonadotrophin, aspartate-aminotransferase and creatinine complete abortions side effects incidence of diarrhoea efficacy and side-effects complete abortion rate complete abortion rates, the frequency and severity (patients' perception) of gastrointestinal side effects, and blood pressure changes efficacy, adverse effects, and acceptability crude complete abortion rate serum levels nausea, vomiting, and heavy bleeding number of women who had aborted by day 8, side effects and acceptability efficacy of treatment to achieve complete abortion and to terminate pregnancy surgical termination pregnancy-related symptoms (nausea, vomiting, breast tenderness, fatigue, dizziness, headache), drug-related side effects (diarrhoea, fever, rash and blood pressure change), side effects related to the abortion process (lower abdominal pain) and women's perceptions of the method expulsion of the conceptus without the need for a surgical procedure, and abortion bleeding necessitating a blood transfusion, no serious side effects pain amenorrhoea length expulsion of the conceptus without the need for a surgical procedure rates of success, side effects, or acceptability side-effects and number of complete abortions intrauterine pregnancy and gestational age need for surgical evacuation cortisol incidence of side-effects such as diarrhoea number requesting opiate detectable fetal heart activity adverse effects actual blood loss timing of expulsions and duration of bleeding|there was no difference in efficacy or side effects whether the prostaglandin was administered 24 or 48 hours after mifepristone intake, which suggests that the treatment period can be reduced from the conventional 48 hours. there was no significant difference in the rate of complete abortion between group a regimen of mifepristone and misoprostol was significantly more effective for termination of pregnancies < or = 56 days than misoprostol alone. the incidence of side-effects, such as vomiting, nausea, headache, diarrhea and lower abdominal pain was similar in the two groups. the rate of complete abortion was very high (>95%) in both groups but significantly higher after treatment with misoprostol than with gemeprost [436/453 (98.7%) versus 451/457 (96.2%), p = 0.019, difference 2.5%, confidence interval 0.4-4.7%] and there were fewer ongoing pregnancies (n = 1 versus n = 8, p < 0.018). nausea, vomiting or diarrhoea in women using the standard regimen (group 2) occurred in 68%, 36%, and 20%, respectively. fever, chills and gastrointestinal side-effects (nausea, vomiting and diarrhoea) were significantly more common in the sublingual group. the incidence of diarrhoea was significantly higher (66, 55.1 and 12.5% respectively) in the groups with oral misoprostol after abortion. vaginal bleeding followed by complete abortion occurred in 18 of 19 women who received ru486 + 1 mg pg pessary as compared to only 12 of 20 women who received ru486 alone (p less than 0.01). there was no difference of side effects between the two groups. there were no differences in rates of success, side effects, or acceptability between groups receiving oral and injected methotrexate. equivalence was also evident for the two intervals of administration: the rate of complete abortion was 93.5% for 24-hour interval and 91.7% for the 48-hour interval (difference -1.8%, 95% ci: -4.0 to 0.5). the complete abortion rate in group 3 was significantly higher than that of both group 1 and group 2 (p < 0.05). while an additional oral dose of 400 microgram misoprostol did not significantly increase the rate of complete abortion without surgical intervention, the additional dose did significantly reduce the rate of continuing pregnancies without compromising the acceptability and ease of use of the method. complete abortion occurred in 98.7% of the sublingual group and 94.0% of the oral group (p value=.006, rr: 1.05, 95% ci=1.01--1.09). the relative risk of failure to have a complete abortion with the lower dose of mifepristone was 1.6 (95% ci: 1.1-2.3) times that with the higher dose. the incidence of diarrhoea was significantly lower for women receiving the sequential dose, and no significant differences were found in the incidence of the other gastrointestinal side effects. five of the seven regimens resulted in complete abortion rates of 60% or less. only three of the six women with treatment failure still had detectable fetal heart activity when the pregnancy was terminated by vacuum aspiration two weeks after the start of treatment. for amenorrhoea length > or =57 days, vaginal misoprostol is more effective than oral when continued with 0.4 mg oral misoprostol twice daily for seven days. efficacy and adverse effects did not differ significantly across the three study groups. repeat administration of misoprostol or surgical treatment was required in 23 women (11%) in the 6-hour group and 8 women (4%) in the 36- to 48-hour group. methotrexate levels peaked within 1 to 2 hours and were nondetectable within 48 hours in all patients in group 1 and 72 hours in group 2. side effects occurred with similar frequency in both treatment groups. intramuscular methotrexate followed by vaginal misoprostol has been shown to be effective for abortion at < or = 49 days gestation. the efficacy of the mifepristone-prostaglandin regimen was not reduced by decreasing the dose of mifepristone from 600 mg to 200 mg. the time elapsed between ru 486 intake and expulsion of the conceptus was significantly shorter in the ru 486+pg group (n = 97, 31 days) than that in the ru 486 alone group (n = 95, 4.4 4.4 days). overall acceptability and route acceptability were similar in the two groups. however, the complete abortion rate was significantly higher in women < or = 49 days compared to women 50-63 days amenorrhoea (97.5 versus 89.1% respectively; p < 0.02). nausea was the most commonly reported side effect, affecting 70% in the buccal group and 62% in the vaginal group. complete abortion rates at 2-week follow-up were recorded for 431 (84%) in the sublingual and for 434 (85%) women in the vaginal group when misoprostol was given at 3-h intervals (difference 0.4%, 95% ci -4.0 to 4.9, p=0.85 equivalence shown), and for 399 (78%) in the sublingual and for 425 (83%) in the vaginal 12-h groups (4.6%, -0.2 to 9.5, p=0.06, equivalence not shown). oral administration of misoprostol was associated with a higher frequency of nausea and vomiting than vaginal administration at 1 hour after administration. surgical intervention was indicated for continuing pregnancy at the second follow-up visit, excessive bleeding, or persistent products of conception 5 weeks later. women with complete abortions had significantly lower pretreatment levels of progesterone and a longer duration of induced bleeding than those who did not abort. there were few gastro-intestinal side effects following prostaglandin. mifepristone and oral misoprostol are typically used for medical abortion in women up to 49 days of gestation, with a 36- to 48-hour interval between the medications. the incidence of diarrhoea in pg05 group (38.7%) was significantly higher than that in the other two groups (21.6 and 20.1%) (p < 0.001), and so was vomiting. complete abortion rates for groups 1 and 2 were 503 of 525 (95.8%, 95% confidence interval 93.7%, 97.3%) and 521 of 531 (98.1%, 95% confidence interval 96.6%, 99.1%), respectively, which were statistically equivalent. success rates in the oral and buccal groups were 91.3% (389 of 426) and 96.2% (405 of 421), respectively (p=.003; relative risk [rr] 0.95, 95% confidence interval [ci] 0.92-0.98). complete abortion occurred in 28 (90%) of 31 patients in group 1 and 14 (47%) of 30 patients in group 2 (p < .001). in each treatment group, women who subsequently aborted completely had significantly lower pretreatment levels of hcg than women with incomplete abortion or continuing pregnancy. treatment failures in group 1 were four continuing pregnancies (9%), two incomplete abortions (4%), and two women who requested surgical termination after receiving both medications (4%). there were no differences in either group between earlier (</=49 days) and later (50-56 days) gestations. vomiting and diarrhea were reported more frequently by the women who received oral misoprostol than by those who received vaginal misoprostol (p = 0.04 and p = 0.002, respectively). cortisol (at 12 and 36 hours after mifepristone) and prolactin (at 12 hours) were significantly higher in the single 600-mg dose group. women receiving misoprostol sublingually were more likely to experience diarrhoea (p < 0.01), shivering (p < 0.01) and unpleasant mouth taste (p < 0.01). cramping and nausea were the most common adverse effects reported, with similar percentages of patients in all 3 groups reporting such effects. in phase 1, the success rate was higher in the methotrexate group (93.0%) compared to the tamoxifen group (85.7%) (p = 0.045). no significant statistical differences were found in the success rates when misoprostol was given days 3, 4, or 5 after the administration of methotrexate (p = 0.69).|march 1998 to june 1999 250 women with gestations < or = 56 days six-hundred women in early pregnancy, who requested medical abortion one hundred and sixty-five women (79%) in the 6-hour group and 197 women (92%) in the 36- to 48-hour group had a successful termination at first follow-up ultrasound or presumed on the basis of other considerations (those not seen for ultrasound but deemed successful by negative pregnancy test, products passed on ward or long-term assessment of notes eighty-six women, requesting elective termination of a pregnancy which has a gestational age of < or = 49 days early human pregnancy patients' perceptions of medical abortion 150 women (gestation <or=63 days four hundred forty-two women were enrolled in the study, and complete data were available on 429 within gestational age strata twenty women 1,128 participants swallowed 150 women of 56 days gestation, or less, allocated to receive early medical abortion 108 subjects who had requested elective termination of pregnancy and medical abortion at 9 weeks gestation or less early pregnancy (amenorrhoea up to 49 days women requesting an abortion at < or = 49 days' gestation consenting women presenting for abortion services with gestations less than 56 days and who met inclusion criteria 23 women (11%) in the 6-hour group and 8 women (4%) in the 36- to 48-hour group one-hundred-and-twenty women of less than 56 days amenorrhoea 1,589 healthy pregnant women with menstrual delay of < or = 35 days who were requesting nonsurgical abortion healthy women with pregnancies through 56 days since the last menstrual period (lmp) as indicated by sonogram 2,181 women with 63 days or less gestation requesting medical abortion fifty-five subjects aborted before taking misoprostol, 9 had early surgery, and 103 did not take seventy-one (95%) women who received a single dose of 1,621 women requesting medical abortion at < or = 49 days from 9 hospitals was conducted in hebei, women 13 departments of obstetrics and gynecology in nine countries those women with a nonviable gestation sac at the follow-up scan subjects who successfully aborted began within 16 women up to 56 days of gestation in order to potentially identify an optimal regimen sixty-three women volunteered for the trial; 61 completed the study and are included in the analysis one-hundred-fifty-three healthy women with a gestational length less than 49 days from the last menstrual period women receiving ru 486 (mifepristone) for termination of early pregnancy women up to 63 days of gestation 2046 women (99%), excluding 20 lost to follow-up for early pregnancy termination medical abortion up to 13 weeks of gestation early pregnancies up to 63 days medical abortions of less than 9 weeks gestation elective termination of early pregnancy women (n = 220) requesting abortion in early pregnancy (< or = 63 days amenorrhoea 39 women in early pregnancy (less than 56 days amenorrhea) with the women at up to 49 days' gestation 800 women seeking an abortion at gestational age < or = 63 days amenorrhoea sixty-four healthy women applying for abortion within the first 8 weeks of pregnancy ten gynecological services, mostly in academic hospitals three hundred eighty-five healthy women up to 35 years of age with amenorrhea less than or equal to 49 days requesting pregnancy termination subjects who had not aborted were offered a second dose of early pregnancy 966 women seeking abortions to 1,224 healthy pregnant women requesting medical abortion at <57 days from last menses 2,126 women (97.5%) excluding 55 lost to follow up 200 women 300 women seeking an abortion with amenorrhoea of 8 weeks or less twenty pregnant women women undergoing medical abortion under the terms of the 1967 abortion act abortion up to 63 days gestation untreated and ru 486-treated early pregnant women 999 women undergoing an abortion at gestational age women of reproductive age a total of 340 women were recruited (171 sublingual and 169 vaginal 2295 healthy patients aged 18 years or older who were 56 or fewer days pregnant four hundred and fifty women undergoing medical termination of pregnancy at up to 63 days of gestation eighty-six women women with menstrual delay of < or = 35 days women requesting early abortion early termination of pregnancy eligible and consenting women 224 women who requested legal termination of pregnancy up to 63 days after mifepristone medical abortion through 63 days' gestational age early pregnancy termination women requesting an abortion at < or = 56 days' gestation mifepristone medical abortion early abortion participants were women presenting for abortion at 49 days or less gestation women undergoing medical termination of pregnancy whose pregnancies have a gestational age up to 49 days medical abortions eligible women 300 pregnant women seeking elective abortion seventeen centres internationally pregnant women (amenorrhoea of less than or equal to 49 days) with ru 486 (25 mg twice daily for 4 days) and 2066 healthy pregnant women requesting medical abortion with 63 days or less of gestation one hundred women in an urban primary care practice termination of early pregnancy study group (n = 1,118) women took healthy adult women up to 63 days pregnant and wanting a medical abortion 2219 healthy pregnant women requesting medical abortion with < or =63 days of amenorrhoea 14 women with successful abortions 270 women seeking abortion within 63 days after the onset of amenorrhea women receiving methotrexate 50 mg and 60 mg per square meter for early abortion 150 healthy women with pregnancies of </=56 days gestational age who desired pregnancy termination 480 women who were 49 days or less pregnant patients with continuing pregnancy, excessive bleeding, or retained pregnancy tissue 5 weeks later received an 198 women presenting for medical abortion at < 7 weeks gestation 422 women eighty participants received women who had not aborted were offered a second dose of a total of 89 cases was excluded from full analysis of outcome because either they aborted after mifepristone alone (n = 2), had an ectopic pregnancy (n = 1), or because the outcome was uncertain as they failed to attend their follow-up appointment (n = 86 pregnant women at 56 days' gestation or less seeking elective abortion early pregnancy (less than or equal to 49 days of amenorrhea) using ru 486 have been conducted in china, including 2321 subjects administered vaginally for elective termination of early pregnancies fifteen gynaecological clinics in 11 countries medical abortion for early pregnancy thirteen hospital gynaecological units in different continents women with a continuing pregnancy were managed with surgical termination early pregnancy (amenorrhoea < = 49 days one thousand one hundred sixty-eight women were enrolled women treated initially with mifepristone
serum calcium, phosphorus, alkaline phosphatase, and urinary calcium/creatinine ratios verbal rating scale significant loss of bone mineral cumulative bone loss chronic pelvic pain hot flushes and sweating mean lumbar bone loss estradiol and biochemical markers of bone metabolism serum estradiol and the biochemical parameters of bone metabolism revised afs endometriosis score bmc urinary calcium-creatinine ratio and serum alkaline phosphatase endometriosis scores daily symptom diary for hot flushes and bleeding episodes, laparoscopic scoring of endometriosis, endocrine and biochemical changes, and bone mineral density scans lumbar spine bone mineral density (bmd frequency of hot flushes and sweating episodes bone mineral density changes bone metabolism total pelvic pain scores tolerability bone mineral density of the lumbar spine trabecular vertebral bone mass, serum e2, and serum calcitonin bone mineral density bone assessments bmd changes adverse hypoestrogenic effects bone formation markers loss of bone density urinary calcium/creatinine ratio androgenic side effects bone resorption markers libido mean subjective signs and symptoms scores physical examination, laboratory indices, occurrence of adverse events, and bone mineral density changes pelvic signs and symptoms scores and revised afs endometriosis scores serum luteinizing hormone (lh) and 17 beta-oestradiol concentrations serum alkaline phosphatase mean (sd) deep dyspareunia scores lumbar spine values association of b-alp and d-pyr bone mineral density and pyridinium crosslinks z scores calcitonin levels efficacy bone turnover efficacy and safety bone biochemical markers control values; urinary calcium-creatinine ratio biochemical markers except urinary calcium and hydroxyproline vertebral bone mass and serum estradiol and calcitonin serum calcium, phosphorus, alkaline phosphatase, and fasting urinary calcium/creatinine ratios bone demineralization seen hypoestrogenic effects bone resorption bone alkaline phosphatase (b-alp) and osteocalcin (oc lumbar spine bone mineral density frequency of genital bleeding vertebral trabecular bone mass bone mineral density (bmd bone loss and vasomotor symptoms positive spine bmd changes endocrine effects serum e2 levels bone loss and symptomatic side effects revised american fertility society score crosslaps (ctx) and deoxypyridinoline (d-pyr mean (sd) endometriosis scores serum estrone and estradiol levels bone loss with la pelvic pain scores trabecular bone mineral content of the lumbar spine and femoral neck trabecular bmc of the 3rd lumbar vertebra bone mineral density loss pelvic endometriosis spinal trabecular bone mineral content bmd bone loss endometriosis, dysmenorrhea, and pelvic pain; effects bone loss at the lumbar spine slight gain in bmc lumbar spine and femoral neck bone densities serum follicle stimulating hormone (fsh) levels bone density serum estradiol levels menstrual pain scores serial serum levels of e2 and calcitonin endometrial implants score gain or loss of bone mass sustained hypoestrogenemia and significant bone loss total revised afs score bone formation and resorption markers bone mass serum calcium levels mean bone mineral density urinary levels of pyridinium crosslinks bone mineral content (bmc hypoestrogenic side effects bone mineral measurement bone mineral serum estrogen levels lumbar spine and femoral neck bone mineral content serum estradiol (e2) levels efficacy and acceptability hot flushes mean serum oestradiol levels|at the end of treatment, serum estrone and estradiol levels in the add-back group (n = 11) were significantly higher than those in the control group (n = 10). 2.3% (p < or = .001) loss in bone density after 52 weeks of treatment, whereas bone density was preserved in all three add-back groups. there was no difference in bone loss in the three groups, at all sites. significant loss of bone mineral (-9.6 g/l; -5.9% p less than 0.001) was demonstrated after 6 months' treatment with nafarelin. hypoestrogenic side effects of hot flushes and loss of libido were significantly less in the group that received hrt. both treatments significantly (p < .0001) reduced mean subjective signs and symptoms scores both during and after therapy. lumbar spine bone mineral density decreased significantly from baseline in the placebo group (-5.1%) but not in the tibolone group (-1.1%). total revised afs score as well as total pelvic pain scores decreased significantly (p < .001) in both groups. serum e2 levels usually were < 25 pg/ml (conversion factor to si unit, 3.671) with la but > 47.3 pg/ml with danazol. before treatment, the trabecular bone mineral content of the lumbar spine and femoral neck was not significantly different between endometriosis patients and age-matched controls (n = 26). six months after stopping nafarelin, with or without norethisterone, bone mass was not different from baseline. parameters of bone resorption tended to increase in the buserelin group. biochemical markers except urinary calcium and hydroxyproline measured at 6 months were positively correlated with the bmd changes at the lumbar spine. significant increases in serum calcium, phosphorus, alkaline phosphatase, and urinary calcium/creatinine ratios were noted in the placebo group. the gnrha + placebo group had significantly higher serum calcium levels and a significantly higher loss of lumbar spine bone mineral density (bmd). the monthly depot caused a slightly more marked inhibition of serum follicle stimulating hormone (fsh) levels with respect to the 3-monthly preparation. bone mineral density was reduced in all four groups, but the percent changes varied slightly, at - 5.25% (group a), -3.72% (p < 0.05 vs. group a) (group b), -4.13% (group c), and -3.59% (p < 0.01 vs. group a) (group d), respectively. all three treatment groups showed significant decreases in bone mineral density compared with baseline but smaller losses were generally observed in the add-back groups.|one hundred ten women (mean age, 46.2+/-0.5 yr), receiving leuprolide therapy for estrogen-dependent diseases (such as endometriosis and uterine leiomyomas thirty-one premenopausal subjects who needed treatment with japanese women with endometriosis japanese women with symptomatic endometriosis women with endometriosis twelve women with symptomatic pelvic endometriosis diagnosed and staged by laparoscopy premenopausal women with endometriosis patients with endometriosis compared with immediate therapy patients with endometriosis 27 patients with endometriosis who were given fifty premenopausal women with laparoscopically diagnosed endometriosis (revised american fertility score for endometriosis implants equal to four or greater) and significant symptoms of dysmenorrhoea, dyspareunia, and other pelvic pain thirty-one patients (33%) left the study prematurely and three patients were non-compliant with the study drug two hundred and one patients patients with endometriosis being treated with ninety-four women with a subjective complaint of heavy menstrual blood loss or objective evidence of endometriosis received women with ovarian deficiency twenty-nine patients with endometriosis and two with fibroids three hundred fifteen patients with stages 28 patients treated for 6 months with a gnrh agonist endometriosis patients treated with patients with uterine fibroids 40 patients with endometriosis symptomatic endometriosis 30 women aged 18-38 years pelvic endometriosis 24 women treated with either nafarelin (15 patients) or postmenopausal women with high bone turnover treated with hrt premenopausal women patients with endometriosis treated with gonadotropin-releasing hormone agonists patients treated with the endometriosis nineteen women with laparoscopically confirmed endometriosis academic university hospital and department of obstetrics and gynecology forty premenopausal women with laparoscopically proven endometriosis entered the study
knee pain quadriceps strength of the index knee function scores visual analog scale pain and rates of attrition car task changes in joint space width leg flexion and extension walking speed exercise tolerance, disease-related measures, and self-reported health status time to lift aerobic capacity, 50-foot walking time, depression, anxiety, and physical activity exercise efficacy physical fitness pain, quality of life, strength of the left m. quadriceps, knowledge, self-efficacy, bmi, physically active lifestyle, and visits to the physical therapist right leg flexion and left leg extension total activity vector magnitude average distance walked range of motion and ambulation speed peak torque and csa of knee muscles 6-minute walk distance and womac score safe, effective, and well tolerated joint tenderness arthritis pain isokinetic quadriceps strength frequency of palpable joint effusions strength, pain, physical function and quality of life pain and physical function scores physical function, pain, and mobility observed disability muscle peak torques walking speed and decrease of disability synovial fluid keratan sulfate (ks) and hydroxyproline faster times on the lifting and carrying task self-reported physical function lequesne's index, knee range of motion, peak muscle torques of knee flexion and extension, and ambulation speed functional capacity (rising from a chair, walking, stair climbing and descending) and pain during rest and activities, peak torque, and cross-sectional area (csa lower extremity stiffness pain and stiffness 6-minute test of walking distance and scores on the physical activity, arthritis impact, pain, and medication subscales of the arthritis impact measurement scale (aims pain or function baseline womac scores and walking distance self-reported pain, function and quality of life pain and functioning aims physical activity subscale pain and disability knee pain scores and quadriceps muscle strength visual analogue scales (vas) for pain on stairs and walking and womac physical function scores pain in the worse knee by 100 mm visual analog scale score, the disability domain of the western ontario and mcmaster university oa index (womac), and quadriceps muscle strength by maximum voluntary contraction functional capacity disability isometric strength gain 6-min distance walk body weight activity and activity related pain balance womac, knee pain scale, sf-36, assessment of quality of life index, quadriceps strength, and balance test change scores for flexibility, number of clinically active joints, duration of morning stiffness, or grip strength clinical signs and symptoms of osteoarthritis (oa knee specific physical function and stiffness (scored on womac index), general physical function (scored on sf-36 questionnaire), psychological outlook (scored on hospital anxiety and depression scale), and isometric muscle strength self-report measures (womac, sf-36) and objective measures of physical performance (gait analysis and muscle strength quality of life positive functional outcomes vas scores for pain physical activity 6-minute walk distance mean (+/-se) time to climb and descend stairs pain, physical function, and health related quality of life hamstring and low back flexibility average womac scores pain, medication use (nonsteroidal antiinflammatory drugs, nsaid) and observed disability levels of ks and hydroxyproline functional status, pain, and use of medication mean baseline function score isokinetic and isometric quadriceps strength, pain and function determined by categorical and visual analog scales, and overall status using physician and patient global evaluations by the arthritis impact scale, version 2, western ontario mcmaster's arthritis index, and medical outcome study short form 36 weight-loss angular velocity peak torques rate of loss self-efficacy knee joint pain knee extensor strength and fast walking speed arthritis impact subscale joint stability or walking endurance abdominal muscle strength physical activity (daily step counts and total activity vector magnitude as measured by a pedometer and tritrac-r3d accelerometer), quadriceps femoris strength (isometric peak torque), and functional performance tasks (100-foot walk-turn-walk, timed stair climb, timed chair rise, and pain status strength and exhibited less frequent progressive jsn efficacy and adherence measures adverse health effects pain, quality of life, activity restrictions, knowledge about oa, self-efficacy, body mass index (bmi), and mobility measures changes of muscle power of leg flexion and extension arthritis activity muscle strength of the hip arthritic symptoms, balance, and physical functioning function, pain, and stiffness subscores of the western ontario and mcmaster universities osteoarthritis index (womac ability to walk and bend incidence and progression of knee oa disability, physical performance, and pain pain reduction, disability reduction walking distance relative health status, and a visual analog scale for pain assessment overall status activity related pain (vas); and improvement in spw and sps test time, passive range of motion, and pase pain levels muscular strength frequency of knee oa progression in jsn consensus ratings physical performance, quality of life, and self-efficacy self-reported physical function as measured with the western ontario and mcmaster universities osteoarthritis index (womac stair-climb time incidence and progression of knee osteoarthritis flexibility and upper-body or knee muscle strength physical activity, muscle strength, and functional performance pain, balance, muscle strength, and perceived difficulties in physical functioning strength gains physical performance measures pain and physical function (western ontario and mcmaster universities osteoarthritis index), general health status (medical outcomes study short form 12 health survey [sf-12], version 2), psychological well-being, and physical performance (up and go test, 50-foot walk time, timed stair climb functional capacity and decrease pain pain and physical functioning knee extension strength extremity strength time to descend and ascend stairs frequency of crepitus psychological disability mean (+/-se) time to get in and out of a car aerobic capacity lower extremity pain undergone knee arthroplasty knee pain (western ontario mcmaster osteoarthritis index (womac physical functioning isokinetic lower-extremity strength and highly standardized knee radiographs range of motion and functional tasks extension and flexion strength of the right and left legs, the 50-foot walk time, range of motion at the knee joint, the osteoarthritis screening index (oasi), and the arthritis impact measurement scale (aims self-reported disability score (range, 1-5 overall compliance synovial fluid muscle strength across the knee (extension and flexion), algofunctional index (afi), pain (0 to 10 point scale), walking speed, clinical findings pain reduction all strength measures change in western ontario and mcmaster universities osteoarthritis index (womac knee injury and osteoarthritis outcome score (koos daily steps physical function perception of changes relating to osteoarthritis of the knee and general condition mobility quadriceps strength, on knee pain and disability knee pain questionnaire mean baseline womac pain score exercise knee pain pain reductions weight loss, 6-minute walk distance, stair-climb time, womac pain and stiffness scores, and joint space width global improvement mean reductions in pain scores mean rate of joint space narrowing (jsn koos subscale quality of life pain measured by visual analogue scale and patient global change quadriceps and hamstring strength average 6-minute walk distances muscle-strength gain reduction of pain leg; isometric strength physical symptoms and fitness, body mass index, cardiovascular functioning, and perceived difficulties in physical functioning koos subscales assessing pain, other symptoms, or function in daily life or in sport and recreation retention rate time to perform all 4 functional tasks pain score clinical knee examination, muscle strength, physical performance measures, and questionnaires to measure quality of life variables physical function scores health perception visual analogue scale, ambulation speed, and lequesne index pain and function sf-12 physical component summary score muscle strength and walking performance womac scores self reported score for knee pain on the western ontario and mcmaster universities (womac) osteoarthritis index functional health status western ontario and mcmaster universities osteoarthritis (womac) index pain and physical function subscales functional capacity, especially stair climbing physical fitness, strength, pain coping, and self-efficacy pain measurements reduction in pain pain physical function, gait, and knee extensor strength knee pain score (range, 1-6), performance measures of physical function, x-ray score, aerobic capacity, and knee muscle strength womac pain score pain scores physical disability questionnaire pain using the western ontario mcmaster (womac) pain, physical disability, and stiffness subscales and a 10 point visual analog scale (vas) before and after self-paced walking (spw) and stepping (sps) functional tasks; (2) physical function using the time to complete a self-paced 40 m walk (spw) and 20 cycles of 2 steps (sps): (3) physical activity level using the physical activity scale for elderly (pase); (4) clinical measures of knee functioning (range of motion functional capacity and symptoms isokinetic strength of the quadriceps health status, physical capacity, and joint tenderness exercise adherence adverse effects x-ray scores|in the diet plus exercise group, significant improvements in self-reported physical function (p < 0.05), 6-minute walk distance (p < 0.05), stair-climb time (p < 0.05), and knee pain (p < 0.05) relative to the healthy lifestyle group were observed. both training groups showed marked decreases (p <.001) in pain scores and increases (p <.001) in functional capacity together with increases (p <.05--.01) in peak torque and csa of knee muscles. no significant differences in the koos subscales assessing pain, other symptoms, or function in daily life or in sport and recreation were seen at any time point between exercisers and controls. additional beneficial effects (p = 0.05) were found for the use of paracetamol (effect size 0.33), global effect as perceived by the patient (effect size 0.68), and muscle strength of the hip (effect size 0.34). both group ii and group iii had significant gains in muscular strength after treatment and at followup; group iii showed the greatest gains. although changes in scores on the arthritis impact subscale were similar in the two groups (p = 0.093), the walking group experienced a decrease in arthritis pain of 27% (cl, 9.6% to 41.4%) (p = 0.003). addition of a progressive exercise program to nonsteroidal antiinflammatory therapy in patients with knee oa can improve measures of activity and activity related pain more than medication alone. compared with rom, st decreased the mean rate of joint space narrowing (jsn) in osteoarthritic knees by 26% (p = not significant). at 24 months, highly significant reductions in knee pain were apparent for the pooled exercise groups compared with the non-exercise groups (mean difference -0.82, 95% confidence interval -1.3 to -0.3). in the isometric group, time to perform all 4 functional tasks decreased (p<.05) by 16% to 23%. alone groups had significant improvements in physical fitness compared to sa-cst alone and patients in sa-cst + et and et alone had significant improvements in leg flexion and extension compared to sa-cst alone and sc, (2) pain coping: patients in sa-cst + et and sa-cst alone groups had significant improvements in coping attempts compared to et alone or sc and spouses in sa-cst + et rated their partners as showing significant improvements in coping attempts compared to et alone or sc, and (3) self-efficacy: after 3 months, significantly greater improvements were observed in the experimental group than the control group in terms of: arthritis pain (p = 0.02), ability to walk and bend (p = 0.03), aerobic capacity (p < 0.0001), hamstring and low back flexibility (p = 0.003), quadriceps and hamstring strength (p <0.01), and the perception of changes relating to osteoarthritis of the knee and general condition (p < 0.0001). the treatment package produced small improvements in knee pain scores and quadriceps muscle strength 10 weeks after the end of the treatment period. womac pain score reduced by 22.5% in the exercise group and by 6.2% in the control group (between group difference p < 0.05, unpaired t test). a significant muscle-strength gain in 180 degrees /second angular velocity peak torques was found only in the isokinetic group after treatment. the experimental group significantly increased in all strength measures, while the control group increased in only right leg flexion and left leg extension across the training period. the aquatics and walking exercise groups showed significant improvement over the control group in aerobic capacity, 50-foot walking time, depression, anxiety, and physical activity after the 12-week exercise program. the physiotherapy programme tested in this trial was no more effective than regular contact with a therapist at reducing pain and disability. older disabled persons with osteoarthritis of the knee had modest improvements in measures of disability, physical performance, and pain from participating in either an aerobic or a resistance exercise program. significantly fewer participants in the physiotherapy group reported consulting their general practitioner for knee pain in the follow-up period, and use of non-steroidal anti-inflammatory drugs was lower in the physiotherapy and pharmacy groups than in the control group. in the physical fitness test, there were significant improvements in balance (t = 3.34, p = 0.002) and abdominal muscle strength (t = 2.74, p = 0.009) for the tai chi exercise group. levels of ks and hydroxyproline did not change. both class allocations achieved significant improvements in the sf-12 physical component summary score, but only allocation to hydrotherapy achieved significant improvements in the physical performance measures. significant manova group x time effects (p < 0.05, one-sided) were found for pain, quality of life, strength of the left m. quadriceps, knowledge, self-efficacy, bmi, physically active lifestyle, and visits to the physical therapist. there was an increase in the frequency of palpable joint effusions (p < .01) on the most affected side. both treatment groups showed significant strength gains (p < .05), which occurred over a wider velocity spectrum for the exercise group. improvements in the self-report measures were substantiated by significant correlated improvements in knee extensor strength and fast walking speed (rho 0.36-0.42). program participants also experienced a significant decrease in lower extremity pain and a borderline significant improvement in efficacy to adhere to exercise over time at 6 months (p =.052). in older adults with symptomatic knee oa, walk + appears to increase walking, with improvements in muscle strength and walking performance. clinically and statistically significant improvements in 6-minute walk distance and womac score at 4 weeks and 8 weeks were seen in the treatment group but not the placebo group. high intensity, home based strength training can produce substantial improvements in strength, pain, physical function and quality of life in patients with knee oa.|patients having persistent osteoarthritic knee pain older persons with knee osteoarthritis patients with severe osteoarthritis (oa) of the knees during and after a general physical training program 152 older persons with chronic symptomatic hip or knee oa knee pain and knee osteoarthritis knee joints with osteoarthritis older overweight and obese adults with knee oa 316 randomized participants, 252 (80%) completed the study elderly subjects older adults in the united states with osteoarthritis twenty volunteers with osteoarthritis of the knee joint patients with hip or knee oa by american college of rheumatology criteria were selected people who have rheumatoid arthritis or osteoarthritis 6 yrs) with radiographic evidence of mild/moderate medial compartment oa 102 volunteer subjects with oa of the knee randomized to isometric (n=32) and dynamic (n=35) resistance training groups or a control (n=35 patients with knee osteoarthritis (oa patients aged 36-65, with oa grade iii (kellgren & lawrence forty-six community dwelling patients, aged 55 years or older with knee pain and radiographic evidence of knee oa older adults with osteoarthritis of the knee older women with oa seventy-two patients with oa eighty-seven patients were recruited to the study, 43 inclusion criteria were diagnosis of oa of the hip or knee according to acr clinical and radiographic criteria and age 55 to 75 years older disabled persons with osteoarthritis of the knee 15 general practices in north staffordshire patients with osteoarthritis of the hip or knee older adults with lower extremity osteoarthritis 126 patients one hundred thirty-two patients with bilateral knee oa (altman grade ii 25 patients (3 men, 22 women) with oa of the knees according to the criteria of the american college of rheumatology (acr knee osteoarthritis with predominant patello-femoral joint involvement twenty-three volunteers, ages 41 to 75 years n = 41; 19 men and 22 women [mean age, 62 patients with osteoarthrosis of the knee patients suffering from pain due to osteoarthritis people aged over 55 presenting to primary care subjects in this study were middle-aged with symptomatic and definite radiographic knee osteoarthritis middle-aged patients with moderate to severe radiographic knee oa patients with oa with exercise knee pain osteoarthritis management individuals with chronic symptomatic hip or knee osteoarthritis (oa sixty-one subjects (mean age 56 (sd 6), 51 % women, mean bmi 29.5 (sd 4.8 patients with knee osteoarthritis patients with osteoarthritis of the knee and may delay or prevent the need for surgical intervention 83 patients with osteoarthritis of the knee who were randomly assigned to receive treatment (n = 42; 15 men and 27 women [mean age, 60 6.7) or edu (n = 17, age = 70.8 older adults with osteoarthritis for the hip or knee 221 older adults (mean age 69 years sedentary individuals with chronic hip or knee oa patello-femoral joint (pfj) osteoarthritis (oa 140 community volunteers with knee osteoarthritis participated and 119 completed the trial pain and disability from osteoarthritis of the knee 786 men and women aged 10 physiotherapists in private practices for 12 weeks persons with osteoarthritis of the knee patients with osteoarthritis (oa) of the knee older persons with osteoarthritis of the knee osteoarthritis of the knee patients with osteoarthritis of the knee joint copyright 2002 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation 600 (76.3%) participants completed the study thirty-four community-dwelling adults, aged 60 and older with symptomatic knee oa and self-reported functional impairment older adults with osteoarthritis (oa participants assigned to walk + (n = 17, mean age knee joint osteoarthritis older adults with osteoarthritis seventy-two married osteoarthritis (oa) patients with persistent knee pain and their spouses older community dwelling patients with unilateral knee osteoarthritis (oa patients with rheumatoid arthritis and osteoarthritis 102 patients with a documented diagnosis of primary osteoarthritis of one or both knees participated in the study 18 months conducted at 2 academic medical centers 120 patients with rheumatoid arthritis or osteoarthritis volunteered to be subjects for this study of outpatient physical therapy department of a large military medical center 439 community-dwelling adults, aged 60 years or older, with radiographically evident knee osteoarthritis, pain, and self-reported physical disability patients with oa of the knee two general practices in nottingham patients with osteoarthritic knee pain older adults with symptomatic knee oa people aged 55 or over with knee pain overweight and obese older adults with knee osteoarthritis 201 patients were randomized one hundred seventy-nine men and women (mean age 74 one hundred thirteen men and women between 50 and 80 years old with diagnosed osteoarthritis of the knee patients with knee oa patients with severe oa of the knee 191 men and women with knee pain aged 40-80 were recruited from the community and randomised to exercise (n = 113) or patients with osteoarthritis of the knee participants, who had knee pain and predominant pfj oa, were recruited from a large population based study knee osteoarthritis (oa patients with osteoarthritis of the knees patients with osteoarthrosis (oa) of both knees oa of the knee 140 subjects with bilateral knee oa (altman grade ii patients participated in 96 of 96 assessments (100%) and in 218 of 280 training sessions (77.9 patients with knee pain three hundred sixteen community-dwelling overweight and obese adults ages 60 years and older, with a body mass index of > or =28 kg/m(2), knee pain, radiographic evidence of knee oa, and self-reported physical disability older women with osteoarthritis (oa middle-aged patients with knee osteoarthritis patients with osteoarthritis (oa) of the hip or knee 325 adults aged 55 years or over (mean 68 years) consulting with knee pain; 297 (91%) reached six month follow-up older adults with knee pain outpatient veterans affairs medical center clinic and an affiliated university hospital older adults with knee osteoarthritis individuals with osteoarthritis of the knee 137 volunteers ages older patients with knee osteoarthritis older overweight and obese adults with knee osteoarthritis (oa older women with osteoarthritis adults with osteoarthritis of the knee a total of 365 (83%) participants completed the trial inpatient and outpatient services of an orthopedic hospital in an academic medical center
milk output mean daily mmv volume of milk expressed and its fat content maternal milk volume prolactin response milk extraction, milk fat content, maternal hormone response, maternal satisfaction, long-term milk production, and duration of breastfeeding following return to the workforce 24-hour milk production mean milk volumes milk volume or fat content volume of milk expressed per expression and its fat content daily milk production log, weekly serum prolactin levels, and a weekly state-trait anxiety inventory (stai exclusive breastfeeding fat concentration milk flow milk yield and prolactin and oxytocin release shorter expression times average stai scores; average prolactin levels; and weekly averages for number of pumping sessions, hours of pumping, and milk production in milliliters breastfeeding duration bacterial colony counts 24-hour milk volume milk extraction efficiency rate of bacterial contamination of ebm morbidity and mortality rates breastfeeding study (bibs mother's knowledge several demographic characteristics, stai scores, prolactin levels, number of pumping sessions per week, or weekly milk production duration of breastfeeding adequate production milk volume breastfeeding knowledge questionnaire, observational checklist of mother's breastfeeding practices, breastfeeding diary, infant's and mother's profile form, and demographic information milk production gram-negative bacilli breastfeeding knowledge and practices breastfeeding problems milk fat concentrations efficiency, efficacy, comfort, and convenience fat content of the breast milk rate of bacterial contamination milk volume, fat content, and pattern of milk flow bibs efficiency and efficacy gradual improvement in breastfeeding practices, i.e., started breast milk expression earlier and had more breast milk expression frequency maternal response onset of milk ejection contamination rates efficiency, efficacy, comfort, and convenience of the symphony breast pump (medela, mchenry, il) (sbp ebm milk volume and fat content milk flow and total volume|when analyses were adjusted for this, there was no difference in bibs 1 between targeted and usual care groups and in bibs 2 among the treatment groups in the proportion of women still breastfeeding at the times studied. the mp was rated significantly better overall and more comfortable and pleasant to use. mother's knowledge significantly increased for the intervention group but not the control group (p = 0.041). the fat content of the breast milk in the two groups was not significantly different. in both limited and unlimited pumping sessions, the simultaneous double pumping option obtained higher mean milk volumes, reaching statistical significance in three of the four comparisons. milk yield per expression was: sequential pumping with no massage, when breast milk was expressed at home, the rates of bacterial contamination by staphylococci (p= 0.003) and gram-negative bacilli (p= 0.002) were significantly higher in the breast-pump group than the manual group. this difference did not reach statistical significance. milk extraction efficiency was greater (p = 0.001) with the standard pump. the tukey revealed significant differences (p < 0.01) between electric breast pump expression and hand expression but not between the electric and pedal pump or the pedal pump and hand expression. mothers who used the ep, who frequently double pumped, showed shorter expression times but produced no more milk than mothers who used the mp. the onset of milk ejection was quicker (p < 0.05) for the single- versus multiphase patterns in the sbp, suggesting that mothers had become conditioned to the unphysiolologic single-phase pattern in the cbp. in multivariate analysis, mothers using sim produced a similar amount of milk by weight during weeks 2 to 5 postpartum compared to those using seq. the two groups did not differ on several demographic characteristics, stai scores, prolactin levels, number of pumping sessions per week, or weekly milk production. no differences were seen among the methods in the oxytocin response. a student's t-test revealed a significant difference between the two groups; women who performed special breast cleansing before breast pumping had significantly lower bacterial colony counts in their cultured breast milks.|mothers of preterm infants 145 women who delivered infants of <35 weeks' gestation to use the mp or the ep and measured total milk volume expressed while using the randomized pump during the infant's hospital stay, pattern of milk output and creamatocrit of milk expressed during a test period in the second week, and pump characteristics by maternal questionnaire wic women returning to work or school in hawaii mothers of premature or sick infants in special care nurseries (scn mothers of term infants mothers who delivered preterm infants preterm infants african nurseries lactating women 39 lactating mothers of non-nursing preterm infants from 2 tertiary care centers 28 mothers of such babies and 92 specimens of ebm were collected: 41 specimens from 13 mothers assigned to the manual group and 51 specimens from 15 mothers in the breast-pump group 36 women were analysed; 19 women used simultaneous pumping and 17 used sequential pumping women with greater education breastfed for a shorter duration egyptian mothers of preterm infants obese mothers sixty-five women whose infants were being cared for in a nicu and who wished to pump their breasts for future breast milk feedings healthy women intending to return to work or school and to breastfeed exclusively for <or=4 months were enrolled in late pregnancy (n = 62 228 ml (n = 22), 463 obese women breast-feeding mothers twenty-three women who were exclusively breast-feeding their infants enrolled obese women who intended to breastfeed in two randomized trials mothers of very low birthweight infants breastfeeding preterm infants 34 obese mothers mothers of preterm infants in cairo, egypt 94% of united kingdom neonatal units with a 40 women received women, infants, and children (wic) branch of the hawaii department of health encourages and assists mothers in breastfeeding mothers of very low birthweight (vlbw) infants (<1501 g mothers of premature infants n = 58) and maternal ranking of pump performance (n = 56 65 mothers whose infants were cared for in two scn in africa (kenya and nigeria) and were unable to feed directly at the breast 60 mothers and their preterm infants who were born before 37 weeks of gestation 280 women, with the duration of breastfeeding analyzed in 229 of these women thirty-two breastfeeding mothers of premature infants 65 mothers who compared single- and multiphase patterns in the sbp for 7 days and then returned to the cbp for 5 days funded by west virginia university department of research and graduate studies hsc all 100 mothers initiated lactation with the cbp 35 mothers who compared each of three suction patterns in the sbp on two separate occasions (six observations) in the neonatal intensive care unit and used the cbp for all other pumpings mothers of non-nursing preterm infants premature infants with a relaxation/imagery audiotape
perioperative morbidity mean operative time blood loss and transfusion rates pelvic lymph node metastases blood loss and shorter hospitalization mean number of harvested lymph nodes yield of pelvic and para-aortic lymph nodes, duration of surgery, and incidence of postoperative complications mean blood loss recurrence or disease-free survival overall detection of advanced stage (stage iiia, iiic, or ivb severe postoperative adverse events disease-free survival blood loss quality of life proportion of patients with a minor complication shorter hospital stay pelvic and para-aortic nodes quality of life (qol metastatic cancer proportion of patients with an intraoperative major complication longer hospital stay postoperative serious adverse events overall and recurrence-free survival mean length of hospital stay disease-free (p = .512) survival operative morbidity intraoperative complications cumulative recurrence rates safety and efficacy data pain medication proportion of major complications functional assessment of cancer therapy-general (fact-g) questionnaire shorter hospital stay, less pain, and quicker resumption of daily activities conversion to laparotomy feasibility, safety and morbidity bleeding hospitalization lymph node number and detection of lymph node metastasis operative time, blood loss, blood transfusion, intraoperative complications, postoperative complications, duration of hospital stay, and number of lymph nodes obtained emotional and social wellbeing measures of fact and the visual analogue scale complication rate postoperative major complication intraoperative adverse events 6-week morbidity and mortality, hospital length of stay, conversion from laparoscopy to laparotomy, recurrence-free survival, site of recurrence, and patient-reported quality-of-life outcomes major complication rate operating time qol change wound infections qol deaths adverse events operative time|no significant differences in overall (p = .535) and disease-free (p = .512) survival were observed. tlh was associated with significantly less blood loss (p<0.0001), less use of pain medication (p<0.0001), a shorter hospital stay (p<0.0001), and a faster recovery (p=0.002), but the procedure took longer than tah (p<0.0001). this procedure is associated with significantly less blood loss and shorter hospitalization; however, it is associated with significantly longer operating time. the mean operative time was 136 min+/-31 (95% ci 118-181) in the lps group and 123 min+/-29 (95% ci 111-198) in the lpt group (p<0.01). pelvic lymph node metastases were detected in 7.7% of the patients in the laparoscopy group and 15.4% in the laparotomy group, and the difference was not significant. overall and recurrence-free survival did not differ significantly for both groups. hospitalization of more than 2 days was significantly lower in laparoscopy versus laparotomy patients (52% v 94%, respectively; p < .0001). improvements in qol up to 6 months after surgery continued to favour tlh, except in the emotional and social wellbeing measures of fact and the visual analogue scale of the euroqol five dimensions (euroqol-vas).|1,682 patients and completed without conversion in 1,248 patients (74.2 stage i endometrial cancer with the traditional transabdominal approach from july 1996 to july 1998, 61 patients with clinical stage i endometrial cancer were treated at the gynaecology oncology unit at the royal north shore of sydney, australia 21 hospitals in the netherlands, and 26 gynaecologists with proven sufficient skills in tlh participated 283 patients with stage i endometrioid adenocarcinoma or complex atypical hyperplasia patients with endometrial cancer early-stage endometrial cancer early stage endometrial cancer 159 patients with clinical stage i endometrial cancer fifty-two patients with endometrial cancer who underwent surgical staging consisting of total hysterectomy, bilateral salpingo-oophorectomy with pelvic lymph node dissection, and cytology between 1998 to 2002 were included in the study 361 participants were enrolled in the qol substudy at 19 centres across australia, new zealand, and hong kong; 332 completed the qol analysis obese women stage i endometrial cancer (lace patients with clinical stage eight of 332 patients (2.4%) had treatment conversion-seven from tlh to tah and one from tah to tlh (patient preference 2010 elsevier ltd endometrial cancer women with early-stage endometrial cancer i to iia uterine cancer 52 patients, 26 underwent laparotomy and the remaining 26 underwent thirty-seven patients were treated in the laparoscopic versus 33 patients in the laparotomy group cancer council queensland, cancer council new south wales, cancer council victoria, cancer council western australia 25 patients by laparoscopy and in 24 patients by laparotomy between july 1995 and august 1999, 70 patients with endometrial cancer figo stage i-iii twenty-nine patients were treated with stage i endometrial cancer (lace), began in 2005 patients with early endometrial cancer 84 patients with clinical stage i endometrial cancer (laparoscopic surgery group, 40 women; laparotomy group, 38 women 159 women the patients with histologically confirmed stage i endometrioid adenocarcinoma and eastern cooperative oncology group performance status less than 2 were randomly assigned to tlh (n=190) or tah (n=142), stratified by histological grade and study centre stage i endometrial cancer
incontinence quality-of-life questionnaire score urinary retention improvement of 1 continence grade maximum urethral closure pressure (mucp), functional urethral length (ful), maximum flow rate and cough test standardized incontinence questionnaire, 1-hour pad test and cough test short-term risk of urgency and urinary retention proportion of women who achieved a 50% reduction in urinary leakage on provocation testing stress urinary incontinence and urethral hypermobility mucp and ful urge incontinence standardized questionnaire, pad test, cough test and urodynamics flow rate continence pad usage continence grade and pad weight testing postoperative contentness pad testing, stamey continence grading, and urodynamics, including abdominal leak point pressures adverse events|outcomes at 12 months from last treatment failed to demonstrate that mid-urethral injected zuidex was equivalent to cystoscopically injected contigen in primary and secondary outcome variables. complications included cystitis in 9 of 189 injections, urinary retention in 6 in the fat injection group, urge incontinence in 9 of 68 patients and pulmonary fat embolism resulting in death in 1 of 189 procedures. both midurethral and bladder neck collagen injections improve patients' satisfaction almost equally with a small advantage for midurethral injections. : long-term follow-up demonstrated that durasphere had greater success than contigen in providing improved continence grades. at 12 months after the first injection, the two materials were equivalent with respect to the improvement in continence grade and pad weight testing. there was a significant higher increase of incontinence quality-of-life questionnaire score in the mpq group compared to controls (p = 0.017).|adult women female urodynamic stress incontinence women with urodynamic stress urinary incontinence (sui) and urethral hypermobility after an unsuccessful conservative treatment 30 elderly female patients with urodynamic stress incontinence to either 355 women diagnosed with sui due to isd and used a standardized pad test and the stamey continence grade as the primary endpoints women without previous incontinence surgery 56 patients completed the study, including 27 in the fat and 29 in the placebo group, for a total of 189 injections (91 fat and 98 saline women with sui and urethral hypermobility stress urinary incontinence women 344 women with intrinsic sphincter deficiency at 23 north american sites, and followed up for >1 year from last treatment stress urinary incontinence caused by intrinsic sphincter deficiency (isd women with stress incontinence durasphere patients and 3/21 (14 female stress urinary incontinence stress urinary incontinence (sui) due to intrinsic sphincter deficiency (isd participants' ages ranged from 26 to 84 years women with intrinsic sphincter deficiency 68 women enrolled 35 received fat and 33 received fifty-two women diagnosed with stress urinary incontinence caused by isd durasphere patients and 21/26 (81 all patients had an abdominal leak point pressure of less than 90 cm h(2)o (average 51 26 patients in each group, 25/26 (96
safety, efficacy, and costs neonatal deaths gestational age at delivery prolongation of pregnancy, number of patients bleeding mean number of maternal hospital days recurrent episodes of bleeding mean birth weights presence of respiratory distress syndrome, intracranial hemorrhage, or culture-proved sepsis maternal and neonatal morbidity blood transfusion neonatal morbidity units of blood transfused, birth weight, hospital stay and costs, and admission to neonatal intensive care unit|the mean number of maternal hospital days differed significantly between the two groups: inpatients required an average of 28.6 +/- no statistically significant differences were observed between the two groups studied.|fifty-three women with the initial diagnosis of placenta previa at 24 to 36 weeks' gestation who required hospitalization for vaginal bleeding outpatients with recurrent bleeding were readmitted for evaluation symptomatic placenta previa women with placenta previa thirty-nine pregnant women with an initial diagnosis of placenta previa at 24 to 30 weeks' gestation women with symptomatic placenta previa initially diagnosed before 37 weeks' gestation are treated as outpatients all subjects who reached 36 weeks' gestation with persistent placenta previa underwent amniocentesis twenty-six outpatients were discharged home after > or = 72 hours of hospitalization
rate of injection site reactions such as erythema, induration and subcutaneous nodules peak anti-pa igg antibody response clinically serious or dose-related toxicity or reactogenicity peak anti-pa igg antibody levels systemic reactogenicity (mostly headache immunogenicity and tolerance igg geometric mean concentration (gmc), geometric mean titer (gmt), and proportion of responders with a 4-fold rise in titer immunogenicity and safety antibody response geometric mean titers (gmt) for lethal toxin neutralization activity (tna safety, reactogenicity and immunogenicity occurrence of injection site aes geometric mean concentrations (gmc odds ratio for ordinal end point pain local reactogenicity (mostly pain occurrence of systemic aes tna response safety, reactogenicity, and immunogenicity peak antibody responses reaction rates injection site reactions|peak antibody responses to adjuvanted rpa given intramuscularly were equivalent to ava, given either intramuscularly or subcutaneously, when measured by either assay. the odds ratio for ordinal end point pain reported immediately after injection was reduced by 50% for the 4-im vs 4-sq groups (p < .001). following the first sq dose of ava, compared to males, females had a significantly higher rate of injection site reactions such as erythema, induration and subcutaneous nodules (p<0.001). systemic reactogenicity (mostly headache) was more common among rpa102 vaccinees, but only following the first vaccination (49.4% versus 15.8%; p = 0.025).|humans hundred healthy volunteers 173 volunteers healthy adults, aged 18-40 years healthy adults
number of migraine attacks propranolol sleep disturbances including nightmares (6), tiredness (8), mental changes (e.g. irritability) (3) and weight gain (4 mean frequency of attacks headache index migraine symptoms efficacy variables (headache attacks, days with headache, analgesic consumption headache parameters frequency of migraine attacks frequency of headaches platelet and plasma camp levels veps efficacy parameter severity nor duration of migraines symptomatological profile of individual migraine attacks mean attack frequency frequency of attacks and their total duration frequency of migraines and use of rescue analgesics number of headache days or the number of migraine attacks frequency of the attacks systolic blood pressure and heart rate medication relieving attacks average number of monthly crises adverse events migraine migraine index, frequency, duration, severity of attacks and headache days vasomotor headaches adverse drug reaction attack frequency and headache index prophylactic effectiveness tolerated and the number of reported side-effects serum prolactin headache efficacy headache frequency, headache severity, nausea frequency or severity frequency, intensity, and duration of migraine attacks, nor on amplitude and latency of the veps efficacy and safety hormones levels average duration or severity of migraine attacks adp-induced platelet aggregability, platelet camp, atp and adp levels, plasma camp and txb2 concentration, as well as the serum production of txb2 efficacy and tolerability migraine headache headache or nausea tolerated reduced duration of headache tolerated and safe headache response to medication global evaluation median intensity of pain and the number of attacks plasma concentration or serum production of txb2 severity of attacks and the number of analgesics blood pressure and heart rate; flunarizine percentage and severity of side-effects mean severity of attacks vep amplitude weight gain platelet function vep latency vep amplitudes number of attacks efficacy parameters (migraine hours, migraine days, and migraine intensity cardiovascular function mild adverse reactions mean duration of attacks anxiety or depression blood brain barrier severe side effects plasma concentrations mean duration of migraine in hours (h) per month migraine index, frequency of attacks and global evaluation patient profile, onset of response to therapy, final response to therapy, incidence of dropout from the trial or incidence of side-effects migraine attacks 5-ht supersensitivity migraine index number of attacks, the total duration of attacks and additional drugs taken vep amplitudes and longer latencies platelet aggregability side effects prolactin (prl), luteinizing hormone (lh) and growth hormone (gh) levels frequency and severity of headaches attack frequency duration of the attacks and the number of analgesics number of sickleave days and the use of symptomatic drugs adverse experiences frequency of attacks consumption of analgesic drugs vasomotor headache migraine frequency dizziness, fatigue, and fall in blood pressure number, duration, and severity of attacks attack frequency, migraine days, severity score, consumption of acute medication and subjective evaluation headache diaries|concerning the frequency and intensity of attacks, additional analgesics consumption and overall evaluation, both drugs proved to be highly effective in the practice as well as in the hospital study. at baseline, migraine patients had significantly higher vep amplitudes and longer latencies than did a group of 87 healthy control subjects. a statistically significant difference in effect could not be ascertained. in both groups no severe side effects were observed. chronic treatments of methysergide and propranolol, drugs exerting antagonist action at 5-ht receptors, induced a significant amelioration in 256m sufferers. among 24 fully assessable sets of tests only four showed a decrease in the frequency of headaches by more than 50%. there were no significant differences between the three treatment periods in headache frequency, headache severity, nausea frequency or severity. after propranolol treatment, the patients showed lower adp threshold values for producing irreversible platelet aggregation and lower platelet and plasma camp levels as compared to metoprolol. based on arima statistics, 39.3% of the patients showed a significant improvement of migraine during treatment with cyclandelate compared with 29.4% placed on propranolol. both tolfenamic acid and propranolol significantly reduced the number of attacks, the total duration of attacks and additional drugs taken when compared with placebo. inderal seemed to be more effective than d-propranolol, but the difference was not statistically significant (p greater than 0.05). la.p was significantly more effective than placebo in reducing the frequency of migraine attacks (p = 0.01 by variance analysis). statistical analysis did not show any significant difference between the two drugs in respect to headache or nausea. the effectiveness of neither drug correlated with a decrease in anxiety or depression demonstrated by psychological testing. headache index 0.95 propranolol and 23 patients on placebo experienced side effects (p less than 0.05). there were no significant effects of mefenamic acid or propranolol on average duration or severity of migraine attacks. both drugs showed a significant reduction in all the efficacy variables (headache attacks, days with headache, analgesic consumption) with no difference between treatments. both drugs were generally well tolerated and the number of reported side-effects was similar to those reported during the run-in period (placebo). it was not found statistical differences between groups, nevertheless there was a trend in the group using two drugs reaching lower values in migraine index, frequency of attacks and global evaluation. there was no significant difference between the two groups in terms of patient profile, onset of response to therapy, final response to therapy, incidence of dropout from the trial or incidence of side-effects. these side effects led 45% (9/20) of the nifedipine patients to withdraw from the study within two weeks. both treatments led to a significant reduction in the frequency of migraines and use of rescue analgesics with a significantly greater decrease in number of attacks for flunarizine after 1 and 4 months. both flunarizine groups were at least as effective as propranolol (p<0.001 in one-sided test). no statistical significant difference in any efficacy parameter was found between the two drugs (level 2 alpha = 0.05, alpha = 0.10). compared to the pretreatment period, prp and asa reduced migraine index, frequency, duration, severity of attacks and headache days. no significant difference was identified between divalproex and propranolol for the prophylaxis of migraine without aura. in the 37 patients who completed the trial there was no significant difference between propranolol 160 mg and femoxetine 400 mg with respect to the number of headache days or the number of migraine attacks during the last 2 months of each treatment, propranolol, however, was superior to femoxetine when the headache index was used ( all three groups reported improvement, the most noticeable being in those patients who received 80 mg of nadolol daily. it is concluded from the results that there are no differences in efficacy between metoprolol and propranolol regarding the studied parameters. adverse experiences were reported by 13 patients (16.0%) treated with cyclandelate, by 5 patients (9.1%) treated with placebo and by 19 patients (24.4%) treated with propranolol. a significant reduction in the use of medication relieving attacks was observed during the propranolol treatment as compared with the pre-treatment period. the treatment with both substances resulted in a statistically significant reduction in frequency of migraine attacks. two and 4 months after treatment withdrawal, most subjects with a negative response to the post-treatment test maintained treatment benefit, whereas benefit was lost in patients with an early onset migraine response. a statistically significant reduction in the frequency of the attacks was demonstrated in both groups.|migraine forty-eight patients (13 men and 35 women eighty-seven patients from 12 outpatient departments were admitted to the first study, while 434 patients from 99 medical practices participated in the second study patients suffering predominantly from "classical migraine 37 patients twelve patients with classical migraine were included migraine prophylaxis common migraine sufferers (25 males, 71 females) with a history of 2-6 attacks per month participated in a 4-centre trial 29 patients commenced the experiment 134 m sufferers 24 patients who continued the study to the end, the periods of 39 migraine patients 87 healthy control subjects patients with migraine 56 patients with classical or common migraine private practice of a general neurologist with a special interest in headache disorders 400 patients 20 migraine patients 142 subjects discontinued the trial prematurely, mainly because of adverse events (n=58 94 patients migraine patients migraine with or without aura 256m sufferers twenty patients discontinued the study: 12 patients on 37 patients (30 women and 7 men) selected, 32 completed the study 214 patients thirty patients with severe classical and common migraine fourty-five migraine without aura patients 58 patients with common or classical migraine 30 patients in a double-blind 76 patients with migraine with or without aura forty-nine patients commenced the trial classical and common migraine migraine without aura twelve patients withdrew because of drug failure or failure to attend checkups (6), side effects (4) or other non-drug related causes (2 fifty-eight patients forty migraineurs (10 males, 30 females 83 patients 84 patients 29 patients patients in whom beta-blockers were contraindicated were excluded from the trial 808 subjects 18 migraine patients group of 19 migraine patients fifty-five of the 74 patients who entered the trial were included at the end of the run-in period forty-one patients completed the study 31 patients with at least 3 migraine attacks migraine without aura prophylaxis 11 patients were treated with patients suffering from migraine thirty-six patients with classical or common migraine were included
time of diagnosis probability of overall survival actuarial 5 year survival incidence of curative re-operations diagnostic efficacy and costs rectal cancer earlier detection of hepatic metastases recurrence, time to detection and death rates quality of life, sf-12; physical and mental component scores, (2) anxiety and depression: hospital anxiety and depression scale and (3) patient satisfaction: patient visit-specific questionnaire asymptomatic chest radiography-detected lung metastasis asymptomatic ct-detected liver metastasis five-year survival rate survival efficacy and cost of risk local recurrence curative re-resection anxiety overall survival recurrence scores for quality of life (physical component score local recurrences survival and recurrence resectability patient satisfaction survival benefit investigations, number and timing of recurrences and deaths number of curative hepatectomies|risk-adapted follow-up has significantly improved the targeting of curative re-operations and overall survival of patients independently of risk of recurrence and has allowed a reduction in the costs of following up of disease-free patients. at 12 and 24 months there were no differences in scores for quality of life (physical component score, p=0.88 at 12 months; p=0.28 at 24 months: mental component score, p=0.51, p=0.47; adjusted), anxiety (p=0.72; p=0.11) depression (p=0.28; p=0.80) or patient satisfaction (p=0.06, 24 months). after a median follow-up of 48 months, there was no difference in the probability of overall survival in the whole series (hazard ratio [hr] = 0.87; 95% ci, 0.49 to 1.54; p = .62). patients subjected to intensive follow-up have recurrence diagnosed earlier, and have more operations for recurrence, but the survival results suggest that any major improvement by intensive follow-up is unlikely. on completion of 5-year follow-up, there was no significant difference in survival between the two groups. the five-year survival rate in group a was 58.3 percent and in group b was 73.1 percent.|patients after colorectal cancer surgery three hundred twenty-five patients who underwent curative resection of colorectal cancer patients with rectal cancer patients after treatment for colon cancer by either general practitioners or surgeons patients with stage ii colorectal cancer or those with rectal tumors patients with colorectal cancer colon cancer patients patients with stage ii or iii colorectal cancer a total of 259 patients were included: 132 were observed according to the simple strategy and 127 were observed according to the intensive strategy 203 consenting patients who had undergone potentially curative treatment for colon cancer 358 patients treated by surgery alone for colorectal cancer 2 patients in group a who had curative re-resections died as a result of cancer colorectal cancer 170 patients were available for follow-up at 12 months and 157 at 24 months between 1987 and 1990, 207 consecutive patients who underwent curative resections for primary untreated large-bowel carcinoma 34 patients in the intensive follow-up group and for the 57 patients in the low-intensity follow-up group who were free from disease after primary surgery was very similar colorectal cancer patients patients with colorectal cancer who have undergone curative resection 597 patients less than 76 years old treated with radical surgery for colorectal cancer were included in the study from 1983 to 1994 192 patients undergoing risk-adapted follow-up, intensive and low-intensity; group 2, 145 patients undergoing minimal surveillance patients with colon cancer
mood and on objective, subjective, and clinician-rated measures of sleep ham-d-17 and ham-d-anxiety symptoms of major depressive illness effectively total hrds score or in subscores for anxiety or suicidality mean ham-d total score 21-item hamilton rating scale for depression (ham-d) and the clinical global impressions-improvement scale (cgi-i), with scores of < or = 7 on the ham-d and < or = 2 on the cgi ham-d17, ham-d17 response, and ham-d17 remission rates sleep efficiency and rem sleep antidepressant and antianxiety efficacies montgomery asberg depressive rating scale (madrs nausea and diarrhoea sleep efficiency or number of awakenings, stage 1 or rem sleep, or rem latency madrs positive treatment response rates efficacy (hdrs, cgi) or safety (adverse events, laboratory examination, vital signs nausea, vomiting and diarrhoea symptoms of dizziness digit symbol substitution test agitation, anxiety, suicidality, and global impressions equivalent antidepressant efficacy full remission of their depression (ham-d21 total score individual ham-d items 9 (agitation), 10 (psychic anxiety), and 11 (somatic anxiety 21-item hamilton rating scale for depression, hamilton rating scale for anxiety, clinical global impressions, raskin depression scale and covi anxiety scale depressive symptoms and concomitant anxiety mean ham-d, madrs, and cgi-s scores baseline hamilton rating scale for depression score montgomery and asberg depression scale (madrs), the hamilton depression scale, the clinical global impressions (cgi), and a checklist of symptoms and side-effects 21-item hamilton rating scale for depression (hrsd hamilton depression rating scale (hdrs), montgomery-asberg depression rating scale and clinical global impression (cgi hamilton depression rating scale (hdrs-17 items) and clinical global impression (cgi) scale ham-a response rate retardation pole of the mood, anxiety, retardation, danger scale nausea and vomiting adverse reactions efficacy and response time five individual items, hamilton depression scale incidence of adverse events weight changes antidepressant efficacy and safety proportion of rem sleep rem latency and suppressed rem sleep sedation, nausea and vomiting total score on the hamilton rating scale for depression and the global improvement score on the clinical global impressions scale clinical global impression (cgi), therapeutic index (ti), tolerance global impression acute treatment efficacy and tolerability hamilton depression rating scale and the montgomery-asberg depression rating scale (montgomery and asberg, 1979)--and a self-rating scale--levine pilowsky depression questionnaire response rates, whether defined by end-of-treatment hamilton rating scale for depression (ham-d) score hamilton anxiety rating scale (hars) and of sleep disturbances adverse drug reactions (adrs objective, subjective, and clinician-rated measures of sleep compliance quality-of-life improvements incidence of early patient withdrawals due to treatment-emergent adverse events response rates quality of life and cognitive function drowsiness/sedation and excessive sweating assessment criteria geriatric depression scale (gds) and clinical global impression (cgi ham-d remission rate hamilton rating scale for depression (ham-d) sleep disturbance factor score dry mouth 21-item hamilton rating scale for depression (ham-d), and depressive symptoms scores of the items "suicide", "psychic anxiety", "somatic anxiety", "agitation" and "insomnia overall depression and anxiety tolerability ratings constipation, dyspepsia, tremor, sweating and abnormal ejaculation sleepiness hamilton psychiatric rating scale for depression (ham-d number of patients reporting at least one adverse event symptoms of anxiety response and remission rates sleep continuity mean values severe depression agitation, anxiety and insomnia therapeutic efficacy hamd score overall response health transition scale of the 36-item short-form health survey questionnaire haematological or clinical chemistry changes central nervous system events psychic anxiety item therapeutic efficacy and safety/tolerability sleep continuity and increased rapid eye movement (rem) sleep dry mouth, drowsiness/sedation, constipation, and dizziness/lightheadedness madrs score hamilton depression rating scale (hdrs) and the montgomery & asberg depression rating scale (madrs hrsd, zung self rating scale for depression, montgomery-asberg scale for depression, clinical global impression for severity and improvement of depressive symptoms shaking. madrs total score covi anxiety scale hamilton depression score sleep polygraphic recordings mean reductions in ham-d total score good antidepressant efficacy body weight, blood pressure, pulse rate, temperature, physical conditions, laboratory tests, adverse experiences and concomitant medication effective antidepressant activity constipation dropout rates hdrs or madrs total scores montgomery and asberg depression rating scale (madrs) score anticholinergic side effects sleep disturbances hamd-total score effectiveness and good tolerability widlcher psychomotor retardation scale, sheehan disability scale, and cgi safety and tolerability profiles clinical efficacy and safety clinical global impressions (cgi)-severity of illness scale score dimensions measuring depression or mental health hamilton rating scale for depression (hrsd nausea and headache hamilton rating scale of depression scores psychological dimensions of general health and moderately impaired on physical dimensions hamilton rating scale for depression (ham-d), hamilton rating scale for anxiety depression (ham-d, had, cgi number of awakenings, stage 1 sleep, and rem latency ham-d response rate sleep somatization factor scores hamilton depression rating scale, a side-effect checklist and a regular ecg assessment hamilton depression scale score hdrs total score final ratings on the hamilton rating scale for depression (ham-d21) total score, ham-d21 depressed mood item, montgomery-asberg depression rating scale total score, and clinical global impressions scale nausea, dyspepsia, anorexia and insomnia baseline and endpoint depression and anxiety severity tolerability and efficacy nausea and influenza-like symptoms 17-item hamilton rating scale for depression (ham-d-17) total score overall incidence of adverse effects rapid-eye-movement (rem) sleep or increase rem latency cognitive improvement on several measures depressive symptoms quality of life adverse events; tolerability profiles some clinician- and patient-rated sleep disturbance scores hamd total score anxiolytic activity clinical global improvement severity of illness score nausea and nervousness ham-d sleep disturbance factor score efficacy and safety normal objective, and clinician- and patient-rated assessments of sleep final madrs scores total ham-a score mean scores for most depression scales change of hamd17 total score mean endpoint scores for all rating scales cardiovascular effects mean hdrs anxiety measured by ham-a total mean score depression ratings total rem sleep time cgi-improvement responder rates sleep and anxiety esrs scale for akathisia rem latency insomnia and asthenia total hamilton depression rating scale score discontinuations for adverse events antidepressant efficacy and tolerability dropout rate due to side effects insomnia improvement sleep efficiency, number of awakenings, percentage of awake and movement time, percentage of rem and stage 1 sleep, and rem latency 17-item hamilton rating scale for depression (hamd), the von zerssen depression scale (ds), clinical global impression (cgi), and patients' overall evaluation depression and insomnia measures of depression, including remission of depressive symptoms total ham-d score montgomery-asberg depression rating scale, cgi-severity of illness and cgi-improvement, and patient global impression of improvement ham-d, clinical global impressions, the visual analogue mood rating scale (vamrs), and the quality of life enjoyment and satisfaction questionnaire (qlesq cardiac function cgi hamilton rating scale for anxiety nausea, other gastrointestinal symptoms, nervousness, dizziness and sleep disorders nausea sexual dysfunction global improvement safety and efficacy hdrs score incidence of discontinuation for adverse events vital signs and adverse experiences antianxiety effects hamilton depression scale scores steady-state levels rem sleep parameters montgomery asberg depression rating scale (madrs), the hard diagram, the check list for somatic symptoms and side-effects headache and blurred vision adverse effects complaints of dry mouth, constipation, and dizziness stis dry mouth and dizziness/lightheadedness sleep measures ham-d-17 total score mean total endpoint hdrs scores and percentages of cgi very good and good responses ham-d scores side-effects overall depression final on-therapy scores on the ham-d, montgomery-asberg depression rating scale (madrs), and clinical global impressions severity of illness (cgi-s) and improvement (cgi-i) scales overall, efficacy ratings ham-d and cgi-severity scores ecg or stis mean hamilton rating scale for depression (21-item ham-d) total score sleep quality weight loss weight increase and somnolence antidepressant and anxiolytic efficacy social functioning ham-a scores frequency or in severity of adverse events clinical evaluation [montgomery-asberg depression rating scale (madrs), clinical global impressions (cgi)] and quality of life [functional status questionnaire (fsq tolerability relieving depression and accompanying symptoms of anxiety hamilton rating scale for depression, hamilton rating scale for anxiety, clinical global impressions-severity, and clinical global impressions-improvement sleep disturbances, nausea, and headaches hdrs rates or mean numbers of adverse events adverse events overall effectiveness rates of treatment response ham-d depressed mood item hamilton rating scales for depression and anxiety, the montgomery asberg depression rating scale, clinical global impressions scale, zung self-rating scale for anxiety and the leeds sleep evaluation questionnaire complaints of dry mouth and dizziness on standing mood and cognitive functions percentage of awake and movement time sleep efficiency depression improvement headache estimated probabilities of response and remission effective and well tolerated cognitive functioning sleep electroencephalographic (eeg) recordings degree of depression and anxiety improvement rate of positive treatment response average total scores on the hamilton rating scale for depression (ham-d remission rates blood pressure, pulse, or weight incidence of aes suggestive of activation or sedation memory performance nervousness/anxiety and nausea frequency of adverse events depression subscale of the irritability, depression and anxiety scale ham-d and clinical global impressions scale tolerated and safe efficacy and tolerance hamilton rating scale for depression (ham-d) and the clinical anxiety scale mean scores on the montgomery-asberg depression rating scale clinical status at base line (diagnosis, history and duration of the depressive illness, madrs and hard diagram scores).(abstract tremor, rash, nausea and headache occurring with fluoxetine, and drowsiness, dizziness and visual disturbance with dothiepin nausea and nervousness for fluoxetine, and dry mouth, dizziness, and drowsiness for amitriptyline initial ham-d score mean score of hamilton rating scale for depression (hrsd efficacy using the hrsd, montgomery-asberg depression rating scale and clinical global impression; for tolerability, adverse events hamilton depression mood item objective measures of sleep, i.e. suppression of rem sleep individual ham-d items including item 4 (insomnia onset dizziness effective and well tolerated antidepressant patient and observer ratings of depression symptoms of depression success rate hamilton depression rating scale, the raskin depression scale, the covi anxiety scale, and a clinical global impression sleep questionnaire covers the complaints listed in criteria for insomnia disorders baseline montgomery and asberg depression rating scale (madrs) total score hamilton psychiatric rating scale for depression (ham-d), the montgomery-asberg depression rating scale (madrs), and the clinician's global impressions-severity of illness scale (cgi-si mean scores on the hamilton depression rating scale anxiety and suicidality 17-item hamilton depression rating scale (hdrs), the montgomery-asberg depression rating scale (madrs) and the clinical global impression (cgi excessive sweating hrsd items "psychic anxiety", "somatic anxiety", "agitation ham-d responder rate final hamilton depression rating scale (ham-d) score sinus cycle length number of awakenings ham-d ham-d sleep disturbance factor cognitive functions suicidal feelings adverse event self evaluation scales mild depressive episodes hamilton depression rating scale generalized tremor qrs duration pr interval social adaptation self-evaluation scale total scores drowsiness and disturbed sleep headache and nausea adherence and efficacy and adherence ham-d, madrs, and cgi-si esrs scores for akathisia number of responders mean total 17-item ham-d scores remission, clinical global impression severity of illness and global improvement scores and montgomery-asberg depression rating scale 17-item hamilton rating scale for depression (ham-d) and the clinical global impressions (cgi) scale safe and well tolerated percentage of hamd responders sleep efficiency, total sleep time, stage 2 sleep, and shorter wake time antidepressant efficacy (ham-d, cgi mean total score tiredness, drowsiness and diarrhoea hamilton depression rating scale (hdrs i, cgi-s), anxiety (covi), sleep (leeds sleep evaluation scale) and quality of life (sip agitation, nausea, fatigue, and insomnia body weight subjective mood ratings hamilton rating scale for depression (ham-d), clinical global impression, and subjective mood ratings (45-item self-rating scale clinical global impressions efficacy leeds sleep evaluation scale and on sip items relating to sleep and rest, emotional behaviour and ambulation 24-item hamilton rating scale for depression and clinical global impressions scale ratings mean hamd sleep factor response rate anxiety total number of adverse events low insomnia additional efficacy assessments (montgomery-asberg depression rating scale, clinical global impression occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes nausea, headache, and dizziness with venlafaxine and nausea, headache, and insomnia with fluoxetine efficacy and tolerability tolerated mean scores of all depression rating scales general health survey (sf-20) and 15d measure of quality of life hamd sleep disturbance scale anxiety (anxious depression safety assessments included treatment-emergent adverse events (aes), reasons for discontinuation, and aes leading to discontinuation weight gain anxiety symptoms objective, subjective, and clinician-rated measures of sleep disturbance clinical global impression (cgi) score weight change: weight loss cognitive performance hamilton depression rating scale (hamd) total score overall symptoms of depression hamilton depression scale rem sleep initial hamilton rating scale for depression (ham-d safety ham-d) or remission rate of adverse events antidepressant efficacy and quality of life in depression hamilton rating scale for depression depression, anxiety, and quality of life agitation and psychic anxiety symptoms raskin depression scale, the covi anxiety scale, and the leeds sleep questionnaire anxiety scores efficacy (madrs, cgi, covi) or in terms of safety, except for the cgi 'severity of illness work or productivity losses electrocardiogram (ecg) and systolic time intervals (stis motor nervousness or restlessness good tolerability and safety profile success rates established rating scales (madrs, ham-d, bprs side effects anticholinergic side-effects insomnia number of hospitalisations and duration of stay frequency and severity of volunteered adverse events overall tolerance utilisation of medical resources somnolence hamilton depression rating scale, the clinical global impression (severity and improvement) scales, and the patient global impression (improvement) scale frequencies of occurrence of adverse reactions patient response 21-item hamilton rating scale for depression (ham-d), and clinical global impressions scale for severity and improvement clinician- and patient-rated measures of depression symptoms and factors, cognitive functioning, and quality of life, as well as plasma drug concentrations adverse events scale anticholinergic effects, dizziness, drowsiness, somatosensory disturbance, and excessive sweating antidepressant efficacy heart rate efficacy and acceptability incidence of treatment-emergent adverse events|common side effects of doxepin were dry mouth, drowsiness/sedation, constipation, and dizziness/lightheadedness. the percentages of patients who achieved full remission of their depression (ham-d21 total score < or = 7) at the end of treatment were 37%, 22% and 18% for the venlafaxine xr, fluoxetine and placebo groups, respectively. the most commonly reported adverse events were nausea, other gastrointestinal symptoms, nervousness, dizziness and sleep disorders. a significantly greater proportion of patients treated with either reboxetine or fluoxetine also achieved a response ( patients taking fluoxetine reported less side-effects than those taking amitriptyline. between groups, the mean score of hamilton rating scale for depression (hrsd) was significantly different only after 3 weeks of treatment (am 14.7+/-5.7 vs fx 17.3+/-6.2 (p = 0.02), whereas at the end of the trial it was similar (am 8.15+/-6.9; fx 8.96+/-6.6). the results confirm the effectiveness and good tolerability of fluoxetine in the treatment of depressive disorders. intragroup analysis showed that amineptine was significantly superior to fluoxetine on the retardation pole of the mood, anxiety, retardation, danger scale. there were differences in the side-effect profiles, with fluvoxamine being associated with less nausea than fluoxetine. in sleep eeg measures, trimipramine demonstrated clear-cut effects on sleep measures resulting in higher values for sleep efficiency, total sleep time, stage 2 sleep, and shorter wake time. there were no statistically significant differences in rates or mean numbers of adverse events between paroxetine-treated patients and fluoxetine-treated patients. fluoxetine was associated more frequently with nausea (p less than .05), while nortriptyline was associated more frequently with dry mouth (p less than .05). there were no significant differences in secondary efficacy outcome measures, but more patients achieved a > or = 50% decrease in hdrs score on moclobemide (71% vs 38%, p < 0.05). both groups showed a significant amelioration at the end point for hamilton rating scale of depression scores compared to the baseline value. discontinuations for adverse events were comparable (fluoxetine, 21.4%; imipramine, 22.6%). among patients who increased their dose at 2 weeks, venlafaxine was significantly (p < 0.05) superior from week 3 onward on the ham-d. 6. both agents were effective according to weekly and endpoint analyses, and there was no evidence of significant effects on blood pressure, pulse, or weight. regardless of how strict the definition of response, we found fluoxetine to be as effective as doxepin in our group of melancholic outpatients. patients in the fluoxetine group reported superior response on the health transition scale of the 36-item short-form health survey questionnaire and numerically greater improvement on the hamilton depression rating scale. on visual analogue scales assessing the clinical profile of the compounds, fluoxetine was rated as exhibiting more psychostimulating activity than milnacipran (p = 0.0008). at study endpoint, both treatments produced a significant improvement over baseline on all efficacy variables (p < 0.001). venlafaxine was superior in efficacy to fluoxetine; total scores for both the madrs and the ham-d were significantly (p < or = 0.05) lower in the venlafaxine group than in the fluoxetine group at weeks 4 and 6. the most frequently reported side effects were nausea and nervousness for fluoxetine, and dry mouth, dizziness, and drowsiness for amitriptyline. both venlafaxine and fluoxetine produced significant reductions from baseline to day 56 in mean ham-d, madrs, and cgi-s scores, but no significant differences were noted between groups. the drugs did not differ with respect to psychiatrists' ratings, but amitriptyline was slightly superior with respect to patients' ratings. the efficacy and tolerability of moclobemide (300 or 600 mg daily) and fluoxetine (20 or 40 mg daily) were compared in a 6-week, double-blind study of 25 inpatients and 24 outpatients who had major depressive episodes without psychotic features (dsm-iii-r). both treatment groups showed a statistically significant improvement from baseline at one week, and this was maintained until the end of treatment for all of the following measures: hamilton rating scales for depression and anxiety, the montgomery asberg depression rating scale, clinical global impressions scale, zung self-rating scale for anxiety and the leeds sleep evaluation questionnaire. suicidal feelings were reduced to a greater degree on fluoxetine than on mianserin and placebo at weeks 6 and 7. headache and blurred vision were reported significantly more often (p < 0.05) in the fluoxetine group, whereas significantly more dry mouth was reported (p < 0.05) in the moclobemide group. side-effect profiles were not significantly different between groups except for a significantly greater frequency of dose-related increase in heart rate > or = 100 bpm in milnacipran recipients and a significantly greater weight loss in fluoxetine recipients. the decrease from baseline on the ham-d was larger in the mirtazapine than in the fluoxetine group throughout the treatment period, reaching statistical significance at days 21 and 28. as measured by ham-d and cgi-severity scores, there was a significant (p < .001) improvement from baseline to each follow-up visit in both treatment groups with no statistically significant difference between groups. no differences in efficacy were found between the two groups. side effects were not predictive of being adherent or not, but a higher initial ham-d score predicted a higher adherence to the medication regimen. assessment of anxiety using the hamilton anxiety rating scale (hars) and of sleep disturbances using a sleep questionnaire was carried out before treatment and at week 4. nefazodone was associated with normal objective, and clinician- and patient-rated assessments of sleep when compared with fluoxetine. we found that although clinically both drugs were equally effective, the improvement of memory performance in the fluoxetine-treated patients was significantly greater compared with that of the desipramine-treated patients. for fluoxetine, ham-d scores were significantly lower at weeks 1 and 2 compared with those of trazodone. a double-blind clinical trial was undertaken to evaluate the clinical efficacy and safety of fluoxetine compared with imipramine in the treatment of 59 outpatients suffering from major depressive disorder. the success rate at the end of the treatment (madrs < or = 10) was significantly higher in the fluoxetine group (fluoxetine group: 48.4% vs tianeptine group: 28.1%) (p = 0.005). ham-a scores decreased by 59% for both treatment groups. fluoxetine produced greater improvement than placebo on all major efficacy parameters and was comparable to imipramine with respect to the primary indicators of depression. there were no consistently significant differences between the two active drugs although a trend favored imipramine on a number of measures. both patient groups had significantly lower mean scores on the hamilton depression rating scale (hdrs) 6 weeks after entry to the trial (p < 0.001), but there were no differences between the groups, either at baseline or after 6 weeks, in total hrds score or in subscores for anxiety or suicidality. amitriptyline 150-200 mg daily shortened the sinus cycle length by a mean of 12%, prolonged the pr interval by 8% and the qrs duration by 10%. cognitive performance was evaluated by means of the buschke selective reminding test, the blessed information and memory test, the clifton assessment schedule, the cancellation task test, and the wechsler paired word test; the hamilton rating scale for depression (ham-d) and the clinical anxiety scale were administered to assess the course of depressive and anxiety symptoms, respectively. analyses revealed no significant differences between treatments in the percentages of patients with substantial worsening, any worsening, worsening at endpoint, or improvement at endpoint in the ham-d sleep disturbance factor in either insomnia subgroup. significantly greater improvement for the sertraline group was apparent on the digit symbol substitution test, but not on two other measures of cognitive functioning. both drugs produced a similarly positive response on the primary efficacy measures, with 12-week responder rates of 73% for sertraline and 71% for fluoxetine. no statistically significant differences between the two treatment groups were noted regarding efficacy (hdrs, cgi) or safety (adverse events, laboratory examination, vital signs). venlafaxine xr but not fluoxetine was significantly better than placebo at week 2 on the ham-d depressed mood item. duloxetine was superior to placebo in change on the ham-d-17 (p = .009). before treatment, patients on average rated themselves as very impaired on psychological dimensions of general health and moderately impaired on physical dimensions, compared with population norms. no significant differences between treatment groups were found in the reductions in mean total score with the madrs, subset analyses of ham-d scores associated with anxiety and sleep revealed no statistically significant differences between the 2 treatments though improvement in anxiety scores was marginally greater for those receiving fluoxetine by the end of the trial. as indicated by the significant decrease in the hamilton depression scale and the montgomery asberg depression scale, fluoxetine showed similar antidepressant effects to amitriptyline with significantly fewer adverse effects. patients taking fluoxetine also showed significant improvements at endpoint on the madrs and earlier in the study on the ham-d. no new or unusual safety concerns were generated during this study. during the six-week course of treatment with lohyp-57, the hamilton global score fell from 16.60 points at entry to 7.91 points, and in the fluoxetine sample it fell from 17.18 to 8.11 points. fluoxetine was comparable to amitriptyline in all efficacy measures except the hamd sleep factor. venlafaxine and fluoxetine were well tolerated, with the most frequently experienced adverse events being nausea and headache. both compounds proved to be similarly effective as measured by change in ham-d17, ham-d17 response, and ham-d17 remission rates. efficacy was measured by the hamilton rating scale for depression (ham-d), clinical global impression, and subjective mood ratings (45-item self-rating scale). recent memory improved significantly in the fluoxetine group but not in the amitriptyline group. at day 42, the mean reductions in ham-d total score (compared with baseline) were 11.8 and 10.6 for the mirtazapine and fluoxetine groups, respectively; however, the changes were not statistically significant. improvement on the hamilton rating scale for depression was significant for both treatments from week 1 through the end of the study and did not differ between the two treatments at any week. in fact clinical efficacy seems to remain comparable while side-effects are significantly less frequent. patients also demonstrated similar change-over-time improvement in ham-d-17 and ham-d-anxiety a final hamilton depression rating scale (ham-d) score < 7 was attained in 41% of venlafaxine-treated and 36% of fluoxetine-treated patients. the impact of both drugs on sleep measured using the leeds sleep evaluation questionnaire showed no significant differences between treatments, however drowsiness and disturbed sleep were reported more frequently as side effects with dothiepin. significant decreases (p<.001) of 50% in the hypericum group and 58% in the fluoxetine group in the hamd score and of 42% and 52% on the ds spoke to the efficacy of both medications. efficacy was measured by the hamilton depression rating scale, the clinical global impression (severity and improvement) scales, and the patient global impression (improvement) scale. paroxetine and fluoxetine showed comparable efficacy at the end of the 6-week treatment period, but a statistically significant difference in the number of responders at week 3 in favour of paroxetine was observed. on comparing treatment by psychiatrist and general practitioner no significant differences were found regarding age, sex, number of previous episodes and duration of the recent episode and outcome. mean scores for most depression scales improved more in patients taking fluoxetine than in those receiving imipramine (p less than .05). both drugs were effective and there were no statistically significant differences between them in the area under the curve of change from baseline in the hamilton depression rating scale (hamd) total score. a double-blind clinical trial was undertaken to evaluate clinical efficacy and safety of fluoxetine in comparison with the standard tricyclic antidepressant, imipramine, in the treatment of depressive illness. no significant differences were observed between dropout rates in the two groups but anti-cholinergic side-effects were significantly more frequent with nortriptyline than with fluoxetine but there was no significant difference in cardiovascular effects in particular qtc prolongation. primary outcome measurements included the 21-item hamilton rating scale for depression (ham-d) and the clinical global impressions-improvement scale (cgi-i), with scores of < or = 7 on the ham-d and < or = 2 on the cgi the 2 treatment groups were similar in terms of number of hospitalisations and duration of stay, whether related to depression or not. compared to imipramine, fluoxetine was associated with fewer complaints of dry mouth, constipation, and dizziness. the frequencies of occurrence of adverse reactions were also similar, but sedation, nausea and vomiting were reported more frequently with fluoxetine, and insomnia was experienced with moclobemide. a significant difference was observed in females (fluoxetine, -17.8; maprotiline, -13.9; p=0.017) between treatment groups, but not in males. madrs responders were 58% and 56% with tianeptine and fluoxetine, respectively (p = 0.710). no differences in efficacy were observed, but the profile of side-effects differed with tremor, rash, nausea and headache occurring with fluoxetine, and drowsiness, dizziness and visual disturbance with dothiepin. fluoxetine was found to have a more marked therapeutic effect than that of amineptine: better efficacy, fewer side-effects, and quicker and better improvement on the self evaluation scales. both treatments resulted in some improvement in social adaptation self-evaluation scale total scores and this was more evident for those patients treated with reboxetine who achieved remission. constipation, dyspepsia, tremor, sweating and abnormal ejaculation were more common in paroxetine-treated subjects, whereas nausea and nervousness were more frequent in fluoxetine-treated patients. significantly fewer fluoxetine-treated patients discontinued due to adverse events than did imipramine-treated patients (7% vs. 30%, respectively). fluoxetine significantly decreased sleep efficiency and rem sleep and increased number of awakenings, stage 1 sleep, and rem latency compared with baseline. in both treatment groups, mean scores on the hamilton depression rating scale decreased significantly between baseline (27.8, venlafaxine; 29.2, fluoxetine) and the end of the study (8.7, venlafaxine; 8.2, fluoxetine). no significant difference was shown between the two drugs, either in terms of efficacy (madrs, cgi, covi) or in terms of safety, except for the cgi 'severity of illness' which was lower at the end point with tianeptine than with fluoxetine. important differences were found in the side-effects profile of each group, their incidence being significantly lower and tending to disappear during the course of treatment in the group of patients treated with fluoxetine. the total score on the hamilton rating scale for depression and the global improvement score on the clinical global impressions scale favored trazodone at the end of 3 weeks of treatment. mean values for all efficacy measurements were improved over baseline with fluoxetine and imipramine treatment (p less than .001).|patients with depression and anxiety moderate to severe major depression three hundred eighty-two patients inpatients with major depression female patients 44 outpatients with major depressive disorder geriatric depression 100 depressed patients (male and female) drawn from 8 general practices twenty-eight elderly inpatients suffering from major depressive episodes (diagnosed according to dsm iii patients (n = 284) with dsm-iv major depressive disorder anxious depression 149 out-patients (129 females and 20 males elderly depressed patients patients age 70 or over with major depression 109 patients with major depression and melancholia seventy inpatients with a dsm-iii-r major depression thirty patients in the mirtazapine group and 22 in the depression in general practice 209 patients with new episodes of depression selected from 612 consecutive depressed patients representative of those consulting psychiatric services in finland depressed patients in double-blind 42 patients randomized, 2 patients never received drugs and 2 65 depressed out-patients major depressive disorder in adults primary-care setting in france mild to moderate depression fifty-eight patients with dsm-iii-r depression atypical depression depressed inpatients and outpatients 128 outpatients (mean age: 41.3 depressed patients with high levels of anxiety major depression (dsm-iii-r 40 patients 48 adult outpatients who met the diagnostic and statistical manual of mental disorders (dsm iv), forth edition for major depression, based on the structured clinical interview for dsm iv participated in the trial outpatients with nonpsychotic major depressive disorder and insomnia the mean age was 37 years, and 70% of the patients were female patients (n = 108) with dsm-iv major depression and high levels of anxiety 169 patients with major depression patients with anxious depression elderly depressed patients followed in general practice 359 outpatients depressed patients 178 patients with major depression six patients were prematurely withdrawn from treatment with the study medication for this reason sd age = 75.4 25 inpatients and 24 outpatients who had major depressive episodes without psychotic features (dsm-iii-r outpatients with major depression major depression 43 evaluable patients (23 major depressive disorder in primary care 237 patients depressed outpatients 81 depressed patients were included 65 inpatients and 34 outpatients suffering from major depressive episodes (dsm iii-r patients suffering from dsm-iii major depression and with a score of 18 or more on the a sample of 120 patients, all of whom met dsm-iii criteria for major unipolar depressive disorder two-hundred and thirty-four patients were included in an itt analysis up to last visit (116 146 moderately depressed patients with associated anxiety 89 patients with bipolar depression met diagnostic criteria for melancholic depression elderly depressed patients (icd-10 criteria major depressive disorders women as men major depression in outpatients elderly depression all patients who received one dose of study medication were included in the observed-case analysis (no missing data were replaced outpatients with depression and concomitant anxiety a total of 150 patients were enrolled in the study and 62 patients receiving adult patients with major depressive disorder eighteen outpatients with major depression (diagnosis was made according to dsm-iii criteria patients with moderate to severe major depressive disorder major depressive episodes elderly patients with mild or moderate depressive episodes according to icd 10 (international statistical classification of diseases and related health problems major depressive disorder with associated anxious symptoms ('anxious depression depressed chinese patients patients hospitalized for major depression and melancholia 59 outpatients suffering from major depressive disorder geriatric out-patients with major depressive illness 128 patients eligible to be randomized, with 66 patients receiving double depression patients (n = 42) with double depression (dsm-iii-r: dysthymia with superimposed major depressive episode patients with dysthymia or major depression in partial remission 387 patients with depressive episode, or recurrent depressive disorder, or bipolar affective disorder (icd-10 27 subjects began active treatment sixty patients were treated with outpatients with dsm-iii-r major depression, a minimum score of 20 on the 286 psychiatric outpatients with dsm-iii-r major depression or bipolar disorder (depressed major depression with associated anxiety (anxious depression 88 patients in the 205 outpatients with acute major depression of moderate severity primary-care setting in france, outpatients fulfilling dsm iv criteria for a major depressive episode hospitalized patients with dsm-iii major depression without psychotic features moderately depressed, ambulatory outpatients 52 patients completed the study major depression with atypical features unipolar major depressive disorder 203 patients 231 patients (116 receiving sertraline, 115 receiving 198 outpatients with dsm-iii major depression, of whom 145 completed at least 2 weeks of active treatment outpatients with depression and anxiety 49 patients receiving three hundred fourteen patients 61 patients 122 patients with major depressive illness 281 patients with dsm iii-r diagnosis of dysthymia or a single episode of major depression in partial remission 12.6; 63 men and 65 women) with moderate to moderately severe major depression without a history of mania or hypomania were recruited between 1993 and 1994 patients with high levels of baseline anxiety symptoms during the acute treatment of major depression depressed elderly outpatients 34 patients fitting the research diagnostic criteria for a major depressive disorder elderly patients suffering from major depressive episode defined according to dsm iii-r criteria, newcastle depression scale < or = -20, without associated dementia mini mental status (mmse), treated by general practitioners in ten different french regions during 3 months outpatients with major depression who do not respond early to treatment patients with major depression 55 patients on young women to non-tricyclic antidepressants 124 subjects with research diagnostic criteria-compatible agitated depression major depressive disorder subjects over the age of 65 years depressive disorders outpatients with major depressive disorder one hundred forty-five patients severely depressed outpatients who fulfilled the dsm-iii-r criteria for nonpsychotic major depressive disorder and had a score of 20 or more on the hamilton rating scale for depression (21 item) participated in this two-center study patients with bipolar depressive disorder 70 patients (mean age, 49.7 years) suffering from mild to moderate depression received one tablet of either 108 out-patients, from nine italian centres, entered into the study, of whom 88 were evaluable (48 19 depressed geriatric patients outpatients, 18 years and older, who met dsm-iv criteria for major depressive disorder were included (n = 301 randomized; 232 completed 44 psychiatric outpatients with dsm-iv unipolar major depressive disorder fifty patients completed the 6-week trial 139 patients patients with a major depressive episode (dsm-iii-r), a baseline score of > or=21 on the 17-item hamilton rating scale for depression (ham-d), and > or=2 on ham-d item 1 (depressed mood fifty-three patients (mean age, 40 years; 22 men, 31 women 8 general practitioners and 7 specialists in the field of psychiatry and neurology participated 40 depressed outpatients forty-two patients with atypical depression by the columbia criteria patients with moderate to severe depression 173 patients (aged 18-65 years) with dsm-iv major depressive disorder subjects with major depression, subtype agitated, the risk fifty-six patients (fluoxetine n = 23, amitriptyline n = 23) completed the 6 week study 105 depressed patients depressed inpatients 63 outpatients with major depressive disorders of mild or moderate severity patients who had received an adequate trial of medication indicated a trend toward relatively more fluoxetine-treated patients meeting clinical criteria for resolved depression 68 patients hospitalized with major depression and melancholia patients were diagnosed as having major depression, according to dsm-iii criteria, when interviewed with the diagnostic interview schedule 133 patients with a diagnosis of major depressive episode (dsm-iv) and scoring 15 or more on the 17-item hamilton rating scale for depression (ham-d patients with major depression and associated anxiety hospitalized and day care patients with dsm-iv major depression and melancholia and a baseline montgomery-asberg depression rating scale (madrs) score of > or = 25 were eligible 66 patients suffering from major depressive disorder and treated in a double-blind manner with n=33) in patients over age 70 with a diagnosis of major depressive disorder 93 major depressive outpatients n = 64) with 64 depressed out-patients inpatient depression outpatients fulfilling dsm-iii-r criteria for major depressive disorder 125 patients with major depression treated for an initial phase of 6 weeks and then followed up for a further 6 months ambulatory therapy of depressed patients one hundred and eighty three patients with dsm-iii-r major depressive illness a total of 157 patients geriatric depressed patients, but only 13 completed 6 weeks on study medication sample population consisting of chinese patients suffering moderate-to-severe depression 100 outpatients with major depressive disorder major depressive episode 124 evaluable patients in each treatment group ambulatory patients with a depressive syndrome in a clinical trial with private practitioners one hundred and sixty-eight patients with acute major depressive episodes depressed out-patients 289 inpatients with endogenous depression 43 outpatients with major depression after a 1-week single-blind patients with major depressive illness all 128 patients completed a 1-week outpatients with major depressive episode; 184 patients forty-four outpatients with moderate to severe, nonpsychotic major depressive disorder (dsm-iii-r) and insomnia geriatric patients with major depressive disorder one hundred fifty-four subjects with dsm-iv major depression who met the columbia criteria for atypical depression outpatients with major depression and concomitant anxiety depressed nondemented elderly patients 118 men and women, ages 18 to 70 years, hospitalized for major depressive disorder twenty-five were studied while hospitalized for treatment, and 33 were studied as outpatients two hundred thirty-six outpatients 60 years of age and older who met dsm-iii-r criteria for major depressive disorder received 1 week of 142 outpatients affected by major depression with relevant anxiety and agitation depressive illness 27 patients given patients with mood-reactive atypical depression 36 depressed ambulatory patients with patients with moderate to severe major depression hospitalized patients with major depression and melancholia 30 hospitalized patients inpatients with major depression and melancholia 72 of these patients were assigned to the icd 10 diagnostic criterion f32.0 (mild depressive episode), while 77 patients were suffering from moderate depressive episodes, corresponding to f32.1 major depressive disorder patients one hundred patients were recruited into the study, of whom 78 were evaluable for the efficacy analysis seventeen patients with major depressive episode depressed geriatric patients major depressive illness and 43 patients receiving major depressive episode in outpatients patients with severe depression 152 patients treated in 10 primary care practices in the united kingdom 381 patients treated with 174 patients with major depression, with or without melancholia and without psychotic features patients with major depressive disorder 242 patients were enrolled (mean patients who met dsm-iv criteria for major depressive disorder and satisfied eligibility criteria outpatients with major depressive disorders
neurologic function ncv oesophageal transit time and cholecystic motility sural sensory velocity exercise cardiac output neurologic function, including nerve conduction studies (ncss), quantitative sensory testing (qst), and clinical neuropathy rating scores neuropathic symptom scores minimum latencies of f-wave of median and tibial motor nerves postural hypotension vitro platelet aggregation, albumin excretion rate (aer) or muscle capillary basement membrane thickness sural nerve zenarestat level and sorbitol suppression number of fibers pupillary light reflex cool thermal qst mild reversible elevations of hepatic transaminases cardiovascular reflexes, pupil reflexes and skin vasomotor reflexes paraesthetic symptoms squatting vagal test symptomatic diabetic neuropathy nerve conduction velocity (ncv heart rate variation and e/i ratio blood pressure, insulin use, or the presence of baseline abnormal heart rate variability coronary artery disease, left ventricular hypertrophy, and valvular heart disease number of myelinated fibers per unit of cross-sectional area of nerve peripheral nerve function peripheral or autonomic nerve function cholecystic function analysed symptoms (pain and paraesthesias) and objective assessments (ncv-db constriction ratio mean ncv of the four motor nerves motor nerve conduction velocities and paraesthetic symptom scores percentage of regenerating myelinated nerve fibers vibration perception thresholds, nerve conduction velocities, and nerve action potential amplitudes severe symptomatic chronic peripheral neuropathy cardiac output fibrinolytic activities of the extrinsic, tissue-type plasminogen activator (t-pa), or in the intrinsic factor xii-dependent or factor xii-independent (urokinase-like) plasminogen activator systems pupillary light reflex test, cardiovascular autonomic function tests, and nerve conduction study oesophageal motility and vibration perception nerve conduction early clinical signs and symptoms of diabetic neuropathy vibration perception median nerve fcv and minimal latency exercise lvef painful and paraesthetic symptoms, vibration sensory threshold, and nerve conduction velocity (ncv adverse reactions deterioration in mean vibration threshold maximum velocity of constriction pupillary light reflex and minimum latency of the f-wave mean motor ncv neurologic decline nerve sorbitol content cardiovascular autonomic nerve functions, the ratio of the longest expiratory r-r interval to the shortest inspiratory r-r interval during deep breathing symptoms of pain, numbness, or paresthesia change in aer median sensory amplitude deep-breathing, maximum/minimum heart rate (expiration/inspiration ratio median motor ncv deterioration of motor nerve conduction velocity and vibration threshold lv stroke volume end diastolic volume cardiac abnormalities sensory, electrophysiological, and autonomic function worsening of clinical measures of distal symmetric polyneuropathy painful and paraesthetic symptoms motor (ulnar, median, and peroneal) or sensory (ulnar and radial) nerve conduction velocities, vibration perception thresholds, adjectival symptom scores or tests of autonomic function (mean electrocardiographic r-r interval variability on deep breathing and orthostatic blood pressure response deterioration of vibration threshold muscle capillary basement membrane thickness diabetic neuropathy nerve function electrophysiological measure objective, neurophysiological variables (biothesiometry, electromyography, nyctometri glycaemic control lying-to-standing heart rate ratio hypersensitivity reaction density of small-diameter platelet reactivity and microalbuminuria sensory thresholds posterior tibial nerve conduction velocity stroke volume metabolic control and severity of neuropathy resting diastolic filling rates motor and sensory nerve conduction velocity efficacy and safety evaluation motor or sensory nerve conduction velocity painful symptoms resting lvef motor and sensory nerve conduction, thermal and vibration sensation thresholds, heart rate variation at rest, e/i ratio, pupillary dilation velocity and pupillary reflex latency pupillary light reflex and f-wave latency measures (vibration qst, neuropathy rating scores, monofilament examination transit time clinical examination, neurophysiological measurements, sensory threshold determinations and tests of autonomic nerve function median deterioration in aer cardiovascular reflex tests (squatting vagal and sympathetic tests, pressure gain, deep breathing, lying-to-standing, valsalva maneuver, and orthostatic hypertension), vibration thresholds, tendon reflexes, and muscle strength median motor and median sensory nerves, changes in velocities side effects median distal motor latency subjective symptoms (including numbness, spontaneous pain, sensation of rigidity, paresthesia in the sole upon walking, heaviness in the foot, and hypesthesia median nerve fcv tendon reflexes and blood pressure fall tibial and peroneal motor nerve conduction velocities collagen and adenosine diphosphate (adp baseline neurophysiological parameters, duration of diabetes, and presence of retinopathy postural hypotension deteriorated electrophysiological measurements of median and tibial motor nerve conduction velocity, f-wave minimum latency, f-wave conduction velocity (fcv), and median sensory nerve conduction velocity (forearm and distal), as well as an assessment of subjective symptoms median motor, median sensory, and peroneal nerves nerve functions|dose-dependent increments in sural nerve zenarestat level and sorbitol suppression were accompanied by significant improvement in ncv. at 52 weeks, no significant differences were observed between the ponalrestat and placebo groups in motor (ulnar, median, and peroneal) or sensory (ulnar and radial) nerve conduction velocities, vibration perception thresholds, adjectival symptom scores or tests of autonomic function (mean electrocardiographic r-r interval variability on deep breathing and orthostatic blood pressure response). there was no evidence of continuing improvement throughout the treatment period and beneficial effects observed were no greater than those seen in previous trials of considerably shorter treatment periods. compared with baseline values, postural hypotension decreased by a value of 5.9 mm hg (95% cl, 1.6 to 8.7); deep-breathing, maximum/minimum heart rate (expiration/inspiration ratio) increased by a value of 0.026 (cl, 0.015 to 0.036); and lying-to-standing heart rate ratio (30:15 ratio) increased by a value of 0.032 (cl, 0.027 to 0.052). over the course of the study, five of the eight electrophysiological measures assessed showed significant improvement from baseline in the fidarestat-treated group, whereas no measure showed significant deterioration. in vitro platelet responsiveness to collagen and adenosine diphosphate (adp) increased in the placebo group (median change max% collagen + 8 (+2 to +30)%; adp +4.5 (0 to +20)% compared with a fall in the sorbinil treated patients (median change; collagen -17.5 (-2 to -40)%, p less than 0.05; adp, -4 (0 to -25)%, p less than 0.05). neurophysiological measurements, particularly of sensory amplitude, were considerably more sensitive than measurements of temperature and vibration sensation and remain of fundamental importance in measuring diabetic neuropathy at an early and potentially reversible stage. at 12 months, nerve function significantly improved in patients receiving tolrestat and deteriorated in patients taking placebo. tolrestat 200 mg once daily was significantly better than placebo in producing concordant improvements in both motor nerve conduction velocities and paraesthetic symptom scores at 24 weeks (p = 0.01), 42 weeks (p = 0.01) and 52 weeks (p = 0.02). they also had quantitative improvement in terms of the degree of paranodal demyelination, segmental demyelination, and myelin wrinkling. neither did sorbinil induce marked changes in the fibrinolytic activities of the extrinsic, tissue-type plasminogen activator (t-pa), or in the intrinsic factor xii-dependent or factor xii-independent (urokinase-like) plasminogen activator systems. sural sensory velocity (p = 0.0008 after six months an improvement of analysed symptoms (pain and paraesthesias) and objective assessments (ncv-db) was observed in patients treated with tolrestat (group a) significantly higher than in patients treated with placebo (group b). it is concluded that one-year treatment with ponalrestat has no beneficial effects on symptoms or electrophysiological parameters in diabetic neuropathy. following the double-blind phase, motor and sensory nerve conduction velocity had significantly deteriorated in the placebo group, which did not occur during treatment with tolrestat. in placebo-treated subjects, there were decreases in exercise cardiac output (p < 0.03), stroke volume (p < 0.02), and end diastolic volume (p < 0.04). neither symptom scores nor cardiovascular reflexes, pupil reflexes and skin vasomotor reflexes improved after statil therapy, which led us to conclude that statil is not effective in the treatment of diabetic autonomic neuropathy. no beneficial effect of sorbinil was demonstrated on either the clinical manifestation or on the neurophysiological measurements made in these neuropathic diabetic patients over 12 months of treatment. for the median motor, median sensory, and peroneal nerves, there were no benefits in maximum amplitudes over the follow-up period. measurement of erythrocyte sorbitol concentrations demonstrated very significant inhibition of aldose reductase activity with sorbinil treatment, but no concomitant improvement in either peripheral or autonomic nerve function was observed. overall, no beneficial effect of ponalrestat on vibration perception thresholds, nerve conduction velocities, and nerve action potential amplitudes was detected. the vibration perception threshold at two sites of the dominant leg improved by at least 3 volts in the tolrestat group and remained unchanged or slightly deteriorated in the control group. minimum latencies of f-wave of median and tibial motor nerves were significantly shortened by epalrestat (p = 0.002 and p = 0.001, respectively); however, no significant effects were observed in motor or sensory nerve conduction velocity. the deterioration in mean vibration threshold of the tolrestat group was less than placebo at 24 weeks at all 3 sites measured, and reached significance at the carpal site (p less than 0.05). no significant changes were observed in symptoms of pain, numbness, or paresthesia between ponalrestat and placebo groups, and there were no improvements in vpt or tt at several sites.|symptomatic diabetic sensory polyneuropathy diabetic patients with neuropathy patients with subclinical diabetic neuropathy 39 patients with diabetic neuropathy patients with mild diabetic neuropathy 497 patients, aged 18 to 56 years with insulin-dependent diabetes mellitus for 1 to 15 years' duration, to treatment with sorbinil, an aldose reductase inhibitor, or to a university hospital clinic 34 diabetic patients with documented cardiac autonomic neuropathy chronic symptomatic diabetic sensorimotor neuropathy patients with established symptomatic disease 60 patients subjects with diabetes patients with mild diabetic autonomic and peripheral neuropathy type 2 diabetic patients with asymptomatic diabetic neuropathy patients with an abnormal heart rate reaction to standing (abnormal 30:15 ratio; n = 84 259 diabetic patients with peripheral neuropathy treated with 21 diabetic patients 50 patients with chronic symptomatic, distal symmetrical diabetic neuropathy 259 diabetes mellitus patients with peripheral neuropathy (defined by abnormal vibration perception threshold and abnormal peroneal motor conduction velocity) in a double-blind placebo-controlled clinical trial running for 18 months one hundred and ninety patients with symptomatic diabetic peripheral neuropathy took part type 2 diabetic patients diabetic peripheral polyneuropathy (dpn chronic symptomatic diabetic peripheral neuropathy neuropathic diabetic patients patients with diabetic neuropathy treated with sorbinil patients with established diabetic neuropathy diabetic neuropathy chronic peripheral diabetic neuropathy twenty patients patients with symptomatic diabetic peripheral neuropathy mild diabetic neuropathy accompany symptomatic diabetic peripheral polyneuropathy forty-five diabetic patients with asymptomatic autonomic neuropathy identified by at least one pathologic cardiovascular reflex test result asymptomatic diabetic neuropathy fifty-seven patients 16 diabetic patients with neuropathy patients with mild to moderate dpn 74 diabetics affected by peripheral neuropathy patients with type 1 and type 2 diabetes and associated peripheral neuropathy diabetes mellitus patients with signs of peripheral neuropathy 30 diabetic patients with subclinical or mild diabetic neuropathy patients with symptomatic diabetic neuropathy 279 patients with diabetic neuropathy patients with vibration perception thresholds (vpts) greater than 35 v at the great toe or thermal difference thresholds (tts) greater than 10 degrees c on the dorsum of the foot were excluded from the trial type-2 diabetic patients with asymptomatic diabetic neuropathy diabetic patients with signs of autonomic neuropathy fifteen patients treated with statil and 12 with fifty-four diabetic patients (median age 56 yr, range 25-65 yr) with chronic neuropathic symptoms patients with confirmed diabetic neuropathy 22 diabetic patients with subclinical abnormalities of nerve function diabetic subjects with neuropathy (n = 81) with either a low diastolic peak filling rate or impaired augmentation of left ventricular (lv) ejection fraction (lvef) during maximal bicycle exercise were identified by gated radionuclide ventriculography patients with chronic symptomatic diabetic neuropathy diabetic peripheral neuropathy forty-six patients, 30 of whom were treated with ponalrestat and 16 with diabetics (n = 19) into a group (n = 12 192 patients sixty-six patients
mean scores alcohol outcomes smoking-cessation rates abstinence rates subjects smoking >16 cigarettes/day sustained cessation rates overall duration and level of nicotine gum use highest quit rates carbon monoxide concentration rate of success 6 month quit rates carbon monoxide-verified abstinence rates and st. george respiratory questionnaire (sgrq continuous abstinence plasma nicotine and cotinine values, expired carbon monoxide and withdrawal symptoms longer length of alcohol abstinence sustained rate of smoking cessation smoking cessation sustained cessation tobacco withdrawal symptoms and enhanced smoking cessation rates level of self-efficacy increase abstinence six-month abstinence rates cessation rates and postcessation weight gain birth weight ad lib smoking, smoking satisfaction, and craving cigarette consumption baseline mucosal lesions nicotine toxicity, and withdrawal symptom relief rate of continuous smoking abstinence 7-day point prevalence weight gained and relapse smoking reduction promotes smoking cessation withdrawal symptoms cessation rates higher cessation rates systemic side effects higher smoking cessation rates likelihood of quitting smoking weight and smoking status chances of recovery from lapses severe reactions 7-day point prevalence rates initial abstinence time to relapse erythema with edema expired air carbon monoxide measurement birth weight and gestational age sgrq scores percentage of nicotine replacement stopped smoking complete abstinence rates time and cotinine values quitting rates rate of smoking abstinence proportions ratios withdrawal symptoms and abstinence rates signs of nicotine toxicity severe skin reactions abstinence proportions smoking rates smoking reduction (cpd and thiocyanate concentrations failure number of cigarettes smoked knowledge, coping and support resources self-reported abstinence and end-expired air carbon monoxide (co relative success rate baseline smoking rate and baseline trough and peak blood cotinine levels short-term quit rates substantial relapse rate self-reported smoking abstinence confirmed by expired carbon monoxide measurements reduction rates and (b) psychological and physiological processes analyzed craving and withdrawal symptoms toxin intake withdrawal, tension, fatigue, and coping frequency with decreased coping effort; coping-to-urge ratio prolonged abstinence from 2 weeks post-quit day through 6 months efficacy of the skin patch abstinence rate retention rates adverse events tolerated, and adverse event profiles relapse risks withdrawal symptoms and nicotine toxicity birth weights rate of abstinence from smoking adverse pregnancy and birth outcomes smoking cessation rates and tobacco withdrawal symptoms 12-month abstinence educational level, duration of smoking, number of cigarettes smoked per day, concomitant disease states or drug use, or fagerstrom score mean success rates cessation efficacy rate of negative birth outcomes body weight quit rates successful abstinence plasma cotinine, exhaled carbon monoxide and plasma thiocyanate specific withdrawal symptoms (anger, anxiety, awakening, difficulty concentrating, depression, hunger, impatience, and craving smoking cessation rate prevalence abstinence rate respective success rates 7-day point prevalence abstinence rates study (death, myocardial infarction, cardiac arrest, and admission to the hospital due to increased severity of angina, arrhythmia, or congestive heart failure); the secondary end points (admission to the hospital for other reasons and outpatient visits necessitated by increased severity of heart disease); any side effects of therapy; and abstinence from smoking adverse cardiovascular events ratings of adverse effects tobacco withdrawal symptoms nicotine dependence point-prevalence abstinence and continuous abstinence body weight nor cessation rates craving sleep disturbance and local skin irritation serious adverse events quit rate short-term smoking abstinence rates smokers' nicotine withdrawal symptoms craving for smoking abstinence outcomes efficacy nicotine abstinence rates nicotine-dependence score or co reductions cigarette smoking rates co-validated abstinence rates efficacy and safety mean smoking rates demographic characteristics, smoking history, depression symptoms, and body mass index 7-day point prevalence abstinence craving and withdrawal symptoms craving for alcohol point abstinence 8-week smoking abstinence rate smoking abstinence rates smoking outcomes 7-day point prevalence abstinence at 1 week, 8 weeks, and 6 months after quitting and number of days to relapse levels of expired co self-reported quit rates smoking reduction validated point prevalence abstinence at discharge nicotine dependence and severity of withdrawal symptoms daily cigarette consumption and severity of withdrawal symptoms (wisconsin scale numbers of cigarettes smoked blood pressure mean value of cotinine in saliva initial cessation, number of days to lapse, number of days to relapse, and latency to relapse rates of adverse pregnancy and birth outcomes smoking abstinence (cotinine plus carbon monoxide compensatory smoking of low tar and nicotine cigarettes relapse rate tolerated rate of continuous abstinence early withdrawal symptoms co-confirmed prolonged abstinence rates 7-day point prevalence smoking abstinence rate efficacy and tolerance daily cigarette consumption 4-week abstinence rates general distress tolerated, and no serious adverse events smoking cessation rates quit rates and tobacco withdrawal symptoms withdrawal symptom relief smoking abstinence self-reported 7-day point prevalence smoking abstinence 6 months after quit day skin reactions mood, withdrawal symptoms, pleasant activities and events, self-efficacy, and optimism and pessimism compliance rates for return visits rate of preterm delivery overall rate of treatment-related adverse events sgrq score quitting rate continuous abstinence through 7 weeks after cessation smoking cessation and suppression of withdrawal severity smoking cessation efficacy lack of power, contamination, and low attendance mean nicotine substitution based on cotinine determinations psychological smoking cessation skin irritation weight gain weight change and cessation rates withdrawal symptom reporting overall success rate for sustained smoking reduction 1-year quit rates rates of dropouts due to adverse events withdrawal symptoms composite score and abstinence rates expired carbon monoxide (co) and serum and salivary cotinine point-prevalence abstinence exhaled carbon monoxide point prevalence cessation rates saliva cotinine functional exercise capacity, and delays weight gain tenseness, difficulty in concentration and feelings of hunger 28-day continuous abstinence success rate continuous abstinence rate tolerated, and adverse events higher long-term rates of smoking cessation cotinine concentration point-prevalence abstinence rates eventually achieving long-term abstinence smoking quit rates expired carbon monoxide (co) levels drinking outcomes serum levels of nicotine and cotinine at baseline, and withdrawal symptom relief rate of low birth weight cessation success rates prolonged abstinence, assessed through self-report and verified with exhaled carbon monoxide (co) levels cessation throat/mouth irritation and coughing expired air carbon monoxide measurements 1-year abstinence rates safety mean birth weight difference smoking status abstinence year smoking cessation rates breath carbon monoxide (co monitoring blood cotinine levels withdrawal severity fagerstrom score successful quitting time to smoking relapse and prolonged abstinence birth weight and preterm delivery sustained smoking cessation level of abstinence craving for cigarettes, negative affect, and appetite continuous abstinence rates transient mild or moderate erythema success rate in quitting smoking cigarette taste continuous abstinence, cotinine-verified abstinence, daily cigarette consumption, withdrawal symptoms and adverse events duration of continuous smoking abstinence; abstinence rates 28-day abstinence 6-week smoking-cessation rate reduction of smoking smoking behavior and compliance insomnia and headache sustained abstinence rates overall sustained abstinence absolute rate of abstinence nausea mean saliva cotinine concentrations rate of abstinence from the quit date until delivery dividing serum nicotine and cotinine levels daily cigarette smoking on cigarette craving vomiting overall rate of relapse equivalent 1-year abstinence rates throat irritation (inhaler) and itching (patch complete abstinence (self-reported) and expired carbon dioxide concentration less successfully quit smoking difficulty in sleeping safety and efficacy reduced craving and withdrawal 6-day inpatient stay, daily nicotine and cotinine levels success rates prolonged abstinence 7-day point prevalence smoking abstinence cotinine levels abstinence from the date of smoking cessation until delivery, as validated by measurement of exhaled carbon monoxide or salivary cotinine rates of point-prevalence abstinence rates of abstinence side effects severe localized erythema cardiovascular events quit smoking functional exercise capacity mean nicotine substitution risk for smoking lapses probability of lapsing expired carbon monoxide concentration adverse event rates minor skin reactions effectiveness and safety smoking abstinence (verified by saliva cotinine and expired carbon monoxide), cessation self-efficacy, and physical fitness and body weight transient local erythema frequency of respiratory symptoms side effects and adverse events severity of some withdrawal symptoms rates of sustained abstinence withdrawal symptoms, including craving relapse mean compliance rate of abstinence from smoking until delivery or the risk of adverse pregnancy or birth outcomes prolonged abstinence rates (co<10 ppm behavioural therapy cessation rate point abstinence at 7 weeks, continuous abstinence at 6- and 12-month follow-up, and self-reported withdrawal symptoms mood disturbance salivary cotinine levels daily cigarette smoking and cigarette craving 10-wk continuous smoking abstinence total abstinence continuous smoking abstinence daily cigarette consumption or craving short- and long-term smoking cessation rates frequency of nausea continuous and prolonged abstinence, lapse and recovery events, cost per additional quitter, and side effects and adherence higher quit rates adverse effects systemic and local adverse drug events mild or moderate side effects number of daily cigarettes co or thiocyanate concentrations|smoking cessation rates were statistically significantly superior with sublingual nicotine vs placebo for all measures of abstinence: 6-month point prevalence, 23% vs 10%; 12-month point prevalence, 17% vs 10%. over the next 6 months, the two higher doses appeared to support more gum self-administration than the two lower doses (4 mg = 2 mg greater than 0.5 mg = 0 mg) in the subsample of long-term quitters (n = 20). survival analysis showed active inhaler was superior to placebo (p < 0.01). at 6 weeks, the 7-day point prevalence smoking abstinence rate for the patch alone (21.1%) was superior to the spray (13.6%) but was significantly lower than the rate for combination therapy (27.1%). nineteen (63%, 95% confidence interval, ci, 46%-80%) of the smokers treated with the transdermal nicotine patch had successfully quit smoking at the end of the program (6 weeks) and nine (30%, 95% ci 14%-46%) remained abstinent 1 year later. a slight increase in adverse cardiovascular events was noted only in the open label-pay group in comparison with the placebo group. precessation mecamylamine significantly prolonged the duration of continuous smoking abstinence; abstinence rates at the end of treatment were 47.5% with mecamylamine and 27.5% without mecamylamine. at 6-month follow-up, abstinence rates for the three treatments were 4.9, 6.5, and 9.7% for the mc, cpp, and cap treatments, respectively. there were significant differences in a 7-day point prevalence but not continuous abstinence rates between treatment groups across targeted end points. the differences in outcomes were significant at the 5 percent level for all comparisons, with the exception of the 2-mg nicotine gum versus the placebo gum at one year. smoking cessation rates for the two nicotine patch doses and three levels of counseling did not differ significantly at either 8 weeks or 26 weeks following the quit date. weight gain at seven weeks was significantly less in the combined-treatment group than in the bupropion group and the placebo group (p<0.05 for both comparisons). cessation rates in smokers attending special clinics or their general practitioners can be increased by transdermal nicotine (tns). the patches were generally well tolerated, although 25% of subjects in the nicotine group and 13% in the placebo group had transient local erythema after application of the patch; 5 members of the nicotine group withdrew because of poor cutaneous tolerance. the abstinence rates were 51, 39 and 29% after 6 weeks, 3 and 6 months, respectively, as compared to 24, 19 and 18% in the placebo group (p=0.0003; p=0.003; p=0.050). the nicotine patch significantly improves short-term quit rates in inner-city african americans who are interested in trying to quit smoking. at six weeks, the nicotine gum group was superior to both the self-help and control conditions. more subjects in the nicotine group (70/94 v 45/93) reported that the gum reduced the craving for smoking. time to relapse is significantly longer in group 1 as compared to that of group 2 (p = 0.041), whereas no significant differences between groups 2 and 3 were observed. at 2 months, tnp produced a higher level of abstinence (36%) than placebo (20%), p < .001. sustained abstinence rates for the patch and nasal spray group and patch only group were 51% v 35% after 6 weeks (odds ratio 1.97, 95% confidence interval 1.17% to 3.32; p=0.011(chi2), 37% v 25% after 3 months (1.76, 1.01 to 3.08; p=0.045), 31% v 16% after 6 months (2.40, 1.27 to 4.50; p=0.005), 27% v 11% after 12 months (3.03, 1.50 to 6.14; p=0.001), and 16% v 9% after 6 years (2.09, 0.93 to 4.72; p=0.08) [corrected]. results showed that smokers with high levels of nicotine dependence were significantly more likely to quit smoking during treatment if they received nicotine gum (31.9%) than high-dependence smokers who did not receive the gum (12.2%). biological verification of gum use and smoking abstinence were assessed in community volunteers who attended an intensive behavioral counseling program for smoking cessation while using nicotine gum for 3 months. there were no significant differences between conditions in point-prevalence abstinence rates or in time to first slip. all participants received open-label transdermal nicotine patches and were randomized to receive either 2 mg nicotine gum or placebo gum under double-blind conditions. skills training produced higher initial cessation and more coping responses posttreatment than did support. at least 1 adverse event was reported by 57% receiving the nicotine patch and 39% receiving placebo (p<.001). continuous smoking abstinence was significantly higher for the active nicotine inhaler group compared with the placebo inhaler group. (relative risk 1.08 95% ci: 0.86, 1.35, p = 0.4, risk difference 1.7%, 95% ci: -3.2%, 6.6%). transdermal nicotine does not cause a significant increase in cardiovascular events in high-risk outpatients with cardiac disease. effects for gum were no longer significant at later follow-ups, however, overall duration and level of nicotine gum use were considerably less than optimal. smoking abstinence was not lower and the odds ratio for nicotine patch therapy was not greater in smokers with a history of alcohol dependence than in smokers with no such history. quit rates were dose-related at all follow-ups (p < 0.01). prolonged abstinence rates (co<10 ppm) did not differ among gradual, abrupt and minimal treatment conditions (4%, 7% and 5%), nor did 7-day point prevalence rates (7%, 11% and 11%). after one year, these rates declined to 23% and 16%, respectively (p=0.476), and converged to 18% and 14% (p=0.797), respectively, at 5-year follow-up. significantly more participants who had used the nicotine inhalers were continuously abstinent compared with those who had used the placebo inhalers. a new, faster-acting nicotine nasal spray (nns) can provide easily self-administered relief from cigarette withdrawal. ratings on smoking types 1, 3, 4, 5, and 6 and f-score were related to success rates. of 200 who were willing to try the gum, 101 were randomly allocated to the nicotine gum and 99 to the placebo gum. the treatment mainly benefited smokers with lower levels of dependence, based on fagerstrm test for nicotine dependence score. relative to the pp group, the aa and ap groups were each significantly more likely to be abstinent at 1 week, end of treatment, and 6 months but not at 12 months postquit. after corrections for marital status and income, 10% of those who received nicotine gum and 7% of those who received placebo gum reported continuous abstinence for 11 months and passed observer and biochemical verification (this difference was not statistically significant). all pharmacotherapies differed from placebo when examined without protection for multiple comparisons (odds ratios, 1.63-2.34). in this latter group there were significant differences (p=0.03) between those who had follow up in clinics (39% stopped) compared to those who were followed up telephone sessions (30%). a double-blind trial of a smoking-withdrawal chewing gum containing 2 mg nicotine was conducted with 100 consecutive patients in a smoking cessation clinic. the success rate was 35.1 in the first group and 13.2 in the second (p less than 0.03), thus confirming the effectiveness of nicotine chewing gum. after a one-year follow-up period, the success rates were in the same order of magnitude for nicotine gum (active treatment: 10%, placebo: 8%) group and for acupuncture (active treatment: 8%, placebo: 10%) group. women in the cbt+nrt arm were almost three times more likely than women in the cbt-only arm to have biochemically validated cessation at both pregnancy time points (after 7 weeks: 24% vs 8%, p=0.02; at 38 weeks gestation: 18% vs 7%, p=0.04), but not at 3 months postpartum (20% vs 14%, p=0.55). those receiving nicotine gum were more likely to be abstinent at the 2- and 6-month follow-ups. a higher percentage of cotinine replacement was associated with the higher 8-week smoking abstinence rate (p = .03), an association not found at long-term follow-up. the 12-month point prevalence was 6% (5-mg patch (placebo)), 16% (15-mg patch) (p<0.05), 9% (inhaler) and 11% (15-mg patch plus inhaler), respectively. mean compliance across groups was higher for the patch (mean: 78.4-82.8%) than for the gum (mean: 38.5-50.7%). at baseline, there were no significant differences among the three treatment groups with regard to age, gender, educational level, duration of smoking, number of cigarettes smoked per day, concomitant disease states or drug use, or fagerstrom score. by 6 months there was no significant difference between the two groups (22/136 (16%) as+nrt and 15/109 (14%) as). decreased cost also increased cessation attempts and 1-week cessation (p less than 0.05) and appeared to increase abstinence at 6-month follow-up (19% vs 6% vs 8%, p less than 0.10). six-months' continuous abstinence rates were also significantly higher among the active nicotine group (25%) compared with placebo (12%). familiarizing with the gum as compared with regular use gave fewer reports of side effects, 15% vs 34%, p < 0.001. point abstinence at 7 weeks was 58% for mecamylamine versus 29% for placebo, p = 0.044. after 6 weeks of treatment, co-validated abstinence rates were 48% in the active group and 23% in the placebo group (p < 0.0001). at 3 months 36.2% of the 2 mg nicotine gum group reported to have stopped smoking, against 44.8% in the 4 mg group (non-significant difference). a logistic regression model of eot quit rates showed smokers who preferred transdermal nicotine, were not reactive to smoking cues, and did not use nicotine to alleviate distress or stimulate cognitive function had higher quit rates on transdermal nicotine. time to relapse was slower with extended versus standard therapy (hazard ratio, 0.50 [ci, 0.35 to 0.73]; p < 0.001). compared with the no-gum group, relapse occurred at a significantly lower rate in the gum group for the entire 12 months of follow-up (odds of relapse in the gum group was 0.72, 95% confidence interval, 0.62 to 0.83). nicotine patch treatment doubled the rate of continuous abstinence up to 1 year (nicotine 9.6%, placebo 4.8%, p < 0.01); it most likely worked by reducing withdrawal symptoms. retention rates were highest in the bup group (59.3%) and lowest in the nrt group (50.5%). more general distress was observed among bt versus btp participants (i.e., increased withdrawal, tension, fatigue, and coping frequency with decreased coping effort; coping-to-urge ratio). there was a main treatment effect for abstinence favoring the high counseling condition in early follow-up (week 12) and for continuous abstinence. the results at 12 months were that long follow-up showed a trend (p less than 0.12 toward being better than short follow-up, while nicotine gum was significantly better than no gum (p less than 0.05) in maintaining abstinence. no treatment differences were found in trends over time for measures of mood, withdrawal symptoms, pleasant activities and events, self-efficacy, and optimism and pessimism. the interaction of nicotine-gum dose and dependence group was not significant (p = 0.42), nor did the 2-mg and 4-mg doses differ significantly in effectiveness, though both 2-mg and 4-mg gum were significantly more effective than placebo gum. eight weeks after the target quit date, self-reported 4-week abstinence rates were 41.6% in the precessation treatment group and 44.4% in the usual care group (p = .61). mean birth weight difference was 186 g (95% ci 35, 336 g) higher in the nicotine than placebo group, and there was an insignificantly lower rate of low birth weight (under 2500 g) in the former group. the 12 month sustained success rates were: 25 mg patch for 22 weeks (l-25), 15.4%; 25 mg patch for 8 weeks (s-25), 15.9%; 15 mg patch for 22 weeks (l-15), 13.7%; 15 mg patch for 8 weeks (s-15), 11.7%; and placebo (p-0) 9.9% (placebo versus 15 mg, p<0.05; 25 mg versus 15 mg, p<0.03; 25 mg versus placebo, p<0.001, chi-squared test). replacement was similar in groups lc-15 and hc-25, but the success rate was significantly lower in hc-25 group, despite similar levels of withdrawal symptoms. the difference between the groups was significant for validated point prevalence abstinence at discharge (55%, 43%, 37% respectively, p=0.045) and at 12 months (17%, 6%, 8%, p=0.03). subjects with high scores (> 7) on fagerstrm's tolerance questionnaire had a significantly lower success rate with placebo than with the nicotine spray. there was no significant difference in the rate of abstinence from the quit date until delivery between the nicotine-replacement and placebo groups (9.4% and 7.6%, respectively; unadjusted odds ratio with nicotine-replacement therapy, 1.26; 95% confidence interval, 0.82 to 1.96), although the rate was higher at 1 month in the nicotine-replacement group than in the placebo group (21.3% vs. 11.7%). there was a significant increase in smoking cessation rates after 8 weeks of follow-up but only among smokers who started on 21-mg/day patches. nicotine mouth spray delivered significantly higher after 1 month the percentage of confirmed non-smokers in the nicotine gum group was 34%, in placebo chewing gum group 37% and the control group 24%. however, at 6-month follow-up, the subjects who had received behavioral treatment had a significantly better abstinence rate (36.7%) than those receiving education (17.5%). in this comparative effectiveness study of 5 tobacco dependence treatments, combination pharmacotherapy significantly increased abstinence compared with monotherapies. in no treatment group was the outcome significantly different from that for one-time counselling at the (p less than 0.05) level. biochemically validated smoking-cessation rates were not significantly higher with nicotine gum compared with placebo (after 6 weeks of treatment: 13% compared with 9.6%, p=.45; at 32-34 weeks of gestation: 18% compared with 14.9%, p=.56). higher smoking cessation rates were also observed in subjects assigned to the active patch who had lower serum levels of nicotine and cotinine at baseline, and withdrawal symptom relief was better in the active patch group compared with placebo. smokers on active gum were significantly more likely to achieve initial cessation (2 mg: or=1.42; 4 mg: or=1.90); 28-day continuous abstinence (2 mg: or=2.01; 4 mg: or=4.66); and continuous abstinence at 6 months (2 mg: or=1.80; 4 mg: or=5.96). abstinence at 1 year was.77% in the otc condition versus 3.08% in the hcp condition [p<.01]. between six months and one year, relapse in the nicotine group accounted for the 30% vs. 20% success rates for nicotine and placebo observed at one year. at 12 weeks 21/315 (6.7%) subjects allocated to active treatment had stopped smoking compared with 6/314 (1.9%) allocated to placebo (absolute difference 4.7%; 95% confidence interval 1.6% to 7.9%; p = 0.003). the nicotine sublingual tablet increased the smoking cessation rate compared to placebo, reduced craving in highly dependent smokers and was well tolerated. the differences in quit rates and tobacco withdrawal symptoms between the two active groups were not statistically significant. after multiple adjustments, the abstinence proportions ratios seemed to follow a "dose-response" pattern: compared to gb, the ratios were 0.85 (g1-g2), 1.13 (g3-g4), 1.51 (gba), 1.66 (g1a-g2a), and 1.75 (g3a-g4a). attendance to sessions did appear to consistently increase the likelihood of quitting smoking at posttest and at each of the follow-ups. subjects who received transdermal nicotine were significantly more likely than placebo-treated subjects to remain abstinent from smoking during treatment, but not at the 1-year follow-up. overall sustained abstinence was documented in 17% of subjects at 6 months; 22% and 12% for ap and pp, respectively (p = 0.03). the results of this trial do not support the routine use of higher dose nicotine patch therapy in the treatment of nicotine dependence. the nicotine lozenge is a safe and effective new treatment for smoking cessation in low- and high-dependence smokers. results showed that precessation nicotine patch treatment was associated with a significantly higher rate of continuous smoking abstinence at 4 weeks, regardless of cigarette condition. nrt dose, level of nicotine dependence and genotype scores displayed significant interactive effects on successful quitting. nicotine abstinence rates in the 21- and 42-mg np conditions on week 36 follow-up were 16.9% and 9.2%, respectively. at one year follow up 15.5% overall had stopped smoking, 14% in the low and 17% in the high contact group. the rate of smoking was significantly reduced in volunteer subjects by providing effective nicotine replacement, self-help material, and weekly visits with a nurse for 6 weeks. tenseness, difficulty in concentration and feelings of hunger were consistently and in part significantly lessened in the tns group. although significant differences in the percentage of abstainers were observed between groups sbcn and sbc three weeks after treatment (39% vs. 26%), the point prevalence abstinence rate for patients at 12 months declined to 19, 18, and 12% for groups sbcn, sbc, and an, respectively. short tns treatment (3 weeks) is at least as effective as a longer one (6 weeks), which is relevant both medically and economically. the overall success rate for sustained smoking reduction was significantly higher at all time-points for active versus placebo gum (6.3% versus 0.5% after 24 months). nicotine-treated subjects reached significantly higher abstinence rates during and at the end of treatment than both placebo- and control-subjects: 69% in the nicotine condition, 51.2% and 44.4% under placebo and control conditions respectively. abstinence rates for the transdermal nicotine and nicotine nasal spray groups were not significantly different at 6-month follow-up (15.0% vs. 12.2%, respectively; p > 0.2). abstinence rates for daily nicotine gum users (n = 64) at 12 months and again at 24 months remained 48.4%, as compared with 26.1% and 31.9% for the daily placebo gum users (n = 69). the present study shows no difference between physician versus nurse counseling and no improvement in the proportion of quitters with the addition of nicotine gum in the physician-counseled group. seven-day quit rates for nicotine gum were no better than for the placebo group (14.2% versus 11.1%, p = 0.232) at 6 months. smoking cessation efficacy was maintained 6 months after initiation of treatment: 34 percent vs 21 percent (p = 0.08 in study 1) and 18 percent vs 7 percent (p = 0.05 in study 2). at 12 months, the frequency of respiratory symptoms in abstinent subjects fell significantly and lung function showed a trend toward improvement. few side effects were reported. compared with placebo control subjects, participants assigned nicotine patches had higher 3-month (23.4% vs 11.4%; p < .01) and 6-month there is no evidence from this study that the offer of 2 mg of nicotine-bearing gum enhances smoking cessation rates when added to a comprehensive intervention offered to all smokers in primary care. rates of sustained abstinence were significantly better with active treatment than with placebo: 53, 41, 24, and 17 percent of those in the nicotine-patch group were abstinent after 6, 12, 26, and 52 weeks, respectively, as compared with 17, 10, 5, and 4 percent of those in the placebo-patch group (p less than 0.0001). the opioid antagonist naltrexone was not found to be effective for smoking cessation and had no significant effect on daily cigarette consumption or craving. there was no significant relationship between weight gained and relapse in individuals. the ncg group had higher rates of abstinence at all follow-up points, but the difference approached statistical significance at 3 months only (p less than .10). abstinence rates at 6 weeks, 3 months, and 6 months were 29.5%, 21.8%, and 20.5% in the active group, and 8.8%, 3.8%, and 2.5% in the placebo group (p < or = .001 for each comparison), respectively. corresponding figures after two years were 19 (9.5%) and 6 (3.0%) (p=0.012). this study was designed to see whether the offer and prescription of nicotine chewing gum would enhance the efficacy of general practitioners' advice to stop smoking.|eighty-eight (study 1) and 112 (study 2 participants were 201 smokers, 22% with a history of mdd smokers who have greater or lesser abstinence rates with either n=119 participants (n = 958) were 18 years or older, had smoked at least 15 cigarettes daily for at least 6 months, and were enrolled at 3 study sites volunteer subjects two hundred sixty participants smoking 6 to 15 cigarettes per day (cpd one hundred six smokers seen in a family practice received smoking cessation 717 smokers hospital patients also given advice and support pregnant smokers subjects within each level of dependence 479 smokers ( 1 cigarette per day) who were treated with either active (n=318) or medical and surgical inpatients who were current smokers at the time of admission women thirty-six chest clinics enrolled a total of 3,575 smokers three hundred fifteen smokers who attended a family practice clinic and wished to quit smoking thirteen- to 17-year-old adolescents who smoked > or =10 cigarettes per day (cpd), scored > or =5 on the fagerstrom test of nicotine dependence, and were motivated to quit smoking persons who are attempting to stop smoking heavy smokers with a history of alcoholism benefit from nicotine patch treatment subjects who were attempting to stop smoking smokers with a history of major depressive disorder (mdd one hundred seventy-three smokers, classified as high or low on nicotine dependence using the fagerstrom tolerance questionnaire three hundred seventy copd patients who smoked a mean of 19.6 cigarettes per day (mean, 42.7 pack-years; mean fev(1), 56% of predicted healthy smokers (n = 200, 45% female 923 smoking clients, unselected for motivation toward quitting, to four different intervention groups: (i patients with cardiac disease two university hospital pulmonary clinics in switzerland participants were recruited via newspaper and radio advertisements nicotine-dependent smokers 299 treatment-seeking smokers who were followed for 6 months after the target quit date 424 smokers mean age was 42 years, 48% were male, mean cigarette consumption was 29 per day and mean duration of smoking was 24 years 311 hospital health professionals included in the study, there were 112 (36%) smokers; 44 (39%) of them were physicians and 68 (61%) nurses one hundred ninety-seven patients five hundred twenty healthy smokers two-hundred and seventy-three persons participants were 439 females who met rigorous screening criteria 314 daily smokers (mean, 23.7 cigarettes/d) enrolled through the internet and by physicians in switzerland from november 2005 to january 2007 participated 1,199 adults, volunteers, in rio de janeiro, brazil, randomly assigned to 10 different groups relapsed smokers 237 smokers aged 22-66 years living in or around reykjavik inner-city, outpatient clinic on the east coast denmark customers with chronic diseases and pregnant or breastfeeding women 369 smokers of 20 or more cigarettes per day 112 smokers two hundred cigarette smokers in thailand n=150) among smokers who wanted to quit now and preferred to quit gradually forty-four nonsmoking general practitioners volunteered for the study subjects smoked (a) their usual brands of cigarettes, (b) conventional low tar and nicotine cigarettes, or (c) denicotinized cigarettes two hundred and ninety seven adult smokers were enrolled forty-two pharmacies in the areas of aarhus and copenhagen in denmark participated in the trial, and 522 customers who smoked 10 or more cigarettes per day seventy-eight smokers trying to quit smoking cessation in pregnancy two hundred forty-seven smokers who smoked at least 10 cigarettes per day and who had previously made a serious attempt to stop smoking using nicotine chewing gum were recruited through advertisements patients hospitalized for a smoking-related illness such as respiratory disease smokers attending special clinics or their general practitioners 131 smokers seventy-one cigarette smokers stratified according to light (n = 23), moderate (n = 24), and heavy (n = 24) smoking rates individual patients with tobacco dependence smokers using the 2-mg tablet for 3-6 months with follow-up to 12 months smokers actively trying to quit 446 smokers (>9 cigarettes x day(-1 one hundred sixty-eight smokers 13 physicians working in the open health care system women who did not quit smoking 755 african american light smokers (66% female, mean age = 45) were enrolled at a community health center over a 16-month period one hundred cigarette smokers 467 current smokers were enrolled 417 women smokers january 1996 and may 1997 participants and all research personnel except the database manager eighty-nine smokers six months' follow-up of those who returned to the hospital-based outpatients smoking cessation clinic 311 subjects (34.8 percent) discontinued one or both medications twenty-one primary care sites in nebraska tobacco dependence 1999-2000 and 2007-2008 tobacco withdrawal 234 inpatients and outpatients with smoking-related respiratory or cardiovascular disease, aged 18-75 years, who were willing to try to stop smoking, were advised by their hospital doctor to stop smoking smoking cessation in family practice primary care clinics in a sample of alcohol-dependent tobacco smokers in an early phase of out-patient alcohol treatment general practice in italy adult volunteers motivated to quit smoking adult smokers of participants with a high nicotine-dependence score patients carrying a wide range of diagnoses smoking cessation among adults in rio de janeiro, brazil forty-eight percent of the 450 patients made an attempt to stop smoking, and 89% reduced their cigarette consumption at some point during the study adolescents who want to quit smoking forty-eight healthy smokers who smoked at least one pack per day were studied at an outpatient smoking cessation research clinic subjects were recruited through advertisements in newspapers and among patients referred to the smoking cessation clinic at sahlgren's hospital, gteborg, sweden patients with copd using nicotine sublingual tablets and behavioral support smokers with a history of alcohol dependence 13-week cognitive behavioral smoking cessation program targeted for women 10 veterans affairs medical centers, we randomly assigned 584 outpatients (of whom 576 were men) with at least one diagnosis of cardiovascular disease to a 10-week course of 1.98 years of age and had been smoking daily for 2.66 160 subjects) for smoking cessation recruited participants from seven hospitals in england who were 16 to 50 years of age with pregnancies of 12 to 24 weeks' gestation and who smoked five or more cigarettes per day pregnant women who smoked daily received controlled trial: 149 subjects to regular healthy smokers health care workers with a smoking habit in split, croatia in smoking cessation all smokers participated in a behavior modification program all participants attended a 13-week cognitive behavioral smoking cessation program and were given smokers subsequently quitting with the nicotine patch 1200 heavy smokers (> or = 15 per day), attending 30 general practices in 15 english counties received 151 patients were advised to stop smoking, and were asked to participate in the program if judged sufficiently motivated by the physicians 182 smokers heavy smokers with a history of alcohol dependence healthy subjects (374 274 inpatient smokers were enrolled smoking cessation among over-the-counter customers in denmark 208 smokers treated with 100 consecutive patients in a smoking cessation clinic 106 individuals out of the 200 recruited in three health centers started the treatment participants started smoking at 11.2 608 cigarette smokers planning a cessation attempt as low or high in nicotine dependence patients referred by their hospital doctor to the smoking cessation counsellor and who agreed to participate in the study physician-based smoking cessation a total of 120 participants were randomized (72% white, 70% female; age: 15.2 one thousand five hundred four adults who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking 629 smokers who had unsuccessfully attempted to stop smoking by using active transdermal nicotine and brief behavioural counselling smokers not motivated or not able to quit smoking with regard to smoking reduction and smoking cessation one-hundred and forty-two inactive female smokers daily cigarette smokers (> or = 15 cigarettes per day for at least 1 year) who volunteered to participate in a study of smoking cessation treatment those with baseline cotinine < or = 250 ng.ml-1 (low cotinine cigarette smokers who attended the surgeries including those who did not wish to stop and those in the gum group who did not try the gum (47 copd patients 568 adult smokers 15 regional cancer control oncology centers within the north central cancer treatment group 1843 smokers who received high intensity cognitive therapy 1938 cigarette smokers who attended the surgeries of 34 general practitioners in six group practices 123 participants receiving hospitalized patients 30 heavy smokers, who had smoked more than 20 cigarettes per day for more than a year, were treated with two hundred smokers who were judged by their general practitioner to be motivated to stop smoking smokers with a history of mdd pregnant women low-dependence smokers 289 smokers (207 women and 82 men) enrolled in the study, 145 were treated with september 2004 to february 2008 245 patients were randomised, 136 as+nrt and 109 as 410 patients randomized, mean age was 48 years, 65% were female, 41% had less than a high school education, 51% had an annual household income of less than $8,000, and the average number of cigarettes smoked per day was 20 1346 primary care patients attending routine appointments were recruited by medical assistants in 12 primary care clinics hospitalised patients smokers admitted to hospital general practitioners' advice to stop smoking one hundred fifty-nine healthy volunteers who smoked at least one pack of cigarettes per day and desired to quit smoking two out-patient substance abuse clinics 300 smokers eleven hundred adult, dependent smokers who called the new zealand quitline between march 2006 and may 2007 for support to stop smoking sixty subjects adolescent smokers 34 abstinent subjects in the n = 94) groups were comparable in age, race/ethnicity, and smoking history 96 subjects smokers 286 volunteers who smoked at least 10 cigarettes daily recruited through a local newspaper healthy volunteers pregnant women who smoked ten or more cigarettes after the first trimester (n = 250 treating smokers one hundred seventy-seven volunteers 411 healthy smokers highly motivated to reduce cigarette use four hundred seventy-nine smokers the years of study were 1994 to 1995 two-hundred forty healthy volunteers who were smoking at least 20 cigarettes per day four groups of smokers (n = 100 per group) who received either and 32 heavy smokers were given cigarette smoking cessation heavy smokers (n = 408, smoking more than 25 cigarettes/day african american light smokers 160 smokers lighter smokers general practice 2 university-based smoking cessation research programs 112 young, nicotine-dependent cigarette smokers were treated for nine weeks with tns (n = 56) or 244 subjects 802 adults (mean age, 39 years) and was 89% white and 54% female as an aid to smoking cessation inner-city african americans two hundred and ten subjects 167 primary care settings 158 smokers health care workers 2110 adult cigarette smokers originally recruited to a study of the effect of antismoking advice in general practice, 429 who reported at follow up after one year that they had tried unsuccessfully to stop smoking were offered "a special antismoking chewing gum," either participants were excluded if they reported using any form of tobacco other than cigarettes; current use of bupropion; having a current psychosis or schizophrenia diagnosis; or having medical contraindications for any of the study medications high-risk outpatients with cardiac disease 5 smokers attending a routine primary care appointment was willing to make a serious quit attempt that included evidence-based counseling and medication before smoking cessation postmenopausal smokers (n=152) received smokers with clinical depression participating smokers (n = 322 496 smokers in a group-support setting subjects ranged in age from 20 to 40 years two hundred eighty-eight of 370 patients were evaluable for the final study end points 247 adult smokers, smoking > or = 10 cigarettes/day for > or = 3 years, of whom 123 received active and 124 placebo treatment 42 abstinent subjects heavy smokers patients attending hospital with smoking-related diseases to stop smoking 400 healthy volunteers, recruited through newspaper advertisements, willing to reduce their smoking but unable or unwilling to stop smoking immediately participants were 96 men and women with a diagnosis of alcohol abuse or dependence and smoking 15 or more cigarettes per day hospital inpatients and to identify variables associated with long-term smoking cessation following hospitalization thailand 289 patients in a family practice setting 12 medical sites participating in the national cancer institute's community clinical oncology program history-positive smokers one hundred fifteen smokers with a history of alcohol dependence (median of 5 years previously data were collected from 2003 through 2005; analyses were conducted in 2006 and 2007 of 200 who were willing to try the gum, 101 smokers (n = 1818 hospital inpatients general practitioner's advice against smoking 1039 smokers (> or = 30 cigarettes/day) at 12 clinical sites in the usa and one in australia 1,218 smokers able to quit smoking for 48 hr 64 participants three hundred and thirteen smokers recruited from the local community 129 smokers postmenopausal women all smokers met individually with their counselor for six rp sessions postmenopausal smokers 1050 participants, 521 were randomly assigned to participants with a history of heavier smoking (> or =20 cpd) and african american smokers smokers unwilling to quit 7128 eligible smokers (> or =10 cigarettes per day) attending routine primary care appointments, 1346 (18.9%) were enrolled in the study patients attending hospital with smoking-related diseases women with a history of depression 608 participants medical outpatient clinic with physicians experienced in smoking cessation assistance 3297 smokers who were interested in quitting gradually smokers aged 18 to 65 years (n = 1,044) who were able to quit for 24 hr smoking cessation with four nicotine replacement regimes in a lung clinic smokers (n = 126 one hundred eighty-five patients two hundred and fifty-five smokers a total of 450 smoking patients 157 smokers chinese smokers lighter smokers with and without a history of heavier smoking smokers with a history of alcoholism one hundred thirty participants two hundred and forty-one adult smokers (> or = 10 cigarettes/day for at least 3 years) used community volunteers who attended an intensive behavioral counseling program for smoking cessation while using nicotine gum for 3 months patients were referred to a telephone quit line for cessation counseling 1384 smokers randomized to the study, 20% were abstinent from smoking at 6 weeks and 8% were abstinent at 6 months 425 smokers attending three urban primary care centers in barcelona 1.33 years; smoking: 18.8 +/- 8.56 cpd; fagerstrom test of nicotine dependence score: 7.04 2560 active smokers smoking relapse prevention n = 33), and the 113 smokers with smokers with ni and sa pulmonary outpatient clinics participants who smoked more than 20 cigarettes a day were treated with the 30 cm2 patch and the others with the 20 cm2 patch adolescent tobacco addiction 400 subjects who had smoked 10 or more cigarettes per day for 3 years or longer patients of primary care physicians to quit smoking and sustain cessation 60 highly dependent smokers 504 participants were enrolled at two sites three hundred forty-nine patients (82%) could be reached by telephone at the two-month follow up one hundred and twenty-nine cigarette smokers recruited through newspaper advertisements two hundred forty-eight smokers women smokers
symptom score, esophageal manometry, and scintigraphy superior long-term success cumulative 12-month remission rate symptom scores botulinum toxin injection pneumatic dilatation cumulative dysphagia-free state symptomatic remission initial failure equal success rates esophageal retention chi-squares, wilcoxon rank-sum test, kaplan-meier method and log-rank tests symptoms and esophageal function relieving symptoms and improving esophageal function les pressure lower esophageal sphincter pressure surgical management of perforation relevant complication les pressure and maximum esophageal diameter clinical relapse major complications recurrent dysphagia failure rates recurrence of symptoms cumulative remission rate symptom scores, and lower oesophageal sphincter pressure, oesophageal barium column height, and oesophageal diameter symptom score and esophageal function test|no significant difference in symptom score and esophageal function test results was found between patients treated with botulinum toxin injections and those undergoing dilation. had superior long-term success ( < 0.01). botulinum toxin produced significant reduction in symptom scores (p<0.001), but no reduction in objective parameters. there was no difference in les pressure and maximum esophageal diameter in the barium esophagogram in the two groups before therapy. the cumulative 12-month remission rate was significantly higher after a single pneumatic dilatation (53%) compared to a single botulinum toxin injection (15%)(p < 0.01). the symptom scores showed no significant differences between the two groups before and one month after treatment.|achalasia cardia achalasia symptomatic patients with achalasia 20 patients, median age 56 years patients with treatment failure crossed over to the alternative treatment patients with achalasia primary achalasia sixteen patients received forty adults with newly diagnosed achalasia thirty four patients were studied, and 31 completed the trial seventeen consecutive patients with achalasia cardia diagnosed during a period between december 1997 and february 2000 24 patients with definitive esophageal achalasia 22 patients, median age 57 years) or patients with tortuous megaesophagus and previous failed pneumatic dilatation
fixation stability fixation performance text reading stimulus detection in hrp saccadic amplitude stimulus detection in high-resolution perimetry (hrp saccadic behavior social domain spatial attention and alertness natural search rt visual skills areas of recognition, mobility, peripheral detection, scanning, tracking, and visual memory detection performance visual skills categories outcome variables (response times [rts] during natural search, number of fixations during natural scene exploration, fixation stability, visual fields, and quality-of-life scores saccadic behavior or visual fields visual functioning ability to detect visual stimuli patient's testimonials concerning their visual abilities saccadic behavior, natural search, and scene exploration seeing side restoration of vision static text reading speed overall and separate skill improvement scores visual field size|only with est did the number of fixations during natural scene exploration increase toward the blind and decrease on the seeing side (follow-up/pre difference, 238%). in group 2, detection performance improved after standard vrt by 2.9% (p < .05) and after extrastriate vrt by 2.9% (p < .05). in post-chiasma patients, vrt led to a significant improvement (29.4%) over baseline in the ability to detect visual stimuli; in optic nerve patients, the effects were even more pronounced (73.6% improvement). analyses revealed that the performance of those in the experimental group exceeded that of the controls, that those patients in the experimental group with severe impairments improved more than those with mild impairments, and that combined multiple-treatment produces greater generalization than the original single treatment program. the patients with homonymous hemianopsia showed improvements in visual functioning using prism lenses, although these improvements were smaller than those found in previous studies with central or bilateral peripheral vision loss groups who were trained to use other optical enhancement devices for navigation and driving using a similar curriculum. mt therapy was associated with a direction-specific effect on saccadic amplitude for rightward but not leftward reading saccades. a more detailed analysis of trained versus untrained visual field areas in 16 patients revealed a superiority of the trained area of only 1.1% in hrp and between 3.5% (os) and 4.4% (od) in tap. analysis revealed the superior performance of the experimental group. in the area of the cue, restoration of vision was significantly greater than during vrt without cueing: cued patients showed a much more pronounced shift of the visual field border toward the blind area than that observed in the cg or in uncued regions of the eg. patients receiving treatment had overall and separate skill improvement scores that were significantly higher than those for control patients.|patients with ha patients (n = 23) with stable homonymous field deficits after trauma, cerebral ischemia, or hemorrhage (lesion age > 6 months) carried out either (a persons with acquired right brain damage due to stroke acquired right brain damage persons with acquired right brain injury due to stroke 16 patients patients with homonymous hemianopsia patients with postgenicular lesions of the visual system, areas of residual vision (arvs acute stroke patients regain important thinking skills patients with optic nerve (n = 19) or post-chiasmatic brain injury (n = 19 57 patients patients with hemianopic alexia (ha people with right brain damage twenty-eight hemianopic patients partial blindness patients with hemianopic alexia patients in a community hospital stroke program were pre-tested in three skill areas--visual scanning, visual-spatial orientation, and time judgment--and randomly assigned to a treatment (n = 16) or control (n = 17) group nineteen patients with ha patients with visual-field defects 18 patients with visual field defects with prior vrt experience patients with visual field defects hemianopic patients 53 patients studied were divided into two groups, experimental (n = 30) and control (n = 23 patients with homonymous hemianopia are disabled on everyday exploratory activities hemianopia patients with postgenicular visual system lesions who received either acute stroke patients patients with peripheral vision loss patients with homonymous hemianopsia, and (2
periprocedural myocardial injury concentrations of tnf-, il-6, il-8, and il-10 liver blood flow ctnt levels renal replacement therapy, mortality, atrial fibrillation, vasoactive medications, and adverse effects gsh levels oxidative stress and inflammation generate edema pulmonary compliance 15 (sd) yrs and acute physiology and chronic health evaluation nuclear factor-kappa b activation il-8 and stnfr-p55 levels cardiovascular state, liver function, and kidney function map, cardiac index, and left ventricular stroke work index hemodynamic and pulmonary data (pulmonary capillary wedge pressure, pulmonary vascular resistance (pvr), cardiac index (ci), shunt flow, dynamic lung compliance and static lung compliance rates of deterioration and recovery of liver function ck-mb perioperative hemodynamic and pulmonary data soluble intercellular adhesion molecule-1 concentrations daily organ failure score partial pressure of oxygen in arterial blood/fractional inspired oxygen 4 h after surgery proportion of patients developing postoperative renal dysfunction hemodynamics and graft function median percent change in egfr liver blood flow index relative change in serum creatinine, peak serum creatinine level, serum cystatin c, and in urinary output arterial and gastric mucosal carbon dioxide tension systemic vascular resistance vo2 when do2 rate of af systemic oxidative stress oxygenation index (pao2/fio2 postoperative acute renal failure luminol (specific for (*)oh, h(2)o(2), and hocl(-) radicals) and lucigenin (specific for o(2) (*-)) levels and the difference ratios after reperfusion patients experiencing postoperative renal dysfunction levels of the major cytokines, duration of ventilation and intensive care unit stay, gastric intramucosal ph and arterial oxygen tension/inspired fractional oxygen ratio tumor necrosis factor-alpha levels transplant-free survival and rate of transplantation venoarterial carbon dioxide gradient (pvaco2 myeloperoxidase (mpo), malondialdehyde (mda), interleukin-6, alpha1-acid glycoprotein (aagp), and c-reactive protein (crp postoperative atrial fibrillation cardiomyocyte staining postoperative interventions and complications, the requirement for renal replacement therapy (rrt), adverse events, hospital mortality, and icu and hospital length of stay static lung compliance incidence of death, myocardial infarction, bleeding, transfusion requirements, intubation time, and hospital length of stay gastric intramucosal ph macr number of days of acute lung injury myocardial oxidative stress st segment depression renal or hepatic injury hospital mortality tolerated; only nausea and vomiting renal replacement therapy, length of ventilation, and length of stay in the intensive care unit and hospital acute renal failure myocardial damage mild vasodilatation, improve oxygen delivery and consumption pao2/fio2 ratio mortality and the required days of inotropic support, mechanical ventilation, and intensive care demographic characteristics, ards categories, severity of illness (simplified acute physiology score [saps ii oxidative response of neutrophils icu mortality and icu length of stay ethane and mda concentrations serum creatinine level oxygen extraction ratio by the liver whole-body oxygen consumption (vo2), gastric intramucosal ph, and veno-arterial co2 gradient (veno-arterial pco2 hemodynamic parameters, oxygen consumption, oxygen delivery, oxygen extraction ratio, and lactates postoperative renal dysfunction, interventions, complications, or mortality glomerular filtration rate (egfr proportion of patients with postoperative renal dysfunction progression of multisystem organ failure cardiac index (ci), left ventricular stroke work index (lvswi systemic and pulmonary hemodynamics, oxygen delivery, and oxygen consumption severity of illness and degree of organ failure development of ards and mortality development of arf nutritive blood flow mean decrease of vo2 oxygen extraction clearance of indocyanine green cardiovascular sofa score liver function morbidity and mortality oxidative burst response of neutrophils cardiac output progression of early postoperative organ dysfunction and improve oxygenation plasma creatinine and serum cystatin c concentrations renoprotective effect survival, graft function or risk of aki oxidative stress and inflammation fio2 severe adult respiratory distress syndrome (ards) and mortality rate do2 and vo2 urinary nag/creatinine ratio tolerated, improved respiratory function, and shortened icu stay oxidative stress, inflammation, fluid requirement, multiple organ dysfunction (mod) score and vasoactive drug requirement serum cystatin c lis and pao2/fio2 ratio pulmonary function coma recovery times efficacy and safety tissue oxygenation expired ethane and malondialdehyde (mda), and oxidized (gssg) and reduced glutathione (gsh baseline scr levels lis vo2 and gastric intramucosal ph hemodynamic response to n-acetylcysteine hepatosplanchnic blood flow myocardial ischemia-reperfusion injury shorter ventilator requirement mortality rate, the need of ventilatory support, the intensive care unit stay, and the pao2/fio2 evolution lung injury score (lis baseline scr and calculated gfr nac improved oxygenation (increase in pao(2)/fio(2 postoperative biochemical markers (troponin t, creatine kinase mb, creatinine, hemoglobin, and platelets overall mortality mod score, use of vasopressor agents and fluid utilisation hemodynamic data and calculated tissue oxygenation parameters pulmonary artery catheter-derived hemodynamics, blood gases, hemoglobin, and arterial lactate ck-mb>5 times normal value transplant-free survival postoperative tracheal extubation mortality, morbidity or postoperative graft function urine nag/creatinine ratio respectively oxygen transport indices, arterial blood gas analyses, pao2/fio2 ratio, and shunt vo2 hospital mortality and need for renal replacement therapy left ventricular cardiomyocyte staining renal dysfunction postoperative interventions and complications, the need for rrt renal function postoperative clinical course higher survival rate percentage of patients receiving ventilatory support adverse reactions benefits of transplant-free survival cause mortality creatine kinase-mb levels cellular composition and mediators ards total antigenic human neutrophil elastase plasma concentrations of tumor necrosis factor-alpha (tnf), interleukin (il)-6, il-8, il-10, and soluble tumor necrosis factor-alpha receptor-p55 (stnfr-p55 nuclear factor-kappa b activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression postoperative organ dysfunction apache (acute physiology and chronic health evaluation urinary f2-isoprostane metabolites mortality rate rbc glutathione creatine kinase mb isoform (ck-mb) mass levels survival rate six organ dysfunction parameters, length of intensive care stay, days of mechanical ventilation and mortality overall incidence of arf postoperative increases in a-a oxygen gradient respiratory dysfunction splanchnic blood flow malondialdehyde (mda levels of glutathione and cysteine microalbuminuria and organ dysfunction mpo and mda values still receiving ventilatory support length of icu stay sofa scores postoperative graft function ii score and the sequential organ failure assessment (sofa) score microalbuminuria and organ failure total number of neutrophils, elastase, mpo and interleukin-8 fractional liver blood flow index (cardiac index-related liver blood flow index oxygen delivery, cardiac index, stroke index, and left ventricular stroke work index hypotension requiring inotropic support cytokine levels and gastric intramucosal ph absolute liver blood flow index plasma creatinine and serum cystatin c values overall survival hepatosplanchnic flow and function cardiovascular, renal, hepatic, haematological and central nervous system admission parasitemia microalbuminuria/creatinine ratio (macr hemodynamics and clinical outcomes global left ventricular function rate of survival complex formation between elastase and alpha 1-proteinase inhibitor pulmonary fibrin uptake vo2, oxygen delivery, ci, lvswi and pvaco2 gsh plasma creatinine parasite clearance time hospital mortality rate nag/creatinine ratio and the albumin/creatinine ratio plasma neutrophil elastase activity simplified acute physiology score (saps aagp and crp values veno-arterial pco2 hemodynamics and postoperative graft function ventilatory support hemodynamic and oxygen transport indices percent change in egfr liver blood flow, hepatosplanchnic oxygen transport-related variables, and liver function serum creatinine absolute change in serum creatinine interleukin-6 concentrations stable clinical conditions (hemodynamic values, body temperature, hemoglobin, fio2 hemodynamics, oxygen transport variables, and plasma levels of cytokines levels of urinary nag/creatinine ratio, plasma creatinine and serum cystatin c ii scores, multiple organ failure scores hemodynamic effects of n-acetylcysteine interleukin-6 production plasma tnf, il-6, or il-10 levels baseline serum bilirubin postoperative clinical data (death, myocardial infarction, low-output syndromes, arrhythmias, bleeding, transfusion requirements, and intensive care unit and hospital lengths of stay) and biochemical markers (creatine kinase mb, troponin t, creatinine, hemoglobin, and platelet levels 1-month mortality rate whole-blood lactate levels release of myeloperoxidase (mpo lipid peroxidation of the lung epithelium activation postoperative a-a oxygen gradient a daily organ failure score organ function cytokine levels, outcomes, or gastric intramucosal ph urine n-acetyl-beta-d-glucosaminidase (nag) and urine creatinine ratio, plasma creatinine, and serum cystatin c levels indicated renal function serum creatinine (scr) levels transplantation rate gsh level intubation time psh level interleukin-8 hemodynamic variables, oxygen delivery (do2), oxygen consumption (vo2), and oxygen extraction serum cytokine levels and gastric intramucosal ph plasma appearance of monoethylglycinexylidide (megx icu and hospital length of stay liver graft performance cardiac index hepatorenal ischaemia-reperfusion injury levels of malondialdehyde, protein sulfhydril (psh) groups, reduced gluthation (gsh), activity of myeloperoxidase, catalase and superoxide dismutase enzymes and induced free radical generating capacity mechanical ventilation renal injury as measured by the increases in urinary n-acetyl-beta-d-glucosaminidase (nag)/creatinine ratio (indicator of renal tubular injury) and urinary albumin/creatinine ratio (indicator of glomerular injury incidence of postoperative af urinary albumin/creatinine ratio serious adverse events, hospital mortality microsomal liver function oxygen transport and uptake chest radiograph or on survival rate liver function tests, renal function tests, graft survival, patient survival, plasma gsh and duration of hospital and icu stay reactive oxygen species-mediated myocardial stress liver blood flow index and megx nuclear factor-kappa b activation and circulating cytokine and adhesion molecules haemodynamic parameters, nasopharyngeal temperature, arterial blood gas changes, plasma cytokine levels, biochemical parameters, intramucosal ph, length of stay in the intensive care unit, duration of of mechanical ventilation and mortality mod score postoperative egfr plasma il-6 systemic oxygenation survival; incidence of cerebral oedema, renal failure, and hypotension requiring inotropic support; liver function mean (sd), pooled mean arterial pressure (map), and cardiac index plasma interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 concentrations mortality cerebral oedema hemodynamics and survival rates aminotransferases, prothrombin time, and monoethylglycinexylidide test adverse effects megx fulminant hepatic failure mortality, lactate clearance times|intravenous administration of n-acetylcysteine does not clearly prevent postoperative acute renal failure in patients with renal insufficiency undergoing cardiac surgery. the urinary nag/creatinine ratio increased significantly from baseline to before crossclamp and remained increased on day 5 in both groups. plasma concentrations of tumor necrosis factor-alpha (tnf), interleukin (il)-6, il-8, il-10, and soluble tumor necrosis factor-alpha receptor-p55 (stnfr-p55) were measured by sensitive immunoassays at 0, 2, 4, 6 and 24 h. the aagp and crp values were both elevated during cpb in the two groups without a significant difference, but 6 and 24 h post-cpb, the values were significantly higher in the control group than in the study group. ethane and mda concentrations were significantly reduced in the treatment groups after day 6. there were no significant differences between groups in any of the measurements before treatment and after the return to baseline f1o2 at the end of the study, respectively. the transplantation rate was lower in the nac group but was not significantly different between groups (32% vs 45%; p = .093). interleukin-8 decreased significantly only in those who received n-acetylcysteine (p =.0081). iv nac did not affect survival, graft function or risk of aki. the oxidative burst response of neutrophils in the patients receiving nac was significantly low at all times during bypass. levels of urinary nag/creatinine ratio, plasma creatinine and serum cystatin c did not significantly differ between nac and placebo groups during five postoperative days. no improvement could be demonstrated in the pao2/fio2 ratio in the study group as compared with the control group on any day. no differences were found between groups in levels of the major cytokines, duration of ventilation and intensive care unit stay, gastric intramucosal ph and arterial oxygen tension/inspired fractional oxygen ratio (p > 0.05). the difference between arterial and gastric mucosal carbon dioxide tension decreased (p = .05) and megx increased (p = .04). nac had no significant effect on mortality, lactate clearance times (p = 0.74), or coma recovery times (p = 0.46). the n-acetylcysteine responders had a higher survival rate (69%) than the non-responders (19%) and were studied earlier after onset of sepsis (37 hrs) than the nonresponders (61 hrs). there was no statistically significant difference between the two groups regarding outcome as indicated by mortality and the required days of inotropic support, mechanical ventilation, and intensive care. both groups exhibited significant postoperative increases in a-a oxygen gradient (p < 0.01), but patients in group ii exhibited significantly lower increases in postoperative a-a oxygen gradient (p < 0.006). the overall mortality was 23% (10/42) and was not different (p = 0.209) in nac group (33.3%) when compared with control (16.7%), the same occurring with the length of icu stay (2.93 +/- the nac and placebo groups (32 and 29 patients, respectively) were comparable at icu admission for severity of illness assessed by the simplified acute physiology score (saps) (10.8 +/- there was no difference in the proportion of patients with postoperative renal dysfunction (29.7% vs 29.0%, p = .89; relative risk [rr], 1.03 [95% confidence interval {ci}, 0.72-1.46]) in the n-acetylcysteine and placebo groups, respectively. plasma il-6 was lower on days 4-5 (p<0.05), il-8 on days 4-6 (p<0.05) and il-10 on days 4-6 (p<0.05) in nac group. the change in left ventricular cardiomyocyte staining (end of cardiopulmonary bypass--before cardiopulmonary bypass) differed significantly between groups for both primary measures: 8-iso-prostaglandin-f(2)alpha, -1.8 +/- this study failed to show any beneficial effect of the intraoperative administration of nac on hemodynamics and graft function in liver transplantation in patients with chronic liver disease. there was no difference in either daily organ failure score over time (p > .01, repeated-measures analysis of variance) or hospital mortality rate (90% n-acetyl-l-cysteine group, 50% placebo group) (p > .1, logistic regression) between the two groups. there was no significant attenuation in the increase in serum creatinine from baseline to peak when comparing n-acetylcysteine with placebo (64.5 +/- acetylcysteine treated patients had a lower incidence of cerebral oedema (40% (10/25) v 68% (17/25); p = 0.047, 95% confidence interval for difference in incidence 2% to 54%), and fewer developed hypotension requiring inotropic support (48% (12/25) v 80% (20/25); p = 0.018, 95% confidence interval 7% to 57%). in group 2, the partial pressure of oxygen in arterial blood/fractional inspired oxygen 4 h after surgery was significantly higher than in group 1 (213 +/- creatine kinase-mb levels at 6 and 12 hours were significantly lower in the nac group (p = 0.02). no differences were found in postoperative biochemical markers (troponin t, creatine kinase mb, creatinine, hemoglobin, and platelets) between the groups. the rate of af was lower in nac group compared with placebo group (three patients in nac group [5.2%] and 12 patients in placebo group [21.1%] had postoperative af; odds ratio [or] 0.20; 95% confidence interval [ci] 0.05 to 0.77; p = 0.019). creatine kinase mb isoform (ck-mb) mass levels did not significantly differ between the groups at both preoperative and postoperative periods. there was no significant difference between the two groups in any of the six organ dysfunction parameters, length of intensive care stay, days of mechanical ventilation and mortality. there was no difference in mortality among groups (placebo, 40%; nac, 36%; otz, 35%). in both groups, the fio2 was significantly lower and the pao2/fio2 ratio was significantly higher than the initial values during the evolution (fio2 at day 3, p < .01 for nac and p there were no significant effects on mortality, morbidity or postoperative graft function. the median percent change in egfr was 5.2% better (absolute difference) in the n-acetylcysteine arm (95% confidence interval 2.4% worse to 12.1% better; p=0.22). 2.1, p < 0.05; nac vs placebo, respectively, at 24 h and at 48 h). n-acetylcysteine infusion did not increase oxygen extraction or result in an improvement in whole-blood lactate levels or base excess during the study period. the results indicated that nac improved oxygenation (increase in pao(2)/fio(2)) and decreased mortality rate in treated patients compared to control group (p<0.05).|36 patients who developed ards less than 24 hours before enrollment in the study cardiac risk patients patients with sepsis 60 septic shock patients within 24 hrs after onset of sepsis high-risk patients undergoing cabg surgery patients with renal insufficiency undergoing cardiac surgery patients with acute lung injury 50 patients twenty patients undergoing elective coronary bypass operation with cardiopulmonary bypass bronchoalveolar lavage fluid septic shock patients kidney injury in abdominal aortic surgery patients with mild-to-moderate acute lung injury one hundred patients (mean age 60.5 years, range 43-78 years, 89% male) undergoing coronary artery bypass grafting at the montreal heart institute septic shock patients admitted to an interdisciplinary surgical intensive care unit patients with early stage non-acetaminophen-related acute liver failure thirty patients, requiring hemodynamic monitoring (radial and pulmonary artery catheters) because of cardiac risk factors twenty consecutive patients within 12 hrs of fulfilling the consensus criteria for sepsis cardiac surgery patients with pre-existing moderate renal insufficiency sixty-six icu patients with ards critically ill patients one hundred eight adult patients with severe falciparum malaria patients who benefit from nac treatment in early septic shock patients with severe fulminant hepatic failure patients with an acute lung injury early stage non-acetaminophen acute liver failure patients with chronic liver disease 295 patients required elective or urgent cabg and had at least 1 of the following: preexisting renal dysfunction, at least 70 years old, diabetes mellitus, impaired left ventricular function, or undergoing concomitant valve or redo surgery patients with uncomplicated malaria and healthy volunteers 9 years; 9 women and 31 men coronary artery bypass surgery severe sepsis adult respiratory distress syndrome 60 cardiac surgery patients at higher risk of postoperative renal failure high-risk cardiac surgery patients 100 patients; 50 received twenty-two patients included within 4 h of diagnosis of septic shock group [n = 10]), 15 male and five female, of mean age 64 patients undergoing coronary artery bypass grafting (cabg) procedures patients with acute lung injury/ards patients with fulminant hepatic failure after paracetamol overdose operating rooms and intensive care units of two tertiary referral hospitals fifty-three patients were included in the study hearts of patients subjected to cardiopulmonary bypass and cardioplegic arrest burns one-hundred-seventy-seven cardiac surgery patients with moderate pre-existing renal insufficiency (egfr <or= 60 mlxmin(-1 patients with septic shock patients undergoing cardiac surgery 50 consecutive patients (21 male) aged 16-60 with fulminant hepatic failure after paracetamol overdose who had not previously received acetylcysteine patients with pre-existing renal failure undergoing cardiac surgery patients with ards severe malaria patients with fulminant hepatic failure patients meeting a predetermined definition of ards and requiring mechanical ventilation forty-two patients (n = 18 for nac group and n = 24 for control liver transplantation two hundred fifty-four consecutive patients with chronic renal insufficiency (estimated creatinine clearance < or = 60 ml/min) undergoing elective cardiac surgery patients undergoing abdominal aortic surgery cardiac surgery patients university cardiology center eight-bed intensive care unit in a university teaching hospital acute liver failure patients without clinical or historical evidence of acetaminophen overdose were stratified by site and coma grade orthotopic liver transplantation 40 patients undergoing on-pump cabg cardiac surgery patients at higher risk of postoperative renal failure major abdominal tumour surgery adult respiratory distress syndrome (ards) in man forty patients undergoing coronary artery bypass grafting (cabg patients with non-acetaminophen-related acute liver failure cardiac risk patients during hyperoxia patients undergoing elective cabg with patients with chronic renal failure undergoing cardiac surgery forty patients undergoing coronary artery surgery (mean age thirty-five patients included within 4 h of fulfilling consensus criteria of severe sepsis a provincial hospital in western thailand and a tertiary referral hospital in chittagong, bangladesh twenty-four adult patients undergoing coronary artery bypass were included in the study twenty patients (n 100 patients recruited (14 withdrew), 86 patients were studied multidisciplinary intensive care unit at a university teaching hospital sixty-one adult patients presenting with mild-to-moderate acute lung injury and various predisposing factors for ards received either twenty patients undergoing elective cabg and early tracheal extubation 115 patients undergoing coronary artery bypass and/or valve surgery acute renal failure (arf) after cardiac surgery patients with chronic renal insufficiency undergoing cardiac surgery seventy patients without previously documented renal dysfunction 56 patients were treated with 11 patients with severe fulminant hepatic failure 80 patients with mild to moderate renal failure undergoing elective heart surgery with cardiopulmonary bypass were recruited high-risk patients undergoing cabg surgery with cpb compared with operating rooms and general intensive care units (icus) of 2 ontario tertiary care centers acute kidney injury after cardiac surgery eighty-nine were randomized to patients with mild renal failure undergoing cardiac surgery patients with stable renal function acute respiratory distress syndrome acute severe sepsis cardiopulmonary bypass (cpb 93 patients, 47 received n-acetylcysteine and 46 were given 18 patients who underwent x m[-2 patients with severe sepsis fifty-eight patients requiring hemodynamic monitoring (radial and pulmonary artery catheters) due to septic shock 42 patients with established ards receiving either 27 icu patients with ali/ards acute lung injury in man acute renal failure related to elective aortic aneurysm repair patients with chronic liver disease undergoing orthotopic liver transplantation by giving nac during operation patients undergoing coronary artery bypass surgery with cardiopulmonary bypass namely established adult respiratory distress syndrome (ards patients with early adult respiratory distress syndrome (ards 173 patients received humans suffering from severe sepsis septic shock patients admitted to the intensive care unit patients undergoing coronary artery bypass grafting with cardiopulmonary bypass patients undergoing coronary artery by-pass grafting (cabg patients with advanced coma grades do not benefit from nac and typically require emergency liver transplantation patients undergoing cabg 59 patients with coma grades bypass surgery patients with newly diagnosed septic shock 22 patients undergoing orthotopic liver transplantation after severe burn coronary artery bypass surgery with cardiopulmonary bypass sixty patients with chronic end-stage liver disease
incidence of diabetes mellitus knowledge and foot self-care scores patients' attitudes regarding the value and importance of footcare, patients' footcare knowledge, healthcare professionals' footcare knowledge and pattern of service utilization baseline foot risk category diabetes-related quality-of-life scores knowledge of diabetic foot care hemoglobin a(1c) levels prevalence of some minor foot problems attitudes towards footcare dermatologic abnormalities serious foot lesions self-management behavior health professionals' knowledge scores knowledge about diabetic foot problems hospitalized with diabetes- or vascular-related admissions reduction of lower extremity clinical abnormalities quality of life self-care|there was a significant improvement in self-management behavior in all six categories evaluated in the study group versus the control group. attitudes towards footcare improved in both intervention and control groups (mean percentage change 3.91, 0.68) with a significant difference in change of 3.18 (95% confidence interval (ci) 1.29-5.07) between the groups. patients in the podiatrist group had greater improvement in knowledge of diabetic foot care (p = 0.004) and self-care (p < 0.001) scores compared with control subjects. over 85% of the results for the semmes-weinstein monofilaments were the same on the first and second measurement. an intervention designed to reduce risk factors for lower extremity amputations positively affected patient self-foot-care behavior as well as the foot care given by health care providers and reduced the prevalence of lower extremity clinical disease in patients with diabetes.|patients with diabetes matched cluster randomization of practices from 10 towns drawn from mid and east devon responsible for the care of 1,939 people with diabetes (age > or =18 years 395 patients with non-insulin-dependent diabetes who underwent the initial patient assessment, 352 completed the study patients with diabetes mellitus who develop end-stage renal disease patients with diabetes mellitus patients at risk of diabetic foot ulceration in a general diabetic outpatient clinic two hundred and twenty-nine patients attended for their second appointment diabetic patients diabetic subjects patients with non-insulin-dependent diabetes mellitus patients with non-insulin-dependent diabetes people with diabetes mellitus eighty-three patients patients attending a general diabetic outpatient clinic at the royal liverpool university hospital underwent screening using the semmes-weinstein monofilaments, the biothesiometer, and palpation of pedal pulses patients without recent visits to a podiatrist and without an obvious need for foot care two hundred and fifty-nine patients who were found to have a deficit on at least one of these tests were given a second appointment where the tests were repeated 733 patients, aged 10-79 years, identified from the national diabetes register
serum free cortisol infectious morbidity and shortens length of stay nitrogen balance, urinary 3-methylhistidine excretion, urinary cortisol, and clinical status nitrogen balance age, percent total and third-degree burn, resting energy expenditure, and calorie and protein intake 3-methylhistidine excretion wound infection better respiratory and nutrition status, and shorter time to healing pneumonia corticosteroid-binding globulin and total and free serum cortisol deaths protein metabolism, morbidity, and length of care incidence of diarrhea, improved glucose tolerance, lower serum triglycerides, reduced total number of infectious episodes and trends toward improved preservation of muscle mass|there was no difference in nitrogen balance between groups, and 3-methylhistidine excretion was higher and serum free cortisol was lower in log-fat--fed patients than in controls. data analysis demonstrated significant superiority of mtf in the reduction of wound infection (p less than 0.03) and length of stay/percent burn (p less than 0.02).|severely burned adults fifty patients, 3 to 76 years of age with burns ranging from 10 to 89% total body surface area 43 patients burn patients
mean duration of improvement after ivmp muscle function efficacy and safety severe side effects failure rate muscular score and functional grade positive treatment response acetylcholine receptor antibody concentrations level of function treatment failure efficacious and safe|of the six patients on prednisone, three showed no improvement and three were improved. the side effects of prednisone were manageable. no severe side effects were found. no difference was observed between the two groups in muscular score and functional grade, assessed at the end of each treatment year, or in tolerance.|myasthenia gravis ten patients with myasthenia gravis from january 1983 to october 1990, 41 patients with generalised myasthenia gravis patients with moderate mg thirteen patients with moderately severe myasthenia gravis
median overall survival overall (fact-g) scores functional assessment of cancer therapy-cervix (fact-cx), neurotoxicity subscale (fact/gog-ntx subscale), and brief pain inventory (bpi anemia quality of life (qol) outcomes response and adverse effects myelosuppression survival time median os diarrhea overall response rate greater myelosuppression percentage of planned dosages median times to progression or death gastrointestinal toxicity response rates, survival, side effects and quality of life severe complaints of asthenia serum creatinine level longer progression-free survival (pfs) time qol scores complete remission rates neurotoxicity subscale complete remission rate, response duration, progression-free interval, or survival partial responses incidence of complete and partial remission rate of qol lower risk of death survival grade 3/4 toxicities were leukopenia, neutropenia, anemia, thrombocytopenia, and nausea and vomiting nausea and vomiting or rate response rate progression-free survival (pfs), or overall survival median duration of response response rate of adriamycin myelosuppression and nephrotoxicity response and survival rates thrombocytopenia and leukopenia nephrotoxicity, peripheral neuropathy, myelosuppression, and ototoxicity leukopenia and thrombocytopenia episodic hypersensitivity unadjusted hazard ratio for overall survival qol overall survival (os mild diarrhea leukopenia leukopenia, renal toxicity, peripheral neurotoxicity, and cns toxicity initial performance score response rate, pfs, survival, and toxicity profile response rate and progression-free survival (pfs response rates neurotoxicity toxicity rate of failure complete remission rates, response duration, progression-free interval, and survival times mild thrombocytopenia myelosuppression, nausea and vomiting, mucositis, rash, and hepatotoxicity frequency of severe toxicity median pfs overall survival incidence of these toxicities duration of complete plus partial remission hematologic toxicity partial response response and pfs renal, otic, and peripheral nervous system toxicities response rate and pfs duration objective response (or) rate, progression-free survival (pfs) and overall survival (os overall survival (os), with response rate, progression-free survival (pfs), and quality of life (qol objective response rates overall qol and pain pfs and survival median survival antitumor responses median survival time overall qol scores qol assessment pain scores patients' quality of life (qol pulmonary toxicity median progression-free interval|hexamethylmelamine had a greater frequency of severe toxicity (50%, 10/20) than adriamycin (10.5%, 2/19) (p = 0.014) and cytoxan (10%, 2/10) (p = 0.014). objective response rates were similar: 2 complete regressions (crs) and 10 partial regressions (prs) were recorded both in the 46 evaluable patients treated with cbdca (response rate, 26.1%; 95% confidence interval, 15-41%) and in the 40 evaluable patients treated with chip (response rate, 30%; 95% confidence interval, 17-47%). cifx had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (pfs) time (p = .003) compared with cisplatin alone. mvac produced a 22% overall response rate (95% ci: 0.13 to 0.34) and median pfs and os of 4.4 months and 9.4 months, respectively. response rates were similar for both agents (15% for carboplatin, 11% for iproplatin) and appear to be inferior to those noted with the parent compound, cisplatin. the response rate for the pif regimen was 40% (4 partial remissions) and 9% for the cisplatin group (1 complete remission). the difference in response rates for regimens 1 and 2 is statistically significant (p = .015) but less than the magnitude originally considered clinically significant. the unadjusted hazard ratio for overall survival between treatment arms was 0.76 although 19 of 43 (44%) evaluable patients receiving bcap and 16 of 42 (38%) evaluable patients receiving bp experienced tumor regression, only 22% of those receiving bcap and 21% of those on bp survived 1 year after beginning treatment. or rate was significantly higher in the itp group (59% versus 33%, p = 0.002). the continuous infusion regimen was associated with a significantly greater percentage of patients who experienced no nausea and vomiting (34% versus 18%, p = 0.002). despite adequate dosage, the incidence of complete and partial remission was low (10% vs 20%) and not superior to that usually obtained with single agent chemotherapy. neither trimetrexate nor didemnin b at these doses and schedules is recommended for the treatment of advanced squamous carcinoma of the uterine cervix. the toxicity of the four-drug regimen was significantly greater than that of the two-drug regimen, while the response rate was greater among those patients treated with two drugs. of 31 patients treated with avf, only three (10%) responded (one complete response and two partial responses). responding patients survived significantly longer (11 months) than either those receiving hydroxyurea or those not responding to combination chemotherapy (4 months). patients with a ps of 0 experienced a lower rate of failure (p =.013) and a lower risk of death (p =.009) compared with patients with ps of 2. the cp arm produced a significantly higher response rate and progression-free survival (pfs) but not overall survival (os).|twenty-four patients were included, 3 of which not eligible, and of the remaining 21 patients 394 patients with advanced, measurable squamous carcinoma of the uterine cervix and no prior chemotherapy twenty-seven eligible patients patients with measurable metastatic or recurrent squamous carcinoma of the uterine cervix who had failed prior surgery or radiation therapy 45 patients with advanced cervical carcinoma from july 1984 to november 1987, 89 patients with recurrent measurable squamous-cell cancer of the uterine cervix advanced cervical carcinoma squamous-cell carcinoma of the cervix three hundred three women were enrolled onto this trial, of which 287 were assessable 34 consecutive patients with advanced or recurrent carcinoma of uterine cervix thirty-five patients with epithelial carcinomas not considered to be surgically resectable advanced squamous carcinoma of the uterine cervix squamous cell carcinoma stage ivb, recurrent, or persistent cervical cancer one hundred eighty-six patients (c = 60; tc = 63; mvac = 63 sixty-one evaluable patients with advanced squamous cell carcinoma of the cervix advanced squamous cell carcinoma of the cervix 30 patients treated with women with stage ivb, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy advanced cervical cancer advanced carcinoma of the uterine cervix women with histologically proven advanced recurrent or persistent squamous cell carcinoma of the cervix metastatic or recurrent squamous carcinoma of the uterine cervix 454 patients entered, 438 were eligible and analyzed for response and survival 23 patients ineligible for the study and 10 patients who were not evaluable; the remaining 361 patients patients with squamous cell carcinoma of the head and neck 331 patients with advanced or recurrent squamous cell carcinoma of the cervix no longer amenable to control with surgery or radiotherapy 59 patients with recurrent squamous carcinoma of the cervix originally treated with four hundred ninety-seven evaluable patients have been accrued on this study recurrent carcinoma of the cervix 37 patients with easily evaluable disease cervical cancer sixteen patients squamous cell carcinoma of the uterine cervix recurrent cervical cancer patients with recurrent or metastatic cancer of the uterine cervix one hundred and fifty-three patients advanced cervix cancer advanced squamous carcinoma of the cervix advanced cervix cancer, response was seen in 57% (including 13% cr) of patients receiving the combination (ddp + mtx) regimen cervical cancer patients carcinoma of the uterine cervix recurrent or metastatic carcinoma of the uterine cervix patients with advanced cervical cancer eligible patients 293 eligible patients eligible women ovarian cancer and small-cell lung cancer squamous carcinoma of the cervix
vomiting overall outcome or tolerability complete cure efficacy, cost, and compliance therapeutic efficacy side effects rapid clearance of tinea capitis hair regrowth clinical cure efficacy and safety adverse reactions absence of clinical signs, hair regrowth or negative mycology trichophyton mentagrophytes mean time to a sterile culture hepatotoxicity or other adverse reactions microsporum audouinii mycologic cure and either clinical cure cure rates mycological cure microsporum canis efficacy and tolerability clinical deterioration subcutaneous skin damage requiring plastic surgery treatment efficacy time for complete scalp clearing trichophyton violaceum adverse effects cure rate|two pulses of standard dose terbinafine were found to be sufficient for treating most cases of microsporum spp. trichophyton violaceum was the major pathogen in both groups (82.1% and 88.9%, respectively). although the 4-week course of terbinafine resulted in a trend to more rapid clearance of tinea capitis, there were no statistically significant differences between the two drugs in terms of overall outcome or tolerability, apart from in a subgroup of patients with trichophyton infections, and weighing > 20 kg, who responded better to terbinafine than to griseofulvin at 4 weeks. the time for complete scalp clearing was significantly longer in patients who received ketoconazole (median, 108 days) compared with those who were treated with griseofulvin (median, 60 days) the responsible organisms were microsporum canis (17 cases) and trichophyton verrucosum (7 cases). isolated pathogens included trichophyton violaceum (71.5%), t. tonsurans (14.9%), t. verrucosum (4.3%), microsporum audouinii (4.3%), m. canis (2.5%), t. schoenleinii (1.9%) and t. mentagrophytes (0.6%). no significant hepatotoxicity or other adverse reactions were observed. complete cure was observed at the end of study in 62% patients treated with terbinafine for 6 weeks, in 60% treated for 8 weeks and in 84% patients treated with griseofulvin for 12 weeks. at the end of study, effective treatment, defined as negative culture and low scores on signs and symptoms, was achieved in 56%, 69%, and 65% of patients who were treated with terbinafine for 1, 2, and 4 weeks, respectively. mild to moderate adverse events believed to be drug related occurred in four patients in each of the two groups. after 6 weeks of therapy there was clinical and mycologic cure or improvement of the lesions in 92% of patients treated with ketoconazole (group a) and in 76% of those given griseofulvin (group b). discontinuation from therapy due to adverse effects occurred only in the griseofulvin group (nausea in one patient). mycologic examinations disclosed trichophyton verrucosum in 40% of patients, t. violaceum in 40% and microsporum canis in 20%. no significant side effects were reported. fifteen of 17 patients were cured by itraconazole (88%) and 15 of 17 patients by griseofulvin (88%). the treatment groups were comparable in terms of age, weight, sex, race, duration of infection, length of therapy, and initial disease severity.|40 patients with a clinical and mycologic diagnosis of tinea capitis patients ranged in age from 2.1 to 11 years (median, 5.2 years fourteen children thirty-four children and one adult with clinical signs and symptoms of tinea capitis and with positive culture and microscopy for dermatophytes 159 patients had culture-confirmed tinea capitis attributable to trichophyton species and constituted the intent-to-treat population used for efficacy analysis (50, 55, and 54 patients in the 1-, 2-, and 4-week arms, respectively tinea capitis caused by trichophyton species 176 patients with a clinical diagnosis of tinea capitis tinea capitis in childhood patients with microsporum audouinii infections 161 evaluable patients, 53 were treated with 2 weeks in tinea capitis fifteen of these 17 itraconazole patients and 14 of the 15 griseofulvin patients had infections caused by microsporum canis trichophyton tinea capitis in a north american population 50 patients with a clinical and mycologic diagnosis of tinea capitis patients with tinea capitis twenty-two patients were enrolled, and 14 completed the protocol patients who discontinued therapy or were lost to follow-up were treating tinea capitis 19 patients had cleared completely with good new hair regrowth two hundred and ten children aged 2--16 years, with mycologically confirmed tinea capitis sixty-three patients children children with tinea capitis patients ranged in age from 1 to 16 years; 80% were boys and 20% were girls twenty four consecutive patients with culture proven tinea capitis centers in canada and south africa seven patients presented with kerion, the remainder with a scaling and patchy alopecia pattern of tinea capitis dermatophytoses forty-eight patients (26 80 children with tinea capitis without kerion one hundred and forty-seven patients were evaluable (terbinafine 77, griseofulvin 70 patients' ages ranged from 1 to 14 years europe and south america fifty-four percent were girls and 46% were boys 47 children with dermatophytosis and positive fungal culture children with tinea capitis due to microsporum species thirty-five patients with mycologically proven scalp infections twenty four patients (16 male, 8 female tinea capitis in children all patients had positive initial mycologic cultures tinea capitis seventy-nine patients were enrolled; 46 received trichophyton tinea capitis dermatophytoses in children 42 individuals patients with trichophyton tonsurans tinea capitis
limb salvage and survival frequency of in-hospital cardiopulmonary complications topas mean ankle-brachial blood-pressure index major hemorrhage incidence of in-hospital cardiopulmonary complications amputation-free survival rates bleeding complications complete dissolution of thrombus cumulative limb salvage rate dissolution of the occluding thrombus duration of hospitalization risk of amputation or death intracranial hemorrhage cumulative survival rate amputation-free survival rate hospital mortality hospital cost partial lysis blood flow patient survival rates|the mortality differences seemed to be primarily attributable to an increased frequency of in-hospital cardiopulmonary complications in the operative treatment group (49% vs 16%, p = 0.001). thrombectomy resulted in an immediate restitution of blood flow in six out of nine cases, in three cases a bypass procedure was performed, and one of these failed with a resultant amputation. amputation-free survival rates in the urokinase group were 71.8 percent at six months and 65.0 percent at one year, as compared with respective rates of 74.8 percent and 69.9 percent in the surgery group; the 95 percent confidence intervals for the differences were -10.5 to 4.5 percentage points at six months (p=0.43) and -12.9 to 3.1 percentage points at one year (p=0.23).|patients diagnosed with acute limb-threatening peripheral arterial occlusion group, and 57 patients peripheral arterial occlusive disease patients with limb-threatening ischemia of less than 7 days' duration twenty patients with a need for intervention owing to ischaemia lasting more than 24 h but less than 14 days were included acute arterial occlusion of the legs patients with acute peripheral arterial occlusion acute peripheral arterial ischemia acute arterial occlusion 57 patients 113 north american and european sites all patients (272 per group) had had acute arterial obstruction of the legs for 14 days or less
mean scores severity of pain and burning sensation using visual analog scales acceptability and efficacy symptom scores symptoms and extension of lesions; adverse effects hospital anxiety-depression (had) scale symptom-free state side-effects visual analog scale (vas) and clinical improvement including lesion type and size efficacy, relative safety, and tolerability tolerated, and only transient burning sensations systemic side effects vas scores painful symptoms measured by visual analog scale, the oral health impact profile score, and objective clinical score clinical response daily cost of ciclosporin treatment severity score oral health impact profile score surface area of oral lesions soreness scores change in symptoms patient's pain scores mucosal erosions and pain sensation patient quality of life erosion severe adverse events blood concentrations of pimecrolimus visual analogue scale (vas clinical score daily cost of ciclosporin blood levels partial to complete clinical improvement symptoms and side effects visual analogue scale (vas), the mcgill pain score, the oral health impact profile (ohip), and oral health quality of life (ohqol) questionnaires log diary recording oral function and soreness scores sustained remission of eolp erythema pain score (by linear visual analogue scale; 0-100); (ii) clinical score; (iii) clinical resolution; and (iv) patient compliance clinical and subjective improvement quality of life condition improved subsequently relapsed ulceration (alpha = 0.068) and erythema efficacy, ease of application, and adverse effects partial response, no response and worsening of the symptoms eolp clinical improvement total surface area of the lesions, including all white, erythematous, and ulcerative lesions efficacy and safety soreness relief following immediate application, oral function and size of erosive/ulcerative area complete clinical remission clinical signs and occurrence of side effects swelling or burning sensation discomfort scores vas scores, a partial to complete response good response partial improvement erosive areas and recorded visual analog scale (vas) scores blood cyclosporine levels burning pain clinical response, pain, burning sensation, area of reticulation, erythema, and ulceration blood level of pimecrolimus psychological disability domain and total ohip-49 score mean score mean lesion sizes and mean pain measures patient documentation, measurement of pimecrolimus levels and blood counts serious side-effects safety painful symptoms clinical candidosis clinical and symptomatological improvement of olp visual analog scale score signs and symptoms of olp transient burning sensation complete pain remission recurrence rates erosive and ulcerative lesions good or partial response side effects reticulation pain severity, burning sensation, and mucosal lesion extension ulcerative areas oelp lesion size total quality of life score symptomatology clinical scoring and grid measurement of the target lesion (reticulation, erythema, ulceration psoriatic lesions initial therapeutic response size of the erosive/ulcerated area relapse pain complete remission adverse effects relation to pain|although clinical response, pain, burning sensation, area of reticulation, erythema, and ulceration at week 4 were all worse in patients receiving cyclosporine than in those receiving steroid, the differences were not statistically significant. clobetasol is more effective than ciclosporin in inducing clinical improvement, but the two drugs have comparable effects on symptoms. topical tacrolimus 0.1% ointment induced a better initial therapeutic response than triamcinolone acetonide 0.1% ointment. no statistical differences were found in comparing the two different formulations. both formulations were found to be similar for parameters ii, iii and iv, although with a better general trend for formulation a; a significant difference was registered for formulation a in terms of a reduction in painful symptoms (parameter i) at time t2 (p = 0.02). the results showed that 13 treated sites compared with six control sites responded significantly favorable to puva therapy. there were no statistical differences in the recurrence rates (33.3% vs. 45.5%, p = 0.386) and intervals (80.89 +/- no serious side-effects were found in both groups. the experimental group showed a decrease in ulceration (alpha = 0.068) and erythema (alpha = 0.005) at the mid-point with continued reduction of erythema at the final (alpha = 0.075) time measurement. the difference in the mean scores within each group was statistically significant from the fourth week onward in group a and eighth week onward in group b, whereas in patients with erosive disease it was second and twelfth week onward, respectively. in relation to quality of life, significant differences were observed between the two groups in the psychological disability domain and total ohip-49 score. mean lesion sizes and mean pain measures differed between control and treatment groups favouring ignatia (p<0.05). application of topical ha produced a significant reduction (p < 0.05) in soreness scores when compared with placebo for up to 4 h post-application. the 1% pimecrolimus cream seems to be an effective and well-tolerated treatment for oral erosive lichen planus. a significant decrease in vas scores was seen at the end of the study period (p < 0.001). the addition of miconazole did not affect in a significant way the signs and symptoms of olp. no adverse effects were noted during follow-up period. the clinical eolp 'composite score' including mucosal erosions and pain sensation was significantly reduced in the pimecrolimus-treated group compared with vehicle (p = 0.025). the first interim analysis did not show a significant difference between the placebo and curcuminoids groups. after eight weeks, the eight recipients of cyclosporine had marked improvement in erythema (p = 0.003), erosion (p = 0.02), reticulation (presence of white lacelike lesions; p = 0.007), and pain (p = 0.002), whereas the eight recipients of vehicle had no change or minimal improvement. both fp and bsp mouthwash caused both a statistically significant reduction in painful symptoms as measured by the vas and improvement in quality of life as measured by the ohip and ohoql indices. at the end of the treatment period, symptom scores were significantly lower in the tacrolimus group than in the clobetasol group. there was no significant difference between changes from baseline median values of pimecrolimus and triamcinolone groups after treatment termination in terms of visual analog scale score (-9.8 +/-|37 biopsy-proven symptomatic olp patients 30 consecutive patients with oral lesions consistent clinically and histologically with erosive patients with symptomatic moderate to severe oral lichen planus patients with symptomatic oral lichen planus atrophic/erosive oral lichen planus eighteen patients with long-standing, bilateral, and severe olp of the buccal mucosa participated in the investigation a total of 49 of 56 patients were followed up forty consecutive patients with oral lichen planus diagnosed on the basis of histopathologic and immunofluorescence findings participated in this study oral lichen planus (olp oral erosive lichen planus (oelp and/or atrophic olp twenty patients (group i) were treated with february 2003 and september 2004 14 patients, 2 did not meet the inclusion criteria and 12 were enrolled in the trial 16 patients with symptomatic oral lichen planus fourteen consecutive patients with oral erosive lichen planus confirmed by histological examination and with a clinical score superior to 3 patients with oral lichen planus twenty patients with oelp one hundred thirty-nine biopsy-proven olp patients oral erosive lichen planus twenty patients forty consecutive patients fifty-four consecutive patients (34 women and 20 men) participated in the study 40 patients unit of oral medicine and pathology of the university of milan patients with moderate to severe oral lichen planus erosive oral lichen planus fifty-four patients 45 patients [12 males and 33 females; mean age 61.1 years oral lichen planus eighteen patients in 49 patients with moderate to severe oral lichen planus thirty-five outpatients with histologically proven olp 100 consecutive, eligible patients with olp presenting to the oral medicine clinic at the university of california, san francisco, were to be selected 124 patients with erosive olp 32 patients (20 females and 12 males; all white, italian origin, mean age of 43.6+/-18.4 years; 16 patients per treatment group) were treated with outpatients of the department of dermatology, university hospital of nice, from december 21, 2004, to april 19, 2005 atrophic-erosive oral lichen planus 56 olp patients symptomatic oral lichen planus 64 patients with olp patients with olp atrophic and erosive oral lichen planus fifty patients with symptomatic olp thirty-five consecutive patients october 2004 using data from the first 33 subjects 48 patients with biopsy-proven symptomatic olp, and 44 patients (92%) completed the study
symptom scores of pfr measurement asthma control steroid dosage, visual analogue symptom scores, response to beta 2 agonist and peak expiratory flow rate (pfr) measurement|in this study an 8 week treatment with hydroxychloroquine was of no benefit to patients with chronic steroid dependent asthma.|a group of nine steroid dependent adult asthmatic patients patients with chronic steroid dependent asthma patient with severe chronic asthma
longer duration of hospital stay neonatal necrotizing enterocolitis necrotizing enterocolitis (nec mortality incidence of nec necrotising enterocolitis protection against necrotising enterocolitis|infants with necrotising enterocolitis were associated with a significant increase in mortality (p = 0.026) and longer duration of hospital stay (p = 0.002). this difference in the incidence of nec between the treatment and control group was significant at the .05 level.|71 infants receiving and 19 of 69 infants receiving the 42 high-risk neonates selected babies at high risk for nec, particularly those born prematurely and those who have a history of perinatal asphyxia or umbilical artery catheterization or both infants with necrotising enterocolitis a tertiary referral centre of a university teaching hospital was conducted on 140 very low birthweight infants consecutively admitted to the neonatal unit necrotising enterocolitis in preterm, very low birthweight infants
mean pretransfusion bleeding times platelet efficacy posttransfusion platelet count increments and days to next transfusion mean 1-hour posttransfusion template bleeding times 24-hour plt count incidence of grade 2 bleeding clinical refractoriness proportion of patients with world health organization (who) grade 2 bleeding 1-hour corrected count increment (cci risk of bleeding clinical hemostasis cci(1hour prolonged bleeding times and transfusion intervals platelet transfusion dose, pretransfusion storage duration, and patient size average number of days to next platelet transfusion therapeutic efficacy and safety hemostatic efficacy 1-hour count increment, time to next transfusion, hemostasis, transfusion reactions, and serious adverse events posttransfusion plt count increments 1 h corrected count increment (cci clinical hemostasis, hemorrhagic adverse events, and overall adverse events number, frequency, and dose of plt transfusions; acute transfusion reactions; and adverse events 1- and 24-h count increment (ci), 24-h cci, time to next pc transfusion, red blood cell (rbc) use, bleeding and adverse events bleeding events overall median time to next transfusion incidence of grade 3 or 4 bleeding time to next plt transfusion median time number of platelet transfusions plt count increments and ccis transfusion-associated bacteremia mean 1-hour posttransfusion plt corrected count increments (ccis corrected count increment (cci mean 1-hour posttransfusion platelet corrected count increment (cci) blood product utilization transfusion reactions bleeding times plt and red blood cell utilization 24-h cci, bleeding, transfusion requirement of red cells and pc, platelet transfusion interval and adverse transfusion reactions|forty-three patients with transfusion-dependent thrombocytopenia were randomly assigned to receive either pct or reference plt transfusions for up to 28 days. twenty-seven patients (32%) had bleeding events in the pr-pasiii arm, as compared to 19 (19%) in the plasma arm and 14 (15%) in the pasiii arm (p = 0.034). pct plts provided correction of prolonged bleeding times and transfusion intervals not significantly different than reference plts despite significantly lower plt count increments and ccis. post-transfusion bleeding and rbc use were not significantly different (p = 044, p = 082 respectively). platelet transfusion dose, pretransfusion storage duration, and patient size were significant covariates (p <.001) for posttransfusion platelet counts. plt and red blood cell utilization in the two groups was not significantly different suggesting that the slightly lower ccis (prt-plts) did not increase blood product utilization. hemostasis was adequate and no transfusion reactions or serious adverse events were reported. transfusion reactions were fewer following pct platelets (3.0% pct versus 4.4% control; p =.02).|patients with chemotherapy-induced thrombocytopenia (six centers twenty patients with thrombocytopenia 29 patients receiving 118 patients 103 patients received one or more transfusions of either pct test (311 transfusions) or 20.8 x 10(9) and 52.3 x 10(9 645 patients (318 pct and 327 control thrombocytopenic patients requiring repeated thrombocytopenic patients patients with thrombocytopenia forty-three patients with transfusion-dependent thrombocytopenia 32 patients with thrombocytopenia received one transfusion of pct and/or one transfusion of untreated (reference) apheresis plts
serum albumin, a/g ratio and colloid oncotic pressure gastric intramucosal psco(2) and arterial paco(2) (ps-aco(2) gap), gastric intramucosal ph (phi) and arterial lactate acid concentration 30 min after induction of anesthesia (baseline value), 1 h and 2 h after skin incision, and at the end of surgery extravascular lung water and cardiac index urine and chest tube outputs serum colloid osmotic pressure (cop), co, pcwp, the gradient between cop and pcwp (cop-pcwp), and intrapulmonary shunt (qs/qt platelet activation, platelet aggregation hemodynamic efficacy and safety superior 28-day survival hemodynamic parameters (heart rate, capillary filling time, pulse volume, and blood pressure urine output sex, age, cause of hypovolemia, revised trauma score (rts), glasgow index, and mean arterial pressure (map) on admission renal function and lactate clearance values of selam-1 concentrations of molecular markers of activated coagulation and fibrinolysis survival rates predicted survival physical parameters and hemodynamic variables plasma sodium content mean arterial pressure (map plasmin/alpha 2-antiplasmin complex blood pressure, ph, and urine output frequency of adult respiratory distress syndrome mean cop gain of body weight cop-pcwp pulmonary vascular resistance index transcapillary fluid flux survival nausea and vomiting adverse reactions negative fluid balance fluid balance and pulmonary functions resolution of acidosis blood pressure hemorrhagic shock inflammatory response risk of death ejection fractions postoperative nausea and vomiting and improves postoperative outcomes biochemical variables and haemodynamics (transpulmonary thermodilution thrombin/antithrombin iii complex, prothrombin f1 +2 fragment) platelet activation (betatg) and compromised coagulation 48-hour mortality; secondary end points included pulmonary edema, increased intracranial pressure, and mortality or neurologic sequelae at 4 weeks days of mechanical ventilation haemodynamic stability mean (+/-sd) numbers of days spent in the icu crossmatching of blood blood loss and coagulation infusion rates and 8-hour intake requirement for rescue colloid at any time after administration of the study fluid fluid balance, total fluid infused, sodium balance, total sodium infused, cop, or cop-pcwp significant diuresis sbp total intravascular albumin multiple organ dysfunction plasma volume (pv), ecfv, cardiac index, and arterial oxygen content severe bleeding colloid oncotic pressures, serum albumin and albumin/globulin (a/g) ratios relative risk of requirement for rescue colloid arterial lactate acid concentration cardiorespiratory functions systolic pressure hydrostatic pressures evlwi, pulmonary shunt fraction, and time on mechanical ventilation platelet function and hemostasis arterial lac preload-recruitable cardiac and left ventricular stroke work indices ejection fraction platelet aggregation plasma sodium arm and thigh circumferences interstitial fluid volume (isfv pop fell pop and mpaop iap mean arterial pressure, central venous pressure, pulmonary capillary wedge pressure, and cardiac index baseline values for pv, isfv, ecfv, and oxygen delivery index maximum sequential organ function scores coagulation and fibrinolytic system mortality itbv left ventricular preload and left ventricular ejection fraction cardiac output, evlw, pcwp, serum colloid osmotic pressure (cop), and intrapulmonary shunt fraction (qs/qt baseline glasgow coma scale scores cop limit the postoperative albumin consumption cumulative fluid balance higher mortality ratio between plasma volume (pv) and ecv plasma volume and global end-diastolic volume, confirming plasma volume and preload augmentation longest recovery times serum concentrations of interleukin (il)-6, il-8 and il-10 and soluble adhesion molecules (selam-1 and sicam-1 urine output and improvement of the glasgow coma score mean arterial blood pressure (map), systolic and diastolic pressure, central venous pressure (cvp), and pulmonary artery occlusion pressure (paop accuracy of colloid oncotic pressure (cop perioperative weight gains serum sodium hemodynamic effects 28-day survival-hsd proportion of patients with new single-organ and multiple-organ failure risk of intra-abdominal hypertension volumes of crystalloids and blood required in their resuscitation intrapulmonary venous admixture and improved pao2 plasma colloid osmotic pressure (copp pulmonary artery occlusion pressure levels of urea and creatinine hemodynamic response 28-day survival plasma colloid osmotic pressure 48-hour mortality cardiac index, central venous pressure, pulmonary capillary wedge pressure, systemic and pulmonary vascular resistance indices, arterial oxygen tension, plasma osmolarity, electrolytes, and urinary output pulmonary arteriovenous admixture factor xiii qs/qt and aado2 systemic vascular resistances mean plasma oncotic pressure (pop splanchnic oxygenation burden of mods normal blood pressure and urine output haemodynamic or lung function variables malaria status renal and thromboembolic complications clinical severity tissue oxygenation 4-week mortality pv and ecfv maximum aggregation, maximum gradient of aggregation, and platelet volume serum albumin thrombotic risk pao2 intrapulmonary venous admixture, arterial oxygen tension, or time on respirator total volume severe hypovolemia oxygen consumption and cardiac output cardiac filling pressures pulmonary capillary wedge pressure, and ventricular arrhythmias survival rate tissue oxygen tension (ptio(2 serum concentrations of sicam-1 hemodynamic stabilization (heart rate, capillary refill time, systolic bp in normal range), plasma volume at the end of fluid resuscitation and incidence of organ dysfunction icu and hospital los, and area under the curve of sofa score maintenance of arterial blood pressure, heart rate, and urine output platelet function requirement of inotropes, incidence of organ dysfunction and case fatality rate splanchnic blood flow and tissue oxygenation prothrombin fragment f1 + 2 blood transfusions nausea and vomiting, use of rescue antiemetics, severe pain, periorbital edema, and double vision extravascular lung water (evlw overall survival mean pulmonary arterial occlusion pressure (mpaop cardiac output and qs/qt apache ii score postoperative values of albumin concentration, circulating albumin mass and pis pulmonary extravascular thermal volume (etvl colloid osmotic pressure cardiac response systolic blood pressures and cardiac outputs prothrombin time (pt), activated partial thromboplastin time (aptt) and levels of plasma tissue plasminogen activator (t-pa), and plasminogen activator inhibitor (pai initial hemodynamic stabilization lactate clearance rate plasma oncotic pressure, renal function and peripheral oedema postoperative weight gain incidence of complications map, arterial lac, lactate clearance rate and apacheii score wedge pressure hemodynamic stability and fluid requirements biometric and perioperative data, hemodynamics and oxygenation intraoperative urine volumes postoperative hemoglobin level extravascular lung water (evlw - double indicator dilution technique mechanical ventilation release of pro-inflammatory cytokines il-6 and il-8 lactate clearance pulmonary capillary wedge pressure fluid balance, major organ complications, the acute physiology and chronic heath evaluation ii score, and the serum levels of c-reactive protein, interleukin-6, and interleukin-8 fluid retention plasma volume (pv) loss plasma volume mortality rates postoperative course blood pressure response; survival hemodynamic stability sublingual capillary density cardiac index, colloid osmotic pressure (cop), pulmonary capillary wedge pressure (pcwp), cop-pcwp gradient, right and left ventricular stroke work indices, and amount of constant positive airway pressure blood products [packed red blood cell volumes plasma creatinine, urea, electrolytes, urinary volume, and sodium excretion time to initial recovery calculated plasma volume expansion systolic blood pressure total body blood flow fluid balance creatinine clearance values plasma sodium content and cardiac index blood pressure, infused volumes necessary to maintain sbp, and overall survival rates next morning (am1), cop number of blood transfusions pao/fio:248.4  17.0,lactate clearance rate capillary microvascular flow index, percent of perfused capillaries, and perfused capillary density activated partial thromboplastin time postsurgery neurologic sequelae thrombin/antithrombin complex urine flow rates severe sepsis urine flow rate pulmonary artery wedge pressure (wp) and the wp-cop gradient likewise, chest tube drainage adverse events coagulation parameters (prothrombin time, partial thromboplastin time, fibrinogen, and factor viii plasma volume expansion frequency of adult respiratory distress syndrome (ards mean (sd plasma volume (saline--53.4 plasma volume and hemodynamic stability cardiac index with increasing pulmonary capillary wedge pressure total postoperative fluid support renal injury anaphylactoid reactions lung water operation time, estimated blood loss, and transfusions diuresis left ventricular stroke work index and pwp death or end-stage kidney failure (dependence on dialysis albumin mortality rate incidence of mods plasma colloid osmotic pressure (cop serum albumin and plasma oncotic pressure positive balance blood loss mean arterial pressure (map), oxygenation index (pao/fio),arterial lactate (lac),lactate clearance rate, acute physiology and chronic health evaluation ii(apacheii) score,fluid infusion volume, urine output as well as incidence of multiple organ dysfunction syndrome (mods), and mortality levels of plasma pai hct using the stat-crit, coulter, and centrifuge methods, and sodium (na), potassium (k), chloride (cl), white blood cell count, total protein (tp), and albumin obligatory contraction or expansion of ecv cop hemodynamic parameters serum colloid oncotic pressure time to reach hds overall survival rate, hypertonic infusion worst multiple organ dysfunction score (mods), excluding the cardiovascular component, to day 14 bleeding manifestations, coagulation derangements, and severity of fluid overload ecfv systemic hemodynamics and oxygenation (pao(2), paco(2 haemodynamic parameters and pulmonary function stroke index maximum gradient of platelet aggregation change in aado2 safety measures oxygen delivery index cardiac output and pulmonary wedge pressure renal function and morbidity larger amounts of fluid extracellular fluid volume, total body water and interstitial fluid volume requirement for rescue colloid subcutaneous oxygen tension and collagen accumulation etvl sequential organ failure assessment score, mean arterial pressure, lactate, or central venous oxygen saturation blood loss and change in platelet aggregation.(abstract truncated at 250 words perioperative blood loss and coagulation profiles perioperative blood loss systolic blood pressure  70 mm hg or systolic blood pressure larger diuresis plasma volume, serum oncotic pressure (pis), serum albumin and total protein concentration, alveolar to arterial oxygen tension differences (aado2, fio2 = 1.0), creatinine clearance, body weight, and fluid and sodium intake hemodynamic response and lung water following thermal injury stat-crit accuracy pop, mpaop, pop-mpaop difference, total sodium intake or net supply of non-colloid fluids left ventricular stroke work index bleeding time plasminogen activator inhibitor-1 systemic vascular resistance index intrapulmonary shunt (qs/qt survival to hospital discharge alveolar-arterial oxygen partial pressure difference concentrations of coagulation factor xiii cardiac output and pulmonary wedge pressure (pwp fluid for successful resuscitation pulmonary edema or increased intracranial pressure acute renal failure cardiac index and myocardial contractility (ejection fraction and mean rate of internal fiber shortening, vcf cardiorespiratory recovery with shorter extubation time sodium balances evlw serum colloid osmotic pressure body weight icu-los blood pressure (bp circulatory variables, alveolo-arterial oxygen tension difference, incidence of wound infection or postoperative restoration of intestinal activity hematocrit, hemoglobin, protein, albumin, blood urea nitrogen (bun), and creatinine efficacy severe trauma with respect to resuscitation, fluid volume, gastrointestinal recovery, renal function, and blood product requirements pulmonary function blood volume deficit fluid balance and cardiorespiratory functions estimated blood losses (ebl tissue plasminogen activator length of intensive care unit stay (icu-los hemodynamic, pulmonary, and renal variables cvp and paop central pontine myelinolysis; bleeding qt mortality, coagulation, or pruritus platelet volume maximum platelet aggregation ventilatory parameters, blood gases, pulmonary function tests, ventilator days, or hospital days pulmonary edema overall complication rates fluid requirements, superior hemodynamic performance, and shortened intensive care stay low baseline glasgow coma scale scores degree and duration of coagulation impairment postoperative plasma volume total quantity weight response profile postoperative lung function and circulatory adaptation total blood volume index (tbvi), intrathoracic blood volume index (itb-vi) and extravascular lung water index (evlwi net lung capillary filtration pressure pv expansion total protein left ventricular end-diastolic area quality of postoperative recovery plasma lactate concentrations oliguria during a course of therapy, weight gain, number of il-2 doses, tachycardia, hypotension, vasopressor use, hospital stay, and clinical response rates pulmonary shunt fraction (qsp/qt cop measure sublingual microcirculation postbypass blood loss colloid osmotic pressure (cop hs-hes and hs filling pressures of the heart and improved cardiac output percentage reduction in base deficit at 8 h. secondary end points included death, the requirement for rescue therapies, and neurological sequelae in survivors total number of saline and albumin fluid boluses haemodynamic data hypotension, tachycardia, and oliguria cardiac index time to recovery of bowel function or mortality endovenous volumes filling pressures of the heart with improved cardiac output psco2 perioperative blood loss (sum of bleeding during the intraoperative and postoperative 24-h period), transfusion requirements, modified thromboelastography and coagulation variables, hemodynamic parameters, and fluid balance severity of shock and status with respect to malaria, coma, sepsis, acidosis, and severe anemia intestinal edema death from any cause during the 28-day period after randomization adequate cardiac output|baseline values for pv, isfv, ecfv, and oxygen delivery index did not differ between treatment groups. both the hs-ns and hs-bs (colloid) groups had a significantly less frequent incidence of nausea and vomiting, use of rescue antiemetics, severe pain, periorbital edema, and double vision. there were no apparent differences in circulatory variables, alveolo-arterial oxygen tension difference, incidence of wound infection or postoperative restoration of intestinal activity between the groups. the post-operative changes observed in ecv were not related to copp in the range 33 mmhg to 21 mmhg. infusion rates and 8-hour intake were higher for the group receiving normal saline solution (p less than 0.001), as was postoperative weight gain (p less than 0.01), although urine and chest tube outputs did not differ. blood pressure in the hypertonic/hyperoncotic group increased 49 mmhg during transport (p less than 0.005); blood pressure in patients given lactated ringer's solution increased 19 mmhg (ns). although patients receiving saline boluses had significantly more oliguria during a course of therapy, weight gain, number of il-2 doses, tachycardia, hypotension, vasopressor use, hospital stay, and clinical response rates did not significantly differ between arms. there was high correlation (r = 0.951) between measured cop and values calculated from tpri in patients receiving hypertonic fluid, colloid containing hypertonic fluid, or no fluid:cop = 4.08 (tpri)--4.61. the proportion of patients with new single-organ and multiple-organ failure was similar in the two groups (p=0.85). there was no significant difference in apache ii score between hs+hes group (13.2  1.9) and hes group (14.0  1.6), and the apacheii score in hs+hes group was significantly lower than that in rl group (15.2  1.7, p <0.01). colloid osmotic pressure (cop) decreased in the saline group and increased in the colloid groups (p< 0.001). in penetrating trauma, maximum sequential organ function scores were lower with hes than with saline (median 2.4 vs 4.5, p=0.012). in the hes group, the iap was significantly lower in 2 to 7 days, and fewer patients received mechanical ventilation (15.0% vs 47.6%). the differences between groups were significant throughout 24 h. urine output and improvement of the glasgow coma score were also higher in h/h patients than in the control group (p less than 0.05). the primary outcome measure--requirement for rescue colloid--was similar for the different fluids in the two severity groups. the results were consistent across centers and across subgroups according to the severity of shock and status with respect to malaria, coma, sepsis, acidosis, and severe anemia. treatment with 5 percent albumin from day 0 to day 14 does not decrease the burden of mods in adult burn patients. despite reduced need for extra i.v. fluid and decreased cumulative fluid balance, after hsd infusion the patients had increased filling pressures of the heart with improved cardiac output. pt, aptt and the levels of t-pa showed no significant differences between two groups at different time points, but the levels of plasma pai (g/l) of the hes group decreased gradually, and was significantly lower than that before resuscitation and rl group at 24 hours after resuscitation (41.76  25.95 vs. 89.11  14.27, 55.08  35.43, both p < 0.05). one liter of saline resulted in a 12% decrease in cop (p less than 0.05). all three colloids led to a transient increase in activated partial thromboplastin time postsurgery and also a transient fall in the concentration of factor viii, which were accompanied by a transient increase in bleeding time, but there was no measurable increase in blood loss. in patients undergoing major surgery, volume resuscitation with medium molecular weight hes improves the splanchnic blood flow and tissue oxygenation. the effects of intraoperative changes in plasma colloid osmotic pressure (cop) on the formation of intestinal edema were studied in patients during modified whipple's operation (hemipancreato-duodenectomy). cardiac output and qs/qt increased in both groups. only 57% of physicians and 54% of nurses correctly guessed the study fluid (p = 0.46 and p = 0.67, respectively). there was no difference in the postoperative course between the two groups; however, by using the lower cop limit the postoperative albumin consumption in the intensive care unit was reduced significantly and thus the costs of treatment were lowered. ml/kg/per cent burn (rl-colloid) at 48 h (p less than 0.01). after volume loading, the stroke index increased in both groups, but the left ventricular stroke work index increased in group 2 only. there were no cases of central pontine myelinolysis; bleeding was not potentiated. the measured lung water in each treatment group was significantly different from one another (p less than 0.001). there was a significant difference (p < .03) in overall (30 days) survival rate between hsd (73%) and is (64%) groups. at 90 days after randomization, 201 of 398 patients (51%) assigned to hes 130/0.42 had died, as compared with 172 of 400 patients (43%) assigned to ringer's acetate (relative risk, 1.17; 95% confidence interval [ci], 1.01 to 1.36; p=0.03); 1 patient in each group had end-stage kidney failure. in conclusion, postoperative fluid substitution with dextran has no advantages over crystalloids only, with regard to granulation tissue formation if postoperative fluid support is optimum, according to psco2 measurements. there was no difference in 28-day survival-hsd: 74.5% (0.1; 95% confidence interval [ci], -7.5 to 7.8); there was no difference in ventilatory parameters, blood gases, pulmonary function tests, ventilator days, or hospital days between the two groups. perioperative blood loss and coagulation profiles were similar between the groups, but the postoperative hemoglobin level was higher in the crystalloid group. there was no significant correlation between left ventricular stroke work index and pwp in these patients, either at the completion of resuscitation or during the following three days. mortality rates were similar in the two groups (p = 0.725). the frequency of adult respiratory distress syndrome (ards) was significantly lower (p less than 0.05) in the dextran group (0 of 12) than in the ringer group (4 of 11). postoperative values of albumin concentration, circulating albumin mass and pis were significantly greater in the albumin group in comparison to the electrolyte group. survival to hospital discharge in patients with baseline glasgow coma scale scores of 8 or less was correlated with treatment group (p < .05 by logistic regression and p < .01 by cox proportional-hazards analysis; with survival in the hypertonic saline solution group [34%] vs lactated ringer's solution group [12%]). infusion of 250 ml hypertonic saline solution in patients with severe hypovolemia was not related to any complications, nor did it affect mortality rates; it improved map significantly, acutely expanded plasma volume by 24%, and reduced significantly the volumes of crystalloids and blood required in their resuscitation. with regard to hemodynamic efficiency and the change in laboratory data no relevant differences between group i, ii and iii could be seen. adverse events were observed only with hypertonic solution administration: hypotensive episodes, sudden increases in pulmonary capillary wedge pressure, and ventricular arrhythmias. there were no complications associated with the infusion of the hypertonic saline-dextran solution, and execution of the protocol by paramedic personnel was both safe and uniformly successful. maximum platelet aggregation (ranging from -23% to -44% relative from baseline value) and maximum gradient of platelet aggregation (ranging from -26% to -45% relative from baseline values) were reduced only in the hmw-hes patients. during knee replacement surgery a pronounced activation of the coagulation/fibrinolytic system was observed, regardless of whether patients received crystalloid or colloid fluids. the 7.5% nacl solution significantly improved upon the predicted survival for the entire cohort and for high-risk patients when compared with the survival estimates from the triss methodology. both normal saline and gelatin polymer solution were equally effective as resuscitation fluid with respect to restoration of plasma volume and hemodynamic stability. haemodynamic stability was achieved in both groups throughout the study period, as judged from mean arterial pressure, central venous pressure, pulmonary capillary wedge pressure, and cardiac index. the accuracy of the stat-crit hematocrit (hct) was compared to coulter and centrifuge methods in this study of the interrelationship between non-red cell blood constituents and accuracy of conductivity-based hct measurements. there was no difference between akin and rifle criteria among groups and no difference in mortality, coagulation, or pruritus up to 90 days after treatment initiation. the group receiving saline solution had better cardiorespiratory recovery with shorter extubation time (p = 0.033), and earlier increase in cardiac index with a positive correlation between plasma sodium content and cardiac index. maximum decrease in cop was 40% (p less than 0.001) in the rl group and was insignificant in the alb group. patients in the colloid groups postoperatively had a higher serum colloid osmotic pressure (s-cop), but a higher net lung capillary filtration pressure (delta p) only on the second postoperative day than the rac group. total intravascular albumin decreased from 0.7 g/kg (1.4 to 0.7 g/kg) in both groups, corresponding to a plasma volume (pv) loss of 13 mg/kg without fluid infusions. there was no significant correlation between venous admixture, on the one hand, and pop, mpaop, pop-mpaop difference, total sodium intake or net supply of non-colloid fluids, on the other. there was no significant difference in the resolution of acidosis between the groups; however, the mortality rate was significantly lower among patients who received albumin (3.6% [2 of 56 patients]) than among those who received saline (18% [11 of 61]; relative risk, 5.5; 95% confidence interval, 1.2-24.8; p=.013). systemic hemodynamics and oxygenation (pao(2), paco(2)) did not differ significantly between the two volume groups throughout the study. pulmonary shunt fraction (qsp/qt) did not change in groups a and c but decreased during cpb in group h (from 0.22 +/- for the duration of the study and at 48 hours, there was no statistically significant difference between groups with respect to the following: cardiac index, colloid osmotic pressure (cop), pulmonary capillary wedge pressure (pcwp), cop-pcwp gradient, right and left ventricular stroke work indices, and amount of constant positive airway pressure required for treatment. all the children survived, and there was no clear advantage to using any of the 4 fluids, but the longest recovery times occurred in the lactated ringer's group. there were significant increases in qs/qt and aado2, 48 hours after operation in group 3. the cvp and paop increased significantly more in the modified fluid gelatin resuscitation group. serum concentrations of interleukin (il)-6, il-8 and il-10 and soluble adhesion molecules (selam-1 and sicam-1) were measured after induction of anesthesia, four hours after the end of surgery, as well as 24 hr and 48 hr postoperatively. sublingual capillary density was similar in both groups (21  8 versus 20  3 vessels/mm(2)); but capillary microvascular flow index, percent of perfused capillaries, and perfused capillary density were higher in 6% hes 130/0.4 (2.5  0.5 versus 1.6  0.7, 84  15 versus 53  26%, and 19  6 versus 11  5 vessels/mm(2), respectively, p < .005).|31 patients twenty patients with 3-vessel coronary artery disease undergoing elective coronary artery bypass surgery were studied injured patients in the field intestinal edema during gastrointestinal surgery hypotensive trauma patients emergency resuscitation of hypovolemic shock patients heterogeneous population of patients in the icu patients with hemorrhagic hypovolemia 24 patients scheduled for major abdominal aortic operations pulmonary extravascular water in the postoperative period after coronary artery bypass grafting patients having abdominal aortic surgery 30 adult patients undergoing elective major abdominal surgery hypotensive victims of penetrating trauma children with severe malaria and metabolic acidosis (base deficit, >8 mmol/l) to receive traumatic shock children with malnutrition or gastroenteritis patients undergoing knee replacement surgery randomly received 106 critically injured patients in two prospective double-blinded emergency department trials surgical patients patients undergoing off-pump coronary artery bypass surgery (opcab pediatric emergency and intensive care unit of a tertiary care referral and teaching hospital early septic shock (finess twenty-six patients who underwent mitral valve repair severe sepsis patients children with severe shock all patients included in the study were discharged from the hospital before the 10th postoperative day patients with hemorrhagic shock children with severe febrile illness and impaired perfusion to receive trauma patients admitted to the emergency room with hemorrhagic hypovolemia: systolic blood pressure (sbp) < 90 mmhg forty-two consecutive patients with septic shock diagnosed between september 2009 and june 2011 patients undergoing cardiopulmonary bypass medical center university hospital in a surgical resuscitation room in the emergency department injured patients with 7.5 twenty-three patients aged 20-58 years in a serious state of shock and suffering from major pelvic and femoral fractures sustained in traffic accidents 129 children with severe shock to receive one of the colloids 152 ng*ml(-1 patients with impaired perfusion major surgery elective hip surgery hypovolemic shock severe sepsis 18 patients received 56 adult respiratory distress syndrome forty-one patients with sap forty-two patients were randomly assigned forty-six patients with severe pulmonary insufficiency trauma patients transported by ambulance to the hospital with a systolic blood pressure of 90 mm hg or less were given 250 ml of (1 383 children with moderately severe shock to receive abdominal aortic operations asian children patients with ovarian carcinoma injured patients with hypovolemic shock 55 patients undergoing primary unilateral total hip replacement patients with septic shock patients with a base deficit of <15 mmol/l patients following major surgery patients undergoing major surgery children with severe falciparum malaria patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery trauma patients with severe injuries children presenting with lower pulse pressures who received one of the colloids 41 patients (21 pentastarch, 20 ringer's lactate) presenting with hemorrhagic shock forty-two consecutive patients scheduled for elective major abdominal surgery patients receiving bolus il-2-based therapy for metastatic cancer kenyan children with severe malaria patients (n=67 6997 patients who underwent randomization, 3497 were assigned to receive fifteen untreated patients served as a control hypovolaemic hypotension after cardiac and major vascular surgery two patients were excluded during the study 31 patients undergoing elective cardiac procedures severe acute pancreatitis (sap) in early stages patients who have undergone mitral valve repair, postoperative infusion of 230 vietnamese children with dss 174 out of 196 patients reached hds (88 and 86 patients for hes and nacl, respectively severe hypovolemia 18 patients subjected to reconstruction of the abdominal aorta patients undergoing major abdominal surgery, a colloid-based (with five patients had abdominal aneurysm, 12 had aortic obstruction disease, and three had aortic renal bypass surgery patients with valvular cardiomyopathy children with septic shock injured patients with systolic blood pressures less than 90 mm hg at any time in the field or during helicopter transport 161 patients screened, 121 were excluded and 40 patients were enrolled, for a recruitment rate of 0.75 patients/site/month severely injured patients requiring >3 litres of fluid resuscitation pneumonia (n = 22; 36%), gut-associated sepsis (n = 13), and dengue hemorrhagic fever (n = 11) were the common primary diagnosis 804 patients who underwent randomization, 798 were included in the modified intention-to-treat population 20 patients suffering from multiple trauma and shock adult burn patients patients admitted to the emergency room with hemorrhagic hypovolemia in a prospective double-blind fashion forty patients patients with recent exposure to dapt undergoing opcab severely burned children 220 patients, 106 were given albumin when their colloid osmotic pressure (cop) fell below 24 cm h2o and 114 were given albumin when their cop fell below 29 cm h2o 38 critically burned patients with symptomatic hypovolemia being treated by heart surgery eighteen patients (asa physical status i or ii 150 children recruited for the trial, 61 received saline, 56 received albumin, and 33 served as control subjects 29 patients undergoing abdominal aortic surgery patients (460 26 patients with hypovolemic circulatory shock lung water following thermal injury, 79 patients orthopaedic patients in early postoperative period after coronary artery bypass surgery patients with severe sepsis or septic shock children with severe hypotension man after traumatic-haemorrhagic shock a total of 115 patients were randomized; of which, 109 were studied patients with continued dapt within 5 days of opcab 16 patients undergoing abdominal vascular reconstructive procedures intensive care unit (icu) of the affiliated hospital of jianghan university hypovolemic patients sixty patients, between 1 month to 12 years of age, with septic shock, without clinical evidence of organ failure at admission or underlying immunodeficiency critically ill children inclusion criteria: injured patients, age  15 years with hypovolemic shock patients with traumatic or neurogenic shock halting recruitment after 3141 of the projected 3600 children in stratum a were enrolled patients with severe sepsis assigned to patients who had been admitted to the icu to receive either 107 patients who completed one cycle of therapy on study, 76 completed a full treatment course (two cycles) on study patients with hemorrhagic shock due to upper gastrointestinal bleeding postoperative mitral valve repair patients hypovolemia treated with halfd 34 patients with either hypovolemic or neurogenic shock who were admitted to the emergency room patients undergoing cytoreductive surgery for ovarian carcinoma eligible adults (>15 years) suffering from thermal injury not more than 12 hours before enrollment received 49 patients african children with severe infection critically ill patients (n = 18 pediatric septic shock trauma patients after traumatic hypovolemic shock 55 patients undergoing elective aorto-coronary bypass surgery efficacy of a low concentrated hydroxyethylstarch (3% hes 200/0.5) was tested after patients during modified whipple's operation (hemipancreato-duodenectomy in septic, critically ill patients 40 patients with early septic shock defined by at least two systemic inflammatory response syndrome criteria, infectious source, and persistent hypotension after >or= 1 l of crystalloid fluid were recruited blunt and penetrating trauma patients undergoing major abdominal surgery 12 patients received 20 consecutive patients undergoing elective aortic reconstructive surgery immediately after mitral valve repair 853 treated patients were enrolled, among whom 62% were with blunt trauma, 38% with penetrating may 2006 to august 2008, 114 emergency medical services agencies in north america within the resuscitation outcomes consortium severe acute pancreatitis patients (n = 212 ninety patients participated in the study, with 30 patients in each group patients with severe sepsis patients admitted to the emergency room group) with 22 patients 18 patients hypotensive trauma patients with 7.5 patients undergoing major elective noncardiac surgery 48 trauma patients with penetrating injuries and a prehospital systolic blood pressure of 90 mm hg or less massachusetts medical society early postoperative period after coronary artery bypass grafting patients with severe pulmonary insufficiency hypovolemic trauma patients emergency room patients suffering from shock traumatic hypotension children with severe malaria vietnamese children with dengue shock syndrome one hundred five adult patients admitted in hypovolemic shock (systolic blood pressure less than 80 mm hg septic patients children with shock and life-threatening infections who live in resource-limited settings consecutive patients, mean age 64 yr children with moderately severe dengue shock syndrome one hundred and thirty five patients with severe sepsis twenty-nine patients, subjected to major abdominal surgery 60 patients undergoing elective aortocoronary bypass grafting using cardiopulmonary bypass (cpb patients undergoing major surgery, volume resuscitation with thirty-six patients scheduled for elective abdominal surgery index of pulmonary extravascular water after coronary artery bypass grafting dengue shock syndrome within 5 days of opcab children and young people ranging in age from 5 months to 21 years, with burns covering greater than or equal to 30 per cent of the body surface area
adherence and adherence levels completion of 28 days of pep depressive psychopathology overall adherence adherence|the intervention was associated with the reading of the pamphlet (p=0.07) and an increased use of the diary (p=0.01), but did not reduce depressive psychopathology.|western and eastern cape and 279 rape survivors
adverse response incidence of later candidiasis|no adverse response to ceftazidime was noted, and the incidence of later candidiasis was similar to that after other broad-spectrum antibiotic combinations.|fifty-five infants less than 48 h old with suspected sepsis 22 infants more than 48 h old, with clinical evidence of sepsis neonates less than forty-eight hours old
clinical response efficacy and tolerability extrapyramidal symptoms mean change in simpson angus scale barnes akathisia scale|olanzapine was superior to conventional neuroleptic haloperidol in treatment safety with lower frequency and severity of extrapyramidal symptoms.|fifty-eight patients experiencing episode of amphetamine psychosis patients with amphetamine psychosis amphetamine psychosis
postexercise pulmonary capillary blood volume forced vital capacity and peak expiratory flow rates fev1 (pd20 morbidity index of asthma lability urinary sodium excretion pef or pef amplitude pre-exercise (baseline) pulmonary function preexercise pulmonary function values sodium intake mean forced expiratory volume exercise-induced asthma (eia dietary salt, airway inflammation, and diffusion capacity bronchial reactivity and mortality symptom score fev1 peak expiratory flow rate bronchodilator consumption postexercise-induced sputum neutrophil and eosinophil differential cell counts and induced sputum supernatant concentration of eosinophil cationic protein, interleukin (il)-1beta, il-8, leukotriene (lt) c(4)-e(4), ltb(4), and prostaglandin d(2 forced vital capacity (fvc), forced expiratory flow rate at 25%-75% fvc and peak expiratory flow rate deterioration of post-exercise pulmonary function peak expiratory flow pulmonary function peak expiratory flow (pef bronchial reactivity pef measurements peak flow rate mean (sd) urine sodium severity of bronchial asthma diary cards to record twice daily peak expiratory flow rates, daily symptom scores, and bronchodilator consumption regressing pd10 against urinary excretion of electrolytes bronchial reactivity rose on slow sodium forced expiratory volume in 1 s (fev1 lung function lsd improved and hsd worsened postexercise pulmonary function values pre- and postexercise spirometry, pulmonary diffusion capacity (dlco) and its subdivisions, and induced sputum spirometry and degree of bronchial responsiveness (methacholine challenge test postexercise pulmonary function values deleterious alterations evening peak expiratory flow rate|the dose of histamine causing a 20% fall in fev1 (pd20) was 1.51 doubling doses lower when the men were taking sodium than when they were taking placebo (p less than 0.05). diet had no effect on preexercise pulmonary function values in either group and had no effect on postexercise pulmonary function values in control subjects. however, postexercise pulmonary capillary blood volume significantly increased (p < 0.05) by 6.3 and 9.6 ml on nsd and hsd, respectively, compared with baseline values, with no significant change (p > 0.05) being observed on lsd. statistical analysis showed that salt loading worsened symptoms (p = 0.06) and increased the use of inhaled steroids (p < 0.05). median differences between treatments were 5.6% (2.2% to 9.8%) for morning and 7.8% (3.9% to 12.9%) for evening peak expiratory flow rate. similar patterns were observed for forced vital capacity (fvc), forced expiratory flow rate at 25%-75% fvc and peak expiratory flow rate. there were no significant differences in pef or pef amplitude (highest--lowest pef), an index of asthma lability, between the three dietary salt periods.|subjects with eia twenty seven mild to moderate asthmatic patients eia subjects patients with bronchial asthma subjects with exercise-induced asthma (eia male asthmatic patients twenty two patients completed the study men with asthma persons with asthma asthmatic patients control subjects asthmatic subjects patients with asthma adult male asthmatic patients patients with mild asthma asthma in men eight subjects who suffered from eia and eight subjects who did not (control) took part in a double-blind crossover study 17 patients with mild asthma 36 subjects having a low sodium diet exercise-induced asthma eight subjects with eia and eight subjects without eia (control
shorter operative time peri-operative outcome index, delayed union, revision surgery and symptoms beyond 16 weeks smaller wound size lower complication rate rate of delayed union mean shoulder score|knowles pinning requires significantly shorter operative time (p<.001), smaller wound size (p<.001), shorter hospital stay p=.03), less meperidine use (p=.02), lower complication rate (p=0.04), and less symptomatic hardware (p=.015). the superior plate group had a higher rate of delayed union and had more symptomatic patients than the 3d group (p < 0.05). time to union in the patients treated with lc-dcp fixation was shorter than in those treated with dcp fixation (p <.001).|62 elderly patients patients with displaced fractures of the clavicle treated by open reduction and fixation by a reconstruction plate which was placed either superiorly or three-dimensionally patients with midclavicular nonunion, treated by a combination of 62 elderly patients (>50 years) with midclavicular fractures patients with midclavicular nonunion elderly patients between 2003 and 2006, 133 consecutive patients with a mean age of 44.2 years (18 to 60) with displaced midshaft fractures of the clavicle
sleep bruxism and tooth-grinding activity pain efficacy and safety clicking and pain signs and symptoms of temporomandibular disorders sleep variables, bruxism-related motor activity, and subjective reports (pain, comfort, oral salivation, and quality of sleep wear facets pantographic reproducibility index (pri number of sleep bruxism episodes sleep bruxism motor activity signs and symptoms of tmd number of sb episodes sb outcome variables muscle activity nocturnal bite plate sleep bruxism number of bruxism episodes per hour of sleep (epi/h), the number of bursts per hour (bur/h), and the bruxism time index prevalence of tmd|neither occlusal stabilization splints nor palatal splints had an influence on the sb outcome variables or on the sleep variables measured on a group level. on the other hand, of the 5 children that used nocturnal bite plate, showed no increase of wear facets, even after the removal of the device. a significant reduction in the number of sleep bruxism episodes per hour (decrease of 42%, p < .001) was observed with the mos. the occlusal splint and tens did not significantly improve the signs and symptoms of tmd in these patients with bruxism. a statistically significant reduction in the number of sb episodes per hour (decrease of 41%, p = 0.05) and sb bursts per hour (decrease of 40%, p < 0.05) was observed with the two devices.|nine subjects with sleep bruxism (sb group (n = 11; mean age = 34.2 patients with bruxism children with bruxism 24 patients with bruxism 13.1 years) or a palatal splint (ie, an acrylic palatal coverage) group (n = 10; mean age = 34.9 3 to 5 year old children tooth-grinding subjects twenty-one participants
episodes of major bleeding therapeutic efficiency clinical pulmonary embolism frequency of hemorrhagic complications maximal venous outflow (mvo recurrent thromboembolic events recurrence or extension of dvt thromboembolic complications hemostatic system activation safety and efficacy fatal pulmonary embolism complete lysis mvo incidence of serious complications recurrent venous thromboembolism bleeding complications pulmonary embolism rate of new pulmonary embolism efficacy and safety retroperitoneal or intramuscular bleedings major bleeding initial anticoagulant response d-dimer recurrent or extension of dvt, bleeding, the number of days spent in hospital, and costs of treatments hemorrhagic complications overall mortality rate of symptomatic pulmonary embolism thrombus size minor bleedings therapeutic anticoagulant response average treatment costs pulmonary embolism (lh) and only 1 minor bleeding episode (uh hospital stay bleedings symptomatic non-fatal pulmonary embolism and one major bleeding episode non-fatal pulmonary emboli deep vein thrombosis mean phlebographic score incidence of major bleeding incidence of pulmonary embolism and of bleeding complications median improvement of mvo and vc thrombosis of deep veins of the lower extremities pain and edema|no significant difference was observed in the therapeutic efficiency as judged by phlebographic examinations and in rate of symptomatic pulmonary embolism between the two groups. it is concluded that subcutaneous fixed dose fraxiparine is safe and at least as effective as subcutaneous adjusted ufh in the treatment of deep vein thrombosis. retroperitoneal or intramuscular bleedings occurred in four patients, two in each group. as judged by repeated thrombin time determination, anticoagulation was ineffective on at least one day in 39% of patients treated subcutaneously and in 60% of patients treated intravenously. significant associations were observed between f1+2 and tat (r=.66, p<.001), tat and d-dimer (r=.36, p<.005) and f1+2 and d-dimer (r=.30, p<.050). there were no significant differences between the two groups in the incidence of serious complications, although almost half of those receiving intravenous heparin had some minor problem with the constant infusion pump and just over half of those receiving subcutaneous heparin had some bruising at the injection site. 9 major bleeding complications occurred in the intravenous group (1 fatal) and 5 in the subcutaneous group (1 fatal). intermittent subcutaneous heparin as administered in this trial was inferior to continuous intravenous heparin in preventing recurrent venous thromboembolism. five of forty-seven patients in the subcutaneous group and 5 of 49 in the intravenous group developed pulmonary embolism (95% confidence interval [ci] for the difference, -13.1% to 12.2%). few reports have addressed the value of unfractionated heparin (ufh) or low-molecular-weight heparin in treating the full spectrum of patients with venous thromboembolism (vte), including recurrent vte and pulmonary embolism. there was 1 incidence of pulmonary embolism (lh) and only 1 minor bleeding episode (uh). hospital stay in patients treated with lmwh was 1.2+/-1.4 days in comparison with 5.4+/-1.2 in those treated with standard heparin. recurrent venous thromboembolism occurred in 13 patients in the unfractionated heparin group (3.8%) compared with 12 patients in the low-molecular-weight heparin group (3.4%; absolute difference, 0.4%; 95% confidence interval, -2.6% to 3.3%). low molecular weight heparin fractions have been demonstrated as efficient as low doses of standard heparin in preventing post-operative deep-vein thrombosis.|patients with venous thromboembolism (vte), including recurrent vte and pulmonary embolism patients with deep-vein thrombosis treated either with acute treatment of venous thromboembolism patients with acute deep vein thrombosis 115 patients with acute proximal deep-vein thrombosis acute proximal deep vein thrombosis deep venous thrombosis patients with deep venous thrombosis 708 patients aged 18 years or older with acute venous thromboembolism from 6 university-affiliated clinical centers in canada and new zealand conducted from september 1998 through february 2004 149 consecutive patients with phlebographically proven proximal and/or distal deep vein thrombosis of the leg one hundred patients with phlebographically proved acute deep vein thrombosis of the legs established acute deep vein thrombosis of the legs patients with acute venous thromboembolism 49 patients who received 325 patients included, 294 completed the study patients with deep-vein thrombosis patients with phlebographically proven deep venous thrombosis (dvt 59 consecutive patients with deep vein thrombosis (dvt 720 consecutive patients with acute symptomatic vte, including 119 noncritically ill patients (16.5%) with pulmonary embolism and 102 (14.2%) with recurrent vte proximal-vein thrombosis setting: university-affiliated general hospital patients with acute deep-vein thrombosis one-hundred and forty-one patients with clinical signs of acute deep venous thrombosis (dvt) in the legs patients 23 patients 48 patients with acute deep venous thrombosis of the lower limbs 47 patients who received 271 patients with acute symptomatic deep venous thrombosis of lower limbs, confirmed by strain-gauge plethysmography and/or venography acute deep vein thrombosis 111 consecutive patients considered, 103 had acute proximal or calf vein thrombosis confirmed by ascending venography and met all other eligibility criteria 294 patients with acute proximal dvt (deep venous thrombosis ninety-four patients with deep vein thrombosis of inferior limbs
edinburgh postnatal depression scale, the beck depression inventory, and the hamilton depression rating scale clinical global impression (cgi) and the hamilton depression scale measured recovery rates of depression maternal mood and mother-infant interaction|the interpersonal psychotherapy treatment group showed significant improvement compared to the parenting education control program on all three measures of mood at termination.|fifty outpatient antepartum women who met dsm-iv criteria for major depressive disorder thirty-eight women remained in the study and were included in the data analysis pregnant women with chronic stressors for antepartum depression to a parenting education control program depressed pregnant women
renal damage median urinary albumin:creatinine ratio rates of renal impairment or major adverse cardiac events median urinary rbp myocardial injury myocardial infarction urinary biomarkers of renal injury saccadic latency deterioration median urinary rbp level cardiac troponin saccadic latency deteriorations renal impairment incidence of myocardial injury renal injury protective effect of ripc on myocardial injury preoperative urinary rbp postoperative myocardial injury, myocardial infarction, and renal impairment urinary retinol binding protein (rbp) and albumin-creatinine ratio (acr serum troponin serum and urinary markers of renal and cardiac injury renal outcome indices urinary retinol binding protein (rbp) levels incidence of myocardial and renal injury|urinary retinol binding protein (rbp) levels increased 10-fold from a median of 235 micromol/l to 2356 micromol/l at 24 hours (p = 0.0001). in patients undergoing elective open abdominal aortic aneurysm repair, ripc reduces the incidence of postoperative myocardial injury, myocardial infarction, and renal impairment. although there were fewer saccadic latency deteriorations in the ripc arm, this did not reach statistical significance (32% versus 53%; p = .11). although control patients' median urinary rbp level was 5 times greater at 3 hours, there were no statistically significant differences in renal outcome indices.|renal protection during elective open infrarenal abdominal aortic aneurysm repair carotid endarterectomy myocardial and renal injury after elective abdominal aortic aneurysm repair patients undergoing elective evar patients with cea elective open aneurysm surgery twenty-two patients (mean age 76 years, range 66-80 forty patients (all men; mean age 76+/-7 years) with abdominal aortic aneurysms averaging 6.3+/-0.8 cm in diameter were enrolled in the trial from november 2006 to january 2008 abdominal aortic aneurysm repair eighteen patients (mean age 74 years, range 72-81 elective open infrarenal abdominal aortic aneurysm (aaa) repair 70 patients were randomized, of whom 55 completed the neurological surveillance protocol patients undergoing elective open abdominal aortic aneurysm repair
pain pain medication global vas pain scores postoperative analgesic consumption cumulative acetylsalicylic acid requirements supplementary analgesic consumption pain scores analgesia postoperative pain pain relief visual analogue pain scores adverse effects pain level, amount of oral intake, or pain on full jaw opening quality of postoperative analgesia postoperative pain relief pain level; (2) oral intake; (3) number of pain medication doses; and (4) level of pain on jaw opening visual analogue scale (vas pain scores (vas|the efficacy of benzydamine hydrochloride (difflam) spray to relieve pain from postoperative tonsillectomy was assessed, but it was found that it did not relieve the symptoms after operation when compared to matching placebo. no difference was noted in pain level, amount of oral intake, or pain on full jaw opening. there were no significant differences between groups in pain scores (vas) at rest or during drinking of 100 ml of water as measured at 4 h postoperatively or on the 1st, 2nd, 3rd and 8th postoperative days. visual analogue pain scores measured during swallowing in the recovery room and on the ward postoperatively were significantly less overall in uvulopalatoplasty patients who had received a block (p = 0.004). global vas pain scores were lower in the groups treated with bupivacaine infiltration during the first 24 h after surgery (p < 0.05).|thirty-five healthy patients aged 15-36 years scheduled for bilateral tonsillectomy adult population fifty-one patients undergoing tonsillectomy with local anesthesia pain after elective adult tonsillectomy and uvulopalatoplasty adult local tonsillectomy after tonsillectomy patients undergoing tonsillectomy adult patients undergoing local tonsillectomy pediatric patients undergoing tonsillectomy 30 patients undergoing uvulopalatoplasty and 38 of 78 patients having tonsillectomy received bilateral glossopharyngeal nerve blocks, using pain after tonsillectomy 68 consecutive healthy patients, ranging in age from 8 to 65 years
number of high-risk|the option of telephone notification significantly increased the proportion of youth who received posttest counseling and results following community-based testing.|351 youth who were tested, 48% followed up to receive test results and posttest counseling high-risk youth adolescents most likely to receive their results were female, older (19-24 years), and white and those who reported high-risk behaviors
relapses of oropharyngeal candidiasis dysphagia durability of clinical success soreness, change in taste, erythema, removable white plaque, and extent of lesions mild adverse events oropharyngeal candidiasis esophageal lesions toxicity (rash alcohol consumption severity of disease episodes of candida esophagitis mycological success clinical response clinical cure opc or ec eradication rate with nystatin rate of fungal infection oropharyngeal and esophageal candidiasis fluconazole-refractory opc or ec infections oropharyngeal and/or esophageal candidiasis, and the rate of post-treatment relapse dermatophytosis and onychomycosis and cryptococcuria serum amphotericin concentrations relapses and colonization mean rates of infection relapse adverse events failure of prophylaxis oropharyngeal candidiasis relapses time to recurrence of oral candidiasis time to development of fluconazole-refractory opc or ec seven with oesophageal candidiasis oral candidiasis rates of colonization clinical side effects oropharyngeal candidiasis (erythema, soreness/burning), extent of oral lesions, and the presence/absence of candida species on fungal culture initial outbreak or recurrence of oral candidiasis frequency of episodes of oral candidiasis efficacy and toxicity complete response (clearance of all symptoms and signs) or marked improvement time to development of a fluconazole-refractory infection safety and effectiveness clinical response rates clinical success (cure or improvement vaginal candidiasis history of oral candidiasis efficacy transient rises in alanine or aspartate aminotransferase resistance nausea, two hepatotoxicity and one rash efficacy and safety clinical cure, colonization at the end of treatment, relapse at day 28, and relapse relapse-free candidiasis on gingiva time of recurrence; frequency of antifungal therapy survival recurrence of oropharyngeal candidiasis higher clinical and mycological cure rates cdc classification, cd4+ cell counts, and number of previous episodes of oropharyngeal or esophageal candidiasis candida albicans carriage frequent relapses of oral candidiasis microbiological resistance gastrointestinal disorders and drug-related adverse events median annual relapse rates tolerated clinical response rate microscopy, time to cure, symptom scores, and safety outcomes efficacy and tolerance prophylaxis failure due to recurrent or refractory mucosal candidiasis liver enzyme values delayed time to onset of histoplasmosis rate of relapse time to oral candidiasis, as determined by potassium hydroxide (koh) smear and fungal culture episodes of orophayngeal candidiasis (opc) or esophageal candidiasis (ec absolute risk reduction severe chills delaying onset of oral candidiasis maintenance of oral candidiasis-free period percentage of patients with negative cultures clinical relapse of oropharyngeal candidiasis lower response rate drug tolerability oral candidiasis score severe nausea proportion of resistant isolates likely to remain asymptomatic clinical efficacy and tolerability esophageal candidiasis clinical relapse candida albicans, maximum recorded plasma d0870 concentration, cfu of culture or cd4 cell count histoplasmosis and cryptococcosis survival benefit treatment creatine concentration side effects (diarrhea and abdominal pain oropharyngeal infection 35 episodes of thrush, one of esophagitis, one of cryptococcemia, and one of dermatophytosis, and preexisting dermatophytosis and onychomycosis fungal colonization tolerance, efficacy, and pharmacokinetics efficacy, tolerability and development of resistance occurrence of oral candidiasis safety and efficacy efficacy, safety, and tolerability episode of candidiasis clinical failure elevated serum glutamic-oxaloacetic transaminase levels magnesium concentration median time to relapse clinical and renal toxicity bioavailability of itraconazole safe and effective in preventing oropharyngeal and vaginal candidiasis cd4 count resolution of clinical lesions of oral candidiasis relapse clinical tolerance (fever, chills, sweats, nausea, arterial pressure, and pulse rate); biological tolerance (serum creatinine, electrolyte, and magnesium values); clinical score of candidiasis; and serum concentrations of amphotericin negative culture plus clinical response clinical success rates of clearing of infection invasive fungal infections total lymphocyte|patients enrolled in this study had a very high mortality (probability of death: 41.6% after 14 days). follow-up examinations 2 and 4 weeks post-treatment showed a comparably high rate of relapse in both patient groups. fluconazole eradicated candida organisms from the oral flora in 60%, vs. a 6% eradication rate with nystatin (p < .001). fluconazole 150 mg once weekly was found to be effective in maintaining patients both clinically and mycologically free of oropharyngeal candidiasis. in the fluconazole group, 15 of 20 (75%) patients were clinically cured on day 8, three (15%) were clinically improved, and two (10%) were treatment failures. both treatments were clinically effective: 98% of evaluable fluconazole-treated patients and 94% of evaluable clotrimazole-treated patients were cured or showed improvement (p = ns). itraconazole significantly delayed time to onset of histoplasmosis (p = .03; log-rank test) and cryptococcosis (p = .0005; log-rank test). microbiological resistance developed in 9 of 16 (56%) patients on continuous treatment, compared with 13 of 28 (46%) on intermittent treatment (p = 0.75). dermatophytosis and onychomycosis and cryptococcuria also improved in the fluconazole-treated patients, and fungal colonization was significantly decreased. weekly fluconazole was effective in preventing oropharyngeal candidiasis (rr, 0.50 [cl, 0.33 to 0.74]; p < 0.001) and vaginal candidiasis (rr, 0.64 a multivariate proportional hazards model showed that four factors were significant (p < 0.001) in predicting time to oral candidiasis: nystatin treatment (hazard ratio 0.59), history of oral candidiasis (3.58), candida albicans carriage (2.79), and cd4 count at randomization (0.65). drug tolerability was comparable between the three groups. itraconazole oral solution is well tolerated and offers an alternative at least as effective as fluconazole in the treatment of oropharyngeal candidiasis. cultures were negative at the end of therapy in 87% of the fluconazole group and 69% of the ketoconazole group. no association was found between clinical outcome; minimum inhibitory concentration of d0870 pre-therapy for candida albicans, maximum recorded plasma d0870 concentration, cfu of culture or cd4 cell count at entry. similar trends were found in the subgroups with esophageal involvement, a history of fluconazole failure, and cd4 counts of < or =50/mm(3). (pons v, greenspan d, debruin m. therapy for oropharyngeal candidiasis in hiv-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. a per-protocol analysis of 332 patients demonstrated that miconazole nitrate was not statistically significantly inferior to ketoconazole treatment. fewer posaconazole recipients than fluconazole recipients experienced clinical relapse (31.5% vs. 38.2%). itraconazole is marginally more efficacious than ketoconazole in the treatment of oropharyngeal and esophageal candidiasis in hiv-positive patients and both drugs appear safe and well tolerated. fluconazole was well tolerated and prevented clinical relapse of oropharyngeal candidiasis in 71% of patients who completed three months of treatment (95% confidence interval [ci], 55-86) and 58% (95% ci, 41-75) who completed six months of treatment. the time to recurrence of oral candidiasis between the chlorhexidine and the saline group was not statistically significant (p > 0.05). both formulations of the melaleuca oral solution appear to be effective alternative regimens for patients with aids suffering from oropharyngeal candidiasis refractory to fluconazole. there were no significant treatment group differences in microbiological resistance whether comparisons were made for all cases or for cases up to 1 month post-study. continuous fluconazole therapy is not associated with significant risk of fluconazole-refractory opc or ec, compared with episodic fluconazole therapy, in hiv-infected patients with access to active antiretroviral therapy. efficacy was judged by changes from baseline in symptoms of oropharyngeal candidiasis (erythema, soreness/burning), extent of oral lesions, and the presence/absence of candida species on fungal culture. also, rates of colonization at the end of therapy and relapse at days 28 and 42 were less with fluconazole tablets than with clotrimazole troches. in the analysis of the participants who actually completed the trial, the lemon juice showed better results than the gentian violet aqueous solution 0.5% in the treatment of oral thrush in an hiv-positive population (p<0.02). after 1 week of treatment, 75 and 82% of the patients on itraconazole and ketoconazole, respectively, had responded clinically. serum amphotericin concentrations were significantly lower and the volume of distribution of the drug higher after infusion of amphotericin-fat emulsion than after amphotericin-glucose. in the prophylaxis group receiving 50 mg/day (group 2), two out of 18 patients had four relapses.|for secondary prevention of oropharyngeal candidiasis hiv-infected women who are at risk for recurrent mucosal candidiasis oral candidosis in aids patients human immunodeficiency virus sixty-five hiv-positive patients were included in the study from may, 1989 to january, 1990 oropharyngeal candidiasis in hiv-infected children oropharyngeal candidiasis 334 hiv-infected patients with oral candidiasis thrush in hiv infection women infected with hiv hiv-positive patients who had no history of clinical resistance to fluconazole patients with advanced human immunodeficiency virus infection oropharyngeal and esophageal candidiasis was conducted in kinshasa (zaire), among 141 inpatients with aids and oropharyngeal candidiasis, of whom 136 also had esophageal candidiasis buccal and oesophageal candidiasis 111 hiv-infected patients with microscopically-confirmed candidiasis oropharyngeal candidiasis in subjects with hiv/aids 14 patients hiv-associated oral candidiasis twenty-five patients with one to four previous thrush episodes who had no thrush at the outset of the study 20 episodes (18 patients) were treated with 323 women with hiv infection and cd4+ cell counts of 300 cells/mm3 or less oropharyngeal candidiasis in immunocompromised patients hiv-positive patients with oropharyngeal or esophageal candidiasis 14 sites participating in the community programs for clinical research on aids (cpcra hiv-infected patients 90 patients, 83 completed the study patients with moderate to severe human immunodeficiency virus (hiv) infection patients with advanced hiv infection and a history of oropharyngeal candidiasis patients with aids thirteen patients were enrolled into cohort 1, and 14 patients were enrolled into cohort 2 women who had a history of mucosal candidiasis (rr, 0.5 n = 37, aged 22-52 years, mean 34 years) and 0.9 patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex oropharyngeal candidiasis in aids oropharyngeal and esophageal candidiasis in zairian aids patients patients with cd4 counts < 200 who are carriers of c. albicans and have a history of oral candidiasis hiv-positive patients treated with hiv-positive patients with oropharyngeal candidiasis 75 hiv/aids subjects with oral candidiasis patients with aids and aids-related complex 22 hiv positive patients with oral candidiasis patients with oropharyngeal and esophageal candidiasis twenty-nine patients (20 men and nine women), with a mean age of 32 years (15-62 years mucosal candidiasis in women hiv-positive patients hiv patients with candidiasis 12 centers in the united states for oropharyngeal candidiasis oral thrush in hiv/aids patients hiv-infected persons with cd4+ t cell counts of <150 cells/mm3 and a history of opc ninety patients n = 38, aged 22-55 years, mean 38 years subjects were 128 hiv-infected men (aged 27-60 years) who either had had no documented episode of oral candidiasis in the previous year or had been clinically clear of oral candidiasis for at least 72 h before randomization 27 patients with aids and oral candidiasis clinically refractory to women with hiv infection patients with acquired immunodeficiency syndrome (aids) and aids-related complex (arc oropharyngeal candidiasis in hiv/aids patients 149 patients with advanced human immunodeficiency virus (hiv) infection aids-related oropharyngeal candidiasis 138 hiv-infected patients patients were excluded if they had been treated with any antifungal agents 2 weeks prior to the study entry, were pregnant or nursing, or had significant liver disease primary health clinic patients j acquir immune defic syndr 1993; 6: 1311-1316. one hundred seventy-nine hiv-positive patients with mycologically documented oropharyngeal candidiasis 11 patients were enrolled in each group human immunodeficiency virus (hiv)-positive patients with cd4 cell count <350 x 10(6)/l and oropharyngeal candidiasis 413 subjects hiv-infected patients with oropharyngeal and/or esophageal candidiasis oropharyngeal candidosis in acquired immunodeficiency syndrome (aids) patients a total of 162 patients 357 patients patients with aids and aids-related complex with severe oropharyngeal and oesophageal candidiasis eighty-four patients with moderate to severe hiv infection who had successfully completed two to four weeks treatment with 140 enrolled patients, 63% had esophageal involvement and 98% were infected with the human immunodeficiency virus (hiv) (median cd4 count, 30/mm(3 oral candidiasis-free period in hiv infection 167 human immunodeficiency virus (hiv)-infected patients with oropharyngeal candidiasis 129 evaluable patients, 98 had oropharyngeal candidiasis and 31 esophageal infection persons infected with human immunodeficiency virus (hiv three hundred fifty subjects received patients with aids suffering from oropharyngeal candidiasis refractory to 40 hiv-positive patients with oropharyngeal candidiasis patients with hiv infection for several years inclusion criteria included being hiv-positive with a diagnosis of oral thrush oropharyngeal and esophageal candidiases patients with hiv infection patients with advanced stages of hiv-infection (cd4 cell count less than 100/mm3 oropharyngeal candidiasis in hiv-infected patients n = 179) in hiv-positive patients with oropharyngeal candidiasis subjects with hiv infection and oropharyngeal candidiasis oropharyngeal candidiasis in human immunodeficiency virus (hiv)-positive patients university-based inner city hiv/aids clinic 46 pediatric patients with oropharyngeal candidiasis and aids or hiv infection 143 adult hiv-positive patients with oropharyngeal and/or esophageal candidiasis patients with acquired immunodeficiency syndrome hiv-positive patients with oral candidiasis hiv infected patients with candidiasis individuals who are positive for the human immunodeficiency virus (hiv) and those who have progressed to aids oropharyngeal candidiasis in patients with aids patients infected with hiv 244 patients 12 patients (eight in the patients with aids and fluconazole-refractory oropharyngeal candidiasis immunocompromised subjects composed primarily of patients with human immunodeficiency virus (hiv)/acquired immunodeficiency syndrome (aids
dysuria, frequency, and incontinence isolated pelvic recurrence actuarial 5-year overall survival rates gastrointestinal toxic effects disease-free survival quality of life 5-year survival rate rates of locoregional relapse (vaginal or pelvic recurrence, or both median duration treatment-related complications toxicity, date and location of recurrence, and overall survival locoregional recurrence and death, with treatment-related morbidity and survival after relapse vaginal recurrence estimated 5-year rates of vaginal recurrence distant metastases pelvic and vaginal recurrences estimated 4-year survival side effects rates of distant metastases vaginal recurrences late intestinal problems risk of recurrence and death 2-year survival after vaginal recurrence 5-year actuarial locoregional recurrence rates locoregional recurrence rate grade 3-4 complications overall survival rates of acute grade 1-2 gastrointestinal toxicity deaths and recurrences overall recurrence rate and survival survival after relapse endometrial-cancer-related death rates locoregional control and survival 5-year vaginal and pelvic recurrences locoregional recurrence rate of vaginal recurrences 2-year cumulative incidence of recurrence (cir|during the follow-up period of 3 to 10 years a significant reduction in vaginal and pelvic recurrences was found in group b as compared with group a (1.9 versus 6.9%, p < .01). the estimated 4-year survival was 86% in the nat arm and 92% for the rt arm, not significantly different (rh: 0.86; p=0.557). the rate of vaginal recurrences was 1.2% in the treatment group versus 3.1% in the control group. rates of acute grade 1-2 gastrointestinal toxicity were significantly lower in the vbt group than in the ebrt group at completion of radiotherapy (12.6% [27/215] vs 53.8% [112/208]). 5-year actuarial locoregional recurrence rates were 4% in the radiotherapy group and 14% in the control group (p<0.001).|figo stage patients with stage-1 endometrial carcinoma below 60 years and patients with grade-2 tumours with superficial invasion i low-risk endometrial cancer 319 patients were treated with 715 patients, 714 could be evaluated international federation of gynaecology and obstetrics (figo) stage-1 endometrial carcinoma intermediate risk endometrial adenocarcinoma patients with endometrial carcinoma of high-intermediate risk 19 dutch radiation oncology centres, 427 patients with stage i or iia endometrial carcinoma with features of high-intermediate risk 645 evaluable low-risk endometrial carcinoma patients from 6 european gynecologic cancer centers endometrial carcinoma women with endometrial adenocarcinoma receive patients with endometrial cancer of high-intermediate risk (portec-2 low-risk international federation of gynecology and obstetrics (figo) stage ia-ib endometrial carcinoma four hundred forty-eight consenting patients with "intermediate risk" endometrial adenocarcinoma patients with low-risk endometrial carcinoma a high intermediate risk (hir) subgroup of patients was defined as those with (1) moderate to poorly differentiated tumor, presence of lymphovascular invasion, and outer third myometrial invasion; (2) age 50 or greater with any two risk factors listed above; or (3) age of at least 70 with any risk factor listed above from 1968 to 1974, 540 patients with stage i adenocarcinoma of the corpus uteri 715 patients from 19 radiation oncology centres women with endometrial cancer international federation of gynaecology and obstetrics (figo) stages ib, ic, and ii (occult disease three hundred ninety-two women met all eligibility requirements (202 nat, 190 rt patients with stage-1 endometrial carcinoma (grade 1 with deep [> or =50%] myometrial invasion, grade 2 with any invasion, or grade 3 with superficial [<50%] invasion) were enrolled 540 patients patients with stage-1 endometrial carcinoma
incidence of maternal and neonatal complications incidence of respiratory distress syndrome neonatal sepsis endometritis rate duration of hospitalization and infection postpartum febrile morbidity risk of maternal infections mean birth weights, perinatal death rates, neonatal infections, or incidences of respiratory distress neonatal morbidity incidence of chorioamnionitis and antepartum hospitalization pregnancy outcome (ie, birth weight, intraventricular hemorrhage, necrotizing enterocolitis, sepsis, respiratory distress syndrome, and perinatal death hospitalization chorioamnionitis and fetal heart rate abnormalities maternal age, gestation at prom, maximum maternal temperature, birth weights, maternal hospital days, respiratory distress, maternal sepsis, or delivery routes chorioamnionitis frequency of prolonged hospital stay prolonged latencies to labor, delivery, and maternal hospitalization mean gestational ages at delivery antepartum hospitalization overall corrected perinatal survival maternal outcome, including chorioamnionitis and cesarean section rates maternal hospital stay prolonged antimicrobial therapy hospitalization, assessment for fetal heart rate abnormalities, chorioamnionitis, and labor proven sepsis ultrasonographically estimated fetal weight|neonatal outcome did not differ in mean birth weights, perinatal death rates, neonatal infections, or incidences of respiratory distress. there was no significant difference in the incidence of respiratory distress syndrome. infants received more frequent (p < 0.001) and prolonged antimicrobial therapy after expectant management (p = 0.003) with no reduction in proven sepsis (6.8% vs 4.4%). neonatal morbidity was similar in each group. however, there was a significant increase in the incidence of chorioamnionitis and antepartum hospitalization in the women managed expectantly. chorioamnionitis occurred more often (16% vs 2%, p = 0.007), and maternal hospital stay (5.2 +/- there were no significant differences in maternal age, gestation at prom, maximum maternal temperature, birth weights, maternal hospital days, respiratory distress, maternal sepsis, or delivery routes in the three groups.|women with preterm prematurely ruptured membranes with 321 gm vs 2297 120 gravid women at > or = 34 weeks 0 days and < 36 weeks 6 days of gestation premature rupture of the membranes and the premature gestation women with preterm premature rupture of the membranes at 32 to 36 weeks with mature surfactant profiles patients with chorioamnionitis, advanced labor, and fetal distress, as well as those with mature lecithin/sphingomyelin ratios a total of 160 patients were randomized, 80 in each group n = 57) or observation (n = 63 premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks ninety-nine patients with premature rupture of the membranes (prom) before 36 weeks' gestation and documented fetal pulmonary maturity 71 women who did not participate patients with premature rupture of the membranes and premature gestations patients in the 28th to 34th week of pregnancy with premature rupture of the membranes (prom premature rupture of membranes estimated gestational age at rupture of membranes (34.3 sixty-eight women with prom were managed expectantly and 61 were delivered intentionally women with preterm premature rupture of the membranes and documented fetal pulmonary maturity preterm prematurely ruptured membranes labor with preterm rupture of membranes between 34 and 37 weeks' gestation with expectant management pregnancies complicated by preterm rupture of membranes (prom) at 30-34 weeks' gestation 73 patients 164 women with preterm premature rupture of the membranes at 32 weeks to 36 weeks 6 days' gestation, 93 eligible and consenting women patients with premature rupture of the membranes between the twenty-eighth week and the thirty-fourth week of pregnancy was conducted women hospitalized for prom at 30-34 weeks' gestation
behavioral changes episodic memory performance episodic memory, perceived burden or depressive symptoms recall of personal information, face-name recall, and performance on the verbal series attention test memory and functional performance depressive symptoms hostility negative coping strategies brain function completed activities of daily living (adls) and everyday memory questionnaires additional neuropsychologic measures of dementia severity, verbal memory, visual memory, word generation, or motor speed, or to caregiver-assessed patient quality of life questionnaires assessing mood, quality of life and career strain, and a brief neuropsychological test battery ratings of goal performance and satisfaction goal performance and satisfaction, assessed using the canadian occupational performance measure improvement over time in cognitive outcomes recall and recognition of test material cognitive and behavioral functioning cognitive and behavioral performance regional cerebral metabolic rate for glucose using positron emission tomography and 18f-2-fluoro-2-deoxy-d-glucose memory, verbal fluency, and problem-solving ability, and caregivers were assessed on marital interaction, emotional status, and physical health, along with stress, coping, and social support face-name association tasks, object recall training, functional tasks (e.g., making change, paying bills), orientation to time and place, visuo-motor speed of processing, and the use of a memory notebook gains in recall of face-name associations, orientation, cognitive processing speed, and specific functional tasks cognitive, behavioural and functional assessment cognitive rehabilitation specific cognitive and functional tasks|cr produced significant improvement in ratings of goal performance and satisfaction, whereas scores in the other two groups did not change. care recipients in the experimental group improved in cognitive and behavioral performance with treatment, but returned to former level of functioning by the 9th month. repeated measures procedures showed that patients in the cognitive stimulation group demonstrated more improvement over time in cognitive outcomes, and caregivers decreased in depressive symptoms. the results showed that following collaborative intervention recall performance in two collaborative tasks became more equally shared between the spouses, reflected in a decrease in recall for the caregiver and in an increase in recall for the spouse with dementia between pre- and post-test; whereas for the other two groups the caregivers dominated collaborative recall both at pre- and post-test. no significant main effects of group (training vs. control) or time were observed on any outcome measures, nor were any significant interactions found. during the intervention, ad patients showed significant improvement in recall of personal information, face-name recall, and performance on the verbal series attention test. a systematic program of cognitive rehabilitation can result in maintained improvement in performance on specific cognitive and functional tasks in mildly impaired ad patients. preliminary results show a significant performance decline only in the control group at the 9-month follow-up compared to both baseline and the 3-month follow-up. before treatment the groups were comparable in respect to resting and activated glucose pattern achieved by a visual recognition task.|mildly impaired alzheimer disease patients on cholinesterase inhibitors nineteen participants in the mental stimulation (ms) condition had equivalent therapist contact and number of sessions, which consisted of interactive computer games involving memory, concentration, and problem-solving skills patients with ad patients with mild cognitive decline 34 patients with probable alzheimer's disease (ad care recipients alzheimer's disease 11 patients with diagnosis of alzheimer's disease (ad) and mild cognitive decline randomly assigned to treatment (a) or control (b) condition (i.e. specific vs. aspecific treatment 70 patients with probable alzheimer's disease early-stage alzheimer disease (ad four groups of patients with alzheimer's disease mildly impaired alzheimer disease (ad) patients receiving a cholinesterase inhibitor twenty-five participants in the cognitive rehabilitation (cr) condition participated dementia: caregiver participation matters sixty-nine individuals (41 women, 28 men; mean age 77.78 years, standard deviation 6.32, range = 56-89) with a diagnosis of ad or mixed ad and vascular dementia and a mini-mental state examination score of 18 or above, and receiving a stable dose of acetylcholinesterase-inhibiting medication mildly impaired ad patients alzheimer disease caregivers (65 women, 38 men) and their dementia-diagnosed spouses (patients older care recipients with the diagnosis of dementia of the alzheimer's type dementia persons with dementia and their spousal caregivers 78 community-dwelling care recipients care recipients with dementia mildly impaired alzheimer's disease patients 37 patients (16 men, 21 women) with probable alzheimer disease (ad people with early-stage alzheimer disease
sustained attention and visual and movement skills efficacy and safety cognitive functions of visual sustained attention and visual and movement skills positive and negative symptom scale ratings tolerated without any serious adverse effects clinical symptoms, side effects, and quality-of-life scores|compared with placebo, dhea administration did not produce significant improvement in clinical symptoms, side effects, and quality-of-life scores.|schizophrenia fifty-five of 62 inpatients and outpatients with diagnostic and statistical manual of mental disorders, fourth edition, diagnosis of schizophrenia completed the trial
blinded rating on the action research arm test fim motor score fma motor recovery and cortical reorganization motor function as assessed by the wolf motor function test and motor activity log. muscle tone, fugl-meyer assessment, and power of wrist and hand fugl-meyer assessment score in the wrist, hand and coordination, as well as power of wrist grip force, spasticity, pain, dexterity, hand-use in daily life, and quality of life neural activation patterns distal function brunnstrom stages of motor recovery, spasticity assessed by the modified ashworth scale (mas), walking ability (functional ambulation categories [fac]), and motor functioning (motor items of the fim instrument pain and enhances upper limb motor function recovery of surface sensibility sensory and attentional deficits brunnstrom stages of motor recovery, spasticity assessed by the modified ashworth scale (mas), and hand-related functioning (self-care items of the fim instrument power of hand flexion, wrist flexion, and wrist extension muscle tone motor recovery scores of the brunnstrom stages for the hand and upper extremity and the fim self-care score fugl-meyer scores of hand, wrist, coordination and power of hand extension fac activation balance visual analogue scale score of pain at rest, on movement, and brush-induced tactile allodynia fugl-meyer motor assessment (fma|the mirror and nmes group showed significant improvements in the fugl-meyer scores of hand, wrist, coordination and power of hand extension compared to the other groups. mt stimulated recovery from hemineglect. . no changes were found on the other outcome measures (all ps >.05). no differences between the treatment groups were found at baseline or outcome on the action research arm test (ancova statistical p=0.77, and effect size partial 2=0.005) or any of the secondary outcome measures. mirror therapy combined with a conventional stroke rehabilitation program enhances lower-extremity motor recovery and motor functioning in subacute stroke patients. the mean scores of both the primary and secondary end points significantly improved in the mirror group (p < .001). in our group of subacute stroke patients, hand functioning improved more after mirror therapy in addition to a conventional rehabilitation program compared with a control treatment immediately after 4 weeks of treatment and at the 6-month follow-up, whereas mirror therapy did not affect spasticity.|twenty patients had nmes applied and simultaneously underwent mirror therapy severe hemiparesis stroke patients with persistent upper limb motor weakness stroke patients with upper limb crpst1 sixty patients with hemiparesis after stroke were included (41 males and 19 females, average age 63.3 years inpatients with subacute stroke mental practice with motor imagery in stroke recovery stroke patients patients with acute stroke. patients with chronic stroke with moderate upper extremity paresis 208 patients with first episode of unilateral stroke admitted to the authors' rehabilitation center, 48 patients with crpst1 of the affected upper limb chronic stroke patients patients with subacute stroke thirty-six patients with severe hemiparesis because of a first-ever ischemic stroke in the territory of the middle cerebral artery were enrolled, no more than 8 weeks after the stroke 39 patients involved in 4 weeks of 121 stroke patients with a residual upper limb weakness within 6 months following stroke (on average <3 months post-stroke subacute stroke patients 40 chronic stroke patients (mean time post subacute stroke motor functioning after stroke 40 inpatients with stroke (mean age, 63.2y), all within 12 months poststroke stroke patients than nmes or mirror therapy only 40 inpatients with stroke (mean age, 63.5 y), all within 12 months poststroke and without volitional ankle dorsiflexion twenty patients had nmes applied only, and twenty patients underwent mirror therapy only
radiological evidence of new scars of pyelonephritis rate of persistent infection clinical pyelonephritis recurrent infection children renal growth|recurrent infection in the treated group was common and was not significantly different from the rate of persistent infection in the untreated control group.|covert bacteriuria of childhood sixty-three girls with covert bacteriuria
pain reduction several quality-of-life measures brief pain inventory average interference from pain score safe and efficacious nausea, headache, constipation, dry mouth, dizziness, diarrhea, and hyperhidrosis physical function (sf-36 physical functioning domain-100 bpi score nausea significant pain reductions pain intensity sf-36 mental component summary adverse events bpi average pain severity, patient-rated scales assessing mood, anxiety, pain, sleep, and stiffness, clinical global impression of severity (cgi-s), multidimensional fatigue inventory, cognitive and physical functioning questionnaire, beck depression inventory (bdi), beck anxiety inventory, and medical outcome study short-form health survey (sf-36 pain severity physical function on the short form 36 (sf-36) physical component summary (pcs) score brief pain inventory (bpi) average pain severity vital signs, laboratory measures, or ecg measures effective and safe fiq stiffness score headache mood, stiffness, fatigue and functioning fiq pain score patient global impression of change [pgic] scale); and physical function (a > or = 6-point improvement on the 36-item short-form health survey [sf-36] physical component summary score bpi average pain severity, mood (including bdi total), anxiety (patient-rated only), stiffness, cgi-s, fatigue, all sf-36 domains (except role-physical and physical component summary), and being less bothered by pain or sleep difficulties multiple ability self-report questionnaire number of tender points fatigue short-form 36 health survey (sf-36) physical component summary fibromyalgia (fm) symptoms assessed by the patient global impression of improvement (pgi-i) scale cgi-severity pain, global status, fatigue, and physical and mental function fibromyalgia impact questionnaire (fiq nausea and headache fibromyalgia symptoms and pain severity efficacy and safety constipation multidimensional fatigue inventory pgi-improvement pgic safe and well tolerated mean tender point pain threshold, number of tender points, fiq fatigue, tiredness on awakening, and stiffness scores, clinical global impression of severity (cgi-severity) scale, patient global impression of improvement (pgi-improvement) scale, brief pain inventory (short form), medical outcomes study short form 36, quality of life in depression scale, and sheehan disability scale pain and other symptoms global status fm composite responders brief pain inventory average pain severity score visual analog scale, 24-hour morning recall) and a rating of "very much" or "much" improved on the patient global impression of change scale mean tender point pain threshold pain (visual analog scale 24-h morning recall), patient global impression of change (pgic), and physical functioning (sf-36 physical component summary efficacy and tolerability pain safety overall improvement overall discontinuation rates multidimensional fatigue inventory total score tolerated fibromyalgia impact questionnaire (fiq) total score (score range 0-80, with 0 indicating no impact) and fiq pain score fiq total score adverse events, and changes in vital sign, laboratory, and ecg measures remaining brief pain inventory pain severity and interference scores, fibromyalgia impact questionnaire, clinical global impression of severity, patient global impression of improvement, and several quality-of-life measures fibromyalgia impact questionnaire pain score, bpi least pain score and average interference score, clinical global impressions of severity scale, area under the curve of pain relief, multidimensional fatigue inventory mental fatigue dimension, beck depression inventory-ii total score, and 36-item short form health survey mental component summary and mental health score fatigue (multidimensional fatigue inventory rates of fm composite responders and fm pain composite responders global improvement with mean pgi-i scores brief pain inventory (bpi) average pain severity score and patient global impressions of improvement (pgi-i) score pain (realtime, daily and weekly recall pain score and a rating of "very much improved" or "much improved" on the patient's global impression of change (pgic) scale fm pain composite responders safe and well tolerated; nausea, hyperhidrosis, and headache 24-hour and weekly recall pain score, pgic score, sf-36 pcs and mental component summary scores, average pain severity score on the brief pain inventory, fibromyalgia impact questionnaire total score|significantly more duloxetine- versus placebo-treated patients (57% vs 32%; p < 0.001) reported feeling "much" or "very much better" (pgi-i score  2). significant improvements were also observed in multiple secondary efficacy endpoints, including short-form 36 health survey (sf-36) physical component summary (p = 0.025), sf-36 mental component summary (p = 0.007), multidimensional fatigue inventory (p = 0.006), and multiple ability self-report questionnaire (p = 0.041). compared with placebo-treated subjects, duloxetine-treated subjects had significantly greater reductions in brief pain inventory average pain severity score (p = 0.008), brief pain inventory average interference from pain score (p = 0.004), number of tender points (p = 0.002), and fiq stiffness score (p = 0.048), and had significantly greater improvement in mean tender point pain threshold (p = 0.002), cgi-severity (p = 0.048), pgi-improvement (p = 0.033), and several quality-of-life measures. compared with placebo, both duloxetine-treated groups improved significantly more (p<0.001) on the brief pain inventory average pain severity score. milnacipran administered at a dosage of 100 mg/day improved pain, global status, fatigue, and physical and mental function in patients with fibromyalgia. milnacipran was safe and well tolerated by the majority of patients during 27 weeks of treatment; nausea and headache were the most common adverse events. there were no significant differences between treatment groups on the co-primary efficacy outcome measures, change in the brief pain inventory (bpi) average pain severity from baseline to endpoint (p = 0.053) and the patient's global impressions of improvement (pgi-i) at endpoint (p = 0.073). p<0.001 for both doses), physical function (sf-36 physical functioning domain-100 the study evaluated the efficacy and safety of milnacipran for the treatment of pain and associated symptoms such as fatigue, depressed mood and sleep. compared with placebo, treatment with duloxetine 60 mg/day also significantly improved the co-primary measures at 3 months and bpi at 6 months.|125 patients fibromyalgia (fm subjects with or without major depressive disorder 354 female patients with primary fibromyalgia, with or without current major depressive disorder patients with fibromyalgia, during six months of treatment fibromyalgia in adults outpatients diagnosed with fm according to 1990 american college of rheumatology criteria (n = 884 fibromyalgia patients with or without major depressive disorder patients both with and without major depressive disorder adult patients (age 18-70 years) who met 1990 american college of rheumatology criteria for fm the population had a mean age of 50.2 years, a mean baseline weight of 180.8 pounds, and a mean baseline body mass index of 30.6 kg/m(2 520 patients meeting american college of rheumatology criteria for fibromyalgia 2270 patients screened, 1196 patients with or without major depressive disorder women with fibromyalgia with or without major depressive disorder fibromyalgia 18 outpatient research centers in the us subjects with primary fibromyalgia, with or without current major depressive disorder fibromyalgia patients with or without current major depressive disorder female subjects patients with fibromyalgia patients (90% caucasian; mean age, 49.6 years; 26% with current major depressive disorder fibromyalgia (fm) in a european population 207 subjects meeting the american college of rheumatology criteria for primary fibromyalgia were enrolled (89% female, 87% white, mean age 49 years, 38% with current major depressive disorder female patients with or without major depressive disorder outpatients  18 years of age who met american college of rheumatology criteria for fm, and had  4 score on the brief pain inventory (bpi) average pain item 888 patients with fm 1,025 patients with fibromyalgia
efficacy and safety voice alteration and dyspnea physiologic indicators of gastric, cardiac, or pulmonary functions occurred total seizure frequency global evaluation scores seizure counts and safety|no changes in physiologic indicators of gastric, cardiac, or pulmonary functions occurred.|patients receiving high stimulation (94 patients, ages 13 to 54 years patients with refractory partial-onset seizures partial-onset seizures patients had at least six partial-onset seizures over 30 days involving complex partial or secondarily generalized seizures
therapeutic success pain relief visual analog scale (vas) for pain and a mandibular functional impairment questionnaire (mfiq subjective pain relief and appreciation of improvement of mobility mobility pain and improved mandibular function maximum interincisal opening and protrusion, recording of clicking and crepitation, and palpation for tenderness of the tmj and jaw muscles pain control pain, mobility, and functional ability pain, joint noise, jaw mobility, and dietary alterations maximum incisal opening and pain scores; the overall success rate mfiq, vas, maximum opening and protrusion, lateral joint tenderness, muscle tenderness, crepitation, and clicking severity of pain function and diminishing pain functional result and in pain control craniomandibular index (cmi) and symptom severity index (ssi) for jaw function and tmj pain respectively pain and function joint tenderness visual analog scale for pain and a questionnaire concerning mandibular functional impairment arthroscopic lysis and lavage (all interincisal opening, lateral excursions, occlusal evaluation, deviation on opening, and tenderness to palpation muscle tenderness and pain pain joint tenderness and pain on lateral palpation|discectomy reduced pain somewhat more effectively than arthroscopic lysis and lavage. patients treated with arthroscopic surgery reported more pain relief and more improvement of mobility than patients treated non-surgically, although clinical assessment results were comparable between the two groups. both groups had significantly less pain in the joint and better jaw opening one year postoperatively. in both the open and arthroscopy groups mandibular function improved significantly (p = .005). using an intention-to-treat analysis, we observed no between-group difference at any follow-up for cmi (p > or = 0.33) or ssi (p > or = 0.08). therapeutic success was not significantly different for arthroscopy and arthrocentesis; both surgical modalities are useful for decreasing patient reports of pain while increasing functional mobility of the mandible. arthroscopy shows better results for functional treatment whereas arthrocentesis and arthroscopy show similar results in pain control.|chronic closed lock of the temporomandibular joint temporomandibular joint disorders patients with stage iii or above tmj internal derangement, who had not responded to three months of non-surgical treatment patients with temporomandibular joint (tmj) osteoarthrosis and internal derangement in 1993 and 1994, 720 patients with pain in the temporo-mandibular joint area thirty-five patients (41 joints) had all and 66 patients (73 joints) had aalcr 106 individuals with tmj closed lock twenty-one patients appeared to obey strict criteria for participation patients with chronic closed lock of the temporomandibular joint (tmj symptomatic patients with a diagnosis of chronic closed lock of the tmj twenty-two patients with a clinical diagnosis of chronic closed lock twenty patients completed the study nineteen patients with clinical and radiographic documentation of internal derangement of the temporomandibular joint(s) unresponsive to nonsurgical therapy twenty patients with a clinical and radiologic diagnosis of chronic closed lock sixty-two patients were not relieved by conservative nonsurgical therapy and were treated by arthroscopy or arthrocentesis
seriously ill or depressed, and average coping and quality of life scores changes in life satisfaction, perceived health, and number and severity of symptoms relieving pain mild adverse events (ae hiv-1 rna level abnormal stool frequency life satisfaction life satisfaction and symptoms plasma viral loads, cd4 cell counts, symptoms, and psychometric parameters abnormal stool frequency of three abnormal stools safety and efficacy dropout rate serious adverse events or laboratory abnormalities severe side-effects adherence, and changes in weight, cd4+ count, depression, anxiety, physical and social function, and mental health toxicities safety and effectiveness median hiv-1 plasma viral loads median cd4 cell counts stool weight efficacy and safety symptoms, hiv disease progression, hiv-1 rna plasma viral loads, cd4 and cd8 cell counts, and scores on standard questionnaires for quality of life, depression, anxiety, and coping pain intensity, pain relief, sensory perception, quality of life, mood, and function rate of disease progression safe and well tolerated stool frequency and weights quality of life, clinical manifestations, plasma virus loads, or cd4 cell counts life satisfaction or symptoms gastrointestinal disturbances current pain scores current pain, worst pain, pain relief, sensory perception, quality of life, mood, or function at study entry or at any time stool weight and frequency viral load cd4 cell count mean reduction from baseline stool weight number of symptoms therapeutic failures|there were no serious adverse events or laboratory abnormalities. there was a statistically significant difference in therapeutic failures between groups in favor of spv(30) number of symptoms was reduced in subjects receiving herbs (-2.2, 95% ci -4.1, -0.3) but not in those receiving placebo (-0.3, 95% ci -3.2, +2.7). patients taking chinese herbs reported significantly more gastrointestinal disturbances (79% versus 38%; p = .003) than those receiving placebo. there were no other statistically significant differences between the capsaicin and vehicle groups with respect to current pain, worst pain, pain relief, sensory perception, quality of life, mood, or function at study entry or at any time during the 4-week trial.|hiv-associated symptoms patients with aids 68 hiv-infected adults with cd4 cell counts hiv-infected asymptomatic patients twenty-six subjects were enrolled in the study 0.5 x 10(9)/l. participants 145 previously untreated subjects with asymptomatic hiv infection (cdc group iv) and cd4 cell counts between 250 and 500  10(6)/1 were recruited a university-affiliated acquired immunodeficiency syndrome (aids) clinic at a public general hospital thirty adults with symptomatic hiv infection, no previous aids-defining diagnosis, and cd4+ counts of 0.200-0.499 x 10(9)/l (200-499/mm3 hiv-1-infected individuals human immunodeficiency virus (hiv) infection 41 subjects (80%) were receiving antiretroviral therapy and 39 subjects (77%) were receiving at least one protease inhibitor patients with aids and diarrhea  1998 26 subjects received hiv-infected persons patients with hiv-associated dspn hiv-positive subjects with a history of a cd4 count <200 or an aids-defining illness were admitted to an inpatient study unit and screened for diarrhea defined as at least three abnormal (i.e., soft or watery) stools and >200 g of abnormal stool weight over a 24-h period hiv asymptomatic patients university-based hiv outpatient clinic hiv-associated peripheral neuropathy
mean frequency of the target behavior target behavior reading condition (b) and the singing condition (c|the singing condition was significantly more effective than the reading condition only in case study iii.|participants in the study were four first- and second-grade students with a primary diagnosis of autism attending an elementary school in eastern iowa students with autism
groin relapses survival metastatic involvement of the groin nodes excessive number of groin relapses progression-free interval|the groin dissection regimen had significantly better progression-free interval (p = 0.03) and survival (p = 0.04).|members of the gynecologic oncology group randomized 58 patients with squamous carcinoma of the vulva and nonsuspicious (n0-1) inguinal nodes to receive either patients with squamous carcinoma of the vulva and n0-1 nodes carcinoma of the vulva
bdp and 5-asa total dai scores endoscopic and histologic remissions mean disease activity index histological index acute response and safety profile clinical and endoscopic activity laboratory variables and vital signs clinical and endoscopic remission sigmoidoscopic remission adverse events, primarily headache and nausea disease activity index mean dai scores histological remission liquid stools frequency of patients with an endoscopic remission active ulcerative proctitis determination of clinical, endoscopic, and histologic remission rates tolerated and produced earlier and more complete relief of rectal bleeding dai score anal burning histologic remission cgi scores clinical and sigmoidoscopic remission adrenal function, monitoring of adverse events, vital signs, and laboratory parameters clinical remission (clinical activity index clinical score adverse events morning cortisol levels treatment tolerability and acceptability disease activity tolerability and efficacy endoscopy and histopathology scores rate of histologic remission distal ulcerative colitis endoscopic remission disease status efficacy efficacy and safety amount of blood in stools, urgency, straining at stools, and abdominal pain in daily diaries complete clinical remission remission rates clinical symptoms, endoscopic and histological findings efficacy and tolerability rectal bleeding tolerated clinical improvement, remission and relapse haematology, chemistry and adverse events quicker clinical and sigmoidoscopic remission efficacy, tolerability and overall acceptability efficacy, tolerance, and acceptance sigmoidoscopic and improved histological score efficacy, tolerance and acceptance symptoms endoscopic, clinical, and histologic improvement compliance mesalazine enema (disease activity index improvement or remission a disease activity index (dai abdominal bloating complete relief of symptoms, and endoscopic and histological evidence of remission or improvement complete mucosal healing practicality and patient compliance disease activity index, which represents a score with four variables: stools frequency, rectal bleeding, mucosal appearance, and physician's assessment of disease severity efficacy, safety and patient tolerability clinical activity discomfort pgi ratings very much improved" or "much improved daily evacuations more than usual, evacuations containing blood, sigmoidoscopy appearance, and physician's overall assessment sigmoidoscopic and histological remission rates median duration of response to alicaforsen enema treatment disease activity index (dai physician-rated disease activity index (dai), which included symptom evaluations and sigmoidoscopic findings, by physician-rated clinical global improvement (cgi) scores, and by patient global improvement (pgi) scores distal ulcerative colitis, proctosigmoiditis, and proctitis clinical remission; endoscopic remission, histological changes, global assessment and standard safety measures absence of blood in stools histologic activity severe discomfort, pain and retention problems difficulty in retention adverse event reports, clinical laboratory tests, and physical examination endoscopic remission rates clinical remission median dais total dai scores and abbreviated dai scores clinical activity index, endoscopic index, histological index, and global efficacy assessment clinical remission rate safety and efficacy recovery tolerability and practicality endoscopic and histological evaluation of colonic mucosa side effects time of initial presentation, symptom resolution, and endoscopic and histologic improvement symptoms (number of bowel movements per day, quality of stools, presence of blood and mucus, and state of well-being clinical remission rates disease activity index value disease activity index scores disease activity index (dai) score absorbed radioactivity mean disease activity index score safety profile tolerability and safety recording of adverse events, laboratory variables and vital signs remission|alicaforsen is an antisense oligonucleotide inhibitor of intercellular adhesion molecule 1 protein expression with activity in subjects with ulcerative colitis and pouchitis. at 4 weeks clinical remission was achieved in 7 of 31 (39%) patients with placebo, in 22 of 32 (69%) patients in the 1 g mesalazine group, and 23 of 31 (74%) patients in the 1.5 g mesalazine group. at the end of the study 5-asa suppositories showed significantly better results in all the parameters recorded than placebo (p less than 0.01). fifty-two patients with mild to moderate distal ulcerative colitis were randomized under double-blind conditions to receive a rectal preparation of either pentasa (1 g/day) or cortenema (100 mg/day) for 3 wk. since no difference was registered between the two types of treatment (p = 0.141, x2 test), 4-asa could be a possible form of treatment for active ulcerative colitis. remission rates at w2 were 48.1 %versus 50.6% in itt (97.5% ci -12.8%) and 49.1%versus 52.1% in pp (97.5% ci -13.8%) in foam versus liquid, respectively. the disease activity index lowered at t8 versus t4 in the beclomethasone diproprionate enema and foam endoscopic, clinical, and histologic improvement were comparable in the two treatment groups. a significant decrease in the dai score (p < 0.05) was observed in both treatment groups, with a clinical remission rate of 36.7% in the bdp group and of 29.2% in the 5-asa group. patient evaluation of therapy showed that foam was much better accepted than enema because foam was more comfortable, more practical, easier to retain, and interfered less with daily living.(abstract truncated at 250 words) salofalk foam and enema are equally effective for the treatment of proctitis, proctosigmoiditis and left-sided ulcerative colitis. patients with active distal proctitis received either 5-aminosalicylic (5-asa) acid or identical placebo suppositories, 500 mg t.i.d. for 6 weeks. no difference could be observed in terms of efficacy; however, it was the patients' opinion that treatment with suppositories was easier than that with enemas (p less than 0.01). the low-volume foam was associated with a lower frequency of severe discomfort, pain and retention problems. improvement in mean disease activity index score was significantly greater with suppositories compared with oral mesalazine, both at two-week and four-week visits (mean disease activity index scores at baseline, two, and four weeks: suppositories = 7.7, 2.59, and 1.48; tablets = 7.42, 5.72, and 3.48, respectively (p < 0.001)). the difference between the treatment groups was statistically significant (p = 0.02) due to a better effect of mesalazine in patients with proctitis. the combination of oral and rectal mesalamine therapy was well tolerated and produced earlier and more complete relief of rectal bleeding than oral or rectal therapy alone. adverse events, primarily headache and nausea, occurred significantly more frequently (p = 0.02) in the sas than in the 5-asa group (83 vs 42%). there was no significant difference with respect to age, male/female ratio, past history of proctosigmoiditis, length of colorectum involved at the time of initial presentation, symptom resolution, and endoscopic and histologic improvement among the three treatment groups. improvement or remission was seen in 77% of the 5-aminosalicylic acid-treated patients and in 72% of the prednisolone-treated patients (p greater than 0.05). the foam enema was shown to be as efficacious as the reference, even though the daily dose in the foam treatment contained only half as much active drug as in the reference treatment. improvement in clinical score was achieved in seven of nine 5-asa enema-treated patients versus one of nine hydrocortisone enema-treated patients (p less than 0.05). all patients who received 5-asa enemas showed significantly better results than those who received a placebo enema (p less than 0.001) but no difference was detected among the patients receiving differing concentrations of 5-asa. the combination of bdp and 5-asa was significantly superior to single-agent therapy in terms of both improved sigmoidoscopic and improved histological score. endoscopic remission was achieved by 45.0% of patients on 5-asa mmx and by 36.8% of those on enema, whereas 15.0% and 8% of patients, respectively, showed histologic remission. budesonide and 5-asa enemas both resulted in a significant improvement in endoscopy and histopathology scores but no difference could be demonstrated between the two treatment groups. the active drug conferred significant benefit compared with placebo as shown by several criteria, but this benefit was confined to patients not already taking sulphasalazine by mouth. the foam enemas were generally well-tolerated, and no treatment-related changes on laboratory variables and vital signs were noted. mean disease activity index declined 55% for patients on 5-aminosalicylic acid and 24% for patients on placebo (p = 0.0001). in this study mesalazine foam enema was superior to prednisolone foam enema with regards to clinical remission, this was supported by favourable trends in sigmoidoscopic and histological remission rates. the patients' evaluation for tolerability and practicality showed that the pentasa suppository was significantly superior to the claversal suppository. endoscopic remission rates at week 4 were 51 and 52% for the mesalazine gel and foam enemas, respectively (p = 0.925).|63 patients, similarly matched for age, sex and extent of disease, took part 217 patients were enrolled and treated with bdp (n = 111) or 5-asa (n = 106 active distal ulcerative colitis distal active ulcerative colitis with 6 patients with inflammatory bowel disease and 6 healthy volunteers patients with proctitis patients with mild-to-moderate active proctitis and proctosigmoiditis thirty-nine patients with documented active distal proctitis (less than 20 cm patients with active mild to moderate distal ulcerative colitis fifty-two patients with mild to moderate distal ulcerative colitis active ulcerative proctitis thirty-seven patients 330 patients were evaluable for n = 149 evaluable patients) and outpatients with mild to moderate proctosigmoiditis a total of 195 patients were enrolled active distal ulcerative colitis in adults seventy-nine patients were enrolled patients presenting to the ferguson clinic with the diagnosis of idiopathic proctosigmoiditis were evaluated for age, sex, prior history of proctitis, duration of symptoms prior to presentation, endoscopic scoring, and mucosal biopsies mildly to moderately active ulcerative colitis patients with distal rectosigmoiditis 103 patients with mild to moderate left-sided colitis or proctosigmoiditis patients with acute distal ulcerative colitis proctitis and distal proctosigmoiditis distal ulcerative colitis 18 patients with persistent active distal ulcerative colitis after at least a 3-wk course of treatment with 100-mg eleven patients, nine receiving inclusion criteria were: disease extension at least 5 cm from anorectal junction and not above splenic flexure and clinical activity index (cai) 1-4 > or = 4 active ulcerative colitis seventy-nine patients with distal ulcerative colitis 111 patients with mildly to moderately active proctitis, proctosigmoiditis, or left-sided ulcerative colitis received ulcerative proctitis patients with ulcerative proctitis or distal proctosigmoiditis 14 patients, with initial mean dai 7.1 left-sided ulcerative colitis fifty patients with active ulcerative colitis extending not beyond 20 cm from the anus on sigmoidoscopy ulcerative colitis patients with active mild-to-moderate distal ulcerative colitis mild to moderate left-sided ulcerative colitis patients with mild to moderate distal ulcerative colitis patients with active distal proctitis 153 patients with ulcerative colitis involving up to 50 cm of distal colon patients with active distal ulcerative colitis patients with active ulcerative colitis twenty patients received enemas, while 19 patients received subjects with mild to moderate active left-sided ulcerative colitis ulcerative proctosigmoiditis 15 referral gastrointestinal units, 99 patients with distal ulcerative colitis were enrolled one hundred and thirteen patients with ulcerative colitis attending our outpatient clinic volunteered to participate subjects with ulcerative colitis and pouchitis ninety-seven patients patients with a mild to moderate attack of ulcerative colitis sixty-two patients with ulcerative colitis localised to the distal sigmoid colon and rectum (less than 20 cm) entered the trial patients with active distal ulcerative colitis [clinical activity index (cai) > 4, endoscopic index > or = 4 27 patients randomized, 14 received active distal ulcerative colitis and proctitis 233 patients from 12 outpatient clinics in italy patients suffering from active ulcerative colitis patients with left-sided ulcerative colitis patients with distal ulcerative colitis patients with active proctitis, proctosigmoiditis and left-sided ulcerative colitis as evaluated by the clinical activity index (cai > or =4) and endoscopic index (ei > or =6 patients with acute left-sided ulcerative colitis ulcerative proctitis or distal proctosigmoiditis a total of 123 patients were included of whom 114 completed the study (53 mild active distal ulcerative colitis patients with mild to moderate distal active uc patients with active ulcerative proctitis 112 patients were in remission and only 59 patients 58 patients with active, histologically confirmed ulcerative proctitis (< or = 15 cm sixty patients with active distal ulcerative colitis patients with active uc, without interference with pituitary adrenal axis twenty-nine patients with attacks of distal ulcerative colitis 116 patients with moderate attacks patients with active left-sided disease and (2 375 patients with mild-to-moderate uc 94 patients with mild to moderate distal proctosigmoiditis (less than 20 cm active left-sided ulcerative colitis seven gastroenterological departments mild-moderate distal ulcerative colitis sixty outpatients with ulcerative colitis at least 5 cm above the anal verge and not more than 50 cm, inclusive, and a total disease activity index (dai) score between 4 and 10, inclusive patients with active distal proctosigmoiditis patients with at least one post-treatment efficacy evaluation were included in the intent-to-treat analysis (n=89 foam, n=96 enema patients with active left-sided ulcerative colitis (uc thirty-four patients with ulcerative colitis patients with slightly to moderately active proctosigmoiditis patients aged over 18 years presenting with a relapse of distal ulcerative colitis 117 patients with mild attacks refractory distal ulcerative colitis
pain (visual analogue scale duration of pain relief disability duration of sick leave pain, muscular contracture and mobility cost-effectiveness ratio for pain, disability, and quality of life immediate lessening of pain pain relief effectiveness and cost-effectiveness median duration of pain clinical effectiveness and cost-effectiveness low back pain (visual analogue scale median intensity of pain|neuroreflexotherapy intervention seems to be a simple and effective treatment for rapid amelioration of pain episodes in patients with chronic low back pain. moreover, neuroreflexotherapy intervention was associated with a significantly (p < 0.035) lower number of consultations to private or public specialists, fewer indications of radiographs by primary care physicians, lower cost of drug treatment, and less duration of sick leave throughout the follow-up period. patients in the treatment group showed immediate clinically and statistically significant improvements (p < 0.0001) in pain, muscular contracture and mobility, allowing them to discontinue pharmacological treatment and keeping them free of symptoms during the study period.|patients with chronic low back pain three physicians who had no connection with the research team physicians recruited patients who had low back pain that had lasted for 14 or more days despite drug treatment and who did not meet criteria for surgery ninety-one patients with a confirmed diagnosis of nonspecific low back pain were referred for treatment from primary health care facilities in the spanish national health system 43 patients 45 patients recruited by physicians from the control group were treated according to the standard protocol, whereas the 59 patients recruited by physicians from the intervention group were, in addition, referred to non specified low back pain 78 patients with chronic low back pain twenty-one primary care physicians working in seven primary care centers of the spanish national health service in palma de mallorca, spain subacute and chronic low back pain in routine general practice exacerbations of chronic low back pain
severe post-concussion symptoms activity, assessed with the assessment of motor and process skill bi and the bicro-39 total score and self organisation and psychological wellbeing subscales difficulties with everyday activities injury severity and shorter hospital stay levels of distress activity level indices of socializing, productive employment, anxiety, or depression rate of pcs and in life satisfaction length of stay social disability social morbidity and severity of post-concussion symptoms hospital anxiety and depression scale barthel index, the functional independence measure (fim), and the newcastle independence assessment form (niaf emotional distress and how well-informed they felt about tbi and available resources spasticity changes functional independence measure (fim) (primary outcome) and neurobehavioural cognitive status examination (ncse) total scores longer hospital stay cognitive, behavioral, or quality-of-life measures ashworth scale, motor status with brunnstrom's stages, functional status with the fim instrument, and cognitive status with the mini-mental state examination maximum glasgow outcome scale (gos) score median changes on individual subscales functional independence measure (fim), brunnstrom stages of motor recovery, timed mobility tasks, and the jebson hand evaluation index of activities of daily living motor, functional, and cognitive outcomes general health questionnaire functional independence measure and the functional assessment measure (fim+fam level of depression, self-esteem, and socialization greater return-to-duty rate rivermead head injury follow up questionnaire, a validated and reliable measure of social disability spasticity barthel index (bi) and the brain injury community rehabilitation outcome-39 (bicro-39)) focused on levels of activity and participation shorter length of hospital stay maximum fim total score average length of stay socialization and self-esteem elicit ratings of post-concussion symptoms (the rivermead postconcussion symptoms questionnaire), and changes in work, relationships, leisure, social, and domestic activities (the rivermead head injury follow up questionnaire defense and veterans head injury program (dvhip|there were significantly more patients in the high intensity group than in the control group who achieved a maximum fim total score at the third month (47% vs. 19%, p = 0.015) and a maximum glasgow outcome scale (gos) score at the second (28% vs. 8%, p = 0.034) and third months (34% vs. 14%, p = 0.044). at 1-year follow-up, there was no significant difference between patients who had received the intensive in-hospital cognitive rehabilitation program vs the limited home rehabilitation program in return to employment (90% vs 94%, respectively; p=.51; difference, 4% there were no significant differences between the groups on any of the four assessments. there were no significant differences overall between the trial and control groups at follow up, but subgroup analysis of the patients with moderate or severe head injuries (posttraumatic amnesia > or = one hour, or admitted to hospital), showed that those in the early intervention group had significantly fewer difficulties with everyday activities (p = 0.03). the different intensities of therapy employed in this study showed no evidence of a 'ceiling' effect and the 'intervention group' made significantly more rapid progress on tests of dependency during the period of admission. no statistical differences were found between the intervention and control groups. two outcomes were compared at 6 months post-injury: carers' emotional distress and how well-informed they felt about tbi and available resources. the early interventions offered by a specialist service significantly reduced social morbidity and severity of post-concussion symptoms in trial group patients at six months after head injury. the treated group improved in terms of socialization and self-esteem as evidenced by a lower sickness impact profile, whereas the controls tended to get worse. improvement was greatest in those receiving intensive treatment, intermediate in those receiving conventional treatment, and least in those receiving no routine treatment. the comparison group, despite initial lower injury severity and shorter hospital stay, did not demonstrate equivalent gains or any posttreatment effect. the groups generally improved a similar amount and did not differ from each other on any symptom-related, functional, or vocational variables 3-4 months after their baseline session. intense inpatient rehabilitation services for stroke survivors provide significantly more favorable functional and cognitive outcomes with relatively low complications than did nonintense rehabilitation efforts in home settings. outreach participants were significantly more likely to show gains on the bi and the bicro-39 total score and self organisation and psychological wellbeing subscales. after controlling for confounders and case mix (as expressed by type of therapy required) patients in the experimental group showed a significant 14-day reduction in length of stay (<0.01).|1094 patients with a confirmed stroke admitted to northwick park, a district general hospital, 364 (33%) died while in hospital, 215 (20%) were fully recovered when discharged, and 329 (30%) were too frail or too ill from diseases other than stroke to be considered for active rehabilitation january 1992 through february 1997 at a us military medical referral center two district general hospitals on the south coast of england postacute stroke patients participants were 111 adults with mtbi who were recruited from consecutive admissions to two hospital emergency wards patients in a rehabilitation unit a mixed rural and urban health district with a population of about 560000 younger patients with stroke patients' posttraumatic amnesia ranged from mild (n=79, 40%), and moderate (n=62, 32%), to severe (n=38, 19%) and very severe (n=17, 9 a mixed rural and urban health district of 560000 people with two accident and emergency departments provided the setting mild traumatic brain injury (mtbi) patients by rehabilitation specialists traumatic brain injury (tbi sixty-eight patients (age 12-65 years) with moderate-to-severe tbi were included mild traumatic brain injury (mtbi after severe traumatic brain injury forty-nine stroke survivors, who were at least l yr (mean, 2.9 yr) poststroke carers of people with traumatic brain injury (tbi of 110 initially allocated, 48 outreach and 46 information participants were successfully followed up patients with traumatic brain injury (tbi home of the patient or the ordinary day rehabilitation clinic at the university hospital after brain injury fifty-eight patients (median age 53 years) consecutively discharged from inpatient rehabilitation with a first occurrence of stroke participated in training directly after discharge young adults participants were aged 16-65, had sustained severe tbi between 3 months and 20 years previously, and had no other neurological conditions traumatic brain injury patients admitted to hospital with a head injury benefit from a routinely offered early intervention service 132 trial and 86 control patients mild traumatic brain injury fifty-six people with moderate and severe head injury consecutively admitted to southampton and poole hospitals between june 1995 and september 1997 stroke survivors who received rehabilitation services in an acute inpatient rehabilitation setting (multidisciplinary rehabilitation team) with outcomes in survivors in a home-based setting (family caregivers, limited team supervision patients were under 65, primarily with stroke, but also with other conditions such as traumatic brain injury, and multiple sclerosis 1156 consecutive patients resident in oxfordshire aged between 16 and 65 years presenting over 13 months to accident and emergency departments or admitted to hospital and diagnosed as having a head injury of any severity, including those with other injuries subjects were 96 adult carers of people consecutively admitted to two local hospitals postacute stroke survivors patients who suffered several pcs and accepted rehabilitation did not recover after one year sixty patients (age range, 43-80yr) who had a stroke between 1996 and 1999 and had been referred after medical stabilization 12 patients referred direct to outpatients after stroke all patients aged 16-65 years admitted to hospital after a head injury of any severity, with or without other injuries entered the trial patients with tbi 78 patients were mainly referred to an occupational therapist mild traumatic brain injuries copyright 2001 by the american congress of rehabilitation medicine and the american academy of physical medicine and rehabilitation 1719 consecutive patients with mtbi, 395 individuals, 16-60 years of age, met the mtbi definition patients with moderate-to-severe tbi fifty-six consecutive severe head injury admissions, with an identified main caregiver, referred for rehabilitation within 4 weeks of their injury severe head injury, provided at hunters moor regional rehabilitation centre people with severe traumatic head injury 314 patients were registered: 184 one hundred twenty active-duty military personnel who had sustained a moderate-to-severe closed head injury, manifested by a glasgow coma scale score of 13 or less, or posttraumatic amnesia lasting at least 24 hours, or focal cerebral contusion or hemorrhage on computed tomography or magnetic resonance imaging
lipid, carbohydrate and coagulation profiles fasting glucose levels haemostatic indices body weight, iri and gpp mild insulin resistance sex hormone binding globulin free thyroxine levels area under the curve (auc) for glucose c-peptide and free fatty acid levels fasting and 2-hour glucose, triglycerides, total cholesterol, hdl-cholesterol, bilirubin, alkaline phosphatase, albumin, and total protein, but not aspartate aminotransferase insulin sensitivity and lipid metabolism triglyceride levels triglycerides lng/ee high-density lipoprotein cholesterol decreased and low-density lipoprotein cholesterol and triglycerides free fatty acid levels hemostatic balance, lipid metabolism and glucose tolerance mean plasma glucose levels glycosylated hemoglobin tolerated and equally efficacious regarding contraception and cycle control fasting insulin and fasting c-peptide levels blood glucose levels fasting samples and plasma samples si decreased during ocs hdl fractions concentrations of cortisol binding globulin and total cortisol carbohydrate metabolism insulin response carbohydrate metabolism and adrenal and thyroid function withdrawal bleeding episode mean aucs hemostatic measurements, lipid profile, glucose tolerance and adverse events mean levels of hba1c and fasting glucose levels percentages of normal menstrual cycles and the percentages of cycles with intermenstrual and withdrawal bleeding insulin insulin secretion hdl-cholesterol changes high-density lipoprotein (hdl)- and low-density lipoprotein (ldl)-cholesterol levels glucose response metabolic and hemostatic effects relative hyperglycemia levels of dehydroepiandrosterone sulfate oral glucose load (2-hours) levels of serum insulin, growth hormone, glucagon, cortisol and blood pyruvate antithrombin iii levels triglycerides, hdl-cholesterol and apoprotein a1 adverse events carbohydrate parameters lipid profile cholesterol and ldl-cholesterol c-peptide/insulin response blood pressure, body mass, blood glucose and serum triglycerides serum resistin levels lipids, hemostatic parameters and carbohydrate metabolism haemostasis, lipids and carbohydrate metabolism mean body weight renin substrate and hemostatic parameters total cholesterol, hdl and triglycerides carbohydrate and lipid metabolism carbohydrate metabolism (glucose, insulin, glycosylated hemoglobin); adrenal function (total cortisol, cortisol binding globulin, dehydroepiandrosterone sulfate); thyroid function (thyroid stimulating hormone, free thyroxine body weight, fasting blood glucose (gp) (bfg), serum immunoreactive insulin (iri), serum growth hormone (gh) and serum glycosylated proteins fasting glycosylated hemoglobin markers of lipid, carbohydrate and coagulation profiles high-density lipoprotein (hdl) cholesterol (p=.02) and triglycerides triglyceride and glucose concentrations ldl-cholesterol serum resistin and insulin levels carbohydrate metabolism, adrenal and thyroid function mean insulin levels response of c-peptide to glucose mean levels of fasting insulin and c-peptide lipid parameters, haemostatic parameters, sex hormone-binding globulin (shbg), cortisol-binding globulin (cbg), carbohydrate metabolism parameters, blood pressure and body weight carbohydrate metabolism, adrenal or thyroid function mean levels of fasting glucose and insulin procoagulant and profibrinolytic parameters blood glucose and c-peptide levels all blood glucose and insulin values mean blood glucose and pyruvate and in mean serum insulin, growth hormone and glucagon total insulin area free androgen and dehydroepiandrosterone sulfate levels serum resistin level body weight and blood pressure haemostasis, lipids, carbohydrate metabolism, c-reactive protein (crp) and sex hormone-binding globulin (shbg area under the curve for both glucose and insulin hemostatic activity glucose or insulin levels glucose and triglyceride change in glucose si and glucose utilization independent of insulin (sg incidence of adverse events cholesterol concentration lipid, hemostatic or carbohydrate parameters efficacy and tolerability blood pressure thyroid stimulating hormone levels insulin sensitivity (si rise in bilirubin tolerated carbohydrate metabolism and liver function glucose metabolism and liver function alkaline phosphatase enzyme serum levels si modifications glucose tolerance fasting serum glucose; insulin; triglycerides and total, low-density lipoprotein (ldl) and high-density lipoprotein (hdl) cholesterol sbp and cbg hepatic-induced parameters (shbg, cbg) and carbohydrate metabolism si mean insulin sensitivity index [isi (composite metabolism and coagulation proteins plasma cholesterol, lipoproteins including hdl subfractions, triglycerides or glucose concentration metabolic effects systolic and diastolic blood pressure or blood glucose levels total, high-density lipoprotein (hdl) and low-density lipoprotein cholesterol and triglycerides circulating levels of resistin blood glucose, serum insulin, serum growth hormone and serum glycosylated proteins si decreased with ee/dsg mean index for insulin resistance (homeostasis model assessment of insulin resistance, homa-ir adverse metabolic effects euglycemic glucose clamp test; lipid metabolism total, hdl and ldl cholesterol and sgot factor x. mean blood pressure fell apolipoprotein b levels risk of diabetes or cardiovascular disease total cholesterol and hdl cholesterol blood glucose and pyruvate, plasma insulin, and glucagon levels as well as erythrocyte insulin receptors total cholesterol lng-oc decreased hdl(2)-c and increased hdl(3)-c; hdl-c cycle control carbohydrate metabolism and its hormonal profile total cholesterol, hdl-cholesterol, ldl-cholesterol, vldl-cholesterol, and triglycerides basal insulin resistance (homa-ir change from baseline to cycle 6 for all indices hemostatic balance, blood lipid levels and carbohydrate metabolism body weight, dietary habits, blood pressure, hdl-cholesterol or carbohydrate metabolism mean  sd ldl cholesterol fasting blood glucose fasting glucose and insulin levels metabolic and haemostatic parameters crp pancreatic beta-cell function hemoglobin, hematocrit and total protein levels but alkaline phosphatase, bilirubin and aspartate transaminase (sgot mean  sd hdl cholesterol oral glucose tolerance test (ogtt insulin sensitivity index (is(ogtt shbg increased 3-fold with dsg-oc coagulatory activity antithrombin iii, total and free protein s and fibrinogen fasting blood glucose levels 2-hour blood glucose and pyruvate, serum insulin, growth hormone and glucagon mean glucose, insulin and log homeostatic model assessment coagulation factor vii and fibrinogen serum triglycerides bfg ldl cholesterol fasting blood glucose and pyruvate and serum insulin hdl-cholesterol glucose and increased insulin responses glucose and insulin parameters fasting glucose and insulin levels and in glucose rate of disappearance hdl/low-density lipoprotein cholesterol changes in other lipid, hemostatic and carbohydrate parameters lipid markers glucose tolerance and insulin resistance ldl-c serum cholesterol levels lipid and biochemical changes fasting plasma glucose values mean intraindividual relative changes from baseline to cycle 7 in high-density lipoprotein (hdl) and low-density lipoprotein (ldl) cholesterol levels serum glucose levels levels of fibrinogen, plasminogen, factor vii, factor x and antithrombin iii metabolic and haemostatic effects atherogenic index, ldl/hdl cholesterol vldl-c and triglycerides plasma total cholesterol, ldl-cholesterol, ldl/hdl-cholesterol ratio and triglyceride concentration dsg-oc increased hdl-c, hdl(2)-c and hdl(3)-c; ldl-c shbg lipid metabolism mean  sd prothrombin fragment 1 + 2 and d-dimer levels apoprotein a1 (apo-a1 number of abnormal parameters renin substrate body mass a(1)c levels glucose tolerance and insulin secretion hemostatic and metabolic effects basal hormonal, metabolic and lipid levels fibrinolytic activity total cholesterol, hdl-cholesterol, and vldl-cholesterol|thyroid stimulating hormone levels increased significantly more in the ring group at cycle 3 (p = 0.0016) but free thyroxine levels were unchanged in both groups. overall there were no statistically significant differences among the three formulations in their effects on carbohydrate metabolism as measured by glucose or insulin levels after 6 months of treatment. both ocs caused a small but statistically significant increase in plasma total cholesterol, ldl-cholesterol, ldl/hdl-cholesterol ratio and triglyceride concentration. most mean changes from baseline laboratory values were comparable between groups, although the mean increase in cholesterol concentration was statistically significantly lower in the levonorgestrel with ethinyl estradiol group. with regard to liver function, both preparations induced a rise in bilirubin, a decrease in alkaline phosphatase, and no change in enzyme serum levels. fasting blood glucose at cycle 13 was significantly (p < 0.01) higher for both treatment groups compared to baseline. marvelon and triquilar users showed rises in triglyceride levels while microgynon 30 users had no change after one year of treatment. at the end of 6 months, there were no significant differences between the two groups with respect to plasma cholesterol, lipoproteins including hdl subfractions, triglycerides or glucose concentration. the mean levels of fasting insulin and c-peptide underwent comparable increases in both regimens, suggesting a similar readjustment of glucose metabolism via slightly increased insulin secretion. mean  sd prothrombin fragment 1 + 2 and d-dimer levels remained essentially unchanged in the e(2)v/dng group (-0.6%  30.3% and -2.1%  43.5%, respectively), but increased in the ee/lng group (by 117.3%  358.0% and 62.9%  99.5%, respectively). at the end of treatment, no difference was found within or between groups in fasting glucose and insulin levels and in glucose rate of disappearance. both groups had no change in hemoglobin, hematocrit and total protein levels but alkaline phosphatase, bilirubin and aspartate transaminase (sgot) were suppressed. the insulin response, measured in 48 treated and eight control subjects, also increased over 12 months in both treated groups, but the total insulin area was within the range of the reference laboratory. lng-oc decreased hdl(2)-c and increased hdl(3)-c; hdl-c was unchanged and ldl-c decreased transiently. no statistically significant differences were found between the two contraceptive regimens with respect to carbohydrate or lipid profiles or in the parameters related to coagulation. we found that serum resistin level remained unchanged in women receiving ethinylestradiol/desogestrel and was reduced in women treated with formulations containing gestodene. free fatty acid levels decreased by 42% in the drospirenone group and increased by 48.9% in the desogestrel group, in terms of means of individual changes. although slightly elevated in both groups, blood glucose and c-peptide levels measured during oral glucose tolerance tests were within normal reference ranges at cycle 7. there was a significant increase in bfg during the study and the values were still rising, when examined 2 months after discontinuation of the pill. dmpa and net-en caused significant changes in mean blood glucose and pyruvate and in mean serum insulin, growth hormone and glucagon, but not in mean fasting cortisol. triglycerides increased during both oral (p=.01) and vaginal (p=.032) contraceptive use. the monophasic coc nomac/e2 had less influence on haemostasis, lipids and carbohydrate metabolism than the coc lng/ee. high-density lipoprotein (hdl) cholesterol (p=.02) and triglycerides (p=.02 and p=.01) increased in both groups, but hdl/low-density lipoprotein cholesterol (p=.02), apoprotein a1 (apo-a1) (p=.04) and apo-a1/apoprotein b (p=.048) increased significantly only with ee/cma. the lower-dose, nonoral hormonal ring had a lesser impact on carbohydrate metabolism and greater reduction of free androgen and dehydroepiandrosterone sulfate levels than pill treatment. there was a small but statistically significant increase in body mass after 1 year in the group taking levonorgestrel 15 microgram and ethinyloestradiol 30 microgram (p < 0,02), but not in the other group, although the mass in this group was significantly increased after 3 months of therapy. the glucose-induced suppression of plasma glucagon levels seemed less effective for treatment with the desogestrel-containing preparations than with the levonorgestrel-containing oral contraceptives. hemostatic activity was increased in both groups but a counteracting increase in fibrinolytic activity occurred together with an increase in coagulatory activity. there was a significant increase in the area under the curve for both glucose and insulin during ogtt within each group with increasing duration of use. in both groups, there was a significant increase in triglycerides, hdl-cholesterol and apoprotein a1; the same increase was observed for sbp and cbg. obesity had little effect on any oc-induced changes in carbohydrate or lipid metabolism except for a borderline adverse interaction between obesity and oc dose with respect to fasting glucose and a positive interaction between obesity and oc use with respect to ldl cholesterol. both pills induced changes in fasting and 2-hour glucose, triglycerides, total cholesterol, hdl-cholesterol, bilirubin, alkaline phosphatase, albumin, and total protein, but not aspartate aminotransferase.|subjects were healthy lean young women, needing a hormonal contraceptive ethnic chinese women are presented healthy women aged 18-40 years seven who collaborating centres for research in human reproduction women who used oral contraceptives containing 78 participants (mean age 27.8 years 60 women, before and after 6 months of treatment 38 normal women before and after 6 months' use of one of three new a total of 847 subjects germany over seven cycles, healthy women aged 18-50 years received women taking combined oral contraceptives containing thirteen patients received 121 healthy women, 18-50 years of age forty-two women completed the study women 167 women for 1 to 4 cycles of treatment twenty-eight young healthy women 155 healthy women forty-nine women participated healthy women one hundred thirty women normal-weight women 195 women using an iud served as a comparison group sixty-five women fifty-seven women chinese women 66 healthy women using phasic formulations of ocs containing either dsg (dsg-oc) or lng (lng-oc 59 women treated with 357 volunteers from four centers (hangzhou, havana, jakarta, and shanghai 124 healthy women 71 normal-weight and 38 obese women initiating the oc fifty-three women were enrolled in the study thirty-six women singaporean women
passage of flatus or stool and tolerating solid food gastric emptying, small-bowel, and colonic transit laxation and reverse slowing of oral cecal-transit time nausea, vomiting, and constipation maximum concentration or area under the concentration curve small-bowel and colon transit morphine-induced subjective rating changes transit time and the drug plasma concentration pain intensity and pain bothersomeness ratings morphine-induced delay in oral-cecal transit time average time to first bowel movement gastrointestinal motility and transit without affecting analgesia incidence of gastritis and esophagitis composite of time to recovery of upper and lower gi function delayed gastrointestinal transit risk of vomiting and pulmonary aspiration proportion of patients having at least one bowel movement (bm median time until patients were ready for discharge average (sd) change morphine analgesia and pupil constriction overall colonic transit intestinal hypomotility maximum concentrations and area under the concentration curve gastric reflux complete reversal of analgesia frequency of gastritis and esophagitis rate of gastric emptying bm adverse events gi recovery median times to first bm morbidity and extend hospitalization small bowel transit time (sbtt) measured by the lactulose/hydrogen breath test, pain scores and the occurrence of adverse events pain relief colonic transit duodenogastral reflux intestinal transit gastral reflux efficacy stool frequency and symptoms related to constipation colonic transit were geometric center of the colonic counts at 24 hours and time for 50% ascending colon emptying pain estimation by visual analogue scale mean time to gastrointestinal recovery urgency to defecate gastrointestinal transit constipation and analgesia bowel motility and increased transit time recovery of gastrointestinal (gi) function postoperative ileus (poi tolerated analgesia and pupil constriction exhaled h2 concentration gastric tube reflux, the frequency of pneumonia, and the time until first defecation frequent bowel movement and better bowel movement quality gastrointestinal motility and transit, without affecting analgesia mean time to the hospital discharge order written gastric, small-bowel, and colonic transit time esophageal or gastral mucosal injuries nausea, vomiting, and hypotension; the incidence of nausea and vomiting oral-cecal transit times analgesic effect gi recovery and time to hospital discharge resting or active vas small bowel and colon (ascending colon and overall colonic transit accelerated time to gi-2 recovery of gastrointestinal function analgesia laxation response, oral-cecal transit time, and central opioid withdrawal symptoms time to gastrointestinal (gi) recovery (measured by toleration of solid food and passage of flatus/stool; gi-3 bowel motility and analgesia time to first bowel movement time to the hospital discharge order written time to gi-2 recovery (toleration of solid food and passage of stool) and hospital discharge order written (dco time to hospital discharge order written reversal of analgesia gastrointestinal recovery median time to the first passage of flatus antagonistic effect shorter time to the first postoperative passage of flatus return of pain transit time hospital stay, contribute to readmission, and increase morbidity plasma concentrations median gastric tube reflux volume median time to the first bowel movement laxative effects fentanyl requirements serum acetaminophen concentrations safety and efficacy laxation response restoration of bowel function, and visual analog scales (vas) for pain during rest and movement side effects pain score time until first defecation, ventilation time, and length of intensive care unit stay postoperative pain relief gastrointestinal motility whole-gut transit time gastrointestinal transit time (lactulose hydrogen breath test mean whole-gut transit time mean colonic geometric center gastric tube reflux and frequency of pneumonia marked laxative effect codeine delayed gastric, small-bowel, proximal, and overall colonic transit frequency of pneumonia bowel frequency gi motility time to recovery of gi function time to return of gastrointestinal function oral-cecal transit time pain scores gastric emptying gastrointestinal transit time weekly bms and overall patient satisfaction adverse effects volume of enteral feeding|no difference in maximum concentration or area under the concentration curve from 0 to 90 min was noted between placebo and methylnaltrexone coadministered with morphine. median gastric tube reflux volume (54 vs. 129 ml, p =.03) and frequency of pneumonia (34% vs. 56%, p =.04) were significantly lower in the naloxone group. naloxone, both alone and with codeine, significantly shortened the mean whole-gut transit time compared with the control period, respectively, from 53.1 to 42.1 h (p=0.005) and to 40.7 h (p=0.024). delayed gastrointestinal transit after nalbuphine is explained by agonist-like effects on peripheral opioid receptors in the gut. alvimopan accelerated gi recovery and time to hospital discharge order written compared with placebo in patients undergoing laparotomy and was well tolerated. oral methylnaltrexone (19.2 mg/kg) completely prevented morphine-induced increase in oral-cecal transit time (110.4 +/- low doses of intravenous naloxone reduce morphine-induced pruritus without reversing analgesia, but the effect of epidural naloxone on bowel motility has not been studied. the median time to the first passage of flatus decreased from 70 to 49 hours (p=0.03), the median time to the first bowel movement decreased from 111 to 70 hours (p=0.01), and the median time until patients were ready for discharge decreased from 91 to 68 hours (p=0.03). no significant difference between placebo and naloxone occurred in the 14 remaining patients receiving total daily doses of naloxone 10% or less of the 24 h dose of morphine. methylnaltrexone did not affect the analgesic effect of morphine on both pain intensity and pain bothersomeness ratings. all the patients who received oral naloxone had some improvement in their bowel frequency. after 0.1 mg/kg subcutaneous methylnaltrexone plus morphine, the transit time reduced to 110 +/- alvimopan significantly accelerated the time to first bowel movement (hazard ratio, 2.33; p <.001). morphine analgesia and pupil constriction were unaffected by adl 8-2698 and differed from placebo (p < .002). no opioid withdrawal was observed in any subject, and no significant adverse effects were reported by the subjects during the study. morphine significantly increased oral-cecal transit time from baseline level of 96.7 +/- mean time to the hospital discharge order written was significantly accelerated in patients treated with alvimopan 6 mg (hazard ratio = 1.50; p < 0.001). weekly bms and overall patient satisfaction were increased after the 1-mg dose (p < .001 at weeks 1 and 2 vs placebo, and p = .046, respectively). in the naloxone group, gastral reflux as well as need for propulsive medication were significantly lower. codeine delayed gastric, small-bowel, proximal, and overall colonic transit (p < .05). alvimopan also significantly accelerated time to gi-2|11 healthy volunteers human volunteers patients undergoing partial colectomy or simple or radical hysterectomy 26 patients in each of the three groups; all received 79 patients--including 1 whose surgery was patients undergoing major abdominal surgery patients undergoing laparotomy for bowel resection or radical hysterectomy 14 healthy volunteers forty-three patients having combined thoracic epidural and general anesthesia for subtotal gastrectomy twenty-two subjects (9 men and 13 women; mean [sd] age, 43.2 [5.5] years) enrolled in a methadone maintenance program and having methadone-induced constipation seventy-four healthy participants (43 women 14 volunteers with oral and intravenous 168 patients with opioid-induced bowel dysfunction (obd) who were receiving chronic opioid therapy (minimum, 1 month) for nonmalignant pain (n = 148) or opioid dependence (n = 20 healthy volunteers patients undergoing open laparotomy (bowel resection, n = 418; hysterectomy, n = 197 women (n = 519 postoperative ileus after major abdominal surgery oral-cecal transit time without affecting analgesia nine patients were recruited for the study 510 patients scheduled for bowel resection or radical hysterectomy 469 patients (451 bowel resection and 18 radical hysterectomy patients fifteen patients underwent 45 patients may 1997 and december 1998 patients taking stable doses of opioids with complaints of constipation critical care patients during opioid analgesia patients who require long-term opioid administration, such as patients with advanced cancer eighty-four mechanically ventilated, fentanyl-treated patients without gastrointestinal surgery or diseases seventeen patients entered the first phase of the study patients who undergo simple total abdominal hysterectomy women who undergo simple total abdominal hysterectomy university hospital intensive care unit patients with far-advanced cancer humans treated patients without gastrointestinal surgery or diseases in four sets of studies; 12 male volunteers ventilated patients mechanically ventilated patients with fentanyl analgesia patients undergoing open laparotomy mechanically ventilated patients volunteers taking codeine twelve healthy volunteers patients with advanced cancer
risk of pneumothorax mean total duration of oxygen therapy length of stay or the duration of oxygen treatment incidence of pulmonary air-leak mortality, requirement for mechanical ventilation, or incidence of pulmonary sequelae outcome of hmd mean levels overall survival rate death, length of nursery stay, time receiving oxygen therapy, cost of care, and other measures of morbidity pneumothorax mortality, cranial ultrasound abnormalities, and pneumothoraces chronic lung disease of prematurity up-transfer or treatment failure mechanical ventilation morbidity or death mortality, respiratory outcome, the presence of cerebral ultrasound abnormalities, patent arterial duct, necrotizing enterocolitis, and retinopathy mortality and complication rates neonatal survival rate oxygenation total duration of oxygen therapy|there was no significant difference between treatment and control groups in mortality, requirement for mechanical ventilation, or incidence of pulmonary sequelae. hudson prong bubble continuous positive airway pressure therapy reduces the need for up-transfer of infants with respiratory distress in nontertiary centers. secondary analysis showed that the use of cnep was associated with an increase in mortality, cranial ultrasound abnormalities, and pneumothoraces, which were not statistically significant. 11 out of 12 infants in the cip-treated group and 10 out of 12 in the control group survived.|infants with severe hyaline membrane disease were admitted who did not meet the criteria for entry to the trial neonatal respiratory failure 14 infants in the continuous positive airway pressure group and 5 in the headbox group patients were admitted to the study if the po2 was less than 50 mm hg with fio2 greater than 0.6 matched pairs of infants infants with respiratory distress in nontertiary centers hyaline membrane disease infants with respiratory distress in non tertiary care centers 300 infants at >30 weeks of gestation with respiratory distress to receive either severe hyaline membrane disease (hmd two hundred forty-four patients (birth weight 1.53 infants with respiratory distress from nontertiary centers sd); gestational age 30.4 neonates with respiratory failure patients requiring mechanical ventilation for apnea or hypercapnia (pco2 greater than 65 mm hg 151 infants who received continuous positive airway pressure therapy, 35 either were up-transferred or experienced treatment failure, as did 60 of the 149 infants given infants with severe hyaline membrane disease who weighed more than 1000 g at birth
problem solving skills task-specific self-awareness, general self-awareness or community integration iadl performances and self-regulation ciq (effect size [es]=0.59) and pqol productivity verbal and visual memory functions global cognitive functioning subjects' cognitive functioning neuropsychological wm-test results community functioning and quality of life rbans total score cognitive functions neuropsychological status (rbans) and trail-making, controlled oral word association, wechsler adult intelligence scale-iii similarities, and stroop tests neuropsychological wm-demanding tests, rated occupational performance, satisfaction with performance and rated overall health individuals' problem-solving skills and self-efficacy community integration questionnaire (ciq) and perceived quality of life scale (pqol cognitive, behavioral, or quality-of-life measures computerized version of the paced auditory serial addition task (pasat) and two computerized matching tasks executive functioning trained wm tasks change in rbans delayed memory score assessment of motor and process skills (amps sustained moderate or severe tbi standardized measures of 'general' self-awareness with collateral reports by informants (e.g. awareness questionnaire); 'task-specific' self-awareness (e.g. assessment of awareness of disability) and self-regulation skills inventory (srsi level of awareness self-efficacy greater return-to-duty rate np functioning, perceived self-efficacy, and community-based employment self-awareness np functioning self-awareness during iadl task performance performance in neuropsychological tests assessing memory and executive functions wisconsin card sorting test (wcst) performance self-awareness of deficits interview (sadi), the functional independence measure (fim) and the lawton instrumental activities of daily living score (lawton iadl wm and attention symptoms of cognitive problems daily life functioning role resumption list (rrl), and two other follow-up measures, the treatment goal attainment (tga) and the executive secretarial task (est), were indications of daily life executive functioning change in rbans total score meal preparation performance defense and veterans head injury program (dvhip wcst performance rated quality-of-life cognitive outcome external inhibition, increased stimulus salience|external inhibition of learned rules reduced perseverative errors, while increased stimuli salience reduced random errors, committed by patients with abi. at 1-year follow-up, there was no significant difference between patients who had received the intensive in-hospital cognitive rehabilitation program vs the limited home rehabilitation program in return to employment (90% vs 94%, respectively; p=.51; difference, 4% the associated difficulties with problem solving (including specific impairments in planning, initiation/plan-implementation and self-monitoring) represent a major challenge to functional recovery and adaptation following brain injury and serve as an important target for rehabilitation. we found a difference among the 3 treatment groups in change in rbans total score (p < .01) and rbans delayed memory score (p < .01). weekly measures included a computerized version of the paced auditory serial addition task (pasat) and two computerized matching tasks. the training program was demonstrated to have a significantly greater effect than the conventional training approach on metacomponential functioning and the component of problem representation. intensive cognitive rehabilitation participants showed greater improvements on the ciq (effect size [es]=0.59) and pqol (es=0.30) as well as improved self-efficacy for the management of symptoms (es=0.26) compared with standard neurorehabilitation treatment. after aip training, the participants in the experimental group demonstrated significant improvement in their level of awareness as compared to the control group. the experimental group improved significantly more over time than the controls on the rrl and attained significantly higher scores on the tga and est. gmt, but not motor skills training, was associated with significant gains on everyday paper-and-pencil tasks designed to mimic tasks that are problematic for patients with goal neglect. the continuous "human touch" characteristics of the therapist-administered group showed significant better improvements in self-efficacy in problem-solving. the training probably has an impact on the rehabilitation outcome, returning to work, as well as on daily activities for individuals with verified wm impairments. no significant treatment effect was observed for task-specific self-awareness, general self-awareness or community integration. there was a significant decrease in symptoms of cognitive problems as measured by the cfq (p < 0.005).|persons with abi adults with acquired brain injuries (abi january 1992 through february 1997 at a us military medical referral center outpatients with acquired brain injury persons with traumatic brain injury traumatic brain injury (tbi seventy-five abi patients sixty-eight participants who met inclusion criteria postacute brain injury rehabilitation center within a suburban rehabilitation hospital patients with brain damage 24 patients with abi patients with traumatic brain injury (tbi a consecutive sample of 21 subjects young adults traumatic brain injury people with traumatic brain injury group; 18 participants (12 males) in a vocational age group (mean age 54 years people with traumatic brain injury (tbi adult patients with stroke participants with abi patients with acquired brain injury (abi individuals with verified wm impairments people with acquired brain injury (abi patients suffering from acquired brain injury 10 participants with moderate-to-severe brain injury received new york city metropolitan area patients with acquired brain injury 33 outpatients with moderate acquired brain injury, in the hong kong context 103 persons with acquired brain injury participants with acquired brain injury on levels of self-awareness and functional performance 15 participants who had suffered a closed traumatic brain injury carried out the everyday descriptions task (dritschel, b. (1991 patients suffering from working memory deficits after acquired brain injury after traumatic brain injury twenty-one patients with traumatic brain injury patients with tbi persons with acquired brain injury n = 43) with thirty adults with abi were matched according to severity of injury, gender, age, and time post-injury, and randomly assigned to the remedial or compensatory group patients with moderate-to-severe tbi one hundred twenty-nine patients executive dysfunction after acquired brain injury on indications of executive functioning in daily life participants with tbi were recruited from clinical referrals and referrals from the community one hundred twenty active-duty military personnel who had sustained a moderate-to-severe closed head injury, manifested by a glasgow coma scale score of 13 or less, or posttraumatic amnesia lasting at least 24 hours, or focal cerebral contusion or hemorrhage on computed tomography or magnetic resonance imaging adults with acquired brain injuries
likelihood of graft survival risk of early occlusion incidence of thrombosis thrombi six major bleeds frequency of side effects relative risk of thrombosis cumulative thrombosis rates overall rate of occlusion survival analysis rate of thrombosis venous outflow resistance and systemic bp actuarial analysis of type vascular perturbations underlying synthetic graft thrombosis risk of thrombosis time to graft failure ptfe graft survival primary patency rates rate of thrombosis of expanded polytetrafluoroethylene (eptfe) grafts|the antiplatelet drug ticlopidine was assessed as an agent for improving the patency of brescia-cimino arteriovenous fistulas as access for hemodialysis. survival analysis revealed a significant difference between fish oil-treated and untreated patients (p < 0.03, mantel-cox test), with a power of 90%. the time-to-event analysis revealed no significant difference in the likelihood of graft survival between the two groups (odds ratio, 1.76 in favor of placebo; 95% confidence interval, 0.72 to 4.34). this effect was achieved without an increased frequency of side effects compared with placebo. the relative risk of thrombosis with dipyridamole was 0.35 the incidence of thrombosis was reduced from 0.46 thrombi per patient month in the placebo group to 0.16 thrombi per patient month in the aspirin group (p less than 0.005). limited risk factor analysis did not clearly identify any subgroup other than females at greater risk of early thrombosis nor any subgroup deriving particular benefit from ticlopidine treatment.|patients with esrd and newly placed ptfe grafts were studied at community and academic dialysis centers in southwestern ontario 24 patients with thrombi and both groups had been under observation for a mean of nearly five months 44 patients on chronic hemodialysis patients with prior thrombosis of eptfe grafts graft thrombosis twenty-four patients chronic uremic patients arteriovenous fistulas for haemodialysis arteriovenous fistulas for hemodialysis one hundred and seven patients were followed for 18 months or until the first thrombotic episode patients with new eptfe grafts hd patients patients with esrd av-fistula surgery in uremia patients with end-stage renal disease (esrd chronic renal failure patients 42 patients were recruited and 36 completed the trial patients on hemodialysis patients on hemodialysis by low-dose 107 patients (56 allocated to two hundred and fifty-eight patients with uremia who were offered surgery for placement of an arteriovenous fistula for hemodialysis were recruited in nine regional dialysis centers chronic uremic patients up to 4 weeks after construction of an arteriovenous fistula
efficacy and safety unfavorable response determination of the lowest stable methylprednisolone dose and assessment of corticosteroid side effects methacholine response forced expiratory volume in 1 second and pulmonary function methylprednisolone clearance blood chemistry and hematology, adrenal function assessment; bone densitometry, and muscle strength testing elevated liver enzyme levels symptom scores, blood chemistries, pulmonary function tests, airway response to methacholine, and glucocorticoid pharmacokinetics corticosteroid side effects glucocorticoid pharmacokinetics and airway hyperresponsiveness mpn clearance serum igg, fasting blood sugar, serum cholesterol, and progression of osteoporosis bronchial hyperresponsiveness|differences were observed between the two treatment groups in serum igg, fasting blood sugar, serum cholesterol, and progression of osteoporosis. troleandomycin decreased mpn clearance by an average of 62% but did not alter prednisolone clearance. two patients who received tao had elevated liver enzyme levels; one required discontinuation of tao and one experienced spontaneous resolution without intervention.|asthmatic subjects who require daily corticosteroids 75 subjects with asthma requiring daily corticosteroids for control 18 children with severe, steroid-requiring asthma patients who are unable to tolerate tapering of their glucocorticoid dosage children with severe, steroid-requiring asthma fifteen hospitalized asthmatic children (8 to 18 years old 30 patients receiving tao and 27 patients receiving placebo completed 1 yr; 17 on tao and 8 on placebo completed 2 yr of double-blind participation severely asthmatic children
rates of intraoperative events eleven intraoperative complications systemic adverse event ophthalmologic and systemic complications incidence of ophthalmologic and systemic complications cumulative rate of medical events medical tests (electrocardiography, complete blood count, and measurement of serum levels of electrolytes, urea nitrogen, creatinine, and glucose rate of complications overall rate of complications systemic adverse events hypertension and arrhythmia (principally bradycardia postoperative events|systemic adverse events occurred intraoperatively in four patients, whereas no systemic adverse event was recorded at 1 month in either group. there were also no significant differences between the no-testing group and the testing group in the rates of intraoperative events (19.2 and 19.7, respectively, per 1000 operations) and postoperative events (12.6 and 12.1 per 1000 operations). the cumulative rate of medical events was similar in the two groups, 9.6% in the routine-testing group and 9.7% in the selective-testing group (p = 0.923).|scheduled cataract operations patients who undergo cataract surgery without preoperative tests compared to subjects undergoing cataract surgery preceded by preoperative tests 9408 patients who underwent 9626 cataract operations that were not preceded by routine testing and in 9411 patients who underwent 9624 operations that were preceded by routine testing cataract surgery adults patients scheduled to undergo cataract surgery 18,189 patients at nine centers to be preceded or not preceded by a standard battery of 1276 consecutive patients admitted to the institute of ophthalmology of the university of modena and reggio emilia for cataract surgery academic medical center in brazil, between 10 february 2000 and 10 january 2001 1,025 patients scheduled to undergo cataract surgery was comprised of 512 assigned to the routine-testing group and of 513 assigned to the selective-testing group
basal and rhtsh-stimulated serum thyroglobulin safe and effective and avoids hypothyroidism mbq rate of radiation clearance from blood, thyroid remnant, and whole body remnant cumulated activity per unit administered activity serum thyroglobulin concentration less short form-36 health assessment scale scores tsh, tg and tgab successful thyroid ablation rate billewicz scale levels of thyroid stimulating hormone (tsh tsh serum level successful ablation ablation rate remnant ablation rates quality of life small thyroid remnants|successful ablation (no visible uptake in the diagnostic whole-body scan after rhtsh stimulation) was achieved in 88.9% of group a and b patients. euthyroid patients had a statistically significant one third lower radiation dose to the blood, compared with patients in the hypothyroid group. at follow-up, 90.0% of patients from group a and 85.0% of patients from group b had tg levels <1 ng/ml; no uptake was observed in 95.2% and in 90.5% of patients from group a or b respectively, with no statistical differences for both ablation criteria. the rh-tsh pre-treated patients seem to have a lower uptake compared to those in hypothyroidism induced by l-t4 withdrawal.|differentiated thyroid carcinoma thyroid cancer patients euthyroid patients on l-thyroxine therapy (euthyroid group) to ablate remnant thyroid tissue with 3.7 gbq (100 mci) 131i, compared with that with conventional remnant ablation performed in the hypothyroid state (hypothyroid group forty-six dtc patients, submitted to i ablative therapy 1850 mbq (131)i had a similar successful rate to 3700 mbq in patients prepared with rhtsh low-risk patients 72 patients with dtc thyroid cancer differentiated thyroid cancer (dtc) patients showed that 3700 mbq 131-iodine ((131)i) after differentiated thyroid cancer patients prepared for 131i remnant ablation with 3.7 gbq by either administering rhtsh or withholding thyroid hormone 14 hypothyroid patients
adverse drug effects left ventricular function left atrium pharmacological restoration of sinus rhythm symptoms related to atrial fibrillation majority of strokes walking distance overall mortality survival advantage quality of life incidence of hospital admission|walking distance in a 6 min walk test was better in group b compared with group a, but assessment of quality of life showed no differences between groups. of the 3311 patients with echocardiograms, the left atrium was enlarged in 64.7 percent and left ventricular function was depressed in 26.0 percent.|patients with atrial fibrillation and a high risk of stroke or death patients with atrial fibrillation 4060 patients (mean [+/-sd] age, 69.7+/-9.0 years) were enrolled in the study 252 patients with atrial fibrillation of between 7 days and 360 days duration, which compared rate (group a, 125 patients) with rhythm control (group b, 127 patients 3311 patients with echocardiograms massachusetts medical society 70.8 percent had a history of hypertension, and 38.2 percent had coronary artery disease atrial fibrillation (piaf
composite clearance rates (clinical and histological assessments) and histological clearance rates histological clearance pathologic response increasing severity of erythema, erosion, and scabbing/crusting partial response (pr response rate, tolerance, and patient compliance total operative costs of mms complete response (cr clinical complete response rate tumor-free rates clearance rates safety and clinical efficacy recurrence rates safety, tolerance, and efficacy cure rate complete response rate safety and efficacy composite clearance rates lesion clearance clinical efficacy cosmesis and lesion recurrence failure rate (persistent or recurrent disease initial inflammatory response noduloulcerative and superficial lesions basal cell carcinomas (bccs complete response rate based on histologic assessment serious adverse events cost and safety rates of recurrence of facial basal-cell carcinoma complete response rates response rates efficacy systemic adverse events highest clearance rate efficacy and safety histologic clearance cure of lesions response rate composite clearance composite response rates (proportion of subjects with clinical and histological clearance) and response rates solely based on histology (proportion of subjects with histological clearance recurrence of carcinoma good cosmetic outcome cure rates highest histologically complete response rate adverse events and scoring of local skin reactions (lsrs 4-year actuarial failure rate histological clearance rates basal cell carcinoma (bcc cosmetic outcome clinical and cosmetic responses size of lesions sustained response rate at 12 months and cosmetic outcome local skin reactions adverse events|imiquimod 5% cream has been investigated for non-surgical treatment of superficial and nodular basal cell carcinoma (bcc) tumours. a complete response was achieved in 95 lesions (86%) in the laser group and 110 lesions (82%) in the bl group 6 months after treatment. the 4-year actuarial failure rate (95% ci) was 0.7% (0.1-3.9%) in the surgery group compared with 7.5% (4.2-13.1%) in the radiotherapy group (log-rank p = 0.003). a sustained-release protamine zinc preparation of interferon alfa-2b shows promise as a practical, effective, and cosmetically elegant treatment for basal cell carcinoma. overall, 65% (95% confidence interval, 58%-71%) of tumors were judged to have good to excellent cosmesis at 24 months. there was a 90% cure rate (9/10) in those lesions treated with 5% 5-fu in pc cream and a 57% cure rate (4/7) in those treated with 5% 5-fu in a petrolatum-based cream. two years after treatment, 4% of tumours treated with radiotherapy and 39% of those treated with cryotherapy had recurred. no clinically significant treatment-related systemic adverse events occurred. total operative costs of mms were higher than those of se (primary 405.79 euros vs 216.86 euros, recurrent 489.06 euros vs 323.49 euros; both p<0.001). more patients treated with methyl aminolevulinate pdt than surgery had an excellent or good cosmetic outcome at all time points (significant at 12 and 24 months on patient assessment, p<.05, and at 3, 12, and 24 months on investigator evaluation, p<.001). histological clearance was demonstrated in 80% and 6% of subjects treated with imiquimod and vehicle cream, respectively. side effects of treatment, mainly flu-like symptoms, were usually mild and transient and occurred more commonly in the interferon-treated group. histological clearance rates for the 5 and 7x/week imiquimod groups were 82% and 79%, respectively. complete response rates were 100% (10/10), 87.1% (27/31), 80.8% (21/26), and 51.7% (15/29) for patients in the twice daily, once daily, 5 times a week, and 3 times a week imiquimod groups, respectively, and 18.8% (6/32) in the vehicle group. interferons (ifn), especially alfa-2a and 2b, are potent inhibitors of normal and malignant cell growth and effective choices in the treatment of basal cell carcinoma (bcc). bcc cleared (on the basis of histologic examination) in all 15 patients (100%) dosed twice daily, once daily, and 3 times weekly; in 3 of 5 (60%) patients dosed twice weekly; 2 of 4 (50%) dosed once weekly; and in 1 of 11 (9%) treated with vehicle. topical 5% imiquimod cream is well tolerated and most effective in treating nodular bcc when applied once daily for 7 days per week for either 12 or 6 weeks. intention-to-treat analysis revealed 100% (3/3) histologic clearance in the twice-daily regimen, 87.9% (29/33) clearance in the once every day regimen, 73.3% (22/30) clearance in the twice-daily 3 times/week regimen, and 69.7% (23/33) clearance in the once-daily 3 times/week regimen.|superficial basal cell carcinoma (sbcc patients were at least 18 years old and had a biopsy-confirmed diagnosis of nodular bcc 173 patients in the 408 primary and 204 recurrent facial carcinomas (374 and 191 patients, respectively basal cell carcinoma 122 patients with biopsy-proven bccs 174 patients in the surgery group, 71% had local anaesthesia and 91% frozen section examination university dermatology departments 101 adults with previously untreated nodular bcc multiple nonmelanoma skin cancers 65 basal cell carcinomas superficial basal cell carcinoma primary bcc of the face measuring less than 4 cm 397 primary (198 mms, 199 se) and 201 recurrent (99, 102) tumours were actually treated patients with multiple synchronous nonmelanoma skin cancers patients with multiple nonmelanoma skin cancers 166 subjects were enrolled in this study 45 patients with histopathologically confirmed bcc thirteen patients with 17 biopsy-proven, moderate thickness bccs basal cell carcinomas (bccs 83 patients with 245 superficial bcc patients diagnosed with bcc were enrolled into either the superficial (93 patients) or nodular (90 patients) study, depending on the histological confirmation of the patient's tumour subtype thirteen patients with a noncomplete response to pdt at 3 months (24% lesions) were retreated subjects with one sbcc superficial and nodular basal cell carcinoma (bcc) tumours each 204 primary, 102 recurrent), and received treatment at two hospitals in the netherlands twenty-four public and private dermatology clinics in australia and new zealand (6-week study) and the united states (12-week study) participated basal-cell carcinomas was carried out in 93 patients 26 centres in europe 347 patients were treated primary nodular basal cell carcinoma (bcc 4 north american university-based dermatology clinics patients with bccs nodular basal cell carcinoma 97 patients (105 lesions superficial and nodular basal cell carcinoma 35 patients with bcc, 24 received nodular basal cell carcinoma (bcc fifty-four patients with 421 multiple nonmelanoma skin cancers including superficial and nodular basal cell carcinoma and squamous cell carcinoma in situ (bowen disease basal cell carcinomas superficial basal cell carcinomas (bcc 172 patients at four medical centers 99 patients enrolled in the 6-week study and 92 patients in the 12-week study ninety-nine patients 66 primary and 13 recurrent carcinomas patients with noduloulcerative or superficial basal cell carcinomas subjects who had at least one histologically confirmed sbcc tumour basal cell carcinoma of the face
reduction in deaths tetanus neonatorum death rate mortality rate neonatal mortality|those in the control group given 2 or 3 injections had a tetanus neonatorum death rate of 7.8 deaths per 100 births, and the corresponding subjects in the study group had none. in the period up to 20 months following vaccination, the reduction in deaths among 4-14-day-old infants after a single dose of tetanus-diptheria toxoids was about the same as that after two doses.|1618 women was conducted between 1961 and 1966 in a rural area of colombia with an estimated existing tetanus neonatorum death rate of 11.6 per 100 births non-pregnant women non-pregnant women in rural bangladesh with two doses of
vaginal bleeding postpartum blood loss quantity of total blood from placental delivery complications or side effects bleeding from placental delivery quantity of blood average blood loss complete blood count, urinalysis, liver and renal function, prothrombin time and activity blood loss occurrences of postpartum hemorrhage total blood loss|tranexamic acid statistically reduces the extent of bleeding from placental delivery to 2 h postpartum and its use was not associated with any side effects or complications. the average blood loss of group i and ii was significantly less than group iii and iv (p < 0.01), however, there was no significant difference between group i and group ii (p > 0.05).|91 women, received one hundred and eighty primiparas four hundred primipara with term singleton pregnancy, vertex presentation, spontaneous delivery were enrolled group i (n = 94
incidences of difficult transfers, blood and/or mucus on the catheter tip, spontaneous miscarriages, and ectopic pregnancies frequency of easy transfers degree of confidence and satisfaction pregnancy rate clinical pregnancy rates and live birth rates implantation and pregnancy rates abortion rate clinical pregnancy or live birth rates live-birth/ongoing pregnancy and clinical pregnancy rates clinical pregnancy rate ectopic pregnancy, miscarriage and multiple pregnancy pregnancy rates ongoing pregnancy/live-birth and clinical pregnancy rates highest pregnancy rate (32.3%/et implantation rate pregnancy and implantation rates rate of implantation and clinical pregnancy live-birth/ongoing pregnancy rate clinical pregnancy rate for ultrasound-guided embryo transfer ongoing pregnancy rate clinical pregnancy rates number of clinical pregnancies|there was no difference in clinical pregnancy or live birth rates between the two groups. the implantation rate was slightly higher in the ultrasound-guided group (15.3%) than the clinical touch group (12.0%) (p = 0.048). for the cases (n = 178), ultrasound-guided was used; controls (n = 152) was performed using routine methods. a better pregnancy rate (19.4%/et) can be achieved when tdt catheter was used under ultrasound guidance. although the clinical pregnancy rate was not statistically different (18.5% in the ultrasound-guided group vs. 17.4% in the clinical touch group), the use of abdominal ultrasound during the embryo transfer procedure provided a greater degree of confidence and satisfaction to both patients and physicians. however, both pregnancy and implantation rates in group 1 (34.4 and 19.8% respectively) were significantly higher than the corresponding values (19.7 and 11.9%) in group 2. there were no statistically significant differences between the two groups with respect to age, cause of infertility and in the characteristics of the ivf cycle. the live-birth/ongoing pregnancy rate was significantly higher in the us et group (68 of 183, 40.98%) than in the clinical touch et group (50 of 190, 28.42%) (odds ratio = 1.66 implantation and pregnancy rates were similar (p = 0.51, p = 0.29) for group i (19.6%, 42%) and group ii (16.3%, 30%), as also was the abortion rate (p = 0.55) us-guided transfer was associated with a decrease in the difficulty of the transfers: 97% of transfers were easy in the us-guided group compared with 81% in the clinical touch group (p < 0.05).|n = 255 women) with clinical touch embryo transfer (n = 260 184 consecutive patients undergoing thawed embryo transfer cycles with hormone replacement under pituitary suppression a total of 800 embryo transfers was studied; 400 400 consecutive embryo transfers (ets 362 patients from our in-vitro fertilization (ivf)-embryo transfer programme people with fertility problems 330 patients 100 patients identified as likely to have easy transfer after mock transfer patients undergoing in vitro fertilization, 50 fresh cycles with day 3 embryo transfer were studied; 27 patients between october 1998 and january 1999 three hundred seventy-three women frozen-thawed embryo transfer
6-month fim motor recovery rates sick-leave profile complete relief of back and radicular pain shorter hospital stay pulmonary complication with mpss neurologic recovery pulmonary (complications pulmonary side effects postoperative complications and functional outcome recovery of motor function motor and sensory functions efficacy and safety 1 full neurologic grade severe sepsis and severe pneumonia motor recovery disabling symptoms postoperative discomfort postoperative pain and length of hospital stay sensation to pinprick motor function (neurologic change scores total number of sick days gastrointestinal complication postoperative narcotic analgesia neurologic outcomes mortality and major morbidity complications and mortality functional independence measure (fim|postoperative complications and functional outcome were not different between the groups. mortality and major morbidity were similar in all three groups. the effect of the 48-hour methylprednisolone regimen was significant at 6 weeks (p=.04) and 6 months (p=.01) among patients whose therapy was initiated 3 to 8 hours after injury. at the follow-up examination 6 months after initial treatment, there was a significant difference in disabling symptoms between the actively treated patients and the placebo group (p = 0.047), total number of sick days (p = 0.01), and sick-leave profile (p = 0.003). aged patients with cervical spinal injury may be more likely to have pulmonary side effects (p = 0.029) after high-dose therapy with mpss and thus deserve special care.|499 patients with acute spinal cord injury diagnosed in national acute spinal cord injury study (nascis) centers within 8 hours of injury patients with acute spinal cord injury patients with acute spinal-cord injury acute spinal-cord injury they were treated without surgery for spinal cord injury in the cervical spine, and were enrolled in the trial if a diagnosis had been made and treatment had begun within 8 hours forty patients, 22 men and 18 women with a mean age of 35 years (range, 19-65 acute cervical spinal cord injury patients with acute spinal-cord injury, 95 percent of whom were treated within 14 hours of injury patients with acute spinal cord injury who receive forty-six patients, 42 men and 4 women (mean age, 60.6 years; range, 18-84), were included in the study: 23 in the mpss group and 23 in the placebo group patients with acute cervical spinal cord injury lumbar disc disease 32 patients at a university-based veterans administration hospital undergoing lumbar microdiscectomy all 32 patients presented with radicular symptoms and had radiographic confirmation of a herniated nucleus pulposus aged patients with cervical spinal injury acute spinal cord injury sixteen acute spinal cord injury centers in north america cases of whiplash injury in car accidents
grade 4 neutropenia leukopenia, anemia, nausea, and vomiting neutropenia and stomatitis/mucositis palmar-plantar erythrodysesthesia activity left ventricular ejection fraction (lvef median survival times median cumulative doxorubicin complete plus partial response rate efficacy and toxicity objective response rates overall response rates nausea and vomiting, stomatitis, and leukopenia clinical toxicities disease progression or unacceptable toxicity median time to disease progression median time to progression median cumulative doxorubicin dose at onset of cardiotoxicity median duration of response and the median survival congestive heart failure (chf response (overall response = complete + partial response rates), time to disease progression, overall survival and cardiac function (left ventricular ejection fraction antitumor efficacy cardiotoxicity complete plus partial response response rate symptomatic congestive heart failure vomiting, mucositis, and leukopenia gastrointestinal and hematological toxicities left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (chf median survival median ttp overall response rate (complete response and partial response [cr + pr median duration of response efficacy and tolerability overall response rate median survival time protocol-defined cardiotoxicity objective tumor response rates (world health organization criteria), time to progression, and survival injection site toxicity alopecia left ventricular ejection fraction median time to treatment failure superior response rate cardiac function cardiotoxicity and grade 4 neutropenia reduced cardiotoxicity and preserved antitumor efficacy doxorubicin cardiotoxicity left ventricular failure|overall response rates were 46% and 39% for mc and ec treatment, respectively (p=0.42). clinical toxicities, commonly associated with doxorubicin, appeared less common with tlc d-99, although the difference was not statistically significant. gastrointestinal and hematological toxicities were moderate for both the drugs, with fewer episodes of nausea and vomiting, stomatitis, and leukopenia following epi administration. vomiting, mucositis, and leukopenia were documented less frequently following administration of epirubicin as compared to doxorubicin. antitumor efficacy of mc versus ac was comparable: objective response rates, 43% versus 43%; median time to progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 months; and median survival, 19 versus 16 months. the overall response rate (complete response and partial response [cr + pr]) was not significantly different: 53.6% for fec and 56.5% for fac.|metastatic breast cancer (mbc two hundred ninety-seven patients with mbc and no prior chemotherapy for metastatic disease 42 patients with advanced breast cancer, 23 of whom were in relapse from prior patients with metastatic breast cancer metastatic breast carcinoma 443 patients (222 in the fec arm and 221 in the fac arm forty-nine patients with advanced breast cancer who had failed from first-line patients with advanced breast cancer patients were removed from study if lvef declined 20 or more ef units from baseline to a final value of greater than or equal to 50%, or by 10 or more units to a final value of less than 50%, or onset of clinical congestive heart failure (chf copyright 2002 american cancer society two hundred twenty-four patients with mbc and no prior therapy for metastatic disease advanced breast cancer metastatic breast carcinoma (mbc from february 1983 to january 1985, 497 patients with advanced breast cancer one hundred and sixty anthracycline-nave metastatic breast cancer patients metastatic breast cancer
haemodynamic modifications (heart rate and/or blood pressure fall incidence of first syncopal recurrence actuarial rate of absence of minor symptoms symptomatic recurrences injurious events sympathetic activity preceding syncope recurrence of vasovagal syncope (vvs mean 24-hour ambulatory bp syncopal recurrence likelihood of syncope recurrent syncope numbers of episodes of syncope and presyncope, and quality-of-life (qol repeat tilt testing responses to head-up tilt free of syncope systolic blood pressure spontaneous episodes of vasovagal syncope svri recurrences of syncope abnormal response to carotid sinus massage lead dislodgement or repositioning postrandomization risk of syncope median time to first syncopal recurrence response rates (negative ttt plasma adrenaline and systemic hypotension syncopal episodes median of 4 episodes of syncope paced heart rate and avoid bradycardia, arterial hypotension and syncope recurrence of two vvss diastolic blood pressure energy and vitality symptomatic pacemaker effect mean sbp decrease mean interval between escape beats time to first recurrence of syncope venous return first recurrence of syncope syncopal and presyncopal episodes and graded their well-being, expressed as the general evaluation of life, general activities, and everyday activities change in health status median time to first syncope initial mean positive therapeutic response risk of recurrent syncope recurrence of neurocardiogenic syncope time to syncope and severity of hypotension neurally mediated syncope symptomatic hypotension myocardial contractility likelihood of recurrent syncope refractory vasovagal syncope ambulatory 24-hour bp monitoring took place orthostatic hypotension while pacing ddi qol scores upright pacemaker effect svri (systemic vascular resistance index) and magnitude of plasma adrenaline presyncopes and total vasovagal events profound hypotension concentration of plasma ca increase and prevented syncope number of falls during one year of follow-up intra-arterial monitoring, impedance cardiography, arterial blood sampling and tracer kinetics of simultaneously infused [3h]noradrenaline and [3h]adrenaline syncopal events quality of life scoring scale occurrence of syncope acute tilt-induced syncope recurrence rates rate of syncope total number of syncopal and presyncopal attacks pacemaker implantation distribution of time of vasovagal events (syncopes or presyncopes syncope recurrences blood pressure recurrence of syncope and presyncope pre-syncope occasional presyncope and their quality of life vasovagal syncope postural blood pressure measurements particular physical function mean+/-standard deviation sbp decrease severity of attack spontaneous syncopal and presyncopal episode recurrence qol recurrent syncopal episodes syncope baroreceptor afferent flow prevention of syncope or presyncope provoked by head-up tilt testing asystolic response to tilt testing median time to the first syncopal recurrence occurrence of symptoms syncopal recurrences recurrence of cardioinhibitory vasovagal syncope symptom events positive for syncope recurrent tilt-induced vasovagal syncope actuarial rate of absence of syncopal recurrence orthostatic tolerance abolishing syncope systolic pressure fall caused by carotid sinus massage vasovagal syncope international study (vasis blood pressure or heart rate plasma ca concentrations pacemaker effect mean number of syncopal episodes symptom reporting and mean sbp decrease after csm time to syncope response rates (negative tilt test falls (without loss of consciousness syncopal attacks symptom frequency, symptoms during head up tilt, and quality of life loss of consciousness (or intolerable symptoms orthostatic hypotension tilt-induced vasodilatation, syncope or elevated plasma adrenaline global assessment of therapeutic response baseline supine systolic blood pressure hypotension and syncope, duration of tilt tolerance presyncopal attacks asystolic response syncopal recurrence burden plasma adrenaline rate of positive responses symptom reproduction and bp and heart rate changes median number of previous syncopal episodes tilt induced syncope vvi (vvi, -31 (sd 19 severe side effects mitral valve prolapse symptoms requiring the withdrawal of vvi pacing and premature dvi/ddd reprogramming haemodynamic patterns of tilt-induced vasovagal reflex 24-hour ambulatory bp acute reproducibility mean duration of follow catecholamine (ca) concentration complete abolition of syncope since pacing risk of syncope relapse low recurrence rate of syncope cumulative risk of syncope plasma ca concentrations and syncope rate of symptom reporting and attenuated sbp decreases syncope recurrence recurrent neurocardiogenic syncope risk of syncope therapeutic efficacy ventriculo-atrial conduction cls mode and no syncope heart rate (electrocardiography), phasic blood pressure (digital photoplethysmography), and thoracic fluid index (transthoracic impedance plethysmography permanent cardiac pacing (recurrence of syncope reproducibility of carotid sinus reflex cardiovascular tests (vasodepression during carotid sinus massage, pacemaker effect, postural blood pressure measurements, and response to head up tilt), and symptoms milder symptoms withdrawal symptoms and side effects relative risk reduction in time to syncope with ddd pacing recurrence of syncope mean time to a vasovagal episode (syncope or presyncope actuarial rates of absence of syncopal recurrences heart rate plasma ca concentration [norepinephrine (ne) and epinephrine (e recurrence of symptoms serious adverse effects|during the 1-year of follow-up, 20 patients of group a and 8 of group b had no recurrence. all drugs improved the patients' well-being (anova: chi-square = 61.9, p < 0.0001). there was no advantage with high rate intervention in delaying the loss of consciousness (or intolerable symptoms) after the initial onset of symptoms. no significant differences in acute tilt-induced syncope recurrence rates were obtained among groups at test repetition since 70.2% of group a, 69.6% of group b and 62.5% of group c experienced syncope. during follow-up spontaneous syncope was reported in six patients (17.6%) in the paroxetine group as compared to 18 patients (52.9%) in the placebo group (p < 0.0001). the likelihood of recurrent syncope was not significantly different between groups. one patient had to discontinue taking midodrine due to severe side effects and another six patients experienced minor side effects that did not require drug discontinuation. eight patients in gr 1 and six patients in gr 2 had mitral valve prolapse (p = 0.5). dual-chamber pacing with rate-drop response reduces the likelihood of syncope in patients with recurrent vasovagal syncope. 14 mmhg) and a higher prevalence of symptomatic pacemaker effect (50% vs 0%), of ventriculo-atrial conduction (78% vs 44%) and of orthostatic hypotension (50% vs 11%), while the entity of the systolic pressure fall caused by carotid sinus massage was similar in the two groups either during vvi mode (group a -51 +/- qol was similar in the two pacing modes. intravenous metoprolol was found to be significantly more effective than placebo in preventing head-up tilt-table induced neurally mediated syncope. the 41 patients programmed to cls had a mean follow-up of 19+/-4 months: none reported vvs, only four (10%) reported occasional presyncope and their quality of life greatly improved. at 12 months, the rate of syncope in the np group was 40% (n = 12) compared with 10% (n = 3) in the p group (p = 0.008). svri was inversely associated with fractional increase in plasma adrenaline during both phases. the primary hypothesis was that atenolol is not superior to placebo for the treatment of vasovagal syncope. atropine was administered to 43 patients and was effective in 30 cases (69.7%, p<0.01 vs placebo). no statistically significant difference was observed between the two groups with respect to recurrence of syncope (p=0.47). 11 patients developed profound hypotension during upright carotid sinus massage while pacing vvi compared with only two while pacing ddi. among the remaining 94, no difference between groups was observed regarding the distribution of time of vasovagal events (syncopes or presyncopes) during follow-up (log-rank test). during an average follow up of 15 (3) months there was a significant reduction in the recurrence of symptoms compared with the previous year in patients who had tilt up guided treatment (18 metoprolol, 1 clonidine). ddd pacing with rate-drop response function is more effective than beta-blockade for the prevention of syncopal recurrences in highly symptomatic vasovagal fainters with relative bradycardia during tilt-induced syncope. the responses to head-up tilt were significantly different on the midodrine and the placebo day: on the placebo day, 67% (8/12) of the subjects suffered neurally mediated syncope, whereas only 17% (2/12) of the subjects developed neurally mediated syncope on the midodrine day (p < 0.02). during follow-up, the group treated with etilefrine had a similar incidence of first syncopal recurrence to that of placebo group both in the intention-to-treat analysis (24% versus 24%) and in on- treatment analysis (26% versus 24%). syncopal events were also reduced during the follow-up period, but there were much fewer syncopal events than falls-28 episodes in paced patients and 47 in controls. this double-blind randomized trial of transdermal scopolamine demonstrated no significant effect of preventing vasovagal syncope. of the 15 patients initially given metoprolol, 2 (13.3%) did not respond; both were crossed over to verapamil, to which they remained unresponsive. thus, the outcome of either treated or untreated patients was favorable (with a low recurrence rate of syncope), and the usefulness of tilting-guided medical therapy remains uncertain. the pacemakers prevented bradycardia but had no effect on the time to syncope in a progressive test of head-up tilt followed by the addition of graded lower body suction. syncope recurred in 16 patients (57%) of the nopacing group (mean follow-up 36 +/- vasovagal syncope was induced in 24 patients during hut alone, and in 30 patients during the hut with isoproterenol. before administration of enalapril, plasma ca concentrations were significantly increased during hut compared with those in the supine position; in contrast, administration of the enalapril (10 mg/day) for >1 year inhibited the concentration of plasma ca increase and prevented syncope in all 12 patients (p < 0.05); however, placebo had no effect on plasma ca concentrations and syncope disappeared in only two of 12 patients after administration of placebo. intravenous disopyramide was ineffective for the prevention of neurally mediated syncope provoked by head-up tilt testing. midodrine had a conspicuous beneficial effect on symptom frequency, symptoms during head up tilt, and quality of life. one patient (5%) in the pacemaker arm experienced recurrence of syncope compared with 14 patients (61%) in the no-pacemaker arm (p=0.0006). there was also no significant difference in the subgroups of patients who had had a mixed response and in those who had had an asystolic response during head-up tilt testing. the head-up tilt test performed 1 month after pacemaker implantation was positive in 3 of 12 patients (25%) with ddd pacing with rate drop response function and in 5 of 8 patients (62.5%) with ddi pacing with rate hysteresis. in this double-blind randomized trial, pacing therapy did not reduce the risk of recurrent syncope in patients with vasovagal syncope. at baseline, the randomized patient groups were similar in their demographic and health characteristics and in the results of their atp tests, for example the mean cardiac pause (21.4 +/- the differences in symptom reporting and mean sbp decrease after csm were both significant (p<.01 and p=.03, respectively). oral etilefrine (10 mg three times a day) was not superior to placebo in preventing a positive response to head-up tilt testing.|patients with vasovagal syncope twenty-eight patients with a positive head-up tilt test 23 patients (21 m, two f; mean age 69 fifty-six patients (44+/-18 years, 36 women) with recurrent syncope (> 1 event in the last 6 months) of suspected neurocardiogenic origin were included in the study 54 patients with recurrent unexplained syncope neurally mediated tilt-positive cardioinhibitory syncope copyright 1999 elderly subjects patients treated with pacing for induced cardioinhibitory carotid sinus syndrome twenty-two consecutive patients with recurrent neurally mediated syncope and two or more successive positive head-up tilt test responses twenty patients (40%) had a positive tilt test twenty patients (mean age 55.4 years, range 23-81, 14 male twenty-nine patients (53 60 patients affected by carotid sinus syndrome whose symptoms were judged to involve risk of major trauma or interfered with their daily activity patients with recurrent vvs patients with induced cardioinhibitory carotid sinus syndrome (icss patients with mixed carotid sinus syndrome recurrent syncope in patients with a positive or negative response to head-up tilt test carotid sinus syndrome patients with neurally-mediated syncope syncopal elderly patients with vasovagal syndrome ten older adults (4 male, 6 female, mean age 75, range 66-86 years) with a history of unexplained syncope who displayed an asymptomatic decrease in systolic bp (sbp) of more than 50 mmhg or a symptomatic decrease of more than 30 mmhg within 30 seconds of carotid sinus massage (csm patients with vasovagal syncope (vvs patients with recurrent neurally mediated syncope patients with malignant vasovagal syndrome neurally mediated syncope patients with vasovagal syncope after 1 month of treatment elderly patients 30 patients (10 men and 20 women, mean age 42 fifty patients with recurrent vasovagal syncope patients with recurrent severe vasovagal syncope 100 patients patients with frequently recurrent vasovagal syncope 75 patients with > or =1 recurrence of syncope forty-two patients from 18 european centers carotid sinus hypersensitivity (carotid sinus syndrome (css patients with severe carotid sinus syndrome five patients older adults with cardioinhibitory carotid sinus hypersensitivity (csh 10 years; 60% women 20 patients (12 males and 8 females; mean age 61.1 ninety-six consecutive patients with vvs patients in whom reproducibility of the hut response was demonstrable in the initial study 24 elderly subjects who had reproducible nms induced with head-up tilt test (hut patients with neurocardiogenic syncope patients with frequent symptoms eight subjects with recurrent neurocardiogenic syncope and previously documented tilt-induced syncope with elevated plasma adrenaline levels participated in the present study patients with severely symptomatic neurocardiogenic syncope inclusion criteria were age >35 years, >/=3 syncopal spells in the preceding 2 years, and positive response to tilt table testing with syncope occurring in association with relative bradycardia patients with severe recurrent tilt-induced vasovagal syncope patients with severe recurrent vasovagal syncope patients with unexplained syncope and positive upright tilt table test results patients with syncope and a positive tilt test response patients with recurrent vasovagal syncope inclusion criteria were (1) > 6 cumulative syncopal episodes or > or = 1 syncope within 6 months of a positive hut, and (2) a positive hut with bradycardia older adults who have non-accidental falls 54 patients enrolled vasovagal syncope one hundred seventy-five eligible patients (mean age 73 30 consecutive patients aged over 60 years with carotid sinus syndrome referred for cardiac pacing 93 patients (38 men and 55 women; mean age, 58.1+/-14.3 years) had been enrolled and randomized, although follow-up data were available for all patients (46 patients in the pacemaker arm, 47 patients in the pharmacological arm patients with syncope and positive head-up tilt test response patients with unexplained syncope provoked during head-up tilt testing sixty patients with a history of syncope or pre-syncope and icss all patients had >2 syncopal spells and a positive tilt test twelve patients with history of recurrent neurally mediated syncope, which was reproduced during head-up tilt patients with rate hysteresis pacemakers implanted for vasovagal syncope patients with recurrent unexplained syncope patients with severe cardioinhibitory tilt-positive neurally mediated syncope 16 years; 19 women) with severe recurrent tilt-induced vasovagal syncope (median 12 syncopes in the lifetime) and 1 syncopal relapse after head-up tilt testing underwent implantation of a pacemaker 15.2 years, 19 men) with recurrent vvs were enrolled at seven european centers and underwent two groups all patients referred to our unit who had had at least one episode of syncope or two episodes of presyncope 1 month before presentation and had a positive isuprel tilt table test (ttt 61 patients 28 patients to no therapy (nonpacing group), and 32 to vvi (n = 18) or ddd (n = 14 patients with cardioinhibitory vasovagal syncope 20 participating centers, 126 patients with recurrent vasovagal syncope (at least 3 episodes in the last 2 years) and a positive baseline head-up tilt response eleven patients sixty-eight consecutive patients (26 men and 42 women, mean age 44.7+/-16.5 years) with recurrent syncope and positive head-up tilt test and in whom standard therapies with beta-adrenergic blocking agents, vagolytic, negative inotropic or mineral corticoid agents were ineffectual or poorly tolerated were referred for study 14 patients, who preferred dvi/ddd period (group a), and the remaining nine patients who noted no preference between dvi/ddd and vvi period (group b 14 yrs) with recurrent syncope (mean number of prior episode = 6.8, range 5-11) and cardioinhibitory responses during two head-up tilt tests: the first diagnostic and the second during drug therapy with either fourteen patients who were given recurrent vasovagal syncope patients resistant to or intolerant of previous traditional therapies patients with neurally mediated syncope vasovagal syncope (invasy 24 patients during hut alone, and in 30 patients during the hut with 15 patients patients with malignant vasovagal syncope one hundred and thirteen consecutive patients (62 male and 51 female, mean age 46.3 years) with recurrent syncope, no evidence of cardiac, neurological or metabolic disease and a positive head-up tilt test were included in the study neurally mediated syncope in a highly symptomatic population eighteen patients discontinued therapy vasovagal patients with abnormal response to atp testing 16 outpatients (mean (sd) age 56 (18) years; five men) with frequent hypotensive symptoms (more than two syncopal episodes and fewer than 20 symptom free days per month), and reproducible syncope with glyceryl trinitrate (gtn) during head up tilt severe recurrent vasovagal syncope 13 years vs 43 208 patients (mean age 42+/-18 years) with a median of 9 syncopal spells over a median of 11 years 30 consecutive patients with recurrent vvs and a positive head-up tilt test tilt-induced neurally mediated syncope malignant vasovagal syncope patients who had at least monthly occurrences of syncope and a positive tilt-table test were included in the study 21 years) who had syncope reproduced in 2 consecutive head-up tilt-table tests without pharmacologic intervention (n = 20) or during 30 consecutive patients with syncope and a baseline positive head-up tilt test 284 patients was originally planned and a pilot study of 60 patients was initiated patients with syncope recurrent vasovagal syncope (vvs patients without structural heart disease vasovagal patients with severe cardioinhibitory reflex eleven patients were unable to tolerate vvi pacing and had to be withdrawn early from this limb of the study (group a consecutive older patients (>50 years) attending an accident and emergency facility because of a non-accidental fall 19.3 years) who had at least one episode of syncope per month during previous 6-months and had positive tilt test one hundred and sixty-nine consecutive patients with vasovagal syncope and positive baseline or nitrate-potentiated tilt test (60 degrees upright position for 45 min, or until syncope occurred; 5 mg patients from 14 centers elderly patients with carotid sinus syndrome outpatients referred to syncope specialists at 15 centers from september 1998 to april 2002 20 patients (9 men and 11 women, mean age 33 (sd 17), range 14 to 62 years) with severe symptoms twenty-three patients (age 61.8 twenty patients hospitalized for syncope, which was considered to be vasovagal, and exhibiting an abnormal atp test--defined by a longer than 10 s cardiac pause cardioinhibitory vasovagal syncope 24 patients recruited in the second stage of the study (second year) were programmed in ddd-cls mode selected patients with recurrent vasovagal syncope (vvs patients affected by tilt-induced neurally mediated syncope patients with > or = 6 lifetime episodes of syncope and with a tilt-table test that induced syncope or presyncope, as well as a relative bradycardia from october 2003 to december 2004, 62 patients (32 men, mean age 44.8 patients with unexplained syncope forty-two patients were enrolled in the study older adults (safe pace fifty patients (27 males, mean age 59+/-18 year) with severe and recurrent vasovagal syncope and positive head
forced expiratory volume admission rate and improved fev1 expiratory flow pefr and fev1 short-term pulmonary function hospital admission rates vital signs, o2 saturation by pulse oximetry, pefr, forced vital capacity, forced expiratory volume at 1 second, and physical examination pulmonary function and decrease admission rate pefr fev1 peak expiratory flow rate clinical asthma score hospitalization peak expiratory flow serum magnesium concentrations admission rates blood pressure forced vital capacity pefr and sao2|at 50 minutes the magnesium group had a significantly greater percentage of improvement from baseline in forced expiratory volume at 1 second (34% vs -1%; p = 0.05); this improvement was sustained and even greater at 110 minutes (75% vs 5%; p = 0.01). mgso4 group showed early and significant improvement as compared to placebo group in pefr and sao2 at 30 min and 1, 2, 3 and 7 hours after stopping the infusion (p ranging from < 0.05 to < 0.01). in addition, the number admitted vs discharged was significantly better for the treatment group (7 vs 12) than the placebo group (15 vs 4). magnesium sulfate administration did not at any time significantly improve either fev1 (f = 0.036, p = 0.96) or pefr (f = 0.51, p = 0.61). 90 minutes in the control group (95% ci, 209 to 247 minutes, p = .832). for the severe group, admission rates were 78.6% (11/14) for the placebo-treated group and 33.3% (7/21) for the magnesium-treated group (p = 0.009).|patients presenting to the emergency department with exacerbations of asthma one hundred twenty consecutive patients aged 18 to 65 years with acute asthma unresponsive to a single albuterol treatment 47 children aged between 1-12 years with acute severe asthma showing inadequate or poor response to 3 doses of acute asthma in the emergency department discharged patients was 224 patients with acute severe exacerbations of asthma emergency departments of a university-affiliated, voluntary hospital and municipal hospital moderate to severe pediatric asthma patients with acute asthma one hundred thirty-five patients were studied thirty-eight patients suffering from acute exacerbations of moderate to severe asthma thirty-one patients aged 6 to 18 years who were being treated for an acute asthma exacerbation with peak expiratory flow rate (pefr) less than 60% of the predicted value after receiving three beta 2-adrenergic nebulizer treatments given at an interval of 20 min each pediatric emergency service of a large teaching hospital moderate to severe asthma exacerbations in pediatric patients urban pediatric emergency department children with acute severe asthma not responding to conventional therapy patients with acute severe asthma nineteen patients urban emergency department patients with moderate to severe asthma exacerbations urban teaching hospital emergency department acute asthma acute severe asthma not responding to conventional therapy patients with moderate asthma patients with moderate to severe asthma acute asthma exacerbations asthmatics aged 18 to 65 years during acute exacerbation with fev1 less than 75% predicted both before and after a single albuterol treatment forty-eight asthmatic patients aged 18 to 60 years with initial peak expiratory flow rate (pefr) < 200 l/min who failed to double their initial pefr after two standardized albuterol treatments
history of upsetting life events and previous child psychiatric contact dry nights p-h scale weekly wetting frequency improvement rate without cure piers-harris self-concept scale (p-h), the state-trait anxiety scale (staic), and the nowicki-strickland locus of control test (nslc mean number of dry nights fewest wetting episodes bladder capacity levels of neuroticism wetting frequency piers-harris children's self-concept scale and harter's perceived competence scale for children (pcsc rate of apparatus malfunction success rate behavioral and self-concept changes response rate rate of sustained continence changes in cbcl, staic, and nslc scores remission rates remission (28 continuous dry nights) and relapse complete and partial response rates total score, and positive changes over time in only 2 subscales, scholastic and social bed-wetting frequency piers-harris subscales and in the cbcl internalizing and externalizing scores, and the social thought and attention problems subscales achenbach child behavior checklist (cbcl number of wet nights rate of cure cumulative response maximum functional bladder capacity (mfbc prechange and postchange in mfbc enuresis tolerance scale levels of extroversion maternal anger treatment efficacy background demographic variables relapse rates serious side effects subjects' level of emotional and behavioral adjustment monosymptomatic nocturnal enuresis improvement rate success rate of arousal training|the patients in group 2, who were older, had a higher rate of cure than did the patients in group 1. after 6 months of treatment there were significant changes over time unrelated to outcome or treatment in the piers-harris subscales and in the cbcl internalizing and externalizing scores, and the social thought and attention problems subscales. improvement rate without cure during treatment was higher for the children treated with imipramine than for those treated with the detector, but at follow-up the reverse was true. at the end of treatment there was a significant difference in the mean number of dry nights per week between the two groups (6.3 in the alarm and desmopressin group and 4.8 in the alarm group) and also in the number of children becoming reliably dry. significant improvements in the p-h scale (p = 0.04) and three of its subscales occurred in children in the treatment group compared with those in whom treatment was delayed. a significantly greater reduction in the number of wet nights was observed after the first 3 weeks of treatment in group 1. results indicated a significantly higher rate of apparatus malfunction for the delayed model of alarm. although remission rates were similar, children treated with desmopressin had significantly more dry nights during treatment than those in the placebo group. in nonresponders the cumulative response after desmopressin treatment increased to 80% and 62% respectively. desmopressin offers better short-term results than enuresis alarm but the latter is significantly more efficient in the long term. both procedures were equally effective, and in the total sample a better response to treatment was predicted by the child's report of being teased by siblings. the success rate of arousal training was still significantly higher (92% continent) when compared to the urine device with specific instructions (77%) and urine alarm only (72%). uristop, a commercially available alarm device based on a theory somewhat different from those used in the common alarm devices, was tried in a prospective randomized double-blind study. similar rates of success were achieved for 47 children, aged 6 to 12 years, who partially or totally completed the 3-month period of alarm use. the enuresis tolerance scale was found to be a highly significant predictor of early termination from conditioning treatment. the 10 children who terminated treatment prematurely had lower self-esteem and more parent-reported conduct problems than the 40 children who completed treatment. using dunn's procedure, a planned comparison showed the control group and delay group did not differ significantly, but both differed significantly from the classic conditioning group (p less than 0.05). two studies examined the effectiveness of the body-worn alarm in out-patient treatment of childhood nocturnal enuresis. the improvement rate was 70% in the group given desmopressin and 86% in the group treated with alarm; the difference was not significant. sem) dry nights per week and resulted in significantly more dry nights per week during the 2 weeks of observation than placebo and alarm (4.1 +/- 0.4, p less than 0.05). the wetting frequency decreased during treatment by 46%, 52%, and 73% in groups 1, 2, and 3, respectively.|monosymptomatic nocturnal enuresis childhood enuresis 169 children with primary enuresis subjects were 182 children referred or recruited through media publicity small mfbc children treated with the ua plus rct and large mfbc youngsters in group d (n = 62), only 27 children were included since 12 (19%) were switched to alarm and 23 (37%) were excluded because they were either non-compliant or lost to follow-up patients (n = 135) aged 6 to 16 years 121 children aged 8 to 14 years to receive 74 enuretic children 134 enuretic children who were examined on an out-patient ward, 53 were selected for inclusion in this study on the basis of certain criteria 47 children, aged 6 to 12 years, who partially or totally completed the 3-month period of alarm use nocturnal enuresis healthy school children children over 7 years of age sixty children youngsters children with nocturnal enuresis who are desmopressin nonresponders, adjunct 40 youngsters who completed treatment, 37 (92.5%) achieved the treatment goal of 14 consecutive dry nights 207 defined as nonresponders (<50% reduction in wet nights inclusion criteria were: primary monosymptomatic nocturnal enuresis in healthy children, age > or = 6 years, absence of previous treatment using either childhood nocturnal enuresis children with severe wetting and those with family and behavioural problems 40 children, previously untreated by conditioning methods, treated with either the body-worn alarm or the traditional pad and bell alarm 39 children who exhibited primary nocturnal enuresis 93 patients 47 10 children who terminated treatment prematurely had lower self-esteem and more parent-reported conduct problems than the 40 children who completed treatment sixty-two children with primary nocturnal enuresis were enrolled between january 1992 and december 1994 study participants were fifty 5- to 13-year-old children (33 boys and 17 girls) with nocturnal enuresis of at least 3 months duration nocturnal enuresis with non-clinical children between 6 and 12 years of age inner-city hospital clinic patients with nocturnal enuresis (n=358; age range, 6-16 years chinese children with monosymptomatic primary nocturnal enuresis eighty-four patients, aged 6 to 14 years old, were studied primary nocturnal enuresis (pne chinese enuretic children non-clinical enuretic children between 6 and 12 years of age primary enuresis on psychologic functioning in children seventy-one children with nocturnal enuresis children with central nervous system disorders or developmental delays, and those currently on ddavp or alarm included were children >7 years old with pne, no daytime symptoms, bladder capacity >50% expected, and wetting >3 times a week primary nocturnal enuresis seventeen children from group 1 and 18 from group 2 were tested with the age-appropriate form of the cattell personality questionnaire on three occasions: at the time of entry into the study, 2 months later and at follow-up, an average of 16 months later twenty-eight children with primary nocturnal enuresis 105 children aged 7-15 years to receive alarms (group 1, 35 patients fifty children with primary nocturnal enuresis older children with primary nocturnal enuresis children with nocturnal enuresis children suffering from nocturnal enuresis isolated nocturnal enuresis
disease-free survival (dfs morbidity relapse-free survival 5-year dfs relapse or death from breast cancer 5-year overall survival time to recurrence overall and disease-free survival 4-year overall and relapse-free survivals disease-free survival, overall survival, or the time to recurrence 3-year relapse-free survival rates 3-year survival rates septic death mean number of positive nodes survival relapse-free or overall survival advantage myelodysplastic syndrome or acute myeloid leukemia disease-free survival rates frequent morbidity overall survival event-free survival risk of relapse disease-free and overall survival 4-year event-free survival (intention-to-treat analysis 3-year disease-free survival|among the 511 eligible patients, there was no significant difference in disease-free survival, overall survival, or the time to recurrence between those who received caf alone and those who received caf plus high-dose chemotherapy and stem-cell transplantation. the 5-year overall survival was 70% for di-ec and 61% for sd-ct, with a hazard ratio of 0.79 (95% ci, 0.56 to 1.11; p = .17). arm b, with its less dose-intensive therapy, requires considerably less support to apply the treatment. no relapse-free or overall survival advantage was associated with the use of high-dose chemotherapy, and morbidity was increased with its use. there was no significant difference in survival between the patients on conventional therapy and those on high-dose therapy. no significant difference was observed in relapse-free survival [hazard ratio 1.06, 95% ci 0.74-1.52, p = 0.76] or overall survival [hazard ratio 1.18, 95% ci 0.80-1.75, p = 0.40]. the pegase 01 adjuvant therapy trial showed that 3-year disease-free survival was significantly better in the hdc arm but overall survival was unchanged. the corresponding overall survival was 75% (69-82) versus 70% (64-77; p=0.02).|and patients with 10 or more positive axillary lymph nodes after primary breast surgery or patients with four or more positive lymph nodes after four cycles of primary (neoadjuvant) chemotherapy were eligible women with primary breast cancer involving 10 or more axillary lymph nodes 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of patients with operable stage ii or iii breast cancer involving 10 or more axillary lymph nodes (calgb protocol 9082 women with hormone receptor-positive tumors patients with at least nine positive nodes 417 patients fulfilling strict eligibility criteria cancer and leukemia group b patients at high risk for relapse breast cancer patients with breast cancer and multiple metastases to the axillary lymph nodes high-risk primary breast carcinoma primary breast cancer patients with four or more lymph nodes involved: long-term seventy-eight patients (48 after primary surgery and 30 after primary chemotherapy patients with primary breast cancer involving multiple axillary lymph nodes patients with primary breast cancer and four or more histologically involved lymph nodes massachusetts medical society three hundred forty-four patients patients with primary breast cancer and at least 10 involved axillary lymph nodes two hundred and eighty one patients entered into a randomised clinical trial thirty-nine patients patients had to be free of overt metastatic disease and be < or =60 years of age high-risk breast cancer operable breast cancer with extensive axillary lymph-node involvement 511 eligible patients women with primary breast cancer and 10 or more involved axillary lymph nodes patients with early-stage breast cancer and a high risk of relapse, defined as stage ii disease with 10 or more positive axillary nodes; or an estrogen receptor-negative or stage iii tumor with five or more positive axillary nodes women with high-risk primary breast cancer 97 women aged younger than 60 years, who had breast cancer with extensive axillary-node metastases (confirmed by a tumour-positive infraclavicular lymph-node biopsy 403 patients were enrolled; 201 were assigned high-dose chemotherapy and 202 conventional treatment patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support postmenopausal patients with estrogen receptor-positive tumors and chest wall
cgic number of (gastrointestinal) side effects clinical global impression score patient's performance self-rating scale for instrumental activities of daily living (nrnberger-alters-alltagsaktivittenskala adas cognitive and non-cognitive subscales saccade duration cognitive subscale of the alzheimer's disease assessment scale (adas-cog), alzheimer's disease cooperative study clinical global impression of change (adcs-cgic psychopathology and cognitive performance safety, compliance, and drug dispensation degree of severity of dementia clinical efficacy number of patients reporting adverse events adas-cog digit copying sub-test of the kendrick battery gerri score mental/mnestic performance cognitive function mental control test (emct) measuring attention and concentration, benton test of visual retention-revised (measures short term visual memory), rey test part 1 (measures short term memory and learning curve), beck depressive inventory (bdi) measuring the presence and severeness of a depression in order to exclude depressive patients and rey test part 2 (measures long term memory: recognition efficacy and safety mental performance sum score in the skt-test for the determination of attention and memory learning rate shortterm memory depression clinical global impressions (cgi item 2) for psychopathological assessment, the syndrom-kurztest (skt number connection test efficacy and tolerability frequency of therapy responders little cognitive and functional decline tolerated furthermore, subjective perception of memory and concentration alzheimer's disease assessment scale-cognitive subscale (adas-cog), geriatric evaluation by relative's rating instrument (gerri), and clinical global impression of change (cgic cerebral disorders psychometric tests (trailmaking test, adas, cgi) and electrophysiological investigations (eeg topography activities of daily living as assessed by the nrnberger-alters-beobachtungsskala (nab cognitive performance and global assessment scores percentage of baseline scores|regarding the safety profile of egb, no significant differences compared with placebo were observed in the number of patients reporting adverse events or in the incidence and severity of these events. the difference between control and treatment groups became significant at 3 months and increased during the following months. after therapy, patients of the active substance group scored significantly better (p < 0.05) on each outcome measure than those who received placebo. the frequency of therapy responders in the two treatment groups differed significantly in favor of egb 761, with p < 0.005 in fisher's exact test. statistically significant improvement in the shortterm memory after 6 weeks and of the learning rate after 24 weeks in the test substance group, but not in the placebo group (longitudinal analysis). a highly significant difference could already been seen after 4 weeks of therapy and also after 8 weeks in the results of both the saccadic test and the psychometric tests compared to the placebo control group. performance on the digit copying sub-test of the kendrick battery was significantly improved at both 12 and 24 weeks, while the median speed of response on a computerized version of a classification task also showed a significant superiority over placebo at 24 weeks. in both double-blind studies the piracetam treated group improved about 60% more than the group who only got speech therapy and placebo. significant improvements in the patient's performance were observed under verum compared to the placebo preparation which was administered to a control group of patients among which the relevant disorder were distributed homogeneously. although the active-treatment group, with a mean sum score of 19.67 points in the, s.k.t., had a poorer baseline level than the placebo group (18.11 points), it experienced an improvement to 16.78 points under treatment with egb 761 whereas the placebo group deteriorated to 18.89 points. in the subjective test, the emct, the rey 1 and rey 2 no significant differences in improvement in time between the groups were observed. for a subgroup of patients with neuropsychiatric symptoms there was a greater decline of placebo-treated patients and significantly better cognitive performance and global assessment scores for the patients on gbe. our study suggests that there is no evidence of relevant differences in the efficacy of egb 761 and donepezil in the treatment of mild to moderate alzheimer's dementia, so the use of both substances can be justified. after 2 weeks the differences were marked for only a few of the symptoms; after 4 and 6 weeks in contrast, in 11 of the 12 symptoms.|197 patients completed the study dyslexic children 90 outpatients with cerebral insufficiency sixty inpatients with cerebral insufficiency and the leading symptom depressive mood nondemented patients complaining of memory problems outpatient clinics of universities and private research centers specialized in dementia 20 outpatients patients: seventy-two outpatients with cerebral insufficiency at three test centers thirty-six patients with classical symptoms of organic syndrome 40 patients with a mean age of 68 (+/- 12.5) years suffering from moderate dementia (alzheimer, vascular, or mixed type) according to dsm-iii-r criteria were included mild to moderate alzheimer's dementia patients aged 50-80 years, suffering from mild to moderate dementia 166 patients dementia of the alzheimer type with special respect to moderately severe stages 60 inpatients patients with dementia of the alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment 90 outpatients with cerebral insufficiency caused by old age results of a placebo-controlled double-blind trial 309 patients included in an intent-to-treat analysis, 202 provided evaluable data for the 52-week end point analysis patients with psychotic organic brain syndrome elderly individuals with memory- and/or concentration complaints patients with moderate dementia patients with cerebral insufficiency thirty-one patients over the age of 50 years and showing a mild to moderate degree of memory impairment mild to moderate dementia of the alzheimer type 27 patients (15 in the placebo group and 12 in the active treatment group severely demented outpatients with alzheimer disease or multi-infarct dementia, without other significant medical conditions 761 in dementia of the alzheimer type patients receiving unpermitted supplementary medication or suffering from acute cardiovascular disturbances or digestive and metabolic disorders outpatients with presenile and senile primary degenerative dementia of the alzheimer type (dat) and multi-infarct dementia (mid) according to dsm-iii-r psychiatric illnesses associated with old age primary degenerative dementia of the alzheimer type (dat 513 outpatients with uncomplicated dementia of the alzheimer's type scoring 10 to 24 on the mini-mental state examination and less than 4 on the modified hachinski ischemic score, free of other serious illnesses and not requiring continuous treatment with any psychoactive drug 216 patients dementia dementia of the alzheimer's type 761 in dementia of the alzheimer type and multi-infarct dementia 241 non-institutionalised patients in the age range 55-86 years  1998 outpatients suffering from mild to moderate primary degenerative dementia of the alzheimer type or multi-infarct dementia cognitive impairment  1994 elderly outpatients with mild to moderate memory impairment alzheimer's dementia in a randomized 156 patients who completed the study in accordance with the study protocol 761 in dementia of the vascular and alzheimer type patients presenting with pathological findings for at least two of the four test criteria were admitted to the trial elderly individuals with cognitive impairment patients with various forms of cognitive impairment or dementia
chronic gastro-oesophageal reflux mean gastrointestinal symptom and general well-being scores frequency of gastroesophageal reflux dis-ease symptoms tolerated symptom relapse requiring titration overall gastroesophageal reflux disease symptom score satisfactory symptom remission psychological general well-being index and the gastrointestinal symptom rating scale time to treatment failure (kaplan-meier analysis mean demeester acid exposure score lower oesophageal sphincter pressure postoperative complications symptoms, ph control, and overall quality of life health index quality of life|the differences in both of these scores were significant between the two groups at 12 months (p = 0.003). surgical patients had improved symptoms, ph control, and overall quality of life health index after surgery at 1 year compared with the medical group. the proportions of patients who remained in remission after 3 years were similar for the two therapies: 90% of surgical patients compared with 93% medically treated for the intention to treat population, p = 0.25|554 patients patients with chronic gastro-oesophageal reflux disease dedicated centres in 11 european countries n = 52) with n = 52 patients with chronic gastroesophageal reflux disease patients with gastroesophageal reflux disease compared between july 1997 and august 2001, 340 patients with a history of gord for at least 6 months were investigated by endoscopy, 24-h ph monitoring and manometry gastro-oesophageal reflux disease (gord
occurrence of symptoms and signs, degree of caloric lateralization, presence of other eng pathologic findings, and dizziness handicap inventory scores peripheral vestibular function relief of vertiginous symptoms earlier recovery of eng lateralization complete resolution relapse of symptoms symptoms and signs, caloric lateralization on the electronystagmography (eng), the presence of other pathologic findings in the eng, and dizziness handicap inventory scores vertigo severity of vestibular paresis vertiginous symptoms vestibular function recovery of peripheral vestibular function|analysis of variance showed a significant effect of methylprednisolone (p<0.001) but not of valacyclovir (p=0.43). the electronystagmogram returned to normal within 1 month in all 16 patients taking methylprednisolone, but remained abnormal in 2 of the 4 patients treated with placebo. no differences were found between the groups in the occurrence of symptoms and signs, degree of caloric lateralization, presence of other eng pathologic findings, and dizziness handicap inventory scores at the end of the study.|acute vestibular vertigo, we randomly selected 20 patients so that half took 10 patients receiving acute vestibular vertigo vestibular neuritis patients with vestibular neuritis patients with acute vestibular vertigo patients with acute vestibular neuritis massachusetts medical society thirty vn patients, 15 in the study and 15 in the control group, were the subjects of the study vestibular neuritis (vn 141 patients who underwent randomization, 38 received
functional independence measure (fim), motor assessment scale (mas) and rankin disability index measured functional outcomes pain final upper limb function presence of neglect or sensory loss skin reactions functional outcomes pain (sromp) assessed passive range of movement and pain pain, range of movement or functional outcomes visual analogue scale (vas|intention to treat analysis showed no significant difference in pain, range of movement or functional outcomes after the intervention phase or at the final assessment.|hemiplegic stroke patients all patients admitted with an acute hemiplegic stroke, who had persisting weakness of shoulder abduction ninety-eight subjects participated (49 strapped, 49 controls care of the elderly wards in a teaching hospital, christchurch, new zealand post-stroke shoulder pain
rate of delayed graft function, the rate of rejections, time to first rejection, whole blood csa concentration, or graft function donor or recipient characteristics, hla-mismatching, and ischaemic time thrombosis leading to graft loss renal function and rejection severe signs of cyclosporin a (csa) nephrotoxicity allograft function renal parenchymal diastolic blood flow velocities renal graft function graft function assessed by serum creatinine concentration and glomerular filtration rate measured as plasma iohexol clearance acute rejection rate, trough blood cyclosporine concentrations, blood pressure, number of antihypertensive drugs, hospitalization rate, and adverse event rate renal plasma flow and anastomotic blood flow actuarial graft survival rejection episodes graft function (plasma iohexol clearance), renal plasma flow, anastomotic arterial blood flow, deterioration of renal function, blood pressure, acute rejection, and hospitalization rate episodes of acute tubular necrosis primary graft function estimated graft survival graft survival blood concentration plasma levels of soluble interleukin-2 receptors incidence and severity of delayed graft function cadaveric kidney transplantation serum creatinine|primary graft function occurred more commonly in the groups receiving diltiazem. actuarial graft survival at 1 yr was different when the two groups were compared (p less than 0.05). for the remaining 35 grafts no beneficial effect of treatment with diltiazem was found for the rate of delayed graft function, the rate of rejections, time to first rejection, whole blood csa concentration, or graft function. graft function assessed by serum creatinine concentration and glomerular filtration rate measured as plasma iohexol clearance, was persistently better in lacidipine-treated patients from 1 year onwards (respectively, p<0.01 and p<0.05). a trend developed showing a decrease in episodes of acute tubular necrosis in gallopamil versus placebo, and became statistically significant when the outcome of kidneys from donors older than 50 years was analyzed separately [gallopamil 6/14 (42%) vs. placebo 10/11 (91%), p <0.01 corrected chi2].|cadaveric renal transplantation 131 de novo recipients of a cadaveric renal allograft on cyclosporine therapy renal allograft recipients receiving triple-drug immunosuppression treated recipients cadaver renal transplant (crt) recipients 11 control subjects and 10 diltiazem subjects 118 recipients were available for intention-to-treat analysis on efficacy 39 graft recipients 59 cadaver renal transplant patients evaluates the outcome from perioperative treatment with vp (n = 30) administered cadaver renal transplantation 22 control patients and 20 diltiazem patients received kidneys from aged donors human renal transplantation 16 subjects who were given iloprost, and 14 subjects who received both 19 control subjects who received no specific treatment, 16 subjects who received
growth velocities and individual amounts of breastfeeding rate of weight gain growth and thermal stability length of stay number of infants returned to an incubator, the growth velocity in an open crib and during the first week at home, the proportions of breastfeeding at discharge and during the first week at home, and the hospital readmission rate mean 24-hour weight gains abdominal temperature rate of growth of the skinfolds birth weight stratum|the rate of weight gain correlated with gross energy intake only and did not differ within or between the two groups. no infant in either group lost weight after successful weaning, and mean 24-hour weight gains were similar for both groups. the length of stay was significantly shorter in the early transition group than in the standard transition group (23.5 vs 33 days; p=.0002).|moderately preterm infants from incubators to open cribs at 1600 premature infants thirty pairs of healthy, growing preterm infants preterm infants with birth weights of <1600 g who were admitted to a neonatal subintensive ward 47 infants who were transferred from an incubator to an open crib at >1600 g (early transition group) were compared with those for 47 infants who were transferred from an incubator to an open crib at >1800 g (standard transition [st] group two infants were weaned at 1800 g requiring return to the incubator due to hypothermia, and four infants weaned at 1700 g likewise requiring return to the incubator preterm infants the number weaned at 1700 g who had birth weight of 1000 g or less and who developed hypothermia appeared substantial (three of six such infants fourteen growing, healthy premature infants
disability clinical and mri measures of inflammation and neurodegeneration progression rates survival curves final 2-year relapse rate clinical and mri-monitored disease activity relapse rate disability status scale change (entry expanded disability status scale kurtzke expanded disability status scale relapse rate and improves disability unconfirmed progression, and progression of 0.5 edss units cumulative number of confirmed relapses intention-to-treat analysis of time to 1 expanded disability status scale (edss safe and well tolerated frequency of relapses and the formation of active brain lesions t2 lesion volumes enhancing lesions disabled on entry (kurtzke disability score rate ratio tolerated overall survival curves ms relapse rate total number of confirmed relapses|more disabled patients worsened by 0.3 (cop 1 group) and 0.4 (placebo group) unit. 0.13 for those receiving placebo, a 29% reduction in favor of copolymer 1 (p = 0.007) (annualized rates = 0.59 for copolymer 1 and 0.84 for placebo). progression rates at 12 and 24 months were higher for the placebo group (p = 0.088) with 2-year probabilities of progressing of 20.4% for cop 1 and 29.5% for placebo. 5 mg and 50 mg glatiramer acetate administered orally on a daily basis do not affect relapse rate or other clinical and mri parameters of disease activity and burden in patients with relapsing-remitting multiple sclerosis. post hoc analysis showed that survival curves for ga-treated male patients diverged early from pbo-treated male subjects (hazard ratio, 0.71 [95% confidence interval, 0.53-0.95];|male patients 1912 patients with relapsing-remitting multiple sclerosis 1644 patients who took at least one dose of study patients with relapsing-remitting multiple sclerosis (ms patients with relapsing-remitting multiple sclerosis two hundred fifty-one patients chronic progressive multiple sclerosis alone daily for two years 106 chronic-progressive patients patients with relapsing multiple sclerosis 50 patients with the exacerbating-remitting form of multiple sclerosis, who self-injected either 20 mg of patients receiving copolymer 1 and 1.68 relapsing-remitting multiple sclerosis 943 patients with primary progressive multiple sclerosis primary progressive multiple sclerosis
intraoperative or postoperative thromboembolic complications duration of intensive care unit admission estimated blood loss blood loss transfusion requirements transfusion requirement blood loss, transfusion requirements, coagulation parameters, and complications perioperative blood loss and the need for autologous blood transfusion perioperative blood transfusion requirements blood loss and transfusion requirements blood transfusion thrombotic complications postoperative suction drainage amount of blood transfused adverse drug effects intraoperative blood loss blood loss, transfusion requirements, days in the intensive care unit, and days in hospital total amount of blood transfused bleeding and transfusion requirements perioperative blood loss|although the difference was not significant statistically, the benefit of aprotinin in reducing blood loss in spinal surgery for idiopathic scoliosis was consistent. patients in the amicar group demonstrated a statistically significant decrease in perioperative blood loss and the need for autologous blood transfusion. no thrombotic complications were detected in either group. the study demonstrated a significant reduction in estimated blood loss (aprotinin 545 cc, placebo 930 cc) and transfusion requirements (aprotinin 1.1 u, placebo 2.2 u). administration of tranexamic acid was a multivariate predictor of blood loss, as was american society of anesthesiologists physical status and preoperative platelet count.|36 patients with idiopathic scoliosis patients undergoing spinal surgery patients with idiopathic scoliosis undergoing posterior spinal fusion and segmental spinal instrumentation pediatric patients who undergo posterior spinal fusion surgery to correct scoliosis often require multiple blood transfusions idiopathic scoliosis 28 consecutive patients receiving amicar compared to a historical control group of the 31 previous consecutive patients with the same study criteria children with scoliosis 44 children and adolescents pediatric patients with spinal deformities undergoing posterior spinal fusions of seven or greater segments scoliosis surgery forty-three patients with idiopathic scoliosis underwent spinal fusion and instrumentation forty-four patients scheduled to undergo elective spinal fusion patients with scoliosis who are undergoing posterior spinal fusion surgery two groups of essentially identical patients undergoing a posterior spinal fusion for idiopathic scoliosis children spinal fusion for idiopathic scoliosis pediatric patients undergoing scoliosis surgery patients with scoliosis undergoing posterior spinal fusion surgery patients with idiopathic scoliosis undergoing a posterior spinal fusion and segmental spinal instrumentation cardiac surgical patients pediatric and adolescent scoliosis surgical patients at increased risk for intraoperative bleeding cardiac surgery and total knee arthroplasty forty patients, 9-18 yr of age idiopathic scoliosis, age at surgery 11 to 18 years, posterior spinal fusion and segmental spinal instrumentation only, autogenous iliac crest bone graft or homologous cancellous bone graft, and a signed agreement to participate in the study spinal surgery in children spinal fusion surgery for idiopathic scoliosis h(-1
plasma potassium concentrations mortality rate arterial blood pressure ratio of fio2 to pao2 weight gain case fatality rate hypotensive (systolic blood pressure less coagulation factors number of infants requiring inotropic support and death or chronic lung disease overall cost duration of normotension, meeting criteria for second bolus, meeting criteria for vasopressor support and cost comparison survival pulmonary perfusion and/or ventilation intraventricular haemorrhage global cerebral blood flow qualify for vasopressor infusion creatinine clearance (ccr) or the urinary sodium excretion rate mean arterial blood pressure (mabp), left ventricular output (lvo) and global cerebral blood flow (cbf fractional urinary sodium excretion blood pressure ccr normotensive state volume expander to maintain normal blood pressure renal function lvo|there was no significant difference in the blood pressure of the three groups before or one hour after beginning the infusion. those receiving alb (n=49 alb and 52 ns) were more likely to achieve a normotensive state (alb=57.1%, ns=32.1% p=0.01) 1 h following the initial bolus therapy. in the groups receiving exchange transfusion, the mortality rate was 41%, whereas the groups receiving either plasma or supportive care alone the mortality was 80%. outcome, as assessed by the number of infants requiring inotropic support and death or chronic lung disease, did not differ between the groups. dopamine was effective in increasing mabp; both treatments increased lvo, whereas no significant difference between the treatment groups and the control group could be demonstrated with regard to cbf. ffp did not significantly influence creatinine clearance (ccr) or the urinary sodium excretion rate either in g less than 30 or g 30-34. no difference was found in coagulation factors measured at birth or at 48 hours of age in both groups.|hypotensive preterm infants infants receiving exchange transfusion 19 infants with birth weights of less than 1,000 gm, without severe respiratory distress, and in the management of 82 infants, birth weights less than 2,000 gm, with severe respiratory distress whose disease manifested itself within the first 24 hours of life 35 infants was studied low-birth-weight infants with and without severe respiratory distress syndrome sixty three preterm infants weighing 540 to 1950 g at birth and with gestational ages of 23 to 34 weeks, who developed hypotension (mean arterial pressure < 25, 30, and 35 mm hg for infants with birthweight < 1, 1-1.49, and 1.5-1.99 kg, respectively) within the first 2 hours of life preterm neonates 36 preterm neonates sick preterm infants neonates preterm infants hypotension in neonates sixty preterm infants preterm infants in intensive care; they were divided into two groups, those with gestational ages less than 30 weeks (g less than 30) and those with gestational ages of 30-34 weeks (g 30-34 mechanically ventilated preterm infants infants with severe rds seventy three preterm infants weighing less than 1500 g or less than 32 weeks' gestation, or both
numbers of people failing attendance at the first appointment; secondary outcomes included hospitalization, transfer of care, continuing attendance, discharge, presentation at accident and emergency and death by 1 year missed initial appointments|individuals assigned to the one day orientation group had significantly lower no-show rates than individuals assigned to the control group (17% vs. 43%). the orientation statement only group had significantly fewer missed initial appointments than the control group (28% vs. 56%). the orientation statement significantly reduced the numbers of people failing to attend [79 out of 388 v. 101 out of 376 subjects, relative risk 0.76, 95% confidence interval (ci) 0.59-0.98, number needed to treat 16, 95% ci 10-187].|setting was seven inner-city uk out-patient clinics in leeds one hundred-fifty individuals who called for an intake appointment individuals who called for an intake appointment participants were 764 subjects of working age with an appointment to attend a psychiatric out-patient clinic for the first time
total x-ray photograph scores cd-3 density of cells expressing interleukin4 symptom scores number of patients withdrawn because of recurrent or persistent diseases symptoms, diary card, and rigid endoscopy scores, acoustic rhinometry, middle meatal swabs, blood tests--crp, esr, wbc, and eosinophil count nasal congestion and discharge scores clinical outcome recurrence rate of nasal polyps and chronic rhinosinusitis clinical efficacy and adverse effects wound healing patients' sense of smell wound healing, leading to recurrences of sinusitis and polyps risk of developing an infection total symptom scores serum morning cortisol values nasal symptoms eosinophils pnif endoscopic combination score (for inflammation, oedema, and polyps), a total symptoms score efficacy and safety adrenal suppression mucosal thickening allergic sinusitis nasal scores percentage of nasal deobstruction tnf-alpha level subjective nasal clinical symptoms (nasal discharge, nasal obstruction, postnasal drip and headache), (2) x-ray photographs (ethmoid and maxillary sinuses) and (3) cytokine levels (il-1beta, il-8 and tnf-alpha) by enzyme-linked immunosorbent assay interleukin-5 messenger rna diary card scores airways' resistance via active anterior rhinomanometry and the volume and area section via acoustic rhinometry nasal airway patency's parameters peak nasal inspiratory flow (pnif facial pain and sensitivity recurrence rate of chronic rhinosinusitis and nasal polyps total nasal symptom scores symptomatic response and improvement in nasal mucociliary clearance, nasal airway resistance, sinus radiographs, and intranasal bacteriology and appearance efficacy and tolerability healing with mfns morning combined symptom scores (css levels of il-1beta and il-8 morning serum cortisol nasal and ocular symptoms tolerated postoperative mean total score for several endoscopic parameters scores total endoscopic scores adverse effects bacterial sinusitis adverse events total number of drug-related adverse events|the percentage of nasal deobstruction was significantly higher with tixocortol pivalate-neomycin than with neomycin alone by the fifth examination (9th day) regardless of the etiology of the sinusitis (allergic or bacterial). twenty-six patients with allergy to house dust mites who had previously had surgery and who had persistent symptoms of disabling rhinorrhea or pressure-pain resistant to oral antibiotics and intranasal corticosteroids were recruited. significant improvements over the baseline were reported in both groups for the primary variable sum of nasal scores (-53.7% in the once-daily group and -59.7 in the twice-daily group), as well as for each nasal and ocular symptoms, without differences between the groups. in allergic patients, bans significantly (p < 0.001) reduced both morning -1.40 when patients were considered as one group, there was an improvement in the diary card scores (p = 0.054), comparing baseline to 8 or 16 weeks. mfns led to greater, although not significant, reductions in total endoscopic scores in all subjects, compared with placebo. both active preparations (with antibiotic 14 of 20 patients responded; without antibiotic 12 of 20 patients responded) were more effective than the placebo (2 of 10 patients responded). budesonide and antral irrigations reduced nasal symptoms more effectively than placebo, and there was a significantly greater reduction in facial pain and sensitivity in the budesonide group than in the placebo group. in both ns and betamethasone patients, the levels of il-1beta and il-8 had significantly decreased by the 3rd and 2nd weeks after therapy, respectively. no differences in the number of patients withdrawn because of recurrent or persistent diseases were found between the patients treated with fpans and patients treated with placebo.|chronic rhinosinusitis patients 40 patients with chronic or recurrent maxillary sinusitis 162 patients aged 18 years and older requiring fess for chronic rhinosinusitis or nasal polyps patients were withdrawn from the trial (but still included in the study for statistical purposes) if there were recurrent or persistent diseases, defined as progressive regrowth of nasal polyps, recurrent signs and symptoms of chronic sinusitis combined with abnormalities on computed tomography scan and persistent complaints for at least 2 months after fess approximately 20% patients with chronic rhinosinusitis undergoing non-allergic patients patients with chronic sinusitis using the yamik sinus catheter with and without chronic mucopurulent rhinosinusitis allergic patients with chronic rhinosinusitis subjects with a chronic rhinosinusitis with/without nasal polyps twenty-six patients with allergy to house dust mites who had previously had surgery and who had persistent symptoms of disabling rhinorrhea or pressure-pain resistant to oral antibiotics and intranasal corticosteroids were recruited adult patients (n=112) with allergic or non-allergic chronic rhinosinusitis 50 patients with chronic mucopurulent rhinosinusitis patients with crs 25 patients (39 sides) with chronic sinusitis chronic rhinosinusitis patients (n = 167) with persistent rhinosinusitis symptoms despite 2-weeks' antibiotic treatment patients with chronic rhinosinusitis allergic patients with chronic rhinosinusitis following surgery chronic rhinosinusitis (crs ninety-nine subjects patients with nasal polyps, high score at fess or no previous sinus surgery after endoscopic sinus surgery maxillary sinusitis subjects with nasal polyps 60 patients, aged 15-51 years, with chronic allergic or bacterial maxillary sinusitis chronic allergic and bacterial sinusitis allergic and non-allergic chronic rhinosinusitis
median ttf rate of response based on intention skin reactions cutaneous reactions|there was a non-significant trend in favour of the active treatment during the initial double-blind placebo-controlled phase of the trial, and no side-effects were observed. the rate of response based on intention to treat patients was 33.3% for miltefosine solution compared with 3.7% for placebo (p = .006).|52 patients with inoperable progressive skin lesions from histologically or cytologically confirmed breast cancer, not manageable by radiotherapy or systemic treatment, with superficial or flat skin lesions (estimated depth of invasion < or = 1 cm 11 patients malodorous fungating tumours cutaneous metastases from breast cancer
preschool behaviour screening questionnaire (bsq proportion of children with recurrence acceptability and efficacy serum drug levels mean log-transformed scores on the behaviour rating scales libido and impotence efficacy and toxicity overall treatment success intolerable acute toxic effects side effects efficacy free of seizures partial seizures frequency of behavioural side-effects; behaviour recurrence of convulsion and side effects 1-year remission odds ratio for behavioural problems dysmorphic effects and hypersensitivity conners parent rating scale failure rates nausea, vomiting, dizziness, and sedation hyperactivity|carbamazepine provided complete control of partial seizures more often than primidone or phenobarbital (p less than 0.03). no significant differences between the four drugs were found for either measure of efficacy at one, two, or three years of follow up. we found no significant differences between the drugs for either measure of efficacy at 1, 2, or 3 years of follow-up. the proportion of children with recurrence did not differ among the 3 groups. the mean log-transformed scores on the behaviour rating scales did not differ significantly between the phenobarbital and phenytoin groups (conners 2.64 [sd 0.71] vs 2.65 [0.89], p = 0.97; n = 32 in each group: bsq 2.12 [1.31] vs 2.18 [1.02], p = 0.94; n = 4 vs 3).|childhood epilepsy in rural india between august, 1995, and february, 1996, 109 unselected children aged 2-18 years with partial and generalised tonic-clonic epilepsy were identified by population screening adult patients newly diagnosed childhood epilepsy 94 children 151 children with gtc, aged 4-12 yrs, from madras city were enrolled newly diagnosed epileptic patients children with newly diagnosed epilepsy between 1981 and 1987 243 adult patients aged 16 years or over, newly referred to two district general hospitals with a minimum of two previously untreated tonic-clonic or partial with or without secondary generalised seizures 127 children remained in the study partial and secondarily generalized tonic-clonic seizures between 1981 and 1987, 167 children aged 3-16 years, who had had at least two previously untreated tonic-clonic or partial seizures, with or without secondary generalisation newly diagnosed adult epilepsy partial and secondarily generalized tonic-clonic seizures in 622 adults patients with newly diagnosed tonic-clonic or partial with or without secondary generalised seizures out-patients in a tertiary care hospital adults with partial or generalized tonic-clonic seizures or with both
morbidity and mortality pneumococcal isolations antibody responses higher infection rates occurrence of pneumococcal bacteremia incidence of infection|serotype-specific igg antibody responses to reimmunization varied according to pneumococcal serotype but in general were mediocre or poor; the poorest response was to serotype 6b. no pneumococcal isolations occurred in the penicillin group while receiving penicillin, although four isolations occurred within one year of stopping penicillin. the children were randomly assigned to receive either 125 mg of penicillin v potassium (105 children) or placebo (110 children) twice daily.|children with sickle cell anemia and (2 children with sickle cell anemia who were under the age of three years at the time of entry children with sickle cell anemia, who had been treated with prophylactic penicillin for at least 2 years before their fifth birthday children with homozygous sickle cell disease children with sickle cell anemia children with sickle cell anemia who received homozygous sickle cell (ss) disease 242 children aged 6 months to 3 years at entry
corrected epidermal atrophy and atypia and improved skin hydration properties overall appearance of photodamaged skin skin wrinkles, mottled hyperpigmentation, laxity, lentigines and roughness facial rhytids improvement in rhytides, patients' subjective reports of postoperative pain, time to reepithelialization, degree of postoperative crusting, and duration of postoperative erythema global response erythema, crusting, pain, itching, swelling, pigmentary changes, and the day of first make-up application intraoperative pain global responses mottled hyperpigmentation and fine wrinkles fine wrinkling and pigmentation tolerated, and skin irritation crusting appearance of photo damaged skin treatment response epidermal and granular layer thickness, decreased melanin content and compaction of the stratum corneum plasma retinoid levels erythema score fine wrinkling, tactile roughness, coarse rhytids, skin laxity/tone, sallowness/yellowing, and overall features skin roughness vascularity postoperative erythema average upper lip laser-treated wrinkle score investigator's global evaluation irritant side effects (erythema and scaling clinical and microscopical manifestations of liver spots roughness, mottled hyperpigmentation, fine wrinkling, and lentigines fine wrinkling, mottled hyperpigmentation, and roughness permanent hyperpigmentation, hypopigmentation, or scarring side effects of erythema, peeling, and stinging were usually mild and well tolerated overall severity of photodamage and sallowness local irritation and adverse events immunologic markers histologic changes local adverse events postoperative crusting and more rapid reepithelialization erythemal index adverse effects (burning, stinging, redness, peeling, dryness, discoloration, itching, and rash duration of itching erythema average upper lip dermabrasion-treated wrinkle score ra and shadows north-south facial axis values overall investigator scores wrinkle score rate of resolution of erythema efficacy objective skin changes efficacy and safety histologic evaluation wrinkle improvement and duration of adverse effects epidermal thickening efficacy and tolerability mottles and telangiectasis elasticity index fine wrinkling, mottled hyperpigmentation, roughness, and laxity good response tolerated overall photoaging effects photoaging hyperpigmentation and wrinkle reduction dryness, peeling, and acne appearance of photodamaged skin posttreatment erythema skin state safe and effective skin elasticity index changes in skin biopsies and silicone skin surface replicas mean erythemal index degree of compaction of stratum corneum, thickness of the granular cell layer, and epidermal thickness rhytide scores skin condition perioral wrinkles histologic features, keratinocyte expression of hla-dr and intercellular adhesion molecule-1, numbers of epidermal langerhans' cells and epidermal and dermal t lymphocytes, and vascularity as measured by dermal endothelial cell area rz, ra, and shadows degree of epidermal pigmentation duration of crusting, swelling, and itching postoperatively epidermal thickness swelling photoaged skin erythema, crusting, pain, and pigmentary changes overall severity of photodamage photographs for erythema, pigmentation, and wrinkle improvement wrinkle improvement general skin texture and discoloration mean epidermal thickness skin wrinkles, tightness, colour and pores vivida overall modest wrinkle improvement overall improvement in photodamaged skin average upper lip phenol-treated wrinkle score mottled hyperpigmentation safety and efficacy medium to deep (grade iii photodamaged skin topography appearance of photo-damaged skin significant lightening of hyperpigmented lesions adverse experiences frequency of erythema duration of crusting variable pulse pain dermal thickness permanent hyperpigmentation, hypopigmentation, or scarring occurred wrinkles and severity and duration of adverse effects restoring actinic damage adverse effects skin biopsies|treatment of upper lip wrinkles with baker's phenol resulted in greater improvement than treatment with the 950 microsec dwell time co2 laser. tazarotene cream and tretinoin cream significantly improved mottled hyperpigmentation and fine wrinkles. after one month of treatment the patients treated with tretinoin had significant lightening of hyperpigmented lesions as compared with the patients who received vehicle (p less than 0.002). both dermabrasion and carbon dioxide laser resurfacing are effective in the treatment of perioral rhytides. the laser treatment had a significantly higher erythema score at 1 month and a small but significantly greater improvement in perioral wrinkles at 6 months. treatment response increased throughout the 36-week treatment period and the overall appearance of photodamaged skin was significantly better than with the vehicle alone. clinical assessment demonstrated significant improvement with active treatment greater than control for fine wrinkling, tactile roughness, coarse rhytids, skin laxity/tone, sallowness/yellowing, and overall features. tretinoin-treated forearms showed significantly greater improvement in roughness, mottled hyperpigmentation, fine wrinkling, and lentigines at 24 and 48 weeks. all 30 patients who completed the study showed statistically significant improvement in photoaging on the tretinoin-treated forearms, but not on the vehicle-treated forearms. results indicate statistically significant improvement in fine wrinkling, coarse wrinkling, and yellowing with the use of tretinoin cream 0.02% at week-24 end point, compared with placebo. ninety percent (9/10) of patients felt that overall they noticed significant improvement, however, there was no distinction between the two treatment options. subjective assessment revealed statistically significant improvements in skin condition in both treatment groups but vivida was significantly (p less than 0.01) more effective than imedeen for all parameters. the effects of vivida cream on mottles and telangiectasis were also significantly (p < 0.01) greater than those of placebo. l-lactic acid cream was significantly superior to the vehicle in reducing the overall severity of photodamage (p < .05), mottled hyperpigmentation (p < .05), sallowness (p < .05), and roughness on the forearms (p < .05) at week 22. significant reductions were found in fine wrinkling, mottled hyperpigmentation, roughness, and laxity after 0.05% tretinoin therapy when compared with controls. clinical examinations after 45 and 90 days' treatment showed significant improvements in skin condition in the actively treated group but not in the placebo group (p less than 0.001). overall there were trends towards greater improvement or less worsening in the glycolic acid group for all clinical assessments for photoaging. mild to moderate skin reactions, such as erythema, peeling, and burning, were the most common side effects and, although most prevalent in the group using the 0.05% concentration, generally did not limit tretinoin use. posttreatment erythema was noted at 2 weeks in 14 subjects (67%) on the er:yag laser-treated side and 20 subjects (95%) on the co2 laser-treated side. laser wavelength/pulse duration options and new techniques continue to shorten the healing phase associated with laser skin resurfacing while maintaining clinical efficacy. it was more efficacious than vehicle in reducing skin roughness and fine wrinkling based on objective measurements. improvement in overall severity of photodamage was significantly greater for tretinoin treated subjects and was progressive over the study period. the addition of the er:yag laser following co2 laser resurfacing reduces the duration of crusting, swelling, and itching postoperatively. both co2 and er:yag laser-treated sites showed overall modest wrinkle improvement compared to the pretreatment photographs. before and after treatment, we assessed histologic features, keratinocyte expression of hla-dr and intercellular adhesion molecule-1, numbers of epidermal langerhans' cells and epidermal and dermal t lymphocytes, and vascularity as measured by dermal endothelial cell area. the degree to which the wrinkle score improved after laser treatment compared with that after dermabrasion was not statistically significant (p =.216).|university hospital-based dermatologic surgery clinic forty-two treatment sites on 21 patients seventy-five volunteers forty treatment sites on 20 patients upper lip wrinkles subjects with cutaneous facial photodamage fifteen patients who responded well were than randomly assigned to 24 patients with facial lesions 30 women with moderate to severe sun-damaged facial skin applied sun-damaged skin in women aged 40-60 years twelve healthy subjects with at least a moderate degree of photodamage outpatient clinical research unit at the massachusetts general hospital, boston fifteen healthy fair-skinned volunteers with moderate to severe perioral rhytides and no history of prior cosmetic surgical procedures to the same anatomic area seventy-four women, aged 40 to 70 years, with moderately severe photodamaged facial skin were enrolled in the study 296 subjects with photodamaged facial skin nineteen female and 2 male volunteers with skin type i to iii and wrinkle class perioral wrinkles photodamaged dorsal forearm skin rhytides photoaged skin 21 subjects with facial rhytides photo-damaged australian skin twenty female subjects with moderate to severe upper lip wrinkles nineteen evaluable volunteer sample patients aged between 36 and 72 years with fitzpatrick skin types i, ii, and iii who were in good physical and mental health with mild to moderately photodamaged facial skin were considered for analysis facial and neck photoaging thirteen patients with facial wrinkles moderate-to-severe facial photodamage a group of 15 women were three hundred forty-nine subjects with facial photodamage 251 subjects with mild to moderate photodamaged facial skin resurfacing of facial rhytides ten healthy female volunteers, aged 45 to 65 years, with moderately photodamaged forearm skin applied tazarotene 0.1% gel to one arm and vehicle gel to the other once daily for 12 weeks fifty-eight patients 40 patients with photoaged skin of the face and forearms 28 patients with facial lesions 99 photoaged patients completed a 48-week study using 0.1 twenty female patients provided informed consent and participated in the study perioral rhytides photodamaged skin university hospitals and clinical research centers sun-damaged or age-damaged facial skin 800 patients with moderate to severe photodamaged skin women aged 40-60 years sun-damaged skin in females photodamaged facial skin facial photodamage
comparative efficacy and tolerability conception rate highest pregnancy rate mean number of oocytes retrieved and embryos implantation, clinical pregnancy and multiple pregnancy rates implantation rates pregnancy rate pregnancy rates or implantation rates clinical outcome of intracytoplasmic sperm injection (icsi) and embryo transfer (et) cycles vitro fertilization and embryo transfer number of embryos transferred clinical pregnancy, ongoing pregnancy, and live birth rates rate of withdrawals at the individual visits delivery rates safety parameters clinical pregnancy pregnancy rates (prs multiple pregnancy and live birth rates luteal e(2) level clinical pregnancy rate per transfer and implantation rate p4 levels safe and well tolerated estradiol (e2 number of beta-hcg-positive results pregnancy outcome progesterone profiles and pregnancy outcomes probability of pregnancy midluteal estradiol levels implantation rate per embryo transfer late luteal progesterone concentrations lower embryo implantation, clinical pregnancy, and live birth rates tolerability ongoing pregnancy rate live birth rates lower e2 levels demographic parameters, infertility etiologies, number of gonadotropin ampules used, number of mature oocytes recovered, rates of testicular sperm usage, number of embryos transferred, and cycle and transfer cancellation rates demographic profile and pregnancy and miscarriage rates pregnancy rate per embryo transfer, early pregnancy loss, multiple pregnancy rate, and midluteal p and e(2) levels multiple pregnancy rate luteal p values hormonal levels pregnancy rates per transfer embryo quality implantation and pregnancy rates patient satisfaction scores live birth rate per transfer lh serious adverse events rates of successful pregnancies luteal-phase gnrh agonist administration increased luteal-phase serum hcg, estradiol and progesterone concentrations e2 or p levels efficacy pregnancy rates efficacy and safety serum progesterone (p) and 17-beta-estradiol (e2) and e2/p ratio levels of the luteal phase pregnancy rate, rate of spontaneous abortion, proportion of normally developing fetuses or rate of chemical pregnancy pregnancy or implantation rates pregnancy and embryo implantation rates furthermore, estradiol (e(2)), progesterone (p) levels and endometrial thickness implantation rate sd), number of oocytes demographics, stimulation parameters and embryological data specific symptoms and usual safety monitoring efficacy and tolerability adverse event profiles biochemical rates serum p levels serum p4 levels clinical pregnancy rates implantation and live birth rates pregnancy rates and the implantation rates levels of oestradiol and progesterone luteal serum e(2) and p profiles probability of conception pregnancy and live birth rates pregnancy rates (prs) and live birth rates per et elevation of serum progesterone ongoing pregnancy rates e2/p ratio vaginal discharge or irritation number of good quality embryos abortion rate spontaneous abortion rates clinical pregnancy rate progesterone pregnancy rates and live birth rates pregnancy rates, ongoing/delivered, failed pregnancy rates, and product satisfaction scores pregnancy, embryo implantation, and live birth rates probability of pregnancy in intracytoplasmic sperm injection (icsi) cycles implantation rate per embryo pregnancy and implantation rates clinical pregnancy rates, implantation rates and live birth rates implantation and pregnancy rate clinical prs rates of implantation and clinical pregnancy rates rate of positive beta-human chorionic gonadotrophin per transfer luteal serum progesterone and oestrogen concentrations living birth rates per transfer ongoing pregnancy rate per transfer cycle pregnancy, implantation and live birth rates late-midluteal estradiol levels similar levels of luteal e2 pregnancy and delivery rates serum levels of p and e2 early pregnancy loss lh levels progesterone levels embryo implantation ratio of newborn babies per embryo transferred rate of implantation and abortion, number and reasons of withdrawals, as well as adverse events, assessment of tolerability, and acceptance icsi clinical outcomes e2 or p levels, endometrial thickness failed pregnancy rates endometrial thickness pregnancy rates and ongoing pregnancy rates miscarriage rate efficacy, safety and tolerability e2 levels bleeding episodes plasma progesterone concentrations pregnancy rate and live birth rate vitro fertilization-embryo transfer (ivf-et median progesterone levels luteal plasmatic values plasma p and 17 beta-estradiol concentrations pregnancy rates (pr overall pregnancy rate and miscarriage rate pr per retrieval luteal phase serum p4 levels number of embryos transferred and the grade of the embryos duration of lps|these progesterone regimes produced no significant differences. ongoing pregnancy rates were 25.2% in the utrogest 200 group and 22.2% in the crinone 8% group when patients were analyzed who normally completed the trial. administration of 0.1 mg of gnrh agonist triptorelin on day 6 after icsi led to a significant improvement of implantation and live birth rates after icsi as compared with placebo. there were, however, no differences in clinical pregnancy rates between the two groups in patients who used either the gnrh antagonist or microdose gnrh agonist protocols. the implantation rate per embryo was significantly higher in the im group (40.9%) than in the oral group (18.1%). the women randomized to luteal phase supplementation with im progesterone had significantly higher clinical pregnancy (48.5% vs. 30.4%; odds ratio [or], 2.16; 95% confidence interval [ci], 1.21, 3.87), embryo implantation (24.1% vs. 17.5%; or, 1.89; 95% ci, 1.08, 3.30), and live birth rates (39.4% vs. 24.5%; or, 2.00; 95% ci, 1.10, 3.70) than women randomized to crinone 8%. twenty-six ongoing pregnancies were achieved in the progesterone (26%) and 30 in the progesterone/e2 group (29.7%). bleeding episodes were 15.9% in group a compared with 20.8% in group b (or = 0.72; 95% ci = 0.38-1.36). the luteal phase was significantly shorter in groups b, c and d, whereas group e was comparable with group a, 13.5 and 13.0 days, respectively. no advantage was found in the addition of e2 valerate to p luteal phase support of gnrh-a- and hmg-induced ivf-et cycles. when the two groups were compared, there were also statistically significant differences in multiple pregnancy and live birth rates ( p < 0.05). although there was no significant difference in the number of good quality embryos transferred in both groups, the implantation and pregnancy rate were significantly higher in the gnrh-a - treated group compared with placebo controls. safety parameters were similar in both groups, except for drowsiness, which was more significantly frequent in the oral progesterone group than in the crinone group at all time points. estradiol supplementation during the luteal phase in women undergoing ivf/icsi-et has a beneficial effect on the outcome without (at least, as seems from this study) having any adverse effects. pregnancy rates, ongoing/delivered, failed pregnancy rates, and product satisfaction scores for patients supplemented with crinone vaginal gel and with imp. extending gnrha treatment through the luteal phase appeared not to have a significant impact on pregnancy or implantation rates in intracytoplasmic sperm injection cycles. pregnancy rates were high and similar in all treatment groups, with biochemical rates exceeding 50%, clinical and ongoing rates >or=40%, and live birth rates at 35%-38%. there were no significant differences in pregnancy rates or implantation rates between groups. despite higher embryo quality in group 1 than in group 2 (60.3 vs. 51.6), clinical (63.0% vs. 62.7%) and ongoing (58.7% vs. 51.0%) pregnancy rates (pr) were not significantly different. gnrh agonist administration in the luteal phase was reported to beneficially affect the clinical outcome of intracytoplasmic sperm injection (icsi) and embryo transfer (et) cycles. the ongoing pregnancy rate per transfer cycle was significantly better with hcg (18.7 versus 9.3). they did not differ in terms of e2 or p levels, endometrial thickness on the day of hcg, number of follicles > 16 mm in diameter, mature oocytes retrieved, or embryos transferred. the pregnancy rate was significantly higher with dydrogesterone than with progesterone in group d (39.1% vs. 26.7%; p < 0.01), group e (41.2% vs. 35.6%; p < 0.01) and group f (48.2% vs. 33.9%; p < 0.001). with oral micronized p4 supplementation the p4 levels were higher (p less than .001) and the luteal phase longer (p less than .05). p resulted in a higher percentage of pregnancies than the vaginal preparation, with statistically significant differences. pregnancy rate in women with low late-midluteal estradiol levels was significantly lower compared to that with medium (100-500 pg/ml) and high (> 500 pg/ml) levels (13.3, 26.8, and 36.3%, respectively). there was no difference between the groups in pregnancy rate, rate of spontaneous abortion, proportion of normally developing fetuses or rate of chemical pregnancy. there were no significant differences in the clinical pregnancy rates (25 vs. 20%) and in the implantation rates (12.7 vs. 9.1%) of patients who received im progesterone and oral chlormadinone acetate. the rate of positive beta-human chorionic gonadotrophin per transfer was 38.4% with imp, 35.0% with vpg once daily and 43.1% with vpg twice daily. efficacy was assessed using the pregnancy rates, which was, per transfer, statistically significantly higher in group a than in group b (32.5 vs. 18.3% respectively). in 148 out of 288 cycles, the luteal phase was supported only by vaginal micronized progesterone (group i). the pregnancy rate was 21.6 versus 15.0% per transfer cycle with dydrogesterone or placebo, respectively. the ongoing pregnancy and the living birth rates per transfer were significantly higher in the patients supplemented with intramuscular p than in those treated with vaginal gel the two groups did not differ in the mean number of oocytes retrieved and embryos replaced, nor in the mean age of the patients and the amount of hmg used. significantly (p<0.05), more patients given dydrogesterone than micronised progesterone were satisfied with the tolerability of their treatment. implantation rate was significantly higher with the vaginal ring compared with i.m. im significantly decreased e2/p ratio (p < 0.05). because pregnancy rates and ongoing pregnancy rates were similar with and without estrogen supplementation (50.0% vs. 55.2% and 36.6% vs. 34.4%, respectively), we concluded that luteal estrogen supplementation in fixed multidose gnrh antagonist cycles did not change the pregnancy rates significantly. hormonal levels did not differ between groups. the overall pregnancy rate and miscarriage rate were comparable among the three groups. following low dose vaginal treatment, a significantly higher implantation rate (30.7 versus 10.7%, p < 0.01), but similar clinical pregnancy rate (47.0 versus 33.3%) and ongoing pregnancy rate (41.1 versus 20.0%) was observed, compared with oral treatment. similar levels of luteal e2 were documented in groups b and c. p levels were similar in the three groups.|40 years of age who were undergoing ivf with luteal gnrh pituitary down-regulation one hundred consecutive patients undergoing et after ivf 257 women, who were pregnant after icsi on day of first ultrasound, into two groups: to 43 patients who received the support of luteal phase through the one-hundred-and-twenty women were eligible for this study vitro fertilization and embryo transfer women subjects undergone down regulated patients undergoing assisted reproduction techniques (art 164 patients who underwent patients who received gnrh antagonist for pituitary suppression two hundred and fifty patients four hundred thirty women who underwent their first ivf or intracytoplasmic sperm injection cycle were randomized after successful transfer of two or three embryos from july 1999 through september 2001 copyright 2010 american society for reproductive medicine 1,373 women undergoing in vitro fertilization the age range of 252 women was 19-41 years and the total number of cycles was 310 six hundred women about to undergo ovarian stimulation for icsi (300 using a long gnrh agonist protocol and 300 using a gnrh antagonist protocol women undergoing icsi cycles, with controlled ovarian hyperstimulation using long agonist protocol women under age 40 years with day-3 follicle-stimulating hormone levels seventeen german ivf centers one hundred seventy-six patients 1,373 infertile women undergoing ivf participated 1,211 art patients 60 patients patients undergoing ivf who are treated with a gnrh agonist four hundred sixty-eight patients were randomized, and 407 completed the study university-based tertiary fertility center university-based ivf center normal responder ivf patients treated with women with fibroids or difficult oocyte retrieval university-affiliated assisted reproduction center a total of 283 patients one hundred eighty-one women underwent a patients stimulated with recombinant fsh (rfsh) and gnrh antagonist for ivf, who received patients were accepted for treatment in the art unit of selcuk university, meram faculty of medicine, between january 2001 and march 2003 310 icsi cycles were carried out in 252 infertile couples between january 2001 and march 2003 patients with low late-midluteal estradiol levels one hundred sixty-six patients undergoing their first cycle of ivf treatment woman undergoing ivf 412 patients, aged between 28 and 37 years infertile women volunteers in an academic research environment women undergoing agonist as well as antagonist protocol; 2) women undergoing ivf/icsi with good-quality embryos available ivf/icsi patients one-hundred-and-fifty-six patients undergoing patients undergoing an in-vitro fertilization (ivf) procedure five hundred and seventy women undergoing et following controlled ovarian stimulation with a long gnrh agonist protocol were included pregnant women 176 women treated for assisted procreation patients undergoing ivf treatment mean age (31.8 years vs. 32.7 years) and reasons for infertility one hundred one patients were enrolled (48 in group 1, 53 in group 2 153 women ivf-embryo transfer trial copyright (c) 2010 american society for reproductive medicine ivf unit of a university hospital, we studied patients who were undergoing ivf 64 high responder patients requiring intracytoplasmic sperm injection due to male factor infertility two hundred and one women undergoing ivf-et.intervention(s): women patients with low late-midluteal estradiol levels in ivf cycles twenty-five u.s. art centers patients stimulated with gnrh antagonist/rfsh for ivf vitro fertilization vaginal gel (vgp) at two different doses for luteal support in ivf 197 women undergoing ivf-et cycles with human vitro fertilization (ivf 430 women underwent patients undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer 132 patients in group a continued patients aged < or = 37 years undergoing an in vitro fertilization (ivf) procedure for the first time, who were stimulated after pituitary desensitization with patients who cannot tolerate intramuscular administration 498 patients were divided into three groups 156 patients 675 patients ninety-three infertile women underwent a total of 143 ivf-et cycle using cc for ovulation induction 436 women undergoing first ivf cycles with long protocol and luteal support with twenty-three patients were randomized patients, undergoing assisted reproductive technology (art) treatment, who were treated with a patients undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (ivf/icsi-et) cycles 86 ivf patients undergoing embryo transfer after oocyte aspiration, 505 women women undergoing ivf/icsi-et vitro fertilization-embryo transplant cycles patients with thin endometrium (<or=7 mm) after ivf treatment patients undergoing in-vitro fertilization (ivf vitro fertilization-embryo transfer cycles 40 patients with normal and high response (serum estradiol > 2,000 pg/ml) in gnrha down-regulation private and university fertility centers women treated with ivf-embryo transfer and for agonadal women participating in an oocyte donation programme 2010 american society for reproductive medicine unsuccessful women with low late-midluteal estradiol levels (< 100 pg/ml) proceeded with the exploratory second ivf cycles women<or=37 years old patients with thin endometrium (<or=7 mm ivf-icsi patients university-affiliated ivf unit normal responder patients treated with fixed multidose gnrh antagonist
walking performance, resting toe pressure, resting and postexercise ankle/brachial pressure ratio, and basal/postischemic toe-pulse ratio vascular endothelial growth factor moderate level of pain serum levels of pentoxifylline and its hydroxy-metabolite walking distance and blood rheology red blood cell filterability, plasma fibrinogen concentration and blood viscosity, resting and post-ischemic calf muscle blood flow, and the resting and post-exercise ankle/brachial systolic pressure ratio withdrawal rates serious drug-related side effects pxf improved walking distance pain relief initial claudication, toe peak-flow time, pulse reappearance time (prt/2), and maximum postischemic flow time diabetes mellitus walking performance (absolute walking time and walking distance on a treadmill ergometer) and by acral plethysmography maximal walking distances nausea median of the maximal walking distance claudication distance and walking distance flux side effects (including headache, palpitations, and diarrhea quality of life painfree walking distance absolute subjective claudication distance absolute claudication distance (acd duration of coad cilostazol peak acd total walking distance (twd walking distance and quality of life circulating vegf levels plasma levels of vegf clinical efficacy and safety whole blood or plasma viscosity maximal walking distance initial and absolute claudication distances walking distance maximal walking distance with constant-speed, variable-grade treadmill testing exercise tolerance ankle-brachial index exercise performance or quality of life subjective response; claudication and maximum walking distances; ankle systolic indices; maximum blood flow in the lower limb by gravimetric plethysmography; plasma fibrinogen; erythrocyte deformability and whole blood viscosity initial claudication distance and quality of life assessment farther walking distance of 2 miles red cell rigidity ankle systolic blood pressure ratio ( asbp -ratio exercise flux (aef efficacy, safety, and cost levels of vegf erythrocyte deformability walking performance walking distances pain-free walking distance postexercise distal flow, ratios, and pressures and enabling faster recuperation of basal pulse rates level of pain pain-free walking distance (pfwd acd adverse reactions pentoxifylline efficacy level of walking claudication pain frequency of minor side effects aef deaths and serious adverse event rates subjective side effects efficacy and tolerability subjective response, ankle systolic indices, maximum limb blood flow or whole blood viscosity tolerated maximal and painfree walking distances and blood viscosity mean erythrocyte deformability vegf levels claudication distance and mean plasma fibrinogen concentration efficacy, safety, and tolerance reduction of lower limb paresthesias efficacy, safety and cost blood viscosity distal pressure and resting microcirculatory blood flow mean maximal walking distance blood flow|pentoxifylline increased acd by 13.9% relative to placebo (p = 0.039). after one and eight weeks, but not after twelve weeks, the maximal walking distances were significantly longer in group a than in group b. microcirculatory evaluation indicated an increase in flux (p < 0.05) in the pxf group (not significant in the placebo group); the after-exercise flux (aef) was increased (p<0.05) in both groups at 6 months but the increase in aef was greater in the pxf group at 12 month. the clear improvement shown for both variables was greater and statistically significant (p less than or equal to 0.05) after treatment with pentoxifylline. pentoxifylline given orally in doses up to 1200 mg/day was significantly more effective than placebo in increasing both the initial and absolute claudication distances in patients with coad. pmax), which was initially elevated, decreased significantly (p less than 0.05) during both medication periods, but there were no significant differences between the two drugs. this was shown by a 'therapeutic effect ratio' of 0.98 for treadmill claudication distance and 0.96 for treadmill walking distance after within-patient analysis at the end of the cross-over (where a ratio of 1.0 means the test drug and placebo effects are identical). patients given either cilostazol or pentoxifylline showed a significant improvements in maximal walking distance compared with the placebo group (34 m and 33 m respectively, compared with 5 m; both p<0.05). there was a significant 60% increase in pain-free walking distance in either pentoxifylline treatment periods, whereas there were no clinically relevant changes in the placebo periods. there was a 38% difference at 6 months and 39% at 12 months in favor of pxf. significant differences within groups were also noted for initial claudication, toe peak-flow time, pulse reappearance time (prt/2), and maximum postischemic flow time, together with significant intergroup variables. the placebo group showed a significant improvement (p less than 0.05) in claudication distance and mean plasma fibrinogen concentration, but no such improvements were observed in the oxpentifylline group. the level of pain did not change significantly with either aspirin or pentoxifylline, but the walking distance was farther with the pentoxifylline group. nausea was the only drug side effect noted. side effects (including headache, palpitations, and diarrhea) were more common in the cilostazol-treated patients, but withdrawal rates were similar in the cilostazol (16%) and pentoxifylline (19%) groups. the results of the overall intention-to-treat analysis of the study population show statistically significant superiority of pentoxifylline over placebo for all absolute claudication distance summary and end point measures.|long-range (>400 m interval) intermittent claudication chronic occlusive arterial disease patients patients with coad 24 patients (19 males, 5 females, aged between 40 and 71 years) suffering from peripheral occlusive arteriopathy of stage ii severity (fontaine's classification walking leg pain in the elderly with pvd 194 included patients, 135 completed the study: 75 in the pxf group and 60 in the placebo group 24 returned for follow-up patients with peripheral arterial disease (fontaine stage ii or iii), with 30 patients receiving 23 returned for follow-up), and 30 patients receiving 45 patients with peripheral arterial disease (fontaine stage ii intermittent claudication patients with pad who have intermittent claudication enrolled patients with moderate-to-severe claudication from 54 outpatient vascular clinics, including sites at air force, veterans affairs, tertiary care, and university medical centers in the united states patients with intermittent claudication claudication 120 included patients, 101 completed the study: 56 in the pxf group and 45 in the placebo group twenty-six patients with severe short-distance claudication 430 patients with intermittent claudication non-diabetic patients intermittent claudication associated with chronic occlusive arterial disease (coad enrolled 150 patients with moderately severe chronic occlusive arterial disease (coad) at three centers in scandinavia human subjects patients with moderately severe chronic occlusive peripheral arterial disease patients sixty-five years or older with claudication 922 consenting patients, 698 met the inclusion criteria 128 outpatients 90 patients who participated, 45 received 50 patients with intermittent claudication severe intermittent claudication thirty-one patients, mean age 60 years (range 45-80 years), with a typical history and objective symptoms of intermittent claudication with a reported maximal walking distance less than 500 m, were included in a cross-over study intermittent claudication of the lower limbs 38 subjects with stable, severe to moderately severe, intermittent claudication 40 patients receiving forty outpatients
recollection of pain patient cooperation, endoscopist satisfaction, and level of sedation severe pain and discomfort duration of colonoscopy time to recover from sedation success, difficulty, or duration of the colonoscopy digit symbol substitution test score lighter sedation (median sedation score early recovery recovery of cognitive and psychomotor functions faster recovery time complete recovery recovery of cognitive function effective analgesia, sedation, amnesia, patient comfort and stable recovery profile without respiratory depression 10-point visual analog scale sedation and pain scores patient satisfaction, procedure and recovery times, neuropsychologic function, and complications safety and efficacy analgesia (median pain score mean arterial pressure, heart rate and end-tidal co2 10-cm visual analog scale full recovery sooner systolic blood pressure drugs cost for naps oxygen saturation and hemodynamics pain (visual analogue scale) and procedure time six minor complications dot test score endoscopist satisfaction cardiopulmonary complication rates, pain scores, satisfaction scores, and patients' willingness to repeat colonoscopy mean time to sedation arterial pressure and heart rate overall satisfaction transcutaneous partial pressure of carbon dioxide hypoventilation nausea and vomiting heart and respiratory rates, blood pressure, and oxygen saturation overall mean satisfaction pain and sedation score patient satisfaction, procedure and recovery times, neuropsychological function, and complications synergistic sedation observer's scale for sedation and alertness (ossa) score mean arterial blood pressure discharge times minor complications (1 hypotension and bradycardia, 2 hypotension alone, and 1 tachycardia patient satisfaction episodes of hypotension, 1 episode of bradycardia, and 1 rash visual analogue scale pain respiratory rate and oxygen saturation values pain and discomfort scores hemodynamic and respiratory data, pain, discomfort and sedation scores, patient and gastroenterologist satisfaction and recovery profiles depth of sedation efficacy, safety and recovery characteristics pain scores tests reflective of learning, memory, working memory span, and mental speed oxygen desaturation requiring mask ventilation and 4 episodes of hypotension oxygen desaturation develop|patients in the pcs group recovered significantly faster (median 5 min vs 35 min; p < 0.0001) and left the department more quickly (median 40 min vs 75 min; p < 0.0001). there were no differences between the groups with respect to pain (visual analogue scale) and procedure time. all patients treated with the synergistic sedation were able to participate (p=0.002), and performed better. although more sedated intraoperatively (sedation score 4 vs. 2; p = 0.03 for a single test of hypothesis; correction for multiple testing of data removes this significance), patients in the propofol pcs group were more alert by 30 minutes and discharged earlier (mean and sd times were 43.3 [12.1] min compared with 61.0 [29.7] min; p = 0.001.) early recovery was delayed in the propofol group (p < 0.002). pcs provided lighter sedation (median sedation score, 3 versus 4; p=0.0001), less analgesia (median pain score, 1 versus 0; p=0.004), a smaller maximum fall in systolic blood pressure (23 mmhg versus 33 mmhg; p=0.02) and a faster recovery time (median 10 min versus 40 min; p=0.0001), irrespective of the dose administered, compared with a diazemuls-pethidine combination. there were no significant differences in cardiopulmonary complication rates, pain scores, satisfaction scores, and patients' willingness to repeat colonoscopy with the same sedation. the endoscopist's evaluation of patient sedation and cardiorespiratory parameters were similar in both groups and in all age groups. at discharge, the propofol group had better scores on tests reflective of learning, memory, working memory span, and mental speed. pain and discomfort scores were better in group r than in group p. sedation levels were higher in group p than in group r. group p needed more supplemental doses than group r. the time to reach an aldrete score of nine or more was shorter in group r, but discharge times were similar in the two groups. the recovery is delayed in the midazolam + alfentanyl's group in comparison with the propofol's group. after recovery, the propofol group scored better on tests reflective of learning, memory, working memory span, and mental speed.|sixty-seven patients undergoing colonoscopy patients undergoing colonoscopy 88 patients 79 patients presenting for colonoscopies forty patients one hundred fifty patients undergoing colonoscopy on an outpatient basis between july 2005 and june 2006, 88 patients 100 patients one hundred patients eighty outpatients (asa class i or ii) undergoing colonoscopy conscious sedation in colonoscopy in a group of patients that included a sufficient number of elderly patients with several comorbidities 66 patients undergoing colonoscopy patients undergoing outpatient colonoscopy 120 consecutive patients undergoing colonoscopies one hundred outpatients undergoing colonoscopy patient-controlled sedation for colonoscopy
pain analgesia pain relief adverse effects postoperative pain adverse effects and/or inadequate relief nausea, vomiting and drowsiness|in the multiple dosing phase, zomepirac was statistically better than dihydrocodeine. non-parametric statistical tests indicated highly significant correlations between single- and multiple-dose analgesic measurements for both zomepirac and dihydrocodeine. dihydrocodeine 60 mg produced four times the number of patients affected by adverse effects compared with ibuprofen, and dihydrocodeine 30 mg three times as many. patients who received ibuprofen as supplementary medication also experienced less pain and had greater pain relief than those receiving dihydrocodeine as supplementary medication, even when their post-operative treatment had been placebo.|for treating moderate to severe pain following the removal of unilateral, impacted mandibular third molar teeth under local anaesthesia relieving pain following wisdom teeth removal 148 patients to compare 400 mg 68 patients undergoing two-stage bilateral lower third molar removal
maternal satisfaction emetic symptoms complete response pruritus incidence of intraoperative/postoperative nausea neonatal apgar scores sedation scores incidence and severity of ionv hypotension and vasopressor use nausea scores, number of vomiting episodes, or patient satisfaction with postoperative nausea and vomiting management intraoperative, postdelivery vomiting neurobehavioral exam results overall satisfaction with postoperative care incidence of vomiting and treatment for vomiting intraoperative nausea intraoperative antiemetic efficacy incidence of nausea severity of vomiting nor the incidence of nausea incidence, onset, duration, and severity of pruritus; the onset and severity of pain; and satisfaction frequency incidence of intra- or postoperative nausea or vomiting/retching total incidence of nausea and vomiting pulse rate or blood pressure incidence and severity of nausea and vomiting vomiting prior to delivery total incidence of nausea and vomiting, incidence of > 4 vomiting episodes mean arterial pressure intraoperative, postdelivery nausea incidence and severity of nausea frequency and severity of the nausea and vomiting episodes nausea, vomiting, and retching maternal characteristics ephedrine requirements nausea than vomiting hypotension after delivery emesis free incidence of vomiting and the severity of nausea frequency of vomiting perioperative nausea and vomiting total number of parturients with no vomiting and/or no antiemetic medication severity of pruritus score total ephedrine consumption severity or incidence of pain, or requests for analgesic or antipruritic medication emesis severity of hypotension antiemetic efficacy severity of nausea and vomiting neonatal outcome efficacy and safety respiratory depression nausea and vomiting cumulative pain score analgesia and nausea frequency and severity of postoperative (24-hour) pruritus, nausea and vomiting, surgical pain, and side effects overall patient satisfaction intraoperative nausea and vomiting efficacy and tolerability blood pressure nausea free nausea and vomiting, sedative score, pain score, and side effects perioperative nausea nausea and/or vomiting vasopressor nausea or vomiting number of women who complained of nausea nausea, vomiting, retching, pain relief, itching, and adverse effects antiemetic efficacy and safety pruritus score patient's perception of the control of nausea and their overall satisfaction neonatal acid-base status and neurobehavioral exams intraoperative nausea and vomiting (ionv severe emetic symptoms frequent incidence of restlessness frequency of intraoperative nausea and vomiting nausea/vomiting score, pain score, sedation score, or shivering score incidence and severity of intraoperative emetic symptoms frequency of retching or vomiting postoperative nausea and vomiting severity of nausea retching or vomiting (1 = vomiting or retching, 0 = no vomiting or retching supplementary intraoperative analgesia postoperative vomiting antiemetic effect episodes and severity of nausea and vomiting, rescue antiemetic requirement, patient satisfaction, and side effects patient satisfaction antiemetic medication frequency and the severity of nausea and vomiting postoperative nausea or vomiting overall rates for all emesis frequency of respiratory depression nausea scores incidence of ponv and side effects severity of nausea and number of vomiting episodes pruritus, nausea, and vomiting postoperative nausea and vomiting/retching nausea incidence of intra- and postoperative nausea or vomiting vomiting safety and efficacy cumulative perioperative pain score frequency of nausea and vomiting, sedative score, respiratory depression, and side effects side effects frequency of intraoperative nausea maximum analog sedation score frequency of intraoperative and postoperative vomiting incidence rates for intraoperative nausea incidence of vomiting pruritus, nausea and vomiting need for rescue antiemetics verbal pain score haemodynamic response blood pressure, heart rate and vasopressor requirements nausea, retching, and vomiting intraoperative vomiting pain scores frequency of nausea incidence of restlessness nausea, retching, and vomiting intraoperatively cumulative nausea, vomiting, and pain scores respiratory depression (respiratory rate|both dexamethasone and droperidol significantly decreased the total incidence of nausea and vomiting compared with saline, with incidences of 18, 21 and 51% for the three treatments respectively (p<0.01 and p<0.05 respectively). this study showed a significantly lower incidence of nausea and vomiting and a tendency toward less severe emetic symptoms in the ondansetron and the droperidol groups than in the placebo group, but the ondansetron group was not statistically different from the droperidol group. control variables were similar in the two groups. patients in group o required significantly less vasopressor (p=0.009) and had significantly lower incidences of nausea and vomiting (p=0.049). the use of acupressure reduced the incidence of nausea or vomiting from 53% to 23% compared with placebo (95% confidence interval (ci) 0.34-0.25; p = 0.002) during the operation and from 66% to 36% compared with placebo (95% ci 0.34-0.19; p = 0.003) after the operation. incidence rates for intraoperative nausea were 64% (acupressure group) and 71% (control group) (p = 0.416), with an incidence of intraoperative vomiting of 22% (acupressure group) and 27% (control group) (p = 0.506). prophylactic iv ondansetron 8 mg is safe and effective in reducing the frequency and the severity of nausea and vomiting, but not pruritus, following cesarean delivery with intrathecal sufentanil-morphine. ondansetron was effective in reducing the incidence of nausea and vomiting in patients receiving intrathecal morphine for caesarean section. there were no differences among groups in nausea/vomiting score, pain score, sedation score, or shivering score at 4, 8, and 24 h after surgery. intraoperative nausea was decreased in the it fentanyl group compared with the iv ondansetron group: the median (interquartile range) difference in nausea scores was 1 (1, 2), p = 0.03. the incidence of vomiting was lower following ondansetron (36%) compared with the control group (58%, p < 0.028). however, there was no statistically significant difference between the two groups in the patient's perception of the control of nausea and their overall satisfaction. maximum analog sedation score was higher in group m compared to groups o and p (p < 0.05). neonatal outcome was similar in the two groups and all the neonates had apgar scores > or = 8 at one and five minutes. acupressure is an effective, non-pharmacologic method to reduce intraoperative nausea during elective cesarean section in the awake patient. there was also no difference between the two groups in nausea scores, number of vomiting episodes, or patient satisfaction with postoperative nausea and vomiting management. the incidence of nausea and vomiting within 6 h postoperatively was lower and incidence of no nausea and vomiting for 24 h postoperatively was significantly higher for the combination group compared to the placebo group and the dexamethasone only group. patients in the group pretreated with glycopyrrolate reported a reduction in the frequency (p = 0.02) and severity (p = 0.03) of nausea. the greatest reduction in emesis in the scopolamine group when compared with placebo was in the 6-24 h time period. no differences were found between the groups in terms of severity or incidence of pain, or requests for analgesic or antipruritic medication. the administration of supplemental oxygen from anesthetic induction until the end of the surgery did not reduce the incidence of intra- and postoperative nausea or vomiting in women undergoing cesarean section under subarachnoid block. the incidence of nausea and vomiting was significantly decreased from 43% and 27% in the control group, to 3% and 0% in the acupressure group, respectively (p < 0.05). the incidence of nausea, retching, and vomiting was significantly higher in the control group, compared to the propofol and midazolam groups. twelve women (30%) in the metoclopramide group, versus eight (20%) in the droperidol group, had intraoperative, postdelivery nausea (p = ns). parturients who received dexamethasone, either 10 mg or 5 mg were different from those who received saline alone in the following parameters: the total incidence of nausea and vomiting, incidence of > 4 vomiting episodes, number the of parturients requiring rescue antiemetics, and the total number of parturients with no vomiting and/or no antiemetic medication (p < 0.05 to p < 0.01). there was no significant difference overall between the two groups in the incidence of intra- or postoperative nausea or vomiting/retching. droperidol reduced nausea and vomiting but did not prevent itching, and that epidural droperidol failed to prevent all side effects. patients in the group receiving metoclopramide had a significantly lower incidence of nausea and vomiting both before and after delivery than the control group (14% versus 81% overall). no extrapyramidal symptoms or significant changes in pulse rate or blood pressure were associated with droperidol administration. reduces the incidence of nausea compared with dexamethasone 8 mg i.v.|patients who have delivered by cesarean section and received caesarean section one hundred and eighty parturients (n=45 in each of four groups) requiring parturients undergoing elective caesarean section parturients patients undergoing caesarean section under spinal anaesthesia 94 parturients undergoing surgical delivery healthy patients undergoing elective cesarean section and receiving epidural morphine for postoperative analgesia 164 nonemergent cesarean section patients given epidural anesthesia sixty parturients receiving patients receiving intrathecal morphine for caesarean section 97 pregnant women undergoing cesarean section 60 women (asa i-ii) receiving post-caesarean section analgesia intrathecal morphine-induced pruritus after cesarean delivery 80 women undergoing elective caesarean section under spinal anaesthesia (using 0.5% bupivacaine 10 mg during cesarean deliveries performed with spinal anesthesia parturients given epidural morphine for post-cesarean section pain relief 42 asa physical status i-ii parturients at term post-cesarean analgesia two-hundred-forty parturients patients receiving term parturients undergoing non-urgent cesarean section with epidural anesthesia without producing unwanted side-effects inpatient obstetric unit at a university hospital center during elective cesarean section under spinal anesthesia during and after elective cesarean section with epidural anesthesia parturients undergoing cesarean section under spinal anesthesia during caesarean section under spinal anaesthesia cesarean section post-cesarean section pain relief patients under general anesthesia after cesarean delivery 128 term parturients undergoing elective and non-urgent cesarean section with epidural anesthesia 120 parturients (n=40 in each group) receiving elective cesarean delivery during spinal anesthesia parturients during spinal anesthesia for cesarean delivery women undergoing cesarean section under subarachnoid block caesarean delivery under spinal anaesthesia after cesarean section peripartum nausea and vomiting during regional anesthesia for elective cesarean section in order to prevent emesis in at least 50% of patients cesarean section patients or in patients under epidural anesthesia for abdominal surgery elective caesarean section under spinal anaesthesia 97 such women caesarean section under spinal anaesthesia with epidural anesthesia for cesarean section during and after spinal anaesthesia for caesarean section for post-cesarean section pain relief forty-eight asa physical status i-ii parturients requiring nonemergent cesarean section gave their consent women using pca after caesarean section nonemergent cesarean section patients given epidural anesthesia intraoperatively and for the first 24-hour period after delivery after caesarean section under spinal anaesthesia with added parturients undergoing caesarean section ninety-four patients scheduled for caesarean section were included women who have undergone cesarean section 100 nonbreastfeeding women undergoing elective cesarean delivery with spinal anesthesia for cesarean section patients receiving epidural morphine fifty-two parturients scheduled for elective caesarean section seventy-five patients 94 patients undergoing cesarean delivery with spinal anesthesia to receive two-hundred forty women undergoing cesarean delivery under spinal anesthesia during epidural anesthesia for cesarean section x kg(-1 after caesarean section for post-cesarean analgesia parturient patients undergoing caesarean section 120 women undergoing elective cesarean section under spinal anesthesia (using 0.5 during and after cesarean delivery under spinal anesthesia during cesarean delivery with spinal anesthesia 31 women and the propofol group 29, of whom 3 were excluded thirty healthy parturients presenting for elective cesarean delivery with standardized bupivacaine spinal anesthesia cesarean section patients under epidural anesthesia anesthesiology department, hacettepe university, turkey, hospitalized care cesarean section patients given 203 patients had either cesarean sections under subarachnoid block fifty women eighty-one consenting women undergoing elective caesarean section under spinal anaesthesia parturients receiving intrathecal morphine while undergoing cesarean delivery 110 parturients scheduled for elective cesarean delivery were enrolled in the study cesarean section patients given epidural anesthesia ninety-nine women undergoing elective caesarean section under spinal anaesthesia 120 women undergoing caesarean section under spinal anaesthesia with 90 parturients with asa physical status i and ii between the ages of 20 and 38 years undergoing spinal anesthesia for elective cesarean delivery
odour, maceration, absorption capacity and leakage maceration delayed healing ulcers lymphangitis and/or fever wound severity score clinical infection total masepsis score and/or tolerability ulcer area wound area closure rate mean wear time poor dressing acceptability ulcer area and healing exudate level adverse events|after 1 and 4 weeks, odour was present in significantly less of the ulcers in the contreet foam group (17% and 19%, respectively) compared with the allevyn hydrocellular group (47% and 39%, respectively) and at the final visit there were significantly fewer leakages in the contreet foam group (19%) compared with the allevyn hydrocellular group (49%). according to the investigators, fewer wounds developed a clinical infection over the four-week follow-up in the test group (33% versus 46%; p = 0.223). wound area was reduced by 50% with the silver foam and 34% with lbp less slough and maceration, a faster reduction in exudate level and more positive wound progress was achieved with the silver foam.|619 patients with ulcers of varying aetiologies critically colonised venous leg ulcers thirteen centres recruited 99 patients with either a venous leg ulcer or a pressure ulcer chronic wounds with signs of local infection critically colonised, chronic venous leg ulcers colonised chronic wounds critically colonised chronic wounds fifty-one and 48 patients were randomised in the test and control groups respectively: 28 pressure ulcers and 71 venous leg ulcers ulcers with delayed healing one hundred and twenty-nine patients were included (contreet foam critically colonised venous leg ulcers with delayed healing
volume losses wellbeing' score number of patients subjectively improving leg circumference mean volume losses circumference measurements symptom relief|analysis of covariance revealed significant mean volume losses for both experimental and control groups, with ponderal index the only significant covariate. a 'perceived wellbeing' score revealed the lymphatic technique group (p<0.0001) significantly increased their wellbeing the most, followed closely by relaxing techniques (p<0.001) and then the control rest group (p<0.03). the number of patients subjectively improving in the active drug group was significantly greater than in the placebo group; patients receiving hr also showed a small but significant decrease in leg circumference.|69 patients control women (n = 18 healthy pregnant women with foot oedema healthy pregnant women with dependent leg edema late pregnancy thirty-five healthy pregnant women with severe pedal edema fifty-five women in the third trimester
fetal tachycardia and repetitive late decelerations|when misoprostol is used in women with previous cesareans, there is a high frequency of disruption of prior uterine incisions.|suspected uterine rupture women with prior cesareans women with previous cesarean delivery women with previous cesareans
apgar scores neonatal deaths premature uterine activity mean arterial and diastolic blood pressure number of admissions to the neonatal intensive care unit (nicu neonatal complications prolongation of pregnancy tocolytic efficacy and maternal tolerance time to uterine quiescence time to uterine quiescence, time gained in utero, recurrence of preterm labor, failure of tocolysis, and pertinent maternal and neonatal outcomes maternal demographic characteristics number of entry variables, including cervical examination, contraction frequency, and gestational age maternal side effects recurrent labor delay of delivery adverse side effects, mainly nausea and vomiting number of neonates admitted into intensive care nor the premature infant center side effects maternal side-effects maternal side effects and haemodynamic changes neonatal outcome efficacy and safety success rate mean term of delivery maternal and fetal complications severe maternal side effects percentage of deliveries efficacy and maternal, fetal, and neonatal outcome adverse medication effects and recurrent preterm labor birth weight, estimated gestational age at delivery, or neonatal complications maternal pulse rate fetal and neonatal outcome suppression of preterm labor maternal heart rate headaches, and with salbutamol, tremors and palpitations apgar scores and umbilical artery and vein phs recurrence of preterm labor necessitating further tocolytic attempts fetal vascular blood flow systolic and diastolic blood pressure|ritodrine and nifedipine proved to be equally effective in the suppression of preterm labor. nifedipine was found to be significantly more effective than ritodrine or withholding therapy, and was almost devoid of side-effects. more women in the ritodrine group delivered within 24 hours (22 versus 11, p = .006), within 48 hours (29 versus 21, p = .03), within 1 week (45 versus 36, p = .009), and within 2 weeks (52 versus 43, p = .005) compared with those receiving nifedipine. maternal side effects were significantly less common in the nifedipine group than in the ritodrine group, however after 7 days of therapy there was no difference between the two groups. maternal side effects were more common and more serious in the group of patients who received ritodrine compared with those who received nifedipine (18 of 38 versus 5 of 38, p less than 0.01); however, fetal and neonatal outcome appeared to be similar when the groups were compared. the success rate was similar in both groups -72% for the ritodrine group and 63.33% for the nifedipine group. there was no statistically significant difference in the number of neonates admitted into intensive care nor the premature infant center between the two groups. maternal side effects were significantly less common in the nifedipine group (27%) than in the ritodrine group (77%) (p < 0.001). both groups were comparable in terms of a number of entry variables, including cervical examination, contraction frequency, and gestational age. the patients in the magnesium sulfate group had more adverse side effects, mainly nausea and vomiting (p =.004). no significant differences were found in the delay of delivery, but significantly fewer maternal side-effects were found in the nifedipine group.|premature labor seventy-one women, including 11 with twin pregnancies, who had uterine contractions and observed cervical changes after stratification women ninety patients admitted to the saint-antoine hospital (paris, france) for premature labor preterm labor 52 singleton pregnancies with preterm labor between 26 and 34 week's gestation threatened preterm labor singleton pregnancies at < 34 weeks in preterm labor 102 pregnant women with gestational ages under 34 weeks, including 24 with twin pregnancies and 45 on betasympathicomimetic drugs, who had regular uterine contractions with either observed cervical changes or preterm rupture of membranes 42 women 45 patients patients between 24 and 34 weeks' gestation with documented preterm labor fifty-five women 62 patients after random selection and 3019 one hundred eighty-five singleton pregnancies with preterm labor preterm labor with beta-sympathomimetics 100 patients 80 were considered eligible, of whom 39 were randomized to the threatened premature labor patients presenting premature labor in order to propose 66 patients preterm labor with those of parenteral magnesium sulfate
motor activity and intraventricular hemorrhage blood ph weight, gestational age, apgar score, way of birth, initial diagnosis, incidence of pneumothorax, mortality and days with mv blood glucose, blood pressure, mean airway pressure, pco2, po2 hemorrhages incidence of intraventricular hemorrhage (ivh severity of intraventricular hemorrhage overall incidence of intraventricular hemorrhage incidence of ventricular dilatation neurodevelopmental handicaps global incidence of intraventricular hemorrhage hemorrhage intraventricular hemorrhage brain hemorrhage blood levels ivh/pvh percentage|the results of this study indicate no effect of phenobarbital on the incidence of subependymal-intraventricular hemorrhage, but a possible beneficial effect on the severity of hemorrhage. the overall incidence of intraventricular hemorrhage was 32% in treated and 46% in control infants, a nonsignificant difference. the blood ph showed statistically significant difference, with better values at 48-72 hours in the group treated with phenobarbital. although phenobarbital significantly suppressed movement, it was associated with an increased incidence of intraventricular hemorrhage (ivh). we found that ivh/pvh percentage is lowest in newborns from group iii, followed by newborns from group ii and group i.|prematurely born infants with intraventricular haemorrhage (ivh high-risk infants preterm infants weighing 1500 g or less at birth forty-two premature infants less than 24 hours of age, with normal admission echoencephalograms 19 low birthweight premature infants with respiratory disease preterm infants with respiratory disease weighing less than 1500 grams infants with low and extremely low birth weight and infants treated with surfactants 130 premature infants of less than 32 weeks gestation with a very low birth weight (vlbw) and extremely low birth weight (elbw very low birth weight infants
get watery diarrhoea growth and indexes of body composition and gross motor development incidence of pneumonia weight, length, and other anthropometric indicators diarrhoea and pneumonia plasma zinc concentrations pneumonia and mortality indicators of copper or iron status change in plasma zinc weight-for-age z score growth, development, or risk of infection diarrhea incidence supplement consumption all cause mortality weekly morbidity histories morbidity data knee-heel length episodes of diarrhea, dysentery, and respiratory illness mean log(10) hiv-1 viral load interleukin-2 production clinical pneumonia and diarrhoea morbidity information incidence of diarrhea children's morbidity and physical growth growth, morbidity, or motor development severity of malaria episodes, prevalence of malaria parasite, mean parasite densities, mean packed cell volume, prevalence of other morbidity, and all cause mortality incidence of pneumonia and diarrhoea morbidity, growth, and micronutrient status prevalence of cough diarrheal morbidity anthropometric indexes, developmental indexes (bayley scales of infant development; bsid), and morbidity incidents of pneumonia mean plasma zinc concentration incidence of infections and hospital admissions markers of copper or iron status development (assessed by use of the griffiths mental development scales), length, and weight diarrhoea and pneumonia morbidity bsid psychomotor development index mean percentage of cd4+ t lymphocytes and median haemoglobin concentrations watery diarrhoea energy intake mean temperature, and mean parasite densities during malaria episodes, nor in malaria parasite rates, mean parasite densities, and mean packed cell volume plasma hiv-1 viral load plasma hiv-1 viral load and the percentage of cd4+ t lymphocytes iron and zinc for weight-for-age z score, knee-heel length, and bsid psychomotor development linear growth gain growth and psychomotor development number of hospitalizations and decreased number of vaso-occlusive pain crisis pneumonia-related deaths fever and cough serum copper and haemoglobin concentrations plasma zinc concentration immunocompetence, growth, and zinc, copper, and iron status rate of pneumonia and diarrhoea plasma zinc concentration, morbidity, and growth of young children baseline characteristics, attained weight or length at 10 mo, growth velocity, gross motor development, and morbidity childhood morbidity growth, psychomotor development, and incidence of infectious disease incidence of symptomatic falciparum malaria diarrhoea growth, final serum copper, and final haemoglobin morbidity plasma zinc and other indicators of micronutrient status mean number of malaria episodes growth, morbidity, and motor development bacteriologically positive infections vomiting rates of other respiratory tract infections safety and efficacy small gain in height lymphocyte and granulocyte zinc incidence of diarrhoea zinc deficiency affects adversely t-helper1 (th1) functions and cell mediated immunity and interleukin (il)-2 production falciparum malaria acute lower respiratory tract infection delayed hypersensitivity skin reactions, enhanced lymphoproliferative response to pha, and increased salivary iga concentrations developmental quotient, hearing and speech, and performance adverse effects|the baseline characteristics, attained weight or length at 10 mo, growth velocity, gross motor development, and morbidity did not differ significantly between groups, even after control for potentially confounding variables. although energy intake was similar in both groups, the zinc-supplemented infants had significantly higher linear growth gain, and their immune function improved as demonstrated by conversion of their delayed hypersensitivity skin reactions, enhanced lymphoproliferative response to pha, and increased salivary iga concentrations. zinc benefited the developmental quotient only in children who received stimulation, and benefits from zinc to hand and eye coordination were greater in stimulated children. the mean percentage of cd4+ t lymphocytes and median haemoglobin concentrations were also similar between the two groups after zinc supplementation. zinc supplementation resulted in a lower incidence of pneumonia than placebo (absolute risk reduction 2.5%, 95% confidence interval 0.4% to 4.6%). the change in plasma zinc concentration from baseline was positively related to the zinc dose (p < 0.001). there were no pneumonia-related deaths in the zinc group, but ten in the placebo group (p=0.013). zinc supplementation was significantly associated with a reduced prevalence of diarrhoea (0.87, 0.79 to 0.95). weight-for-age z score was higher in the zn group than in the placebo and fe+zn groups, knee-heel length was higher in the zn and fe groups than in the placebo group, and the bsid psychomotor development index was higher in the fe group than in the placebo group. the zn group had fewer episodes of diarrhea, dysentery, and respiratory illness and a lower prevalence of fever and cough than did the zn+vm group and a lower prevalence of cough than did the placebo group (p = 0.05). prolonged zinc supplementation resulted in an increase in lymphocyte and granulocyte zinc (p = 0.0001), and an increase in interleukin-2 production (p = 0.0001), decreased incidence of documented bacteriologically positive infections (p = 0.0026), decreased number of hospitalizations and decreased number of vaso-occlusive pain crisis (p = 0.0001).|adult sickle-cell disease (scd) patients 709 children were enrolled; 685 completed the trial young children children in rural west africa subjects were 114 children aged 9-30 mo and below -1.5 z scores of the national center for health statistics weight-for-age references who were recruited from 18 health clinics 96 children with hiv-1 infection severely malnourished infants children younger than 2 years in an urban, low-income population in bangladesh children aged 6 months to 3 years young children in high-risk populations young children living in an area holoendemic for malaria in west africa eighty-five infants were enrolled, and 70 completed the study patients with scd 631 ecuadorian children who were 12-30 mo old at baseline and who had initial length-for-age z scores <-1.3 2482 children aged 6 to 30 months children on the incidence of acute lower respiratory tract infections and pneumonia two hundred forty-six children aged 6-35 mo with persistent diarrhea 1665 poor, urban children aged 60 days to 12 months 34 children children with hiv-1 infection in south africa young peruvian children undernourished jamaican children children with hiv-1 infection west african children 809 children were assigned zinc, and 812 indonesian infants (n = 680 19 infants fed a children younger than 2 years 103 children in the treatment group and 44 in the control group withdrew malnourished infants at grey's hospital in pietermaritzburg, south africa sickle cell disease (scd children younger than 5 years 18 villages in rural northwestern burkina faso breastfed infants aged 4-10 mo undernourished children hiv-1-infected children urban slum healthy, term, breastfed infants young ecuadorian children at risk of zinc deficiency 32 scd subjects indonesian infants marasmic infants during nutritional rehabilitation
psychosocial functioning, anxiety, and depression axillary dissection sf-36 mental health subscale quality of life or patient satisfaction social support questionnaire and an uncertainty questionnaire pain (brief pain inventory); secondary outcomes of interest were all other symptoms (memorial symptom assessment scale) and quality of life (functional assessment of cancer therapy scale qol summary scores (total and overall qol higher social support and lower disease uncertainty type and use of cancer-specific therapies patient satisfaction, arm morbidity, impact on community nurses, health service costs, surgical cancellations and in-patient nursing dependency hrql improvement psychosocial problems (uncertainty, anxiety, loneliness, disturbed sleep, loss of control, threat to self esteem), physical or psychological complaints, or in the coping strategies used total per capita health care costs, including hbhc pain control functional decline ability to perform activities of daily living, physical performance, utilization of health services, and costs periodic pain assessments satisfaction with care, communication, or the discussion of patient problems qol outcomes pain management index (pmi quality of life, sf-12; physical and mental component scores, (2) anxiety and depression: hospital anxiety and depression scale and (3) patient satisfaction: patient visit-specific questionnaire average pain uncertainty, mood states, well-being, charges, and reimbursement patient survival, activities of daily living (adl), cognitive functioning, or morale cancer needs, qol, or psychosocial functioning relative hazard of death patients' quality of life scores for quality of life (physical component score incidence of wound complications higher satisfaction eortc qlq-c30 scales/items explicit use of hrql data patient satisfaction and arm function on the affected side 2 months after diagnosis confidence treating patients who were receiving ct (confidence), knowledge of adverse effects and reasons to refer the patient to the treatment center (knowledge), and satisfaction with information and shared care of patients (satisfaction leakage along the drain physical symptoms and health-related quality of life (hrqol global health status presence and severity of physical symptoms, psychiatric morbidity, use of and satisfaction with services, and carers' problems contact rates quality of life (qol) and cost outcomes peripheral neuropathy pain relief cornell medical index m-r scales (greater emotional disturbance psychosocial morbidity knowledge and beliefs quality of life quality of care average and worst pain levels satisfaction survey and maklebusts ostomy adjustment scale overall costs quality-of-life scores severe dyspnoea usual pain intensity cognitive functioning psychological functioning survival knowledge, confidence, and satisfaction average and worst pain costs anxiety analgesic prescriptions telephone questionnaire patient functioning, and patient and caregiver morale and satisfaction with care symptom severity satisfaction with care qol, psychosocial functioning, or satisfaction incidence of pain physical well-being dimension of health-related quality of life breast reconstruction surgery quality of life outcomes debilitating physical symptom median number of seroma aspirations per patient symptom distress, enforced social dependency, and health perceptions pain control, sleep, cancer-related symptoms, or analgesic dosing quality of pain treatment discussion of pain, and role function emotional functioning symptom distress and social dependency health related quality of life (eortc qlq-c30 apmi score at baseline, patients' level of physical functioning, patients' level of social functioning, the extent of adherence to pain medication, patients' pain knowledge pain levels survival and health-related quality of life, measured with the use of the medical outcomes study 36-item short-form general health survey (sf-36), one year after randomization 2-year survival synergistic effects global health status, emotional functioning, and cognitive functioning pain medication level sexual functioning and cancer worry patient hrql over time, measured by the functional assessment of cancer therapy-general questionnaire, physician-patient communication, and clinical management, measured by content analysis of tape-recorded encounters total costs recurrence, time to detection and death rates qol assessments included the center for epidemiological studies-depression scale , the ambiguity subscale of the mishel uncertainty in illness scale , the symptom distress scale, and the short-form health survey (sf-12 global quality of life (qol) scores health services utilization satisfaction depressive symptoms, symptom distress, functional status, comorbidities, length of hospital stay, age of patient, and stage of disease hrql subscales of complexity, inconsistency, and unpredictability symptom distress scale, brief fatigue inventory, and functional assessment of cancer therapy scale-general version depression measuring quality of life symptom distress, and better sf-12 mental and physical qol over time outcome measures: quality of life, patients' satisfaction, general practitioners' satisfaction, survival, symptom-free survival, progression-free survival, use of resources, and comparison of costs pain intensity, interference because of pain, adequacy of analgesics used, or pain relief patient satisfaction general practitioners' overall satisfaction mean (sd) scores duration of drainage patient satisfaction or gp confidence hospital doctor satisfaction with communication, participation in care, or quality of life type of care, costs, patient satisfaction, ostomy adjustment, and time to achieve ostomy self-care quality of life and carer burden scales of depression patient satisfaction and confidence mental health role-emotional and mental health subscales qol, and psychosocial functioning and satisfaction with overall care received pain level incidence of complications ratings of pain intensity quality of life and cost outcomes quality-of-life outcomes vomiting subscale qol scores and carer burden chronic nonspecific symptoms qol indicators most satisfaction subscales global qol measures pain, mood disturbance, and concerns symptom distress, fatigue level, quality of life, and healthcare usage symptom distress, fatigue, quality of life, and healthcare usage symptoms or quality of life pain and nausea levels qol over time (measured by the functional assessment of cancer therapy-lung questionnaire and the palliative care quality of life index), discussion of patient problems, and satisfaction with communication and general care symptoms, hrqol, mood and 'emotional bother' in 'full-pct continuity of care physical and emotional functioning, pain, and psychologic distress assessed monthly by using the european organization for research and treatment of cancer quality of life questionnaire-c30 (eortc qlq-c30) questionnaire and impact of event scale (ies 1) disease-specific quality of life, including sexual, urinary, and bowel outcomes and cancer worry; 2) depression; 3) dyadic adjustment; and 4) general quality of life length of survival complication rate, patient satisfaction, and psychosocial outcomes health perceptions normal arm function confidence investigations, number and timing of recurrences and deaths levels of anxiety, depression and perceived needs quality of life or nhs resource use sf-36 subscales, activities of daily living, and physical performance mortality survival or rates of objective progression amsterdam pain management index (apmi), consisting of an integrated score of patients' present pain intensity, average pain intensity, and worst pain intensity|after 3 weeks, the average and worst pain experienced by patients randomized to the clinical intervention group was significantly inferior to the average pain experienced by patients in the control group (2.9/10 vs. 4.4/10 and 4.2/10 vs. 5.5/10, respectively). unmarried women and women with no family history of breast cancer benefited from nurse interventions in mood states and well-being. the cards did not impact on the utilization of the primary health care team and women in the intervention group were no more likely to utilize primary care sources of information than women in the non-intervention group. there were highly significant improvements in symptoms, hrqol, mood and 'emotional bother' in 'full-pct' at 1 week, maintained over the 4-week follow-up. nurse-led early discharge had no adverse effects on quality of life or patient satisfaction, had little effect on carer burden, improved communication between primary and secondary care, reduced cancellations and was safely implemented in a mixed rural/urban setting. findings included no differences in patient survival, activities of daily living (adl), cognitive functioning, or morale, but a significant increase in patient (p = .02) and caregiver (p = .005) satisfaction with care at one month. overall, the specialized home care intervention group was found to have increased survival (p = .002 using stratified log-rank test). intervention patients were more likely to die at home rather than in a hospital or hospice (p=0.04), attended fewer consultations with a hospital doctor during the first 3 months (p=0.004), had fewer radiographs during the first 6 months (p=0.04), and had more radiotherapy within the first 3 months (p=0.01). there were no significant differences in other symptoms or quality of life between the two treatment groups. patients in the intervention and attention-control groups had better hrql than the control group (p =.006 and p =.01, respectively), but the intervention and attention-control groups were not significantly different (p =.80). while no statistically significant improvements in patient satisfaction or gp confidence were shown, the data suggested that gps value contact to meet patient information needs. gps receiving the ct sheet found correspondence significantly more useful (p < .001) and instructive (p < .001) than gps who received standard correspondence alone. at the end of the study, there were no differences in pain, mood disturbance, and concerns among the three groups. furthermore, in the general practice group there was a significant increase in satisfaction over baseline; a similar significant increase in satisfaction over baseline was not found in the hospital group. there were no significant differences between the two arms with respect to changes in cancer needs, qol, or psychosocial functioning between the baseline and follow-up assessments, nor with respect to satisfaction with care. the apn intervention resulted in significantly less uncertainty than the attention control intervention 6 months after surgery. pain and nausea levels were measured at entry to trial and at one month, as were quality of life for patients and care givers' health. the structured information pack improved gp knowledge of oncology; gps found themselves better equipped to support and counsel patients during the course of their illness, and practitioner satisfaction with the department rose. reductions in levels of anxiety, depression and perceived needs among intervention patients were not significantly different to control patients. 554 patients expected to survive less than one year entered the trial and were randomly allocated to a coordination or a control group. a decrease in the incidence of pain described as more than life's usual aches and pains was found for the intervention group (p = .05). pain problems later in the course of cancer seem to be predictable in those patients with higher scores on the cornell medical index m-r scales (greater emotional disturbance) and on the rotter locus of control while the level of inadequacy in the control groups remained relatively stable at all assessment points, a slight increase in the percentage of patients being treated inadequately was found in the intervention group patients over time. patients with advanced disease were more likely than patients with non-advanced disease to report a continuing contact, and living in a rural district was positively associated with reporting a contact. analysis of variance revealed no differences in the physical well-being dimension of health-related quality of life between patients who received telephone follow-up and a control group who did not. there were significant reductions in functional decline with inpatient geriatric evaluation and management and improvements in mental health with outpatient geriatric evaluation and management, with no increase in costs. no statistically significant differences were found in patients' experienced continuity between the trial arms, but important trends were seen in measures of needs for care in favour of those receiving the intervention. the patient held record did not have an impact on communication but was significantly helpful to patients in preparing for appointments, reducing difficulties in monitoring their own progress, and helping them to feel more in control (p<0.05). participants in both groups completed the symptom distress scale, brief fatigue inventory, and functional assessment of cancer therapy scale-general version 4 at eight intervals over six months. continued access to pain related information using either a patient- or provider-initiated format did not affect long-term pain outcomes. the experimental group reported significantly higher social support and lower disease uncertainty compared with the control group at 1 month after surgery and 3 months after diagnosis. of women undergoing breast-conserving surgery, greater percentages in the case management group received adjuvant radiation (78.3% vs 44.8%; p=.001) and axillary dissection (71.4% vs 44.8%; no effects were found in relation to satisfaction with care, communication, or the discussion of patient problems. telenursing participants believed that telenursing made care more accessible; they preferred telemedicine rather than waiting for face-to-face visits but still believed that face-to-face visits were best. at 12 and 24 months there were no differences in scores for quality of life (physical component score, p=0.88 at 12 months; p=0.28 at 24 months: mental component score, p=0.51, p=0.47; adjusted), anxiety (p=0.72; p=0.11) depression (p=0.28; p=0.80) or patient satisfaction (p=0.06, 24 months). patients in the intervention arm experienced long-term improvements in quality-of-life outcomes related to sexual functioning and cancer worry compared with patients who received standard care. the two groups did not differ in scores for psychosocial problems (uncertainty, anxiety, loneliness, disturbed sleep, loss of control, threat to self esteem), physical or psychological complaints, or in the coping strategies used. compared with conventional care alone, the experimental intervention was effective among patients who entered the trial with higher levels of symptom severity. the results failed to show a significant beneficial effect of the intervention on pain control, sleep, cancer-related symptoms, or analgesic dosing, but confidence intervals were broad. there was no difference between groups in the magnitude of change in global qol measures from baseline to any time point up to 9 weeks post-case conference, or at any time before death. a supplementary patient-held record for radiotherapy outpatients appears to have no effect on satisfaction with communication, participation in care, or quality of life. during the initial 4 months of follow-up, the compliance was good (72%) and comparable among treatment groups. patients in the augmented group improved significantly over the control group in ratings of pain intensity at its worst, whereas patients in the basic group had better ratings of pain intensity on average. further work is needed to determine why depression and mental health were affected yet physical health and symptoms did not differ between groups.|cancer patients with chronic pain surgical cancer patients cancer patients were routinely notified from 1987 to 1990 lung cancer patients and general practitioners 320 patients who reported cancer-related pain were used in the analysis: 160 to 260 in the control group and 160 of 250 in the intervention group terminally ill cancer patients and their families of coordinating the services available within the nhs and from local authorities and the voluntary sector patients after treatment for colon cancer by either general practitioners or surgeons women diagnosed with breast cancer breast cancer newly diagnosed patients with cancer 115 patients with inoperable lung cancer 28 oncologists, 286 cancer patients 203 consenting patients who had undergone potentially curative treatment for colon cancer 510 cancer outpatients and 13 oncologists was conducted at 23 clinics in indiana outpatients with cancer treated by radiation therapy general hospital and cancer clinic in rotterdam with a socioeconomically diverse population midwestern suburban community women with newly diagnosed breast cancer in taiwan 300 nurses were randomized and outcomes of 673 of their patients were reviewed 170 patients were available for follow-up at 12 months and 157 at 24 months 501 patients under the care of the department of oncology, singleton hospital, swansea women newly diagnosed with breast cancer terminally ill cancer patients breast cancer patients 313 chronic cancer patients two hundred and ninety-six women with breast cancer in remission receiving regular follow-up care at two district general hospitals in england were included in the study older post-surgical cancer patients who received a community health care districts defined as the clusters breast specialist secondary care professionals for members of the primary health care team older post-surgical cancer patients patients with prostate carcinoma patients with colon cancer the trial recruited 261 out of 684 new inpatient referrals; 175 were allocated to patients with advanced cancer 1148 patients were eligible for the study; 501 were recruited (44%) and 344 completed the study (172 in each group women with breast cancer ambulatory patients with breast or lung cancer during active treatment patients with breast cancer unmarried women and women with no family history of breast cancer 554 patients expected to survive less than one year entered the trial women newly diagnosed with breast cancer in taiwan cancer patients' hrql women recovering from cancer surgery and undergoing cancer pain management cancer patients' home care nurse contacts patients with advanced disease patients with lung cancer large tertiary care center in the southwestern united states home visiting nurse practitioners patients with lung or breast cancer cancer patients attending one cancer centre for their first visit three hundred seventy-five patients aged 60 to 92, newly diagnosed with solid cancers, were treated surgically between february 1993 and december 1995 one hundred fifty patients with cancer who were discharged to home from the hospital patients with cancer-related pain and their primary caregivers patients with cancer in the community sixty-four patients inpatients with cancer-related pain patients with breast cancer who require axillary clearance traditionally remain in hospital until their wound drains are removed eighty-one cancer patients, aged 37 to 76 years, were enrolled onto a prospective, longitudinal, randomized controlled study from the outpatient clinic settings of 26 western washington-area medical oncologists eligible cancer patient with pain 48 participants (25 intervention and 23 control) completed the survey four times patients from these districts who had malignant disease and survival expectancy between 2 to 9 months were entered onto the trial 450 people with cancer newly referred patients had visited a department of oncology for the first time patients with progressive lung cancer 108 patients undergoing axillary clearance with mastectomy or wide local excision for breast cancer 1388 patients were enrolled and followed three outpatient ambulatory oncology clinics in a large university health center in quebec, canada patients discharged with ostomies resulting from cancer treatment 203 patients with lung cancer who had completed their initial treatment and were expected to survive for at least 3 months outpatients with cancer older women with breast cancer sixty surgeons practicing at 13 community and two public hospitals in southeast texas 125 women with operable breast cancer 109 patients newly diagnosed with breast, colon, or lung cancer who were receiving chemotherapy; 54 received standard care, and 55 participated in the intervention group one hundred sixty-six patients patients with cancer frail patients 65 years of age or older who were hospitalized at 11 veterans affairs medical centers palliative cancer care sixty-four patients and their primary caregivers were recruited colon cancer patients breast cancer patients in specialist clinics 99 patients, along with their partners specialist cancer hospital and three cancer units in southeastern england women with breast cancer in remission from hospital outpatient clinics to general practice a city of 300,000 people with a publicly funded home care service and about 200 general practitioners, most of whom provide home care newly referred cancer patients ninety-seven gps managed 97 patients receiving 23 types of ct 200 patients admitted to a gynaecological oncology ward, and their gps older cancer patients after cancer surgery newly diagnosed cancer patients (n=527 248 cancer patients and their 199 gps 28 patients with cancer in two groups: traditional home health and home health plus telenursing lung cancer patients nurses from a large urban non-profit home care organization patients diagnosed with solid tumors and undergoing a first course of three hundred thirty-five women (166 control and 169 intervention) aged 65 and older newly diagnosed with breast cancer patients with cancer with new ostomies patients with cancer holding their own records discharged older cancer patients after surgery at a comprehensive cancer center in southeastern pennsylvania hospitalized patients with cancer patients both with and without district nursing palliative care patients 235 intervention patients and 199 controls were included sixty-one women younger than 60 years, newly diagnosed with breast cancer and undergoing surgery, were recruited from 2 urban teaching hospitals in northern taiwan general practitioners and hospitals patients and families experiencing cancer six hundred and fifty radiotherapy outpatients with any form of cancer inoperable lung cancer patients cancer patients in chronic pain newly diagnosed patients with cancer undergoing treatment patients (n = 237) were accrued from comprehensive and community cancer centers women with breast cancer in taiwan cancer patients post-surgical women with gynecological cancers hospital 4 days after surgery (with drain in situ) with discharge after drain removal (mean 9 days in hospital patients with incurable cancer and an estimated prognosis of three months to one year post-surgical cancer patients breast cancer patient satisfaction with follow-up in primary care versus specialist care one hundred ninety patients were randomized to the intervention groups and 185 to the usual care group all admissions to a 1,100-bed department of veterans affairs (va) hospital were screened to identify 171 terminally ill patients with informal caregivers patients due to commence ct 210 women with newly diagnosed breast cancer with an age range of 30-85 years women with gynecological cancers patients undergoing major gynaecological surgery, by increasing their general practitioners' contact with the hospital and providing a comprehensive discharge summary sample: 113 patients with lung cancer and 77 patients with breast cancer a large, urban, midwestern, tertiary-cancer center and a community-based cancer center in a medium-sized midwestern city
progressive radiolucent lines quality of the fixation inducible displacement red blood cell count, hemoglobin level, and hematocrit returned to the preoperative levels perioperative blood loss tibial components total blood loss|after two years, rotation of the femoral components in the transverse, longitudinal and sagittal planes did not differ between the cemented and the hydroxyapatite-coated implants (p = 0.2 to 0.9). the red blood cell count, hemoglobin level, and hematocrit returned to the preoperative levels within 3 months in both groups. the c-f knees rotated and migrated less than uc-f and ucha-f knees over 5 years. inducible displacement was found in all knees at both the six-week and the one-year follow-up examination, but no differences were detected with respect to the type of fixation (p > 0.05). between 1 and 2 years, 4 of 24 ha-coated and 10 of 23 cemented implants migrated >0.2 mm and were categorized unstable, which has been shown to have a prognostic value as regards future aseptic loosening.|cementless or hybrid total knee arthroplasty without patellar resurfacing 57 patients (60 knees) who underwent fifty-three consecutive patients (57 knees; mean age, 69 years 40 patients (19 ha-coated, 21 cemented) remaining at 5 years 50 patients (54 knees) with osteoarthritis of the knee who total knee arthroplasty knee arthroplasty 30 patients who had simultaneous bilateral tkr surgery, and who were stratified into 3 subgroups of pairwise comparisons of the 3 types of fixation 86 unilateral tkrs stratified into 1 of the 3 types of fixation 116 patients with osteoarthrosis, who had 146 tkrs
visual analogue scales anxiety and depression levels vestibular time constants subjective improvement in health, enablement (ability to understand and cope with symptoms), and adherence visual analogue scale anxiety score subsequent relapse ability to hear persisting peripheral vestibular deficit subjective visual vertical (svv) for perception, and 3) the total sway path (sp) values equilibrium scores in dynamic posturography, asymmetry index in rotation testing, motion sensitivity quotient (msq), and dizziness handicap inventory (dhi peak-to-peak magnitude and total amount of anterior-posterior body sway, and of horizontal (shear) ground reaction force dynamic gait index results and anxiety dynamic visual acuity locomotor stability dynamic gait index vsi mean scores, vdiss mean scores, and vss mean scores vertigo intensity and frequency, low-frequency vestibulo-ocular reflex (vor), posturography and path integration hearing ability, tinnitus and dizziness visual dependence dynamic visual acuity (dva visual analogue scale, physical examination, and need to use the medication optokinetic reflex (okn) response to 60 degrees/s constant velocity optokinetic stimuli visual acuity dizziness and imbalance vor gain, vor time constant, and okn gain standing balance performance postural stability changes in oscillopsia balance ability and functional gait performance psychological symptoms hearing improvement gait velocity and stability baseline, 3-month, and 6-month assessment of self-reported spontaneous and provoked symptoms of dizziness, dizziness-related quality of life, and objective measurement of postural stability with eyes open and eyes closed increased independence and decreased vertigo vor response cure rates tinnitus, dizziness or increasing hearing ability vertigo intensity and frequency with the use of the vertigo symptom scale, the vertigo handicap questionnaire, the vestibular disorders activities of daily living scale, and the dizziness handicap inventory adherence levels visual vertigo (scq reduced handicap vertigo, dizziness, imbalance questionnaire (vdi), which consists of two subscales, the vdi symptom subscale (vdi-ss) and the vdi health-related quality of life (vdi-hrqol) subscale, and the vertigo symptom scale (vss reductions of eyes-opened length and of eyes-opened correlation function between length and surface static balance and a dizziness handicap posturography scores symptom, disability, balance, and postural stability balance scores symptom remission dizziness handicap questionnaire and a visual analogue scale for anxiety vertigo standing balance, timed up and go test and tandem gait vestibulospinal compensation benign paroxysmal positional vertigo static balance tests, tandem walk test, dynamic gait index and subjective rating of the intensity of vertigo dynamic posturography, vestibular time constants, and questionnaires concerning symptoms, symptom-triggers and emotional status dizziness symptoms (visual analog scale [vas]), disability (dizziness handicap inventory [dhi]), balance (berg balance scale [bbs]), and postural stability (modified clinical test for sensory interaction on balance [mctsib reduced symptoms, anxiety, handicap, and negative beliefs about dizziness postexercise vas, dhi (emotional, functional, physical, total), bbs, and mctsib (standing on a firm surface with eyes open, standing on a foam surface with eyes open, standing on a foam surface with eyes closed, mctsib mean perception of dysequilibrium vertigo intensity and frequency symptoms, handicap, anxiety and depression, and negative beliefs about symptoms reduction of symptoms vestibulo-ocular reflex (vor eyes-opened length of the oscillations and eyes-opened and eyes-closed surface of the body sway total sp values dysequilibrium and nausea dva-predictable vdi-hrqol mean scores cure rate central vestibulospinal compensation balance performance symptoms, postural stability, and dizziness-related handicap posturography and subjective scores vertigo decreased and independence in activities of daily living odds ratios clear locomotor gains visual vertigo symptoms visual vertigo symptom scores changes of pitch and loudness dizziness, only vestibular rehabilitation also improves balance symptom, disability, balance, and postural stability in chronic unilateral vestibular dysfunction mean scores of the vdi vss physical indices of balance and subjective indices of symptoms and distress parameters (vas, dhi, bbs, mctsib normalization of ot and svv single leg stance timed up and go test, tandem gait and dynamic gait index motion sensitivity and dizziness handicap demographics data and duration and intensity of symptoms|a multiple comparison of the overall outcome measures showed no significant differences in group performance over an 8-week period. as a group, patients who performed vestibular exercises showed a significant improvement in dva-predictable (p<.001) and dva-unpredictable (p<.001), while those performing placebo exercises did not (p =.07). the use of exercises in the treatment of patients with vestibular deficits has become increasingly popular, and evidence exists that these exercises are beneficial in patients with chronic vestibular deficits. at 3 months, the vr group had reduced symptoms, anxiety, handicap, and negative beliefs about dizziness; the sc group had reduced handicap; but the control group showed no improvement. compared with the control group, subjects in the experimental group demonstrated a statistically significant improvement in single leg stance with eyes closed at the two-week assessment (p<0.05). rehabilitation therapy is proved to be effective in reducing disability in patients with persistent symptoms of disequilibrium after acute unilateral peripheral vestibular deficit. vestibular rehabilitation delivered by nurses in general practice improves symptoms, postural stability, and dizziness-related handicap in patients with chronic dizziness. group a (6 weeks of vr) significantly (p < 0.01) increased their gait velocity and stability compared with group b (6 weeks of strengthening exercise), but there was a smaller difference (p = 0.05) between groups at 12 weeks, when both had had vr; there were no group differences at 1 year. the greatest difference in the rehabilitated subjects, compared with the control group, was for the dynamic gait index test; however, this difference was not statistically significant. vestibular exercises are effective in reducing the duration of symptoms and the need of medication of patients in the early stages of peripheral vestibular disorders. a statistically significant improvement for visual vertigo symptom scores was noted only for group s (p < 0.01; total improvement 53.5 %). balance performance was assessed by measuring the peak-to-peak magnitude and total amount of anterior-posterior body sway, and of horizontal (shear) ground reaction force during six test conditions, in which visual and somatosensory orientation cues were reduced or altered by rotation of the visual surround or support surface in proportion to the subject's sway, and in which vision was eliminated (eyes closed). patients with positional and/or movement-related dizziness and abnormal posturography were randomly assigned to the three treatment groups. odds ratios for improvement in treated patients relative to untreated patients were 3.1:1 at six weeks (95% ci = 1.4-6.8) and 3.8:1 at six months (95% ci = 1.6-8.7). the results from this study did not show tns to be superior to ar in reducing tinnitus, dizziness or increasing hearing ability. vor on the unoperated side returned to normal values but on the lesioned side did not. at the one-week follow-up, similar cure rates were obtained with the semont and epley maneuver (74% and 71% respectively), both cure rates being significantly higher than that obtained with brandt & daroff exercises (24%). there were significant differences between groups regarding the change in the mean scores of the vdi (p = .001) and the vss (p = .001) at the end of the study in favour of the exercise group. however, older subjects receiving vestibular rehabilitation performed significantly (p<0.05) better on standing balance, timed up and go test and tandem gait, when compared with the older group that received only general instructions. the sm was effective in 80% of the patients at 15 days of treatment versus 45% of those receiving only vre. although normalization of ot and svv was similar in the control and physiotherapy groups, the total sp values on day 30 after symptom onset differed significantly: 3.2 +/- significant improvements were seen in symptom, disability, balance, and postural stability in chronic unilateral vestibular dysfunction after an exercise program. multilevel analyses showed that vertigo decreased significantly after lm, crp, and brandt-daroff exercise; those three groups did not differ significantly. for many patients a simple home program of vestibular habituation head movement exercises is related to reduction in symptoms and increasing independence in activities of daily living.|patients after acoustic neuroma surgery forty patients with the clinical and electronystagmographic diagnosis of bppv patients following acute onset of vestibular disturbance forty chronic peripheral vestibular patients who had previously undergone conventional vestibular rehabilitation without notable improvement patients with unilateral vestibular hypofunction 20 patients diagnosed with menire's disease, transcutaneous nerve stimulation (tns) and applied relaxation (ar forty patients recently hospitalised for an acute episode of rotational vertigo which lasted days after stratification for age (<50 years; >or=50 years unilateral peripheral vestibular deficit older subjects receiving 18 years old) with unilateral (n = 51) or bilateral (n = 73) vestibular hypofunction, of whom 86 completed a 12-week intervention 28 patients, using static posturography and.the dizziness handicap inventory short form patients with chronic peripheral vestibular disorders all patients were adults and symptomatic for less than 5 days 13 years) diagnosed as having bppv patients with bppv acute vertigo patients (n=42) with chronic vestibular dysfunction patients with chronic unilateral vestibular dysfunction outpatient clinic of a university hospital patients with chronic vestibular symptoms of at least 6 months duration benign paroxysmal vertigo patients with recent unilateral vestibular disorders benign paroxysmal positional vertigo of the posterior canal patients with chronic peripheral vestibular dysfunction mnire disease 170 adult patients with chronic dizziness benign paroxysmal positional vertigo patients with persistent symptoms of disequilibrium after acute unilateral peripheral vestibular deficit patients with chronic vestibular symptoms rehabilitation after acute vestibular disorders patients with acute peripheral vestibular lesions chronic dizziness patients over 50, early vestibular rehabilitation facilitates recovery of postural control after acoustic neuroma surgery unilateral vestibular hypofunction patients with benign paroxysmal positional vertigo (bppv twenty-one patients with unilateral vestibular hypofunction, aged 20 to 86 years benign paroxysmal postural vertigo dizzy patients in primary care after vestibular neuritis patients during the acute stage after resection of acoustic neuroma adults consulting their general practitioner (gp) with dizziness or vertigo patients (n = 124) with bppv of the posterior semicircular canal patients with benign paroxysmal positional vertigo who had already undergone the canalith repositioning manoeuvre 124 patients (59 patients with refractory dizziness acute unilateral peripheral vestibular lesions in humans patients who had chronic vertigo due to peripheral vestibular impairments were seen at a tertiary care center dizzy patients after recent acute vestibular disturbance benign paraoxysmal postural vertigo (bppv patients with chronic vestibular deficits patients with menire's disease 106 bppv patients patients with positional and/or movement-related dizziness and abnormal posturography 20 general practices in southern england patients with persistent or chronic vertigo patients with chronic dizziness acoustic neuroma resection fifty-three patients after surgery patients with persistent dizziness dizziness and vertigo in primary care patients with an acute/subacute unilateral vestibular lesion (vestibular neuritis thirty-eight patients (10 males, 28 females; mean age 46 patients with acute unilateral vestibular loss twenty-six subjects with benign paroxysmal positional vertigo involving the unilateral posterior semicircular canal participants (n = 360 twenty-four subjects 19 patients with and 20 patients without vestibular exercises patients with vestibular deficits acoustic neuroma resection, acutely postoperative patients patients with benign paroxysmal positional vertigo
serum markers of collagen synthesis frequency of complications intraocular pressure from preoperative level postoperative complications final postoperative visual acuities transient elevations of iop preoperative iop, log mean angle of resolution (logmar) visual acuity, or number of preoperative medications final visual acuity final intraocular pressure hypertensive phase 1- and 2-year life-table success rates (success [survival short- or intermediate-term success rates survival rates successful intraocular pressure control complications mean preoperative intraocular pressures mean iop, number of glaucoma medications, and complications visual acuity visual acuities, implant-related complications, and average iops overall success rates rate of hypertension mean number of preoperative antiglaucoma medication intraocular pressure (iop) and the appearance of the bleb iop reductions postoperative antiglaucoma medication preoperative visual acuities efficacy and safety complete success rate intraocular pressures (iop surgical success postoperative intraocular pressure (iop severe complications postoperative visual acuity, visual field, anterior chamber depth, and short-term or long-term complications mean intraocular pressures postoperative pressure spikes iop reduction rate of complications shallow or flat anterior chambers with hypotony postoperative intraocular pressure success rate with mmc and without mmc rate of hypotony and surgical complications iop mean intraocular pressure collagen synthesis cataract formation preoperative iops and visual acuities complications or inadequate pressure control requiring further surgical intervention intraocular pressures final intraocular pressure [iop mean numbers of postoperative antiglaucoma medications life-table success rates introcular pressure (iop shallow anterior chamber success rate postoperative visual acuity, glaucoma medications, and complications iops and the cumulative probabilities of success mean postoperative iop cumulative probabilities of success (intraocular pressure lower iops visual acuities intraocular pressure incidence of complications and the success rate surgical outcome cumulative success rate probability of success hyphema visual acuity, visual field, lens status, and final anterior chamber depth devastating complication early postoperative hypotony postoperative iops, visual acuities, number of medications used, and implant-related complications incidence of complications molteno tube shunt surgery choroidal detachment intraocular pressure, visual acuity, and complications success rates cumulative probabilities of success preoperative mean iop adjunctive medication requirement intraocular pressure (iop), visual acuity, and complication rates final success rate mean iop choroidal hemorrhages and/or effusions, corneal decompensation, flat anterior chambers, and phthisis bulbi overall iop control elevated iop|there were no significant differences in survival rates between the 2 groups with either criterion (p = 0.75 and p = 0.37, respectively). the final postoperative visual acuities were within one line of the preoperative visual acuities or had improved in 73% and 80% of patients, respectively. except for week 1, there were no differences between the groups at any of the clinic visits with respect to iop and percent change from baseline iop. complications or inadequate pressure control requiring further surgical intervention were seen in nine (47%) of 19 eyes in the molteno group and 12 (57%) of 21 eyes in the actseb group.(abstract truncated at 250 words) the serum markers indicated a systemic effect of oral prednisolone on collagen synthesis in group b but it did not improve the surgical outcome as compared to the controls. complications included choroidal detachment (ahmed 17.64%, ecp 2.94%), shallow anterior chamber (ahmed 17.64%, ecp 0.0%), and hyphema (ahmed 14.7%, ecp 17.64%). complete success rate was 90% in the e-agv group and 70% in the agv group (p = 0.291). the overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (p = 0.05). postoperative intraocular pressure was significantly higher at day 1 and week 2 in the suture-ligation implant group, although the final pressure at 12 weeks was not different between the two groups. early postoperative hypotony occurred in 1 of 16 (6.3%) patients with partial ligation and 4 of 16 (25%) patients without ligation. the success rate with mmc and without mmc were 90.0%, 77.3% (p < 0.05) at the 1st year, 87.1%, 67.3% (p < 0.05) at the 2nd year, 83.3%, 61.1% (p < 0.05) at the 3rd year, 81.3%, 56.7% (p < 0.05) at the 4th year, and 75.0%, 50.0% (p < 0.05) at the 5th year using kaplan-meier life-table analysis. however, the molteno implant produced a statistically lower intraocular pressure at 6 months compared with the schocket shunt. no statistically significant differences between groups were noted for postoperative visual acuity, visual field, anterior chamber depth, and short-term or long-term complications. in eyes undergoing ahmed valve implantation for neovascular glaucoma, pctr with mmc augmentation showed no additional benefits or complications over mmc augmentation alone; no avascular bleb was obtained with this technique. with a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm|thirty eyes consecutive patients with primary glaucoma and without prior intraocular surgery twenty-five eyes of twenty-five consecutive patients undergoing double-plate molteno implant surgery 117 patients, 62 were randomized to sixty eyes of 60 patients with refractory glaucoma refractory glaucoma between march 1991 and april 1993, 107 patients with uncontrolled intraocular pressure (iop) due to non-neovascular glaucoma associated with aphakia, pseudophakia, or failed filters molteno implant surgery ten eyes of agv implant surgery using pericardial membrane (preclude) that were designed to have surface area of 300 mm (e-agv group) and 10 eyes of agv implant surgery without surface area extension (agv group twenty-two patients requiring single stage, single-plate molteno implantation from march 1988 to february 1990, 132 patients who underwent molteno implantation for medically uncontrollable non-neovascular glaucomas in aphakia or pseudophakia 92 eyes from 92 patients were included in the study exclusion criteria included eyes that had had previous glaucoma drainage device implantation or a cyclodestructive procedure sixty patients with refractory glaucoma 123 patients, 64 were randomized to four latin american countries (argentina, brazil, colombia, and peru ahmed glaucoma valve implantation eyes with complicated glaucoma eyes with aphakia/pseudophakia, uveitis, previous penetrating keratoplasty, previous unsuccessful trabeculectomy, and neovascular glaucoma large university-affiliated eye hospital in columbo, sri lanka sixty-eight eyes of 68 patients with refractory glaucoma thirty-two korean patients glaucomas in aphakia and pseudophakia consecutive patients requiring glaucoma surgery for intraocular pressure control eyes undergoing ahmed glaucoma valve insertion complicated glaucoma 154 cases (159 eyes) with refractory glaucoma underwent hunan aqueous drainage (had) implantation from july 1995 to july 2001 ahmed glaucoma valve implant surgery eyes that were included were pseudophakic with a history of at least one trabeculectomy with antimetabolite, an intraocular pressure (iop) equal to or above 35 mm hg on maximum tolerated medical therapy, and a visual acuity better than light perception eyes undergoing ahmed glaucoma valve implantation glaucoma
gleason score 3-year progression rate serum prostate-specific antigen (psa) measurements biopsy gleason score, and baseline serum psa levels biochemical failure median cycle length and percentage of time off therapy time to androgen-independence of the tumor serum psa levels despite androgen blockade median psa level|of the 157 cases treated with ebrt, 153 cases (97.5%) had no biochemical failure in the mean follow-up of 17.3 months. the estimated 3-year progression rate was significantly lower in the iad group (7.0% +/-|2004 men with locally advanced prostate cancer patients were registered as primary candidates of the study and were treated with 6 months of lhrh agonist, with short-term of antiandrogen treatment for flare-up prevention 68 evaluable patients with hormone-naive advanced or relapsing prostate cancer patients with advanced prostate cancer between 2001 and 2003, 215 patients with locally advanced prostate cancer were enrolled in the study patients with psa levels below 10 ng/ml after the 6-month endocrine treatment patients with locally advanced prostate cancer patients with advanced hormone-naive prostate cancer
subjective state, hemodynamic parameters, and arrhythmias proarrhythmic effects (24-hour electrocardiography reversible neutropenia reduction in risk lower morbidity and mortality exercise duration (bicycle ergometry mortality and morbidity mortality and quality of life increased ventricular arrhythmias longer survival quality of life and for increased arrhythmias exercise performance treadmill exercise time, responses to the minnesota living with heart failure questionnaire (lwhf), and clinical assessments heart rate, ventricular ectopic activity, and mortality rate left ventricular ejection fraction diuretic doses symptom limited exercise tolerance cardiovascular mortality deaths frequency of decompensation from heart failure adverse events serious adverse cardiovascular reactions, including hypotension worsening heart failure oxygen consumption placebo mortality quality of life morbidity and mortality physical activity ejection fraction and plasma norepinephrine headache adverse cardiac events and physical activities adverse effect hemodynamic parameters of left-ventricular performance efficacy survival exercise time efficacy and safety maximal treadmill exercise time peak vo2 cardiac status physical mobility score hospitalizations early mortality tolerated syncope death and hospitalization for cardiac causes adverse effect on survival exercise duration maximal oxygen consumption degree of dyspnea and patient and physician assessments of clinical status overall lwhf score hazard of death borderline significance symptom score exercise capacity exercise tolerance and quality of life exercise tolerance exercise time, ejection fraction, frequency of ventricular premature complexes or ventricular tachycardia mean heart rate and ventricular ectopic activity exercise tolerance, ventricular function, and symptoms of heart failure new york heart association classification median exercise time symptoms or exercise duration heart failure symptoms imazodan mortality mean ejection fraction frequency of worsened heart failure sudden death ventricular arrhythmias morbidity died dropout rate exercise duration, peak vo2, and quality of life quality of life measured with the minnesota living with heart failure questionnaire treadmill exercise time exercise capacity and adverse events mean specific activity scale score agranulocytosis left ventricular ejection fraction at rest cumulative incidence of combined adverse cardiac events cardiac events combined adverse cardiac events mortality adverse effects severe worsening of heart failure|furthermore, quality of life improved to a greater extent in the vesnarinone group than in the placebo group over 12 weeks (p = 0.008). the quality of life had improved significantly more in the 60-mg vesnarinone group than in the placebo group at 8 weeks (p<0.001) and 16 weeks (p=0.003) after randomization. maximal oxygen consumption increased by 1.7 ml/kg per min in the flosequinan group (n = 17) but by only 0.6 ml/kg per min in the placebo group (n = 23), p = 0.05 between the groups. enoximone produced significantly greater increases in exercise time than placebo treatment at weeks 4 and 8 (p = 0.012, p = 0.029, respectively) but not after 12 weeks. new york heart association classification was improved at week 16 in the flosequinan group relative to those randomised to placebo (p < 0.01). twelve weeks of treatment with low-dose enoximone improves exercise capacity in patients with chf, without increasing adverse events. patients treated with milrinone had more hospitalizations (44 vs. 39 percent, p = 0.041), were withdrawn from double-blind therapy more frequently (12.7 vs. 8.7 percent, p = 0.041), and had serious adverse cardiovascular reactions, including hypotension (p = 0.006) and syncope (p = 0.002), more often than the patients given placebo. the dropout rate was significantly higher (p less than 0.02) with enoximone (46%) than with placebo (25%). flosequinan (100 mg once daily) also improved the overall lwhf score significantly compared with placebo; both active therapies decreased the physical component, but 75 mg flosequinan twice daily was associated with a trend toward worsening of the emotional component. death and hospitalization for cardiac causes occurred in 12 patients in the pimobendan group (10.1%), vs 19 patients in the placebo group (15.3%), but without significant difference. treatment with milrinone or digoxin significantly increased treadmill exercise time as compared with placebo (by 82 and 64 seconds respectively; 95 percent confidence limits, 44 and 123, and 30 and 100). no significant effects on oxygen consumption (assessed in a subgroup of patients) and on quality of life (assessed by questionnaire) were observed. there were no significant differences between the placebo and pimobendan groups with respect to changes in ejection fraction and plasma norepinephrine measured at baseline and at the completion of the 12-week study, proarrhythmic effect, or the number of patients with a significant adjustment in background therapy. after 3 months, pimobendan-treated patients showed a significant clinical improvement (p < 0.03). with the nottingham health profile questionnaire the physical mobility score was improved after three months in the enoximone group, median 21.3 compared with 41.8 in the placebo group (p = 0.008). there was no significant difference observed between the placebo group and any of the treated groups with regard to exercise time, ejection fraction, frequency of ventricular premature complexes or ventricular tachycardia.|322 patients with predominantly new york heart association class ii or iii congestive heart failure and left ventricular ejection fractions of 35% or less, who were stabilized on a diuretic, angiotensin converting enzyme inhibitor, and 147 patients with congestive heart failure to determine clinical efficacy and safety 102 outpatients (50 receiving patients with chronic heart failure who are also on conventional treatment moderate heart failure one hundred fifty-eight (80%) patients were taking a converting enzyme inhibitor (cei) and 28 (14%) patients were taking a non-cei vasodilator planned 200 patients with severe, symptomatic heart failure despite treatment with diuretics and where appropriate and tolerated angiotensin converting enzyme inhibitors and digoxin severe chronic heart failure 527 patients 105 patients with new york heart association class ii to iii, ischemic or nonischemic chronic heart failure (chf patients with symptomatic heart failure patients with moderate to moderately severe congestive heart failure 306 patients with stable new york heart association class iim or iii chf, and a radionuclide or echocardiographic left ventricular ejection fraction (lvef 561 patients) or patients with chronic heart failure who remain symptomatic despite treatment with digoxin and diuretic drugs patients with heart failure patients with chronic heart failure all patients were receiving digitalis and/or diuretics and had left ventricular ejection fractions less than or equal to 45 heart failure patients 164 patients with new york heart association functional class ii or iii heart failure with moderate to moderately severe congestive heart failure patients with chronic congestive heart failure patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor outpatient cardiology clinics in six european countries district general hospitals and cardiological referral centres in the united kingdom patients with severe heart failure chronic heart failure (chf 317 patients with stable symptomatic heart failure, objectively impaired exercise capacity, and an ejection fraction of 45% or lower who were treated with at least an angiotensin converting enzyme inhibitor and a diuretic and who tolerated a test dose of pimobendan patients with congestive heart failure nyha classes ii and iii patients with chf severe heart failure 253 patients one hundred ninety-eight ambulatory patients with symptoms of moderate to severe heart failure despite therapy with digitalis and diuretics with or without a single vasodilator patients with mild to moderate chronic heart failure patients with severe heart failure who remain incapacitated despite conventional treatment one hundred-thirty five patients with moderate heart failure, recruited from 18 centres group: 27 deaths compared with 18 in the patients with mild to moderate chf 1,088 patients with severe chronic heart failure (new york heart association class iii or iv) and advanced left ventricular dysfunction to double-blind treatment with (40 mg of 230 patients in sinus rhythm with moderately severe heart failure to treatment with patients with severe end stage heart failure 3833 patients who had symptoms of new york heart association class iii or iv heart failure and a left ventricular ejection fraction of 30 percent or less despite optimal treatment patients receiving concomitant therapy with digoxin (87 percent) and an angiotensin-converting-enzyme inhibitor (90 percent) who had ejection fractions of 30 percent or less patients with severe chronic heart failure chronic congestive heart failure patients with congestive heart failure fifteen patients in the chronic heart failure one hundred ninety-three patients with chronic heart failure (new york heart association functional class ii or iii and left ventricular ejection fraction < 40%) receiving digoxin and diuretic drugs
rates of venous thromboembolism venous thromboembolism provoked venous thromboembolism pulmonary embolism or deep-vein thrombosis symptomatic venous thromboembolism rates of deep-vein thrombosis rates of pulmonary embolism rates of bleeding episodes occurrence of symptomatic venous thromboembolism|the rates of pulmonary embolism were 0.09 in the rosuvastatin group and 0.12 in the placebo group (hazard ratio, 0.77; 95% ci, 0.41 to 1.45; p=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (hazard ratio, 0.45; 95% ci, 0.25 to 0.79; p=0.004).|apparently healthy persons 2009 massachusetts medical society 17,802 apparently healthy men and women with both low-density lipoprotein (ldl) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity c-reactive protein levels of 2.0 mg per liter or higher to receive
geometric mean titers (gmt) and 4-fold rises in hai titers hemagglutination inhibition titer immune response protective titer rates immunoglobulin levels and neutropenia seroconversion rate total white cell count or neutrophil count at immunisation, type of cancer, or length of time on treatment for acute lymphoblastic leukaemia seroconversion rates protective" titers immune responses hemagglutinin-inhibition (hai) antibody titers immune response and the peripheral white blood cell count protective antibody titres influenza virus susceptibility hemagglutination inhibition (hi) titers titer of antibody response rates response rate hai titers seroconversion and seroresponse rates antibody responses hi titers antibody titers tolerated protective responses low white blood cell (wbc) count hemagglutinin-inhibition (hi) antibody titers protective response seroresponse rates|there was a difference in hi titers to a/vic/75 between patients on and off chemotherapy after a single injection, 34% vs. 71%, p less than 0.001 for a four-fold rise. seroresponse rates (4-fold rise in hi) for h1n1, h3n2 and b were 52%, 33% and 51% in 65 episodes. older age was associated with increased response to the h1n1 and h3n2 vaccine components, but total white cell count or neutrophil count at immunisation, type of cancer, or length of time on treatment for acute lymphoblastic leukaemia did not affect response. there was no correlation between the immune response and the peripheral white blood cell count except at counts less than or equal to 1,000. children with all developed significant antibody titers to a/panama /2007/ 99 antigen 4 weeks after the second immunization. after the second immunization, children off therapy showed significantly higher antibody titers to both antigens than did children receiving therapy or controls (p less than 0.01 for both a/nj/76 and a/vic/75). although post-immunization gmt were lower in children with all compared to healthy children for the h1n1 antigen (p<0.001), the h3n2 antigen (p=0.03), and for the influenza b antigen (p=0.003), at least 60% of children with all had at least a 4-fold rise in hai titers to each of the influenza antigens. multivariate analysis revealed that factors significantly associated with a lower immune response were low igg (p < 0.001) and administration of chemotherapy (p = 0.003) for h1n1, administration of chemotherapy (p = 0.008) for h3n2, and low white blood cell (wbc) count (p = 0.030) and low igg (p = 0.030) for influenza b. influenza vaccination given to children with cancer was safe and induced immune reaction comparable to healthy children, although patients on chemotherapy and/or with chemotherapy-related conditions had a limited ability to produce a sufficient immune response.|children receiving maintenance chemotherapy for acute lymphoblastic leukemia individuals with malignancy and other immunodeficient states children with all who are receiving immunosuppressed children 65 children under 15 years old were studied, including 25 children with all undergoing chemotherapy, 30 with asthma in remission who were regularly followed at clinics, and 10 healthy children 22 children receiving maintenance chemotherapy for acute lymphoblastic leukemia (all), 16 children no longer receiving therapy for all, and 50 sibling controls children with solid tumours children with acute lymphoblastic leukemia (all children with neoplastic diseases sixty six children were assessed prior to 69 episodes of vaccination children with acute lymphoblastic leukemia (all) receiving maintenance chemotherapy with those in healthy children eighty four children with cancer were tested for susceptibility to the circulating strains of influenza virus in autumn 1995 and 1996 children being treated for cancer 40) against all three of the prevalent influenza virus strains children with leukemia undergoing chemotherapy 1976, 147 children with neoplastic diseases received children with acute lymphoblastic leukemia children with solid tumours and lymphoma children with non-leukaemic malignant disease forty-four children with various types of malignancies children with all who received children with either all or asthma in taiwan children with cancer thirteen normal siblings served as controls children with acute lymphocytic leukemia and other malignancies between three and 17 years of age were immunized with children receiving children with all and healthy controls cancer
hypoxia community-acquired pneumonia treatment failure (persistence of lower chest indrawing or new danger signs very fast breathing treatment failure|the results support the use of co-trimoxazole as the antibiotic of first choice in outpatient management of young children with pneumonia in developing countries. treatment failure was 19% in each group (161 patients, pencillin; 167 amoxillin; risk difference -0.4%; 95% ci -4.2 to 3.3) at 48 h. infancy (age 3-11 months; odds ratio 2.72, 95% ci 1.95 to 3.79), very fast breathing (1.94, 1.42 to 2.65), and hypoxia (1.95, 1.34 to 2.82) at baseline predicted treatment failure by multivariate analysis.|severe pneumonia in children aged 3-59 months young gambian children children aged 3-59 months with severe pneumonia were admitted for 48 h and, if symptoms improved, were discharged with a 5-day course of oral severe pneumonia in children aged 3 to 59 months tertiary-care centres in eight developing countries in africa, asia, and south america 1702 children young children with pneumonia in developing countries 134 gambian children under 5 years of age with severe pneumonia (as defined by the world health organisation classification of acute respiratory infections who-defined severe pneumonia (lower chest indrawing
recall of diagnostic information patient satisfaction with communication, mood state or quality of life retention of information quality of medical consultations patient recall, anxiety and depression, satisfaction with and use of the communication aids, and patient preferences for six communication options quality of life levels of anxiety levels of depression patient satisfaction, psychologic adjustment, and recall of information cancer patients' satisfaction, recall, and quality of life spontaneous (ie, unprompted) recall degree of information provision; audiotape satisfaction and use; communication satisfaction with oncologist; mood state; and cancer-specific quality of life length of time required for the consultation total recall recall, anxiety, or depression enhancing satisfaction satisfaction perception of being informed about clinical trials, knowledge of information relevant to providing informed consent to a clinical trial, and satisfaction with communication during the consultation final decision quality scores degree of information provision, audiotape satisfaction and use, communication satisfaction with oncologist, mood state, and cancer-specific quality of life average recall sociodemographics, preferences for information, coping styles, and clinical characteristics recall of the information given during the consultation patient satisfaction with communication, mood state, or quality of life satisfaction, recall, and quality of life patient satisfaction recall of having discussed side effects state anxiety levels|2.0 on a scale of 0-10; p = 0.04) and significantly improved recall of the information given during the consultation (88% +/- satisfaction with the tape itself was higher in patients who received the consultation tape (satisfaction score, 61%) compared with those who received the general tape (43%). expectations were confirmed; patients provided with the tape were more satisfied (p <.05) and recalled more information (p <.01) than patients without the tape. patients in the intervention achieved significantly higher final decision quality scores compared with control patients (median score, 14 v 10, respectively; p =.008) and a significantly higher level of intersubjective agreement with their physicians about decision quality (cohen's kappa, 0.49 v 0.285, respectively; p <.0001). the consultation audiotapes contained less trial-related information than the standardized audiotape but there were no differences in clinical trial knowledge or perception of being informed across the intervention groups. a content analysis revealed no significant differences between tape and control group in the mean number of questions asked during the second consultation. the method is cheap and easy to use, acceptable to patients and their families, and does not inhibit the consultation process. audiotape benefit was not significantly related to patient satisfaction with communication, mood state or quality of life at 12 weeks post-consultation, and was not significantly affected by choice of receiving the audiotape. satisfaction with the tape and letter were uniformly high and they did not differentially affect recall, anxiety, or depression. patients receiving the consultation audiotape had significantly better recall of having discussed side effects of treatment than patients who did not receive the audiotape. sixty newly diagnosed men were randomly assigned to receive either a self-efficacy information intervention that consisted of a written information package with discussion, a list of questions they could ask their physician, and an audiotape of the medical consultation (n = 30), or a written information package alone (n = 30).|we enrolled 24 predominantly white, well-educated, early-stage breast cancer patients who were facing local or systemic treatment decisions in a sequential, controlled trial older patients 2006 117 newly referred medical oncology patients randomised to receive a tape (n = 63) or not (n = 54) had two linked consultations which were both audiotaped physicians and patients breast cancer consecutive cancer patients referred to either the gynecology or medical oncology outpatient clinic were eligible older men physicians and advanced cancer patients patients (n = 142 two hundred one patients were included (response, 71%), 105 in the experimental group and 96 in the control group participants included 628 women newly diagnosed with breast cancer and 40 oncologists from six cancer centers in canada sixty patients with advanced cancer men newly diagnosed with prostate cancer sixty newly diagnosed men one hundred eighty-two cancer patients participants were 69 women with newly diagnosed breast cancer and 21 oncologists from 5 canadian cancer centers breast cancer patients and physicians men with prostate cancer with an audiotape of their primary treatment consultation patients after their first consultation with a medical oncologist men with prostate cancer participants included 425 men newly diagnosed with prostate cancer and 15 radiation oncologists from 4 cancer centers in canada respondents were recruited from one community urology clinic in winnipeg, manitoba copyright 1999 american cancer society patients with advanced cancer women with breast cancer
ttf disease free survival colorectal carcinoma develop liver metastases 1-year, 2-year, and 3-year disease free survival rates probability of remaining free of recurrent disease grade 3 and 4 toxicities (world health organization), mainly stomatitis nausea intrahepatic recurrence initial tumour relapse 5-year survival rate 1-year, 3-year, and 5-year cumulative survival rates 4-year liver recurrence-free rate adverse effect median time to failure (ttf median time to progression two- and 5-year cumulative survivals rate of intrahepatic recurrence and improve survival survival recurrence median survival ttf and survival median disease free interval after hepatectomy 4-year recurrence-free rate time to recurrence and hepatic disease-free survival, not overall survival dead of disease risk of death 5-year survival|the 4-year liver recurrence-free rate was 43% in the control group and 67% in the chemotherapy group (p =.03). significant prolongation of disease free survival was observed in the hai group (p = 0.045). the initial tumour relapse was shifted towards extrahepatic sites in group-a patients, but no difference was obtained regarding the definite distribution of recurrent disease. the median time to progression was 14.2 months for the chemotherapy group versus 13.7 months for the control group. arm a2 had an improved ttf when compared with arm a1 (p = .03).|91 patients with solitary or multiple metastases from colorectal cancer 12 patients with no mesenteric lymph-node metastases (dukes a/b colorectal cancer metastatic to the liver patients with one to three potentially resectable metastases colorectal liver metastases between april 5, 1991, and december 31, 1996, patients with colorectal liver metastases from 26 hospitals were stratified by the number of metastases and the site of the primary tumor and randomized to resection of the liver metastases followed by resectable metastatic colorectal carcinoma patients with resection of colorectal liver metastases copyright 2000 american cancer society nineteen patients who underwent curative hepatectomy for metastatic colorectal carcinoma high-risk patients patients undergoing hepatic resection of liver metastases from colorectal cancer curative resection of colorectal liver metastases thirty patients with mesenteric lymph-node metastases (dukes c patients with radical resection of colorectal liver metastases german cooperative on liver metastases (arbeitsgruppe lebermetastasen from july 1984 to december 1985, a total of 42 consecutive patients underwent r0 resection of colorectal liver metastases liver metastases of colorectal cancer
pain asymptomatic with activities of daily living external rotation pain scores, range of motion, internal rotation impingement, muscular force, and patient outcomes shoulder pain with activity mild pain headache mean pain duration, activity of the extremity and hours of sleep intensity of pain internal rotation impingement age, sex, pain (measured with an analog visual scale) and adverse events internal rotation subscapularis pushoff range of motion in abduction and internal rotation free of symptoms|topical glyceryl trinitrate treatment significantly improved pain scores, range of motion, internal rotation impingement, muscular force, and patient outcomes in patients with supraspinatus tendinopathy. the difference between groups was statistically significant. the mean pain duration, activity of the extremity and hours of sleep also improved in the ntg group, with no significant modification in the placebo group.|patients with rotator cuff tendinitis (rct patients with rct mean age was 61 years a total of 48 patients were included; 33 (69%) were women and 15 (31%) were men patients with supraspinatus tendinopathy fifty-three patients (57 shoulders 20 patients with shoulder pain syndrome caused by supraspinatus tendinitis semirural basic health area in the garraf region of barcelona province, spain, with a population of public health service users of 12000 patients diagnosed as having rct of less than 6 weeks' evolution who had not responded to treatment with oral nonsteroid antiinflammatory drugs rotator cuff tendinitis chronic supraspinatus tendinopathy
hospital discharge acute physiologic and chronic health evaluation ii score gastric mucosal ph (phi new-onset tachyarrhythmias norepinephrine requirements length of stay cardiac index and oxygen consumption phi milrinone requirements systemic and pulmonary hemodynamic or blood gas systemic vascular resistance index 28-day mortality acute coronary syndrome heart rate, ne requirements, and incidence of new-onset tachyarrhythmias pao2/fio2 rates, length of stay, and mortality rate in picu overall rates of serious adverse events mean arterial pressure (map) goal mortality, organ-failure-free days, length of critical care unit stay, and adverse events cardiac output by decreasing heart rate, increased creatinine clearance, and improved sofa score systemic vascular resistance number of days without need for organ support and the occurrence of adverse events bilirubin concentrations gastric mucosal blood flow mean arterial pressure and pao2/fio2 systemic and pulmonary hemodynamics (arterial and swan-ganz catheters), gastric mucosal blood flow (laser doppler flowmetry technique), hepatic function (indocyanine green clearance), and blood gases systemic blood flow and vo2 gastric mucosal acidosis and global metabolic changes total bilirubin concentrations arterial pressure cutaneous reactive hyperaemia or the oscillatory pattern of vascular tone cardiac output and global oxygen supply mean arterial pressure, systemic vascular resistance, pulmonary vascular resistance, and left and right ventricular stroke work mean arterial pressure gastric tonometry time to achieve map goals global hemodynamic variables, oxygen consumption, urine flow, creatinine clearance, and arterial blood lactate levels adverse events septic shock hemodynamic and tonometric parameters, arterial and mixed venous gases, and lactate and pyruvate blood levels oscillation frequency of the doppler signal before ischaemia peripheral vasoconstriction (systemic vascular resistance terlipressin-linked decrease in svo2 catecholamine pressors withdrawn and blood pressure time to vasopressor withdrawal systolic arterial pressure intraoperative maximum and minimum values of blood pressure and heart rate, and the time spent with systolic arterial blood pressure incidence of sinus tachycardia with da systolic arterial blood pressure and heart rate hemodynamic parameters and sequential organ failure assessment (sofa) score arterial pressure and systemic vascular resistance oxygen consumption (vo2 hemodynamics, lactate metabolism, and gastric tonometric variables reactive hyperaemia and oscillatory changes in the doppler signal hemodynamic profile, oxygen delivery, oxygen consumption (determined by indirect calorimetry), and gastric intramucosal ph (phi) (determined by gastric tonometry mean arterial pressure, cardiac index, stroke volume index, and left ventricular stroke work index gastrointestinal perfusion urine flow and creatinine clearance peripheral blood flow or on renal blood flow efficacy and safety 28-day mortality rate arrhythmia adverse event rate ratios systemic, pulmonary, and regional haemodynamic variables acute circulatory failure oxygen transport splanchnic oxygen requirements systemic and regional hemodynamics blood pressure renal function and sofa score lactate levels renal function rebound hypotension cause 28-day mortality intraoperative refractory arterial hypotension rate of death mortality rate splanchnic tissue oxygen utilization died of refractory hypotension time spent with systolic arterial blood pressure oxygenation, pao2/fio2, heart rate, mean arterial pressure, and mortality oxygen delivery and oxygen consumption systemic and regional hemodynamics and oxygen transport mean arterial pressure, pao2/fio2, and survival time arrhythmic events platelet count catecholamine requirements cutaneous vascular reactivity and flow motion response blood urea nitrogen, creatinine, ast, alt, and urine output time course of sofa score 90-day mortality blood lactate concentrations stroke volume organ dysfunction, hospital and intensive care unit length of stay, and safety (primarily occurrence of arrhythmias splanchnic blood flow and vo2 consumption index regional blood flow and oxygen transport time to haemodynamic success oxygen uptake partial pressure of carbon dioxide (pco2) gap (tonometer pco2-arterial pco2 terlipressin and norepinephrine corrected arterial hypotension oxygen delivery index 28-day all-cause mortality time to vasoactive-free hemodynamic stability maintain mean arterial pressure (map cutaneous microcirculatory response hemodynamic variables, organ dysfunction, and adverse events cardiac index cardiac arrhythmias lactate/pyruvate ratio blood flow distribution and regional oxygen transport mean stay in the picu median time to achieve the map goal mean arterial blood pressure systemic and splanchnic oxygen utilization severe septic shock achievement of map goal >24 h without vasopressors rates of serious adverse events mortality rates mortality heart rate normal systolic arterial blood pressure systemic hemodynamic measurements|blood urea nitrogen, creatinine, ast, alt, and urine output of patients in the tp group did not change after terlipressin. splanchnic blood flow and vo2 (p < .05) were increased in septic shock during hypotension and during vasopressor therapy. no statistical difference was found between epinephrine and norepinephrine-dobutamine for systemic hemodynamic measurements. mean arterial blood pressure significantly increased (p < 0.001) and norepinephrine requirements significantly decreased (p < 0.001) in the avp/norepinephrine group. compared to baseline, avp increased systemic vascular resistance, decreased exposure to ne, decreased cardiac output by decreasing heart rate, increased creatinine clearance, and improved sofa score. there were no significant differences with respect to organ failure-free days (22 vs. 25.5 days; p = 0.11), ventilator-free days (16.5 23 days; p = 0.15), length of stay (8 vs. 8.5 days; p = 0.93), or adverse event rate ratios (12.0%; 95% confidence interval, -2.6 to 26.7; p = 0.15). there were no significant differences in the overall rates of serious adverse events (10.3% and 10.5%, respectively; p=1.00). a subgroup analysis showed that dopamine, as compared with norepinephrine, was associated with an increased rate of death at 28 days among the 280 patients with cardiogenic shock but not among the 1044 patients with septic shock or the 263 with hypovolemic shock (p=0.03 for cardiogenic shock, p=0.19 for septic shock, and p=0.84 for hypovolemic shock, in kaplan-meier analyses). in patients with hyperdynamic septic shock, both norepinephrine and terlipressin were effective to raise mean arterial blood pressure. although oxygen delivery and oxygen consumption increased in both groups of patients, the phi increased significantly in those patients treated with norepinephrine whereas the phi decreased significantly in those patients receiving dopamine (p < .001, for corrected 3-hour value). mean arterial pressure, cardiac index, stroke volume index, and left ventricular stroke work index were significantly higher in avp patients. there was a significantly greater incidence of sinus tachycardia with da (24.6%; 33/134) than ne (5.9%; 7/118) and arrhythmias noted with da treatment (19.4%; 26/134) compared with ne treatment (3.4%; 4/118; p < 0.0001), respectively. in patients with septic shock, at doses that induced the same mean arterial pressure, epinephrine enhanced more gastric mucosal blood flow than the combination of dobutamine at 5 microg/kg per minute and norepinephrine. there was no difference in the time to achieve map goals in the subgroups of patients with severe sepsis (n = 158; rr 0.81; 95% ci 0.59-1.12; p = 0.18) or those with acute circulatory failure (n = 192; rr 0.89; 95% ci 0.62-1.27; p = 0.49) between epinephrine and norepinephrine. [svo2 at 4 h: 59 (11)% vs 69 (12)%, p=0.028]. arterial pressure and systemic vascular resistance were statistically unaffected in the placebo group. there is no evidence for a difference in efficacy and safety between epinephrine alone and norepinephrine plus dobutamine for the management of septic shock. the intraoperative maximum and minimum values of blood pressure and heart rate, and the time spent with systolic arterial blood pressure below 90 mmhg and above 160 mmhg, were used as indices of hemodynamic stability. in the great majority of the study patients, norepinephrine was able to increase mean perfusing pressure without apparent adverse effect on peripheral blood flow or on renal blood flow (since urine flow was reestablished). there were no differences among groups in terms of systemic and regional hemodynamics.|septic shock 16.6 yrs) and a control group of 11 postoperative cardiac surgery patients (ages ranging from 54.8 medical intensive care unit comparing da with ne as the initial vasopressor in fluid-resuscitated 252 adult patients with septic shock 218 to 1,190 patients admitted to a trauma intensive care unit with vasodilatory septic shock 18 patients who had undergone cardiac or major surgery and had a mean arterial blood pressure below 65 mmhg, despite infusion of more than 0.5 microg/kg per min two hundred and eighty patients ten patients with hyperdynamic septic shock during hypotension and after advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome children with septic shock refractory to high doses of patients with septic shock who were treated with catecholamine vasopressors patients who had septic shock and were receiving a minimum of 5 microg of twenty septic patients with a cardiac index greater than 3.2 l-min-1.m-2 and either a mean arterial pressure (map) less than 60 mm hg or a systemic vascular resistance index 2010 massachusetts medical society patients with catecholamine-resistant vasodilatory shock intensive care (icu) patients children with vasodilatory shock adults and children ten patients with hyperdynamic septic shock (ages ranging from 45.1 778 patients underwent randomization, were infused with the study drug (396 patients received septic shock patients who were managed with a specific treatment protocol twenty-three patients with early (12h) hyperdynamic septic shock in two teaching hospitals forty-eight patients with catecholamine-resistant vasodilatory shock patients with hyperdynamic septic shock patients with septic shock early hyperdynamic septic shock septic shock patients 330 patients with septic shock admitted to one of 19 participating intensive care units in france four australian university-affiliated multidisciplinary icus enrolled septic shock patients (n = 45) with a mean arterial pressure below 65 mmhg despite adequate volume resuscitation sixty-five of 69 children (94%) who were randomized received the study drug (33 critically ill patients pediatric vasodilatory shock intensive care unit of a university, tertiary, and referral center 131 to 701 advanced vasodilatory shock 58 children with septic shock and refractory hypotension despite fluid loading and high doses of catecholamines, randomly enrolled to terlipressin (tp, n=30) or control (n=28 children septic patients patients with catecholamine-dependent septic shock shock patients who have received long-term treatment with renin-angiotensin system inhibitors hyperdynamic septic shock 1679 patients, of whom 858 were assigned to patients with shock to receive either university hospital intensive care unit patients with septic shock and acute circulatory failure patients with advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome pediatric intensive care unit of a university hospital adult patients with hyperdynamic septic shock after fluid resuscitation septic shock (terlivap ten of 11 patients who did not respond to dopamine and remained hypotensive and oliguric patients who required vasopressors for any cause at randomisation patients with septic shock who were being treated with conventional (catecholamine) vasopressors 30 patients with a cardiac index (ci) > 3.51 x min(-1) x m(-2) and a mean arterial pressure (map) < or = 60 mmhg after volume loading and dopamine 20 microg/kg per min and either oliguria or hyperlactatemia hyperdynamic sepsis patients with hyperdynamic sepsis twenty adult patients with hyperdynamic septic shock, after fluid resuscitation septic shock patients requiring a continuous infusion of norepinephrine (0.9 microg kg(-1 adult medical/surgical intensive care unit in a university hospital patients chronically treated with renin-angiotensin system inhibitors 42 patients scheduled for elective carotid endarterectomy, 20 had arterial hypotension following general anesthesia that was refractory to
eventual presence of urinary keton bodies and hypoglycemic crisis mean glycemic values need of insulin, the maternal body weight gain, the week and mode of delivery, the neonatal weight and the maternal and fetal complications control of foetal growth blood glucose levels mean insulin requirement metabolic parameters considered (24-hour mean blood glucose and glycosylated hemoglobin mean insulin requirements|in both the groups the mean glycemic values during fast and two hours after meals, and the eventual presence of urinary keton bodies and hypoglycemic crisis were evaluated during the course of pregnancy: these parameters turned out to be identical in the two groups. no significant differences in mean insulin requirement at the different stages of gestation were found between the patients receiving csii and those receiving ict of either group.|type i and type ii diabetic pregnancy ten non-diabetic pregnant women ten pregnant women, affected by type i diabetes mellitus, observed for the first time during the ii-iii month of pregnancy pregnant women with type 1 diabetes mellitus patients with type ii diabetes pregnant diabetic women, fifteen with type i and fourteen with type ii diabetes pregnant diabetic women patients with type
post-ercp pancreatitis serum amylase levels incidence of bacteraemia absolute risk reduction bacteremia liver chemical values cholangitis diagnosis of acute pancreatitis absence of fever, cholangitis, and clinical signs of sepsis frequency, duration and extent of such temporary symptoms as abdominal discomfort, fever, leukocytosis, hyperamylasemia, hyperamylasuria and cholestasis serum amylase level c-reactive protein (crp) level hyperamylasemia crp level, and leukocyte count normal biliary tracts leukocyte count and liver function values malignant distal strictures septic complications clinical signs of acute pancreatitis with leukocytosis, crp reaction, and pain risk of pancreatitis frequency of pancreatitis and bacterial complications lack of antibiotic prophylaxis septicaemia rate clinical success acute cholangitis frequency of cholangitis following ercp number of septicaemias (bacteraemia with fever, rigor, circulatory reactions, leukocytosis or leukopenia bacteriologic failure (bacteremia complications (pancreatitis, pancreatic and biliary sepsis total rate of complications|in a multivariate analysis, the lack of antibiotic prophylaxis (odds ratio 6.63, p = 0.03) and sphincterotomy (odds ratio 5.60, p = 0.05) were independent risk factors for the development of post-ercp pancreatitis. single-dose prophylaxis with piperacillin is not associated with a clinically significant reduction in the incidence of acute cholangitis after ercp in patients suspected of having biliary tract stones or distal common bile duct stricture. statistical comparison of the groups produced no significant differences, i.e. neither the antibiotic nor the infusion prophylaxis proved advantageous with respect to the frequency of pancreatitis and bacterial complications. sixty-one consecutive patients referred for ercp were prospectively randomized to receive either clindamicine 600mg and gentamicine 80mg, both intramuscularly one hour before the ercp (group i; 31 patients) or not (group ii; 30 patients). the frequency of cholangitis following ercp was not significantly reduced by antibiotic prophylaxis (4% vs. 2%). all seven instances of bacteriologic failure (bacteremia) involved patients in the placebo group (p < .01). incidence of bacteraemia was 6.1% (3 of 49) in group a, 16% (8 of 50) in group b, but this difference is not statistically significant.|82 uninfected patients with cholestasis due to biliary tree obstruction of single or multiple causes ninety-six patients who underwent 100 endoscopic retrograde cholangiopancreatographies were included in the study sixty-one consecutive patients referred for ercp two patients, one from each group, developed post-ercp cholangitis that were solved with medical treatment 551 consecutive patients were enrolled patients having ercp 321 consecutive patients all patients admitted to the hospital for ercp who had not taken any antibiotics during the preceding week were included seventeen of the 281 patients who received bile duct endoscopy 68 clinically evaluable patients underwent 81 therapeutic ercp procedures 99 patients (51 men, 48 women; mean age 60.6 infectious complications after therapeutic endoscopic retrograde cholangiopancreatography a patients (n = 50 patients who had ercp for suspected biliary tract stones or distal common bile duct stricture were eligible 56 patients with indwelling biliary drainage cholangitis after endoscopic retrograde cholangiopancreatography 118 patients patients who were allergic to cephalosporins, patients with immune deficiency or any other condition requiring antibiotic prophylaxis, patients with clinical jaundice, and pregnant patients were excluded patients suspected of having biliary tract stones or distal common bile duct stricture patients presenting with cholestasis
bout duration scripps neurological rating scale (nrs) and kurtzke expanded disability status scale expanded disability status scale score frequency of improvement nrs and vas scores nrs score and answers to an efficacy questionnaire kurtzke functional and expanded disability status scales p3 peak latency serious adverse events visual analog scale (vas erps disability scores pyramidal function rate of cns igg synthesis vas scores nrs scores cns igg production clinical disability scores|after hdmp therapy the p3 peak latency was significantly shortened (p=0.006), while peak latencies of other waves (i.e. n1, p2, and n2) remained unchanged. in patients with relapse, there was a significant decrease in clinical disability scores at 1 and 4 weeks in the methylprednisolone treated group compared with controls (p less than 0.05 for each comparison). the frequency of improvement was significantly higher and the bout duration significantly lower in the mp group than in the placebo group. changes in nrs scores among methylprednisolone- and placebo-treated patients differed significantly in the first 3 weeks and after 8 weeks (p = 0.005 and p = 0.0007).|50 individuals with multiple sclerosis; 22 patients were in acute relapse and 28 had chronic progressive disease multiple sclerosis twenty-five patients with an attack of ms lasting less than 4 weeks attacks of ms patients with clinically active multiple sclerosis patients with multiple sclerosis forty-four consecutive inpatients were randomly assigned in two clinically similar groups of 22 subjects each; one treated with 23 patients with acute ms
abdominal pain postoperatively frequency and severity of dysmenorrhea frequency and severity of dysmenorrhea, dyspareunia, and chronic pelvic pain urinary urgency recurrence of pain relief of lateral pain, back pain, and dyspareunia efficacy of lpsn dysmenorrhea frequency and severity of dysmenorrhea, pelvic pain, and dyspareunia midline component of menstrual pain acceptable pain relief of dysmenorrhea, pelvic pain, and deep dyspareunia after surgery according to a multidimensional and an analog pain scale postoperative ischemic pain moderate or severe dysmenorrhea dysmenorrhea improvement significant relief from menstrual pain continued relief of menstrual pain frequency and severity of postoperative pain age, history of abdominopelvic surgery, intraperitoneal adhesions, endometriosis, concomitant surgery, and operating time recurrence of moderate or severe dysmenorrhea relief of midline pain cure rate|in a double-blind study of 21 patients with primary dysmenorrhea, 81% (9 of 11) reported significant relief from menstrual pain after the surgery. the cure rate was significantly higher in group b compared with group a at a follow-up examination at 6 months (87.3% vs 60.3%) and 12 months (85.7% vs 57.1%). the frequency and severity of postoperative pain were less in group a than in group b (both p <0.05). insertion of an lng-iud after laparoscopic surgery for symptomatic endometriosis significantly reduced the medium-term risk of recurrence of moderate or severe dysmenorrhea. the efficacy of both surgical methods was almost equal (87.9% vs. 82.9%) at the 3-month postoperative follow-up visit, but the efficacy of lpsn was significantly better than that of luna (81.8% vs 51.4%) at the 12-month visit. relief of lateral pain, back pain, and dyspareunia was variable in both groups. presacral neurectomy markedly reduced the midline component of menstrual pain, but no statistically significant differences were observed between the two groups in the frequency and severity of dysmenorrhea, pelvic pain, and dyspareunia in the long-term follow-up.|primary dysmenorrhea private practice, university-affiliated hospital eighty-five women with uterine leiomyomas and associated dysmenorrhea all patients had moderate to severe dysmenorrhea and stage iii-iv endometriosis patients with endometriosis patients undergoing resection of endometriosis but not presacral neurectomy (n = 9 44 women assigned to have tertiary institution 71 patients with moderate or severe endometriosis and midline dysmenorrhea women with severe dysmenorrhea caused by endometriosis that was treated with conservative surgical intervention women with severe dysmenorrhea caused by endometriosis who were treated with women with uterine myomas and dysmenorrhea sixty-eight patients with primary dysmenorrhea and a poor response to medical treatment parous women with moderate or severe dysmenorrhea undergoing first-line operative laparoscopy for symptomatic endometriosis 21 patients with primary dysmenorrhea, 81% (9 of 11) reported eighty women completed 1-, 3-, and 6-month follow-up women with symptomatic endometriosis in whom a levonorgestrel-releasing intrauterine device (lng-iud symptomatic endometriosis women who are treated with conservative laparoscopic surgery for severe dysmenorrhea caused by endometriosis primary dysmenorrhea with laparoscopic uterine nerve ablation 85 patients who entered the study, 41 were assigned to undergo women with dysmenorrhea caused by uterine myomas treated by laparoscopic bipolar coagulation of uterine vessels (lbcuv pelvic pain associated with endometriosis midline dysmenorrhea one hundred forty-one sexually active women of fertile age with chronic severe dysmenorrhea caused by endometriosis
incidence of cmv disease 90 days after transplantation rate of cmv infection urine cultures positive for cmv death from cmv disease cmv infection, disease, and disease severity without increased ganciclovir resistance or toxicity pneumonitis and myocarditis cmv viremia serum creatinine concentrations time to asymptomatic cmv infection, symptomatic cmv infections, and end-organ cmv disease cmv diseases obliterative bronchiolitis or time to onset of grade 2 bronchiolitis obliterans syndrome overall patient survival time to cmv viremia cmv serostatus, cmv disease, graft outcome, and ganciclovir side effects time-to-onset of cmv disease and to viremia time to cmv disease or viremia biopsy-confirmed acute rejection rate rate of cmv disease laboratory-confirmed cmv disease risk of cmv disease incidence of overt cmv shedding and/or pneumonitis occurrence of cmv infections opportunistic infections, and acute graft rejection leucopaenia cmv disease, plasma viremia, acute graft rejection, graft loss and safety renal transplantation cytomegalovirus syndromes incidence of cytomegalovirus (cmv) disease neutropenia with valganciclovir nephrotoxicity incidence of cmv infection duration of disease acute allograft rejection rate of viral shedding adverse events probability of presenting cmv disease severity of cmv disease time to development of cmv antigenemia estimated cost of valacyclovir treatment incidence of investigator-treated cmv disease events confirmed cmv disease incidence of cytomegalovirus disease time to cmv infection and disease the first 6 months after transplantation incidence of cmv disease, and delayed the onset of cmv infection rate of ebv disease incidence of cmv disease cmv infection cytomegalovirus (cmv) disease length of hospitalization actuarial incidence of cytomegalovirus disease survival advantage number of bacterial infections hallucinations and confusion incidence of documented cytomegalovirus infection cmv colitis delay between transplantation and cmv infection concanavalin a stimulation delayed cmv infection efficacy, safety, and cost efficacy and safety adverse reactions cmv infection, symptomatic cmv infection, and cmv disease rate of biopsy-confirmed acute graft rejection rate of cmv infection and cmv disease demography, immunosuppression, or donor/recipient cmv serology incidences of leukopenia, thrombocytopenia, renal failure, and other adverse events lymphocyte proliferation frequency of adverse events time to cmv disease cytomegalovirus infection incidence of cmv disease and viremia tolerated incidence of cmv infection in both cmv antibody positive sequelae of cytomegalovirus (cmv) infections pcr evidence for cmv viremia detection of cmv dna, virus infections other than cmv, acute rejection episodes, and serum creatinine levels rate of biopsy-proven acute rejection ganciclovir resistance surveillance blood cultures leukopenia cytomegalovirus disease cumulative incidence of all cmv infections (including seroconversions cytomegalovirus pneumonia reversible leukopenia symptomatic herpes-simplex infections neurotoxicity cmv infection, cmv disease, rejection, opportunistic infections, and possible drug toxicity median time to onset of cmv disease disease severity peripheral blood leukocytes (pp 65), shell vial culture (blood), and virus isolation/early antigen detection (urine 12-month incidence of cmv disease excessive occurrence of cytomegalovirus disease lymphocyte function rate of cytomegalovirus infection and disease without affecting the survival rate infection with candida albicans infection, disease, or sequelae of cytomegalovirus infection symptomatic cytomegalovirus disease frequency of cmv or ebv disease number of rejection, steroid pulses, and okt3 treatments demographics, primary renal disease, graft source, hla matching, immunosuppressive therapy and donor-recipient cmv antibody status rates of acute rejection, opportunistic infections, adverse events, cmv ul97 ganciclovir-resistance mutations, and laboratory abnormalities rates of other adverse events severe cmv disease acute rejection episodes prevalence of obliterative bronchiolitis (ob cmv incidence of allograft rejection median time to onset of cmv infection cytomegalovirus (cmv) infection and disease tissue invasive disease cytomegalovirus disease and cytomegalovirus viremia frequency of clinical infections morbidity liver function tests lower activated t-cell count (cd3(+)hla-dr(+) cells time to disease cmv and ob cmv illness cmv-specific immunoglobulin m antibodies, cmv immunofluorescence assay [standard culture tube and shell vial] (blood) and virus isolation (urine and tissue allograft survival safety and efficacy cmv infection and cmv disease) and secondary endpoints (rates of fungal and bacterial infection, allograft rejection, and survival after transplantation median time to cmv antigenemia infection rates incidence or delayed the onset of cmv disease risk of acute renal allograft rejection tissue-invasive infection total mortality morbidity of cytomegalovirus disease cmv disease clinically effective and well-tolerated delayed acute rejection transplant function rates of recovery of virus from the blood and urine cytomegalovirus opportunistic or other herpesvirus infections freedom from cmv disease (syndrome or tissue-invasive risk of acute rejection cmv disease and infection safety profile rates of cmv viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources symptomatic cmv disease cmv disease severity, cmv infection, acute rejection, opportunistic infections, ganciclovir resistance, and safety average cmv-associated costs per patient incidence and severity of cmv disease, length of hospitalization, and patient and allograft survival incidence of symptomatic disease or viremia delayed infections episodes of biopsy proven allograft rejections tissue invasive disease and recurrent cmv disease|the 12-month incidence of cmv disease was 67% in the def group compared with 6% in the gan group and 3% in the val group (p<0.001 gan or val vs. def; p=0.575 gan vs. val). this superior protection against cmv disease extends up to 1 year after transplantation and is not associated with ganciclovir resistance. the time to cmv disease was significantly prolonged in patients on acyclovir as compared to patients on placebo (p=0.013). cmv disease developed in 23% of patients treated with acv and in 11% of patients treated with gcv + acv (p=0.03). there was also a trend for delayed acute rejection, and fewer opportunistic or other herpesvirus infections occurred in the valacyclovir group. there was no significant difference between the two groups for age, immunosuppressive regimen, number of rejection, steroid pulses, and okt3 treatments. ganciclovir reduced the incidence of cmv infection in both cmv antibody positive (37 vs 4%, p = 0.001) and negative patients (42 vs 11%, p = 0.06). there were no differences between the groups in the frequency of adverse events or in the rate of survival of either grafts or patients. treatment with valacyclovir reduced the incidence or delayed the onset of cmv disease in both the seronegative patients (p<0.001) and the seropositive patients (p=0.03). no difference was observed between the two treatment groups with respect to detection of cmv dna, virus infections other than cmv, acute rejection episodes, and serum creatinine levels at 3 and 6 months following transplantation. preemptive ganciclovir therapy significantly reduced the incidence of cmv disease (p < .05) in cmv-seropositive renal transplant patients who were treated with ala and was well tolerated. the rate of ebv disease among patients treated with the combination regimen (eight [33%] of 24) was similar to that among patients treated with ganciclovir alone (five [21%] of 24; p = not significant). with respect to primary cmv infection, there was no difference in the rates in the 2 groups, but tissue invasive disease and recurrent cmv disease were less frequent in the ganciclovir group. prophylactic ganciclovir was associated with a lower incidence of serologically diagnosed secondary infection and the development of the igm anti-cmv antibody. the onst of cmv disease was not delayed significantly in acyclovir-treated patients compared with controls (acy, 47 +/- leukopenia was more common in the ganciclovir group (p<0.05), but in no case did it require drug discontinuation. there were no significant differences between the daily and 3-times-weekly groups with respect to survival free from cytomegalovirus infection or survival free from cytomegalovirus disease. the incidence of cmv disease was significantly lower in the acyclovir group (5%) than in the control group (27%; p < 0.05). cytomegalovirus was isolated from buffy-coat specimens from 17% of patients (11 of 64) receiving preemptive ganciclovir and from 35% of controls (17 of 49) (p = 0.03). oral and intravenous ganciclovir showed no significant difference to reduce the rate of cmv infection among high-risk kidney recipients. significantly fewer patients in the 200-day group versus the 100-day group developed confirmed cmv disease up to month 12 posttransplant (16.1% vs. 36.8%; p < 0.0001). cmv disease occurred in 3 of 32 patients (9.3%) receiving oral ganciclovir and in 4 of 32 patients (12.5%) receiving iv ganciclovir within the first year after transplantation (p>0.2). no patients in the ganciclovir group, compared with 14 of 23 patients (61%) in the deferred-therapy group (p<0.0001), developed cmv disease during the first 12 weeks. neither, the cmv status of donors and recipients nor the treatment for acute rejection had any significant impact on the occurrence of cmv infections. infection rates for acyclovir vs. ganciclovir, respectively, stratified by cmv serology were: d+r-, 54 vs. 0%, p=0.0008; d+r+, 43 vs. 6.6%, p=0.01; d-r+, 8.3 vs. 0%, p=ns. from day 15 through day 60, the patients who took ganciclovir had significantly fewer urine cultures positive for cmv, but by day 90 there was no difference. at termination of study enrollment, the cumulative incidence of all cmv infections (including seroconversions) was increased in group a compared with that in group g (75% versus 15%, p < 0.01), as was the incidence of overt cmv shedding and/or pneumonitis (50% versus 15%, p < 0.043). oral ganciclovir reduced the incidence of cmv infection (placebo 79 [51.5%] of 154; ganciclovir 37 [24.5%] of 150; p < 0.001) and also reduced symptomatic herpes-simplex infections (kaplan-meier estimates: placebo 36 [23.5%] of 154; ganciclovir five [3.5%] of 150; p < 0.001). significant reductions were observed with cmv infection (64% vs. 10%; p < 0.001) and disease severity (110 000 vs. 3200 copies/ml, p = 0.009) with extended treatment. cmv viremia during prophylaxis was significantly lower with valganciclovir (2.9% vs. 10.4%; p=0.001), but was comparable by 12 months (48.5% valganciclovir vs 48.8% ganciclovir). ganciclovir prophylaxis reduced the actuarial incidence of cytomegalovirus disease from 71% to 11% in cytomegalovirus-mismatched patients (p < 0.01). antiviral prophylaxis against cytomegalovirus has been associated with reduced risk of allograft rejection and improved allograft survival after renal transplantation.|twenty-seven d+r-, 29 d+r+, and 23 d-r+ patients adult liver transplant recipients lung transplant recipients renal-transplant recipients thirty-four, cytomegalovirus (cmv after liver transplantation in adults fifty-six consecutive patients were stratified into two groups: cytomegalovirus-positive recipients (n = 40) and cytomegalovirus-negative recipients of organs from cytomegalovirus-positive donors (n = 16 cytomegalovirus disease after heart transplantation 326 high-risk (d+/r-) kidney allograft recipients high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors renal transplant recipients who are positive for cytomegalovirus antibody high-risk kidney transplant recipients high-risk seronegative solid organ transplant (sot) recipients of organs from seropositive donors (d+/r seronegative patients who had received a kidney from a seropositive donor renal transplant recipients using either liver-transplant recipients clinical cytomegalovirus disease after heart transplantation seropositive recipients of kidneys from seropositive donors who had undergone antilymphocytic immunosuppressive therapy recipients of renal allografts from cadavers post-kidney transplant patients primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis cmv high-risk renal transplant recipients 118 patients enrolled in the study, 104 completed at least 30 days on the study medication and were included in our analysis of the results after lung and heart-lung transplantation adult renal transplant recipients 208 cmv-negative recipients of a kidney from a seropositive donor and 408 cmv-positive recipients adult lung transplant recipients 11 u.s. lung transplant centers cytomegalovirus and epstein-barr virus disease after liver transplantation in children cmv disease after orthotopic liver transplantation high-risk kidney recipients thirty-two patients were included in this study (15 in the control group, 17 in the ganciclovir group renal transplant recipients during prophylaxis seronegative recipients of seronegative livers organ transplant patients at risk for primary infection (donor seropositive, recipient seronegative, d+r cytomegalovirus (cmv)-seropositive renal transplant recipients treated with antilymphocyte antibody (ala) preparations seventy-two consecutive subjects who had either donor or recipient cytomegalovirus seropositivity liver transplant recipients high-risk cmv-seronegative liver transplant recipients with cmv-seropositive donors cytomegalovirus after lung transplantation 37 seronegative patients cytomegalovirus (cmv) disease after renal transplantation (tx patients who undergo renal transplantation, and cytomegalovirus disease after lung transplantation, 25 allograft recipients cmv-seropositive patients treated with ala liver transplantation high-risk patients high-risk renal transplant recipients (cmv-seropositive donor, seronegative recipient) treated prophylactically with 18 control patients who did not receive prophylaxis for cmv disease (group 2 liver-transplant patients with 14 days of kidney transplant recipients all patients with clinical cytomegalovirus disease cytomegalovirus-positive recipients eighty-three renal transplant recipients 650-bed tertiary medical center hospital orthotopic liver transplantation one hundred sixty-seven liver-transplant recipients cytomegalovirus disease after renal transplantation seronegative recipients heart transplant recipients orthotopic liver-transplant patients cytomegalovirus antibody-positive renal transplant recipients patients were stratified into two groups: those who were seropositive for cmv before transplantation and those who were seronegative but who received hearts from seropositive donors cytomegalovirus-seropositive renal transplants recipients cytomegalovirus reactivation after heart transplantation 65 patients after liver transplantation cmv disease after renal transplantation recipients of renal allografts forty consecutive cmv-seropositive renal allograft recipients who underwent transplantation between january 1992 and january 1994 and were treated with ala for induction immunosuppression or acute rejection therapy one hundred forty-three patients cmv seronegative recipients of a renal allograft from cmv seropositive donors 101 recipients of cadaveric (83) and zero haplotype-matched live donor (18) kidney transplants renal transplant recipients treated prophylactically with 364 cmv d+/r- patients received 113 renal transplant recipients who were positive for cytomegalovirus antibody sixteen patients in the oral group and 14 in the intravenous group completed the study a total of 83 patients 155 evaluable d+r- organ transplant recipients from 13 transplant centers cmv-seropositive liver transplant recipients renal transplant patients 136 lung transplant recipients who completed 3 months of valganciclovir prophylaxis cytomegalovirus-seropositive liver transplant recipients solid organ transplant recipients seventy-three adult liver transplant recipients, seropositive for cmv recipients of seropositive donor kidneys patients treated with modern immunosuppression patients after renal transplantation liver recipients cytomegalovirus (cmv) and epstein-barr virus (ebv) disease after pediatric liver transplantation between december, 1993, and april, 1995, 304 liver-transplant recipients twenty-seven cmv seropositive adults due to receive a heart transplant after liver transplantation renal transplant recipients liver transplant patients recipients of seronegative donor kidneys fifty-five patients cytomegalovirus (cmv)-seronegative liver transplant recipients with cmv-seropositive donors 6 university-affiliated transplantation centers renal transplant recipients who were positive for cytomegalovirus antibody after renal transplantation
incidence rates of mucositis, pain, xerostomia and taste disturbance frequency of severe (who grades 3 or 4) mucositis percentage of neutrophil phagocytosis and the sag levels shorter mean radiotherapy duration mean area under the mucositis curve colonization index of viridans streptococci major toxicities similar time to engraftment time until healing grade 3 or greater mucositis with morning rt severity of radiation-induced mucositis incidence of oral mucositis of world health organization (who) grade 3 or 4 toxicity profiles average time for oral lesion oral mucositis assessment scale (omas) and the world health organization (who) scale severity and duration of chemotherapy-induced oral mucositis ip test score incidence of mucositis requiring morphine sulfate (mso4 risk of mucositis grade three or four mucositis fever duration of mouth pain ulcerative om severity of subsequent mucositis nasogastric tube feeding protective activity median duration of grade >or= 2 mucositis plasma levels grade 2 or higher late xerostomia pain relief engraftment of neutrophil pain on swallowing and use of pain medication specifically for mucositis deaths from disseminated candidiasis mucositis, dysphagia, and xerostomia objective and subjective mucositis scores weight loss, mucositis, pain, nutritional intake platelet recovery, erythrocyte recovery, incidence of veno-occlusive disease, gvhd severity, relapse or survival oral mucosal complications om characteristics, fever of unknown origin (fuo) and other infections mean duration of the use of this feeding tube severity of stomatitis qol scales mean quality-of-life scores mucositis score hemoglobin level incidence of radiation therapy oncology group grade 3 mucositis incidence of adverse events grade > or =2 acute xerostomia tumor growth and patient survival weight changes oral complications incidence of chemotherapy-related oral mucositis mean toxicity score for cryotherapy nausea and/or vomiting severity and duration of oral mucositis frequency of mucositis grade grade 3/4 thrombocytopenia occurrence of mucositis body temperature or application of antibiotics grades of oral mucosa ulceration acute nausea/vomiting pain visual analogue scale (vas) scores, mucositis index scores and medical and nursing charts ulcer free median saliva production incidence or severity of diarrhea or in overall survival median time of mucositis occurrence alleviate oral mucositis subsequent mucositis grade 3 or higher acute mucositis acute radiation morbidity objective score of edema, erythema, erosion and ulcerations neutrophil phagocytic function duration and severity of chemotherapy-associated stomatitis grade iii/iv mucositis protective effect against 5-fu-induced mucositis radiotherapy duration aerobic elevated mucositis score stomatitis severity, incidence of uom, peak mouth pain, peak difficulty swallowing, amount of opiate analgesics used, or adverse event type or incidence amount of food intake number of severe (i.e., grade 3) mucositis scores frequency and duration of om lactulose-mannitol ratio mucositis distribution radiation-induced oropharyngeal mucositis influenza type symptoms incidence of grades 3-4 mucositis mean auc values complete responses (cr) and 6 (24%) partial responses (pr severity (maximum extent) of acute radiation therapy side effects neutrophil functions and prevention of chemotherapy-induced side-effects mucositis, changes in the oral flora, quality of feeding and changes of total body weight radiation-associated xerostomia toxicity, engraftment, supportive care, response and survival severe oral mucositis tolerance to head-and-neck radiotherapy, decrease mucositis, reduce soreness acute gvhd incidence or severity, survival, or day 100 relapse rates disease-free survival soreness grades of stomatitis and diarrhea severity and duration of mucositis numbers of salivary enterococci, enterobacteria, and/or pseudomonas mucositis and adm-induced leukopenia median ip test score severity of oral mucositis adm-induced mucositis severity and duration of mucositis, pain measurement, radiation therapy interruption, and quality of life healing of mucositis and dermatitis subjective intolerance, mucositis, dysphagia, dermatitis and nausea mean duration detectable plasma concentration of gm-csf intestinal permeability interval to healing average repairing time milder mucositis and dermatitis incidence of acute perineal skin and bladder toxicity persistent clinical oral candidiasis percentage of patients who developed intermediate or thick pseudomembranes frequency of grade 2 to 4 mucositis development of grade 3 mucositis and dermatitis c-reactive protein (crp) increase >50mg/l acute toxicity grade 3-4 mucositis oropharyngeal toxicity incidence of grade 4 oral mucositis tooth staining complete eradication of agnb suppression of oral flora and a lowering of the severity of mucositis neutrophil phagocytosis, superoxide anion generation (sag), prevention of chemotherapy-induced side-effects and cost-effectiveness mean toxicity score salivary lactoferrin radiation mucositis and body weight, serum prealbumin level, and blood cell counts intensity of radiation-induced mucositis and oral discomfort median duration of fever severity of radiation-induced oral/oropharyngeal mucositis incidence of teaes serum interleukin-6 grade 2 mucositis and dermatitis earlier and sooner tumor response or survival grading of acute and late nonhematologic toxicities (mucositis, dysphagia, xerostomia soreness of the mouth and throat pain control partial remission severity of late xerostomia median maximum neutrophil counts mucositis grade mucositis, the inflammation and necrosis of mucosal membranes mucosal toxicity incidence of grade > or = 2 graft-versus-host disease survival time cervical muscular sclerosis grade 2 mucositis erythema, ulceration, and pain associated with oral mucositis delayed emesis cure rates, extend survival, and reduce morbidity radiation-induced oral mucositis grade iii skin reaction rtog grade 3 or greater mucositis salivary gland function adm-induced oral mucositis nephrotoxicity, gastrointestinal side effects, haematopoietic recovery mean maximal intensity for nci score mucositis reduction severity (ctc-grading) and duration of om skin and mucosal reactions wbc toxicity degree of mouth-opening proinflammatory cytokines (tumor necrosis factor, interleukin [il]-1, and il-6) and lower levels of anti-inflammatory cytokines (il-13 radiation- and chemotherapy-induced mouth lesions radiation-related mucositis mucositis and oral pain median length of stay and the median number of days of total parenteral nutrition (tpn nausea, vomiting, hypotension, and allergic reactions quality of life toxicity incidences incidence of severe (grade 3-4) oral mucositis oral candidiasis frequency or severity of oral mucositis complete blood count hospitalization for mucositis acute toxicities (mucositis and dysphagia intensity of mucositis tumour control rates mucositis area estimated odds ratio (placebo/active) of developing an intermediate or thick pseudomembrane percutaneous endoscopic gastrostomy efficacy and safety nutritional status and overall patient outcome as assessed by days receiving tpn, number of days required until oral intake resumed, length of hospitalization, number of days and highest grade of mucositis, and quantity and number of days of diarrhea average unstimulated salivary flow pain and mucositis functional activation of wbc grade 2 xerostomia occurrence of mucositis, the median duration of oral mucositis stomatitis grade iii/iv total parenteral nutrition (tpn), narcotic use, hospitalization, weight loss and resumption of oral caloric intake incidence of renal insufficiency healing of mucositis symptomatic grade 3/4 mucositis adverse effect of sod injection frequency of fever and infections duration of > or = grade 3 subjective mucositis thickening of oral mucosa mucositis and dysphagia skin reactions plasma glutamine level parenteral nutrition and morphine, incidence of fever and infections, and duration of neutropenia and hospitalization some mucositis absolute neutrophil count of > 0.5 x 10(9) cells/l edema, infection, skin pain, or rash mean auc of gross/functional scores and duration of moderate gross mucositis 5-year overall survival rate grade of mucositis, skin reactions and related parameters mean patient-judged mucositis scores median total tumour and biologically effective dose (bed) gy10 frequency or type of mouth lesions locoregional failure, progression-free survival, and overall survival om grade (who mucosal pain aerobic pathogenic bacteria oral ulcerative mucositis swallowing difficulty need for percutaneous endoscopic gastrostomy placement peak stomatitis nci-ctc grade total duration of treatment overall survival duration of objective oral mucositis proportion of patients with grade 2 xerostomia intensity of pain, severity of mucositis and use of opioids oral ulceration simple visual analogue scale grade 3 mucositis mucositis or oral pain maximal grade of toxicity, duration of grade 2 or worse mucositis, quality-of-life scores, percentage of weight loss, use of pain medications, hydration requirement, oral infections, and prolonged radiation breaks karnofsky performance status, body weight, cutaneous side effects, and alopecia objective severity of mucositis, anorexia, and swallowing difficulty nausea amelioration of mucositis incidences of grade iii-iv mucositis and infection grade 4 mucositis severe mucositis acute oral mucositis safety and efficacy safety and for om incidence and severity iv degree toxicity severe leukopenia clinical evolution of iatrogenic tissue damage maximum severity of mouth pain and difficulty swallowing mucositis/stomatitis of grade 2-4 stomatitis expression of ki-67 and pcna antigens severity of oral pain length of hospitalization or weight loss numbers of aerobic and anaerobic bacteria rates of xerostomia and mucositis objective mucositis score (oms) and the world health organization (who) grading system 5-fu-induced mucositis pain neutrophilic granulocyte toxicity incidence and severity of oral/oropharyngeal mucositis episodes of mucositis duration and severity of stomatitis percentage of patients with positive cultures of agnb adverse effects skin toxicity mean duration of "at least grade 3" mucositis (who average mucositis score development and severity of mucositis intensity or duration of mucositis incidence of severe oral mucositis radiation mucositis, pain, dysphagia and weight loss skin and oral events severity of acute side effects severe (grade 3 or 4) mucositis need for feeding tubes mean area under the curve stomatitis scores overall survival rate degree toxicity om alive without disease recurrence om severity weight loss duration and severity of objective oral mucositis stomatitis and diarrhea duration and severity of subjective oral mucositis chronic xerostomia grade positive gain in body weight frequency tumor response rate who toxicity scale for mucositis, oral assessment scale, and a subjective pain scale acute oropharyngeal toxicity mucositis and xerostomia frequency of culture-positive herpes simplex virus mean duration of oral mucositis cr severity of mucositis duration of neutropenia grade 0 mucositis varying degrees of radiation-induced mucositis adverse events pain requiring opioids (chi(2) exact test, ns crp increase efficacy/toxicity incidence of mucositis acute and chronic xerostomia neck dissection median subjective pain scores, who scores, and oral assessment scores frequency and severity of therapy-induced oral mucositis oral assessment of mucositis by using world health organization (who) oral toxicity scale buccal toxicity highest serum creatinine value morbidity and mortality hypotension mucositis and dermatitis salivation and decrease oral mucositis quality of life by impairing eating, swallowing, and talking and by disturbing sleep frequency and duration of severe oral mucositis radiation-induced mucositis incidence, mean duration, and mean area under the curve (auc) of severe oral gross mucositis stomatitis scores candida colonisation occurrence rate of grade 1-2 mucositis of the oral cavity oral candida erythema and ulceration intestinal permeability (ip duration of severe mucositis oral soft tissue disease and oral microbial burden occurrence of severe oral and intestinal mucositis incidence of grade > or =2 acute xerostomia, grade > or =3 acute mucositis, and grade > or =2 late xerostomia safety, tolerability and efficacy who grade 1-4 oral mucositis cumulative asthenia salivary lactoferrin concentrations cumulative incidence of moderate to severe (grade 2 or higher) mucositis pharyngeal, esophageal, and rectal mucositis incidence and severity of oral mucositis mean body weight change serum cytokine levels and the severity of oral mucositis time to development of severe mucositis local effectivity mucositis/stomatitis leukopenia oral mucositis (om oral mucositis and pain stage iv disease longer interval to the development of grade 3 or greater mucositis oral mucositis, pain, xerostomia and taste disturbance acute xerostomia later onset of stomatitis mean of grade 1-4 mucositis, anorexia, difficulty in swallowing, and body weight change effective, safe, and well tolerated lower number of days with fever and a shortened duration of hospital stay median grade of oral mucositis incidence of om and diarrhea, safety, disease progression, and survival hematological toxicity mean questionnaire scores degree of mucositis antitumor treatment efficacy additional toxicity salivary flow, xerostomia, mucositis, and quality of life (qol acute mucositis treatment-emergent adverse events (teaes number of patients with severe objective mucositis degree of oropharyngeal and hematological toxicity, radiotherapy duration, and curative effect degree of mucomembranous reaction mean maximum grade of objective oral mucositis plasma glutamine level, intestinal permeability (lactulose-mannitol test), and tumor size total of 11 dose-limiting toxicities (most often skin, respiratory, or oral mucositis leukocyte recovery minimal or absent mucosal inflammation pain or dysphagia probability of grade > or = 3 mucositis oropharyngeal ecology 4-year survival frequency of chemotherapy-induced mucositis neutrophil and platelet engraftment oral mucositis grade, oral pain, use of analgesic drugs, weight loss, or survival skin and mucosa reactions acute grade 2 xerostomia duration and severity of oral mucositis radiation-induced early oral mucositis oral mucomembranous reaction tolerance problems (vomiting, liver enzyme elevation, generalized erythema reduced incidence and mean severity of mucositis incidence and duration of adm-induced oral mucositis incidence and severity of acute and late toxicities highest grade of mucositis grade three mucositis radiation mucositis duration of hospitalization occurrence rate of skin, oral mucosal, pelvic visceral and systematic adverse reaction mean pain sure and mucositis grade gfr tolerated and no adverse events incidence of loss of taste median survival world health organization (who) step analgesic medication and body weight change oral discomfort survival outcomes incidence and severity of mucositis complete remission incidence, severity and duration of oral mucositis burning sensation numeric rating scale scores frequency of "severe pain alleviation of radiation-induced mucositis oral health maximum mucositis scores incidence of use of total parenteral nutrition dysphagia hematologic toxicity, transfusion requirements, duration of fever, and hepatic toxicity median fall of the glomerular filtration rate (gfr rates of percutaneous endoscopic gastrostomy placement severe mucositis and dermatitis bone pain degree of mucositis and dermatitis toxicity (eg, mouthwash-induced discomfort, taste alteration, and teeth staining urinary excretion of 51cr-edta and the severity of mucositis mucositis, skin reaction, dysphagia grade four mucositis oral mucositis (om) and diarrhea safe and well tolerated platelet toxicity incidence of oral mucositis grade 2-4 and the duration of oral mucositis grade total oral streptococci median time to percutaneous endoscopic gastrostomy removal oral pain oral mucositis (omas, nci score), oral pain (vas), oral function and salivary flow rate acute xerostomia and mucositis xerostomia and mucositis severe mucosal reactions subjective reporting of discomfort, objective scoring of the severity of mucositis, and the maximal percent of body weight lost median duration of mucositis moderate/severe mucositis confluent mucositis preexisting colonization mucositis incidence and severity of acute mucositis, acute and late xerostomia adverse events, mainly rash, pruritus, erythema, mouth and tongue disorders, and taste alteration safety and tolerability anesthetic mouth washing and their salivary lactoferrin and albumin levels objective and subjective mucositis scores and microbiologic counts of the oral flora severity of radiation mucositis radiation reactions mucosal reactions, pain and difficulty in swallowing incidence of who grade 2 or higher om total body irradiation (tbi grades of mucositis mucositis incidence and severity saliva production 2-year local-regional control, disease-free survival, and overall survival outcome questionnaire; and daily symptom record diary mouth pain and difficulty swallowing risk of oral mucositis grade of mucositis albumin and low molecular weight protein urinary excretion oropharyngeal mucositis treatment duration, hematologic toxicity, and clinical outcome prevention and reduction of severity of conditioning-induced oral mucositis (om mean mucositis scores tolerated whole saliva production oral mucositis and symptoms local-regional control eosinophil counts mean total duration of mucositis colonisation index of candida species and gram-negative bacilli delays in radiotherapy because of grade 3 mucositis c-reactive protein levels worsens oral mucositis incidence of severe mucositis pain, swallowing, drinking, eating, sleeping and taste alterations cr rate incidence of grade 2 late xerostomia severity of om weight median interval to observation of grade > or =2 mucositis oral mucositis incidence of grade 3/4 mucositis toxicity earlier onset of mucositis gastrointestinal bleeding skin reaction degree of oropharyngeal mucosa reaction, dryness in mouth and radiation dermatitis in cervical region dental plaque levels and the degree of gingivitis and mucositis expression of ki-67 and pcna antigens in breast carcinoma mild radiation side-effects unadjusted chi-square test, and time to first episode of mucositis toxicity data equal rate of non-compliance visual analogue scale for oral pain and oral function mucositis scores median time to development of severe mucositis oral mucositis daily fraction feasible and well-tolerated type of mouthwash, incidence, days to onset, and severity of chemotherapy-induced oral mucositis grade 2 or higher acute xerostomia patients' weight, taste, oral mucous reaction, and tongue mucous reaction grade of radiation mucositis and blood cell counts incidence, days to onset, and severity of mucositis engraftment, acute gvhd, or survival diarrhoea oral mucositis and selective elimination of oral flora mucositis and mouthwash toxicity median number of amifostine doses development of infection, mucositis and diarrhoea anorexia incidence of hsv infection duration of moderate/severe mucositis narcotics and tpn severity of oral mucositis and pain scores progression of mucositis using the oral mucositis assessing scale (omas colonization patterns of candida species, streptococcus faecalis, staphylococci, and enterobacteriaceae, pseudomonadaceae, and acinetobacter species delayed mucositis number of days with fever, number of oral lesions, plaque score, gingival bleeding score, or occurrence of candidiasis occurrence rate of grade 3-4 mucositis mucositis grade 3-4 mean weight loss salivary flow and qol scores oral flora and irradiation mucositis grade of oral mucositis crp >50mg/l median progression-free or overall survival times complete remission (cr) rate morbidity of concurrent chemotherapy and radiotherapy hazard ratio (hr mean onset of mucositis grade > or =3 mucositis standard error of the mean) maximum mucositis scores episode of febrile neutropenia skin desquamation oral toxicities demographic parameters, medical status, quality of life survey and mucosal injury scoring table (based on world health organization scales for mucositis documented infections, use of broad-spectrum antibiotics, and number of days with fever weight, prealbumin level, or blood cell count degree of oral injury levels of selected cytokines and mucositis severity|we found no differences regarding myelosuppression, infections or other chemotherapy complications. no statistically significant difference was found between the results with na sos and those with placebo for any of the variables, with the exception of skin desquamation, which showed a significant difference in the placebo group. we found no significant difference between the molgramostim and the control groups in the oral mucositis grade, oral pain, use of analgesic drugs, weight loss, or survival. we evaluated the efficacy of topically applied human recombinant epidermal growth factor (rhegf) for the treatment of oral mucositis induced by radiotherapy (rt), with or without chemotherapy, in patients with head and neck cancer. there was no significant difference between the cohorts in stomatitis severity, incidence of uom, peak mouth pain, peak difficulty swallowing, amount of opiate analgesics used, or adverse event type or incidence. duration was significantly longer in b than in both a (p= .035) and c (p= .003). the study demonstrated that the proportion of patients with severe mucosal reactions was significantly lower in the sucralfate group than in the placebo group. the analysis showed that the higher education level and the use of dentures significantly reduced the occurrence of mucositis, and allopurinol mouth rinse (1 mg/ml) was ineffective in the prophylaxis of fluorouracil-induced mucositis. visual analogue scale for oral pain and oral function was not significantly different between the two groups. subsequent mucositis was significantly reduced in the group assigned to receive cryotherapy as judged by the attending physicians (p = .0002) and by the patients themselves (p = .0001). early during radiation therapy less oral pain was reported in the sucralfate group, but as treatment progressed all patients experienced pain. no differences were found in the median subjective pain scores, who scores, and oral assessment scores between the placebo and the gm-csf groups. adverse events leading to study drug discontinuation and death did not differ significantly between groups. grade 3 mucositis was more common in patients receiving chemotherapy (p = 0.05) or bid fractionation (p = 0.04) or having a poor kps (p = 0.02). evaluation of the data showed delayed mucositis in the experimental group for grades 1 to 3, with a significant difference at grade 3 compared with controls. their scores were also significantly lower when compared to the salt/soda and chlorhexidine groups from the fourth and fifth week, respectively, after radiotherapy. the incidence rates of mucositis, pain, xerostomia and taste disturbance were all markedly lower in polaprezinc group than in control. acute nausea/vomiting was frequently observed immediately during or after the application of amifostine despite intensive antiemetic prophylaxis consisting of 5-ht3-receptor antagonists/dexamethasone/trifluorpromazine. local effectivity appeared to be less in the hypopharynx due to shorter time of application compared with mouth and oropharynx. compared to the normal saline group, patients using cryotherapy experienced less grade 3-4 mucositis, 14 vs 74%, p=0.0005. although the frequency of culture-positive herpes simplex virus was low in the untreated group, it was significantly lower, zero, in the acyclovir-treated group. the chinese herbal preparation yhd could alleviate oral mucomembranous reaction to radiation applied in patients with head-neck tumor. in univariate and multivariate analysis, severe oral mucositis correlated with tbi in the conditioning regimen and lack of folinic acid rescue following mtx administration. amifostine significantly reduced the mean questionnaire scores from 6.49 to 3.73, the incidence of grade > or = 2 mucositis from 75% to 36% and acute xerostomia from 82% to 39%. conversion to complete remission post-asct occurred in 30 and 14% of the amifostine and control groups, respectively (p=0.09). wbc toxicity (z=-0.604,p=0.546), neutrophilic granulocyte toxicity (z=-0.226,p=0.821), and platelet toxicity (z=-0.099,p=0.922) were compared; there was no statistic significance of difference (p >0.05); amifostine significantly reduced the incidence of acute perineal skin and bladder toxicity (p <.0006). we could not identify any significant difference in the incidence of severe mucositis based on whether patients were allocated to receive misoprostol or placebo. om occurred significantly more often in females than in males (86% vs 60%, p=0.0016) and was worse and of longer duration. both study and control groups were compared with respect to the frequency [30% versus 36%, chi(2) exact test, not significant (ns)] and mean duration (4.8 +/- the treatment duration was significantly shorter in the amifostine-treated group (p = 0.013), because treatment interruptions were more frequent in the control group. the clinical trial showed that application of ir can reduce the severity of radiation mucositis (p = 0.01), anorexia (p = 0.002), and swallowing difficulty (p = 0.002). sfr has definite effect in preventing and treating radiation reaction and late stage radiation injury in patients with head and neck tumor. colonisation index of candida species and gram-negative bacilli was reduced in the pta group and not in the placebo group (p<0.05). no statistically significant difference for the objective and subjective mucositis scores was observed between the two study arms (p = 0.33). patients who received gm-csf had less mucosal pain (p = 0.058) and were less often prescribed opioids for pain (p = 0.042). the benzydamine topical application was more effective than placebo in the control of mucositis symptoms and signs produced by radiotherapy and/or intra-arterial antineoplastic chemotherapy. the duration of objective oral mucositis > or = grade 1 (p = 0.0097), grade 2 (p = 0.0232), and grade 3 (p = 0.0168) was shorter in the glutamine arm. no statistically significant between-group differences were seen in mean worst scores across time using repeated measures analysis of variance (hickey, p = 0.231; who, p= 0.288). patients in the control group developed grade 2 mucositis and dermatitis earlier and sooner than patients in the experimental group. in the control group, stomatitis occurred in 9 of the 10 patients receiving pf therapy and in all of the 5 receiving vac. comparing the time course of the mean scores for subjective intolerance, mucositis, dysphagia, dermatitis and nausea, no statistically significant differences between the two treatment arms (sucralfate, n = 38; placebo, n = 45) were observed. the severity of mucositis was reduced in the gm-csf arm (p<0.05). remarkably, the hazard ratio (hr) for grades 2, 3, and 4 om was 0.41 (range, 0.22-0.75; p = .002) and for grades 3 and 4 it was 0.07 ( the incidences of grade iii-iv mucositis and infection were significantly reduced (p = 0.005, p = 0.001, respectively) and duration of hospitalization was modestly shortened by 1 day (p = 0.02) in rhgm-csf treated patients. pilocarpine has no benefit for the moderation of the incidence, severity, or duration of mucositis in patients receiving autologous blood stem cell transplantation. the highest grade of mucositis during the treatment time was significantly different between two groups (p = 0.049). as compared with placebo, palifermin was associated with significant reductions in the incidence of grade 4 oral mucositis (20 percent vs. 62 percent, p<0.001), patient-reported soreness of the mouth and throat (area-under-the-curve score, 29.0 [range, 0 to 98] vs. 46.8 [range, 0 to 110]; p<0.001), the use of opioid analgesics (median, 212 mg of morphine equivalents [range, 0 to 9418] vs. 535 mg of morphine equivalents [range, 0 to 9418], p<0.001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 percent, p<0.001). compared with placebo, palifermin reduced the cumulative incidence of moderate to severe (grade 2 or higher) mucositis (44% vs. 88%; p < 0.001; difference, -44 percentage points [95% ci, -71 to -16 percentage points) and severe (grade 3 or 4) mucositis (13% vs. 51%; p = 0.002; difference, -38 percentage points [ci, -67 to -9 percentage points]). the distribution of grade 4 mucositis (who) was 1 case versus 8 cases, with and without amifostine, respectively. fu dose reductions in the second chemotherapy cycle were more frequent in the placebo group (31%) than in the palifermin group (14%). stomatitis worsened in only 7 patients (47%) in the traumeel s treatment group compared with 14 patients (93%) in the placebo group. no difference in the visually assessed degree of mucositis or oral pain reported by the patients was found between the study and the control groups. the result showed a significant difference in pain and mucositis (p<0.001) between the two groups. positive cultures for aerobic pathogenic bacteria were observed in 15 per cent of the treatment group and 65 per cent of the control group, during or after radiotherapy (p = 0.007). however, there was significantly less mucositis (p < 0.01, analysis of variance) from weeks 3--6 in the 17 patients treated with misoprostol at loyola compared to the 18 placebo-treated patients. one-year rates of locoregional failure, progression-free survival, and overall survival were not significantly different between treatments. the gln-treated patients lost significantly less weight, tended to have shorter in-patient duration and had less severe oral mucositis than controls. the colonization index of viridans streptococci was significantly reduced only after 5 weeks of chlorhexidine 0.1% treatment. g-csf therapy reduced both the incidence and duration of adm-induced oral mucositis, and a positive correlation was also seen between the incidence of mucositis and adm-induced leukopenia (< 2,000/mm3). the main endpoint was severe mucositis that was more frequent in the placebo group than in the sucralfate group (47% vs. 29%, p = 0.07). there was significant reduction in the symptomatic grade 3/4 mucositis among honey-treated patients compared to controls; i.e. 20% versus 75% ( p 0.00058). the trends of decreased median length of stay and the median number of days of total parenteral nutrition (tpn) were seen in the group supplemented with the >0.285-g/kg (the recommended dosage) dose of glutamine; however, there was no statistically significant difference in the nutritional status and overall patient outcome as assessed by days receiving tpn, number of days required until oral intake resumed, length of hospitalization, number of days and highest grade of mucositis, and quantity and number of days of diarrhea. of 205 evaluable patients, 52.9% vs. 62.4% developed rtog grade 3 or greater mucositis after morning vs. afternoon rt, respectively (p = 0.17). ip test score was significantly higher than those of the control group [6.78% (4.63, 10.66) vs. 2.17% (1.38, 2.40), p<0.001]. concomitant reductions in total oral streptococci (p less than 0.02-p less than 0.001) and oral candida (p less than 0.004) were seen in patients using chlorhexidine. a 42% risk (15/36) of mucositis grade > or = 3 was evident on day 15 in patients receiving gm-csf compared to 2 of 9 patients on the placebo arm. the 650 nm wavelength reduced the severity of oral mucositis and pain scores. the severity (maximum extent) of acute radiation therapy side effects was significantly less in enzyme-treated patients than in control patients: mucositis (mean: 1.3 vs 2.2, p < 0.001), skin reaction (1.2 vs 2.4, p < 0.001) and dysphagia (1.4 vs 2.2, p < 0.001). the prophylactic value of twice-daily mouth rinses with a solution of 0.1% chlorhexidine gluconate in minimizing oral complications during remission-induction chemotherapy was tested in sixteen patients with acute myeloblastic leukemia. mucositis was significantly reduced by cryotherapy considering both the first cycle of therapy (the mean toxicity score for cryotherapy was 0.59 and it was 1.1 for the control group, p < or = 0.05) and all the chemotherapeutic courses (the mean toxicity score for cryotherapy was 0.36 when it was 0.69 for the control group, p < or = 0.05). there was a trend for more mucositis and there was substantially more toxicity (eg, mouthwash-induced discomfort, taste alteration, and teeth staining) on the chlorhexidine arm. assessment of the area under the curve revealed statistically significant reductions in om severity in the rhitf-treated groups versus placebo. the frequency of grade 2 to 4 mucositis was 43% in patients treated with kgf, compared with 67% in patients treated with placebo (p =.06). the supplement was well tolerated with no apparent adverse effects, but failed to have any significant effect on oral mucositis assessed by the patients or investigator. duration of moderate/severe mucositis was, although not significantly, lower in the int group (17 days, s.d. = 12) than in the lim group (19 days, s.d. = 13). grade 3 mucositis occured with a frequency of 35.2% without lel and of 7.6% with lel (p<0.01). there was a significant reduction in the incidence of grade 3/4 mucositis (p < 0.0001), acute grade 2 xerostomia (p < 0.0001) and grade 3/4 thrombocytopenia (p = 0.012) in these patients who received a. opioids than the control group. patients given sucralfate suspension were less likely than subjects receiving placebo to acquire colonization with potentially pathogenic microorganisms: 14 (58%) of 24 versus 22 (92%) of 24, respectively (p = 0.008). the duration of severe mucositis did not differ between pge and placebo groups (chi-square 0.95, p = ns). palifermin appeared to reduce mucositis, dysphagia, and xerostomia during hyperfractionated radiotherapy (n = 40) but not standard radiation therapy (n = 59). analysis of variance indicated significant direct gm-csf treatment effects on the mean auc of gross/functional scores and duration of moderate gross mucositis (grade > or = 2) over both periods. oral aloe vera did not improve tolerance to head-and-neck radiotherapy, decrease mucositis, reduce soreness, or otherwise improve patient well-being. in the chlorhexidine-based group, a significant decrease of the aerobic (p=0.042) and anaerobic (p=0.008) bacterial flora was identified. propantheline is effective in reducing the incidence and severity of mucositis in patients receiving high-dose etoposide. amifostine given subcutaneously did not improve the rates of xerostomia and mucositis with this fairly intensive chemoradiotherapy regimen. -csf only improved the incidence of severe mucositis during the induction course (p = 0.003) and probably also improved the median duration of fever (p = 0.07). oral enzymes act as a potent antiinflammatory, antiedematous agents thereby decreasing acute toxigenic effect of radiation and increasing compliance, quality of life of our patients. the grades of mucositis were marginally higher in the evening-irradiated group than in the morning-irradiated group 38% vs. 26% (p = 0.08). there was a reduction in mucositis distribution (p = 0.002), mucositis area (p = 0.028), dysphagia (p = 0.006) and weight loss (p = 0.009) in the active arm. our findings revealed that the patients in the e2 group not only had later onset of stomatitis than those in the control and the e1 groups, but also had lesser degree of oral injury measured by the overall assessment score. a significant reduction in mucositis among honey-received patients compared with controls (p=0.000) occurred. amifostine reduced grade > or =2 acute xerostomia from 78% to 51% (p<.0001) and chronic xerostomia grade > or = 2 from 57% to 34% (p=.002). in patients receiving less toxic regimens, a decrease in who grade 1-4 oral mucositis was noted in the gum arm compared with the standard arm (49% vs. 72%, p=0.03). both cryotherapy groups had similar degrees of mucositis. no significant differences existed between the two mouthwashes in regard to incidence, days to onset, and severity of mucositis. prophylactic oral glutamine could ameliorate the neoadjuvant chemotherapy-induced increase in intestinal permeability, but had no significant positive clinical effect on stomatitis and diarrhea and did not interfere with the antitumor effect of chemotherapy. the mean total duration of mucositis was 2.75 weeks in treatment patients and 9.25 weeks in control patients. there was no difference in the frequency or severity of oral mucositis between the sucralfate- and the placebo-treated group. there were no significant differences or substantial trends in the mucositis scores between the two study arms as measured by either the physicians or the patients. palifermin was associated with reduced incidence and mean severity of mucositis in patients conditioned with cy/tbi but not bu/cy. the results of the qol scales did not reveal any significant difference between the pilocarpine and placebo groups with regard to xerostomia and mucositis. during cycle 1, placebo-treated patients had more episodes of mucositis (47%) compared with those patients randomized to filgrastim (28%). the frequency of grade 2 to 4 mucositis was 100% for patients in the placebo group, 64% for patients in the 25 microg/kg group (p = 0.041 versus placebo), and 50% for patients in the 50 microg/kg group (p = 0.006 versus placebo). amifostine provided reduction in acute xerostomia and mucositis but had no obvious influence on karnofsky performance status, body weight, cutaneous side effects, and alopecia. patients in the sucralfate group experienced significantly lower degree of mucositis than placebo group (p < 0.05). l-alanyl-l-glutamine patients experienced less pain (three highest numeric rating scale scores of 1.3/10 vs. 6.3/10 respectively, p = 0.008) and need for feeding tubes (14% vs. 60% respectively, p = 0.020) compared with placebo patients. no significant difference was observed in hematologic toxicity, transfusion requirements, duration of fever, and hepatic toxicity between the treatment groups. a trend favouring shorter treatment interruptions in the prednisone arm was also found, but not a reduction in the intensity or duration of mucositis. the safety and efficacy of 0.15% benzydamine oral rinse in preventing or decreasing erythema, ulceration, and pain associated with oral mucositis during rt were evaluated in a randomized, placebo-controlled trial conducted in patients with head and neck carcinoma. in the zinc sulfate group, grade 3-4 mucositis was not detected in any patient; grade 0 mucositis was detected in 2, and grade 1 in 8, and grade 2 in 5 patients. benzydamine hydrochloride rinse was shown to prevent oral mucositis in radiation therapy. there were no statistically significant differences between the arms in the extent of severe mucositis as measured by physician, in oral toxicities as recorded by patients, or in radiotherapy delays. the occurrence rate of grade 1-2 mucositis of the oral cavity was higher in trial group than in control group (73.68% vs. 62.50%), but the occurrence rate of grade 3-4 mucositis was lower in trial group than in control group (26.32% vs. 37.50%, p=0.470). there were no substantial differences in mucositis attributable to the two mouthwashes in the patients who crossed-over on their second cycle of chemotherapy. in previous studies oral glutamine was found to protect animals from the effects of whole abdominal radiation and methotrexate-induced enteritis. subset analysis did reveal unsuspected differential effects between males and females that could not be explained by reasons other than chance. there was no significant difference between groups concerning the grades of mucositis on day 8 (p = 0.234) or on day 15 (p = 0.208). patient preference favored sucralfate, but this preference failed to reach statistical significance (p = 0.06). overall survival was significantly greater in the granulocyte-colony stimulating factor arm (hazard ratio, 0.37; p = 0.037). for the maximum mucositis scores, no statistically significant differences were found between the placebo and the verum group. injection of 4000u sod immediately after receiving radiotherapy significantly reduced the occurrence rate of skin, oral mucosal, pelvic visceral and systematic adverse reaction, only the reduction of leukopenia did not reach the statistical significant level. chlorhexidine had no effects of any clinical significance on parameters such as number of days with fever, number of oral lesions, plaque score, gingival bleeding score, or occurrence of candidiasis.|head and neck cancer patients who had radiotherapy patients had to be treated with radiotherapy with curative intent at stanford university between february 1999 and march 2002 one hundred patients forty patients receiving of head and neck malignancies 30 evaluable patients, 15 were assigned head and neck cancer causes acute and chronic xerostomia and acute mucositis nasopharyngeal carcinoma (npc) treated with patients with head and neck tumors treated with 225 patients randomized, 206 answered the questionnaire (70, 64, and 63 patients in arms a, b, and c, respectively) and were well balanced with respect to diagnoses, stage, age, sex, smoking habits, and performance status between october 1988 and december 1990, 60 patients with leukaemia (25 with aml, 19 all and 16 cml) undergoing bmt nasopharyngeal carcinoma copyright 1999 american cancer society sixty-six patients gastrointestinal malignancies patients receiving definitive chemoradiotherapy, definitive rt, or postoperative rt to the oral cavity or oropharynx were recruited from 6 institutions and enrolled induced mucositis patients undergoing marrow transplantation one hundred and thirty patients undergoing myeloablative ahsct and mtx-containing gvhd prophylaxis patients with head and neck carcinoma for treatment of radiation-induced oral mucositis 275 patients with t1-t4 tumours entered the study; 136 patients with metastatic colorectal cancer treated with stage ii-iv squamous head and neck cancer patients receiving autologous blood stem cell transplantation sixteen patients with acute myeloblastic leukemia 14 patients who received intraarterial (i.a patients scheduled to receive radiation therapy to include greater than one third of the oral cavity mucosa were selected for study patients undergoing hla-identical allogeneic bmt children receiving chemotherapy sixty-seven head and neck cancer patients patients treated with curative intent for malignancies in the head and neck region patients post hematopoietic stem cell transplantation forty-one patients were enrolled (132 planned acute leukemia patients who had severe mucositis received forty patients diagnosed with head and neck cancer requiring radiation to the oropharyngeal mucosal area primary nasopharyngeal carcinoma patients 222 patients who were starting a cycle of mucositis-inducing chemotherapy irradiated head and neck cancer patients from radiation mucositis head & neck cancer patients from april 1993 to september 1993, 15 patients with lymphoid or solid neoplasms underwent 16 non-cryopreserved peripheral stem cell transplantation courses using the head and neck cancer patients who had normal or mild impaired salivary gland function patients with metastatic colorectal cancer healthy volunteers patients with local advanced npc 21 patients receiving 30 patients with head and neck cancer who had comparable irradiation portals patients with newly diagnosed small-cell lung cancer (sclc head and neck cancer 132 patients head and neck carcinoma patients irradiated in the morning (08:00-11:00 h) versus late afternoon/evening (15:00-18:00 h radiation-induced oropharyngeal mucositis patients with head-and-neck cancer receiving 54 patients were unevaluable (24 active, 30 placebo from september 1994 to march 1998, 30 patients were randomized 29 patients who were to receive head-and-neck tumors, particularly oral mucositis hematologic cancers 23 outpatient clinics and office practices in california 50 consecutive patients n = 31) in patients conditioned with children undergoing stem cell transplantation 140 patients undergoing either allogeneic (n = 51) or patients receiving curative intent rt for advanced head and neck cancers morning vs. evening irradiated patients patients with head and neck cancer treated by patients during antineoplastic radiochemotherapy bone marrow transplantation patients undergoing accelerated radiotherapy for neoplasms of the head and neck patients treated with myeloablative therapy before bmt patients with high-dose vic chemotherapy plus autologous blood stem cell transplantation patients with laryngeal cancer between november 2001 and june 2002, 502 patients nasopharyngeal cancer patients undergoing laryngeal cancer fifty-eight patients were enrolled, 29 in each arm 212 patients of head and neck carcinoma head-and-neck cancer patients receiving radiotherapy for head-and-neck malignancy mean ages were 56.9 advanced head and neck cancers forty patients diagnosed with head and neck cancer patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation thirty-four hines va and 35 loyola university patients were accrued (69 total) over a 2-year period patients receiving chemotherapy 13 patients who received patients with advanced head and neck squamous cell carcinoma (hnscc 40 patients fifty-one patients with advanced or metastatic cancer hct patients conditioned with chemotherapy or chemoradiotherapy patients undergoing bmt patients undergoing humans patients with advanced breast cancer eighty patients with head and neck malignancies, scheduled to undergo curative radiotherapy head and neck irradiation patients patients with breast cancer cancer chemotherapy patients fifty patients cancer patients receiving chemotherapy allogeneic hematopoietic stem cell transplantation (hsct) recipients acute myeloid leukaemia (aml) patients receiving chemotherapy over 3 weeks for early stage laryngeal cancer patients undergoing myeloablative ahsct patients receiving patients up to age 45 years who had an hla-identical sibling 45 patients post-hsct 33 patients with malignant disorders, who were going to receive 2009 american cancer society myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation patients of head and neck cancer undergoing radiotherapy develop oral mucositis 51 bone marrow transplant patients twenty-eight patients with head and neck cancer children and adolescents with cancer treated with oral mucositis during autologous blood stem cell transplantation head and neck cancers patients with head and neck carcinoma patient had cancer of oral or extraoral regions head and neck cancer patients one hundred and forty patients with head and neck tumor, including nasopharyngeal carcinoma, carcinoma of tonsil or tongue assiut university hospital, egypt, between january 2005 and july 2006 cancer after stem cell transplantation patients receiving primary rt, primary chemoradiotherapy or postoperative rt 69 patients, 61 (dresden: 46) were available for analysis patients receiving radiation therapy to the oral mucosa patients receiving multicycle chemotherapy 90 patients undergoing autologous stem cell transplantation (asct head-neck neoplasms locally advanced head and neck cancer sixty-five patients with a malignant tumour in the head and neck regions patients treated with high-dose chemotherapy and bone marrow transplantation forty patients with radically operated head-and-neck cancer 178 evaluable patients were studied sixty patients with thoracic, 40 with head and neck, and 40 with pelvic tumors who were undergoing patients with head and neck cancer received patients undergoing myeloablative allogeneic hsct 56 patients with oro-/hypopharynx or larynx cancer (t1-2 n1-2 g3, t3-4 n0-2 g1-3 sixteen aml patients patients undergoing head and neck radiotherapy patients receiving radical dose radiotherapy a total of 545 patients patients receiving head and neck conventionally treated patients with head and neck cancer patients with carcinoma of oral cavity with stages ii-iv a being uniformly treated with curative total tumour dose of 66 gy in 33 fractions over 6 wk were selected for the study patients after high-dose chemotherapy and apbsct--results of a randomized multicentre study bone marrow transplantation patients twenty-five patients acute myeloid leukaemia patients patients with head-neck tumor undergoing radiotherapy hematopoietic stem cell transplantation (hsct) patients patients (n = 64 selected patients were required to have > or = 50% of the volume of the major salivary glands receive > or = 50gy twelve patients receiving etoposide 1800 mg/m2 as part of a myeloablative pre-transplant regimen head and neck cancer patients receiving patients treated for head-and-neck tumors subjects were seen every other day and evaluated for gingival, oral, and oropharyngeal mucositis; nutrition; oral hygiene; eating; speaking; sleeping; pain at rest and/or with swallowing; and mouth dryness patients who develop mucositis during radiation therapy forty patients with multiple myeloma scheduled to receive twenty-nine patients head and neck cancer patients after children undergoing bone marrow transplantation patients undergoing hematopoietic stem-cell transplantation 95 patients scheduled to receive their first cycle of patients undergoing radical radiotherapy for head and neck cancer patients with head-and-neck cancer patients with head and neck cancers large adult patient population with solid tumors receiving highly om-inducing chemotherapy patients from 3 to 18 years of age treated with chemotherapy or hematopoietic stem-cell transplantation between may, 2003 and february, 2005 were eligible adult patients with all 1 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation patients receiving concurrent chemoradiotherapy for advanced head and neck squamous cell carcinoma 43 patients 32 patients ages 3-25 years who had undergone allogeneic (16 patients) or autologous (16 patients) stem cell transplantation patients after radiotherapy for head-and-neck cancers ninety consecutive patients affected by solid tumors and undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue primary npc patients in radiotherapy patients with head and neck cancer who have irradiation mucositis fourteen of a planned 54 patients head and neck cancer treated with gynecologic patients seventy patients radiation-induced mucositis twenty patients with stage iv squamous cell carcinoma of head and neck were studied 216 patients patients receiving primary or postoperative rt alone were eligible patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer sixty patients were evaluable for analysis; thirty-nine (65%) were males, 35 (58 squamous head and neck cancer 19 patients received 300 rad/day of patients receiving treatment for acute leukemia patients with colorectal cancer who are receiving fluorouracil-based chemotherapy head-and-neck cancer patients 50 patients were evaluable (25 patients in the patients undergoing hematopoietic cell transplantation allogeneic bone marrow transplantation after cytotoxic cancer chemotherapy autologous blood stem cell transplantation 145 children receiving chemotherapy regimens expected to induce who grade 3-4 oral mucositis in at least 30% of patients forty head and neck cancer patients 69 patients with carcinomas of the oropharynx or the oral cavity were enrolled between 1996 and 2000 in five centers; 54 of these were recruited in dresden hematopoietic stem cell transplantation (hsct patients with head-neck tumor patients with acute leukemia twenty-nine patients received the thirty-two patients with head-and-neck cancer n = 89 47 patients patients with previously untreated gi cancer receiving bolus thirty patients with head-and-neck cancer hsct patients postsurgical patients who had no detectable cancer and who were referred for postoperative irradiation were candidates for this study forty patients with head and neck cancer patients undergoing a stem cell transplantation sixty patients with breast cancer twenty-eight patients with gastrointestinal cancers children with cancer receiving chemotherapy twenty (20) patients local advanced npc patients patients undergoing prior ninety-nine patients with colorectal cancer who had moderate to severe om (who grade >or= 2) in the first cycle of chemotherapy patients with and without total body irradiation (tbi) and in patients with a good or bad ios 245 evaluable patients patients treated with myeloablative therapy before bone marrow transplantation (bmt patients undergoing bone marrow transplantation eighty patients 18 years and older, scheduled for bmt radiation mucositis cancer patients patients with cancers of the head and neck patients with head and neck cancer 38 patients who underwent patients receiving head and neck radiotherapy adults with acute lymphoblastic leukemia 40 patients with head and neck cancer requiring radiation to the oropharyngeal mucosa between february 1986 and november 1989, 166 patients who were candidates for a bone marrow transplantation 19 patients were excluded from the analysis because they did not use the medication for the assigned period malignancies in the head and neck region between may 1996 and february 1998, 26 patients with an inoperable nonmetastatic stage iv hnscc patients with head and neck cancer receiving radiotherapy at tian sheng memorial hospital, taiwan were recruited for this trial twenty-four patients (16 children and 8 adults 58 autologous and allogeneic bmt patients patients with head and neck cancers, who were referred in 2004-2005, received an oral rinse of either patients with colorectal cancer forty-forty-two patients with head-neck tumor undergoing one hundred two patients copyright 2001 american cancer society unresectable head and neck cancer seventy-seven patients were evaluable patients receiving bone marrow transplant (bmt) and peripheral blood progenitor cell transplant (pbpct) experience gastrointestinal (gi) toxicity from the preparative regimen of sixty patients patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue nasopharyngeal cancer patients undergoing radiotherapy, 30 eligible patients with a mean age of 56.2 years patients with head-and-neck neoplasms patients with breast cancer during the first treatment cycle of a combination chemotherapy regimen which has historically produced dose-limiting (grade > or = 3) mucositis in approximately 39% of patients 48 patients with sarcoma 76 patients who completed the study, patients in the patients with head and neck malignancies 13 patients in arm a and 11 patients in arm b) of subjects at baseline and then on alternate weeks 36 consecutive patients undergoing a stem cell transplantation patients receiving stomatotoxic chemotherapy patients undergoing autologous hematopoietic stem cell transplantation 84 patients treated with a one hundred patients from two centres were entered into the study 58 head-and-neck cancer patients between gastrointestinal (gi) cancer 18 healthy volunteers patients undergoing rt for head and neck cancer patients undergoing accelerated radiotherapy for laryngeal cancer patients with hsv infection receiving head neck 21: 760-766, 1999 patients with locally advanced squamous cell carcinoma of the head and neck (scchn marrow transplantation patients with head and neck cancer receiving conventional fractionated radiation therapy patients who were receiving their first course of a between 1999 and 2002, 83 patients were recruited into the study at westmead and nepean hospitals, sydney patients receiving high-dose etoposide 212 patients with hematologic cancers; 106 patients received 113 patients included in the study, 28 received head and neck squamous cell carcinoma patients with cancer 47 patients developed patients had a diagnosis of leukemia or lymphoma, and 25 (42%) had solid tumors patients with head and neck tumor from july 1997 through june 1998, 17 patients with head and neck cancer receiving primary or adjuvant irradiation 81 patients with colorectal cancer were enrolled seventy-seven patients, receiving their first 5-day course of chemotherapy with 5-fu primary npc patients in radiotherapy by pushing the tongue and a part of oral mucous membrane away from the radiation fields twenty-eight patients 101 patients in stage iii- iva (fuzhou 1992 for head-and-neck cancer patients with stage t3/t4 head and neck cancer were eligible head and neck region patients with metastatic crc cancer patients with chemotherapy-induced leukopenia benefit from an 159 patients forty-eight children and adolescents with newly diagnosed acute nonlymphocytic leukemia between november 1990 and april 1992, 67 patients ages 15-55 years with de novo patients with metastatic colorectal cancer (crc) receiving in the head and neck region develop oral mucositis patients with locally advanced head and neck cancer patients receiving intensive therapy for hematologic cancers patients with newly diagnosed, locally advanced stage iii or iv scchn received 4 weekly doses of irradiated cancers of the head and neck patient population with advanced scchn 40 patients with solid tumours patients with carcinoma of the oropharynx, hypopharynx and oral cavity, treated by patients with previously untreated head and neck squamous cell carcinoma were eligible forty patients were evaluable for planned outcomes patients experiencing radiation-induced mucositis intensive oral hygiene care included an initial treatment of dental lesions and tooth and gum brushing during aplasia patients who receive myeloablative therapy before bmt one hundred thirty-seven eligible patients
myofascial pains symptom status cumulative incidence rate disclusion time, as well as, myofascial pains muscular symptom remissions muscles of mastication and/or jaw joint subjective symptoms number of tender muscles subjective symptoms of cmd disclusion times incidence of temporomandibular disorders symptom remissions globus symptom presence of symptoms and signs of tmj dysfunction frequency of headaches, facial pain, or pain on mandibular movements frequency of headaches, facial pain, pain on mandibular function, or duration of headaches and facial pain occlusal centric slides occurrence of tmd signs disclusion time|the difference between the groups in the increase of sites tender to palpation was less clear, showing only a trend. the number of subjects with palpatory pain of the masticatory muscles, and with occlusal centric slides decreased significantly in the intervention group but not in the control group (p < 0.001). binomial tests showed that there was a significant association between the success of occlusal adjustment and disappearance of the globus symptom. there were no significant differences between groups with regard to frequency of headaches, facial pain, pain on mandibular function, or duration of headaches and facial pain. the cumulative incidence rate was 9/67 in the mock adjustment group and 1/60 in the real adjustment group, for a relative risk of 8.06. additionally, mock icagd occlusal adjustments did not appear to be a factor in the control subjects treatment response, as this group showed no statistically significant symptom remissions.|orthodontically treated healthy adolescents 123 orthodontically treated healthy adolescents (88 girls, 35 boys; 14.8 temporomandibular disorder-related signs and symptoms in orthodontically treated adolescents 146 healthy children and adolescents, half of the subjects underwent occlusal adjustment aimed at elimination of the presumed structural risk, and the other half underwent mock adjustment twenty-five dental students, who exhibited symptomatology consistent with myofascial pains patient craniomandibular disorders including headaches fifty patients subjects were interviewed and examined for signs and symptoms related to temporomandibular disorder (tmd dental student population sixty-two dental students judged not to be in need of treatment for craniomandibular disorder (cmd chronic myofascial pain dysfunction patients young adults
mean dmft values severity of fluorosis tfi score fluorosis prevalence overall prevalence prevalence of dental caries early toothbrushing habits odds of experiencing fluorosis overall, levels of fluorosis jarman score social deprivation prevalences of tf child's birth weight and liking for or swallowing of toothpaste fluorosis mild fluorosis mean dmf score moderate to severe fluorosis dental fluorosis prevalences caries prevalence demographic information, details of f history, and dental attendance data risk of enamel fluorosis tf index the child and tooth prevalence of opacities enamel opacities and dental caries thylstrup and fejerskov (tf) index for fluorosis and the modified developmental defects of enamel (dde) index early forming (fluorosis risk index (fri) classification i) enamel surfaces dental fluorosis (tf index df levels tfi scores prevalence of caries dental caries experience prevalences of fluorosis behavior problems and dental fluorosis prevalence of fluorosis thystrup-fejerskov index (tfi) scores fluorosis risk index (fri caries (dmft, who criteria, no radiographs) and dental fluorosis (tf index, dry permanent incisors fluorosis community index (fci risk of fluorosis mainly tfi score risk factor exposure prevalence of dental fluorosis dental fluorosis prevalence of fluorosis by tf1+ case definition risk of dental fluorosis prevalence prevalence of aesthetically important df ('mild' and 'moderate|higher fluoride exposure slightly increased the likelihood that a child had a higher tfi score, especially when more fluoridation technologies were used at home. the prevalence of aesthetically important df ('mild' and 'moderate') was low and similar in both communities and considerably lower than the expected level at water fluoridation concentrations of 1 ppm. logistic regression established tooth brushing frequency and fluoride supplement use, in addition to tap water fluoride concentrations above 0.7 mg/l, as significant risk factors when the presence of fluorosis on at least one tooth was used as outcome variable. children with dental fluorosis were 1.75 times more likely to be free of caries (or = 1.75-ci:0.43, 6.68). there was no association between behavior problems and dental fluorosis in this population. there was no significant difference in the prevalence of caries in either primary or permanent teeth although the trend in both cases was for slightly more disease in children who had used the test paste. from logistic regression, the prevalence of caries was significantly associated with age, dental attendance, and the use of a water supply fluoridated at 1.0 ppm. in bivariate analyses, mild fluorosis was significantly related to ingestion of fluoride dentifrice at ages 24 and 36 months (p = .02 for both). the prevalence of fluorosis among children in acorn group a-c was significantly greater than in groups d-f. a very strong association was observed with inappropriate fluoride supplement use (or = 23.74, 95% ci 3.43-164.30). the prevalence of fluorosis in respondents was 23.3%, with 4.9% scoring tsif of 2 or more. there was a strong association between mild-to-moderate fluorosis on later forming (fri classification ii) enamel surfaces and infant formula use in the form of powdered concentrate (or=10.77, 95% ci 1.89-61.25), fluoride supplement use (or=10.83, 95% ci 1.90-61.55), and early fluoride toothpaste use (or=8.37, 95% ci 1.68-41.72). those who brushed their teeth before the age of 25 months had 11 times the odds of fluorosis compared with those beginning toothbrushing later; prolonged use of infant formula (greater than or equal to 13 months) was associated with 3.5 times the risk of fluorosis, compared with no, or shorter duration of, formula use. swallowed fluoride toothpaste in the early years of life has been postulated to be a risk factor for fluorosis, but the epidemiological evidence is weakened by the fact that most of the relevant studies were done in developed countries where an individual is exposed to multiple sources of fluoride. the multivariate model showed that the effect of the supplementary fluoride sources was different between children that started brushing with toothpaste before two years of age (or = 6.15; ic 95% = 2.03-18.67) and after (or = 2.14; ic 95% = 1.16-3.94). there was no statistically significant increased risk of dental fluorosis prevalence associated with any of the fluoride exposure risk factors examined, including reported usage of (1000 ppm) fluoride toothpaste from time of first deciduous tooth eruption. the child's birth weight and liking for or swallowing of toothpaste did not influence the prevalence of fluorosis. in the deprived districts the prevalences of fluorosis were 25.2 and 19.5% (p = 0.2). the risk of fluorosis was significantly greater for children who had greater exposure to fluoridated water and who used larger amounts of fluoridated toothpaste up to age eight. mean dmft values in perth and bunbury were 0.32 and 0.28 (p > 0.05). the prevalence of fluorosis by tf1+ case definition declined from 34.7% to 22.1% and by tf2+ case definition from 17.9% to 8.3%. multivariate analysis indicated that area of residence (odds ratio = 4.5), jarman score (odds ratio = 0.99 per jarman unit) and type of toothpaste (odds ratio = 1.6) were statistically significantly related to presence or absence of fluorosis: the risk factors were--fluoridated area, affluence, and use of adult toothpaste. weaning before 9 months of age, swallowing toothpaste and liking toothpaste were also statistically significant risk factors. there was a strong association between mild-to-moderate fluorosis on later forming (fri classification ii) enamel surfaces and both supplement use (or = 7.97, 95% ci 2.98-21.33) and early toothbrushing habits (or = 4.23, 95% ci 1.72-10.41). an odds ratio of 1.7 associated with infant formula use was suggestive of an increased risk of enamel fluorosis as was an odds ratio of 2.9 associated with fluoride dentifrice use.|dental fluorosis, dental caries and fluoride exposure among 7-year-olds pediatric patients seeking dental treatment in a university pediatric dental clinic enamel fluorosis in a fluoridated population 157 children aged 8 to 17 years were examined for dental fluorosis using the tooth surface index of fluorosis (tsif subjects in the middle median household income group who had used children were resident in non-fluoridated districts in the north-west of england 8,277 children infancy and fluorosis of permanent maxillary incisors at age 8-9 years 8-year-old children dental fluorosis in a fluoridated community children from non-water-fluoridated halmstad, sweden 401 residents of fluoridated communities in connecticut, who were 12-16 years old and born prior to 1980 14 school classes were selected children (n = 1,268) were 8-10 years old permanent teeth in children whose domestic water supply was fluoridated since birth with that in a community where fluoridated salt was available 1189 seventh grade children with a mean age of 12.2 years children aged 7-9 years from non-water-fluoridated halmstad, sweden eight hundred fifty 11- to 14-year-old residents of nonfluoridated communities in massachusetts and connecticut, who were born between 1972 and 1975, were investigated in a case-control study of the possible association between enamel fluorosis and exposure to fluoride supplements, infant formula, and/or fluoride dentifrice dental caries and fluorosis prevalence study in a nonfluoridated brazilian community dental fluorosis in permanent incisor teeth in relation to water fluoridation, social deprivation and toothpaste use in infancy 1039 parents enquired into their child's early oral health behaviors and included a "photographic toothpaste menu between may-july 2000, 582 10-year-olds were examined for dental fluorosis (tf index) and dental caries (dmft) in school dental clinics children who received toothpaste containing either 440 or 1,450 ppm f from the age of 12 months in deprived and less deprived communities children between the ages of 7 and 1 years (n = 197) were included in the study and were examined for dental fluorosis using the modified dean's index 377 children in dublin and 322 children in freiburg were examined permanent teeth of canadian children in perth (western australia fluorosis risk in grade 2 students residing in a rural area with widely varying natural fluoride children ages six to 12 were screened for caries by means of the nidr criteria and for fluorosis by means of the tsif index michigan schoolchildren 350 children (mean age 7.5 years) ultimately included gave fluoride exposure data for the period birth to 4 years of age children with dental fluorosis children born in 1983 cases and non-cases were identified by the screening of 8-, 9-, and 10-year-old schoolchildren in the fluoridated community of east york, ontario pre-school children who were 2-years-old at the start of the 3-year trial 233 children, aged 10-14 years flemish schoolchildren children two years of age and younger children who began brushing with upper central incisors of children from socially diverse backgrounds who had received either 440- or 1,450-ppm f toothpaste from 12 months of age pediatric dental patients children aged 10 years maxillary central incisors of 325 consecutive children a representative, random sample of 12-year-old children was examined in water fluoridated dublin (ireland) and non-water fluoridated freiburg (germany children who used a low fluoride toothpaste between 2 and 5 years of age parents of subjects completed and returned three questionnaires which investigated their children's history of exposures to fluoride, social and medical backgrounds, and behavior using the child behavior checklist (cbcl dental caries and dental fluorosis in eleven- and twelve-year-olds in a non-fluoridated brazilian community (< 0.2 ppm f school-age children 383 children australian children mean age of weaning of those who had been breast-fed was 7.7 months; by 9 months, 74% had been weaned children aged 11 years (4,128 children examined children into high fluorosis (hf) and low fluorosis (lf) groups 460 10- to 13-year-old children, born after 1979, who were residents of six nonfluoridated communities in massachusetts and connecticut south australian children school children aged 6-9 group of second grade students in a rural, non-fluoridated area of ontario, canada all children (n = 551, born 1988) in a municipality in norway were invited to participate 112 children had fluorosis and 213 did not 752 children (55 permanent incisor teeth and of caries in children who had taken part 1,523 children were examined in schools and had photographs taken of their upper permanent incisor teeth nonfluoridated communities 677 children for fluorosis using the thylstrup and fejerskov (tf) index children < 6 years of age five primary schools in the city of birmingham children in two canadian communities exposed to fluoride 320 children attending elementary schools protected by a public preventive dental program in the city of campeche, mexico permanent incisor teeth in young children in a fluoridated and a fluoride-deficient community 1739 students screened during routine health surveillance, 1367 had erupted maxillary central incisors schoolchildren of campeche, mexico sample subjects are randomly selected schoolchildren who were examined with a dental probe and buccal mirror under natural light south australian children born in 1989-1994 was selected in 2002/2003, stratified by fluoridation status and urban/rural residence children aged 8-9 years who had been continuous residents in fluoridated newcastle or fluoride-deficient northumberland
levels of impairment for all pain domains and reduced morphine usage hemodynamic stability arterial oxygen tension flow and endothelium of internal thoracic artery bcl-2 positive cardiomyocytes faster extubation times perioperative arrhythmia quality of recovery length of stay respiratory tract infections survival free from myocardial infarction, pulmonary complications, renal failure, and stroke 30-day survival free from myocardial infarction, pulmonary complications, renal failure, and stroke mean ita free flow hemodynamic function and reduced arrhythmias levels of il-10 peak expiratory flow rate heart rate and mean arterial pressure postoperative hospital length of stay and patients' perception of their quality of recovery hypoxemia myocardial damage, inflammatory, and stress response posttraumatic stress subscales interstitial fluid colloid osmotic pressure (copif) and interstitial fluid pressure (pif epinephrine serum levels cardiac norepinephrine spillover, map, systemic vascular resistance index (svri), pulmonary capillary wedge pressure (pcwp), gcvf, and reg-mvo2 myocardial cell damage, inflammatory, and stress responses troponin i, 8-isoprostane, cortisol, c3alpha, interleukin (il)-6, il-8, and il-10 lung volumes and pulmonary function follows cardiac surgery ita free blood flow significantly via increased vegf, i-nos, and adenosine-a2b receptor expressions postoperative complications recorded to 14 days and mortality recorded to 720 days release of troponin t global and regional myocardial function subcutaneous interstitial tissue simultaneously plasma colloid osmotic pressure (coppl sap plasma levels af mean arterial pressure oxygen delivery and mixed venous oxygen saturation acute renal failure lower visual analog scores with coughing postextubation crp concentrations postoperative pain hemodynamic measurements and blood sampling time to awakening and time to extubation intramyocardial oxygen partial pressure forced vital capacity, forced expiratory volume in 1 s (fev1.0) and peak expiratory flow rate (pefr new supraventricular arrhythmias intraoperative hemodynamics or ventricular function thirty-day survival free from myocardial infarction, pulmonary complications, renal failure, and stroke i concentrations vasoactive medication, mean arterial blood pressure incidence of perioperative dysarrhythmias perioperative lung functions and pain scores plasma levels overall incidence of episodic hypoxemia pain relief postoperative global quality of recovery score mean arterial pressure (map extensive bilateral atelectasis regional left ventricular function after myocardial revascularization, assessed by transesophageal echocardiography serum amyloid p-component (sap serum epinephrine levels analgesia, early tracheal extubation and shorter icu stay incidence of perioperative arrhythmias such as atrial fibrillation, serum epinephrine levels, heart rate variability, and hemodynamic parameters plasma epinephrine increased perioperatively postoperative pain scores shunt, va/q matching, or oxygenation splanchnic blood flow nor oxygen delivery and consumption quality of recovery score hospital length of stay, quality of recovery, or morbidity vasoactive and inotropic drugs and fluid balance cardiac troponin release of il-6, il-8, and il-10 extubation consumption of anesthetics hemodynamic changes visual analogue scale at rest and on coughing median postoperative stay interleukin-6 levels transcapillary forces (coppl, copif, pif transcapillary cop-gradient (coppl-copif incidence of tachycardia vital capacity pulmonary function acute confusion postoperative stress troponin i, time to tracheal extubation, and analgesia troponin t release blood flow of the ita troponin transcapillary fluid balance myocardial, inflammatory, and stress responses ventilator dependency and analgesia levels of postoperative stress, serum cortisol, and beta-endorphin cardiac sympathetic activity, myocardial blood flow and metabolism, and central hemodynamics myocardial oxygen availability ventilation-perfusion (va/q) relationships, atelectasis, and oxygenation plasma levels of bactericidal permeability-increasing protein, lipopolysaccharide-binding protein, and c-reactive protein pif regional left ventricular function hospital discharge time cardiac, renal, and neurologic outcomes paco2 perioperative arrhythmias such as atrial fibrillation tracheal intubation time and length of hospital stay morphine analgesia arrhythmia, inotropic support, intubation time, perioperative myocardial infarction, neurologic events, intensive care stay, pain scores, and analgesia requirement incidence of arrhythmias and the median intubation time blood glucose values adequate postoperative pulmonary and cardiovascular functions; nausea and vomiting incidence of stroke vas score, ss, and postoperative pao2 time to tracheal extubation immunostaining intensity constant hypoxemia mean troponin t levels postoperative analgesia mean arterial pressure (map), great cardiac vein flow (gcvf), and regional myocardial oxygen consumption (reg-mvo2 postoperative heart rate transient and almost simultaneous proinflammatory and anti-inflammatory cytokine response the starling forces" (coppl, copif, pif pulmonary function (maximal inspiratory lung volume mean systolic arterial pressure pct, tnf-alpha and leukocyte count splanchnic blood flow hemodynamics, plasma epinephrine and norepinephrine, cortisol, the myocardial-specific contractile protein troponin t, and other cardiac enzymes minnesota multiphasic personality inventory natriuretic peptide concentrations analgesia procalcitonin (pct), tumor necrosis factor (tnf-alpha), soluble tnf receptor, human soluble intercellular adhesion molecule-1, c-reactive protein (crp) and leukocyte count metabolic (lactate) or electrocardiographic signs of myocardial ischemia postoperative spirometry or chest radiograph changes arterial and mixed venous blood gases and hemodynamic variables elisa, crp and sap mere measured with rocket immunoelectrophoresis (rie ci stress response and pain scores intraoperative sinus bradycardia episodic hypoxemia total and cardiac sympathetic activity physiotherapy cooperation number of bcl-2 positive cardiomyocytes systemic vascular resistance (svr c3alpha, troponin i, 8-isoprostane, and cortisol release abg values and pao2/fio2 ratio atrial fibrillation (af intensity of the immunostaining rapid recovery and shorter hospital stay postoperative pain relief and stress hormones postoperative myocardial ischemia time to tracheal extubation, duration of postoperative intensive care unit stay, duration of postoperative hospitalization, pain control, urinary free cortisol, cardiopulmonary complication rate, and total hospital charges ita free blood flow incidence of postoperative arrhythmias and improves pain control and overall quality of recovery, allowing earlier extubation and hospital discharge psychologic morbidity, intraoperative hemodynamics, ventricular function, lung function, and physiotherapy cooperation cardiac function plasma cortisol cytokine production cortisol response pain relief, degree of sedation, ambulation, and lung volumes tracheal extubation time, oxygen withdrawal time and icu stay length of postoperative hospital stay perioperative stress response and postoperative myocardial ischemia ischaemic damage il-6 troponin release myocardial ischemia effective analgesia brain natriuretic peptide length of hospital stay myocardial sympathetic response major postoperative complications immunoreactivity rates neurologic complications pulmonary shunt and alveolo-arterial oxygen difference serum morphine postoperative length of stay, time to eligibility for hospital discharge, pain and sedation scores, degree of ambulation, lung volumes, and organ morbidities il-6 and il-8 levels postoperative depression cardiopulmonary bypass- and surgery-associated stress response and incidence of myocardial ischemia haemodynamic effects mean arterial blood pressure poststernotomy and systemic vascular resistance time to endotracheal extubation, oxygen withdrawal time and intensive care unit length of stay pain score va/q matching, oxygenation, or atelectasis formation cardiac index forced vital capacity and forced expiratory volume time to extubation mean (sd) peak concentrations of atrial natriuretic peptide postoperative pain management perioperative atrial fibrillation postoperative myocardial ischemia or infarction biochemical markers of myocardial damage cardiac sympathetic nerve activity, myocardial blood flow and metabolism, and central hemodynamics mean pulmonary arterial pressure pneumonia need vasoconstrictors intraoperatively pain hospital stay recovery time catecholamine response pain scores cytokine levels heart rate myocardial oxygen demand postoperative ischemia spirometric data, arterial oxygenation, pulmonary shunt, haemodynamics, use of vasoactive drugs and fluid balance length of stay and time to eligibility for hospital discharge intramyocardial partial oxygen pressure recovery time, postoperative pulmonary and cardiac parameters, visual analog scale (vas) scores, and sedation scores (ss number of patients showing ventricular fibrillation (vf), atrial fibrillation or heart block after release of the acc plasma concentrations of cardiac troponin|more than 30 episodes of hypoxemia developed on the second night in 22% of patients (11 of 50 patients), and on the third night in 30% of patients (14 of 46 patients). the gae, compared with ga, group reported significantly lower levels of impairment for all pain domains and reduced morphine usage (odds ratio = 0.07, 95% ci [0.03-0.17]; p < 0.001). on the first postoperative day, a slight reduction in paco2 was seen in the tea group, but no differences in shunt, va/q matching, or oxygenation compared with the ga group. thirty-day survival free from myocardial infarction, pulmonary complications, renal failure, and stroke was 85.2% in the tea group and 89.7% in the ga group (p = 0.23). during bypass svr and mean arterial pressure (map) were significantly higher and pump flow lower in the hf group compared to the lf+tea group. the increase in the plasma levels of bactericidal permeability-increasing protein, lipopolysaccharide-binding protein, and c-reactive protein showed the same pattern in all groups, and no significant differences among the 4 groups were observed. there were no demographic or hemodynamic differences between the groups before intervention. like il-10, opioids downregulate the immune responses in vivo and in vitro, including the activity of the cytokine-producing monocytes and granulocytes. this method of analgesia was also associated with minimal side effects and provides an alternate approach for treatment of pain after cardiac operations. extubation was achieved earlier (p < 0.0001) and with significantly fewer lower respiratory tract infections in group tea (tea = 31 of 206, ga = 59 of 202; p = 0.0007). time to extubation was shorter (p < 0.001) and consumption of anesthetics was lower in the patient-controlled thoracic epidural analgesia group. there were no differences in troponin vas score, ss, and postoperative pao2 were significantly (p less than or equal to 0.01) better in the tea group. a 50-70% reduction in forced vital capacity, forced expiratory volume in 1 s (fev1.0) and peak expiratory flow rate (pefr) was seen after surgery, but higher fev1.0 and pefr on days 2 and 3 were seen in the epidural group than in the control group. during sternotomy there was a pronounced increase in cardiac norepinephrine spillover, map, systemic vascular resistance index (svri), pulmonary capillary wedge pressure (pcwp), gcvf, and reg-mvo2 in the control group. in group e 22 of 44 (50%), in group e+a 10 of 35 (28.6%), in group a 10 of 36 (27.8%), and in the control group 20 of 48 (41.7%) patients developed af (odds ratio amiodarone/nonamiodarone 0.47 [0.24-0.90]; p = 0.02). the incidence of perioperative dysarrhythmias was significantly lower (p < .01) in the ga+tea group (3%) than in the ga group (23.7%). forced vital capacity and forced expiratory volume in one second followed the same pattern for first four postoperative days and peak expiratory flow rate remained statistically high till second postoperative day. preoperatively no intergroup differences were observed in "the starling forces" (coppl, copif, pif). pain score in the epidural group was lower on the first postoperative day than in the extubated group with general anesthesia (3.0 plus minus 1.6 visual analog scale v 4.6 plus minus 1.8 visual analog scale; p = 0.01). there were no significant differences in cardiac index between the two groups of patients, although heart rate and mean arterial pressure decreased before surgery in patients who received extradural analgesia. both tea and clonidine reduced the postoperative heart rate compared with the control group without jeopardizing cardiac output or perfusion pressure. immunostaining intensity in the sections after incubation with each primary antibody increased in the ga + tea group compared with the ga group. mean troponin t levels at 24 h were not significantly different between the groups (p = 0.41). in the tea+ga group, the bcl-2 positive cardiomyocytes were distinctly statistically increased compared to the ga group (p<0.001). htea showed improved physiotherapy cooperation (p < 0.001), arterial oxygen tension (p = 0.041), and peak expiratory flow rate (p = 0.001). no statistically significant differences between the 2 study groups were found in these main measurements. increases of pct, tnf-alpha and leukocyte count were significantly attenuated in the dpx and epi groups at different time points. high tea was effective in all patients of this group, the somatosensory block extended from t1 through t7 vertebrae. the c3alpha, troponin i, 8-isoprostane, and cortisol release was similar in the two groups throughout (p > or = 0.12). there were no differences in postoperative spirometry or chest radiograph changes or in markers for postoperative myocardial ischemia or infarction.|patients undergoing elective coronary bypass graft (cabg) surgery twenty-eight patients undergoing elective cabg pain relief after cardiac operations 420 patients undergoing cardiothoracic clinic at a major university referral center patients (n = 90) scheduled for elective midcab surgery fifty-four male patients, under 65 years and with an ejection fraction of more than 0.5 36 patients who received high tea and 3 of 37 controls died sixty patients undergoing elective surgery patients undergoing off-pump coronary artery bypass grafting subcutaneous tissue one hundred thirteen patients undergoing elective cardiac surgery cardiac surgery unit at a university hospital after coronary artery bypass grafting 73 randomized patients, 37 were control subjects (who received general anesthesia only) and 36 were in the group who received 30 patients randomly allocated to receive either coronary diseased patients prior to surgical revascularization without deleterious hemodynamic disturbances coronary artery bypass graft surgery sixteen patients submitted to elective coronary artery bypass grafting (cabg) surgery sixty obese patients with body mass index >30 kg/m2 for elective opcab fifty patients received humans before cardiopulmonary bypass (cpb patients having general anesthesia only patients undergoing aortocoronary bypass surgery major university teaching hospital after coronary artery bypass surgery 73 patients scheduled for coronary artery bypass grafting who had a left ventricular ejection fraction of 50% or more conducted from february 1, 2000, through august 31, 2000, at university hospital, mnster, germany patients undergoing emergency surgery and those with unstable angina were excluded patients undergoing opcabg surgery patients undergoing cardiac surgery nine patients undergoing coronary artery bypass surgery 30 male patients < 65 years old and with ejection fraction > 0.5 14 patients, and 14 patients receiving ga alone served as controls obese patients with body mass index of more than 30 kg/m2 for off pump coronary artery bypass surgery 20 patients undergoing coronary artery bypass grafting (cabg patients were divided into 3 groups: 30 patients had general anesthesia and were extubated immediately after surgery (extubated group), 30 patients had a after coronary artery surgery eighty patients scheduled for elective cabg one-hundred-twenty patients elective cardiac surgical patients who receive cardiac surgery with cardiopulmonary bypass patients managed with general anesthesia alone during surgery followed by parenteral opiate analgesia after surgery 654 elective cardiac surgical patients obese patients undergoing opcab 40 patients scheduled for patients undergoing off-pump coronary artery bypass graft (opcabg) surgery patients scheduled for cardiothoracic surgery, including coronary artery bypass grafting patients with ischemic heart disease tertiary health care center associated with a university seventy-four patients (66 male [89%], mean age 65.2 years [sd 9.6]) undergoing opcabg surgery 50 patients undergoing elective cabg surgery patients undergoing elective coronary bypass surgery 132 patients undergoing elective off-pump coronary bypass grafting using either general anesthesia (ga) (n = 66) or sixteen male patients fifty adult patients patients undergoing patients with coronary heart disease going through major surgery cardiac surgical patients who require full heparinization atrial fibrillation after coronary artery bypass grafting after cardiac surgery patients undergoing off-pump coronary artery bypass surgery sixty participants eighty patients one hundred sixty-three patients scheduled for coronary artery bypass graft surgery sixty patients scheduled for elective cardiac surgery with cardiopulmonary bypass obese patients undergoing off pump coronary artery bypass surgery (opcab cardiac surgery coronary surgery patients two hundred and twenty-six patients thirty patients scheduled for elective cabg surgery patients undergoing coronary artery bypass grafting patients submitted for surgical revascularization seventy patients scheduled for elective coronary artery bypass graft (cabg) received general anesthesia with patients with thoracic epidural anesthesia and supplemental general anesthesia
postoperative pain and recovery modified objective pain score, and the time taken to first requirement of analgesia postoperative analgesia pain relief induction-incision time frequency of vomiting analgesia time interval between operation and subsequent analgesic administration and the number of analgesic doses motor weakness, time to first micturition, postoperative nausea and vomiting (ponv), eating habits, sleep disturbance and behaviour incidence of vomiting duration of analgesia time to first requirement for analgesia or number of doses of paracetamol recovery of consciousness efficacy, complication rates, and parental satisfaction analgesic effects level of consciousness and apparent pain ponv, eating, sleeping or behavioural disturbance motor weakness incidence of adverse effects pain and caudal analgesia postoperative pain time to first micturition|for 90 minutes following circumcision there was significantly less pain and caudal analgesia, but better pain relief could not be demonstrated following inguinal herniotomy and orchidopexy. for caudal block, 1 ml.kg(-1) body weight of 0.25% bupivacaine was administered. subjects in the dnb group micturated earlier (p less than 0.05) and stood unaided earlier (p less than 0.025) than patients in the caudal group. the only detectable difference between the groups was a more rapid, but transient, recovery in the group receiving plain bupivacaine only. incidence of adverse effects was the same in the two groups. caudal analgesia is shown to be significantly better than morphine by means of a linear analogue scale designed to quantify behaviour immediately after operation. there was no difference between the groups in time to first requirement for analgesia or number of doses of paracetamol given in the first 24 h. almost half the boys in the caudal group had motor weakness, and there was a significant increase in time to first micturition in that group.|181 children who had undergone either circumcision, inguinal herniotomy or orchidopexy performed under general anaesthesia children one patient undergoing penile block and nine patients undergoing caudal block vomited boys paediatric circumcision forty boys were studied 100 asa 1 and 2 boys aged 3 to 8 years who were undergoing circumcision for religious reasons sixty boys undergoing elective circumcision boys undergoing circumcision fifty boys presenting for day case circumcision 40 children scheduled for circumcision children undergoing circumcision with respect to
caries incidence and plaque accumulation caries incidence mean approximal caries increment, including initial caries lesions caries development incidence of caries fluoride levels dental caries plaque indices approximal caries|the apf gel provided a 34.3% reduction in caries incidence (p-value = 0.03) among the children with 3-14 cavities on their primary teeth at the beginning of the study. when the children were examined for total decayed, missing, and filled surfaces (dmfs) increments 2 years later, no significant differences were observed. only the group that brushed with the 1.25% amf gel showed a significant decrease in caries development compared to the group that brushed with the 0.125% amf toothpaste. after 3 years, the mean approximal caries increment, including initial caries lesions, was 2.8 in the naf, 2.4 in the snf2, and 4.0 in the placebo gel group (p< 0.05 for snf2 vs placebo); a reduction compared to the placebo of 30% and 39% in the naf and snf2 groups, respectively. frequent, but less than daily, topical fluoride therapy appeared to have little effect in pre-school children consuming water-borne fluoride and receiving other traditionally recommended modalities of prevention.|high-risk children 13-16-year-old schoolchildren two-hundred-and-eighty 13-year-old schoolchildren high-risk children living in non-fluoridated communities four hundred and sixty-eight children, ages 6 to 13 children by an schoolchildren at caries risk, after brushing the teeth fortnightly with gels containing 0, 0.4% f, 1.25% f as amine fluoride (amf) or the common primary dentition of 2-6-year-olds after 8, 18 and 28 months caries development on approximal tooth surfaces dental caries in primary teeth after frequent fluoride toplications in a program involving other preventives 488 children 6 yr old, presenting at least three cavities on proximal surfaces of their primary teeth caries-prone subjects
fatty acid (fa) composition abbreviated symptom questionnaire (asq attention problem and motor excess of the revised behavior problem checklist total omega-6/omega-3 ratios visual short-term memory and errors of commission (continuous performance subscales scores symptoms attention deficit, hyperactivity and impulsivity (ad/hd-related symptoms according to dsm-iv criteria); (2) aggression assessed by both parents and teachers; (3) visual perception (finding symbols out of a table); (4) visual and auditory short-term memory; (5) development of visual-motor integration; (6) continuous performance; (7) impatience ability to switch and control attention (creature counting adhd clinical symptoms plasma phospholipid fatty acid patterns, scores on laboratory measures of inattention and impulsivity (test of variables of attention, children's color trails test) while not taking stimulant medication, and scores on parental behavioral rating scales (child behavior checklist, conners' rating scale lower epa concentrations fo attention-deficit/hyperactivity disorder(ad/hd) symptoms objective or subjective measure of adhd symptoms plasma and erythrocyte fa profile and continuous performance test results (test of variables of attention; tova blood fa composition and behavior higher aa/epa disruptive behavior blood fatty acid composition and visual sustained attention performance conners' parent and teacher rating scales (crs-p,t), strengths and difficulties questionnaire (sdq), and child health questionnaire (chq cognitive measures plasma phospholipid dha content n-3 pufa safety and tolerability serum phospholipids and red blood cell membranes (rbc baseline efa concentrations oppositional defiant behavior plasma pufa composition efficacy sustained efficacy multiple outcomes parent version of the conners' questionnaire cognitive performance aa/dha symptoms of attention-deficit/hyperactivity disorder inattention and global diagnostic and statistical manual of mental disorders, fourth edition, total conners' subscales adhd symptoms parent impact-emotional (pe) subscale fatty acids epa and dha in the rbc and the teachers' disruptive behavior disorders (dbd) rating scale for attention total tova scores higher aa/dha ratios symptoms of adhd symptoms of attention-deficit/hyperactivity disorder (adhd proportions of epa, dha, and alpha-tocopherol in the plasma phospholipids and red blood cell (rbc) total lipids alterations in fas and increased tova scores cgi scores teacher-rated behaviour and oppositional symptoms tolerated ad/hd-related symptoms eicosapentaenoic and docosahexaenoic acids alpha-tocopherol concentrations omega-6 fatty acid concentrations efficacy measure was conners' parent/teacher rating scales (cprs/ctrs investigator-rated adhd rating scale-iv and clinical global impression (cgi) scale ctrs total score epa improved ctrs inattention/cognitive subscale|a significant correlation between the alterations in fas and increased tova scores mainly occurred in the pl-n-3 group. this improvement was also observed in the placebo group after taking pufa from weeks 16 to 30 (n=104). children that switched to ps-omega3 treatment from placebo showed a significant reduction in subscales scores of both crs-p and the crs-t, as compare to baseline scores. however, visual short-term memory and errors of commission (continuous performance) significantly improved in the control group compared with the changes over time in the dha group (p=0.02 and 0.001, respectively). epa improved ctrs inattention/cognitive subscale (p = 0.04), but not conners' total score. supplementation was also associated with significant changes on two performance tasks and with significant improvement to parent ratings on the subscales designated as attention problem and motor excess of the revised behavior problem checklist. analysis of variance for repeated measures revealed that both treatments ameliorated some of the symptoms, but no significant differences were found between the groups in any of the treatment effects. the trend reached significance (p less than 0.05) only on conners hyperactivity factor. a statistically significant improvement in symptoms was noted based on the parent version of the conners' questionnaire from baseline to the end of phase 1, and this amelioration continued from phases 1 to 2, although the latter changes from phases 1 and 2 were not statistically significant in any of the subscales except for the subscale measuring inattention in group b. however, a subgroup of 26% responded with more than 25% reduction of adhd symptoms and a drop of cgi scores to the near-normal range. conduct problems rated by parents (-42.7 vs. -9.9%, n = 47, p = 0.05), and attention symptoms rated by teachers (-14.8 vs. +3.4%, n = 47, p = 0.03). plasma phospholipid dha content of the dha-supplemented group was 2.6-fold higher at the end of the study than that of the placebo group (4.85 +/-|children with attention-deficit hyperactivity disorder two hundred adhd children subjects of a dha group (n=20) took 6- to-12-year-old children with adhd, all receiving effective maintenance therapy with stimulant medication thirty-one children, selected for marked inattention and overactivity 75 children and adolescents (8-18 years), followed by 3 months with omega 3/6 for all patients with attention-deficit hyperactivity disorder (adhd sixty-three children with attention-deficit/hyperactivity disorder (ad/hd)-like symptoms also reporting thirst and skin problems 2010 18 boys, aged 6-12 years, with attention-deficit hyperactivity disorder received 1 month each of 92 children (7-12 years) with adhd ad/hd children children with attention deficit hyperactivity disorder (adhd 40 ad/hd (including eight ad/hd-suspected) children of 6-12 y of age who were mostly without medication 37 children (only 26 children completed the study from zero to 16 weeks children with behavioral disorders children aged 8-13 y with impaired visual sustained attention performance received fifty children children sixty of the 83 children enrolled completed the interventions (n = 18-21 per group children and adolescents children with attention-deficit/hyperactivity disorder children with attention deficit hyperactivity disorder symptoms children with attention-deficit/hyperactivity disorder (adhd children with inattention children with inattention, hyperactivity, and other disruptive behaviors hyperactive children french canadian primary school children canadian youth with adhd patients with psychiatric disorders attention deficit hyperactivity disorder 73 unmedicated children aged 7-13 years with a diagnosis of adhd participated in the study; 63 children completed the study children with adhd children with adhd symptoms 7-12-year-old children with symptoms 2 s.d. on conners' adhd index were given
gastrointestinal bleeding and one genitourinary bleeding nonfatal major bleeding odds ratio for recurrence higher risk of major hemorrhage recurrent vte major bleeding episodes idiopathic deep venous thrombosis episodes of pulmonary embolism recurrent venous thromboembolism 123 recurrences of venous thromboembolism relative risk of major hemorrhage relative risk of recurrence pulmonary embolism recurrence of symptomatic, objectively confirmed venous thromboembolism 23 recurrences of venous thromboembolism recurrence rate incidence of recurrent venous thromboembolism 26 recurrences of venous thromboembolism recurrence non-fatal major bleeding initial episodes of deep-vein thrombosis rate ratio major bleeds recurrences and major, minor, or fatal bleeding complications recurrent thrombosis mortality or the rate of major hemorrhage incidence of recurrence rates of recurrent symptomatic venous thromboembolism and bleeding duration of oral anticoagulant therapy recurrent episode of venous thromboembolism rates of recurrence risk of recurrent venous thromboembolism rate of recurrent venous thromboembolism mortality recurrence of venous thromboembolism rate of recurrence|among 165 patients assigned to extended anticoagulant therapy, 15 patients (9.1%) had a recurrence of venous thromboembolism (3.1% per patient-year; average follow-up, 34.9 months), as compared with 18 of 161 patients (11.2%) assigned to discontinue treatment (4.1% per patient-year; average follow-up, 32.7 months); the rate ratio was 0.81 (95% ci, 0.42 to 1.56). a consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism. in patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated with a reduced incidence of recurrent thrombosis during the period of therapy. of 84 patients assigned to placebo, five (6.0%) had recurrent venous thromboembolism, compared with three of 81 (3.7%) assigned to warfarin, resulting in an absolute risk difference of 2.3%[95% confidence interval (ci) - 5.2, 10.0]. subgroup analysis demonstrated that the rate of recurrence was lower for c-dvt than for p-dvt or pe. warfarin resulted in a 95 percent reduction in the risk of recurrent venous thromboembolism (95 percent confidence interval, 63 to 99 percent). nineteen of the 192 patients with an abnormal four week ipg experienced recurrence during the nine months after discontinuing warfarin. after two years of follow-up, there had been 123 recurrences of venous thromboembolism that met the diagnostic criteria, 80 in the six-week group (18.1 percent; 95 percent confidence interval, 14.5 to 21.6) and 43 in the six-month group (9.5 percent; 95 percent confidence interval, 6.8 to 12.2).|proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis patients with an abnormal four week ipg received 736 patients were enrolled 165 patients assigned to 227 patients enrolled, 111 patients with proximal deep vein thrombosis patients who have a first episode of venous thromboembolism in the absence of known risk factors for thrombosis (idiopathic thrombosis 902 patients enrolled, 5 were later excluded because they had congenital protein c deficiency; 443 patients with acute proximal deep vein thrombosis (dvt patients with a first episode of idiopathic venous thromboembolism randomly assigned patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolism to continue receiving warfarin, with the dose adjusted to achieve an international normalized ratio of 2.0 to 3.0, or to receive nineteen of the 192 patients with an abnormal four week ipg experienced 212 patients with continuing risk factors.(abstract truncated at 250 words 301 patients who received three months of 19 italian hospitals patients with pulmonary embolism patients with idiopathic venous thromboembolism, 11 of 90 patients assigned to extended anticoagulation and 11 of 91 patients assigned to 162 patients had been enrolled and followed for an average of 10 months patients who had a first episode of venous thromboembolism patients who had had a second episode of venous thromboembolism patients with idiopathic deep venous thrombosis 326 patients who had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding patients with venographically confirmed acute proximal dvt who had received four weeks of warfarin after initial heparin and whose four week ipg was normal patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy (with warfarin, in 97 percent of the cases and acenocoumarol in 3 percent patients with a first episode of pulmonary embolism patients who had completed 1 month of anticoagulant therapy for a first episode of venous thromboembolism provoked by a transient risk factor patients with idiopathic venous thromboembolism or permanent risk factors
symptoms of water retention mean number of bleeding-spotting days per cycle adrenal and peripheral androgens estimated pearl indices for nomac/e2 and drsp/ee lng reduced androgen levels inflammatory lesion count inflammatory, noninflammatory, and total lesion counts mean objective acne score changes in weight clinical efficacy echogenic texture of the ovaries acne lesion counts and clinician global assessment unacceptable bleeding bioavailable withdrawal bleeding number of lesions and the degree of severity relative frequency of women with complete resolution symptoms of water retention and impaired concentration facial acne lesion counts, an investigator's global assessment, a subject's self-assessment, and an analysis of within-cycle variation (cycle 6) in lesion counts mean shbg facial acne lesion counts, the investigator's global assessment, and the subject's self-assessment tolerability number of acne lesions blood pressure and weight mean total scores of pgwbi or poms somatic and psychological symptoms acne resolution rates efficacy, cycle control and tolerability normalization of biochemical hyperandrogenism shbg and acne scores 3 alpha-17 beta-androstanediol acne lesions and plasma androstenedione (a), total testosterone (t), sex hormone binding globulin (shbg) and "free androgen index" (fai hepatic tolerance shbg elevation self-administered questionnaires psychological general well-being index (pgwbi) and the profile of mood states (poms normalization of the echogenic ovarian texture reduction (+/-sd) rates cycle control, dysmenorrhea and premenstrual syndrome (pms serum total and unbound testosterone and sex hormone binding globulin (shbg efficacy measures (total comedones, open comedones, closed comedones, papules, pustules, and the subject's self-assessment of study treatment levels of shbg elevated total t acne lesions, sebum production, and hair growth on the upper lip, chin, and chest type and frequency of adverse events initial values of plasma shbg efficacy inflammatory, noninflammatory and total lesion counts investigator static global assessment rating of acne percentage of severe/moderate acne efficacy and safety shbg with neta than lng, bioavailable testosterone (t relative numbers of comedones, papules, pustules and nodules at cycle 6 acne and seborrhea sebum production and hair growth on the upper lip and chin blood pressure and body weight efficacy and tolerability serum total an unbound testosterone (t) and sex hormone binding globulin (shbg) levels dysmenorrhea and pms acne tolerated moderate papulopustular acne of the dcollet signs of biochemical hyperandrogenism, including elevated fai irregular bleeding and minor side effects number of comedones, papules, pustules and nodules inflammatory and total lesion count and the percentage of patients with acne improvement according to the investigator global assessment number of inflammatory and total lesions intracyclic bleeding/spotting pre-existing acne number of papules and/or pustules of the face from admission to medication cycle 6 proportion of subjects with acne number and severity of acne lesions time serum free testosterone number of papules/pustules per half of the face present on admission excellent improvement" or "complete resolution" of moderate acne level of sex hormone-binding globulin (shbg contraceptive efficacy objective and subjective severity of acne, and related biochemical variables such as sex hormone-binding globulin and free and total testosterone emotional well-being free testosterone clinician global and patient self-assessment scores scheduled withdrawal bleedings inflammatory lesions hormone levels androgenic markers and acne facial acne acne lesions subjective acne scores total testosterone and 3 alpha-17 beta-androstanediol glucuronide biochemical markers of androgenicity mean acne lesion counts total lesions median reduction in papules/pustules clinician global and patient self-assessments mean age, body mass index, acne lesion counts, shbg, dheas, or free and total testosterone lesion numbers objective (acne counts) and subjective (no, moderate, mild, severe) acne scoring of the facial area occurrence rate of irregular bleeding and spotting early withdrawal bleeding levels of total and free testosterone, androstenedione, dehydroepiandrosterone sulfate (dheas), sex hormone-binding globulin (shbg), and luteinizing hormone (lh total lesion count severe acne category severity of acne and shbg irregular bleeding and side effects mean acne score shbg plasma levels of sex hormone binding globulin reduction rates median total acne lesion count sex hormone-binding globulin (shbg), dehydroepiandrosterone sulfate (dheas), and free and total testosterone tolerability and quality of life cycle control, quality of life and acne therapeutic effect, sebum production, and hormone levels incidences of irregular bleeding and minor side-effects sex hormone-binding globulin acne lesion counts and investigator static global assessment scale ratings menstrual distress questionnaire (mdq) normative t scores; the proportion of subjects with acne; and menstrual symptoms efficacy and acceptability acne lesion counts|of the 160 subjects in whom efficacy could be evaluated, the oc group showed a statistically significantly greater improvement than the placebo group for all primary efficacy measures. for comedonal lesions of the face, the reduction in lesion numbers was 54.8% (ee/cma) compared with 32.4% (placebo). the percentage reduction from baseline to endpoint for total lesions is 46.3% for 3-mg drospirenone/20-microgram ethinyl estradiol 24/4 combination oral contraceptive group and 30.6% for placebo group (p<.001). there were no differences between groups for the mean total scores of pgwbi or poms at all time-points. both preparations increased plasma levels of sex hormone binding globulin and seemed to decrease those of total and free testosterone, but no statistically significant relationships between acne severity and biochemical variables could be detected. free testosterone decreased significantly and sex hormone-binding globulin increased significantly in the oc group, but remained unchanged in the placebo group. the preparation containing ee/drsp was superior to ee/ngm for reduction in total lesion count (-3.3% in favor of ee/drsp [95% ci, -6.5 to -0.1; p = .020]) and for investigators' assessment of therapeutic effect on facial acne (+3.6% in favor of ee/drsp [95% ci, 0.8 to 6.3; p = .006]). it was not possible to establish a significant difference between the two preparations in the case of hirsutism in its various locations from the limited number of cases observed. cycle control was observed to be excellent; the incidences of irregular bleeding and minor side-effects were low in both groups and decreased after an initial increase in the first cycle. low-dose oc (ee, 20 micrograms) are effective in reducing circulating androgens and acne lesions without causing weight gain. after only 4 months of treatment the patients on diane and diane mite had a significantly greater reduction in the number of acne lesions compared with those on neovletta.(abstract truncated at 250 words) by the end of the third cycle of treatment, the hormonal changes observed in both groups included significant decreases, with normalization of individual elevated levels of t, and a 3-fold rise of the initial values of plasma shbg, which showed a further gradual increase at cycle 9 of ee-dsg administration. the number of comedones, papules, pustules and nodules significantly decreased in both groups over the 6-month study. in both treatment groups, a decrease in total testosterone and 3 alpha-17 beta-androstanediol glucuronide was observed and an increase in shbg. the incidences of irregular bleeding and minor side effects in both groups were very low and decreased after an initial increase in the first cycle. ee/cma is an efficient treatment for women with mild and moderate papulopustular acne of the face and related disorders, reflecting the well-known anti-androgenic properties of the progestogen cma. a 3-fold increase in the levels of shbg was observed in both treatment groups, and levels of androgens and lh decreased. more subjects in the drsp 3 mg/ee 30 microg group reported improved physical well-being compared with the lng 150 microg/ee 30 microg group. at baseline, the two treatment groups did not differ in the mean age, body mass index, acne lesion counts, shbg, dheas, or free and total testosterone. inflammatory, noninflammatory, and total lesion counts at cycle 6 with lng/ee were significantly lower compared to placebo. estimated pearl indices for nomac/e2 and drsp/ee were 0.38 and 0.81 in women aged35 years and 0.31 and 0.66 for all women (18-50 years), respectively. at the end of the study, the number of inflammatory and total lesions was significantly lower with ee/lng compared with placebo (p <.05). ee 24/4 regimen coc was significantly more effective than placebo in treating moderate acne vulgaris. ater six months' treatment a 250% increase in shbg was seen in desogestrel/ee group and no significant change in shbg in levonorgestrel/ee group. all primary analyses proved that ee/dng was superior to placebo and non-inferior to ee/cpa (p<.05).|acne vulgaris moderate acne women with androgen-dependent disorders who also require contraception healthy female subjects 199 female acne patients healthy females (aged 14-45 years old) with moderate facial acne 394 women and an oral contraceptive with the same amount of 88 patients took part in the study 19 patients aged 18-35 years affected with postpubertal or persistent non-severe acne vulgaris papulopustular acne of the face, dcollet (low neck) and back; on moderate comedonal acne of the face; and on seborrhea, alopecia and hirsutism intervention(s a woman was eligible for the study if she was found by a dermatologist to have at least eight acne lesions (sum of papules, pustules, cysts and nodules) on her face, was otherwise healthy and without medication 133 women were recruited at eight different centers mild to moderate papulopustular acne of the face and acne-related disorders in comparison to ee/levonorgestrel (lng; microgynon healthy females aged 14-45 years with moderate acne two hundred fifty women moderate acne resolution fifty-eight healthy women (18-28 years old women with acne healthy women women (aged 18-50 years outpatient dermatology clinics women with mild and moderate papulopustular acne of the face and related disorders six family planning centers and outpatient gynaecological clinics in urban areas in thailand, 783 healthy women who were at risk for pregnancy and did not have contraindications to oral contraceptive use fifty-four female acne patients women seeking oral contraception subjects were 15-49 years old and had moderate acne vulgaris 172 women randomized to treatment with either healthy women between 16 and 45 years old with mild to moderate facial acne moderate acne vulgaris female acne patients treated with two different oral contraceptives one-hundred-and-eighty-three women women (> or =14 years old; n = 350) with normal menstrual cycles and moderate acne moderate acne vulgaris in women with no known contraindication to oc therapy female patients with mild to moderate acne patients with acne oriental women suffering from acne 128 women with mild-to-moderate facial acne, with or without seborrhea and/or hirsutism caucasian women 389 women during 6 cycles female subjects two hundred fifty-seven healthy female subjects, 15 to 49 years of age with moderate acne vulgaris thai women three hundred seventy-seven women healthy female subjects (n = 371; >/=14 years old) with regular menstrual cycles and moderate facial acne papulopustular acne in comparison with 32 women using marvelon and 34 using diane were followed for 6 treatment cycles thirty-four women with acne young women with acne vulgaris 595 women enrolled, 274 (86.7%) in the treating moderate acne vulgaris
pain efficacy and safety therapeutic gain safe and well tolerated nausea, photophobia, and phonophobia pain relief analgesic efficacy recurrence acute headaches pain intensity differences, maximum pain intensity difference, number of patients with at least 50% pain reduction, time to 50% pain reduction, maximum pain relief and total pain relief duration of the aura|the patients receiving dipyrone showed a statistically significant improvement (p<0.05) of pain compared to placebo up to 30 min after drug administration. dipyrone and chlorpromazine reduced the duration of the aura, when compared to placebo, 60 minutes following their administration. patients receiving dipyrone demonstrated a statistically superior improvement (p<.05 and p<.01) in pain and all associated symptoms compared with control subjects. the analgesic efficacy of 0.5 and 1 g metamizol vs. placebo was highly statistically significant (alpha: 0.025; one-sided) for sum of pain intensity differences, maximum pain intensity difference, number of patients with at least 50% pain reduction, time to 50% pain reduction, maximum pain relief and total pain relief.|migraine without aura and migraine with aura migrainous aura patients with moderate episodic tension-type headache brazilian public health units patients presenting migrainous aura 417 patients with moderate episodic tension-type headache episodic tension-type headache eligibility criteria included 18-65 years of age, history of at least two episodes of tension-type headache per month in the 3 months prior to enrollment, and successful previous pain relief with a non-opioid analgesic 86 patients during an acute migrainous attack, with aura at the moment of the evaluation sixty patients
pain mean postoperative days of pain mean postoperative days of analgesic use pain scores pain relief analgesic efficacy analgesic effect postoperative hemorrhage visual analog scale pain levels twice daily using a visual analogue scale postoperative pain relief|results showed that the benzydamine spray was more effective than placebo in the control of post-operative pain. the efficacy of benzydamine hydrochloride (difflam) spray to relieve pain from postoperative tonsillectomy was assessed, but it was found that it did not relieve the symptoms after operation when compared to matching placebo. in the seventh post-operative day the results of bupivacaine, dexamethasone, lidocaine and placebo groups were similar (p>0.05). mean postoperative days of pain were 10.3 and 8.3, respectively, and differed significantly (p = .008).|thirty-seven patients completed the study, 21 in the treatment group and 16 in the control group eighty patients were enrolled in the study in ent clinic, firat university, and in ent clinic elazi ssk hospital, elazi (turkey thirty-seven patients from 5 to 14 years old undergoing 56 subjects of ages ranging from 4-11 years after tonsillectomy children between 6 and 14 years of age referred to our department for bilateral tonsillectomy for either recurrent tonsillitis or tonsillar hypertrophy children undergoing tonsillectomy pain after tonsillectomy 80 patients were analyzed
survival rates median survival durations probability of response included initial performance status, age, histologic grade, and progesterone receptor concentration survival median durations of progression-free survival response rate longer survival overall response rates overall response rate mpa levels moderate toxicities serum levels and response rates life-threatening case of pulmonary embolism poorer progression-free and overall survival times median survival times|only mild and moderate toxicities were observed on megestrol compared with more toxic complications observed on the combination of megestrol and tamoxifen, including a life-threatening case of pulmonary embolism. using a multivariate analysis of the results, this difference is significant (p value 0.05). the adjusted relative odds of responding to the high-dose regimen compared with the low-dose regimen was 0.61 (90% confidence interval, 0.36 to 1.04). the group of patients who received progestagens had significantly longer survival than the control group without hormonotherapy (logrank test; p < 0.001). survival rates were much higher in the differentiated than in the undifferentiated carcinomas.|patients with a well-differentiated histology and positive progesterone receptor status advanced or recurrent endometrial carcinoma forty-six eligible women with metastatic endometrial cancer 41 patients advanced endometrial carcinoma endometrial cancer after surgery two hundred ninety-nine eligible women with advanced or recurrent endometrial carcinoma 8 patients with operable endometrial cancer, negative estrogen receptor concentration (er less than 15 fmole/mg protein) and grade 3 disease, the clinical course was aggressive in 4 patients with systemic and local relapse advanced endometrial adenocarcinoma patients with advanced endometrial cancer 93 patients with stage iii or iv endometrial adenocarcinoma after random allocation to therapy with postoperative endometrial cancer two hundred and five patients patients with endometrial cancer after hysterectomy advanced endometrial cancer, 66 patients were entered in this study
nonsteroidal anti-inflammatory drugs and pd risk of parkinson's disease risk of parkinson disease pd risk frequency of diseases of immediate-type hypersensitivity risk reduction odds ratios onset of pd risk of pd lower risk of pd risk of developing pd protective effect relative risks incidence of parkinson disease (pd pd and environmental measures (history, status, dosage, duration, and intensity) of smoking, coffee, caffeine, nonsteroidal anti-inflammatory drugs, and non-aspirin nonsteroidal anti-inflammatory drugs increasing intensity of coffee drinking total caffeine consumption|the frequency of diseases of immediate-type hypersensitivity was significantly higher in cases than controls. current users of nsaids had a slightly higher risk of developing pd (rr=1.49 [95% ci, 1.11-2.01]). nonsteroidal anti-inflammatory drugs (nsaids) reduce dopaminergic neuron degeneration in animal models of parkinson disease (pd). the odds ratios (95% ci) for ever vs never use were 0.93 (0.80 to 1.08) for nonaspirin nsaids, 1.29 (1.05 to 1.58) for aspirin, and 1.16 (1.00 to 1.35) for acetaminophen. users of ibuprofen had a significantly lower pd risk than nonusers (relative risk [rr], adjusted for age, smoking, caffeine, and other covariates = 0.62; 95% confidence interval [ci] 0.42-0.93; p = 0.02). increasing dosage (trend p = .009) and intensity (trend p = .01) of total caffeine consumption were also inversely associated, with high dosage presenting a significant inverse association for pd (odds ratio = 0.58; 95% confidence interval, 0.34-0.99). the two-way and three-way combinations were associated with risk reduction of 37% to 49%, and 62%, respectively. markers of neuroinflammation, including activated microglia and increased levels of circulating proinflammatory cytokines, have been observed in the brains and csf of patients with parkinson disease (pd). compared with nonusers, the relative risks were 0.73 for users of fewer than 2 tablets/week, 0.72 for 2 to 6.9 tablets/week, and 0.62 for 1 or more tablets/day (p trend = 0.03). the results of our study did not show a protective effect of nsaids for pd (rate ratio 0.84, 95% ci 0.81-1.09). there was an increased risk of parkinson's disease in men who had 1-2 years of regular non-aspirin nsaid use (odds ratio 1.35 (1.07 to 1.70)), a finding that remained significant after matching for confounder scores as well (odds ratio 1.35 (1.05 to 1.75)). use of ibuprofen was not associated with pd (or: 0.89; 95% ci: 0.60-1.32). no association was found between use of nsaids and the risk of parkinson disease (adjusted hazard ratio for any nsaid use, 1.50; 95% confidence interval, 0.95-2.37).|356 case subjects and 317 family controls who self-reported environmental exposures 6,512 participants aged >or=55 years, with repeated in-person examination, we evaluated the association between cumulative use of nonsteroidal anti-inflammatory drugs (nsaids) and the risk of parkinson disease 1,258 pd cases and 6,638 controls from the general practice research database parkinson disease (pd 1,186 pd patients and 928 controls was conducted 415 incident pd cases (236 men and 179 women 44 057 men and 98 845 women free of pd, stroke, or cancer (health professionals follow-up study, 1986-2000, and nurses' health study, 1980-1998 older adults in the province of british columbia from 1997 to 2003 136,197 participants in the nurses' health study (nhs) and the health professionals follow-up study (hpfs) free of pd at baseline (1998 for nhs and 2000 for hpfs parkinson's disease (pd) in a large cohort of us men and women parkinson's disease (pd 2007 movement disorder society up to five controls were matched to each of 616 cases by age and 565 cases by age and confounder scores participants' age, smoking, and medical history from interview patients with parkinson disease (pd subjects included 206 cases between ages 35 and 89 with a new diagnosis of idiopathic pd between 1992 and 2002, and 383 randomly selected controls frequency-matched by age, sex, duration of enrollment, and clinic 22,007 male physicians aged 40-84 years without indications for or contraindications to regular nsaid use and free of parkinson's disease at baseline 293 incident idiopathic pd cases and 286 age-, race-, and gender-matched controls from three rural california counties families with parkinson disease 291 incident pd cases during 6 years of follow-up a population-based case-control study among enrollees of group health cooperative, a health maintenance organization in the seattle area
responder rate severe and unbearable pain effectiveness number of subjects with adverse events (aes), withdrawals due to an ae and adverse drug reactions (adrs adverse events maximal platelet aggregation induced by arachidonic acid modified arhus index, its pain component and the total pain index numbers of pain compound pain subscore pain component total pain index systemic side-effects severe pain, radiation or neurological deficit pain without rescue medication spontaneous pain, muscular contracture and in both the patient's and physician's opinions pain free without the permitted rescue medication (tramadol platelet aggregation efficacy rating "symptomfree" or "improved severe allergic reaction vas reduction compound pain subscore of the arhus low back rating scale (continuous variable), and a response criterion of a reduction in pain subscore=30 efficacy and safety main efficacy parameter vas reduction finger-floor distance and the degree of lumbar extension severe and radiating pain accompanied by neurological deficit severity, duration, nature and accompaniments of their pain; and in laboratory indices of organ system function severity of pain, duration, nature and accompaniments of their pain, the arhus low back pain index and in laboratory indices of organ system function mean maximal arachidonic acid induced platelet aggregation human platelet aggregation pain pain free proportion of patients who were pain-free without tramadol pain scores adverse local drug reactions efficacy and tolerance adverse effects number of pain-free patients (visual analogue scale score partial pain scores, disability and mobility restriction subscores, the total score of the arhus low back rating scale, the global evaluation of efficacy by investigator and patient, adverse events|after 4 weeks of treatment, the arhus index had improved by about 20%, its pain component by about 30% and the total pain index by about 35%. statistically significant improvements in spontaneous pain, muscular contracture and in both the patient's and physician's opinions occurred by day 3. ten paid and 5 nsaid patients reported no pain without rescue medication for at least 5 days of the 6th week of treatment. after 3 weeks treatment with capsicum and placebo plaster respectively, the compound pain subscore was reduced by 42% (capsicum) and 31% (placebo) from values on entry. significantly more patients in the placebo group required tramadol (p <0.001) during each week of the study. there was no evidence for harpagophytum-related side-effects, except possibly for mild and infrequent gastrointestinal symptoms. spiroflor srl gel is preferable to capsicum-based products for the topical treatment of low back pain, because of the lower risk of adverse effects. the percentage change was greater in those patients who received harpagophytum extract than in those who received placebo, but inferential testing (mann whitney) allowed only 94% degree of confidence that this had not arisen by chance. acetylsalicylate had a significant inhibitory effect on platelet aggregation compared to salicis cortex extract (p = 0.001) and placebo (p = 0.001).|21 paid patients and 13 nsaid patients forty-three paid and 36 nsaid patients completed the study exacerbation of low back pain mechanical low-back pain 118 patients with chronic back problems seeking treatment for acute attacks of pain low back pain patients with impaired thrombocyte function out-patients clinic on two groups of patients aged 18 to 80 yr presenting over a 6-month period with acute exacerbations of low back pain chronic low back pain with a capsicum plaster patients with acute low back pain acute low back pain non-specific low back pain 191 patients completed the study 183 patients completed the study 197 patients with chronic susceptibility to back pain and current exacerbations that were producing pain worse than 5 on a 0-10 visual analogue scale sixteen patients with stable chronic ischemic heart disease acutely exacerbated low back pain one hundred and sixty-one subjects suffering from acute low back pain forty patients with acute mechanical low-back pain  1996 114 patients practices of 19 gps in the districts of bristol and manchester, uk a total of 51 patients were enrolled in the study 109 patients completed the study 320 patients were randomly assigned to two groups of n=160 subjects treated by the active or the 210 patients with an exacerbation of chronic low back pain who reported current pain of 5 or more (out of 10) on a visual analog scale thirty-five patients suffering from acute exacerbations of chronic low back pain
mean daily symptom score clinical status (respiratory rate, degree of wheezing and accessory muscle use, total clinical score, and arterial oxygen saturation compliance and forced expiratory flows arterial oxygen tension clinical effect number of symptom free days values of thoracic gas volume (tgv), airway conductance (gaw) and specific airway conductance (sgaw improvement of gaw symptom score pulmonary hyperinflation bronchial response sgaw arterial oxygen saturation symptom score or pulmonary function symptoms of wheeze and cough lung volume or air flow obstruction clinical status and lung function maximum flow at frc (vmaxfrc concentration of histamine lung function bronchial responsiveness heart rate clinical symptoms or pulmonary function number of treatment failures|all of the infants responded to low concentrations of histamine during control tests before and after nebulised saline (mean pc30 1.07 and 0.51 g/l). none of the patients in the albuterol group experienced a decrease of arterial oxygen saturation of greater than or equal to 2%. there was no difference in the number of treatment failures between babies treated with a combination of salbutamol and placebo and those treated with salbutamol and prednisolone (relative risk 0.71; 95% confidence intervals for relative risk 0.18-2.80). bronchial responsiveness decreased significantly after the administration of salbutamol by babyhaler, the pc30 (provoking concentration of methacholine causing a 30% fall in maximal flow at functional residual capacity by the squeeze technique) increasing from a median of 3.8 g/l after placebo to 12.5 g/l after salbutamol. no significant difference in clinical effect was shown between albuterol and saline in the youngest group of children. in wheezy infants with an atopic background, there was no significant beneficial effect of salbutamol on either clinical symptoms or pulmonary function. no significant differences were found between the bdp-s and s group and/or between the s and p groups.|sixty-two acute episodes of wheezing were studied in 59 babies (age range 3-14 months; mean 7 months), who had all suffered at least one previous wheezy episode 28 acutely ill children younger than 18 months and in 13 children 18 to 36 months of age five wheezy infants aged 3-12 months twenty-nine of initially 42 infants with recurrent wheeze (20 male and 9 female) with an age range of 2.1-25.2 months eighty infants under 1 year, with persistent or recurrent wheeze and a personal or family history of atopy children older than 18 months forty eight infants completed the diary study; 40 infants underwent pulmonary function testing infants and young children acute episodes of wheezing in infants under 15 months of age infants who wheeze children younger than 2 years of age with acute asthma 28 children younger than 2 years of age who visited the emergency department during an episode of acute asthma were studied acute episodes of wheezing in infancy wheezy infants
decreased activity and oxygen desaturation tidal volume proportion of ventilation to the good lung breathing increased and static compliance transcutaneous carbon dioxide pressure vigorous motor activity and crying colony counts tcpo2 and tcpco2 functional residual capacity, tidal volume, or dynamic lung compliance blood gases and ventilation volume minute ventilation mean tcpo2 or tcpco2 static compliance and the work of breathing of spontaneous breaths low birthweight and respiratory distress syndrome cardiorespiratory stability and weaning outcome tcpco2 and paco2 values tcpco2 median fraction of inspiratory oxygen transcutaneous carbon dioxide tension pulmonary resistance spontaneous respiratory rate episodes of oxygen desaturation respiratory rate, heart rate and transcutaneous oxygen saturation, however, oxygen desaturation episodes heart rate, respiratory rate, transcutaneous oxygen saturation and ventilatory parameters arterial oxygen saturation transcutaneous carbon dioxide tension values duration of spo(2 mean length of the weaning process mean tcpco2 values dynamic compliance, tidal volume/kg, and total, inspiratory and expiratory pulmonary resistance thoracic gas volumes pao2 or paco2 numbers of positive tracheal cultures transcutaneous oxygen pressure blood gases and lung mechanics sleep state pulmonary mechanics of spontaneous breaths or arterial blood gases transcutaneous oxygen and carbon dioxide pressures heart rate transcutaneous (tc) oxygen (tcpo2) and carbon dioxide measurements (tcpco2 oxygen saturation (spo(2)), desaturation episodes (spo(2) < 90% and >or= 20 seconds), and motor activity motor activity lung mechanics and blood gases|after 2 days, the numbers of positive tracheal cultures in the supine group (67%) and in the lateral group (47%) showed no statistical difference. no significant differences were detected between positions for dynamic compliance, tidal volume/kg, and total, inspiratory and expiratory pulmonary resistance. no significant differences in duration of spo(2) less than 90%, 85%, and 80% were found between the 2 positions. there were no statistically significant differences in mean tcpco2 values between the three positions (f = .45; df 2,39; p = .64). there were no significant changes with position in functional residual capacity, tidal volume, or dynamic lung compliance. a significant difference in mean tcpo2 or tcpco2 was not detected for any of the positions. ventilatory parameters decreased faster and reintubation was less frequent in the prone group (4% versus 33%). the prone position resulted in a significant increase in arterial oxygen saturation before and after feeding, whereas the tidal volume demonstrated an increase only before feeding. in the supine position, work of breathing increased and static compliance decreased significantly with time, while in the prone position, those values did not change significantly.|42 preterm infants, with birthweight < 2,000 g, mechanically ventilated in the first week of life 10 infants with unilateral lung disease sixteen stable intubated premature infants without a clinically significant patent ductus arteriosus mean postnatal age of 47.5 days (range, 21 to 85 days ventilated preterm infants during their first postnatal week preterm infants preterm infants during weaning from mechanical ventilation neonates recovering from respiratory distress syndrome vlbw infants ventilated preterm infants four of the infants six extremely immature infants who were being mechanically ventilated because of chronic lung disease infants their mean birthweight and gestational age were 722.7 g (range, 540 to 994) and 24.9 weeks (range, 23.9 to 26.0), respectively 28 infants receiving neonates with respiratory distress ventilated infants 60 intubated infants; 30 infants were positioned supine (supine group), and 30 infants were maintained in the lateral position (lateral group eighteen stable very-low-birth-weight (vlbw) mechanically ventilated infants with chronic lung disease neonatal intensive care units at 2 tertiary care centers in taiwan infants with unilateral lung disease infants with chronic lung disease before and after feeding infants with chronic lung disease during tube feeding fourteen ventilated infants adults with unilateral lung disease sick preterm infants respiratory distress syndrome very low birthweight infants with chronic lung disease (cld prone ventilated preterm infants neonates were studied at a median postnatal age of 31 days (range, 17 to 57 days) and had median birth weights and gestational ages of 975 g (range, 570 to 1360 g) and 27.5 weeks (range, 24 to 30 weeks), respectively
delivery time rates of cesarean section and induction of labor time elapsed from the time of randomization to delivery labor spontaneously mean time to delivery cervical length shorter duration of active phase overall duration of labor, and first and second stage of labor duration of active labor, the amount of oxytocin given, and number of inductions likely to deliver by cesarean section labor length of birth and use of oxytocin duration of labor|labor was induced in 20% of women in the ag (n = 5) and in 35% in the cg (n = 7) (p = 0.3). acupuncture is well tolerated among term nulliparous women and holds promise in reducing interventions that occur in post-term pregnancies. duration of labor was significantly reduced (mean difference 1.7 h, p=0.03) and there was significant reduction in the need for oxytocin infusion to augment labor in the study group compared to the control group (odds ratio 2.0, p=0.018).|nulliparous women fifty-six women exclusion criteria were as follows: cervical dilation > 3 cm, active labor, premature rupture of membranes, previous cesarean section, pathologies in mother or fetus 100 healthy parturients, with spontaneous rupture of membranes at term 45 women were evaluated (ag, n = 25; cg, n = 20 term nulliparous women women with prelabor rupture of membranes nulliparous women at 39 4/7 weeks or greater with a singleton gestation and bishop score of less than 7 were randomized to
adverse effects conversion rate of hbsag|adverse effects were not observed in all patients receiving the plant.|thirty-four received chronic carriers sixty-five adult asymptomatic chronic carriers of hepatitis b virus
pulmonary tuberculosis complete response (cr), disease-free interval and recurrence rate response rate local and systemic side effects disease recurrence toxicity efficacy|no statistical differences were observed in toxicity between the two strains of bcg, but local and systemic side effects were more frequent in the bcg groups versus the mitomycin group. the result was in favour of bcg, as shown by the measurements with complete response (cr), disease-free interval and recurrence rate.|patients with pta-pt1 papillary carcinoma and carcinoma in situ of the urinary bladder patients with papillary tumors superficial bladder cancer 437 evaluable patients, 50 had cis, 254 had pta tumors, and 133 had pt1 tumors dutch south east cooperative urological group 469 patients with pta/pt1 carcinoma and cis of the urinary bladder after tur 91 patients with frequently recurrent superficial (ta-t1) bladder cancer
health status rating scale utilities pain, medicine use, activity, and depression arthritis self-efficacy scale (ases-s chronic pain fibromyalgia impact questionnaire helplessness and passive coping pain reductions quality of life depression, self-reported pain behaviors, observed pain behaviors, and myalgia scores pain control work stability helplessness, number of days feeling bad, physical dysfunction, and pain in the tender points quality of life and self-efficacy exercise level since patient made drawing of pain distribution, dolorimetry of tender points, ergometer cycle test, global subjective improvement, and vas registrations of: pain, disturbed sleep, lack of energy, and depression ases-s knowledge about fm pain ratings self-efficacy fibromyalgia (fms) symptoms and increasing physical and psychological well being pain pain, depression, disability, pain behaviors, and intervening variables rating scale or standard gamble utilities pain coping health care costs total direct health care costs indirect costs|although improvement across time was found in depression, self-reported pain behaviors, observed pain behaviors, and myalgia scores, no differences in these criteria were found between the behavioral and education/control conditions. longterm followup of 67 treated subjects showed significant positive changes on the fibromyalgia impact questionnaire primarily in the physical training group. edi patients improved on pain coping (p = 0.005) and pain control (p = 0.002). the results concerning return to work and re-sick-listing during a follow-up period of five years were evaluated for swedes and immigrants separately. applied relaxation plus the operant programme was significantly better than relaxation for medicine reduction, and applied relaxation was better than relaxation and operant conditioning for a patient evaluation of reaching treatment goals. ae was the overall most effective treatment, despite being subject to the most sceptical patient attitude prior to the study. however, no significant differences in either rating scale or standard gamble utilities were found between the eco and edi groups immediately after treatment, or at the 6 or 12 month followups. evidence of construct validity of the ases-s was revealed in the factor analysis which produced a three factor solution similar to previous results.|women with fibromyalgia ninetynine women with fibromyalgia (fs general population with 90 days of sick-leave due to non-specific musculoskeletal pain 131 patients with fibromyalgia people with fibromyalgia waiting patients chronic pain fibromyalgia ninety-nine women with fms patients with non-specific musculoskeletal pain patients with the fibromyalgia (fm) syndrome fibromyalgia, 60 patients patients with fibromyalgia (fm patients with fs 131 patients with fm chronic back/joint pain patients
child's runny nose, nasal congestion, cough, and sleep status sputum thickness cough counts, latency and total effort cough frequency nocturnal cough and sleep quality proportion of children considered "better" overall nocturnal symptom relief symptom scores for the cough frequency and severity during the day, sputum quantity or ease of expectoration drowsiness cough diurnal variation in cough frequency cough frequency and subjective scores of cough severity speed of action, and objective and subjective measures cough counts, intensity, latency and total effort expended sedative effects individual symptoms uri symptoms cough severity symptom improvement side effects sleep quality insomnia suppression of cough at night sputum quantity cough latency cspls, cough frequency or subjective symptom scores severity of cough, nasal obstruction, nasal discharge, and throat-clearing subjective methods and cough counts body temperature, cough, thoracic objectivity, respiratory function indices fever frequency of drowsiness sneezing and total symptom scores nasal congestion/runny nose/cough/pain relief scores 30-min intervals: cough bouts, cough components, cough effort, cough intensity, and cough latency nasal congestion, sneezing, postnasal drainage, and nasal discharge cough bouts, cough components, and cough effort satisfaction on sleep nocturnal cough and sleep difficulty associated with upper respiratory infections overall night-time relief mean cspl changes cough: cough sound-pressure levels (cspls frequency, severity, and bothersome nature of the nocturnal cough night-time symptom relief and sleep satisfaction assessments cough sound pressure level (cspl), cough frequency (cf) and subjective scores for cough severity rate of regression of thoracic symptomatology symptoms of upper respiratory tract infection nervousness quality of sleep thoracic objectivity cough frequency and the subjective severity of cough|diphenhydramine and dextromethorphan are not superior to placebo in providing nocturnal symptom relief for children with cough and sleep difficulty as a result of an upper respiratory infection. it is concluded that treatment with letosteine leads to a significant increase in the rate of regression of thoracic symptomatology and a faster, more substantial reduction in fever in children suffering from acute bronchitis. no statistically significant differences between the treatments were shown in the symptom scores for the cough frequency and severity during the day, sputum quantity or ease of expectoration. differences between groups for the following side effects were found: dry mouth (9% for the combination vs 2% for placebo), insomnia (6% vs 3%), and nervousness (4% vs 2%). evaluations by both subjects and physicians suggest that terfenadine at 120 mg given twice daily marginally improved sneezing and total symptom scores at day 4. there were no differences among the three study groups in the proportion of children considered "better" overall by the parent 48 hours after the initial assessment (drug, 67%; placebo, 71%; no treatment, 57%; p = 0.53). cough frequency and subjective scores of cough severity were significantly decreased during the 3-h laboratory phase but at no time point was there a significant difference between the codeine- and placebo-treated groups. antihistamine-decongestant therapy reduced postnasal drip and significantly decreased the severity of cough, nasal obstruction, nasal discharge, and throat-clearing during the first few days of the common cold. reproducible cough suppressant effects were demonstrated after a single 30 mg dose using objective measures of cough counts, latency and total effort. improvement in individual symptoms after 3 hours was obtained in 16-42% more subjects in group t than in group p, whereas the percentage of subjects in group t having good or very good relief the morning after dosing increased by 25-68% compared to subjects in group p. 14 subjects (5 in group t; 9 in group p) reported aes but none of these occurred with an incidence greater than 1%. the results showed similar trends in both treatment groups with statistically significant reductions (p < 0.05) in cough sound pressure level (cspl), cough frequency (cf) and subjective scores for cough severity within treatment groups but little difference between the treatment groups during the study period. it demonstrated significantly greater overall reductions in cough bouts, cough components, and cough effort, and an increase in cough latency for patients treated with dextromethorphan hydrobromide, 30 mg, vs those treated with placebo. there were no statistically significant differences in symptom improvement between the adc and the placebo group (runny nose, p = 0.48; nasal congestion, p = 0.94; cough, p = 0.66). on study day 1 a highly significant (p < 0.0001) decrease in all three measures of cough was found after treatment with both placebo and codeine yet there was no significant difference between the treatment groups. twenty-three of 26 (88 percent) patients receiving guaifenesin also reported reduction in sputum quantity compared to 15 of 24 (62.5 percent) receiving the vehicle (p = 0.07, fisher exact test).|patients with cough associated with acute upper respiratory tract infection acute cough young adults with acute respiratory disease coughing children and their parents patients with cough due to uncomplicated upper respiratory tract infection (urti children suffering from acute bronchitis forty-nine subjects cough associated with common cold young children with the common cold forty-three patients (30 females and 13 males), mean age 22.9 years (range 18-46 years), with acute dry or slightly productive cough and otherwise healthy were included in the study one hundred forty-two (142) subjects were treated with the children 6 months through 5 years of age with a uri of less than 7 days' duration cough associated with acute upper respiratory tract infection patients with productive cough due to chronic bronchopulmonary disease young children by randomly assigning 96 children eligible subjects had to have at least moderate nasal congestion and a runny nose, at least mild cough and at least mild pain with one or more of the following: sore throat, sore chest, headache or body pain/aches children with cough young adults with natural colds preschool children subjects with multiple common cold symptoms parents of 100 children with upper respiratory infections 26 patients with productive cough receiving acute febrile bronchitis in children paediatric patients suffering from acute febrile bronchitis volunteers with uncomplicated common colds seven hundred ten adult patients with cough due to uncomplicated urti who were otherwise healthy and who satisfied the inclusion/exclusion criteria for the meta-analysis rhinitis symptoms associated with the common cold 485 subjects who took the study product, 432 (224 in group t; 208 in group p) were evaluable for analysis 108 out-patients with cough associated with acute respiratory infection man one study was conducted in durban, south africa, and five studies were conducted in bombay, india 82 subjects (51 females and 31 males; mean age 23.5 years, range 18-46 years) with cough owing to acute urti were included in the study subjects with multiple cold symptoms forty children were recruited for the research: 20 were treated with
ulcerative colitis scoring system (ucss) symptoms score and induction of endoscopically confirmed remission powell-tuck index, ibdq score, and histological disease activity scoring median endoscopic index complete response moderate side effects rectal histological activity scores serious adverse events active left-sided ulcerative colitis reduction of the cai of 6 points or greater (response clinical remission rates clinical response seven serious adverse events efficacy and safety baseline characteristics and disease severity levels of c reactive protein rectal histological scores powell-tuck index, inflammatory bowel disease questionnaire (ibdq) score, and rectal histological activities powell-tuck index ibdq score efficacy and tolerability median prestudy clinical activity index (cai ibdq scores depression of the disease activity steroid reduction remission|the higher pegifn dose was associated with a significant decrease in levels of c reactive protein (p=0.003, day 0 v 85). rifn-beta-1a was safe but not significant, at the dosage and/or duration of treatment used, in steroid-refractory ulcerative colitis. most adverse reactions associated with ifn-beta-1a were influenza-like symptoms or injection site reactions, and were mild or moderate in severity. in the enema group, significant improvements were found in the powell-tuck index (p = 0.0009), whereas no significant improvements were detected in the ibdq scores (p = 0.055) or rectal histological scores (p = 0.052).|sixteen ulcerative colitis patients active ulcerative colitis patients receiving 5-aminosalicylates, steroids, and/or azathioprine in stable dosages were included steroid-refractory ulcerative colitis outpatients with active steroid-refractory ulcerative colitis patients with ulcerative colitis patients with active ulcerative colitis patients (n=18) with moderately active ulcerative colitis left-sided ulcerative colitis ulcerative colitis sixty patients with a clinical activity score (cai) of >6 17 patients are included in this report (10 patients in the ifn-beta-1a group and seven patients in the placebo group thirteen patients in the
tolerated and colonic transit time (ctt abdominal pain orocecal transit time total protein, albumin, iron, electrolytes, and vitamins b9 (folates), a and d (25ohd3 total incidence rate of adverse events seen frequency of bowel movements straining on defaecation (p<0.001), stool consistency (p<0.001) and percentage of hard stools week stool frequency side-effect laboratory tests and physical examinations frequent bowel movements encopresis frequency proportion of patients with a successful treatment response: >or=3 bowel movements (bm consistency of stools bristol score of stool consistency fecal incontinence serious adverse effects adverse events vomiting complained abdominal pain number of stools successful rectal disimpaction, defecation and fecal incontinence frequencies, occurrence of abdominal pain and watery stools, ctts (before and after disimpaction), and behavior scores faecal impaction total number of complete and incomplete defaecations per week, pain on defaecation, straining on defaecation, faecal incontinence, stool consistency, global assessment of treatment, adverse events and physical examination efficacy, safety, acceptance, and 1-year outcomes clinical efficacy clinical complete remission rate of constipation behavior scores abdominal pain and flatulence scores chronic functional constipation peg + e side effects effective clearance of abdominal and rectal lumps stool consistency bowel movement frequency, stool consistency, clinical complete remission rate of constipation and abdominal symptoms, and the safety of forlax and lactulose total colonic transit time incontinence frequency, stool consistency, presence of abdominal pain and flatulence, necessity for step-up medication, and dry weight of feces defecation frequency vomiting and meteorism successful disimpaction taking peg + e efficacy and safety constipation success rate median weekly frequency of bowel movement number of days on which normal stools number and frequency of the side-effects safe and well tolerated defecation and encopresis frequency/week and successful treatment abdominal faecal masses, presence and consistency of rectal mass, perineal soiling flatus clinical tolerance resolution of constipation, fecal incontinence, and abdominal pain peg regarding stool consistency, appetite, fecaloma and use of additional laxatives vomiting and flatulence pain on defaecation paediatric constipation and evaluate clinical efficacy/side effects mean number of complete defaecations stool consistency and frequency abdominal pain, straining, and pain at defecation abdominal pain and fecal incontinence compliance rates frequency of incontinence episodes, and resolution of abdominal pain tolerated fecal incontinence and watery stools stool consistency, frequency of bowel movements, fecal incontinence, abdominal pain, straining and acceptance of the drugs fecal incontinence frequency efficacy and acceptability bm encopresis frequency meaningfully|the mean number of complete defaecations per week was significantly higher for children on peg+e than on placebo (3.12 (sd 2.05) v 1.45 (sd 1.20), respectively; p<0.001). no difference was found between the groups after the treatment period concerning defecation frequency (p = 0.481) and fecal incontinence frequency (p = 0.084). a statistically significant increase of week stool frequency was found after treatment both with lactitol or lactulose (p < 0.001). there was a significant difference, in favour of lactulose, in the number of days on which normal stools were passed during the treatment weeks. at each follow-up visit, significant improvement was seen in both groups, with significant increases in the frequency of bowel movements, decreases in the frequency of incontinence episodes, and resolution of abdominal pain. peg 3350 significantly decreased the total colonic transit time compared to lactulose (47.6+/-2.7 vs 55.3+/-2.4 hours, mean +/- the total incidence rate of adverse events seen was higher in the lactulose group (83%) than in the peg + e group (64%). vitamin a values were above normal range in 56% and 41% of children at baseline versus 33% and 36% at day 84 in the peg and lactulose groups, respectively. there was a significant increase in bm (p < .001) and straining improvement (p < .05) with the different peg3350 doses. improvement in the number of stools per week was also significantly higher in the liquid paraffin group during the last 4 weeks of therapy (p < 0.05). however, success was significantly higher in the peg group (56%) compared with the lactulose group (29%). successful disimpaction was achieved with enemas (80%) and peg (68%; p = .28). however, they had some vomiting and were less compliant (p < 0.01) when compared to mineral oil patients. abdominal pain disappeared in 75% of patients in the forlax group but in only 57% in the lactulose group by week 2 of treatment (p < 0.05). all variables analyzed improved for both groups, with no statistically significant differences. compared with the baseline, defecation frequency/ week increased significantly and encopresis frequency meaningfully decreased in two groups during the period of the study.|147 children were eligible; 12 children wished not to participate fifty-one children affected by chronic idiopathic constipation (23 males, 28 females), ranging in age from 8 months to 16 years were enrolled in the study; 42 completed the trial childhood constipation childhood functional constipation pediatric patients seventeen children thirty-eight children children with constipation and fecal incontinence chronic constipation in children children over 8 years old 3.1 years) were enrolled constipation in children over 8 years old ninety-five patients were eligible, of whom 90 participated (male, n = 60; mean age: 7.5 children with functional constipation pediatric functional constipation 103 children (mean, 8.5 20 children one hundred patients (aged 6 months-15 years) with paediatric constipation children 47 children chronic idiopathic constipation in childhood 97 children completed the study faecal impaction in children 216 patients one hundred and sixty children of 2-12 years old with functional constipation 40 children with chronic functional constipation six uk paediatric departments constipation in childhood 216 children with constipation from 8-18 years old from 7 hospitals across china who were matched with a uniform entry criteria were enrolled in this study 96 ambulatory constipated children aged 6 months to 3 years, treated daily with 4-8 g peg or 3.33 g-6.66 g lactulose 51 children (29 girls, 22 boys) aged 24 months to 11 years with chronic constipation (lasting > or =3 months), defined as < or =2 complete bowel movements per week and one of the following: pain on defaecation on 25% of days; > or =25% of bowel movements with straining; > or =25% of bowel movements with hard/lumpy stools thirty-nine children chronic idiopathic constipation in children children aged 2 to 11 years with a clinical diagnosis of faecal impaction seventy-nine children with chronic constipation and fecal incontinence twenty-one children under 15-years' old with chronic constipation children (4-16 years) with functional constipation and rfi participated constipated children 37 children aged 2 to 16 years children with functional constipation in sari toba clinic during the period of 2008-2009 children with a history of functional constipation thirty-six patients over 2 years of age 91 patients (49 male) completed the study children with constipation 96 constipated children aged 6 months to 3 years confirms the long-term tolerance of peg 4000 in pediatrics and indicates a peg efficacy similar to or greater than that of lactulose chronic functional constipation in children
brief psychiatric rating scale (bprs), clinical global impression (cgi diastolic blood pressure (lying and standing bprs, cgi, or nosie items or factors or in the reduction of overall psychopathology clinical global impressions and brief psychiatric rating scales severity of illness on the cgi scale global severity of illness rating of mild or better demonstrable anti-psychotic activity behavioral, extrapyramidal, and sedative incidence and severity of side effects clinical efficacy bprs and cgi bprs scores side effects therapeutic efficacy and safety drowsiness and extrapyramidal signs median time to tranquilization nosie scale, "manifest psychosis discharge and termination rates adverse reactions anticholinergic effects, excitement, dizziness and faintness number and severity of adverse experiences bprs, cgi scale, nurses' observation scale for in-patient evaluation (nosie) or side-effect records dystonic reactions and akathisia improvement rating of moderate or marked|side-effects were similar with the two drugs but anticholinergic effects, excitement, dizziness and faintness occurred rather more commonly with loxapine. on several variables, positive trends were noted, but the differences from pl did not attain the critical values necessary for statistical significance at p smaller than 0.05. median time to tranquilization was significantly less with loxapine (60 minutes) than with thiothixene (95 minutes); during the oral phase, there were no significant differences between the two treatment groups. the discharge and termination rates of the two groups were not significantly different and the incidence and severity of side effects, most frequently extrapyramidal signs, were similar in both groups. intramuscular loxapine was at least as effective as haloperidol in the initial management of hostile and aggressive schizophrenic patients. both lox and tfp displayed essentially the same profile and incidence of side effects. the authors compared loxapine with chlorpromazine in inpatients with paranoid schizophrenia and found no difference in clinical efficacy. the principal side effects were drowsiness and extrapyramidal signs. adverse reactions were also less troublesome with loxapine. there were no significant treatment differences in bprs, cgi, or nosie items or factors or in the reduction of overall psychopathology. after 3-weeks' treatment, no significant differences were found between the two treatment groups according to the brief psychiatric rating scale (bprs), clinical global impression (cgi)|22 patients were included in diagnostic group i (cases of acute schizophrenia and psychogenic (reactive) psychoses 57 acute and chronic schizophrenic patients 54 acutely psychotic schizophrenics 49 chronic schizophrenic inpatients twenty-five patients were included in diagnostic group ii (cases of chronic schizophrenia psychotic patients hostile and aggressive schizophrenic patients acutely disturbed, psychotic patients paranoid schizophrenia newly admitted chronic schizophrenic patients 50 hospitalized chronic schizophrenic patients newly admitted schizophrenic patients inpatients with paranoid schizophrenia hostile and aggressive acutely schizophrenic patients 47 psychotic patients chronic schizophrenic inpatients using 50 mg chronic schizophrenia acute and chronic schizophrenic patients chronic schizophrenic patients newly admitted paranoid schizophrenic patients (n = 68
mean plasma total cholesterol hdl-cholesterol, and positive instrumental changes maximal walking time mild adverse events ankle/arm pressure ratio quality of life domains walking distance ankle-brachial index red cell deformability walking performance, ankle-brachial indexes, and questionnaire scores changes in icd and acd serious vascular aes change in treadmill exercise time and patient-reported measures of physical activity and quality of life based on questionnaires vascular events total high-density lipoprotein cholesterol density lipoprotein-cholesterol (hdl-c) levels walking performance and symptoms of intermittent claudication incidence of coronary heart disease and stroke 6 adverse events (ae fibrinogen levels arterial edge roughness or amount of aorto-femoral atherosclerosis adverse events (ae progression of atherosclerosis frequency of patients reporting improvement of lower limb symptoms fibrinogen claudication symptoms ankle/arm pressure index pain-free walking distance walking performance, ankle-brachial pressure indexes, and symptoms of claudication efficacy and tolerability total cholesterol (tc) and low-density lipoprotein-cholesterol (ldl-c tolerated total walking distance maximum walking distance beneficial effects on non-fatal events severity of intermittent claudication plaque area walking ability of peripheral arterial obstructive disease edge irregularity index absolute claudication distance (acd 2 quality of life instruments, the walking impairment questionnaire nonfatal myocardial infarction lumen volume exercise tests or ankle/arm blood pressure walking performance walking distances blood pressure, blood lipids, and platelet responsiveness absolute claudication distance rest flow values--and consequently also winsor's index density lipoprotein2 cholesterol levels coronary heart disease and of stroke initial claudication distance blood triglycerides and fibrinogen mean pain-free walking distance reduction of lower limb symptoms plasma fibrinogen pain-free walking time initial claudication distance (icd low-density lipoprotein cholesterol ldl-c claudication distance values pain-free walking distance and community-based physical activity mean low density lipoprotein (ldl) cholesterol ambulatory ability viscosity mean plasma triglycerides pain-free and total walking distance, resting and postexercise ankle-brachial indexes, and questionnaire scores cardiovascular events total of 10 serious adverse events blood pressure, red cell deformability, fibrinogen, and lipid levels serum cholesterol change in atheroma volume estimated as change in lumen volume of the femoral artery assessed by quantitative arteriography roughness of the femoral artery walking distances and pressure indices mean arterial blood pressure plasma ldl cholesterol concentration blood lipids femoral atherosclerosis doubling of the pain-free walking distance blood viscosity|compared with the fifteen control patients (treated with placebo), the fifteen patients treated with sulodexide showed a significant decrease in blood triglycerides and fibrinogen as well as a significantly increased hdl-cholesterol, and positive instrumental changes: at the end of treatment peak and rest flow values--and consequently also winsor's index--were significantly increased only in patients treated with sulodexide. sulodexide improved the walking ability of peripheral arterial obstructive disease patients to a significantly greater extent than placebo, with a concurrent significant decrease in fibrinogen. high-dose short-term therapy with simvastatin may improve walking performance, ankle-brachial pressure indexes, and symptoms of claudication in hypercholesterolemic patients with peripheral vascular disease. no significant changes in walking distances and pressure indices during rest and after exercise occurred, despite a significant increase in red cell deformability in the fish oil group. the mean increase in plaque area (mm2/segment/year) in the treatment group was only one third of that in the usual-care group. in the control group, lumen volume increased (p < 0.001) and roughness of the femoral artery decreased (p < 0.05).(abstract truncated at 250 words) policosanol increased significantly (p < 0.01) the initial claudication distance from 132.5+/-13.5 m (baseline) to 205.7+/-36.3 m (after therapy) and the absolute claudication distance (p<0.0001) from 229.5+/-22.0 m to 365.4+/-46.9 m; meanwhile both variables remained unchanged in the placebo group (p<0.05). there were 150 and 160 events in the active and placebo groups respectively (relative risk 0.96, 95% confidence interval 0.76 to 1.21). policosanol significantly (p < 0.001) lowered total cholesterol (tc) and low-density lipoprotein-cholesterol (ldl-c) by 17.5% and 31.0%, respectively, and meanwhile increased (p < 0.01) high-density lipoprotein-cholesterol (hdl-c) levels by 31.5%. a physical activity questionnaire demonstrated improvement in ambulatory ability for the 10- and 80-mg groups (p=0.011), whereas 2 quality of life instruments, the walking impairment questionnaire and short form 36 questionnaire, did not show significant change. after 6 months of therapy, policosanol significantly increased (p < 0.01) the initial claudication distance from 125.9 +/-|three hundred three patients with visible atherosclerosis men with lower extremity arterial disease 1568 men, mean age 68.2 years (range 35 to 92) at recruitment hypercholesterolemic patients with peripheral vascular disease patients with stable claudication 85 general practices and nine hospital vascular clinics hyperlipidaemic patients with stable intermittent claudication intermittent claudication patients with intermittent claudication older men patients with type ii diabetes patients with peripheral arterial obstructive disease require treatment to prevent major cardiovascular events and to relieve intermittent claudication thirty patients suffering from peripheral vascular disease (stage-ii according to fontaine twenty-eight patients who met study entry criteria 286 patients with leriche-fontaine stage ii peripheral arterial obstructive disease patients with moderately severe intermittent claudication fifty-six patients who met study entry criteria seventeen percent had intermittent claudication and 24% had angina pectoris patients with claudication patients with peripheral arterial disease patients with atherosclerosis, including those with peripheral arterial disease 354 persons with claudication attributable to peripheral arterial disease 62 patients eighty-six patients with peripheral arterial disease (fontaine stage ii), intermittent claudication, and total cholesterol levels twenty-nine patients were excluded because of inadequate primary end point measurements 785 men 32 patients with stable claudication 24 patients hypercholesterolemic persons with probucol for 3 years affected femoral atherosclerosis peripheral arterial obstructive disease patients the mean age of the remaining 274 subjects (158 were men) was 55 years
median time to detection of resistance m. tuberculosis xpert mtb/rif assay rifampicin resistance m. tuberculosis viability overall, xpert mtb/rif hiv prevalence median time to detection of tuberculosis rapid tb case detection rate mtb/rif test sensitivity rmp resistance sensitivity of the xpert mtb/rif test rapid diagnosis of tuberculosis and detection of rifampin (rif) resistance mycobacteria or mycobacterial dna indeterminate rate of mtb/rif testing overall specificity total equivocal results is6110 ldt sensitivities unlike microscopy, mtb/rif test sensitivity overall sensitivity of the xpert mtb/rif assay for culture-positive tb mtbdr, xpert, and liquid culture rifampin resistance bactec 460tb 12b (bd diagnostic, usa), lwenstein-jensen (lj) culture and direct microscopy of smears stained with ziehl mtb/rif test sensitivity for rifampicin resistance sensitivity, specificity, positive and negative predictive values of xpert mtb/rif test immediate identification of rifampicin (rif) resistance limit of detection (lod overall sensitivity and specificity direct fluorescence microscopy, genotype mtbdrplus assay (mtbdr), xpert mtb/rif assay (xpert), and liquid mycobacterial culture sensitivity of the mtb/rif ruo assay sensitivity for smear-negative, culture-positive tb negative predictive value reduced sensitivity smear status and culture time-to-positivity sensitivity and specificity of pcr mycobacterium tuberculosis specificity for detecting m. tuberculosis sensitivity and specificity of mtbdr for detection of isoniazid resistance specificity sensitivity, specificity, and positive and negative predictive values|the genexpert mtb/rif assay is a novel integrated diagnostic device for the diagnosis of tuberculosis and rapid detection of rif resistance in clinical specimens. in patients infected with hiv compared with patients uninfected with hiv xpert mtb/rif showed a trend to reduced sensitivity (p=0.09) and significantly reduced negative predictive value (p=0.01). median time to detection of tuberculosis for the mtb/rif test was 0 days (iqr 0-1), compared with 1 day (0-1) for microscopy, 30 days (23-43) for solid culture, and 16 days (13-21) for liquid culture. the genexpert assay was highly effective for tuberculosis diagnosis and identification of rifampin-resistant strains in smear-negative samples. based on culture as the gold standard, the overall sensitivity and specificity for all sample types for the xpert mtb/rif assay were 90.9 and 89%, respectively, while for the mtd assay, the overall sensitivity and specificity were 97.3 and 87.1%, respectively. high consistency was detected between the results of bactec 460tb and xpert mtb/rif when bactec 460tb was considered as the gold standard method (r= 0.943; p= 0.000). global control of tuberculosis is hampered by slow, insensitive diagnostic methods, particularly for the detection of drug-resistant forms and in patients with human immunodeficiency virus infection. m. tuberculosis was not detected in 25/25 (100%) of the culture-negative samples. the xpert mtb/rif test has superior performance for rapid diagnosis of mycobacterium tuberculosis over existing afb smear microscopy and other molecular methodologies in an hiv- and tb-endemic region. both molecular assays are suitable for the detection of m. tuberculosis isolates in smear-positive pulmonary and extrapulmonary specimens, while the sensitivity of the detection of m. tuberculosis isolates in smear-negative specimens was variable. the sensitivity and specificity of pcr were respectively 100% and 100%, and 85.7% and 97.3% for respiratory and non-respiratory samples. the test was negative in 20 culture-negative and 20 nontuberculous culture-positive samples (100% specificity). sensitivity and specificity of mtbdr for detection of isoniazid resistance were 83.3% and 100%, respectively. overall agreement compared to culture was 89% (98% for smear positives and 72% for smear negatives) for detection of mycobacterium tuberculosis. the accuracy of the xpert mtb/rif assay for diagnosing tb and drug resistance was assessed in comparison with other tests, including fluorescence smear microscopy and automated liquid culture (gold standard) and drug susceptibility testing. the specificity for detecting m. tuberculosis was 92.0% (23/25) and for rmp resistance it was 100% (8/8). xpert mtb/rif assay achieved 88.4% (95%ci = 78.4% to 94.9%) sensitivity among patients with a positive culture and 99% (95%ci = 94.7% to 100.0%) specificity in patients who had no tb.|one hundred ten (89 culture positive and 21 culture negative for m. tuberculosis) of the 429 patients were considered to have tuberculosis hiv-infected patients with advanced immunodeficiency enrolling in antiretroviral therapy (art) services 132 patients suspected of tuberculosis (tb 496 south african patients with suspected tb patients with active tb respiratory specimens sixty-four of 85 (75.3%) smear-negative respiratory (n = 78) and nonrespiratory (n = 7) samples with positive cultures of mycobacterium tuberculosis complex (mtc 604 of 609 patients without tuberculosis (99.2 consecutive adult hiv-infected patients with no current tb diagnosis enrolling in an art clinic in a south african township were recruited regardless of symptoms eligible patients in peru, azerbaijan, south africa, and india provided three sputum specimens each 292 consecutively enrolled adults from mbeya, tanzania, with suspected tb were subject to analysis by the xpert mtb/rif assay 172 hiv-infected patients (58.9% of all participants 319 patients without tuberculosis studied consecutive adults with suspected tb attending a primary health care clinic in johannesburg, south africa, were prospectively enrolled and evaluated for tb according to the guidelines of the national tb control programme, including assessment for smear-negative tb by chest x-ray, clinical evaluation, and hiv testing 140 consecutive pulmonary tuberculosis patients 107 clinical sputum samples from suspected tuberculosis cases in vietnam detected 29/29 (100%) smear-positive culture-positive cases and 33/39 (84.6%) or 38/53 (71.7%) smear-negative culture-positive cases, as determined by growth on solid medium or on both solid and liquid media, respectively 112 specimens from 90 patients, including 89 pulmonary specimens and 23 extrapulmonary specimens 1730 patients with suspected drug-sensitive or multidrug-resistant pulmonary tuberculosis we enrolled 6648 participants between aug 11, 2009, and june 26, 2010 patients infected with hiv, especially those with advanced immunosuppression, warrants further study patients with substantial clinical indications of tuberculosis and smear-negative microscopy results a total of 85 clinical specimens (50 sputum, 25 bronchoalveolar lavage, five thorasynthesis fluid and five urine samples) obtained from tuberculosis-suspected patients were included to the study patients with human immunodeficiency virus infection 515 patients enrolled, 468 patients (median cd4 cell count, 171 cells/l; interquartile range, 102-236) produced at least one sputum sample, yielding complete sets of results from 839 samples adults (18 years) with suspected tuberculosis or multidrug-resistant tuberculosis consecutively presenting with cough lasting at least 2 weeks to urban health centres in south africa, peru, and india, drug-resistance screening facilities in azerbaijan and the philippines, and an emergency room in uganda pulmonary and extrapulmonary specimens 217 specimens submitted for routine smear and culture from three different sites within the western united states were used to evaluate the genexpert mtb/rif assay (for research use only two hundred fifty-three pulmonary and 176 extrapulmonary specimens obtained from 429 patients were included in the study 64 smear-positive culture-positive sputa from retreatment tuberculosis cases in uganda detected 63/64 (98.4%) culture-positive cases and 9/9 (100%) cases of rifampin resistance
relative tachycardia relief of pulsus paradoxus pulse rate of 8 beats per minute and 2 beats per minute severe acute asthma mean pao2 oxygen to maintain oxygen saturation simple clinical score, the heart and respiratory rates, the peak expiratory flow (pef) and the blood gases mean increase in pef beta agonist-induced hypokalemia oxygen tension mean proportionate increase in fev peak expiratory flow rate systemic side-effects blood gas pressures pulse rate and blood pressure recovery time (no longer requiring inhaled salbutamol) and persistent moderate to severe asthma peak expiratory flow rate of recovery pa(co2) values pao2 cardiovascular side effects pef recovery time side effects, i.e. tachycardia, blood pressure changes and tremor heart rate plasma theophylline concentration production of side-effects|hydrocortisone was given after 2 hours, but did not appear to affect the rate of recovery. there was no difference in the production of side-effects. salbutamol given intravenously produced a mean increase in heart rate of over 20 beats/min five minutes after treatment compared with the relief of tachycardia that occurred after administration by ippb. age, severity and maintenance therapy of asthma, and severity of the acute episode, were not significantly different in both groups. differences in results did not reach conventional levels of significance and no serious side effects were noted. 66 l/min, p = 0.01) as well as the decrease in pa(co2) values (-10 the intravenous salbutamol group were ready for discharge from the emergency department 9.7 h earlier than the control group. there was a significantly larger increase in peak expiratory flow after the first inhaled dose in the group that received inhalation treatment than in the i.v. pao2 initially was 7.55 kpa in the intravenous group and rose by 1.4 after 60 minutes (p less than .02) and by 1.33 after 120 minutes (p less than .01).|severe acute asthma 22 episodes of life-threatening asthma in 19 patients to compare severe asthma attacks in childhood 10 children (control-group) received life-threatening asthma 47 patients admitted to hospital with severe acute asthma defined as a peak expiratory flow (pef) below 150 l/min and hypercapnia (pa(co2) > or = 40 mm hg children who did not improve were eligible to enter phase one of the study severe, acute asthma in childhood 23 patients with acute exacerbations of asthma 176 adult patients (53% men) with severe acute asthma (peak expiratory flow (pef), 15-50% of predicted values acute severe asthma acute asthma in children children with acute severe asthma patients with acute severe asthma acute severe asthma in children children who presented to the emergency department of westmead hospital, sydney, australia with asthma were assessed with a clinical assessment scale, and those with severe acute asthma 20 children (age range 0.8-14.7 years) with acute severe asthma acute asthma 10 children (reproterol-group) received acutely sick child with asthma twenty-three patients with acute severe asthma hypercapnic acute asthma
rate of serious adverse cardiac events change in hrsd (for depression) or essi scores (for lpss rapid rate of recovery il-6 postoperative infectious illnesses patient's emotional and functional outcomes mean ham-d difference favoring clinical management left ventricular ejection fraction (lvef); secondary measures included surrogate cardiac measures and cardiovascular adverse events, as well as scores on the ham-d scale and clinical global impression improvement scale (cgi-i depression and social isolation 12-week ham-d scores depressive symptoms hostility depression symptoms safety of fluoxetine, cardiac function efficacy, cardiovascular effects, and safety safety and efficacy baseline 24-item hamilton depression rating scale (ham-d) scores of 20 or higher adverse cardiac events heart rate or rhythm or indexes of heart rate variability depression, anxiety, hopelessness, stress, and quality of life blood pressure or conduction intervals 17-item hamilton rating scale for depression (hrsd); lpss mean (sd) change in essi score rate of recovery of sdnn qtc interval beck depression inventory, (2) natural killer cell cytotoxicity (nkcc) measured by 51cr-release assay, (3) infectious illness episodes measured by the modified health review, (4) interleukin (il)-6 and c reactive protein (crp heart rate variability mean (sd) lvef infection, depression, and immunity 17-item hamilton depression rating scale (hamd-17) and the hostility scale of the 90-item symptom check list (scl-90 death or recurrent mi ham-d score of at least 18 and history of 2 or more prior episodes of mdd ventricular premature complex (vpc remission of depression beck depression inventory scores survival hamd-17 scores efficacy and safety 24-item ham-d, administered blindly during centralized telephone interviews hostility scores hospital fevers and infectious illness depression and hostility bdi-ii scores response rate severe cardiovascular adverse events sd of 24-hour n-n intervals (sdnn mean ham-d response depression antidepressive efficacy remission rates increase event-free survival cardiovascular safety, heart rate and rhythm, supine and standing systolic and diastolic blood pressures, electrocardiogram conduction intervals, indexes of heart rate variability, and rate of adverse events event-free survival recovery rate of cardiac autonomic function hads and the workplace social adjustment scale (wsas cgi-i and ham-d measures psychosocial outcomes hamilton rating scale for depression emotional distress antidepressant efficacy major depressive disorder (mdd mean (sd) change in hrsd score self-reported beck depression inventory ii (bdi-ii) score hospital and anxiety depression scale (hads covariate-adjusted hamilton scores cgi-i responder rates for sertraline heart rate cardiac function depressive symptoms, inflammatory biomarkers, and post-cabg infections 17-item hamilton rating scale for depression depressive symptomatology on the 17-item hamilton-depression rating scale (ham-d), and secondary outcomes the beck depression inventory (bdi) and depression subscale of the symptom check list 90 items (dscl-90) as well as the clinical global impression (cgi) scale mortality and recurrent infarction rate of recovery of hrv ham-d, bdi, and cgi bdi, dscl-90, and cgi scale|using mixed models analysis over the entire 24 weeks of treatment (n = 40), we did find a significant difference favoring mirtazapine to placebo on the ham-d, bdi, and cgi, but on the dscl-90, this difference was not significant. there was a linear rate of increase in the sd of 24-hour n-n intervals (sdnn) in the sertraline-treated group that paralleled that of the nondepressed reference group. specifically, only modest but statistically significant improvement was observed in the alprazolam-treated groups at 1-month follow-up; however, alprazolam-treated patients were significantly more likely to experience a very rapid anxiolytic effect by postoperative day 8. also, hostility scores at week 25 were significantly reduced among patients receiving fluoxetine (p = .02). cognitive behavior therapy was superior to usual care at most points on secondary measures of depression, anxiety, hopelessness, stress, and quality of life. findings confirmed that the intervention group had a 27% improvement in depression symptoms (p=.05), 27% in anxiety (p=.02), and a 38% improvement in home limitations (p=.04) compared with controls. in the latter 2 groups, both cgi-i and ham-d measures were significantly better in those assigned to sertraline. clinically depressed post-cabg women exhibited decreased nkcc and a higher incidence of in-hospital fevers and infectious illness in the first 6 months after cabg. paroxetine had no sustained effects on heart rate or rhythm or indexes of heart rate variability, whereas patients treated with nortriptyline had a sustained 11% increase in heart rate from a mean of 75 to 83 beats per minute (p<.001) and a reduction in heart rate variability, as measured by the sd of all normal r-r intervals over a 24-hour period, from 112 to 96 (p<.01). there were also no differences in survival between the psychosocial intervention and usual care arms in any of the 3 psychosocial risk groups (depression, lpss, and depression and lpss patients). mean ham-d response (52.8% vs 40.1%; p = .03) and remission rates (35.9% vs 22.5%; p = .01) and the reduction in bdi-ii scores (difference, 3.6 points; 98.3% ci, 0.58-6.64; p = .005; effect size = 0.33) also favored citalopram.|60 patients undergoing coronary bypass surgery 284 patients with cad from 9 canadian academic centers coronary heart disease patients (enrichd postcoronary bypass anxiety and depression patients with depression after their first mi twenty-seven patients completed the randomization outpatient research clinic at washington university school of medicine, st louis, missouri fifteen clinically depressed women in the first month after cabg, along with a comparison group of 37 non-depressed postcabg women patients hospitalized for acute myocardial infarction (mi) or unstable angina and free of other life-threatening medical conditions mean age was 60; 67% of the patients were male fifty-four patients with major depression after mi we enrolled 100 patients inclusion criteria were: < or = 75 years old, english-speaking, undergoing first-time cabg, available for 6 months offollow-up, and without malignancy or autoimmune disorders depressed patients with ischemic heart disease ninety-one patients who met the diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv) criteria for major or minor depressive disorder patients with heart disease need a safe and effective treatment for depression patients with depression patients with coronary artery disease (cad two urban tertiary care centers postoperative patient populations thirty-eight post-mi depressed patients 369 patients with mdd (64% male; mean age, 57.1 years; mean 17-item hamilton depression [ham-d] score, 19.6; mi, 74%; unstable angina, 26 women after coronary artery bypass patients with cardiovascular disease patients with unstable ischemic heart disease patients with acute mi or unstable angina 2177 patients with mi were evaluated for depressive disorder during the first year post mi patients with major depression after first myocardial infarction patients with cad and found no evidence of added value of ipt over clinical management eleven stable post-mi nondepressed patients patients with recent mi or unstable angina and without other life-threatening medical conditions patients with coronary artery disease all patients met diagnostic and statistical manual of mental disorders, fourth edition criteria for diagnosis of major depression of 4 weeks' duration or longer and had depressed post-cabg women 40 outpatient cardiology centers and psychiatry clinics in the united states, europe, canada, and australia post-myocardial infarction depressive disorder 4 university centers eighty-one outpatients meeting diagnostic and statistical manual of mental disorders, fourth edition criteria for major depressive disorder and with documented ischemic heart disease one hundred twenty-three patients who met the dsm-iv criteria for major or minor depression within 1 year after surgery patients enrolled within 28 days after mi.design, setting, and randomized clinical trial conducted from october 1996 to april 2001 in 2481 mi patients (1084 women, 1397 men) enrolled from 8 clinical centers depressed patients after acute myocardial infarction patients with cad and major depression cardiac patients patients with post-myocardial infarction (mi) depressive disorder
positive expression rate of cd62p in platelet and content of tumor necrosis factor-alpha (tnf-alpha) and interleukin-6 (il-6 platelet level of cd62p and serum content of tnf-alpha and il-6 levels of platelet cd62p and serum tnf-alpha and il-6 positive expression of platelet cd62p and the serum tnf-alpha and il-6 total curative effect|the total curative effect in the treated group were significantly higher than that in the control group (p < 0.05).|sixty-eight patients with aci aci patients patients with acute cerebral infarction patients with acute cerebral infarction (aci
infection rate incidence of shunt infection or malfunction craniotomy infections overall rate of shunt infection postoperative wound sepsis wound sepsis classical infection parameters hypotension time of development of cerebrospinal fluid infection rates of infection leucocytosis and temperature infection rates efficacy csf infection incidence of shunt malfunction risk of shunt malfunction local infection average time to infection adverse reactions cerebrospinal fluid infections risk of catheter-related infections postoperative shunt infection ventricular catheter incidence of infections occurring postoperative ventriculoperitoneal shunt infections positive csf cultures thirteen shunt infections infection rate with antibiotics infection or overall malfunction rate postoperative infection|fifty children of up to 14 years of age suffering from hydrocephalus of various etiologies were treated prophylactically and compared with a similar untreated group. in the high risk subgroup infection rate was 14.3% with and 26.3% without cefotiam as opposed to 4.3% and 6.9%, respectively, in the normal risk subgroup. the rates of infection in areas of the body other than the surgical wound were no different in the antibiotic-treated and nontreated groups. staphylococcus species accounted for the majority of shunt infections (83%): all 10 control shunts were found to have a positive culture of staphylococci, whereas none of the aiss had any staphylococci (p = 0.038). no case of local infection was observed in either group, and the percentage of patients with remote infections was the same in both groups. the antibiotic protected against early infections (nine of the 60 patients in group 2 against none of the patients in group 1), but not against late infections (four of the 62 in group 1 compared with five of the 60 in group 2). six patients in the control group developed cerebrospinal fluid infections (20%) as compared with only a single patient in the oxacillin group (3.3%); this difference was statistically significant (p less than 0.05). the risk of shunt malfunction in the 2nd to 6th month after surgery was significantly greater in the placebo group (7 of 26 patients) than in the methicillin-treated group (1 of 26 patients). positive csf cultures were seven times less frequent in patients with antibiotic-impregnated catheters compared with those in the control group (1.3 compared with 9.4%, respectively, p = 0.002). postoperative infection developed in 6% of the treatment group, compared with 10% of the placebo group, a difference that was not statistically significant, although a clinical significance may have been masked by the small sample size. among the patients receiving antibiotics there was an infection rate of 12%, versus 19% among patients receiving placebo. we did not find that the perioperative use of sulfamethoxazole and trimethoprim reduced the incidence of shunt infection or malfunction. twelve of the 205 patients treated with placebo developed postoperative wound sepsis, and four of the 192 piperacillin-treated patients developed wound sepsis--a statistically significant difference (p less than 0.05, fisher's exact test). in the 35 cases that could be evaluated, shunt-associated infections developed in three (17%) of 18 patients who received vancomycin and in four (23%) of the 17 placebo recipients.|cerebrospinal fluid shunt procedures sixty-three children who presented for elective vp shunt insertion between january 1982 and december 1985 and who did not have a history of shunt infections elective neurosurgery cerebrospinal fluid shunting twenty cases were excluded from analysis because either an unforeseen second operation was performed or clean neurosurgical operations one hundred ten patients were recruited; 60 received fifty children of up to 14 years of age suffering from hydrocephalus of various etiologies ventriculoperitoneal shunt surgery between 1980 and 1983, 122 patients undergoing shunting procedures 120 patients who completed the study according to protocol, 55 received after ventriculoperitoneal shunt surgery 288 patients, 139 were assigned to the control group and 149 to the treatment group 129 patients undergoing cerebrospinal fluid shunting hydrocephalus 52 patients undergoing ventriculostomy only 37 children undergoing csf shunt procedures in two different countries 306 patients enrolled in the study, data from 288 were included in the final analysis cerebrospinal fluid shunt surgery children with hydrocephalus 60 hydrocephalic patients being shunted for the first time 417 patients undergoing "clean" elective neurosurgical operative procedures ventriculostomy or shunting operations 129 patients six academic medical centers sick children from march 1984 to october 1987, in which 243 patients undergoing 300 cerebrospinal fluid (csf) shunting procedures 74 children sixteen patients, none of whom developed infections, were excluded from final statistical analysis because they had inadvertently been entered into the study while failing to meet entry criteria 846 patients treated between october, 1979, and june, 1984 all hospitalized patients 18 years or older who required placement of an evd catheter were eligible for inclusion in the study eighteen patients were excluded from analysis: 14 because the neurosurgery hydrocephalic patients 60 hydrocephalic patients
low 5-minute apgar scores fetal distress fetal blood sampling rate incidence of fbs rate of neonatal acidemia incidence of metabolic acidosis number of operative deliveries, low apgar scores, neonatal admissions, and newborns with hypoxic-ischemic encephalopathy fetal blood sampling (fbs rate of umbilical-artery metabolic acidosis operative delivery for fetal distress caesarean section rate rates of umbilical-artery metabolic acidosis neonatal outcome operative deliveries for "fetal distress apgar score, neonatal admissions, hypoxic-ischemic encephalopathy, or operative deliveries metabolic acidosis vo rate metabolic acidosis in blood, operative deliveries, apgar scores, neonatal admissions, and hypoxic-ischemic encephalopathy metabolic acidosis, defined as an umbilical cord artery ph neonatal acidemia (umbilical artery ph <7.10), neonatal metabolic acidosis (umbilical artery ph <7.05 and base excess <-12 mmol/l) and operative interventions: caesarean section rate, vacuum outlet (vo) rate and fbs rate proportion of babies who had an umbilical arterial ph rates of operative intervention, and neonatal outcome neonatal acidemia frequency of unsuspected acidaemia|intrapartum fetal monitoring by means of automatic stan did not improve the neonatal outcome or decrease the caesarean section rate. there was a 46% reduction (p < 0.001, odds ratio 1.85 [1.35-2.66]) in operative deliveries for "fetal distress" and a trend to less metabolic acidosis (p = 0.09, odds ratio 0.38 [0.13-1.07]) and fewer low 5-minute apgar scores (p = 0.12, odds ratio 0.62 [0.35-1.08]) in the st waveform plus cardiotocogram arm. the number of operative deliveries, low apgar scores, neonatal admissions, and newborns with hypoxic-ischemic encephalopathy was comparable in both groups. the ctg+st group showed significantly lower rates of umbilical-artery metabolic acidosis than the cardiotocography group (15 of 2159 [0.7%] vs 31 of 2079 [2%], relative risk 0.47 [95% ci 0.25-0.86], p=0.02) and of operative delivery for fetal distress (193 of 2519 [8%] vs 227 of 2447 [9%], 0.83 there was a trend towards fewer operative interventions for presumed fetal distress in the time-interval analysis plus cardiotocography group (63 [13%] vs 78 [16%]), but this was not significant (relative risk 0.80 [95% ci 0.59-1.08], p=0.17).|515 women intrapartum fetal monitoring laboring women with a high-risk singleton pregnancy in cephalic presentation beyond 36 weeks of gestation labour ward in tertiary-level university hospital five hospitals in the uk, hong kong, the netherlands, and singapore 2400 cases 1038 women undergoing high-risk labours 2434 high-risk labors in a district general hospital in plymouth, england 1483 women in active labour with singleton term fetus in cephalic presentation 5,681 women to the two groups (2,832 index, 2,849 control 4966 women with term fetuses in the cephalic presentation entered the trial during labour after a clinical decision had been made to apply a fetal scalp electrode for internal cardiotocography
duration of the acute phase of hepatitis severe hepatic lesions with lower histological activity serum alt levels serum hcv-rna measured by reverse transcription-polymerase chain reaction raised serum aminotransferase concentrations normal serum aminotransferase severe side effects of interferon-alpha normal alt levels aminotransferase flare-ups rate of chronic evolution of acute hepatitis c biochemical, histological and serological parameters normal alt and no hcv rna normal serum alt activity chronicity rate recurrence serum hcv-rna serum hepatitis c virus rna serum alanine aminotransferase persistent undetectable serum hcv-rna persistent liver damage normal alt levels and no hcv rna biochemical and virological parameters|4 patients in the treatment group who continued to have raised serum aminotransferase concentrations after a year's follow-up were given a second course of interferon. anti-hepatitis c virus seroconversion occurred later and at a lower rate in the group of patients who received interferon-alpha. two (13%) patients in the control group had persistent undetectable serum hcv-rna (p = 0.08). beta interferon at the suggested regimen is well tolerated but does not seem to significantly influence the natural course of acute hepatitis c. the effect of ifn therapy was 93.8% in the treated group and only 12.5% in the control group (p < 0.005). thirty-nine percent had normal alt and no hcv rna, compared with none of the controls (p = 0.035).|21 cases and was positive in 19 cases at baseline and in 15/17 chronic and 1/4 non chronic cases at the end of follow-up patients with acute post-transfusion hepatitis c 25 patients; 11 were treated for an average of 30 days with a mean of 52 megaunits of interferon and 14 acted as controls acute posttransfusion hepatitis c 33 acute post-transfusion hepatitis c patients; 16 patients received twenty-six patients (22 with hcv thirty-eight patients had hepatitis c virus infection, and 7 had non-a, non-b, non-c hepatitis patients with acute hepatitis c 28 patients with acute posttransfusion hepatitis patients with acute transfusion-associated hepatitis c 45 consecutive patients with transfusion-associated hepatitis patients with acute hcv infection northern italy in 1991 sixteen patients with acute hepatitis c having a duration of illness more than three months without recovery chinese patients with acute post-transfusion hepatitis c forty acute hepatitis c patients acute type-c hepatitis patients
episiotomy pain pain intensity difference (spid stronger analgesia relative efficacy, safety, and time course of analgesia drowsiness highest mean rating for summed pain intensity differences dizziness and drowsiness highest summed analgesic ratings pain intensity, pain relief, and side effects uterine cramp and episiotomy pain analgesic response side effects aspirin analgesia pain intensity, pain relief and side effects analgesic efficacy pain intensity differences (pid analgesic effects uterine cramp, episiotomy, or surgical pain uterine cramps greatest analgesic response pain intensity differences and total pain relief postpartum pain relief mean pain intensity scores, began within 1 hr and had similar time-effect patterns relative efficacy, safety and time course of analgesia pain intensity difference [spid] scores adverse effects uterine pain|the treatments did not differ significantly in a two-sided test in 56 patients. there were significant differences for sum of pain intensity differences and total pain relief between the active drugs and placebo but not between n and c. time to onset of analgesia favored n (mean = 0.65 min) over c (mean = 0.74 min), but the analgetic effect of n diminished more rapidly at this dose. side effects were unremarkable except for dizziness and drowsiness after the 120-mg codeine dose. there was no significant side effects. paracetamol was significantly superior to placebo at the 5% level. in patients with severe episiotomy pain, aspirin-caffeine was more effective than 650 mg aspirin (p less than 0.05) at the second and third hours. highest summed analgesic ratings over placebo were induced by anirolac, 100 mg (p less than or equal to 0.001), and naproxen (p less than or equal to 0.001), followed by anirolac, 50 mg (p less than or equal to 0.005). ketorolac 10 mg gave the highest mean rating for summed pain intensity differences (13.6, p = 0.0002 versus placebo), followed by aspirin (11.9, p = 0.012), ketorolac 5 mg (10.9, p = 0.072) and placebo (8.6). side effects were not significant with any of the treatments. in their ability to distinguish codeine from placebo, patients with uterine cramp, episiotomy, or surgical pain did not appear to differ.|women with severe uterine pain 120 hospitalized women (4 groups of 30) with moderate or severe postpartum uterine pain treated with single oral doses of 159 hospitalized women with moderate or severe postpartum uterine cramps 850 patients participated in the trial one hundred twenty-one patients with postpartum pain caused by uterine cramp or episiotomy pain 100 patients with postpartum uterine pain in a single oral dose two separate trials involving 140 and 90 patients, respectively, with postpartum uterine pain in a single-dose patients with moderate to severe uterine or episiotomy pain 75 patients were included in the trial, whereas in a fixed sample study 90 patients postpartum uterine pain postpartum patients included women with episiotomy pain and with uterine cramping postpartum pain 140 women patients with postpartum uterine pain 120 hospitalized women with moderate or severe postpartum uterine pain
radiographic damage muscle strength, and joint mobility in the high intensity exercise programme radiographic progression in large joints disease activity emotional status change scores for flexibility, number of clinically active joints, duration of morning stiffness, or grip strength haq score aerobic capacity, exercise time, and joint counts aerobic capacity, muscle strength, and joint mobility median radiographic damage of the large joints blood mononuclear cell subpopulations, proliferative response, or natural killer cell activity erythrocyte sedimentation rate, tender joints, or morning stiffness exercise tolerance, disease-related measures, and self-reported health status aerobic capacity, 50-foot walking time, depression, anxiety, and physical activity mactar questionnaire score resting levels of a number of immune parameters swollen joints functional ability (assessed by the mcmaster toronto arthritis [mactar] patient preference disability questionnaire and the health assessment questionnaire [haq retention rate deterioration of disease activity effectiveness and safety heart rate at stage 2 and rate of perceived exertion activities of daily living and reduced joint pain and fatigue emotional status and disease activity aerobic capacity, joint mobility, and muscle strength functional ability aerobic capacity morning stiffness, a pain score, number of swollen joints, a health assessment score, a functional score, esr, hb, the cost of medicine, and progression using x-rays of hands and feet physical condition, muscle strength, joint mobility, daily functioning (haq), and disease activity plasma concentrations of interleukin-1 alpha, interleukin-1 beta, and interleukin-6 maximal o2 uptake|intensive dynamic training is more effective in increasing aerobic capacity, joint mobility, and muscle strength than rom exercises and isometric training in rheumatoid arthritis patients with well controlled disease. the aquatics and walking exercise groups showed significant improvement over the control group in aerobic capacity, 50-foot walking time, depression, anxiety, and physical activity after the 12-week exercise program. the results showed no effect of training on the disease activity or on the progression of the disease. maximal o2 uptake increased significantly, whereas heart rate at stage 2 and rate of perceived exertion decreased significantly, in the training group compared with the controls. intensive exercise does not increase radiographic damage of the large joints, except possibly in patients with considerable baseline damage of the large joints. all exercise groups improved their aerobic capacity, exercise time, and joint counts. no significant changes were noticed in erythrocyte sedimentation rate, tender joints, or morning stiffness.|rheumatoid arthritis patients with well controlled disease 100 consecutive rheumatoid arthritis patients on stable medication elderly, fragile patients with rheumatoid arthritis (ra patients with rheumatoid arthritis women with rheumatoid arthritis 75 patients participating elderly rheumatoid arthritis patients rheumatoid arthritis patients in training [rapit]) with those of physical therapy (termed usual care [uc patients with rheumatoid arthritis and osteoarthritis 24 patients who had been treated with low-dose steroids for 2 years people who have rheumatoid arthritis or osteoarthritis elderly rheumatoid arthritis patients on steroid treatment 120 patients with rheumatoid arthritis or osteoarthritis volunteered to be subjects for this study of ra patients rheumatoid arthritis three hundred nine ra patients 18 patients with rheumatoid arthritis and moderate disease activity patients with rheumatoid arthritis (ra rheumatoid arthritis patients with severe limitations
serum concentrations of ca-125 endometriosis scores, pregnancy rates (prs), and pain total american fertility society scoring ca-125 changes safety and tolerability emotional balance symptom scores vas score adverse event profile, laboratory parameters, bone mineral density (bmd), bone markers and bleeding patterns severity of dysmenorrhoea body weight increase visual analogue scale (vas mean total endometriosis scores quality of life weight quality of life such as sleep disturbances and anxiety-depression hirsutism ca-125 concentrations concentration of ca-125 symptom score weight gain and acne pelvic pain and dysmenorrhea side effects dysmenorrhea endometriosis scores painful symptoms of endometriosis anxiety-depression and sleep disturbances bleeding episodes efficacy and safety paid working life mild, moderate or severe degrees of lower abdominal pain, dysmenorrhoea and deep dyspareunia anxiety-depression score frequency breakthrough bleeding pain pattern and quality of life pelvic pain mean lumbar bmd pain cumulative pregnancy rate leg cramps pain symptoms hypoestrogenic effects lack of efficacy, pregnancy, elevated hepatic function tests natural history of endometriosis or prs sleep disturbances and anxiety-depression score bone resorption|dienogest 2 mg/day orally demonstrated equivalent efficacy to depot la at standard dose in relieving the pain associated with endometriosis, although offering advantages in safety and tolerability. a total of 67% of patients reported side effects. twenty nine of 40 subjects (72.5%) in the depot medroxyprogesterone acetate group were satisfied after 1 year of therapy compared with 23 of 40 (57.5%) in the oral contraceptive plus danazol group (chi 2(1) = factors of importance for quality of life such as sleep disturbances and anxiety-depression improved significantly after treatment with nafarelin or medroxyprogesterone acetate. pain was reduced significantly during treatment with 60 mg dydrogesterone and this improvement still was evident at 12-month follow-up. pain symptoms recurred during the follow-up in 57% of the gestrinone and 53% of the danazol group. a significant improvement of both pelvic pain and dysmenorrhea was observed following each type of treatment (p<0.001). the results showed a significant reduction in the severity of dysmenorrhoea by the third month in the danazol group and at 6 months in both groups. during the 6-month follow-up after medication, the ca-125 concentrations tended to increase, especially in danazol-treated women.|patients with confirmed endometriosis recurrent pelvic pain after conservative surgery for endometriosis 269 patients with confirmed endometriosis an additional 22 patients, including 10 from the gestrinone group and 12 from the women with endometriosis thirty-nine women had a laparoscopy after treatment and 56 women 30 women who participated all through the study and the 18 who dropped out women with minimal to mild endometriosis women with endometriosis (n=40) who showed recurrent dysmenorrhea and/or pelvic pain after conservative surgery, and did not desire a pregnancy 48 women with verified endometriosis, the 15 patients from the gestrinone group, including four patients with hirsutism, and 17 patients from the danazol group, including six patients with headache, withdrew because of adverse symptoms twenty nine of 40 subjects (72.5%) in the sixty-two premenopausal women with complaints of pain (n = 12) and infertility with or without pain (n = 50) with minimal to mild endometriosis diagnosed at laparoscopy minimal to mild endometriosis a total of 252 women eighty patients with endometriosis and moderate or severe pelvic pain 101 patients receiving gestrinone and 72.7% in 99 patients receiving endometriosis pelvic pain associated with endometriosis thirty-nine infertile patients with laparoscopic diagnosis of endometriosis
survival benefit survival times of patients after the operations and the application of an active drug or placebo 6-month survival median time from surgery to death intracranial hypertension survival adverse reactions risk of death survival proportions survival advantage csf leak median survival adverse events|the median time from surgery to death was 58.1 weeks for the active treatment group versus 39.9 weeks for the placebo group (p = 0.012). time to decline in kps and in 10/11 neuroperformance measures was statistically significantly prolonged in the bcnu wafer-treated group ( p </= 0.05). this survival advantage was maintained at 1, 2, and 3 years and was statistically significant (p = 0.01) at 3 years. there were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically.|patients with recurrent glioblastoma multiforme patients with high-grade gliomas patients with primary malignant glioma two hundred forty patients primary malignant glioma patients beyond 12-18 months 32 patients with newly diagnosed malignant glioma high-grade gliomas recurrent gliomas patients with newly diagnosed malignant glioma departments of neurosurgery of the university hospitals of helsinki, tampere, and turku in finland and trondheim in norway 100 patients but had to be terminated prematurely, because the drug that was being used had become unobtainable 27 patients with grade iv tumors 207 gbm patients 222 patients with recurrent malignant brain tumours requiring re-operation malignant glioma patients treated with 32 patients (16 in each treatment group) enrolled between march 23, 1992, and march 19, 1993 59 patients available for long-term follow-up, 11 were alive at 56 months: 9 had received bcnu wafers and 2 had received
total bprs scores number of patients in remission positive and negative psychotic symptoms baseline saps scores plasma sulpiride levels and therapeutic response total prs adverse reactions motor retardation, delusion, hallucination or disturbance of self-consciousness, social isolation or withdrawal, and recreation or work final global improvement rating 16-item brief psychiatric rating scale (bprs side-effects brief psychiatric rating scale (bprs), scale for the assessment of positive symptoms (saps), scale for the assessment of negative symptoms, and hamilton rating scale for depression time course of the total psychiatric rating scales (prs emotional withdrawal and hallucinatory behavior rate of side-effects and abnormal laboratory test results antipsychotic efficacy|both timiperone and sulpiride increased the number of patients in remission and decreased the number of patients who relapsed, compared with the placebo group. for patients suffering from chronic schizophrenia, a statistically significant decline was observed in total bprs scores at 4 months compared with pretreatment scores in both sulpiride and perphenazine groups. the clozapine-sulpiride group exhibited substantially greater and significant improvements in positive and negative psychotic symptoms. there was an association between plasma sulpiride levels and therapeutic response after four weeks' treatment. regarding bprs items and compared to sulpiride, bromperidol was particularly effective to relieve emotional withdrawal and hallucinatory behavior, although the only significant between group difference was in favour of sulpiride for improvements of somatic concern. the effect of the two preparations was very similar as were the type and frequency of side effects, except that sulpiride did not cause sunrash. the time course of the total psychiatric rating scales (prs) showed a progressive decline during treatment for both drugs, and at the end of treatment clocapramine proved significantly lower in total prs than did sulpiride. using "armitage's restricted sequential design", there was no significant difference between the therapeutic effects of these 2 neuroleptics.|hospitalized chronic schizophrenic patients psychoses patients with chronic schizophrenia symptom-free schizophrenics seventeen patients with acute schizophrenia and 30 with chronic schizophrenia 38 chronic schizophrenic patients 71 patients admitted because of acute or chronic psychoses, 32 were treated with remitted schizophrenic outpatients hospitalized schizophrenics fourty-five schizophrenic inpatients schizophrenic hospitalized patients chronic schizophrenic patients 82 patients of both sexes, aged 20 to 56 years 82 schizophrenic patients all were chronic patients with a symptomatic profile of apathy, lack of initiative but with the personality relatively well preserved in 56 patients people with schizophrenia partially responsive to 52 hospitalized chronic schizophrenic patients using a single-blind method during an 8-week trial period twenty-eight people with schizophrenia, previously unresponsive to typical antipsychotics and only partially responsive to current treatment with
pressure ulcers wound healing healing time|results showed that us/uvc treatment had a greater effect on wound healing than did nursing care, either alone or combined with laser.|patients with spinal cord injury twenty patients (22 wounds patients with spinal cord injury who have pressure ulcers
duration of hospital stay overall duration of pneumonia and incidence of adverse outcomes basal serum retinol concentration remission of respiratory signs mean number of days of fever, rapid respiratory rate, or hypoxia mean number of days of hospitalization relative mortality duration of signs of pneumonia|children who received vitamin a, however, were less likely to have fever by day 3 (p = 0.008) and were 29% less likely to fail to respond to the first line antibiotic (p = 0.054). duration of clinical signs was less in children with basal serum retinol concentrations >200 microg/l who received vitamin a supplements than in children with similar concentrations who received placebo (69.9 +/- there were no differences between the vitamin a and placebo groups in the duration of hospital stay when examined within categories of children stratified by age, sex, breast-feeding status, nutritional status at baseline, or quartile of dietary vitamin a intake in the 4 mo before admission to the hospital.|pneumonia in underweight and normal-weight children non-measles childhood pneumonia children children, aged 2-59 mo, with pneumonia and weight-for-age <50th percentile who had been admitted to the baca ortz children's hospital in quito, ecuador, were randomly assigned to receive 50,000 iu (aged 2-12 mo) or 100,000 iu (aged >12-59 mo children with high basal serum retinol concentrations hospitalized tanzanian children 472 children aged 6 to 59 months with clinical diagnosis of pneumonia children admitted to the hospital in dar es salaam, tanzania study children were recruited at a public hospital in recife, north east brazil, an area of marginal vitamin a deficiency 287 children enrolled, 145 received children with pneumonia tanzanian children who are admitted to the hospital with nonmeasles pneumonia childhood pneumonia six hundred eighty-seven children uncomplicated pneumonia in underweight or normal-weight children aged <5 y
anxiety scores video rating scale for motor conversion symptoms, the d(isabilities) code items from the international classification of impairments, disabilities and handicaps and the symptom checklist-90 stanford hypnotic clinical scale hypnotisability conversion symptoms|the effect size of hypnotizability as a predictor of treatment outcome was comparable to that found for other individual patient differences associated with psychotherapy outcome although non-significant. paradoxical intention-treated patients appeared to have greater improvements in anxiety scores (z=2.43, p<0.015) and conversion symptoms (t=2.27, p=0.034) than the diazepam-treated patients. significant treatment results for all outcome measures were found for the total sample.|subjects were selected by the emergency unit psychiatrist from patients who were admitted to the emergency unit with pseudoseizure patients with conversion disorder, motor type patients with a persistent conversion disorder of the motor type; (2 patients with long-standing conversion symptoms study population consisted of 45 in-patients between 18 and 65 years of age meeting the dsm-iii-r criteria for conversion disorder of the motor type or somatisation disorder with motor conversion symptoms 30 patients with conversion disorders forty-four outpatients with conversion disorder, motor type, or somatization disorder with motor conversion symptoms patients with conversion disorder of the motor type
hepatorenal syndrome incidence of infections 1-year probability of developing spontaneous bacterial peritonitis lower incidence of extraperitoneal infections spontaneous bacterial peritonitis or spontaneous bacteremia overall rate of infection or in survival peritonitis recurrence sbp and sepsis overall probability of spontaneous bacterial peritonitis recurrence spontaneous bacterial peritonitis recurrence bacterial peritonitis recurrences median duration of follow probability of spontaneous bacterial peritonitis recurrence side effects probability of survival severe infections (spontaneous bacterial peritonitis, neutrocytic ascites and bacteremia spontaneous bacterial peritonitis probability of gram-negative infection gastrointestinal bleeding survival efficacy and safety 1-year probability of survival duration of hospitalization sbp incidence of sbp probability of remaining free of bacterial infections death spontaneous bacterial peritonitis (sbp 1-year probability of development of spontaneous bacterial peritonitis and hepatorenal syndrome spontaneous bacterial peritonitis recurrences mean time of observation extraperitoneal infections renal function (serum creatinine level adverse effects cumulative one-year probability of peritonitis recurrence rate of mortality e. coli counts, quinolone susceptibility, and drug concentrations in feces six gram-negative bacilli infections|in the ciprofloxacin group, sbp occurred almost four times less frequently than in the placebo group but it was not statistically significant. spontaneous bacterial peritonitis occurred in three patients receiving norfloxacin (9.4%) and in four patients receiving trimethoprim-sulfamethoxazole (16.0%). severe infections (spontaneous bacterial peritonitis, neutrocytic ascites and bacteremia) developed in nine patients in the placebo group (17%) and in one patient in the norfloxacin group (2%; p<0.03). the overall probability of spontaneous bacterial peritonitis recurrence at 1 yr of follow-up was 20% in the norfloxacin group and 68% in the placebo group (p = 0.0063) and the probability of spontaneous bacterial peritonitis recurrence caused by aerobic gram-negative bacilli at 1 yr of follow-up was 3% and 60%, respectively (p = 0.0013).(abstract we found a significantly lower incidence of infections [1/32 (3.1%) vs. 13/31 (41.9%); p less than 0.005] and spontaneous bacterial peritonitis [0/32 (0%) vs. 7/31 (22.5%); p less than 0.05] in patients receiving norfloxacin. there were no adverse effects in the treated group. norfloxacin was more effective in the prevention of peritonitis recurrence due to enterobacteriaceae (0% vs 22%, p = .01). norfloxacin administration reduced the 1-year probability of developing spontaneous bacterial peritonitis (7% vs 61%, p < .001) and hepatorenal syndrome (28% vs 41%, p = .02), and improved the 3-month (94% vs 62%, p = .003) and the 1-year (60% vs 48%, p = .05) probability of survival compared with placebo. trimethoprim-sulfamethoxazole was efficacious, safe, and cost-effective for the prevention of spontaneous bacterial peritonitis in patients with cirrhosis.|eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis 60 cirrhotic patients with low ascitic fluid protein levels (< 15 g/l 60 consecutive patients with cirrhosis and ascites fecal escherichia coli hospitalized cirrhotic patients with low ascitic fluid protein concentrations twelve patients developed an intercurrent disorder, and 10 patients died during the trial patients with cirrhosis and ascites spontaneous bacterial peritonitis in cirrhosis patients had no history of infection since cirrhosis diagnosis and no active infection patients with cirrhosis and low protein concentration in ascitic fluid primary prophylaxis of spontaneous bacterial peritonitis patients with cirrhosis and low protein ascitic levels (<15 g/l) with advanced liver failure (child 12 patients patients on long-term quinolone prophylaxis cirrhotic patients spontaneous bacterial peritonitis 79 patients who received either patients with cirrhosis cirrhosis cirrhotic patients with low ascitic fluid protein levels (<15 g/l consecutive patients one hundred and seven patients cirrhotic patients with low ascitic fluid total protein levels patients with advanced cirrhosis hospitalized cirrhotic patients with low ascitic fluid total protein levels one hundred cirrhotic patients with <1.5 g/dl of total protein in ascitic fluid cirrhotic patients with ascites patients with chronic liver disease and spontaneous bacterial peritonitis university-affiliated veterans affairs medical center 32 cirrhotic patients with low ascitic fluid total protein levels fifty seven patients with cirrhosis and ascites were evaluated between march 1999 and march 2001
developmental status median length of therapy frequency of withdrawal symptoms restarting opium hypertension, hypotension, bradycardia, or desaturations severity of now severity of withdrawal and hospital cost shorter duration of hospitalization, less severe withdrawal, and reduced hospital cost treatment failures amount of opium required to control symptoms, number of treatment failures, and differences in blood pressure, heart rate, and oxygen saturation bayley scales of mental development withdrawal symptoms therapeutic response duration of hospitalization total length of treatment/observation average duration of outpatient phenobarbital use hospital cost time with mild withdrawal duration of opioid therapy myocarditis, sudden infant death syndrome, and homicide|no significant differences were determined in therapeutic response among those infants treated with methadone, phenobarbital, and diazepam. higher dosages of opium were required by 40% of the infants in the placebo group versus 20% in the clonidine group. the duration of hospitalization was reduced by 48% (79-38 days) (p <.001) and hospital cost per patient reduced by $35,856 (p <.001) for the dto and phenobarbital group. results of one way analysis of variance revealed no differences in developmental status between groups (p greater than 0.10, f = 0.25).|infants who required pharmacotherapy 110 infants born to mothers who were either in a methadone maintenance program, using heroin, or recently detoxified, were studied during the neonatal period neonatal abstinence syndrome infants born to drug-dependent women undergo neonatal abstinence syndrome (nas 20 term infants exposed to methadone and/or heroin in utero were studied 85 infants born to drug-dependent women who were maintained on methadone during pregnancy all enrolled infants (80) received neonatal opiate withdrawal in term infants infants with intrauterine exposure to methadone or heroin and neonatal abstinence syndrome (2 consecutive modified finnegan scores of > or =9) were enrolled at 2 hospitals during 2002-2005 and followed until final hospital discharge
survival efficacy and safety survival of at least one twin at six months of age, and survival without neurologic complications perinatal survival free of neurologic complications cystic periventricular leukomalacia|infants in the laser group also had a lower incidence of cystic periventricular leukomalacia (6 percent vs. 14 percent, p=0.02) and were more likely to be free of neurologic complications at six months of age (52 percent vs. 31 percent, p=0.003).|massachusetts medical society 72 women had been assigned to the laser group and 70 to the amnioreduction group pregnant women with severe twin-to-twin transfusion syndrome before 26 weeks of gestation severe twin-to-twin transfusion syndrome
ptsd symptoms global functioning depression symptoms, severity of suicidal ideation, feelings of guilt, and perceived stigmatization total number of ptsd symptoms scores on the k-sads-pl (ptsd symptom clusters), screen for child anxiety related emotional disorders (scared) (anxiety), children's depression inventory (depression), kaufman brief intelligence test (cognitive functioning), and child behavior checklist (total behavior problems children's reaction inventory (cri cri scores posttraumatic stress disorder and depression symptom severity re-experiencing symptoms severity of ptsd symptoms, level of functioning and physical health posttraumatic stress disorder symptoms and self-reports of fear and anxiety maladaptive cognitions k-sads-pl avoidance ptsd symptom severity posttraumatic stress symptom scale ptsd symptom scores serious adverse events scared rcmas and cdi scores multiple traumas and higher levels of depression ptsd diagnostic remission total ptss-c scores, ptsd-related symptom scale, and the subscales re-experiencing and avoidance cbt gains symptoms and functioning total child ptsd symptoms assessed using child and parent structured interview (kiddie schedule for affective disorders and schizophrenia, present and lifetime version symptoms of ptsd, depression, and related impairment symptoms of ptsd, feelings of shame, and abuse-specific parental distress preintervention and postintervention scores relation to parent-completed measures and clinician ratings of global functioning symptoms of ptsd, depression, and anxiety ptsd symptoms and impairment in functioning total k-sads-pl k-sads-pl hyperarousal ptsd symptom change ptsd-non-related symptom scale waiting-list health visits recovery rates efficacy of cognitive-behavioral therapy symptoms of ptsd and trauma-related feelings of guilt posttraumatic stress disorder and depression and increased functioning revised children's manifest anxiety scale (rcmas) and the children's depression inventory (cdi children's ipv-related ptsd and anxiety symptoms of ptsd severe abuse-specific distress|ss evidenced significantly better outcomes than tau in a variety of domains at posttreatment, including substance use and associated problems, some trauma-related symptoms, cognitions related to sud and ptsd, and several areas of pathology not targeted in the treatment (e.g., anorexia, somatization). significant treatment by time interactions on all ptsd-relevant variables indicated that the kidnet group, but not the controls, showed a clinically significant improvement in symptoms and functioning. treatment resulted in substantial reductions in both groups' cri scores and in significant, though more modest, reductions in rcmas and cdi scores. narrative exposure therapy produced a larger within-treatment effect size (cohen d = 1.80) than academic catch-up (d = 0.83) and wait-listing (d = 0.81). compared to the wl group, participants who received cbt showed significantly greater improvement in symptoms of ptsd, depression, and anxiety, with significantly better functioning. students in the immediate intervention group had significantly lower ptsd symptom scores following the intervention than those in the wait-list control group (f = 29.8, df = 1,76; p < .001). compared with controls, children who received treatment exhibited significant improvements in posttraumatic stress disorder symptoms and self-reports of fear and anxiety. post-treatment scores of the emdr group were significantly lower than the wlc indicating improvement in total ptss-c scores, ptsd-related symptom scale, and the subscales re-experiencing and avoidance among subjects in the emdr group, while untreated children improved in ptsd-non-related symptom scale. children and caregivers assigned to tf-cbt continued to have fewer symptoms of ptsd, feelings of shame, and abuse-specific parental distress at 6- and 12-month assessments as compared to participants assigned to cct. pe-a exhibited a greater decrease of posttraumatic stress disorder and depression symptom severity and a greater increase in global functioning than did tdlp-a. in both treatment conditions, ptsd symptoms and impairment in functioning were significantly reduced at one month post-test and remained stable over time. the tf-cbt completers experienced significantly greater ptsd diagnostic remission ((2) = 4.67, p = .03) and had significantly fewer serious adverse events.|children with ptsd september 2004 to may 2005 by the center for mind-body medicine at a high school in the suhareka region of kosovo in north-east sri lanka twenty-six children traumatized by organized violence posttraumatic stress disorder (ptsd) in formerly abducted individuals children suffering disaster-related ptsd children and young people of 140 consecutively referred 7- to 14-year-old children, 124 participated to 32 of these children who met clinical criteria for ptsd thirty-eight adolescents (12 to 18 years old 31 children who presented with a preliminary diagnosis of ptsd thirty-six sexually abused children (aged 5-17 years adolescent ptsd elementary school children with disaster-related posttraumatic stress disorder children with intimate partner violence (ipv)-related posttraumatic stress disorder (ptsd) symptoms adolescents (pe-a refugee camp in a severely affected community war-traumatized high school students children and mothers children  2010 american academy of child and adolescent psychiatry northern uganda children and adolescents 183 children 8 to 14 years old and their primary caregivers children suffering from ptsd adolescent victims of single-event traumas children with sexual abuse-related ptsd symptoms postwar kosovar adolescents children with post-traumatic stress disorder (ptsd refugee children living in exile sexually abused children with posttraumatic stress symptoms adolescent girls with ptsd and substance use disorder posttraumatic stress disorder (ptsd) and substance use disorder (sud) in adolescent females treating sexually abused children with posttraumatic stress symptoms traumatized refugee children 24 children and young people (8-18 years old) who met full dsm-iv ptsd diagnostic criteria after experiencing single-incident traumatic events (motor vehicle accidents, interpersonal violence, or witnessing violence thirty-three 6-16-year-old children with a dsm-iv diagnosis of ptsd eighty-two adolescents meeting criteria for ptsd according to the harvard trauma questionnaire (which corresponds with 16 of the 17 diagnostic criteria for ptsd in dsm-iv 85 former child soldiers with ptsd from a population-based survey of 1113 northern ugandans aged 12 to 25 years, conducted between november 2007 and october 2009 in camps for internally displaced persons posttraumatic stress disorder for children exposed to intimate partner violence
successful delivery of placenta, while removal of placenta success rate for delivery of placenta, blood pressure, pulse rate, blood loss, and various side effects|no adverse effects of clinical importance were registered.|twenty-four women
survival rates septic shock need for tracheotomy to withdraw ventilation shorter periods of invasive ventilation probability of survival and weaning during ventilation incidence of nosocomial pneumonia incidence of reintubation lower rate of ventilator associated pneumonia (vap total duration of ventilatory support type of chronic respiratory failure (crf), pulmonary function data, age, simplified acute physiology score (saps ii), and severity of acrf on admission similar age, sex, apache scores, rr, hr, map, pao2 and paco2 at the time of commencement and pic window arterial blood gases, duration of mechanical ventilation, time in the intensive care unit, occurrence of nosocomial pneumonia, and survival at 60 days shorter mechanical ventilation and length of stay, less need for tracheotomy, lower incidence of complications, and improved survival 90-day survival time of pic window 60-day survival rates mv duration, the length of ricu stay and hospital stay shorter duration of invasive mv time in the intensive care unit intensive care unit (icu occurrence of vap, reintubation and hospital mortality icu durations of icu and hospital stays and the 3-mo survival durations of invasive mechanical ventilation (mv) and total mv lower incidence of nosocomial pneumonia severe hypercapnic respiratory failure lower hospital mortality nosocomial pneumonia duration of etmv durations of ricu stay and hospital stay hospital mortality hospital stays rate of weaning failure mean duration of mechanical ventilation mean period of daily ventilatory support duration of invasive mv, the risk of vap and hospital mortality incidence of ventilation associated pneumonia (vap|11) days, p = 0.047] and lower hospital mortality (1/47 vs 7/43, p = 0.025). the conventional-weaning approach was an independent risk factor of decreased icu (odds ratio: 6.6; p = 0.035) and 90-day survival (odds ratio: 3.5; p = 0.018). the incidence of ventilation associated pneumonia (vap) was 18.4% (7/38) in the niv group, 39.5% (15/38) in the control group respectively (p < 0.05). among patients who received noninvasive ventilation, the probability of survival and weaning during ventilation was higher (p = 0.002) and time in the intensive care unit was shorter (15.1+/-5.4 days compared with 24.0+/-13.7 days for patients who received invasive ventilation; p = 0.005). niv like ipsv significantly and similarly improved gas exchange in relation to that achieved during 2 h-wt (p < 0.05).|from november 2001 to october 2004, 76 case of copd patients with severe respiratory failure due to pulmonary infection were intubated and recruited in the study patients with acute exacerbations of chronic obstructive pulmonary disease 33 patients who failed a 2-h t-piece weaning trial (2 h-wt) although they met simple criteria for weaning 43 mechanically ventilated patients who had failed a weaning trial for 3 consecutive days patients with respiratory failure due to chronic obstructive pulmonary disease copd patients with severe respiratory failure eleven teaching hospitals; respiratory or medical intensive care units in china acute-on-chronic respiratory failure (acrf thirty eight cases among 76 patients were in the niv group, and the rest in the control group acute-on-chronic respiratory failure chronic obstructive pulmonary disease (copd) patients with severe respiratory failure patients with persistent weaning failure intensive care unit (icu) patients patients with acrf who are difficult to wean copd patients requiring intubation and mechanical ventilantion who have severe respiratory failure intubated patients with chronic obstructive pulmonary disease and acute hypercapnic respiratory failure 16 patients (ipsv group), and niv was applied immediately after extubation in 17 patients (niv group severe respiratory failure of chronic obstructive pulmonary diseases persistent weaning failure study group (n = 47) and control group (n = 43) had similar clinical characteristics initially and at the time of pic window ninety intubated copd patients with severe hypercapnic respiratory failure triggered by pulmonary infection (pneumonia or purulent bronchitis copd patients requiring intubation and invasive mv for hypercapnic respiratory failure patients with exacerbated hypercapnic respiratory failure caused by chronic obstructive pulmonary diseases (copd 53 consecutively intubated patients admitted for acrf
proximal screw failure screw failure average blood loss compartment pressures and deltap ([diastolic blood pressure] - [compartment pressure healing and complications delayed union and breakage of screws union and infection rate peak average pressures deep posterior compartment pressures elective nail removal isokinetic thigh-muscle strength average total duration of the procedures performed without reaming durations of hospital stay, and time needed to achieve union tibia fractures average estimated blood loss duration of fluoroscopy nonunions, time to fracture healing, and rate of malunions open type i and ii fractures union time deltap values time to fracture healing anterior knee pain mal-union, delayed union, and device failure chronic anterior knee pain or functional impairment malunion average time to fracture healing|the deep posterior compartment pressures were lower in the reamed group than in the unreamed group at ten, twelve, fourteen, sixteen, eighteen, twenty, twenty-two, and twenty-four hours postoperatively (p < 0.05 at each of these times. one distal screw failed (59.1 per cent) significantly more often than two distal screws (5 per cent). unreamed nailing in patients with tibial shaft fractures may be associated with higher rates of secondary operations and malunions compared with reamed nailing. ender nail still has its superior usefulness in some aspects of treatment of less comminuted unstable tibial shaft fractures, but for the more comminuted unstable tibial shaft fractures, the interlocking nail is undoubtedly better used. fourteen (67%) of the twenty-one patients treated with transtendinous nailing reported anterior knee pain at the final evaluation. union and infection rate were higher in the ender group (p<0.05). a screw fractured after two procedures with reaming and after ten without reaming (p = 0.012); multiple screws fractured after three procedures in the latter group.|131 patients with tibial fractures of the central two thirds of the tibia were admitted to the emergency ward of shohada hospital, tabriz, iran closed fractures of the tibial shaft of eligible patients, 22 had one distal locking screw and 20 had two distal locking screws tibial shaft fractures forty-eight adults with forty-nine fractures treated with skeletally mature patients with diaphyseal tibial fractures one hundred and fifty-two patients who had 154 closed fractures of the shaft of the tibia one hundred and seven cases of unstable tibial shaft fractures sixty-seven patients underwent surgery with interlocking nails and 64 with ender nails anterior knee pain after intramedullary nailing of fractures of the tibial shaft seventy-two patients (seventy-three fractures) who had been managed with nailing with reaming and sixty-three patients (sixty-three fractures) who had been managed with nailing without reaming were available for follow-up at an average of twelve months (range, three to thirty-three months) postoperatively fifty patients with a tibial shaft fracture requiring intramedullary nailing thirteen patients who had been randomized to treatment without reaming were switched to the group that had reaming because of technical reasons; these patients were excluded from the analysis of the results university hospital/level closed tibial shaft fractures patients with tibial shaft fractures unstable tibial fractures with forty-five patients with displaced closed and open gustilo type i-iiia fractures of the central two thirds of the tibia
time to treatment failure eps-related events movement rating scales, eps-related adverse events, and use of anti-eps medications free of hospitalization for exacerbation of schizophrenia tolerated eps panss, bprs, and cgi effective, well tolerated positive and negative syndrome scale (panss), brief psychiatric rating scale (bprs), and clinical global impression (cgi cgi final improvement score extrapyramidal symptoms (eps|a dose-related improvement was observed for panss, bprs, and cgi, with statistically significant mean differences (p < 0.05) between placebo and 20-mg/day sertindole (decreases from baseline of -5.8 versus -16.9 for panss, -4.8 versus -10.4 for bprs, respectively). time to treatment failure was numerically superior in sertindole-treated patients compared with haloperidol-treated patients, although this difference was not statistically significant.|schizophrenia 282 clinically stable neuroleptic-responsive outpatients with schizophrenia hospitalized schizophrenic patients (n = 205 patients with schizophrenia
rdai score values rr acute bronchiolitis but l-adrenaline relapse rate ed discharge respiratory rate (rr), heart rate (hr), oxygen saturation (spo(2)), respiratory distress assessment instrument (rdai), and activity levels respiratory rate, blood pressure, or respiratory-effort scores mean clinical score, respiratory rate, and room air saturation over time inspiratory, expiratory, and total pulmonary resistance degree of change in the respiratory rate, the heart rate, and the respiratory-effort score and the time that supplemental oxygen was required spo(2) or rdai hospital admissions clinical score and pulmonary mechanics clinical score and respiratory rate mean los clinical scores or oxygen saturations hospital admission within 7 days after the day of enrollment (the initial visit to the emergency department room air oxygen saturation, elapsed time to meeting clinical criteria for ed discharge, hospitalization rate, and proportion of patients relapsed within 72 hours of ed discharge (relapse rate changes in clinical scores and oxygen saturations clinical score, oxygen saturation and heart rate oxygen saturation and mrdai score length of the hospital stay time from admission until the infant had normal hydration, oxygenation, and minimal respiratory distress median time heart rate, respiratory rate and respiratory distress assessment instrument (rdai) score length of hospital stay (los oxygen saturation and clinical modified respiratory distress assessment instrument (mrdai) scores need for hospital admission or home oxygen respiratory rate heart rate adverse effects length of the hospital stay and the time until the infant was ready for discharge clinical score mean percent oxygen saturation|group differences were not statistically significant in any of the secondary outcomes. thirty minutes later, there was a significant decrease in clinical score after treatment with racemic epinephrine compared with the baseline score (p < 0.001); this difference was not present after salbutamol inhalation (p = 0.42). there were no significant differences between the outcome variables of the four groups within the first 120 min and at 24 hours, or between the rates of requirement of a second dose of the same bronchodilator. there were no significant overall differences between the groups in the length of the hospital stay (p=0.16) or the time until the infant was ready for discharge (p=0.86). both treatment groups experienced a similar pattern of change in mean clinical score, respiratory rate, and room air saturation over time. the outcome of patients at 120 min was found significantly better than the baseline values (p < 0.05). supportive therapy prior to study treatment resulted in significant reductions in rr (by 4.3 breaths/min) and hr (by 4.6 beats/min); there were no changes in spo(2) or rdai. racemic epinephrine and albuterol at equivalent doses had no effect on the need for hospitalization or supplemental oxygen in bronchiolitis in the outpatient setting compared to nebulized saline placebo, though this study may have missed less dramatic clinical effects due to small sample size. after 02 doses of nebulizations by the studied drugs, a significant improvement in respect to oxygen saturation and mrdai score were noted among the children in both the groups, compared to their baseline status (p=0.000). among infants with bronchiolitis treated in the emergency department, combined therapy with dexamethasone and epinephrine may significantly reduce hospital admissions. the mean percent oxygen saturation at 60 minutes was significantly higher in the epinephrine group.|infants with their first episode of acute bronchiolitis mildly affected ambulatory infants with acute bronchiolitis infants with acute bronchiolitis seen in an emergency department twenty-four infants, 4.6 +/- 0.5 (mean infants hospitalized with acute viral bronchiolitis 2005 mildly affected infants with acute bronchiolitis infants with bronchiolitis treated in the emergency department, combined therapy with acute bronchiolitis children with acute bronchiolitis infants admitted to the hospital with bronchiolitis 2009 massachusetts medical society thirty eight infants were recruited, 19 in each treatment group bronchiolitis infants hospitalized for acute viral bronchiolitis massachusetts medical society 60 children aged less than 02 years, admitted in the department of pediatrics, dhaka medical college hospital, during january through december 2005 with acute bronchiolitis infants with acute bronchiolitis emergency department treatment of bronchiolitis outpatients with acute bronchiolitis sixty-five patients between ages 6 weeks and 24 months with a diagnosis of bronchiolitis, defined as first-time wheezing, upper respiratory symptoms and/or fever, and a respiratory distress assessment instrument score of at least 4 194 infants admitted to four hospitals in queens-land, australia, with a clinical diagnosis of bronchiolitis treated infants with acute bronchiolitis a total of 149 infants were randomized; 50 186 children (mean age 9.5 800 infants (6 weeks to 12 months of age) with bronchiolitis who were seen in the pediatric emergency department infants with moderately severe acute bronchiolitis infants with bronchiolitis sixty-six patients between 0 and 12 months of age with new-onset wheezing, an antecedent upper respiratory tract infection, and a clinical score (respiratory distress assessment instrument) of 8 to 15 69 infants aged 2-21 months who were admitted to the pediatrics department of the faculty of medicine, mersin university, with acute bronchiolitis moderately ill infants with bronchiolitis infants hospitalized with bronchiolitis mild bronchiolitis children with bronchiolitis
postextubation problems clinical or radiologic incidence of pneumonia|there was no difference in the clinical or radiologic incidence of pneumonia.|neonates requiring ventilatory assistance 91 neonates to be intubated via either of the two routes: 46 infants were assigned to the ot group and 45 infants were assigned to the nt group
occurrence of any acts of verbal or physical aggression rates of cluster b personality disorders substance abuse and personality disorders personality disorder, psychiatric symptoms, early maladaptive schemas, interpersonal problems, and addiction-related psychosocial impairment frequency of self-harm episodes problematic drinking, social functioning and beliefs about others alcohol misuse, mental state, beliefs and social functioning personality disturbance cost effective alcohol consumption total costs lower anger expression comparison of scores on the social problem solving inventory and the social functioning questionnaire diagnostic interview schedule success; therapist's personal qualities problem-solving skills overall social functioning drug use and alcohol intoxication psychiatric symptoms, criminality, and psychosocial impairment counseling attendance and some indication of lower psychosocial impairment parasuicide events|profound differences were discovered in the therapists' success with the patients in their case loads. the experimental intervention increased attendance in subjects with low and high levels of psychopathy and with and without other psychiatric comorbidity. primary outcome was comparison of scores on the social problem solving inventory and the social functioning questionnaire between intervention and control arms at the conclusion of treatment, on average at 24 weeks after randomisation. participants randomized to receive the first offender incarceration and treatment program reported greater reductions in alcohol consumption from baseline levels when compared with participants who were only incarcerated. a 2-way analysis of variance showed that patients with aspd were more likely to abstain from cocaine use during treatment than patients without aspd. cbt did not improve outcomes more than usual treatment for men with aspd who are aggressive and living in the community in this exploratory study. fifty-two homeless clients were assessed after program admission and randomly assigned to receive either individual psychotherapy focused on personality disorder and substance abuse relapse prevention (dual-focus schema therapy [dfst]) or standard group substance abuse counseling (sac). total costs were significantly greater in those with personality disorder and were reduced in those allocated to mact; this saving was reversed in those with borderline disorder. results confirmed that high-risk participants graduated at a higher rate, provided more drug-negative urine specimens at 6 months post-admission, and reported significantly less drug use and alcohol intoxication at 6 months post-admission when they were matched to bi-weekly hearings as compared to the usual schedule of hearings. providing case management services to idus with comorbid aspd may facilitate treatment entry and reduce the negative consequences of drug abuse.|conjunction with 28 days of incarceration, of a treatment program incorporating motivational interviewing principles for first-time dwi offenders 244 participants subjects (n = 100) met diagnostic and statistical manual of mental disorders criteria for opioid dependence and apd using a structured clinical interview 305 offenders including 52 diagnosed as aspd by the 274 participants were available for analysis personality-disordered substance abusers receiving services within a homeless drop-in center antisocial personality disorder (aspd fifty-two homeless clients men with aspd subjects with low and high levels of psychopathy and with and without other psychiatric comorbidity injection drug users attending the baltimore needle exchange program who sought and were granted referrals to opioid agonist treatment patients with apd intoxicated (dwi) offenders who are primarily american indian men with aspd who were aggressive recurrent deliberate self-harm and personality disturbance dwi offenders with aspd maintained patients with and without antisocial personality disorder (aspd injection drug users (idus) with and without comorbid antisocial personality disorder (aspd adults with personality disorder in the community under conditions resembling routine clinical practice violent men with antisocial personality disorder in the community 480 patients fifty-two adult men with a diagnosis of aspd, with acts of aggression in the 6 months prior to the study adults with personality disorder treatment-seeking injection drug users with and without comorbid antisocial personality disorder homeless drop-in center clients antisocial personality disorder (apd dependent patients with antisocial personality disorder to cognitive-behavioral and contingency management interventions first offenders: intervention outcomes and interactions with antisocial personality disorder among a primarily american-indian sample opioid-dependent patients with antisocial personality
number of angina attacks visits systolic blood pressure recurrent stenosis plasma lipids, insulin resistance and blood pressure morbidity and mortality idlc plasma lipid levels thickening of the intima/media complex thickness of the intima/media complex degree of stenosis, interventricular septal thickness, crurobrachial pressure ratios of dorsalis pedis and posterior tibial arteries, distance to claudication and total vessel diameter major cardiovascular events marked reduction in septal thickness arterial wall thickness concentration of triglycerides intima/media thickness risk of clinical outcomes arterial imt arterial intima-media thickness (imt) of the carotid and femoral arteries and fasting lipid parameters plasma lipids imt of combined carotid and femoral arterial walls blood pressure and increases insulin resistance fasting lipids and on progression of peripheral atherosclerosis ankle brachial blood pressure index blood pressure rate of restenosis hdlc tolerated mortality ankle blood pressure index (abi imt|blood pressure was effectively reduced by perindopril irrespective of the associated disease. a low abi was a strong predictor of morbidity and mortality during the follow-up even in patients with no clinical symptoms of pad (n=6769). a significant reduction of the imt of combined carotid and femoral arterial walls was shown in both treatment groups (p < 0.005). the rate of restenosis was also significantly lower in the verapamil group (p < 0.001).|patients with mild essential hypertension and concomitant diseases and therapies patients with subclinical pad hypertensive males with hypercholesterolaemia (the daphne study 3099 patients and normal in 5887 patients patients with peripheral vascular disease and hypercholesterolaemia patients at high risk for reoccurrence after successful percutaneous transluminal coronary angioplasty (ptca patients with no clinical symptoms of pad (n=6769 pad patients included in the heart outcomes prevention evaluation (hope) study many hypertensive patients eighty males (45 to 70 years) with peripheral atherosclerotic disease and increased cholesterol levels (5.2-8.0 mmol/l) were treated for essential hypertension with either hypertensives in the netherlands 490 patients with mild essential hypertension and any one of the following concomitant diseases: hyperlipidemia, type ii diabetes mellitus, ischemic heart disease, cardiac arrhythmia, peripheral arterial occlusive disease, nephropathy with proteinuria, chronic obstructive pulmonary disease, or degenerative joint disease treated with nonsteroidal anti-inflammatory drugs (nsaids patients with clinical as well as subclinical pad essential hypertensive patients with concomitant diseases 8986 patients 98 patients with peripheral occlusive arterial disease (poad), stable angina pectoris, mild hypertension and at least one additional risk factor increasing the likelihood of restenosis after angioplasty patients with evidence of clinical or subclinical peripheral arterial disease
cardiac arrest, hf (with or without ht frequency of adverse events survival lactate concentration and o2 extraction ratio cvo2 improved survival survival with a follow-up time of six months relative risk of death by intractable shock haemodynamics, electrolytes, lactate, arterial ph, cao2, cvo2 and o2 extraction ratio median tympanic temperature median tympanic temperature at admission six-month survival curves survival to hospital discharge with sufficiently good neurologic function to be discharged to home or to a rehabilitation facility bladder and tympanic temperature complications neurologic outcome mild hypothermia lower cardiac index, higher systemic vascular resistance, and hyperglycemia|mild hypothermia induced by a helmet device was feasible, easy to perform, inexpensive and effective, with no increase in complications. there was no difference in the frequency of adverse events. compared to control group, the relative risk of death by intractable shock was 0.29 (95% ci, 0.09 to 0.91) in the hf+ht group and 0.21 (95% ci, 0.05 to 0.85) in the hf group.|patients who remained unconscious after resuscitation from out-of-hospital cardiac arrest patients with coma after resuscitation from out-of-hospital cardiac arrest sixty-one patients admitted between may 2000 and march 2002 in the intensive care units of two hospitals in france thirty patients were eligible for the study, 16 were randomised into the hg and 14 study subjects were 77 patients who were randomly assigned to treatment with comatose survivors of out-of-hospital cardiac arrest with induced hypothermia patients with cardiac arrest due to asystole or pulseless electrical activity (pea) who remained unconscious after restoration of spontaneous circulation (rosc
troponin i, myoglobin, creatine kinase-mb mass, and high-sensitivity c-reactive protein levels of interleukin, il-6 and il-8; tumor necrosis factor alpha; sdf-1alpha; granulocyte colony-stimulating factor; and vascular endothelial growth factor risk of af plasma crp levels postoperative peak n-terminal pro-brain natriuretic peptide levels sp-selectin values plasma levels of any cytokine and number of epcs plasma levels systemic inflammatory response syndrome score incidence of af peak postoperative values of troponin myocardial disease epc count length of stay creatine kinase-mb mass cd11b expression on neutrophils neutrophil-endothelial adhesion high-sensitivity c-reactive protein values incidence of postoperative af and the postoperative peak c-reactive protein (crp) level incidence of major adverse cardiac and cerebrovascular events and persistent af occurrence of postoperative af incidence of postoperative af; secondary end points were length of stay, 30-day major adverse cardiac and cerebrovascular events, and postoperative c-reactive protein (crp) variations peak crp levels serum levels of the proinflammatory cytokines (il-6, il-8, tnf-alpha), and leukocytes, and the sirs score postoperative interleukin-6 (il-6) levels systemic inflammatory responses endothelial progenitor cells p-selectin levels concentrations of soluble p-selectin (sp-selectin postoperative clinical outcomes plasma levels of interleukins 6 and 8, p-selectin, soluble intercellular adhesion molecule-1, and lactoferrin blood samples mean high postoperative crp levels intraoperative inotropic agents incidence of major adverse cardiac and cerebrovascular events occurrence of postoperative af; secondary endpoints were major adverse in-hospital cardiac and cerebrovascular events and identification of variables predicting postoperative af incidence of postoperative af postoperative af systemic inflammatory response and perioperative morbidity atrial fibrillation (af leukocyte-endothelial cell interactions c-reactive protein (crp plasma levels of interleukins (il-6, il-8, tnf-alpha), and systemic inflammatory response score (sirs operation time, blood loss, need for inotropic support, intubation time, and length of intensive care unit or hospital stay sdf-1alpha, granulocyte colony-stimulating factor, and vascular endothelial growth factor peak levels cytokine release and neutrophil adhesion postoperative atrial fibrillation systemic inflammatory response higher postoperative peak n-terminus pro-b-type natriuretic peptide levels plasma il-1 and tnf-alpha precocious modulation of il-6 expression hospital stay plasma levels of selected inflammatory mediators levels of proinflammatory cytokines inflammatory response expression of nf-kappab risk of complications, length of stay, and cost of care cytokine levels preoperative and postoperative course sd values myocardial damage plasma levels of cytokines and cholesterol amount of epcs major adverse cardiac and cerebrovascular events, persistent af at 1 month, and identification of the markers to predict inhospital postoperative af postoperative serum levels of both interleukin-6 and interleukin-8 myocardial dysrhythmia postoperative crp level levels of il-6, il-8, tnf-alpha and sirs score length of icu and hospital stay|postoperative peak n-terminal pro-brain natriuretic peptide levels were significantly higher in the patients with af (p = .03). high-sensitivity c-reactive protein values were increased in 58% of pretreated versus 88% of the control patients (15.4 +/- there was less use of intraoperative inotropic agents in the fluvastatin group ( p < 0.015) and the difference in the length of icu and hospital stay showed a significantly shorter stay for the fluvastatin group. atorvastatin significantly reduced the incidence of postoperative af and the postoperative peak c-reactive protein (crp) level vs placebo (14% vs 34%, p=0.009; 126.5 +/-22.3 vs 145.2 +/-31.6 mg/l, p<0.0001). atorvastatin significantly reduced the incidence of af versus placebo (35% versus 57%, p=0.003). postoperative serum levels of both interleukin-6 and interleukin-8 increased significantly over baseline, but the peak levels observed 4 hrs postoperatively were significantly lower in the atorvastatin group. statin did not affect levels of sdf-1alpha, granulocyte colony-stimulating factor, and vascular endothelial growth factor. plasma levels of interleukins 6 and 8, p-selectin, soluble intercellular adhesion molecule-1, and lactoferrin were measured by enzyme-linked immunosorbent assay (elisa). in both groups the serum levels of the proinflammatory cytokines (il-6, il-8, tnf-alpha), and leukocytes, and the sirs score increased significantly over the baseline, though no significant differences were observed between the two groups. pravastatin reduced postoperative interleukin-6 (il-6) levels significantly at 24 and 48 hours, and at seven days.|myocardial damage after coronary surgery after off-pump coronary artery bypass grafting surgery 50 patients undergoing elective coronary surgery one hundred twenty-four patients without a history of af or previous statin use, who were scheduled to undergo elective off-pump cabg, were enrolled two hundred patients undergoing elective cardiac surgery with cardiopulmonary bypass, without previous statin treatment or history of af, were enrolled forty patients patients undergoing cardiac surgery twenty patients undergoing valve or coronary operations with tepid (34 degrees c) cpb forty-six patients referred to cabg operation were included in the study 140 consecutive patients undergoing elective off-pump cabg, without a history of af or previous statin treatment atrial fibrillation following off-pump coronary artery bypass grafting cardiopulmonary bypass forty three patients undergoing cpb patients undergoing coronary artery bypass grafting with cardiopulmonary bypass two hundred patients undergoing coronary surgery were enrolled forty-four subjects undergoing elective coronary artery bypass grafting who fulfilled the inclusion criteria patients undergoing open heart surgery patients undergoing cardiac surgical patients patients with coronary heart disease undergoing coronary artery bypass grafting surgery (cabg patients who have undergone previous after cardiac surgery patients with coronary artery disease coronary bypass surgery
recurrence of active cdd safety and efficacy initial cdd (recurrence rate recurrence of cdd effectiveness serious adverse reactions relative risk (rr) of cdd recurrence recurrences recurrence of clinical symptoms clostridium difficile-associated diarrhoea (rcdad|although the small sample size does not allow any conclusion to be drawn concerning the efficacy of l. plantarum in patients with rcdad, these results may contribute to the ongoing discussion about the benefits of probiotics in patients with rcdad and encourage the performance of larger multicentre studies. the efficacy of s boulardii was significant (recurrence rate 34.6%, compared with 64.7% on placebo; p = .04) in patients with recurrent cdd, but not in patients with initial cdd (recurrence rate 19.3% compared with 24.2% on placebo; p = .86). no serious adverse reactions were observed in these patients.|recurrent clostridium difficile disease (cdd patients with active cdd 124 eligible consenting adult patients, including 64 who were enrolled with an initial episode of cdd, and 60 who had a history of at least one prior cdd episode patients with recurrent cdd recurrent clostridium difficile-associated diarrhoea patients with rcdad patients who were immunosuppressed due to acquired immunodeficiency syndrome or cancer chemotherapy within 3 months were not eligible clostridium difficile disease national referral study of ambulatory or hospitalized patients from three main study coordinating centers recurrent clostridium difficile disease patients with clostridium difficile-associated disease (cdd
attitudes, behaviors and intentions related to sexual activity intention to engage in sex and increased abstinence sexual consequences self-efficacy sexual intentions, abstinence, and a trend toward fewer virgins initiating intercourse sexual risk sexual behavior|they also reported less intention to have sex before finishing high school (0.4 vs. 0.5), and more frequent parent-child communications about prevention (1.6 vs. 1.0) and sexual consequences (1.6 vs. 1.1). hierarchical logistic regression analyses showed significant effects for the intervention on sexual intentions, abstinence, and a trend toward fewer virgins initiating intercourse for the first time, 19 weeks after baseline. the evaluation demonstrated significant improvements in communication between parents and children immediately following the intervention; however, these improvements were no longer present 12 months postintervention. at neither follow-up were there significant positive changes in sexual behavior; youths in treatment and control groups were equally likely to have become sexually active, and youths in treatment groups were not less likely than youths in control groups to report a pregnancy or a sexually transmitted infection.|young adolescents' risk for early onset of sexual intercourse 251 male and female early adolescents 9 through 14 years of age participated with their parents in this abstinence-based adolescent pregnancy prevention program 351 middle school students african-american seventh grade students early adolescents youths in california twenty middle school classes of african-american seventh graders seventh and eighth graders in california, 10,600 youths from schools and community-based organizations statewide middle school adolescents diverse sociocultural communities in los angeles county african-american seventh graders
patency rate patency, limb salvage, and survival secondary patency rates benefits, morbidity, and mortality median blood loss patency clotting of blood within the grafts or native vessels mortality rate risk of morbidity and mortality major complication rates and cardiovascular morbidity heparin levels (anti xa duration of patency, limb salvage rates, and complication rates perioperative blood transfusions and complications overall complication rate level of the reconstruction; survival cumulative 5-year survival rate patency and limb salvage limb salvage rate bypass patency, and mortality and morbidity median durations of primary patency and limb salvage graft reocclusion and limb loss rate of occlusion and bleeding rest pain or tissue loss incidence rate of wound hematomas intraoperative graft thrombosis limb salvage rates ages, indications, bypass graft types, risk classifications (ie, conduit, runoff, or graft failure), or comorbid conditions (except diabetes mellitus major hemorrhagic events levels of fpa survival cumulative limb salvage rates anti xa levels graft patency, limb salvage, and survival overall patency fpa limb salvage serious bleeding complications 30-day graft patency, operative blood loss, and hemorrhagic complications major bleeding events patent reconstruction at day 1, perioperative blood loss, and the percentage of patients requiring protamin reoperation because of bleeding levels of fm limb salvage or survival rates levels of fibrinogen, fpa, thrombin antithrombin complex and fm incidence rate of postoperative hematoma excessive bleeding soluble fibrin, measured as fibrin monomers (fm) and fibrinopeptide a (fpa graft patency rates, limb salvage rates, and survival rates immediate postoperative primary graft patency rates heart failure elevated levels of fibrinogen, fibrinopeptide a (fpa) and thrombin-antithrombin (t-at) complexes 30-day data for mortality, repeat operation, and recurrent occlusion operative procedure, complication rate, and hospital course fibrinogen prothrombin complex, thrombin-antithrombin complex, platelets and antithrombin graft performance graft patency graft occlusion fpa levels patient mortality, morbidity and bypass patency rates primary patency of peripheral arterial bypass grafts (pabg primary patency rate early graft patency|no clotting of blood within the grafts or native vessels was noted during the conduct of the surgical procedures in either group. stratified survival analysis showed that this benefit was confined to those having salvage surgery (log rank test p = 0.0006); for those having surgery for claudication there was no significant benefit. increased levels of fibrinogen, fpa, thrombin antithrombin complex and fm were recorded prior to surgery. lmwh was comparable to ufh during peripheral vascular reconstruction in terms of 1-day and 30-day graft patency, operative blood loss, and hemorrhagic complications. as expected, limb salvage was lower in patients with critical ischemia (p less than 0.03), and this was also true for survival (p less than 0.04), which was also influenced by the level of the reconstruction; survival was lower in patients with femoro-distal reconstructions (p less than 0.001). major complication rates and cardiovascular morbidity were not different between the two groups. following autologous vein bypass surgery in the treated group, the results were superior in terms of graft patency, limb salvage, and survival. in the prosthetic bypass group, there was no significant difference in patency rate in the 8-mm bypass subgroup, but there was a significant difference in patency rate in the 6-mm bypass subgroup (femoral-popliteal; 71.4% in the wasa group versus 57.9% in the asa group; p =.02). the incidence rate of postoperative hematoma (32% vs 3.7%; p = .004) was greater in the war group, but no differences were seen between the war group and the aspirin group in the number of packed red blood cells transfused, in the incidence rate of overall nonhemorrhagic wound complications, or in the overall complication rate (62% vs 52%). there was no difference in patency at any time point between the two regimens, the crude 90 days patency being 88 and 83%, respectively. preoperatively and during surgery the patients had elevated levels of fibrinogen, fibrinopeptide a (fpa) and thrombin-antithrombin (t-at) complexes.|fifty-six patients who were at high risk for graft failure patients suffering from atherosclerosis patients with lower extremity arterial bypass surgery patients with peripheral arterial bypass procedures lower limb ischemia patients patients with critical limb ischaemia undergoing salvage surgery 284 patients with lower limb ischemia, most with pre-operative ischemic ulceration or partial gangrene, from 12 hospitals study subjects included patients undergoing peripheral vascular procedures, except carotid surgery patients at high risk for graft failure sixty-one of the 64 bypass grafts infrainguinal vein bypass grafting at high risk for failure 28 patients requiring infrainguinal bypass surgery 94 patients patients undergoing femoropopliteal bypass grafting patients with a potential heart insufficiency after peripheral arterial reconstructive surgery early occlusion following arterial bypass surgery distal to the groin 130 patients had electively received a eighteen patients three hundred and fourteen patients 849 patients included, 817 were followed up to 30 days femoropopliteal atherosclerosis infrainguinal bypass surgery patients undergoing infrainguinal bypass surgery after femoropopliteal bypass grafting 831 patients who underwent 20 swedish surgical and vascular surgical departments that report to the swedish vascular registry (swedvasc 116 randomized patients (61 in the study group and 55 in the control group patients with marginal venous conduit, poor arterial runoff, and prior failed bypass grafts university tertiary care hospital and in a veterans affairs hospital
mean scores negative appraisal of caregiving sleep quality, depressive symptoms, and quality of life presence and severity of physical symptoms, psychiatric morbidity, use of and satisfaction with services, and carers' problems carer strain and quality of life, satisfaction with care, and bereavement outcome quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress overall caregiving mastery, caregiver mastery specific to caregiving tasks, problem-focused or emotion-focused coping levels of caregiver strain partners' ratings of their self-efficacy burden of patient symptoms vomiting caregiving task burden quality of life social interaction appraisal variables (appraisal of illness or caregiving, uncertainty, hopelessness), coping resources (coping strategies, self-efficacy, communication), symptom distress, and quality of life positive caregiver experience quality of life (qol family caregivers' qol, burden, coping, and mastery caregiver qol, reducing burden related to patients' symptoms, and caregiving tasks caregiver qol, caregiver burden due to patient symptoms, caregiver burden due to tasks, and caregiver mastery legacy improved family communication caregiving stress global family functioning distress and depression quality of life and other psychosocial outcomes preparedness to care, self-efficacy, competence, and anxiety quality of life scores psqi and ces-d scores sleep quality and depressive symptoms actigraphs measured latency, duration, efficiency, and wake after sleep onset (waso) scores hopelessness and less negative appraisal of illness depression pittsburgh sleep quality index (psqi), center for epidemiological studies-depression scale (ces-d), and caregiver quality of life-cancer scale (cqolc brief symptom inventory, beck depression inventory, and social adjustment scale quality of life of dyads legacy activity emotional distress breathing difficulty and increased religious meaning stimulus control, relaxation, cognitive therapy, and sleep hygiene elements caregiver qol carer distress (ghq-28 stress brief symptom inventory and beck depression inventory|the intervention consisted of five sessions and addressed family involvement, optimistic attitude, coping effectiveness, uncertainty reduction, and symptom management. improvement was seen across groups; however, intervention caregivers showed more improvement in psqi and ces-d scores than control caregivers. data analyses revealed that the partner-guided pain management protocol produced significant increases in partners' ratings of their self-efficacy for helping the patient control pain and self-efficacy for controlling other symptoms. at 4-month follow-up, intervention patients reported less uncertainty and better communication with spouses than control patients, but they reported no other effects. intervention caregivers showed reduced caregiving stress in comparison with control group caregivers, who showed increases in stress. global family functioning did not change. scores on the ghq-28 fell below the threshold of 5/6 in a third of participants in each trial arm at any follow-up point. 554 patients expected to survive less than one year entered the trial and were randomly allocated to a coordination or a control group. no intervention effects were identified with respect to preparedness to care, self-efficacy, competence, and anxiety. the coping skills intervention was effective in improving caregiver qol, reducing burden related to patients' symptoms, and caregiving tasks compared with hospice care alone or hospice plus emotional support.|women with recurrent breast cancer and their family caregivers 554 patients expected to survive less than one year entered the trial cancer patients were routinely notified from 1987 to 1990 354 family caregivers of community dwelling hospice patients with advanced cancer patient/caregiver dyads terminally ill cancer patients and their families of coordinating the services available within the nhs and from local authorities and the voluntary sector 235 couples: 123 couples in the control group and 112 couples in the experimental group people caring for patients receiving specialist palliative care 2007 american cancer society thirty adult caregivers participated seventy-eight advanced cancer patients meeting criteria for hospice eligibility and their partners individuals with chronic, life-limiting illnesses and their family caregivers family caregivers of hospice patients with cancer participants (n = 106) received family caregivers of patients dying of cancer at home caregivers of persons with cancer family caregivers of patients receiving palliative care family caregivers of persons with cancer 53 families, 233 individuals) or a control condition (28 families, 130 individuals distressed, informal carers of patients receiving palliative care men with prostate cancer and their spouses 134 patients and their family caregivers 263 patient-spouse dyads copyright 2005 american cancer society informal carers of patients with cancer patients who are at the end of life family caregivers of persons with advanced stage cancer 257 families of patients dying from cancer: 183 (71%) were at risk, and 81 of those (44%) participated in the trial prostate cancer patients and their spouses men with prostate cancer terminally ill cancer patients 271 informal carers who scored over 5 on the 28-item general health questionnaire (ghq-28 patients with advanced breast cancer and their family caregivers, who participated in a family based intervention patients' homes that relatives with advanced cancer patients with advanced cancer
time for mobilization, and costs for time and drug consumption severity of nausea, vomiting, dizziness, and drowsiness prolactin pregnancy rate analgesia requirements hr, map, etco2, spo2, fev1, and fvc ivf pregnancy rate pain intensity and analgesic consumption abdominal pain, other pain, nausea and stress pain intensity and psychological well-being were assessed by means of visual analogue scales (vas); tiredness, nausea and vomiting and analgesic drug consumption median abdominal pain levels pain relief, peroperative pain, clouding of memory and the surgeons' assessment of operating conditions pain tolerance oxygen saturation levels follicular cortisol levels of vaginal and abdominal pain visual analogue scale (vas 5-point scale while severity of pain, and doctor and patient satisfaction state trait anxiety inventory (stai p-deletion and critical flicker fusion scores hemodynamic parameters, pain, sedation, and recovery score pain relief mean and maximum pain, and 'pain now anaesthetic effect fertility outcomes plasma remifentanil concentrations heart rate (hr), mean arterial pressure (map), peripheral oxygen saturation (spo2), end tidal carbon dioxide (etco2) tension, forced expiratory volume in 1 second (fev1) and forced vital capacity (fvc), and amount of remifentanil implantation rate number of oocytes harmful to oocytes or embryos visual analogue scale pain-relieving effect postoperative abdominal pain vas pain ratings median pain levels rate of gestation neuropeptide y (npy) concentrations in follicular fluid (ff p-deletion, reaction time, and critical flicker fusion tests revealed similar depression intraoperative analgesia level of stress a visual analogue scale (vas levels of sedation and co-operation adequate peroperative analgesia pain levels time to discharge and costs rate of embryo transfers and pregnancies pain rating and pain score postoperative nausea average alfentanil dosage requirements hemodynamic parameters analgesic effects postoperative abdominal pain, nausea and stress intra-operative sedation and co-operation pain and subjective expectations and experiences incidence rate of abdominal pain visual analogue scales (vas pain and anxiety pain directly related to oocyte aspiration, adequacy of anaesthesia during oocyte aspiration, abdominal pain, or degree of nausea mean age, weight, duration of procedure and dose of alfentanil plasma remifentanil concentrations and pulmonary function tests time and drug consumption abdominal pain pain relief; secondary end-points were costs, time to discharge and clinical outcome parameters nausea mean (sd) pain score overall, patient satisfaction pain score hemodynamic variables, sedation, pain, the aldrete recovery score, and side effects cumulative scores of pain pain relief and subjective well-being npy concentrations in ff oversedation or peri-operative complications time and costs for drug consumption pain sensation number of oocytes retrieved and fertilization, cleavage and clinical pregnancy rates pain thresholds pain hemodynamic variables, sedation and pain scores and the number of patients with the maximum aldrete recovery score pain scores take home baby rate adverse effects efficacy and acceptability vas ratings pregnancy rate and npy concentrations|after 30 min the p-deletion and critical flicker fusion scores were still impaired in the midazolam, but not in the propofol, group. significantly more fentanyl (97.5 microg) was used in the pca group than in the other group (84.6 microg) (p = 0.03). plasma increases in prolactin and hormonal responses to follicular puncture were fully attenuated by spinal anesthesia and partially attenuated by the techniques requiring sedation. there were no significant differences between the two groups in the severity of nausea, vomiting, dizziness, and drowsiness. sedated patients were more arousable than anaesthetized patients during the procedure and experienced less postoperative abdominal pain at 30 min. both anesthesia regimens provided satisfactory analgesia without affecting fev1 and fvc, but significantly higher plasma remifentanil concentrations were calculated when only ri was used as an anesthetic technique. women's satisfaction with pain relief, peroperative pain, clouding of memory and the surgeons' assessment of operating conditions were evaluated. the incidence of postoperative nausea was the same in both treatment groups (8%). analysis of pain perception using visual analogue scoring showed a similar pain tolerance in both groups for the procedures of vaginal ultrasound scanning, needle insertion, and follicular aspiration. the acupuncture compound anesthesia group was significantly better than the simple pethidine group in the pain rating and pain score (p < 0.01); the incidence rate of abdominal pain at 1 h and 2-5 h after oocyte retrieval in the acupuncture compound anesthesia group was lower than that in the simple pethidine group (p < 0.01). for the patients with pain thresholds of 0.5 ma, 2.5 ma and 3 ma, in cumulative scores of pain there were no significant differences between the two groups (p > 0.05). auricular ea significantly reduces pain intensity and analgesic consumption of the opioid remifentanil during oocyte aspiration in ivf treatment. the number of patients in group iii with the maximum aldrete recovery score 5 min after the procedure was significantly lower than that in groups i and ii. directly after opu, the ea group reported significantly higher mean and maximum pain, and 'pain now' than the cma group. there were no oversedation or peri-operative complications. although vas pain ratings were significantly higher at oocyte aspiration (p < 0.0001) and after retrieval (p < 0.01) in the ea than in the ca group, they were similar 60 min after surgery. after 2 h, the ea group reported significantly less abdominal pain, other pain, nausea and stress than the alfentanil group. before oocyte aspiration, the level of stress was significantly higher in the ea group than in the alfentanil group (p < 0.05), and the ea group experienced discomfort for a significantly longer period during oocyte aspiration (p < 0. 01).|thirty-eight women in the inhalation group (67%) and 41 (75%) women in the intravenous group were 'very satisfied' with their analgesia (p = 0. 41 follicular fluid oocyte aspiration and patients' experiences of well-being after surgery patients of different pain thresholds 50 patients with no premedication forty american society ofanesthesiologists i subjects requiring tugor outpatients undergoing minor diagnostic and therapeutic procedures associated with intermittent discomfort 80 healthy women undergoing vaginal ovum pickup procedures thirty-nine women 106 patients patients in an assisted reproduction program 150 patients undergoing egg collection subjects receiving two hundred patients undergoing opu 150 women undergoing in-vitro fertilization (ivf) and embryo transfer 286 women undergoing oocyte aspiration seven hundred cases of infertility who will be taken ova under ultrasound guidance via the va gina and receive in vitro fertilization and embryo transfer (ivf-et 57 women undergoing outpatient oocyte recovery sixty-nine women were scheduled for oocyte retrieval three hundred and sixteen cases undergoing in vitro fertilization and embryo transfer (ivf-et after ovarian hyperstimulation, subjects patients receiving a paracervical block (pcb) with and without conscious sedation vitro fertilization 90 patients 160 women undergoing ivf 94 women undergoing ivf 30 patients comparing
blood pressure and components of systemic ras severe renal or extrarenal toxicity partial remission (urinary protein-creatinine ratio serum creatinine and creatinine clearance remission serum creatinine, triglyceride, cholesterol, urine protein and creatinine clearance proteinuria and alleviated renal tubular damage cosmetic side effects (hypertrichosis and gum hypertrophy complete resolution of proteinuria serum albumin levels partial remission proteinuria blood pressure and components of the renin-angiotensin system (ras nephrotic-range proteinuria hypertension and hypokalemia, while vomiting and reversible alopecia steady-state blood pressure and serum concentrations of serum angiotensin-converting enzyme (ace) and plasma renin activity or angiotensin ii (at-ii number of adverse events ua/uc ratio complete remission (urinary protein-creatinine ratio mean score hyperlipidemia and proteinuria efficacy and safety fractional decline in gfr average csa level and proteinuria change urine albumin-to-creatinine (ua/uc) ratio and the percentage reduction mean urinary protein excretion, the mean serum proteins and plasma cholesterol sustained remissions serum concentrations of urinary retinol-binding protein and beta(2)-microglobulin median ua/uc ratio baseline clinical, biochemical, and histological features remission of the nephrotic syndrome treatment failure blood cholesterol levels rates of remission blood pressure diminution of their proteinuria prestudy serum cholesterol levels cushingoid features and serious infections complete remission proteinuria and serum albumin levels systolic and diastolic blood pressure reductions proportion of patients who experienced relapse values of 24-h urinary protein excretion serum creatinine|at month 6 the mean urinary protein excretion, the mean serum proteins and plasma cholesterol had significantly improved in the csa group but were not changed in the controls. the results showed no statistically significant difference in serum creatinine, triglyceride, cholesterol, urine protein and creatinine clearance between fish oil supplemented group and placebo group. the children who received iv cyclophosphamide had more sustained remissions, longer periods without proteinuria and fewer significant side effects; this was achieved at a lower cumulative dose. the median ua/uc ratio at the end of 20 weeks was 1.1 and 1.8 in groups a and b, respectively ( p>0.05). treatment failure occurred in 36% of the control group and 57% of the experimental group (p > 0.1). following treatment, complete remission was seen in 53.8% and 47.8% patients in groups i and ii, respectively (p = 0.6). cph patients responded (p < 0.05, intention-to-treat). there were no significant changes in serum albumin levels in either group during the trial. patients in group i showed lower serum concentrations of urinary retinol-binding protein and beta(2)-microglobulin (p<0.01) at the end of the study, but the patients' blood pressure and components of the renin-angiotensin system (ras) had no change during treatment. rates of remission at 12 months were also similar (rr, 1.14; 95% ci, 0.84 to 1.55). the fractional decline in gfr over the course of the study was not significantly different between the csa and placebo-treated groups.|patients with steroid-resistant nephrotic syndrome (srns twenty-five patients with fsgs normotensive children with srins forty-five patients with steroid-resistant ins children with steroid-resistant nephrotic syndrome patients with steroid-resistant minimal lesion nephrotic syndrome or focal segmental glomerulosclerosis children with steroid-resistant fsgs sixty children, with biopsy diagnosed focal segmental glomerulosclerosis (fsgs) and with unremitting nephrotic syndrome despite intensive therapy with adrenocortical steroids adults and children steroid-resistant idiopathic nephrotic syndrome kidney disease in children tertiary-care hospital; 41 consecutive patients with idiopathic srns, estimated glomerular filtration rate greater than 60 ml/min/1.73 m(2), and histological characteristics showing minimal change disease, focal segmental glomerulosclerosis, or mesangioproliferative glomerulonephritis steroid-resistant nephrotic syndrome forty-five normotensive patients with srins children patients with srns 13 children with biopsy-proven steroid-resistant mcns children with newly diagnosed primary steroid-resistant nephrotic syndrome and histologically proven minimal change disease, focal segmental glomerulosclerosis or mesangial hypercellularity patients with steroid-resistant ins patients with proteinuria normotensive children with steroid-resistant idiopathic nephrotic syndrome (srins children with srns children under this treatment eight patients with steroid-resistant nephrotic syndrome (four with idiopathic minimal lesion nephrotic syndrome and four with focal segmental glomerulosclerosis patients with steroid-resistant idiopathic nephrotic syndrome (ins during april 2001 to december 2003, 52 consecutive patients with idiopathic srns, normal renal function and renal histology findings showing minimal change disease, focal segmental glomerulosclerosis or mesangioproliferative glomerulonephritis were enrolled into the study 25 consecutive patients with steroid-resistant nephrotic syndrome (srns children with corticosteroid-resistant fsgs patients with focal segmental glomerulosclerosis children with steroid-resistant idiopathic nephrotic syndrome childhood nephrotic syndrome
continuous cocaine abstinence weekly assessments of the frequency and quantity of drug and alcohol use, weekly urine toxicology screens and breathalyzer readings medication adherence cocaine dependence positive urinalysis visual analogue scales (vas quantity and frequency of cocaine total number of weeks abstinent from cocaine number of cocaine-negative urine tests rates of cocaine-negative urine tests|the two active psychotherapies (cbt and tsf) were associated with reduced cocaine use over time compared with supportive psychotherapy (cm). the number of cocaine-negative urine tests during the trial were also higher on disulfiram (14.7) than on placebo (8.6); furthermore, subjects in the disulfiram group achieved consistently higher rates of cocaine-negative urine tests in each 3-week interval and the increase over time was faster in the disulfiram compared with placebo. disulfiram treated subjects decreased the quantity and frequency of cocaine use significantly more than those treated with placebo. results show that cbt treated subjects remained in treatment longer than those assigned to either dis/cbt or ntx/cbt therapies. more patients taking the disulfiram-naltrexone combination achieved 3 consecutive weeks of abstinence in treatment than placebo-treated patients.|urban methadone maintenance clinic dependent subjects (n = 20 cocaine dependence in methadone-maintained opioid addicts individuals with comorbid alcohol and cocaine abuse individuals with cocaine dependence and concurrent alcohol abuse or dependence patients with co-occurring cocaine and alcohol dependence maintained opioid addicts 12 subjects co-abusers of sixty-seven cocaine-dependent, methadone-maintained, opioid-dependent subjects (52% female; 51% caucasian cocaine abusers maintained subjects treating co-occurring cocaine and alcohol dependence urban substance abuse treatment center maintained patients one hundred and twenty-two cocaine/alcohol abusers (27% female; 61% african-american or hispanic 208 patients fifteen subjects completed the study, including 8 subjects randomized to disulfiram (72.7%) and 7 subjects randomized to 12 subjects enrolled in the study only 4 (33%) completed the 12-week treatment
pain reduction time to return to uninterrupted sleep resolution of pain chronic pain and quality-of-life outcomes relieved pain frequency of postherpetic neuralgia progression of the rash total crusting quality of life laboratory adverse events postherpetic neuralgia time to a first or a complete cessation of pain post-herpetic neuralgia lesion healing, resolution of pain, return to usual activity, and return to uninterrupted sleep analgesic requirements each day, and adverse events and laboratory abnormalities risk ratios time to total crusting and healing time to return to usual daily activity accelerated time to cessation of acute neuritis adverse events|time to total crusting and healing was accelerated for patients receiving acyclovir plus prednisone compared with patients receiving two placebos; the risk ratios were 2.27 18 (23%) of the patients had post-herpetic neuralgia at 6 months after the acute zoster, 9 (24.3%) having received prednisolone and 9 (22.5%) placebo. no significant differences were detected between the four groups in the progression of the rash (p > 0.1).|post-herpetic neuralgia 78 patients with herpes zoster whose pain and exanthema 208 immunocompetent patients older than 50 years of age who had localized herpes zoster that developed less than 72 hours before study enrollment 15 university hospitals or affilliated clinics herpes zoster patients with acute herpes zoster acute herpes zoster relatively healthy persons older than 50 years of age who have localized herpes zoster, combined 400 patients recruited, 349 completed the study patients with a rash of less than 72 hours' duration
rdai score values prevalence of post-bronchioltis wheezing symptoms of acute bronchiolitis or prevented postbronchiolitic wheezing mean oxygen requirements, or length of hospital stay mean duration of symptoms wheeze and hospitalization rates clinical score or in the sao2 oxygen saturation (sao2 length of hospital stay oxygen saturation, respiratory rate, rdai measurement twice daily for the first 4 days, and the length of hospitalization poor racs time from study entry to resolution of respiratory distress, determined by a clinical score derived from the respiratory rate, occurrence of wheezing, chest retraction, and oxygen saturation racs time needed for resolution of respiratory distress rdai improvement rate of hospitalisation or respiratory status respiratory re-admission rates length of hospitalization hospital admissions hospital admission rate duration of hospital admission, time taken to become symptom free, re-admission rates, general practitioner consultation rates, and use of anti-wheeze medication cumulative proportion of in-hospital stay respiratory syncytial viral (rsv) bronchiolitis hospital stay, later medical visits or admissions, and adverse events duration of oxygen therapy frequency of hospital release shorter hospitalization period rate of hospital admission, the respiratory status time to clinical resolution mean length of hospital stay disease severity median length of stay evolution of respiratory rate, oxygen saturation, clinical score, or pulmonary function tests respiratory status hospital admission within 7 days after the day of enrollment (the initial visit to the emergency department length of hospital stay, duration of oxygen therapy and time to clinical improvement during the hospitalization admission rate prevalence of post-bronchiolitis wheezing respiratory assessment change score (racs mean duration of oxygen therapy prevalence of wheeze, respiratory symptom scores, or proportion requiring bronchodilators or steroids median time respiratory distress assessment instrument (rdai), heart and respiratory rates, and transcutaneous haemoglobin oxygen saturation (spo(2 heart and respiratory rate; respiratory distress index, oxygen saturation, and silverman andersen scores hospital admission after 4 hours of emergency department observation mean 4-hour racs heart rate, respiratory rate and respiratory distress assessment instrument (rdai) score duration of illness prior to enrollment, pretrial medication use, clinical severity of bronchiolitis, history of atopy, and family history of atopy chronic respiratory symptoms postbronchiolitic wheezing hospitalisation rate rdai, heart and respiratory rate and spo(2 baseline characteristics and respiratory status rdai score clinical score, oxygen saturation, or iv fluid requirement oxygen saturation, respiratory rate, and rdai score|the hospitalisation rate was similar between groups (21 % vs. 25 %, p = 0.9, respectively), independently of the virus identified. there were no significant differences between the two groups in change in oxygen saturation, respiratory rate, and rdai score at any assessment period. both groups had respiratory improvement during observation; the mean 4-hour racs was -5.3 for dexamethasone, as compared with -4.8 for placebo (absolute difference, -0.5 there were no significant differences between the outcome variables of the four groups within the first 120 min and at 24 hours, or between the rates of requirement of a second dose of the same bronchodilator. the administration of salbutamol plus dexamethasone is more effective in the control of respiratory distress in children with bronchiolitis compared with the use of salbutamol alone. there are no short or long term clinical benefits from the administration of nebulised corticosteroids in the acute phase of rsv bronchiolitis. no reduction was observed in the prednisolone group, compared with the control group, in terms of length of hospital stay (6.0 vs 5.0 days, p = 0.7), duration of oxygen therapy (24.0 vs 24.0 h, p = 0.4) and time to clinical resolution (4.0 vs 4.0 days, p = 0.8). inhaled dexamethasone may reduce the length of hospitalization among infants with acute viral bronchiolitis, especially among those born prematurely. 1.5 in all patients evaluated, p < 0.05) than placebo, whereas there was no detectable difference on day 6, suggesting that addition of prednisolone to albuterol transiently accelerates recovery from bronchiolitis. among infants with bronchiolitis treated in the emergency department, combined therapy with dexamethasone and epinephrine may significantly reduce hospital admissions. no significant differences were found between the budesonide and placebo groups in change in clinical score 48 hours after trial entry, mean oxygen requirements, or length of hospital stay during the acute illness. after 3 and 7 days of treatment, both groups showed similar clinical improvement and there were no statistically significant differences between the two groups in the clinical score or in the sao2. poor racs occurred in 41% and 17% of the placebo and dexamethasone groups, respectively (p =.034). a single-dose, dexamethasone injection versus placebo produced a significant: (1) decrease in the time needed for resolution of respiratory distress (hazard ratio 1.56; 95% ci, 1.14-2.13; p = 0.005), no significant differences were found between the groups in evolution of respiratory rate, oxygen saturation, clinical score, or pulmonary function tests on day 3.|infants with mild to moderate bronchiolitis who are also treated with an inhaled beta2-agonist outpatients with moderate-to-severe acute bronchiolitis outpatients with bronchiolitis enrolled patients at 20 emergency departments during the months of november through april over a 3-year period mild to moderate bronchiolitis 65 infants (33 in the dexamethasone vs. 32 in the placebo group) finished the study federal university of rio grande, rio grande-rs, brazil infants with mild to moderate bronchiolitis (defined as the first episode of wheezing associated with low grade fever, rhinitis, tachypnea, and increased respiratory effort in a previously healthy infant during the winter months 70 children < 24 months old in the emergency department with respiratory disease assessment instrument > or = 6 infants with moderate to severe bronchiolitis presenting to an emergency department acute bronchiolitis infants with bronchiolitis treated in the emergency department, combined therapy with pediatric wards of a university hospital and its affiliated hospital in thailand, included 174 previously healthy children under 2 years of age, hospitalized with acute bronchiolitis 2009 massachusetts medical society patients were excluded if they had any one of the following: an underlying disease that might affect cardiopulmonary status, asthma, recent treatment with steroids (within 2 weeks), or any history of adverse reaction to steroids acute bronchiolitis in young hospitalized children acute bronchiolitis in hospitalized children thirty-eight infants were enrolled in the study; 20 received bronchiolitis children hospitalized with bronchiolitis respiratory syncytial virus bronchiolitis 240 infants who consulted with acute respiratory illness fulfilled the inclusion criteria previously healthy, young children hospitalized with acute bronchiolitis outpatients with acute bronchiolitis sixty-one infants with bronchiolitis aged 3 to 12 mo were included 161 infants were studied 49 patients between 1-18 months diagnosed with bronchiolitis with three days or less of disease evolution infants with acute moderate-to-severe bronchiolitis treated infants with acute bronchiolitis primary respiratory syncytial virus bronchiolitis 29 previously healthy infants (median age, 194 days infants admitted to hospital with their first episode of rsv positive bronchiolitis for 5 days 800 infants (6 weeks to 12 months of age) with bronchiolitis who were seen in the pediatric emergency department twenty-eight patients infants with moderate-severe bronchiolitis infants with acute viral bronchiolitis hospitalized infants with acute bronchiolitis forty infants with bronchiolitis (83% rsv), mean age 13.5 weeks (range 4 to 41 weeks), were admitted to the royal alexandra children's hospital, brighton, uk participants, children aged 6 weeks to 15 months, admitted with first-time wheezing, were eligible if their oxygen saturation was less than 95% on admission to the hospital and their respiratory distress assessment instrument (rdai) score was greater than 6 infants with bronchiolitis treated inpatients with acute bronchiolitis 69 infants aged 2-21 months who were admitted to the pediatrics department of the faculty of medicine, mersin university, with acute bronchiolitis children admitted to the hospital with bronchiolitis treated with nebulized salbutamol median respiratory related general practitioner attendances 600 children (age range, 2 to 12 months) with a first episode of wheezing diagnosed in the emergency department as moderate-to-severe bronchiolitis (defined by a respiratory distress assessment instrument score > or =6 inpatient wards of a pediatric tertiary care hospital infants with mild to moderate bronchiolitis hospitalized infants with bronchiolitis acute respiratory syncytial viral bronchiolitis mild to moderate bronchiolitis with bronchiodilators and corticosteroids, we treated 51 young children with first-time wheezing and symptoms of respiratory tract infection with albuterol plus either patients with bronchiolitis rsv bronchiolitis children with bronchiolitis
hypoesthesia number of days on acute medication responder rate migraine status, quality of life, level of physical activity, and oxygen uptake mean monthly rate of acute abortive medication use, mean monthly migraine duration, and mean monthly migraine severity transformation of episodic migraine sd monthly migraine frequency symptoms with migraine duration, monthly frequency, and intensity of headache fatigue weight loss role function-restrictive, role function-preventive, and emotional function domains of the msq responder rate, time to onset of action, mean change in migraine days per month, and mean change in rescue medication days per month weight increase mean monthly number of migraine episodes quantity of symptomatic drugs taken rate of mean monthly migraine episodes satisfaction with tolerability frequency of migraine crises mean sd of monthly headache frequency adverse events 28-day migraine frequency headache intensity average weight change migraine frequency, responder rate, migraine days, and daily rescue medication usage efficacy reduction in mean monthly migraine frequency adverse reactions and weight changes quality of life mean monthly (28-day) rate of days with migraine, mean monthly rate of days with headache (migraine and nonmigraine mean standard deviation (sd) of monthly migraine frequency migraine-specific quality of life questionnaire (msq) and the weight satisfaction scale questionnaire paresthesia, fatigue, nausea, anorexia, and taste per version weight satisfaction efficacy and safety headache frequency, and migraine associated symptoms responder rate for frequency reduction of headache severity mean monthly days and severity of headache migraine episodes weight loss and improved weight satisfaction chronic daily headache efficacy and tolerability migraine headache tolerated number of days of disability frequency, intensity, and duration of migraine headaches as well as midas score and symptomatic medications headache duration serious aes (depression, abdominal pain, leg pain visual analog scale, and headache duration migraine and headache days eeg synchronization paresthesia, fatigue, and nausea dizziness mean reduction of the frequency of migraine attacks mean weight gain efficacy-evaluable alpha-band phase synchronization responder rate (proportion of patients with > or =50% reduction in monthly migraine frequency), reductions in mean number of monthly migraine days, severity, duration, and days a month requiring rescue medication, and adverse events dry mouth reduction in mean monthly frequency, intensity, duration, rescue medication use, migraine associated symptoms, and adverse events overall deterioration in weight satisfaction headache days and migraine headache days and generally well tolerated paresthesia efficacy, safety, and side effects paresthesia, weight loss, altered taste, anorexia, and memory impairment mean functional disability scores headache days mean monthly severity of migraine-associated symptoms (photophobia, phonophobia, and nausea), change in the mean monthly frequency f migraine-associated vomiting, and response rates (based on monthly migraine days and total headache days mean 28-day migraine frequency nausea number of migraine days side effects mean weight loss mean (+/-sd) of monthly migraine frequency reduction in mean monthly migraine days and severity of headache somnolence monthly migraine frequency monthly headache frequency mean number of migraine days number of days with migraine development of cdh teaes of mild or moderate severity migraine frequency rescue medication use visual analog scale (vas), and headache duration migraine headache frequency, intensity, and duration adverse effects frequency, intensity, duration, associated symptoms with headaches, analgesics use, as well as drugs' side effects mean monthly migraine frequency|topiramate was associated with improvement in some quality-of-life indicators compared with amitriptyline and was associated with weight loss and improved weight satisfaction. compared with placebo, topiramate treatment was associated with statistically significant reductions in mean number of migraine days (6.6 vs. 5.3/28 days; p = .001) and headache days (6.6 vs 5.3/28 days; p = .001). the tpm 100 mg/d and prop groups were similar with respect to reductions in migraine frequency, responder rate, migraine days, and daily rescue medication usage. significantly more topiramate-treated patients (50 mg/d, 35.9% [p =.04]; 100 mg/d, 54.0% [p <.001]; and 200 mg/d, 52.3% [p <.001]) exhibited a 50% or more reduction in monthly migraine frequency than placebo-treated patients (22.6%). a significantly larger proportion of tpm-treated subjects had a > or =75% reduction in monthly migraine frequency compared with placebo (p=0.03). the mean 28-day migraine frequency was reduced by 36% in patients receiving topiramate as compared with 14% in patients receiving placebo (p =.004). a total of 64 patients with migraine headache, aged 14 to 57 years, were randomly allocated to the 2 treatment groups. topiramate showed statistically significant benefits (p < .017) in most of the secondary efficacy measures while lamotrigine was beneficial for reduction in headache frequency, and migraine associated symptoms. the primary efficacy variable showed a mean reduction of 0.93 (95% confidence interval (ci) 0.31-1.54) attacks in the exercise group, 0.83 the reduction of headache severity in the topiramate group was significantly more than that in the valproate group (p = .027). statistically significant reductions (p<.05) occurred within the first month with topiramate at 100 and 200 mg/d. in the tpm group, side effects were transient and well tolerated. the mean monthly days and severity of headache in the three groups also declined and was more significant in the flunarizine plus topiramate group than in the flunarizine group and the topiramate group (p<0.05). patients in the placebo group had a greater number of days on acute medication than did those in the topiramate group (mean difference between groups -0.95, -1.49 to -0.41; p=0.0007). the topiramate group showed a reduction in the mean (+/-sd) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the visual analog scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (p < 0.001). both levetiracetam and topiramate significantly decreased migraine frequency, compared with placebo.|adult migraineurs patients were aged 12 to 65 years and had a 6-month history of migraine (international headache society criteria) and 3 to 12 migraines a month but no more than 15 headache days a month during a 28-day prospective baseline phase adults with 3 to 12 migraines per month forty patients, aged 19 to 62 years (mean, 38.2 years 24 non-migraine healthy controls 56 patients who completed the course of study fifty-seven patients comprised the intent-to-treat population 559 patients (68.3%) completed the open-label phase; 514 entered the double-blind phase and were assigned to migraine prophylaxis migraine prevention subjects with hfem outpatient treatment at 52 north american clinical centers n = 21; 20 women, 1 man patients with migraine 35 patients completed the study in the tpm group and 37 patients in the subjects with episodic migraine with and without aura 150 patients with migraine recruited into the study and randomly assigned to one of three conditions, 126 completed the trial in their group october 2003 to september 2004 adults and children 45 subjects who discontinued the study in the tpm group, 21 discontinued during the titration period, compared with 3 of 13 subjects who discontinued in the placebo group adult subjects with high-frequency episodic migraine (hfem, 9-14 migraine headache days/month 118 subjects (66.7%) in the topiramate group and 112 subjects (66.3%) in the amitriptyline group migraine with/without aura in adults sixty patients with frequent migraine (more than 4 attacks per month) from the headache clinic at a tertiary referral centre in india adults with migraine four hundred eighty-seven patients were randomized, and 469 composed the intent-to-treat population 818 patients who have migraines were enrolled from 88 clinics in 21 countries five hundred and seventy-five subjects were enrolled from 61 centres in 13 countries 62 patients with frequent migraine headaches (> or = 3 attacks per month 483 patients randomized, 468 provided at least 1 postbaseline efficacy assessment and comprised the intent-to-treat population forty-five migraine without aura outpatients (mo 64 patients with migraine headache, aged 14 to 57 years 331 subjects (172 topiramate, 159 amitriptyline; 84.9% female; 84.6% white; mean [sd] age, 38.8 [11.0] years; mean weight, 77.1 [20.1] kg) who provided at least 1 efficacy assessment one hundred and fifteen patients patients who do not benefit from or do not want to take daily medication alpha rhythm in migraine patients patients were aged 12 to 65 years, had a 6-month international headache society migraine history, and experienced 3 to 12 migraines per month, but had 15 or fewer headache days per month during the 28-day baseline period 211 subjects (138 tpm, 73 placebo; mean [sd] mean weight, 76.7 [18.7] kg 159 topiramate subjects and 171 placebo subjects 100 adult subjects with a history of migraine with or without aura patients with frequent migraine
oesophagitis esophageal acid sensitivity heartburn-dominant, uninvestigated dyspepsia heartburn-specific questionnaire relapse rate concordance analyses, daytime and nighttime heartburn with antacid usage free of heartburn median percentages of 24-h heartburn-free days complete endoscopic healing frequency and severity of symptoms rate of complete resolution of heartburn symptomatic relief early satiety relief of heartburn free from key gerd symptoms symptom relief erosive reflux oesophagitis, symptom relief relieving heartburn gerd symptoms (heartburn, acid eructation, and pain on swallowing endoscopic healing median time to first 24-hour heartburn-free interval diarrhea percentage of heartburn-free days and antacid-free nights symptoms of mild-moderate gastroesophageal reflux disease (gerd endoscopic appearance of the esophageal mucosa mild heartburn patient quality of life reflux score erosive oesophagitis daily proportions of patients with no heartburn adverse events incidence of possible or probable treatment-related adverse reactions severity of heartburn and endoscopic grade total heartburn relief quality of life improvements relief of symptoms of gastroesophageal reflux reflux symptom relief symptom control complete relief relief of non-reflux symptoms gastroesophageal reflux disease (gerd quality of life mean heartburn pain scores gastro-oesophageal reflux disease symptoms antacid consumption total time off active treatment, time to failure of intermittent treatment, and outcomes ranked from best to worst general health status dimensions of physical functioning, bodily pain, and vitality resolution of heartburn cumulative relapse rates recurrences of moderate or severe heartburn frequency of gastro-oesophageal reflux disease symptoms and health-related quality of life percentage of heartburn-free days and the time to first and sustained resolution of heartburn relief from key gerd symptoms (heartburn, acid eructation, and pain on swallowing reflux dimension of the gastrointestinal symptom rating scale (gsrs) score percentages of 24-h heartburn-free days (primary) and nights without heartburn (secondary effective and well tolerated proportion of patients in whom heartburn proportion of patients with complete relief of daytime heartburn acid regurgitation, dysphagia, epigastric pain, and nausea efficacy and safety mean basal pressure erosive esophagitis anxiety gastrointestinal symptoms (epigastric pain, vomiting, nausea, flatulence, retching, and retrosternal feeling of tightness) and safety profiles rates of complete control of gord symptoms response of low-esophageal-sphincter pressure complete relief from upper gi symptoms tolerated quality of life and symptom severity questionnaires symptom frequency and severity endoscopic classification mean number of heartburn episodes heartburn nonerosive gastroesophageal reflux disease reflux index scores, quality of life (sf-36), and the hospital anxiety and depression (had) scale and symptom relief pathological gastroesophageal reflux symptomatic improvement nights without heartburn abdominal pain and diarrhea gerdq index median times to relapse heartburn symptoms of reflux disease health-related quality of life severity of oesophagitis or frequency of positive acid perfusion tests symptoms and quality of life symptomatic relief of heartburn clinical outcomes and quality of life heartburn symptoms symptomatic response adequate control of heartburn gerd-associated symptoms (e.g., regurgitation, belching, early satiety esophageal endoscopic appearance or sphincter pressures global scores heartburn-free complete relief rate completely symptom free lower severity of heartburn complete upper gi symptom relief percentage of heartburn-free days frequency and degree of symptoms adverse events and laboratory assessments rate of adverse events quality-of-life effects esophagoscopy, esophageal acid sensitivity, and lower esophageal pressures reflux chronic heartburn similar sensitivity pain severity of both day and night heartburn complete resolution of heartburn lower-esophageal-sphincter pressure median number of days off active treatment esophageal erosions or ulcerations gastroesophageal reflux disease and heals erosions and ulcerations total heartburn relief defined as no heartburn symptoms oesophageal acid hypersensitivity frequency and the severity of heartburn reflux score irrespective of h. pylori infection daytime and nighttime heartburn effective and safe rapid relief of heartburn healing heartburn severity rapidity of symptom relief and 4-week efficacy total use of rescue antacid medication regurgitation and epigastric pain symptomatic relapse total regurgitation free of regurgitation complete heartburn relief overall quality-of-life measures or the had scale heartburn relief safety and symptom relief efficacy rate of sufficient relief from heartburn evidence of erosions and ulcerations percentage of patients self-rated as having minimal or better symptomatic improvement frequency and severity of heartburn using the gastrointestinal symptom rating scale (gsrs) and a patient heartburn diary alginate/antacid relief medication|lansoprazole therapy is more effective than standard dosages of ranitidine or placebo in relieving symptoms in patients with endoscopically confirmed non-erosive reflux esophagitis. in both treatment periods, metoclopramide-treated patients had significantly more symptomatic improvement than the control group (p less than 0.05). the percentage of heartburn-free days was significantly higher with esomeprazole 40 mg (63%, 66%) or 20 mg (63%, 68%) than with placebo (46%, 36%; p < or = 0.001) in each of the two studies. there was a significant correlation between the ph registration result and response to omeprazole (p = 0.04, chi2), but not to placebo (p = 0.16). dexlansoprazole mr 30 and 60 mg were superior to placebo in providing 24-h heartburn-free days and nights in nerd patients. pantoprazole is significantly superior to ranitidine in the treatment of key and associated gastrointestinal symptoms of gerd and is well tolerated. patients in the esomeprazole group (n = 85) demonstrated statistically significant reductions in their gerdq index, from 19.45 to 15.37 and to 14.32 (p = 0.013, p = 0.005) at weeks 4 and 8, respectively. complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (p < or = .001). compared with placebo, cisapride significantly reduced scores for daytime and nighttime heartburn (p < 0.001), total regurgitation (p < 0.001), eructation (p = 0.04), and early satiety (p = 0.04). significant (p less than 0.05) decreases in symptom frequency and severity were noted throughout the study in the cimetidine-treated patients, as compared with the placebo group. proportions of patients with total heartburn relief were higher in patients with eo (71%-80% of patients from day 4 onwards) compared to those without eo (52%-67% of patients from day 4 onwards). ranitidine was superior to placebo with regard to effect on symptoms, improvement of oesophagitis as assessed by endoscopy and biopsy, and decrease of oesophageal acid hypersensitivity. omeprazole 20 mg once daily was highly effective in relieving heartburn whereas cisapride 20 mg twice daily was not significantly more effective than placebo. endoscopic healing at 4 weeks occurred in 76% of oesophagitis patients on ome20 and in 56% on ome10. omeprazole significantly improved reflux score irrespective of h. pylori infection while famotidine significantly improved reflux score in h. pylori-positive patients but not in h. pylori-negative patients. symptom relief after 4 weeks was achieved by 61% (om20), 49% (om10), and 40% (ran) patients (om20 versus om10, p < 0.0167; om20 versus ran, p < 0.0001; om10 versus ran, p < 0.01). at two weeks there was no significant difference between placebo and ranitidine, regarding the proportion of patients with complete relief from symptoms or satisfied with treatment. on completion, symptom relief favoured omeprazole: 57% of patients on omeprazole were free of heartburn (vs. 19% on placebo), 75% were free of regurgitation (47%) and 43% were completely asymptomatic (14%), each with p < 0.0001. omeprazole was significantly (p< or =.003) more effective than placebo for the treatment of acid regurgitation, dysphagia, epigastric pain, and nausea. both famotidine regimens resulted in a significantly greater proportion of patients with complete endoscopic healing than placebo, with the bid dosing being numerically superior to the 40-mg hs dose. pantoprazole was associated with significantly higher rates of complete control of gord symptoms than ranitidine at four weeks (40% v 19%; p < 0.001), eight weeks (55% v 33%; p < 0.001), six months (71% v 56%; p = 0.007) and 12 months (77% v 59%; p = 0.001). patients with heartburn and normal endoscopy results or mild erosive changes received omeprazole 10 mg or 20 mg daily or ranitidine 150 mg twice daily for 2 weeks. quality of life was improved in all treatment groups, and the improvement in the reflux dimension of the gastrointestinal symptom rating scale (gsrs) score was significantly different between groups (p = 0.002). daily diaries documented heartburn relief (score < or = 3/7 on < or = of 7 prior days) and relapse (score > or = 4 on > or = 2 of 7 prior days). we conclude that omeprazole is superior to cimetidine for the relief of all grades of heartburn in gerd, whether or not the patient has unequivocal endoscopic oesophagitis. ranitidine-treated patients had more favorable scores on the general health status dimensions of physical functioning, bodily pain, and vitality (p < .05), and more favorable scores on all dimensions of the heartburn-specific questionnaire (p < .05). at two weeks cimetidine was significantly more effective than placebo. the rate of complete resolution of heartburn in week 4 was significantly higher in patients treated with omeprazole 10 mg [32.3%, 95% confidence interval (ci), 22.9%-41.6%] or 20 mg (25.8%, 95% ci, 16.9%-34.7%) than in the placebo group (12.0%, 95% ci, 5.3%-18.6%). at 4 weeks the proportion of patients with complete absence of heartburn was 46% (95% confidence interval, 39-53%) with 20 mg omeprazole, 31% (25-38%) with 10 mg omeprazole, and 13% (7-20%) with placebo. there were no differences between the groups with respect to changes in esophageal mucosal sensitivity to acid perfusion or changes in histologic grading of esophageal mucosal biopsy specimens.|patients with heartburn following treatment with patients with oesophagitis chronic mild to moderate gastroesophageal reflux disease japanese patients with non-erosive gastro-oesophageal reflux disease 221 patients with heartburn and oesophageal mucosa grade 0 (normal, n = 51), 1 (no macroscopic erosions, n = 52), 2 (isolated erosions, n = 97) or 3 (confluent erosions, n = 21 patients with erosive and non-erosive disease patients presenting with troublesome reflux symptoms 901 patients with symptomatic reflux disease, which was confirmed by endoscopy to be nonerosive, received chinese patients with non-erosive reflux disease patients without erosive oesophagitis patients with uncomplicated gastro-oesophageal reflux disease 31 patients with chronic heartburn patients with essentially normal oesophageal mucosa gastro-oesophageal reflux disease patients with moderately severe nonerosive gastroesophageal reflux disease patients with non-erosive reflux disease patients with chronic heartburn but with no endoscopic evidence of erosive oesophagitis require gastric acid suppression to relieve symptoms patients with reflux esophagitis grade 0 or 1 were included in the study patients with gastroesophageal reflux disease patients with a history of heartburn (> or =12 months) and episodes of moderate to severe heartburn on 4 or more of the 7 days before endoscopy heartburn-dominant uninvestigated dyspepsia patients from 46 primary care centres 704 patients were randomised, 677 were eligible for analyses; 318 reached the end of the study with intermittent treatment without recourse to maintenance antisecretory drugs patients without unequivocal oesophagitis nerd patients 240 patients had erosive esophagitis (eo) and patients with gerd eligible patients patients were recruited using a symptom-based questionnaire for diagnosis of gastro-oesophageal reflux disease patients with or without endoscopic oesophagitis patients with heartburn for at least 2 days a week during the month before entry into the study and no endoscopic signs of a mucosal break (grade m or n according to hoshihara's modification of the los angeles classification patients with symptomatic gerd gastroesophageal reflux disease (gerd patients receiving 355 patients were enrolled, of whom 284 patients with nonerosive reflux disease patients with chronic gastroesophageal reflux ninety-eight patients were included; however, 13 were excluded from the final analysis because of protocol violation symptomatic gastro-oesophageal reflux disease patients suffering from symptomatic gerd patients without endoscopic oesophagitis patients with symptoms suggestive of gerd underwent upper gastrointestinal endoscopy and 24-h esophageal ph monitoring patients (n = 209 patients with symptomatic gastro-oesophageal reflux disease eighteen patients primary care patients japanese patients with nerd patients with gastro-oesophageal reflux (paired comparison in 38 patients patients with a clinical diagnosis of gastroesophageal reflux, and a locally validated reflux index, the chinese gerdq, of equal to or greater than 12 307 patients aged 18 years or over presenting with symptomatic gord 483 untreated patients with complaints of heartburn >/=3 days a week, with at most grade 1 reflux oesophagitis patients with moderate intensity heartburn and no history of erosive esophagitis gastro-oesophageal reflux disease in primary care patients with stage 0 gastro-oesophageal reflux disease one hundred and twenty-five patients with symptoms of heartburn and acid regurgitation but without endoscopic abnormalities patients who were symptomatic or mildly symptomatic were followed up for 12 months patients with frequent heartburn for >or = 6 months and no evidence of erosive oesophagitis on endoscopy patients with gastro-oesophageal reflux disease (gord patients with heartburn and normal endoscopy results or mild erosive changes received 677 patients with gastro-oesophageal reflux disease 284 patients with gastroesophageal reflux disease 359 randomized patients, 355 were included in the statistical analysis (intention-to-treat population 398 patients who continued to experience moderate intensity heartburn symptomatic gerd without erosive esophagitis 114 patients had gerd defined by ph-monitoring gastroesophageal reflux disease patients patients with gastroesophageal reflux patients with symptomatic gastroesophageal reflux disease patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (gerd) patients with reflux symptoms but without endoscopic abnormality patients with reflux symptoms eligible patients included those who were at least 18 years old and had at least a 3-month history of heartburn or heartburn therapy and a minimum of 4 days with at least one heart-burn episode in the week preceding the baseline visit run-in period, patients (n = 261 symptomatic acid reflux disease without esophagitis hospitals and primary care practices between 1994 and 1996 of the remaining 85 patients, 54 had no signs of esophagitis at endoscopy, and 31 had esophagitis grade 1 patients with gastroesophageal reflux disease (gerd patients with reflux disease patients with heartburn chinese patients symptomatic gastroesophageal reflux patients [338 intention-to-treat (itt) population; 284 per-protocol (pp) population patients with heartburn, without endoscopic signs of oesophagitis 338 patients were randomized: 135 to receive setting: 65 primary care practices in norway following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease 947 nerd patients randomly received non-erosive gastro-oesophageal reflux disease symptomatic gastroesophageal reflux disease 440 patients patients with endoscopically confirmed non-erosive reflux esophagitis four hundred and twenty-seven patients were randomised uninvestigated heartburn in primary care patients with symptomatic gord patients with heartburn (for > or = 6 months 76 general practices in north-west sydney and newcastle, new south wales (australia), from 19 january 1999 to 22 september 2000 patients without oesophagitis 175 patients were randomized patients with nerd regardless of their endoscopic classification patients with symptomatic non-ulcerative oesophagitis and in those with heartburn but without oesophagitis non-erosive gastro-oesophageal reflux disease in japan gastro-oesophageal reflux disease in general practice japanese patients with nonerosive reflux disease gastroesophageal reflux disease patients with symptoms typical of gastro-oesophageal reflux disease but without endoscopic evidence of oesophagitis forty-one patients patients with or without reflux oesophagitis patients with esophagitis patients (n = 994) presenting with heartburn to their general practitioner underwent endoscopy to exclude peptic ulcer disease gastro-oesophageal reflux disease (gord non-erosive reflux disease in chinese patients
total number of dressing changes efficacy and safety wound size success rate proportion of patients with granulation tissue diabetic foot ulcers (dfus dfu healing mean time to healing all ulcer healing outcomes complete healing wound area efficacy and tolerance pain on dressing change pain on dressing changes, the number of dressing changes, and adverse events overall ulcer improvement and less deterioration healing outcomes and primarily healing speed adverse events aqag-treated ulcers|pain on dressing change was lower in the calcium alginate group (p=0.047) and the total number of dressing changes tended also to be lower (p=0.07). thirty-nine (78%) patients treated with the collagen-alginate dressing achieved > or = 75% wound area reduction, compared with 15 (60%) of gauze-treated patients. there was more overall ulcer improvement and less deterioration in aqag subjects (p = 0.058), particularly in the subset initially using antibiotics (p = 0.02).|diabetic foot lesions managing out-patients with type 1 or 2 diabetes mellitus and non-ischaemic wagner grade 1 or 2 dfus diabetic foot ulcers seventy-five patients with foot ulcers patients stratified by antibiotic use on enrolment non-ischaemic diabetic foot ulcers seventy-seven patients were enrolled 13 patients
risk of child mortality risk of adverse pregnancy outcomes pregnancy outcomes and t cell counts pregnancy outcomes, hematologic indicators, and t cell counts red blood cell count and in packed cell volume adverse pregnancy outcomes risk of fetal death hemoglobin concentrations risk of low birth weight birth weight, duration of gestation, or fetal and neonatal mortality adverse birth outcomes cd4(+), cd8(+), or cd3(+) cell counts cd4, cd8, and cd3 counts risk of preterm birth birth outcomes, hematologic indicators, and counts of t lymphocyte subsets rise in hemoglobin maternal mortality risk of low birthweight hiv disease progression or pregnancy outcomes child survival early infant death reduced risk of low birth weight severe preterm birth neonatal or overall child mortality mean birth weights cd4 cell counts, viral load, pregnancy outcomes, and maternal and infant mortality 30 fetal deaths maternal cd4 cell counts or viral load birth outcomes and counts of t lymphocyte subsets|however, the rise in hemoglobin over this period was significantly lower (p = 0.03) in the zinc group (x +/- multivitamin supplementation decreased the risk of low birthweight (<2500 g) by 44% (0.56 [0.38-0.82] p=0.003), severe preterm birth (<34 weeks of gestation) by 39% (0.61 [0.38-0.96] p=0.03), and small size for gestational age at birth by 43% (0.57 [0.39-0.82] p=0.002). the regimen had no significant effect on maternal mortality (rr = 1.02; 95% ci = 0.51, 2.04; p = 0.96). there were no significant differences between the 2 groups in the risk of fetal death (p = 0.99) or early infant death (p = 0.19).|hiv-infected women in tanzania 913 hiv-infected pregnant women such women eligible women between 12 and 27 gestational weeks hiv-infected women hiv-infected pregnant women in tanzania 400 hiv-infected pregnant women hiv-1-infected women in tanzania eligible women between 12 and 27 wk of gestation 1129 hiv-infected pregnant women in tanzania hiv-1-infected women pregnant hiv-infected women eligible women between 12 and 27 wk of gestation were given 1075 hiv-1-infected pregnant women at between 12 and 27 weeks' gestation received
median overall survival 6-month survival prolonged survival incidence of grade 3/4 flu-like symptoms tolerated with only additive toxicity 1-year survivals durable responses severe and life-threatening toxic events os, time to progression, or or complete and partial response rate median time to treatment failure (ttf) and median survival progression-free survival or overall survival percentage of cd4 or cd4 t-cell subsets median pfs time tolerated and produced a noncumulative, transient myelosuppression late quality of life poor performance status (ps), hepatic metastases, and weight loss overall median survival severe toxicity functional living index overall median ttf response rate, ttf, or survival efficacy and toxicity health-related qol objective response (complete plus partial remission [cr + pr response rates, overall survival, and tolerability ttf or survival toxicities response rates survival advantage fatigue acceptable level of toxicity toxicity response or disease stabilization response or survival median time to progression (ttp survival duration of partial responses severe thrombocytopenia grade 3 or 4 nonhematologic toxicities median os nine complete (crs) and 18 partial responses (prs drug safety median durations of response lymphopenia, evidence of immune activation objective responses, survival, and toxicity complete response (cr) and seven partial responses (pr response rate, time to treatment failure (ttf), overall survival, and toxicity median survival median progression free survival constitutional, hemodynamic, and myelosuppressive toxic effects overall response rate death survival benefit nonhematologic toxicities median duration of response median survival time percentage of cd56- (nk cells) and cd3/hla-dr-positive (activated t cells) subsets total response rate overall survival, progression-free survival (pfs), objective response, and safety, and to assess health-related quality of life (qol) and pharmacokinetics of both drugs and their metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboximide (mtic overall response rate of bcdt with il-2/ifn-alpha fatigue, nausea and anorexia, flu-like symptoms and neutropenia ttp and survival five crs and 20 prs overall survival (os|in addition, patients receiving the combined treatment schedule had a significantly prolonged survival (median 19 months) when compared to a median of 10 months for interferon alone and 5 months for vindesine alone. grade 3 or 4 nonhematologic toxicities were similar in each arm except for infection, which was more frequent with 8-hourly temozolomide. objective responses, survival, and toxicity in the two groups were evaluated at a median potential follow-up of 42 months. temozolomide therapy improved health-related qol; more patients showed improvement or maintenance of physical functioning at week 12. there was no significant difference in median progression free survival (0 months vs 4 months) and in median overall survival (12 months vs 13 months) for combined chemoimmunotherapy and for chemotherapy, respectively. response rates were 48% for biochemotherapy and 25% for chemotherapy (p =.001); six patients given biochemotherapy and two given chemotherapy had complete responses. median time to treatment failure (ttf) and median survival are significantly better on the combination arm, with some long-term crs observed. there was no difference between the two groups in progression-free survival or overall survival (median survival 5 months for bcdt with il-2/ifnalpha and 5.5 months for bcdt alone). neither ifn, tmx, nor the combination significantly improved the response rate, ttf, or survival when added to dacarbazine, but ifn significantly increased toxicity. toxicity was worse in the combination arm, with more patients experiencing fatigue, nausea and anorexia, flu-like symptoms and neutropenia. the addition of low-dose immunotherapy did not produce a statistically significant advantage in os, time to progression, or or. there was no significant difference in survival between the two treatment arms (chi2 unadjusted = 0.15, p = 0.70; chi2 adjusted = 0.01, p = 0.91).|190 patients enrolled, 91 were assessable for biochemotherapy and 92 for chemotherapy metastatic malignant melanoma one hundred eighty-one patients with metastatic melanoma one hundred two patients with metastatic melanoma metastatic melanoma 60 patients cooperative advanced malignant melanoma chemoimmunotherapy group (acimm patients with metastatic melanoma patients with metastatic malignant melanoma patients receiving ifn-alpha in combination with dtic sixty-four patients with histologically confirmed metastatic malignant melanoma eighty seven patients were randomized to the combination and 83 patients to patients with metastatic melanoma using patients with advanced metastatic malignant melanoma advanced melanoma outpatients sixty-five patients with metastatic melanoma (ecog performance status 0 or 1 124 patients patients with metastatic melanoma treated with two hundred seventy-one patients (258 were eligible 305 patients with advanced metastatic melanoma advanced malignant melanoma patients with advanced metastatic melanoma metastatic melanoma patients who had not previously received fifty-seven patients died during the study symptomatic, measurable metastatic malignant melanoma outpatients with metastatic melanoma 61 patients were randomized between april 1995 and april 1998 six patients on dtic and in 16 patients on dtic plus ifn alfa-2b one hundred seventy-six eligible patients with advanced melanoma
mean scores baseline-adjusted cde recommendation and performance rates mammography prescribing quality and volume influenza and pneumococcal immunisation rates raised total cholesterol average prescription costs frequency and quality of counseling overall benzodiazepine prescribing rate fell patient care processes (lab work, nursing, dietary management, ventilator management, ventilator weaning mammography completion pneumococcal vaccination rates effectiveness and efficiency physician behaviour endorsement of psa screening by professional bodies preventive care performance cognitive function overall cost prescribing of psychotics cde recommendation and performance cde recommendation and performance rates vaccination rates antibiotic use, diazepam prescribing, drug costs per patient, and a composite process index for diabetes care mean cost prescribing of tranexamic acid health outcomes psychotic disorder initial prescriptions hyperlipidaemia or frequency of pleasurable activities, and (c) self rated health prescription of cpvd referral rates proportion of residents with any psychotropic drug, polymedicine, and therapeutic duplication and proportion of residents with nonrecommended and acceptable drugs percentage of records containing at least one periodontal diagnostic notation adr reports angina pectoris cost effectiveness rate of unnecessary use of the 2 target antibiotics total length of stay and icu length of stay fell influenza and pneumococcal vaccination rates preventive cardiovascular care overall index of preventive performance cerebral and peripheral vasodilators (cpvd) and antibiotics total antimicrobial use median psa testing rate appropriateness (based upon the guidelines) of sale or no sale of otc anti-fungals influenza vaccination quality of selective case finding and quality of diagnostic procedures quality of life quality of care discontinuation rates processes of care, patient symptoms, quality of life, costs, and work days lost number of prescriptions of lipid-lowering drugs per month length of stay, intensive care unit transfers, readmission rates, and in-hospital death rates patient satisfaction scores rates of preventive services risky sexual behavior prescription of first-line lipid-lowering drugs blood pressure control, defined as a blood pressure measurement quantity of cholesterol testing sales of asthma medication pneumococcal immunization benzodiazepine hypnotics proportion of "correct" responses influenza immunization anxiety blood pressure control minimal intervention" components of the kit, ratings of overall acceptability of delivery, perceptions of cultural and structural barriers to using the kit, and ratings of the overall acceptability of the kit tetanus immunization patient quality of life or symptoms rates of ventouse delivery prescribing behaviour pattern of prescription of asthma medicines antibiotics in caesarean section and use of polyglycolic acid sutures patient care processes, patient morbidity and mortality outcomes, and resource use intervention delayed time to first attendance with acute asthma blood pressure antibiotic prescribing rates and patients' symptom resolution compliance rates cost-effectiveness effectiveness and cost-effectiveness admissions to hospital or mortality benzodiazepine prescribing proportions of gps implementing the programme and numbers of patients screened and intervened with transfusion risks (eg, viral hepatitis quality of rural icu care quality of asthma care back pain unit number of prescriptions written asthma related quality of life clinical breast examination recording of review of inhaler technique, smoking habit, and review of asthma symptoms total number of antibiotic prescriptions discontinuation of long-acting benzodiazepines weight and physical activity level psa testing rates and gp knowledge in key areas relating to prostate cancer and psa testing personal care scores numbers of patients "at risk of stroke respiratory infections total costs mean stay in the icu diagnosis of depression physician reporting of adverse drug reactions outpatient prescribing costs percentage of participants attending with acute asthma levels of knowledge of prescribers about the appropriate management of acute diarrhoea patient recall of assessment of smoking status and fp use of "quit dates," behavioral advice, and written materials blood transfusion practice knowledge about diarrhoea proportion of appropriate outcomes following educational outreach [odds ratio (or) number of days that unnecessary levofloxacin or ceftazidime provision of preventive care steroid prescribing average prescribing cost prescribing for anxiety diagnoses higher self-reported and observed rates for several risk assessment questions and counseling recommendations tranexamic acid hypertension control mean stay in hospital net annual savings suspected urinary tract infections adr reporting rates volume of prescribing for ibuprofen, diclofenac and naproxen as a percentage of total nsaid prescribing global scores in 4 areas--quality of care, charting, prevention and overall use of medications--and patient ratings of satisfaction with care and preventive practices anxiety and insomnia diagnosis rates clinical outcomes of mortality or nosocomial events reduced mortality blood pressure and total cholesterol values antimicrobial usage child diarrhoea total cost of antibiotics prescribed by doctors proportion of prescribing of the five most frequently used drugs glycosylated haemoglobin, patient satisfaction with care and treatment, functional health status and professional ability to apply the intervention risk factors primary outcome measure: practices receiving outreach visits acute respiratory tract infection oral rehydration solution (ors) usage management of patients' problems moderate rates of improvement time to symptom resolution index of psychoactive-drug use, measuring both the magnitude and the probable inappropriateness of medication use patient recall of fp advice about nicotine replacement patches and gum physical activity, functional status, self rated health, immunisation status, social contacts, psychological wellbeing, drug usage, and rate of influenza vaccination risk factor management helicobacter pylori testing diagnosis of dementia hypertension prescribing practice overall benzodiazepine prescribing index of preventive performance drug usage, rate of influenza vaccination, functional status, or psychological wellbeing antibiotic dispensing relative reduction in r05c1 prescription rates of diuretic or beta-blocker use mean rate of inappropriate prescribing per control practitioner loss of memory mean costs of inappropriate prescriptions per practitioner per patient visit antidiarrhoeal sales reporting adrs overall net annual cost (cost minimization baseline prescribing costs peak flow rate, review of inhaler technique, review of asthma symptoms, prophylaxis, occupation, and smoking habit; diabetes: blood glucose concentration, glycaemic control, funduscopy, feet examination, weight, and smoking habit); size of practice disease registers; prescribing in asthma; and use of structured consultation "prompts diagnoses of hypertension mean global scores discussion of dehydration during pharmacy visits hospital ventilator days days of enteral nutrition average improvement|a total of 64.3% of the physicians rated the par as useful, 26.5% found the cmep to be useful, and 41.0% considered the mentor strategy to be a useful form of continuing medical education. adjusted odds ratios were 1.03 (95% confidence interval 0.78-1.36) in patients whose blood pressure was controlled at baseline and 1.25 (95% confidence interval 0.94-1.65) in those whose blood pressure was not. brief, focused educational outreach visits by transfusion specialists can substantially improve the appropriateness and cost-effectiveness of blood product use in surgery. a marked decrease in benzodiazepine prescribing was seen over the course of the study in both intervention and control groups but no differential effect due to the educational outreach visit was found. local guidelines disseminated via practice based education improve the management of diabetes and possibly of asthma in inner city, non-training practices. patients in intervention practices had greater improvements than those in control practices for diagnoses of hypertension (improvement difference, 15.7 percentage points [95% ci, 5.2 to 26.3 percentage points]) and blood pressure control in patients with hypertension (improvement difference, 8.0 percentage points [ci, 0.0 to 16.0 percentage points]). mammography completion within 8 weeks of clinic visits was significantly higher among intervention (49%) than control (22%) asthma specialist nurses using a liaison model of care reduced unscheduled care for asthma in a deprived multiethnic health district. patient satisfaction scores improved significantly in the comprehensive intervention group (by 0.06 points on a 1 to 5 scale, p = 0.02) but not in the education only group (by 0.02 points, p = 0.42); however, the improvement was not significantly greater in the comprehensive intervention group (p = 0.20). our objective was to evaluate the effect of training in a patient-centred intervention for gps and practice nurses on outcomes for patients with type ii diabetes. the number of goals set and the increase in the use of medical record tools were greatest in the combined intervention group, with improvements noted in all groups. the tailored intervention was evaluated in a randomized trial, and was shown to significantly increase the use of thiazides for patients started on antihypertensive medication, but had little or no impact on other outcomes. practices where primary care teams received an educational outreach visit demonstrated a significantly greater improvement in uptake in high-risk groups for pneumococcal but not influenza vaccine. the mean stay in the icu did not differ between the control and intervention groups (10.9 v. 11.8 days; p = 0.7). the visits by non-physician observers resulted in a higher score on extent of use of records and on assessment on outcome and year report. in the experimental nursing homes residents who were initially taking antipsychotic drugs showed less deterioration on several measures of cognitive function than similar residents in the control facilities, but they were more likely to report depression. face-to-face visits proved the most successful of the two methods to influence gp prescribing, although the workbook promoted more change than that seen in the control group. the use of oral cephalosporins increased in the ig and was reduced in the cg (p less than 0.01). the number of prescriptions of lipid-lowering drugs per month increased in the intervention health centres and the increase was statistically different from the corresponding change in the control health centres among women in the age group 30-65 years (p = 0.03). a multifaceted intervention using algorithms can reduce the number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes. clinical guidelines implemented with workshops and educational outreach visits improved some but not all aspects of prescribing in the short-term. length of stay, intensive care unit transfers, readmission rates, and in-hospital death rates were similar in both groups (p> or =.10 for all). there were no significant differences between study groups in the proportion of patients who were referred for x-ray, issued with a sickness certificate, prescribed opioids or muscle relaxants, or who were referred to secondary care, but significantly more patients in the intervention group were referred to physiotherapy or the back pain unit (difference in proportion = 12.2%, 95% confidence interval [ci] = 2.8% to 21.6%). neither strategy was effective in improving the appropriateness of otc management of vulvovaginal candidiasis by community pharmacy staff. we conclude that the academic detailing process was successful in modifying prescribing patterns and that it also decreased prescription numbers and costs. smaller practices improved their performance in line with the guidelines by 13.5% (95% ci = 6% to 20.9%) attributable to outreach, while larger practices improved by only 1.4% (95% ci = -2.4% to 5.3%, p-value for interaction <0.001). a limited simultaneous educational outreach intervention for parents and providers reduced antibiotic use among children in primary care practices, even in the setting of substantial secular trends toward decreased prescribing. there were no differences between the intervention and control groups for the three month fall rate. printed educational materials alone may be as effective as audit and feedback and educational outreach in improving nurses' performance and outcomes of care for people with ui. both group and individual academic detailing improved antihypertensive prescribing over and above usual care but may require reinforcement to sustain improvements. after training, there was a significant increase in knowledge about diarrhoea and its treatment among counter attendants in kenya, where these changes were measured. compared with usual practice, disease management was associated with improvements in helicobacter pylori testing (61% vs 9%; p = .001), use of recommended h pylori treatment regimens (96% vs 10%; p = .001), and discontinuation rates of proton pump therapy after treatment (70% vs 36%; p = .04). no significant differences were observed for the primary outcome measure: practices receiving outreach visits prescribed only 2.1% [95% confidence interval (ci): -0.8 to 5.0] more of the three recommended nsaids than the control practices did and 1.6% (95% ci: -1.4 to 4.7) more than practices that received guidelines only. no evidence was found for an improvement in asthma related quality of life among newly surveyed patients in intervention practices compared with control practices. accepting a visit had little effect on prescribing: a change of 0.003 (95 per cent ci -0.021 to +0.027) dose units. performance of the procedure necessary to diagnose hypercholesterolaemia even deteriorated. practices were randomized to receive either the intervention for hyperlipidaemia or for hypertension; practices acted as control for the intervention not received. results indicated that the outreach program significantly improved many patient care processes (lab work, nursing, dietary management, ventilator management, ventilator weaning). a follow-up survey conducted 4 weeks after the intervention showed that the oral information campaign positively affected physicians' attitudes about the value of oral drug information from an industry-independent source. one-to-one education obtained an average prescribing behavior improvement of 6.5% (p < 0.001) in the 9 months after intervention. prescribing in both the intervention and control group moved towards that recommended by the guidelines but there was no difference between the groups in either the proportion of prescriptions in line with the guidelines or the overall cost. professional standards review organization claims data were used in defining, planning, implementing and evaluating an approach to an ambulatory medical care problem utilizing educational intervention. experimental homes participated in an outreach program that was designed to influence drug use through improved teamwork among physicians, pharmacists, nurses, and nurses' assistants. no differences in appropriateness were found between the two intervention groups, but in the first postintervention month the mean rate of inappropriate prescribing per control practitioner was 80%, versus less than 32% for the intervention groups (p less than 0.01). practices participating in the intervention showed increases in the percentage of records containing at least one periodontal diagnostic notation, and those practices employing hygienists showed an increase in the percentage of records with at least one preventive notation and one treatment item.(abstract truncated at 250 words) the patient care appraisal did not lead to significant improvement of physicians' management of the conditions. they were also partially effective in improving the appropriate use of drugs, reducing the use of non-rehydration medications. no change was seen in drug usage, rate of influenza vaccination, functional status, or psychological wellbeing as a result of the intervention. the adjusted increase in adr reporting rates attributable to intervention was 90.19 for total adrs there were no significant differences in use of "minimal intervention" components of the kit, ratings of overall acceptability of delivery, perceptions of cultural and structural barriers to using the kit, and ratings of the overall acceptability of the kit. the tailored multifaceted intervention delivered by nurse facilitators was effective in modifying physician practice patterns and significantly improved preventive care performance. in the 6 months post-intervention, median psa testing rate in the eov group was significantly lower than in the postal group, which in turn was significantly lower than the control group (p < 0.001). during the intervention year intervention practices made 292 more requests (99% increase) and control practices made 74 fewer requests (23% decrease; p=0.001 for difference in median change). there was no significant decrease in the number of prescriptions written by the face-to-face group compared with the control group, suggesting that drug substitution rather than deletion was the method used by physicians to lower drug costs. intervention produced a significant increase (p less than 0.005) in the prescribing cost of ibuprofen, the non-steroidal promoted as first choice agent, which was sustained for at least 5 months. after adjusting for confounders, there was a differential downward trend in prescriptions per diagnosis of insomnia but not to a statistical level. physicians in the combined intervention group had higher self-reported and observed rates for several risk assessment questions and counseling recommendations than did physicians in the control group or the group that only received educational materials. practice-based training plus support telephone calls was the most effective and cost-effective strategy to encourage implementation of sbi by gps. compliance rates for 12 evidence-based indicators for the management of patients with hypertension, hypercholesterolaemia, angina pectoris, or heart failure. educational outreach visits, particularly when combined with social marketing, appear to be a promising approach to modifying health professional behaviour, especially prescribing. there were significantly fewer referrals (20% v 29%; odds ratio 0. at endpoint, cde recommendation and performance rates were both significantly higher for the intervention as compared to the control practices (or = 2.28; 95% ci: 1.37, 3.78, and or = 1.63; 95% ci: 1.06, 2.50, respectively). improvements between baseline and posttest in patient recall of fp advice about nicotine replacement patches and gum were significantly greater in the intervention than in the control group (p = 0.0056 and p = 0.0002, respectively). no significant differences were found between the groups for the time to symptom resolution. scores on a counseling measure also significantly increased from a mean of 2.7 to 9.9 in the counseling group, whereas scores in the control group remained low and stable (2.3 and 1.9, respectively). rates of ventouse delivery increased significantly in intervention units but not in control units; there was no difference between the two types of units in uptake of other practices.|nursing homes 324 people aged 4-60 years admitted to or attending hospital or the general practitioner out of hours service with acute asthma; 164 (50%) were south asian patients, 108 (34%) were white patients, and 52 (16%) were from other, largely african and afro-caribbean, ethnicities 10,696 patients with a diagnosis of hypertension cared for by 93 primary care providers 124 general practices in the netherlands 33 nursing homes: 15 experimental homes and 18 control homes representing 5% of all swedish nursing homes 264 randomly selected general practitioners subjects were 128 gps, one per practice, from the former northern and yorkshire regional health authority, who agreed to use the 'drink-less' sbi programme in an earlier dissemination trial one hundred and two out of 140 practitioners in intervention group practices received at least one visit from an industry representative 44 physicians, 17 midlevel providers, and approximately 200 staff members; data from the electronic medical records of 87,291 patients children younger than 6 years old asthmatic patients, attendance at accident and emergency departments, admissions to local hospitals, and steroid prescribing by general practitioners patients in rural hospitals sixty fps in 39 practices participated patients with hypertension, hypercholesterolaemia, angina pectoris, or heart failure experimental homes participated in an outreach program that was designed to influence drug use through improved teamwork among physicians, pharmacists, nurses, and nurses' assistants sixteen family physicians were involved breast cancer screening guidelines among inner-city women 25 of the 26 district general obstetric units in two former nhs regions countries (n = 107 pharmacies in kenya; n = 87 in indonesia eligible patients, a multidisciplinary team of intensive care unit specialists from an academic medical center delivered an educational program with content specific to the findings and capacity of the hospital one hundred one transfusing staff surgeons and attending medical physicians districts were randomly assigned into 3 groups and 15 health centers were selected from each district outpatients in a health maintenance organization (hmo thirty-six of 42 gps received the intervention and 35 of 43 gps served as controls; 1503 patients were eligible for analysis forty-six health service organizations (hsos) were recruited from 100 sites in ontario thirty general practices in the trent region, uk residential care asthmatic patients twenty-four health centres general practitioners (gps 12 nursing homes allocated to a half the practices in a danish county with 100 practices were visited once enrolled patients included those presenting with new dyspepsia and chronic users of antisecretory drugs in 8 geographically separate physician offices associated with the orlando health care group community pharmacists on prescribing in uk general practice asthma practices employing hygienists (n = 12) and not employing dental hygienists (n = 12 of 24 400 patients newly surveyed in 1996, 10 783 (1616 asthmatic) replied randomly selected private general dental practices in adelaide, south australia general practice to type ii diabetic patients 20 community-based family or general internal medicine practices in 14 states royal college of general practitioners (rcgp elderly patients general practitioners (gps) in the latter group received two one-to-one outreach visits from community pharmacists 17 general medical, oncology, and cardiology services either received women with regular heavy menstrual loss (menorrhagia) over 1 year an 18-month (july 1997 to december 1998 patients aged 65 years and over, and patients with coronary heart disease (chd), diabetes and a history of splenectomy metropolitan general practices in melbourne, australia 101 general practitioners selected at random from the leeds family practitioner committee (fpc elderly people australian primary care four hundred seventy primary care physicians (pcps) in 318 practices participated in the study 44 general practices in two boroughs in east london 112 general practitioners patients with diabetes diarrhoea treatment in pharmacies general practices in east anglia sexually transmitted diseases children general practices in the netherlands in 1993 and 1994 6 districts in yogyakarta and central java provinces, indonesia patient records cardiovascular care 2395 patients randomly sampled from the practices returned questionnaires and consented to have their medical records abstracted general practices in southern adelaide 244 physicians of the management area adult patients with acute cough consulting in the periods february-april 2000 and 2001 swedish primary care women aged 50 to 74 years with at least one routine clinic appointment (when they were due for mammography) during the study period were enrolled in the trial (n = 314 41 general practices in greenwich with a practice nurse cases of diarrhoea in children in 194 private pharmacies in two developing countries high-risk patients eleven physicians people with ui asthmatics registered with study practices in 1993 and followed up in 1996 veterans administration hospital general medicine clinic subjects were 252 type ii diabetic patients recruited by 15 experimental and 14 control practices general practitioners on the health behaviours and wellbeing of elderly patients patients regarding sexually transmitted diseases and the human immunodeficiency virus (hiv family physicians in ontario participants were 56 family physicians and general practitioners (27 in the par group and 29 in the cmep group) in southern ontario who agreed to participate in the interventions and provide data thirty-two dutch gps in 20 general practices, 3950 patient records 1388 physicians were assigned in 4 spatial clusters to the intervention group, and 5063 were assigned in 11 clusters to the control group persons with an abnormal screening fecal occult blood test (fobt+) result office-based primary care physicians (family or general practice, internal medicine, and obstetrics-gynecology 128 primary practitioners danish general practice national health system physicians in the north of portugal, with intervention in march 2004 through july 2004, and 13 to 16 months of follow-up six matched pairs of nursing homes; at one randomly selected nursing home in each pair, physicians, nurses, and aides participated in an educational program in geriatric psychopharmacology 4217 residents twelve practices affiliated with 2 managed care organizations (mcos) in eastern massachusetts and northwest washington state swedish nursing homes nurses run primary health centres in thailand upper respiratory infection primary care practices were recruited from 4 midwestern states study population included general and family practitioners in galicia (northwestern spain city women patients presenting with low back pain to primary care 20 general practices within avon, england primary care 1854 long-term care residents with an average age of 83 years clinical pharmacists visited one group of 11 physicians during weekly clinic sessions to counterdetail the prescribing of certain targeted drugs all enrolled children younger than 6 years old unselected population of general practitioners an approximately representative sample of 286 general practitioners acute low back pain australian general practitioners patients for sexually transmitted diseases and hiv infection heart disease prevention services 100 practices (348 doctors) in primary care academic representative on prescribing by general practitioners general practices in 12 health authorities in england inner-city women kenyan pharmacy employees after training general practice 24 inner city, non-training general practices family practice trained surrogate patients posing as mothers of a child under five with diarrhoea, we measured sales of oral rehydration salts (ors); sales of antidiarrhoeal agents; and history-taking and advice to continue fluids and food general practitioners (gps) in cardiovascular care eighteen nurse-led health centres 29 general practices in south glamorgan who had participated for at least 2 years in a local scheme of audit and cme in relation to type ii diabetes care 11 community and 3 teaching hospitals between october 1997 and september 1998 24 nursing homes in ontario, canada, and idaho, united states outpatients in an hmo subjects (n=9820) were patients with newly treated hypertension in the year preceding the intervention (n=3692), the 9 months following the intervention (n=3556), and the second year following intervention (n=2572 acute diarrhoea a deprived multiethnic area general internal medicine clinic in the university-affiliated county hospital serving metropolitan seattle 194 community nurses in 157 family practices and 1078 patients with diagnosis of urinary incontinence (ui) for nurses compliance with evidence-linked review criteria for the assessment and management of ui and impact on psychologic and social well-being and symptoms acute cough in general practice patients with acid-related disorders general practices in east london children and tranquilizer in adults sixty-six practices within one family health services authority all registered patients aged 15-50 years patients at least 16 years of age with an expected icu stay of at least 48 hours were enrolled in the study (n = 499 fifteen practices primary care practices 146 general practices from two geographical areas in norway patients with obesity were surveyed immediately after their visit to the physician's office 25 obstetric units 90 general practitioners (gps) in 68 practices; follow up after one year comprised 81 gps in 62 practices 406 patients comparing a disease management program with "usual practice from 44 practices, 10 303 subjects presenting in general practice with raised blood pressure suspected urinary tract infections in residents of nursing homes prescribing in general practice 23 practices who did not wish to participate were used as a self selected control group (group 3 patients under five years old with acute diarrhoea patients with type ii diabetes 42 general practitioners and 267 of their patients aged over 65 years groups of doctors at 134 community health centres colorectal cancer screening residents of nursing homes 4508 pregnancies practice registrars (n = 157) in new south wales 41 primary care physicians who cared for 1,810 randomly selected patients aged 65 to 75 years old at kaiser permanente woodland hills, a group-model health maintenance organization in southern california patients with diabetes in primary care general practitioners and practice nurses 20 general practices asthma specialist nurses using a liaison model of care reduced unscheduled care for asthma in a deprived multiethnic health district 24 400 patients randomly selected and surveyed in 1993, 12 238 replied; 1621 were asthmatic of whom 1291 were sent a repeat questionnaire in 1996 and 780 replied data were available from case notes at baseline (n = 897) and seven months follow-up (n = 902), 452 residential care staff were surveyed and 121 physicians were involved with 61 receiving outreach visits 715 participants 60 community pharmacies in the grampian region of scotland 67 intervention health centres twenty-four centres were randomised 20 rural iowa hospitals as the unit of analysis surgical and medical services of two pairs of matched community and teaching hospitals in massachusetts the practices cared for 14 468 and 13 460 children in the 2 study years, respectively; 8815 children contributed data in both years general practitioners on health promotion for elderly people two thousand, one hundred and eighty-seven eligible patients presented with acute low back pain during the study period: 1049 in the intervention group and 1138 in the control group primary care teams in north-west england after a control group (n = 8) was selected, prescribers (n = 16 subjects: 26 of the 93 practices using the services of the area's haematology laboratory agreed to take part patients with hypertension
systemic infection or death number of painful iv procedures incidence of phlebitis length of the neonatal intensive care unit stay and in the incidence of sepsis total duration of iv use skin punctures systemic infection (defined as a positive blood or cerebrospinal fluid (csf) culture treated for at least 5 days) or death sepsis rates number of courses of antibiotics incidence of sepsis number of total catheters utilized length of neonatal intensive care unit stay and incidence of sepsis and phlebitis number of insertion attempts required for total iv therapy number of skin punctures sepsis rates and efficacy of pn delivery|interim analysis (49 neonates) revealed no difference in sepsis rates (cvc group 46%, cannula group 40%, p = 0.57). the number of insertion attempts required for total iv therapy was significantly lower in the picc group than in the piv group (p = .008). there was no significant difference in systemic infection or death (expressed either as a combined outcome or as separate component outcomes) between the groups. there were no statistically significant differences in the length of the neonatal intensive care unit stay and in the incidence of sepsis between groups.|96 infants < or =1250 g or < or =30 weeks gestation newborns in the neonatal intensive care unit 63 vlbw infants (<1,251 g) who required iv therapy neonates receiving pn by cvc and by peripheral cannula infants with very low birth weight (vlbw seventy-four high-risk newborns preterm infants with neonates infants with very low birth weight newborns
frequency of cough ambulatory cough meter, kept cough diaries cough frequency or score, irrespective of the presence of ahr|salbutamol or beclomethasone had no effect on cough frequency or score, irrespective of the presence of ahr.|recurrent cough children with recurrent cough without other evidence of airway obstruction 43 children (age 6-17 years) with recurrent cough children with recurrent cough
viral replication biological and/or virological relapse sustained biochemical or virologic response complete response (normal levels of alanine aminotransferase and no detectable serum hepatitis delta virus [hdv] rna serum alt levels clearance of serum hdv-rna relapses alt levels portal inflammation histologic findings (reduced periportal necrosis and portal and lobular inflammation alanine aminotransferase values positive for hepatitis d virus rna hdv-rna negative anti-hd titer, igm anti-hd and hbsag concentration percentage of hepatitis d virus rna positivity hepatitis d virus rna levels serum alanine aminotransferase level becomes normal, hdv rna normalization of serum alt levels histologic deterioration hepatic inflammation histological improvement serum hdv-rna serum alanine aminotransferase values antiviral activity (serum hepatitis delta virus rna and intrahepatic hepatitis delta antigen hdv-rna levels normal serum alt levels|moreover, in seven of nine treated patients, interferon was associated with the clearance of serum hdv-rna, associated with amelioration of the histological picture, whereas this occurred in only four of 11 untreated patients. no changes in anti-hd titer, igm anti-hd and hbsag concentration were detected. treatment with 9 million units of interferon was associated with a marked improvement in the histologic findings (reduced periportal necrosis and portal and lobular inflammation), whereas in the untreated controls there was considerable histologic deterioration. measures of antiviral activity (serum hepatitis delta virus rna and intrahepatic hepatitis delta antigen) showed similar levels in treated and control patients. a decrease in the percentage of hepatitis d virus rna positivity was observed in both groups at the end of treatment.|a total of 20 hbsag, anti-hd carriers with a chronic active hepatitis nine treated patients completed the trial: one was withdrawn with hyperthyroidism and one committed suicide chronic delta (type d) hepatitis chronic hepatitis delta virus infection 61 italian patients with this disease patients with chronic hepatitis d hepatitis b virus chronic carriers 42 patients with chronic hepatitis d chronic delta hepatitis, 22 patients
average weight gain brief social phobia scale (bsps) and the clinical global impression of improvement scale (cgi residual gad symptoms social anxiety disorder (sad brief social phobia scale (bsps), social phobia inventory (spin), liebowitz social anxiety scale and sheehan disability scale, as well as clinical global impression-improvement ratings negligible weight gain headache, weight increase, and increased appetite response rates sad social phobia inventory (spin) and the sheehan disability inventory (sdi hamilton anxiety scale (hama-a) score ham-a scores core anxiety symptoms anxiety cgi-i change from baseline to week 4 endpoint in parts-a. improvement from baseline to week 4 endpoint in parts-a total score rates of remission ham-a psychic anxiety factor scores ham-a total scores drowsiness and dry mouth clinical global impression-severity scale (cgi-s) end point score hamilton rating scale for anxiety bsps score|in the intent-to-treat analysis, olanzapine yielded greater improvement than placebo on the primary measures: bsps (p = 0.02) and spin (p = 0.01). adjunctive risperidone was associated with statistically significant improvements in core anxiety symptoms, as demonstrated by greater reductions in ham-a total scores (p = .034) and ham-a psychic anxiety factor scores (p = .047) compared with placebo. those remaining symptomatic (hamilton anxiety scale [ham-a] >or= 7) at week 10 were randomized to quetiapine or placebo augmentation flexibly dosed from 25 to 400 mg/day. headache, weight increase, and increased appetite were the most frequently reported adverse events in both groups. there were no other statistically significant differences for olanzapine compared with placebo augmentation in outcome measures, though rates of remission (ham-a <or= 7) on olanzapine were higher at the level of a trend (fet, p = .1). there was no significant difference in responders (cgi-i score of 1 or 2) versus non-responder (cgi-i score of 3 or more) across the groups.|patients with more severe gad forty patients with a primary diagnosis of dsm-iv gad, who continued to experience gad symptoms despite current anxiolytic treatment of at least 4 weeks' duration patients remaining symptomatic on fluoxetine adult outpatients with gad were recruited from 2004 to 2007 at two academic centers those remaining symptomatic (hamilton anxiety scale [ham-a] >or= 7) at week 10 were randomized to june 2001 through march 2003 fifteen patients primary care and psychiatry clinicians enrolled adults (n = 417) with gad and a clinical global impressions of severity rating  4 despite  8 weeks of anxiolytic treatment symptomatic gad patients patients with generalized anxiety disorder (gad) who remain symptomatic despite initial pharmacotherapy patients with generalized anxiety disorder (gad) remaining symptomatic despite initial pharmacotherapy individuals with gad remaining symptomatic with initial paroxetine cr pharmacotherapy social anxiety disorder 12 patients with the dsm-iv diagnosis of sad generalized anxiety disorder twenty-four of 46 fluoxetine-treated patients were randomized refractory generalized anxiety disorder
amplitude of the compound motor action potential (cmap safety and potential efficacy facial grading scale change scores facial grading scale subcomponents house-brackmann scale facial grading scale scores house-brackmann scores overall improvement of clinical stage facial grading scale|individualized facial neuromuscular re-education is more effective in improving facial symmetry in patients with bell's palsy than conventional therapeutic measures. when applied at an early stage, kabat's rehabilitation was shown to provide a better and faster recovery rate in comparison with non-rehabilitated patients. the house-brackmann scale of the control group improved between 17% and 50% with a mean of 30%.|patients with bell's palsy bell's palsy patients fifty-nine patients diagnosed with bell's palsy 20 consecutive patients (10 males, 10 females; aged 35-42 years) affected by bell's palsy, classified according to the house-brackmann (hb) grading system and grouped on the basis of undergoing or not early physical rehabilitation according to kabat, i.e. a proprioceptive neuromuscular rehabilitation adult patients with clinical diagnosis of bell's palsy 16 patients with bell's palsy of less than 30 days' duration bell's palsy early bell's palsy
quality of life (qol) measure positive and negative syndrome scale (panss) total score, derived brief psychiatric rating scale (bprsd) total score, as well as panss and bprsd subscales body weight extrapyramidal side effects, hyperprolactinemia, and sexual dysfunction core symptoms of schizophrenia and motor side effects yale-brown obsessive compulsive scale (ybocs changes in positive and negative syndrome scale (panss) total scores and rates of extrapyramidal symptoms (eps brief psychiatric rating scale, scale for the assessment of negative symptoms and montgomery and asberg depression rating scale scores severity of extrapyramidal symptoms safe and effective quality of life scale (qls) intrapsychic foundation and medical outcomes study short form 36-item instrument (sf-36) role functioning limitations-emotional subscale scores safety and efficacy extrapyramidal symptoms five panss factor scores (positive symptoms, negative symptoms, disorganized thoughts, and anxiety/depression general antipsychotic efficacy severity of psychotic and extrapyramidal symptoms weight gain who-qol-bref physical, psychological and health satisfaction domains ocs motor side-effects, efficacy, safety and quality of life (qol response rates panss total score frequency and severity of extrapyramidal symptoms efficacy psychotic symptoms positive and negative syndrome scale factors for positive symptoms and anxiety/depression positive and negative syndrome scale total score total positive and negative syndrome scale scores and scores on the five positive and negative syndrome scale factors efficacy and safety severity of ocs severity of obsessive-compulsive symptoms (ocs panss positive and negative scores and clinical global impression-severity of illness scale (cgi-s psychological qol severity of positive and affective symptoms dyskinetic symptoms obsessive-compulsive symptoms comprehensive battery of tests to assess (1) motor skills, (2) attention span, (3) verbal fluency and reasoning, (4) nonverbal fluency and construction, (5) executive skills, and (6) immediate recall total scores on the extrapyramidal symptom rating scale positive and negative syndrome scale (panss) total, brief psychiatric rating scale (bprs) total, and panss general psychopathology scores severe ocs total score on the positive and negative syndrome scale panss total scores panss positive scale scores overall response rate neuropsychological change greater weight gain eps-related adverse events mean duration of illness psychological domain of the world health organisation-quality of life [brief] (who-qol-bref) scale tolerated efficacy in negative symptoms (scale for assessment of negative symptoms summary score general cognitive index hooper visual organization test total and negative symptom scores tolerated and efficacious adverse events efficacy, safety|clozapine, risperidone, and olanzapine (but not haloperidol) resulted in statistically significant improvements in total score on the positive and negative syndrome scale. the 35 subjects treated with olanzapine at both assessments had significantly (p = .01) more severe ocs at week 6 than the 20 subjects treated with risperidone at both assessments. olanzapine and risperidone were equivalent in their improvement of panss positive and negative scores and clinical global impression-severity of illness scale (cgi-s) at endpoint. treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia. total scores on the extrapyramidal symptom rating scale were reduced in both groups at endpoint; between-treatment differences were not significant. total positive and negative syndrome scale scores and scores on the five positive and negative syndrome scale factors were improved in both groups at week 8 (subjects who completed the study) and endpoint (all subjects, including dropouts). exploratory within-group analyses of the 6 cognitive domains after a conservative bonferroni adjustment revealed a significant improvement with olanzapine only on the immediate recall domain, and similar analyses of the 17 individual tests revealed a significant improvement with olanzapine only on the hooper visual organization test. the incidence of extrapyramidal side effects, hyperprolactinemia, and sexual dysfunction was statistically significantly lower in olanzapine-treated than risperidone-treated patients. after switching from a conventional antipsychotic, olanzapine and risperidone were associated with improvement in core symptoms of schizophrenia and motor side effects.|stable elderly patients with chronic schizophrenia receiving appropriate doses of 339 patients who met dsm-iv criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder patients hospitalized for acute exacerbation of schizophrenia treatment (n = 23) prior to admission continued with that medication if they showed initial clinical response patients (outpatients, hospital inpatients, and residents of nursing or boarding homes australia and new zealand elderly patients with schizophrenia 175 elderly patients with chronic schizophrenia 157 inpatients with a history of suboptimal treatment response acutely hospitalized patients with schizophrenia patients with chronic schizophrenia or schizoaffective disorder patients who were drug-naive or were treated with typical antipsychotics before admission (n = 36 patients who had started olanzapine (n = 39) or 66 patients were randomised (mean age 69.6 [sd schizophrenia and other psychotic disorders schizophrenia patients with an acute exacerbation of schizophrenia consecutively hospitalized young patients (mean age = 22.4 years) with dsm-iv schizophrenia or related disorders (n = 113) who were treated with people with schizophrenia 113 patients with recent-onset schizophrenia or related disorders 65 patients who met dsm-iv criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder cognitive impairment in early phase schizophrenia patients with chronic schizophrenia and schizoaffective disorder patients (n = 249) who met dsm-iv criteria for schizophrenia elderly patients with schizophrenia from conventional antipsychotics to prior to admission schizophrenia or schizoaffective disorder subjects were 175 patients age 60 years or over with schizophrenia or schizoaffective disorder subjects (n=377) who met dsm-iv criteria for schizophrenia or schizoaffective disorder
overall incidence of avn rate of union or the development of avn femoral head vitality|there was no significant difference between the groups in terms of union (p = 0.93) and avn at two years (p = 0.85). irrespective of the displacement, no difference was noted in the two groups. in surviving patients followed for at least 1 year, union occurred in 57/85 with compression and 58/71 without compression.|102 patients aged between 15 and 50 years fractures of the neck of the femur in young adults young adults with displaced intracapsular fractures (garden grades iii and iv) of the neck of the femur 220 displaced femoral neck fractures treated with a femoral head vitality after peroperative impaction of hip fractures 102 patients, 92 were available for review osteosynthesis of femoral neck fracture 94 patients with femoral neck fracture the vitality of the femoral head was determined pre- and postoperatively with 99mtc-mdp-scintimetry
tiredness mean amplitude and increased ratio (turns/amplitude head position and pain serious or systemic side effects efficacy and safety profile involuntary activity side effects dystonia and neck pain direction of head turning, severity of torticollis, and presence or absence of jerky movements severity of torticollis, disability, pain, and degree of head turning efficacy and safety spontaneous remission tsui scores neck pain neck posture pain scores serious side effects pain-free activities of daily living (adl adverse events|toxin was more effective than placebo for improving both head position and pain which was measured by an objective rating scale and videofilm assessments. subjective rating noted improvement in some patients, but there was no change in objective measures. the remaining 18 patients completed the study and showed a significant improvement after the injections of botulinum toxin in comparison with that of the placebo. compared with placebo, botox produced statistically significant improvement in the severity of torticollis, disability, pain, and degree of head turning. there was a statistically significant benefit for those treated with toxin; 12 on toxin improved objectively, compared with four on placebo (p less than 0.04). six weeks after the first bt treatment the sternocleidomastoid muscle contralateral to the involuntary head rotation and the ipsilateral and contralateral posterior neck muscles (pnm) showed a reduction of involuntary activity, as indicated by reduced turns/sec and mean amplitude at rest. no serious or systemic side effects were noted. open phase treatment produced improvements in tsui (p < 0.001) and pain scores (p=0.011), and 23/24 patients were classified as responders.|twenty-three patients spasmodic torticollis 60 patients with torticollis received toxin in a total of 117 treatment periods 19 patients with cervical dystonia cervical dystonia 30 patients with torticollis in a double-blind, placebo-controlled, crossover study 21 patients (11 dysport, 10 and 47 patients (24 dysport, 23 19 patients in a double-blind 68 patients with moderate to severe cd (tsui score > or = 9 patients with the major clinical types of cervical dystonia patients with complex cervical dystonia 39 patients with pain population of cd patients more representative of those seen in a typical dystonia clinic 23 patients with cervical dystonia heterogeneous cervical dystonia population dysport patients and 14/33 (42 20 patients with spasmodic torticollis 23 patients suffering from intractable spasmodic torticollis (st patients with rotational cervical dystonia (cd
serious bile duct injury il-6 increase c-reactive protein (crp), alpha-1-antitrypsin (aat), retinol-binding protein (rbp), transferrin, and albumin immune function forced vital capacity (fvc), forced expiratory volume at 1 second (fev1), and forced expiratory flow median operating times complications fvc duration of convalescence incidence of complications hospital stay (postoperative nights in hospital shorter hospital stay, less postoperative dysfunction, and quicker return to normal activities operation without injury to bile duct, viscera or vessels, minimal pain and discomfort at 4 weeks, no wound infection total cost for lc plasma il-6 levels conversion to open cholecystectomy fev1 median time off work monocyte superoxide anion (o2-) and tumor necrosis factor release, neutrophil o2- levels and chemotaxis, total white blood cell counts, partial arterial oxygen pressure, and serum cortisol and c-reactive protein levels median hospital stay hospital costs and social costs hospital stay or postoperative recovery duration of anesthesia and operation time, perioperative complications or postoperative need for analgetics systemic concentrations of interleukin-6 (il-6), interleukin-1 (il-1), tumor necrosis factor (tnf), and c-reactive protein (crp il-1 and tnf response intraoperative complications median post-operative hospital stay total cost of each case included cost of investigations, cost of disposable articles for operation, cost of drugs, cost of hospital stay, and cost of operation including anesthesia mean operation time pain and depression interleukin-1 receptor antagonist (il-1ra), il-6, and tumor necrosis factor (tnf-alpha quality of life scores crp, aat, and albumin pulmonary function systemic acute-phase response postoperative hospital stay postoperative deficits of respiratory function hospital and social costs time back to work for employed persons crp hospital costs postoperative analgesia requirements successful, hospital stay time to full activity monocyte release of o2- and tumor necrosis factor, neutrophil release of o2- and chemotaxis, and white blood cell count peak expiratory flow rate, forced expiratory volume in 1 second, and forced vital capacity hospital stay postoperative complication rate physical and social functioning physical functioning and depression scores cytokine levels success or failure pre- and postoperative white blood cell (wbc) counts, postoperative body temperature, and length of postoperative hospitalization hospital stay and time off work rate of return to normal activities mean hospital stay partial arterial oxygen pressure median sick leave and time for return to normal recreational activities plasma cortisol or c-reactive protein levels serum crp concentrations postoperative septic complications postoperative pain, less restriction of total vital capacity operative time|there were significant increases (p < .001) in monocyte release of o2- and tumor necrosis factor, neutrophil release of o2- and chemotaxis, and white blood cell count in the open vs laparoscopic cholecystectomy study groups, with a concommitant decrease in partial arterial oxygen pressure. intraoperative complications were less frequent in the mc group, but there was no difference in the postoperative complication rate between the groups. operative time (median time: 35 minutes) and hospital stay (median stay: 3 days) were the same for both surgical procedures. at 4 weeks, only physical functioning and depression scores were better in the laparoscopic group, and by 3 months there were no differences. systemic concentrations of interleukin-6 (il-6), interleukin-1 (il-1), tumor necrosis factor (tnf), and c-reactive protein (crp) were measured before and after the operation. if laparoscopic cholecystectomy was successful, hospital stay was significantly shorter than for mini-cholecystectomy (2 versus 3 days respectively), but overall the hospital stay was not significantly different. the percent reduction of fvc (p = 0.0170), fev1 (p = 0.0191), and fef25-75% (p = 0.0045) was smaller after laparoscopic cholecystectomy than after kocher's incision cholecystectomy. the il-6 increase was more persistent and marked in the mc patients from hour 8 to day 7 postoperatively (p < 0.05). success was defined as operation without injury to bile duct, viscera or vessels, minimal pain and discomfort at 4 weeks, no wound infection up to 4 weeks, and resumption of work within 2 weeks of operation. patients with lcce had significant less postoperative pain, less restriction of total vital capacity and a shorter postoperative hospital stay as parameters of a diminished operative trauma. although there was significant postoperative improvement in all of three quality of life scores in both groups, lc patients improved more quickly than did mc patients. laparoscopic cholecystectomy takes longer to do than small-incision cholecystectomy and does not have any significant advantages in terms of hospital stay or postoperative recovery.|40 patients were studied of 1,705 cholecystectomies performed at participating units during the randomization period, 724 entered the trial and 362 patients three hundred and ten patients having elective cholecystectomy 155 patients in each group 302 patients patients undergoing open vs laparoscopic cholecystectomy 77 patients with symptomatic cholelithiasis forty-five patients cases with acute cholecystitis and raised alkaline phosphatase gallstone disease all surgeons normally performing cholecystectomy, both trainees under supervision and consultants, operated on randomized patients one hundred and eighty-one patients with simple, symptomatic gallstone disease were included in the study; of these, 9 cases were excluded because of conversion to conventional cholecystectomy two similar groups of patients randomized to open (n = 22) vs laparoscopic (n = 22) cholecystectomy 200 patients which was designed to eliminate bias for or against either technique patients with gallstones shown on ultrasound with normal common bile duct and no history of icterus were included after an informed consent laparoscopic patients one hundred adult subjects with painful gallstone disease 70 patients with ultrasound-proven cholelithiasis were randomly allocated lc (38) or mc (32
seroconversion to opv and geometric means of antibody titers mean number of diarrheal episodes cause of death rates of any sign or symptom intracranial haemorrhage potential acute side-effects breast milk retinol levels relative risk of mortality maternal serum retinol infant survival incidence of diarrhea incidence of diarrhea and acute respiratory infection (ari anthropometric status, or on overall or severe morbidity pregnancy-related mortality and all-cause female mortality infant mortality milk retinol vitamin a deficiency rate ratio to compare all deaths cumulative effect of toxicity safety and toxicity morbidity and child growth serum retinol infant serum retinol ri mortality through 24 weeks of age side effects episodes of bulging of the fontanelle antipolio antibody titer, antitetanus toxoid antibodies, and avidity of antibodies to tetanus child growth gram fat, milk retinol mortality; the mortality rate ratio mrr of vitamin a supplementation fetal loss and early infant mortality mortality rate ratios rate of fetal loss intracranial pressure serum retinol levels acute toxicity linear or ponderal growth or infectious disease morbidity serum retinol and infant stores vitamin a status infant retinol stores mean ri values mortality, calculated as mortality rate ratios (mrrs miscarriage, stillbirth, maternal death, or live birth fetal or early infant survival vitamin a intakes mortality rate ratio antibody titers risk of death mortality fetal loss and survival vitamin a status, signs of acute toxic effects, anthropometric indicators, and severe morbidity 24-wk mortality rate mean ri fell adverse events|we found no evidence that vitamin a supplementation affects infants' antibody responses to tetanus toxoid or oral polio vaccine delivered at epi contacts. vitamin a supplementation at birth was not significantly associated with mortality: the mrr of vitamin a supplementation compared with placebo, controlled for randomisation to "early bcg" versus "no early bcg" was 1.08 (95% ci 0.79 to 1.47). there were 130 deaths (51.6/1000 child-y) in the control group and 150 deaths (57.1/1000 child-y) in the vitamin a group, yielding a relative risk of 1.11 (95% ci: 0.86, 1.42), which is indicative of no overall effect on early infant mortality. vitamin a supplementation was not significantly associated with mortality; the mortality rate ratio was 1.07 (95% confidence interval 0.79 to 1.44). no other side effects were noted. the rate of fetal loss was 92.0/1000 pregnancies in the placebo group, comparable with rates in the vitamin a and beta-carotene groups, which had relative risks of 1.06 (95% ci: 0.91, 1.25) and 1.03 (95% ci: 0.87, 1.19), respectively. at the 6-month follow-up, there was a small decrease in vitamin a deficiency in the vitamin a group compared with controls (serum retinol < or =0.70 micromol/l 101 [29.9%] vs 122 [37.1%; 95% ci of the difference -14.3% to -0.2%]). in the itt analysis, there were 39 601 pregnancies and 138 pregnancy-related deaths in the vitamin a supplementation group (348 deaths per 100 000 pregnancies) compared with 39 234 pregnancies and 148 pregnancy-related deaths in the placebo group (377 per 100 000 pregnancies); adjusted odds ratio 0.92, 95% ci 0.73-1.17; p=0.51. infant serum retinol was not different between groups. the finding that increased numbers of vitamin a doses were associated with a higher probability of bulging of the fontanelle suggests a cumulative effect. relative to control subjects, the risk of death in vitamin a-supplemented infants was 0.85, reflecting a 15% reduction in all-cause mortality. vitamin a supplementation had no apparent impact upon linear or ponderal growth or infectious disease morbidity in the first 15 mo of age when integrated with the expanded programme on immunization. a bulging fontanelle was not associated with increased rates of any sign or symptom or with an increase in ri. prophylactic administration of mega doses of vitamin a to the mother soon after delivery and to the infant at six months do not have any beneficial impact on the incidence of diarrhea and ari in infancy. seroconversion to opv and geometric means of antibody titers to the three types of polio viruses were comparable between the groups of infants belonging to the experimental and control mothers.|infants <6 mo of age 11,918 infants < 1 mo and 1-5 mo of age with vitamin a (15,000 and 30,000 micrograms retinol equivalents or 50,000 and 100,000 iu, respectively) or a 191 infants one hundred mothers having uncomplicated deliveries study-defined sectors (n = 596 and 542 clusters (103 297 women from january, 1995, we enrolled 9424 mother-infant pairs from ghana, india, and peru infants in guinea-bissau guinea-bissau, covering approximately 90,000 inhabitants infancy 564 women kenyan mother-infant pairs dosed infants (n = 15902 all women of reproductive age (15-45 years) who gave informed consent and who planned to remain in the area for at least 3 months were recruited 909 newly delivered mother-and-infant pairs low birthweight neonates seven districts in brong ahafo region in ghana 2067 indonesian neonates married women of reproductive age in 270 wards of sarlahi district, nepal, were eligible to participate rural bangladesh infants < 6 mo of age supplemented with guinea-bissau 4716 mothers of infants in the 544 clusters (104 484 women mother and infant on morbidity in infancy bangladesh in west java, indonesia, 467 six-week-old infants women of reproductive age on maternal survival in ghana women in ghana older children young infants (n = 1085 17116 live-born infants (99.8% of all eligible) among whom 15937 (93.1%) were visited to be supplemented <30 days after birth and for whom vital status at 24 weeks of age was known 1086 small geographical clusters of compounds with fieldwork areas consisting of four contiguous clusters 1326 women died in 292 560 woman-years in the early infancy african setting with high infant mortality 4708 mothers and their infants received on all-cause infant mortality through 24 weeks of age 1717 low birthweight neonates born at the national hospital one hundred and sixty-seven infants normal birthweight neonates a total of 43559 women were enrolled; 15832 contributed 17373 pregnancies and 15987 live born infants to the trial infants aged <6 mo early infancy using dpt/opv immunization contracts kenya breastfed infants 51 villages in two contiguous primary health centers in villupuram health unit district of tamil nadu, south india mothers and infants 19 unions in rural northwest bangladesh 3933 (93%) of the eligible 4212 infants on vitamin a and 3938 (93%) of the eligible 4227 controls participants 4345 infants due to receive bcg 174 children died during follow-up (mortality=47/1000 person-years neonates who weighed less than 2.5 kg infants' immune responses to tetanus and polio vaccines women within 24 hrs after delivery on response to ppv administered to the newborn
clinical success rate failure frequencies number of failures presence of marginal gaps|there was no difference between the number of failures caused by post decementations and the presence of marginal gaps observed in the 2 groups (95% confidence intervals, -9.7 to 16.2 and -17.8 to 9.27).|subjects included in this study had one maxillary or mandibular premolar for which endodontic treatment and crown build up was indicated and met specific inclusion/exclusion criteria only premolars with class ii carious lesions and preserved cusp structure were included sixty teeth were included in the first group and 57 in the second
prolonged bleeding condom and contraceptive use, rates of pregnancy and stds, and other outcomes and mediators knowledge of ocs frequent sexual activity menstrual changes questionnaire data number of missed pills per cycle adolescent compliance clinic utilization or satisfaction repeat pregnancy mean number of missed pills per cycle noncompliance level levels of condom and contraceptive use, and rates of pregnancy and stds study termination rates cumulative life table discontinuation rates rate of continuation and the rate of on-time injections oral contraceptive pill adherence|more women in the intervention group were not pregnant and still using contraception, and were able to successfully switch contraceptive methods compared to women in the control group. although contraceptive use increased from baseline to follow-up at six months in both groups, levels of condom and contraceptive use, and rates of pregnancy and stds, did not differ between the intervention and control groups at any of the follow-up assessments. adolescents with more frequent sexual activity (p less than or equal to .027), with one sexual partner (p less than .04), and who worried that they might become pregnant (p less than or equal to .01) had significantly lower levels of noncompliance when counseled by a peer than by a nurse. this randomized controlled trial estimated whether there was an effect of daily text-message reminders on oral contraceptive pill adherence of new oral contraceptive pill users. the rate of continuation and the rate of on-time injections did not differ between groups. study termination rates were significantly lower in the structured counseling group than in the control group.|fifty-seven females aged 14 to 19 years from a lower socioeconomic background new oral contraceptive pill users eighty-two women mexican women receiving women receiving depot between 2005 and 2007, a total of 805 females aged 14-18 attending a reproductive health clinic in san francisco 43 young, pregnant women attending prentice ambulatory care, northwestern hospital, were enrolled and 33 participants were 79% white, non-hispanic, 99% high school graduates, and 99% nulliparous with a mean age of 22 years adolescent females young, african american women in the year following an unplanned pregnancy 350 mexican women participated: 175 received female adolescent clinic patients
serum ferritin and hemoglobin infant haematological status and iron status at 6 months of age, and analysis was by intention-to-treat bilirubin concentration total serum bilirubin levels clinical jaundice or plethora iron and haematological status maternal or newborn morbidity, in infant behavior in the first hour of life haematological status odds ratio for iron deficiency anaemia polycythaemia without symptoms maternal perceptions of her infant and the experience of giving birth delayed cord clamping and haemoglobin levels mean infant ferritin and hb iron stores mean infant haemoglobin level total body iron duration of cord adherence and neonatal and maternal outcomes rate of jaundice infant and maternal safety 6-month iron stores delayed clamping of the umbilical cord increases the infant's iron endowment at birth and haemoglobin concentration shorter active labors maternal haemoglobin ferritin beneficial haematological effect red cell mass infant's hemoglobin and serum ferritin 3 months after delivery mean corpuscular volume maternal haematological status rate of breast feeding infant haematological status odds for anemia maternal and cord ferritin and hemoglobin values haemoglobin (hb) change from cord values haematological effects adverse events|throughout the observation period infant hb levels in both groups declined, but more rapidly in controls than in the dcc group [difference in hb change from baseline at 4 months 1.1 g/dl, 95% confidence interval (ci) 0.2; 2.1]. there appeared to be a higher rate of jaundice in the late clamped group which did not reach statistical significance. the odds for anemia (<100 g/l) at 3 months was 7.7 (95% ci 1.84-34.9) times higher in the early compared to the delayed clamping group. delayed clamping of the umbilical cord increases the infant's iron endowment at birth and haemoglobin concentration at 2 months of age. it is a safe, simple and low cost delivery procedure that should be incorporated in integrated programmes aimed at reducing iron deficiency anaemia in infants in developing countries. no differences were noted in maternal or newborn morbidity, in infant behavior in the first hour of life, at 24 or 72 hours post partum, or at eight months of age; or in maternal perceptions of her infant and the experience of giving birth, except that eight months after delivery, mothers who had used the leboyer method were more likely to say that the event had influenced their child's behavior (p = 0.05). the groups were comparable for maternal age, parity, weight, supplemental iron intake in pregnancy, infant's birth weight, gestation and sex.|107 term neonates born to mothers with uncomplicated pregnancies and with hemoglobin more than 10 g/dl infants at 3 months infants born to mothers with hemoglobin (hb)<100 g/l mother-infant pairs infancy infants born to anemic mothers mexican infants 554 women term infants at 3 months of age term infants 24 h after birth in libya 104 mother-infant pairs 358 (75%) mother-infant pairs completed the trial infants born to mothers with low ferritin at delivery, breastfed infants not receiving iron-fortified milk or formula, and infants born with birthweight between 2500 g and 3000 g. a cord clamping delay of 2 minutes increased infants born to anemic mothers at 3 months of age neonates born to anemic mothers 102 neonates randomized to early (n = 43) or delayed cord clamping (n = 59 term infants born to libyan mothers 476 mother-infant pairs were recruited at a large obstetrics hospital in mexico city, mexico, randomly assigned to 56 women to either a 107 infants
maximal workload, muscle strength, gait speed, and the berg balance scale score generic health-related quality of life survey (sf-36 functional capacity, physical aspects, pain, general state of health, vitality, social aspects and mental health muscle strength and gait quality of life postural balance and knee flexor strength berg balance scale scores, forward and backward weight-bearing abilities of the affected limbs, and knee flexor strength postural balance and muscle strength cardiovascular fitness, maximal workload, gait speed, and paretic lower-extremity muscle strength cardiovascular fitness (v(o2)max cardiovascular fitness berg balance scale score and weight-bearing ability, as measured by vertical ground reaction force during four standing tasks (rising from a chair and weight-shifting forward, backward and laterally motor behaviour|the experimental group attained significant improvements over the control group in cardiovascular fitness, maximal workload, gait speed, and paretic lower-extremity muscle strength. postural balance and knee flexor strength were improved after aquatic therapy based on the halliwick and ai chi methods in stroke survivors. doing physical exercises in water tends to improve motor behaviour, with a greater degree of independence, significant improvements in functional capacity and other aspects linked to physical aptitude.|15 subjects aged 50.3 rehabilitation department of a university hospital 12 community-dwelling people with stroke with mild to moderate residual motor deficits stroke survivors people with stroke 13 subjects aged 52.5 +/- 7.7 years ambulatory chronic stroke patients (n = 25):13 in an aquatic therapy group and 12 in a conventional therapy group people with chronic stroke patients who have had an ischaemic cva
parental anxiety scores state anxiety and blood pressure preoperative anxiety levels lower anxiety anxiety (mypas) and compliance (icc anxiety and compliance during induction of anesthesia level of anxiety parental preoperative anxiety low trait anxiety level of anxiety postoperatively anxiety levels perioperative outcomes postoperative behavior changes median induction (coping) vas level reducing anxiety anxious amsterdam preoperative anxiety and information scale (apais) questionnaires analgesia parental anxiety quality of mask induction cortisol concentrations maternal anxiety anxiety and distress level of parental anxiety behavioral and physiologic anxiety anxiety changes preoperative anxiety behavioral disorders state-trait anxiety inventory (y-1/y-2) instrument (self-report anxiety behavioral instrument that measures trait/baseline and state/situational anxiety anxious on entrance to the operating room child's behaviour and the visual analogue scale (vas maternal blood pressure and heart rate modified yale preoperative anxiety scale (mypas) score sensory stimuli and anxiety behavioral or physiologic measures of anxiety anxiety levels and health care attitudes infant behavioural distress incidence of electrocardiogram abnormalities postoperative behavioral disorders change in anxiety scl changes over time pediatric preoperative anxiety post hospitalization behavior questionnaire anxiety emergence delirium observed anxiety in the holding area (t1), entrance to the operating room (t2), and introduction of the anesthesia mask (t3 fear and anxiety anxiety of the parent and compliance of the child during induction parental hr and scl parental heart rate (hr), parental blood pressure, and parental skin conductance level (scl hospital fears inventory (hfi) and behavioural questionnaire (bq), and parental anxiety by the parents' questionnaire (pq anxiety and satisfaction posthospitalization behavioral questionnaire (phbq posthospital behavior questionnaire (phbq number of anxious children mean arterial pressure a visual analog scale (vas) and modified child dental anxiety scale (mcdas parental satisfaction preoperative parental anxiety levels global mood scale (gms anxiety and desire for information median recovery (coping) vas levels percentage of inductions in which compliance of the child frequency of behavior disorders parental hr anxiety, health care attitudes and satisfaction with the anaesthesia and surgery experience children's perioperative anxiety postoperative behavioral changes|analysis of variance demonstrated that three groups showed diminished cortisol concentrations with parental presence: children older than 4 yr (p = 0.001), children whose parent had a low trait anxiety (p = 0.02), and children who had a low baseline level of activity as assessed by temperament (p = 0.05). anxiety in the holding area, at entrance to the operating room, and at introduction of the anesthesia mask did not differ significantly between the two groups (f[2,192] = 1.26, p = 0.28). preoperative parental anxiety levels also correlated with the child's fears and behaviour one week after surgery.(abstract truncated at 250 words) children in the midazolam group were the least anxious even after controlling for therapist effect (p < 0.05). post hoc analysis indicated that children in the midazolam group exhibited significantly less anxiety compared with the children in the parental-presence group or control group (p = 0.0171). effects of parental presence on infant and parental outcomes, including anxiety, health care attitudes and satisfaction with the anaesthesia and surgery experience were evaluated. mean arterial pressure for children in group 1 was significantly lower during preoperative holding and following induction (p < .05). children in the advance group exhibited a lower incidence of emergence delirium after surgery (p=0.038), required significantly less analgesia in the recovery room (p=0.016), and were discharged from the recovery room earlier (p=0.04) as compared with children in the three other groups. there was a statistically significant increase in anxiety (p<0.01) in groups m and pp at induction of anesthesia compared with baseline, but not in vg group. there was a statistically significant reduction in anxiety and desire for information in the intervention group compared with the control group (p < 0.05). state anxiety and blood pressure following induction of anesthesia did not differ significantly between groups ( p= nonsignificant). we found that the lssg was significantly less anxious compared with the control group on entrance to the or (p = 0.03) and on the introduction of the anesthesia mask (p = 0.003). the number of anxious children was less during induction of anesthesia in the hypnosis group (t3: 39% vs 68%) (p < 0.05). the children in the midazolam group showed a better quality of mask induction compared with those in the ppia group, the addition of parental presence to oral midazolam did not provide additional improvement of mask induction. the mann-whitney u-test showed that the computer group coped significantly better than the control group at induction (p = 0.014) and significantly better than the cartoon group upon recovery (p = 0.016). in the control group there was an increased level of anxiety in the induction room in comparison to in the waiting room; in the clown group anxiety was not significantly different in the 2 locations. there were no significant differences in maternal blood pressure and heart rate between the two groups.|73 infants (aged 1-12 months in adults children and their parents (n = 408 children undergoing surgery that targets the family as a whole children and their parents (n = 80 children scheduled for surgery children undergoing dental general anesthetic (dga) tooth extraction children to being accompanied by a parent at induction of anaesthesia in a paediatric day-care surgical centre fifty children from 2 to 11 years of age 198 children sixty children one hundred and eleven parents subjects (n = 103 children (n = 88 eighty-four children preoperative anxiety in children children with sedatives alone children undergoing surgery parents pediatric anesthesia children who were older children children undergoing outpatient surgery 112 children aged 4-12 years undergoing outpatient surgery, anxiety was assessed after admission and again at mask induction of anesthesia, using the modified yale preoperative anxiety scale (mypas children undergoing dga induction elective pediatric procedures children undergoing anesthesia and surgery mothers of children who were scheduled to undergo surgery female and male patients children prior to dental general anesthesia one hundred and thirty-four patients (aged 2-10 yr, asa physical status i or ii outpatient surgery of the infant children undergoing general anesthesia children undergoing outpatient surgery was conducted children requiring surgery children of mothers who underwent children's median age was 5 (range 3-10) years, 57% were boys, a median of seven teeth were extracted (range 1-20 eighty patients requiring an inhalation anesthetic induction parents before their child's induction of anesthesia 40 subjects (5-12 years of age) who had to undergo minor day surgery
patients' subjective experience of pain 10-point visual analogue scale systolic and diastolic blood pressure, pulse rate and peripheral oxygen saturation tissue manipulation minimal discomfort central endothelial cell counts level of intraoperative pain discomfort pain scores no sensation rate of potential visual acuity recovery intraoperative pain scores best corrected visual acuity (bcva safety and efficacy endothelial cell loss intraoperative pain systolic blood pressure, pulse rate, oxygen saturation and pain score subjective experience of pain level of intraoperative discomfort pressure or pain visual analog scale discomfort or pain patient cooperation intraoperative discomfort, postoperative discomfort, and discomfort intraocular sensation mean pain score diastolic blood pressure 4-point pain scale discomfort visual analog pain scale patient-reported pain scores for delivery of anesthesia operative conditions, patient cooperation, and intraoperative complications bcva improvement patient satisfaction blood pressure pain pain scores 5-point satisfaction scale cell density parameters or kowa laser flare-cell meter measurements surgeon satisfaction score cell loss or adverse events|there was a small reduction in the discomfort caused by the operating microscope when intracameral lidocaine was used (p = 0.04). the advantage of using intracameral lidocaine 1% over a placebo was a significant decrease in the patients' subjective experience of pain and in the surgeon's satisfaction with the anesthesia used. twenty-six percent in the control group and 9% in the lidocaine group had discomfort pain scores of 2 or more; 10% in the bss group felt increased pressure or pain during phacoemulsification. in a rigorously double-masked, prospective, randomized, controlled trial there was no significant reduction in intraoperative pain when intracameral 1% lidocaine was used during phacoemulsification under topical anesthesia. seventy-eight percent of lidocaine patients and 56% of controls reported no sensation (p = .048, fisher's exact test). the difference between the pain scores for the two groups was statistically significant (p = 0.0053). there was no significant difference in patient-reported pain scores for delivery of anesthesia (p = 0.902), surgery (p = 0.170), or after surgery (p = 0.680). this study found no additional benefit of intracameral unpreserved lignocaine when performing routine clear corneal phacoemulsification under topical anaesthesia.|routine phacoemulsification under topical anesthesia cataract surgery ninety-three patients completed the study 204 patients undergoing phacoemulsification surgery with lens implantation under planned topical anesthesia fifty-nine consecutive patients (60 eyes) having phacoemulsification with implantation of a foldable acrylic iol (acrysof cataract surgery under topical anaesthesia 100 patients having phacoemulsification under topical anesthesia phacoemulsification with intraocular lens (iol) implantation carolina eye associates, southern pines, north carolina, usa both men and women between 45 and 85 years of age who were scheduled for elective cataract surgery while under topical anesthesia participated outpatient ambulatory surgical center routine clear corneal phacoemulsification under topical anaesthesia sixty-eight patients 200 patients undergoing routine phacoemulsification under topical 1 patients having phacoemulsification with iol implantation between january and july 1997, a total of 162 patients (162 eyes) scheduled for cataract surgery one hundred and thirty-five consecutive cases undergoing clear corneal phacoemulsification phacoemulsification under topical anesthesia comparable eligible patients
pain reduction peak pain score pattern repositioning and percentage of united fractures pain relief visual analogue scale (vas number of analgesic medications pain alleviation processing time or time to operation femoral neck fractures pain score processing time pain medication vas pain evaluation pain relief treatment pain consumption of analgesics of no clinical importance analgesic requirement pain suffered, analgesia required, frequency of pressure sores or ease of operation pain experienced, the need for supplementary analgesics, or complications during the hospital stay total consumption of analgesics intertrochanteric fractures visual analog scale (vas|we found a significant difference in pain score on the evening of admission and the first morning after admission between the groups with traction compared the group without. the number of analgesic medications needed was no higher in patients without traction. there was no difference in the total consumption of analgesics in the emergency department or on the ward and no effect of immobilization type on the processing time or time to operation. no differences were found between the groups in terms of pain suffered, analgesia required, frequency of pressure sores or ease of operation. using pain assessment scales and records of analgesic consumption, there was found to be little difference between the two groups. these patients also requested a statistically significant lower amount of pain medication (p < 0.01). patients treated without a weight-loaded skin traction kit had better pain relief compared to the other two groups; this outcome was statistically significant. no differences were found between the groups in terms of pain experienced, the need for supplementary analgesics, or complications during the hospital stay. there was a small significant increase in consumption of analgesics of no clinical importance in patients with skin traction, and no effect of traction type on the processing time or time to operation.|patients awaiting operation for hip fracture patients with hip fractures average patient age was seventy-eight years 108 pre-operative patients with hip fractures hip fractures in the elderly 100 patients with femoral neck fractures one hundred twenty patients with cervical or trochanteric hip fractures patients with persistent pain 252 patients awaiting surgery for fractures of the proximal femur patients with skin traction 153 consecutive patients with displaced cervical and trochanteric hip fractures one hundred consecutive patients with hip fractures admitted to the authors' institution who met inclusion criteria were enrolled hip fractures 123 patients 123 consecutive patients with displaced cervical and trochanteric hip fractures patients with fractures of the upper femur 80 patients with cervical, trochanteric or subtrochanteric hip fractures hip fracture 78 patients 311 patients patients with collum and intertrochanteric femur fractures hip fracture patients 75 were excluded because of senile confusion and the remaining 78 were randomized to skeletal or skin traction preoperatively university-affiliated teaching institution fifty patients were enrolled in each intervention group patients with acute proximal femur fracture 67 scoring within the normal range fractures of the proximal femur
radial nerve palsy internal fixation of humeral shaft fractures fracture alignment, time to healing, delayed union, and nonunion complications american shoulder and elbow surgeons' score (ases average union time union rate restriction of shoulder movements shoulder pain elbow rom shoulder range of motion (rom rate of union and functional outcome elbow pain union time, union rate, functional outcome and the incidence of complications function of the shoulder and elbow, as determined by the american shoulder and elbow surgeons' score, the visual analogue pain score, range of movement, or the time taken to return to normal activity fracture healing, radial nerve recovery, infection, and elbow and shoulder discomfort healing times ases scores rate of non-union|healing times did not differ between the two treatment groups (p>0.05). a decrement in elbow rom was significantly associated with plt (p = 0.03), especially for fractures of the distal third of the diaphysis, whereas elbow pain was not (p = 0.123). the average union time was found to be significantly lower for imn as compared to dcp (p<0.05). there were no significant differences in the function of the shoulder and elbow, as determined by the american shoulder and elbow surgeons' score, the visual analogue pain score, range of movement, or the time taken to return to normal activity.|humerus fractures forty-seven patients with diaphyseal fracture of the shaft of the humerus group; n = 46 patients admitted consecutively to a university-affiliated level i trauma center all skeletally mature patients admitted to harborview medical center with acute humeral shaft fractures requiring surgical stabilization and 27 patients with dynamic compression plates diaphyseal fractures of the humerus patients with pathological fractures, grade 3 open fractures, refractures and old neglected fractures of the humerus were excluded from the study humeral diaphyseal fractures patients requiring surgical treatment of a humeral shaft fracture 60 patients (43 males, 17 females; mean age 38 years; range 19 to 61 years) with humerus fractures 44 patients with fractures of the shaft of the humerus to open reduction and
number of infections infection rate deep infection superficial thromboplebitis|a statistically significant difference was found between the number of infections in the antibiotic groups and the number in the placebo group. in the cloxacillin group two infections were observed as compared to 12 in the control group. no significant infection prophylaxis was demonstrated by the use of intravenous antibiotics in these injuries. in four patients in each group clinical signs of infection eventually developed; osteomyelitis did not develop in any patients, and no secondary surgical procedures were required in either group. three different antibiotics regimes were compared, with no difference in the infection rate: therefore the simplest and surest method, a single pre-operative dose and a single post-operative dose, is recommended.|91 open fractures of the finger open phalangeal fractures in fingers with intact digital arteries low-velocity gunshot fractures sixty-seven patients (73 fractures ninety-six consecutive patients open and closed fractures twelve patients with grade ii & iii wounds patients with grade i wounds, 17 received fifty-eight patients with closed malleolar fractures 90 patients with open fractures of various bones and 180 patients with closed malleolar fractures treated by open surgery 85 adult patients with open fractures of the distal phalanges of less than 6 hours duration, treated by conventional surgery open fractures 100 patients with first-, second-, and third-degree open fractures